病理号,姓名,住院号,性别,年龄,T分期,N分期,M分期,综合分期,"分组（1=2633,2=357,3=269）",大体类型,"Lauren分型（肠型=0，混合型=1，弥散性=2,3=不确定型）",淋巴管癌栓（0=阴性，1=阳性）,静脉侵袭（0=阴性，1=阳性）,神经浸润（0=阴性，1=阳性）,癌旁上皮,转移淋巴结数,总淋巴结数,间质量（少=髓样型，中=中间型，多=硬型）,癌的浸润方式,HER-2（0=阴性，1=1+，2=2+，3=3+）,KI-67,VEGF（0=阴性，1=阳性）,VIMENTIN（0=阴性，1=阳性）,CD4（0=阴性，1=阳性）,CD8（0=阴性，1=阳性）,CD34（0=阴性，1=阳性）,"cMET（0=阴性，1=阳性,2=弱阳性）",手术日期,最后一次随访时间,五年生存状态（0=失访，1=存活，2=死亡）,新辅助化疗方案,新辅助化疗（1=是）,第一次化疗,第二次化疗,第三次化疗,第四次化疗,第五次化疗,第六次化疗,总化疗次数,组织学类型,neoplasm_histologic_grade,分转移度,肿瘤部位,肿瘤大小 P,肿瘤大小 C,肿瘤大小 V,根治性手术,非根治性手术,白细胞,中性粒细胞,淋巴细胞,血红蛋白,血小板,纤维蛋白原含量,ALT,AST,乳酸脱氢酶,碱性磷酸酶,γ-谷氨酰胺转肽酶,总胆红素,直接胆红素,总蛋白,前白蛋白,白蛋白,球蛋白,葡萄糖,尿素氮,肌酐,尿酸,CD3+,CD3+/CD4+,CD3+/CD8+,CD4/CD8,CD3+/CD4+CD8+,CD19+,CD3-/CD16+56+,CD3+/CD16+56+,IgM,IgA,IgG,IgE,CEA,CA-199,CA724,幽门螺杆菌,膀胱（子宫）直肠窝结节,卵巢肿瘤,腹膜转移,肝脏转移,腹腔细胞检查,特殊检查,MLH1,MSH2,MSH6,PMS2,OS,patient
1400865,王伟,549645,男,46,T2,N0,M0, ⅠB,1,3,,,,, 肠化生+,0.0,32,中间型（int）,INFb,3.0,,,,,,,,2014-01-09,2020-12-17,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a) 03(1b) 03(2) 01(3a)03 (3b)03 (4sa)01 (7) 02(8a)02 (8p)01 (9)05 (11p)02 (19)02 (4sb) 02(4d)02," GE, 小弯侧Less,",50,40,18, R0 D2,,6.83,3.65,2.01,147.0,161.0,3.49,21.0,30.0,124.0,51.0,13.0,7.85,3.53,62.0,191.0,40.0,22.0,4.9,4.7,78.0,301.0,,,,,,,,,,,,,3.81,7.18,0.955, 未做,无, 无, P0,H0,已做,,,,,,83.24572930354796,1400865
1400793,魏进波,551394,男,32,T2,N3a,M0, ⅢA,1,3,,1.0,1.0,1.0,肠化生+ 异型增生,9.0,29,硬型（sci）,INFc,0.0,,,,,,,,2014-01-09,2022-09-01,1,,,XELOX,XELOX,XELOX,,,,3, 低粘附腺癌 低分化腺癌（G3)(por),G3, (1a)00 (1b)02 (3a)04 (3b)22 (4sb)16 (4d)47 (5)00 (6)24 (7)00 (8a)01 (8p)00 (9)02 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,30,3, D2,,5.19,3.06,1.72,145.1,139.0,1.79,20.2,26.0,135.0,101.0,15.0,14.37,3.71,55.0,166.32,34.5,20.5,,,,,,,,,,,,,,,,,1.39,9.4,1.45,,无,, P0,H0,已做,,,,,,103.71222076215506,1400793
1401410,田珍,551441,男,61,T3,N2,M0, ⅢA,1,3,,,,, 肠化生+,4.0,45,中间型（int）,INFc,3.0,0.85,,,,,,,2014-01-14,2019-07-09,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 粘液腺癌（muc）,G2, (1a) 00(1b)02 (2) 02(3a)312 (3b) 110(4sa)01 (4sb)01 (4d)00 (7)04 (8a) 04(8p) 04(9)03 (11p)02," U（胃底部）, 前Ant, 后Post, 小弯侧Less,",33,35,10, R0 D2,,4.75,2.03,1.91,143.0,248.0,4.66,29.0,52.0,186.0,80.0,23.0,19.55,6.91,76.0,228.0,41.0,35.0,,,,,,,,,,,,,,,,,3.63,29.16,3.73, 未做,无, 无, P0,H0,已做,,,,,,65.76872536136662,1401410
1401025,李忠霞,551272,女,57,T4b,N0,M0, ⅢA,1,2,,0.0,0.0,0.0, 肠化生+,0.0,47,中间型（int）,INFc,2.0,,,,,,,,2014-01-10,2020-04-28,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)01 (1b)00 (3a)07 (3b)02 (4sb)00 (4d)06 (6)010 (7)02 (8a) (8p)02 (9)05 (11p)012 (12a)00," L（幽门窦部）, 后Post,",70,70,15,,R1,7.16,4.78,1.84,113.9,254.0,5.16,11.0,30.0,119.0,101.0,8.0,9.14,3.46,68.0,144.0,42.0,26.0,5.7,5.2,62.0,166.0,,,,,,,,,,,,,2.05,5.64,2.75, 未做,无, 无, P0,H0,未做,,,,,,75.55847568988173,1401025
1400716,宋长库,551575,男,53,T2,N0,M0, ⅠB,1,2,,,,1.0, 腺体萎缩+ 肠化生+,0.0,33,硬型（sci）,INFb,1.0,0.8,,,,,,,2014-01-08,2019-04-15,0,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低粘附腺癌,G2, (1a)01 (1b)00 (3a)014 (3b)05 (4sb)00 (4d)04 (5)00 (6)00 (7)07 (8a) (8p) (9)02," L（幽门窦部）, 前Ant,",20,5,5, D2,,5.04,2.06,2.47,125.0,212.0,2.27,10.0,16.0,113.0,77.0,12.8,4.57,1.11,64.1,311.0,41.0,23.1,,,,,,,,,,,,,,,,,1.86,15.8,0.953, 未做,无,,,H0,已做,,,,,,63.17345597897503,1400716
1401233,吴德友,551600,男,62,T3,N3b,M1, Ⅳ,1,3,,1.0,1.0,1.0, 腺体萎缩+,19.0,35,中间型（int）,INFc,0.0,,,,,,,,2014-01-13,2014-06-17,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 85低粘附腺癌15,G2, (1a)04 (3a)17 (3b)22 (4sb)00 (4d) 7 11(6)77 (7)01 (8a)23," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",60,50,10,,R2,5.62,2.87,2.16,142.5,209.0,2.54,9.2,9.0,130.0,110.0,25.3,14.27,3.88,75.1,200.43,42.6,32.5,4.8,4.05,92.0,211.0,,,,,,,,,,,,,10.56,1000.0,1.38, 未做,无, 无, p1盆(M1 PER),H0,已做,,,,,,5.091984231274639,1401233
1401283,李玉琴,550529,男,77,T3,N0,M0, ⅡA,1,2,,,,, 肠化生+,0.0,25,髓样型（med）,INFc,0.0,0.85,,,,,,,2014-01-14,2014-09-29,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a) 00(1b)02 (3a)05 (3b)03 (4sb)00 (4d) 06(5)01 (6)01 (7) 02(8a) 01(8p)01 (9)00 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",70,60,10, R0 D2,,5.35,2.73,1.53,106.6,252.0,3.14,20.6,20.0,155.0,101.0,8.7,6.26,1.84,64.4,182.18,36.2,28.2,5.4,6.11,82.0,265.0,,,,,,,,,,,,,1.44,4.62,4.16, 未做,无, 无, P0,H0,已做,,,,,,8.47568988173456,1401283
1401417,曲殿波,551623,男,48,T1b,N2,M0, ⅡA,1,2,,,,,,5.0,23,,,3.0,0.6,,,,,,,2014-01-14,2020-10-10,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)01 (3a)03 (3b)02 (4sb)00 (4d)58 (5)00 (6)03 (7)01 (8a)00 (8p)02 (9)01 (12a)02 (11p)00," L（幽门窦部）, 大弯侧Gre,",30,25,8, R0 D2,,8.12,4.67,2.9,167.0,231.0,1.81,12.0,15.0,136.0,59.0,13.0,19.74,7.09,71.0,266.0,44.0,27.0,4.2,6.0,103.0,317.0,,,,,,,,,,,,,1.63,11.79,1.11,,无, 无, P0,H0,未做,,,,,,80.84756898817345,1401417
1400894,王彦忠,550034,男,49,T3,N0,M0, ⅡA,1,2,,0.0,0.0,1.0, 正常,0.0,39,中间型（int）,INFb,0.0,,,,,,,,2014-01-09,2019-01-15,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)05 (1b)02 (3a)00 (3b)06 (4sb)03 (4d)03 (5)09 (6)00 (7)02 (8a)00 (8p)01 (9)02 (11p)01 (12a)00 (14)05," L（幽门窦部）, 后Post,",40,40,18, D2,,4.3,2.6,1.27,149.3,275.0,3.59,11.0,19.0,129.0,84.0,34.0,7.29,5.03,75.0,324.0,50.0,25.0,5.4,5.9,80.0,399.0,,,,,,,,,,,,,1.31,8.52,1.08,,无,, P0,H0,未做,,,,,,60.183968462549274,1400894
1401589,毕于忠,550010,男,61,T2,N2,M0, ⅡB,1,3,,,,,,6.0,34,,,0.0,0.4,,,,,,,2014-01-15,2019-05-01,0,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)05 (1b)04 (3a)00 (3b)24 (4d)314 (4sb)00 (5)00 (6)00 (7) (8a) (8p) (9) (11p)17 (12a)00," L（幽门窦部）, 后Post,",40,40,8, R0 D2,,5.23,2.05,2.49,144.5,189.0,2.24,17.1,12.0,140.0,75.0,22.0,22.95,4.41,71.6,211.0,43.0,28.6,,,,,,,,,,,,,,,,,1.18,2.66,2.43, ,无, 无, P0,H0,未做,,,,,,63.469119579500656,1401589
1401110,刘桂芬,551255,女,66,T4b,N3b,M0, ⅢC,1,4,,1.0,1.0,1.0, 肠化生+,19.0,24,中间型（int）,INFc,0.0,0.8,,,,,,,2014-01-13,2014-07-07,2,,,,,,,,,0, 低分化腺癌（G3)(por) （GIST）,G3, (9)44 (1a)22 (1b)01 (2)03 (3b)00 (3a)33 (4sa)00 (4d)23 (5)11 (6)44 (7) (8a)22 (8p)11," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,7,,R2,7.22,4.74,2.02,134.2,248.0,3.46,6.2,38.0,157.0,71.0,10.8,10.25,3.27,56.4,123.96,35.8,20.6,5.3,2.93,52.0,458.0,,,,,,,,,,,,,2.32,6.55,1.26,,无, 无, P0,H0,已做,,,,,,5.7490144546649145,1401110
1402081,李广平,550530,男,55,T4b,N0,M0, ⅢA,1,2,,1.0,1.0,0.0, 肠化生+,0.0,27,中间型（int）,INFc,0.0,0.85,,,,,,,2014-01-21,2015-09-01,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)02 (1b)02 (2)00 (3a) 00(3b)010 (4sa) 01(4sb) 00(5)00 (7) 00(8a)05 (8p)02 (9) 00(11p)04 (12a)01," GE, 大弯侧Gre,",70,60,8,,R1,7.41,6.0,0.9,156.1,164.0,5.16,12.0,14.0,179.0,90.0,42.0,18.65,7.47,74.0,203.0,43.0,31.0,5.9,6.4,83.0,306.0,,,,,,,,,,,,,2.07,8.99,2.0, 未做,无, 无, P0,H0,未做,,,,,,19.316688567674113,1402081
1401654,李艳霞,548386,女,59,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,19,,,2.0,0.5,,,,,,,2014-01-16,2018-06-04,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)01 (3a)01 (3b)01 (4sb)00 (4d) 03(5)00 (6) 02(7)01 (8a)03 (8p) 01(9) 02(11p)02," L（幽门窦部）, 大弯侧Gre,",20,20,8, R0 D2,,4.54,2.44,1.44,129.0,230.0,2.18,15.0,26.0,150.0,71.0,10.0,12.25,4.29,71.0,248.0,42.0,29.0,5.0,5.2,59.0,243.0,,,,,,,,,,,,,0.459,16.41,3.96, 未做,无, 无, P0,H0,未做,,,,,,52.562417871222074,1401654
1401419,臧日军,551931,男,32,T4b,N3a,M0, ⅢC,1,4,,1.0,1.0,1.0, 腺体萎缩+,14.0,37,中间型（int）,INFc,0.0,0.85,,,,,,,2014-01-14,2018-01-20,0,,,,,,,,,0, 粘液腺癌（muc） 低粘附腺癌 低分化腺癌（G3)(por),G3, (1a)23 (1b)05 (2)00 (3a)12 (3b)00  (4sa)00 (4sb)210 (4d)810 (5)00 (6)02 (7)00 (8a)00 (8p)11 (9)02 (11p)00 (12a)02," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,8, R0 D2,R2,4.52,2.36,1.36,77.0,448.0,3.59,3.0,15.0,102.0,60.0,14.0,5.85,2.43,59.0,202.0,38.0,21.0,,,,,,,,,,,,,,,,,2.32,2.9,17.2,,无, 无,,H0,未做,,,,,,48.19316688567674,1401419
1401737,于文俭,551285,男,62,T3,N0,M0, ⅡA,1,2,,0.0,0.0,0.0, 肠化生+,0.0,16,中间型（int）,INFc,0.0,0.7,,,,,,,2014-01-16,2020-07-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a) 03(1b) 00(3a)04 (3b) 00(4sb) 00(4d) 03(5)00 (6)00 (7)00 (8a)00 (8p)02 (9) 01(11p)02," L（幽门窦部）, 前Ant,",30,30,2, R0 D2,,6.98,3.76,2.66,146.0,224.0,2.72,18.0,19.0,229.0,79.0,49.0,16.39,6.09,71.0,288.0,46.0,25.0,5.9,6.0,92.0,432.0,,,,,,,,,,,,,2.43,13.25,1.18, 未做,无, 无, P0,H0,已做,,,,,,77.46386333771353,1401737
1401463,李永利,551433,男,57,T1b,N0,M0,ⅠA,1,2,,,,,,0.0,24,,,1.0,0.7,,,,,,,2014-01-15,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 90粘液腺癌（muc）10,G3, (1a)00 (1b) 05(3a) 03(3b) 00(4sb) 00(4d) 00(5)01 (6) 04(7)03 (8a)01 (8p)01 (9)04 (11p)02," L（幽门窦部）, 小弯侧Less,",35,32,3, R0 D2,,6.27,3.23,2.49,166.0,222.0,2.22,20.1,13.0,157.0,72.0,45.6,9.87,2.8,74.8,469.0,44.6,30.2,4.6,4.28,93.0,274.0,,,,,,,,,,,,,1.68,12.35,2.06, 未做,无, 无, P0,H0,,,,,,,103.51511169513797,1401463
1401396,杨运军,551445,男,62,T3,N2,M1, Ⅳ,1,3,,,,, 肠化生+,5.0,26,中间型（int）,INFc,0.0,0.6,,,,,,,2014-01-14,2014-05-01,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (5)15 (6)00 (7)00 (8a)02 (8p)00 (9)03 (11p)00 (12a)11 (1a)00 (1b)11 (3a)17 (3b)11 (4sb)05 (4d)01,L,40,40,6,,R2,4.67,2.98,1.24,148.0,182.0,3.16,22.1,21.0,184.0,183.0,97.0,16.57,5.03,72.4,202.0,42.7,29.7,,,,,,,,,,,,,,,,,97.0,21.0,47.0,,无,, P0,H1多（M1 HEP),未做,,,,,,3.515111695137976,1401396
1401504,杨少滨,547098,男,54,T3,N0,M0, ⅡA,1,3,,0.0,0.0,0.0, 肠化生+,0.0,11,中间型（int）,INFc,0.0,0.5,,,,,,,2014-01-15,2019-04-23,1,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)01 (5)01 (6)02 (7)01 (8a) (8p)03 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",25,20,8, D2,,6.27,3.65,1.98,123.0,225.0,5.16,32.2,30.0,133.0,149.0,99.0,12.63,3.9,76.5,178.0,44.8,31.7,5.3,3.99,94.0,301.0,,,,,,,,,,,,,0.8,4.13,2.69, 未做,无,, P0,H0,未做,,,,,,63.206307490144546,1401504
1402174,刘明秋,551277,男,53,T2,N0,M0, ⅠB,1,3,,,,,,0.0,32,,,3.0,0.6,,,,,,,2014-01-22,2020-10-10,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a) 04(1b) 06(3a) 05(3b) 00(4sb)00 (4d) 02(5) 00(6)05 (7)01 (8a)01 (8p)04 (9)00 (11p)04," L（幽门窦部）, 小弯侧Less,",70,50,9, R0 D2,,3.87,2.06,1.34,87.7,330.0,2.68,6.0,26.0,153.0,62.0,12.0,8.72,3.31,63.0,191.0,45.0,18.0,4.6,3.1,76.0,379.0,,,,,,,,,,,,,1.42,9.98,1.05, 未做,无, 无, P0,H0,未做,,,,,,80.58475689881735,1402174
1402133,王化芝,547225,女,50,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,23,,,2.0,0.3,,,,,,,2014-01-21,2020-09-16,1,SOX*2,1.0,XELOX,XELOX,XELOX,XELOX,,,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)06 (1b) 01(3a) 00(3b)00 (4sb)02 (4d)01 (5)00 (6) 00(7) 03(8a)01 (8p)03 (9) 05(11p)01 (12a)00," L（幽门窦部）, 前Ant,",20,20,,,R1,11.4,9.62,0.93,90.0,198.0,2.0,11.2,11.0,255.0,65.0,19.1,18.2,4.43,65.4,335.33,41.9,23.5,4.7,2.8,66.0,208.0,,,,,,,,,,,,,52.12,28.22,4.05, 未做,无, 无, P0,H0,未做,,,,,,79.82917214191852,1402133
1401796,刘瑞珍,551300,女,73,T4b,N3a,M0, ⅢC,1,4,,,,, 腺体萎缩+,9.0,18,中间型（int）,INFc,1.0,,,,,,,,2014-01-17,2015-01-20,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (4d)11 (1a)11 (5)02 (7)12 (6)35 (4sb)00 (3a)36 (8a)01,L（幽门窦部） 前Ant  后Post ,90,60,15,,R1,4.58,3.71,0.54,94.0,195.0,2.49,11.5,14.0,163.0,107.0,12.0,5.4,1.54,52.6,135.0,32.7,19.9,8.1,4.79,59.0,346.0,,,,,,,,,,,,,1.86,2.81,0.96, 未做,无, 无, P0,H0,未做,,,,,,12.089356110381077,1401796
1401886,李兴业,552152,男,70,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,18,,,0.0,,,,,,,,2014-01-17,2020-04-29,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1b)05 (1a)05 (3a)02 (3b)00 (4sb)02 (5)00 (6)00 (7)00 (8a) (8p)03 (9)01 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",60,50,, R0 D2+,,6.98,3.69,2.29,150.0,249.0,2.85,10.0,24.0,108.0,63.0,15.0,52.24,18.14,73.0,240.0,46.0,27.0,4.7,6.5,93.0,295.0,,,,,,,,,,,,,2.97,28.83,1.4, 未做,无, 无, P0,H0,未做,,,,,,75.36136662286465,1401886
1401933,闫福增,551968,男,59,T4b,N2,M1, Ⅳ,1,3,,1.0,1.0,1.0,腺体萎缩+,4.0,16,中间型（int）,INFc,3.0,0.8,,,,,,,2014-01-20,2014-05-20,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (2)00 (3a)00 (3b)38 (5)01 (6)00 (7)00 (8a)00 (8p)00 (9)00 (11p)02 (12a)01 (4sa)01 (4sb)01 (4d)12," G（胃底部）, 小弯侧Less,",50,40,10,,R2,6.92,4.24,2.08,150.7,122.0,3.21,20.0,28.0,120.0,81.0,63.0,14.21,6.77,59.0,194.0,35.0,24.0,11.4,5.7,57.0,225.0,,,,,,,,,,,,,5.07,46.12,9.77, 未做,粟粒状,, p1盆(M1 PER),H0,未做,,,,,,3.9421813403416555,1401933
1401970,寇继安,552660,男,70,T3,N3a,M0,ⅢB,1,3,,1.0,1.0,1.0, 肠化生+,15.0,26,中间型（int）,INFc,1.0,0.4,,,,,,,2014-01-20,2015-02-05,2,,,SOX,,,,,,1, 低分化腺癌（G3)(por)90 粘液腺癌（muc）10,G3, (1a)00 (1b)00 (2)23 (3a)34 (3b)00 (5)22 (6)00 (7)11 (8a)13 (12a)12 (9)11 (8p)12 (11p)02 (4sa)02 (4sb)00 (4d)34," G（胃底部）, 小弯侧Less,",80,60,10, D2,,3.93,2.43,0.95,146.0,221.0,3.14,15.0,23.0,146.0,122.0,16.0,10.96,4.01,67.0,190.0,40.0,27.0,4.5,7.0,82.0,365.0,,,,,,,,,,,,,1.21,42.42,5.01, 未做,无, , P0,H0,未做,,,,,,12.516425755584756,1401970
1402025,张辉,552666,男,59,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,26,,,1.0,0.3,,,,,,,2014-01-20,2020-10-10,1,,,,,,,,,0, 低分化腺癌（G3)(por)70 低粘附腺癌30,G3, (1a)01 (1b)04 (3a)02 (3b)05 (4sb)01 (4d)02 (5)00 (6)02 (7)03 (8a)01 (8p)01 (9)02 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",20,20,18, R0 D2,,4.49,3.06,0.72,138.0,163.0,2.89,17.0,18.0,127.0,87.0,34.0,14.28,5.27,74.0,244.0,49.0,25.0,5.8,5.9,77.0,258.0,,,,,,,,,,,,,2.23,6.63,2.17,,无, 无, P0,H0,未做,,,,,,80.65045992115637,1402025
1402031,肖海,548485,男,58,T3,N2,M0, ⅢA,1,2,,1.0,1.0,1.0, 肠化生+,5.0,18,中间型（int）,INFc,0.0,0.7,,,,,,,2014-01-20,2018-06-20,2,,,SOX,,,,,,1, 粘液腺癌（muc）80 低粘附腺癌20,GX, (5)00 (6)24 (7)01 (8a)12 (8p)04 (9)00 (11p)00 (12a)13 (4sb)00 (4d)01 (3b)13 (3a)00 (1b)00 (1a)00," L（幽门窦部）, 小弯侧Less,  后Post,",60,45,10, D2,,5.55,3.01,1.88,129.0,237.0,2.34,8.0,15.0,115.0,66.0,13.0,8.25,3.41,61.0,200.0,38.0,23.0,4.0,6.4,76.0,240.0,,,,,,,,,,,,,4.28,33.53,20.22, 未做,无,, P0,H0,未做,,,,,,52.95663600525624,1402031
1402079,郝凤兰,551367,女,72,T3,N1,M0, ⅡB,1,3,,,,1.0, 肠化生+,1.0,14,中间型（int）,INFc,1.0,0.7,,,,,,,2014-01-21,2017-09-10,0,,,替吉奥单药,,,,,,0, 低分化腺癌（G3)(por),G3, (5)00 (6)00 (7)01 (8a)02 (8p)13 (9)00 (11p)00 (12a)00 (1a)00 (2)04 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)03," L（幽门窦部）, 小弯侧Less,",40,35,6, D2,,3.22,1.76,1.07,123.0,173.0,4.02,10.3,9.0,134.0,103.0,14.0,10.9,7.71,65.9,253.0,39.0,26.9,5.4,4.81,67.0,222.0,,,,,,,,,,,,,1.33,32.33,1.68, 未做,无, 无, P0,H0,未做,,,,,,43.62680683311432,1402079
1402023,刘春艳,552565,女,48,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,27,,,0.0,0.8,,,,,,,2014-01-20,2020-04-29,1,,,替吉奥单药,替吉奥单药,,,,,2, 粘液腺癌（muc）70% 低分化腺癌（G3)(por)25% 低粘附腺癌5%,G3, (1a)02 (1b)03 (3a)02 (3b)00 (4d)03 (5)00 (4sb)01 (6)012 (7)01 (8a) (8p)02 (11p)01 (12a)00 (9)00," L（幽门窦部）, 小弯侧Less,",,,, R0 D2,,4.59,2.28,1.81,131.6,228.0,2.34,8.8,10.0,135.0,71.0,11.4,11.05,1.81,65.9,196.97,40.4,25.5,4.7,2.81,52.0,201.0,,,,,,,,,,,,,1.86,10.24,5.52, 未做,无, 无, P0,H0,未做,,,,,,75.2628120893561,1402023
1401949,王伟民,551983,男,50,T3,N0,M0, ⅡA,1,2,,,,1.0, 肠化生+,0.0,19,中间型（int）,INFc,0.0,0.6,,,,,,,2014-01-20,2020-04-29,1,,,XELOX,XELOX,XELOX,,,,0, 低分化腺癌（G3)(por)70 粘液腺癌（muc）10% 低粘附腺癌30%,G3, (4sb)00 (14v)00 (12a)00 (11p)02 (8a) (8p)04 (6)01 (5)00 (1b)00 (1a)00 (7)04 (3b)01 (3a)00 (9)01 (4d)06," L（幽门窦部）, 小弯侧Less,",40,40,10, R0 D2,,8.86,4.63,3.16,138.5,236.0,4.03,9.0,18.0,158.0,80.0,25.0,9.74,3.33,74.0,260.0,45.0,29.0,5.4,5.9,92.0,253.0,,,,,,,,,,,,,3.14,11.36,3.52, 未做,无, 无, P0,H0,未做,,,,,,75.2628120893561,1401949
1402318,柴玉国,551325,男,61,T3,N3b,M0, ⅢC,1,3,,1.0,1.0,1.0, 肠化生+,18.0,42,中间型（int）,INFc,2.0,,,,,,,,2014-01-24,2019-04-17,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,8, 乳头状癌（G1）（pap） 低分化腺癌（G3)(por) 粘液腺癌（muc）,G3, (1a)00 (1b)00 (3a)16 (3b)410  (11p)00 (12a)11 (5)02 (6)00 (7)01 (8a) (9)01 (4sb)04 (4d)1213," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,70,8,,R1,5.76,3.71,1.43,133.0,249.0,3.59,9.0,25.0,122.0,102.0,10.0,8.6,4.23,57.0,179.0,38.0,19.0,6.9,6.7,87.0,290.0,,,,,,,,,,,,,1.64,68.58,12.46, 未做,无,, P0,H0,未做,,,,,,62.71353482260184,1402318
1402337,王德连,552555,男,70,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,26,,,2.0,,,,,,,,2014-01-24,2017-09-10,0,,,,,,,,,0,低分化腺癌（G3)(por),G3, (1a)02 (1b)00 (3a)00 (3b)04 (4sb)00 (4d)03 (5)04 (6)01 (7)02 (8a)00 (8p)04 (9)02 (11p)02 (12a)02," L（幽门窦部）, 小弯侧Less,",20,20,8, D2 R0,,2.99,1.16,1.29,139.0,198.0,1.79,22.0,26.0,117.0,78.0,8.0,16.1,6.97,59.0,195.0,38.0,21.0,4.2,3.9,83.0,250.0,,,,,,,,,,,,,0.606,5.46,2.1, 未做,无, 无, P0,H0,未做,,,,,,43.52825229960578,1402337
1402524,杨世功,551802,男,58,T2,N0,M0, ⅠB,1,3,,0.0,0.0,0.0,正常,0.0,32,髓样型（med）,INFc,0.0,0.7,,,,,,,2014-02-08,2019-09-02,0,,,XELOX,XELOX,希罗达口服,替吉奥单药,替吉奥单药,替吉奥单药（6.7.）,12, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)08 (1b)00 (3a)05 (2)00 (3b)00 (4sa)01 (4sb)00 (4d)04 (5)00 (6)05 (7)06 (8a)01 (8p)00 (9)00 (11p)02," MU 小弯侧Less,",40,30,10, R0 D2,,6.32,3.0,2.66,154.0,212.0,1.44,12.0,19.0,137.0,46.0,15.0,12.08,3.92,65.0,229.0,39.0,26.0,4.6,5.3,81.0,237.0,,,,,,,,,,,,,1.47,3.28,14.21, 未做,无, 无, P0,H0,未做,,,,,,66.75427069645204,1402524
1402604,徐常斌,552725,男,64,T2,N0,M0, ⅠB,1,1,,,,,,0.0,9,,,0.0,0.65,,,,,,,2014-02-10,2019-04-15,1,,,,,,,,,0, 低黏附性癌（印戒细胞癌）,GX, (1a)00 (1b)00 (3a)00 (4sb)14 (4d)00 (5)01 (6)00 (7)01 (8a)00 (8p)01 (9)01 (11p)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,30,12, D2,,4.12,1.92,1.76,133.0,232.0,2.09,10.0,15.0,163.0,49.0,11.0,23.04,7.28,64.0,263.0,37.0,27.0,6.5,6.5,71.0,400.0,,,,,,,,,,,,,1.84,26.37,13.66, 未做,无,, P0,H0,未做,,,,,,62.089356110381075,1402604
1402694,刘贵华,552778,男,63,T3,N0,M0, ⅡA,1,2,,1.0,1.0,0.0, 肠化生+,0.0,18,中间型（int）,INFc,1.0,0.8,,,,,,,2014-02-10,2020-04-29,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)04 (3b)01 (4sb)01 (4d)03 (5)00 (6)02 (7)03 (8a)00 (9)01 (11p)02," L（幽门窦部）, 前Ant,",45,40,10, R0 D2,,4.05,1.65,1.82,145.0,184.0,2.14,16.0,18.0,152.0,39.0,10.0,16.03,5.86,60.0,225.0,38.0,22.0,5.2,4.9,91.0,385.0,,,,,,,,,,,,,1.77,22.8,3.23, 未做,无, 无, P0,H0, 未做,,,,,,74.57293035479631,1402694
1403174,于井元,553462,男,54,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,31,,,0.0,0.7,,,,,,,2014-02-13,2020-10-10,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a) 00(1b)03 (3a) 06(3b)02 (4sb)00 (4d)09 (5) 00(6) 04(7) 04(8a) 01(9) 00(11p) 02(12a)00," L（幽门窦部）, 后Post,",18,13,, R0 D2,,3.73,1.49,1.73,147.7,177.0,2.17,25.0,19.0,137.0,59.0,17.0,14.63,4.52,63.0,241.0,41.0,22.0,5.3,8.0,85.0,408.0,,,,,,,,,,,,,3.49,10.87,2.75, 未做,无, 无, P0,H0,,,,,,,79.86202365308804,1403174
1403939,彭艳,525592,女,35,T4a,N1,M0, ⅢA,1,4,,0.0,0.0,1.0,,2.0,45,,,1.0,,,,,,,,2014-02-20,2019-05-01,0,SOX*3,1.0,SOX,SOX,,,,,6, 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (2)04 (3a)09 (3b)13 (4d)06 (4sb)03 (5)01 (6)16 (7)06 (8a)01 (8p)01 (9)01 (11p)01 (12a)02 (14v)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,45,, R0 D2+,,3.45,1.33,1.37,1.5,115.0,2.73,94.2,62.0,199.0,69.0,20.4,14.05,3.15,66.8,209.37,40.6,26.2,5.3,3.24,44.0,250.0,,,,,,,,,,,,,2.84,0.844,7.11,,无, 无, P0,H0,未做,CK+,,,,,62.286465177398156,1403939
1403088,王颖,553373,女,50,T4b,N2,M0, ⅢB,1,2,,1.0,1.0,0.0, 腺体萎缩+,6.0,33,中间型（int）,INFc,0.0,0.4,,,,,,,2014-02-13,2015-01-01,2,,,XELOX,XELOX,XELOX,紫衫醇联合替吉奥,,,4, 粘液腺癌（muc） 低粘附腺癌,GX, (1a) 02(1b) 05(3a) 05(3b) 11(4sb) 01(4d) 06(5) 01(6)47 (7)04 (8a)11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,30,,R2,3.13,1.37,1.36,84.3,269.0,1.95,6.2,9.0,125.0,64.0,6.5,5.7,2.0,62.1,131.49,39.7,22.4,4.5,3.81,65.0,142.0,,,,,,,,,,,,,2.6,196.1,18.06, 未做,无, 无, P0,H0,,,,,,,10.578186596583443,1403088
1403395,王春玲,553398,女,43,T3,N2,M0, ⅢA,1,2,,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（++）,6.0,24,中间型（int）,INFb,2.0,0.6,,,,,,,2014-02-17,2019-04-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 乳头状癌（G1）（pap）,G1,大弯02 小弯01 (6)12 (7)07 (8a、8p)22 (9)13 (12a)00 (11p)00 (5)00 (4sb)00 (1a)00 (4sa)01 (4d)22 (1b)00 (2)02 (3b)01 (3a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",65,55,8, D2,,6.12,3.33,2.29,134.9,228.0,4.66,9.0,14.0,168.0,63.0,13.0,16.89,6.37,66.0,183.0,42.0,24.0,5.3,5.0,76.0,382.0,,,,,,,,,,,,,1.43,5.25,1.19,,无, 无, P0,H0,未做,,,,,,61.399474375821285,1403395
1403376,曲显文,552497,男,63,T3,N3a,M0,ⅢB,1,3,,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,30,中间型（int）,INFc,1.0,0.5,,,,,,,2014-02-17,2014-08-10,2,,,,,,,,,0,管状腺癌（中分化【G2】【tub2】  低分化腺癌（G3)(por) ,G3, (1a) (1b)01 (3a)24 (3b)13 (5)01 (6)22 (7)05 (4d)212 (4sb)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,40,8,,R2,11.01,7.44,2.57,137.0,250.0,3.59,14.0,29.0,150.0,92.0,15.0,12.53,4.58,71.0,329.0,45.0,26.0,4.3,7.8,119.0,519.0,,,,,,,,,,,,,2.81,6.23,3.22, 未做,粟粒状,,,H0,未做,,,,,,5.716162943495401,1403376
1403404,裴少海,552510,男,56,T4b,N3a,M0, ⅢC,1,2,,1.0,1.0,1.0, 肠化生+ 慢性炎症（++）,7.0,39,中间型（int）,INFb,0.0,0.7,,,,,,,2014-02-17,2015-08-05,2,,,,,,,,,0, 低分化腺癌（G3)(por)90 乳头状癌（G1）（pap）10,G3, (1a)13 (1b)00 (3a)01 (5)01 (6)01 (2)02 (7)13 (8a)(8p)06 (9)02 (11p)00 (4sa)00 (3b)13 (4d)06 (4sb)03," G, 小弯侧Less 前Ant 后Post ",90,80,2, D2,,6.05,3.68,1.75,67.0,208.0,3.21,10.0,25.0,103.0,30.0,12.0,7.29,3.12,52.0,163.0,31.0,21.0,5.8,5.5,72.0,285.0,,,,,,,,,,,,,0.622,3.3,1.08, 未做,无,, P0,H0,未做,,,,,,17.542706964520367,1403404
1403642,侯庆才,552504,男,50,T3,N3a,M0,ⅢB,1,4,,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,14.0,19,中间型（int）,INFc,1.0,0.8,,,,,,,2014-02-18,2015-12-01,2,,,SOX,SOX,SOX,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)11 (3a) 55(3b)11 (4sa)00 (4sb) 00(4d) 01(5)01 (6)00 (7)22 (8a)01 (8p)02 (11p)11 (12a) 00(19)11 (2)33," U（胃底部）, 后Post, 小弯侧Less,",50,50,5,,R1,5.37,3.13,1.71,159.1,232.0,3.01,24.0,28.0,148.0,62.0,13.0,9.4,2.97,68.0,351.0,41.0,27.0,4.7,5.7,84.0,238.0,,,,,,,,,,,,,2.81,4.77,3.56, 未做,无, 无, P0,H0, 已冲,,,,,,21.38633377135348,1403642
1403666,张宝山,547722,男,45,T3,N1,M0, ⅡB,1,3,,0.0,0.0,1.0, 腺体萎缩+ 慢性炎症（+）,1.0,15,中间型（int）,INFc,0.0,0.2,,,,,,,2014-02-18,2016-02-10,2,SOX*3,1.0,SOX,SOX,SOX,紫衫醇联合卡培他滨,紫衫醇联合卡培他滨,紫衫醇联合卡培他滨,6, 管状腺癌（中分化【G2】【tub2】,G2, (1a) 01(1b)02 (2) 02（3a)12 (3b)00 (4sa) 00(4sb) 00(5)00 (7)00 (8a)01 (8p)01 (9) 04(11p) 01(12p) 01(19)00," GE, 后Post,",35,30,5,,R1,4.15,2.05,1.27,119.0,99.0,1.93,75.0,55.0,169.0,116.0,55.0,9.06,3.16,60.0,110.0,33.0,27.0,5.1,2.6,81.0,271.0,,,,,,,,,,,,,2.69,123.6,170.7, 未做,无, 无, P0,H0,未做,,,,,,23.71879106438896,1403666
1411905,刁喜朋,552496,男,53,T3,N3a,M0,ⅢB,1,4,,0.0,,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,9.0,14,中间型（int）,INFb,1.0,,0.0,0.0,,,,,2014-04-29,2017-01-31,2,SOX*3,1.0,,,,,,,4, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)02 (3a)11 (3b)01 (4d)22 (5)22 (6)22 (7)11 (8a)11 (8p) (9)00 (12p)00 (4sb)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,50,6, R0 D2,,3.89,2.31,1.0,114.7,100.0,2.58,40.0,49.0,157.0,91.0,27.0,14.64,6.67,73.0,159.0,40.0,33.0,5.2,4.6,71.0,159.0,,,,,,,,,,,,,0.828,16.49,2.69,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF-,,,,,33.11432325886991,1411905
1403671,刘纪发,553430,男,75,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,29,,,0.0,0.7,,,,,,,2014-02-18,2020-04-29,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (9)03 (6)04 (11p)01 (1a)02 (1b)00 (12a)00 (5)00 (3a)04 (7)06 (3b)02 (4sb)01 (4d)06," L（幽门窦部）, 小弯侧Less,",8,8,, R0 D2,,6.98,3.9,2.5,137.0,234.0,4.03,18.0,16.0,124.0,68.0,36.0,7.53,3.26,78.0,321.0,42.0,36.0,5.2,6.0,76.0,260.0,,,,,,,,,,,,,1.49,12.68,0.897, 未做,无, 无, P0,H0,已做,,,,,,74.31011826544021,1403671
1404047,陈建英,550880,男,66,T2,N1,M0, ⅡA,1,2,,0.0,0.0,0.0, 肠化生++ 慢性炎症（+）,1.0,31,中间型（int）,INFc,2.0,0.6,,,,,,,2014-02-20,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)01 (3a)00 (3b)06 (4sb)00 (4d)04 (5)00 (12a)04 (6)13 (7)01 (8a)02 (8p)05 (9)01 (11p)01," L（幽门窦部）, 小弯侧Less,",15,15,3, R0 D2,,3.74,1.52,1.51,133.0,137.0,2.03,16.0,32.0,139.0,57.0,29.0,10.83,3.44,59.0,345.0,36.0,23.0,4.7,7.3,86.0,311.0,,,,,,,,,,,,,31.92,6.18,1.17,,无, 无, P0,H0,未做,,,,,,102.33245729303547,1404047
1403650,袁和,553382,男,55,T3,N1,M0, ⅡB,1,2,,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,1.0,6,中间型（int）,INFc,0.0,0.7,,,,,,,2014-02-18,2019-04-22,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a) (1b)00 (3a)11 (3b)00 (4sb)00 (4d)01 (5)00 (6)01 (7)02 (8a) (8p)00 (9)01 (11p)00," L（幽门窦部）, 小弯侧Less,",25,20,5, D2,,6.14,2.86,2.72,165.0,225.0,2.0,17.0,30.0,180.0,80.0,48.0,16.28,5.04,80.0,432.0,47.0,33.0,7.1,6.8,101.0,312.0,,,,,,,,,,,,,1.81,9.1,1.14, 未做,无,, P0,H0,未做,,,,,,62.056504599211564,1403650
1403677,马军,553383,男,40,T2,N0,M0, ⅠB,1,3,,0.0,0.0,1.0, 腺体萎缩+ 慢性炎症（+）,0.0,34,中间型（int）,INFc,0.0,0.6,,,,,,,2014-02-19,2017-09-10,0,,,,,,,,,0, 低分化腺癌（G3)(por) ,G3, (1a)03 (1b)00 (3a)08 (3b)08 (4sb)00 (4d)04 (6)06 (8a)00 (8p)00 (9)02 (11p)01 (12a)02, L（幽门窦部） 小弯侧Less 前Ant 后Post 大弯侧Gre  ,30,20,8, D2,,4.76,1.97,2.25,139.0,238.0,1.62,24.0,34.0,160.0,70.0,20.0,12.17,4.41,69.0,326.0,40.0,29.0,4.6,7.7,92.0,317.0,,,,,,,,,,,,,1.76,9.85,0.945, 未做,无,, P0,H0,未做,,,,,,42.67411300919842,1403677
1404598,王永庆,553866,男,67,T3,N0,M0, ⅡA,1,2,,1.0,1.0,1.0, 肠化生++ 慢性炎症（+）,0.0,18,中间型（int）,INFc,0.0,0.7,,,,,,,2014-02-25,2015-01-19,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a) 01(1b)00 (3a) 05(3b)00 (4sb)00 (4d)02 (5) 01(6) 01(7)01 (8a)01 (8p) 03(9)02 (12p)01," L（幽门窦部）, 后Post,",30,30,4, R0 D2,,7.52,3.5,3.5,189.8,148.0,3.05,31.0,37.0,230.0,69.0,30.0,28.72,13.8,88.0,162.0,45.0,43.0,,,,,,,,,,,,,,,,,4.84,50.83,1.68, 未做,无, 无, P0,H0,未做,,,,,,10.775295663600525,1404598
1405344,汤义,554031,男,54,T3,N1,M0, ⅡB,1,2,,,,, 肠化生+ 慢性炎症（+）,2.0,7,中间型（int）,INFc,0.0,0.6,,,,,,,2014-03-03,2015-05-30,2,,,替吉奥单药,替吉奥单药,替吉奥单药,替吉奥单药,,,4, 管状腺癌（中分化【G2】【tub2】,G2, (3a)00 (6)02 (7)11 (4sb)00 (5)00 (4d)01 (11p)00 (9)11 (8a)00 (3b)00 (1a)00 (1b)00 (8p)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,30,10, D2,,6.8,5.04,1.15,121.4,319.0,3.33,9.0,16.0,122.0,64.0,32.7,6.8,2.24,57.1,197.69,35.3,21.8,,,,,,,,,,,,,,,,,6.19,3.97,1.76,,无,, P0,H0,未做,,,,,,14.88173455978975,1405344
1404434,张桂琴,361177,女,67,T3,N3a,M0,ⅢB,1,3,,1.0,1.0,, 肠化生+ 慢性炎症（+）,7.0,26,中间型（int）,INFc,1.0,0.7,,,,,,,2014-02-24,2015-03-25,2,,,SOX,SOX,SOX,SOX,FOLFOX(2),多西他噻+顺铂（2）,8, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)04 (3a)00 (3b)03 (4sa)59 (4sb)00 (4d)02 (5)00 (6)00 (7)22 (8a) (8p) (9)06 (11p)00," L（幽门窦部）, 小弯侧Less,",60,60,7, D2,,7.82,4.23,2.86,124.0,296.0,3.16,8.0,15.0,191.0,87.0,11.0,5.53,1.58,70.0,210.0,39.0,31.0,6.3,5.7,70.0,,,,,,,,,,,,,,7.31,500.0,17.16, 未做,无, 无, P0,H0,未做,,,,,,12.943495400788436,1404434
1403761,朱秋梅,553679,女,68,T3,N3b,M0, ⅢC,1,4,,,,, 肠化生++ 慢性炎症（++）,37.0,67,中间型（int）,INFc,0.0,0.6,,,,,,,2014-02-20,2015-08-18,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a) (1b)59 (2)01 (3a)22 (3b)68 (4sa)04 (4sb)11 (4d)22 (5)02 (6)01 (7)39 (8a) (8p)44 (9)00 (11p)02 (12a)410," G, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",110,100,15, D2,,4.86,2.72,1.22,117.0,136.0,2.09,39.1,39.0,183.0,58.0,21.5,15.36,6.52,51.1,84.1,26.4,24.7,,,,,,,,,,,,,,,,,1.5,16.97,2.14, 未做,无, 无, P0,H0,未做,,,,,,17.871222076215506,1403761
1403850,于庆金,553697,男,69,T4b,N0,M0, ⅢA,1,3,,,,, 肠化生+ 慢性炎症（+）,0.0,38,中间型（int）,INFc,0.0,0.9,,,,,,,2014-03-19,2019-04-22,1,,,SOX,SOX,,,,,2, 管状腺癌（中分化【G2】【tub2】,G2, (1a) (1b)06 (3a) (3b)013 (4sb)02 (4d)08 (5)00 (6)00 (7) (8a) (8p) (9) (11p)09, 胃癌 L (幽门窦部）前Ant 后Post 大弯侧Gre  小弯侧Less,105,60,12, D2,,9.51,6.04,2.55,127.0,370.0,4.36,6.3,9.0,121.0,88.0,20.0,9.31,6.91,60.4,136.0,37.0,23.4,,,,,,,,,,,,,,,,,9.85,5.9,,,无,, P0,H0,未做,,,,,,61.10381077529566,1403850
1404036,程湖,553703,男,65,T3,N3a,M0,ⅢB,1,2,,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,7.0,36,中间型（int）,INFc,,,,,,,,,2014-02-20,2020-09-08,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 乳头状癌（G1）（pap）30,G3,(1a)01 (1b)01 (3a)15 (3b)22 (4sb)03 (4d)19 (5)00 (6)36 (7)00 (8a)02 (8p)01 (9)00 (11p)02 大网01 小弯03," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",60,60,9, R0 D2,,5.96,4.2,1.05,69.1,342.0,4.03,9.6,7.0,124.0,82.0,13.6,4.98,3.71,60.0,184.34,34.7,25.3,,,,,,,,,,,,,,,,,0.726,6.62,2.73, 未做,无, 无, P0,H0,已冲,,,,,,78.580814717477,1404036
1403937,孙贵成,553685,男,62,T3,N1,M0, ⅡB,1,3,,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,1.0,21,中间型（int）,INFc,2.0,0.5,,,,,,,2014-02-20,2019-04-20,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】,G2, (1a) 01(1b)01 (3a)04 (3b)11 (4sb)00 (4d) 04(5)00 (6) 02(7) 04(9) 02(11p)02 (14v)00," L（幽门窦部）, 前Ant,",70,60,15, R0 D2,,6.37,3.25,2.24,155.2,179.0,3.21,23.7,12.0,141.0,79.0,29.3,10.59,6.75,69.6,308.71,43.9,25.7,,,,,,,,,,,,,,,,,2.55,100.8,6.02, 未做,无, 无, P0,H0, 已冲,,,,,,61.925098554533506,1403937
1404291,李强,553734,男,45,T2,N0,M0, ⅠB,1,3,,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,15,硬型（sci）,INFc,0.0,0.3,,,,,,,2014-02-22,2020-10-10,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a) (1b)02 (3a) (3b)03 (6)(4d)05 (5) (12a)00 (4sb)02  (7) (8a) (8p) (9) (11p)03," L（幽门窦部）, 小弯侧Less,",30,35,, R0 D2,,7.32,2.79,3.98,159.0,182.0,2.76,14.9,16.0,142.0,57.0,18.1,15.92,6.58,67.1,418.38,42.1,25.0,,,,,,,,,,,,,,,,,1.55,5.54,2.72,,无, 无, P0,H0,未做,,,,,,79.56636005256242,1404291
1404888,马长山,554027,男,62,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,33,,,0.0,0.5,,,,,,,2014-02-27,2017-09-07,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)03 (3a)06 (3b)04 (4sb)00 (4d)00 (5)00 (6)03 (7)05 (8a)04 (8p)00 (9)01 (11p)02 (12a)04," L（幽门窦部）, 小弯侧Less,",20,15,3, R0 D2,,5.0,2.04,2.27,167.9,173.0,1.98,56.1,28.0,184.0,65.0,14.7,11.8,3.7,75.6,230.39,48.1,27.5,,,,,,,,,,,,,,,,,1.01,8.11,300.0,,无, 无, P0,H0,未做,,,,,,42.31274638633377,1404888
1404071,王志斌,553618,男,62,T3,N1,M0, ⅡB,1,2,,,,, 肠化生+ 慢性炎症（+）,1.0,17,中间型（int）,INFc,3.0,0.6,,,,,,,2014-02-20,2019-04-20,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)01 (3a) 02(3b)00 (4sb)00 (4d) 01(5) 00(6) 14(7) 02(8a)03 (8p)00 (9)00 (11p) 01(12a)00," L（幽门窦部）, 后Post, 大弯侧Gre,",40,25,8, R0 D2,,5.44,3.24,1.79,135.5,265.0,2.89,20.0,29.0,132.0,69.0,34.0,11.69,3.79,70.0,204.0,42.0,28.0,,,,,,,,,,,,,,,,,20.01,324.3,2.97, 未做,无, 无, P0,H0,已做,,,,,,61.925098554533506,1404071
1404633,李超英,554052,男,54,T3,N1,M0, ⅡB,1,2,,,,, 肠化生+ 慢性炎症（+）,2.0,29,中间型（int）,INFc,1.0,0.6,,,,,,,2014-02-25,2019-04-22,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 粘液腺癌（muc）10 低粘附腺癌10,G2, (8a)03 (6)01 (8p) (9)02 (7)01 (3a)00 (1b)02 (11p)00 (1a)00 (12a)00 (4sb)01 (3b)06 (5)01 (4d)212," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,8, D2,,7.71,4.23,2.7,131.0,180.0,2.21,12.0,16.0,115.0,65.0,10.0,9.23,3.3,59.0,232.0,36.0,23.0,,,,,,,,,,,,,,,,,12.45,115.8,9.6, 未做,无,, P0,H0,未做,,,,,,61.826544021024965,1404633
1404602,王淑文,553588,女,67,T2,N0,M0, ⅠB,1,2,,0.0,0.0,0.0, 慢性炎症（+）,0.0,26,髓样型（med）,INFa,1.0,0.85,,,,,,,2014-02-25,2020-12-17,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a) (1b)04 (3a)05 (3b)00 (4sb)00 (4d)06 (5)01 (6)02 (7)01 (8a)00 (8p)01 (9)02 (11p)00 (12a)03 (14v)01," L（幽门窦部）, 后Post,",30,35,2, R0 D2+,,4.11,2.33,1.49,136.7,199.0,2.18,10.0,16.0,162.0,104.0,17.0,16.27,4.19,73.0,268.0,45.0,28.0,,,,,,,,,,,,,,,,,6.33,1.02,1.71,,无, 无, P0,H0,未做,,,,,,81.70170827858081,1404602
1404886,冉玉环,552507,女,65,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,4,,,,,,,,,,,2014-02-27,2019-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (7)00(4sa)00 (2)03 (1)00 (3)01 (4sb)00 (6)00 (5)00 (11p)00," U（胃底部）, 小弯侧Less,",20,15,, D2,,3.9,1.92,1.61,131.9,88.0,1.78,87.0,66.0,159.0,96.0,53.0,12.35,4.62,61.0,135.0,35.0,26.0,,,,,,,,,,,,,,,,,1.15,69.33,2.75,,无, 无, P0,H0,,,,,,,66.13009198423127,1404886
1404856,李德龙,553555,男,63,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,12,,,0.0,0.5,,,,,,,2014-02-27,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a) 02(1b) 00(3a)00 (3b) 00(4sb)01 (4d)01 (5)00 (6)02 (7)01 (8a)02 (8p)00 (9) 02(11p)01," L（幽门窦部）, 小弯侧Less,",10,10,, R0 D2,,4.19,1.71,2.25,152.3,133.0,2.12,17.1,10.0,156.0,80.0,18.8,9.99,2.14,70.4,424.0,45.0,25.4,,,,,,,,,,,,,,,,,2.64,0.765,40.42, 未做,无, 无, P0,H0,已冲,,,,,,102.10249671484888,1404856
1404966,鲁春仁,553640,男,61,T3,N1,M0, ⅡB,1,1,,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,1.0,35,髓样型（med）,INFc,0.0,0.7,,,,,,,2014-02-27,2019-05-01,0,,,XELOX,XELOX,XELOX,XELOX,,,4, 粘液腺癌（muc）,GX, (1a)01 (1b)00 (3a)113 (3b)00 (4sb)02 (4d)04 (5)01 (6)00 (7)01 (8a)02 (8p)00 (9)04 (10)01 (11p)04 (12a)02," L（幽门窦部）, 后Post,",70,50,20, R0 D2,,6.3,4.6,1.05,141.0,232.0,2.84,14.0,23.0,137.0,87.0,20.0,12.7,4.22,66.0,186.0,38.0,28.0,,,,,,,,,,,,,,,,,3.73,359.2,29.26,,无, 无, P0,H0,未做,,,,,,62.056504599211564,1404966
1404601,单国华,555293,女,46,T3,N0,M0, ⅡA,1,4,,0.0,0.0,1.0, 肠化生+ 慢性炎症（++）,0.0,35,中间型（int）,INFc,1.0,0.8,,,,,,,2014-02-25,2014-05-04,2,,,XELOX,XELOX,,,,,0, 低分化腺癌（G3)(por),G3, (3b)014 (3a)01 (2)00 (1b)00 (1a)01 (6)00 (5)00 (4d)011 (4sb)00 (4sa)00 (12a)00 (11p)01 (9)03 (8p)03 (8a)00 (7)01," U（胃底部）, M（胃体部）, UM",60,45,15, D2,,8.19,4.96,2.31,136.7,306.0,5.16,11.0,16.0,104.0,62.0,15.0,5.74,2.25,69.0,133.0,39.0,30.0,,,,,,,,,,,,,,,,,2.73,20.07,1.33,,无, 无, P0,H0,未做,,,,,,2.2339027595269383,1404601
1404967,刘俊,555353,男,71,T2,N0,M0, ⅠB,1,2,,,,, 腺体萎缩+ 慢性炎症（+）,0.0,39,中间型（int）,INFc,0.0,0.7,,,,,,,2014-02-27,2015-05-05,0,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1b)02 (12a)0001 (8p)01 (4sb)01  (5)01 (8a)04 (1a)02 (7)07 (3a)01 (3b)01 (4d)010 (11p)04 (9)04," L（幽门窦部）, 小弯侧Less, 前Ant, 后Post, 大弯侧Gre,",80,80,20, R0 D2+,,4.1,1.85,1.94,102.0,322.0,3.27,23.0,31.0,100.0,80.0,7.0,9.06,3.71,62.0,141.0,36.0,26.0,,,,,,,,,,,,,,,,,2.04,1.23,24.34,,无, 无, P0,H0,未做,,,,,,14.19185282522996,1404967
1404711,徐振宽,555417,男,63,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,35,,,3.0,0.7,,,,,,,2014-02-26,2019-04-22,1,,,,,,,,,0,管状腺癌（中分化【G2】【tub2】,G2, (1a) (1b)00 (3a)06 (3b)00 (4sb)00 (5)00 (6)09 (7)03 (8a) (8p)02 (9)05 (11p)02 (4d)08," L（幽门窦部）, 小弯侧Less, 后Post,",25,20,5, D2,,5.7,2.35,2.71,150.0,207.0,3.27,22.0,24.0,137.0,64.0,18.0,6.65,2.52,71.0,216.0,41.0,30.0,,,,,,,,,,,,,,,,,1.62,7.18,7.15,,无,, P0,H0,未做,,,,,,61.793692509855454,1404711
1404814,王强,555373,男,37,T3,N1,M0, ⅡB,1,3,,,,,,1.0,6,中间型（int）,INFc,1.0,0.6,,,,,,,2014-02-26,2017-01-13,2,,,,,,,,,0, 低分化腺癌（G3)(por)80  粘液腺癌（muc）20,G3, (1a) (1b)00 (3a)02 (4d)02 (5)00 (4sb)00 (6)00 (7) (8a) (8p) (9)11 (11p)00," U（胃底部）, E（食道）, G=E, SiewerⅡ, 小弯侧Less,",45,35,10, D2,,3.1,1.44,1.26,162.0,109.0,2.6,19.0,21.0,165.0,139.0,165.0,39.23,12.95,71.0,222.0,43.0,28.0,,,,,,,,,,,,,,,,,1.63,6.0,11.17, 未做,无,, P0,H0,未做,,,,,,34.55978975032851,1404814
1405253,刘金龙,555354,男,43,T3,N0,M0, ⅡA,1,3,,,,1.0, 腺体萎缩+ 慢性炎症（+）,0.0,13,中间型（int）,INFc,1.0,0.3,,,,,,,2014-03-03,2019-03-01,1,,,,,,,,,0, 粘液腺癌（muc）45% 低粘附腺癌45% 低分化腺癌（G3)(por)10%,G3, (1a)02 (9)01 (3b)00 (4sb)00 (4d)02 (12a)01 (5)02 (11p)00 (8a)01 (7)02 (6)00 (3a)00 (1b)02," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",50,45,15, R0 D2,,7.32,5.06,1.79,145.0,352.0,2.73,14.0,15.0,156.0,61.0,16.0,5.69,1.77,67.0,285.0,45.0,22.0,5.7,5.8,79.0,291.0,,,,,,,,,,,,,0.865,2.98,6.39, 未做,无, 无, P0,H0, 未做,,,,,,59.92115637319316,1405253
1405233,赵淑娟,555342,女,46,T2,N0,M0, ⅠB,1,2,,,,, 肠化生+ 慢性炎症（+）,0.0,12,中间型（int）,INFc,1.0,0.6,,,,,,,2014-03-03,2022-09-01,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (3a) 01(3b) 01(4sb)00 (4d)01 (5)00 (6)03 (7)01 (8a)03 (8p) 01(9) 00(11p) 00(12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",20,20,5, R0 D2,,6.17,3.18,2.21,140.0,288.0,2.3,9.0,12.0,187.0,56.0,15.0,10.06,2.67,71.0,199.0,41.0,30.0,,,,,,,,,,,,,,,,,1.68,41.23,1.09, 未做,无, 无, P0,H0,已冲,,,,,,101.97109067017082,1405233
1405327,陈晓红,554817,女,61,T3,N3a,M1,ⅢB,1,4,,,,, 腺体萎缩+ 慢性炎症（+）,11.0,47,中间型（int）,INFc,0.0,0.5,,,,,,,2014-03-03,2016-11-20,0,,,紫衫醇联合替吉奥,替吉奥单药,替吉奥单药,替吉奥单药,,,4, 低分化腺癌（G3)(por),G3, (1a)010 (1b)01 (2)00 (3a) 06(3b)88 (4sa) 01(4sb)00 (4d)08 (5)03 (6) 03(7)22 (8a) 01(8p)01 (9) 13(12a)00," ML 前Ant, 后Post, 小弯侧Less,",80,70,12,,R2,4.81,2.86,1.55,115.7,234.0,2.95,32.0,29.0,168.0,46.0,9.3,23.39,6.88,61.0,235.0,40.0,21.0,,,,,,,,,,,,,,,,,0.65,3.74,2.16, 未做,无, 无, p1局腹膜(M1 PER),H0, 已冲,,,,,,32.6215505913272,1405327
1405119,王文章,554099,男,66,T3,N3b,M0, ⅢC,1,2,,1.0,1.0,1.0, 腺体萎缩+,18.0,36,中间型（int）,INFc,1.0,0.3,,,,,,,2014-02-28,2015-09-23,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)02 (1b)01 (2)04 (3a)79 (3b)33 (4sa)01 (4sb)00 (4d)02 (5)12 (6)66 (7)00 (8a) (8p)02 (9)02 (11d)00 (11p)01 (12a)00 (16a1)11," M（胃体部）, 小弯侧Less,",50,40,10, R0 D2+,,5.65,3.13,1.88,116.0,177.0,2.89,12.6,17.0,158.0,80.0,15.5,12.69,2.99,65.7,165.39,38.9,26.8,4.5,5.0,86.0,333.0,,,,,,,,,,,,,1.64,11.48,3.79,,无, 无, P0,H0,未做,,,,,,18.791064388961892,1405119
1405421,马成录,555403,男,51,T3,N3a,M0,ⅢB,1,4,,,,1.0, 腺体萎缩+,9.0,47,中间型（int）,INFc,0.0,0.8,,,,,,,2014-03-04,2016-01-01,2,,,,,,,,,0, 低粘附腺癌,GX, (4sb)00 (3b)24 (12a)12 (4sa)00 (2)04 (3a)14 (6)24 (7)00 (11p)07 (8a)06 (8p)03 (1a)04 (9)14 (5)11 (4d)14," ML 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,35,10,,R1,6.88,4.4,1.37,112.0,311.0,4.03,23.0,18.0,170.0,109.0,13.0,4.84,2.24,67.0,187.0,44.0,23.0,,,,,,,,,,,,,,,,,5.96,27.75,5.6,,无, 无, P0,H0,已冲,,,,,,21.944809461235216,1405421
1405350,田桂华,555824,女,59,T3,N3a,M0,ⅢB,1,2,,,,1.0, 肠化生+,14.0,37,中间型（int）,INFa,0.0,0.7,,,,,,,2014-03-03,2014-10-09,2,,,XELOX,奥沙利铂单药,DF,DF,,,4,管状腺癌（中分化【G2】【tub2】,G2, (1a) (1b)00 (3a)78 (3b)211 (5)02 (6)05 (7) (8a) (8p) (9)49 (4sb)12 (4d)00," L（幽门窦部）, 大弯侧Gre,",40,40,10, D2,,10.71,6.44,3.6,111.1,347.0,3.85,12.3,8.0,148.0,81.0,21.8,4.77,1.37,73.4,141.7,41.3,32.1,,,,,,,,,,,,,,,,,13.8,0.674,8.29, 未做,无, 无, P0,H0,未做,,,,,,7.227332457293035,1405350
1405650,丁太,555194,男,57,T3,N1,M0, ⅡB,1,2,,1.0,1.0,1.0, 腺体萎缩+,2.0,42,中间型（int）,INFb,3.0,0.25,,,,,,,2014-03-05,2019-04-20,1,,,替吉奥单药,SOX,SOX,,,,0, 管状腺癌（中分化【G2】【tub2】60 乳头状癌（G1）（pap）40,G2, (1a) 02(1b)02 (3a)25 (3b)05 (4sb)01 (4d) 017(5)00 (6)00 (7) 01(8a)02 (8p) 02(9)01(11p) 04(12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",45,45,15, R0 D2,,7.36,2.93,3.75,161.1,218.0,2.45,15.0,19.0,139.0,83.0,9.0,18.44,7.5,71.0,214.0,44.0,27.0,,,,,,,,,,,,,,,,,7.43,5.06,4.96, 未做,无, 无, P0,H0,已冲,,,,,,61.498028909329825,1405650
1405652,崔井芳,555586,女,55,T3,N2,M0, ⅢA,1,2,,1.0,1.0,0.0, 腺体萎缩+,5.0,40,硬型（sci）,INFc,1.0,0.6,,,,,,,2014-03-05,2019-04-22,0,,,,,,,,,0, 低粘附腺癌 （GIST）,GX, (12a)00 (4d)11 (6)013 (5)01 (4sb)14 (2)00 (1b)01 (1a)17 (7)16 (9)03 (8a) (8p)14," L（幽门窦部）, 小弯侧Less,",35,25,10, D2,,4.32,2.08,1.89,139.2,246.0,2.34,20.0,20.0,137.0,86.0,9.0,11.25,3.69,70.0,182.0,45.0,25.0,,,,,,,,,,,,,,,,,2.8,4.75,2.46, 未做,无,, P0,H0,已做,,,,,,61.563731931668855,1405652
1405554,王树森,554868,男,72,T3,N1,M0, ⅡB,1,2,,,,1.0, 肠化生+,1.0,19,中间型（int）,INFb,1.0,0.75,,,,,,,2014-03-05,2017-09-06,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 高级别上皮内瘤变,G2, (11p)00 (9)14 (8p)01 (8a)02 (7)03 (6)01 (5)00 (4d)01 (3a) (3b)07 (1b)00 (1a)00 (4sb)00," L（幽门窦部）, 小弯侧Less,",52,35,5, D2,,6.42,4.26,1.55,154.0,193.0,3.61,10.6,9.0,132.0,98.0,29.7,15.82,6.12,69.4,263.0,41.9,27.5,,,,,,,,,,,,,,,,,1.6,7.93,,,无,, P0,H0,已冲,,,,,,42.08278580814717,1405554
1405651,马富贵,460012,男,69,T3,N2,M0, ⅢA,1,3,,1.0,1.0,, 腺体萎缩+,5.0,12,硬型（sci）,INFc,0.0,0.75,,,,,,,2014-03-05,2020-12-20,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌 粘液腺癌（muc）,GX, (1a)00 (1b)33 (3a)02 (4sb)00 (5)00 (6)12 (8a)11 (8p)04 (9)00 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",35,25,8, R0 D2,,5.9,3.42,1.86,146.0,219.0,2.39,19.0,23.0,216.0,68.0,10.0,24.94,7.55,60.0,177.0,38.0,22.0,,,,,,,,,,,,,,,,,3.37,26.0,81.44,,无, 无, P0,H0,未做,,,,,,81.53745072273324,1405651
1405581,胡世文,556062,男,56,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,21,,,0.0,0.7,,,,,,,2014-03-05,2020-04-29,1,,,,,,,,,0, 低粘附腺癌,GX, (6)04 (3a)01 (3b)00 (1b)03 (9)03 (7)00 (11p)05 (8a) (8p)01 (5)02 (4sa)02 (4sb)00," L（幽门窦部）, 前Ant, 大弯侧Gre,",30,15,, R0 D2,,7.24,3.51,2.79,149.0,180.0,1.71,15.0,21.0,138.0,66.0,13.0,22.54,8.09,64.0,204.0,40.0,24.0,5.3,7.1,99.0,233.0,,,,,,,,,,,,,1.54,8.28,1.36, 未做,无, 无, P0,H0, 未做,,,,,,73.8173455978975,1405581
1406416,任胜武,555925,男,74,T3,N2,M0, ⅢA,1,5,,,,, 腺体萎缩+ 慢性炎症（+）,4.0,34,中间型（int）,INFb,1.0,0.8,,,,,,,2014-03-12,2020-09-08,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90 粘液腺癌（muc）10,G2, (3a)12 (4d)14 (15)24 (5)01 (3b)00 (8p)05 (11p)03 (6)06 (12a)01 (9)04 (7)00 (4sb)00 (1a)03 (1b)01," L（幽门窦部）, 前Ant, 小弯侧Less,",30,40,8, R0 D2,,9.35,4.28,4.36,137.5,348.0,2.73,14.0,21.0,175.0,63.0,9.0,5.36,1.6,48.0,251.0,31.0,17.0,,,,,,,,,,,,,,,,,6.04,0.633,24.21,,无, 无, P0,H0, 已冲,,,,,,77.92378449408672,1406416
1406588,谭敦国,554890,男,61,T4b,N2,M0, ⅢB,1,2,,,,, 腺体萎缩+ 慢性炎症（+）,5.0,37,中间型（int）,INFa,0.0,,,,,,1.0,,2014-03-13,2016-11-22,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】90 粘液腺癌（muc）10,G2, (1a)01 (1b)01 (4sa)00 (5)22 (6)010 (9)03 (3b)00 (7)02 (11p)04 (14v)00 (15)11 (8a)11 (8p)11 (3a)010 (4d)01 (4sb)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,30,10,,R1,7.1,3.65,2.7,151.6,266.0,4.43,21.0,28.0,149.0,71.0,26.0,10.23,4.08,74.0,200.0,44.0,30.0,,,,,,,,,,,,,,,,,5.15,31.31,11.61,,无, 无, P0,H0, 已冲,,,,,,32.35873850197109,1406588
1406717,孙振明,556122,男,64,T4b,N3a,M0, ⅢC,1,2,,0.0,0.0,0.0, 腺体萎缩+,9.0,32,髓样型（med）,INFa,0.0,0.25,,,,,,,2014-03-13,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (8a)12 (7)01 (1b)01 (6)35 (1a)00 (5)23 (9)04 (8p)08 (4sb)00 (3a)04 (4d)23 (3b)11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,60,12,,R1,5.26,3.23,1.17,71.5,382.0,3.43,18.0,16.0,127.0,82.0,19.0,13.7,4.66,60.0,180.0,35.0,25.0,,,,,,,,,,,,,,,,,4.92,7.94,3.25,,无, 无, P0,H0,已冲,,,,,,81.17608409986859,1406717
1406035,姜明海,554089,男,63,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,1,,,,,,,,,,,2014-03-10,2019-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,,U（胃底部） 小弯侧Less ,20,20,, R0,,4.88,2.96,1.46,137.1,174.0,3.21,22.5,17.0,179.0,135.0,13.8,11.9,1.61,70.8,258.03,40.5,30.3,,,,,,,,,,,,,,,,,1.9,0.6,0.924, 未做,无,, P0,H0,未做,,,,,,65.76872536136662,1406035
1405843,孙胜民,552808,男,60,T3,N3a,M0,ⅢB,1,2,,1.0,1.0,, 腺体萎缩+ 肠化生+,8.0,22,中间型（int）,INFb,2.0,0.9,,,,,,,2014-03-06,2019-05-01,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)710 (4sb)00 (7)01 (8a)01 (8p)04 (9)01 (11p)04 (12a)00 (12p)00 (3b)00 (4d)00 (5)11 (6)00," LM 前Ant, 后Post, 小弯侧Less,",40,40,5, R0 D2,,6.01,3.39,1.83,153.0,226.0,2.95,23.0,24.0,171.0,76.0,11.0,17.23,7.43,64.0,240.0,37.0,27.0,,,,,,,,,,,,,,,,,1.07,5.98,3.55,,无, 无, P0,H0,未做,,,,,,61.826544021024965,1405843
1405715,张国民,556246,男,60,T3,N3b,M0, ⅢC,1,3,,1.0,1.0,1.0, 肠化生++,22.0,53,硬型（sci）,INFc,1.0,0.8,,,,,,,2014-03-06,2020-04-29,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a) (1b)03 (3a) (3b)15 (4sb)00 (4d)27 (5)11 (6)68 (7)412 (8a)33 (9)512 (11d)01 (11p)00 (12a)01," L（幽门窦部）, 前Ant, 小弯侧Less,",40,33,4, R0 D2,,7.12,3.72,2.41,154.3,310.0,3.14,28.0,24.0,135.0,68.0,25.0,9.95,3.24,72.0,368.0,43.0,29.0,5.7,9.1,85.0,327.0,,,,,,,,,,,,,1.24,6.03,4.7,,无, 无, P0,H0,已做,,,,,,73.78449408672799,1405715
1407063,董成国,552827,男,47,T3,N0,M0, ⅡA,1,2,,,,,,0.0,17,,,1.0,0.2,,,,,,,2014-03-17,2019-03-16,1,,,SOX,SOX,SOX,SOX,SOX,替吉奥单药,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 粘液腺癌（muc）15,G3, (7)00 (4sa)00 (4sb)00 (3b)01 (3a)00 (4d)00 (5)00 (6)02 (11p)04 (9)01 (8a)01 (8p)02 (2)00 (1a)01 (1b)05," SiewerⅡ,",30,30,8, R0 D2,,7.92,4.03,3.37,168.1,227.0,2.27,26.0,27.0,169.0,59.0,28.0,17.68,6.2,70.0,238.0,43.0,27.0,,,,,,,,,,,,,,,,,1.38,7.32,5.54,,无, 无, P0,H0,已做,,,,,,59.95400788436268,1407063
1406925,刘长文,551879,男,71,T3,N3b,M0, ⅢC,1,5,,1.0,1.0,1.0, 腺体萎缩+ 肠化生+,36.0,41,髓样型（med）,INFa,1.0,0.6,,,,,,,2014-03-17,2019-05-01,0,,,多西他赛,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40,G3, (1a)00 (1b)00 (3a)1010 (3b)1313 (4sa)00 (4d)45 (5)00 (6)02 (8a)23 (8p)44 (9)00 (11p)22 (12a)00 (2)01 (4sb)00 (7)11," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",60,60,5, R0 D2,,7.42,5.32,1.34,100.9,250.0,2.21,20.0,35.0,216.0,54.0,27.0,9.67,4.18,59.0,158.0,34.0,25.0,,,,,,,,,,,,,,,,,3.22,0.6,35.28,,无, 无, P0,H0,已冲,,,,,,61.465177398160314,1406925
1406944,李德智,554929,男,77,T3,N3a,M0,ⅢB,1,3,,,,1.0, 腺体萎缩++ 慢性炎症（+）,12.0,38,硬型（sci）,INFc,2.0,0.75,,,,,,,2014-03-17,2014-11-11,2,,,,,,,,,0,管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85  粘液腺癌（muc）10 低粘附腺癌5,G3, (1a)02 (1b)01 (5)00 (3b)413 (8a)05 (9)02 (11p)00 (7)68 (2)24 (3a)01 (4sa)01 (4sb)00 (4d)01," U（胃底部）, GE, SiewerⅢ,",60,45,4, D2,,5.3,3.36,1.24,88.0,210.0,3.46,13.0,23.0,119.0,74.0,39.0,10.86,4.03,86.0,208.0,45.0,41.0,,,,,,,,,,,,,,,,,33.25,10.16,2.35,,,, P0,H0,未做,,,,,,7.851511169513797,1406944
1407381,鄂立成,556226,男,36,T3,N1,M0, ⅡB,1,2,,,,1.0, 腺体萎缩+,1.0,43,髓样型（med）,INFa,1.0,0.8,,,,,,,2014-03-19,2020-10-10,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)06 (1b)112 (2)05 (3a)011 (3b)00 (4sa)04 (4sb)00 (5)01 (8a)01 (9)01 (11p)01 (12p)01,胃癌 U(胃底） 后Post,60,50,10, R0 D2,,7.8,4.51,2.54,160.0,341.0,3.35,25.0,27.0,138.0,77.0,23.0,13.14,4.77,72.0,251.0,45.0,27.0,,,,,,,,,,,,,,,,,2.65,4.91,3.4,,无, 无, P0,H0, 已冲,,,,,,78.74507227332457,1407381
1407929,邢艳梅,459759,女,40,T4b,N0,M0, ⅢA,1,2,,0.0,0.0,1.0, 腺体萎缩+,0.0,8,髓样型（med）,INFa,0.0,0.85,,,,,,,2014-03-25,2021-07-01,1,,,XELOX,XELOX,XELOX,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b) (3a) (7)02 (4d)00 (5)00 (6)00 (8a) (8p)01 (9)02 (11p)02 (12a)00 (14v)00 (4sb)00," LM 前Ant, 后Post, 小弯侧Less,",45,45,4,,R1,5.05,3.0,1.6,101.0,282.0,2.6,18.0,37.0,174.0,72.0,20.0,9.11,3.69,75.0,193.0,43.0,32.0,,,,,,,,,,,,,,,,,1.28,32.37,1.44,,无, 无, P0,H0,已做,,,,,,87.22076215505913,1407929
1407286,李文秀,556432,女,40,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,29,,,0.0,0.75,,,,,,,2014-03-19,2019-05-01,0,,,,,,,,,0, 低粘附腺癌,GX, (1a)03 (1b)00 (3a)04 (3b)02 (4d)01 (5)03 (6)05 (7)05 (8a)01 (8p)02 (9)01 (11p)02 (12a)00 (4sb)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,30,6, R0 D2,,2.79,1.27,1.12,54.9,183.0,1.52,20.0,19.0,95.0,42.0,8.0,7.06,3.1,64.0,143.0,41.0,23.0,,,,,,,,,,,,,,,,,0.689,15.11,0.971,,无, 无, P0,H0,已做,,,,,,61.399474375821285,1407286
1407361,王志国,556408,男,78,T3,N3b,M0, ⅢC,1,4,,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,33.0,43,中间型（int）,INFc,2.0,0.8,,,,,,,2014-03-19,2014-12-12,2,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)20 乳头状癌（G1）（pap）10,G3, (1a)00 (1b)26 (2)23 (3a)88 (4d)13 (4sa)11 (5)22 (6)58 (7)33 (8a)55 (8p)11 (9)00 (11p)33 (12a)00 (4sb)00," M（胃体部）, 后Post, 大弯侧Gre, 小弯侧Less,",35,20,18, R0 D2,,5.67,2.8,1.85,145.0,233.0,1.93,11.0,29.0,170.0,72.0,8.0,25.91,9.42,58.0,173.0,36.0,22.0,,,,,,,,,,,,,,,,,34.15,5.68,79.08,,无, 无, P0,H0,已冲,,,,,,8.804204993429698,1407361
1407066,张兆仁,551875,男,57,T1b,N0,M0,ⅠA,1,3,,,,, 慢性炎症（+）,0.0,26,髓样型（med）,INFc,0.0,0.45,,,,,,,2014-03-17,2018-06-14,0,,,,,,,,,0, 乳头状癌（G1）（pap）80  管状腺癌（中分化【G2】【tub2】20,G2,,L（幽门窦部） 前Ant 小弯侧Less ,25,25,6, R0 D2,,5.84,2.66,1.88,124.0,226.0,3.85,12.3,16.0,105.0,69.0,34.6,13.99,5.22,64.3,190.03,39.6,24.7,,,,,,,,,,,,,,,,,2.62,13.3,0.83,,无,, P0,H0,,,,,,,50.91984231274638,1407066
1407216,李秀安,556385,男,65,T1a,N0,M0,ⅠA,1,2,,,,,,0.0,17,,,0.0,0.8,,,,,,,2014-03-18,2019-05-03,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (3a) (3b)00 (4sb)00 (1a) (1b)02 (4d)01 (5)01 (11p)01 (12a)00 (6)05 (9)02 (7)01 (8a)04," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,20,3, R0,,4.85,2.64,1.71,142.6,159.0,2.18,10.0,22.0,130.0,42.0,16.0,20.42,7.76,63.0,146.0,37.0,26.0,4.4,7.1,76.0,314.0,,,,,,,,,,,,,3.12,14.74,1.04, 未做,无, 无, P0,H0,未做,,,,,,61.498028909329825,1407216
1407114,孙其科,556355,男,64,T4a,N1,M0, ⅢA,1,3,,1.0,1.0,1.0, 慢性炎症（+）,2.0,41,髓样型（med）,INFc,0.0,0.6,,,,,,,2014-03-18,2015-04-30,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (3a) (3b)02 (1a) (1b)05 (9)05 (12a)00 (11p)02 (8a)06 (7)05 (6)15 (5)18 (4sb)00 (4d)03," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,22,5, R0,,7.03,4.78,1.63,134.8,247.0,2.89,17.0,18.0,147.0,53.0,10.0,13.95,4.81,59.0,143.0,37.0,22.0,5.7,5.7,75.0,236.0,,,,,,,,,,,,,1.91,51.9,6.2,,无, 无, P0,H0,已冲,,,,,,13.403416557161629,1407114
1407031,孟宪彬,556351,男,62,T4b,N2,M1, Ⅳ,1,3,,1.0,1.0,1.0, 腺体萎缩+,4.0,20,中间型（int）,INFb,1.0,0.55,,,,,,,2014-03-17,2014-10-01,2,,,替吉奥单药,TX,TX,TX,TX,TX,7, 管状腺癌（中分化【G2】【tub2】70 乳头状癌（G1）（pap）30,G2, (1a)01 (2)11 (3a)25 (3b)01 (4sa)11 (4sb)00 (5)00 (7)03 (8a) (8p)04 (9)01 (11p)02 (12a)01," L（幽门窦部）, 后Post, 大弯侧Gre,",30,30,10,,R1,7.93,5.4,1.95,123.0,177.0,4.76,9.0,22.0,127.0,63.0,11.0,11.86,5.25,63.0,83.0,36.0,27.0,,,,,,,,,,,,,,,,,1.61,150.8,1.96, 未做,无,, P0,H1单（M1 HEP), 已冲,,,,,,6.504599211563732,1407031
1407293,石振生,555074,男,73,T1b,N1,M0, ⅠB,1,0,,,,,,1.0,5,,,1.0,0.25,,,,,,,2014-03-19,2022-09-01,1,,,,,,,,,0, 低粘附腺癌,GX,  (1a)00 (1b)00 (2)02 (3a)00 (3b)00 (4sb)00 (4d)13 (5)00 (6)00 (7)00 (8a)00 (9)00 (11p)00 ,L（幽门窦部） 大弯侧Gre  ,12,10,6, R0 D1+,,5.99,3.86,1.55,74.0,338.0,6.42,10.0,14.0,153.0,72.0,12.0,11.08,4.8,66.0,139.0,36.0,30.0,,,,,,,,,,,,,,,,,1.48,6.6,1.08, 未做,无, 无, P0,H0,已做,,,,,,101.4454664914586,1407293
1407378,高淑琴,557579,女,66,T3,N3a,M0,ⅢB,1,3,,,,1.0,腺体萎缩+,11.0,32,中间型（int）,INFb,1.0,0.6,,,,,,,2014-03-19,2014-10-16,2,,,替吉奥单药,替吉奥单药,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (4d)00 (3b)11 (5)55 (6)16 (7)02 (8a)11 (8p)01 (9)00 (11p)14 (4sb)01 (12a)01, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less,60,50,15, D2,,6.84,3.2,3.01,90.0,460.0,3.51,19.0,22.0,149.0,84.0,4.0,6.57,2.72,66.0,94.0,43.0,23.0,,,,,,,,,,,,,,,,,2.19,3.65,4.42, 未做,无, 无, P0,H0,未做,,,,,,6.931668856767411,1407378
1407525,丁立波,555564,女,46,T4b,N3a,M1, Ⅳ,1,3,,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,14.0,26,髓样型（med）,INFc,0.0,0.55,,,,,,,2014-03-20,2014-06-06,2,,,,,,,,,0, 低粘附腺癌85 管状腺癌（中分化【G2】【tub2】15,G2, (1a)02 (1b)23 (2)01 (3a)33 (3b)44 (5)01 (6)03 (7)11 (8a)22 (9)00 (11p)11 (12a)01 (12p)04 (16a1)00 (4sa)00 (4sb)01," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",40,35,8,,R2,8.51,5.89,2.08,134.0,333.0,3.53,11.0,18.0,175.0,108.0,15.0,11.32,3.59,77.0,206.0,48.0,29.0,,,,,,,,,,,,,,,,,25.73,50.06,13.42, 未做,无, 无, P0,H0, 已冲,,,,,,2.562417871222076,1407525
1407908,朱香芝,556527,女,58,T3,N1,M0, ⅡB,1,2,,,,, 腺体萎缩+ 慢性炎症（+）,1.0,78,硬型（sci）,INFb,0.0,0.8,,,,,,,2014-03-25,2020-12-17,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)06 (1b)01 (3a)017 (3b)00 (4d)012 (5)00 (6)110 (7)016 (8a) (8p)06 (9)01 (11p)09 (4sb)00," L（幽门窦部）, 后Post,",15,15,, R0 D2,,8.86,5.54,2.58,136.0,225.0,5.44,18.0,19.0,160.0,87.0,35.0,9.95,3.14,68.0,246.0,45.0,23.0,5.8,6.3,88.0,353.0,,,,,,,,,,,,,1.16,10.48,3.76,,无, 无, P0,H0, 未做,,,,,,80.78186596583443,1407908
1407093,王钧,557686,男,51,T3,N3a,M0,ⅢB,1,3,,1.0,1.0,, 腺体萎缩+,9.0,56,中间型（int）,INFb,2.0,0.75,,,,,,,2014-03-18,2014-04-22,0,,,SOX,,,,,,0, 低分化腺癌（G3)(por)85  低粘附腺癌15,G3,,L（幽门窦部） 前Ant 小弯侧Less ,40,30,10, R0 D2,,8.17,5.01,2.23,136.2,410.0,4.83,21.0,25.0,150.0,99.0,193.0,5.02,1.75,68.0,297.0,40.0,28.0,,,,,,,,,,,,,,,,,3.45,58.67,10.15, 未做,无,, P0,H0,未做,,,,,,1.149802890932983,1407093
1407455,祝凯,555552,男,61,T3,N3b,M0, ⅢC,1,3,,1.0,1.0,, 腺体萎缩+ 慢性炎症（+）,25.0,58,中间型（int）,INFb,1.0,0.9,,,,,,,2014-03-20,2015-06-25,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)16 (1b)04 (2)02 (3a)99 (3b)512 (4sa)00 (4sb)01 (4d)36 (5)11 (6)46 (7)02 (8a)03 (8p)22 (9)03 (11p) (11d)00 (12a)00 (14v)01 (15)00," L（幽门窦部）, M（胃体部）, 小弯侧Less,",40,45,8, R0,,8.59,5.99,1.96,169.0,270.0,4.43,25.0,22.0,194.0,154.0,47.0,9.19,2.6,73.0,252.0,44.0,29.0,4.7,7.8,100.0,450.0,,,,,,,,,,,,,76.61,0.6,1.82,,无, 无, P0,H0, 已冲,,,,,,15.177398160315374,1407455
1407720,崔长国,555649,男,38,T2,N0,M0, ⅠB,1,1,,,,, 腺体萎缩+,0.0,29,中间型（int）,INFb,1.0,0.85,,,,,,,2014-03-24,2019-05-01,0,,,,,,,,,0, 乳头状癌（G1）（pap）75 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)25,G3, (1a)00 (1b)02 (3b)00 (4d)01 (5)00 (6)05 (8a)04 (8p)07 (9)01 (7)02 (11p)02 (12a)00 (3a)02 (4sb)03," M（胃体部）, 后Post,",35,30,10, R0 D2,,6.22,3.51,2.24,116.2,240.0,2.9,17.8,16.0,130.0,85.0,19.1,7.38,2.33,61.4,263.48,37.8,23.6,,,,,,,,,,,,,,,,,3.11,6.56,1.63, 未做,无, 无, P0,H0, 已冲,,,,,,61.235216819973715,1407720
1407538,王名,555699,女,30,T3,N3b,M0, ⅢC,1,2,,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,24.0,46,硬型（sci）,INFc,0.0,0.55,,,,,,,2014-03-20,2015-07-02,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌85 低分化腺癌（G3)(por)15,G3, (1a)22 (1b)11 (3a)02 (3b)11 (4sb)00 (4d)13 (5)02 (6)417 (7)78 (8a)22 (8p)12 (9)44 (11p)01 (12a)11," L（幽门窦部）, 前Ant, 大弯侧Gre,",35,35,5, R0 D2,,7.0,4.62,1.76,131.7,232.0,2.68,11.0,15.0,179.0,56.0,6.0,7.71,3.26,79.0,147.0,47.0,32.0,,,,,,,,,,,,,,,,,2.04,0.89,18.85,,无, 无, P0,H0,未做,,,,,,15.407358738501971,1407538
1408000,徐淑芝,442618,女,64,T3,N3a,M0,ⅢB,1,5,,1.0,1.0,1.0, 腺体萎缩+,10.0,38,髓样型（med）,INFa,0.0,0.7,,,,,,,2014-03-25,2020-04-29,1,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (5)01 (6)37 (7)02 (8a) (8p)02 (9)02 (11p)01 (12a)0(12b)00 (14v)00 (1a)04 (1b)00 (2)00 (3a)04 (3b)23 (4sa)04 (4sb)00 (4d)58," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",100,90,15, R0 D2,,5.6,3.2,1.66,107.3,162.0,2.78,13.8,16.0,130.0,66.0,14.7,10.98,2.19,66.3,162.93,39.6,26.7,6.2,6.29,83.0,344.0,,,,,,,,,,,,,3.81,807.2,2.38,,无, 无, P0,H0,已冲,,,,,,73.16031537450722,1408000
1408250,初彦卫,553164,男,47,T3,N1,M0, ⅡB,1,3,,,,, 肠化生+,2.0,33,髓样型（med）,INFb,0.0,0.35,,,,,,,2014-03-27,2020-04-29,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 粘液腺癌（muc）90% 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】10%,G2,小湾12 (6)01 (7)01 (8a)06 (8p)05 (9)01 (11p)01 (12a)12 (14v)00 (1a)02 (1b)04," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,60,6, R0 D2,,5.54,2.89,2.04,151.0,162.0,3.4,45.0,38.0,111.0,96.0,37.0,15.01,5.55,68.0,245.0,43.0,25.0,6.3,5.8,81.0,311.0,,,,,,,,,,,,,2.6,39.36,, 未做,无, 无, P0,H0,未做,,,,,,73.0946123521682,1408250
1407510,季根柱,557333,男,55,T3,N0,M0, ⅡA,1,3,,1.0,1.0,1.0, 慢性炎症（+）,0.0,59,髓样型（med）,INFb,0.0,0.6,,,,,,,2014-03-20,2017-06-02,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)04 (1b)07 (2)09 (3a)011 (3b)04 (4sa)02 (4sb)00 (4d)07 (5)01 (6)04 (7)03 (8a) (8p)03 (9)01 (11p)01 (12a)02 (14v)00," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",80,50,4, R0 D2+,,8.51,5.48,2.29,109.9,382.0,3.85,8.0,12.0,101.0,70.0,6.0,4.88,1.75,63.0,151.0,37.0,26.0,5.7,4.4,89.0,206.0,,,,,,,,,,,,,0.344,5.06,4.61, 未做,无, 无, P0,H0,已冲,,,,,,38.43626806833114,1407510
1408567,姜国军,557495,男,46,T2,N1,M0, ⅡA,1,2,,0.0,0.0,0.0, 正常,1.0,31,中间型（int）,INFb,0.0,0.85,,,,,,,2014-03-31,2017-05-10,0,,,,,,,,,0, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30,G3, (1a)00 (1b)04 (3a)08 (3b)00 (4sb)00 (4d)03 (5)00 (6)16 (7)00 (8a)07 (9)03 (12a)00," LM 前Ant, 大弯侧Gre,",50,40,15, R0 D2,,11.31,6.42,3.84,159.7,289.0,4.9,10.0,17.0,128.0,79.0,29.0,10.12,3.46,66.0,258.0,43.0,23.0,,,,,,,,,,,,,,,,,0.824,4.81,15.97,,无, 无, P0,H0, 已冲,,,,,,37.319316688567675,1408567
1408008,苗春海,555053,男,57,T3,N1,M0, ⅡB,1,3,,1.0,1.0,, 腺体萎缩+ 慢性炎症（+）,2.0,23,中间型（int）,INFb,3.0,0.7,,,,,,,2014-03-25,2019-04-22,0,,,FOLFOX,FOLFOX,,,,,2, 管状腺癌（中分化【G2】【tub2】60 乳头状癌（G1）（pap）35 粘液腺癌（muc）5,G2, (12p)02 (7)01 (6)16 (1a)01 (1b)01 (4sb)01 (4d)03 (11p)03 (8a) (8p)12 (12a)02 (5)01, L（幽门窦部） 前Ant 小弯侧Less 后Post ,40,40,12, D2,,6.77,3.84,2.17,116.0,627.0,4.22,23.0,24.0,141.0,69.0,19.0,11.65,5.64,72.0,236.0,42.0,30.0,,,,,,,,,,,,,,,,,123.4,7.08,82.81, 未做,无,, P0,H0,未做,,,,,,60.906701708278575,1408008
1408658,刘连发,556594,男,55,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,27,,,2.0,0.55,,,,,,,2014-03-31,2019-05-01,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)00 (2)00 (3a)02 (3b)09 (4sa)00 (4sb)03 (4d)03 (5)00 (6)00 (7)00 (8a)04 (8p)00 (9)00 (11p)05," U（胃底部）, 小弯侧Less,",15,10,2, R0 D2,,4.07,2.19,1.5,143.0,162.0,2.38,10.0,20.0,154.0,59.0,15.0,14.17,4.84,66.0,274.0,41.0,25.0,,,,,,,,,,,,,,,,,1.82,7.35,7.34,,无, 无, P0,H0,已冲,,,,,,61.00525624178712,1408658
1409164,张井生,557623,男,69,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,9,,,0.0,0.7,,,,,1.0,,2014-04-03,2019-09-02,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (8a)03 (4sa)00 (7)00 (5)00 (8p)02 (3b)00 (3a)02 (1a)00 (1b)00 (2)02 (4sb)00," U（胃底部）, 后Post, 小弯侧Less,",40,40,, R0 D2,,7.19,4.72,1.81,160.0,152.0,3.35,15.5,16.0,168.0,66.0,20.9,17.78,6.52,69.8,185.0,43.8,26.0,,,,,,,,,,,,,,,,,1.38,7.63,4.49,,无, 无, P0,H0,已冲,CD34+:D2-40+,,,,,64.98028909329828,1409164
1408164,王久家,556683,男,75,T4b,N3b,M0, ⅢC,1,4,,1.0,1.0,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,32.0,32,中间型（int）,INFb,1.0,0.7,,,,,,,2014-03-26,2014-10-30,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (2)77 (4d)13 13 (5)33 (6)77 (7)22,LMU,120,100,20,,R2,4.48,2.27,1.63,139.0,86.0,4.22,12.0,23.0,161.0,68.0,10.0,15.71,6.55,66.0,166.0,40.0,26.0,,,,,,,,,,,,,,,,,5.0,1000.0,24.67, 未做,无, 无, P0,H0,未做,,,,,,7.1616294349540075,1408164
1408245,王文信,557659,男,60,T2,N0,M0, ⅠB,1,3,,,,, 腺体萎缩+ 慢性炎症（+）,0.0,36,中间型（int）,INFb,2.0,0.25,,,,,,,2014-03-27,2019-05-01,1,,,替吉奥单药,替吉奥单药,,,,,2, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)08 (1b)05 (2)06 (8a)02 (8p)01 (11p)04 (12a)00 (3a)01 (3b)00 (4sa)00 (4sb)02 (4d)02 (5)00 (6)03 (7)02," U（胃底部）, 小弯侧Less,",15,15,5, R0 D2,,4.75,4.51,0.03,83.2,171.0,1.86,11.0,16.0,142.0,78.0,10.0,8.68,4.0,59.0,251.0,37.0,22.0,,,,,,,,,,,,,,,,,2.52,20.95,0.921,,无,, P0,H0,未做,,,,,,61.136662286465175,1408245
1407436,韩淑云,555209,女,64,T3,N0,M0, ⅡA,1,2,,1.0,1.0,, 腺体萎缩+ 慢性炎症（+）,0.0,20,中间型（int）,INFb,1.0,0.6,,,,,1.0,,2014-03-20,2017-07-29,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)05 (1b)00 (3a)00 (3b)01 (5)00 (6)03 (7)02 (8a)02 (8p)03 (9)02 (11p)02 (12a)00 (4d)00 (4sb)00," L（幽门窦部）, 后Post, 大弯侧Gre,",30,30,6, R0 D2,,5.4,2.71,2.05,122.7,242.0,1.55,20.0,24.0,152.0,75.0,25.0,6.68,2.54,69.0,242.0,40.0,29.0,14.2,7.8,80.0,281.0,,,,,,,,,,,,,3.0,51.24,16.09,,无, 无, P0,H0, 已冲,,,,,,40.30880420499343,1407436
1408160,马常玲,556618,女,65,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,24,,,1.0,0.15,,,,,,,2014-03-26,2020-10-10,1,,,,,,,,,0, 低粘附腺癌 印戒细胞癌(sig),GX, (1a)06 (1b)01 (3a)02 (3b)00 (4sb)06 (4d)04 (5)00 (6)02 (7)00 (8a)02 (8p)00 (9)01 (12a)00 (12p)00," LM 小弯侧Less,",40,20,5, R0 D2,,5.37,2.33,2.71,137.0,206.0,2.73,19.0,24.0,197.0,65.0,12.0,13.91,4.44,85.0,208.0,45.0,40.0,5.8,5.9,82.0,398.0,,,,,,,,,,,,,1.22,0.6,6.62,,无, 无, P0,H0, 已冲,,,,,,78.51511169513797,1408160
1408195,鞠远洪,557619,男,66,T3,N3b,M0, ⅢC,1,3,,1.0,1.0,, 腺体萎缩+ 慢性炎症（+）,29.0,39,髓样型（med）,INFb,1.0,0.85,,,,,,,2014-03-26,2016-08-02,0,,,XELOX,,,,,,1, 低粘附腺癌40 粘液腺癌（muc）30 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)25 乳头状癌（G1）（pap）5,G3,小弯1010 (1a)00 (1b)00 (3a)13 (3b)11 (4d)00 (4sb)26 (5)01 (7)02 (8a)22 (8p)44 (9)23 (11p)00 (12a)00 (12p)0 (6)77," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,50,4, R0 D2,,6.8,4.06,2.1,148.0,219.0,2.24,23.0,17.0,184.0,69.0,18.0,11.69,3.97,71.0,258.0,45.0,26.0,,,,,,,,,,,,,,,,,1.03,78.9,15.41,,无,, P0,H0,未做,,,,,,28.252299605781864,1408195
1408072,邓玉权,555691,男,57,T3,N1,M0, ⅡB,1,3,,1.0,1.0,1.0,  慢性炎症（+）,2.0,44,硬型（sci）,INFc,0.0,0.6,,,,,,,2014-03-26,2015-09-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90 粘液腺癌（muc）10,G2, (1a)04 (1b)01 (3a)00 (3b)04 (5)00 (6)01 (7)011 (8a)01 (8p)05 (9)03 (11p)03 (12a)00 (16a1)03 (4d)28 (4sb)00," L（幽门窦部）, 前Ant, 小弯侧Less, 后Post,",25,50,15, D2,,5.68,4.69,0.73,139.1,164.0,2.27,9.0,15.0,175.0,44.0,10.0,10.66,4.24,55.0,177.0,34.0,21.0,,,,,,,,,,,,,,,,,2.5,23.52,3.1, 未做,无,, P0,H0,未做,,,,,,17.67411300919842,1408072
1408026,井绪伟,557335,男,34,T3,N1,M0, ⅡB,1,2,,,,, 腺体萎缩+ 慢性炎症（+）,2.0,49,中间型（int）,INFb,0.0,0.75,,,,,,,2014-03-25,2019-04-22,1,,,XELOX,奥+卡+氟,奥+卡+氟,XELOX,XELOX,XELOX,7, 管状腺癌（中分化【G2】【tub2】,G2, (4sb)00 (5)02 (12a)00 (8a)12 (9)05 (7)03 (6)05 (3b)00 (1b)010 (1a)012 (4d)00 (3a)19 (8p)01,L（幽门窦部） 前Ant 小弯侧Less 后Post ,50,30,9, D2,,8.22,4.75,2.67,155.0,245.0,3.28,15.6,16.0,160.0,54.0,14.7,10.73,2.43,71.0,352.0,44.5,26.5,,,,,,,,,,,,,,,,,1.18,0.6,3.38, 未做,无,, P0,H0,未做,,,,,,60.906701708278575,1408026
1408816,王宝付,555720,男,60,T4b,N3b,M0, ⅢC,1,4,,1.0,1.0,1.0, 腺体萎缩+,38.0,54,硬型（sci）,INFc,0.0,0.8,,,,,,,2014-04-01,2019-05-01,0,,,替吉奥单药,紫衫+替吉奥,紫衫+替吉奥,紫衫+替吉奥,紫衫+替吉奥,紫衫+替吉奥,9, 低粘附腺癌60 粘液腺癌（muc）25 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)15,G3,(3a)89 (9)22 (2)01 (6)33 (3b)55  (12b)12 (8a)00 (8p)15 (14v)00 (11d)00 (12p)55 (12a)57 (1a)04 (1b)01 (4sa)01," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,7,,R1,6.91,4.28,1.84,146.1,205.0,3.61,9.0,21.0,149.0,50.0,1.0,8.61,4.05,66.0,164.0,38.0,28.0,,,,,,,,,,,,,,,,,21.74,16.03,7.47,,无, 无, P0,H0,已冲,,,,,,60.972404730617605,1408816
1408340,刘淑珍,557737,女,66,T4a,N0,M0, ⅡB,1,2,,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,0.0,40,髓样型（med）,INFa,1.0,0.8,,,,,,,2014-03-27,2020-04-28,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (5)02 (6)00 (7)01 (8a) (8p)06 (9)06 (11p)01 (12a) (12b)03 (1a)00 (3a)04 (3b)03 (4sb)00 (4d)08 (14v)04," L（幽门窦部）, 小弯侧Less, 后Post,",40,50,9, R0 D2,,5.62,3.12,1.79,116.0,254.0,3.07,13.0,20.0,139.0,69.0,5.0,8.43,2.63,63.0,248.0,37.0,26.0,4.6,7.9,70.0,267.0,,,,,,,,,,,,,1.5,9.64,3.37, 未做,无, 无, P0,H0, 已冲,,,,,,73.06176084099869,1408340
1408729,张凤英,557932,女,60,T1a,N2,M0, ⅡA,1,0,,,,,,3.0,23,,,0.0,0.6,,,,,,,2014-04-01,2020-04-29,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 低粘附腺癌30%,G3, (1a)00 (1b)00 (3a)01 (3b)00 (4d)01 (4sb)00 (14v)03 (5)00 (6)37 (7)05 (8a) (8p)02 (9)04 (11p)00 (12a) (12b)00," L（幽门窦部）,  后Post,",20,15,5, R0 D2+,,7.69,59.74,33.81,148.9,197.0,2.41,15.0,20.0,227.0,88.0,18.0,10.79,3.19,68.0,236.0,45.0,23.0,6.2,5.8,61.0,196.0,,,,,,,,,,,,,1.68,15.84,15.6, 未做,无, 无, P0,H0,已做, CK（+）,,,,,72.93035479632063,1408729
1408659,杨秀英,557048,女,57,T1b,N2,M0, ⅡA,1,0,,,,, 腺体萎缩++,4.0,19,中间型（int）,INFb,0.0,0.8,,,,,,,2014-03-31,2019-04-15,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6,管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)03 (3b)00 (3a)00 (4sb)00 (4d)00 (5)11 (6)36 (7)00 (8a)00 (8p)01 (9)00 (11p)03 (12a)00 (12p)02,L（幽门窦部） 前Ant 小弯侧Less,40,25,5, D2,,5.12,2.76,1.81,120.2,318.0,2.85,18.0,21.0,172.0,113.0,13.0,8.16,2.57,77.0,252.0,44.0,33.0,,,,,,,,,,,,,,,,,6.97,36.76,1.44, 未做,无, 无, P0,H0,未做,,,,,,60.4796320630749,1408659
1408832,岳成才,557487,男,62,T4b,N2,M0, ⅢB,1,5,,,,1.0, 腺体萎缩+ 肠化生+,3.0,27,髓样型（med）,INFb,2.0,0.6,,,,,,,2014-04-01,2015-02-02,2,,,SOX,SOX,SOX,SOX,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)03 (3a)02 (3b)24 (4d)02 (4sb)00 (5)00 (6)01 (7)15 (8a)02 (8p)03 (9)00 (11p)01 (12a)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,35,10,,R2,6.57,4.41,1.21,55.2,447.0,3.43,13.0,16.0,164.0,59.0,7.0,18.08,7.71,58.0,152.0,32.0,26.0,,,,,,,,,,,,,,,,,0.76,7.06,5.31,,无,, P0,H0,未做,,,,,,10.085413929040735,1408832
1408569,王敏杰,558014,男,61,T4b,N2,M0, ⅢB,1,3,,,,1.0, 肠化生+ 慢性炎症（+）,4.0,27,中间型（int）,INFb,2.0,0.65,,,,,,,2014-03-31,2020-09-08,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】60 乳头状癌（G1）（pap）40,G2, (1a)02 (1b)00 (3a)17 (4sb)02 (4d)13 (6)11 (7)02 (8a)11 (8p)03 (5)00 (9)02 (11p)00 (12a)02 (12p)01 (14v)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,20, R0 D2,,7.74,4.41,2.63,130.2,247.0,2.95,19.0,22.0,145.0,104.0,19.0,13.42,8.74,66.0,231.0,40.0,26.0,,,,,,,,,,,,,,,,,4.63,6.67,19.31,,无,, P0,H0,未做,,,,,,77.29960578186596,1408569
1408696,王红艳,558006,女,40,T3,N3a,M0,ⅢB,1,4,,,,,,8.0,36,,,0.0,0.7,,,,,,,2014-03-31,2020-09-08,1,,,DX,DX,DX,DX,DX,DX,8, 低粘附腺癌 95 低分化腺癌（G3)(por)5,G3, (1a)28 (1b)02 (2)00 (3a)25 (3b)02 (4sa)00 (4sb) 01(4d) 3 14(5)00 (6) 00(7)01 (8a)00 (8p)00 (9) 00(11p)00 (12a) 13(14v)00 (12p)00,ML 小弯侧Less 前Ant 后Post,60,50,12, R0 D2,,6.1,3.63,1.81,116.8,388.0,2.12,13.0,18.0,124.0,47.0,13.0,9.24,5.26,75.0,310.0,47.0,28.0,,,,,,,,,,,,,,,,,0.2,0.793,5.16, 未做,无, 无, P0,H0,未做,,,,,,77.29960578186596,1408696
1409150,邓忠惠,558001,女,73,T2,N1,M1, Ⅳ,1,4,,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,2.0,29,硬型（sci）,INFc,0.0,0.6,,,,,1.0,,2014-04-03,2019-04-22,1,,,替吉奥单药,替吉奥单药,,,,,2, 低粘附腺癌,GX, (1a)00 (1b)06 (3a)04 (3b)04 (4sb)00 (4d)11 (5)01 (6)04 (7)11 (8a) (8p)03 (9)01 (11p)02 (12a)00 (16a1)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",15,10,10,,R1,3.67,2.48,0.78,94.4,305.0,2.49,11.0,21.0,150.0,59.0,10.0,4.54,2.67,55.0,176.0,33.0,22.0,,,,,,,,,,,,,,,,,0.92,5.52,1.06, 未做,无, 单侧, P0,H0,未做,,,,,,60.611038107752954,1409150
1415397,陈明,557505,男,54,T3,N0,M0, ⅡA,1,3,,,,,,0.0,31,,,2.0,,,,,,,,2014-06-05,2022-09-01,1,SOX*3,1.0,SOX,SOX,SOX,SOX,SOX,,8, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,(4sb)00 (4d)08 (8a)04 (8p)03 (9)01 (11p)01 (12a)00 (12p)06 (1a)00 (1b)00 (3a)02 (3b)00 (5)00 (6)03 (7)03," LM 小弯侧Less,",40,35,5, R0 D2,,4.73,2.12,2.05,98.0,120.0,3.86,18.0,31.0,148.0,126.0,72.0,10.74,4.75,63.0,234.0,35.0,28.0,,,,,,,,,,,,,,,,,6.82,49.33,5.04,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(-),,,,,98.88304862023652,1415397
1409089,郑永春,550601,男,73,T4b,N1,M0, ⅢB,1,3,,0.0,0.0,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,1.0,16,硬型（sci）,INFc,2.0,0.75,,,,,,,2014-04-03,2015-06-18,2,XELOX*2,1.0,,,,,,,2, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40,G3, (3b)01 (6)11 (1a)03 (1b)01 (5)00 (7)00 (8a)02 (8p)03 (9)00 (11p)00 (12a)00 (14v)00 (3a)01 (4sb)01 (4d)03," M（胃体部）, 前Ant, 大弯侧Gre,",35,25,10,,R1,3.59,1.91,1.09,104.0,102.0,2.34,26.0,28.0,130.0,67.0,10.0,13.87,5.55,63.0,180.0,37.0,26.0,,,,,,,,,,,,,,,,,9.72,11.86,2.88,,无, 无, P0,H0, 已冲,,,,,,14.487516425755585,1409089
1409787,金在林,557076,男,61,T3,N3a,M0,ⅢB,1,3,,0.0,0.0,0.0, 腺体萎缩+ 慢性炎症（+）,9.0,29,硬型（sci）,INFb,1.0,0.85,,,,,1.0,,2014-04-10,2019-05-30,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)01 (3a)27  (7)25 (8a)11 (8p)01 (9)00 (11p)03 (12a)00 (12p)00 (14v)03 (3b)00 (5)00 (6)22 (4sb)00 (4d)25," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,15,10, R0 D2+,,4.45,2.5,1.43,119.0,278.0,2.76,22.0,18.0,142.0,98.0,23.0,10.3,3.48,62.0,246.0,38.0,24.0,,,,,,,,,,,,,,,,,1.01,4.46,3.6,,无, 无, P0,H0,已冲,"cd34+,d2-40+",,,,,61.629434954007884,1409787
1409480,王少春,558874,男,60,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,17,,,0.0,0.15,,,,,,,2014-04-08,2016-01-01,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (5)00 (6)01 (3b)00 (7)04 (1a)00 (12a)01 (9)00 (11p)00 (4sb)00 (4sa)03 (8a)01 (2)01 (4d)02 (1b)01 (3a)01肿物旁02," L（幽门窦部）, 后Post,； G=E,后Post",25,20,10, R0 D2,,8.13,5.87,1.68,144.0,173.0,2.63,25.0,26.0,223.0,92.0,16.0,15.55,5.02,72.0,297.0,44.0,28.0,,,,,,,,,,,,,,,,,1.17,11.01,3.9,,无, 无, P0,H0, 已冲,,,,,,20.795006570302235,1409480
1409135,陈子贵,558534,男,64,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,26,,,2.0,0.7,,,,,1.0,,2014-04-03,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)01 (2)05 (3a)09 (7)01 (8a)01 (8p)03 (9)04 (5)00 (6)02 (3b)00 (4d)00 (4sb)00," L（幽门窦部）, 小弯侧Less,",30,15,5, R0 D2,,5.64,2.7,2.34,157.0,198.0,2.3,38.0,20.0,196.0,71.0,38.0,6.3,2.12,70.0,304.0,40.0,30.0,,,,,,,,,,,,,,,,,1.1,8.51,1.99,,无, 无, P0,H0,已做,CD34+;D2-40+,,,,,100.9526938239159,1409135
1408698,姜学山,557083,男,50,T1b,N1,M0, ⅠB,1,2,,,,, 腺体萎缩+ 慢性炎症（+）,1.0,23,中间型（int）,INFc,1.0,0.55,,,,,,,2014-03-31,2019-04-23,1,,,SOX,SOX,SOX,,,,3, 管状腺癌（高分化【G1】【tub1】中分化【G2】【tub2】）,G2, (1a)02 (1b)00 (3a)04 (4sb)00 (3b)00 (4d)01 (5)00 (6)19 (7)01 (8a) (8p)02 (9)01 (11p)01 (12a)00," L（幽门窦部）, 大弯侧Gre, 后Post,",60,35,10, D2,,7.19,4.98,1.65,162.0,190.0,3.14,9.0,16.0,188.0,78.0,18.0,8.86,1.97,66.0,416.0,44.0,22.0,,,,,,,,,,,,,,,,,1.9,11.89,28.04, 未做,无,, P0,H0,未做,,,,,,60.74244415243101,1408698
1408805,李志伟,558533,男,50,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,41,,,0.0,0.5,,,,,,,2014-04-01,2018-05-07,0,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20,G3, (1a)00 (1b)05 (3a)05 (3b)00 (4sb)01 (4d)03 (5)01 (7)05 (8a)05 (8p)02 (9)03 (11p)05 (12a)00 (6)06," L（幽门窦部）, 小弯侧Less,",18,15,3, R0 D2,,6.03,2.87,2.47,144.0,188.0,2.21,13.0,18.0,117.0,65.0,13.0,16.75,5.36,70.0,288.0,44.0,26.0,,,,,,,,,,,,,,,,,1.33,6.29,1.4,,无,, P0,H0,未做,,,,,,49.17871222076215,1408805
1409008,刘凤民,558606,男,55,T3,N2,M0, ⅢA,1,3,,,,,,3.0,55,,,1.0,0.6,,,,,,,2014-04-02,2016-08-02,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1b)04 (2)03 (3b)218 (3a)02 (4sa)00 (4sb)01 (4d)111 (5)01 (6)01 (9)01 (7)03 (8a)02 (12a)00 (11p)05 (1a)00 (8p)03," L（幽门窦部）, M（胃体部）, LM 前Ant, 后Post, 小弯侧Less,",40,30,10, R0 D2,,7.7,4.24,2.77,157.0,277.0,2.76,15.0,16.0,144.0,90.0,8.0,8.89,2.86,65.0,319.0,41.0,24.0,,,,,,,,,,,,,,,,,2.39,13.12,2.15, 未做,无,, P0,H0,未做,,,,,,28.02233902759527,1409008
1409461,宋凤琴,557790,女,67,T1b,N1,M0, ⅠB,1,0,,,,,,2.0,27,,,1.0,0.75,,,,,,,2014-04-08,2020-10-10,0,,,,,,,,,0, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40,G3, (11p)00 (9)00 (3a)211 (12a)00 (1a)01 (6)03 (8a)02 (3b)01 (5)00 (4d)03 (1b)05 (7)01 (4sb)00," L（幽门窦部）, 前Ant, 后Post,",25,15,5, R0 D2,,5.2,3.23,1.48,130.0,189.0,2.85,10.0,15.0,138.0,95.0,8.0,10.22,3.27,64.0,246.0,39.0,25.0,,,,,,,,,,,,,,,,,1.18,8.71,3.17,,无, 无, P0,H0,已做,,,,,,78.08804204993429,1409461
1408972,焦鹏,558612,男,32,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,25,,,2.0,0.8,,,,,,,2014-04-02,2020-12-17,1,,,,,,,,,0, 低粘附腺癌 印戒细胞癌(sig),GX, (1b)01 (3a)04 (3b)01 (5)02 (4sb)01 (4d)04 (6)04 (7)01 (8a)02 (8p)01 (9)02 (11p)01 (14v)01," L（幽门窦部）, 小弯侧Less,",30,40,8, R0 D2+,,7.42,4.56,2.3,159.0,223.0,2.3,29.0,20.0,137.0,72.0,17.0,12.66,4.59,72.0,371.0,47.0,25.0,4.5,,,,,,,,,,,,,,,,1.84,18.63,0.965,,无, 无, P0,H0, 未做,,,,,,80.51905387647831,1408972
1408877,王立功,558684,男,49,T3,N0,M0, ⅡA,1,1,,,,1.0, 腺体萎缩+,0.0,23,髓样型（med）,INFb,2.0,0.3,,,,,,,2014-04-02,2017-09-06,0,,,SOX,,,,,,1, 乳头状癌（G1）（pap）65 管状腺癌（中分化【G2】【tub2】35,G2, (8a) (8p)02 (9)03 (12a)00 (1a) (1b)04 (2)01 (3a) (7)00 (3b)00 (4sa)00 (5)00 (6) (14v)05 (4sb)00 (4d)06,U（胃底部） 小弯侧Less 后Post 大弯侧Gre  ,70,60,25, D2,,4.15,2.5,1.27,107.0,240.0,1.7,17.0,18.0,125.0,58.0,18.0,17.65,5.96,67.0,325.0,42.0,25.0,,,,,,,,,,,,,,,,,1.11,0.6,2.89, 未做,无,, P0,H0,未做,,,,,,41.16294349540079,1408877
1419677,商玉林,558660,男,66,T3,N0,M0, ⅡA,1,3,1.0,,,, 慢性炎症（+） 肠化生+,0.0,26,中间型（int）,INFc,0.0,,,,,,,1.0,2014-07-14,2018-12-03,2,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】50 粘液腺癌（muc）50 Lauren混合型,G2, (1a)00 (1b)01 (3a)02 (3b)03 (4sb)01 (4d)08 (5)00 (6)05 (7)00 (8a)00 (8p)00 (9)03 (11p)01 (12a)01 (12p)01," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,12,,R1,4.73,2.61,1.45,107.0,119.0,3.11,19.0,26.0,159.0,107.0,12.0,7.64,3.13,63.0,156.0,37.0,26.0,,,,,,,,,,,,,,,,,4.87,12.3,9.12,,无, 无, P0,H0, 未做, CK + VEGF- Vimentin- CMET 弱+,,,,,52.660972404730614,1419677
1409636,孙殿学,558566,男,56,T2,N0,M0, ⅠB,1,2,,,,,,0.0,12,,,1.0,0.6,,,,,,,2014-04-09,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (4sb)00 (4d)01 (9)00 (5)02 (1b)01 (8a)02 (3b)00 (7)00 (6)01 (11p)01 (1a)00 (3a)04," L（幽门窦部）, 小弯侧Less,",10,8,3, R0 D2,,5.15,2.44,2.21,167.7,244.0,2.41,22.0,25.0,136.0,73.0,96.0,19.42,9.19,72.0,287.0,45.0,27.0,,,,,,,,,,,,,,,,,2.33,7.23,4.24,,无, 无, P0,H0,已冲,,,,,,100.75558475689881,1409636
1409474,倪桂兰,557762,女,47,T3,N3a,M0,ⅢB,1,2,,1.0,1.0,1.0, 腺体萎缩+,13.0,48,髓样型（med）,INFb,0.0,0.4,,,,,,,2014-04-08,2020-09-08,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)11 (3a)12 (3b)35 (4sa)01 (4d)05 (4sb)01 (5)22 (6)07 (7)02 (8a)06 (8p)09 (9)66,"L（幽门窦部） M（胃体部）, U（胃底部）, MU 前Ant, 后Post, 小弯侧Less,",50,40,10, R0 D2,,4.4,2.76,1.4,107.0,338.0,2.45,24.0,26.0,182.0,61.0,10.0,7.39,3.42,69.0,164.0,44.0,25.0,,,,,,,,,,,,,,,,,0.406,4.14,1.18,,无, 无, P0,H0,未做,,,,,,77.03679369250985,1409474
1409132,薛善东,557767,男,45,T4b,N2,M0, ⅢB,1,3,,,,1.0, 腺体萎缩+ 慢性炎症（+）,6.0,25,髓样型（med）,INFb,0.0,0.3,,,,,,,2014-04-03,2018-04-18,2,,,XELOX,XELOX,SOX,SOX,SOX,SOX,8, 粘液腺癌（muc）,GX, (3a、6)22 (3b)02 (4sb)00 (4d)01 (5)17 (6)58 (7)03 (8)04," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,12,,R2,6.67,4.31,1.81,140.0,230.0,3.51,16.0,21.0,117.0,60.0,5.0,10.5,4.83,70.0,148.0,44.0,26.0,,,,,,,,,,,,,,,,,0.852,126.7,1.67,,无,, P0,H0,未做,,,,,,48.48883048620236,1409132
1408984,马根春,558972,男,56,T3,N3a,M0,ⅢB,1,2,,,,, 腺体萎缩+ 慢性炎症（+）,10.0,56,硬型（sci）,INFc,1.0,0.15,,,,,,,2014-04-02,2018-11-14,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)04 (3a)824 (3b)13 (4sb)01 (4d)06 (5)12 (6)07 (7)01 (8a、8p)02 (9)05 (12a、12b)00, 胃癌 L（幽门窦部） 前Ant 后Post,30,40,8, R0 D2,,4.53,2.48,1.66,143.2,171.0,3.07,11.0,15.0,145.0,73.0,11.0,12.1,3.63,69.0,257.0,42.0,27.0,,,,,,,,,,,,,,,,,1.7,10.56,3.83,,无,, P0,H0,未做,,,,,,55.42049934296978,1408984
1409472,唐桂芝,557803,女,59,T3,N1,M0, ⅡB,1,3,,1.0,1.0,, 腺体萎缩++ 慢性炎症（+）,1.0,24,硬型（sci）,INFc,0.0,0.65,,,,,,,2014-04-08,2019-04-22,1,,,,,,,,,0, 低粘附腺癌75 管状腺癌（高分化【G1】【tub1】）25,G1, (5)01 (6)00 (7)01 (8a) (8p)02 (9)04 (11p)02 (11d)00 (12a)00 (1a)00 (1b)03 (3b)00 (3a)13 (4sb)04 (4d)04," L（幽门窦部）, 后Post,",40,30,10, D2 R0,,4.4,2.44,1.51,134.0,180.0,2.34,11.0,17.0,166.0,88.0,7.0,12.29,4.14,69.0,234.0,41.0,28.0,,,,,,,,,,,,,,,,,0.73,8.05,5.34,,无, 无, P0,H0,已冲,,,,,,60.446780551905384,1409472
1409684,赵义,557804,男,48,T3,N1,M0, ⅡB,1,2,,0.0,0.0,1.0, 慢性炎症（+）,2.0,44,中间型（int）,INFb,1.0,0.8,,,,,,,2014-04-10,2019-05-01,0,,,SOX,SOX,SOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)03 (3a)117 (3b)02 (4sa)00 (4sb)01 (8a)02 (8p)04 (9)03 (7)14 (2)06 (11p)00 (12a)00 (19)00," GE, 前Ant, 后Post, 小弯侧Less,",90,50,15, R0 D2,,8.98,5.87,2.25,155.0,333.0,4.66,10.0,15.0,140.0,92.0,12.0,6.33,2.0,68.0,217.0,38.0,30.0,,,,,,,,,,,,,,,,,4.95,5.71,2.12,,无, 无, P0,H0,已冲,,,,,,60.67674113009198,1409684
1409810,张彩凤,557792,女,54,T3,N0,M0, ⅡA,1,3,,0.0,0.0,1.0, 腺体萎缩+,0.0,35,硬型（sci）,INFc,0.0,0.55,,,,,,,2014-04-10,2020-10-10,1,,,FLO,FLO,,,,,2, 低分化腺癌（G3)(por) 低粘附腺癌,G3, (1a)02 (1b)00 (3a)011 (8a)03 (8p)00  (9)00 (7)01 (11p)04 (5)00 (6)010 (4d)04 (4sb)00," LM 前Ant, 后Post, 小弯侧Less,",45,30,10, R0 D2,,3.43,1.49,1.6,122.2,237.0,3.59,11.0,24.0,193.0,101.0,7.0,11.94,4.04,72.0,264.0,45.0,27.0,,7.3,67.0,229.0,,,,,,,,,,,,,1.85,8.78,3.56,,无, 无, P0,H0,已冲,,,,,,78.02233902759527,1409810
1410207,张清银,558961,男,64,T4b,N1,M0, ⅢB,1,5,,,,, 腺体萎缩+ 肠化生+,1.0,35,中间型（int）,INFb,1.0,0.85,,,,,,,2014-04-15,2019-05-03,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (9)07 (8a) (8p)02 (7)02 (6)03 (5)00 (4d)15 (4sb)00 (3b)09 (2)03 (3a)01 (1b)01 (1a)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",80,60,12, R0,,6.45,3.84,1.83,92.8,283.0,3.53,14.0,18.0,163.0,42.0,25.0,4.63,1.52,67.0,211.0,40.0,27.0,6.0,6.8,78.0,306.0,,,,,,,,,,,,,2.62,0.6,1.99,,无, 无, P0,H0,已冲,,,,,,60.57818659658344,1410207
1409451,孙雨珊,557130,男,59,T4b,N3a,M1, Ⅳ,1,3,,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,7.0,16,中间型（int）,INFb,1.0,0.8,,,,,,,2014-04-08,2014-10-23,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)11 (3a)11 (3b)00 (5)00 (6)46 (7)02 (12a)00 (4sb)01 (4d)14," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",50,45,20,,R2,5.81,3.95,1.27,151.0,176.0,2.73,19.0,27.0,178.0,55.0,20.0,11.25,3.93,65.0,195.0,40.0,25.0,6.0,5.1,84.0,349.0,,,,,,,,,,,,,1.53,767.9,3.42,,融合块状,, p1泛(M1 PER),H1多（M1 HEP),已冲,,,,,,6.504599211563732,1409451
1409626,李敏,559107,女,39,T3,N3a,M1, Ⅳ,1,2,,1.0,1.0,, 腺体萎缩+,9.0,35,中间型（int）,INFb,3.0,0.8,,,,,,,2014-04-09,2014-11-27,2,,,SOX,XELOX,FOLFOX,,,,0, 低粘附腺癌75 管状腺癌（中分化【G2】【tub2】25,G2, (9)01 (8p)03 (5)00 (8a)02 (6)59 (4sb)00 (11p)13 (1a)01 (1b)02 (3a)16 (7)04 (3b)13 (4d)11," L（幽门窦部）, 后Post,",50,40,10,,R2,6.93,5.03,1.35,98.4,309.0,4.22,33.0,41.0,155.0,74.0,27.0,6.86,2.61,72.0,198.0,44.0,28.0,5.4,5.8,68.0,218.0,,,,,,,,,,,,,16.43,0.6,16.29, 未做,粟粒状, 无,p1泛(M1 PER),H0, 已冲,,,,,,7.621550591327201,1409626
1409648,刘淑华,559240,女,55,T3,N0,M0, ⅡA,1,3,,,,1.0, 腺体萎缩++ 慢性炎症（+）,0.0,22,髓样型（med）,INFb,1.0,0.4,,,,,,,2014-04-09,2019-04-22,1,,,XELOX,XELOX,XELOX,,,,3, 乳头状癌（G1）（pap）90 管状腺癌（中分化【G2】【tub2】10,G2, (5)03 (3b)01 (3a)03 (1a)00 (4d)00 (1b)00 (4sb)00 (9)07 (8a) (8p)01 (11p)02 (7)02 (6)02 (16a1)01," L（幽门窦部）, 后Post, 大弯侧Gre,",60,12,11, D2 R0,,6.18,2.24,3.14,141.0,275.0,3.43,31.0,25.0,186.0,115.0,26.0,9.98,3.27,71.0,214.0,44.0,27.0,12.1,5.2,73.0,187.0,,,,,,,,,,,,,1.48,0.6,4.78, 未做,无, 无, P0,H0,已冲,,,,,,60.41392904073587,1409648
1409540,高显君,557134,男,53,T3,N2,M0, ⅢA,1,3,,,,1.0, 腺体萎缩+ 慢性炎症（+）,3.0,23,中间型（int）,INFc,0.0,0.15,,,,,,,2014-04-09,2015-08-29,2,,,SOX,SOX,SOX,SOX,SOX,SOX,8, 低粘附腺癌,GX, (1a)04 (1b)00 (3a)2 10 (3b)00 (4sb)00 (4d)00 (5)00 (6)14 (7)01 (8a) (8p) 03(9)01,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,15,30,6,,R1,6.73,3.89,1.93,115.6,224.0,2.95,11.0,15.0,134.0,65.0,10.0,13.26,5.07,68.0,183.0,42.0,26.0,4.8,6.0,69.0,194.0,,,,,,,,,,,,,1.78,21.65,1.25, 未做,无, 无, P0,H0,未做,,,,,,16.655716162943495,1409540
1409448,赵守彬,559069,男,64,T4b,N3a,M0, ⅢC,1,2,,1.0,1.0,, 正常,11.0,52,髓样型（med）,INFb,0.0,0.65,,,,,,,2014-04-08,2020-04-29,1,,,草酸铂联合替加氟,草酸铂联合替加氟,奥沙利铂联合替加氟,草酸铂联合替加氟,,,4, 乳头状癌（G1）（pap）,G1, (1a)01 (1b)16 (2)012 (3a)35 (3b)01 (4sa)02 (4sb)11 (4d)56 (5)01 (6)00 (7)00 (8a)15 (8p)05 (9)05 (11d)01 (14v)01," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre,",80,70,15,,R1,9.78,7.09,1.61,68.0,440.0,3.85,15.0,19.0,139.0,84.0,12.0,7.23,2.73,63.0,156.0,42.0,21.0,5.3,5.5,69.0,235.0,,,,,,,,,,,,,1.55,0.6,5.51,,无, 无, P0,H0,已冲,,,,,,72.70039421813404,1409448
1409366,刘春波,559165,男,56,T2,N0,M0, ⅠB,1,2,,,,,,0.0,16,,,2.0,0.65,,,,,,,2014-04-08,2020-04-29,1,,,XELOX,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】75% 乳头状癌（G1）（pap）15% 粘液腺癌（muc）10%,G2, (1a)02 (1b)05 (3a)03 (3b)00 (4sb)03 (4d)03 (5)00 (6)00 (7)00," L（幽门窦部）, 小弯侧Less,",15,15,2, R0 D1+,,8.27,4.1,3.28,152.6,252.0,2.73,39.0,28.0,166.0,113.0,19.0,12.21,4.59,73.0,303.0,45.0,28.0,5.2,6.4,78.0,270.0,,,,,,,,,,,,,1.23,7.93,1.21, 未做,无, 无, P0,H0, 未做,,,,,,72.70039421813404,1409366
1409808,管志军,559228,男,48,T3,N0,M0, ⅡA,1,3,,1.0,1.0,1.0, 慢性炎症（+）,0.0,25,中间型（int）,INFb,2.0,0.7,,,,,,,2014-04-10,2019-04-22,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)02 (5)04 (6)05 (7)04 (8a) (8p) (9)03 (11p)03 (16a1)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",75,60,12, D2+ R0,,7.63,5.63,1.24,79.0,418.0,3.68,12.0,17.0,172.0,82.0,2.0,8.51,3.07,73.0,171.0,48.0,25.0,5.8,6.5,88.0,318.0,,,,,,,,,,,,,2.51,5.1,10.23, 未做,无,, P0,H0,已做,,,,,,60.381077529566355,1409808
1410453,李淑荣,559158,女,68,T4a,N1,M0, ⅢA,1,3,,,,1.0,,1.0,20,,,0.0,0.45,,,,,,,2014-04-16,2020-04-08,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 75 乳头状癌（G1）（pap）25,G3, (1a)04 (1b)08 (2)00 (3a)16 (3b)02 (4sa) 00(4sb)00,GE 前Ant 后Post 大弯侧Gre  小弯侧Less  SiewerⅢ,30,20,8, D0 D1,,5.52,2.95,1.97,134.0,224.0,2.9,10.0,27.0,153.0,55.0,5.0,7.31,2.66,64.0,180.0,40.0,24.0,4.6,6.1,74.0,206.0,,,,,,,,,,,,,5.59,128.0,, 未做,无, 无, P0,H0,未做,,,,,,71.74770039421813,1410453
1410147,李贵文,559047,男,47,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,44,,,0.0,0.45,,,,,,,2014-04-14,2019-05-01,0,,,,,,,,,0, 低粘附腺癌85 低分化腺癌（G3)(por)15,G3, (1a)01 (1b)05 (3a)08 (3b)00 (4d)013 (5)00 (6)05 (7)00 (8a)02 (8p)02 (9)01 (11p)04 (14v)02 (4sb)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,15,5, R0 D2+,,4.81,2.76,1.6,146.9,192.0,3.1,21.0,20.0,148.0,84.0,13.0,17.81,6.42,70.0,301.0,47.0,23.0,5.1,5.1,95.0,264.0,,,,,,,,,,,,,1.67,17.4,6.43,,无, 无, P0,H0,已冲,,,,,,60.545335085413925,1410147
1409804,王文华,559205,男,45,T4b,N1,M0, ⅢB,1,3,,,,, 腺体萎缩+,2.0,32,髓样型（med）,INFb,0.0,0.4,,,,,,,2014-04-10,2019-03-03,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (3b)06 (4sb)11 (7)011 (8a)03 (8p)03 (9)06 (11p)12," L（幽门窦部）, 后Post,",60,50,12,,R1,7.7,5.14,1.93,117.0,231.0,3.85,24.0,23.0,159.0,105.0,10.0,8.13,2.47,69.0,231.0,44.0,25.0,5.9,8.0,84.0,267.0,,,,,,,,,,,,,1.34,20.28,1.15,,无,, P0,H0,未做,,,,,,58.73850197109067,1409804
1410347,丁振川,560148,男,72,T3,N2,M1, Ⅳ,1,2,,0.0,0.0,0.0, 腺体萎缩+,5.0,35,中间型（int）,INFb,2.0,0.55,,,,,,,2014-04-16,2017-07-24,2,,,MFOLFOX6(2),MFOLFOX6,MFOLFOX6,MFOLFOX6,,,5, 乳头状癌（G1）（pap）75 管状腺癌（中分化【G2】【tub2】25,G2, (1a)01 (1b)02 (3b)22 (3a)016 (4d)13 (5)00 (6)15 (7)12 (8a)02 (9)01 (12a)01 (4sb)00," L（幽门窦部）, 后Post, 大弯侧Gre, ",60,50,16,,R2,6.95,4.36,1.72,105.6,524.0,3.21,18.3,18.0,159.0,119.0,28.6,9.04,2.07,63.5,237.36,41.7,21.8,5.3,5.01,64.0,314.0,,,,,,,,,,,,,4.1,4.84,1.87,,无, 无, P0,H1单（M1 HEP),已做,,,,,,39.25755584756899,1410347
1410661,刘晓茹,560626,女,49,T4a,N3a,M0, ⅢB,1,4,,1.0,1.0,1.0, 正常,9.0,23,硬型（sci）,INFc,0.0,0.65,,,,,,,2014-04-17,2014-06-26,2,,,,,,,,,0, 低粘附腺癌,GX, (1a)02 (1b)03 (3a)44 (3b)01 (4sb)01 (4d)25 (5)00 (6)13 (7)00 (8a)00 (8p)00 (9)01 (11p)23," LM 前Ant, 后Post, 小弯侧Less,",50,50,10, R0 D2,,6.28,52.0,36.7,119.0,259.0,2.9,14.0,18.0,177.0,49.0,8.0,8.91,2.97,69.0,159.0,42.0,27.0,4.3,2.8,78.0,206.0,,,,,,,,,,,,,0.563,6.73,3.89,,无, 无, P0,H0,未做,,,,,,2.299605781865966,1410661
1411493,王建国,559994,男,44,T4a,N3a,M0, ⅢB,1,4,,1.0,1.0,0.0, 正常,15.0,31,硬型（sci）,INFc,1.0,0.35,,,,,1.0,,2014-04-16,2016-12-07,2,,,,,,,,,0, 低粘附腺癌,GX, (1a)00 (8p)01 (12a)00 (7)27 (1b)00 (11p)04 (14v)00 (8a)11 (9)01 (3a)34 (3b)22 (6)25 (4d)56," L（幽门窦部）, 后Post,",90,50,20, R0  D2+,,6.75,4.14,2.08,122.6,276.0,3.14,9.0,12.0,125.0,70.0,12.0,11.3,4.17,63.0,239.0,41.0,22.0,,,,,,,,,,,,,,,,,0.436,3.72,2.05,,无, 无, P0,H0,已做,"CD34+,D2-40+",,,,,31.734559789750328,1411493
1410878,孙继文,553229,男,62,T4b,N3a,M0, ⅢC,1,2,,1.0,,,,8.0,39,,,0.0,0.65,,,,,,,2014-04-21,2017-02-28,2,XELOX*2,1.0,XELOX,XELOX,XELOX(2),FOFIRI,FOFIRI,FOFIRI,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 粘液腺癌（muc）15,G3, (1a)02 (1b)03 (3a)05 (4sb)01 (7)07 (8a)05 (8p)11 (9)01 (11p)02 (14v)00 (5)11 (4d)47 (3b)11 (6)13," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,30,7,,R1,6.43,3.54,2.2,103.0,218.0,2.2,38.0,45.0,179.0,86.0,24.0,12.71,4.0,73.0,228.0,45.0,28.0,5.0,8.3,82.0,287.0,,,,,,,,,,,,,1.14,10.72,3.88,,无, 无, P0,H0,已冲,,,,,,34.2969776609724,1410878
1410205,姜文喜,560519,男,65,T4b,N3b,M0, ⅢC,1,4,,1.0,1.0,, 腺体萎缩+,35.0,42,髓样型（med）,INFa,0.0,0.75,,,,,,,2014-04-15,2015-06-03,2,,,SOX,SOX,SOX,SOX,,,4, 低分化腺癌（G3)(por)80 低粘附腺癌20,G3,胃壁旁22 (1a)12 (1b)34 (2)04 (3a)66 (4sa)00(4sb)00 (5)77 (6)22 (8a、8p)12 (9)11 (11p)77 (7)11 (12a)00  (4d)44," L（幽门窦部）, M（胃体部）, ML 前Ant, 后Post, 大弯侧Gre,",75,60,12,,R1,9.73,7.32,1.42,121.0,438.0,4.9,16.0,20.0,162.0,106.0,58.0,6.08,2.46,70.0,193.0,44.0,26.0,4.9,5.1,82.0,226.0,,,,,,,,,,,,,0.881,11.08,1.85,,无,, P0,H0, 已冲,,,,,,13.600525624178712,1410205
1410310,黄福林,560498,男,52,T3,N3a,M0,ⅢB,1,2,,1.0,1.0,, 腺体萎缩+ 肠化生+,10.0,30,中间型（int）,INFb,2.0,0.7,,,,,,,2014-04-15,2014-09-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85  管状腺癌（高分化【G1】【tub1】）15,G3, (1a)02 (1b) 01(2) 02(3a)5 10 (3b)33 (4sa) 00(4sb)00 (4d)01 (5) 00(6) 09(8a) (8p) (9)22, ML 后Post,50,40,4,,R2,6.89,2.99,2.97,132.8,232.0,3.28,13.0,22.0,161.0,98.0,15.0,7.68,2.44,85.0,236.0,48.0,37.0,6.4,9.3,111.0,346.0,,,,,,,,,,,,,1000.0,7.06,2.16, 未做,无,, P0,H0,未做,,,,,,5.026281208935611,1410310
1410672,胡志秀,559330,男,51,T4b,N3a,M0, ⅢC,1,2,,1.0,1.0,0.0, 正常,7.0,36,髓样型（med）,INFa,0.0,0.95,,,,,,,2014-04-17,2019-05-01,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)13 (1b)01 (2)02 (3a)26 (3b)11 (4sa)01 (4sb)00 (4d)15 (5)00 (6)01 (7)27 (8a)01 (8p)03 (9)00 (11p)02 (14v)02," LM 前Ant, 后Post, 小弯侧Less,",100,80,20,,R1,6.26,3.99,1.57,85.0,386.0,4.43,17.0,15.0,136.0,89.0,13.0,5.9,2.55,67.0,174.0,38.0,29.0,5.7,5.1,85.0,275.0,,,,,,,,,,,,,1.1,8.63,5.7,,无, 无, P0,H0,未做,,,,,,60.446780551905384,1410672
1410468,吴继有,559249,男,58,T3,N2,M0, ⅢA,1,3,,1.0,1.0,0.0, 腺体萎缩+ 慢性炎症（+）,6.0,32,中间型（int）,INFb,0.0,0.9,,,,,,,2014-04-16,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (5)02 (6)47 (7)01 (8a)01 (8p)03 (9)01 (11p)03 (12a)00 (1b)05 (1a)01 (3a)02 (3b)11 (4d)15 (4sb)00," L（幽门窦部）, 后Post,",30,25,3, R0 D2,,9.3,6.19,2.41,157.3,235.0,2.68,13.0,20.0,157.0,77.0,26.0,15.98,3.93,74.0,232.0,45.0,29.0,4.8,5.8,99.0,434.0,,,,,,,,,,,,,2.09,32.29,11.41,,无, 无, P0,H0,未做,,,,,,100.52562417871222,1410468
1410323,于坤,557186,女,49,T3,N0,M0, ⅡA,1,2,,1.0,1.0,1.0, 腺体萎缩+,0.0,21,中间型（int）,INFb,0.0,0.85,,,,,,,2014-04-15,2020-10-10,1,,,SOX,SOX,SOX,SOX,SOX,SOX,8, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,(5)00 (3b)02 (6)03 (8a)01 (3a)02 (8p)02 (9)00 (14v)00 (1a)01 (1b)03 (4sb)00 (11p)05 (4d)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,20,8, R0 D2+,,3.55,58.57,30.57,84.9,274.0,3.43,18.0,25.0,136.0,55.0,7.0,9.67,3.61,71.0,135.0,42.0,29.0,4.7,4.4,64.0,115.0,,,,,,,,,,,,,3.98,52.71,17.99,,无, 无, P0,H0,已冲,,,,,,77.8580814717477,1410323
1410354,冯臣,560300,男,53,T1a,N2,M0, ⅡA,1,0,,,,,,3.0,13,,,0.0,0.8,,,,,,,2014-04-16,2019-04-20,1,,,替吉奥单药,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌 印戒细胞癌(sig),GX, (1a)12 (1b)02 (3a)00 (3b)00 (4sb)00 (4d)00 (5)22 (6)01 (7)01 (8a) (8p) 05(9)00,L（幽门窦部） 小弯侧Less 前Ant 后Post ,30,30,8, R0 D2,,7.83,58.99,31.66,155.4,228.0,3.07,56.0,26.0,146.0,72.0,51.0,11.61,3.37,68.0,242.0,41.0,27.0,5.5,7.6,90.0,474.0,,,,,,,,,,,,,7.66,15.6,8.72, 未做,无, 无, P0,H0,未做,,,,,,60.118265440210244,1410354
1410492,巩德奎,560050,男,58,T2,N1,M0, ⅡA,1,1,,0.0,0.0,0.0, 腺体萎缩+ 肠化生+,1.0,27,中间型（int）,INFb,3.0,0.6,,,,,,,2014-04-11,2019-06-02,1,,,,,,,,,0, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】15 粘液腺癌（muc）15,G2, (1a)01 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)04 (5) 01(6)19 (7)00 (8a) (8p)01 (9) 08(11p) (11d)02,L（幽门窦部） 大弯侧Gre  前Ant 后Post ,40,40,10, R0 D2,,7.01,66.46,23.32,156.4,256.0,2.85,14.0,21.0,219.0,65.0,27.0,14.79,4.56,71.0,310.0,45.0,26.0,5.1,6.6,85.0,305.0,,,,,,,,,,,,,1.41,11.16,20.33, 未做,无, 无, P0,H0,未做,,,,,,61.695137976346906,1410492
1410974,范忠贺,559262,男,54,T3,N3a,M0,ⅢB,1,2,,,,, 腺体萎缩+,7.0,50,中间型（int）,INFb,0.0,0.9,,,,,,,2014-04-21,2020-09-08,1,,,,,,,,,0, 乳头状癌（G1）（pap）80 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)20,G3, (1a)34 (1b)04 (2)02 (3a)49 (3b)04 (4sa)01 (4sb)00 (4d)04 (5)04 (6)02 (7)02 (8a、8p)05 (9)02 (10)02 (12p)01食管下段旁04," M（胃体部）, U（胃底部）, UM G=E, SiewerⅡ, 前Ant, 后Post, 小弯侧Less,",50,45,6, R0 D2,,5.6,3.13,1.69,137.0,273.0,3.07,20.0,23.0,145.0,68.0,10.0,9.49,3.44,71.0,220.0,43.0,28.0,4.6,6.5,77.0,227.0,,,,,,,,,,,,,11.17,6.45,3.42,,无,, P0,H0,已冲,,,,,,76.60972404730617,1410974
1410670,张凤龙,559871,男,50,T3,N1,M0, ⅡB,1,3,,,,1.0, 腺体萎缩+ 肠化生+,2.0,34,硬型（sci）,INFc,1.0,0.7,,,,,,,2014-04-17,2019-01-15,0,,,FOLFOX6,FOLFOX6,FOLFOX6,FOLFOX6,FOLFOX6,FOLFOX6,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1b)01 (4sb)00 (3b)19 (4d)01 (8a、8p、9、11p)07 (6)03 (1a)01 (5)00 (7)09 (8p)01 (3a)12," L（幽门窦部）, M（胃体部）, LM 前Ant, 后Post, 小弯侧Less,",25,20,7, R0 D2,,6.74,3.61,2.47,153.0,202.0,2.03,25.0,23.0,198.0,74.0,10.0,13.15,4.1,70.0,219.0,43.0,27.0,5.4,8.4,85.0,341.0,,,,,,,,,,,,,2.5,10.02,1.44,,无,, P0,H0, 已冲,,,,,,56.96452036793692,1410670
1410564,纪秉海,560579,男,49,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,21,,,0.0,0.25,,,,,,,2014-04-17,2018-06-07,0,,,,,,,,,0, 印戒细胞癌(sig),GX, (1a)01 (1b)04 (3a)02 (3b)01 (4sb)00 (4d)04 (5)02 (6)03 (7)00 (8a) (8p)04 (9)00 (11p)00,L（幽门窦部） 小弯侧Less 前Ant 后Post ,35,45,2, R0 D2,,5.83,63.08,27.24,109.0,253.0,2.49,15.0,19.0,129.0,83.0,5.0,7.095,3.12,6.0,188.0,40.0,25.0,5.3,7.5,70.0,300.0,,,,,,,,,,,,,0.394,10.73,1.4, 未做,无,, P0,H0,未做,,,,,,49.67148488830486,1410564
1411300,朱东明,559894,男,31,T2,N1,M0, ⅡA,1,2,,,,, 慢性炎症（+）,2.0,17,硬型（sci）,INFc,0.0,,,,,,,,2014-04-23,2019-06-02,1,,,,,,,,,0, 低粘附腺癌 90 低分化腺癌（G3)(por)10,G3, (1a)00 (1b)05 (3a)01 (3b)00 (4sb)00 (4d)02 (5)12 (6)11 (7)03 (8a)03 (11p)00,L（幽门窦部） 前Ant 小弯侧Less ,18,18,4, R0 D2,,6.04,54.3,35.3,157.0,175.0,1.44,160.0,72.0,150.0,72.0,32.0,15.37,6.82,77.0,177.0,46.0,31.0,4.8,5.7,98.0,374.0,,,,,,,,,,,,,1.8,24.67,1.45, 未做,无,, P0,H0,未做,,,,,,61.300919842312744,1411300
1410637,杨凤华,559902,男,63,T4b,N3b,M0, ⅢC,1,3,,1.0,1.0,1.0, 慢性炎症（+）,17.0,19,中间型（int）,INFb,1.0,0.75,,,,,,,2014-04-17,2016-01-06,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a) 11(1b)00 (2)00 (3a)33 (3b)33 (4sa)00 (4sb)11 (4d)77 (5)00 (6)22 肿物旁11 大网01,ML 小弯侧Less 前Ant 后Post ,80,60,5, R0 D2,,4.94,63.0,25.5,94.0,246.0,3.35,20.0,26.0,182.0,63.0,9.0,7.43,2.76,79.0,256.0,47.0,32.0,5.4,6.8,104.0,277.0,,,,,,,,,,,,,3.25,0.6,1.53, 未做,无,, P0,H0,未做,,,,,,20.66360052562418,1410637
1411741,董爱兰,560599,女,47,T3,N3a,M0,ⅢB,1,3,2.0,,,, 正常,8.0,37,硬型（sci）,INFc,2.0,,,,,,,,2014-05-28,2015-06-27,2,,,TCF,,,,,,1, 低粘附腺癌 （GIST） Lauren弥漫型,GX, (1a)01 (1b)12 (3a)06 (3b)36 (11p)01 (8a)01 (8p)00 (4sb)03 (4d)06 (5)11 (6)00 (7)38 (9)02, L（幽门窦部） 小弯侧Less ,40,20,6, D2,,5.26,3.32,1.63,131.0,271.0,2.95,13.0,21.0,156.0,50.0,9.0,14.24,4.05,76.0,224.0,45.0,31.0,4.8,4.7,76.0,236.0,,,,,,,,,,,,,1.14,6.63,9.2, 未做,无, 无, P0,H0,已冲,ck（+），vimentin（-），VEGF(-),,,,,12.976346911957949,1411741
1411274,朱建林,560576,女,37,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 异型增生+ 慢性炎症（+）,11.0,34,硬型（sci）,INFc,1.0,,,,,,,,2014-04-23,2019-04-14,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)01 (1b)07 (2)03 (3a)22 (3b)37 (4sa)01 (4sb)11 (4d)00 (5)02 (6)34 (7)(8)(9)(11)26,ML 后Post 小弯侧Less 大弯侧Gre  ,70,65,8, R0 D2,,9.02,75.11,17.32,57.0,452.0,3.28,19.0,17.0,119.0,47.0,28.0,7.55,2.59,67.0,173.0,43.0,24.0,5.1,3.1,59.0,209.0,,,,,,,,,,,,,0.516,5.73,1.1, 未做,无, 无, P0,H0,未做,CK+,,,,,59.69119579500657,1411274
1411112,丁玉福,559857,男,53,T3,N3a,M0,ⅢB,1,3,,1.0,1.0,1.0, 肠化生 慢性炎症,12.0,57,中间型（int）,INFb,2.0,0.55,,,,,,,2014-04-22,2017-05-15,0,,,,,,,,,0,管状腺癌中低分化,G3,,"G  前Ant, 小弯侧Less,",70,38,7, D2,,5.94,4.06,1.41,131.0,337.0,3.68,9.0,15.0,165.0,123.0,12.4,4.28,7.78,71.4,160.0,44.9,26.5,,5.56,68.0,197.0,,,,,,,,,,,,,12.21,10.73,22.12, 未做,无,, P0,H0, 已冲,,,,,,36.760840998685936,1411112
1411103,杜德财,560322,男,60,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,23,,,3.0,0.75,,,,,,,2014-04-22,2020-10-10,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)04 (3a)01 (4d)04 (4sb)02 (5)01 (6)04 (7)02 (9)01," L（幽门窦部）,  前Ant,",20,10,5, R0 D2,,6.18,46.3,38.7,171.0,235.0,3.68,24.0,24.0,201.0,125.0,18.0,11.23,4.2,73.0,269.0,47.0,26.0,4.9,5.6,88.0,334.0,,,,,,,,,,,,,5.48,0.6,4.75, 未做,无, 无, P0,H0,已冲,,,,,,77.6281208935611,1411103
1411136,吴凤兰,560976,女,76,T2,N0,M0, ⅠB,1,3,,0.0,0.0,0.0, 腺体萎缩+ 慢性炎症（+）,0.0,16,中间型（int）,INFb,2.0,0.2,,,,,1.0,,2014-04-22,2020-12-17,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (8p)01 (9)00 (7)01 (8a)02 (5)03 (6)04 (3a)01 (4d)04 (3b)00 (1b)00 (4sb)00," L（幽门窦部）, 前Ant,",20,18,3, R0 D2,,5.87,51.07,38.72,132.4,207.0,2.06,23.0,28.0,209.0,64.0,17.0,7.85,4.17,69.0,234.0,45.0,24.0,5.7,5.4,85.0,273.0,,,,,,,,,,,,,0.971,7.64,0.863,,无, 无, P0,H0,未做,CD34+ ，D2-40+,,,,,79.86202365308804,1411136
1411353,田庆学,560046,男,65,T2,N0,M0, ⅠB,1,3,,0.0,0.0,0.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,0.0,40,中间型（int）,INFb,2.0,,,,,,,,2014-04-24,2018-01-25,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)06 (3a)06 (3b)06 (4sb)06 (4d)03 (5)02 (6)06 (7)00 (8a)00 (8p)00 (9)03 (14v)00," L（幽门窦部）,  小弯侧Less, 前Ant, 后Post,",35,50,8, R0 D2,,7.13,57.3,31.8,149.0,267.0,4.22,25.0,33.0,143.0,91.0,11.0,8.64,3.46,66.0,194.0,42.0,24.0,4.9,6.6,66.0,328.0,,,,,,,,,,,,,1.84,3.93,1.9,,无, 无, P0,H0,已做,,,,,,45.072273324572926,1411353
1411283,孙小平,560049,女,51,T3,N2,M0, ⅢA,1,2,0.0,,,, 肠化生+,4.0,37,中间型（int）,INFb,3.0,,,,,,,,2014-04-23,2019-04-03,0,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 粘液腺癌（muc）30 Lauren肠型,G3, (7)312 (6)04 (5)01 (4sb)01 (3b)00 (3a)18 (4d)04 (1a)00 (1b)00 (12a)00 (11d)01 (9)02 (8p)02,L（幽门窦部） 前Ant 小弯侧Less 后Post ,70,50,6, D2,,8.46,4.23,3.35,116.0,350.0,4.03,13.0,21.0,125.0,75.0,8.0,6.75,2.16,54.0,122.0,34.0,22.0,,,,,,,,,,,,,,,,,13.756,0.6,18.3, 未做,无, 无, P0,H0,已冲,ck（+）,,,,,59.32982917214191,1411283
1410981,陈凤艳,559118,女,45,T4b,N3b,M1, Ⅳ,1,4,2.0,1.0,1.0,1.0, 腺体萎缩+ 肠化生+,21.0,26,中间型（int）,INFc,0.0,,,,,,,,2014-04-21,2014-08-08,2,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)35 粘液腺癌（muc）5 Lauren弥漫型,G3, (1a)01 (1b)11 (2)33 (3a)55 (3b)11 (4sa)00 (4sb)00 (4d)59 (5)11 (6)44 (7)00 (8a)11 (12a)00," M（胃体部）, 后Post, 小弯侧Less,",40,50,6,,R2,8.65,5.24,2.53,144.0,266.0,4.22,21.0,19.0,127.0,60.0,16.0,22.79,7.89,74.0,229.0,44.0,30.0,6.1,7.0,70.0,233.0,,,,,,,,,,,,,1.62,0.6,9.01,,粟粒状, 无, p1泛(M1 PER),H0,已冲,CK(+),,,,,3.5808147174770038,1410981
1411130,王宪荣,561928,女,49,T3,N2,M0, ⅢA,1,3,,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,6.0,42,硬型（sci）,INFc,1.0,0.8,,,,,,,2014-04-22,2017-01-05,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)00 (3a)56 (3b)00 (4sb)00 (4d)04 (5)01 (6)03 (7)112 (8a)01 (8p)012 (9)01," L（幽门窦部）, 后Post,",30,25,5, R0 D2,,9.61,5.58,3.19,145.1,314.0,1.88,19.0,24.0,171.0,67.0,18.0,9.97,3.5,70.0,211.0,46.0,24.0,6.6,8.6,68.0,349.0,,,,,,,,,,,,,2.8,51.3,2.34,,无, 无, P0,H0,已冲,,,,,,32.49014454664914,1411130
1411354,吴全义,550382,男,58,T4b,N0,M0, ⅢA,1,4,2.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,44,髓样型（med）,INFb,0.0,,,,,,,,2014-04-24,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por) Lauren弥漫型,G3,小弯03 (1a)00 (1b)01 (2)00 (3a)07 (3b)07 (4sa)02 (4d)05 (4sb)03 (5)00 (6)06 (7)01 (8a)01 (8p)02 (9)05 (11p)01," L（幽门窦部）, M（胃体部）, U（胃底部）, LMU 前Ant, 后Post, 大弯侧Gre,",50,60,8,,R1,6.62,3.74,2.16,92.0,391.0,2.41,15.0,22.0,179.0,80.0,15.0,6.31,2.42,63.0,265.0,41.0,22.0,4.4,3.8,71.0,181.0,,,,,,,,,,,,,1.09,6.27,1.33,,无,, P0,H0,未做,CK(+),,,,,100.2628120893561,1411354
1411438,王东红,561149,女,32,T3,N2,M0, ⅢA,1,5,2.0,,,1.0, 腺体萎缩+ 异型增生+,6.0,20,硬型（sci）,INFc,0.0,,,,,,,,2014-04-24,2016-08-02,0,,,,,,,,,0, 低粘附腺癌 粘液腺癌（muc） Lauren弥漫型,GX, (1a)01 (1b)01 (3a)00 (3b)00 (4d)04 (4sb)00 (5)00 (6)33 (7)14 (8a)22 (8p)01 (9)04 (11p)00 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",45,45,25, R0 D2,,3.99,1.26,2.46,144.0,217.0,2.3,13.0,17.0,152.0,63.0,11.0,9.75,4.35,76.0,202.0,45.0,31.0,5.5,3.2,76.0,202.0,,,,,,,,,,,,,0.856,11.69,1.53,,无,, P0,H0,已冲,,,,,,27.299605781865964,1411438
1411742,任和平,561024,男,60,T4b,N2,M0, ⅢB,1,2,3.0,1.0,1.0,, 正常,6.0,29,髓样型（med）,INFb,0.0,,,,,,,,2014-04-28,2019-05-16,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)03 (1b)00 (3a)13 (3b)01 (4sb)02 (4d)56 (5)00 (6)03 (7)04 (8a、8p、9、12p)07 (11d)00," L（幽门窦部）,  后Post,",55,50,10, R0 D2,,8.0,4.01,2.85,165.0,191.0,3.07,21.0,18.0,136.0,84.0,17.0,26.12,8.67,70.0,198.0,43.0,27.0,7.7,6.0,95.0,287.0,,,,,,,,,,,,,1.72,21.08,10.22,,无,, P0,H0,已冲,CK(+),,,,,60.57818659658344,1411742
1411640,薛忠良,561788,男,62,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+,0.0,27,中间型（int）,INFa,0.0,,,,,,,,2014-04-28,2019-09-02,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)03 (3b)00 (3a)05 (4sb)00 (4d)01 (5)00 (6)05 (7)03 (8a)04 (8p)02 (9)01 (11p)02," L（幽门窦部）, 后Post,",22,15,2, R0 D2,,4.5,43.26,44.83,133.8,156.0,2.78,9.0,15.0,144.0,48.0,10.0,14.66,4.97,62.0,218.0,38.0,24.0,4.7,6.5,79.0,323.0,,,,,,,,,,,,,1.43,4.81,0.973,,无, 无, P0,H0,未做,"CK+，vimentin-,VEGF-",,,,,64.15900131406045,1411640
1411756,许文志,561014,男,69,T1b,N0,M0,ⅠA,1,0,0.0,,,,,0.0,18,中间型（int）,,1.0,,,,,,,,2014-04-28,2020-10-10,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)03 (3a)04 (4sb)00 (7)04 (8a)02 (8p)03 (9)00 (11p)01 (12a)00 (12p)01 (3b)00 (4d)00 (5)00 (6)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,20,, R0 D2,,5.62,48.2,44.3,138.0,161.0,2.63,18.0,23.0,122.0,69.0,14.0,9.12,2.64,66.0,273.0,40.0,26.0,5.4,6.4,90.0,327.0,,,,,,,,,,,,,0.672,8.51,1.3,,无, 无, P0,H0, 已冲,"CK+,vimentin-,VEGF-",,,,,77.43101182654402,1411756
1412196,刘玉玲,561800,女,50,T4a,N2,M1, Ⅳ,1,4,1.0,0.0,0.0,0.0, 正常,6.0,28,硬型（sci）,INFc,0.0,,,,,,,,2014-05-05,2015-07-02,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G3, (8a)01 (8p)02 (9)03 (11p)22 (12p)00 (1a)11 (1b)05 (2)11 (3a)00 (3b)00 (4sa)00 (4sb)01 (4d)02 (5)00 (6)07 (7)22 ," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",50,30,13,,R2,6.56,58.2,34.9,98.0,433.0,2.89,12.0,18.0,148.0,69.0,9.0,5.61,1.71,77.0,237.0,44.0,33.0,7.4,4.8,79.0,190.0,,,,,,,,,,,,,2.7,12.65,2.04,,无, 无, P0,H0,已冲,"CK+ vimentin-,VEGF-",,,,,13.896189224704337,1412196
1412264,车仁德,561019,男,57,T1a,N0,M0,ⅠA,1,0,0.0,,,,肠上皮化生，慢性炎,0.0,11,,,0.0,,,,,,,,2014-05-05,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (9)00 (8p)01 (7)02 (1b)01 (12a)00 (1a)00 (5)01 (8a)01 (3b)01 (6)02 (4d)00 (4sb)00 (3a)02," M（胃体部）, 小弯侧Less,",8,8,2, R0 D2,,7.76,62.3,27.8,143.0,248.0,2.54,20.0,19.0,193.0,73.0,26.0,9.31,3.77,67.0,217.0,40.0,27.0,6.2,5.8,89.0,343.0,,,,,,,,,,,,,1.61,5.15,1.12,,无, 无, P0,H0,已做,"CK+ vimentin-,VEGF-",,,,,99.90144546649145,1412264
1411609,徐贵范,561736,男,51,T3,N2,M0, ⅢA,1,4,0.0,,,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,4.0,23,中间型（int）,INFc,1.0,,,,,,,,2014-04-26,2014-12-19,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)02 (8a) (8p)14 (9)03 (16a1)01 (5)00 (3a) (3b)22 (4d)02 (7) (11p) (11d)16 (6)00 (4sb)00 (14v) (14a)00,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,70,18, D2,,9.04,5.33,2.93,132.3,328.0,4.03,37.0,47.0,203.0,100.0,11.0,4.53,1.92,73.0,150.0,44.0,29.0,4.6,6.5,81.0,201.0,,,,,,,,,,,,,188.5,13.37,5.28, 未做,无,, P0,H0,未做,ck（+），vimentin（-），VEGF(-),,,,,7.7858081471747695,1411609
1411608,王建洛,561038,女,57,T4b,N3b,M0, ⅢC,1,4,2.0,,,1.0, 正常,21.0,34,硬型（sci）,INFb,0.0,,,,,,,,2014-04-26,2014-12-14,2,,,SOX,,,,,,1, 粘液腺癌（muc） Lauren弥漫型,GX, (11p)02 (2)05 (7) (8a) (8p) (9)22 (6)22 (3a) (3b)23 (1a) (1b)58 (5)12 (4sa)00 (4sb)44 (4d)56,G 前Ant 后Post 大弯侧Gre  小弯侧Less ,70,100,20,,R1,5.63,4.24,0.79,115.6,250.0,4.22,14.0,30.0,187.0,87.0,5.0,13.8,4.23,61.0,192.0,40.0,21.0,6.1,5.6,54.0,185.0,,,,,,,,,,,,,2.95,207.0,50.0, 未做,无, 无, P0,H0,已做,ck（+），vimentin（-），VEGF(-),,,,,7.621550591327201,1411608
1411768,李学全,561718,男,61,T2,N1,M0, ⅡA,1,3,0.0,,,, 慢性炎症（+）,1.0,16,中间型（int）,INFb,1.0,,0.0,0.0,,,,,2014-04-28,2022-09-01,1,,,,,,,,,0, 蕈伞型管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)05 (3b)00 (4d)00 (4sb)00 (5)00 (11p)00 (12a)11 (6)00 (7)03 (8a01 (8p)03 (9)03," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",40,30,6, R0 D2,,4.85,2.76,1.62,141.6,196.0,3.21,13.0,24.0,131.0,50.0,13.0,21.45,6.22,73.0,222.0,33.0,25.0,7.0,9.3,114.0,687.0,,,,,,,,,,,,,0.523,16.97,4.13,,无,, P0,H0,已冲,CK(+) vimentin(-) VEGF（-）,,,,,100.13140604467804,1411768
1411880,刘国庆,561737,男,48,T4a,N1,M1, Ⅳ,1,5,1.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,2.0,27,中间型（int）,INFc,1.0,,0.0,0.0,,,,,2014-04-29,2019-05-15,1,,,XELOX,XELOX,XELOX,SOX,SOX,口服替吉奥,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren混合型,G2, (1a)01 (1b)16 (3a)02 (3b)00 (4d)00 (5)00 (6)03 (7)02 (8a)13 (8p)02 (9)05 (11p)00 (12a)00 (12p)03 (4sb)00," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,35,5,,R1,6.86,4.05,1.85,130.8,255.0,3.35,24.0,31.0,153.0,53.0,22.0,4.63,7.37,68.0,185.0,44.0,24.0,5.3,5.3,73.0,303.0,,,,,,,,,,,,,4.54,1.47,0.99,,无,, p1局腹膜(M1 PER),H0,未做,CK(+) vimentin(-) VEGF（-）,,,,,60.51248357424441,1411880
1412029,许树忠,561731,男,63,T3,N1,M0, ⅡB,1,3,1.0,,,, 肠化生+,2.0,17,中间型（int）,INFb,0.0,,0.0,0.0,,,,,2014-04-30,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)50% 粘液腺癌（muc）50% Lauren混合型,G3, (1a)00 (1b)00 (2)00 (3a)11 (3b)04 (4sa)00 (4sb)16 (7)01 (8a) (8p) (9)05," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,60,8, R0 D2,,7.54,60.6,30.7,143.0,248.0,4.66,11.0,14.0,128.0,90.0,14.0,8.87,3.3,73.0,190.0,41.0,32.0,5.2,4.6,115.0,352.0,,,,,,,,,,,,,0.891,15.83,11.3,,无, 无, P0,H0,未做,ck（+）、vimentin（-）、VEGF（-）,,,,,100.06570302233902,1412029
1411947,高志杰,561150,男,75,T4b,N2,M1, Ⅳ,1,2,1.0,,,1.0, 肠化生+ 慢性炎症（+）,3.0,8,硬型（sci）,INFb,0.0,,0.0,0.0,,,,,2014-04-30,2015-07-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)00 (1b)00 (2)00 (3a)11 (3b)11 (4sa)00 (4sb)00 (4d)02 (5)00 (6)00 (7)14,MU 前Ant 后Post 小弯侧Less ,40,40,10,,R2,6.88,51.61,38.2,114.4,241.0,4.03,9.0,16.0,145.0,69.0,13.0,9.97,4.4,72.0,212.0,43.0,29.0,5.3,6.3,90.0,238.0,,,,,,,,,,,,,30.71,529.8,6.44, 未做,无,, p1局腹膜(M1 PER),H0, 未做,ck(+)  vimentin(-)  VEGF(-) ,,,,,14.487516425755585,1411947
1411807,王秀云,559148,女,64,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 腺体萎缩+ 肠化生+,5.0,15,中间型（int）,INFc,3.0,,0.0,0.0,,,,,2014-04-29,2015-11-23,2,,,XELOX,口服替吉奥,,,,,2, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)02 (3a)00 (3b)00 (4sb)00 (4d)36 (5)00 (6)11 (7)12 (8a)01 (8p)00 (9)02 (11p)00 (12a)00 (12p)01," L（幽门窦部）, 前Ant,",40,40,8,,R1,4.89,2.47,1.86,121.8,433.0,3.85,13.0,25.0,167.0,91.0,10.0,7.91,1.91,73.0,199.0,44.0,29.0,5.7,6.2,63.0,240.0,,,,,,,,,,,,,2.86,12.13,7.14,,无, 无, P0,H0,已冲,ck(+) vimentin(-) VEGF(-),,,,,18.823915900131404,1411807
1411878,吕继民,561897,男,45,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 腺体萎缩+ 肠化生+,0.0,21,中间型（int）,INFa,1.0,,0.0,0.0,,,,,2014-04-29,2021-07-22,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)05 (3a)03 (4sb)00 (8a)03 (8p)01 (9)00 (11p)02 (7)00 (12a)00 (3b)00 (4d)03 (5)00 (16a1)03," L（幽门窦部）, M（胃体部）,",10,10,1, R0 D2,,8.74,62.4,25.1,165.0,199.0,2.89,26.0,27.0,135.0,81.0,14.0,15.06,6.09,70.0,294.0,45.0,25.0,4.4,6.3,75.0,311.0,,,,,,,,,,,,,2.83,0.6,6.3,,无, 无, P0,H0,已做,"CK+,vimentin-,VEGF-",,,,,86.76084099868594,1411878
1411914,张树梅,561803,女,51,T4b,N2,M0, ⅢB,1,3,0.0,,,1.0, 正常,4.0,47,髓样型（med）,INFb,0.0,,0.0,0.0,,,,,2014-04-29,2015-10-07,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)12 (3b)16 (4d)217 (5)00 (7)011 (8a)01 (8p)00 (9)01 (11p)06 (12a)00 (14v)01 (16a1)01 (6)01 (4sb)00, L（幽门窦部） 后Post,40,40,8, D2+ R0,,4.7,2.41,1.83,127.0,209.0,2.9,11.0,13.0,142.0,79.0,2.0,7.33,2.66,63.0,165.0,38.0,25.0,4.8,6.7,78.0,199.0,,,,,,,,,,,,,1.94,13.35,4.22, 未做,无, 无, P0,H0,未做,ck（+），vimentin（-），VEGF(-),,,,,17.279894875164256,1411914
1411906,于淑贤,561804,女,68,T4b,N2,M0, ⅢB,1,5,1.0,0.0,0.0,0.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,4.0,38,中间型（int）,INFb,0.0,,0.0,0.0,,,,,2014-05-29,2015-07-22,2,,,,,,,,,0, 管状腺癌中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3,(3b)00 (4sa)00 (4sb)05 (4d)05 (5)01 (7)04 (8p) (9)01 (3a)38 (8a)04 (6)00 (11p)01 (1a)00 (1b)18 (2)01,G 前Ant 小弯侧Less 后Post ,65,30,15,,R2,5.96,2.95,2.64,104.0,186.0,2.58,14.0,21.0,208.0,70.0,12.0,7.54,2.91,70.0,121.0,39.0,31.0,5.0,7.6,77.0,229.0,,,,,,,,,,,,,1.56,7.42,1.46, 未做,无, 无, P0,H0,已冲,ck（+），vimentin（-），VEGF(-),,,,,13.764783180026281,1411906
1411760,王德华,561840,女,46,T3,N2,M0, ⅢA,1,4,1.0,1.0,1.0,, 正常,3.0,35,硬型（sci）,INFb,2.0,,0.0,0.0,,,,,2014-04-28,2019-04-23,1,,,,,,,,,0, 粘液腺癌（muc）90 低分化腺癌（G3)(por)5 低粘附腺癌5 Lauren混合型,G3, (1a)00 (1b)03 (4sb)01 (3b)12 (8a)11 (8p) (9)03 (3a)01 (4d)04 (14v)02 (5)02 (7)013 (6)13,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,110,40,12, D2+ R0,,6.39,3.91,1.79,124.0,280.0,2.68,18.0,21.0,174.0,83.0,12.0,8.17,2.56,69.0,236.0,42.0,27.0,4.8,5.1,72.0,,,,,,,,,,,,,,1.65,36.29,15.8, 未做,无, 无, P0,H0,未做,ck（+），vimentin（-），VEGF(-),,,,,59.82260183968462,1411760
1412105,林森,561751,男,55,T4b,N3a,M0, ⅢC,1,5,3.0,1.0,1.0,, 肠化生+,12.0,20,髓样型（med）,INFb,0.0,,0.0,0.0,,,,,2014-05-04,2016-01-01,0,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (3a)55 (2)02 (1b)11 (1a)01 (6)23 (5)00 (3b)11 (4sa)04 (4sb)11 (4d)22," M（胃体部）, L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,25,,R2,7.86,63.5,21.6,55.0,375.0,4.43,,,,41.0,12.0,,,,124.0,32.0,27.0,,,,,,,,,,,,,,,,,0.761,2.82,13.79,,无, 无, P0,H0, 已冲,ck（+）、vimentin（-）、VEGF(-),,,,,19.940867279894874,1412105
1412063,赵永力,561442,男,53,T4b,N1,M0, ⅢB,1,2,2.0,,,1.0, 正常,2.0,24,髓样型（med）,INFc,3.0,,0.0,0.0,,,,,2014-04-30,2014-10-27,2,,,SOX,SOX,SOX,口服替吉奥,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)11 (2)03 (3a)11 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)00 (6)07 (7)02 (8a)00 (8p)04 (9)04 (11p)01 (12a)00," M（胃体部）, U（胃底部）, MU 前Ant, 后Post, 小弯侧Less,",35,30,10,,R1,8.5,5.66,2.28,129.6,360.0,5.16,15.0,16.0,136.0,82.0,33.0,8.74,3.52,77.0,175.0,45.0,32.0,5.8,6.1,104.0,340.0,,,,,,,,,,,,,0.719,5.29,1.01,,无,, P0,H0,已冲,CK(+) vimentin(-) VEGF（-）,,,,,5.913272010512483,1412063
1412011,侯淑贞,561814,女,73,T4b,N3a,M1, Ⅳ,1,3,0.0,,,1.0, 腺体萎缩+ 慢性炎症（+）,10.0,38,中间型（int）,INFc,1.0,,0.0,0.0,,,,,2014-04-30,2014-12-02,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 低粘附腺癌10 粘液腺癌（muc）5 Lauren肠型,G3, (1a)03 (1b)13 (3a)15 (3b)36 (4d)08 (5)00 (6)33 (7)04 (8a)11 (9)02 (11p)02 (14v)11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",55,40,8,,R1,4.94,3.26,1.19,88.0,243.0,2.28,8.0,14.0,168.0,44.0,4.0,13.78,4.81,52.0,142.0,35.0,17.0,5.4,7.4,78.0,195.0,,,,,,,,,,,,,1.7,5.28,6.65,,无, 无, p1局腹膜(M1 PER),H0,未做,CK(+) vimentin(-) VEGF（-）,,,,,7.09592641261498,1412011
1411977,王国全,561151,男,52,T3,N3a,M0,ⅢB,1,3,2.0,,,1.0, 慢性炎症（+）,7.0,16,髓样型（med）,INFc,1.0,,0.0,0.0,,,,,2014-04-30,2020-09-08,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌90 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)01 (1b)00 (3a)23  (4sb)11 (7)11 (8a)00 (9)02 (10)11 (11p)15 (14v)12," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,15, R0 D2,,5.64,2.72,2.28,137.0,237.0,3.85,19.0,22.0,163.0,77.0,16.0,11.09,4.31,69.0,187.0,41.0,28.0,5.4,7.0,81.0,454.0,,,,,,,,,,,,,11.27,7.07,9.2,,无, 无, P0,H0, 未做, CK+， Vimentin- VEGF-,,,,,76.31406044678054,1411977
1412181,赵殿武,561875,男,82,T3,N3a,M0,ⅢB,1,5,1.0,1.0,1.0,1.0, 慢性炎症（+）,13.0,20,硬型（sci）,INFc,2.0,,0.0,0.0,,,,,2014-05-05,2014-12-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 50 低粘附腺癌 40 粘液腺癌（muc）10 Lauren混合型,G3, (1a) 01(1b) 44(2)11 (3a)55 (3b) 00(4sa)00 (4sb)01 (4d) 02(5) 00(6)03 (7)33," GE, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,30,8,,R1,5.16,60.73,26.84,127.4,216.0,2.45,12.0,15.0,160.0,79.0,7.0,16.7,5.89,71.0,207.0,42.0,29.0,4.5,8.3,90.0,287.0,,,,,,,,,,,,,29.57,19.38,20.18, 未做,无,, P0,H0,未做,"VEGF-,CK+,vimentin-",,,,,6.898817345597897,1412181
1412107,牟桂琴,554703,女,71,T4b,N3b,M1, Ⅳ,1,5,2.0,1.0,1.0,1.0, 异型增生+ 慢性炎症（+）,34.0,40,髓样型（med）,INFc,1.0,,0.0,0.0,,,,,2014-05-04,2014-07-27,2,,,S1,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,小弯00  (4sb)33 (1a)11 (1b)22 (2)00 (3a)11 (3b)11 (4sa)11 (5)00 (6)05 (7)11 (8a、8p)22 (10)99 (11p)44 (12p)11 (4d)89," M（胃体部）, U（胃底部）, UM 前Ant, 后Post, 小弯侧Less,",80,70,10,,R2,5.0,2.52,1.59,90.4,220.0,3.21,12.0,24.0,188.0,93.0,8.0,9.68,3.72,77.0,160.0,41.0,36.0,4.8,4.1,76.0,280.0,,,,,,,,,,,,,0.475,26.33,15.34,,无, 无, p1局腹膜(M1 PER),H0,未做,CK(+) vimentin(-) VEGF（-）,,,,,2.759526938239159,1412107
1412395,冯立凯,561048,男,52,T1a,N0,M0,ⅠA,1,0,0.0,,,,,0.0,34,髓样型（med）,,1.0,,0.0,0.0,,,,,2014-05-06,2019-03-08,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1b)05 (8a) (8p)03 (5)01 (7)02 (3a)01 (6)05 (4sb)01 (1a)03 (9)04 (3b)02 (4d)07," L（幽门窦部）, 后Post,",15,10,3, R0 D2,,6.69,51.77,38.25,144.5,319.0,2.12,16.0,21.0,178.0,63.0,8.0,13.08,5.14,67.0,283.0,41.0,26.0,4.9,9.0,90.0,344.0,,,,,,,,,,,,,3.25,12.51,2.58, 未做,无, 无, P0,H0,未做, CK（+） Vimentin（-） VEGF（-）,,,,,58.04862023653088,1412395
1412317,张福君,561899,男,36,T4a,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 正常,21.0,24,硬型（sci）,INFc,0.0,,0.0,0.0,,,,,2014-05-06,2015-04-15,0,,,紫衫醇联合替吉奥,,,,,,0, 粘液腺癌（muc）60% 低粘附腺癌40% Lauren弥漫型,GX, (1a)00 (1b)02 (3a)55 (3b)11 (5)00 (6)55 (7)12 (8a) (8p)11 (9)22 (4sa) (4sb) (4d)66," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,40,6,,R1,6.65,55.16,31.61,155.5,198.0,2.24,20.0,18.0,161.0,85.0,32.0,14.83,5.17,77.0,247.0,45.0,32.0,5.2,8.3,87.0,401.0,,,,,,,,,,,,,3.93,0.6,300.0,,无, 无, P0,H0,未做,,,,,,11.300919842312746,1412317
1412172,隋淑范,561052,女,73,T1a,N1,M0, ⅠB,1,0,1.0,1.0,1.0,, 异型增生+ 慢性炎,1.0,21,,,0.0,,0.0,0.0,,,,,2014-05-04,2020-04-29,1,,,,,,,,,0, 低粘附腺癌50% 低分化腺癌（G3)(por)50% Lauren混合型,G3, (1a)04 (1b)04 (4d)11 (3b)00 (5)01 (8a) (8p)08 (4sb)00 (3a)00 (6)00 (7)00 (9)03," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,15,2, R0 D2+,,6.74,48.56,41.5,125.0,194.0,4.9,15.0,20.0,178.0,116.0,10.0,9.17,3.14,66.0,199.0,35.0,31.0,4.7,6.5,74.0,262.0,,,,,,,,,,,,,1.66,8.75,2.8, 未做,无, 无, P0,H0,未做, CK （+）Vimentin（-） VEGF （-）,,,,,71.84625492772668,1412172
1412452,陈茂德,561905,男,74,T4b,N3a,M1, Ⅳ,1,4,3.0,,,, 腺体萎缩+ 肠化生+,10.0,24,硬型（sci）,INFc,0.0,,0.0,0.0,,,,,2014-05-07,2015-11-11,2,,,,,,,,,0, 粘液腺癌（muc） Lauren不确定型,GX, (4d)613 (3b)01 (6)22 (5)11 (12a)00 (11p)00 (9)00 (8p)01 (8a)11 (7)01 (4sb)01 (3a)01 (1b)02 (1a)00," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,50,20,,R1,7.71,64.0,25.34,148.6,262.0,2.68,19.0,29.0,154.0,107.0,13.0,7.21,2.7,73.0,288.0,44.0,29.0,7.1,6.2,99.0,387.0,,,,,,,,,,,,,6.74,444.7,105.2,,无, 无, p1局腹膜(M1 PER),H0,已冲,"CK+,vimentin,VEGF",,,,,18.166885676741128,1412452
1412713,艾厚臣,561869,男,61,T4a,N2,M0, ⅢA,1,2,1.0,1.0,1.0,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,5.0,24,中间型（int）,INFc,0.0,,0.0,0.0,,,,,2014-05-08,2016-07-13,2,,,XELOX,XELOX,SOX,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3, (3a)04 (3b)12 (4d)22 (5)00 (1b)00 (1a)00 (6)25 (8p) (9)04 (8a)(8p) 03 (12a)00 (4sb)00 (7)02 (16a1)02,L（幽门窦部） 小弯侧Less 后Post ,40,35,10, D2,,7.4,4.3,2.28,128.0,520.0,3.43,13.0,18.0,154.0,85.0,18.0,8.4,3.32,67.0,142.0,35.0,32.0,10.3,12.6,88.0,234.0,,,,,,,,,,,,,5.15,0.6,13.91, 未做,无,, P0,H0,已冲,ck（+），vimentin（-），VEGF(-),,,,,26.182654402102497,1412713
1412535,初云阁,561860,男,78,T3,N1,M0, ⅡB,1,2,0.0,,,1.0, 正常,1.0,9,中间型（int）,INFb,1.0,,0.0,0.0,,,,,2014-05-07,2019-04-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,,U（胃底部） 小弯侧Less 前Ant 后Post  ,30,35,6, R0 D1+,,4.75,50.06,38.75,151.7,313.0,2.84,35.0,27.0,184.0,65.0,28.0,11.21,4.21,72.0,232.0,42.0,30.0,5.4,6.1,87.0,355.0,,,,,,,,,,,,,3.49,11.12,2.18, 未做,无,, P0,H0,未做,CK+ VEGF- vimentin-,,,,,58.96846254927726,1412535
1413126,胡玉才,561270,男,63,T2,N1,M0, ⅡA,1,4,2.0,,,, 腺体萎缩+ 慢性炎症（+）,2.0,40,硬型（sci）,INFc,0.0,,,,,,,,2014-05-15,2015-10-24,0,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)06 (1b)02 (3a)01 (3b)16 (4sb)00 (4d)19 (5)00 (6)03 (7)05 (8a) (8p)03 (9)01 (11p) (11d)03 (12a)00," L（幽门窦部）, 后Post,",60,40,3, D2,,8.17,3.88,3.22,145.5,294.0,3.85,15.0,21.0,130.0,105.0,20.0,8.98,3.03,71.0,269.0,42.0,29.0,4.0,5.6,76.0,233.0,,,,,,,,,,,,,4.06,0.6,4.58,,无,, P0,H0,未做,ck（+），vimentin（-），VEGF(-),,,,,17.31274638633377,1413126
1412588,牟其昌,561091,男,67,T3,N1,M0, ⅡB,1,3,0.0,,,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,1.0,21,中间型（int）,INFc,1.0,,,,,,,,2014-05-08,2017-06-06,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (3b)01 (4d)05 (5)00 (1a)00 (1b)01 (3a)06 (4sb)00 (6)11 (7)00 (8a)00 (8p)03 (9)03 (11p)01 (12a)00," L（幽门窦部）, 前Ant,",35,35,20, R0 D2,,5.18,3.05,1.74,139.0,147.0,3.35,18.0,19.0,162.0,52.0,8.0,8.61,3.38,76.0,226.0,44.0,32.0,5.9,7.2,102.0,347.0,,,,,,,,,,,,,5.2,34.16,2.8,,无,, P0,H0, 已冲,CK(+) vimentin(-) VEGF（-）,,,,,36.957950065703024,1412588
1412908,李信,561206,男,65,T4b,N3a,M0, ⅢC,1,2,1.0,,,, 腺体萎缩+ 肠化生+ 异型增生+,14.0,32,硬型（sci）,INFb,2.0,,,,,,,,2014-05-12,2016-06-15,2,,,,,,,,,0, 粘液腺癌（muc）70 乳头状癌（G1）（pap）30 Lauren混合型,G1, (1a)04 (1b)03 (3a)34 (4sb)00 (6) (14v)55 (7)13 (8a)11 (8p)11  (9)06 (12a)11 (13)11 (3b)00 (4d)13 (5)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,50,10,,R1,3.81,55.6,32.3,125.0,203.0,3.35,14.0,20.0,152.0,55.0,12.3,5.3,2.44,56.0,155.0,33.0,23.0,5.1,5.7,74.0,124.0,,,,,,,,,,,,,177.9,11.78,300.0,,无, 无, P0,H0,已做,"CK+,vimentin-,VEGF-",,,,,25.131406044678055,1412908
1412696,杨财,560436,男,52,T2,N0,M0, ⅠB,1,2,1.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,0.0,18,中间型（int）,INFa,0.0,,,,,,,,2014-05-08,2022-09-01,1,,,XELOX,XELOX,XELOX,,,,3, 低分化管状腺癌60% 低黏附性癌40%,G3, (1a)02 (1b)01 (3a)02 (3b)00 (4sb)00 (4d)05 (5)00 (6)00 (7)02 (8a)01 (8p)00 (9)00 (11p)04 (12a)01," L（幽门窦部）, 小弯侧Less,",20,15,5, R0 D2,,5.63,57.5,34.4,161.0,183.0,3.07,22.0,25.0,130.0,61.0,12.0,10.17,3.96,71.0,322.0,43.0,28.0,8.3,6.0,74.0,321.0,,,,,,,,,,,,,1.36,8.27,6.43,,无, 无, P0,H0, 已冲, CK+  VEGF-  Vimentin- C-erbB-2 0,,,,,99.80289093298292,1412696
1412710,孙跃武,561361,男,52,T3,N1,M0, ⅡB,1,3,1.0,1.0,1.0,, 肠化生+ 异型增生+,1.0,24,中间型（int）,INFb,1.0,,,,,,,,2014-05-08,2019-05-01,0,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)50 乳头状癌（G1）（pap）30 粘液腺癌（muc）20 Lauren混合型,G3, (2)07 (8a)02 (4sb)00 (12a)00 (8p)04 (9)03 (11p)02 (5)00 (6)00 (7)01 (4sa)00 (1a)01 (1b)00 (3a)12 (3b)00 (4d)02," M（胃体部）, 后Post,",25,20,3, R0 D2,,4.61,49.9,39.0,145.0,182.0,1.83,43.0,36.0,156.0,76.0,183.0,13.58,4.65,67.0,288.0,43.0,24.0,6.5,5.6,89.0,289.0,,,,,,,,,,,,,5.39,13.32,1.91,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-,,,,,59.75689881734559,1412710
1413006,李玉芳,561210,女,56,T1a,N1,M0, ⅠB,1,0,0.0,,,,,1.0,12,髓样型（med）,,2.0,,,,,,,,2014-05-12,2019-04-23,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (4sb)00 (5)00 (7)11 (11p)03 (12a)00 (6)01 (3b)00 (4d)03 (8a) (8p) (9)02," L（幽门窦部）, 小弯侧Less,",80,50,50, D2 R0,,9.14,6.35,2.33,148.0,264.0,3.01,15.0,23.0,170.0,15.0,9.0,12.42,3.79,74.0,245.0,45.0,29.0,6.1,5.3,82.0,205.0,,,,,,,,,,,,,1.96,8.86,1.12, 未做,无, 无, P0,H0,已冲,"ck(+) vimentin(-),VEGF(-)",,,,,59.36268068331143,1413006
1412577,王娟,561272,女,51,T3,N0,M0, ⅡA,1,3,0.0,,,, 正常,0.0,28,硬型（sci）,INFb,1.0,,,,,,,,2014-05-08,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a)00 (1b)00 (2)05 (3a)02 (3b)03 (4sa)00 (4sb)00 (4d)00 (5)00 (6)07 (7)02 (8a) 01(8p)02 (9)04 (11p)02, LM 小弯侧Less 前Ant 后Post ,70,60,4, R0 D2,,6.61,46.7,40.78,150.3,253.0,2.68,13.0,20.0,142.0,87.0,12.0,19.07,5.65,71.0,227.0,43.0,28.0,5.3,5.5,67.0,244.0,,,,,,,,,,,,,1.94,198.3,9.38, 未做,无, 无, P0,H0,未做,"CK+,VEGF+，vinmentin-",,,,,99.80289093298292,1412577
1413117,母德军,562581,男,54,T2,N0,M0, ⅠB,1,3,2.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,0.0,12,中间型（int）,INFb,0.0,,,,,,,,2014-05-13,2022-09-01,1,,,,,,,,,0, 低粘附腺癌40% 低分化腺癌（G3)(por)30% 粘液腺癌（muc）30% Lauren弥漫型,G3, (1a)00 (1b)02 (3a)04 (5)00 (6)00 (3b)00 (4d)01 (7)03 (8a) (8p)01 (9)01 (10)00 (4sb)00," L（幽门窦部）, 后Post, 大弯侧Gre,",15,12,5, R0,,5.27,48.54,31.97,133.1,333.0,2.78,25.0,19.0,167.0,112.0,33.0,10.7,3.99,75.0,240.0,46.0,29.0,5.5,4.9,81.0,222.0,,,,,,,,,,,,,3.76,8.24,5.01, 阳性+,无, 无, P0,H0,未做,ck(-)、VEGF(-)、vimentin(-),,,,,99.63863337713535,1413117
1413061,席忠国,562315,男,57,T4b,N1,M0, ⅢB,1,3,0.0,,,, 肠化生+ 慢性炎症（+）,1.0,45,硬型（sci）,INFb,0.0,,,,,,,,2014-05-13,2016-03-01,2,,,,,,,,,0,蕈伞型 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (2)03 (3a)03 (3b)13 (4sa)01 (4sb)01 (1b)03 (11p)010 (11d)00 (12a)02 (4d)04 (5)00 (6)00 (7)01 (8a)04 (8p)02 (9)05," LMU 前Ant, 后Post, 小弯侧Less,",83,80,10,,R1,6.45,4.72,1.34,79.0,448.0,3.85,11.0,18.0,148.0,102.0,32.0,13.02,5.24,75.0,196.0,44.0,31.0,6.3,7.6,67.0,308.0,,,,,,,,,,,,,1.27,5.65,1.64,,无,, P0,H0,已冲,CK(+) vimentin(-) VEGF（-）,,,,,21.616294349540077,1413061
1413649,丛龙柱,560752,男,65,T2,N0,M0, ⅠB,1,4,1.0,,,, 异型增生+,0.0,19,中间型（int）,INFa,0.0,,,,,,,,2014-05-17,2017-09-06,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3, (15)01  (6)01 (7)03 (8a) (8p)01 (9)00 (11p)00 (12a)00 (1a)04 (1b)03 (3a)02 (3b)01 (4d)00 (4sb)00 (5)03,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,60,, D2,,4.98,2.71,1.73,138.0,360.0,3.85,12.0,14.0,161.0,55.0,2.0,4.68,8.54,72.0,200.0,41.0,31.0,5.3,5.4,88.0,271.0,,,,,,,,,,,,,3.38,5.96,1.05,,无,, P0,H0,未做,ck（+），vimentin（-），VEGF(-),,,,,39.68462549277267,1413649
1413390,卜庆发,562115,男,49,T1b,N0,M0,ⅠA,1,0,0.0,,,,,0.0,22,中间型（int）,INFa,0.0,,,,,,,,2014-05-14,2018-06-21,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)010 (1b)02 (3a)01 (3b) 02 (4sb)00 (4d)02 (5)00 (6)02 (7) 01(8a) (8p) (9) (11p)02," L（幽门窦部）, 小弯侧Less,",15,15,5, R0 D2,,4.4,50.86,39.28,148.3,204.0,1.64,56.0,65.0,181.0,56.0,72.0,17.89,5.28,72.0,404.0,42.0,30.0,5.5,5.0,73.0,345.0,,,,,,,,,,,,,0.612,4.39,1.44, 未做,无,, P0,H0,未做,CK+ VEGF- vimentin-,,,,,49.24441524310118,1413390
1413900,于士良,562352,男,43,T3,N2,M0, ⅢA,1,3,3.0,1.0,1.0,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,4.0,31,硬型（sci）,INFc,0.0,,,,,,,,2014-05-20,2017-09-06,0,,,XELOX,XELOX,,,,,2, 粘液腺癌（muc）70 低分化腺癌（G3)(por)15 低粘附腺癌15 Lauren不确定,G3, (1a)03 (9)06 (8a) (8p)04 (7)02 (6)06 (5)00 (4sb)00 (4d)01 (3b)01 (3a)48 (1b)00,L（幽门窦部） 前Ant 后Post 小弯侧Less ,30,40,8, D2 R0,,7.79,4.0,3.1,148.0,154.0,1.93,93.0,50.0,142.0,145.0,66.0,7.77,3.52,69.0,193.0,41.0,28.0,4.7,5.6,82.0,270.0,,,,,,,,,,,,,1.43,3.98,12.71, 未做,无,, P0,H0,未做,ck（+），vimentin（-），VEGF(-),,,,,39.58607095926413,1413900
1413444,周福珍,558828,女,70,T3,N0,M0, ⅡA,1,2,1.0,,,, 腺体萎缩+ 慢性炎症（+）,0.0,4,硬型（sci）,INFc,0.0,,,,,,,,2014-05-15,2020-04-29,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】50% 低粘附腺癌50% Lauren混合型,G3, (8a)01大弯02小湾01," L（幽门窦部）, 大弯侧Gre,",30,30,12, R0,,6.61,53.5,35.5,136.4,203.0,2.24,18.0,15.0,150.0,73.0,13.0,12.96,5.69,73.0,209.0,41.0,32.0,5.5,4.0,57.0,215.0,,,,,,,,,,,,,10.28,9.86,1.13, 未做,无, 无, P0,H0,未做,,,,,,71.48488830486203,1413444
1413812,曹淑香,562111,女,64,T2,N2,M0, ⅡB,1,2,3.0,1.0,1.0,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,4.0,31,中间型（int）,INFb,1.0,,,,,,,,2014-05-20,2020-04-29,1,,,,,,,,,0, 低分化腺癌（G3)(por)70% 低粘附腺癌30%  Lauren不确定型,G3, (1a) (1b)05 (5)00 (3a) (3b)03 (4d)06 (6)35 (7)02 (8a)15 (9)04 (12a)00 (8p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,35,5, R0,,4.2,39.62,46.56,119.1,232.0,4.66,15.0,22.0,148.0,87.0,7.0,7.64,2.27,61.0,264.0,37.0,24.0,4.8,5.0,74.0,210.0,,,,,,,,,,,,,1.87,17.3,8.29, 未做,无, 无, P0,H0,已冲,ck（-）、vimentin（-）、VEGF(-),,,,,71.32063074901446,1413812
1413539,朱全顺,558852,男,59,T1b,N0,M0,ⅠA,1,0,0.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,0.0,8,中间型（int）,,1.0,,,,,,,,2014-05-16,2019-04-15,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (8a) (8p)00 (4sb)00 (4d)00 (14v)01 (6)03 (5)00 (7) (9)01 (1a) (1b) (3a) (3b)04,L（幽门窦部） 前Ant 小弯侧Less ,30,30,5, D2 R0,,5.9,3.08,1.96,151.0,233.0,2.54,21.0,26.0,150.0,,,27.8,10.03,71.0,341.0,41.0,30.0,5.5,5.6,74.0,274.0,,,,,,,,,,,,,2.6,26.15,0.963, 未做,无,, P0,H0,未做,ck（+），vimentin（-），VEGF(+),,,,,58.96846254927726,1413539
1414058,李敬成,561934,男,74,T3,N3a,M0,ⅢB,1,1,1.0,1.0,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,8.0,19,硬型（sci）,INFc,0.0,,,,,,,0.0,2014-05-21,2019-05-01,0,,,,,,,,,0, 粘液腺癌（muc）60 低粘附腺癌30 乳头状癌（G1）（pap）10 Lauren混合型,G1, (1a)02 (1b)11 (2)35 (3a)00 (3b)12 (4sa)00 (4sb)00 (6)00 (7)34 (8a)00 (8p)01 (9)02 (11p)00,"EG SiewerⅢ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",65,35,12, R0 D2,,5.78,58.23,27.71,139.6,243.0,2.27,15.0,25.0,200.0,79.0,21.0,11.22,4.3,74.0,219.0,40.0,34.0,4.8,6.0,90.0,351.0,,,,,,,,,,,,,2.59,27.22,0.981,,无, 无, P0,H0,未做,"ck+,vimentin-,VEGF-,cMET-",,,,,59.32982917214191,1414058
1413810,李金芝,562018,女,65,T4b,N3a,M1, Ⅳ,1,3,2.0,,,1.0, 正常,7.0,45,硬型（sci）,INFc,2.0,,,,,,,,2014-05-20,2014-09-02,2,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)00 (1b)03 (3a)48 (3b)00 (4sb)02 (4d)212 (5)00 (6)15 (7)01 (8a)04 (8p、9)07 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,30,8,,R2,6.81,4.42,1.38,142.0,142.0,2.89,10.0,12.0,132.0,65.0,7.0,7.46,3.04,67.0,217.0,39.0,28.0,7.1,7.2,73.0,217.0,,,,,,,,,,,,,2.32,322.3,3.41,,无,, p1局腹膜(M1 PER),H0,已做,CK(+) vimentin(-) VEGF（-）,,,,,3.4494086727989486,1413810
1414033,陈文忠,560138,男,64,T1a,N0,M0,ⅠA,1,1,0.0,,,, 腺体萎缩+ 肠化生+,0.0,28,髓样型（med）,,1.0,,,,,,,,2014-05-21,2017-09-06,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)   Lauren肠型,G3, (1a)03 (1b)02 (3a)07 (3b)00 (4sb)00 (4d)05 (5)00 (6)03 (7)06 (8a)(8p)01 (9)01 (11)00 (14v)00,L（幽门窦部） 前Ant 小弯侧Less 后Post ,25,25,, R0 D2,,8.08,4.9,2.66,176.6,214.0,2.76,26.0,27.0,239.0,99.0,39.0,15.94,5.29,75.0,258.0,45.0,30.0,5.6,5.4,101.0,215.0,,,,,,,,,,,,,10.36,7.15,1.47,,无,, P0,H0,已冲, CK+  VEGF-  Vimentin- C-erbB-21+,,,,,39.55321944809461,1414033
1414027,陈国柱,562603,男,59,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,30.0,42,中间型（int）,INFb,1.0,,,,,,,,2014-05-21,2015-05-18,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)13 (1b)23 (2)00 (3a)99 (3b)77 (4sa)00 (4sb)00 (4d)310 (5)11 (6)13 (7)22 (8a)33 (8p)11,M（胃体部） 小弯侧Less 前Ant 后Post ,40,30,20,,R1,5.06,58.9,32.4,147.0,194.0,2.89,18.0,19.0,144.0,93.0,14.0,13.99,4.8,72.0,243.0,43.0,29.0,5.0,4.8,82.0,257.0,,,,,,,,,,,,,2.23,18.1,3.21, 未做,无,, P0,H0,未做,CK+ VEGF- vimentin-,,,,,11.892247043363994,1414027
1413936,崔玉芳,562085,女,44,T2,N2,M0, ⅡB,1,5,3.0,,,,,3.0,25,硬型（sci）,INFb,0.0,,,,,,,,2014-05-21,2019-07-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 粘液腺癌（muc）80   低分化腺癌（G3)(por) 10 低粘附腺癌10 Lauren不确定型,G3, (1a)12 (1b)02 (3a)02 (3b)00 (4sb)00 (4d)02 (5)00 (6)00 (7)15 (8a)01 (8p)01 (9)05 (11p)03 (12a)00,L（幽门窦部） 后Post 大弯侧Gre  ,20,15,5, D2,,5.72,3.95,1.3,122.0,193.0,2.39,12.0,18.0,146.0,68.0,11.0,8.7,2.8,66.0,172.0,38.0,28.0,4.3,3.5,60.0,147.0,,,,,,,,,,,,,0.351,13.75,3.04, 未做,无, 无, P0,H0, 已冲,ck（+），vimentin（-），VEGF(-),,,,,61.333771353482256,1413936
1413922,杨志俊,561494,男,62,T1b,N0,M0,ⅠA,1,0,0.0,,,, 腺体萎缩+ 肠化生+ 异型增生+ 慢性炎症（+）,0.0,17,中间型（int）,INFa,1.0,,,,,,,,2014-05-21,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)00 (3b)00 (4sb)00 (4d) 02(5)00 (6)03 (7) 07(8a)04 (8p)00 (9)00 ," L（幽门窦部）, 后Post,",15,10,3, R0 D2,,4.98,43.4,41.6,144.0,235.0,2.49,23.0,20.0,142.0,65.0,15.0,12.2,4.94,70.0,257.0,39.0,31.0,6.4,6.2,94.0,255.0,,,,,,,,,,,,,0.931,5.64,0.825, 未做,无,, P0,H0,,CK+ VEGF- vimentin-,,,,,99.37582128777923,1413922
1414198,刘宝民,561532,男,76,T4b,N3a,M0, ⅢC,1,2,3.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,15.0,39,中间型（int）,INFc,0.0,,,,,,,0.0,2014-05-22,2014-11-20,2,,,,,,,,,0, 低分化腺癌（G3)(por) 粘液腺癌（muc） Lauren不确定型,G3, (1a) (1b) (3a) (3b) (7)215 (4sb)02 (4d)614 (5)00 (6)00 (8a)44 (8p)22 (9)12,L（幽门窦部） 前Ant 后Post 大弯侧Gre  ,70,70,20,,R2,7.61,5.03,1.72,114.0,294.0,4.23,8.6,12.0,174.0,133.0,21.2,6.29,5.55,69.6,160.0,40.2,29.4,11.8,3.94,73.0,167.0,,,,,,,,,,,,,2.33,59.06,4.18,,无,, P0,H0,已做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,5.978975032851511,1414198
1414115,徐永华,562607,女,46,T4a,N3a,M0, ⅢB,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,14.0,25,中间型（int）,INFc,0.0,,,,,,,1.0,2014-05-22,2021-07-09,1,,,SOX,SOX,SOX,SOX,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)01 (3a)33 (3b)44 (4sb)00 (4d)00 (5)12 (6)01 (7)56 (8a)11 (8p)02 (9)02 (11p)02 (12a)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,50,15, R0 D2,,5.37,2.75,2.14,123.0,291.0,2.54,9.4,13.0,143.0,84.0,15.5,9.06,5.39,69.0,193.59,45.6,24.0,5.4,4.3,70.0,227.0,,,,,,,,,,,,,0.824,15.48,2.3,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(弱+) ,,,,,85.57818659658344,1414115
1414543,冯桂云,562710,女,42,T3,N0,M0, ⅡA,1,3,2.0,,,1.0, 正常,0.0,22,中间型（int）,INFc,0.0,,0.0,1.0,,,,0.0,2014-05-27,2020-05-11,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,7, 低粘附腺癌80% 低分化腺癌（G3)(por)20% Lauren弥漫型,G3, (1a) (1b)03 (3a) (3b)04 (4sb)00 (4d)02 (5)01 (6)02 (7)03 (8a)02 (9)03 (11p)00 (12a)00 (14v)02," L（幽门窦部）, 小弯侧Less,",35,30,6, R0 D2+,,5.16,63.1,28.9,128.0,276.0,2.68,38.0,30.0,216.0,61.0,11.8,7.32,6.87,58.3,118.37,37.5,32.0,4.7,1.11,53.0,215.0,,,,,,,,,,,,,1.9,23.44,1.41, 未做,无, 无, P0,H0,已冲,ck（+）、vimentin(+)、VEGF(-)、cMET(-),,,,,71.48488830486203,1414543
1414658,刘财,561555,男,71,T1b,N1,M0, ⅠB,1,0,0.0,,,, 肠化生 异型增生 慢性炎症,1.0,28,髓样型（med）,INFa,2.0,,,,,,,0.0,2014-05-27,2019-05-01,0,,,,,,,,,0, Lauren肠型  管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 ,G3, (1a)00 (1b)00 (3a)05 (3b)00 (4sb)00 (4d)01 (5)01 (6)14 (7)04 (8a)02 (8p)02 (9)02 (11p)02," L（幽门窦部）, 大弯侧Gre,",10,8,5, R0 D2,,7.82,51.47,38.17,154.3,168.0,2.89,24.0,27.0,183.0,86.0,21.0,8.85,3.57,75.0,380.0,43.0,32.0,5.1,6.4,75.0,268.0,,,,,,,,,,,,,0.996,9.05,9.96,,无, 无, P0,H0, 已冲, CK+  VEGF-  Vimentin- C-erbB-2 2+,,,,,59.13272010512483,1414658
1414114,王广利,561523,男,50,T2,N0,M0, ⅠB,1,0,3.0,,,,,0.0,7,中间型（int）,INFb,0.0,,,,,,,0.0,2014-05-22,2020-12-17,1,,,卡培他滨单药口服,,,,,,0, 低分化腺癌（G3)(por) Lauren不确定型,G3, (1a)00 (1b)00 (2)03 (3a)00 (3b)02 (4sb)00 (7)01 (9)00肠系膜动脉根01," M（胃体部）, 大弯侧Gre,",20,20,, R0 D2,,3.05,46.9,40.3,117.0,194.0,1.95,18.0,19.0,175.0,60.0,26.0,11.19,3.95,70.0,360.0,42.0,28.0,4.9,6.2,68.0,284.0,,,,,,,,,,,,,1.51,4.7,2.66,,无, 无, P0,H0,已做,"CK+,vimentin-,VEGF-,cMET-",,,,,78.87647831800263,1414114
1414876,黄殿和,561944,男,68,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 正常,11.0,27,中间型（int）,INFb,0.0,,,,,,,0.0,2014-05-29,2019-05-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)48 (1b)36 (2)22 (3a)16 (3b)00 (4sb)00 (7)11 (8a)02 (9)01 (11p)01 (11d)00," SiewerⅡ, 前Ant, 后Post, 大弯侧Gre,",40,30,12, R0 D2,,7.27,56.21,33.14,144.2,238.0,19.1,15.0,18.0,130.0,109.0,31.0,14.52,5.33,74.0,232.0,42.0,32.0,5.0,7.0,86.0,430.0,,,,,,,,,,,,,5.48,791.4,1.05,,无, 无, P0,H0, 已冲, CK+， Vimentin-， VEGF-， CMET-,,,,,59.0670170827858,1414876
1414500,曹文玉,562515,男,63,T1a,N0,M0,ⅠA,1,0,0.0,,,,,0.0,8,髓样型（med）,,2.0,,,,,,,1.0,2014-05-26,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (2)00 (3a) 01(3b)00 (4sa) 02(4sb)00 (7)01 (8a) (8p)01 (9)01," U（胃底部）, 小弯侧Less,",25,20,5, R0 D2,,6.12,59.26,31.25,150.1,240.0,2.45,24.0,17.0,164.0,51.0,30.0,10.79,5.43,73.0,237.0,40.0,33.0,5.7,6.8,75.0,344.0,,,,,,,,,,,,,1.33,4.72,1.0, 未做,无,, P0,H0,未做,CK+ VEGF+ vimentvin— cMET-,,,,,99.21156373193166,1414500
1414539,袁士友,562688,男,52,T3,N0,M0, ⅡA,1,3,0.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,0.0,70,硬型（sci）,INFb,2.0,,,,,,,1.0,2014-05-27,2020-10-11,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)03 (3a)018 (3b)010 (4d)014 (4sb)00 (5)01 (6)08 (7)04 (8a)03 (8p)01 (9)02 (11p)03 (12a)01," L（幽门窦部）, 小弯侧Less,",30,25,8, R0 D2,,5.65,59.2,20.7,162.0,214.0,2.28,10.0,26.0,114.0,74.0,18.0,14.27,4.17,66.0,221.0,38.0,28.0,4.4,4.7,78.0,296.0,,,,,,,,,,,,,1.13,7.53,5.83, 未做,无, 无, P0,H0, 未做," CK +, Vimentin-, VEGF- CMET+",,,,,76.51116951379763,1414539
1414952,张维国,563290,男,62,T3,N3a,M0,ⅢB,1,3,0.0,,,, 腺体萎缩+ 异型增生+ 慢性炎症（+）,7.0,40,中间型（int）,INFb,1.0,,,,,,,,2014-05-29,2019-07-08,1,,,SOX,SOX,,,,,2,息肉型乳头状腺癌 Lauren肠型,GX, (1a)01 (1b)01 (3a)00 (3b)46 (4d)24 (4sb)00 (5)00 (6)02 (7)14 (8a)02 (8p)01 (9)07 (11p)010 (12a)00 (12p)2," LM 前Ant, 后Post, 小弯侧Less,",50,50,10, R0 D2,,10.32,7.18,2.28,147.9,241.0,2.51,18.0,21.0,159.0,109.0,35.0,8.92,3.33,67.0,220.0,38.0,29.0,4.5,7.7,82.0,373.0,,,,,,,,,,,,,101.5,163.1,4.98,,无,, P0,H0,已冲,CK(+) vimentin(-) VEGF（-）cMET(+/-),,,,,61.300919842312744,1414952
1414962,吴春和,560755,男,45,T4a,N2,M1, Ⅳ,1,2,3.0,,,1.0, 正常,4.0,29,硬型（sci）,INFc,0.0,,,,,,,0.0,2014-05-29,2016-12-15,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 粘液腺癌（muc）60 低分化腺癌（G3)(por)40 Lauren不确定型,G3, (1a)00 (1b)05 (3a)07 (3b)00 (4sb)00 (4d)23 (5)00 (6)22 (7)00 (8a)07 (8p)00 (9)02 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,18,,R1,5.73,3.79,1.11,121.7,359.0,,16.0,18.0,219.0,114.0,41.0,4.22,1.34,67.0,183.0,39.0,28.0,5.3,6.3,79.0,413.0,,,,,,,,,,,,,3.62,152.8,3.18,,粟粒状, 无, p1局腹膜(M1 PER),H0, 已冲, CK+， Vimentin-， VEGF-， CMET-,,,,,30.584756898817343,1414962
1414967,张俊,562081,男,34,T4b,N0,M0, ⅢA,1,2,2.0,,,, 腺体萎缩+ 慢性炎症（+）,0.0,31,硬型（sci）,INFc,0.0,,,,,,,1.0,2014-05-29,2015-05-06,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (4sb)00 (1a)00 (1b)05 (8a)04 (7)02 (12a)00 (6)01 (5)03 (4d)04 (3b)03 (3a)03 (8p)03 (9)02 (11p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,30,15,,R1,6.94,3.94,2.46,142.8,159.0,2.66,11.0,11.0,161.0,69.0,5.0,7.43,4.35,63.0,209.0,40.0,23.0,5.1,3.9,87.0,301.0,,,,,,,,,,,,,0.791,5.46,1.16,,无,, P0,H0,已冲,CK(+) vimentin(+/-) VEGF（-）cMET(+),,,,,11.235216819973719,1414967
1414860,吕彦武,563369,男,56,T3,N2,M0, ⅢA,1,2,0.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,5.0,19,中间型（int）,INFb,2.0,,,,,,,0.0,2014-05-29,2017-08-06,2,,,SOX,SOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) (1b)01 (3a)02 (3b)00 (4sb)00 (4d)11 (5)00 (6)38 (7)00 (8p)00 (9)00 (11p)02 (8a) (12a)15,L（幽门窦部） 小弯侧Less 前Ant 后Post ,60,40,8, R0 D2,,6.86,53.64,37.2,138.1,354.0,1.48,27.0,26.0,186.0,53.0,16.0,5.24,2.18,65.0,259.0,40.0,25.0,5.1,6.9,79.0,233.0,,,,,,,,,,,,,1.8,0.689,3.47, 未做,无,, P0,H0,,CK+ VEGF- cMET- vimentin-,,,,,38.272010512483575,1414860
1415216,谷乃友,563339,男,56,T3,N1,M0, ⅡB,1,3,1.0,,,1.0,肠化生+,1.0,51,中间型（int）,INFc,1.0,,,,,,,1.0,2014-06-03,2017-09-06,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】50 低粘附腺癌40 粘液腺癌（muc）10,G3,, L（幽门窦部） 前Ant 后Post 大弯侧Gre  ,45,35,8, D2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,无,, P0,H0,未做,,,,,,39.12614980289093,1415216
1415220,刘艳霞,561534,女,57,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,6.0,29,硬型（sci）,INFc,0.0,,,,,,,0.0,2014-06-03,2020-07-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)50 低粘附腺癌50 Lauren混合型,G3, (1a)02 (1b)00 (3a)13 (4sb)00 (3b)13 (7)04 (8a)02 (8p)01 (9)05 (11p)02 (6)02 (5)00 (4d)15," L（幽门窦部）, 大弯侧Gre,",25,25,6, R0 D2,,4.16,1.83,1.7,137.6,192.0,2.41,21.0,19.0,144.0,99.0,19.0,14.56,4.77,63.0,319.0,40.0,23.0,4.6,3.4,53.0,254.0,,,,,,,,,,,,,0.2,6.62,1.27,,无, 无, P0,H0, 已冲, CK+， Vimentin-， VEGF-， CMET-,,,,,72.93035479632063,1415220
1415347,赵广奇,562512,男,50,T4a,N3a,M0, ⅢB,1,3,2.0,,,1.0, 肠化生+ 慢性炎症（+）,7.0,24,硬型（sci）,INFc,0.0,,,,,,,0.0,2014-06-04,2015-09-14,2,,,,,,,,,0, 低粘附腺癌 50 粘液腺癌（muc）50 Lauren弥漫型,GX, (1a)00 (1b)03 (3a)02 (3b)01 (4d)59 (4sb)00 (5)11 (6)01 (7) (11p)15 (8a) (8p) (9)02,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,40,40,15,,R2,5.43,3.27,1.49,148.0,389.0,3.27,11.0,14.0,124.0,74.0,9.0,20.38,9.27,64.0,256.0,38.0,26.0,4.5,3.5,78.0,278.0,,,,,,,,,,,,,0.826,7.32,22.71, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,15.341655716162943,1415347
1416196,王玉书,562915,男,76,T2,N0,M0, ⅠB,1,2,0.0,,,, 腺体萎缩+,0.0,17,中间型（int）,INFb,1.0,,,,,,,0.0,2014-06-12,2019-04-01,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)02 (3a)01 (3b)00 (4d)01 (5)00 (6)04 (7)01 (8a) (11p)03 (8p)01 (9)04," L（幽门窦部）, 后Post, 大弯侧Gre,",22,15,6, R0 D2,,4.06,2.5,1.25,86.6,240.0,2.74,9.0,13.0,164.0,50.0,12.0,9.38,3.75,62.0,258.0,38.0,24.0,4.6,9.3,116.0,526.0,,,,,,,,,,,,,2.63,8.67,1.1,,无, 无, P0,H0,,"ck+,vimentin-,VEGF-,cMET-",,,,,57.6215505913272,1416196
1415266,张立国,563596,男,44,T1a,N0,M0,ⅠA,1,0,,,,0.0,,0.0,50,,,0.0,,,,,,,1.0,2014-06-04,2019-05-01,0,,,,,,,,,0, 低粘附腺癌,GX, (6)04 (5)00 (3b)00 (4d)04 (1a)07 (1b)02 (3a)013 (7)02 (8a)05 (11p)03 (9)04 (4sb)01 (12a)00 (8p)04 (12p)00 (2)01," L（幽门窦部）, 大弯侧Gre, 小弯侧Less,",5,5,5, R0 D2,,4.93,2.12,2.13,102.0,214.0,2.03,23.0,22.0,114.0,45.0,15.0,6.79,1.85,57.0,222.0,36.0,21.0,5.8,6.4,86.0,404.0,,,,,,,,,,,,,1.96,9.85,1.99, 未做,无, 无, P0,H0,已冲,"ck+,vimentin-,VEGF-,cMET弱+",,,,,58.86990801576872,1415266
1415150,王世福,563722,男,45,T1b,N0,M0,ⅠA,1,0,0.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,0.0,19,中间型（int）,INFa,0.0,,,,,,,1.0,2014-06-03,2019-04-23,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (5)00 (6)00 (12a)00 (7)01 (11p) (11d)04 (3a) (3b)00 (8a) (8p)04 (1a) (1b)03 (9)02 (4sb)01 (4d)04, L（幽门窦部） 前Ant,5,5,2, D2,,4.1,2.07,1.38,146.0,158.0,2.54,25.0,24.0,155.0,59.0,35.0,13.34,4.33,64.0,382.0,42.0,22.0,4.9,5.6,83.0,431.0,,,,,,,,,,,,,6.68,0.687,6.54, 未做,无,, P0,H0,未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,58.63994743758212,1415150
1415469,李桂侠,563610,女,44,T4a,N2,M0, ⅢA,1,3,2.0,,,1.0, 腺体萎缩+ 慢性炎症（+）,3.0,22,中间型（int）,INFc,1.0,,,,,,,1.0,2014-06-05,2020-04-08,1,,,,,,,,,0, 低粘附腺癌50 低分化腺癌（G3)(por)50 Lauren弥漫型,G3, (1a)03 (1b)00 (3a)03 (3b)12 (4d)02 (5)00 (6)12 (7)03 (8a) (8p) (9)15 (11p)02 (12a)00,L（幽门窦部） 前Ant ,40,40,10, D2,,5.03,3.17,1.32,139.3,242.0,3.46,13.0,15.0,160.0,89.0,6.0,23.28,7.44,71.0,193.0,42.0,29.0,5.6,6.4,71.0,222.0,,,,,,,,,,,,,1.08,19.13,1.06,,无, 无, P0,H0,未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,70.10512483574244,1415469
1415498,庄秀英,563587,女,51,T1b,N0,M0,ⅠA,1,0,0.0,,,,,0.0,25,中间型（int）,INFa,1.0,,,,,,,0.0,2014-06-05,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)05 (1b)01 (3a)03 (3b)00 (4d)05 (4sb)00 (5)01 (6)01 (7)02 (8a)04 (8p)02 (9)00 (11p)00 (14v)01," M（胃体部部）, 小弯侧Less,",12,10,3, R0 D2,,5.62,2.86,1.95,83.6,375.0,2.1,78.0,75.0,241.0,130.0,139.0,17.21,11.48,57.0,167.0,34.0,23.0,5.3,3.7,47.0,68.0,,,,,,,,,,,,,1.2,5.26,1.05, 未做,无, 无, P0,H0,,"ck+,vimentin-,VEGF-,cMET-",,,,,78.41655716162943,1415498
1415735,姜明礼,563570,男,70,T1b,N0,M0,ⅠA,1,0,0.0,,,,,0.0,11,中间型（int）,,1.0,,,,,,,0.0,2014-06-09,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,(3a)01 (3b)00 (4sb)00 (4d)05 (5)00 (6)01 (7)02 (8a) (8p)01 (9)01 (11p)00," L（幽门窦部）, 小弯侧Less,",50,40,, R0 D2,,4.92,28.92,55.51,153.0,87.0,2.32,33.0,36.0,178.0,64.0,15.0,19.47,6.98,67.0,239.0,37.0,30.0,5.2,9.5,75.0,369.0,,,,,,,,,,,,,1.78,10.69,1.79, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-) ,,,,,98.75164257555848,1415735
1415696,顾国伟,563913,男,65,T4a,N2,M0, ⅢA,1,3,0.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,6.0,32,中间型（int）,INFb,0.0,,,,,,,0.0,2014-06-09,2014-08-04,0,,,SOX,SOX,SOX,,,,3,乳头状癌（G1）（pap）50 管状腺癌（中分化【G2】【tub2】50  Lauren肠型,G2, (1a)02 (1b)06 (9)04 (7)06 (3a)00 (3b)11 (12a)00 (5)00 (11p)01 (8a) (8p)03 (4d)00 (4sb)48 (6)00,L（幽门窦部） 前Ant ,70,90,10,,R1,7.22,4.16,1.8,91.0,341.0,3.16,10.0,19.0,149.0,83.0,23.0,8.26,3.09,63.0,249.0,36.0,27.0,4.5,5.7,62.0,362.0,,,,,,,,,,,,,262.5,10.1,, 未做,无, 无, P0,H0,未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,1.8396846254927726,1415696
1415848,王振民,563865,男,39,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,25,,,1.0,,,,,,,0.0,2014-06-10,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 50低粘附腺癌50,G3,," L（幽门窦部）, 小弯侧Less,",20,18,, R0 D2,,5.66,49.4,37.4,156.4,183.0,2.26,17.0,22.0,193.0,63.0,16.0,30.19,15.55,62.0,328.0,44.0,30.0,4.6,2.8,62.0,261.0,,,,,,,,,,,,,1.44,6.18,1.83,,无, 无, P0,H0,未做,,,,,,78.25229960578186,1415848
1415849,崔永利,563836,男,47,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 正常,13.0,29,中间型（int）,INFc,1.0,,,,,,,1.0,2014-06-10,2016-01-02,0,,,XELOX,,,,,,1, 低分化腺癌（G3)(por)50 低粘附腺癌50 Lauren弥漫型,G3, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)01 (4d)00 (5)00 (6) 00(7) 00(8a) 4 10 (8p)01 (9) (11p)37 (12a)47 (14v)01, LM  后Post ,55,45,4, R0 D2,,3.99,42.1,40.26,116.9,234.0,2.66,10.0,16.0,126.0,71.0,10.0,9.94,3.02,63.0,246.0,37.0,26.0,4.8,6.9,85.0,28.0,,,,,,,,,,,,,1.2,6.35,0.934, 未做,无, 无, P0,H0,未做,ck(+)  vimentin(-)  VEGF(-)  cMET(弱+),,,,,18.758212877792378,1415849
1416130,姜桂梅,563670,女,50,T4b,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,25.0,30,中间型（int）,INFc,0.0,,,,,,,0.0,2014-06-11,2015-07-10,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌60 粘液腺癌（muc）40 Lauren弥漫型,GX, (1a)00 (1b)22 (2)11 (3a)55 (3b)00 (4sa)00 (4sb)00 (4d)910 (5)24 (6)22 (7)00 (8a)11 (8p)22 (9)01 (11p)12 (12a)00," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,30,10,,R1,5.64,2.68,1.74,138.1,217.0,3.01,9.0,16.0,128.0,59.0,19.0,10.56,4.55,75.0,241.0,40.0,35.0,5.5,4.0,79.0,339.0,,,,,,,,,,,,,1.1,1.0,56.17,,无, 无, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(-),,,,,12.943495400788436,1416130
1416129,陈淑云,563209,女,53,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,18,,,1.0,,,,,,,0.0,2014-06-11,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)03 (1b)00 (4sb)01 (4d)06 (5)00 (6)01 (7)02 (8a)00 (9)00 (11p)01 (12a)01," L（幽门窦部）, 前Ant,",5,5,5, R0 D2,,4.54,39.34,49.14,113.0,233.0,2.32,17.0,24.0,199.0,42.0,12.0,8.39,3.33,68.0,252.0,41.0,27.0,4.5,5.3,48.0,270.0,,,,,,,,,,,,,0.63,6.32,, 未做,无, 无, P0,H0,未做,ck（+）、vimentin（-）、VEGF（-）、cMET(-),,,,,98.68593955321944,1416129
1416514,苏桂清,563625,女,57,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,, 正常,10.0,24,硬型（sci）,INFc,0.0,,,,,,,0.0,2014-06-16,2016-06-06,2,,,SOX,SOX,SOX,SOX,SOX,SOX,8, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】50 低粘附腺癌50 Lauren混合型,G3, (12a)00 (4sb)00 (9)01 (8p)14 (8a)12 (7)25 (11p)13 (3a)13 (1b)22 (1a)00 (14v)00 (3b)00 (5)01 (6)22 (4d)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,15, R0 D2+,,6.69,4.47,1.78,143.5,178.0,3.53,18.0,21.0,182.0,89.0,2.0,10.32,2.82,72.0,327.0,46.0,26.0,6.6,8.4,64.0,299.0,,,,,,,,,,,,,1.36,1.36,3.94,,无, 无, P0,H0,未做,"ck+,vimentin-,VEGF-,cMET-",,,,,23.68593955321945,1416514
1416282,汪友琴,565792,女,63,T3,N2,M0, ⅢA,1,3,2.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,6.0,21,硬型（sci）,INFc,1.0,,,,,,,0.0,2014-06-12,2018-12-11,2,,,,,,,,,0, 低分化腺癌（G3)(por)50 低粘附腺癌50 Lauren弥漫型,G3, (1a) (1b)05 (3a) (3b)00 (4sb)00 (4d)04 (5)00 (6)24 (7)35 (8a)11 (8p)00 (9)02,L（幽门窦部） 后Post ,13,20,2, R0 D2,,3.41,36.66,50.66,147.5,164.0,2.78,10.0,16.0,143.0,73.0,13.0,15.12,5.1,40.0,280.0,42.0,28.0,5.4,6.5,56.0,204.0,,,,,,,,,,,,,1.72,21.31,0.967, 未做,无, 无, P0,H0,未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,53.975032851511166,1416282
1416312,于长林,565142,男,62,T2,N0,M0, ⅠB,1,3,0.0,,,, 腺体萎缩+ 肠化生+ 慢性炎症（+）,0.0,50,中间型（int）,INFb,0.0,,,,,,,1.0,2014-06-12,2022-09-01,1,,,SOX,SOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)06 (3a)07 (3b)03 (4d)014 (4sb)00 (5)02 (6)02 (7)03 (8a)04 (8p、9)06 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",38,38,10, R0 D2,,6.76,3.32,2.74,133.4,197.0,2.54,19.0,19.0,149.0,119.0,20.0,10.04,3.59,68.0,327.0,40.0,28.0,5.2,6.0,89.0,357.0,,,,,,,,,,,,,4.5,17.08,1.1,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(+),,,,,98.65308804204993,1416312
1417111,刘伟,563157,女,49,T3,N3a,M0,ⅢB,1,3,1.0,,,, 慢性炎症（+）,15.0,30,中间型（int）,INFc,1.0,,,,,,,0.0,2014-06-19,2020-04-28,1,,,SOX,SOX,SOX,SOX,SOX,SOX,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)411 (1b)01 (2)01 (3a)01 (3b)12 (4sb)00 (4d)45 (5)11 (6)01 (7)02 (8a)11 (8p)44 (9)00," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",70,60,10, R0 D2,,4.41,35.52,56.71,138.0,226.0,3.22,12.0,19.0,171.0,57.0,18.0,10.65,3.26,61.0,328.0,37.0,24.0,10.9,2.5,45.0,276.0,,,,,,,,,,,,,1.97,1.17,9.23,,无, 无, P0,H0,未做,ck（+）、vimentin（-）、VEGF（-）、cMET(-),,,,,70.30223390275953,1417111
1416644,耿淑华,564565,女,62,T3,N0,M0, ⅡA,1,3,3.0,,,, 腺体萎缩+ 慢性炎症（+）,0.0,9,中间型（int）,INFb,0.0,,,,,,,,2014-06-17,2014-11-28,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a) 00(1b)01 (2)06 (3a)01 (3b)00 (4sa)00 (4sb) 00(7) 00(8a) 00(9)00 (11p)00,GE 大弯侧Gre  前Ant 后Post ,55,40,8,,R2,7.77,5.31,1.78,118.5,244.0,4.59,11.0,21.0,170.0,88.0,28.0,7.57,2.93,77.0,210.0,46.0,31.0,5.9,5.1,74.0,274.0,,,,,,,,,,,,,1.64,15.18,1.69, 未做,无, 无, P0,H0,未做,ck7(+) ck5/6(+) ck8/18(+) p63（+）,,,,,5.387647831800263,1416644
1416727,刘起民,565778,男,64,T4a,N3a,M0, ⅢB,1,2,0.0,1.0,1.0,1.0, 正常,14.0,22,中间型（int）,INFc,1.0,,,,,,,1.0,2014-06-17,2017-02-15,2,,,FOLFOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 乳头状癌（G1）（pap）10 Lauren肠型,G3, (1a) 11(1b)11 (2)02 (3a)23 (3b)34 (4sa) 00(4sb)00 (4d)22 (5)00 (6)23 (7)22 (8a)01 (8p) (9)02 (11p)11 (12a)00,ML 小弯侧Less 前Ant 后Post ,40,45,10, R0 D2,,9.14,7.05,1.09,138.8,220.0,3.86,12.0,21.0,167.0,111.0,52.0,9.18,3.84,,265.0,38.0,25.0,2.9,7.9,78.0,339.0,,,,,,,,,,,,,1.28,16.73,13.5, 未做,无, 无, P0,H0,未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+),,,,,31.99737187910644,1416727
1416752,孙茂福,563063,男,58,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,11,,,0.0,,,,,,,0.0,2014-06-17,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (3a)00 (3b) 00(4sb)00 (4d) 01(5)00 (6)00 (7)00 (8a)02 (8p)04 (9)01 (11p)02," L（幽门窦部）, 后Post,",10,5,1, R0 D2,,4.99,2.5,1.89,149.3,243.0,2.91,22.0,21.0,142.0,60.0,42.0,6.16,4.82,65.0,311.0,41.0,24.0,4.9,5.8,89.0,486.0,,,,,,,,,,,,,2.39,10.52,0.966, 未做,无, 无, P0,H0,未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,98.48883048620236,1416752
1417190,刘显玉,565717,女,58,T4b,N1,M0, ⅢB,1,3,2.0,,,, 肠化生+ 慢性炎症（+）,2.0,19,中间型（int）,INFc,0.0,,,,,,,0.0,2014-06-20,2014-09-13,2,,,SOX,,,,,,1, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)02 (1b)11 (2)05 (3a)00 (3b)00 (4sa)01 (4sb)00 (4d)04 (5)11 (6)02 (7)00 (8a、8p)00 (9)01 (11d)02 (12a)00 (1b、3a、7、8a、8p)组可见4枚癌结节," LMU 前Ant, 后Post, 小弯侧Less,",55,45,18,,R1,5.01,2.76,1.7,101.7,272.0,3.52,10.0,33.0,163.0,54.0,15.0,7.86,3.75,59.0,186.0,35.0,24.0,3.1,6.9,51.0,472.0,,,,,,,,,,,,,1.28,7.0,1.29,,无, 无, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(-),,,,,2.7923784494086727,1417190
1416912,潘玉富,565334,男,58,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,40,,,0.0,,,,,,,1.0,2014-06-18,2016-07-28,0,,,,,,,,,0, 低粘附腺癌,GX, (1a)01 (1b)01 (3a)010 (3b)00 (4sb)01 (4d)010 (5)01 (6)01 (7)02 (8a)03 (8p)02 (9)03 (11p)01 (12a)00 (12p)04," L（幽门窦部）, 后Post, 小弯侧Less,",15,10,5, R0 D2,,5.06,2.93,1.56,145.0,212.0,2.29,13.0,19.0,138.0,77.0,13.0,10.93,3.49,65.0,369.0,42.0,23.0,4.5,7.6,72.0,299.0,,,,,,,,,,,,,1.79,11.78,3.58,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(弱+),,,,,25.328515111695136,1416912
1416895,戴鹏,564576,男,48,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,21,,,1.0,,,,,,,0.0,2014-06-18,2019-04-15,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90 粘液腺癌（muc）10,G2, (6)00 (4sb)00 (4d)02 (12a)00 (11p)02 (9)02 (8a)01 (8p)01 (7)09 (5)00 (3b)00 (3a)00 (1b)01 (1a)03," L（幽门窦部）, 小弯侧Less,",20,15,5, D2,,5.99,3.32,1.95,149.0,250.0,3.23,18.0,19.0,156.0,82.0,24.0,8.61,3.15,74.0,290.0,46.0,28.0,4.3,5.0,81.0,349.0,,,,,,,,,,,,,2.27,6.39,1.43,,无,, P0,H0,未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,57.88436268068331,1416895
1416799,宋玉福,565421,男,59,T3,N3b,M0, ⅢC,1,2,1.0,,,, 肠化生+ 慢性炎症（+）,18.0,35,中间型（int）,INFc,0.0,,,,,,,1.0,2014-06-18,2019-04-17,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 粘液腺癌（muc）50 管状腺癌（中分化【G2】【tub2】40 低粘附腺癌10 Lauren混合型,G2, (1a)02 (1b)01 (3a)02 (3b)11 (4sb)00 (4d)88 (5)00 (6)610 (7)03 (8a)33 (8p)00 (9)03 (11p)02 (14v)00,L（幽门窦部） 前Ant 小弯侧Less 后Post ,40,40,10,,,5.95,3.64,1.75,140.1,229.0,3.75,11.0,17.0,150.0,104.0,7.0,6.45,5.28,72.0,152.0,38.0,34.0,5.0,6.8,82.0,274.0,,,,,,,,,,,,,0.748,12.7,2.02, 未做,无,, P0,H0,已做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,57.95006570302234,1416799
1417107,郭志臣,565201,男,57,T3,N2,M0, ⅢA,1,3,1.0,1.0,,, 肠化生+ 慢性炎症（+）,5.0,32,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2014-06-19,2017-09-06,0,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)95 粘液腺癌（muc）5 Lauren混合型,G3, (1a)05 (1b)00 (3a)06 (3b)02 (4sb)00 (4d) (6)00 (5) (12a)13 (7)38 (8a)11 (8p)03 (9)03 (11p)01,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,70,50,18,,R1,12.24,10.99,0.52,124.1,266.0,4.36,19.0,14.0,180.0,108.0,9.3,7.29,3.6,59.0,174.0,36.0,23.0,5.6,4.6,76.0,240.0,,,,,,,,,,,,,16.29,7.05,41.71, 未做,无,, P0,H0,已做,ck（+），vimentin（-），VEGF(+)，cMET(-),,,,,38.60052562417871,1417107
1417380,韩祥,565177,男,64,T3,N2,M0, ⅢA,1,3,1.0,,,, 肠化生+,3.0,38,髓样型（med）,INFc,0.0,,1.0,,,,,1.0,2014-06-23,2020-04-08,1,,,,,,,,,0, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)00 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)16 (5)11 (6)14 (7)05 (8)01 (9)03 (11p)02 (12a)02 (14)02 (15)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,17,8, R0 D2+,,5.91,3.5,1.81,135.0,229.0,4.25,17.0,17.0,139.0,75.0,8.0,8.51,2.99,65.0,173.0,39.0,26.0,5.2,7.3,75.0,163.0,,,,,,,,,,,,,7.07,22.64,7.64,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（+）cMET(+),,,,,69.51379763469119,1417380
1417318,孙继权,565707,男,64,T3,N0,M0, ⅡA,1,2,2.0,,,, 肠化生+,0.0,20,髓样型（med）,INFc,0.0,,,,,,,1.0,2014-06-23,2020-10-11,1,,,SOX,SOX,SOX,,,,3, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)02 (3a)03 (3b)00 (4sb)00 (4d)05 (5)00 (6)01 (7)03 (8a)02 (8p)00 (9)02 (11p)01 (12a)00 (14v)00," L（幽门窦部）, 后Post, 大弯侧Gre,",25,15,5, R0 D2,,6.0,3.89,1.24,132.0,194.0,3.22,27.0,14.0,114.0,76.0,18.0,3.97,3.1,56.0,196.0,36.0,20.0,6.0,7.0,93.0,220.0,,,,,,,,,,,,,0.842,8.49,0.883,,无, 无, P0,H0,未做,"ck+,vimentin-,VEGF+,cMET+",,,,,75.62417871222075,1417318
1417115,鲁萍,561588,女,51,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,23,,,0.0,,,,,,,0.0,2014-06-19,2020-05-11,1,,,,,,,,,0, 低粘附腺癌,GX, (1a) (1b)08 (3a) (3b)00 (4sb)00 (4d)07 (5)01 (6)06 (7)00 (8a)01 (9)00 (11p)00," L（幽门窦部）, 大弯侧Gre,",8,,, R0 D2,,5.4,2.54,2.38,138.0,225.0,2.44,59.0,24.0,160.0,62.0,28.0,6.99,2.56,67.0,328.0,40.0,27.0,4.8,4.8,58.0,381.0,,,,,,,,,,,,,1.79,6.85,0.844, 未做,无, 无, P0,H0,未做,ck（+）、VEGF(-)、cMET(+)、vimentin（-）,,,,,70.7293035479632,1417115
1417549,袁清柏,565288,男,61,T4b,N3b,M0, ⅢC,1,4,1.0,,,1.0, 肠化生+,46.0,56,中间型（int）,INFc,1.0,,,,,,,1.0,2014-06-24,2015-05-14,2,,,,,,,,,0, 低粘附腺癌85 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)15 Lauren混合型,G3, (1a)33 (1b)22 (3a)55 (3b)44 (4sa)11 (4sb)03 (4d)99 (5)13 (6)1111 (7)33 (8a)22 (8p)12 (9)46 (11p)00 (12a)00 (12p)02," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,60,10,,R1,5.28,2.43,2.05,161.4,149.0,2.58,53.0,34.0,350.0,82.0,64.5,13.41,5.46,50.0,103.1,31.5,18.5,,7.35,55.0,151.0,,,,,,,,,,,,,4.1,14.93,1.89,,无, 无, P0,H0,未做,"ck+,vimentin-,VEGF-,cMET",,,,,10.64388961892247,1417549
1418294,张世文,566320,男,63,T1a,N0,M0,ⅠA,1,0,0.0,,,, 肠化生+,0.0,27,中间型（int）,INFc,1.0,,,,,,,1.0,2014-07-01,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G2, (1a)01 (1b)00 (2)05 (3a)01 (4sa)010 (4sb)03 (5)00 (8a)01 (8p)05 (9)00 (11p)01," U（胃底部）, 后Post,",8,8,, R0 D1+,,4.75,2.7,1.72,134.0,136.0,1.88,19.0,23.0,179.0,57.0,15.0,16.43,5.9,66.0,207.0,39.0,27.0,4.8,7.0,91.0,237.0,,,,,,,,,,,,,1.52,5.78,0.889,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(部分+),,,,,98.02890932982916,1418294
1417699,杨国良,566796,男,57,T2,N0,M0, ⅠB,1,3,1.0,,,, 肠化生+,0.0,10,中间型（int）,INFc,1.0,,,,,,,1.0,2014-06-25,2019-05-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)50% 低粘附腺癌50% Lauren混合型,G3, (1a)00 (1b)00 (3a)00 (3b)01 (4sb)00 (4d)02 (5)00 (6)00 (7)01 (8a) (8p)04 (9)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",20,18,2, R0 D2,,6.27,65.6,23.1,136.0,377.0,4.2,14.0,20.0,167.0,60.0,41.0,6.4,2.28,73.0,334.0,42.0,31.0,4.9,8.0,81.0,447.0,,,,,,,,,,,,,0.582,4.64,3.15, 未做,无, 无, P0,H0,未做,ck(+)、vimentin（-）、VEGF（-）、cMET弱(+),,,,,58.18002628120893,1417699
1417503,张文成,566490,男,64,T3,N3a,M0,ⅢB,1,3,3.0,1.0,1.0,1.0, 肠化生+,15.0,20,髓样型（med）,INFc,0.0,0.7,,,,,,0.0,2014-06-24,2019-04-13,1,,,SOX,,,,,,6, 低分化腺癌（G3)(por) Lauren混合型 Lauren弥漫型 Lauren肠型,G3, (1a) (1b) (3a) (3b)66 (4sb)00 (4d)14 (5)33 (6)44 (7)02 (12a)11, LM 前Ant 小弯侧Less 后Post 大弯侧Gre,80,80,8,,R2,5.78,3.68,1.21,79.3,374.0,4.88,13.0,19.0,220.0,70.0,22.0,5.03,1.75,60.0,130.0,38.0,22.0,6.1,4.4,86.0,299.0,,,,,,,,,,,,,3.26,11.91,0.892, 未做,无, 无, P0,H0,未做,vimentin(-)  VEGF(-)  cMET(-),,,,,57.6215505913272,1417503
1418064,高彦明,566364,男,54,T3,N1,M0, ⅡB,1,2,0.0,,,, 慢性炎症（+）,2.0,11,中间型（int）,INFc,0.0,,,,,,,1.0,2014-06-30,2020-12-17,1,,,XELOX,,,,,,5, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)02 (1b)01 (3a)12 (3b)01 (4sb)00 (4d)00 (5)00 (6)00 (7)11 (8a)03 (8p)00 (9)01 (12a)00, L（幽门窦部） 前Ant,20,15,10, R0 D2,,7.6,4.16,2.69,158.0,249.0,2.96,29.0,25.0,155.0,62.0,184.0,9.23,3.17,73.0,422.0,48.0,25.0,5.3,6.8,80.0,439.0,,,,,,,,,,,,,2.86,7.97,2.36,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET弱+,,,,,77.59526938239159,1418064
1418224,迟令香,566400,男,62,T4b,N3a,M0, ⅢC,1,2,1.0,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,12.0,41,髓样型（med）,INFc,1.0,,,,,,,1.0,2014-07-01,2015-05-20,2,,,XELOX,XELOX,XELOX,XELOX,SOX,,5, 粘液腺癌（muc）80 低分化腺癌（G3)(por)10 低粘附腺癌10 Lauren混合型,G3,(14)25 (1a)03 (1b)15 (3b)17 (4sb)04 (4d)03 (5)00 (6)33 (7)01 (8a)22 (8p)02 (9)23 (11p)12 (12a)00 (12p)01 ," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,10, R0 D2,,7.05,4.52,1.74,145.0,281.0,3.59,10.0,19.0,166.0,93.0,18.0,13.45,5.1,65.0,226.0,40.0,25.0,4.9,8.0,47.0,249.0,,,,,,,,,,,,,57.29,957.8,9.69,,无,, P0,H0, 已冲,CK(+) vimentin(-) VEGF（-）cMET(+),,,,,10.611038107752956,1418224
1418634,韩秀芹,566895,女,69,T1a,N0,M0,ⅠA,1,0,,,,0.0,,0.0,20,,,1.0,,,,,,,0.0,2014-07-03,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)02 (3a)04 (3b)06 (4sb)01 (4d)02 (5)00 (6)00 (7)00 (8a)00 (8p)00 (9)0 (11p)03 (12a)00," L（幽门窦部）, 前Ant,",35,30,, R0 D2,,4.87,2.22,2.2,112.0,332.0,1.53,28.0,21.0,168.0,59.0,25.0,5.38,2.06,69.0,326.0,43.0,26.0,5.1,8.2,75.0,435.0,,,,,,,,,,,,,1.92,9.09,6.85,,无, 无, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(-),,,,,97.96320630749014,1418634
1417755,邱进校,566376,男,54,T3,N3a,M0,ⅢB,1,4,2.0,,,, 肠化生+ 慢性炎症（+）,10.0,25,髓样型（med）,INFc,0.0,,,,,,,0.0,2014-06-26,2017-08-03,2,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a) 25(1b)02 (2)01 (3a)00 (3b)01 (4sa)00 (4sb)00 (4d)22 (5)22 (6)03 (7) 00(8a)01 (8p)01 (9) 00(11p)47 (12a)00,ML 前Ant 小弯侧Less ,90,80,18, R0 D2,,7.07,4.47,1.91,128.5,273.0,3.46,12.0,18.0,118.0,56.0,14.0,7.15,2.36,64.0,262.0,41.0,23.0,5.1,7.9,82.0,380.0,,,,,,,,,,,,,2.69,3.85,13.07, 未做,无, 无, P0,H0,未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,37.253613666228645,1417755
1418150,宋德舜,563000,男,65,T2,N0,M0, ⅠB,1,2,,,,,,0.0,16,,,2.0,,,,,,,0.0,2014-06-30,2018-05-07,0,,,口服替吉奥,口服替吉奥,,,,,2, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)02 (3a)01 (3b)00 (4sb)02 (4d)00 (5)05 (6)02 (7)01 (8a)02 (9)03 (11p)00," L（幽门窦部）, 小弯侧Less,",10,10,2, R0 D2,,6.95,4.2,2.11,141.0,174.0,1.84,19.0,23.0,167.0,67.0,17.0,8.23,2.16,69.0,249.0,43.0,26.0,3.9,6.4,96.0,305.0,,,,,,,,,,,,,4.99,23.63,1.23,,无, , P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(-),,,,,46.222076215505915,1418150
1418145,杨臣,566437,男,45,T3,N0,M0, ⅡA,1,2,1.0,,,1.0, 肠化生+,0.0,40,中间型（int）,INFc,2.0,,,,,,,1.0,2014-06-30,2019-05-01,0,,,,,,,,,0, 粘液腺癌（muc）70 管状腺癌（中分化【G2】【tub2】30 Lauren弥漫型,G2, (1a)06 (1b)01 (3a)04 (3b)03 (4sb)00 (4d)03 (5)01 (6)02 (7)06 (8p)02 (9)04 (11p)03 (12a)00 (14v)04," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,10, R0 D2,,5.35,3.06,1.61,147.0,338.0,2.66,17.0,20.0,170.0,82.0,13.0,8.87,4.29,68.0,199.0,41.0,27.0,5.3,3.4,73.0,294.0,,,,,,,,,,,,,18.92,5.32,8.31, 未做,无, 无, P0,H0,未做,"ck+,vimentin-,VEGF-,cMET弱+",,,,,58.01576872536136,1418145
1418301,王继永,566521,男,51,T3,N3b,M0, ⅢC,1,4,2.0,,,1.0, 肠化生+,24.0,45,中间型（int）,INFc,1.0,,,,,,,1.0,2014-07-01,2015-06-27,2,,,,,,,,,0, 低粘附腺癌85 粘液腺癌（muc）15 Lauren弥漫型,GX, (1a)00 (1b)00 (2)02 (3a)33 (3b)14 (4sa)01  (4sb)00 (4d)1111 (5)00 (6)03 (7)00 (8a)918 (8p)01 (9)01 (11p)01 (11d)00 (12a)00, L（幽门窦部） 小弯侧Less 大弯侧Gre  后Post ,50,40,10, D2,,6.25,3.34,1.95,148.0,258.0,3.12,41.0,24.0,165.0,67.0,14.0,15.05,6.14,58.0,188.0,39.0,19.0,4.5,2.2,81.0,173.0,,,,,,,,,,,,,239.9,1.41,28.97,,无,, P0,H0,未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,11.85939553219448,1418301
1418311,王殿臣,566575,男,56,T3,N1,M0, ⅡB,1,3,0.0,,,1.0, 肠化生 慢性炎症,1.0,36,中间型（int）,INFc,1.0,,,,,,,1.0,2014-07-01,2022-09-01,1,,,XELOX,,,,,,6, 管状腺癌中高分化 Lauren肠型,G1, (3a)12,L（幽门窦部） 小弯侧Less 前Ant 后Post ,40,35,8, R0 D2,,5.81,3.64,1.63,169.0,176.0,2.54,,,,57.0,8.0,,,,356.0,41.0,29.0,,,,,,,,,,,,,,,,,2.54,1.05,1.16, 未做,无,, P0,H0,未做, CK+ Vimentin- VEGF- CMET+ ,,,,,98.02890932982916,1418311
1419369,张安平,567065,男,62,T2,N0,M0, ⅠB,1,2,,,,,,0.0,26,,,0.0,,,,,,,,2014-07-10,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)95 低粘附腺癌5,G3, (1a)01 (1b)04 (2)02 (3a)04 (3b)01 (4sb)00 (4d)01 (5)00 (6)04 (7)02 (8a)01 (8p)02 (9)01 (11p)02 (12a)01 (12p)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",15,15,6, R0 D2+,,4.98,3.15,1.45,138.3,231.0,3.46,13.0,20.0,183.0,60.0,31.0,8.32,2.86,73.0,387.0,44.0,29.0,11.8,6.5,71.0,253.0,,,,,,,,,,,,,1.38,15.62,1.06, 未做,无, 无, P0,H0, 已冲 已刷,CK+， Vimentin-， VEGF-， CMET-,,,,,97.73324572930355,1419369
1418625,付显春,567053,男,54,T3,N2,M0, ⅢA,1,4,1.0,,,1.0,肠上皮化生，慢性炎,5.0,48,中间型（int）,INFc,2.0,,,,,,,0.0,2014-07-03,2020-10-12,1,,,XELOX,XELOX,,,,,6,混合型 管状腺癌（高分化【G1】【tub1】 中分化【G2】【tub2】70% 低黏附性癌30%,G2, (1a)03 (1b)04 (3a)010 (3b)00 (4sb)01 (4d)28 (5)01 (6)37 (7)01 (8a)02 (8p)01 (9)02 (11p)04 (12a)00 (12b)02 (12p)02 (14v)00, LM 前Ant 后Post 大弯侧Gre  小弯侧Less,60,50,10, R0 D2+,,,,,,,2.87,24.0,23.0,132.0,42.0,17.0,23.43,9.88,61.0,236.0,38.0,23.0,4.6,5.2,67.0,295.0,,,,,,,,,,,,,0.833,17.11,3.88,,,, P0,H0,, CK + VEGF- Vimentin- C-erbB-22+,,,,,75.32851511169514,1418625
1418484,李玉忠,566823,男,56,T3,N1,M0, ⅡB,1,3,1.0,,,, 肠化生+ 慢性炎症（+）,2.0,24,中间型（int）,INFc,0.0,,,,,,,0.0,2014-07-02,2019-05-03,0,,,紫杉醇联合希罗达,紫杉醇联合希罗达,紫杉醇联合替吉奥,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3, (1a)00 (1b)01 (3a)13 (3b)00 (4sb)00 (4d)06 (5)01 (6)03 (7)03 (8a)01 (8p)12 (9)02 (11p)02 (12a)00, L（幽门窦部） 前Ant 大弯侧Gre 小弯侧Less 后Post,50,40,12, R0 D2,,6.46,4.7,1.04,133.0,216.0,2.1,38.0,22.0,148.0,75.0,47.0,14.75,4.32,65.0,327.0,39.0,26.0,4.0,7.8,60.0,295.0,,,,,,,,,,,,,3.29,5.83,1.43,,无, 无, P0,H0,已冲,"ck+,vimentin-,VEGF,cMET-",,,,,58.01576872536136,1418484
1418385,马凤珍,567037,女,57,T4b,N0,M0, ⅢA,1,2,1.0,,,0.0,肠化生+,0.0,18,硬型（sci）,INFa,0.0,,,,,,,1.0,2014-07-02,2016-11-23,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】70 粘液腺癌（muc）20 乳头状癌（G1）（pap）10 Lauren混合型,G2, (1a) (1b) (3a) (3b) (7)09 (4sb)00 (4d)04 (5)01 (6)00 (8a)02 (12a)00,L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre  ,40,40,3,,R2,6.1,4.13,1.47,109.0,208.0,3.52,8.0,17.0,399.0,51.0,3.0,7.86,2.75,68.0,157.0,43.0,25.0,5.5,5.3,70.0,168.0,,,,,,,,,,,,,0.357,7.2,300.0,,无, 无, P0,H0, 已冲,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,28.74507227332457,1418385
1427004,赵瑞琦,567018,男,57,T4b,N3a,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生 ,10.0,45,髓样型（med）,INFa,0.0,,,,,,,1.0,2014-09-18,2019-03-20,0,替吉奥*3,1.0,SOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）80 低粘附腺癌20 Lauren混合型,G2, (1a)02 (1b)11 (2)01 (3a)210 (3b)04 (4sb)00 (4d)25 (5)00 (6)37 (7)14 (8a)12 (8p)02 (9)04 (11p)03 (12a)00 (14v)00," M（胃体部）, 后Post,",35,30,10,,R1,6.91,4.52,1.62,98.3,577.0,18.0,165.0,67.0,165.0,67.0,19.0,4.67,2.09,60.0,218.0,34.0,26.0,,,,,,,,,,,,,,,,,27.15,618.3,1.61,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET弱+,,,,,54.007884362680684,1427004
1418990,王志刚,566967,男,60,T4b,N3b,M0, ⅢC,1,3,1.0,,,1.0, 肠化生+ 慢性炎症（+）,25.0,31,中间型（int）,INFc,0.0,,,,,,,0.0,2014-07-08,2015-04-16,2,,,口服替吉奥,,,,,,1, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren混合型,G3, (1a)01 (1b)33 (3a)35 (3b)11 (4sb)00 (4d)910 (5)00 (6)22 (7)11 (8a)11 (8p)00 (9)23 (11p)34," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,35,12,,R1,7.77,4.99,2.14,136.1,253.0,3.97,53.0,52.0,237.0,329.0,297.0,21.52,14.22,68.0,176.0,36.0,32.0,3.1,8.4,55.0,125.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 已冲 已刷, CK +， Vimentin -， VEGF-， CMET-,,,,,9.264126149802891,1418990
1419660,谭美伦,564779,女,68,T2,N0,M0, ⅠB,1,2,0.0,,,, 肠化生+ 慢性炎症（+）,0.0,19,中间型（int）,INFa,0.0,,,,,,,0.0,2014-07-14,2021-04-15,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) (1b)00 (3a) (3b)07 (4sb)00 (4d)00 (5)00 (6)01 (7)00 (8a) (8p)04 (9)05 (11p)02 (12a)00 (14v)00,L（幽门窦部） 前Ant ,25,20,4, D2,,7.88,4.13,3.0,109.9,223.0,3.29,16.0,18.0,169.0,53.0,29.0,9.28,3.54,73.0,297.0,45.0,28.0,5.1,8.6,122.0,376.0,,,,,,,,,,,,,3.24,20.83,2.16,,无, 无, P0,H0,未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,81.04467805519053,1419660
1418650,李友,566705,男,72,T4b,N2,M0, ⅢB,1,2,1.0,1.0,1.0,1.0, 肠化生+,6.0,22,髓样型（med）,INFc,1.0,,,,,,,1.0,2014-07-03,2016-10-15,2,,,XELOX,,,,,,5, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)00 (1b)00 (3a)01 (3b)57 (4sb)00 (4d)02 (5)00 (6)01 (7)11 (8a)01 (8p)02 (9)02 (11p)03 (12a)00 (12p)02," LM 前Ant, 后Post, 小弯侧Less,",30,20,5,,R1,7.23,4.31,2.3,139.6,240.0,4.32,14.0,24.0,161.0,87.0,13.0,10.6,4.18,73.0,226.0,44.0,29.0,4.7,,,,,,,,,,,,,,,,2.33,1000.0,3.33,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET弱+,,,,,27.43101182654402,1418650
1418816,迟禹,564776,男,49,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,27,,,1.0,,,,,,,1.0,2015-07-07,2020-12-17,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)02 (3a)05 (3b)01 (4sb)00 (4d)08 (5)00 (6)00 (7)02 (8a)02 (8p)02 (9)01 (11p)01 (12a)00 (14v)03," L（幽门窦部）,",30,20,, R0 D2,,9.01,5.05,3.08,157.1,223.0,2.26,14.0,17.0,154.0,71.0,21.0,14.05,5.42,66.0,214.0,41.0,25.0,6.2,8.8,80.0,233.0,,,,,,,,,,,,,2.28,6.81,2.97,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF- CMET+,,,,,65.37450722733246,1418816
1418483,陈军,567073,男,59,T4b,N3a,M0, ⅢC,1,2,1.0,,,, 肠化生+,14.0,22,中间型（int）,INFc,0.0,,,,,,,1.0,2014-07-02,2014-12-16,2,,,XELOX,SOX,XELOX,XELOX,,,4, 乳头状癌（G1）（pap）60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)00 (1b)00 (3a)55 (3b)00 (4sb)00 (4d)66 (5)01 (6)11 (7)14 (8a) (8p)02 (9)00 (11p)13,ML（幽门窦部） 前Ant 后Post 大弯侧Gre,70,60,12, D2,,7.36,4.42,2.02,92.0,254.0,2.57,16.0,17.0,128.0,75.0,39.0,4.97,2.62,64.0,302.0,44.0,20.0,4.9,5.2,73.0,253.0,,,,,,,,,,,,,9.77,503.2,6.58,,无,, P0,H0,未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,5.486202365308804,1418483
1418965,李春艳,527893,女,29,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,39,,,1.0,,,,,,,0.0,2014-07-08,2018-04-22,0,,,SOX,SOX,口服替吉奥,,,,3, 管状腺癌（中分化【G2】【tub2】70% 粘液腺癌（muc）30%,G2, (1a)05 (1b)04 (3a)00 (3b)00 (4sb)00 (4d)09 (5)00 (6)05 (7)08 (8a)01 (8p)01 (9)01 (11p)04 (12a)00 (12p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,30,6, R0 D2,,5.16,2.84,1.82,82.4,304.0,2.91,11.0,13.0,141.0,51.0,11.0,182.0,67.0,67.0,182.0,41.0,26.0,4.6,3.9,71.0,255.0,,,,,,,,,,,,,0.567,12.76,1.3,,无, 无, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(-),,,,,45.466491458607095,1418965
1419114,卢凤久,568282,男,58,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,11,,,0.0,,,,,,,0.0,2014-07-09,2019-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)01 (3a)04 (3b)02 (4sb) (4d)01 (5)00 (6)02 (7)00 (8a)02 (8p)00 (9)01 (11p)04 (12a)00 (12p)00,"L（幽门窦部 ）M（胃体部）, 小弯侧Less,",10,8,3, R0 D2,,4.55,3.15,1.05,133.0,146.0,2.74,26.0,28.0,147.0,57.0,36.0,30.74,12.85,75.0,158.0,36.0,26.0,5.0,7.0,66.0,370.0,,,,,,,,,,,,,1.79,16.37,2.88, 未做,无, 无, P0,H0, 已冲 已刷,CK+， Vimentin-， VEGF-， CMET-,,,,,61.793692509855454,1419114
1419113,于功林,568234,男,40,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,13,,,0.0,,,,,,,0.0,2014-07-09,2017-09-06,0,,,,,,,,,0, 低粘附腺癌,GX, (1a)00 (1b)00 (3a) (3b)02 (4sb)00 (4d)02 (5)00 (6)01 (7)05 (8a)01 (9)01 (11p)01 (14v)00," L（幽门窦部）, 后Post,",10,10,3, D2+ R0,,7.35,4.75,1.92,149.0,236.0,1.98,29.0,22.0,156.0,63.0,26.0,19.46,6.57,71.0,290.0,45.0,26.0,5.8,8.3,99.0,388.0,,,,,,,,,,,,,2.23,22.6,1.63,,无, 无, P0,H0,未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,37.943495400788436,1419113
1419210,刘山,568423,男,54,T1b,N0,M0,ⅠA,1,0,1.0,,,, 肠化生+,0.0,22,中间型（int）,INFc,1.0,,,,,,,1.0,2014-07-09,2019-05-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 粘液腺癌（muc）20 Lauren混合型,G2, (1a)01 (1b)01 (2)01 (3a)05 (3b)06 (4sb)00 (4d)00 (5)00 (6)03 (7)01 (8a)01 (8p)00 (9)01 (11p)01 (12a)00 (14v)01," LM 前Ant, 后Post, 小弯侧Less,",25,25,5, R0 D2+,,7.58,4.61,2.34,154.8,182.0,2.78,20.0,19.0,168.0,84.0,49.0,8.29,5.23,64.0,347.0,42.0,22.0,4.7,3.7,81.0,348.0,,,,,,,,,,,,,3.46,6.32,0.954, 未做,无, 无, P0,H0, 已冲 已刷, CK + Vimentin- VEGF- CMET 弱+,,,,,57.72010512483574,1419210
1419219,李畅,568425,女,42,T3,N2,M0, ⅢA,1,4,,,,,,4.0,18,,,0.0,,,,,,,0.0,2014-07-09,2017-04-13,2,,,XELOX,,,,,,6, 低粘附腺癌90 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10,G3, (1a)02 (1b)14 (2)01 (3a)23 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)00 (6)14 (8a)01 (8p)02 (9)01 (11p)02 (12a)00," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",10,10,5, R0 D2,,4.96,2.62,1.83,120.7,171.0,3.11,15.0,16.0,183.0,64.0,12.0,36.61,10.29,73.0,216.0,43.0,30.0,5.0,5.4,64.0,323.0,,,,,,,,,,,,,0.211,15.87,2.3, 未做,无, 无, P0,H0, 未做, CK + Vimentin - VEGF- CMET-,,,,,33.14717477003942,1419219
1419858,舒群,565834,男,64,T3,N2,M0, ⅢA,1,2,1.0,,,, 肠化生+,3.0,29,髓样型（med）,INFa,0.0,,,,,,,1.0,2014-07-16,2020-05-11,1,,,XELOX,,,,,,6, 粘液腺癌（muc）60% 低粘附腺癌30% 管状腺癌（中分化【G2】【tub2】10% Lauren混合型,G2, (1a)02 (1b)00 (3a)12 (3b)01 (4sb)01 (4d)07 (5)00 (6)210 (7)03 (8a) (8p)02 (9)00 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",35,25,9, R0 D2,,6.65,4.6,1.49,153.0,240.0,3.4,23.0,28.0,224.0,69.0,25.0,15.45,5.69,77.0,296.0,42.0,35.0,4.6,5.7,61.0,265.0,,,,,,,,,,,,,3.5,33.08,6.85,,无, 无, P0,H0,已冲,ck（+）、vimentin（-）、VEGF(-)、cMET（弱+）,,,,,69.84231274638633,1419858
1419208,王兴国,568146,男,58,T4b,N2,M0, ⅢB,1,2,1.0,,,, 肠化生+ 慢性炎症（+）,4.0,31,中间型（int）,INFa,1.0,,,,,,,1.0,2014-07-09,2015-04-03,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)03 (1b)02 (3a)00 (3b)02 (4sb)00 (4d)05 (5)00 (6)25 (7)01 (8a)13 (8p)03 (9)02 (11p)15 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",80,55,5,,R1,9.19,6.67,1.66,128.0,382.0,5.34,18.0,15.0,140.0,116.0,62.0,8.08,2.99,66.0,188.0,39.0,27.0,5.0,7.4,87.0,284.0,,,,,,,,,,,,,1.66,4.82,2.54,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(+),,,,,8.804204993429698,1419208
1419347,王学先,567306,男,68,T1b,N1,M0, ⅠB,1,0,,,,,,1.0,11,,,0.0,,,,,,,1.0,2014-07-10,2020-12-17,1,,,XELOX,,,,,,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20,G3, (1a)00 (1b)01 (3a)13 (3b)00 (4sb)03 (4d)00 (5)00 (6)00 (7)01 (8a)01 (8p)00 (9)01 (11p)01," LM 小弯侧Less,",20,20,10, R0 D2,,6.48,4.1,1.91,90.0,314.0,3.18,12.0,15.0,205.0,62.0,13.0,10.89,3.92,69.0,222.0,42.0,27.0,4.9,5.4,115.0,489.0,,,,,,,,,,,,,1.29,8.36,1.51, 未做,无, 无, P0,H0, 已冲 已刷, CK + Vimentin- VEGF- CMET 弱+,,,,,77.26675427069645,1419347
1419645,万子玉,564801,男,70,T3,N1,M0, ⅡB,1,2,0.0,,,1.0, 肠化生+,1.0,17,中间型（int）,INFb,0.0,,,,,,,0.0,2014-07-14,2017-05-15,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)04 (3b)12 (4sb)00 (4d)01 (5)01 (6)01 (7)00 (8a)02 (8p)01 (9)02 (11p)01 (12a)00 (14v)01," L（幽门窦部） 前Ant, 后Post, 小弯侧Less,",40,35,5, R0 D2+,,3.88,2.22,1.29,131.6,145.0,2.29,8.0,18.0,175.0,81.0,10.0,13.94,4.74,72.0,329.0,43.0,29.0,5.2,8.3,86.0,478.0,,,,,,,,,,,,,1.42,7.57,6.56, 未做,无, 无, P0,H0, 已冲 已刷, CK + Vimentin - VEGF- CMET-,,,,,34.03416557161629,1419645
1419579,范志中,568463,男,62,T3,N3a,M0,ⅢB,1,2,1.0,,,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,7.0,35,中间型（int）,INFa,0.0,,,,,,,1.0,2014-07-14,2014-10-09,2,,,SOX,SOX,XELOX,,,,3, 低分化腺癌（G3)(por)60 粘液腺癌（muc）40 Lauren混合型,G3,大弯01 小弯49 (1a)01 (1b)12 (2)12 (3a)13 (3b)02 (4sa)02 (4sb)00 (4d)04 (5)00 (6)02 (7)00 (8a)02 (8p)03 (9)01 (11p)01 (12a)00," U（胃底部）, 前Ant, 后Post, 小弯侧Less,",55,50,15, R0 D2,,10.48,6.18,2.97,159.9,283.0,4.32,15.0,19.0,238.0,120.0,20.0,9.2,3.04,66.0,392.0,36.0,30.0,4.4,8.4,64.0,281.0,,,,,,,,,,,,,2.99,21.76,3.26,,无,, P0,H0,已做,CK(+) vimentin(-) VEGF（-）cMET(+),,,,,2.8580814717477003,1419579
1419580,李方甫,567176,男,64,T3,N2,M0, ⅢA,1,2,1.0,,,, 肠化生+,5.0,25,中间型（int）,INFa,0.0,,,,,,,1.0,2014-07-14,2016-04-06,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)50 低粘附腺癌40 粘液腺癌（muc）10 Lauren混合型,G3, (1a)04 (1b)00 (3a)13 (3b)23 (4sb)00 (4d)13 (5)02 (6)14 (7、8、9、11p)04 (8a)00 (12a)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",80,50,10, R0 D2,,6.38,5.0,0.77,141.2,214.0,3.22,14.0,19.0,161.0,67.0,29.0,13.81,4.58,72.0,217.0,37.0,27.0,6.0,7.6,105.0,280.0,,,,,,,,,,,,,10.67,16.81,12.57,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(+),,,,,20.76215505913272,1419580
1419670,杨淑春,568190,女,61,T3,N3b,M0, ⅢC,1,3,1.0,,,, 肠化生+,20.0,41,中间型（int）,INFa,0.0,,,,,,,1.0,2014-07-14,2018-04-21,0,,,SOX,,,,,,1, 低粘附腺癌50 低分化腺癌（G3)(por)50 Lauren混合型,G3, (1a)00 (1b)02 (2)11 (3a)1314 (3b)01 (4sa)00 (4sb)02 (4d)01 (5)02 (6)02 (7)11 (8a)13 (8p)06 (9)45 (11p)00 (12a)00 (12p)01," MU 前Ant, 后Post, 小弯侧Less,",80,70,15, R0 D2,,3.69,2.47,0.72,120.9,279.0,3.16,7.0,11.0,136.0,96.0,10.0,8.45,2.82,66.0,253.0,38.0,28.0,4.5,8.1,49.0,259.0,,,,,,,,,,,,,2.02,21.45,5.11,,无, 无, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(+),,,,,45.236530880420496,1419670
1419674,王秀英,568382,女,64,T3,N0,M0, ⅡA,1,2,0.0,,,, 肠化生+ 慢性炎症（+）,0.0,23,髓样型（med）,INFa,0.0,,,,,,,0.0,2014-07-14,2019-03-05,0,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a) (3b)01 (4sb)02 (4d)02 (5)01 (6)00 (7)07 (8a)01 (8p)01 (9)02 (11p)03 (12a)01,L（幽门窦部） 前Ant 小弯侧Less 后Post ,60,30,8, D2,,7.62,5.15,1.86,100.0,464.0,3.66,2.0,11.0,154.0,87.0,7.0,9.93,3.47,70.0,291.0,42.0,28.0,5.3,7.3,66.0,217.0,,,,,,,,,,,,,0.458,5.5,43.39,,无, 无, P0,H0,未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,55.68331143232589,1419674
1420141,孟凡友,568744,男,57,T3,N3b,M0, ⅢC,1,3,1.0,,,1.0, 肠化生+,32.0,40,中间型（int）,INFc,1.0,,,,,,,1.0,2014-07-17,2018-04-21,0,,,XELOX,,,,,,8, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G3,小弯55 (1a)00 (1b)44 (2)44 (3a)01 (3b)01 (4sa)22 (4sb)00 (4d)911 (5)11 (6)02 (7)11 (8a)00 (8p)35 (9)00 (11p)00 (11d)00 (12a)22, UM 前Ant,60,60,10, R0 D2,,3.95,2.3,1.33,140.4,118.0,2.26,22.0,20.0,205.0,57.0,21.0,8.64,3.31,66.0,295.0,39.0,27.0,5.7,7.0,73.0,273.0,,,,,,,,,,,,,2.91,9.89,1.28,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(弱+),,,,,45.137976346911955,1420141
1420994,李海顺,564896,男,65,T3,N0,M0, ⅡA,1,1,1.0,,,, 肠化生+,0.0,13,中间型（int）,INFa,0.0,,,,,,,0.0,2014-07-24,2019-05-03,0,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G2, (1a)00 (1b)03 (2)00 (3a)00 (3b)00 (4sa)02 (4sb)00 (4d)00 (5)00 (6)01 (8a)03 (8p)02 (9)02 (11p)00 (12a)00 (19)00," GE, SiewerⅢ,前Ant 后Post 大弯侧Gre  小弯侧Less Borrmann1型",40,30,10, R0 D2,,3.5,2.62,0.46,84.3,153.0,4.08,12.0,19.0,164.0,71.0,13.0,12.74,4.32,67.0,220.0,42.0,25.0,5.0,3.7,78.0,257.0,,,,,,,,,,,,,3.01,11.18,0.887, 未做,无, 无, P0,H0, 未做, CK +， Vimentin-， VEGF-， CMET -,,,,,57.29303547963206,1420994
1419813,马景江,568834,男,61,T4b,N0,M0, ⅢA,1,3,0.0,1.0,1.0,, 肠化生+,0.0,29,中间型（int）,INFa,1.0,,,,,,,0.0,2014-07-15,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3,小弯03 (1a)00 (1b)01 (3a、3b)01 (4sb)01 (4d)00 (5)01 (6)05 (7)06 (8a)02 (8p)02 (9)04 (11p)02 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,20,5,,R2,6.47,4.65,1.35,130.7,294.0,4.45,16.0,19.0,116.0,90.0,16.0,8.46,2.73,67.0,215.0,42.0,25.0,5.1,7.2,88.0,279.0,,,,,,,,,,,,,1.8,4.47,1.74,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(-),,,,,97.56898817345598,1419813
1420630,刘军,568493,女,42,T3,N3b,M0, ⅢC,1,4,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,16.0,25,中间型（int）,INFa,1.0,,,,,,,1.0,2014-07-22,2016-03-16,2,,,XELOX,,,,,,5, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3, (1a)01 (1b)11 (2)03 (3a)11 (3b)00 (4sa)01 (4sb)02 (4d)44 (5)11 (6)33 (7)22 (8a)12 (9)12 (14v)11, L（幽门窦部） 小弯侧Less ,60,50,5, D2+  R0,,6.33,3.64,2.09,85.0,302.0,2.87,13.0,21.0,141.0,41.0,10.0,11.19,4.07,69.0,179.0,35.0,24.0,5.0,5.5,77.0,174.0,,,,,,,,,,,,,0.216,17.14,4.67,,无, 无, P0,H0,已冲,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,19.80946123521682,1420630
1419788,王璟,568613,男,71,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,9,,,2.0,,,,,,,1.0,2014-07-15,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (3a)00 (3b)01 (4sb)00 (4d)02 (5)00 (6)01 (7)00 (8a)02 (8p)00 (9)01 (11p)00 (12a)00 (14v)01," L（幽门窦部）, 前Ant, 小弯侧Less,",25,12,, R0 D2+,,6.68,4.16,1.76,126.0,250.0,3.52,12.0,14.0,137.0,47.0,15.0,8.48,3.08,64.0,259.0,40.0,24.0,6.5,7.2,90.0,304.0,,,,,,,,,,,,,3.83,12.16,6.13, 未做,无, 无, P0,H0, 未做, CK + Vimentin- VEGF- CMET+,,,,,77.10249671484888,1419788
1419864,李井复,568753,男,64,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,28,,,0.0,,,,,,,1.0,2014-07-16,2022-09-01,1,,,,,,,,,0, 低粘附腺癌90 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10,G3, (1a)01 (1b)00 (3a) (3b)06 (4sb)00 (4d)02 (5)01 (6)03 (7)09 (8a)01 (8p)02 (9)01 (11p)02 (14v)00,L,40,25,, D2,,7.76,5.55,1.76,154.1,142.0,2.26,18.0,20.0,208.0,102.0,49.0,8.3,2.88,70.0,305.0,42.0,28.0,5.1,6.0,86.0,247.0,,,,,,,,,,,,,1.7,9.02,3.49,,无, , P0,H0,已冲,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,97.53613666228647,1419864
1419796,卢景泉,568573,男,66,T2,N1,M0, ⅡA,1,2,0.0,,,, 肠化生+ 慢性炎症（+）,1.0,11,中间型（int）,INFa,1.0,,,,,,,0.0,2014-07-15,2022-09-01,1,,,SOX,SOX,SOX,SOX,替吉奥单药,,5, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)01 (3a)00 (3b)02 (4sb)00 (4d)01 (5)00 (6)00 (7)00 (8a)12 (8p)02 (9)01 (11p)02 (12a)00 (12p)00," L（幽门窦部）, 前Ant, 后Post,",20,18,8, R0 D2,,8.2,5.18,2.28,160.0,282.0,4.36,35.0,31.0,167.0,124.0,50.0,17.14,5.94,72.0,313.0,41.0,31.0,5.3,6.2,78.0,323.0,,,,,,,,,,,,,13.79,7.15,2.13,,无,, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(-),,,,,97.56898817345598,1419796
1420025,宋桂芝,569055,女,43,T1a,N2,M0, ⅡA,1,0,,,,,,3.0,28,,,0.0,,,,,,,0.0,2014-07-17,2022-09-01,1,,,XELOX,,,,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】50 低粘附腺癌50,G3, (1a)01 (1b)14 (3a)11 (3b)00 (4sb)01 (4d)02 (5)01 (6)03 (7)12 (8a)01 (8p)05 (9)02 (11p)04 (12a)01," L（幽门窦部）, 前Ant, 小弯侧Less,",20,20,3, R0 D2,,5.35,3.76,1.02,149.0,152.0,3.27,43.0,21.0,182.0,81.0,25.6,11.39,2.74,82.5,252.19,47.7,34.8,4.4,3.83,61.0,302.0,,,,,,,,,,,,,3.13,33.86,4.78,,无, 无, P0,H0,未做,CK(+) vimentin(-) VEGF（-）cMET(-),,,,,97.50328515111694,1420025
1420540,王贵尧,568646,男,63,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,11,,,2.0,,,,,,,1.0,2014-07-22,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)03 (1b)02 (3a)01 (3b)00 (4sb)00 (4d)02 (5)00 (6)01 (7)02 ,L（幽门窦部） 后Post ,15,10,, R0 D1+,,6.17,3.24,2.05,130.2,204.0,3.01,12.0,18.0,212.0,61.0,14.0,87.16,9.07,66.0,216.0,43.0,23.0,5.1,7.0,73.0,357.0,,,,,,,,,,,,,1.73,7.21,0.961, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+),,,,,97.33902759526937,1420540
1420800,王建民,569002,男,48,T3,N0,M0, ⅡA,1,4,1.0,,,, 肠化生+,0.0,28,中间型（int）,INFa,0.0,,,,,,,1.0,2014-07-23,2017-06-06,2,,,FOLFOX6,FOLFOX6,FOLFOX6,FOLFOX6,FOLFOX6,XELOX,6, 低粘附腺癌80 低分化腺癌（G3)(por)220 Lauren混合型,G3, (1a)02 (1b)00 (3a)02 (3b)04 (4sb)04 (4d)03 (5)00 (6)00 (7)04 (8a)01 (9)02,L,60,40,, D2,,7.04,3.03,3.02,166.6,193.0,3.52,21.0,29.0,198.0,61.0,13.0,16.56,5.79,73.0,347.0,43.0,30.0,4.9,4.3,78.0,334.0,,,,,,,,,,,,,1.7,10.79,1.07,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,34.46123521681997,1420800
1420302,刘汉岩,568914,男,59,T3,N1,M0, ⅡB,1,4,1.0,,,,肠化生+,2.0,22,中间型（int）,INFc,1.0,,,,,,,0.0,2014-07-18,2017-09-06,0,,,XELOX,,,,,,6,中低分化管状腺癌80，低黏附20,G3,, L（幽门窦部） 小弯侧Less 后Post ,40,30,8,R0,,5.69,3.3,1.84,157.0,265.0,3.86,16.0,19.0,174.0,63.0,24.0,17.93,6.61,67.0,210.0,42.0,25.0,5.3,5.2,81.0,270.0,,,,,,,,,,,,,2.07,5.16,5.25,,无,, P0,H0,,,,,,,37.64783180026281,1420302
1420648,张艳玲,569082,女,59,T3,N0,M0, ⅡA,1,2,1.0,,,, 肠化生+,0.0,14,中间型（int）,INFb,0.0,,,,,,,1.0,2014-07-22,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】50 粘液腺癌（muc）40 低粘附腺癌10 Lauren混合型,G3, (1a)00 (1b)01 (3a)03 (3b)00 (4sb)00 (4d)02 (5)00 (6)01 (7) (11p)01 (8a)02 (9)02 (12a)00 (14v)01,L（幽门窦部） 前Ant 小弯侧Less 后Post ,30,22,3, D2+ R0,,7.03,3.31,2.84,126.9,279.0,3.06,16.0,23.0,174.0,94.0,11.0,9.47,2.91,75.0,308.0,42.0,33.0,5.3,7.0,70.0,204.0,,,,,,,,,,,,,1.91,8.83,0.96,,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,97.33902759526937,1420648
1420478,蒋铁勇,568722,男,50,T3,N2,M0, ⅢA,1,2,1.0,,,, 慢性炎症（+） 肠化生+,5.0,32,中间型（int）,INFa,0.0,,,,,,,1.0,2014-07-21,2016-06-17,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G3, (1a)01 (1b)00 (3a)00 (3b)00 (4sb)01 (4d)010 (5)00 (6)04 (7)46 (8a)03 (8p)12 (9)02 (11p)00 (12a)02, L（幽门窦部）小弯侧Less,75,30,6,,,6.96,4.18,1.96,124.0,245.0,4.59,28.0,28.0,109.0,28.0,109.0,5.34,2.2,70.0,248.0,41.0,29.0,5.3,6.5,89.0,332.0,,,,,,,,,,,,,1.31,65.62,10.44,,无,, P0,H0,,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,22.897503285151117,1420478
1421217,王友库,568653,男,56,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,45,,,1.0,,,,,,,0.0,2014-07-28,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40,G2, (1a)03 (1b)01 (3a)015 (3b)02 (4sb)01 (4d)010 (5)00 (6)01 (7)05 (8a)01 (8p)03 (9)03 (11p)00 (12a)00 (12p)00," M（胃体部）, 小弯侧Less,",4,,, R0 D2,,8.02,4.19,3.11,160.0,235.0,3.84,79.0,29.0,169.0,99.0,217.2,18.98,6.52,69.5,256.0,43.7,25.8,5.5,4.56,64.0,297.0,,,,,,,,,,,,,1.49,13.8,1.38,,无, 无, P0,H0, 已冲 已刷,CK+， Vimentin-， VEGF-， CMET-,,,,,76.6754270696452,1421217
1420888,李宝山,568710,男,69,T4b,N3b,M0, ⅢC,1,3,1.0,,,, 肠化生+,17.0,25,中间型（int）,INFa,1.0,,,,,,,1.0,2014-07-24,2015-08-12,2,,,紫杉醇联合替吉奥,紫杉醇联合替吉奥,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 粘液腺癌（muc）30 Lauren混合型,G3, (1a)00 (1b)17 (3a)22 (3b)44 (4sb)00 (4d)12 (5)22 (6)55 (7)01 (8a)22," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,35,6,,R2,6.64,4.54,1.45,112.0,264.0,3.46,18.0,17.0,128.0,34.0,9.0,18.94,6.95,62.0,158.0,36.0,26.0,6.4,6.3,94.0,343.0,,,,,,,,,,,,,2.69,1000.0,4.75,,无, 无, P0,H0, 已冲,CK+， Vimentin-， VEGF- ，CMET+ 弱,,,,,12.614980289093298,1420888
1420964,张立学,565609,男,40,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,35,,,1.0,,,,,,,1.0,2014-07-24,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）,G2, (1a)05 (1b)01 (3a)08 (3b)00 (4sb)00 (4d)02 (5)00 (6)03 (7)04 (8a)01 (8p)04 (9)06 (11p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,30,1, R0 D2,,4.21,2.72,0.97,148.5,130.0,2.51,395.0,250.0,224.0,101.0,224.0,14.21,6.37,69.0,216.0,40.0,29.0,4.3,5.5,73.0,337.0,,,,,,,,,,,,,1.73,9.14,2.39,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET弱+,,,,,76.80683311432325,1420964
1421328,张信,568946,男,52,T1b,N1,M0, ⅠB,1,0,0.0,,,, 肠化生+,1.0,29,中间型（int）,INFa,0.0,,,,,,,2.0,2014-07-28,2020-12-17,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 粘液腺癌（muc） Lauren肠型,G2, (1a)03 (1b)02 (3a)19 (3b)02 (4sb)04 (4d)00 (5)00 (6)00 (7)01 (8a)01 (8p)02 (9)01 (11p)04," LM 前Ant,",23,20,4, R0 D2,,10.5,6.32,3.4,151.1,184.0,3.33,29.0,22.0,157.0,92.0,30.0,9.63,3.79,72.0,293.0,43.0,29.0,5.5,8.3,88.0,423.0,,,,,,,,,,,,,5.14,11.32,1.41, 未做,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET弱+,,,,,76.6754270696452,1421328
1421370,闫成金,568719,男,67,T2,N1,M0, ⅡA,1,3,1.0,,,, 肠化生+,1.0,20,中间型（int）,INFa,3.0,,,,,,,2.0,2014-07-29,2020-10-12,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3, (1a)02 (1b)02 (3a)01 (3b)11 (4sb)01 (4d)01 (5)00 (6)02 (7)00 (8a)02 (8p)01 (9)03 (11p)04 (12a)00," L（幽门窦部）,M 后Post, 小弯侧Less,",20,15,3, R0 D2,,6.81,2.65,3.13,149.0,186.0,3.66,14.0,19.0,161.0,68.0,30.0,14.21,5.45,75.0,223.0,42.0,33.0,7.7,6.3,118.0,338.0,,,,,,,,,,,,,2.01,8.0,1.07, 未做,无, 无, P0,H0, 已冲 已刷, CK +， Vimentin -， VEGF-， CMET 弱+,,,,,74.47437582128778,1421370
1421310,苗俊田,568701,男,77,T3,N0,M0, ⅡA,1,4,2.0,1.0,1.0,, 肠化生+ 异型增生+,0.0,26,髓样型（med）,INFa,2.0,,,,,,,,2014-07-28,2020-10-12,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)01 (3a)03 (3b)03 (4sb)00 (4d)03 (5)00 (6)04 (7)01 (8a)04 (8p)00 (9)01 (11p)03 (12a)00 (12p)02 (14v)00," LM 前Ant, 大弯侧Gre, 小弯侧Less,",80,80,18, R0 D2,,4.46,2.81,1.12,100.8,233.0,3.27,14.0,19.0,121.0,55.0,18.0,4.1,1.9,60.0,189.0,33.0,27.0,6.5,6.1,86.0,361.0,,,,,,,,,,,,,0.846,5.85,2.64, 未做,无, 无, P0,H0, 未做,,,,,,74.50722733245729,1421310
1420551,张淑云,569159,女,56,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,26,,,0.0,,,,,,,2.0,2014-07-22,2016-01-01,0,,,,,,,,,0, 低粘附腺癌,GX, (1a)00 (1b)02 (3a)03 (3b)03 (4sb)00 (4d)00 (5)02 (6)03 (7)03 (8a)01 (8p)04 (9)03 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,40,, R0 D2,,7.46,4.53,2.35,140.9,197.0,2.58,,13.0,177.0,98.0,24.0,13.4,4.48,65.0,198.0,35.0,30.0,7.2,6.7,60.0,114.0,,,,,,,,,,,,,1.31,5.23,3.67, 未做,无, 无, P0,H0, 已冲 已刷, CK + Vimentin+ VEGF- CMET 弱+,,,,,17.345597897503286,1420551
1420876,王凤庚,569558,男,59,T3,N1,M0, ⅡB,1,2,1.0,,,, 肠化生+ 慢性炎症（+）,1.0,19,中间型（int）,INFa,0.0,,,,,,,1.0,2014-07-24,2022-09-01,1,,,FOLFOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G2, (1a)03 (1b)01 (3a)00 (3b)03 (4sb)02 (4d)13 (5) 00(6)03 (7) 00(8a)01 (8p)02 (9)01 (11p)00 (12a)00,L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre,60,60,8, R0 D2,,6.58,4.58,1.28,95.5,370.0,3.46,12.0,15.0,157.0,73.0,25.0,3.06,4.95,63.0,169.0,37.0,26.0,5.7,4.8,88.0,371.0,,,,,,,,,,,,,0.622,21.54,15.56,,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+),,,,,97.27332457293035,1420876
1420963,曹云凯,569707,男,59,T4a,N3b,M0, ⅢC,1,5,1.0,1.0,1.0,, 异型增生+,19.0,32,中间型（int）,INFa,2.0,,,,,,,0.0,2014-07-24,2022-09-01,1,,,FOLFOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 90乳头状癌（G1）（pap）10 Lauren混合型,G3, (1a)22 (1b)55 (2)09 (3a)33 (3b)01 (4sa) 00(4sb) 00(4d)11(5)00 (6)45 (7)11 (8a)02 (8p) 11(9)00 (11p)00,ML 小弯侧Less 前Ant 后Post ,80,50,10,,R2,6.73,3.95,2.16,110.0,209.0,3.01,13.0,16.0,197.0,57.0,22.0,21.51,89.0,66.0,245.0,42.0,24.0,6.9,4.4,86.0,356.0,,,,,,,,,,,,,17.97,1000.0,31.85, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,97.27332457293035,1420963
1420997,李希花,569708,女,64,T3,N3a,M1, Ⅳ,1,3,1.0,1.0,1.0,, 肠化生+ 慢性炎症（+）,15.0,20,中间型（int）,INFa,0.0,,,,,,,2.0,2014-07-24,2014-11-28,2,,,,,,,,,0, 粘液腺癌（muc）60 低粘附腺癌30 低分化腺癌（G3)(por)10 Lauren混合型,G3, (1a)13 (1b)33 (3a) 00(3b)00 (4sb)00 (4d)69 (5)00 (6)44 (7)11,L（幽门窦部） 小弯侧Less 后Post 大弯侧Gre  ,40,30,8,,R2,7.9,5.67,1.69,146.0,241.0,3.59,16.0,22.0,220.0,77.0,10.0,6.8,4.02,70.0,175.0,43.0,27.0,5.9,5.7,76.0,318.0,,,,,,,,,,,,,,,, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET弱(+),,,,,4.1721419185282524,1420997
1422441,管英梅,569550,女,37,T2,N0,M0, ⅠB,1,2,1.0,,,, 肠化生+,0.0,24,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-07,2020-12-17,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】50 低粘附腺癌50 Lauren混合型,G3, (1a)02 (1b)02 (3a)04 (3b)00 (4sb)01 (4d)011 (5)02 (6)00 (7)00 (8a)01 (9)00 (11p)01 (12a)00," L（幽门窦部）, 后Post,",10,8,5, R0 D2,,4.28,2.79,1.09,118.9,203.0,2.58,12.0,20.0,51.0,41.0,7.0,13.17,5.45,72.0,161.0,40.0,32.0,4.8,5.6,81.0,308.0,,,,,,,,,,,,,0.294,13.62,1.01,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,76.34691195795006,1422441
1420981,张树文,569660,男,65,T2,N0,M0, ⅠB,1,2,0.0,,,, 肠化生+ 异型增生+,0.0,16,中间型（int）,INFa,0.0,,,,,,,1.0,2014-07-24,2020-05-11,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】  Lauren肠型,G2,小弯01 (1a) (1b)00 (3a) (3b)02 (4sb)00 (4d)02 (5)00 (6)00 (7)02 (8a)05 (9)02 (11p)01 (12a)01," L（幽门窦部）, 小弯侧Less,",22,13,4, R0 D2,,8.18,5.21,2.4,171.0,159.0,2.96,17.0,21.0,214.0,78.0,17.0,11.29,4.38,72.0,320.0,41.0,31.0,5.0,9.3,86.0,390.0,,,,,,,,,,,,,7.98,1.16,4.06, 未做,无, 无, P0,H0,已冲,ck（+）、vimentin（-）、VEGF（-）、cMET（+）,,,,,69.57950065703022,1420981
1421241,冯得友,569604,男,58,T3,N3b,M0, ⅢC,1,4,1.0,,,1.0, 肠化生+,31.0,35,中间型（int）,INFc,0.0,,,,,,,1.0,2014-07-28,2016-06-06,0,,,,,,,,,0, 低粘附腺癌60% 粘液腺癌（muc）30% 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】10%,G3, (1a)57 (1b)79 (3a) (3b)44 (4sb)00 (4d)11 (5)00 (6)88 (7) (8a) (8p) (9) (12a) (12p)66," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",23,10,8, R0 D2,,8.16,4.76,2.56,148.0,298.0,2.12,,,,85.0,21.0,,,,312.0,42.0,28.0,,,,,,,,,,,,,,,,,119.3,6.24,131.9, 未做,无, 无, P0,H0, 未做,ck(+)、vimeETntin（-）、VEGF（-）cMET（+）,,,,,22.306176084099867,1421241
1421469,张凤奇,569866,男,39,T4b,N3a,M0, ⅢC,1,3,1.0,,,, 肠化生+,8.0,25,中间型（int）,INFa,0.0,,,,,,,1.0,2014-07-29,2019-09-02,0,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90% 低粘附腺癌10%  Lauren混合型,G3, (1a)11 (1b)12 (3a)02 (3b)00 (4sb)03 (4d)04 (5)00 (6)25 (7)23 (8a)11 (8p)01 (9)00 (11p)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,30,12,,R1,7.18,2.78,3.6,159.0,302.0,2.15,13.0,21.0,144.0,65.0,9.0,61.8,19.3,70.0,178.0,43.0,27.0,4.7,4.8,59.0,63.0,,,,,,,,,,,,,1.27,5.7,1.06,,无, 无, P0,H0, 已冲 已刷, CK +， Vimentin-， VEGF-， CMET +,,,,,61.136662286465175,1421469
1421971,张桂云,569185,女,78,T3,N3b,M0, ⅢC,1,4,1.0,,,1.0, 肠化生+ 慢性炎症（++）,33.0,42,中间型（int）,INFa,3.0,,,,,,,0.0,2014-08-04,2015-04-15,2,,,赫赛停联合希罗达,,,,,,1, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）60 低分化腺癌（G3)(por)20 低粘附腺癌10 粘液腺癌（muc）10 Lauren混合型,G3, (1a)23 (1b)66 (2)12 (3a)1010 (3b)22 (4sa)00 (4sb)24 (4d)57 (5)11 (6)33 (7)00 (8a)11 (8p)01 (9)00 (11p)02 (12a)00 (12p)00," LMU 前Ant, 后Post, 小弯侧Less,",100,90,10,,R1,6.46,4.59,1.09,59.3,302.0,3.39,,,,130.0,12.0,,,,193.0,34.0,27.0,10.4,3.19,53.0,187.0,,,,,,,,,,,,,4.66,106.0,2.74,,无, 无, P0,H0, 未做,CK +， Vimentin-， VEGF- ；CMET-,,,,,8.344283837056505,1421971
1421639,范慧荣,569674,女,61,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,30,,,2.0,,,,,,,,2014-07-30,2020-05-28,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40,G3, (1a)00 (1b)00 (3a)014 (3b)05 (4sb)01 (4d)00 (5)00 (6)02 (7)01 (8a)01 (8p)02 (9)03 (11p)01 (12p)00," L（幽门窦部）M（胃体部）, 前Ant, 后Post, 小弯侧Less,",25,20,10, R0 D2,,7.17,62.67,30.15,123.7,224.0,4.14,32.0,28.0,151.0,63.0,21.0,9.3,3.14,70.0,349.0,42.0,37.0,5.3,4.4,85.0,437.0,,,,,,,,,,,,,0.625,0.8,0.788,,无, 无, P0,H0, 未做, CK +， ,,,,,69.94086727989487,1421639
1421615,陈有良,569510,男,58,T3,N1,M0, ⅡB,1,2,0.0,,,1.0, 慢性炎症（+）,2.0,39,中间型（int）,INFa,1.0,,,,,,,1.0,2014-07-30,2019-09-02,0,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)02  (2)04 (3a)010 (3b)01 (4sb)02 (4d)05 (5)00 (6)15 (7)05 (8a)11 (9)01 (11p)01 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",45,25,5, R0 D2,,2.45,54.4,32.63,74.7,168.0,4.61,15.0,18.0,171.0,74.0,9.0,6.31,2.27,69.0,274.0,42.0,27.0,4.9,2.7,70.0,194.0,,,,,,,,,,,,,7.72,0.895,3.45,,无, 无, P0,H0, 已冲 已刷, CK +， Vimentin-， VEGF-， CMET +,,,,,61.10381077529566,1421615
1421300,刘志学,569267,男,58,T2,N1,M0, ⅡA,1,1,0.0,,,,重度不典型增生,1.0,25,中间型（int）,INFa,2.0,,,,,,,1.0,2014-07-28,2016-05-01,2,,,SOX,,,,,,4,中高分化20 低分化80,G3,, L（幽门窦部） 前Ant 小弯侧Less,25,25,10, R0 D2,,7.44,4.57,2.22,163.0,210.0,2.26,40.0,31.0,168.0,54.0,49.0,18.15,5.75,70.0,400.0,45.0,25.0,4.6,4.0,80.0,240.0,,,,,,,,,,,,,2.99,1.17,1.78, 未做,,, P0,H0,,,,,,,21.12352168199737,1421300
1421830,侯思学,564676,男,78,T3,N0,M0, ⅡA,1,3,1.0,,,, 肠化生+,0.0,19,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-01,2020-04-29,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3, (1a) (1b)02 (3a) (3b)05 (4sb)00 (4d)02 (5)00 (6)04 (7) (8a) (8p) (9)04 (11p)01 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,65,15, R0 D2,,4.62,3.6,0.62,105.2,205.0,4.08,14.0,17.0,158.0,100.0,15.0,9.53,6.49,60.0,130.0,35.0,25.0,4.8,6.4,69.0,216.0,,,,,,,,,,,,,0.918,5.22,2.16, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,68.92247043363994,1421830
1422204,李凤明,569921,男,61,T2,N1,M0, ⅡA,1,3,1.0,,,, 肠化生+,1.0,34,中间型（int）,INFa,1.0,,,,,,,0.0,2014-08-05,2022-09-01,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G3, (1a)09 (1b)04 (3a)04 (3b)01 (4sb)00 (4d)17 (5)00 (6)02 (7)03 (8a)01 (8p)01 (9)01 (11p)01 (12a)00, L（幽门窦部） 后Post,50,40,8, D2 R0,,10.84,6.7,3.33,148.0,243.0,3.75,18.0,23.0,180.0,109.0,33.0,8.78,2.52,74.0,291.0,44.0,30.0,6.3,3.4,71.0,271.0,,,,,,,,,,,,,2.67,14.34,3.18,,无,, P0,H0, 已冲,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,96.87910643889619,1422204
1421688,宋百玲,569689,女,50,T1b,N2,M0, ⅡA,1,0,1.0,,,, 肠化生+,3.0,20,中间型（int）,INFa,1.0,,,,,,,0.0,2014-07-31,2020-10-12,0,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40 Lauren混合型,G2, (1a)00 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)04 (5)03 (6)26 (7)01 (8a)11 (8p)01 (9)02 (11p)00 (12p)00 (14v)00," L（幽门窦部）, 前Ant,",20,15,3, R0 D2+,,5.95,3.21,2.15,101.0,331.0,3.46,19.0,24.0,166.0,97.0,9.0,10.84,2.51,72.0,284.0,43.0,29.0,4.1,3.3,56.0,228.0,,,,,,,,,,,,,1.6,10.14,1.46,,无, 无, P0,H0, 已冲 已刷, CK +， Vimentin-， VEGF-， CMET -,,,,,74.40867279894874,1421688
1421972,祁伦香,569956,女,62,T2,N0,M0, ⅠB,1,3,,,,,,0.0,21,,,1.0,,,,,,,0.0,2014-08-04,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）,G2, (1a)00 (1b)01 (3a)03 (3b)02 (4sb)01 (4d)01 (5)00 (6)03 (7) (11p)04 (8a)04 (8p) (9)02 (12a)00 (14v)00,L（幽门窦部） 小弯侧Less ,15,8,, D2+ R0,,8.83,4.42,3.68,112.0,337.0,4.14,45.0,46.0,166.0,52.0,8.0,7.37,2.37,69.0,286.0,43.0,26.0,7.9,2.8,56.0,240.0,,,,,,,,,,,,,0.692,12.11,0.804,,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(-),,,,,96.9119579500657,1421972
1421464,李淑清,569838,女,60,T4b,N3b,M1, ⅢC,1,4,1.0,,,, 肠化生+,33.0,43,中间型（int）,INFc,1.0,,,,,,,0.0,2014-07-29,2016-02-17,2,,,,,,,,,0, 低粘附腺癌 60低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】40 Lauren混合型,G3, (1a) 24(1b)11 (2)44 (3a)17 17 (3b)88 (4sa)00 (4sb)00 (4d)12 (5)00 (6)07 ,GE 前Ant 后Post 大弯侧Gre  小弯侧Less ,90,70,,,R2,4.24,1.72,1.93,144.0,215.0,3.52,54.0,51.0,238.0,94.0,75.0,6.61,4.93,69.0,248.0,41.0,28.0,5.0,3.1,72.0,283.0,,,,,,,,,,,,,3.4,24.97,2.42, 未做,无,,p1盆(M1 PER),H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,18.659658344283837,1421464
1422228,庞连喜,569797,男,43,T3,N3a,M0,ⅢB,1,3,1.0,,,, 肠化生+ 慢性炎症（+）,14.0,21,中间型（int）,INFa,1.0,,,,,,,2.0,2014-08-05,2015-04-20,2,,,SOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40 Lauren混合型,G3, (1a)03 (1b)00 (3a)55 (3b)00 (4sb)00 (4d)01 (5)00 (6)44 (7)33 (8a) (8p)22 (9)02 (11p)01 (12a)00 (14v)00,L（幽门窦部） 小弯侧Less 后Post ,45,30,8, D2+ R0,,9.02,4.7,3.36,160.0,245.0,1.55,40.0,30.0,158.0,55.0,45.0,21.69,6.3,73.0,336.0,42.0,31.0,4.3,3.5,76.0,265.0,,,,,,,,,,,,,2.33,7.24,1.65, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,8.47568988173456,1422228
1421970,聂士英,569905,男,64,T1b,N0,M0,ⅠA,1,0,1.0,,,, 肠化生+,0.0,23,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-01,2020-05-11,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）80% 低粘附腺癌20% Lauren混合型,G2, (1a) (1b)04 (3a) (3b)00 (4sb)03 (4d)01 (5)04 (6)00 (7)09 (8a)00 (9)02 (12a)00," L（幽门窦部）, 小弯侧Less,",12,,, R0 D2,,7.07,3.58,2.43,148.8,177.0,3.27,26.0,26.0,167.0,89.0,44.0,15.8,3.94,68.0,322.0,39.0,29.0,7.6,4.4,53.0,262.0,,,,,,,,,,,,,4.89,14.75,0.961, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,69.3166885676741,1421970
1421381,张华忠,569815,男,63,T3,N0,M0, ⅡA,1,2,0.0,,,, 肠化生+,0.0,18,中间型（int）,INFa,1.0,,,,,,,2.0,2014-07-29,2019-06-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)02 (3a)04 (3b) 00(4sb）01(4d)02 (5)03 (6)00 (7) 02(8a) (8p)01 (9)01,L（幽门窦部） 后Post 小弯侧Less ,50,30,8, R0 D2,,9.28,5.97,2.52,115.0,286.0,3.86,15.0,22.0,136.0,79.0,11.0,6.64,2.35,78.0,292.0,42.0,36.0,5.2,3.9,93.0,334.0,,,,,,,,,,,,,0.286,3.94,0.944, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET弱(+),,,,,58.1143232588699,1421381
1421716,李景宽,569538,男,54,T1b,N0,M0,ⅠA,1,0,0.0,,,, 肠化生+ 慢性炎症（+）,0.0,18,中间型（int）,INFa,1.0,,,,,,,2.0,2014-07-31,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 粘液腺癌（muc）20 Lauren混合型,G2, (1a)03 (1b)00 (3a)00 (3b) 02(4sb) 00(4d)04 (5)(11p)02 (6) 02(7)05 (8a)00 (8p) (9)00  (12a)00, M（胃体部） 后Post,15,15,2, R0 D2,,6.59,3.63,2.36,151.0,159.0,2.74,18.0,19.0,137.0,60.0,29.0,8.78,2.8,66.0,361.0,41.0,25.0,5.1,7.6,100.0,413.0,,,,,,,,,,,,,3.93,14.72,1.33, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET弱(+),,,,,97.04336399474376,1421716
1421777,张连珍,569912,女,74,T1b,N1,M0, ⅠB,1,0,0.0,,,, 肠化生+,1.0,13,中间型（int）,INFa,1.0,,,,,,,0.0,2014-07-31,2017-11-01,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】80% 乳头状癌（G1）（pap）20% Lauren肠型,G2, (1a)01 (1b)02 (3a)02 (3b)00 (4sb)03 (4d)02 (11p)01 (6)01 (7)00 (8a)11 (8p) (9)00 (12a)00," L（幽门窦部）, 后Post,",30,20,5, R0 D2,,7.07,3.44,2.74,134.4,137.0,2.82,20.0,27.0,211.0,71.0,21.0,24.59,7.17,72.0,242.0,41.0,31.0,4.7,6.6,66.0,356.0,,,,,,,,,,,,,6.54,20.24,1.98, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,39.060446780551906,1421777
1422754,明丞,565624,男,56,T2,N2,M0, ⅡB,1,2,1.0,1.0,1.0,, 肠化生+,3.0,31,中间型（int）,INFa,1.0,,,,,,,0.0,2014-08-11,2022-09-01,1,,,SOX,,,,,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)01 (1b)011 (3a)07 (3b)00 (4sb)00 (4d)12 (5)02 (6)13 (7)02 (8a)12 (8p)00 (9)01 (11p)00 (12a)00," L（幽门窦部）, 前Ant,",15,15,6, D2 R0,,6.73,3.89,2.33,147.8,222.0,3.76,14.0,18.0,144.0,49.0,15.0,8.25,3.7,67.0,225.0,43.0,24.0,4.5,8.2,84.0,296.0,,,,,,,,,,,,,2.8,9.05,1.27,,无,, P0,H0, 未做, CK + Vimentin - VEGF-  CMET- ,,,,,96.6819973718791,1422754
1422545,孙国君,569500,男,47,T1b,N2,M0, ⅡA,1,0,1.0,,,, 肠化生+,3.0,45,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-07,2018-04-26,0,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)00 (1b)00 (3a)08 (3b)06 (4sb)00 (4d)311 (5、11p)00 (6)06 (7)06 (8a)01 (8p)00 (9)07," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,15, R0 D2,,6.37,2.93,2.31,161.7,130.0,2.38,40.0,37.0,194.0,107.0,35.0,5.55,9.53,67.0,287.0,41.0,26.0,4.6,7.5,87.0,374.0,,,,,,,,,,,,,2.88,15.85,1.1,,无,, P0,H0,未做, CK + Vimentin - VEGF - CMET -,,,,,44.612352168199735,1422545
1422129,荣学军,569840,男,56,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（++）,8.0,35,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2014-08-05,2020-04-29,1,,,XELOX,XELOX,希罗达 ,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 低粘附腺癌30% Lauren混合型,G3,小弯25 (1a)02 (1b)00 (2)01 (3a)48 (3b)11 (4sa)03 (4sb)00 (4d)03 (5)00 (6)01 (7)14 (8a) (8p)05 (9)02," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",35,30,5, R0 D2,,5.21,2.69,1.91,156.2,227.0,2.96,17.0,22.0,140.0,66.0,18.0,8.63,3.29,72.0,363.0,44.0,28.0,5.2,9.3,79.0,334.0,,,,,,,,,,,,,4.93,17.21,1.53, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（-）,,,,,68.79106438896189,1422129
1422364,王忠远,570373,男,67,T2,N0,M0, ⅠB,1,2,0.0,,,, 肠化生+,0.0,49,中间型（int）,INFa,1.0,,,,,,,0.0,2014-08-06,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)014 (3b)011 (4sb)01 (4d)010 (5)00 (6)04 (7)02 (8a)03 (8p)01 (9)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",90,60,8, R0 D2,,7.72,3.78,3.11,95.8,327.0,3.97,17.0,23.0,160.0,78.0,19.0,8.34,3.24,73.0,344.0,42.0,31.0,5.9,7.0,71.0,394.0,,,,,,,,,,,,,1.76,14.26,3.04, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,96.84625492772668,1422364
1422057,耿忠香,569339,女,47,T1b,N0,M0,ⅠA,1,0,0.0,,,, 肠化生+ 慢性炎症（+）,0.0,37,中间型（int）,INFa,1.0,,,,,,,0.0,2014-08-04,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)00 (3a)05 (3b)06 (4sb)00 (4d)06 (5)00 (6)01 (7)03 (8a)04 (8p)03 (9)00 (11p)05 (12a)01," L（幽门窦部）, 小弯侧Less,",30,15,10, R0 D2,,11.77,7.97,2.92,118.5,257.0,3.59,17.0,23.0,192.0,88.0,12.0,9.14,2.63,67.0,225.0,38.0,29.0,4.5,5.9,56.0,183.0,,,,,,,,,,,,,6.14,22.55,0.938, 未做,无, 无, P0,H0, 已冲 已刷, CK +， Vimentin-， VEGF- CMET-,,,,,96.9119579500657,1422057
1422503,张伟,569271,男,56,T3,N0,M0, ⅡA,1,2,0.0,,,, 肠化生+,0.0,16,中间型（int）,INFa,3.0,,,,,,,1.0,2014-08-07,2020-10-12,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 乳头状癌（G1）（pap） Lauren肠型,G2, (1a)02 (1b)03 (3a)01 (3b)01 (4sb)00 (4d)02 (5)00 (6)03 (7)00 (8a)01 (9)00 (11p)03," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,30,8, R0 D2,,9.85,5.95,3.19,149.3,327.0,3.39,18.0,23.0,149.0,65.0,7.0,10.36,3.29,72.0,271.0,29.0,22.0,4.8,8.0,80.0,336.0,,,,,,,,,,,,,2.5,10.03,2.03,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,74.17871222076215,1422503
1422220,张波,569311,男,48,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,21,,,1.0,,,,,,,0.0,2014-08-05,2020-12-17,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40,G3, (1a)02 (1b)04 (3a)05 (3b)00 (4sb)00 (4d)00 (5)00 (6)03 (7)00 (8a)01 (8p)01 (9)01 (11p)03 (14v)00 (15)01," M（胃体部）, 小弯侧Less,",25,20,, R0 D2+,,3.91,1.84,1.8,111.7,377.0,2.87,16.0,25.0,145.0,70.0,23.0,6.81,2.95,69.0,337.0,46.0,23.0,5.2,4.4,106.0,350.0,,,,,,,,,,,,,2.48,6.97,0.756,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,76.41261498028909,1422220
1422797,王金昌,571173,男,55,T2,N0,M0, ⅠB,1,2,1.0,,,, 肠化生+,0.0,47,中间型（int）,INFa,1.0,,,,,,,2.0,2014-08-11,2021-12-12,1,,,XELOX,,,,,,3, 粘液腺癌（muc）50 管状腺癌（中分化【G2】【tub2】40 低粘附腺癌10 Lauren混合型,G2, (1a)03 (1b)01 (3a)016 (3b)01 (4sb)03 (4d)05 (5)00 (6)07 (7)03 (8a)01 (8p)01 (9)03 (11p)03 (12a)00," L（幽门窦部）, 小弯侧Less,",20,12,6, R0 D2,,5.19,2.67,1.77,143.0,231.0,2.8,26.0,20.0,180.0,86.0,42.0,16.48,6.51,66.0,265.0,44.0,22.0,5.2,7.1,70.0,306.0,,,,,,,,,,,,,2.01,14.6,6.63,,无, 无, P0,H0, 已冲, CK+， Vimentin-， VEGF-， CMET弱+,,,,,88.04204993429697,1422797
1422260,张亚文,569335,男,63,T3,N3b,M0, ⅢC,1,4,1.0,1.0,,1.0, 肠化生+ 慢性炎症（++）,32.0,45,中间型（int）,INFc,0.0,,,,,,,2.0,2014-08-06,2016-05-26,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren混合型,G3, (1a)00 (1b)11 (2)00 (3a)11 (3b)11 (4sa)11 (4sb)11 (4d)1418 (5)33 (6)03 (7)11 (8a)12 (8p)13 (9)14 (11p)22, U（胃底部）  小弯侧Less ,100,60,20,,R1,6.39,3.69,2.12,106.0,235.0,4.25,7.0,14.0,167.0,59.0,12.0,8.28,3.48,65.0,146.0,38.0,27.0,5.0,5.8,95.0,489.0,,,,,,,,,,,,,1.81,164.2,19.73, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,21.64914586070959,1422260
1422389,王德民,567419,男,42,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,, 肠化生+,8.0,44,中间型（int）,INFa,3.0,,,,,,,,2014-08-06,2015-12-21,2,,,雷替区赛,,,,,,5, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)02 (3a)312 (3b)22 (4sb)00 (4d)18 (5)00 (6)01 (7)07 (8a) (8p)24 (9)03 (12b)01 (14v)02 (15)01, L（幽门窦部） 前Ant ,30,25,8, R0 D2+,,6.72,3.88,2.3,154.5,309.0,3.76,49.0,53.0,169.0,93.0,255.0,8.23,2.35,63.0,482.0,42.0,21.0,4.6,6.3,69.0,385.0,,,,,,,,,,,,,7.04,4.68,1.66, 未做,无, 无, P0,H0, 未做, CK(+)、 CD56（-）、NSE(-)、Syn（-）,,,,,16.491458607095925,1422389
1422231,王庆,571228,男,54,T4b,N3a,M0, ⅢC,1,4,3.0,,,1.0, 肠化生+,10.0,27,中间型（int）,INFc,0.0,,,,,,,2.0,2014-08-05,2016-02-10,2,,,XELOX,,,,,,2, 低粘附腺癌40% 粘液腺癌（muc）40% 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)20% Lauren弥漫型,G3, (1a) (1b)06 (2)01 (3a) (3b)23 (4sa)00 (4sb)00 (4d)11 (5)00 (6)66 (7)13 (8a)03 (9)02 (11p)01 (12a)00 (15)01," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,6,,R1,7.31,5.27,1.7,133.4,215.0,5.04,14.0,15.0,162.0,54.0,38.0,10.94,4.08,72.0,205.0,46.0,26.0,5.2,6.5,99.0,386.0,,,,,,,,,,,,,1.15,15.86,5.31, 未做,无, 无, P0,H0, 未做,ck（+）、vimentin（-）、VEGF（-）、cMET（弱+）,,,,,18.199737187910642,1422231
1431502,逄树君,570851,男,43,T2,N0,M0, ⅠB,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,28,中间型（int）,INFc,1.0,,,,,,,2.0,2014-10-30,2017-07-27,0,,,SOX,,,,,,4, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)03 (1b)03 (2)01 (3a)03 (3b)00 (4sb)00 (4d)03 (5)01 (6)03 (8a)02 (9)05 (11p)02 (12a)01 (12p)01," M（胃体部）, 前Ant, 后Post, 大弯侧Gre,",30,25,10,,R2,6.5,3.7,2.16,125.2,333.0,5.04,,,,79.0,15.0,,,,256.0,40.0,25.0,,,,,,,,,,,,,,,,,1.23,8.11,1.56,,无,, P0,H0, 未做, CK + Vimentin- VEGF- CMET灶弱+,,,,,32.88436268068331,1431502
1422398,王子军,571178,男,51,T4b,N3b,M0, ⅢC,1,4,1.0,,,, 肠化生+,19.0,33,髓样型（med）,INFa,0.0,,,,,,,0.0,2014-08-06,2015-02-01,2,,,XELOX,XELOX,FOLFOX4,FOLFOX4,FOLFOX4,,5, 低粘附腺癌70% 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30% Lauren混合型,G3, (1a)01 (1b)00 (2)04 (3a)611 (3b)34  (4sa)00 (4sb)00 (4d)47 (5)22 (6)44 (7)00," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",120,100,6,,R2,4.71,2.82,1.41,92.8,197.0,4.08,15.0,18.0,125.0,84.0,16.0,10.0,3.22,69.0,347.0,42.0,27.0,5.7,5.2,85.0,327.0,,,,,,,,,,,,,118.5,8.34,3.25, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,5.88042049934297,1422398
1422857,杨晓飞,570016,男,51,T3,N1,M0, ⅡB,1,2,,,,1.0, 肠化生+ 慢性炎症（+）,2.0,25,髓样型（med）,INFa,1.0,,,,,,,0.0,2014-08-11,2020-10-12,1,,,XELOX,XELOX,,,,,2, 粘液腺癌（muc）70 低粘附腺癌20 管状腺癌（中分化【G2】【tub2】10,G2, (1a)00 (1b)05 (3a)05 (3b)00 (4sb)00 (4d)17 (5)00 (6)15 (7)01 (8a)00 (8p)01 (9)01 (11p)00 (12a)00 (12p)00," LM 前Ant, 后Post, 小弯侧Less,",30,25,22, R0 D2,,4.68,2.35,1.78,120.7,226.0,3.29,22.0,25.0,152.0,86.0,13.0,9.49,3.76,73.0,252.0,41.0,32.0,5.2,5.2,83.0,458.0,,,,,,,,,,,,,14.18,1.04,3.84,,无, 无, P0,H0, 未做," CK+, Vimentin-, VEGF-, CMET-",,,,,74.04730617608409,1422857
1423210,沈春梅,567481,女,56,T3,N1,M0, ⅡB,1,3,0.0,,,, 肠化生+,1.0,28,中间型（int）,INFa,3.0,,1.0,,,,,0.0,2014-08-14,2021-03-01,1,,,SOX,SOX,,,,,2, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】30 Lauren肠型,G2, (1a)08 (1b)04 (3a)03 (3b)00 (4sb)00 (4d)04 (5)00 (6)12 (7)01 (8a)01 (8p)01 (9)02 (11p)01 (12a)00 (12p)01 (14v)00," LM 前Ant, 大弯侧Gre, 小弯侧Less,",70,50,18, R0 D2+,,4.63,1.86,2.13,122.1,224.0,5.77,45.0,44.0,162.0,58.0,13.0,23.31,7.57,68.0,251.0,39.0,29.0,4.9,3.2,58.0,357.0,,,,,,,,,,,,,99.76,18.09,1.28,,无, 无, P0,H0, 已冲 已刷,CK+， Vimentin-， VEGF+ ，CMET-,,,,,78.54796320630749,1423210
1423150,姚启焕,571195,男,54,T3,N0,M0, ⅡA,1,3,1.0,,,, 肠化生+,0.0,23,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-13,2019-05-01,0,,,,,,,,,0, 粘液腺癌（muc）40% 低粘附腺癌40% 管状腺癌（中分化【G2】【tub2】20% Lauren混合型,G2, (1a)02 (1b)04 (3a)03 (3b)00 (4sb)01 (4d)04 (5)02 (6)03 (7) (8a) (8p) (9)04, L（幽门窦部） 前Ant,20,13,4, R0 D2,,9.7,5.19,3.47,146.0,221.0,3.66,20.0,25.0,164.0,69.0,35.0,10.58,3.48,63.0,265.0,39.0,24.0,4.6,5.1,72.0,267.0,,,,,,,,,,,,,3.6,12.55,1.76, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,56.57030223390276,1423150
1422876,于春清,570917,女,51,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,20,,,0.0,,,,,,,0.0,2014-08-11,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）,G2, (1a)00 (1b)01 (3a)02 (3b)02 (4sb)01 (4d)02 (5)02 (6)01 (7)01 (8a)04 (8p)02 (9)00 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",20,18,2, R0 D2,,8.31,5.47,2.12,132.3,299.0,3.27,26.0,31.0,189.0,110.0,39.0,7.76,3.0,75.0,298.0,43.0,32.0,4.7,5.8,61.0,335.0,,,,,,,,,,,,,0.394,6.19,1.48,,无, 无, P0,H0, 未做, CK + Vimentin -VEGF -CMET -,,,,,96.6819973718791,1422876
1423969,邹本奎,571208,男,73,T1a,N0,M0,ⅠA,1,0,1.0,,,, 肠化生+,0.0,20,中间型（int）,INFa,0.0,,1.0,,,,,2.0,2014-08-20,2019-05-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80% 低粘附腺癌20% Lauren混合型,G3, (1a)05 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)03 (5) (11p)02 (6)03 (7)03 (8a)00 (8p) (9)02 (12a)01," L（幽门窦部）, 小弯侧Less,",6,6,2, R0 D2,,7.32,4.15,2.55,140.5,216.0,2.7,22.0,19.0,130.0,94.0,14.0,7.53,2.85,68.0,204.0,44.0,24.0,4.9,5.1,85.0,351.0,,,,,,,,,,,,,3.34,14.62,2.91, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF部分（弱+）、 CMET弱（+）,,,,,56.34034165571616,1423969
1422355,刘广学,569826,男,59,T3,N1,M0, ⅡB,1,2,0.0,,,,肠化生+,1.0,32,中间型（int）,INFb,3.0,,,,,,,2.0,2014-08-06,2022-09-01,1,,,XELOX,,,,,,4,乳头腺癌70 中分化30,G2,, 胃癌 L（幽门窦部） 前Ant 后Post  小弯侧Less,45,40,8, R0 D2,,6.3,3.58,1.86,130.0,275.0,3.03,21.0,23.0,153.0,77.0,7.0,71.0,41.0,30.0,291.0,41.0,30.0,4.6,4.1,73.0,165.0,,,,,,,,,,,,,1.8,62.75,54.77, 未做,,,,,,,,,,,96.84625492772668,1422355
1422841,任淑玲,571018,女,50,T1a,N0,M0,ⅠA,1,0,1.0,,,, 肠化生+,0.0,24,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-11,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3, (1a)00 (1b)00 (3a) (3b)01 (4sb)01 (4d) 04(5) 00(6)00 (7)06 (8a)03 (8p) (9)07 (11p)02," L（幽门窦部）, 小弯侧Less, 后Post,",40,20,5, R0 D2,,7.87,4.74,2.64,136.5,312.0,6.21,19.0,20.0,210.0,112.0,22.0,9.35,3.28,71.0,179.0,46.0,25.0,4.5,4.6,74.0,222.0,,,,,,,,,,,,,2.21,14.51,11.9, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-）,,,,,96.6819973718791,1422841
1422911,孙理先,571351,男,72,T4b,N1,M0, ⅢB,1,2,1.0,,,1.0, 肠化生+ 慢性炎症（+）,1.0,30,中间型（int）,INFa,0.0,,,,,,,2.0,2014-08-12,2022-09-01,1,,,口服替吉奥,,,,,,6, 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren混合型,G2,大弯02 (1a)06 (1b)14 (2)05 (3a)05 (3b)00 (4sa)00 (4sb)00 (8a)04 (9)03 (12a)01," U（胃底部）, GE, SiewerⅢ, 后Post,",25,20,4,,R1,7.38,3.96,2.69,119.6,222.0,3.01,22.0,30.0,141.0,102.0,21.0,6.38,2.23,65.0,291.0,38.0,27.0,4.8,8.1,76.0,349.0,,,,,,,,,,,,,5.07,25.08,2.22,,无,, P0,H0, 未做, CK+ Vimentin- VEGF- CMET弱+,,,,,96.6491458607096,1422911
1422983,苏跃奎,571486,男,62,T3,N3b,M0, ⅢC,1,3,2.0,,,, 肠化生+,21.0,38,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-12,2015-05-07,2,,,XELOX,,,,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)11 (3a)19 (3b)01 (4sb)00 (4d)24 (5)00 (6)25 (7)33 (8a)11 (8p)45 (9)77 (11p)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,25,5, R0 D2,,12.05,9.03,2.41,117.0,420.0,3.11,11.0,14.0,171.0,72.0,16.0,9.96,3.94,63.0,256.0,43.0,20.0,5.4,5.3,86.0,213.0,,,,,,,,,,,,,6.95,389.1,1.23,,无,, P0,H0, 未做, CK + Vimentin- VEGF- CMET -,,,,,8.804204993429698,1422983
1422768,郝庆友,565607,男,62,T4b,N2,M0, ⅢB,1,3,1.0,,,1.0, 肠化生+,5.0,32,中间型（int）,INFa,2.0,,,,,,,,2014-08-11,2018-08-11,2,,,,,,,,,0, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)00 (1b)03 (3a) (3b)02 (4sb)00 (4d)1 10 (5)(11p)06 (6) 01(7)03 (8a)00 (8p) (9) 03,L（幽门窦部） 后Post 前Ant 大弯侧Gre  ,20,20,15,,R1,7.59,4.63,1.82,89.0,356.0,4.2,20.0,26.0,168.0,55.0,35.0,5.0,2.45,60.0,173.0,38.0,22.0,5.4,6.9,94.0,384.0,,,,,,,,,,,,,2.49,6.26,1.38, 未做,无,, P0,H0, 未做, CK +,,,,,47.99605781865966,1422768
1423065,李兴三,567510,男,62,T3,N2,M0, ⅢA,1,3,1.0,,,1.0, 肠化生+,3.0,34,中间型（int）,INFa,1.0,,,,,,,0.0,2014-08-13,2020-09-08,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren混合型,G3, (1a)00 (1b)00 (3a)05 (3b)28 (4sb)00 (4d)03 (5)01 (6)02 (7)16 (8a)02 (8p) (9)07 (12a)00,L（幽门窦部） 前Ant 小弯侧Less 后Post ,50,40,10, D2,,4.57,2.39,1.57,149.0,292.0,2.51,13.0,17.0,137.0,67.0,25.0,15.44,6.2,67.0,203.0,43.0,23.0,4.3,4.7,96.0,428.0,,,,,,,,,,,,,3.46,0.945,2.46, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,72.8646517739816,1423065
1423507,姜海宽,571379,男,41,T3,N0,M0, ⅡA,1,3,1.0,1.0,1.0,1.0, 肠化生+,0.0,18,髓样型（med）,INFb,0.0,,,,,,,2.0,2014-08-18,2020-12-17,1,,,XELOX,,,,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G3, (1a)00 (1b)01 (2)01 (3a)04 (3b)01 (4sa)00 (4sb)00 (4d)02 (5)00 (6)03 (7)01 (8a)02 (8p)00 (9)00 (11p)01 (12a)00 (12p)01 (14v)01," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",60,50,10, R0 D2+,,5.5,3.29,1.76,164.5,165.0,2.44,29.0,16.0,132.0,66.0,66.0,12.1,4.19,69.0,263.0,50.0,19.0,5.7,4.6,90.0,256.0,,,,,,,,,,,,,1.95,46.94,4.27, 未做,无, 无, P0,H0, 已冲 已刷,CK+， Vimentin-， VEGF- ，CMET+ 弱,,,,,75.9855453350854,1423507
1423319,李占才,567516,男,59,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,22,,,1.0,,,,,,,2.0,2014-08-14,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90 粘液腺癌（muc） 低粘附腺癌10,G2, (1a)01 (1b)01 (3a)011 (3b)01 (4sb)00 (4d)00 (5)00 (6)03 (7)03 (8a) (11p)02 (9)00 (14v)00, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less M（胃体部） 前Ant 后Post 小弯侧Less,12,10,3, R0 D2+,,5.36,3.46,1.48,154.0,296.0,2.66,12.0,18.0,185.0,62.0,17.0,17.99,6.64,69.0,256.0,47.0,22.0,4.6,3.5,91.0,442.0,,,,,,,,,,,,,0.73,4.8,2.32,,无, 无, P0,H0, 已冲 已刷, CK+， Vimentin-， VEGF+， CMET 弱+,,,,,76.11695137976346,1423319
1423615,刘福君,571410,男,60,T1b,N0,M0,ⅠA,1,0,1.0,,,, 肠化生+,0.0,9,中间型（int）,INFa,1.0,,,,,,,2.0,2014-08-18,2019-09-02,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】80 乳头状癌（G1）（pap）10 粘液腺癌（muc）10 Lauren混合型,G2, (1a)00 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)00 (5)00 (6)02 (7)01 (8a)01 (8p)01 (9)03 (11p)00," L（幽门窦部）, 后Post, 小弯侧Less,",20,15,8, R0 D2,,4.6,3.02,1.23,147.6,204.0,2.82,20.0,21.0,154.0,67.0,30.0,16.37,5.28,69.0,261.0,44.0,25.0,6.5,5.3,90.0,308.0,,,,,,,,,,,,,3.09,6.94,1.61, 未做,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET弱+,,,,,60.4796320630749,1423615
1423178,谷秀霞,570878,女,56,T1b,N1,M0, ⅠB,1,0,1.0,,,, 肠化生+ 慢性炎症（+） 异型增生+,1.0,22,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-13,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40 Lauren混合型,G3, (1a)02 (1b)02 (3a)05 (3b)01 (4sb)00 (4d)02 (5)01 (6)12 (7)03 (8a、8p)00 (9)04," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,15,3, R0 D2,,3.37,1.85,1.24,137.6,207.0,3.06,16.0,18.0,210.0,75.0,11.0,13.48,4.44,74.0,248.0,48.0,26.0,5.4,5.1,75.0,287.0,,,,,,,,,,,,,1.23,10.51,1.94,,无, 无, P0,H0,, CK + Vimentin- VEGF- CMET-,,,,,96.61629434954007,1423178
1422910,刘德福,568506,男,54,T2,N0,M0, ⅠB,1,2,0.0,,,, 肠化生+,0.0,32,中间型（int）,INFa,2.0,,,,,,,0.0,2014-08-12,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G2,,L（幽门窦部） 小弯侧Less 前Ant 后Post ,40,25,6, R0 D2,,9.91,4.69,4.28,147.0,273.0,2.41,42.0,31.0,211.0,52.0,14.0,15.99,5.17,60.0,335.0,32.0,28.0,5.5,5.8,83.0,317.0,,,,,,,,,,,,,2.36,6.47,1.1,,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,96.6491458607096,1422910
1423624,孟庆玲,571388,女,49,T1b,N2,M0, ⅡA,1,0,,,,,,4.0,19,,,0.0,,,,,,,0.0,2014-08-18,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌40,G3, (1a)00 (1b)01 (3a)01 (3b)01 (4sb)00 (4d)14 (5)00 (6)33 (7)04 (8a) (8p)01 (9)01 (11p)02 (12a)00 (14v)01,L（幽门窦部） 前Ant 小弯侧Less 后Post ,30,25,, D2+ R0,,3.75,1.46,1.79,101.7,189.0,2.41,17.0,22.0,162.0,52.0,9.0,13.78,5.29,70.0,229.0,46.0,24.0,4.0,6.1,61.0,343.0,,,,,,,,,,,,,1.38,6.36,1.49,,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,96.4520367936925,1423624
1423881,李明军,570903,男,63,T4b,N3b,M0, ⅢC,1,4,1.0,,,1.0, 肠化生+,21.0,44,中间型（int）,INFa,0.0,,,,,,,2.0,2014-08-20,2015-01-13,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)50 低粘附腺癌30 粘液腺癌（muc）20 Lauren混合型,G3, (1a)916 (1b)12 (2)46 (3a)00 (3b)00 (4sa)11 (4sb)12 (4d)14 (5)11 (6)03 (7)01 (8a)02 (8p)01 (9)01 (11p)01,G 前Ant 小弯侧Less 后Post ,65,65,12,,R1,4.66,2.27,1.97,135.0,216.0,3.53,40.0,3.0,132.0,93.0,24.0,12.44,4.57,81.0,260.0,44.0,37.0,5.3,6.6,59.0,348.0,,,,,,,,,,,,,2.58,25.42,3.76,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,4.7963206307490145,1423881
1422871,王立成,571442,男,43,T2,N1,M0, ⅡA,1,3,1.0,,,, 肠化生+,1.0,14,中间型（int）,INFa,1.0,,,,,,,0.0,2014-08-11,2022-09-01,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)02 (1b)14 (2)02 (3a)01 (3b)02 (4sa)00 (4sb)01 (7) 01(8a) 00(8p)01 ,L（幽门窦部） 前Ant,35,22,16, R0 D2,,6.87,2.41,3.99,154.4,239.0,3.33,26.0,27.0,140.0,87.0,37.0,7.29,1.75,82.0,407.0,44.0,38.0,4.8,5.4,90.0,440.0,,,,,,,,,,,,,0.869,5.79,1.44, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,96.6819973718791,1422871
1423151,杨有才,571530,男,30,T3,N2,M0, ⅢA,1,3,1.0,,,, 肠化生+,6.0,31,中间型（int）,INFc,1.0,,,,,,,0.0,2014-08-13,2016-12-04,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)50 低粘附腺癌50 Lauren混合型,G3,(1a)05 (1b)00 (2) 01(3a)35 (3b)00 (4sa) 00(4sb)00 (4d)18 (5)01 (6)11 (7)13 (8a) (8p)04 (9)01(11p)01,胃癌 ML 前Ant,30,25,3, R0 D2,,9.52,4.29,4.35,152.0,177.0,1.8,25.0,27.0,134.0,71.0,25.0,16.06,4.96,68.0,373.0,40.0,28.0,4.0,6.8,69.0,445.0,,,,,,,,,,,,,1.11,8.02,14.29, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,27.726675427069644,1423151
1423694,李晓军,571579,男,46,T3,N0,M0, ⅡA,1,3,1.0,,,1.0, 肠化生+,0.0,31,中间型（int）,INFa,0.0,,,,,,,2.0,2014-08-19,2016-01-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 60低粘附腺癌40 Lauren混合型,G3, (1a)02 (1b)04 (3a)04 (3b)01 (4sb)02 (4d)05 (5)02 (6)02 (7)00 (8a)02 (8p)02 (9)01 (11p)02 (12a)00 (12p)00 (14v)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,40,10, R0 D2+,,6.76,4.21,2.0,146.1,208.0,2.26,35.0,16.0,131.0,70.0,22.6,20.39,3.76,62.8,305.3,44.3,18.5,4.9,4.12,79.0,327.0,,,,,,,,,,,,,1.67,12.29,0.87, 未做,无, 无, P0,H0, 已冲, CK+， Vimentin-， VEGF-， CMET弱+,,,,,16.4257555847569,1423694
1423952,陈井志,571011,男,45,T3,N2,M0, ⅢA,1,2,1.0,,,, 肠化生+,4.0,31,中间型（int）,INFa,1.0,,1.0,,,,,2.0,2014-08-19,2017-07-28,0,,,XELOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)00 (1b)01 (3a)37 (3b)02 (4sb)00 (4d)12 (5)01 (6)00 (7)04 (8a)02 (8p)05 (9)03 (11p)03 (12a)00 (14v)00 (15)01," L（幽门窦部）, 小弯侧Less,",20,20,5, R0 D2+,,6.77,4.38,1.78,156.3,194.0,2.32,59.0,37.0,195.0,111.0,14.0,13.91,3.99,69.0,251.0,44.0,25.0,5.0,6.9,89.0,356.0,,,,,,,,,,,,,4.2,8.57,43.34,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF弱+， CMET弱+,,,,,35.282522996057814,1423952
1424014,蔡景和,571624,男,64,T1a,N0,M0,ⅠA,1,0,0.0,,,, 肠化生+ 慢性炎症（+）,0.0,22,中间型（int）,INFa,3.0,,,,,,,2.0,2014-08-21,2016-01-01,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)02 (1b)00 (3a)04 (3b)01 (4sb)00 (4d)05 (5)01 (6)01 (7)00 (8a)01 (8p)03 (9)02 (11p)02 (12a)00 (12p)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,35,1, R0 D2,,5.38,3.07,1.87,151.0,214.0,2.82,28.0,23.0,161.0,67.0,31.0,11.53,3.92,72.0,274.0,46.0,26.0,5.5,7.1,80.0,339.0,,,,,,,,,,,,,1.93,12.19,5.3, 未做,无, 无, P0,H0, 已冲 已刷,CK+， Vimentin-， VEGF- ，CMET+ 弱,,,,,16.36005256241787,1424014
1423305,袁玉辉,571015,男,55,T2,N3b,M0, ⅢB,1,3,2.0,,,, 肠化生+ 慢性炎症（+）,17.0,30,髓样型（med）,INFa,0.0,,1.0,,,,,0.0,2014-08-14,2019-04-13,0,,,,,,,,,0, 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren弥漫型,G3, (1a)02 (1b)00 (3a)00 (3b)12 (4sb)00 (4d)9 10 (5) (11p)12 (6)4 11(7) 12(8a) 11(8p) 00(9)00 (12a) 00,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,80,45,8, R0 D2,,5.08,3.72,0.96,83.1,309.0,3.97,16.0,17.0,152.0,58.0,9.0,17.0,16.0,58.0,187.0,38.0,20.0,5.1,4.6,80.0,309.0,,,,,,,,,,,,,2.22,11.72,15.9, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(-),,,,,55.946123521682,1423305
1423331,孙桂林,571588,男,61,T4b,N3a,M0, ⅢC,1,4,1.0,,,1.0, 肠化生+,7.0,50,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-14,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren混合型,G3, (1a)04 (1b)3 16 (2)02 (3a) 13(3b)00 (4sa)2 11 (4sb)01 (4d)02 (5)00 (6)04 (7) 01(8a)01 (8p) (9) 02(11p)00 (12a),胃癌 L（幽门窦部）M（胃体部）后Post,70,60,10,,R1,5.85,3.75,1.51,101.0,341.0,4.32,19.0,16.0,207.0,95.0,20.0,8.93,3.68,67.0,212.0,44.0,23.0,7.7,8.1,78.0,297.0,,,,,,,,,,,,,2.14,5.48,1.04, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,96.58344283837056,1423331
1423693,高淑霞,571476,女,50,T2,N0,M0, ⅠB,1,0,1.0,,,, 肠化生+ 慢性炎症（++）,0.0,39,中间型（int）,INFa,1.0,,,,,,,0.0,2014-08-19,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G2, (1a) 00(1b)02 (3a)06 (3b)03 (4sb)00 (4d)0 16 (5)00 (6)04 (7)03 (8a) (8p)02 (9)03,L（幽门窦部） 前Ant 小弯侧Less ,10,5,2, R0 D2,,8.98,4.91,3.27,132.1,319.0,3.27,12.0,17.0,145.0,95.0,10.0,8.37,2.55,76.0,230.0,48.0,28.0,5.0,7.2,83.0,295.0,,,,,,,,,,,,,1.93,8.99,2.66, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,96.41918528252299,1423693
1423695,马玉兰,571649,女,50,T2,N0,M0, ⅠB,1,3,1.0,,,,肠上皮化生，慢性炎,0.0,20,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-19,2020-05-11,1,,,,,,,,,0,中低分化管状腺癌,G3,," L（幽门窦部）, 前Ant,",30,25,8,R0,,3.37,1.38,1.58,128.0,228.0,2.41,20.0,20.0,129.0,34.0,13.0,11.28,3.01,73.0,273.0,42.0,31.0,5.3,3.9,59.0,277.0,,,,,,,,,,,,,1.41,7.6,0.701, 未做,无, 无, P0,H0, 未做,,,,,,68.72536136662286,1423695
1423804,拉喜那木吉拉,571131,男,60,T4b,N3b,M0, ⅢC,1,3,1.0,,,, 肠化生+,21.0,26,中间型（int）,INFc,3.0,,,,,,,0.0,2014-08-19,2017-03-01,2,,,TX,SOX,TX,,,,3, 粘液腺癌（muc）80% 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)20% Lauren混合型,G3,小湾02 (1a)00 (1b)23 (2)01 (3a)55 (3b)11 (4sa)00 (4sb)00 (4d)99 (5)22 (6)22 (7)01 (8a) (8p)00 (9)00,胃癌 L（幽门窦部） 前Ant ,60,50,9,,R2,7.86,5.67,1.24,116.6,309.0,4.2,13.0,22.0,171.0,74.0,17.0,24.44,8.15,65.0,230.0,35.0,30.0,6.7,7.91,120.0,426.0,,,,,,,,,,,,,1.1,194.3,3.19, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,30.387647831800262,1423804
1423385,魏玉林,572133,男,59,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,, 肠化生+,7.0,15,中间型（int）,INFa,0.0,,1.0,,,,,0.0,2014-08-15,2020-09-08,1,,,FOLFOX,FOLFOX,,,,,2, 低粘附腺癌60 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】40 Lauren混合型,G3, (1a) 00(1b)00 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)7 14 (5)00 (6)00 (7) 01(8a)00 (8p)00 (9)00 (11p)00,ML 小弯侧Less ,90,70,10, R0 D2,,4.54,2.56,1.6,146.3,278.0,3.39,17.0,22.0,164.0,73.0,18.0,13.19,4.36,70.0,304.0,49.0,21.0,4.2,7.6,84.0,315.0,,,,,,,,,,,,,,,, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(-),,,,,72.79894875164257,1423385
1423975,张岚利,571609,男,64,T1b,N0,M0,ⅠA,1,2,1.0,,,, 肠化生+,0.0,10,中间型（int）,INFa,0.0,,,,,,,2.0,2014-08-20,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G2, (1a)01 (1b)01 (3a)00 (3b)02 (4sb)00 (4d)02 (5、11p)00 (6)01 (7)02 (8a)00 (8p、9)00 (12a)01," L（幽门窦部）, 前Ant, 小弯侧Less,",10,10,2, R0 D2,,6.7,3.65,2.5,143.6,200.0,2.74,31.0,23.0,157.0,69.0,33.0,11.48,3.4,73.0,394.0,43.0,30.0,7.3,7.0,76.0,342.0,,,,,,,,,,,,,3.74,1.1,4.37,,无,, P0,H0, 未做, CK + Vimentin - VEGF- CMET弱+,,,,,96.38633377135348,1423975
1425562,苏绍佳,571055,男,57,T4b,N3b,M0, ⅢC,1,4,2.0,,,1.0, 正常,26.0,37,髓样型（med）,INFc,2.0,,1.0,,,,,1.0,2014-09-04,2019-05-01,0,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)03 (1b)00 (2)04 (3a)99 (3b)22 (4sa)00 (4sb)00 (4d)913 (5)11 (6)00 (7)33 (8a)11 (8p)00 (9)00 (11p)00 (12p)11 (14v)00,胃癌 LMU 前Ant 后Post 大弯侧Gre  小弯侧Less,60,50,10,,R1,5.34,2.72,2.11,139.2,222.0,3.27,35.0,32.0,159.0,74.0,,10.59,3.9,83.0,299.0,40.0,43.0,4.1,7.5,99.0,416.0,,,,,,,,,,,,,1.64,6.68,1.86,,无, 无, P0,H0, 未做,CK +， Vimentin-， VEGF+ ；CMET+,,,,,55.84756898817346,1425562
1423797,张立民,571085,男,42,T4b,N3a,M0, ⅢC,1,4,1.0,1.0,,, 肠化生+,15.0,39,硬型（sci）,INFc,1.0,,,,,,,2.0,2014-08-19,2015-05-13,2,,,XELOX,,,,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G3, (1a)01 (1b)13 (2)05 (3a)22 (3b)00 (4sa)01 (4sb)01 (4d)66 (5)00 (6)47 (7)23 (8a)03 (8p)03 (9)00 (11p)02 (11d)00 (12a)00 (10)02," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",160,100,,,R1,9.57,5.89,2.76,169.0,253.0,3.16,9.0,19.0,192.0,69.0,12.0,16.19,6.02,72.0,300.0,47.0,25.0,4.5,7.0,130.0,417.0,,,,,,,,,,,,,1.58,0.667,13.21, 未做,无, 无, P0,H0, 已冲 已刷,CK+， Vimentin-， VEGF- ，CMET+,,,,,8.771353482260183,1423797
1424335,梁耀文,565500,男,72,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,18,,,0.0,,,,,,,2.0,2014-08-25,2019-05-01,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)00 (3a)04 (3b)00 (4sb)00 (4d)02 (5)00 (6)03 (7)01 (8a)01 (8p)02 (9)01 (11p)01 (12a)00 (14v)00," L（幽门窦部）, 小弯侧Less,",10,8,2, R0 D2+,,7.18,4.4,1.89,149.0,191.0,3.06,14.0,15.0,171.0,74.0,17.0,20.34,6.02,64.0,220.0,40.0,24.0,4.7,8.3,99.0,36.0,,,,,,,,,,,,,1.88,1.51,2.16,,无, 无, P0,H0, 已刷 已冲, CK +， Vimentin-， VEGF-， CMET 弱+,,,,,56.17608409986859,1424335
1424048,牛成春,572113,男,44,T3,N2,M0, ⅢA,1,2,0.0,,,1.0, 肠化生+,3.0,31,中间型（int）,INFa,2.0,,,,,,,0.0,2014-08-21,2020-09-08,1,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)112 (3b)11 (4sb)00 (4d)04 (5)00 (6)03 (7)02 (8a)12 (8p)02 (9)04 (11p)00 (12p)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,25,7, R0 D2,,5.51,1.47,3.49,140.5,273.0,2.82,40.0,38.0,147.0,75.0,40.0,3.63,0.81,67.0,423.0,39.0,28.0,5.4,7.8,72.0,426.0,,,,,,,,,,,,,2.46,17.96,1.77, 未做,无, 无, P0,H0, 已冲 已刷,CK+， Vimentin-， VEGF- ，CMET-,,,,,72.60183968462549,1424048
1423773,吴艳玲,571888,女,53,T3,N2,M0, ⅢA,1,4,1.0,,,, 肠化生+,4.0,28,中间型（int）,INFa,0.0,,,,,,,2.0,2014-08-19,2016-01-01,2,,,替吉奥,奥沙利铂单药,替吉奥,替吉奥,,,4, 低粘附腺癌 80低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20 Lauren混合型,G3, (1a)00 (1b)22 (2)01 (3a) 01(3b)12 (4sa) 00(4sb)00 (4d)0 12 (5) 00(6)05 (7)00 (8a)00 (8p) 00(9)04小弯11,ML 前Ant 小弯侧Less 后Post ,90,70,10, R0 D2,,6.56,3.25,2.69,126.8,236.0,3.01,12.0,13.0,145.0,53.0,11.0,14.47,5.36,71.0,208.0,47.0,24.0,6.7,5.9,82.0,269.0,,,,,,,,,,,,,0.871,388.8,1.91, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET弱(+),,,,,16.4257555847569,1423773
1423880,赵庆福,572119,男,62,T4b,N3b,M0, ⅢC,1,5,1.0,1.0,1.0,1.0, 肠化生+,18.0,22,中间型（int）,INFc,0.0,,,,,,,0.0,2014-08-20,2015-07-01,2,,,,,,,,,0, 低粘附腺癌50% 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40% 粘液腺癌（muc）10% Lauren混合型,G3,小湾11 (1a)99 (1b)22 (2)00 (3a) (3b)11 (4sa)00 (4sb)01 (4d)56 (6)02," U（胃底部）, M（胃体部）, 前Ant, 大弯侧Gre, 小弯侧Less,",45,40,5,,R2,7.21,3.77,2.46,153.8,199.0,3.39,18.0,17.0,211.0,77.0,21.0,9.5,2.99,78.0,249.0,51.0,27.0,8.5,6.7,90.0,301.0,,,,,,,,,,,,,2.35,16.42,8.81,,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、,,,,,10.348226018396845,1423880
1423536,李有,563420,男,59,T3,N0,M0, ⅡA,1,3,2.0,,,, 肠化生+,0.0,27,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-18,2022-09-01,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)04 (3a)08 (3b)02 (4sb)01 (4d)03 (5)00 (6)02 (7)01 (8、12a)02 (8p)01 (9)03 (11)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",20,15,10, R0 D2,,11.64,8.82,1.78,144.1,246.0,5.04,22.0,24.0,158.0,105.0,19.0,19.86,7.46,77.0,224.0,40.0,30.0,4.7,5.8,69.0,378.0,,,,,,,,,,,,,0.238,9.1,5.72,,无,, P0,H0,, CK + Vimentin - VEGF- CMET-,,,,,96.4520367936925,1423536
1424756,依淑清,572011,女,60,T3,N2,M0, ⅢA,1,4,0.0,,,1.0, 正常,3.0,27,髓样型（med）,INFa,3.0,,,,,,,0.0,2014-08-27,2019-05-03,0,,,FOLFOX,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)01 (3a)04 (3b)04 (4sb)00 (4d)24 (11p)15 (6)05 (7)01 (8a)01 (8p) (9)00," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",60,50,12, R0 D2,,4.65,2.83,24.9,69.0,382.0,3.97,10.0,15.0,179.0,85.0,8.0,7.39,2.28,66.0,162.0,39.0,27.0,5.0,4.5,68.0,391.0,,,,,,,,,,,,,3.7,63.47,2.07, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,56.17608409986859,1424756
1424896,管朝,570804,男,55,T3,N1,M0, ⅡB,1,2,1.0,,,1.0, 肠化生+ 异型增生+,2.0,25,中间型（int）,INFc,1.0,,1.0,,,,,1.0,2014-08-28,2022-09-01,1,,,,,,,,,0, 低粘附腺癌80  低分化腺癌（G3)(por)20 Lauren混合型,G3, (1a)00 (1b)00 (3a)07 (3b)00 (4sb)00 (4d)01 (5)00 (6)23 (7)03 (8a)02 (8p)03 (9)01 (11p)05 (12a)00 (12p)00," L（幽门窦部）,  大弯侧Gre, 小弯侧Less, 后Post,",35,5,25, R0 D2,,5.13,2.6,2.05,125.6,221.0,3.18,15.0,18.0,135.0,65.0,28.0,14.58,4.72,68.0,250.0,45.0,23.0,5.2,5.8,85.0,351.0,,,,,,,,,,,,,3.49,7.9,1.76,,无, 无, P0,H0, 已冲 已刷,CK+， Vimentin-， VEGF+ ，CMET+,,,,,96.12352168199737,1424896
1424594,刘桂琴,571811,女,52,T3,N0,M0, ⅡA,1,3,1.0,,,, 肠化生+ 慢性炎症（+）,0.0,51,髓样型（med）,INFa,0.0,,,,,,,0.0,2014-08-26,2019-09-20,1,,,,,,,,,0, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3, (1a)04 (1b)06 (2)03 (3a)06 (3b)03 (4sa)07 (4sb)02 (4d)09 (5) (11p)00 (6)03 (7)00 (8a)05 (8p) (9)04, G 前Ant 小弯侧Less 后Post,50,12,40, D2,,5.99,3.55,1.89,126.3,348.0,,10.0,12.0,140.0,81.0,11.0,5.07,2.1,68.0,186.0,43.0,25.0,5.5,5.4,79.0,222.0,,,,,,,,,,,,,1.65,24.1,1.28, 未做,无, 无, P0,H0,,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,60.808147174770035,1424594
1424581,张伟真,572244,男,48,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,11,,,0.0,,,,,,,1.0,2014-08-26,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)05 (1b)01 (2)00 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)01 (5)00 (11p)00 (6)00 (7)01 (8a)03 (9) (8p)00 (12a)00,L（幽门窦部） 前Ant 小弯侧Less ,15,2,8, D2 R0,,5.87,3.47,1.79,156.5,203.0,2.51,44.0,29.0,165.0,100.0,67.0,20.7,5.51,81.0,441.0,47.0,37.0,4.6,5.7,68.0,365.0,,,,,,,,,,,,,2.33,6.86,6.6,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,96.1892247043364,1424581
1424334,胡春玲,571798,女,52,T2,N1,M0, ⅡA,1,3,1.0,,,, 肠化生+,1.0,23,髓样型（med）,INFb,2.0,,,,,,,2.0,2014-08-25,2020-10-12,1,,,XELOX,,,,,,2, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】60 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)03 (1b)00 (3a)05 (3b)00 (4sb)00 (4d)14 (5)00 (6)00 (7)04 (8a)01 (8p)01 (9)02 (11p)03 (12a)00,胃癌 L（幽门窦部） 小弯侧Less,18,10,15, D2 R0,,8.55,6.11,1.85,129.5,166.0,2.35,21.0,26.0,171.0,7.0,49.0,8.95,2.81,57.0,254.0,33.0,24.0,4.9,6.1,74.0,322.0,,,,,,,,,,,,,0.412,15.03,3.21,,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,73.58738501971091,1424334
1424374,李金,572173,男,41,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,23,,,0.0,,,,,,,2.0,2014-08-25,2022-09-01,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)01 (1b)02 (3a)05 (3b)00 (4sb)00 (4d)04 (5)00 (6)04 (7)04 (8a)00 (8p)02 (9)01 (11p)00 (12a)00 (12p)00," L（幽门窦部）, 小弯侧Less,",10,10,4, R0 D2,,5.3,2.17,2.72,150.1,239.0,2.66,24.0,25.0,190.0,84.0,40.0,35.51,11.12,,355.0,43.0,32.0,5.5,4.1,82.0,342.0,,,,,,,,,,,,,3.03,7.76,0.204,,无, 无, P0,H0, 已冲 已刷,CK+， Vimentin-， VEGF+ ，CMET+ 弱,,,,,96.22207621550591,1424374
1425771,王素敏,570697,女,57,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,26,,,0.0,,,,,,,0.0,2014-09-05,2019-05-01,0,,,,,,,,,0, 低粘附腺癌,GX, (1a)01 (1b)06 (3a)07 (3b)00 (4sb)00 (4d)03 (5)00 (6)03 (7)01 (8a)04 (8p)00 (9)01 (12a)00 (14v)00," L（幽门窦部）, 小弯侧Less,",,,, R0 D2+,,6.52,3.54,2.48,136.7,172.0,3.16,,,,89.0,10.0,,,,274.0,36.0,28.0,,,,,,,,,,,,,,,,,0.668,5.66,1.18,,无, 无, P0,H0, 未做, CK +， Vimentin-， VEGF- ；CMET-,,,,,55.81471747700394,1425771
1424133,周志云,571948,女,61,T4b,N3a,M0, ⅢC,1,2,1.0,,,, 肠化生+,13.0,42,中间型（int）,INFa,0.0,,,,,,,0.0,2014-08-21,2022-09-01,1,,,SOX,,,,,,1, 乳头状癌（G1）（pap）50 管状腺癌（中分化【G2】【tub2】40 低粘附腺癌10 Lauren混合型,G2, (1a)04 (1b)11 (3a)01 (3b)46 (4sb)00 (4d)38 (5)37 (6)22 (7)03 (8a)01 (8p)02 (9)03 (11p)03 (12a)01," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",50,15,50, R0 D2,,7.44,3.95,2.53,137.0,180.0,3.06,14.0,25.0,157.0,92.0,7.0,13.81,5.47,62.0,156.0,37.0,25.0,4.0,6.1,66.0,486.0,,,,,,,,,,,,,1.67,11.43,1.21,,无, 无, P0,H0,, CK + Vimentin - VEGF- CMET-,,,,,96.35348226018397,1424133
1425160,王金恒,570753,男,62,T3,N3a,M0,ⅢB,1,3,2.0,,,, 正常,10.0,17,硬型（sci）,INFc,1.0,,1.0,,,,,1.0,2014-09-01,2015-07-14,2,,,XELOX,XELOX,XELOX,SOX,SOX,SOX,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (2)00 (3a) (3b)00 (4sa)00 (4sb)00 (4d)00 (5)00 (6)00 (7)01 (8a)00 (8p)17 (9)44," G, 前Ant, 小弯侧Less, 后Post,",55,8,30,,R1,7.27,3.55,2.34,158.0,339.0,3.16,20.0,23.0,173.0,85.0,43.0,24.52,7.18,73.0,262.0,48.0,25.0,6.5,5.0,83.0,415.0,,,,,,,,,,,,,2.97,6.34,1.14, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+),,,,,10.38107752956636,1425160
1424784,刘占华,571854,女,41,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,46,,,1.0,,,,,,,1.0,2014-08-28,2020-12-17,1,,,,,,,,,0, 低粘附腺癌90 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10,G3, (1a)00 (1b)01 (2)02 (3a)04 (3b)05 (4sa)01 (4sb)01 (4d)06 (5)00 (6)010 (7)00 (8a)01 (8p)04 (9)00 (12a)011," U（胃底部）, 前Ant,",18,1,13, R0 D2,,6.62,4.08,2.04,122.8,220.0,2.96,13.0,14.0,161.0,80.0,13.0,8.18,3.0,70.0,216.0,43.0,27.0,4.7,4.3,68.0,259.0,,,,,,,,,,,,,0.377,6.92,0.9,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF- ，CMET+,,,,,75.65703022339028,1424784
1424811,赵英华,570758,女,59,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,21,,,0.0,,1.0,,,,,2.0,2014-08-28,2021-01-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)01 (3a)03 (3b)01 (4sb)00 (4d)04 (5)00 (6)02 (7)00 (8a)01 (8p)03 (9)02 (11p)02 (12a)00 (12p)00," LM 小弯侧Less,",15,5,15, R0 D2,,5.85,3.77,1.7,132.9,327.0,2.87,17.0,18.0,199.0,78.0,12.0,12.46,4.15,74.0,254.0,44.0,30.0,4.9,3.6,79.0,451.0,,,,,,,,,,,,,1.84,19.87,1.78,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF+ ，CMET+,,,,,76.14980289093297,1424811
1424651,毕文彬,570943,男,40,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,22,,,1.0,,,,,,,1.0,2014-08-27,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)03 (3a)01 (3b)02 (4sb)00 (4d)05 (5)01 (6)01 (7)02 (8a) (8p)07,L（幽门窦部） 小弯侧Less ,12,3,12, D2,,6.84,4.09,2.28,165.5,291.0,1.98,25.0,24.0,142.0,57.0,25.0,19.86,5.75,71.0,417.0,46.0,25.0,5.6,5.8,73.0,354.0,,,,,,,,,,,,,1.12,1.02,1.53, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,96.15637319316689,1424651
1425628,姜淑美,571932,女,71,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,14,,,0.0,,,,,,,0.0,2014-09-04,2020-12-17,1,,,,,,,,,0, 乳头状癌（G1）（pap） 粘液腺癌（muc）,G1, (1a)02 (1b)05 (3a)00 (3b)00 (4sb)00 (4d)00 (5)00 (6)01 (7)01 (8a)02 (8p)00 (9)02," M（胃体部）, 小弯侧Less,",30,10,25, R0 D2,,7.36,3.95,2.81,134.5,287.0,4.08,12.0,13.0,134.0,122.0,18.0,8.17,2.91,66.0,200.0,42.0,24.0,6.2,8.1,89.0,317.0,,,,,,,,,,,,,0.975,7.59,6.45,,无, 无, P0,H0, 未做, CK +， Vimentin-， VEGF- ；CMET-,,,,,75.42706964520367,1425628
1425490,郑忠凯,571878,男,66,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,24,,,1.0,,1.0,,,,,1.0,2014-09-03,2020-12-17,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)01 (3a)01 (3b)01 (4sb)00 (4d)04 (5)01 (6)03 (7)05 (8a)02 (8p)01 (9)01 (11p)04,胃癌 L（幽门窦部） 大弯侧Gre ,15,5,10, R0 D2,,7.43,4.87,1.69,162.2,234.0,3.27,20.0,27.0,166.0,57.0,21.0,15.22,5.01,63.0,282.0,38.0,25.0,3.7,6.6,81.0,366.0,,,,,,,,,,,,,3.22,9.43,0.773,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF+ ，CMET+,,,,,75.45992115637318,1425490
1424520,孙诗臣,572295,男,48,T3,N2,M0, ⅢA,1,3,0.0,,,, 肠化生+ 异型增生+,5.0,39,髓样型（med）,INFa,2.0,,,,,,,1.0,2014-08-28,2020-09-08,1,,,XELOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)05 (2)01 (3a)03 (3b)33 (4sa)00 (4sb)00 (4d)13 (5)(11p) 01(6)04 (7)02 (8a)17 (8p)03 (9) 02 (11d)01小肠系膜01,M（胃体部） 前Ant 小弯侧Less ,60,40,10, R0 D2,,8.89,5.57,1.81,136.0,346.0,4.08,20.0,24.0,189.0,70.0,19.0,6.11,1.82,72.0,370.0,42.0,30.0,4.7,6.2,72.0,286.0,,,,,,,,,,,,,6.91,1.01,1.08, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+),,,,,72.3718791064389,1424520
1425646,王显彬,572330,男,56,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,16,,,0.0,,1.0,,,,,1.0,2014-09-04,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10,G3, (1a)00 (1b)04 (3a)03 (3b)00 (4sb)00 (4d)00 (5)01 (6)02 (7)01 (8a)02 (8p)00 (9)01 (11p)02 (12a)00 (12p)00," L（幽门窦部）, 小弯侧Less,",6,1,6, R0 D2,,12.25,8.74,2.48,157.8,260.0,2.91,28.0,23.0,162.0,77.0,24.0,20.58,7.16,68.0,385.0,43.0,25.0,4.9,4.7,71.0,325.0,,,,,,,,,,,,,2.87,0.994,9.75,,无, 无, P0,H0,,CK+， Vimentin-， VEGF+ ，CMET+,,,,,75.42706964520367,1425646
1424590,邢明江,570819,男,62,T2,N0,M0, ⅠB,1,3,,,,,,0.0,24,,,2.0,,,1.0,,,,2.0,2014-08-26,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)01 (1b)00 (3a)08 (3b)00 (4sb)00 (4d)03 (5)01 (6)01 (7) (11p)06 (8a) (8p)01 (9)03 (12a)00,L（幽门窦部） 小弯侧Less ,12,3,8, D2,,16.74,15.21,0.7,132.7,257.0,4.14,18.0,15.0,148.0,83.0,14.0,8.36,3.66,63.0,204.0,41.0,22.0,4.7,5.8,87.0,271.0,,,,,,,,,,,,,0.832,6.11,1.07,,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(+),,,,,96.1892247043364,1424590
1425320,徐祺慧,573283,女,48,T3,N1,M0, ⅡB,1,3,0.0,,,1.0, 肠化生+,1.0,34,髓样型（med）,INFb,0.0,,1.0,,,,,2.0,2014-09-02,2018-07-18,2,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】,G2, (1a)04 (1b)00 (3a)17 (3b)00 (4sb)00 (4d)05 (5)00 (6)02 (7) (11p)014 (8a)01 (9)00 (12a)01,L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre  ,20,20,8,R0 D2,,6.31,4.04,1.6,104.0,341.0,19.9,28.0,17.0,196.0,85.0,10.9,6.12,1.83,73.5,232.0,42.3,42.3,4.4,3.73,51.0,190.0,,,,,,,,,,,,,1.54,52.98,14.58,,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(-),,,,,46.484888304862025,1425320
1425415,罗春才,572476,男,51,T3,N0,M0, ⅡA,1,3,0.0,,,, 肠化生+,0.0,41,髓样型（med）,INFa,1.0,,1.0,1.0,,,,0.0,2014-09-03,2017-08-04,0,,,XELOX,XELOX,,,,,2, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)03 (1b)05 (3a)01 (3b)00 (4sb)02 (4d)03 (5)03 (6)010 (7)03 (8a)02 (8p)05 (9)00 (11p)01 (12a)00 (12p)03,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,60,7, D2+ R0,,7.54,5.55,1.49,135.0,315.0,4.04,15.0,15.0,139.0,67.0,12.0,12.14,4.0,68.0,228.0,42.0,26.0,4.3,5.4,59.0,350.0,,,,,,,,,,,,,2.71,9.25,11.25, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(-),,,,,35.019710906701704,1425415
1425648,金显君,572422,男,60,T3,N3b,M0, ⅢC,1,2,1.0,,,1.0, 异型增生+,17.0,27,髓样型（med）,INFc,1.0,,1.0,,,,,2.0,2014-09-04,2019-10-01,1,,,SOX,,,,,,2, 低粘附腺癌50 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)50 Lauren混合型,G3, (1a)03 (1b)00 (3a)1314 (3b)00 (4sb)00 (4d)03 (5)00 (6)00 (7)00 (8a)01 (8p)24 (9)11 (11p)11 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",20,20,6, R0 D2,,3.74,1.69,1.65,129.0,153.0,2.87,13.0,18.0,139.0,86.0,14.0,14.58,4.87,63.0,284.0,37.0,26.0,4.8,4.5,72.0,296.0,,,,,,,,,,,,,2.99,18.49,0.989,,无, 无, P0,H0,, CK +， Vimentin-， VEGF+ CMET+ 弱,,,,,60.873850197109064,1425648
1425202,金朝波,573199,男,41,T3,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 肠化生+,6.0,18,中间型（int）,INFc,1.0,,,,,,,2.0,2014-09-01,2018-04-21,0,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por)10 粘液腺癌（muc） Lauren弥漫型,G3, (1a)24 (1b)00 (3a)15 (3b)00 (4sb)00 (4d)02 (5)00 (6)12 (7)00 (8a)01 (8p)11 (9)00 (11p)02 (12a)11," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,35,12, R0 D2,,6.75,4.18,1.8,155.0,197.0,2.26,23.0,25.0,143.0,60.0,14.0,9.38,3.82,68.0,436.0,42.0,26.0,4.9,5.8,67.0,250.0,,,,,,,,,,,,,1.57,12.19,9.36,,无,, P0,H0, 未做, CK + Vimentin - VEGF-  CMET部分+,,,,,43.62680683311432,1425202
1425347,鲍淑影,572426,女,43,T3,N0,M0, ⅡA,1,3,2.0,,,1.0, 异型增生+,0.0,29,髓样型（med）,INFc,0.0,,,,,,,1.0,2014-09-02,2018-01-04,2,,,SOX,,,,,,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)01 (2)00 (3a)08 (3b)00 (4sa)00 (4sb)05 (4d)00 (5)02 (6)03 (7)04 (8a)01 (8p)02 (9)00 (11p)00 (12a)03," M（胃体部）, 小弯侧Less,",15,15,5, R0 D2,,7.84,5.22,2.18,133.0,237.0,2.12,15.0,22.0,161.0,57.0,11.0,12.15,4.32,73.0,263.0,42.0,31.0,4.2,5.3,56.0,218.0,,,,,,,,,,,,,0.697,8.48,1.23,,无, 无, P0,H0, 未做, CK+ Vimentin-  VEGF- CMET+,,,,,40.07884362680683,1425347
1425403,王立香,571665,女,46,T3,N0,M0, ⅡA,1,3,0.0,,,1.0, 肠化生+ 异型增生+,0.0,20,髓样型（med）,INFa,0.0,,,,,,,2.0,2014-09-03,2022-09-01,1,,,XELOX,XELOX,,,,,2, 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (2)00 (3a)01 (3b)00 (4sa)00 (4sb)00 (4d)01 (5)00 (6)04 (7)01 (8a) (8p)03 (9)02 (11p)01 (12a)00 (14v)00 (15)01,M（胃体部） 小弯侧Less ,65,50,9, R0 D2,,4.14,2.04,1.35,83.8,346.0,2.66,14.0,24.0,131.0,66.0,10.0,7.86,2.68,76.0,240.0,42.0,34.0,4.5,4.6,56.0,306.0,,,,,,,,,,,,,1.16,33.0,3.05, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(部分弱+),,,,,95.92641261498028,1425403
1425513,单作富,573218,男,72,T4b,N3b,M0, ⅢC,1,2,1.0,1.0,1.0,1.0, 正常,16.0,17,中间型（int）,INFc,1.0,,1.0,1.0,,,,2.0,2014-09-04,2014-10-23,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30 低粘附腺癌70,G3, (1a)44 (1b)11 (2)22 (3a)00 (3b)11 (4sa)44 (4sb)00 (4d)00 (5)00 (6)11 (7)01 小弯33,M（胃体部） 小弯侧Less,30,25,10, R0 D1+,,7.0,4.46,1.8,109.0,256.0,4.08,40.0,30.0,152.0,66.0,37.0,8.09,2.8,69.0,375.0,42.0,27.0,6.3,5.7,91.0,374.0,,,,,,,,,,,,,0.895,117.2,3.85, 未做,无,, P0,H0, 未做,ck(+)  vimentin(局灶+)  VEGF(+)  cMET(部分弱+),,,,,1.609724047306176,1425513
1426687,马忠和,573210,男,70,T3,N2,M0, ⅢA,1,4,2.0,1.0,1.0,1.0, 肠化生+,5.0,38,髓样型（med）,INFc,1.0,,,,,,,2.0,2014-09-16,2017-06-28,0,,,SOX,,,,,,3, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)00 (1b)02 (2)02 (3a)12 (3b)02 (4sa)00 (4sb)00 (4d)38 (5)00 (6)04 (7)02 (8a)01 (9)110 (11p)05 (12a)00," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,70,12,,R1,8.34,6.28,1.13,122.9,326.0,4.74,13.0,20.0,152.0,96.0,8.0,4.34,1.55,64.0,197.0,37.0,27.0,4.6,6.2,58.0,223.0,,,,,,,,,,,,,3.52,10.79,20.63,,无,, P0,H0, 未做, CK + Vimentin - VEGF- CMET(小区弱+),,,,,33.37713534822602,1426687
1425978,高铁,570603,男,59,T4b,N2,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+,4.0,39,髓样型（med）,INFb,3.0,,,,,,,0.0,2014-09-10,2015-10-08,2,,,XELOX,XELOX,XELOX,XELOX,紫杉醇联合替吉奥,紫杉醇联合替吉奥,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3, (1a)03 (1b)03 (2)03 (3a)35 (3b)12 (4sa)03 (4sb)00 (4d)07 (5)00 (6)00 (7)00 (8a)01 (8p)03 (9)05 (11p)04 (12a)00 (14v)00," LM 前Ant, 后Post, 小弯侧Less,",50,48,8,,R1,8.03,4.84,2.31,91.3,385.0,4.14,12.0,13.0,121.0,61.0,23.0,4.76,1.25,70.0,247.0,48.0,22.0,7.0,6.4,75.0,267.0,,,,,,,,,,,,,2.08,276.9,1.96,,无,, P0,H0, 未做, CK + Vimentin - VEGF- CMET- CD34+ S-100+,,,,,12.910643889618921,1425978
1426226,李勇,570584,男,51,T3,N3a,M0,ⅢB,1,2,1.0,1.0,1.0,1.0, 正常,14.0,27,中间型（int）,INFb,0.0,,,,,,,0.0,2014-09-11,2016-12-22,2,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3,小弯33 (1a)02 (1b)11 (2)33 (3a)45 (3b)11 (4sb)00 (4d)01 (5)01 (6)02 (7)00 (8a)01 (8p)11 (9)12 (11p)04," MU SiewerⅢ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,6, D2+,R1,11.09,8.25,1.99,163.0,215.0,3.94,16.0,16.0,136.0,106.0,17.0,8.4,3.02,72.0,256.0,46.0,26.0,4.6,5.7,76.0,283.0,,,,,,,,,,,,,4.18,10.23,3.51,,无,, P0,H0, 未做, CK + Vimentin - VEGF- CMET-,,,,,27.365308804204993,1426226
1426923,肖明会,572274,男,72,T2,N1,M0, ⅡA,1,5,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+,1.0,16,髓样型（med）,INFa,1.0,,,,,,,0.0,2014-09-18,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)13 (3a)02 (3b)00 (4sb)00 (4d)05 (5)00 (6)00 (7)01 (8a)01 (8p)00 (9)00 (11p)03 (12a)00 (12p)00 (14v)00," L（幽门窦部）, 小弯侧Less,",50,45,, R0 D2+,,7.22,4.91,1.35,139.0,250.0,3.11,59.0,51.0,205.0,81.0,15.0,12.77,5.1,81.0,235.0,49.0,32.0,5.0,5.2,97.0,195.0,,,,,,,,,,,,,3.58,15.14,1.41,,无,, P0,H0, 未做, CK + Vimentin - VEGF- CMET-,,,,,95.43363994743758,1426923
1425930,邱礼慧,572457,男,40,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,25,,,2.0,,,,,,1.0,2.0,2014-09-09,2020-04-16,1,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】10,G3, (1a)03 (1b)00 (3a)03 (3b)04 (4sb)00 (4d)02 (5)00 (6)03 (7)01 (8a)02 (8p)03 (9)01 (11p)02 (12a)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",20,15,2, R0 D2,,6.87,3.54,2.53,146.6,254.0,2.51,18.0,19.0,151.0,52.0,32.0,12.94,4.37,71.0,379.0,43.0,28.0,4.4,8.4,88.0,395.0,,,,,,,,,,,,,2.05,0.789,1.77,,无,, P0,H0, 未做, CK + Vimentin - VEGF- CMET(部分弱+) CD34（脉管周+）S100(神经+),,,,,67.21419185282522,1425930
1425979,王安,573270,男,65,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 肠化生+,6.0,39,髓样型（med）,INFc,3.0,,,,,,,0.0,2014-09-10,2015-09-08,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (3a)213 (3b)14 (4sb)01 (4d)114 (5)11 (6)00 (7)03 (8a)11 (8p)01 (9)01 (11p)00 (12a) (12p)00 (14v)00,L（幽门窦部） 前Ant,80,60,20, D2+ R0,,10.78,7.49,2.32,123.3,310.0,4.2,24.0,10.0,171.0,92.0,14.7,7.9,2.11,67.9,221.89,45.4,22.5,,5.19,80.0,279.0,,,,,,,,,,,,,4.41,1000.0,52.79, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,11.925098554533507,1425979
1425934,孙杰,573650,女,81,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,1.0,29,髓样型（med）,INFa,1.0,,1.0,,,,,2.0,2014-09-09,2019-09-01,0,,,,,,,,,0, 腺癌 低分化腺癌（G3)(por),G3,"小弯1/2 (1a)0/1, (1b)0/3, (2)0/3, (3a)0/8, (3b)0/1, (4sa)0/1, (4sb)0/1, (5)0/0, (6)0/3, (7)0/0 (8a)0/3 (9)0/3",胃癌 L（胃窦部） 前Ant,110,80,20, R0,,8.12,5.81,1.73,88.6,357.0,3.46,11.0,21.0,164.0,58.0,9.0,9.34,3.78,61.0,71.0,35.0,26.0,5.2,3.7,94.0,262.0,,,,,,,,,,,,,0.907,9.95,3.22, 未做,无, 无, P0,H0, 未做,,,,,,59.72404730617608,1425934
1425950,张辉,572898,男,55,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,29,,,0.0,,1.0,,,,,,2014-09-09,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3," (1a)0/2, (1b)0/0, (3a)0/5, (3b)0/0, (4sb)0/0, (4d)0/6, (5)0/0, (6)0/9, (7)0/1, (8a)0/2, (9)0/3, (11p)0/1"," L（幽门窦部）, 小弯侧Less",25,20,3, R0 D2,,6.09,3.83,1.66,145.7,230.0,3.76,18.0,23.0,162.0,52.0,9.0,29.0,11.79,48.7,309.0,35.2,13.5,8.1,6.2,73.0,191.0,,,,,,,,,,,,,0.605,7.2,28.62, 未做,无,, P0,H0, 未做,,,,,,95.7293035479632,1425950
1425735,张培忠,572526,男,61,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,11,,,0.0,,,,,,,2.0,2014-09-05,2019-09-01,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1," (1a)0/0, (1b)0/1, (3a)0/2, (3b)0/0, (4sb)0/0, (4d)0/4, (5)0/0, (6)0/2, (7)0/1, (8a)0/1, (9)0/0, (11p)0/0",胃癌 L（幽门窦部） 前Ant,10,6,6, R0 D2,,6.91,4.53,1.89,153.2,216.0,2.05,15.0,16.0,180.0,79.0,21.0,9.81,2.98,70.0,243.0,47.0,23.0,5.2,7.9,92.0,352.0,,,,,,,,,,,,,2.67,3.63,1.02, 未做,无,, P0,H0, 未做,,,,,,59.855453350854134,1425735
1425606,杨玉荣,573633,女,45,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0, 正常,0.0,30,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2014-09-04,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90%低黏附腺癌10% ,G3, (1a)00 (1b)06 (3a)011 (3b)00 (4sb)00 (4d)01 (5)00 (6)01 (7)00 (8a)03 (8p)01 (9)00 (11p)05 (12a)01 ,胃癌 L（幽门窦部） 前Ant ,20,20,3, R0 D2,,7.2,3.12,3.22,121.9,218.0,2.82,11.0,16.0,157.0,62.0,9.0,10.44,3.26,65.0,200.0,43.0,22.0,4.7,5.5,63.0,199.0,,,,,,,,,,,,,1.56,6.57,5.15, 未做,无, 无, P0,H0, 未做,,,,,,67.3784494086728,1425606
1425775,张振田,573630,男,64,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 正常,4.0,39,髓样型（med）,INFa,1.0,,,,,,,0.0,2014-09-05,2020-04-16,1,,,XELOX,,,,,,4, 乳头状癌（G1）（pap） 管状腺癌（中分化【G2】【tub2】,G2," (1a)0/1, (1b)0/1, (3a)1/6, (3b)0/3, (4sb)0/0, (4d)0/1, (5)0/0, (6)3/5, (7)0/3, (8a)0/1 (9)0/4 (11p)0/3",胃癌 L（幽门窦部）前Ant 后post,80,70,20, R0 D2,,7.18,5.07,1.53,95.0,220.0,2.66,19.0,15.0,118.0,33.0,8.7,4.97,1.48,52.3,186.4,38.5,13.8,5.2,5.2,83.0,307.0,,,,,,,,,,,,,1.7,20.7,1.25, 未做,无,,,, 未做,,,,,,67.34559789750328,1425775
1425641,车承龙,573449,男,56,T3,N1,M0, ⅡB,1,3,1.0,0.0,0.0,1.0, 正常,1.0,18,中间型（int）,INFc,0.0,,,1.0,,,,,2014-09-04,2019-09-01,0,,,,,,,,,0,低黏附性癌约70，中低分化管状腺癌约30% ,G3," (1a)0/0, (1b)0/1, (3a)0/0, (3b)0/0, (4sb)0/5, (4d)0/0, (5)0/1, (6)0/0, (7)1/2, (8a)0/1, (8p)0/3, (9)0/2, (11p)0/3, (12a)0/0"," L（幽门窦部）, 小弯侧Less",45,35,6, R0,,4.73,2.06,2.06,128.0,225.0,2.82,19.0,20.0,148.0,68.0,16.0,13.83,6.43,54.0,176.0,32.0,22.0,6.9,3.9,89.0,188.0,,,,,,,,,,,,,7.0,12.0,6.0, 未做,无,, P0,H0, 未做,,,,,,59.88830486202365,1425641
1426147,马德文,563229,男,53,T3,N0,M0, ⅡA,1,2,2.0,1.0,1.0,1.0, 肠化生+ 异型增生+,0.0,34,髓样型（med）,INFc,0.0,,1.0,,,,,0.0,2014-09-11,2018-11-14,2,,,SOX,,,,,,2, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3, (1a)02 (1b)07 (3a)06 (3b)01 (4sb)01 (4d)04 (5)00 (6)01 (7)01 (8a)04 (8p)02 (9)00 (11p)03 (12a)00 (12p)01 (13)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,8,,R1,8.77,5.36,1.91,126.0,222.0,5.04,26.0,25.0,182.0,114.0,36.0,3.71,8.3,73.0,268.0,46.0,27.0,5.2,6.8,74.0,461.0,,,,,,,,,,,,,3.55,12.01,6.06,,无,, P0,H0, 未做, CK + Vimentin - VEGF(小区+) CMET- CD34(脉管周+)  S-100(神经+),,,,,50.09855453350854,1426147
1426148,张福山,573593,男,58,T3,N1,M0, ⅡB,1,3,1.0,1.0,1.0,1.0, 正常,1.0,22,髓样型（med）,INFc,2.0,,,,,,,0.0,2014-09-11,2016-11-15,2,,,口服替吉奥,,,,,,2, 低粘附腺癌,GX," (1a)0/0, (1b)0/0, (3a)0/8, (3b)0/2, (4sb)0/0, (4d)0/0 (5)0/0, (6)1/3, (7)0/1, (8a)0/2, (9)0/4, (11p)0/2",L 前Ant ,55,35,12, R0 D2,,4.89,2.63,1.75,153.2,176.0,3.27,25.0,24.0,129.0,62.0,29.0,17.9,7.34,61.0,156.0,40.0,21.0,5.5,4.1,76.0,284.0,,,,,,,,,,,,,2.39,16.69,1.12, 未做,无,, P0,H0, 未做,,,,,,26.149802890932982,1426148
1426873,李敬波,573347,男,76,T4a,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0,腺体萎缩 慢性炎症（+）,5.0,29,髓样型（med）,INFa,0.0,,,,,,,0.0,2014-09-17,2018-09-11,2,,,,,,,,,0,低分化管状腺癌,G3,,L,85,50,10,R0,,6.16,4.68,0.88,77.2,377.0,3.23,11.0,18.0,122.0,55.0,7.0,10.22,4.37,58.0,154.0,36.0,22.0,6.6,3.9,85.0,293.0,,,,,,,,,,,,,1.13,7.16,, 未做,,,,,,,,,,,47.79894875164258,1426873
1426076,郝长海,573549,男,49,T4b,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 正常,22.0,28,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2014-09-10,2015-05-01,2,,,紫杉醇联合替吉奥,,,,,,5, 低粘附腺癌95% 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】5%,G3, (1a)00 (1b)00 (2)22 (3a)22 (3b)00 (4sa)01 (4sb)67 (4d)25 (5)11 (6)34 (7)33 (8a)22 (8p)11 (9)00 (12a)00, LM  前Ant 后Post  小弯侧Less,50,40,8,,R1,5.24,2.66,2.08,146.2,218.0,2.78,14.0,19.0,101.0,58.0,7.0,9.37,4.17,59.0,310.0,36.0,23.0,5.0,7.8,101.0,317.0,,,,,,,,,,,,,1.81,19.6,3.73, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（局灶+）、 VEGF（-）、 CMET（-）,,,,,7.654402102496714,1426076
1426207,栾君龙,574092,男,51,T3,N3a,M1, Ⅳ,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,7.0,27,中间型（int）,INFb,1.0,,,,,,,2.0,2014-09-11,2015-07-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3," (1a)0/0, (1b)0/1, (3a)3/7, (3b)1/2, (4sb)0/0, (4d)1/7, (5)0/0, (6)2/4, (7)0/6", L（幽门窦部）,100,80,20,,R2,5.69,3.3,1.78,146.7,215.0,3.46,15.0,16.0,149.0,129.0,21.0,9.65,3.33,65.0,217.0,45.0,20.0,5.1,7.0,85.0,340.0,,,,,,,,,,,,,3.11,14.48,16.48, 未做,粟粒状,, p1盆(M1 PER),H0, 未做,,,,,,10.085413929040735,1426207
1426630,曾照兰,574178,女,45,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,22,,,1.0,,,,,,,0.0,2014-09-16,2019-06-01,0,,,,,,,,,0, 低粘附腺癌,GX, (1a)01 (1b)00 (3a)02 (3b)05 (4sb)02 (4d)00 (5)00 (6)09 (7)01 (8a)01 (8p)01 (9)00," L（幽门窦部）, 小弯侧Less,",17,15,, R0 D2,,6.24,3.75,1.87,119.0,289.0,2.39,19.0,19.0,167.0,61.0,11.0,14.51,6.1,71.0,301.0,42.0,29.0,6.5,5.1,61.0,244.0,,,,,,,,,,,,,0.85,8.93,2.16, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,56.47174770039422,1426630
1426406,张兴梅,574168,女,37,T2,N0,M0, ⅠB,1,5,1.0,0.0,0.0,0.0, 腺体萎缩+,0.0,46,髓样型（med）,INFb,0.0,,,,,,,0.0,2014-09-15,2020-04-16,1,,,XELOX,,,,,,3, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3, (1a)05 (1b)03 (3a)09 (3b)00 (4sb)00 (4d)05 (5)01 (6)09 (7)03 (8p)07 (9)02 (12p)01 (14v)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,30,10, R0 D2+,,5.75,2.1,2.82,108.0,304.0,2.98,32.0,32.0,141.0,76.0,27.0,6.16,2.29,62.0,294.0,37.0,25.0,4.7,5.5,56.0,372.0,,,,,,,,,,,,,0.482,4.23,1.01,,无, 无, P0,H0, 未做, CK + Vimentin - VEGF- CMET-,,,,,67.01708278580814,1426406
1426489,赵国文,574522,男,40,T3,N2,M0, ⅢA,1,5,0.0,1.0,1.0,1.0, 腺体萎缩+ 异型增生+ 慢性炎症（+）,3.0,48,髓样型（med）,INFa,1.0,,,,,,,0.0,2014-09-15,2020-04-16,1,,,,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)14 (2)01 (3a)26 (3b)02 (4sa)01 (4sb)00 (4d)016 (5)01 (6)07 (7)03 (8a)01 (8p)01 (9)06 (11p)00 (12a)00," M（胃体部）, 后Post, 小弯侧Less,",80,80,18, R0 D2,,3.63,1.95,1.3,76.7,283.0,2.78,9.0,10.0,106.0,69.0,8.0,1.8,2.27,51.0,235.0,35.0,16.0,5.4,4.3,65.0,347.0,,,,,,,,,,,,,0.767,4.56,1.52,,无,, P0,H0, 未做,CK + Vimentin - VEGF(-) CMET- CD34(脉管周+)  S-100(神经+),,,,,67.01708278580814,1426489
1426843,李金龙,574381,男,33,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,34,髓样型（med）,INFa,2.0,,,,,,,2.0,2014-09-17,2019-06-01,0,,,SOX,,,,,,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)00 (3a)02 (3b)00 (4sb)01 (4d)05 (5)02 (6)04 (7)04 (8a)02 (8p)02 (9)02 (11p)06 (12a)00 (12p)01," L（幽门窦部）, 前Ant,",30,25,4, R0 D2,,8.16,0.77,2.86,146.0,249.0,2.29,36.0,40.0,164.0,77.0,89.0,11.85,4.47,73.0,374.0,50.0,23.0,59.0,6.0,65.0,315.0,,,,,,,,,,,,,1.54,6.53,2.62, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（部分弱+） S-100（+）,,,,,56.4388961892247,1426843
1426698,王德军,573433,男,52,T4a,N3a ,M0, ⅢB,1,3,2.0,0.0,0.0,1.0, 正常,12.0,14,髓样型（med）,INFc,0.0,,,,,,,,2014-09-16,2015-07-15,2,,,,,,,,,0, 低粘附腺癌,GX," (1a)0/1, (3a)1/1, (3b)3/3, (4sb)0/0, (4d)5/5, (5)1/1, (6)2/2, (7)0/1", M（胃体部）,40,30,,,R2,5.72,3.41,1.84,163.0,212.0,2.57,28.0,24.0,138.0,91.0,36.0,17.05,5.99,73.0,392.0,46.0,27.0,5.0,5.9,78.0,511.0,,,,,,,,,,,,,0.763,3.61,5.28, 未做,无,, p1局肠缘(M1 PER),H0, 未做,,,,,,9.921156373193167,1426698
1437655,李德发,570681,男,63,T4b,N2,M0, ⅢB,1,4,2.0,0.0,0.0,1.0, 慢性炎症（+）,5.0,17,硬型（sci）,INFc,2.0,,,,,,,0.0,2014-12-23,2019-05-03,2,,,SOX,,,,,,1, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren弥漫型,G2,小湾22 (1a)00 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)02 (10)00 (5)01 (6)00 (7)11 (8a)02 (8p)01 (9)01 (11p)06 (12a)00 软组织可见癌," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",65,35,25,,R2,7.17,4.04,2.03,125.9,154.0,2.97,28.0,55.0,180.0,105.0,24.0,8.1,3.45,77.0,237.0,47.0,30.0,4.8,5.8,81.0,310.0,64.8,44.9,15.9,2.82,0.1,5.1,27.8,2.1,1.11,2.87,13.6,162.0,1.33,10.13,4.4, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,52.299605781865964,1437655
1426924,王德明,574515,男,51,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+,0.0,11,髓样型（med）,INFa,0.0,,,,,,,2.0,2014-09-18,2020-04-16,1,,,SOX,,,,,,4, 粘液腺癌（muc） 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a)00 (1b)02 (3a)00 (3b)01 (4sb)00 (4d)00 (5)03 (6)00 (7)01 (8a)00 (8p)00 (11p)04,胃癌 L（幽门窦部） 前Ant ,30,20,13, D2,,7.12,4.19,2.26,138.4,255.0,3.4,23.0,18.0,11.0,76.0,11.0,9.75,3.18,70.0,344.0,43.0,27.0,5.2,7.2,69.0,467.0,,,,,,,,,,,,,5.18,1.4,5.27, 未做,无,, P0,H0,,ck（+），vimentin（-），VEGF(-)，cMET(+/-)CD34(+)， S100(+),,,,,66.91852825229961,1426924
1426754,张波,574475,男,50,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+,0.0,19,中间型（int）,INFa,1.0,,,,,,,2.0,2014-09-17,2019-06-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)02 (5)00 (6)02 (7)01 (8a)02 (8p)04 (9)02 (11p)02 (12a)00," L（幽门窦部）, 前Ant,",30,20,8, R0 D2,,7.69,5.17,1.91,152.0,210.0,3.27,33.0,24.0,168.0,74.0,64.0,7.58,4.25,67.0,234.0,44.0,23.0,5.9,4.2,84.0,290.0,,,,,,,,,,,,,0.661,4.63,1.75, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（部分弱+）,,,,,56.4388961892247,1426754
1427385,陈福禄,572955,男,76,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 正常,21.0,34,髓样型（med）,INFc,0.0,,1.0,,,,,1.0,2014-09-23,2017-09-04,0,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por)10,G3, (1a)11 (1b)02 (3a)11 16 (3b)00 (4sb)22 (4d)00 (5)13 (6)66 (7)01 (8a) (8p) (9)02 (11p)00 (12a)01,L（幽门窦部）前Ant 后Post 小弯侧Less ,45,40,15, R0 D2,,6.59,4.72,1.1,84.5,307.0,2.84,,,,32.0,10.0,,,,254.0,32.0,28.0,,,,,,,,,,,,,,,,,0.693,6.84,1.54, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(灶+)  cMET(+),,,,,35.38107752956636,1427385
1427437,朴龙洙,574479,男,71,T3,N1,M0, ⅡB,1,3,1.0,,,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,2.0,29,髓样型（med）,INFb,0.0,,,,,,,0.0,2014-09-23,2016-11-26,0,,,卡培他滨单药口服,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30,G3, (1a)02 (1b)00 (3a)04 (3b)13 (4sb)01 (4d)03 (5)00 (6)14 (7) 07(8a) (8p)01 (9)03 (11p)01 (12a)00,L（幽门窦部） 小弯侧Less 后Post 大弯侧Gre  ,50,50,15, R0 D2,,6.48,4.44,1.63,150.6,215.0,2.89,27.0,27.0,159.0,96.0,47.0,10.26,4.57,70.0,393.0,44.0,26.0,5.5,6.0,88.0,311.0,,,,,,,,,,,,,2.1,0.6,1.39, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,26.116951379763467,1427437
1427232,于广会,574925,男,55,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,0.0,40,髓样型（med）,INFa,1.0,,,,,,,0.0,2014-09-22,2016-08-03,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)03 (3a)013 (3b)00 (4sb)00 (4d)00 (5)00 (6)05 (7)05 (8a)01 (8p)01 (9)01 (11p)02 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",50,50,10, R0 D2,,7.04,3.92,2.3,140.6,209.0,3.66,,,,85.0,19.0,,,,339.0,45.0,26.0,,,,,,,,,,,,,,,,,4.12,2.74,,,无, , P0,H0, 未做, CK + Vimentin - VEGF- CMET-CD34(脉管+)S100(神经+),,,,,22.371879106438897,1427232
1427248,芦秀明,573374,男,58,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,10.0,44,髓样型（med）,INFa,3.0,,,,,,,0.0,2014-09-22,2016-01-12,2,,,SOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 粘液腺癌（muc） Lauren肠型,G3, (1a)04 (1b)05 (3a)00 (3b)11 (4sb)00 (4d)11 (5)08 (6)23 (7)01 (8a) (8p) (12p)24 (9)02 (11d)15 (11p)07 (14v)33,胃癌 L（幽门窦部） 前Ant,45,35,8, D2,,6.87,4.63,1.74,160.6,214.0,2.62,27.0,16.0,180.0,72.0,14.7,14.66,2.78,72.2,277.8,44.3,27.9,5.0,2.6,78.0,340.0,,,,,,,,,,,,,3.18,394.7,3.33,,, , P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,15.670170827858081,1427248
1427615,赵旭东,574572,男,51,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,28,,,1.0,,,,,,,0.0,2014-09-24,2015-10-10,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)00 (1b)01 (3a)03 (3b)06 (4sb)02 (4d)06 (5)00 (6)05 (7)00 (8a)02 (8p)00 (9)01 (11p)02 (12a)00,L,,,,,,8.1,5.39,2.13,154.0,173.0,2.65,,,,165.0,98.6,,,,356.0,46.3,29.7,,,,,,,,,,,,,,,,,1.2,3.81,1.86,,无,, P0,H0,,CK + Vimentin - VEGF(-) CMET- ,,,,,12.516425755584756,1427615
1427476,相秀芬,574679,女,72,T1b,N2,M0, ⅡA,1,0,,,,,,3.0,10,,,1.0,,,,,,,2.0,2014-09-23,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60% 低粘附腺癌40%,G3, (1a)01 (1b)00 (3a)22 (3b)11 (4sb)00 (4d)00 (5)00 (6)01 (7)03 (8a) (8p)01 (9)01," L（幽门窦部）, 小弯侧Less,",20,20,5, R0 D2,,12.03,10.65,0.71,124.6,148.0,2.54,10.0,15.0,150.0,108.0,16.0,13.41,5.03,63.0,192.0,38.0,25.0,6.1,7.3,98.0,390.0,,,,,,,,,,,,,4.6,0.6,1.18, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（弱+）,,,,,66.75427069645204,1427476
1427509,罗振莲,575055,女,59,T3,N1,M0, ⅡB,1,3,1.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,2.0,18,髓样型（med）,INFc,0.0,,1.0,,,,,0.0,2014-09-24,2020-04-16,1,,,XELOX,,,,,,2, 低粘附腺癌 60 低分化腺癌（G3)(por)40,G3, (1a)01 (1b)02 (3a)01 (3b)00 (4sb)00 (4d)00 (5)11 (6)00 (7)03 (8a)02 (8p) (9)06 (11p) 11(12a)01 (15)00," L（幽门窦部）, 前Ant,",25,20,5, R0 D2,,6.48,4.06,1.91,132.8,266.0,3.4,30.0,33.0,221.0,54.0,9.0,21.48,7.68,56.0,298.0,32.0,24.0,7.3,2.9,56.0,170.0,,,,,,,,,,,,,0.898,7.46,2.88, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(部分弱+)  cMET(-),,,,,66.72141918528251,1427509
1427323,孙学先,573984,男,63,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,28,髓样型（med）,INFa,1.0,,,,,,,0.0,2014-09-22,2022-09-01,1,,,XELOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)00 (2)02 (3a)03 (3b)06 (4sa)01 (4sb)00 (4d)01 (5)04 (6)01 (7)01 (8a)02 (8p)01 (9)02 (11p)00 (12a)02," 前Ant 小弯侧Less 后Post  G,",90,60,13,,R1,8.31,5.77,1.96,100.4,464.0,4.59,17.0,23.0,128.0,79.0,19.0,5.01,1.95,66.0,256.0,42.0,24.0,6.1,6.4,77.0,,,,,,,,,,,,,,1.38,7.54,12.93,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,95.30223390275953,1427323
1427617,颜廷江,574946,男,60,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,21,,,0.0,,,,,,,2.0,2014-09-24,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)07 (1b)01 (3a)01 (3b)01 (4sb)00 (4d)05 (5)00 (6)00 (7)00 (8a)03 (8p)01 (9)02 (11p)00 (12a)00 (12p)00 (15)00," L（幽门窦部）, 小弯侧Less,",30,25,2, R0 D2+,,4.35,2.1,1.78,149.3,183.0,2.89,15.0,19.0,209.0,54.0,26.0,20.32,6.31,72.0,279.0,47.0,25.0,6.1,6.9,105.0,338.0,,,,,,,,,,,,,0.635,3.44,1.1, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(小区弱+),,,,,66.72141918528251,1427617
1427791,邹继贵,574732,男,55,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,24,,,0.0,,,,,,,0.0,2014-09-25,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)03 (3a)01 (3b)00 (4sb)00 (4d)00 (5)01 (6)00 (7)0 15 (8a)01 (8p)00 (9)02 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",10,10,5, R0 D2,,6.97,3.7,2.33,147.0,284.0,2.8,21.0,25.0,164.0,92.0,98.0,7.97,11.88,67.0,209.0,45.0,22.0,5.1,5.1,86.0,385.0,,,,,,,,,,,,,1.83,3.66,1.09, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,66.688567674113,1427791
1427507,温继才,574956,男,48,T4b,N3a ,M0, ⅢC,1,4,0.0,0.0,0.0,0.0, 肠化生+,15.0,21,髓样型（med）,INFa,3.0,,1.0,,,,,2.0,2014-09-24,2015-05-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80% 粘液腺癌（muc）20% Lauren肠型,G3, (1a)23 (1b)00 (2)13 (3a)00 (3b)00 (4sa)01 (4sb)00 (4d)12 (5)00 (6)34 (7)66 (8a)11 (10)11," M（胃体部）, L（幽门窦部）, 前Ant, 后Post, 小弯侧Less, 大弯侧Gre,",50,50,10,,R2,6.39,3.85,1.92,126.6,426.0,4.45,13.0,20.0,198.0,79.0,32.0,5.59,2.55,80.0,190.0,48.0,32.0,7.0,8.9,114.0,655.0,,,,,,,,,,,,,2.8,1000.0,26.46, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（小区弱+）、 CMET（弱+）,,,,,7.194480946123521,1427507
1427400,鞠凤,562933,女,60,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 异型增生+ 慢性炎症（+）,4.0,27,髓样型（med）,INFb,0.0,,,,,,,2.0,2014-10-23,2015-09-17,2,紫杉醇联合替吉奥*3,1.0,紫杉醇联合替吉奥,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80% 低粘附腺癌15% 粘液腺癌（muc）5% Lauren混合型,G3, (1a)00 (1b)00 (2)00 (3a)01 (3b)00 (4sa)00 (4sb)03 (4d)25 (5)00 (6)07 (7)14 (8a)11 (8p)01 (9)00 (11p)04 (15)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,12,3, R0 D2,,5.54,2.93,1.65,98.6,340.0,3.33,22.0,25.0,167.0,68.0,10.0,7.14,2.44,61.0,186.0,43.0,18.0,5.6,6.1,65.0,185.0,,,,,,,,,,,,,2.38,21.51,154.9, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（弱+）,,,,,10.808147174770038,1427400
1427755,历平,575240,女,46,T3,N0,M0, ⅡA,1,3,2.0,,,1.0,正常,0.0,38,髓样型（med）,INFc,0.0,,,,,,,0.0,2014-09-25,2020-04-16,1,,,XELOX,,,,,,5,低黏附性癌90% 低分化管状腺癌10%,G3, (1a)05 (1b)01 (3a)09 (3b)00 (4sb)00 (4d)02 (5)00 (6)05 (7)010 (8a)03 (9)02 (11p)01,胃癌 L（幽门窦部）前Ant,25,20,8, R0 D2,,4.72,2.75,1.59,134.8,180.0,2.47,31.0,12.0,166.0,83.0,12.6,10.51,2.03,77.3,296.7,48.3,29.0,4.7,5.76,49.0,238.0,,,,,,,,,,,,,0.448,5.93,28.73, 未做,无, 无, P0,H0, 未做,,,,,,66.688567674113,1427755
1427676,马长利,572656,男,61,T2,N1,M0, ⅡA,1,3,1.0,1.0,1.0,1.0, 腺体萎缩+ 肠化生+,2.0,21,髓样型（med）,INFa,1.0,,,,,,,2.0,2014-09-25,2020-04-16,1,,,XELOX,,,,,,6,管状腺癌（低分化（G3)(por) 中分化【G2】【tub2】70% 低粘附腺癌30%,G3,(1a)00 (1b)04 (3a)23 (3b)00 (4sb)00 (4d)04 (5)00 (6)01 (7)06 (8a)01 (8p)01 (9)01 (11p)01 ,胃癌 L（幽门窦部）前Ant,18,18,5, R0 D2,,8.38,3.99,3.58,148.3,234.0,3.22,26.0,19.0,166.0,84.0,33.0,11.57,3.3,76.0,296.0,50.0,26.0,7.9,6.7,84.0,364.0,,,,,,,,,,,,,1.63,3.49,1.27, 未做,,,,,,,,,,,66.688567674113,1427676
1428228,赵文彬,575358,男,62,T4b,N0,M0, ⅢA,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,30,中间型（int）,INFa,1.0,,,,,,,2.0,2014-09-29,2020-04-16,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)04 (1b)03 (2)01 (3a)06 (3b)03 (4sb)00 (4d)00 (6)02 (7)00 (8a)02 (8p)02 (9)02 (11p)02 (12a)01 (14v)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,30,8, R0 D2+,,6.39,3.95,1.62,123.7,239.0,3.84,39.0,18.0,148.0,94.0,34.5,12.38,2.41,75.9,374.78,45.4,30.5,6.2,7.28,93.0,304.0,,,,,,,,,,,,,37.13,33.71,5.34,,无,, P0,H0, 未做,CK + Vimentin - VEGF(-) CMET（部分弱+） CD34(脉管周+)  S-100(神经+),,,,,66.55716162943496,1428228
1427637,徐德树,574609,男,58,T4b,N2,M1, Ⅳ,1,4,2.0,0.0,0.0,1.0, 正常,3.0,18,髓样型（med）,INFc,0.0,,,,,,,0.0,2014-09-25,2016-04-06,2,,,FOLFOX,,,,,,5, 低粘附腺癌 Lauren弥漫型,GX, (1)18 (2)02 (3)00 (4sb)00 (4d)24 (5)00 (6)04 (7)00 (12a)00 (3、4sb、4d、5、7及12a组软组织内均见癌," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,40,5,,R2,5.39,3.3,1.67,129.4,222.0,4.59,12.0,17.0,148.0,69.0,17.0,15.43,6.15,66.0,217.0,46.0,20.0,6.3,6.9,96.0,355.0,,,,,,,,,,,,,2.49,10.4,1.85,,粟粒状,, p1泛(M1 PER),H0, 未做,CK + Vimentin - VEGF(-) CMET- CD34(脉管周+)  S-100(神经+),,,,,18.363994743758212,1427637
1427765,樊守文,574745,男,58,T2,N1,M0, ⅡA,1,3,,,,,,2.0,68,,,0.0,,,,,,,2.0,2014-09-25,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)03 (1b)07 (3a)00 (3b)03 (4sb)01 (4d)07 (5)11 (6)17 (7)08 (8a)024 (8p)01 (9)06 (11p)00 (12a)00,L（幽门窦部） 小弯侧Less ,15,13,, D2,,11.85,6.9,2.94,141.0,285.0,3.06,13.0,16.0,122.0,90.0,21.0,9.96,3.88,70.0,286.0,47.0,23.0,6.9,6.8,81.0,,,,,,,,,,,,,,1.77,3.81,5.07,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,66.688567674113,1427765
1427802,王兴龙,574896,男,54,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 正常,35.0,50,髓样型（med）,INFc,1.0,,1.0,,,,,1.0,2014-09-25,2017-03-25,2,,,XELOX,,,,,,1, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40,G3, (1a)03 (1b)03 (3a)23 (3b)56 (4sb)00 (4d)45 (5)00 (6)79 (7)22 (8a)12 (8p)34 (9)810, L（幽门窦部） 前Ant 小弯侧Less 后Post ,30,25,10, D2 R0,,3.66,1.82,1.49,124.0,211.0,2.96,19.0,16.0,125.0,53.0,13.0,8.08,3.09,65.0,275.0,65.0,44.0,6.0,8.5,75.0,258.0,,,,,,,,,,,,,1.84,4.28,6.39, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+),,,,,29.96057818659658,1427802
1427841,隋作庆,574662,男,31,T4b,N3b,M1, Ⅳ,1,3,2.0,1.0,1.0,1.0, 正常,30.0,31,中间型（int）,INFc,0.0,,1.0,1.0,,,,2.0,2014-09-26,2016-01-02,0,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)22 (2)12 (3a)00 (3b)00 (4sa)11 (4sb)00 (4d)10 10 (5)22 (6)11 11 (7)11小弯22,M 前Ant 小弯侧Less 后Post ,35,30,10,,R2,9.0,4.5,3.49,147.0,308.0,3.12,20.0,19.0,160.0,89.0,20.0,9.34,3.39,73.0,345.0,45.0,28.0,4.9,5.4,77.0,412.0,,,,,,,,,,,,,15.87,37.81,79.53, 未做,无, 无, p1盆(M1 PER),H0, 未做,ck(+)  vimentin(局灶+)  VEGF(小区弱+)  cMET(部分弱+)  CD34+ S-100 +,,,,,15.210249671484888,1427841
1427631,王积海,574663,男,58,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,0.0, 腺体萎缩++ 肠化生+ 慢性炎症（+）,1.0,39,中间型（int）,INFa,0.0,,,,,,,0.0,2014-09-24,2019-10-01,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) Lauren肠型,G3,小弯11 (1a)05 (1b)02 (2)00 (3a)011 (3b)00 (4sb)01 (4d)03 (5)00 (6)00 (7)07 (8a)01 (8p)04 (9)01 (11p)03 (12a)00," LM 后Post,",60,55,8, R0 D2,,4.79,2.4,1.64,86.0,306.0,3.34,34.0,35.0,196.0,72.0,31.0,6.17,2.27,72.0,331.0,44.0,28.0,5.2,5.8,66.0,337.0,,,,,,,,,,,,,1.25,2.39,1.07,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF(-) CMET- CD34(脉管周+)  S-100(神经+),,,,,60.21681997371879,1427631
1428270,陈桂秀,575259,女,64,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,23.0,23,髓样型（med）,INFa,0.0,,1.0,,,,,2.0,2014-10-01,2015-05-20,2,,,替吉奥单药,紫杉醇联合替吉奥,紫杉醇联合替吉奥,SOX,SOX,,5, 粘液腺癌（muc）60 低粘附腺癌30 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】10,G3, (1a) (1b)22 (2)00 (3a) (3b)00 (4sa)00 (4sb)1010 (4d)33 (5)44 (6)33 (7) (8p) (9)00 (8a)11," G, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",170,150,15,,R2,8.01,6.11,0.87,89.0,333.0,4.88,18.0,26.0,130.0,61.0,10.0,6.74,2.77,54.0,237.0,31.0,23.0,9.6,3.0,47.0,201.0,,,,,,,,,,,,,36.5,845.0,300.0,,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+),,,,,7.588699080157687,1428270
1428096,程彩玲,564735,女,48,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,8,,,1.0,,,,,,,2.0,2014-09-28,2019-09-01,2,TX*2,1.0,TX,,,,,,2,浸润型混合性癌 低粘附腺癌60%中低分化管状腺癌40%,G3,(3a)01 (3b)00 (4sb)00 (4d)01 (5)00 (6)04 (7)01 ," L（幽门窦部）,  前Ant,",20,20,3, R0,,6.02,3.88,1.44,113.0,239.0,3.86,24.0,23.0,186.0,88.0,28.0,14.6,4.49,64.0,360.0,42.0,22.0,5.1,4.0,48.0,321.0,,,,,,,,,,,,,2.88,8.22,, 未做,无, 无, P0,H0, 未做, CK+ CD34（脉管+）S100(神经+)  Vimentin- VEGF- CMET（小区弱）,,,,,59.09986859395532,1428096
1428114,孔凡轩,573044,男,59,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 异型增生+,13.0,17,髓样型（med）,INFb,1.0,,1.0,,,,,2.0,2014-09-28,2015-06-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,小湾11 (1a)01 (1b)11 (3a)11 (3b)00 (4sb)00 (4d)12 (5)00 (6)22 (7)22 (8a)11 (8p)44 (9)02 (12a)00," L（幽门窦部）, 小弯侧Less,",35,25,10, ,R1,6.86,3.36,2.3,139.5,243.0,3.33,22.0,25.0,175.0,72.0,9.0,7.57,2.66,70.0,296.0,40.0,30.0,5.2,4.5,69.0,267.0,,,,,,,,,,,,,1.24,3.05,2.94, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（小区弱+）、 CMET（小区弱+）、 CD34+、 S-100+,,,,,8.377135348226018,1428114
1428094,艾秀玲,573603,女,51,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,29,,,0.0,,,1.0,,,,0.0,2014-09-28,2019-06-08,0,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)01 (3a)00 (3b)012 (4sb)00 (4d)00 (5)00 (6)04 (7) 00(8a)01 (8p) (9)01 (11p)03 (12a)00 (16a1)01," L（幽门窦部）, 小弯侧Less,",8,7,5, R0 D2+,,4.65,2.25,1.98,126.9,204.0,2.98,27.0,29.0,175.0,80.0,18.0,12.19,3.79,81.0,360.0,49.0,32.0,5.9,5.1,81.0,359.0,,,,,,,,,,,,,0.583,4.11,1.11, 未做,无, 无, P0,H0, 未做,vimentin(局灶+)  VEGF(-)  cMET(+),,,,,56.30749014454665,1428094
1428964,杜景利,574688,男,61,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,1.0,,0.0,18,,,0.0,,1.0,,,,,0.0,2014-10-09,2020-01-01,2,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20,G3, (1a)01 (1b)00 (3a)09 (3b)00 (4sa)01 (4sb)00 (4d)01 (5)00 (6)01 (7)00 (8a)01 (8p)02 (9)00 (11p)01 (12p)01," M（胃体部）, 后Post,",15,15,3, R0 D2,,7.24,3.89,2.48,159.0,230.0,3.53,21.0,20.0,132.0,102.0,28.0,12.11,4.85,64.0,322.0,40.0,24.0,6.1,5.5,72.0,305.0,,,,,,,,,,,,,0.897,14.0,,,无,, P0,H0, 未做,CK + Vimentin - VEGF(部分弱+) CMET- CD34(脉管周+)  S-100(神经+),,,,,62.74638633377135,1428964
1429365,丰海涛,566180,男,65,T4b,N0,M0, ⅢA,1,3,1.0,,,1.0, 肠化生+ 异型增生+,0.0,32,硬型（sci）,INFb,0.0,,1.0,,,,,0.0,2014-10-13,2016-06-15,2,紫杉醇联合替吉奥*2,1.0,,,,,,,0,腺癌 Lauren混合型,GX, (1a)01 (1b)00 (3a)08 (3b)01 (4sb)02 (4d)02 (5)05 (6)03 (7)05 (8a) (8p)01 (9)04,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,50,20,,R1,8.97,4.1,3.92,124.7,155.0,4.04,59.0,49.0,171.0,105.0,34.0,7.33,2.98,85.0,216.0,42.0,43.0,5.1,6.2,95.0,408.0,,,,,,,,,,,,,3.22,6.99,10.61,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(-)CD34(+)， S100(+),,,,,20.07227332457293,1429365
1428133,李松,577073,男,50,T3,N1,M0, ⅡB,1,3,2.0,0.0,0.0,1.0, 正常,1.0,28,髓样型（med）,INFc,2.0,,,1.0,,,,2.0,2014-09-29,2020-04-16,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3, (1a)03 (1b)02 (3a)01 (3b)00 (4sb)00 (4d)14 (5)00 (6)03 (7)07 (8a) (8p)03 (9)05," L（幽门窦部）, 前Ant,",20,18,4,R0 D2,,5.9,2.97,2.34,146.0,344.0,3.16,32.0,11.0,174.0,88.0,25.1,17.03,3.78,70.4,325.18,47.7,22.7,4.3,7.38,82.0,224.0,,,,,,,,,,,,,5.47,0.6,1.95,,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(+)CD34(+)， S100(+),,,,,66.55716162943496,1428133
1428902,刘城,574764,男,50,T2,N0,M0, ⅠB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,20,中间型（int）,INFa,1.0,,,,,,,2.0,2014-10-08,2020-04-16,1,,,XELOX,XELOX,XELOX,卡培他滨,,,4, 管状腺癌（中分化【G2】【tub2】,G2, (1a) (1b)00 (2)01 (3a)09 (3b)01 (4sa)00 (4sb)00 (4d) (6)02 (5) (12a)01 (7) (8a) (8p) (9) (11p)06," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",15,10,8, R0 D2,,5.85,2.51,2.75,142.0,135.0,2.41,46.0,38.0,113.0,83.0,52.0,9.51,3.67,66.0,176.0,44.0,22.0,6.4,5.7,76.0,418.0,,,,,,,,,,,,,3.17,14.78,3.81,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET部分弱+,,,,,66.26149802890933,1428902
1429011,梁凯,562725,男,58,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,0.0, 腺体萎缩+ 肠化生+ 异型增生+,4.0,17,髓样型（med）,INFa,1.0,,,,,,,0.0,2014-10-09,2020-04-16,1,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap）,G2, (1a)02 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)02 (5)12 (6)24 (7)02 (8a)11 (9)02 (11p)01," LM 前Ant, 后Post, 大弯侧Gre,",70,70,8, R0 D2,,5.82,3.22,1.73,92.0,279.0,3.66,19.0,24.0,132.0,79.0,34.0,12.79,5.13,63.0,206.0,41.0,22.0,4.9,4.0,71.0,278.0,,,,,,,,,,,,,1.61,6.71,1.68,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,66.22864651773982,1429011
1429364,隋建侠,574758,女,36,T3,N3a,M0,ⅢB,1,4,2.0,0.0,0.0,0.0, 肠化生+,11.0,40,髓样型（med）,INFc,1.0,,1.0,,,,,0.0,2014-10-13,2016-09-30,2,,,XELOX,,,,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)11 (1b)13 (2)04 (3a)58 (3b)00 (4sb)01 (4d)35 (5)00 (6)16 (7)02 (8a)02 (8p)01 (9)01 (10)00 (11d)02 (11p)03 (12a)01 (14v)00," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,15, R0 D2+,,4.51,1.8,2.35,91.0,316.0,3.27,11.0,15.0,131.0,79.0,5.0,9.41,4.05,67.0,180.0,45.0,22.0,5.0,5.4,66.0,215.0,,,,,,,,,,,,,1.36,21.08,1.04,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF(部分弱+) CMET- CD34(脉管周+)  S-100(神经+),,,,,23.587385019710904,1429364
1429731,刘德中,576357,男,40,T3,N0,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,0.0,22,髓样型（med）,INFa,0.0,,,,,,,2.0,2014-10-15,2020-04-16,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)04 (3b)00 (4sb)00 (4d)03 (5)00 (6)03 (7)02 (8a)01 (8p、9)01 (11p)03 (12a)00 (12p)01 (14a)01 (14v)02   (3b)组软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,10, R0 D2+,,5.96,3.4,1.84,153.4,283.0,2.46,15.0,13.0,126.0,81.0,18.0,11.99,4.4,72.0,199.0,49.0,23.0,6.7,6.3,91.0,344.0,69.2,,,,,6.3,,,1.16,1.82,11.7,33.9,2.73,13.48,4.23,,无,, P0,H0, 未做,CK + Vimentin - VEGF - CMET(灶状弱+) CD34+ S-100+,,,,,66.03153745072274,1429731
1429224,胡井阳,574787,男,63,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,23,,,0.0,,1.0,,,,,0.0,2014-10-11,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)03 (1b)00 (3a)03 (3b)00 (4sb)02 (4d)01 (5)01 (6)00 (7)02 (8a)01 (8p) (9)04 (11p)06 (12a)00 (14v)00," L（幽门窦部）, 后Post, 大弯侧Gre,",10,,, R0 D2,,4.93,2.47,1.87,144.0,175.0,1.58,9.0,19.0,124.0,103.0,12.0,18.61,8.48,68.0,194.0,45.0,23.0,5.1,6.5,75.0,256.0,,,,,,,,,,,,,1.02,3.32,1.63, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(弱+)  cMET(-)  ,,,,,66.16294349540078,1429224
1429567,董宾,576985,男,53,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,6.0,27,硬型（sci）,INFb,1.0,,,,,,,2.0,2014-10-14,2020-04-16,1,,,XELOX,,,,,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90% 低粘附腺癌10% Lauren混合型,G3, (1a)02 (1b)00 (2)01 (3a)03 (3b)14 (4sa)02 (4sb)00 (4d)00 (5)28 (7)02 (8a)00 (8p)01 (9)12 (10) (11d)00 (11p)22," U（胃底部）, 小弯侧Less,",40,40,15, R0 D2,,6.14,5.02,0.61,86.3,175.0,3.06,23.0,31.0,128.0,64.0,15.0,5.12,2.48,54.0,233.0,34.0,20.0,6.6,3.6,64.0,263.0,,,,,,,,,,,,,1.43,5.39,1.04, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（部分弱+）、 CD34+、 S-100+,,,,,66.06438896189225,1429567
1429663,付春发,574846,男,50,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 正常,3.0,40,髓样型（med）,INFa,1.0,,1.0,1.0,,,,2.0,2014-10-14,2020-09-08,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3,小弯017 大弯及肠旁320 (5)01 (7)01 (11p)01," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",95,70,50, R0 D2,,9.01,5.23,3.02,135.8,182.0,3.76,23.0,25.0,252.0,107.0,37.0,6.07,2.76,62.0,164.0,41.0,21.0,6.1,7.3,79.0,261.0,,,,,,,,,,,,,2.37,17.56,11.42,,无, 无, P0,H0, 未做,CK+， Vimentin部分+， VEGF 散在+， CMET小区弱+,,,,,70.82785808147175,1429663
1429671,陈洪光,574861,男,54,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,23,,,1.0,,,,,,,0.0,2014-10-14,2020-04-16,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)02 (1b)02 (3a)03 (3b)00 (4sb)00 (4d)03 (5)00 (6)05 (7)00 (8a)06 (9)02 (12a)00," L（幽门窦部）, 小弯侧Less,",12,15,, D2 R0,,5.77,3.09,2.05,157.0,189.0,2.72,16.0,16.0,132.0,86.0,10.0,10.43,3.93,70.0,263.0,48.0,22.0,5.0,5.1,85.0,286.0,,,,,,,,,,,,,1.94,0.6,2.59,,无,, P0,H0, 未做, CK + Vimentin - VEGF -CMET-,,,,,66.06438896189225,1429671
1430225,张慧智,574870,女,77,T2,N3a,M0, ⅢA,1,5,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,9.0,36,中间型（int）,INFa,1.0,,,,,,,2.0,2014-10-20,2018-11-23,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)00 (3a)36 (3b)27 (4sb)00 (4d)12 (5)00 (6)35 (7)04 (8a)01 (8p)04 (9)00 (11p)04 (12a)00 (14v)01 (16a1)00," L（幽门窦部）, 小弯侧Less,",30,30,5,,R1,5.43,3.35,1.32,79.0,244.0,4.45,21.0,13.0,165.0,33.0,34.0,9.62,4.1,54.0,132.0,36.0,18.0,6.1,3.7,62.0,199.0,53.3,,,,,14.9,,,1.34,1.88,13.7,72.3,0.643,7.62,1.94,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF - CMET(小区弱+) CD34+ S-100+,,,,,49.11300919842313,1430225
1429837,王玉敏,575537,女,54,T3,N2,M0, ⅢA,1,4,2.0,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,5.0,53,硬型（sci）,INFc,0.0,,,,,,,0.0,2014-10-15,2017-03-05,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)12 (1b)04 (2)00 (3a)33 (3b)00 (4sa)03 (4sb)11 (4d)015 (5)04 (6)02 (7)03 (8a)01 (8p)03 (9)02 (10)00 (11d)02 (11p)01 (12a)00 (14v)05 (16a1)01 (19)01," MU 前Ant,",100,70,20, R0 D2+,,3.97,2.15,1.5,132.9,169.0,2.58,14.0,19.0,132.0,72.0,9.0,31.63,10.51,72.0,219.0,47.0,25.0,5.1,5.7,61.0,188.0,77.7,38.9,32.3,1.2,0.1,14.2,7.0,0.3,,,,,1.97,18.37,0.827,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF(-) CMET- CD34(脉管周+)  S-100(神经+),,,,,28.64651773981603,1429837
1429555,陈德才,577023,男,62,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,24,,,3.0,,,,,,,0.0,2014-10-14,2020-04-16,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a) (1b) (3a)012 (3b)00 (4sb)00 (6) (4d)02 (5) (12a)00 (7) (8a) (8p) (9) (11p)010," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,50,, R0 D2,,6.88,4.46,1.73,131.1,184.0,2.82,32.0,15.0,124.0,55.0,20.0,7.27,5.35,59.4,336.18,41.8,17.6,4.4,7.19,92.0,270.0,,,,,,,,,,,,,2.26,7.35,3.23,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF -， CMET-,,,,,66.06438896189225,1429555
1429730,沈贵仁,576432,男,74,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,0.0, 肠化生+,1.0,17,中间型（int）,INFa,1.0,,,,,,,1.0,2014-10-15,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (11p)03 大弯0/9，小弯1/5,L,25,20,20, R0 D2+,,5.56,3.2,1.59,127.0,149.0,3.97,41.0,14.0,131.0,95.0,30.8,7.53,5.67,64.6,168.8,36.6,28.0,4.8,9.22,68.0,244.0,,,,,,,,,,,,,2.13,18.14,1.18,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+) ,,,,,94.54664914586071,1429730
1430356,陈军,577161,男,54,T3,N3a,M0,ⅢB,1,3,2.0,0.0,0.0,1.0, 肠化生+,14.0,19,硬型（sci）,INFc,0.0,,,1.0,,,,2.0,2014-10-20,2016-12-22,2,,,SOX,,,,,,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)22 (1b)22 (3a)66 (3b)00 (4sb)00 (4d)00 (5)00 (6)04 (7)00 (8a)11 (8p)01 (9)22 (11p)11 (12a)00," LM 小弯侧Less,",45,30,13,,R1,7.58,1.84,2.37,166.4,152.0,2.98,29.0,28.0,198.0,61.0,78.0,19.57,6.77,70.0,340.0,43.0,27.0,6.1,5.6,78.0,247.0,77.3,,,,,7.2,,,0.956,5.4,11.0,66.6,1.47,0.991,19.91,,无,, P0,H0, 未做,CK + Vimentin (局灶+) VEGF - CMET(小区弱+),,,,,26.084099868593952,1430356
1429998,吴丽萍,576705,女,43,T3,N3a ,M0,ⅢB,1,4,2.0,1.0,1.0,1.0, 肠化生+,15.0,23,硬型（sci）,INFc,1.0,,,1.0,,,,1.0,2014-10-16,2016-01-13,2,,,替吉奥联合多西他赛,替吉奥联合多西他赛,替吉奥联合多西他赛,替吉奥联合多西他赛,替吉奥 紫衫醇 表柔比星,,5, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)01 (1b)00(3a)44(3b)00(4sb) 00(4d)26 (5)33 (6)22 (7)12(8a) (8p)11 (9)01 (11p)00 (12a)00 小弯23   软组织可见癌,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,70,70,14, R0 D2,,4.59,2.93,1.46,71.2,385.0,3.53,18.0,25.0,170.0,34.0,2.0,13.48,6.08,66.0,248.0,41.0,25.0,4.4,3.9,43.0,211.0,,,,,,,,,,,,,0.482,8.73,2.47, 未做,无,, P0,H0, 未做,ck(+)  vimentin(局灶+)  VEGF(-)  cMET(部分+)  CD34(+)  S100(+),,,,,14.914586070959263,1429998
1430023,艾丽萍,576740,女,32,T1b,N2,M0, ⅡA,1,3,,1.0,1.0,1.0,,3.0,24,,,0.0,,,1.0,,,,0.0,2014-10-16,2022-09-01,1,,,XELOX,,,,,,1, 低粘附腺癌 70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30,G3, (1a)00 (1b)00 (3a)02 (3b)11 (4sb)00 (4d)01 (5)00 (6)05 (7)03 (8a)02 (8p)01 (9)05 (11p)01 (12a)00 (14v)00小弯23,L（幽门窦部） 小弯侧Less 后Post,35,20,, R0 D2+,,10.77,8.16,2.1,122.2,245.0,1.99,23.0,23.0,147.0,46.0,7.0,11.95,4.4,72.0,272.0,45.0,27.0,5.4,7.6,45.0,194.0,57.6,33.4,18.0,1.86,0.1,13.4,25.8,1.4,2.37,2.99,13.1,31.1,2.36,25.15,3.36, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(局灶+)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,94.51379763469119,1430023
1430404,付营传,574229,男,46,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+,0.0,18,中间型（int）,INFa,2.0,,,,,,,2.0,2014-10-21,2017-05-15,2,,,SOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)03 (3a)04 (3b)00 (4sb)00 (4d)00 (5)00 (6)03 (7)00 (8a)02 (8p)00 (9)01 (11p)02," L（幽门窦部）, 小弯侧Less,",20,20,10, R0 D2,,6.19,2.6,2.52,153.1,158.0,2.08,36.0,28.0,175.0,57.0,25.0,13.74,5.03,67.0,283.0,44.0,23.0,4.9,8.4,60.0,216.0,,,,,,,,,,,,,4.11,9.36,1.97, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（小区弱+）、 S-100+、CD34-,,,,,30.781865965834427,1430404
1430467,范昌明,577053,男,57,T3,N2,M0, ⅢA,1,5,1.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,6.0,15,髓样型（med）,INFa,2.0,,,,,,,0.0,2014-10-21,2019-09-02,0,*1,1.0,XELOX,XELOX,XELOX,XELOX,卡培他滨,,5, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a) (1b)36 (3a) (3b)00 (4sb)14 (5)00 (6) (4d)11 (7)14," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,72,20,,R2,15.3,10.88,2.92,84.0,390.0,3.97,24.0,24.0,152.0,75.0,19.0,3.99,2.0,67.0,234.0,37.0,30.0,9.6,7.0,85.0,339.0,,,,,,,,,,,,,5.1,221.8,12.4,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET-,,,,,58.37713534822601,1430467
1430680,李文,577912,男,66,T4b,N3b,M1, Ⅳ,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,19.0,27,中间型（int）,INFa,1.0,,,,,,,2.0,2014-10-22,2015-06-01,2,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)11 (3b)00 (4sb)00 (4d)33 (5)22 (6)77 (7)48 (8a)11 (8p) (9)03 (12a)12 (15)00,L（幽门窦部） 小弯侧Less 前Ant 后Post ,70,50,15,,R2,7.47,4.64,1.82,126.8,232.0,4.14,24.0,23.0,162.0,67.0,15.0,7.5,2.77,69.0,229.0,39.0,30.0,5.2,3.7,71.0,367.0,,,,,,,,,,,,,3.58,16.14,9.19, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(弱+)  CD34(+)  S100(+),,,,,7.293035479632063,1430680
1430659,高侠,576439,男,55,T4b,N3a,M1, Ⅳ,1,5,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,11,中间型（int）,INFa,1.0,,1.0,,,,,0.0,2014-10-22,2015-05-06,2,,,,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (2)03 (3a)00 (3b)00 (4sb)00 (4d)12 (5)11 (6)33 (7)11 (8a)11   (3a、3b、4sb、4d、6、7、8a)组软组织均可见癌 ," LMU 后Post, 大弯侧Gre,",40,25,13,,R2,8.63,5.51,2.24,133.8,303.0,3.66,13.0,16.0,162.0,83.0,8.0,10.74,3.96,68.0,190.0,42.0,26.0,5.0,7.0,86.0,225.0,64.6,,,,,10.8,,,0.739,4.61,13.3,36.5,5.85,3.35,3.73,,粟粒状,, p1盆(M1 PER),H0, 未做,CK + Vimentin - VEGF (小区弱+) CMET(-) CD34+ S-100+,,,,,6.438896189224704,1430659
1431886,孙晓虎,576474,男,37,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,39,,,1.0,,,,,,,0.0,2014-11-03,2020-04-16,1,,,,,,,,,0, 低粘附腺癌,GX, (1a) 02(1b)01 (3a)07 (3b)00 (4sb)02 (4d)02 (5)090（6）07 (7)06 (8a)00 (8p)04 (9)03 (11p)02 (12a)00 (14v)03," L（幽门窦部）, 小弯侧Less,",15,10,, R0 D2+,,8.38,4.63,3.05,156.7,175.0,2.72,64.0,36.0,187.0,77.0,24.0,7.77,2.59,74.0,414.0,49.0,25.0,5.5,5.4,81.0,359.0,59.1,40.4,13.5,2.99,0.0,7.8,32.7,0.8,0.944,2.27,9.5,34.7,2.71,6.31,5.44, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,65.40735873850197,1431886
1430382,赵文顺,577962,男,53,T3,N1,M0, ⅡB,1,3,1.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,2.0,20,髓样型（med）,INFa,0.0,,1.0,,,,,0.0,2014-10-21,2016-09-07,2,,,XELOX,4,,,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3, (1b)02 (2)01 (3a)00 (3b)00 (4sb)00 (4d)02 (5)00 (6)02 (7)17 (8a)01 (8p)02 (9)02 (12a)00 (14a)01 (14v)00," L（幽门窦部）, 小弯侧Less,",30,20,10, R0 D2,,3.86,1.8,1.64,128.0,171.0,1.64,33.0,26.0,102.0,47.0,39.0,10.4,3.2,63.0,312.0,40.0,23.0,5.2,5.7,69.0,381.0,76.9,49.1,21.0,2.34,0.3,10.9,10.8,0.8,,,,,3.57,14.48,2.98,,无,, P0,H0, 未做,CK + Vimentin - VEGF (局灶+) CMET- CD34+ S-100+,,,,,22.568988173455978,1430382
1430852,周永民,576531,男,58,T4b,N1,M0, ⅢB,1,3,1.0,0.0,0.0,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,2.0,22,硬型（sci）,INFb,1.0,,,,,,,0.0,2014-10-23,2020-04-16,1,,,口服替吉奥,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3, (1a) (1b)13 (3a) (3b)17 (2)02 (4sa)00 (4sb)02 (6) (4d)02 (5) (12a)01 (7) (8a) (8p) (9) (10) (11p) (11d)05," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",40,30,8, R0 D2,,4.91,3.01,1.33,141.5,115.0,2.29,35.0,35.0,162.0,87.0,45.0,16.96,7.67,64.0,188.0,37.0,27.0,5.1,4.6,68.0,331.0,,,,,,,,,,,,,2.73,15.24,1.13,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,65.76872536136662,1430852
1430809,马世荣,577907,女,55,T4b,N1,M0, ⅢB,1,2,2.0,1.0,1.0,1.0, 肠化生+ 异型增生+,2.0,35,中间型（int）,INFa,0.0,,,1.0,,,,0.0,2014-10-23,2022-09-01,1,,,XELOX,,,,,,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)00 (3a)07 (3b)02 (4sb)00 (4d)01 (5)01 (6)04 (7)11 (8a)07 (9)06 (11p)04 (14v)11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,25,,R1,6.01,3.13,2.27,86.1,269.0,3.35,27.0,27.0,130.0,82.0,4.0,7.18,2.71,64.0,172.0,36.0,28.0,5.1,7.0,83.0,185.0,,,,,,,,,,,,,2.11,3.46,290.1,,, 无, P0,H0, 未做,CK + Vimentin (局灶+) VEGF- CMET- CD34+ S-100+,,,,,94.2838370565046,1430809
1430578,王世成,577902,男,50,T3,N3a,M0,ⅢB,1,5,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,36,中间型（int）,INFa,2.0,,,,,,,0.0,2014-10-22,2016-08-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)110 (3b)00 (4sb)01 (4d)410 (5)00 (6)12 (7)00 (8a)12 (8p)01 (9)02 (11p)06 (12a)00 (14v)00," L（幽门窦部）, 大弯侧Gre,",35,35,5, R0 D2,,7.51,4.64,1.97,131.9,240.0,3.39,26.0,26.0,130.0,81.0,12.0,7.14,2.67,57.0,233.0,39.0,18.0,4.2,3.8,83.0,211.0,,,,,,,,,,,,,1.52,6.95,3.86,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF - CMET- CD34+ S-100+,,,,,21.320630749014455,1430578
1430737,刘桂英,577687,女,66,T3,N3a,M0,ⅢB,1,5,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+,9.0,29,髓样型（med）,INFa,0.0,,1.0,,,,,2.0,2014-10-23,2022-09-01,1,,,,,,,,,0, 低粘附腺癌60 粘液腺癌（muc）40 Lauren混合型,GX,小弯11 (1a)01 (1b)00 (3a)33 (3b)00 (4sb)00(4d)13 (5)00 (6)49 (7)02 (8a)01 (8p)02 (9)04 (11p)01 (12p)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,35,12, D2 R0,,3.8,1.77,1.61,108.9,170.0,2.12,17.0,23.0,150.0,61.0,16.0,9.14,3.77,59.0,166.0,39.0,20.0,4.9,5.3,72.0,257.0,67.1,,,,,10.2,,,1.47,3.79,8.15,16.7,3.28,54.6,6.02,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF (小区弱+) CMET(小区弱+) CD34+ S-100+,,,,,94.2838370565046,1430737
1430581,黄永海,577677,男,60,T1b,N2,M0, ⅡA,1,0,,1.0,1.0,1.0,,3.0,26,,,0.0,,,,,,,0.0,2014-10-22,2016-08-25,2,,,XELOX,,,,,,5, 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (3a)04 (3b)04 (4sb)13 (4d)25 (5)01 (6)02 (7) (8a) (8p) (9)04 (11p)02 (12a)00,L（幽门窦部） 前Ant 大弯侧Gre  ,30,15,2,R0 D2,,7.52,3.77,2.95,158.2,244.0,2.36,25.0,27.0,210.0,62.0,15.0,34.34,11.98,72.0,311.0,45.0,27.0,4.8,6.3,83.0,403.0,,,,,,,,,,,,,7.48,6.71,7.48,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,22.109067017082786,1430581
1430838,刘建民,575010,男,62,T1b,N1,M0, ⅠB,1,0,,1.0,1.0,0.0,,1.0,17,,,0.0,,,,,,,2.0,2014-10-23,2020-04-16,1,,,SOX,,,,,,6, 低粘附腺癌70 低分化腺癌（G3)(por)30,G3, (1a)02 (1b)00 (3a)12 (3b)02 (4sb)00 (4d)00 (5)00 (6)01 (7)00 (8a)02 (8p)03 (9)01 (11p)04 (12a)00 (14a)00 (14v)00," LM 小弯侧Less,",20,20,, R0 D2,,4.46,2.15,1.67,138.0,265.0,3.66,21.0,21.0,154.0,77.0,23.0,17.75,7.86,69.0,231.0,46.0,23.0,6.1,5.2,82.0,320.0,,,,,,,,,,,,,3.56,0.6,1.95,,无,, P0,H0, 未做,CK + Vimentin - VEGF (-) CMET(局灶弱+) CD34+ S-100+,,,,,65.76872536136662,1430838
1431352,刘春林,577714,男,56,T2,N0,M0, ⅠB,1,2,,,,,,0.0,32,,,2.0,,,,,,,0.0,2014-10-29,2020-04-16,1,,,SOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap）,G2, (1a)03 (1b)01 (3a)07 (3b)00 (4sb)00 (4d)05 (5)00 (6)05 (7)03 (8a)01 (8p)03 (9)02 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",30,30,2, R0 D2,,6.02,3.12,1.96,154.3,243.0,2.4,15.0,233.0,161.0,71.0,26.0,15.19,4.36,71.0,297.0,48.0,23.0,5.1,5.5,77.0,272.0,,,,,,,,,0.878,3.46,10.4,46.2,3.02,17.84,3.47,,无,, P0,H0, 未做,CK + Vimentin - VEGF - CMET- CD34+ S-100+,,,,,65.57161629434954,1431352
1431433,孙成华,576818,女,62,T1b,N2,M0, ⅡA,1,0,,1.0,1.0,,,5.0,19,,,1.0,,,,,,,0.0,2014-10-29,2022-09-01,1,,,SOX,口服替吉奥,,,,,2, 低粘附腺癌60 低分化腺癌（G3)(por)30 乳头状癌（G1）（pap）10,G3, (1b)01 (3a)01 (3b)22 (4sb)00 (4d)00 (5)01 (6)00 (7)00 (8a)11 (8p)02 (9)06 (11p)01 (12a)00 (12p)01 (14v)12 小弯11," L（幽门窦部）, 前Ant, 小弯侧Less,",40,25,8, R0 D2,,7.41,3.49,3.25,123.4,197.0,2.48,25.0,24.0,125.0,49.0,24.0,10.84,4.09,71.0,319.0,42.0,29.0,5.1,6.4,71.0,385.0,75.2,,,,,14.5,,,,,,,2.93,5.44,1.65,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF - CMET- CD34+ S-100+,,,,,94.08672798948751,1431433
1430582,陈海,577683,男,61,T3,N2,M0, ⅢA,1,5,0.0,0.0,0.0,0.0, 异型增生+,3.0,25,髓样型（med）,INFa,1.0,0.6,,,,,,0.0,2014-10-22,2015-03-20,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)02 (2)03 (3a)13 (3b)00 (4sa)00 (4sb)03 (4d)02 (5)11 (6)01 (7)00 (8a)04 (8p)14 (9)01 (11p)01 (12a)00 软组织可见癌," M（胃体部）, L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",90,40,10, R0 D2,,5.34,3.22,1.9,75.7,386.0,3.06,11.0,17.0,128.0,43.0,14.0,16.77,6.46,68.0,247.0,46.0,22.0,4.6,6.31,73.0,304.0,,,,,,,,,,,,,0.948,3.84,0.881, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34（+）、 S-100（+）、 CD56（局灶+）、 Syn（部分弱+）、 CgA（小区+）,,,,,4.894875164257556,1430582
1430736,车延波,575727,男,62,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,11,,,0.0,,,,,,1.0,,2014-10-23,2019-06-01,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a) (1b)04 (3a) (3b)03 (4sb)01 (5) (12a)01 (6) (4d)00 (7)01 (9)01," L（幽门窦部）, 后Post,",15,12,3, R0 D2,,5.25,2.86,1.89,131.2,193.0,2.66,55.0,41.0,153.0,80.0,39.0,7.98,3.42,64.0,347.0,41.0,23.0,5.3,4.9,71.0,363.0,,,,,,,,,,,,,0.608,6.97,10.95,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET-,,,,,55.25624178712221,1430736
1430808,徐晓天,576787,男,59,T2,N1,M0, ⅡA,1,2,0.0,1.0,,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,10,中间型（int）,INFa,3.0,,,,,,,2.0,2014-10-23,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a) (1b)02 (3a) (3b)15 (4sb)00 (5) (12a)00 (6) (4d)01 (7)00 (8a) (8p) (9) (11p)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,18,5, R0 D2,,8.16,4.81,2.41,155.8,155.0,2.12,24.0,26.0,171.0,85.0,39.0,11.52,3.61,74.0,249.0,46.0,28.0,4.9,6.7,75.0,346.0,,,,,,,,,,,,,1.99,8.98,12.47,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET灶弱+,,,,,65.76872536136662,1430808
1431026,李树山,576805,男,72,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,13,,,2.0,,,,,,,1.0,2014-10-27,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)90 低粘附腺癌10,G3, (1a)00 (1b)00 (2)00 (3a)03 (3b)00 (4sa)00 (4sb)00 (5)00 (7)01 (8a)04 (8p)02 (9)01 (10)01 小弯01," UM 小弯侧Less,",8,8,2, R0 D2,,6.03,2.95,2.26,154.9,239.0,2.77,30.0,29.0,165.0,145.0,15.0,6.9,2.85,68.0,313.0,42.0,26.0,5.7,5.0,72.0,267.0,,,,,,,,,0.85,3.66,12.3,30.2,2.4,10.62,10.14,,无,, P0,H0, 未做,CK + Vimentin - VEGF - CMET(局灶+) CD34+ S-100+,,,,,94.15243101182654,1431026
1431008,邢明智,576779,男,76,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,9,,,1.0,,,,,,,0.0,2014-10-27,2019-05-01,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 中度不典型增生 重度不典型增生,G2, (1a) (1b)04 (3a)03 (3b)00 (4sb)00 (4d)01 (5)00 (6)00 (7)01," L（幽门窦部）, 前Ant,",10,,, R0 D1+,,7.1,3.85,2.33,138.4,157.0,3.15,16.0,24.0,203.0,68.0,10.0,14.02,4.85,66.0,173.0,41.0,25.0,3.8,7.2,97.0,314.0,,,,,,,,,,,,,2.75,7.69,9.73,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,54.106438896189225,1431008
1431189,初长发,578063,男,63,T3,N1,M0, ⅡB,1,2,1.0,1.0,1.0,0.0, 正常,2.0,44,中间型（int）,INFb,0.0,,,1.0,,,,2.0,2014-10-28,2020-04-13,1,,,FOLFOX,,,,,,4, 低粘附腺癌70% 低分化腺癌（G3)(por)30% Lauren混合型,G3, (1a)09 (1b)04 (3a)02 (3b)00 (4sb)06 (4d)06 (5)11 (6)00 (7)14 (8a)02 (8p)02 (9)03 (11p)05," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",20,20,8, R0 D2,,6.91,3.66,2.61,152.0,214.0,2.91,34.0,33.0,171.0,94.0,15.0,15.47,6.13,71.0,315.0,43.0,28.0,4.3,6.1,72.0,246.0,55.5,39.8,8.6,4.63,0.2,8.8,32.3,0.8,1.49,4.29,11.4,350.0,2.23,6.39,2.79, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（灶+）、 VEGF（-）、 CMET（部分弱+）、 CD34（+）、 S-100（+）,,,,,65.50591327201052,1431189
1431480,郭福林,578075,男,58,T3,N1,M0, ⅡB,1,5,0.0,1.0,1.0,1.0, 慢性炎症（+）,1.0,37,髓样型（med）,INFa,3.0,,,1.0,,,,0.0,2014-10-30,2022-09-01,1,,,SOX,,,,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3, 小弯05(1a)00 (1b)01 (3a)07 (3b)00 (4sb)01 (4d)05 (5)00 (6)09 (7)02 (8a)11 (8p)00 (11p)02 (12a)00 (12p)01 (14a)01 (14v)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",50,40,22,,R1,10.29,6.11,2.95,132.0,208.0,2.7,23.0,23.0,141.0,58.0,23.0,16.58,6.38,16.58,173.0,37.0,26.0,4.7,6.3,86.0,300.0,,,,,,,,,0.633,5.1,10.7,16.7,3.79,6.85,10.32,,无,, P0,H0, 未做,CK + Vimentin (点灶+) VEGF - CMET- CD34+ S-100+,,,,,94.053876478318,1431480
1431044,韩殿福,577759,男,87,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,0.0,21,中间型（int）,INFa,0.0,,,,,,,2.0,2014-10-27,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a) (1b)06 (3a) (3b)02 (4sb)00 (6) (4d)01 (5) (12a)02 (8a)06 (7) (8p) (9) (11p)04," LM 前Ant, 后Post, 大弯侧Gre,",60,55,14, R0 D2,,5.4,3.81,0.94,125.0,141.0,2.8,23.0,29.0,213.0,108.0,23.0,20.68,10.3,60.0,159.0,39.0,21.0,4.5,8.8,82.0,334.0,,,,,,,,,,,,,1.42,11.81,1.78,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET部分弱+,,,,,65.63731931668856,1431044
1431126,张福生,578123,男,72,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,13,中间型（int）,INFa,1.0,,1.0,,,,,1.0,2014-10-27,2015-12-08,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型 +（GIST）,G2, (1a) (1b)04 (2)03 (3a) (3b)03 (4sa)00 (4sb)01 (7) (8a) (9)01 (10)01, 胃癌 U 小弯侧Less Borrmann2型 T2 N0 M0 疣状胃炎,20,20,12,R0 D2,,7.31,4.6,1.92,154.9,255.0,,27.0,29.0,141.0,80.0,12.0,15.38,5.64,70.0,189.0,41.0,29.0,4.5,5.9,112.0,487.0,60.3,37.2,20.7,1.8,0.1,5.3,28.7,0.6,1.17,2.8,16.2,26.2,1.45,8.61,2.37, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+),,,,,13.370565045992116,1431126
1431041,李翠琴,577764,女,47,T1b,N0,M0,ⅠA,1,0,,,,1.0,,0.0,11,,,0.0,,,,,,1.0,2.0,2014-10-27,2020-04-16,1,,,XELOX,,,,,,2, 粘液腺癌（muc）70 低分化腺癌（G3)(por)30,G3, (1a) (1b)00 (3a) (3b)03 (4sb)03 (4d)01 (5)01 (6)00 (7)02 (8a)00 (9)01 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",20,10,8,R0 D2,,6.74,3.92,2.09,134.0,186.0,2.32,21.0,24.0,151.0,96.0,8.0,15.7,5.07,69.0,283.0,42.0,27.0,5.5,7.1,54.0,180.0,79.3,37.7,36.9,1.02,0.1,7.3,10.8,0.4,0.635,4.26,11.5,5.39,0.2,6.59,2.4, 阴性,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,65.63731931668856,1431041
1431118,刘海波,578248,男,47,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,26,中间型（int）,INFa,3.0,,,,,,,0.0,2014-10-27,2020-10-12,1,,,奥沙利铂联合替加氟,奥沙利铂联合替加氟,奥沙利铂联合替加氟,奥沙利铂联合替加氟,奥沙利铂联合替加氟联合亚叶酸钙,,5, 管状腺癌（中分化【G2】【tub2】,G2, (1a)012 (1b)00 (2)03 (3a)07 (3b)00 (4sa)00 (4sb)00 (4d)01 (5)01 (8a) (8p) (9) (11p) (11d)02, 胃癌 U（胃底部） 前Ant 后Post 大弯侧Gre  Borrmann3型 T3 N0 M0,45,40,7, R0 D2,,8.35,4.2,3.23,176.0,204.0,3.35,23.0,23.0,213.0,93.0,62.0,12.31,3.84,71.0,373.0,48.0,23.0,4.8,6.7,90.0,289.0,,,,,,,,,,,,,2.94,7.6,4.26,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,71.51773981603154,1431118
1431795,王九菊,577419,女,68,T3,N1,M0, ⅡB,1,4,2.0,0.0,0.0,1.0, 慢性炎症（+）,1.0,25,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2014-11-03,2016-12-01,2,,,替吉奥单药,,,,,,5, 低粘附腺癌 Lauren弥漫型,GX, (1a)03 (1b)03 (2)03 (3a)11 (3b)01 (4sa)01 (4sb)00 (4d)01 (5)00 (6)02 (7)02 (8a)02 (8p)01 (9)03 (11p)01 (12a)00 (14v)01," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,10,,R1,3.26,1.55,1.37,119.0,168.0,1.87,24.0,24.0,160.0,36.0,14.0,9.13,2.57,62.0,240.0,37.0,25.0,4.6,4.8,55.0,285.0,,,,,,,,,,,,,0.553,7.0,2.43,,无, 无, P0,H0, 未做,CK + Vimentin (部分+) VEGF - CMET- CD34+ S-100+,,,,,24.93429697766097,1431795
1431501,马德民,578432,男,63,T3,N0,M0, ⅡA,1,5,0.0,1.0,,0.0, 慢性炎症（+）,0.0,38,中间型（int）,INFa,2.0,,,,,,,0.0,2014-10-30,2019-06-01,0,,,奥沙利铂联合替加氟,奥沙利铂联合替加氟,奥沙利铂联合替加氟,,,,3, 管状腺癌（中分化【G2】【tub2】,G2, (1a) (1b)06 (3b)06 (4sb)00 (4d)09 (5)02 (6)09 (7) (8a)04 (9)01 (11p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",70,60,10, R0 D2,,9.33,6.95,1.6,72.0,301.0,5.89,20.0,21.0,111.0,88.0,16.0,6.82,2.59,66.0,223.0,36.0,30.0,4.4,6.6,71.0,196.0,66.9,45.9,15.9,2.89,0.2,13.8,17.8,1.1,1.09,3.27,18.4,123.0,0.629,16.7,1.14,,无, 无, P0,H0, 未做,CK+， Vimentin-，VEGF-， CMET-,,,,,55.02628120893561,1431501
1431408,张凤云,573610,女,58,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,20,硬型（sci）,INFa,1.0,,,,,,,0.0,2014-10-29,2019-05-01,0,SOX*2,1.0,SOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (2)01 (3a)03 (3b)00 (4sa)00 (4sb)00 (7)04 (8a)02 (8p)03 (9)05 (11p)01," U（胃底部）, SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",20,8,15, R0 D2,,6.63,4.18,1.73,124.0,278.0,3.09,21.0,28.0,199.0,90.0,9.0,11.34,3.43,73.0,261.0,47.0,26.0,5.6,3.9,70.0,214.0,59.2,28.1,22.6,1.24,0.1,5.3,33.2,0.6,1.31,2.39,12.6,5.9,2.05,28.71,1.21, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,54.040735873850196,1431408
1432013,权基善,577439,男,62,T4b,N3b,M0, ⅢC,1,5,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+） 异型增生+,21.0,24,中间型（int）,INFb,1.0,,,1.0,,,,2.0,2014-11-04,2016-12-14,2,,,SOX,,,,,,6, 乳头状癌（G1）（pap）40 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30 低粘附腺癌30,G3, (1a)02 (1b)11 (3a)66 (3b)22 (4sb)00 (5)11 (6)11 (4d)01 (7)00 (8a)22 (8p)22 (9)22 (11p)44  (4d)组可见一枚结节内见有癌  (12a、12p)组软组织内见有癌," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,40,10,,R1,7.43,4.91,1.6,78.0,338.0,3.147,20.0,24.0,111.0,61.0,6.0,4.57,1.64,63.0,240.0,38.0,25.0,6.1,4.9,77.0,321.0,52.7,30.0,18.4,1.63,0.2,10.8,35.4,0.5,0.817,2.79,10.0,48.1,7.67,56.93,11.7,,无,, P0,H0, 未做,CK + Vimentin(点灶+)VEGF (-) CMET(局灶弱+) CD34+ S-100+,,,,,25.328515111695136,1432013
1431570,孙立祥,578270,男,59,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+） 异型增生+,0.0,22,硬型（sci）,INFa,0.0,,,,,,,0.0,2014-10-30,2020-04-13,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)00 (3a)02 (3b)00 (4d)06 (4sb)00 (5)00 (6)00 (7)05 (8a)04 (8p)02 (9)01 (11p)01 (12a)01," L（幽门窦部）, 小弯侧Less,",20,20,2, R0 D2,,7.07,4.33,2.15,151.4,159.0,2.27,28.0,24.0,125.0,79.0,8.0,8.01,2.78,64.0,331.0,42.0,22.0,4.5,8.4,63.0,251.0,60.2,33.7,21.5,1.57,0.2,24.6,13.9,1.6,0.681,1.61,9.78,81.9,2.31,7.61,1.33, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,65.44021024967148,1431570
1431580,高影,577446,女,46,T4b,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 正常,18.0,33,中间型（int）,INFc,2.0,,,1.0,,,,0.0,2014-10-30,2016-01-06,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)11 (3a)34 (4sa)11 (4sb)13 (4d)28 (14v)00 (5)00 (6)35 (8a)22 (8p)02 (9)01 (11p)00 (12a)00 大网边缘56," MU 前Ant, 后Post, 小弯侧Less,",60,55,10,,R1,6.34,3.37,2.37,126.0,238.0,2.53,12.0,18.0,164.0,51.0,18.0,12.18,3.65,68.0,218.0,45.0,23.0,5.2,4.5,70.0,188.0,,,,,,,,,,,,,0.723,10.54,71.39,,无, 无, P0,H0, 未做,CK + Vimentin(点灶+) VEGF- CMET- CD34+ S-100+,,,,,14.224704336399475,1431580
1431633,刘桂英,578193,女,48,T4a,N1,M0, ⅢA,1,5,0.0,0.0,0.0,1.0, 正常,1.0,9,中间型（int）,INFa,0.0,,,,,,,2.0,2014-10-31,2016-01-04,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1b)00 (2)11 (3a)01 (3b)00 (4sa)02 (4sb) 01(7)01(8a)00 (9)00 (11p)03 (11d)00,GE 前Ant 小弯侧Less 大弯侧Gre SiewerⅢ型,90,85,6, R0 D2,,4.1,2.66,0.8,96.0,320.0,2.94,16.0,24.0,149.0,76.0,3.0,7.6,2.32,70.0,236.0,41.0,29.0,4.1,5.1,60.0,261.0,72.7,32.0,29.1,1.1,0.1,16.2,9.7,1.0,0.562,1.65,13.4,2470.0,0.39,416.9,2.75, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET弱(+)  CD34(+)  S100(+),,,,,14.126149802890932,1431633
1431865,冯树森,573917,男,64,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 正常,3.0,19,中间型（int）,INFa,0.0,,,,,,,0.0,2014-11-03,2020-04-16,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)04 (1b)01 (3a)04 (3b)02 (4sb)12 (4d)01 (5)01 (6)22 (7)02 (8a)00 (8p)00 (9)00 (11p)00 , L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,30,15,R0,,4.41,2.69,1.27,122.1,207.0,2.06,26.0,28.0,152.0,39.0,10.0,14.41,6.14,60.0,215.0,36.0,24.0,5.0,6.0,72.0,323.0,70.3,45.8,17.9,2.56,0.2,15.7,11.9,1.4,1.44,1.86,11.8,58.5,0.924,21.6,2.23,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,65.40735873850197,1431865
1431575,汪文忠,577455,男,69,T1a,N0,M0,ⅠA,1,0,,1.0,,1.0,,0.0,12,,,0.0,,,,,,,0.0,2014-10-30,2019-07-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)00 (3a)00 (3b)00 (4sb)02 (4d)02 (5)00 (6)00 (7) (8a) (8p) (9) (11p)07," L（幽门窦部）, 前Ant, 大弯侧Gre,",10,10,5, R0 D2,,7.6,3.8,2.9,142.0,224.0,2.45,17.0,19.0,151.0,67.0,8.0,8.74,4.4,66.0,192.0,45.0,21.0,6.4,5.3,81.0,278.0,40.6,26.0,11.1,2.34,0.2,15.4,35.9,0.4,0.757,2.68,10.4,39.3,0.71,7.17,46.68,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET-,,,,,56.47174770039422,1431575
1431665,徐全军,578435,男,50,T4b,N1,M0, ⅢB,1,2,0.0,1.0,,1.0, 慢性炎症（+）,2.0,27,中间型（int）,INFa,0.0,,,1.0,,,,0.0,2014-10-31,2019-06-01,0,,,SOX,,,,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a) (1b)07 (3a) (3b)03 (4sb)08 (6) (4d)13 (7) (8a) (8p) (9) (11p)14 (5) (12a)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,35,7, R0 D2,,5.79,3.56,1.84,111.6,162.0,4.03,24.0,16.0,135.0,67.0,17.0,6.95,3.2,51.0,189.0,33.0,18.0,3.9,5.0,48.0,206.0,89.3,58.8,21.1,2.79,0.1,5.6,4.4,6.9,0.678,1.08,7.23,81.2,50.71,217.3,14.4,,无, 无, P0,H0, 未做,CK+， Vimentin点灶+， VEGF-， CMET-,,,,,54.993429697766096,1431665
1431966,贾福成,576664,男,59,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,11,,,0.0,,,,,,,0.0,2014-11-04,2020-04-13,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)00 (3a)01 (3b)01 (4sb)00 (4d)00 (5)00 (6)00 (7)03 (8a)02 (9)01 (11p)02 (12a)01," L（幽门窦部）, 小弯侧Less,",10,10,3, R0 D2,,3.74,1.46,1.85,116.0,147.0,2.03,17.0,21.0,,67.0,17.0,12.22,5.14,68.0,204.0,43.0,25.0,4.8,7.5,100.0,358.0,73.5,33.8,37.8,0.89,0.1,8.7,16.9,0.5,0.938,3.39,13.4,157.0,0.581,,13.76, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,65.27595269382391,1431966
1432053,孙美良,573867,男,59,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 异型增生+ 慢性炎症（+）,4.0,30,髓样型（med）,INFa,0.0,,,1.0,,,,0.0,2014-11-04,2020-09-08,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)23 (2)13 (3a)14 (4sa)00 (4sb)00 (7)07 (8a)01 (8p)01 (9)03 (11p)02 (12p)00 (16a1)01 (19)03," U（胃底部）, SiewerⅡ, 前Ant, 后Post, 小弯侧Less,",70,55,13, R0 D2,,7.49,4.5,1.84,97.0,238.0,,28.0,34.0,161.0,76.0,16.0,8.33,3.24,60.0,217.0,37.0,23.0,4.3,9.7,80.0,359.0,65.0,39.0,24.2,1.61,0.0,14.8,18.9,0.7,0.754,1.38,12.3,5.0,0.337,6.16,3.21,,无,, P0,H0, 未做,CK + Vimentin (局灶+) VEGF- CMET- CD34(脉管周+)  S-100(神经+) CD56- Syn- CgA-,,,,,70.13797634691196,1432053
1432230,乔树郁,573822,男,62,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+） 异型增生+,0.0,29,中间型（int）,INFa,0.0,,2.0,,,,,2.0,2014-11-05,2020-04-13,1,,,SOX,SOX,SOX,替吉奥单药,,,4, 管状腺癌（中分化【G2】【tub2】90% 粘液腺癌（muc）10%,G2, (1a)00 (1b)05 (3a)00 (3b)01 (4sb)00 (4d)05 (5)00 (6)00 (7)07 (8a)03 (8p)02 (9)05 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",25,25,10, R0 D2,,6.32,4.19,1.56,161.6,210.0,2.73,16.0,18.0,,127.0,15.0,11.84,3.51,75.0,308.0,47.0,28.0,5.9,6.1,85.0,270.0,55.4,29.0,24.2,1.2,0.1,10.3,29.2,0.4,0.903,2.41,13.8,486.0,2.07,2.93,18.94, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（局灶弱+）、 CMET（弱+）、 CD34+、 S-100+,,,,,65.2431011826544,1432230
1432395,裴子海,579616,男,60,T4a,N3a,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,9.0,44,中间型（int）,INFa,1.0,,,,,,,2.0,2014-12-06,2020-04-13,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)03 (1b)01 (3a)111 (3b)23 (4sb)01 (4d)14 (5)11 (6)35 (7)01 (8a)12 (8p)02 (9)05 (11p)03 (16a1)02," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",40,40,20, R0 D2,,5.52,3.42,1.39,146.0,255.0,2.58,11.0,20.0,154.0,81.0,10.0,7.57,3.01,68.0,212.0,45.0,23.0,7.1,5.7,86.0,221.0,59.9,38.7,18.0,2.15,0.2,11.5,26.1,0.3,0.922,2.12,11.2,13.9,2.38,6.1,1.65, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（局灶弱+） CD34+ S-100+,,,,,64.22470433639947,1432395
1431961,李国卿,578955,男,56,T1b,N0,M0,ⅠA,1,2,,0.0,0.0,0.0,,0.0,22,,,1.0,,,,,,,0.0,2014-11-04,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)03 (3a)01 (3b)00 (4sb)04 (4d)02 (5)00 (6)03 (7) (8a) (8p) (9) (11p)07," L（幽门窦部）, 小弯侧Less,",25,20,3, R0 D2,,5.33,3.22,1.65,117.0,248.0,3.85,41.0,42.0,200.0,63.0,19.0,31.87,12.26,70.0,360.0,44.0,26.0,5.5,3.8,69.0,227.0,,,,,,,,,,,,,1.74,8.71,1.84,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET-,,,,,65.37450722733246,1431961
1432028,邹兰荣,573836,女,47,T1b,N0,M0,ⅠA,1,3,,0.0,0.0,0.0,,0.0,35,,,0.0,,,,,,,0.0,2014-11-04,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)02 (3a)05 (3b)00 (4sb)01 (4d)07 (5)00 (6)02 (7)07 (8a) (8p) (9)05 (11p)03," L（幽门窦部）, 后Post, 小弯侧Less,",20,20,4, R0 D2,,5.53,3.47,1.7,117.8,420.0,2.38,22.0,23.0,140.0,46.0,8.0,6.12,2.16,72.0,271.0,42.0,30.0,4.5,4.8,59.0,172.0,,,,,,,,,,,,,0.2,15.16,2.84,,无, 无, P0,H0, 未做, CK +， Vimentin-， VEGF-， CMET-,,,,,65.37450722733246,1432028
1432783,刘香兰,579753,女,72,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,2.0,41,中间型（int）,INFa,1.0,,,1.0,,,,0.0,2014-11-11,2018-04-25,0,,,替吉奥单药,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 粘液腺癌（muc）30 Lauren肠型,G3, (1a)04 (1b)03 (3a)08 (3b)00 (4d)06 (4sb)01 (5)00 (6)02 (7)02 (8a)12 (8p)01 (9)01 (11p)03 (14v)18," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",85,85,10,,R1,7.27,5.5,1.26,75.7,450.0,4.66,10.0,11.0,145.0,60.0,15.0,7.71,2.15,60.0,166.0,39.0,21.0,5.2,4.4,56.0,264.0,83.9,44.3,33.5,1.89,0.0,7.9,6.2,0.2,,,,,0.409,6.57,12.31,,无, 无, P0,H0, 未做,CK + Vimentin(点灶+) VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,41.4257555847569,1432783
1432852,刘玉波,579745,女,55,T4b,N1,M0, ⅢB,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+）,2.0,35,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2014-11-11,2018-05-10,2,,,,,,,,,0, 低粘附腺癌,GX, (1a)09 (1b)01 (3a)00 (3b)00 (4sb)26 (4d)02 (5)02 (6)04 (8a) (8p) (9)011," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",50,35,12, R0 D2,,3.92,2.19,1.13,121.5,180.0,2.84,15.0,16.0,,37.0,7.3,19.92,7.04,62.0,165.0,42.0,20.0,3.8,4.3,65.0,147.0,78.9,61.0,14.9,4.09,0.0,10.6,9.7,0.2,0.603,2.73,10.9,1050.0,0.2,7.73,9.8, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（局灶+）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,41.9185282522996,1432852
1432795,姚淑敏,579166,女,50,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,32,,,1.0,,,,,,,0.0,2014-11-11,2019-06-01,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)04 (1b)03 (3a)00 (3b)06 (4sb)03 (4d)01 (5)06 (6)00 (7)02 (8a)00 (8p)01 (9)03 (11p)01 (12a)02," L（幽门窦部）, 小弯侧Less,",20,15,5, R0 D2,,4.61,2.33,1.81,140.0,255.0,2.41,10.0,16.0,133.0,47.0,10.0,18.72,6.39,78.0,229.0,52.0,26.0,4.7,4.9,69.0,223.0,,,,,,,,,,,,,0.262,9.25,0.926, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,54.632063074901446,1432795
1433000,姚春礼,579107,男,62,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,14.0,47,中间型（int）,INFa,1.0,,,,,,,0.0,2014-11-12,2017-12-08,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)00 (3a)00 (3b)11 (4sb)5 14 (4d)45 (5) 00(6) 17(7)24 (8a) (8p)16 (9) 03(11p) 04(12a)00小弯01 软组织可见癌, 胃癌 M（胃体） 小弯侧Less 后Post Borrmann3型 T4b N0 M0,60,40,10,,R1,7.1,4.7,1.73,116.0,359.0,4.9,10.0,16.0,125.0,65.0,13.0,7.09,3.06,62.0,139.0,36.0,26.0,4.2,6.3,89.0,418.0,72.3,50.6,18.9,2.67,0.2,16.5,10.0,0.9,1.01,2.1,10.7,136.0,1.38,56.83,3.87, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,36.859395532194476,1433000
1433106,刘丽敏,579203,女,54,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,21,,,0.0,,,,,,,0.0,2014-11-13,2020-04-13,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)04 (3a)00 (3b)00 (4sb)02 (4d)01 (5)01 (6)03 (7)01 (8a)02 (8p)01 (9)01 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,40,2, R0 D2,,7.54,4.77,2.26,154.0,272.0,2.41,18.0,17.0,208.0,94.0,25.0,14.64,5.73,70.0,276.0,45.0,25.0,5.5,5.5,67.0,321.0,72.3,34.6,18.6,1.86,0.1,11.8,12.5,0.8,1.95,1.75,8.77,75.3,1.63,9.27,13.22,,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+ C-erbB-2 0,,,,,64.98028909329828,1433106
1433179,林吉庆,576667,男,65,T4b,N1,M0, ⅢB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,1.0,9,中间型（int）,INFa,2.0,,1.0,1.0,,,,0.0,2014-11-13,2017-04-01,2,,,替吉奥,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1b)12 (3a)02 (4sb)00 (4d)02 (5)02 (6)00 (8a)00 (8p)01  (1a) (3b) (7) 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,30,16,,R2,4.54,2.86,1.08,90.9,190.0,4.23,29.0,43.0,,63.0,20.0,10.08,5.03,63.0,163.0,39.0,24.0,4.7,10.3,71.0,514.0,80.6,56.1,21.3,2.63,0.2,7.0,11.1,1.9,0.734,1.82,8.2,256.0,4.03,68.64,1.51, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（灶弱+）、 VEGF（灶弱+）、 CMET（-）、 CD34+、 S-100+,,,,,28.580814717477004,1433179
1432853,颜召军,579092,男,47,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,44,,,0.0,,,,,,,0.0,2014-11-11,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)03 (3a)011 (3b)00 (4sb)00 (4d)01 (5)02 (6)09 (7)00 (8a)01 (8p)02 (9)06 (11p)07 (12a)00 (12p)01 (14v)01," L（幽门窦部）, 前Ant, 小弯侧Less,",10,8,5, R0 D2+,,6.57,3.24,2.47,136.0,224.0,2.41,21.0,25.0,132.0,68.0,12.0,7.59,2.89,64.0,318.0,39.0,25.0,4.3,8.5,66.0,314.0,62.2,42.3,16.1,2.63,0.1,18.9,17.1,0.2,0.807,2.45,9.21,122.0,1.52,7.82,4.63,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET-,,,,,65.14454664914585,1432853
1432630,周廷和,579729,男,66,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,17,,,0.0,,,,,,,0.0,2014-11-10,2020-04-13,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)00 (1b)03 (3a)01 (3b)01 (4d)00 (4sb)03 (5)01 (6)01 (7)01 (8a)01 (8p)01 (9)02 (11p)00, 胃癌 L（幽门窦部） Borrmann3型 T3 N0 M0 前Ant,6,5,5,R0 D2,,6.21,3.28,2.41,159.0,182.0,2.28,29.0,32.0,178.0,81.0,24.0,11.83,4.17,78.0,427.0,47.0,31.0,5.3,5.5,78.0,297.0,56.7,25.5,15.9,1.6,0.1,5.0,38.9,1.9,1.38,2.81,13.0,28.6,2.13,5.89,2.48,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,65.07884362680683,1432630
1433023,李占成,579575,男,62,T4a,N3a,M0, ⅢB,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+）,14.0,36,中间型（int）,INFc,0.0,,,,,,,0.0,2014-11-12,2015-11-01,2,,,,,,,,,0, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren弥漫型,G3, (1a)01 (1b)00 (3a)37 (3b)00 (4sb)02 (4d)58 (5)00 (6)58 (7)14 (8a)03 (8p)01 (9)02 (11p)00 (12a)00 ,L（幽门窦部） 小弯侧Less 前Ant 后Post ,50,50,10, R0 D2+,,7.41,4.5,2.4,153.0,213.0,2.6,27.0,38.0,179.0,95.0,28.0,11.51,3.93,71.0,345.0,43.0,28.0,4.9,7.5,63.0,345.0,,,,,,,,,,,,,0.602,10.85,1.84, 未做,无,, P0,H0, 未做,,,,,,11.629434954007884,1433023
1432845,李洪玉,579498,女,59,T3,N3a,M0,ⅢB,1,5,2.0,1.0,1.0,1.0, 慢性炎症（+）,14.0,23,中间型（int）,INFc,2.0,,,1.0,,,,0.0,2014-11-11,2020-04-16,1,,,,,,,,,0, 低粘附腺癌 60粘液腺癌（muc）40 Lauren弥漫型,GX, (1a)00 (1b)00 (2)00 (3a)12 (3b)00 (4sa)33 (4sb)00 (4d) (5)00 (6)01 (7)44 (8a) (8p)01 (9)01 (11p)01 (12a) 01(14v)00 (16a1)02 (11d)11 大弯12,ML 小弯侧Less 后Post ,40,,, R0 D2,,7.01,4.36,2.06,138.3,247.0,4.44,22.0,32.0,178.0,77.0,10.0,12.45,4.47,72.0,208.0,41.0,31.0,5.0,7.4,59.0,206.0,,,,,,,,,,,,,2.39,15.89,193.7, 未做,无, 无, P0,H0, 未做,ck(局灶+)  vimentin(局灶+)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,65.14454664914585,1432845
1432919,李香云,579566,女,73,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,34,髓样型（med）,INFc,0.0,,,1.0,,,,0.0,2014-11-12,2020-04-16,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a) 09(3b)00 (4sb)02 (4d)01 (5)00 (6)04 (7)03 (8a)02 (8p)02 (9) 02(11p)06 (14v)02 小弯01,胃癌  LM  后Post 平坦弥漫性 Borrmann3型 T3 N0 M0,25,25,, R0 D2+,,7.65,4.42,2.69,125.8,295.0,4.23,19.0,26.0,106.0,101.0,9.0,9.09,2.98,71.0,269.0,42.0,29.0,4.9,3.9,44.0,248.0,,,,,,,,,0.597,3.54,12.2,52.0,0.791,7.67,1.5, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(部分+)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,65.11169513797634,1432919
1433863,姜万仁,579177,男,59,T4b,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 慢性炎症（+）,22.0,24,中间型（int）,INFc,0.0,,1.0,1.0,,,,2.0,2014-11-19,2016-03-01,2,,,,,,,,,0, 低粘附腺癌 90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)00 (1b)00 (3a)11 (4sb)00 (4d)77 (5)11 (6)33 (7)67(8p) 12(9)00 (11p)33 (12a) 3b软组织可见癌 (8a)12,L（幽门窦部） 小弯侧Less 前Ant 后Post ,25,20,6,,R1,3.61,2.09,0.96,92.0,234.0,2.45,24.0,22.0,114.0,43.0,9.0,5.26,2.86,50.0,196.0,27.0,23.0,5.2,6.6,74.0,140.0,,,,,,,,,,,,,27.85,2.0,31.04, 未做,无,, P0,H0, 未做,ck(+)  vimentin部分(+)  VEGF灶弱(+)  cMET灶弱(+)  CD34(+)  S100(+),,,,,15.374507227332456,1433863
1433872,杨联耀,577597,男,56,T4b,N3a,M0, ⅢC,1,2,0.0,,,1.0, 慢性炎症（+）,9.0,35,髓样型（med）,INFa,3.0,,,1.0,,,,2.0,2014-11-19,2018-02-08,2,,,SOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)314 (3b)00 (4d)45 (4sb)02 (5)00 (6)22 (7)01 (8a)02 (8p)02 (9)01 (11p)03 (12a)00 (12p)00 (14a)00 (14v)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",60,60,8,,R1,3.78,1.87,1.49,43.8,237.0,3.33,25.0,23.0,126.0,55.0,6.0,5.88,2.62,51.0,169.0,34.0,17.0,4.0,8.2,81.0,296.0,81.3,51.9,27.8,1.87,0.1,10.5,6.2,1.4,0.894,0.483,5.53,5.95,22.82,143.4,2.21,,无,, P0,H0, 未做,CK + Vimentin(点灶+) VEGF- CMET(灶弱+) CD34(脉管周+)  S-100(神经+),,,,,38.66622864651774,1433872
1433647,赵君,579217,男,62,T4b,N3a,M0, ⅢC,1,4,2.0,0.0,0.0,1.0, 慢性炎症（+）,10.0,28,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2014-11-18,2022-09-01,1,,,,,,,,,0, 低粘附腺癌 60粘液腺癌（muc）40 Lauren弥漫型,GX, (1a)02 (3a)11 (3b) 11(4sb)00 (4d)59 (5)02 (6) 17(7)12 (8a)02 大网边缘12 1b及4d软组织可见癌,L（幽门窦部） 小弯侧Less 前Ant 后Post ,40,30,10,,R2,5.85,2.77,2.14,150.0,173.0,2.22,22.0,32.0,137.0,71.0,12.0,12.62,5.94,61.0,211.0,36.0,25.0,3.5,8.1,78.0,384.0,80.6,24.0,38.8,0.62,0.3,5.4,13.0,2.0,0.804,2.17,10.8,27.7,1.07,4.98,65.41, 未做,无,, P0,H0, 未做,ck(+)  vimentin部分(+)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,93.42969776609723,1433647
1433385,赵越超,579956,男,50,T4a,N0,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,32,中间型（int）,INFa,2.0,,,,,,,2.0,2014-11-17,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)04 (3a)03 (3b)00 (4sb)00 (4d)07 (5)01 (6)05 (7)01 (8a)02 (8p)03 (9)01 (10)02 (11p)00 (12a) (12b)00,"L（幽门窦部） 前Ant,",20,15,10,R0 D2,,7.09,3.69,2.77,139.0,245.0,2.78,20.0,22.0,182.0,53.0,15.0,6.72,2.44,64.0,230.0,41.0,23.0,4.5,6.4,80.0,242.0,66.1,45.4,11.1,4.09,0.0,11.8,20.1,0.3,0.741,1.97,10.9,478.0,1.26,7.08,1.08,,无, , P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,64.94743758212877,1433385
1433086,周国珍,579434,男,69,T1b,N1,M0, ⅠB,1,0,,1.0,1.0,0.0,,1.0,12,,,1.0,,,,,,,2.0,2014-11-13,2019-05-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 粘液腺癌（muc）20,G3, (1a)02 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)14 (5)00 (6)01 (7)00 (8a)01 (8p)01 (9)02 (11p)00 (12a)00," LM 小弯侧Less,",10,5,3, R0 D2,,7.1,4.46,2.01,138.6,283.0,3.51,48.0,45.0,231.0,79.0,40.0,7.91,3.29,61.0,310.0,36.0,25.0,4.8,3.0,82.0,434.0,77.6,39.3,33.6,1.17,0.2,10.5,9.6,1.4,0.756,1.43,10.4,41.1,0.2,6.53,33.78,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET弱+,,,,,53.547963206307486,1433086
1433851,高殿宗,580161,男,58,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,22,中间型（int）,INFa,0.0,,,,,,,0.0,2014-11-19,2020-04-13,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)03 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)02 (5)00 (6)00 (7) (8a) (8p) (9) (11p)015 (12a)01,L（幽门窦部） 后Post,20,15,4,R0 D2,,9.62,5.02,3.5,143.4,300.0,2.06,28.0,29.0,157.0,75.0,19.0,6.5,2.79,62.0,327.0,39.0,23.0,5.1,7.6,72.0,302.0,61.4,42.9,14.2,3.02,0.1,19.5,18.1,0.3,0.818,2.53,8.13,78.1,1.72,8.71,1.68,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,64.7831800262812,1433851
1434281,王宝森,581054,男,60,T3,N1,M0, ⅡB,1,5,1.0,0.0,0.0,1.0, 肠化生+,2.0,20,髓样型（med）,INFc,1.0,,,1.0,,,,0.0,2014-11-24,2017-09-01,0,,,SOX,SOX,SOX,奥沙利铂单药,,,4, 低粘附腺癌 Lauren混合型,GX, (1a)01 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)15 (5)00 (6)16 (7)03 (8a) (8p)04 (9)00 (11p)00,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,55,20,R0 D2,,9.35,5.54,3.08,159.4,315.0,3.27,27.0,23.0,170.0,93.0,46.0,4.96,1.78,67.0,342.0,41.0,26.0,6.4,5.1,56.0,242.0,,,,,,,,,,,,,3.36,7.32,,,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-),,,,,33.24572930354796,1434281
1434046,王秋林,580372,男,59,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,18,中间型（int）,INFa,0.0,,,1.0,,,,0.0,2014-11-20,2022-09-01,1,,,,,,,,,0, 粘液腺癌（muc）70 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30 Lauren肠型,G3, (1a)00 (1b)00 (2)00 (3a)01 (3b)00 (4sb)01 (4d)04 (5)00 (6)02 (7)03 (8a)02 (8p)03 (9)01 (11p)01 (12a)00 (12p)00 (14a)00 (14v)00," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",60,40,20, R0 D2+,,4.95,2.6,1.69,128.0,197.0,2.27,38.0,29.0,129.0,87.0,67.0,13.94,5.44,57.0,198.0,38.0,19.0,4.8,5.7,65.0,314.0,,,,,,,,,,,,,3.32,157.0,4.45,,无,, P0,H0, 未做,CK + Vimentin(灶+)  VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,93.36399474375821,1434046
1434016,王学春,580125,男,66,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,28,中间型（int）,INFa,0.0,,,1.0,,,,0.0,2014-11-20,2020-04-16,1,,,XELOX,,,,,,3, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)010 (3b)03 (4sb)00 (4d)02 (5)00 (6)01 (7)02 (8a)03 (8p)01 (9)01 (11p)03 (12a)01 (14v)01," LM 前Ant, 后Post, 小弯侧Less,",70,50,20, R0 D2+,,6.11,4.19,1.08,134.0,238.0,2.73,10.0,15.0,131.0,47.0,10.0,12.06,5.36,76.0,185.0,35.0,41.0,4.8,7.0,74.0,258.0,77.6,57.0,19.3,2.95,0.3,11.2,9.5,0.7,0.501,2.8,10.9,46.0,3.29,36.59,2.36,,无,, P0,H0, 未做,CK + Vimentin(部分+) VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,64.84888304862024,1434016
1433466,姜仟成,580254,男,61,T4b,N2,M1, Ⅳ,1,3,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,4.0,22,中间型（int）,INFa,2.0,,,,,,,0.0,2014-11-17,2015-12-08,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 乳头状癌（G1）（pap）30 Lauren肠型,G3, (1a)01 (1b)02 (2)02 (3a)11 (3b)03 (4sa)02 (4d)15 (4sb)01 (5)00 (6)11 (7)03," LM 前Ant, 后Post, 小弯侧Less,",60,60,10,,R2,6.84,4.57,1.56,154.0,224.0,3.68,33.0,28.0,177.0,78.0,18.0,9.82,4.48,67.0,229.0,42.0,25.0,4.9,7.0,86.0,298.0,55.0,32.9,16.7,1.97,0.1,15.5,27.9,0.4,0.99,2.69,10.3,67.8,0.829,10.33,5.81,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET弱+,,,,,12.680683311432325,1433466
1434389,张继学,580130,男,54,T4b,N1,M0, ⅢB,1,2,0.0,1.0,1.0,1.0, 肠化生+,2.0,38,硬型（sci）,INFa,0.0,,,,,,,0.0,2014-11-24,2015-08-28,2,,,XELOX,,,,,,3, 低分化腺癌（G3)(por) Lauren肠型,G3,大弯02 (3b)00 (1a)03 (2)16 (3a)04 (4d)03 (5)00 (4sb)02 (4sa)01 (1b)02 (11p)01 (10)2 (14v)00 (12a)00 (7)04 (6)07 (8a)01 (9)05 (4sa)组软组织内可见癌," MU 后Post, 大弯侧Gre,",100,90,20,,R1,8.26,5.63,1.49,101.0,214.0,4.23,8.0,10.0,161.0,104.0,48.0,8.06,3.47,71.0,232.0,42.0,29.0,10.3,7.0,63.0,323.0,82.3,50.5,26.7,1.89,0.1,10.3,5.8,0.9,0.744,2.76,13.0,219.0,1.48,7.6,1.44,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,9.099868593955321,1434389
1433869,赵录,580140,男,58,T4b,N3a,M0, ⅢC,1,3,2.0,0.0,0.0,1.0, 肠化生+,11.0,21,中间型（int）,INFc,0.0,,1.0,1.0,,,,2.0,2014-11-19,2016-11-30,2,,,,,,,,,0, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren弥漫型,G3, (1a)00 (1b)00 (3a)12 (3b)00 (4d)44 (4sb)01 (5)00 (6)55 (7)01 (8a)11 (8p)01 (9)03 (11p)02 (12a)01 (12p)00," L（幽门窦部）, 大弯侧Gre,",40,35,5,,R1,4.93,2.7,1.88,161.0,187.0,3.53,32.0,26.0,128.0,61.0,27.0,12.52,4.21,68.0,356.0,42.0,26.0,4.9,13.2,128.0,575.0,73.4,51.2,19.9,2.57,0.1,10.4,14.1,0.8,1.42,1.53,8.08,108.0,2.92,6.82,5.37,,无, , P0,H0, 未做,CK + Vimentin (部分+) VEGF(灶弱+) CMET(灶弱+) CD34(脉管周+)  S-100(神经+),,,,,24.375821287779235,1433869
1434087,潘文录,580428,男,63,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,43,中间型（int）,INFa,1.0,,,1.0,,,,0.0,2014-11-21,2020-04-16,1,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (2)04 (3a)03 (3b)05 (4sa)04 (4d)03 (4sb)03 (7)015 (9)02 小弯03," LM 前Ant, 小弯侧Less,",60,60,10, R0 D2,,4.3,3.7,0.53,94.8,265.0,1.79,22.0,25.0,116.0,50.0,13.0,7.11,3.78,38.0,115.0,22.0,16.0,6.5,5.0,63.0,253.0,62.8,49.6,9.2,5.39,0.0,12.2,22.8,1.9,0.355,0.871,6.25,246.0,0.339,6.84,3.13,,无,, P0,H0, 未做,CK + Vimentin(灶+) VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,64.81603153745073,1434087
1434367,尚宝珠,577304,男,64,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,13,,,2.0,,,,,,,0.0,2014-11-24,2020-05-26,1,,,,,,,,,0, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】40,G2, (1a)02 (1b)00 (2)00 (3a)02 (3b)00 (4sa)00 (4sb)00 (5)00 (7)05 (8a)02 (8p)01 (9)00 (11p)01," U（胃底部）,（食道）, GE, SiewerⅠ, 小弯侧Less,",30,30,, R0 D2,,7.53,4.38,2.13,152.0,220.0,2.84,28.0,25.0,182.0,86.0,25.0,11.55,4.47,68.0,351.0,41.0,27.0,4.3,7.3,80.0,378.0,80.6,49.9,27.8,1.79,0.6,8.0,6.9,2.9,0.351,1.89,13.2,285.0,1.03,7.61,3.97,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- ,,,,,66.03153745072274,1434367
1434665,邸向春,581053,男,72,T4a,N0,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,43,硬型（sci）,INFa,2.0,,,,,,,0.0,2014-11-26,2019-06-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)00 (3a)00 (3b)00 (4sb)01 (4d)014 (5)00 (6)04 (7)012 (8a) (8p)03 (9)05 (11p)01 软组织可见癌3B," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,35,8, R0 D2,,6.86,3.99,2.06,133.0,244.0,4.03,21.0,26.0,129.0,49.0,6.0,11.73,5.05,63.0,155.0,37.0,26.0,4.8,4.3,53.0,153.0,63.9,48.1,13.3,3.62,0.3,12.0,22.4,0.2,0.622,2.43,9.23,64.3,8.33,90.76,3.63,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,54.139290407358736,1434665
1434508,于希全,580388,男,54,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,24.0,54,硬型（sci）,INFa,2.0,,,1.0,,,,2.0,2014-11-25,2020-04-16,1,,,XELOX,,,,,,3, 低粘附腺癌 Lauren肠型,GX, 小弯56 (1a)811 (1b)01 (3a)46 (3b)11 (5)00 (6)011 (8a)02 (8p)02 (9) (11p)49 (11d)01 (12a)00 (2)24," M（胃体部）, 后Post, 小弯侧Less,",50,45,12, R0 D2,,12.32,6.68,4.47,163.0,306.0,4.23,13.0,16.0,153.0,101.0,13.0,10.57,3.37,67.0,259.0,42.0,25.0,4.3,6.6,81.0,354.0,64.4,43.9,14.1,3.11,0.1,21.2,12.8,0.5,0.622,1.52,9.4,87.6,1.62,6.15,4.4, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin部分（+）、 VEGF（-）、 CMET灶弱（+）、 CD34+、 S-100+,,,,,64.68462549277267,1434508
1434582,庄吉祥,581878,男,63,T4a,N3a,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,9.0,32,硬型（sci）,INFa,1.0,,,1.0,,,,0.0,2014-11-26,2019-10-01,1,,,SOX,,,,,,6,管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (2)00 (3a)35 (3b)02 (4sa)00 (4sb)11 (4d)36 (5)00 (6)24 (7) (8a) (8p) (9)09 (11p)00 (12a)04,G 小弯侧Less ,65,20,8,R0 D2,,5.54,2.93,2.01,68.0,526.0,3.08,9.0,13.0,133.0,40.0,10.0,6.62,2.7,59.0,180.0,35.0,24.0,5.0,7.2,85.0,409.0,,,,,,,,,,,,,1.71,12.48,1.61,,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-),,,,,58.14717477003942,1434582
1434666,苏彦红,581934,女,51,T4a,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,10,硬型（sci）,INFa,2.0,,,1.0,,,,2.0,2014-11-26,2015-05-01,2,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00(3b)11 (4sb)00 (4d)00 (5)00 (6)11  (8a)01 (8p)02 (7)(11p)24 (12a)11 (14v)00,L（幽门窦部） 后Post 大弯侧Gre  小弯侧Less ,60,50,8, R0 D2+,,8.5,5.38,2.26,117.4,265.0,3.68,12.0,14.0,121.0,50.0,15.0,6.44,2.01,59.0,210.0,37.0,22.0,4.1,4.1,68.0,250.0,,,,,,,,,,,,,1.36,9.86,1.47, 未做,无,, P0,H0, 未做,ck(+)  vimentin(灶+)  VEGF(-)  cMET部分弱(+)  CD34(+)  S100(+),,,,,5.124835742444152,1434666
1434537,黄海洋,577277,男,38,T2,N3a,M0, ⅢA,1,3,1.0,1.0,1.0,0.0, 腺体萎缩+,13.0,21,髓样型（med）,INFc,1.0,,,1.0,,,,2.0,2014-11-25,2016-07-29,0,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 粘液腺癌（muc）20 Lauren混合型,G3, (1a)01 (1b)01 (3a)77 (3b)22 (4sb)00 (4d)13 (5)00 (6)12 (7)00 (8a)11 (8p)00 (9)03 (11p)11 (12a)00 (14v)00," LM 后Post, 大弯侧Gre,",120,100,10, R0 D2+,,8.08,5.69,1.77,148.0,288.0,3.68,17.0,17.0,133.0,49.0,14.0,14.98,5.52,68.0,346.0,44.0,24.0,5.3,6.4,97.0,373.0,,,,,,,,,,,,,0.473,5.44,8.88,,无,, P0,H0, 未做,CK + Vimentin  (灶+) VEGF(-) CMET(灶弱+) CD34(脉管周+)  S-100(神经+),,,,,20.105124835742444,1434537
1435663,李东生,579778,男,67,T3,N0,M0, ⅡA,1,1,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,33,硬型（sci）,INFa,1.0,,,1.0,,,,2.0,2014-12-04,2020-04-16,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)05 (3a)06 (3b)03 (4sb)00 (4d)012 (5)03 (6)00 (7)00 (8a)01 (9)01 (11p)00 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",80,60,20, R0,,14.09,9.97,2.21,138.5,340.0,4.66,14.0,13.0,167.0,81.0,46.0,8.82,3.76,65.0,153.0,42.0,23.0,5.7,6.7,72.0,217.0,,,,,,,,,,,,,10.93,7.11,11.9,,无,, P0,H0, 未做,CK + Vimentin(部分+) VEGF- CMET(灶弱+) CD34(脉管周+)  S-100(神经+),,,,,64.38896189224704,1435663
1434856,梁万利,579812,男,59,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,30,硬型（sci）,INFa,1.0,,,,,,,0.0,2014-11-27,2020-04-13,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) (1b)014 (3a) (3b)00 (4sb)04 (5) (12a)00 (6) (4d)05 (7) (8a) (8p) (9) (11p)07," L（幽门窦部）, 小弯侧Less,",25,20,3, R0 D2,,4.01,1.24,2.28,148.1,183.0,2.09,22.0,27.0,132.0,74.0,13.0,16.75,6.48,63.0,292.0,41.0,22.0,4.5,5.1,66.0,267.0,73.9,50.9,20.2,2.52,0.3,14.7,9.2,0.5,0.671,0.92,9.66,499.0,0.934,8.77,1.32,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,64.5203679369251,1434856
1435410,王福军,581626,男,71,T4a,N3a,M1, Ⅳ,1,4,1.0,0.0,0.0,1.0, 肠化生+,14.0,27,髓样型（med）,INFc,2.0,,,1.0,,,,0.0,2014-12-03,2015-05-07,2,,,,,,,,,0, 低粘附腺癌 Lauren混合型,GX, (1a)00 (1b)11 (2)00 (3a)00 (3b)00 (4sa)01 (4sb)02 (4d)03 (5)00 (6)00 (7、8、9)613 (11p)77 (20)00(1b)、(2)、(3a)、(3b)、(4sa)、(4sb)、(6)、(7)、(8)、(9)、(11p)组软组织内可见癌 ," LMU 前Ant, 小弯侧Less,",90,70,,,R2,2.65,1.18,1.17,76.7,66.0,2.06,14.0,21.0,795.0,73.0,16.0,24.27,12.75,56.0,124.0,35.0,21.0,4.4,2.5,69.0,450.0,71.6,66.2,4.4,15.0,0.1,27.1,0.2,0.1,0.37,3.1,7.98,59.7,105.7,90.53,8.17,,无,, p1局腹膜(M1 PER),H0, 未做,CK + Vimentin(灶+) VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,5.091984231274639,1435410
1435335,刘雅冬,582022,女,57,T1a,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,30,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2014-12-02,2020-04-16,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,小弯01 (1b)03 (3a)07 (3b)00 (4sb)00 (4d)07 (5)01 (6)08 (7)00 (8a)02 (9)00 (11p)01 (12a)00," L（幽门窦部）, 后Post,",10,6,1, R0 D2,,9.78,7.01,1.97,128.0,227.0,2.39,16.0,17.0,192.0,75.0,14.0,14.87,6.01,69.0,196.0,40.0,29.0,4.5,4.5,63.0,203.0,66.6,41.0,21.5,1.91,0.5,15.7,15.4,1.9,1.09,2.39,13.8,7.51,0.2,7.36,2.65,,无, 无, P0,H0, 未做,CK + Vimentin + VEGF- CMET- ,,,,,64.45466491458606,1435335
1435590,方仁焕,581984,男,77,T4b,N3a,M1, Ⅳ,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,8.0,22,硬型（sci）,INFa,1.0,,,1.0,,,,2.0,2014-12-04,2015-08-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 乳头状癌（G1）（pap）10 粘液腺癌（muc）10 Lauren肠型,G2, (1a)00 (1b)00 (2)07 (3a)00 (3b)01 (4sa)00 (4sb)00 (4d)59 (5)11 (6)02 (7、8、9)11 (11p)11," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",130,110,15,,R2,7.2,6.14,0.54,79.0,348.0,4.9,9.0,11.0,119.0,61.0,24.0,5.12,2.43,64.0,137.0,36.0,28.0,5.4,6.2,118.0,467.0,59.3,37.8,12.6,3.0,0.1,5.2,27.5,1.5,1.29,3.15,13.1,13.2,6.9,7.34,2.9,,无,, P0,H1多（M1 HEP), 未做,CK + Vimentin(灶+) VEGF- CMET(弱+) CD34(脉管周+)  S-100(神经+),,,,,7.884362680683311,1435590
1435493,崔长生,581596,男,34,T2,N0,M0, ⅠB,1,2,2.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,24,硬型（sci）,INFc,1.0,,,1.0,,,,0.0,2014-12-03,2020-04-16,1,,,XELOX,,,,,,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)03 (2)00 (3a)06 (3b)00 (4sb)00 (4d)03 (5)00 (6)02 (7)01 (8a)02 (8p)02 (9)01 (11p)03 (12a)01," M（胃体部）, 后Post, 小弯侧Less,",30,30,2, R0 D2+,,13.54,8.18,4.22,166.0,312.0,2.21,20.0,21.0,227.0,83.0,24.0,17.34,6.3,79.0,254.0,47.0,32.0,4.9,7.8,83.0,404.0,71.2,40.7,23.9,1.7,0.1,13.9,13.1,2.0,1.2,1.92,15.6,34.4,5.41,13.38,1.14,,无,, P0,H0, 未做,CK + Vimentin(灶+) VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,64.42181340341655,1435493
1435183,杨忠臣,581948,男,60,T3,N0,M0, ⅡA,1,1,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,33,硬型（sci）,INFa,0.0,,,,,,,0.0,2014-12-01,2017-12-26,2,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)04 (2)06 (3a)011 (4sb)01 (7)05 (8a)01 (8p)00 (9)02 (11p)02," U（胃底部）, SiewerⅢ, 后Post,",30,30,10, R0 D2,,7.44,4.49,2.16,147.2,206.0,3.28,18.0,25.0,122.0,96.0,54.0,7.06,2.64,65.0,194.0,38.0,27.0,5.2,6.3,73.0,333.0,67.3,51.5,10.7,4.81,0.3,19.2,12.0,0.3,1.72,2.36,11.9,58.5,,,,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,36.826544021024965,1435183
1435316,马德礼,578144,男,60,T1b,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+,0.0,16,硬型（sci）,INFc,1.0,,,1.0,,,,0.0,2014-12-02,2021-05-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren弥漫型,G2, (1a)02 (1b)01 (3a)05 (3b)00 (4sb)00 (4d)00 (5)00 (6)02 (7)04 (8a) (8p) 00(9)00 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",10,8,1, R0 D2,,7.14,3.62,2.78,154.1,227.0,2.94,52.0,33.0,137.0,58.0,31.0,9.54,3.53,68.0,288.0,41.0,27.0,5.0,7.0,81.0,374.0,68.0,38.3,24.5,1.56,0.3,14.9,15.3,0.4,0.671,1.94,12.2,164.0,1.73,7.54,4.2, 未做,无,, P0,H0, 未做,ck(+)  vimentin(灶+)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,77.59526938239159,1435316
1435060,郭喜全,581636,男,60,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,29,硬型（sci）,INFa,3.0,,,1.0,,,,0.0,2014-12-01,2020-04-13,1,,,XELOX,SOX,SOX,SOX,替吉奥单药,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)03 (3a)00 (3b)00 (4sb)00 (4d)011 (5)00 (6)01 (7) (8a) (8p) (9)08 (11p)03 软组织可见癌1B," L（幽门窦部）,",70,40,15, R0 D2,,7.7,4.1,2.84,139.1,376.0,4.66,31.0,30.0,160.0,111.0,39.0,10.08,3.26,71.0,254.0,43.0,28.0,5.7,5.4,75.0,381.0,70.1,39.6,27.0,1.47,0.5,5.3,23.6,0.1,0.94,3.0,9.95,317.0,1.73,221.1,21.29,,无, 无, P0,H0, 未做, CK+， Vimentin灶+， VEGF-， CMET-,,,,,64.38896189224704,1435060
1435253,崔建泉,582346,男,57,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,43,硬型（sci）,INFa,2.0,,,,,,,,2014-12-02,2019-06-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型 息肉,G2, (1a)00 (1b)05 (3a)03 (3b)00 (4sb) 00(4d)0 18 (5)00 (6)01 (7)0 10 (8a)01 (8p) (9)04 (11p) 01(12a)00 (16a1)00,L（幽门窦部） 后Post ,22,15,3, R0 D2+,,4.81,2.57,1.8,141.6,156.0,2.04,44.0,39.0,166.0,49.0,19.0,15.66,6.22,66.0,234.0,39.0,27.0,5.0,7.2,68.0,408.0,70.9,43.9,23.8,1.84,0.1,5.9,19.6,0.4,1.29,2.69,12.3,104.0,4.98,29.37,2.94, 未做,无,, P0,H0, 未做,,,,,,53.942181340341655,1435253
1435956,刘晓东,576960,男,48,T4a,N3b,M1, Ⅳ,1,5,0.0,1.0,1.0,1.0, 慢性炎症（+）,59.0,77,硬型（sci）,INFa,2.0,,,1.0,,,,0.0,2014-12-08,2016-04-06,2,替吉奥*2,1.0,多西他赛联合顺铂,多西他赛联合顺铂,多西他赛联合顺铂,多西他赛联合顺铂,,,4, 低分化腺癌（G3)(por) 中分化 90% 粘液腺癌（muc）10% Lauren肠型,G3, (1b)0/0 (2)2/3 (3a)7/7 (3b)2/3 (4sb)7/8 (4d) 27/30(5) 1/1(6) 8/10(7) 0/3(8a)0/1 (8p) 2/2(9) 0/0(11p) 2/4(12a)0/0 3a 8p 12a 见4枚癌结节，1b、3a、3b、4d、5、6、11p软组织可见癌," M（胃体部）, 后Post,",130,60,15,,R1,6.95,51.0,2.62,146.0,172.0,3.01,32.0,34.0,152.0,69.0,19.0,11.48,4.37,69.0,204.0,40.0,29.0,4.2,4.3,50.0,210.0,72.6,46.7,22.8,2.05,0.1,15.7,11.1,0.8,1.05,2.41,12.5,33.8,36.83,563.8,160.5, 未做,无, 无, P0,H1单（M1 HEP), 未做, CMET- Vimentin+ VEGF - CK+ CD34+ S-100+,,,,,15.932982917214192,1435956
1435661,赵德平,580795,男,52,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,3.0,36,硬型（sci）,INFa,2.0,,1.0,1.0,,,,0.0,2014-12-04,2015-01-21,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)05 (1b)03 (2)00 (3a)00 (3b)00 (4sa)12 (4sb)00 (4d)09 (5)00 (6)02 (7)06 (8a)02 (8p)00 (9)02 (10)11 (11p)02 (11d)12 (12a)00 软组织可见癌," U（胃底部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,50,8, R0 D2,,10.25,6.05,2.97,145.0,439.0,3.85,24.0,28.0,139.0,103.0,11.0,5.78,2.42,68.0,187.0,42.0,26.0,4.4,3.1,57.0,251.0,73.0,38.4,10.4,1.26,0.6,14.6,7.9,1.6,0.583,2.27,8.29,125.0,2.3,263.7,4.78, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（灶+）、 VEGF（灶弱+）、 CMET（-）、 CD34+、 S-100+,,,,,1.5768725361366622,1435661
1435691,张立平,581833,女,39,T3,N2,M1, Ⅳ,1,4,1.0,0.0,0.0,1.0, 肠化生+,4.0,14,髓样型（med）,INFc,0.0,,,1.0,,,,0.0,2014-12-04,2016-05-13,2,,,SOX,,,,,,6, 低粘附腺癌 Lauren混合型,GX,"(1a)00,(1b)00, (3a)00,(3b)2/4 (4sb)01,(4d)1/4 (5)00 (6)0/1 (8a)0/1 (9)02  (11p)1/1; 1a、1b、3b、4d软组织可见癌  "," L（幽门窦部）, 大弯侧Gre, 小弯侧Less, 后Post, 前Ant,",,,,,R2,9.03,67.9,1.96,142.0,334.0,2.8,54.0,33.0,115.0,49.0,12.0,17.54,7.3,69.0,252.0,42.0,27.0,4.5,2.7,50.0,207.0,70.2,46.2,21.9,2.11,0.2,11.9,15.0,2.4,1.42,1.15,11.7,88.4,1.11,221.6,8.26, 未做,无, 无, P0,H0, 未做," CMET-, Vimentin-, VEGF-, CK+, CD34+, S-100+.",,,,,17.279894875164256,1435691
1436110,刘景君,581675,男,48,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,23,硬型（sci）,INFa,0.0,,,1.0,,,,0.0,2014-12-09,2016-12-15,0,,,,,,,,,0, 管状腺癌（低分化 中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)01 (4d)00 (5)00 (6)06 (7)04 (8a)02 (8p)01 (9)02 (11p)03 (12a)00 (14v)00大弯04,L（幽门窦部） 前Ant 小弯侧Less ,25,20,8, R0 D2+,,9.03,5.23,3.07,160.5,203.0,1.88,27.0,24.0,160.0,59.0,19.0,6.16,2.32,69.0,329.0,42.0,27.0,5.0,7.4,65.0,422.0,44.5,25.5,15.3,1.67,0.1,7.8,46.0,2.4,0.836,1.62,10.0,39.5,6.6,2.76,10.42, 未做,无,, P0,H0, 未做,ck(+)  vimentin(灶+)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,24.21156373193167,1436110
1435986,姜海涛,582363,男,41,T4b,N3a,M0, ⅢC,1,1,0.0,0.0,0.0,1.0, 慢性炎症（+）,11.0,14,硬型（sci）,INFa,0.0,,,1.0,,,,0.0,2014-12-08,2015-04-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3,小弯33 (1a)00 (1b)11 (2)01 (3a)01 (4sb)01 (4d)22 (6)00 (7)00 (8a、8p)44 (12a)11   (4d、6、8a、8p)组软组织可见癌," LMU 前Ant, 后Post, 小弯侧Less,",80,60,25,,R2,8.39,5.78,1.72,53.0,334.0,4.9,16.0,19.0,178.0,49.0,27.0,5.24,2.63,63.0,104.0,35.0,28.0,4.7,4.1,61.0,354.0,80.9,35.9,39.2,0.92,0.1,7.0,10.0,6.3,0.934,2.11,10.3,57.6,2.95,5.62,10.79,,无,, P0,H0, 未做,CK + Vimentin+ VEGF- CMET弱+ CD34(脉管周+)  S-100(神经+),,,,,3.7450722733245727,1435986
1435944,张敏,582051,男,44,T3,N3b,M0, ⅢC,1,5,1.0,1.0,1.0,0.0, 肠化生+,18.0,21,硬型（sci）,INFb,1.0,,,1.0,,,,2.0,2014-12-08,2020-04-14,1,,,XELOX,,,,,,4, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren混合型,G3, (1a)02 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)66 (6)11 (7)33 (8a) (8p)22 (9)01 (11p)44 (12a)11," L（幽门窦部）, 前Ant, 大弯侧Gre,",80,70,10, R0 D2,,7.25,3.9,38.9,166.0,229.0,3.08,31.0,31.0,188.0,66.0,10.0,16.38,4.83,65.0,266.0,41.0,24.0,5.2,6.1,66.0,286.0,,,,,,,,,,,,,1.67,7.37,15.93,,无, 无, P0,H0, 未做,CK+， Vimentin+， VEGF-，cMET弱+,,,,,64.19185282522996,1435944
1436018,吴桂芝,581687,女,66,T2,N1,M0, ⅡA,1,1,0.0,0.0,0.0,0.0, 肠化生+,2.0,16,硬型（sci）,INFa,2.0,,,1.0,,,,0.0,2014-12-09,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)01 (3b)00 (4sb)01 (4d)00 (5)00 (6)24 (7)07 (8a)02 (8p) (9)01 (11p)00 (12a)00,L（幽门窦部） 前Ant 小弯侧Less ,30,25,10, R0 D2,,6.96,4.09,2.16,139.0,244.0,2.63,29.0,29.0,222.0,81.0,35.0,7.35,2.41,76.0,164.0,43.0,33.0,5.2,5.0,57.0,272.0,63.7,50.1,10.4,4.82,0.3,9.5,22.3,0.9,1.08,1.69,13.6,125.0,3.19,4.93,3.87, 未做,无,, P0,H0, 未做,ck(+)  vimentin(灶+)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,92.73981603153744,1436018
1436045,冯乐阳,582210,男,50,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,29,硬型（sci）,INFa,2.0,,,1.0,,,,2.0,2014-12-09,2019-10-29,2,,,SOX,,,,,,2, 低粘附腺癌80% 管状腺癌（中分化【G2】【tub2】20% Lauren肠型,G2, (1a)03 (1b)04 (3a)02 (3b)00 (4sb)00 (4d)03 (5)01 (6)04 (7)01 (8a)03 (8p)01 (9)02 (11p)03 (12a)02," L（幽门窦部）, 小弯侧Less,",30,30,10, R0 D2,,6.42,3.59,2.26,145.2,171.0,2.18,45.0,38.0,148.0,182.0,30.0,14.2,5.8,66.0,182.0,37.0,29.0,14.8,4.9,62.0,203.0,76.8,48.1,25.3,1.9,0.4,12.8,7.8,3.9,0.57,3.67,12.1,72.2,3.73,47.36,38.74, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin部分（+）、 VEGF（-）、 CMET（弱+）、 CD34+、 S-100+,,,,,58.63994743758212,1436045
1436911,李福修,582276,男,49,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,9.0,33,硬型（sci）,INFa,2.0,,,1.0,,,,0.0,2014-12-16,2016-01-21,2,,,卡培他滨,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (2)26 (3a)01 (3b)13 (4sb)26 (4d)3 11 (5)00 (6)01 (7)00 (8a)11 (8p)02 (9)02 (11p) 00(16a1)00,UM 小弯侧Less 前Ant 后Post ,50,45,20,,R1,8.17,5.62,1.84,151.0,254.0,2.8,31.0,24.0,161.0,64.0,16.0,6.84,2.49,74.0,296.0,45.0,29.0,6.9,7.9,69.0,298.0,63.9,37.1,24.1,1.54,0.3,9.6,21.2,2.7,1.14,1.92,10.3,5.03,0.661,3.06,1.61, 未做,无,, P0,H0, 未做,ck(+)  vimentin(灶+)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,13.173455978975033,1436911
1436177,夏春平,582470,女,44,T4b,N1,M0, ⅢB,1,2,0.0,0.0,0.0,0.0, 肠化生+,1.0,30,硬型（sci）,INFa,3.0,,,1.0,,,,0.0,2014-12-10,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3,肠系膜00 (1a)04 (1b)02 (3a)07 (3b)00 (4sb)00 (4d)12 (5)00 (6)07 (7)02 (8a)02 (9)02 (11p)02," L（幽门窦部）, 后Post, 大弯侧Gre,",80,70,22,,R1,10.0,8.1,1.23,62.3,390.0,3.85,17.0,19.0,133.0,68.0,14.0,6.65,2.86,65.0,119.0,34.0,31.0,6.1,2.8,41.0,181.0,77.8,36.0,40.2,0.9,0.3,3.9,14.8,4.9,2.1,3.13,11.9,10.4,0.2,12.81,4.3, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（灶+）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,92.70696452036793,1436177
1436158,苏卫红,575107,男,44,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,0.0, 慢性炎症（+）,10.0,27,硬型（sci）,INFa,0.0,,,,,,,,2014-12-09,2015-08-06,2,,,SOX,SOX,SOX,SOX,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3," (1a)13 (1b)11 (2)05 (3a)68 (3b)01 (4sa)00 (4sb)01 (4d)06 (5)11 (6)11 软组织可见癌1b,4d,5"," LMU 前Ant, 后Post, 大弯侧Gre,",140,70,25,,R2,6.88,4.39,1.8,63.9,520.0,4.23,18.0,22.0,193.0,46.0,11.0,3.64,1.69,58.0,119.0,29.0,29.0,5.1,2.7,62.0,206.0,71.1,44.6,20.4,2.19,0.1,14.7,11.7,3.7,0.482,4.26,10.7,29.2,2.69,36.41,12.69,,无, 无, P0,H0, 未做,CK+， Vimentin+， VEGF-，cMET灶- S-100- CD56- CD34-  Syn-,,,,,7.884362680683311,1436158
1436933,曹海军,582489,男,53,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,20,硬型（sci）,INFa,0.0,,,1.0,,,,0.0,2014-12-16,2018-06-06,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)03 (1b)00 (3a)03 (3b)00 (4sb)02 (4d)01 (5)01 (6)03 (7)02 (8a) (8p)03 (11p)00 (12a)02," L（幽门窦部）, 后Post, 大弯侧Gre,",50,35,15, R0 D2,,6.44,3.34,2.45,152.0,262.0,3.21,32.0,15.0,116.0,73.0,30.0,8.18,3.43,69.0,286.0,43.0,26.0,4.8,5.7,94.0,316.0,73.7,32.8,31.3,1.05,0.1,5.3,19.7,7.9,0.972,1.81,9.44,26.2,0.621,7.2,7.88, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（灶+）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,41.65571616294349,1436933
1435842,杨瑞昕,580574,女,47,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,5.0,27,硬型（sci）,INFa,0.0,,1.0,1.0,,,,0.0,2014-12-07,2020-04-14,1,,,,,,,,,0, 低分化腺癌（G3)(por)50 低粘附腺癌40 粘液腺癌（muc）10 Lauren肠型,G3, (1a) (1b)06 (2)00 (3a) (3b)24 (4sa)01 (4sb)02 (4d)01 (5)12 (6)07 (7) (8a) (8p) (9)24 (11p)00 (12a)00,G 小弯侧Less 后Post ,20,15,10, D2 R0,,7.8,5.43,1.82,99.3,321.0,,70.0,43.0,160.0,61.0,14.7,19.59,3.36,51.2,186.05,34.5,16.7,,2.4,49.0,91.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(-)CD34(+)， S100(+),,,,,64.22470433639947,1435842
1436440,王宝财,583173,男,64,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,24,硬型（sci）,INFa,2.0,,,,,,,0.0,2015-01-11,2019-04-25,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)0/2 (1b)0/1 (3a)0/1 (3b)0/0 (4sb)0/0 (4d)0/2 (5)0/1 (6)0/7 (7)0/4 (8a)0/1 (8p)0/1 (9)0/2 (11p)0/2 (12a)0/0," L（幽门窦部）, 小弯侧Less,",20,20,10, R0 D2,,9.35,44.8,4.11,159.2,263.0,2.95,31.0,31.0,157.0,80.0,18.0,10.97,3.6,77.0,269.0,46.0,31.0,4.8,5.7,65.0,313.0,66.3,25.0,39.4,0.63,0.2,10.8,20.2,16.1,0.894,2.64,10.1,122.0,1.96,11.91,1.89, 未做,无, 无, P0,H0, 未做," Vimentin-, CK-, VEGF-, CMET-",,,,,51.41261498028909,1436440
1436354,赵国军,583207,男,62,T4b,N0,M0, ⅢA,1,1,0.0,0.0,0.0,1.0, 肠化生+,0.0,31,硬型（sci）,INFa,1.0,,,,,,,0.0,2014-12-11,2022-09-01,1,,,DX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (2)05 (3a)03 (3b)00 (4sb)02 (4d)06 (5)03 (6)00 (7)03 (8a)02 (8p)04 (9)00 (11p)00,G 小弯侧Less 前Ant 后Post ,105,80,15,R0,,7.12,4.57,1.99,66.9,264.0,3.68,10.0,19.0,189.0,62.0,17.0,5.57,2.01,56.0,123.0,31.0,25.0,4.8,8.8,78.0,317.0,66.1,34.1,29.6,1.15,0.5,11.2,20.4,0.7,0.919,1.13,11.4,236.0,2.98,11.35,6.07, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,92.67411300919842,1436354
1436663,岳林发,582156,男,55,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,14,硬型（sci）,INFa,1.0,,,1.0,,,,2.0,2014-12-15,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (2)00 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)01 (7) (8a) (8p) (9)09," GE, SiewerⅢ, 大弯侧Gre,",10,10,, R0 D2,,4.11,1.99,1.66,142.0,200.0,2.12,17.0,17.0,133.0,75.0,63.0,13.0,4.35,59.0,179.0,37.0,22.0,5.3,6.4,83.0,237.0,,,,,,,,,,,,,0.573,7.89,1.17,,无, 无, P0,H0, 未做, CK+， Vimentin灶+， VEGF-，cMET灶弱+,,,,,72.07621550591327,1436663
1436912,宫立奎,582218,男,73,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,22,硬型（sci）,INFa,2.0,,,1.0,,,,2.0,2014-12-16,2021-05-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)04 (3b)00 (4sb)01 (4d)06 (5)00 (6)04 (7)01 (8a)01 (8p)03 (9)01 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",30,20,, R0 D2+,,6.61,4.04,1.93,153.2,207.0,2.84,10.0,16.0,172.0,121.0,6.0,6.61,2.94,67.0,186.0,42.0,25.0,4.4,8.2,74.0,342.0,61.0,45.1,13.8,3.27,0.1,18.2,16.5,2.0,1.04,1.93,9.67,24.2,1.66,6.27,31.94,,无,, P0,H0, 未做,CK + Vimentin(灶+) VEGF- CMET(灶弱+) CD34(脉管周+)  S-100(神经+),,,,,77.1353482260184,1436912
1436601,马海龙,582499,男,58,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,0.0, 肠化生+,1.0,16,硬型（sci）,INFa,0.0,,,,,,,0.0,2014-12-12,2022-09-01,1,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)02 (3b)00 (4sb)00 (4d)04 (5)00 (6)01 (7)01 (8a)13 (8p)00 (9)02 (11p)01 (12a)00," L（幽门窦部）, 大弯侧Gre,",30,30,4, R0 D2,,6.09,4.0,1.61,130.3,303.0,3.68,12.0,16.0,117.0,46.0,26.0,16.57,6.84,69.0,185.0,41.0,28.0,5.6,5.0,73.0,373.0,74.7,52.4,20.8,2.52,0.1,5.9,18.4,1.7,0.401,3.23,9.37,42.1,8.75,13.62,, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,92.64126149802891,1436601
1436993,张国芬,583015,女,64,T4b,N1,M0, ⅢB,1,5,0.0,1.0,1.0,0.0, 慢性炎症（+）,1.0,20,硬型（sci）,INFa,1.0,,,1.0,,,,0.0,2014-12-17,2020-04-13,1,,,SOX,SOX,SOX,SOX,XELOX,XELOX,6, 低分化管状腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)03 (5)00 (6)11 (7)02 (8a)02 (8p)04 (9)02 (11p)02 (12a)01 (12b)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",80,80,20,,R1,4.5,2.8,1.27,98.9,272.0,2.21,35.0,31.0,158.0,70.0,25.0,6.93,2.87,61.0,141.0,35.0,26.0,5.9,4.5,62.0,268.0,74.5,34.5,26.1,1.32,0.1,6.8,17.0,3.5,0.517,1.9,10.6,5.0,2.11,8.62,4.08, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（灶+）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,63.86333771353482,1436993
1436992,肖桂华,583255,女,56,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,17.0,30,硬型（sci）,INFa,1.0,,,1.0,,,,2.0,2014-12-17,2020-04-13,1,,,FOLFOX6,,,,,,9, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)01 (3b)78 (4sb)02 (4d)12 (5)00 (6)66 (7)00 (8p) (8a)22 (9)02 (11p)03 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,45,4, R0 D2,,6.13,3.35,2.12,67.7,283.0,2.8,11.0,11.0,128.0,65.0,9.0,12.3,4.72,63.0,135.0,36.0,27.0,6.2,3.0,65.0,227.0,58.0,42.5,11.3,3.76,0.0,10.3,26.2,0.9,1.15,2.9,10.7,26.0,0.485,15.2,0.691,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET灶弱+,,,,,63.86333771353482,1436992
1437237,刘凤金,582821,男,55,T3,N1,M0, ⅡB,1,1,0.0,0.0,0.0,1.0, 慢性炎症（+）,1.0,21,硬型（sci）,INFa,2.0,,,,,,,0.0,2014-12-18,2020-01-09,1,,,SOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 粘液腺癌（muc）35 低粘附腺癌5 Lauren肠型,G3, (1a)02 (1b)03 (2)06 (3a)03 (3b)00 (4sb)02 (4d)11 (5)00 (6)01 (7)01 (8a)01 (8p)00 (9)00 (11p)01  转移成分为低黏附性癌, LM,40 35,30 35,5 5, R0 D2+,,10.55,7.87,1.72,171.8,246.0,2.45,30.0,31.0,178.0,114.0,122.0,20.29,6.92,77.0,230.0,42.0,35.0,4.8,7.4,74.0,351.0,73.7,51.7,20.0,2.59,0.8,7.8,14.5,3.1,0.822,2.73,14.6,8.32,3.42,4.74,5.26,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,60.709592641261494,1437237
1437101,孙井海,583251,男,60,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,9.0,14,硬型（sci）,INFa,0.0,,,,,,,0.0,2014-12-17,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40 Lauren肠型,G2, (1a)00 (1b)00 (3a)24 (3b)00 (4sa)00 (4sb)00 (4d)13 (5)00 (6)00 (7)33 (8a)22 (8p)11 (9)00 (12p)01," L（幽门窦部）, 小弯侧Less,",40,35,8,,R1,5.4,2.98,1.89,146.0,228.0,2.78,52.0,24.0,164.0,69.0,38.0,12.18,4.21,74.0,261.0,42.0,32.0,5.3,5.2,73.0,356.0,53.2,27.1,20.3,1.33,0.6,7.5,35.3,0.5,1.06,3.14,24.7,556.0,1.71,2.97,7.43,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,92.47700394218134,1437101
1438368,宁淑华,583241,女,69,T3,N0,M0, ⅡA,1,5,0.0,1.0,1.0,1.0, 肠化生+,0.0,16,中间型（int）,INFa,0.0,,,1.0,,,,0.0,2014-12-30,2020-04-13,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)01 (3a)03 (3b)00 (4sb)00 (4d)03 (5)00 (6)00 (7)05 (8a)00 (8p)03 (9)00 (11p)00 软组织可见癌," L（幽门窦部）, 后Post, 大弯侧Gre,",45,35,10, R0 D2,,6.27,3.67,1.92,98.8,254.0,3.51,22.0,29.0,214.0,89.0,8.0,6.23,2.22,66.0,168.0,38.0,28.0,6.4,4.8,51.0,223.0,70.8,34.1,37.4,0.92,0.7,11.3,11.5,1.9,0.818,2.45,9.92,59.5,2.29,3.18,8.49, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin散在（+）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,63.43626806833114,1438368
1437159,赫秀云,583588,女,80,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,17,硬型（sci）,INFa,2.0,,,1.0,,,,2.0,2014-12-18,2017-08-01,0,,,,,,,,,0," 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 低粘附腺癌 30%,Lauren肠型",G3, (1a)0/2 (1b)1/1 (3a)1/3 (3b)0/0 (4sb)0/0 (4d)1/2 (5)1/1 (6)0/1 (7)0/1 (8a)1/1 (8p)0/2 (9)0/0 (11p)0/3," L（幽门窦部）, 前Ant, 小弯侧Less,",25,15,8, R0 D2,,7.42,5.03,1.88,123.0,241.0,3.1,23.0,24.0,153.0,53.0,28.0,4.07,2.01,67.0,122.0,39.0,28.0,10.3,7.7,60.0,314.0,58.2,36.0,20.2,1.78,0.4,10.1,28.1,0.2,0.712,2.51,13.2,12.9,1.8,22.29,1.87, 未做,无, 无, P0,H0, 未做, CK+,,,,,31.438896189224703,1437159
1437482,刘培珍,583627,女,68,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,17,硬型（sci）,INFa,2.0,,,,,,,0.0,2014-12-22,2020-04-13,1,,,,,,,,,0,绒毛状腺瘤，局部癌变-高中分化管状腺癌（粘膜内癌） Lauren肠型,G2, (1a) 0/0(1b)0/2 (3a)0/6 (3b)0/0 (4sb)0/0 (4d)0/2 (5)0/1 (6)0/0 (7)0/3 (8a)0/2 (8p)0/0 (9)0/1 (11p)0/0," L（幽门窦部）, 小弯侧Less, 大弯侧Gre,",30,20,5, R0 D2,,7.53,3.16,3.49,142.0,240.0,2.6,28.0,29.0,152.0,87.0,19.0,9.31,3.23,66.0,204.0,37.0,29.0,5.1,7.9,59.0,395.0,65.6,46.6,16.2,2.81,0.1,14.9,13.2,0.8,1.58,2.51,12.1,59.1,1.36,14.95,1.69, 未做,无, 无, P0,H0, 未做," CMET-, Vimentin-, VEGF-, CK+, CD34+, S-100+",,,,,63.69908015768725,1437482
1437597,任东海,580949,男,57,T4b,N3b,M0, ⅢC,1,2,1.0,1.0,1.0,1.0, 肠化生+,24.0,26,髓样型（med）,INFc,0.0,,,1.0,,,,1.0,2014-12-22,2016-07-29,2,,,SOX,,,,,,4, 低粘附腺癌90 管状腺癌（中分化【G2】【tub2】10 Lauren混合型,G2, (1a)00 (1b)01 (3a)56 (3b)33 (4sb)22 (4d)00 (5)22 (6)00 (7)22 (8a)11 (8p)11 (9)00 (11p)44 (14v)44," L（幽门窦部）, 大弯侧Gre,",30,30,5,,R1,5.56,3.05,1.5,149.0,184.0,4.44,41.0,41.0,196.0,95.0,100.0,14.23,5.61,73.0,237.0,43.0,30.0,8.9,3.1,64.0,391.0,77.7,40.1,35.2,1.14,0.5,4.9,15.4,12.1,1.5,1.79,10.9,115.0,531.7,14.0,8.53,,无,, P0,H0, 未做,CK + Vimentin(部分+) VEGF- CMET(灶+) CD34(脉管周+)  S-100(神经+),,,,,19.21813403416557,1437597
1437868,郭殿兴,583878,男,70,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,20,硬型（sci）,INFb,1.0,,,1.0,,,,0.0,2014-12-24,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren肠型,G3, (1a)01 (1b)02 (3a)02 (3b)00 (4sb)00 (4d)03 (5)01 (6)03 (7)01 (8a)03 (8p)01 (9)01 (11p)01 (12a)01," L（幽门窦部）, 小弯侧Less,",10,8,, R0 D2+,,5.46,3.06,1.95,147.0,177.0,3.85,31.0,29.0,164.0,72.0,6.0,17.91,6.71,67.0,234.0,39.0,28.0,7.7,4.5,64.0,258.0,77.0,33.0,41.6,0.79,0.1,4.6,17.0,4.7,0.51,1.5,11.1,22.6,2.46,10.38,1.01,,无,, P0,H0, 未做,CK + Vimentin+ VEGF- CMET- ,,,,,92.24704336399473,1437868
1437028,李景玉,583552,男,64,T3,N2,M0, ⅢA,1,2,0.0,0.0,0.0,1.0, 肠化生+,3.0,24,硬型（sci）,INFa,0.0,,,1.0,,,,0.0,2014-12-17,2020-04-13,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)00 (3b)33 (4sb)00 (4d)07 (5)01 (6)01 (7)07 (8a) (8p) (11p) (12a)05 (9)00," L（幽门窦部）, 小弯侧Less,",30,20,7, R0 D2,,7.75,3.7,2.66,157.0,186.0,3.05,26.0,29.0,182.0,54.0,7.0,9.3,3.0,66.0,251.0,39.0,27.0,4.8,7.0,64.0,269.0,77.6,39.3,33.6,1.17,0.2,10.5,9.6,1.4,0.756,1.43,10.4,41.1,1.8,11.73,17.61,,无, 无, P0,H0, 未做,CK+， Vimentin+， VEGF-， CMET-,,,,,63.86333771353482,1437028
1437183,陈亚娟,583634,女,48,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,10,硬型（sci）,INFa,0.0,,,,,,,0.0,2014-12-18,2020-04-14,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)00 (3a)00 (3b)02 (4sb)00 (4d)04 (5)00 (6)01 (7)00 (8a) (8p)00 (9)01 (11p)00, L（幽门窦部） 小弯侧Less ,8,5,, R0 D2,,5.7,2.98,2.21,136.0,240.0,2.49,27.0,31.0,170.0,63.0,22.0,10.69,3.42,73.0,290.0,41.0,32.0,5.1,6.6,49.0,271.0,72.9,48.4,18.8,2.57,0.1,14.7,9.3,6.0,0.97,3.41,12.6,8.03,0.736,14.19,0.853, 未做,无,无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,63.86333771353482,1437183
1437812,付志春,583051,男,60,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+,4.0,18,硬型（sci）,INFa,1.0,,,,,,,0.0,2014-12-24,2017-09-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (2)00 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)00 (6)13 (7)16 (8a) (8p)01 (9)22 (11p)00 (19)01 (110)01，1a软组织可见癌，9软组织可见癌,U（胃底部） 前Ant 小弯侧Less 后Post ,25,20,8, R0 D2,,8.53,6.17,1.77,166.3,229.0,3.59,22.0,25.0,173.0,105.0,17.0,11.41,4.19,79.0,287.0,46.0,33.0,5.9,6.9,73.0,311.0,72.2,45.3,24.3,1.86,0.1,11.8,13.0,2.7,0.941,2.54,10.5,122.0,2.75,84.26,7.93, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,32.26018396846255,1437812
1437251,高洪喜,583040,男,51,T4b,N1,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,2.0,25,硬型（sci）,INFa,2.0,,,,,,,0.0,2014-12-18,2017-09-01,0,,,,,,,,,0, 粘液腺癌（muc）60 乳头状癌（G1）（pap）30 管状腺癌（中分化【G2】【tub2】10 Lauren肠型,G2, (1a)02 (1b)03 (2)02 (3a)03 (3b)01 (4sa)00 (4sb)01 (4d)01 (5)01 (6)22 (7)05 (8a) (8p)02 (9)01 (11p)01 4sa 4sb 6软组织可见癌,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,80,60,10, R0 D2,,11.58,10.43,0.5,66.4,484.0,4.03,23.0,22.0,110.0,61.0,10.0,9.3,5.01,44.0,69.0,25.0,19.0,4.9,4.9,48.0,176.0,78.4,50.7,24.6,2.0,0.1,14.8,3.4,4.6,0.664,0.786,4.63,25.0,1.31,8.97,4.38, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-) CD34(+)， S100(+),,,,,32.45729303547963,1437251
1437598,佟拉噶,582041,男,46,T3,N0,M0, ⅡA,1,2,1.0,0.0,0.0,0.0, 肠化生+,0.0,33,髓样型（med）,INFc,3.0,,,,,,,2.0,2014-12-22,2022-09-01,1,,,SOX,,,,,,2, 粘液腺癌（muc）80 乳头状癌（G1）（pap）20,G1, (1a)00 (1b)02 (2)00 (3a)012 (3b)02 (4sa)02 (4sb)01 (4d)03 (5)01 (6)04 (7)01 (8a) (8p)02 (9)03 (11p)00 (11d)00 3a软组织可见癌,"胃癌  U（胃底部）,前Ant 小弯侧Less 后Post  T4 N0 M0",55,45,5, R0 D2 ,,8.7,4.44,3.58,142.7,235.0,2.84,34.0,23.0,139.0,61.0,35.0,12.44,5.03,69.0,197.0,42.0,27.0,5.0,4.5,80.0,409.0,60.1,40.1,16.1,2.49,0.2,15.4,20.2,1.0,0.355,1.76,11.0,1630.0,3.08,10.02,10.16, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+),,,,,92.31274638633377,1437598
1437744,王淑英,583097,女,50,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,22.0,36,硬型（sci）,INFa,1.0,,1.0,1.0,,,,2.0,2014-12-23,2015-10-21,2,,,XELOX,,,,,,1, 低粘附腺癌伴低分化腺癌 Lauren肠型,G3, (1a) 0/2(1b)0/0 (3a)5/5 (3b)1/1 (4sb)0/0 (4d)5/6 (5)0/1 (6)3/3 (7)3/3 (8a)1/3 (8p)0/5 (9)2/5 (11p)2/2;3a组软组织内可见1枚结节见有癌。," L（幽门窦部）, 后Post, 前Ant, 小弯侧Less,",80,70,20,,R1,8.26,5.1,2.46,76.4,350.0,4.44,40.0,30.0,219.0,72.0,37.0,6.53,2.54,69.0,164.0,39.0,30.0,6.3,5.0,65.0,155.0,51.2,32.3,12.2,2.65,0.1,3.8,40.4,0.9,0.612,2.54,13.2,27.21,5.35,15.5,3.52, 未做,无, 无, P0,H0, 未做, Vimentin（灶+） VEGF（弱+） CMET（弱+） CK+ CD34 + S-100+,,,,,9.921156373193167,1437744
1437963,王尚波,583892,男,54,T4a,N0,M0, ⅡB,1,5,2.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,30,硬型（sci）,INFc,1.0,,,1.0,,,,0.0,2014-12-25,2020-04-14,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,SOX,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)04 (3a)04 (3b)00 (4sb)03 (4d)09 (5)00 (6)03 (7)02 (8a)02 (8p)01 (9)02 (11p)00 (12)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,10, R0 D2+,,7.2,3.55,2.74,133.5,277.0,2.73,27.0,31.0,160.0,103.0,12.0,6.29,1.47,69.0,311.0,43.0,26.0,5.0,7.6,51.0,216.0,75.8,64.0,10.0,6.4,1.0,7.8,13.7,0.3,2.02,2.52,9.78,173.0,3.59,19.72,9.17,,无,, P0,H0, 未做,CK + Vimentin局部+ VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,63.633377135348226,1437963
1437465,王玉栋,583867,男,76,T4b,N2,M1, Ⅳ,1,3,2.0,1.0,1.0,1.0, 肠化生+,3.0,5,硬型（sci）,INFc,1.0,,,,,,,2.0,2014-12-22,2017-07-26,2,,,口服替吉奥,,,,,,2, 低粘附腺癌 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)00 (1b)11 (2)00 (3a)00 (3b)00 (4sb)00 (4d)01 (5)11 (6)01 (7)11 软组织可见癌1、3、7," GE, 前Ant, 后Post, 小弯侧Less, SiewerⅢ,",90,80,12,,R2,9.87,8.45,0.98,88.5,133.0,1.21,15.0,20.0,162.0,50.0,10.0,17.61,10.04,49.0,58.0,28.0,21.0,4.7,9.7,65.0,182.0,74.7,52.1,19.1,2.73,0.0,6.3,14.3,1.1,0.734,2.06,14.8,531.0,5.08,25.37,2.13,,无, 无, p1局腹膜(M1 PER),H0, 未做,CK+， Vimentin-， VEGF-， CMET弱+,,,,,31.110381077529563,1437465
1437781,夏德芝,584980,女,77,T2,N1,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 肠化生+,2.0,12,硬型（sci）,INFa,1.0,,,,,,,0.0,2014-12-24,2019-09-02,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 粘液腺癌（muc）,G3, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)01 (4d)03 (5)00 (6)12 (7)02 (8a) (8p)13 (9)01 (11p)00," L（幽门窦部）, 前Ant,",20,17,6, R0 D2,,5.88,3.33,2.13,130.0,185.0,1.88,35.0,28.0,142.0,76.0,12.0,12.41,4.16,66.0,275.0,42.0,24.0,4.7,6.1,50.0,208.0,,,,,,,,,,,,,1.71,7.21,3.07,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET-,,,,,56.27463863337713,1437781
1437964,刘加雨,583862,男,60,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,13,硬型（sci）,INFa,3.0,,,,,,,0.0,2014-12-25,2022-09-01,1,,,SOX,,,,,,5, 管状腺癌（中分化【G2】【tub2】60 乳头状癌（G1）（pap）30 低粘附腺癌10 Lauren肠型,G2, (1a)01 (1b)01 (3a)00 (3b)07 (4sb)00 (4d)00 (5)01 (6)00 (7)00 (8a)02 (8p)01 (9)00 (11p)00,U（胃底部） 前Ant 小弯侧Less 后Post ,50,50,15, R0 D2+,,6.93,3.56,2.63,155.0,306.0,3.25,29.0,27.0,157.0,52.0,20.0,10.53,3.08,70.0,263.0,45.0,25.0,4.9,4.0,74.0,305.0,56.8,33.9,20.2,1.68,0.1,9.7,30.6,0.8,0.595,0.919,11.4,1140.0,2.72,33.81,9.14,,无,,P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-) CD34(+)， S100(+),,,,,92.21419185282522,1437964
1438048,雷岩,584206,男,46,T4b,N1,M0, ⅢB,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,1.0,42,髓样型（med）,INFa,1.0,,,1.0,,,,0.0,2014-12-25,2022-09-01,1,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,小弯01 (1a)03 (1b)00 (3a)08 (3b)00 (4sb)01 (4d)014 (5)00 (6)12 (7)00 (8a)01 (8p)02 (9)01 (11p)06 (12a)00 (12p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",55,45,5,,R1,6.64,4.07,1.86,122.8,270.0,2.27,26.0,27.0,107.0,82.0,11.0,6.58,2.52,75.0,328.0,47.0,28.0,5.7,3.7,67.0,299.0,67.6,46.2,15.9,2.91,0.1,20.4,6.8,0.4,0.336,1.57,14.9,38.4,1.19,7.0,1.98,,无,, P0,H0, 未做,CK + Vimentin局部+ VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,92.21419185282522,1438048
1438229,马桂芝,584176,女,66,T1b,N0,M0,ⅠA,1,0,1.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,14,髓样型（med）,INFc,0.0,,,1.0,,,,0.0,2014-12-29,2022-09-01,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren混合型,G3, (1a)00 (1b)01 (3a)04 (3b)00 (4d)00 (4sb)01 (5)00 (6)03 (7)02 (8a)01 (8p)01 (9)01 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",22,15,1, R0 D2,,5.89,3.62,1.67,132.7,268.0,2.68,21.0,29.0,178.0,83.0,14.0,10.53,3.96,73.0,216.0,46.0,27.0,4.3,3.6,59.0,402.0,52.7,37.6,14.4,2.61,0.5,11.6,31.0,0.3,0.874,2.06,13.6,19.7,0.438,8.03,1.37,,无, 无, P0,H0, 未做,CK + Vimentin(部分+) VEGF- CMET-,,,,,92.08278580814716,1438229
1437888,张建华,584231,男,42,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,15,髓样型（med）,INFa,0.0,,,1.0,,,,0.0,2014-12-24,2019-06-01,0,,,,,,,,,0, 低粘附腺癌60 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】40,G3, (1a) (3a) (3b)03 (1b)00 (4sb)06 (6) (4d)01 (8a)02 (7) (8p) (9) (11p)01 (5) (12a)02," L（幽门窦部）,  小弯侧Less,",8,5,, R0 D2,,6.09,3.69,1.79,155.9,226.0,2.03,33.0,23.0,134.0,65.0,76.0,20.79,6.92,79.0,330.0,52.0,27.0,4.8,6.6,63.0,448.0,,,,,,,,,,,,,0.477,6.66,1.37,,无, 无, P0,H0, 未做,CK+， Vimentin散在+， VEGF-， CMET-,,,,,53.21944809461235,1437888
1437825,王丽,584824,女,42,T3,N3a,M0,ⅢB,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,11.0,36,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2014-12-24,2022-09-01,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)35 (3a)46 (3b)01 (4d)37 (4sb)00 (5)00 (6)00 (7) (8a) (8p) (9)012 (11p)02 (12a)12," L（幽门窦部）, 小弯侧Less,",30,45,5, R0 D2,,5.15,2.82,1.58,127.0,305.0,2.58,24.0,23.0,131.0,60.0,15.0,4.32,1.55,66.0,262.0,39.0,27.0,4.8,6.9,62.0,307.0,81.7,47.6,30.4,1.57,0.1,10.3,5.9,2.7,0.816,1.58,14.2,78.5,0.2,3.44,6.35,,无, 无, P0,H0, 未做,CK+， Vimentin部分+， VEGF-， CMET-,,,,,92.24704336399473,1437825
1438191,金玉民,582718,男,66,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,25,髓样型（med）,INFa,3.0,,,,,,,0.0,2014-12-26,2020-04-13,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 乳头状癌（G1）（pap）20 Lauren肠型,G2, (1a)02 (1b)02 (3a) (3b)07 (4sb)01 (4d)02 (5)00 (6)04 (7) 03(8a)03 (9)00 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",8,6,, R0 D2,,8.88,4.68,3.13,162.1,195.0,17.4,20.0,26.0,175.0,72.0,35.0,11.84,3.93,67.0,244.0,43.0,24.0,4.4,4.8,61.0,383.0,73.3,51.4,20.0,2.57,0.1,16.2,8.0,1.4,8.29,3.99,13.8,73.1,2.87,14.84,3.58, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-) ,,,,,63.5676741130092,1438191
1438369,王文艳,584785,女,67,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,5,髓样型（med）,INFa,1.0,,,1.0,,,,0.0,2014-12-30,2020-04-09,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)01 (3b)01 (4sb)00 (4d)00 (5)00 (6)00 (7)02 (8a)01 (8p)02 (9)01 (11p)00," L（幽门窦部）, 前Ant, 小弯侧Less,",20,10,, R0 D2,,6.16,2.58,2.96,135.0,230.0,2.84,26.0,27.0,204.0,123.0,14.0,5.35,1.96,70.0,220.0,46.0,24.0,10.7,6.7,60.0,147.0,64.9,45.1,17.8,2.53,0.4,10.5,22.8,0.7,1.03,2.33,8.46,84.8,3.84,3.43,16.0,,无, 无, P0,H0, 未做,CK + Vimentin散在+  VEGF- CMET- ,,,,,63.30486202365309,1438369
1438452,杨向武,585088,男,64,T3,N2,M0, ⅢA,1,1,0.0,1.0,1.0,1.0, 慢性炎症（+）,4.0,39,中间型（int）,INFb,3.0,,,,,,,0.0,2014-12-30,2020-04-13,1,,,SOX,,,,,,2, 粘液腺癌（muc）60% 乳头状癌（G1）（pap）40% Lauren肠型,G1, (1a)03 (1b)15 (3a)06 (3b)02 (4sb)01 (4d)27 (5)00 (6)01 (7)05 (8a)04 (8p)02 (9)01 (11p)12 (12p)00 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",90,60,10, R0 D2,,5.93,3.53,1.72,131.4,183.0,2.58,21.0,21.0,138.0,52.0,7.0,10.71,3.74,60.0,229.0,39.0,21.0,4.6,7.2,68.0,305.0,72.5,41.5,28.1,1.48,0.4,12.0,13.3,1.7,0.496,0.659,10.4,22.1,1.43,363.9,3.93, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin部分（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,63.43626806833114,1438452
1438325,耿国富,580975,男,62,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,24,,,,,,,,,,,2014-12-29,2020-04-14,1,,,,,,,,,0, 中度不典型增生 管状腺癌（高分化【G1】【tub1】,G1, (8a)01 大弯010 小弯013,L（幽门窦部）小弯侧Less,70,40,, R0  D1+,,6.07,2.58,2.77,143.3,170.0,2.24,32.0,33.0,227.0,54.0,5.0,12.83,3.83,70.0,320.0,44.0,26.0,5.3,7.0,73.0,468.0,69.2,46.1,21.2,2.17,0.3,9.2,18.3,1.6,0.57,3.38,12.8,16.6,3.05,11.81,2.94, 未做,无,, P0,H0, 未做,,,,,,63.50197109067017,1438325
1438312,富陶,584518,男,70,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,0.0, 肠化生+,1.0,23,中间型（int）,INFb,1.0,,,,,,,0.0,2014-12-29,2016-06-06,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 乳头状癌（G1）（pap）30 Lauren肠型,G3, (1a)01 (1b)02 (3a)06 (3b)02 (4sb)00 (4d)17 (5)02 (6)01 (7)00 (8a)00 (8p)01 (9)00 (11p)01," L（幽门窦部）, 后Post, 小弯侧Less,",35,15,10, R0 D2,,6.04,4.16,1.36,73.6,293.0,2.53,23.0,25.0,145.0,65.0,22.0,12.17,6.24,66.0,229.0,42.0,24.0,6.8,5.6,55.0,342.0,76.1,54.9,14.0,3.92,0.6,7.9,12.0,2.5,1.01,1.22,12.4,34.9,1.53,17.78,1.81,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET-,,,,,17.24704336399474,1438312
1438228,郭小春,584914,男,54,T2,N3a,M0, ⅢA,1,2,2.0,0.0,0.0,1.0, 慢性炎症（+）,10.0,29,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2014-12-29,2020-04-14,1,,,SOX,,,,,,5, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a) (1b)01 (3a)15 (3b)01 (4sb)01 (4d)44 (5)11 (6)33 (7)17 (8a)03 (8p)02 (9)01 (11p)00," L（幽门窦部）, 小弯侧Less,",50,40,8, R0 D2,,5.89,3.08,2.2,136.0,198.0,2.74,24.0,22.0,122.0,77.0,11.0,12.68,4.64,58.0,230.0,36.0,22.0,4.2,3.3,63.0,333.0,77.6,51.2,23.5,2.18,0.2,15.7,4.5,1.7,0.896,0.938,12.6,31.6,0.468,6.82,1.04,,无, 无, P0,H0, 未做,CK+， Vimentin散在+， VEGF-， CMET-,,,,,63.50197109067017,1438228
1438333,孙海春,585089,男,55,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,31,,,,0.9,,,,,,,2014-12-29,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)03 (1b)03 (2)02 (3a)02 (3b)06 (4sa)06 (4sb)03 (7)01 (8a) (8p)00 (9)01 (10)04,"GE,  后Post",,,,R0 D1+,,10.79,8.1,1.58,156.5,209.0,3.43,26.0,22.0,191.0,74.0,9.0,28.21,9.41,62.0,221.0,40.0,22.0,4.7,4.6,64.0,227.0,71.3,49.1,16.5,2.98,0.0,14.4,9.0,0.9,1.11,1.43,14.2,,1.08,7.4,1.92,,无,, P0,H0, 未做,ck（+）,,,,,92.08278580814716,1438333
1500026,杨志武,583378,男,54,T1b,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+,0.0,23,硬型（sci）,INFb,0.0,,,,,,,0.0,2015-01-04,2020-04-13,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren弥漫型,G3, (1a)04 (1b)00 (3a)04 (3b)012 (4sb)00 (4d)00 (5)00 (7)01 (8a)01 (8p)01 (9)00 (11p)00," L（幽门窦部）, 大弯侧Gre,",30,20,, R0 D2,,11.86,8.42,2.54,153.0,278.0,2.07,25.0,26.0,162.0,89.0,28.0,9.95,3.71,63.0,252.0,42.0,21.0,4.9,5.0,70.0,296.0,81.1,61.7,17.7,3.48,6.8,7.1,5.7,34.0,0.758,1.28,10.1,16.2,2.81,7.92,3.27,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,63.27201051248357,1500026
1500036,闫玉福,584532,男,44,T3,N3a,M0,ⅢB,1,4,2.0,1.0,1.0,1.0, 慢性炎症（+）,12.0,21,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2015-01-04,2016-12-16,2,,,XELOX,,,,,,6, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren弥漫型,G3, (1a)00 (1b)00 (2)00 (3a)22 (3b)00 (4sa)11 (4sb)00 (4d)00 (5)00 (6)15 (7)14 (8a)33 (8p)01 (9)00 (10)11 (11p)11 (11d)12 (12a)11,G 前Ant 大弯侧Gre  后Post ,60,30,10,R0 D2,,5.12,3.04,1.42,150.6,228.0,2.36,22.0,22.0,119.0,100.0,25.0,16.79,6.9,70.0,237.0,46.0,24.0,7.5,4.4,67.0,225.0,60.1,40.1,16.1,2.49,0.2,15.4,20.2,1.0,0.335,1.76,11.0,163.0,1.63,15.6,1.67, 未做,无,,P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-) CD34(+)， S100(+),,,,,23.390275952693823,1500036
1500193,齐秀英,585055,女,46,T1a,N0,M0,ⅠA,1,2,0.0,0.0,0.0,0.0, 肠化生+,0.0,14,髓样型（med）,INFa,0.0,,,1.0,,,,0.0,2015-01-05,2020-04-13,1,,,,,,,,,0,  管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 Lauren肠型,G3, (1a)0/14 (1b)0/0 (3a)0/4 (3b)0/0 (4sb)0/0 (4d)0/0 (5)0/0 (6)0/0 (7)0/0 (8a)0/1 (9)0/3 (11p)0/2," L（幽门窦部）, 小弯侧Less, 后Post,",13,10,2, R0 D2,,3.02,1.31,1.27,144.9,171.0,2.01,22.0,24.0,143.0,47.0,8.0,10.19,4.04,71.0,212.0,45.0,26.0,4.9,5.3,51.0,202.0,82.3,43.7,30.2,1.45,0.2,4.8,11.1,6.0,1.33,3.3,14.5,6.88,0.2,6.18,2.7, 未做,无, 无, P0,H0, 未做," CK+, Vimentin散在+， VEGF-， CMET-",,,,,63.23915900131406,1500193
1501077,王文名,584573,男,47,T3,N3a,M0,ⅢB,1,5,2.0,1.0,1.0,1.0, 慢性炎症（+）,13.0,23,中间型（int）,INFc,3.0,,,1.0,,,,0.0,2015-01-13,2017-12-07,2,,,XELOX,,,,,,4, 低粘附腺癌60% 低分化腺癌（G3)(por)40%Lauren弥漫型,G3, (1a)00 (1b)00 (2)01 (3a)89 (3b)22 (4sb)00 (4d)23 (5)00 (6)00 (7)01 (8a)01 (8p)01 (9)01 (11p)02 (12b)01 (12p)11   (3a、5)组软组织可见癌," ML 前Ant, 后Post, 小弯侧Less,",35,20,10, R0 D2,,4.34,2.55,1.35,138.0,304.0,1.98,11.0,13.0,129.0,49.0,10.0,14.95,6.48,65.0,243.0,43.0,22.0,4.4,3.2,79.0,291.0,78.1,43.2,30.6,1.41,0.4,11.5,6.6,2.4,0.732,2.62,12.9,6.21,1.04,16.38,1.26,,无,, P0,H0, 未做,CK + Vimentin散在+ VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,34.78975032851511,1501077
1500137,韩凤科,582565,男,54,T4a,N3a,M1, Ⅳ,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,9.0,36,硬型（sci）,INFc,0.0,,,,,,,0.0,2015-01-05,2016-07-30,2,,,,,,,,,0, 低粘附腺癌70 粘液腺癌（muc）20 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)00 (1b)35 (2)02 (3a)47 (3b)01 (4sa)00 (4sb)00 (4d)04 (5)02 (6)27 (7)01 (8a)02 (8p)01 (9)03 (11p)01 (12a)00  (3a、12a)组软组织内可见癌结节(+)," LMU 后Post, 小弯侧Less,",60,60,10,,R2,4.33,2.41,1.21,122.2,205.0,3.25,9.0,12.0,130.0,70.0,8.0,7.39,3.11,65.0,159.0,42.0,23.0,5.1,6.9,81.0,323.0,66.7,47.7,16.8,2.84,0.3,11.2,18.4,1.4,0.69,1.51,12.9,19.3,1.53,24.32,167.7,,粟粒状,, p1盆(M1 PER),H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,18.791064388961892,1500137
1500084,赵春,584603,男,46,T1b,N0,M0,ⅠA,1,0,1.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,34,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2015-01-04,2020-04-13,1,,,,,,,,,0, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3, (1a)03 (1b)05 (3a)04 (3b)02 (4sb)00 (4d)05 (6)05 (7)(9)02 (8a)01 (8p)03 (11p)04," L（幽门窦部）, 前Ant,",15,15,6, R0 D2,,5.68,2.44,2.82,159.6,195.0,2.04,16.0,17.0,139.0,67.0,40.0,8.69,3.35,67.0,266.0,47.0,20.0,4.6,4.1,77.0,222.0,81.3,50.7,25.8,1.97,0.2,4.6,12.5,4.1,0.401,0.89,11.5,102.0,1.95,10.47,1.05,,无, 无, P0,H0, 未做,CK+， Vimentin散在+， VEGF-， CMET-,,,,,63.27201051248357,1500084
1500575,张士华,582583,男,51,T2,N0,M0, ⅠB,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,33,中间型（int）,INFc,0.0,,,,,,,0.0,2015-01-08,2022-09-01,1,,,XELOX,,,,,,6,浸润溃疡型低粘附性癌 Lauren弥漫型,GX, (1a)0/0 (1b)0/3 (2)0/0 (3a)0/8  (3b)0/0 (4sb)0/1 (4d)0/5 (5)0/0 (6)0/5 (8a)0/5 (8p)0/2 (9)0/1 (11p)0/3 (12a)0/0," M（胃体部）, 后Post,",40,30,8, R0 D2,,10.48,6.43,3.22,156.6,320.0,3.11,22.0,25.0,133.0,100.0,21.0,12.42,4.7,68.0,273.0,44.0,24.0,4.8,4.2,67.0,261.0,66.4,29.5,12.7,2.32,0.2,5.6,24.9,5.2,0.546,0.742,11.6,5.0,1.01,3.25,1.15, 未做,无, 无, P0,H0, 未做," CK+, Vimentin-, VEGF-, CMET-, CD34+, S-100+.",,,,,91.75427069645204,1500575
1502828,段福平,585135,男,50,T1a,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+,0.0,20,硬型（sci）,INFc,0.0,,1.0,1.0,,,,0.0,2015-01-26,2020-04-13,1,,,,,,,,,0,浅表隆起型低粘附性癌（粘膜内癌） Lauren弥漫型,GX, (1a)0/0 (1b)0/1 (3a)0/3 (3b)0/0 (4sb)0/0 (4d)0/7 (5)0/2 (6)0/1 (7)0/1 (8a)0/1 (8p)0/1 (9) 0/1(11p)0/2," L（幽门窦部）, 大弯侧Gre,",25,20,3, R0 D2,,6.86,3.71,2.53,154.0,279.0,3.41,29.0,24.0,123.0,88.0,13.0,24.87,8.64,65.0,322.0,44.0,21.0,5.2,5.0,71.0,360.0,72.4,47.6,20.9,2.28,0.2,9.8,15.7,1.5,0.583,1.04,9.05,14.4,1.34,15.84,2.46, 未做,无, 无, P0,H0, 未做, CK（+） Vimentin部分（+） VEGF散在弱（+） CMET（-）,,,,,62.54927726675427,1502828
1500557,孙玉胜,584180,男,59,T3,N2,M0, ⅢA,1,4,0.0,1.0,1.0,1.0, 肠化生+,3.0,5,中间型（int）,INFc,0.0,,,,,,,0.0,2015-01-08,2015-10-21,2,,,奥沙利铂 亚叶酸钙 替加氟,,,,,,3, 低分化腺癌（G3)(por)80 粘液腺癌（muc）20 Lauren肠型,G3, (1a)00 (1b)00 (2)00 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)02 (6)22 (7)11 1a，3a，3b，6 软组织可见癌,G 前Ant 后Post 小弯侧Less ,45,40,12,,R2,5.74,3.06,1.98,137.0,198.0,3.43,17.0,23.0,109.0,,10.0,6.58,2.63,58.0,241.0,38.0,20.0,5.7,6.2,76.0,415.0,76.5,52.2,18.9,2.76,0.0,7.9,13.1,6.1,0.977,1.31,10.5,13.9,2.26,11.49,3.64, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,9.395532194480946,1500557
1500912,李桂兰,585022,女,70,T3,N0,M0, ⅡA,1,5,2.0,0.0,0.0,1.0, 肠化生+,0.0,18,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2015-01-12,2021-05-17,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)00 (3a)03 (3b)00 (4sb)00 (4d)01 (5)00 (6)01 (7)02 (8a)02 (8p)01 (9)02 (11p)01 (12a)00 (12p)01 (14v)03," LM 小弯侧Less,",55,35,, R0 D2+,,6.42,3.46,2.49,127.0,252.0,2.95,21.0,25.0,195.0,84.0,13.0,10.89,4.25,68.0,190.0,39.0,29.0,5.2,5.5,63.0,293.0,58.5,32.7,19.3,1.69,0.1,7.7,30.6,1.9,0.839,2.66,16.5,51.7,1.06,3.15,1.92,,无, 无, P0,H0, 未做,CK + Vimentin散在+ VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,76.11695137976346,1500912
1500648,吴淑凤,584240,女,40,T2,N0,M0, ⅠB,1,2,2.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,15,髓样型（med）,INFc,0.0,,,1.0,,,,0.0,2015-01-08,2021-05-17,1,,,,,,,,,3,溃疡型混合型癌（低分化管状腺癌占70%，低黏附性癌占30%） Lauren弥漫型,G3," (1a) 0/0,(1b)0/3 ,(3a)0/3， (3b)0/0， (4sb)0/2 ,(4d)0/2， (5)0/0， (6)0/2， (7)0/2， (8a)0/1， (9)0/0"," L（幽门窦部）, 小弯侧Less,",25,20,5, R0 D2,,6.47,3.98,1.99,130.4,258.0,2.04,17.0,27.0,135.0,46.0,8.0,13.03,4.46,70.0,197.0,44.0,26.0,5.1,2.7,52.0,235.0,67.9,46.2,15.7,2.94,0.1,5.8,23.0,2.6,1.28,2.35,14.3,82.8,2.32,3.42,1.44, 未做,无, 无, P0,H0, 未做," CK+, Vimentin部分+， VEGF-， CMET-， CD34(脉管+)， S-100（神经+）",,,,,76.24835742444152,1500648
1500993,王秀荣,585712,女,42,T4b,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,20.0,25,髓样型（med）,INFc,0.0,,,1.0,,,,0.0,2015-01-12,2017-06-09,2,,,XELOX,,,,,,6,低粘附性癌， Lauren弥漫型,GX, (1a)1/1 (1b)0/0 (3a)6/6 (3b)2/3 (4sb)0/0 (4d)6/9 (5)0/0 (6)0/1 (7)1/1 (8a)1/1 (8p)1/1 (9)2/2 5组软组织内可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,60,10,,R1,6.52,4.63,1.32,50.0,769.0,3.67,16.0,21.0,132.0,44.0,8.0,5.12,1.99,48.0,164.0,30.0,18.0,4.4,4.5,30.0,165.0,81.9,42.4,27.3,1.55,0.1,7.4,7.6,4.9,1.16,1.58,7.1,16.3,0.832,11.17,6.2, 未做,无, 无, P0,H0, 未做, CK+， Vimentin部分+， VEGF-， CMET-， CD34（脉管周+）， S-100（神经+）,,,,,28.876478318002626,1500993
1501076,王凤贤,584739,女,74,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,11,中间型（int）,INFb,0.0,,,1.0,,,,0.0,2015-01-13,2021-05-17,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)00 (3b)02 (4sb)00 (4d)02 (5)00 (6)01 (7)06 (8a)00 (9)00 (11p)00," L（幽门窦部）, 小弯侧Less,",10,8,5, R0 D2,,3.37,48.07,41.73,121.8,197.0,2.54,18.0,29.0,184.0,82.0,8.0,9.62,3.24,68.0,157.0,42.0,26.0,5.9,7.5,56.0,221.0,68.8,31.1,36.1,0.86,0.1,6.1,22.5,1.7,1.15,1.41,14.8,72.3,0.986,6.99,1.51, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin散在（+）、 VEGF（-）、 CMET（-）,,,,,76.08409986859395,1501076
1500911,魏显明,571936,男,65,T3,N0,M1, Ⅳ,1,2,0.0,1.0,1.0,0.0, 肠化生+,0.0,13,中间型（int）,INFb,2.0,,,,,,,0.0,2015-01-02,2015-11-15,2,多西他赛+奥沙利铂*1、奥沙利铂*雷替曲塞*5,1.0,奥沙利铂 雷替曲塞,奥沙利铂 雷替曲塞,希罗达口服,希罗达,雷替曲塞,替吉奥,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)03 (3a)00 (3b)00 (4sb)00 (4d)00 (5)01 (6)00 (7)03 (8a)02 (8p)01 (9)02 (11p)01," L（幽门窦部）, 前Ant, 小弯侧Less,",30,25,2,,R2,5.54,2.17,2.67,141.0,152.0,2.29,31.0,38.0,209.0,76.0,35.0,16.57,6.07,68.0,215.0,46.0,22.0,4.9,6.3,91.0,322.0,71.2,36.3,31.2,1.16,0.8,11.1,14.6,8.7,0.69,1.73,9.25,28.8,6.43,14.28,12.76,,无, 无, P0,H1多（M1 HEP), 未做, CK+， Vimentin部分-， VEGF-， CMET-， ,,,,,10.413929040735873,1500911
1501732,翟朝花,585159,女,48,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,14,,,0.0,,,1.0,,,,0.0,2015-01-16,2020-12-17,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)00 (1b)02 (3a)02 (3b)00 (4sb)00 (4d)02 (5)01 (6)02 (7)02 (8a)01 (8p)00 (9)02 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",10,10,8, R0 D2,,5.25,3.24,1.53,133.0,234.0,2.36,9.0,13.0,154.0,38.0,9.0,15.22,5.64,72.0,204.0,45.0,27.0,5.3,3.5,65.0,269.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK+， Vimentin散在+， VEGF-， CMET-,,,,,71.02496714848883,1501732
1500676,姚洪岩,584571,女,44,T2,N0,M0, ⅠB,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,27,硬型（sci）,INFc,0.0,,,,,,,0.0,2015-01-08,2021-05-24,1,,,S1,,,,,,2, 粘液腺癌（muc）90% Lauren弥漫型,GX, (1a)03 (1b)00 (3a)04 (3b)00 (4sb)02 (4d)02 (5)00 (6)03 (7)03 (8a)02 (8p)04 (11p)02 (14v)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,20,10, R0 D2,,4.33,2.38,1.64,97.2,197.0,1.84,20.0,25.0,120.0,46.0,9.0,8.89,3.1,56.0,149.0,35.0,21.0,4.5,6.0,47.0,130.0,72.1,37.5,22.8,1.64,0.1,10.2,14.4,1.8,0.96,1.79,11.1,14.0,1.75,18.36,2.84, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,76.47831800262811,1500676
1500411,陶永刚,585587,男,39,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,29,,,0.0,,,,,,,0.0,2015-01-05,2019-08-07,0,,,SOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90% 低粘附腺癌10%,G3, (1a)01 (1b)02 (3a)04 (3b)01 (4sb)00 (4d)07 (5)00 (6)04 (7)07 (8a)01 (8p)02 (9)00 (11p)00," L（幽门窦部）, 小弯侧Less,",15,15,8, R0 D2,,4.06,2.0,1.68,151.6,160.0,2.12,38.0,35.0,158.0,28.0,15.0,10.12,3.63,59.0,310.0,40.0,19.0,5.0,7.5,69.0,262.0,70.1,47.3,17.1,2.77,0.1,15.0,10.9,1.1,0.814,1.71,7.8,17.0,2.26,5.99,1.26, 阳性+++,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,55.02628120893561,1500411
1501142,王翠英,585644,女,66,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+,0.0,8,中间型（int）,INFc,0.0,,,,,,,0.0,2015-01-13,2021-05-17,1,,,,,,,,,0, 低分化腺癌（G3)(por) 50乳头状癌（G1）（pap） 40 低粘附腺癌10 Lauren肠型,G3, (1a)00 (1b)00 (2)02 (3a)00 (3b)00 (4sa)00 (4sb)01 (4d)01 (5)00 (6)00 (7)00 (8a)01 (8p)00 (9)02 (11p)02 ," GE, SiewerⅢ, 小弯侧Less, 前Ant, 后Post,",60,40,5, R0 D2,,6.67,3.26,2.77,128.6,301.0,3.43,10.0,15.0,154.0,85.0,8.0,10.65,2.97,66.0,217.0,42.0,24.0,4.6,6.4,66.0,309.0,68.1,45.8,18.7,2.45,0.2,15.4,12.1,4.3,0.953,1.52,17.6,19.0,1.92,40.04,3.82, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-) ,,,,,76.08409986859395,1501142
1501034,关海红,586262,女,54,T3,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,3.0,19,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2015-01-12,2016-12-15,2,,,XELOX,,,,,,2, 低粘附腺癌 Lauren弥漫型,GX,小弯11 (1a)02 (1b)02 (3a)13 (3b)01 (4sb)00 (4d)14 (5)00 (6)00 (7)00 (8a)03 (8p)01 (9)01 (11p)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,27,10, R0 D2+,,3.19,1.76,0.87,141.5,162.0,2.84,14.0,17.0,182.0,40.0,8.0,11.13,4.78,69.0,228.0,43.0,26.0,5.3,5.9,80.0,226.0,74.9,43.5,22.5,1.93,0.4,5.8,17.1,7.5,0.636,2.43,14.6,35.4,1.85,8.34,5.95,,无, 无, P0,H0, 未做,CK + Vimentin部分+ VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,23.0946123521682,1501034
1501002,于风胶,585779,女,52,T4b,N0,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,32,中间型（int）,INFb,0.0,,,,,,,0.0,2015-01-12,2021-05-24,1,,,XELOX,,,,,,2, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】95 粘液腺癌（muc）5 Lauren肠型,G3, (1a)00 (1b)06 (3a)01 (3b)01 (4sb)00 (4d)012 (5)01 (6)02 (7)01 (8a) (9)06 (11p)01 (8p)01(3a) (3b) 软组织可见癌,G 前Ant 小弯侧Less 后Post ,70,60,10,,R1,7.35,5.65,1.19,57.7,494.0,5.16,10.0,12.0,127.0,54.0,7.0,8.74,2.95,61.0,138.0,39.0,22.0,4.4,3.6,53.0,137.0,65.7,42.7,18.9,2.26,0.5,9.8,19.1,2.1,1.63,2.76,12.7,59.6,0.2,10.01,4.98, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,76.34691195795006,1501002
1501033,王春,585655,女,56,T3,N2,M0, ⅢA,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+）,3.0,11,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2015-01-12,2018-05-23,2,,,AC,,,,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)11 (3a)22 (3b)00 (4sb)00 (4d)02 (5)00 (6)01 (7)01 (8p)01 (8a) (9)02 (11p)00 (14v)003b 软组织可见癌,G 前Ant 小弯侧Less 后Post ,35,20,8, D2 R0,,5.23,2.52,1.53,135.1,243.0,4.9,13.0,18.0,139.0,90.0,39.0,15.77,4.79,82.0,240.0,52.0,30.0,10.5,4.3,77.0,325.0,63.9,42.4,19.4,2.19,1.0,11.7,21.3,3.6,1.9,3.98,20.3,29.8,2.4,9.91,27.16, 未做,无, 无,P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,40.30880420499343,1501033
1500994,丁志芹,585810,女,62,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 肠化生+,3.0,19,硬型（sci）,INFb,0.0,,,1.0,,,,0.0,2015-01-12,2021-05-24,1,,,XELOX,XELOX,XELOX,XELOX,SOX,,5, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)07 (3a)00 (3b)00 (4sb)01 (4d)01 (5)01 (6)01 (7)22 (8a)11 (8p)02 (9)01 (11p)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,8,4, R0 D2,,3.6,1.73,1.62,139.1,125.0,2.01,25.0,35.0,160.0,71.0,10.0,25.06,8.76,62.0,146.0,39.0,23.0,4.3,5.3,59.0,114.0,81.3,52.3,23.5,2.23,0.4,3.9,13.5,1.4,0.764,1.72,15.8,51.1,1.85,31.16,2.86,,无, 无, P0,H0, 未做,"CK+, Vimentin部分+， VEGF-， CMET-",,,,,76.34691195795006,1500994
1501376,赵庆春,585722,男,58,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 肠化生++,16.0,25,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-01-14,2016-12-15,2,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40 Lauren弥漫型,G3, (1a)01 (1b)22 (2)02 (3a)33 (3b)11 (4sa)00 (4sb)01 (4d)01 (5)00 (6)11 (7)35 (8a)33 (8p)11 (9)11 (10)01 (11p)12 (12a)00 (12b)00,G 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,50,15,R0 D2,,4.27,2.08,1.66,143.3,211.0,1.09,29.0,31.0,135.0,77.0,10.0,10.84,3.66,79.0,211.0,46.0,33.0,5.6,5.3,76.0,341.0,60.6,43.2,15.8,2.73,0.0,10.2,26.3,1.0,0.935,2.99,19.1,55.2,1.11,6.35,1.07, 未做,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,23.028909329829172,1501376
1501320,迟桂敏,585799,女,57,T2,N0,M0, ⅠB,1,2,0.0,1.0,1.0,1.0, 肠化生+,0.0,24,髓样型（med）,INFa,0.0,,,1.0,,,,0.0,2015-01-14,2021-05-24,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)01 (4d)00 (5)01 (6)12 (7)03 (8a)01 (8p)01 (9)02 (11p)02 (12a)01,L（幽门窦部） 前Ant 小弯侧Less 后Post ,35,30,10, R0 D2,,8.75,5.61,2.61,149.1,186.0,2.33,31.0,34.0,134.0,96.0,12.0,10.11,4.4,65.0,173.0,43.0,22.0,5.2,4.2,62.0,238.0,63.7,45.4,17.5,2.59,0.4,10.6,23.0,2.9,1.39,1.6,15.6,32.8,1.13,16.06,9.88, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin散在(+)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,76.28120893561103,1501320
1501224,孙国存,585734,男,56,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,16,,,0.0,,,1.0,,,,0.0,2015-01-14,2019-08-07,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)01 (1b)01 (3a) 02(3b)01 (4sb)00 (4d)02 (5)00 (6)03 (7)02 (8a)01 (9)02 (11p)01," L（幽门窦部）, 小弯侧Less,",20,20,10, R0 D2,,6.16,3.56,1.81,156.5,332.0,3.33,30.0,25.0,164.0,102.0,50.0,8.97,3.57,68.0,264.0,43.0,25.0,4.7,5.2,61.0,295.0,63.8,37.2,24.2,1.54,0.4,11.7,22.0,7.8,0.975,1.65,13.8,80.7,0.2,5.78,3.17, 未做,无,, P0,H0, 未做,ck(+)  vimentin散在(+)  VEGF(-)  cMET(-) ,,,,,54.730617608409986,1501224
1501179,张艳军,585953,男,46,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,14,,,0.0,,,1.0,,,,0.0,2015-01-13,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)00 (1b)02 (3a)00 (3b)00 (4sb)00 (4d)04 (5)01 (6)06 (7)00 (8a)01 (8p)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",50,45,, R0 D2,,10.08,6.83,2.65,158.7,253.0,2.53,19.0,17.0,163.0,78.0,25.0,16.1,5.54,70.0,317.0,48.0,22.0,8.8,5.6,83.0,392.0,77.2,50.7,24.7,2.05,0.2,9.8,10.6,1.9,1.33,1.48,14.5,21.1,1.97,12.66,9.55, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin散在（+）、 VEGF（-）、 CMET（-）、,,,,,76.31406044678054,1501179
1501223,王富,587044,男,66,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,10.0,11,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-01-14,2022-09-01,1,,,SOX,SOX,S1,XELOX,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)11 (2)01 (3a)11 (3b)00 (4sb)00 (4d)66 (5)00 (6)22 (7)00 (9)00 软组织可见癌3a、3b、4d、5、6、9," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",100,50,12,,R2,7.48,5.68,1.0,91.6,360.0,,12.0,15.0,156.0,74.0,8.0,7.51,3.64,53.0,130.0,32.0,21.0,4.7,5.1,61.0,251.0,76.3,40.7,32.1,1.27,0.0,7.0,14.0,2.9,2.25,1.73,10.4,38.7,17.04,7.55,108.9,,无, 无, P0,H0, 未做,"CK+, Vimentin散在+， VEGF-， CMET-",,,,,91.55716162943494,1501223
1501812,郭凤琴,585836,女,70,T2,N1,M0, ⅡA,1,2,1.0,0.0,0.0,1.0, 肠化生+,1.0,19,髓样型（med）,INFc,0.0,,1.0,1.0,,,,1.0,2015-01-19,2021-05-24,1,,,,,,,,,0, 低粘附腺癌70% 低分化腺癌（G3)(por)30% Lauren混合型,G3, (1a)02 (1b)02 (3a)03 (3b)03 (4sb)00 (4d)12 (5)00 (6)00 (7)05 (8a)03 (8p)01 (9)00 (11p)01,L,15,10,6, R0 D2,,4.6,2.67,1.55,126.1,342.0,3.35,16.0,18.0,147.0,87.0,6.0,7.15,2.84,68.0,183.0,38.0,30.0,5.5,4.6,78.0,201.0,77.9,51.7,20.7,2.5,0.1,10.6,7.2,4.7,1.2,3.43,21.3,470.0,0.827,7.62,5.66, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin散在（+）、 VEGF散在（+）、 CMET散在（+）、 CD34+、 S-100+,,,,,76.11695137976346,1501812
1501349,王月英,585806,女,50,T2,N0,M0, ⅠB,1,3,0.0,1.0,1.0,0.0, 肠化生+,0.0,32,中间型（int）,INFc,2.0,,,1.0,,,,0.0,2015-01-14,2021-05-24,1,,,SOX,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren肠型,G3, (1a)01 (1b)00 (3a)012 (3b)02 (4sb)01 (4d)07 (5)00 (6)00 (7)04 (8a) (8p)01 (9)01 (11p)01 (12a) (12b)02 3b软组织可见癌,L（幽门窦部） 小弯侧Less 后Post ,,,,R0 D2,,8.39,4.41,3.11,148.5,258.0,2.49,11.0,18.0,217.0,70.0,24.0,8.3,0.29,71.0,253.0,43.0,28.0,4.7,7.5,70.0,371.0,79.3,53.4,22.4,2.38,0.2,8.2,9.0,1.5,1.54,2.52,17.2,22.2,2.75,47.08,10.96, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,76.28120893561103,1501349
1501426,周玉山,587086,男,55,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,8.0,36,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-01-15,2015-09-14,2,,,SOX,SOX,SOX,安慰剂联合紫杉醇,安慰剂联合紫杉醇,,5, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40 Lauren肠型,G3, (1a)06 (1b)01 (3a)12 (3b)23 (4sb)00 (4d)00 (5)22 (6)25 (7)14 (8a)02 (8p)01(9)02 (11p)02  (12a)04 (13)01,G 前Ant 后Post 大弯侧Gre  小弯侧Less ,80,60,15,R0 D2+,,5.41,3.64,1.33,137.0,285.0,3.01,37.0,26.0,198.0,60.0,12.0,5.29,2.6,59.0,212.0,36.0,23.0,4.5,4.9,72.0,215.0,65.3,45.7,16.1,2.84,0.2,15.8,7.1,1.0,0.643,2.25,10.5,23.5,0.49,6.31,3.89, 未做,无,,P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,7.9500657030223385,1501426
1501506,方绍波,585842,男,49,T2,N1,M0, ⅡA,1,5,0.0,1.0,1.0,1.0, 肠化生+,2.0,19,髓样型（med）,INFa,0.0,,,1.0,,,,0.0,2015-01-15,2022-09-01,1,,,SOX,SOX,SOX,AZD2281,,,9, 低分化腺癌（G3)(por)90% 低粘附腺癌10% Lauren肠型,G3, (1a)00 (1b)00 (3a)12 (3b)12 (4sb)00 (4d)06 (5)00 (6)03 (7)00 (8a)01 (8p)03 (9)00 (11p)02 (12a)00," L（幽门窦部）, 后Post,",35,25,8,,R1,4.09,1.75,1.91,75.6,216.0,2.44,11.0,13.0,99.0,42.0,6.0,8.25,3.26,53.0,191.0,33.0,20.0,4.1,5.5,73.0,300.0,80.9,54.4,21.8,2.5,0.1,6.6,10.8,3.3,0.226,1.85,11.9,32.4,0.855,5.04,3.13, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin散在（+）、 VEGF（-）、 CMET（-）、 CD56-、 CgA（-）、 Syn（-）、 CD34+、 S-100+,,,,,91.52431011826543,1501506
1501711,张军,587111,男,52,T1b,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+,0.0,12,中间型（int）,INFb,0.0,,,1.0,,,,0.0,2015-01-16,2021-05-24,1,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a)00 (1b)00 (3a)01 (3b)01 (4sb)01 (4d)01 (5)00 (6)04 (7)01 (8a)02 (8p)01 (9)00 (12a)00," L（幽门窦部）, 小弯侧Less,",10,8,5, R0 D2,,6.37,4.62,1.21,143.1,167.0,2.53,16.0,19.0,139.0,62.0,13.0,9.52,3.28,61.0,216.0,37.0,24.0,7.5,7.0,86.0,412.0,69.0,44.7,22.6,1.98,1.0,13.3,14.7,6.9,0.501,1.61,12.3,10.6,2.84,25.45,1.7,,无, 无, P0,H0, 未做, CK+， Vimentin散在+， VEGF-， CMET-,,,,,76.21550591327201,1501711
1502005,张雨林,587386,男,74,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,1.0, 肠化生+,1.0,19,中间型（int）,INFb,0.0,,,,,,,0.0,2015-01-20,2017-07-27,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)16 (3a)02 (3b)00 (4sa)01 (4sb)00 (4d)00 (5)00 (6)05 (7)01 (8a)01 (9)01 (11p)01," L（幽门窦部）, 后Post,",90,80,10, R0 D2,,6.66,4.33,1.61,120.8,242.0,4.45,22.0,24.0,157.0,60.0,30.0,8.29,2.99,57.0,145.0,33.0,24.0,4.6,7.0,49.0,202.0,53.9,37.3,14.6,2.55,0.1,10.4,33.5,2.2,0.535,1.03,10.9,174.0,0.721,7.11,11.26, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,30.190538764783177,1502005
1502078,杨万礼,587375,男,58,T3,N1,M0, ⅡB,1,2,2.0,1.0,1.0,1.0, 肠化生+,1.0,16,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2015-01-19,2019-04-15,0,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)01 (4d)00 (5)01 (6)12 (7)03 (8a)01 (8p)01 (9)02 (11p)02 (12a)01,L（幽门窦部） 前Ant 小弯侧Less ,45,40,8, R0 D2,,7.33,3.81,2.74,135.2,195.0,2.79,32.0,27.0,175.0,103.0,12.0,11.37,4.39,66.0,220.0,39.0,27.0,4.7,8.3,76.0,267.0,62.9,32.0,19.8,1.62,0.3,8.9,26.2,2.9,1.35,1.8,13.0,9.87,35.2,3.18,134.8, 未做,无,, P0,H0,,ck(+)  vimentin散在(+)  VEGF(-)  cMET(—)  CD34(+)  S100(+),,,,,50.82128777923784,1502078
1501935,李茂春,587170,男,70,T3,N3a,M0,ⅢB,1,2,0.0,,,, 慢性炎症（+）,8.0,19,中间型（int）,INFb,1.0,,,1.0,,,,0.0,2015-01-19,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a) 00(1b)00 (3a)04 (3b) 11 (4d)02 (5) 00(6)66 (7)15 (8a) (8p)01 (9)00 (11p)00 （6）(8a) (8p)软组织可见癌,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,40,6, R0 D2,,9.58,6.68,1.95,51.0,334.0,4.58,15.0,20.0,122.0,68.0,12.0,8.29,3.77,60.0,161.0,34.0,26.0,6.5,5.5,57.0,270.0,52.7,34.6,16.8,2.06,0.2,2.9,43.3,1.3,0.579,2.89,11.4,8.14,0.242,16.29,12.39, 未做,无,, P0,H0, 未做,ck(+)  vimentin散在(+)  VEGF(-)  cMET（-) ,,,,,76.11695137976346,1501935
1501436,孙仁,582040,男,51,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+,2.0,16,中间型（int）,INFb,1.0,,,1.0,,,,0.0,2015-01-15,2019-08-07,0,SOX*1,1.0,SOX,替吉奥单药,,,,,2, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 Lauren肠型,G3, (1a)02 (1b)02 (3a)00 (3b)00 (4sb)11 (4d)02 (5)00 (6)00 (7)01 (8a)11 (8p)03 (9)02 (11p)01 (12a)00 (14v)01 软组织可见癌," L（幽门窦部）, 前Ant,",30,30,12,,R1,9.97,6.48,2.41,157.9,129.0,2.73,9.0,35.0,137.0,89.0,64.0,15.59,4.93,65.0,280.0,40.0,25.0,5.0,5.9,64.0,360.0,,,,,,,,,,,,,1.22,5.5,1.43, 未做,无, 无, P0,H0, 未做, CK(+)、 Vimentin散在（+）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,54.69776609724047,1501436
1502006,张永奎,586992,男,55,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,16,,,0.0,,,1.0,,,,0.0,2015-01-20,2019-08-07,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)03 (3a)01 (3b)04 (4sb)01 (4d)02 (5)00 (6)01 (7)00 (8a)01 (9)00 (11p)00 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",20,10,, R0 D2,,4.36,2.73,1.25,165.0,193.0,2.27,29.0,29.0,212.0,89.0,29.0,10.37,3.1,72.0,253.0,39.0,33.0,4.7,8.2,89.0,350.0,61.8,37.1,20.6,1.8,0.2,18.3,14.0,3.5,0.988,2.31,20.8,5.0,2.0,11.76,1.14, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin散在（+）、 VEGF（-）、 CMET（-）,,,,,54.533508541392905,1502006
1501780,唐喜忠,587316,男,44,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,13,中间型（int）,INFb,0.0,,,,,,,,2015-01-17,2022-09-01,1,,,SOX,SOX,SOX,替吉奥,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)04 (4sb)00 (4d)00 (6)01 (7) 03(8a)01 (8p)00 (9)02 (11p) 02(12a)00," L（幽门窦部）, 小弯侧Less,",60,50,, R0 D2,,8.0,5.64,1.77,107.2,201.0,1.7,18.0,29.0,140.0,42.0,14.0,8.88,4.08,51.0,254.0,35.0,16.0,5.4,7.7,65.0,301.0,75.0,54.0,16.5,3.27,0.1,12.5,8.4,1.0,0.344,1.34,7.99,9.93,0.824,6.06,2.22, 未做,无,, P0,H0, 未做,ck(+) VEGF(-) CD34(+),,,,,91.45860709592641,1501780
1502165,高照乾,587346,男,72,T4b,N1,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,2.0,2,中间型（int）,INFb,0.0,,,1.0,,,,1.0,2015-01-21,2015-03-13,2,,,,,,,,,0,"（低粘附性癌占70%,低分化腺癌占30%） Lauren肠型",G3,（1a）0/0 (1b)0/0 (2)0/0 (3a)0/0 (3b)0/0 (4d)1/1 (5)0/0 (6)1/1 (7)0/0 (8a)0/0。1a，1b，2，3a，3b，4d，5，6，7，8a软组织可见癌结节（+），大网组织（-），胰腺下缘结节内见癌。," L（幽门窦部）, 大弯侧Gre, 后Post, 前Ant,",60,50,15,,R2,4.07,3.1,0.57,139.0,175.0,3.18,14.0,43.0,342.0,93.0,20.0,23.0,9.66,80.0,131.0,43.0,37.0,3.4,8.3,101.0,587.0,33.7,19.4,12.2,1.59,0.0,2.9,58.6,4.0,0.423,2.54,28.2,5.0,5.72,642.6,300.0, 未做,无, 无, P0,H0, 未做, CK +，Vimentin散在（+）， VEGF（-）， CMET部分（弱+）， CD34（脉管+）， S-100（神经+）。,,,,,1.6754270696452036,1502165
1501970,姜清深,587436,男,81,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,33,中间型（int）,INFb,0.0,,,,,,,0.0,2015-01-20,2020-03-27,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren弥漫型,G3, (1a)03 (1b)01 (3a)05 (3b)02 (4sb) (4d)00 (5)02 (6) (7)0 11 (8a)00 (9)01 (11p)02 (12a)00, L（幽门窦部） 前Ant 小弯侧Less 后Post ,30,20,8, R0 D2+,,5.05,2.88,1.78,98.6,391.0,2.68,26.0,22.0,138.0,69.0,12.0,7.43,3.23,61.0,135.0,34.0,27.0,3.8,6.8,95.0,256.0,65.7,45.2,19.0,2.38,0.3,11.2,19.7,1.9,0.349,3.15,19.3,202.0,0.99,10.08,1.56, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,62.187910643889616,1501970
1501944,徐信荣,587119,女,58,T2,N1,M0, ⅡA,1,2,2.0,0.0,0.0,1.0, 肠化生+,2.0,14,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2015-01-19,2021-05-24,1,,,SOX,,,,,,6, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)00 (5)01 (6)02 (7)01 (8a)02 (8p)02 (9)01 (11p)11 (12a)02 (14v)12,L（幽门窦部） 小弯侧Less ,20,15,10,R0,,12.75,6.97,4.89,155.2,365.0,2.95,16.0,19.0,178.0,102.0,17.0,7.96,2.14,81.0,263.0,47.0,34.0,5.5,4.1,71.0,316.0,56.0,26.7,21.6,1.24,0.29,9.1,39.0,2.2,0.776,11.3,21.6,121.0,0.509,6.63,2.87, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,76.11695137976346,1501944
1503658,张桂芝,582525,女,66,T1b,N1,M0, ⅠB,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,1.0,13,中间型（int）,INFb,3.0,,,,,,,0.0,2015-02-02,2021-05-17,1,,,XELOX,,,,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren肠型,G3, (1a)01 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)01 (5)00 (6)14 (7)00 (8a)01 (8p)02 (9)02 (11p)01," L（幽门窦部）, 前Ant,",25,20,3, R0 D2+,,6.03,4.36,1.13,125.4,204.0,2.84,13.0,17.0,148.0,62.0,11.0,15.08,4.27,71.0,238.0,44.0,27.0,5.6,3.7,74.0,256.0,,,,,,,,,,,,,0.926,13.93,3.58,,无, 无, P0,H0, 未做,CK + Vimentin(-)间质散在(+) VEGF- CMET- ,,,,,75.42706964520367,1503658
1502258,赵艳坤,587484,男,38,T2,N1,M0, ⅡA,1,3,2.0,0.0,0.0,0.0, 肠化生+,1.0,22,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-01-21,2021-05-24,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren弥漫型,G3, (1a)02 (1b)00 (3a) 03(3b)04 (4sb)00 (4d)00(6)19 (7)02 (8a) (8p)01 (9)01 (11p)00 (12a)00, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,30,25,8, R0 D2,,5.65,3.2,1.96,150.6,210.0,2.58,14.0,14.0,163.0,57.0,10.0,7.63,3.8,68.0,267.0,46.0,22.0,4.0,3.0,89.0,428.0,,,,,,,,,,,,,1.2,13.76,1.08, 未做,无,, P0,H0, 未做,ck(+)  vimentin散在(+)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,76.05124835742444,1502258
1501905,贾宝元,582573,男,52,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,37,中间型（int）,INFb,0.0,,,,,,,0.0,2015-01-19,2019-08-07,0,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)04 (2)03 (3a)06 (3b)02 (4sa)00 (4sb)00 (4d)08 (5)01 (6)02 (7)03 (8a)01 (8p)02 (9)01 (11p)01," M（胃体部）, 小弯侧Less,",30,20,10, R0 D2,,4.27,2.42,1.49,148.7,194.0,2.49,32.0,30.0,165.0,90.0,22.0,24.66,10.11,66.0,292.0,43.0,23.0,4.2,7.4,59.0,264.0,61.4,37.5,19.4,1.93,0.1,9.9,27.0,1.8,1.15,1.41,13.2,33.5,1.14,5.69,1.49,,无, 无, P0,H0, 未做, CK+， Vimentin散在+， VEGF-， CMET-,,,,,54.566360052562416,1501905
1502334,李燕,587363,女,54,T3,N2,M0, ⅢA,1,5,2.0,0.0,0.0,1.0, 慢性炎症（+）,5.0,46,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-01-22,2020-10-12,1,,,,,,,,,1,（低粘附性癌约占90%，低分化管状腺癌约占10%） Lauren弥漫型,G3, (1a)0/2 (1b)0/2 (3a)2/8 (3b)0/4 (4sb)0/1 (4d)2/14 (5)0/0 (6)1/8 (7)0/0 (8a)0/1 (8p)0/1 (9)0/2 (11p)0/3 (12p)0/0," L（幽门窦部）, 小弯侧Less,",65,55,12, R0 D2,,7.51,3.69,3.11,139.0,337.0,3.01,9.0,11.0,149.0,51.0,9.0,12.76,4.2,65.0,230.0,39.0,26.0,5.0,4.5,73.0,267.0,75.6,25.2,42.8,0.59,0.1,6.0,16.6,4.6,0.715,2.05,15.8,21.0,0.2,5.64,25.66, 未做,无, 无, P0,H0, 未做," CK(+) ,Vimentin散在（+）， VEGF（-）， CMET（—） ，CD34（脉管周围+）， S-100（神经+）",,,,,68.65965834428384,1502334
1502272,李士忠,587490,男,51,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,13,,,0.0,,,1.0,,,,0.0,2015-01-21,2021-05-17,1,,,,,,,,,0, 中度不典型增生 重度不典型增生 管状腺癌（高分化【G1】【tub1】）,G1, (1a)01 (1b)01 (3a)02 (3b)01 (4sb)02 (4d)01 (5)0 (6)03 (7)01 (9)01," L（幽门窦部）, 小弯侧Less,",10,10,, R0 D2,,6.5,3.73,1.98,157.5,232.0,2.49,11.0,15.0,163.0,71.0,9.0,21.98,8.93,78.0,253.0,49.0,29.0,4.8,3.9,86.0,310.0,65.3,37.9,21.5,1.76,0.1,13.4,16.9,3.8,0.869,2.07,16.6,20.2,0.453,8.09,2.91,,无,, P0,H0, 未做,CK + Vimentin散在+ VEGF- CMET- ,,,,,75.82128777923784,1502272
1503326,孙吉平,585573,男,56,T3,N0,M0, ⅡA,1,5,2.0,0.0,0.0,1.0, 肠化生+,0.0,20,髓样型（med）,INFc,0.0,,1.0,,,,,0.0,2015-01-29,2016-04-06,2,,,XELOX,XELOX,XELOX,AZD2281,,,4, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3, (1a)03 (1b)01 (3a)03 (3b)00 (4sb)00 (4d)05 (5)00 (6)00 (7)01 (8a)03 (8p)00 (9)02 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,25,15, R0 D2+,,6.75,3.59,2.12,145.1,233.0,3.11,32.0,28.0,164.0,72.0,12.0,13.32,6.33,67.0,227.0,42.0,25.0,5.2,6.2,76.0,171.0,72.9,37.8,31.3,1.21,0.0,10.9,13.3,1.5,0.952,1.96,13.1,147.0,1.27,24.06,2.13,,无,, P0,H0, 未做,CK + Vimentin(-) 间质散在(+) VEGF弱(+) CMET- CD34(脉管周+)  S-100(神经+),,,,,14.224704336399475,1503326
1502410,尹广明,587640,男,49,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,19,中间型（int）,INFb,0.0,,,,,,,0.0,2015-01-22,2021-05-24,1,,,SOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)01 (3a)04 (3b)00 (4sb)00 (4d)01 (5)00 (6)06 (7)01 (8a)01 (8p)00 (9)02 (11p)01 (12a)00," L（幽门窦部）, 后Post,",25,20,10, R0 D2+,,7.66,4.78,2.51,143.0,193.0,2.84,37.0,30.0,172.0,49.0,23.0,5.44,2.68,70.0,303.0,44.0,26.0,5.5,5.6,47.0,214.0,71.8,31.5,35.4,0.89,0.1,8.8,16.9,4.6,1.13,2.06,16.2,149.0,3.12,32.02,1.67,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,76.01839684625493,1502410
1502440,姚淑杰,587622,女,60,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,1.0, 肠化生+,1.0,45,中间型（int）,INFa,3.0,,,,,,,0.0,2015-01-22,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80  乳头状癌（G1）（pap）20 Lauren肠型,G3, (1a)03 (1b)01 (3a)09 (3b)02 (4sb)01 (4d)06 (5)00 (6)111 (7)03 (8a) (8p)01 (9)04 (11p)01, L（幽门窦部） 前Ant 大弯侧Gre  小弯侧Less ,60,60,4,R0 D2,,3.95,2.29,1.32,91.0,327.0,3.21,26.0,29.0,166.0,88.0,29.0,3.37,1.28,58.0,205.0,36.0,22.0,4.4,6.3,49.0,241.0,55.1,37.9,13.3,2.85,0.3,12.9,28.8,1.8,0.749,2.52,16.4,20.35,5.51,11.44,2.19, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)CD34(+)， S100(+),,,,,76.01839684625493,1502440
1502409,龚克辛,587609,男,47,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,7,髓样型（med）,INFa,0.0,,,1.0,,,,0.0,2015-01-22,2021-05-17,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40 Lauren肠型,G3, (1a)00 (1b)01 (3a)00 (3b)01 (4sb)00 (4d)01 (5)00 (6)02 (7)00 (8a)01 (8p)00 (9)00 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",20,10,2,R0 D2,,10.03,7.55,1.76,157.0,167.0,2.49,52.0,46.0,232.0,86.0,18.0,12.69,4.83,71.0,333.0,46.0,25.0,5.0,5.1,43.0,422.0,58.0,27.8,25.1,1.11,0.1,6.6,33.6,2.1,1.17,2.57,21.5,8.3,2.03,10.12,10.78, 未做,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-),,,,,75.78843626806832,1502409
1502233,罗胜义,587646,男,67,T4b,N3a,M1, Ⅳ,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,9.0,13,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-01-21,2015-09-23,2,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20 Lauren弥漫型,G3, (1a)34 (1b)12 (3a)00 (3b)11 (4sb)00 (4d)00 (5)11 (6)11 (7)24," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,30,8,,R2,4.96,2.67,1.76,134.0,319.0,2.15,28.0,36.0,217.0,82.0,9.0,7.67,2.58,63.0,200.0,37.0,26.0,5.4,6.7,56.0,239.0,55.9,29.3,22.2,1.32,0.1,7.3,33.9,4.1,3.06,3.98,16.5,164.0,1.44,12.16,2.28,,无, 无, P0,H0, 未做,"CK+, Vimentin散在+， VEGF-， CMET-",,,,,8.04862023653088,1502233
1503419,王敏,587557,女,58,T4b,N0,M0, ⅢA,1,3,2.0,0.0,0.0,1.0, 肠化生+,0.0,31,中间型（int）,INFc,0.0,,1.0,1.0,,,,0.0,2015-01-29,2021-07-01,1,,,,,,,,,2, 低粘附腺癌80%， 低分化腺癌（G3)(por)20%。 Lauren弥漫型,G3, (1a)0/1 (1b)0/3 (3a)0/6 (3b)0/1 (4sb)0/0 (4d)0/5 (5)0/0 (6)0/6 (7)0/0 (8a)0/1 (8p)0/3 (9)0/1 (11p)0/1 (14v)0/3 (14a)0/0.4d软组织内可见癌（+）.," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,50,10,,R1,8.14,4.85,2.35,111.7,344.0,3.49,21.0,25.0,184.0,84.0,4.0,12.18,3.87,70.0,228.0,42.0,28.0,4.9,4.6,62.0,186.0,60.5,37.5,21.3,1.76,0.1,13.1,24.8,0.9,1.6,3.09,17.8,41.4,1.85,29.27,1.33, 未做,无, 无, P0,H0, 未做," CK +,Vimentin 散在+，VEGF散在弱+， CMET-， CD34（脉管周+） S-100（神经+）",,,,,77.03679369250985,1503419
1502708,金仁吉,587594,男,70,T4b,N1,M1, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,2.0,3,中间型（int）,INFa,2.0,,1.0,1.0,,,,0.0,2015-01-26,2015-08-04,2,,,SOX,SOX,紫杉醇联合替吉奥,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60% 乳头状癌（G1）（pap）30% 低粘附腺癌10% Lauren肠型,G3, (1a)00 (1b)00 (3a)22 (3b)00 (4sb)00 (4d)00 (5)00 (6)00 (7)01 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,90,20,,R2,17.16,14.63,1.73,46.7,531.0,3.08,13.0,15.0,132.0,53.0,8.0,11.91,5.92,54.0,129.0,32.0,22.0,7.7,6.17,67.0,234.0,63.3,47.1,15.0,3.14,0.0,23.5,12.6,0.5,0.497,2.89,17.4,84.7,47.42,1000.0,7.0, 未做,无, 无, P0,H1单（M1 HEP), 未做, CK（+）、 Vimentin散在（+）、 VEGF弱（+）、 CMET（-）、 CD34+、 S-100+,,,,,6.241787122207621,1502708
1502784,徐淑霞,588341,女,60,T1b,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,18,中间型（int）,INFb,0.0,,1.0,1.0,,,,0.0,2015-01-26,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren弥漫型,G3, (1a)00 (1b)04 (3a)04 (3b)00 (4sb)00 (4d)03 (5)00 (6)01 (7)04 (8a)01 (8p)01 (9)00 (11p)00 (11d)00," LM 小弯侧Less,",45,30,6, R0 D2,,7.65,4.55,2.46,157.8,321.0,3.67,21.0,26.0,140.0,107.0,73.0,8.34,2.53,73.0,237.0,46.0,27.0,5.1,7.1,48.0,208.0,69.4,48.2,13.8,3.49,0.1,17.1,12.1,2.6,1.19,1.07,12.6,14.5,2.46,15.9,1.96,,无, 无, P0,H0, 未做,"CK+, Vimentin部分+， VEGF弱+， CMET-",,,,,75.88699080157687,1502784
1502891,芦永军,588340,男,48,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+,5.0,22,中间型（int）,INFb,1.0,,1.0,1.0,,,,2.0,2015-01-27,2022-09-01,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren肠型,G3, (1a)03 (1b)05 (3a)28 (3b)33 (4sb)00 (4d)00 (5)02 (6)00 (7)01 (8a) (8p)00 (9)00 (3a 3b)软组织可见癌 小弯00,L（幽门窦部） 大弯侧Gre  前Ant 后Post ,90,90,10, R0 D2,,10.44,7.13,2.2,128.0,461.0,4.66,10.0,14.0,158.0,64.0,27.0,9.59,4.17,64.0,177.0,41.0,23.0,5.2,5.9,73.0,304.0,57.7,40.2,13.7,2.93,0.2,9.4,31.2,1.3,1.25,2.69,10.7,17.9,59.07,332.8,2.27, 未做,无,, P0,H0, 未做,ck(+)  vimentin散在(+)  VEGF弱(+)  cMET散在弱(+)  CD34(+)  S100(+),,,,,91.13009198423127,1502891
1502821,杨黎明,582639,女,61,T3,N1,M0, ⅡB,1,5,2.0,0.0,0.0,1.0, 肠化生+,1.0,14,中间型（int）,INFc,0.0,,1.0,1.0,,,,0.0,2015-01-26,2019-08-05,0,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3, (1a)01 (1b)00 (3a)02 (3b)01 (4sb)02 (4d)13 (5)00 (6)00 (7)01 (8a)01 (8p)01 (9)01 (11p)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,10, R0 D2,,6.48,3.49,1.98,136.6,214.0,5.27,14.0,18.0,237.0,70.0,7.0,5.98,2.29,62.0,177.0,39.0,23.0,5.7,5.2,78.0,286.0,67.6,28.8,29.5,0.98,1.1,21.3,9.4,13.1,0.584,1.21,8.63,27.3,0.41,27.14,1.58,,无, 无, P0,H0, 未做, CK+， Vimentin部分-， VEGF弱+， CMET-,,,,,54.270696452036795,1502821
1502804,石井山,588203,男,50,T4b,N2,M0, ⅢB,1,2,2.0,0.0,0.0,1.0, 慢性炎症（+）,3.0,23,硬型（sci）,INFc,1.0,,1.0,1.0,,,,0.0,2015-01-26,2016-03-01,2,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20 Lauren弥漫型,G3, (1a)01 (1b)04 (3a)01 (3b)12 (4sb)00 (4d)04 (5)00 (6)00 (7)05 (8a)22 (8p)01 (9)02 (11p)01 (12a)00,L（幽门窦部） 前Ant 后Post 小弯侧Less ,45,30,8,,R2,7.98,4.71,2.6,82.6,538.0,,36.0,20.0,174.0,69.0,11.0,8.17,3.32,71.0,254.0,46.0,25.0,5.8,9.6,81.0,198.0,73.7,43.8,18.7,2.34,0.2,8.3,17.0,2.0,1.08,1.55,12.6,10.8,1.17,8.0,20.53, 未做,无,, P0,H0, 未做,ck(+)  vimentin散在(+)  VEGF弱(+)  cMET(-)  CD34(+)  S100(+),,,,,13.140604467805518,1502804
1503429,石秀艳,588381,女,52,T3,N2,M0, ⅢA,1,3,2.0,0.0,0.0,1.0, 肠化生+,3.0,27,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-01-28,2020-04-27,1,,,SOX,,,,,,1, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a)02 (1b)00 (2)00 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)01 (6)00 (7)01 (8a)04 (8p)02 (9)02 (11p)01 (12a)01,G 前Ant 小弯侧Less 后Post ,50,50,10,R0 D2,,6.86,3.17,3.09,137.2,210.0,,16.0,16.0,129.0,97.0,9.0,14.45,4.28,77.0,220.0,45.0,32.0,5.8,6.2,66.0,343.0,63.0,32.2,28.4,1.13,0.1,15.7,20.1,9.5,0.965,3.06,20.9,19.3,0.384,10.26,,,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-) CD34(+)， S100(+),,,,,62.943495400788436,1503429
1503764,史庆刚,588528,男,60,T2,N0,M0, ⅠB,1,1,0.0,0.0,0.0,0.0, 肠化生+,0.0,19,中间型（int）,INFb,2.0,,,,,,,0.0,2015-02-02,2022-09-01,1,,,,,,,,,0, 乳头状癌（G1）（pap）60% 管状腺癌（中分化【G2】【tub2】40% Lauren肠型,G2, (1a)00 (1b)00 (3a)03 (3b)01 (4sb)01 (4d)02 (5)00 (6)00 (7)01 (8a)02 (8p)02 (9)01 (11p)06 (12a)00," L（幽门窦部）, 小弯侧Less, 后Post,",50,40,10, R0 D2,,10.41,5.3,4.1,154.1,353.0,3.21,33.0,29.0,216.0,86.0,18.0,13.76,4.53,76.0,294.0,47.0,29.0,5.2,6.2,100.0,346.0,62.7,32.8,27.3,1.2,0.1,18.4,17.5,12.6,0.546,1.2,14.8,111.0,2.6,3.2,8.26, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,90.93298291721419,1503764
1503801,胡书德,588368,男,59,T1a,N1,M0, ⅠB,1,0,,,,,,1.0,10,,,0.0,0.2,,,,,,,2015-02-02,2019-06-29,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) （GIST）,G3, (1a)01 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)02 (5)02 (6)01 (7)00 (8a)11 (9)01," L（幽门窦部）, 小弯侧Less,",35,20,5, R0 D2,,6.58,3.56,2.15,156.8,225.0,2.58,28.0,26.0,184.0,78.0,16.0,16.63,5.39,76.0,395.0,48.0,28.0,4.9,9.2,78.0,309.0,84.7,41.7,39.2,1.06,0.4,7.7,6.1,6.3,0.954,1.82,15.1,100.0,1.91,6.3,1.91,,粟粒状,,,H0, 未做, CK+ CD117+  CD34+ DOG-1+ Desmin- S-100- SMA-,,,,,52.825229960578184,1503801
1503448,孟庆海,588738,男,46,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,39,,,0.0,,1.0,,,,,0.0,2015-01-29,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20,G3, (1a)01 (1b)01 (3a)06 (3b)01 (4sb)01 (4d)010 (5)01 (6)03 (7)04 (8a) (8p)02 (9)04 (11p)01 (12a)00 (12b)00 (14v)04,L（幽门窦部） 前Ant 小弯侧Less ,10,5,5,R0 D2,,7.3,4.35,2.06,144.9,216.0,2.34,20.0,19.0,145.0,92.0,20.0,20.35,8.63,71.0,225.0,43.0,28.0,4.2,5.8,76.0,342.0,72.9,43.8,26.6,1.65,0.1,7.8,18.2,2.2,0.614,4.16,18.1,93.5,1.36,16.96,1.41, 未做,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(-),,,,,91.06438896189225,1503448
1503399,邹永财,588744,男,56,T3,N3b,M1, Ⅳ,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,18.0,54,中间型（int）,INFb,0.0,,1.0,1.0,,,,0.0,2015-01-29,2015-08-20,2,,,SOX,,,,,,4, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren弥漫型,G3, (1a)02 (1b)01 (3a)421 (3b)00 (4sb)01 (4d)917 (5)00 (6)11 (7)11 (8a)11 (8p)04 (9)00 (11p)01 (13)22 (16a1)02,L（幽门窦部） 前Ant 小弯侧Less 后Post ,50,50,10,,R1,7.55,4.82,2.16,135.6,292.0,3.51,29.0,17.0,127.0,83.0,11.0,19.32,8.43,65.0,325.0,40.0,25.0,5.0,7.1,81.0,299.0,59.4,25.4,30.0,0.85,0.1,2.8,36.4,1.9,0.53,2.41,13.8,32.3,4.53,1.08,15.66, 未做,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(-) CD34(+)， S100(+),,,,,6.668856767411301,1503399
1503223,唐文海,588458,男,60,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,9,,,0.0,,1.0,1.0,,,,0.0,2015-01-28,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20,G3, (1a)00 (1b)00 (3a)01 (3b)01 (4sb)00 (4d)01 (5)00 (6)02 (7)01 (8a)00 (8p)00 (9)02 (11p)01,L（幽门窦部） 小弯侧Less ,35,15,,R0 D2,,7.81,3.14,3.8,133.0,306.0,3.43,12.0,15.0,119.0,70.0,13.0,9.41,3.31,72.0,231.0,42.0,30.0,4.9,3.8,67.0,331.0,88.5,39.7,46.3,0.86,0.2,4.7,5.9,9.9,0.528,3.28,11.4,32.7,1.17,5.78,1.31, 未做,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(-),,,,,91.09724047306176,1503223
1503231,王雪辉,588434,男,41,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 肠化生+,0.0,13,硬型（sci）,INFc,0.0,,1.0,1.0,,,,2.0,2015-01-28,2019-08-07,0,,,MFOLFOX6(2),,,,,,4, 低粘附腺癌  Lauren弥漫型,GX, (1a)01 (1b)01 (2)00 (3a)00 (3b)02 (4sa)01 (4sb)00 (4d)01 (5)00 (6)04 (7)00 (8a)00 (8p)00 (9)01 (11p)01 (12a)00,G 小弯侧Less ,15,15,5,R0 D2,,5.29,2.23,2.37,143.0,273.0,4.1,14.0,16.0,130.0,79.0,13.0,16.94,5.27,75.0,286.0,43.0,32.0,4.9,5.5,73.0,423.0,56.6,29.9,21.7,1.38,0.1,15.8,23.5,0.7,0.582,3.28,11.4,32.7,0.2,6.36,3.47, 未做,无,,P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(+)CD34(+)， S100(+),,,,,54.270696452036795,1503231
1503786,宫本春,588484,男,55,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,15,中间型（int）,INFa,0.0,,1.0,,,,,0.0,2015-02-02,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)00 (5)00 (6)00 (7)02 (8a)02 (8p)04 (9)03 (11p)02 (12a)01," L（幽门窦部）, 后Post,",40,35,10, R0 D2,,8.75,5.9,2.28,160.5,201.0,2.9,25.0,20.0,205.0,68.0,24.0,12.67,4.74,71.0,345.0,45.0,26.0,4.5,7.1,85.0,502.0,65.6,35.0,27.4,1.28,0.1,11.6,21.2,4.3,1.72,4.35,14.6,33.7,2.41,8.05,0.928, 未做,无, 无, P0,H0, 未做, CK(+)、 Vimentin（-）间质（+）、 VEGF弱（+）、 CD34+、 S-100+,,,,,90.93298291721419,1503786
1503880,马占刚,588482,男,54,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0,  慢性炎症（+）,0.0,33,髓样型（med）,INFa,0.0,,,,,,,,2015-02-03,2021-05-24,1,,,,,,,,,0, 低粘附腺癌60% 低分化腺癌（G3)(por)40% Lauren肠型,G3, (1a)02 (1b)01 (3a)03 (3b)01 (4d)04 (5)01 (6)07 (7)01 (8a) (12a)01 (8p)07 (11p)05," L（幽门窦部）, 小弯侧Less,",15,15,5, R0 D2,,6.97,4.75,1.69,139.5,173.0,2.68,20.0,27.0,186.0,71.0,32.0,13.24,4.09,76.0,410.0,47.0,29.0,5.3,5.0,80.0,408.0,54.4,38.4,12.8,3.0,0.1,7.6,37.3,1.2,0.528,3.28,11.4,32.7,3.98,3.13,1.05, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）间质（+）、 VEGF（-）,,,,,75.62417871222075,1503880
1504684,李兴昌,588941,男,60,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0,  慢性炎症（+）,9.0,26,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2015-02-09,2015-09-15,2,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/1 (1b)0/0 (3a)3/8 (3b)0/0 (4sb)0/0 (4d) 4/6(5)0/0 (6)0/2 (7) 2/3(8a)0/1 (8p)0/1 (9)0/2 (11p)0/2，3a组，3b组软组织见癌+," M（胃体部）, 前Ant, 大弯侧Gre,",60,40,10, R0 D2,,8.4,4.75,2.73,143.5,300.0,2.84,20.0,19.0,154.0,81.0,20.0,10.7,4.31,73.0,266.0,48.0,25.0,5.1,4.1,72.0,256.0,78.7,52.8,23.0,2.3,0.2,15.2,4.6,1.3,0.961,1.35,12.4,974.0,3.45,52.32,4.48, 未做,无, 无, P0,H0, 未做,"CK+, Vimentin-, CMET-, VEGF局灶弱+ CD34脉管周+  S-100神经侵犯+",,,,,7.1616294349540075,1504684
1504181,郑永臣,588938,男,50,T3,N1,M0, ⅡB,1,1,2.0,0.0,0.0,1.0, 肠化生+,1.0,38,髓样型（med）,INFc,0.0,,,,,,,0.0,2015-02-04,2017-08-01,0,,,XELOX,,,,,,5, 低粘附腺癌90%， 低分化腺癌（G3)(por)10% Lauren弥漫型,G3, (1a)0/0 (1b)0/3 (3a)0/4 (3b)0/2 (4sb)0/3 (4d)0/8 (5)1/2 (6)0/4 (7)0/1 (8a)0/1 (8p)0/1 (9)0/5 (11p)0/4," L（幽门窦部）, 前Ant, 大弯侧Gre, 后Post,",50,50,14,,R1,6.56,3.55,2.21,152.8,330.0,2.63,18.0,24.0,156.0,61.0,8.0,9.93,3.45,72.0,266.0,43.0,29.0,4.5,5.6,73.0,319.0,62.1,39.5,18.5,2.14,0.4,8.6,27.6,3.2,0.355,4.17,16.7,146.0,1.09,41.72,2.66, 未做,无, 无, P0,H0, 未做," CK+, Vimentin-, CMET-. VEGF- CD34(脉管+) S-100神经（+）",,,,,29.86202365308804,1504181
1504127,孙长所,588930,男,78,T4b,N1,M0, ⅢB,1,3,0.0,0.0,0.0,0.0, 肠化生+,1.0,21,中间型（int）,INFc,2.0,0.6,,,,,,,2015-02-04,2021-06-21,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70  乳头状癌（G1）（pap）20    低粘附腺癌10 Lauren肠型  类癌(神经内分泌癌),G3, (1a)00 (1b)02 (3a)02 (3b)01 (4sb)01 (4d)06 (5)01 (6)00 (7)04 (8a) (12a)11 (8p)01 (9)01 (11p)01 6 软组织可见癌,L（幽门窦部）小弯侧Less 大弯侧Gre  后Post ,28,25,7,,R1,6.35,3.5,2.18,137.5,223.0,3.59,20.0,25.0,143.0,63.0,12.0,22.25,9.06,65.0,220.0,37.0,28.0,4.8,7.1,76.0,274.0,58.4,31.8,22.7,1.4,0.9,14.0,26.0,2.0,1.08,2.47,16.9,15.4,372.8,5.8,11.72, 未做,无, 无, P0,H0, 未做,"ck（+），vimentin（-），VEGF(-)，CD56(+),CgA(+),Syn（+）",,,,,76.51116951379763,1504127
1503776,朱桂芝,588844,男,70,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 肠化生+,0.0,20,硬型（sci）,INFc,0.0,,1.0,,,,,0.0,2015-02-02,2021-06-21,1,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)10  粘液腺癌（muc）10 Lauren弥漫型,G3, (1a)00 (1b)04 (2)00 (3a)05 (3b)00 (4sb)02 (4d)02 (5)00 (6)06 (7)00 (8a)00 (8p)00 (9)00 (10)01 (11p)00 (12a)00,G 小弯侧Less ,50,50,15,R0 D2,,5.95,2.5,2.68,142.0,209.0,2.84,21.0,28.0,195.0,53.0,19.0,7.48,3.26,62.0,217.0,40.0,22.0,5.3,5.2,55.0,289.0,64.6,53.9,10.3,5.23,0.5,7.1,26.1,0.8,0.307,1.82,15.7,7.14,1.65,20.23,1.85, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(-) CD34(+)， S100(+),,,,,76.57687253613666,1503776
1504689,卢义财,588934,男,63,T3,N0,M0, ⅡA,1,4,2.0,0.0,0.0,0.0, 肠化生+,0.0,26,中间型（int）,INFc,0.0,,1.0,,,,,2.0,2015-02-09,2017-06-07,2,,,替吉奥单药,替吉奥单药,替吉奥单药,卡佩他滨单药,卡佩他滨单药,,5, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3, (1a)00 (1b)06 (2)02 (3a)00 (3b)01 (4sa)02 (4sb)00 (4d)07 (5)02 (6)01 (7)03 (8a) (8p)01 (9)01 (10)00 (11p)00 (12a)00 (12b)00,G 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,40,15,R0 D2,,4.52,3.12,0.99,147.0,153.0,2.3,41.0,36.0,145.0,77.0,65.0,35.27,13.26,61.0,226.0,40.0,21.0,4.3,6.0,55.0,261.0,79.7,52.7,24.4,2.16,0.5,6.5,12.3,3.2,0.613,1.49,9.63,15.7,0.815,15.47,22.96, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+) CD34(+)， S100(+),,,,,27.890932982917214,1504689
1504055,王政举,588478,男,70,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,18,,,0.0,,1.0,,,,,0.0,2015-02-04,2021-05-24,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)0/1， (1b) 0/1.(3a)0/6， (3b)0/0 (4sb)0/0， (4d)0/6， (5)0/3 (7)0/0， (8a)0/1 (9)0/0," L（幽门窦部）, 小弯侧Less,",15,12,, R0 D2,,4.89,2.09,2.31,149.0,205.0,2.25,25.0,38.0,147.0,77.0,11.0,22.18,7.4,75.0,232.0,46.0,29.0,4.1,4.4,73.0,354.0,73.7,51.2,17.5,2.93,0.2,8.5,16.3,1.2,1.37,2.17,16.5,252.0,0.813,10.89,2.47, 未做,无, 无, P0,H0, 未做," CK+, VEGF局灶弱（+）， Vimentin-， CMET-",,,,,75.59132720105124,1504055
1503790,程凤,588862,女,43,T2,N0,M0, ⅠB,1,5,2.0,0.0,0.0,1.0, 肠化生+,0.0,18,中间型（int）,INFb,0.0,,1.0,1.0,,,,0.0,2015-02-02,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren弥漫型,G3, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)02 (5)01 (6)04 (7)03 (8a)02 (8p)01 (9)01 (11p)04,L（幽门窦部） 后Post,40,40,,R0 D2,,,,,,,,31.0,31.0,173.0,72.0,23.0,14.13,5.57,78.0,99.0,45.0,33.0,5.4,5.2,46.0,353.0,58.4,41.7,12.8,3.26,0.3,10.0,29.4,1.1,0.89,2.78,21.4,21.7,0.451,6.92,10.8, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(-),,,,,75.65703022339028,1503790
1503089,秦国柱,588312,男,58,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 肠化生+,0.0,15,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-01-28,2019-08-05,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G2, (1a)02 (1b)01 (3a)03 (3b)00 (4sb)00 (4d)02 (5)00 (6)01 (7)01 (8a)01 (8p)01 (9)02 (11p)01," L（幽门窦部）, 小弯侧Less,",20,10,2, R0 D2,,6.61,3.95,2.15,99.0,264.0,3.21,51.0,58.0,132.0,76.0,111.0,6.37,4.11,58.0,254.0,37.0,21.0,9.3,3.5,46.0,274.0,65.2,41.9,21.8,1.92,0.3,22.8,9.8,1.8,0.459,3.19,11.7,41.2,0.587,11.45,1.21,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF散在弱+， CMET-,,,,,54.204993429697765,1503089
1503670,倪月坤,588450,男,50,T4b,N2,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,3.0,31,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-02-02,2015-06-10,2,,,替吉奥单药,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)02 (1b)02 (2)00 (3a)14 (3b)00 (4sa)00 (4sb)01 (4d)14 (5)11 (6)04 (7)00 (9)00 (11d)04 (11p)02胰腺旁07," LMU 前Ant, 后Post, 小弯侧Less,",60,50,12, R0 D2,,6.54,3.8,2.0,95.1,500.0,4.9,28.0,55.0,171.0,151.0,569.0,21.79,10.08,61.0,186.0,36.0,25.0,6.5,6.5,52.0,372.0,70.3,41.0,20.4,2.01,1.0,6.8,21.5,7.1,1.05,3.09,10.5,631.0,4.4,13.41,3.77,,无, 无, P0,H0, 未做,"CK+, Vimentin-、间质散在+， VEGF弱+， CMET-",,,,,4.204993429697766,1503670
1503780,张武,588947,男,53,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0,肠化生+,0.0,13,髓样型（med）,INFa,1.0,,1.0,,,,,0.0,2015-02-02,2019-08-05,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 乳头状癌（G1）（pap）30% Lauren肠型,G3, (1a)00 (1b)02 (3a)04 (3b)00 (4sb)05 (4d)01 (5)00 (6)00 (7)01 (8a)00 (8p)00 (9)00 (11p)00," L（幽门窦部）, 小弯侧Less,",30,25,3, R0 D2,,7.12,3.28,3.0,168.0,226.0,2.58,30.0,30.0,181.0,90.0,22.0,8.92,3.18,67.0,309.0,43.0,24.0,5.4,6.3,63.0,271.0,73.0,48.7,20.6,2.36,1.2,18.4,6.9,2.0,1.1,0.975,11.8,27.4,0.992,12.02,79.26, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）散在（+）、 VEGF弱（+）、 CMET（-）,,,,,54.040735873850196,1503780
1503187,张晓琳,588274,女,45,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 肠化生+,4.0,19,髓样型（med）,INFb,1.0,,1.0,1.0,,,,0.0,2015-01-28,2021-05-24,1,,,XELOX,,,,,,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)46 (5)00 (6)02 (7)02 (8a)00 (8p)04 (9)00 (11p)01 (12a)00," L（幽门窦部）, 大弯侧Gre,",35,15,8, R0 D2,,10.2,7.1,2.28,145.7,306.0,3.21,30.0,28.0,187.0,56.0,10.0,15.52,6.06,77.0,270.0,47.0,30.0,5.4,6.0,59.0,282.0,78.7,59.1,17.7,3.34,0.1,7.3,13.5,59.5,1.58,2.02,16.3,166.0,1.7,6.13,2.5, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin散在（+）、 VEGF弱（+）、 CMET（-）、 CD34+、 S-100+,,,,,75.82128777923784,1503187
1503694,杜景贵,587938,男,77,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 肠化生+,3.0,25,髓样型（med）,INFc,0.0,,1.0,,,,,0.0,2015-02-02,2017-11-14,2,,,,,,,,,0, 粘液腺癌（muc）60 低粘附腺癌40 Lauren混合型,GX, (1a)01 (1b)01 (3a)09 (3b)00 (4sb)02 (4d)25 (5)00 (6)15 (7)00 (8a)00 (8p)00 (9)00 (11p)02 3d 56 软组织可见癌,L（幽门窦部） 前Ant 小弯侧Less 后Post  ,50,30,18,R0 D2,,4.56,3.1,0.94,136.0,235.0,3.21,17.0,27.0,200.0,107.0,12.0,16.43,7.23,7.0,161.0,47.0,23.0,4.3,4.7,73.0,252.0,72.5,44.1,26.5,1.66,0.2,14.8,11.2,0.8,0.77,2.57,16.8,38.4,3.91,20.73,9.05, 未做,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(-) CD34(+)， S100(+),,,,,33.37713534822602,1503694
1503952,朱桂珍,587607,女,49,T3,N0,M0, ⅡA,1,2,2.0,0.0,0.0,0.0, 肠化生+,0.0,15,髓样型（med）,INFa,0.0,,1.0,,,,,0.0,2015-02-12,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por)60%， 低粘附腺癌40% Lauren弥漫型,G3," (1a) 0/0(1b)0/1 (3a)0/2 (3b)0/0 (4sb)0/0 (4d)0/0 (5)0/0 (6)0/3 (7)0/4 (8a)0/1 (8p)0/2 (9)0/0 (11p)0/2 (12a)0/0, 大网组织（-） 左输卵管组织伴系膜囊肿。"," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,, R0 D2,,5.47,2.7,2.19,151.0,139.0,2.09,29.0,30.0,153.0,69.0,30.0,9.47,2.7,62.0,325.0,39.0,23.0,4.6,5.2,39.0,266.0,81.1,48.5,25.6,1.89,0.2,12.8,4.9,2.5,0.706,1.89,8.81,7.87,0.2,7.38,1.12, 未做,无, 无, P0,H0, 未做, CK +，Vimentin —，VEGF弱+， CMET—,,,,,75.32851511169514,1503952
1503098,苏纪祥,588791,男,44,T3,N1,M0, ⅡB,1,2,2.0,0.0,0.0,1.0, 肠化生+,2.0,22,中间型（int）,INFb,0.0,,1.0,1.0,,,,0.0,2015-01-28,2021-05-24,1,,,XELOX,,,,,,1, 低粘附腺癌70% 低分化腺癌（G3)(por)30% Lauren弥漫型,G3, (1a)01 (3a)13 (3b)01 (4sb)00 (4d)16 (5)00 (6)00 (7)01 (8a)01 (8p)00 (9)01 (11p)08 (12a)00," L（幽门窦部）, 前Ant, 大弯侧Gre,",50,40,8, R0 D2,,7.41,3.25,3.3,132.0,324.0,2.94,24.0,24.0,161.0,61.0,47.0,11.7,5.02,69.0,288.0,46.0,23.0,5.7,6.0,85.0,533.0,71.7,40.2,27.8,1.45,0.1,17.5,8.8,8.8,0.687,1.96,14.8,5.65,3.06,22.61,2.47, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin散在（+）、 VEGF弱（+）、 CMET（-）、 CD34+、 S-100+,,,,,75.82128777923784,1503098
1503206,徐卫明,588755,男,34,T3,N0,M0, ⅡA,1,2,2.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,32,中间型（int）,INFc,0.0,,,,,,,0.0,2015-01-28,2021-05-24,1,,,SOX,,,,,,6, 低粘附腺癌80% 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20% Lauren弥漫型,G3, (1a)00 (1b)04 (3a)02 (3b)02 (4sb)01 (4d)00 (5)00 (6)05 (7)02 (8a)05 (8p)03 (9)06 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",20,15,8, R0 D2,,6.7,4.09,1.93,160.3,180.0,3.21,27.0,31.0,173.0,82.0,30.0,12.14,4.94,77.0,215.0,47.0,30.0,5.1,7.9,71.0,454.0,85.3,42.9,27.4,1.57,0.1,6.9,5.6,4.1,0.867,1.0,19.1,28.3,2.36,10.96,2.51, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）间质（+）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,75.82128777923784,1503206
1503547,郭福林,588687,男,62,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,26,,,0.0,,,,,,,,2015-01-30,2019-04-15,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)01 (1b)07 (2)00 (3a)03 (3b)01 (4sa)01 (4sb)00 (4d)01 (5)01 (6)00 (7)00 (8a)03 (8p)03 (9)03 (11p)00 (12a)02,G 前Ant ,15,10,5,R0 D2,,5.97,3.15,1.83,14.3,249.0,2.45,17.0,20.0,132.0,52.0,19.0,8.69,3.97,62.0,221.0,41.0,21.0,4.5,7.5,81.0,409.0,66.9,44.3,20.3,2.18,0.8,4.4,27.6,1.1,2.52,3.76,20.2,245.0,1.3,6.36,2.06, 未做,无,, P0,H0, 未做,ck（+）,,,,,50.45992115637319,1503547
1503745,郑广文,588231,男,58,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,21,,,0.0,,,,,,,0.0,2015-02-02,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)06 (3a)01 (3b)02 (4sb)00 (4d)01 (5)00 (6)05 (7)01 (8a)00 (8p)00 (9)02 (11p)01," L（幽门窦部）, 小弯侧Less,",15,15,, R0 D2,,4.99,2.05,2.45,154.6,166.0,3.4,12.0,22.0,166.0,71.0,32.0,6.44,2.02,68.0,274.0,47.0,21.0,5.2,5.5,90.0,327.0,83.5,48.1,23.7,2.03,0.3,12.2,3.8,3.3,0.8,1.16,13.0,76.4,0.827,9.17,1.2,,无, 无, P0,H0, 未做,"CK+, Vimentin-，VEGF-， CMET-",,,,,75.65703022339028,1503745
1504177,马程义,588610,男,56,T1b,N0,M0,ⅠA,1,0,1.0,0.0,0.0,0.0, 肠化生+,0.0,7,髓样型（med）,INFb,1.0,,,,,,,0.0,2015-02-04,2020-04-27,0,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3, (1a)01 (1b)01 (3a)00 (3b)00 (4sb)03 (4d)00 (5)00 (6)00 (7)01 (8a)00 (8p)01 (9)00 (11p)00,L（幽门窦部） 大弯侧Gre  ,30,25,,R0 D2,,4.27,2.02,1.82,158.0,254.0,2.54,12.0,21.0,161.0,79.0,17.0,24.66,8.67,70.0,291.0,46.0,24.0,4.7,3.8,78.0,342.0,73.0,48.7,20.6,2.36,1.2,18.4,6.9,2.0,1.1,0.975,11.8,27.4,1.79,9.13,9.03,,无, , P0,H0, 未做,ck（+），vimentin（-），VEGF(-),,,,,62.71353482260184,1504177
1504235,王永河,586331,男,50,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,13,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-02-05,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】低分化腺癌（G3)(por)  Lauren肠型,G3, (1a)00 (1b)02 (3a)04 (3b)00 (4sb)03 (4d)00 (5)01 (6)02 (7)00 (8a)01 (8p)00 (9)00 (11p)00," L（幽门窦部）, 后Post,",20,20,8,R0 D2,,7.2,3.73,2.75,185.2,234.0,2.34,26.0,21.0,153.0,62.0,31.0,19.63,6.35,79.0,343.0,52.0,27.0,5.5,6.3,93.0,255.0,,,,,,,,,,,,,7.37,24.45,1.33, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(-) CD34(+)， S100(+),,,,,76.47831800262811,1504235
1503974,李有才,587963,男,55,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,20,硬型（sci）,INFc,0.0,,1.0,,,,,0.0,2015-02-03,2020-04-27,0,,,SOX,,,,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)02 (1b)01 (2)02 (3a)05 (3b)01 (4sb)00 (4d)02 (5)00 (6)01 (7)00 (8a)01 (8p)00 (9)03 (11p)02 (12a)00," LM 小弯侧Less,",50,40,10, R0 D2+,,9.39,5.97,2.59,154.0,371.0,2.9,31.0,19.0,154.0,79.0,36.0,17.92,6.6,64.0,276.0,43.0,21.0,5.8,7.7,94.0,336.0,79.0,46.8,23.8,1.97,0.3,13.4,6.8,8.5,0.529,1.57,12.8,107.0,1.88,9.44,5.11,,无,, P0,H0, 未做,CK + Vimentin(-)间质(+) VEGF散在弱（+） CMET- CD34(脉管周+)  S-100(神经+),,,,,62.74638633377135,1503974
1503858,焦锡山,589468,男,56,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,32,硬型（sci）,INFc,0.0,,1.0,,,,,0.0,2015-02-03,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren弥漫型 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (3a)08 (3b)00 (4d)05 (5)00 (6)02 (7)02 (8a)01 (8p)01 (9)02 (11p)04 (12a)00 胃旁06," L（幽门窦部）, 大弯侧Gre,",50,40,10, R0 D2,,7.72,4.4,2.18,161.0,331.0,17.7,14.0,22.0,162.0,88.0,94.0,9.37,3.51,85.0,404.0,52.0,33.0,5.8,8.3,150.0,557.0,42.8,28.1,13.2,2.13,0.3,3.1,53.6,1.6,1.14,3.33,18.0,162.0,2.38,10.23,0.942, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(-)  CD34(+)  ,,,,,90.90013140604468,1503858
1504149,刘保国,588460,男,48,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,6.0,25,中间型（int）,INFc,1.0,,1.0,,,,,2.0,2015-02-04,2021-05-24,1,,,SOX,,,,,,8, 低分化腺癌（G3)(por) Lauren肠型,G3,小弯11 (1a)02 (1b)00 (2)01 (3a)46 (3b)00 (4sb)00 (4d)02 (5)00 (6)04 (7)00 (8a)02 (8p)02 (9)11 (11p)03 (12a)00 (12p)01  (3a)软组织内可见癌," UM 前Ant, 后Post, 小弯侧Less,",70,70,8, R0 D2+,,9.57,5.98,2.61,86.8,508.0,3.21,10.0,16.0,149.0,71.0,18.0,6.71,2.82,70.0,216.0,45.0,25.0,5.7,7.3,97.0,392.0,58.6,28.7,27.6,1.04,0.1,2.3,38.6,2.5,0.545,4.1,12.4,451.0,0.681,5.92,3.8,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,75.59132720105124,1504149
1504307,高成礼,589025,男,64,T3,N1,M0, ⅡB,1,1,0.0,1.0,1.0,1.0, 肠化生+,2.0,18,中间型（int）,INFb,3.0,,,,,,,0.0,2015-02-05,2016-11-16,2,,,XELOX,,,,,,1, 乳头状癌（G1）（pap）60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren肠型,G3, (1a)03 (1b)03 (3a)01 (3b)05 (4sb)01 (4d)01 (5)00 (6)00 (7)00 (8a)01 (8p)00 (9)00 (11p)00 (14v)23,L（幽门窦部） 大弯侧Gre  ,60,,,R0 D2,,6.25,4.07,1.64,142.0,196.0,3.35,12.0,22.0,165.0,70.0,10.0,17.88,6.82,76.0,196.0,48.0,28.0,5.9,5.0,92.0,233.0,64.6,53.9,10.3,5.23,0.5,7.1,26.1,0.8,0.307,1.82,15.7,7.14,10.3,204.4,31.76, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-) CD34(+)， S100(+),,,,,21.353482260183966,1504307
1504082,王兴茹,589313,男,60,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,36,中间型（int）,INFb,0.0,,,,,,,0.0,2015-02-04,2019-06-01,0,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)06 (1b)06 (3a)02 (3b)02 (4sb)02 (4d)05 (5)00 (6)01 (7)06 (8a)01 (8p)01 (9)02 (11p)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",15,15,2, R0 D2,,5.02,2.97,1.15,138.0,200.0,2.34,25.0,25.0,160.0,100.0,25.0,13.05,4.29,68.0,199.0,38.0,30.0,5.0,4.6,64.0,231.0,82.2,53.3,22.8,2.34,0.1,6.8,10.2,0.7,0.83,9.04,14.5,121.0,2.14,14.03,1.16,,无, 无, P0,H0, 未做,"CK+, Vimentin-， VEGF-， CMET-",,,,,51.83968462549277,1504082
1500035,刘亚新,584509,男,48,T2,N0,M0, ⅠB,1,2,2.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,18,硬型（sci）,INFc,0.0,,,,,,,0.0,2015-01-04,2017-08-01,0,,,XELOX,,,,,,4,中低分化管状腺癌（90%），低粘附性癌（10%）。 Lauren弥漫型,G3, (1a)0/3 (1b)0/1 (2)0/4 (3a)0/4 (3b)0/0 (4sb)0/0 (4d)0/0 (5)0/1 (6)0/0 (7)0/1 (8a)0/1 (8p)0/1 (9)0/1 (11p)0/1," SiewerⅢ,",35,30,10, R0 D2,,6.76,3.78,34.3,149.0,195.0,4.32,43.0,44.0,123.0,95.0,179.0,14.68,5.4,72.0,263.0,47.0,25.0,5.4,6.8,75.0,323.0,69.8,46.8,17.9,2.61,0.3,5.8,21.9,2.5,0.725,1.78,13.5,12.4,2.2,19.38,1.16, 未做,无, 无, P0,H0, 未做," CK+, Vimentin(0), VEGF-, CMET- S-100+ CD34 +",,,,,30.880420499342968,1500035
1504314,贾新臣,589433,男,51,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,14,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-02-05,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (2)00 (3a)03 (3b)02 (4sb)00 (4d)04 (5)00 (6)00 (7)02 (8a)00 (8p)00 (9)00 (11p)00," M（胃体部）, 小弯侧Less,",20,18,16, R0 D2,,6.77,3.48,2.59,159.0,177.0,2.34,65.0,32.0,147.0,66.0,87.0,26.51,10.35,71.0,370.0,46.0,25.0,5.5,6.0,89.0,636.0,69.9,39.7,19.6,2.03,0.1,7.4,22.0,3.0,1.07,3.21,15.6,105.0,0.299,8.12,1.41,,无, 无, P0,H0, 未做,"CK+, Vimentin-， VEGF弱+， CMET-",,,,,75.55847568988173,1504314
1504157,陈兴贵,589463,男,75,T4b,N3a,M0, ⅢC,1,3,0.0,0.0,0.0,1.0, 肠化生+,7.0,22,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2015-02-04,2019-06-06,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌20 乳头状癌（G1）（pap）10 Lauren肠型,G3, (1a)03 (1b)00 (3a)26 (3b)00 (4sb)00 (4d)02 (5)03 (6)00 (7)01大弯46小弯11 软组织可见癌3a," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,10,,R1,7.73,6.04,1.22,83.5,334.0,5.44,6.0,18.0,134.0,58.0,6.0,5.13,1.79,45.0,142.0,30.0,15.0,3.8,6.3,69.0,222.0,72.8,62.1,8.9,6.98,0.2,11.2,14.4,2.2,0.564,0.998,5.17,5.0,1.84,123.5,1.4,,无, 无, P0,H0, 未做,"CK+, Vimentin-， VEGF局灶弱+， CMET-",,,,,52.00394218134034,1504157
1504236,李斌,588010,男,58,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,21,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-02-05,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/0 (1b)0/1 (3a)0/5 (3b)0/0 (4sb)0/0 (4d)0/7 (5)0/0 (6)0/0 (7)0/3 (8a)0/3 (9)0/1 (11p)0/0 (12a)0/0 (14v)0/1," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,20,5, R0 D2,,6.22,3.55,2.01,146.0,216.0,,18.0,16.0,160.0,73.0,27.0,21.98,8.87,64.0,222.0,39.0,25.0,5.1,5.1,82.0,238.0,84.5,56.7,25.4,2.23,0.0,7.0,8.1,1.8,0.626,1.37,20.7,19.6,0.83,9.39,0.836, 未做,无, 无, P0,H0, 未做," CK+,Vimentin-, CMET-, VEGF 弱+",,,,,75.55847568988173,1504236
1503917,姜洪昌,588555,男,51,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,24,中间型（int）,INFb,3.0,,1.0,,,,,0.0,2015-02-03,2016-11-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）90 乳头状癌（G1）（pap）10 Lauren肠型,G2, (1a)01 (1b)00 (3a)04 (3b)01 (4sb) 00(4d)04 (5)00 (6)00 (7)09 (8a) (8p)04 (9)01 (11p)00,L（幽门窦部） 大弯侧Gre,40,30,12, R0 D2,,5.96,2.67,2.6,95.1,216.0,2.41,15.0,23.0,131.0,70.0,6.0,9.29,4.05,71.0,183.0,40.0,31.0,5.4,4.6,77.0,342.0,76.4,31.8,32.6,0.98,0.0,5.5,17.9,9.3,0.875,10.8,20.2,5.0,0.221,47.88,1.44, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(-)  CD34(+)  S100(+),,,,,21.22207621550591,1503917
1503949,于恒仁,589057,男,49,T3,N0,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+,0.0,21,中间型（int）,INFc,2.0,,1.0,,,,,2.0,2015-02-03,2021-06-21,1,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 Lauren肠型 低分化腺癌（G3)(por),G3, (1a)02 (1b)01 (3a)02 (3b)01 (4sb)00 (4d)02 (5)00 (6)00 (7) 02(8a)02 (8p)01 (9)06 (11p)02 (12a)00 (14v)00," L（幽门窦部）, 小弯侧Less,",40,35,10, R0 D2,,6.28,4.17,1.54,138.3,195.0,17.6,19.0,21.0,188.0,88.0,41.0,11.66,4.46,71.0,255.0,47.0,24.0,6.2,4.8,76.0,301.0,44.1,20.7,21.7,0.95,0.6,3.9,11.3,5.2,0.959,1.69,13.5,16.7,2.14,81.14,4.5, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF局灶弱(+)  cMET局灶弱(+)  CD34(+)  S100(+),,,,,76.54402102496715,1503949
1504597,吴景贵,589067,男,49,T4b,N3a,M0, ⅢC,1,2,0.0,0.0,0.0,0.0, 肠化生+,7.0,60,中间型（int）,INFb,0.0,,,,,,,0.0,2015-02-09,2021-07-01,1,,,XELOX,XELOX,SOX,SOX,SOX,SOX,8, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 乳头状癌（G1）（pap）40 Lauren肠型,G3, (1a)00 (1b)03 (3a)09 (3b)29 (4sb)00 (4d)118 (5)02 (6)45 (7)01 (8a)02 (8p)02 (9)00 (11p)09 (12a)00 (14v)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,12, R0 D2+,,7.32,4.2,2.16,139.0,268.0,2.76,13.0,17.0,170.0,74.0,31.0,6.85,2.45,69.0,307.0,47.0,22.0,5.7,4.4,75.0,333.0,81.2,41.8,37.1,1.13,0.1,11.5,6.4,1.5,0.877,1.96,11.8,11.7,6.31,22.25,1.31,,无, , P0,H0, 未做,CK + VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,76.6754270696452,1504597
1504316,申利敏,582666,男,59,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,4,中间型（int）,INFb,0.0,,,,,,,0.0,2015-02-05,2021-05-24,1,,,奥沙利铂 雷替曲塞,,,,,,5, 乳头状癌（G1）（pap）为主， 中低分化腺癌（G3)(por)20%， 低粘附腺癌20%， Lauren肠型,G3, (1a) 0/0(1b)0/2 (3a)0/0 (3b)0/0 (4sb)0/0 (4d)0/2 (5)0/0 (6)0/0 (7)0/0," L（幽门窦部）, 前Ant, 大弯侧Gre,",20,15,, R0 D2,,7.31,3.85,2.79,141.4,180.0,1.91,15.0,18.0,177.0,50.0,30.0,10.21,3.92,72.0,327.0,50.0,22.0,6.6,5.7,108.0,500.0,61.3,33.5,23.0,1.46,0.0,12.4,25.3,2.1,0.91,2.14,10.5,7.58,0.935,16.19,3.92, 未做,无, 无, P0,H0, 未做," CK+, Vimentin-, CMET-, VEGF-, CD34(脉管周+)， S-100（神经+）",,,,,75.55847568988173,1504316
1504743,宋典杰,589271,男,61,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+,1.0,22,髓样型（med）,INFb,0.0,,,,,,,0.0,2015-02-10,2015-10-28,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) 0/1(1b)0/1 (3a)0/4(3b)1/1 (4sb) 0/6(4d) 0/0(5)0/0 (6) 0/0(7)0/1 (8a)0/1 (8p)0/1 (9)0/3 (11p) 0/2 (12a) 0/0(14v)0/1.小弯侧可见2枚癌结节，大弯、3b、5、6组分别见1枚癌结节。大网可见癌（+）," L（幽门窦部）, 后Post, 小弯侧Less,",40,30,5, R0 D2,,4.44,2.62,1.4,169.7,164.0,2.85,49.0,55.0,205.0,108.0,121.0,10.04,4.7,69.0,294.0,43.0,26.0,6.4,4.9,71.0,416.0,65.1,49.2,14.1,3.49,0.1,12.7,21.5,0.8,1.3,3.5,12.3,79.1,1.64,13.37,2.31, 未做,无, 无, P0,H0, 未做, CK(+) Vimentin(-) VEGF(-) CMET(-) CD34(脉管周+) S-100（神经+）,,,,,8.541392904073588,1504743
1504742,王俊荣,582557,女,52,T1b,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+,0.0,47,髓样型（med）,INFc,0.0,,1.0,,,,,2.0,2015-02-10,2021-05-17,1,,,,,,,,,0, 低分化腺癌（G3)(por)70% 低粘附腺癌30%,G3, 小弯07 (1a)01 (1b)01 (3a)012 (3b)01 (4sb)02 (4d)09 (5)01 (6)02 (7)01 (8a)03 (8p)06 (9)01 (11p)00," L（幽门窦部）, 大弯侧Gre,",30,15,1, R0 D2,,6.99,4.25,2.35,129.0,190.0,18.9,27.0,32.0,174.0,93.0,7.0,17.76,5.23,73.0,238.0,44.0,29.0,5.7,5.9,53.0,171.0,48.6,31.0,15.5,2.0,0.1,9.9,39.9,0.7,0.578,2.29,18.9,66.5,2.07,17.79,2.24, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF灶（+）、 CMET弱（+）、 CD34+、 S-100+,,,,,75.16425755584757,1504742
1504038,张庆军,589259,男,50,T1b,N1,M0, ⅠB,1,0,2.0,0.0,0.0,0.0, 肠化生+,1.0,12,硬型（sci）,INFc,0.0,,,1.0,,,,0.0,2015-02-04,2021-05-24,1,,,FOLFOX,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)01 (3a)04 (3b)00 (4sb)00 (4d)00 (5)00 (6)13 (7)01 (8a)01 (8p)01 (9)00 (11p)00," L（幽门窦部）, 前Ant,",15,10,1, R0 D2,,7.69,4.5,2.37,93.0,465.0,3.68,33.0,51.0,169.0,70.0,339.0,13.37,4.7,66.0,297.0,40.0,26.0,5.4,3.6,56.0,358.0,68.2,46.9,18.5,2.54,0.1,11.4,19.1,3.1,0.669,2.65,10.7,404.0,2.23,16.24,0.563,,无, 无, P0,H0, 未做,"CK+, Vimentin散在+， VEGF-， CMET-",,,,,75.59132720105124,1504038
1504577,李兴华,589357,男,63,T3,N1,M0, ⅡB,1,4,0.0,1.0,1.0,1.0, 肠化生+,2.0,38,髓样型（med）,INFb,1.0,,1.0,,,,,0.0,2015-02-09,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 粘液腺癌（muc）40 Lauren肠型,G3, (1a)01 (1b)00 (2)07 (3a)117 (3b)02 (4sa)00 (4sb)00 (4d)02 (5)00 (6)05 (7)13 (8a)00 (8p)00 (9)01 (11p)00," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",60,60,8, R0 D2,,6.9,3.25,2.41,163.0,249.0,2.85,20.0,24.0,180.0,74.0,44.0,12.73,4.23,64.0,293.0,41.0,23.0,4.8,5.0,65.0,285.0,,,,,,,,,,,,,4.71,2.02,27.3,,无, 无, P0,H0, 未做,"CK+, Vimentin-，VEGF散在+， CMET-",,,,,70.2365308804205,1504577
1504907,赵金刚,587710,男,55,T4b,N2,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,3.0,24,中间型（int）,INFb,0.0,,1.0,,,,,2.0,2015-02-11,2015-07-08,2,,,SOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,小弯01 (1a)00 (1b)00 (3a)16 (3b)12 (4sb)00 (4d)11 (5)00 (6)04 (7)03 (8a)01 (8p)01 (9)02 (11p)03  (4d)软组织内可见癌结节," LM 后Post, 小弯侧Less,",50,50,20,,R1,5.58,3.28,1.58,137.0,213.0,3.1,17.0,20.0,170.0,62.0,36.0,10.76,4.05,74.0,203.0,49.0,25.0,6.2,6.5,75.0,313.0,,,,,,,,,,,,,1.29,98.89,3.12,,无,, P0,H0, 未做,CK + Vimentin - VEGF弱+ CMET弱+ CD34(脉管周+)  S-100(神经+),,,,,4.829172141918528,1504907
1504701,蒋中海,589707,男,59,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,0.0, 肠化生+,4.0,33,髓样型（med）,INFb,3.0,,1.0,,,,,1.0,2015-02-09,2015-10-07,2,,,,,,,,,0, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30 Lauren肠型,G3, (1a)08 (1b)17 (3a)00 (3b)00 (4sb)00 (4d)38 (5)00 (6)01 (7)01 (8a)01 (8p)00 (9)05 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",50,50,10, R0 D2+,,8.43,7.06,0.94,120.0,190.0,3.21,21.0,29.0,152.0,126.0,14.0,6.79,2.17,67.0,197.0,41.0,26.0,5.5,6.0,68.0,329.0,61.9,45.5,12.4,3.67,0.1,16.2,21.3,2.7,0.861,4.0,11.0,45.8,21.86,1.66,2.29,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,7.884362680683311,1504701
1504802,李忠林,589440,男,70,T3,N1,M0, ⅡB,1,5,0.0,1.0,1.0,1.0, 肠化生+,1.0,42,中间型（int）,INFb,0.0,,,,,,,2.0,2015-02-10,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)05 (3a)03 (3b)00 (4sb)00 (4d)02 (5)00 (6)06 (7)08 (8a)13 (8p)06 (9)04 (11p)03 (12p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,20, R0 D2+,,6.43,3.42,2.3,160.0,143.0,2.68,18.0,25.0,163.0,81.0,13.0,20.99,8.4,73.0,245.0,46.0,27.0,6.2,5.9,66.0,221.0,36.8,20.5,12.7,1.61,0.1,6.5,56.8,5.8,0.351,7.82,12.9,38.0,2.78,7.7,2.7,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET（局灶弱+） CD34(脉管周+)  S-100(神经+),,,,,90.67017082785807,1504802
1504857,景秀文,589219,女,59,T1b,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0,,0.0,37,,INFc,0.0,,1.0,,,,,2.0,2015-02-11,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por)70%， 低粘附腺癌30% Lauren弥漫型,G3, (1a)0/0 (1b)0/0 (3a)0/12 (3b)0/2 (4sb)0/0 (4d)0/1 (5)0/0 (6)0/6 (7)0/5 (8a)0/6 (9)0/2 (11p)0/3 (12a)0/0," L（幽门窦部）, 前Ant, 小弯侧Less,",40,30,5, R0 D2,,6.95,4.73,26.3,148.0,233.0,2.42,20.0,22.0,165.0,75.0,11.0,14.05,4.33,73.0,230.0,47.0,26.0,6.7,5.9,67.0,242.0,84.7,36.6,38.8,0.94,0.2,8.5,5.3,10.8,1.09,0.964,11.2,23.7,1.31,22.17,1.17, 未做,无, 无, P0,H0, 未做," CK+, Vimentin散在弱+ CMET散在弱+",,,,,75.36136662286465,1504857
1504602,宁绍纯,589448,男,50,T3,N3a,M1, Ⅳ,1,4,2.0,0.0,0.0,1.0, 肠化生+,9.0,27,中间型（int）,INFc,0.0,,1.0,,,,,2.0,2015-02-07,2015-07-08,2,,,XELOX,,,,,,2, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren弥漫型,G3, (1a)01 (1b)06 (2)14 (3a)45 (3b)01 (4sa)00 (4sb)00 (4d)00 (5)01 (6)33 (7)16 软组织可见癌," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,25,5,,R2,7.44,4.47,1.96,165.0,337.0,2.9,18.0,24.0,180.0,84.0,12.0,16.16,5.07,68.0,239.0,42.0,26.0,5.7,6.4,75.0,283.0,,,,,,,,,,,,,1.73,21.82,2.42, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF局灶弱（+）、 CMET散在弱（+）、 CD34+、 S-100+,,,,,4.9605781865965834,1504602
1504606,孙凤霞,587941,女,65,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,3.0,33,硬型（sci）,INFb,0.0,,1.0,,,,,0.0,2015-02-09,2017-09-06,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)00 (3a)07 (3b)12 (4sb)00 (4d)04 (5)12 (6)05 (7)02 (8a)14 (8p)03 (9)02 (11p)00 (12a)00 (12b)00,L（幽门窦部） 小弯侧Less 前Ant 后Post ,50,35,5,R0 D2,,8.55,6.11,1.93,119.1,388.0,1.88,21.0,23.0,158.0,75.0,8.0,5.34,2.2,56.0,169.0,36.0,20.0,5.0,4.9,43.0,215.0,,,,,,,,,,,,,1.24,12.5,2.44,,无, 无, P0,H0,,ck（+），vimentin（-），VEGF(+)，cMET(-) CD34(+)， S100(+),,,,,30.880420499342968,1504606
1504650,芦学斌,587936,男,53,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,3.0,19,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-02-09,2019-06-06,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (2)02 (3a)03 (3b)23 (4sa)01 (4sb)01 (4d)19 (5)00 (6)00 软组织可见癌3a、3b," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",100,80,15,,R2,9.86,6.38,2.59,105.0,482.0,6.79,25.0,21.0,161.0,211.0,121.0,15.94,7.68,78.0,160.0,42.0,36.0,5.7,4.4,74.0,340.0,69.5,28.4,38.0,0.75,0.0,5.9,23.6,3.7,0.77,3.44,16.6,63.4,2.47,28.63,1.53,,无, 无, P0,H0, 未做,"CK+, Vimentin-，VEGF弱+， CMET-",,,,,51.83968462549277,1504650
1504694,郑敏,589364,男,58,T3,N0,M0, ⅡA,1,5,0.0,0.0,0.0,1.0, 肠化生+,0.0,46,中间型（int）,INFb,0.0,,,,,,,0.0,2015-02-09,2021-06-21,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)05 (1b)05 (2)02 (3a)03 (3b)02 (4sa)00 (4sb)00 (4d)01 (5)02 (6)08 (7)05 (8a)03 (8p)00 (9)01 (11p)08 (11d)01," M（胃体部）, L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",80,80,10, R0 D2,,10.91,7.33,2.51,140.0,441.0,3.59,13.0,19.0,174.0,89.0,60.0,6.45,2.55,65.0,162.0,41.0,24.0,6.1,7.1,84.0,343.0,64.5,40.7,20.1,2.02,0.0,10.0,24.9,3.5,0.763,1.74,11.5,9.28,0.729,19.81,1.99, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34-、 S-100+,,,,,76.34691195795006,1504694
1504965,南永燮,589383,男,60,T4b,N0,M0, ⅢA,1,4,2.0,1.0,1.0,1.0,,0.0,14,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-02-12,2015-11-05,2,,,SOX,,,,,,5, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren弥漫型,G3, (8a)03,MU,55,50,12,R0 D2,,8.46,4.58,1.88,79.0,647.0,3.59,20.0,16.0,164.0,128.0,17.0,6.57,2.43,71.0,202.0,42.0,29.0,6.4,4.2,62.0,155.0,,,,,,,,,,,,,0.901,14.18,0.864, 未做,无,, P0,H0,,ck（+），vimentin（-），VEGF(+)，cMET(+) CD34(+)， S100(+),,,,,8.73850197109067,1504965
1504991,鲍桂琴,589658,女,64,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0,肠化生+,0.0,23,中间型（int）,INFb,0.0,,1.0,,,,,2.0,2015-02-12,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】低分化腺癌（G3)(por) Lauren肠型 ,G3, (1a)00 (1b)02 (3a)05 (3b)00 (4sb)02 (4d)01 (5)00 (6)03 (7)04 (8a) (8p)02 (9)04 (11p)00 (12a) (12b)00," L（幽门窦部）, 大弯侧Gre,",15,10,, D2 R0 ,,6.39,3.49,2.44,142.0,194.0,2.68,33.0,34.0,247.0,82.0,13.0,13.2,4.54,72.0,209.0,44.0,28.0,6.2,4.0,68.0,317.0,50.4,38.7,9.4,4.12,0.2,22.9,25.1,1.9,0.865,5.0,16.6,283.0,0.2,8.03,0.76, 未做,无,无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+) CD34(+)， S100(+),,,,,75.32851511169514,1504991
1504922,姜艳春,589661,女,50,T4b,N2,M0, ⅢB,1,3,2.0,1.0,1.0,1.0, 肠化生+,4.0,24,髓样型（med）,INFc,0.0,,1.0,,,,,2.0,2015-02-11,2021-05-24,1,,,XELOX,,,,,,6," 低粘附腺癌70%, 低分化腺癌（G3)(por)30%. Lauren弥漫型",G3, (1a)0/0 (1b)0/0 (2)2/9 (3a)2/9 (3b)0/0 (4sb)0/1 (4d)2/8 (5)0/0 (6)0/0 (7)0/1 (8a)0/1 (8p)0/1 (9)0/1 (11p)0/2 (12p)0/0," 后Post, 小弯侧Less, M（胃体部）,",35,25,16,,R1,7.35,4.6,2.22,135.0,232.0,2.99,23.0,24.0,126.0,74.0,13.0,10.44,3.94,72.0,194.0,44.0,28.0,5.3,5.2,58.0,228.0,54.6,33.4,17.2,1.94,0.2,13.4,30.8,2.8,2.04,1.51,16.3,19.5,1.07,8.65,2.68, 未做,无, 无, P0,H0, 未做, CMET弱+， Vimentin-， VEGF弱+， CK+， CD34（脉管周+） S-100（神经+）,,,,,75.36136662286465,1504922
1504744,刘明瀚,589618,男,46,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,16,髓样型（med）,INFa,0.0,,1.0,,,,,0.0,2015-02-10,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1b)01 (3a)04 (3b)00 (4sb)01 (4d)01 (5)00 (6)03 (7)00 (8a)01 (8p)00 (9)01 (11p)04," L（幽门窦部）,  小弯侧Less,",30,25,3, R0 D2,,6.76,4.92,1.06,122.0,206.0,2.48,32.0,32.0,149.0,66.0,27.0,15.25,5.49,69.0,381.0,44.0,25.0,6.3,3.6,90.0,447.0,48.8,27.1,19.3,1.4,0.7,7.3,41.0,3.8,0.286,4.05,9.87,5.0,2.31,9.87,1.83, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）间质（+）、 VEGF弱（+）、 CMET（-）,,,,,75.39421813403416,1504744
1504945,吴士福,589680,男,61,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,15.0,35,硬型（sci）,INFb,1.0,,1.0,,,,,0.0,2015-02-12,2016-04-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren肠型,G3, (1a)04 (1b)00 (2)03 (3a)14 (3b)00 (4sb)01 (4d)22 (5)01 (6)02 (7)01 (8a)1213 (8p)00 (9)00 (11p)00小弯04," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,25,10, R0 D2,,7.18,6.08,0.71,62.4,225.0,3.21,19.0,26.0,125.0,49.0,6.0,5.13,1.86,50.0,114.0,30.0,20.0,4.7,7.65,94.0,182.0,85.2,55.4,26.9,2.06,0.1,8.6,5.4,1.3,0.993,2.42,12.0,96.9,1.85,218.4,11.67,,无, 无, P0,H0, 未做,"CK+, Vimentin-， VEGF弱+， CMET-",,,,,13.600525624178712,1504945
1504858,董长福,589347,男,42,T3,N2,M0, ⅢA,1,2,2.0,1.0,1.0,1.0, 肠化生+,5.0,33,硬型（sci）,INFc,0.0,,,,,,,0.0,2015-02-11,2019-08-06,0,,,SOX,,,,,,6, 低分化腺癌（G3)(por)70% 低粘附腺癌30% Lauren弥漫型,G3, (1a)05 (1b)24 (3a)12 (3b)00 (4sb)00 (4d)05 (5)00 (6)05 (7)11 (8a)11 (8p)03 (9)04 (11p)03 (12a)00," L（幽门窦部）, 小弯侧Less,",40,30,10, R0 D2,,4.96,1.99,2.46,160.0,279.0,1.98,35.0,13.0,158.0,65.0,20.0,7.37,2.42,75.0,327.0,45.0,30.0,5.3,7.1,75.0,413.0,72.5,36.1,34.0,1.06,0.0,11.9,14.1,5.3,1.91,1.26,18.7,10.8,0.849,9.67,6.81, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,53.777923784494085,1504858
1504946,冯福,589785,女,76,T1b,N1,M0, ⅠB,1,0,0.0,0.0,0.0,0.0, 肠化生+,2.0,22,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-02-12,2021-05-17,1,,,,,,,,,0," 管状腺癌（中分化【G2】【tub2】70%, 低粘附腺癌30%. Lauren肠型",G2,肿物旁2/2 (1a)0/1 (1b)0/4 (2)0/1 (3a)0/0 (3b)0/0 (4sb)0/3 (4d)0/7 (5)0/1 (7)0/0 (8a)0/2 (8p)0/0 (9)0/0 (11p)0/1,"SiewerⅢ, 小弯侧Less,",55,40,8, R0 D2,,6.53,4.4,4.4,128.0,181.0,2.68,42.0,32.0,160.0,72.0,51.0,12.03,5.79,59.0,229.0,34.0,25.0,5.8,6.8,50.0,193.0,89.1,30.2,58.0,0.52,0.0,7.0,3.0,0.7,0.404,0.782,15.0,182.0,6.85,0.6,2.95, 未做,无, 无, P0,H0, 未做, CK+ VEGF局灶弱+ Vimentin- CMET- CD34（脉管周+） S-100（神经+）,,,,,75.09855453350853,1504946
1505134,曹彦秋,589605,女,63,T2,N1,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+,2.0,78,髓样型（med）,INFb,0.0,,1.0,,,,,0.0,2015-02-26,2021-06-21,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)06 (1b)03 (3a)010 (3b)00 (4sb)06 (4d)129 (5)15 (6)06 (7)01 (8a)00 (8p)01 (9)09 (11p)02," L（幽门窦部）, 大弯侧Gre,",20,15,10, R0 D2,,5.96,3.67,1.68,118.0,261.0,3.14,15.0,22.0,163.0,113.0,7.0,9.3,3.17,69.0,156.0,40.0,29.0,5.3,4.7,35.0,180.0,,,,,,,,,,,,,0.496,10.87,1.23, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(-)，CD34(+)， S100(+),,,,,75.78843626806832,1505134
1505005,尚广库,590947,男,48,T1a,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0,,0.0,4,中间型（int）,INFc,0.0,,1.0,,,,,2.0,2015-02-13,2020-12-17,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,大弯01小弯02 (8p)01," L（幽门窦部）, 小弯侧Less,",15,10,, R0 D2,,5.06,2.88,1.77,160.6,220.0,2.41,15.0,14.0,143.0,89.0,15.0,17.23,6.2,79.0,302.0,53.0,26.0,5.4,5.9,101.0,371.0,,,,,,,,,,,,,1.68,11.99,2.52,,无, 无, P0,H0, 未做,"CK+, Vimentin-， VEGF散在弱+， CMET散在弱+",,,,,70.10512483574244,1505005
1505126,蒋友和,591004,男,67,T2,N2,M0, ⅡB,1,2,1.0,1.0,1.0,1.0, 肠化生+,6.0,34,中间型（int）,INFc,1.0,,,,,,,0.0,2015-02-26,2016-06-24,2,,,XELOX,,,,,,8, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌20 乳头状癌（G1）（pap）10 Lauren混合型,G3, (1a)00 (1b)03 (3a)14 (3b)02 (4sb)01 (4d)03 (5)01 (6)35 (7)03 (8a)01 (8p)16 (9)03 (11p)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",90,40,10, R0 D2,,8.37,5.93,1.52,77.0,381.0,2.9,37.0,24.0,135.0,54.0,35.0,13.81,5.15,70.0,328.0,42.0,28.0,7.6,6.1,83.0,408.0,,,,,,,,,,,,,20.74,1.75,2.06,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET-,,,,,15.900131406044677,1505126
1505083,陈连军,591028,男,50,T4b,N1,M1, ⅢB,1,5,2.0,0.0,0.0,1.0, 肠化生+,2.0,19,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-02-25,2019-09-02,0,,,FOLFOX,,,,,,6, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a)12 (1b)05 (2)00 (3a)13 (3b)06 (4sb)00 (4d)02 (5)01 (6)00 (7)00," GE, SiewerⅢ, 大弯侧Gre,",30,20,10,,R2,6.74,3.51,2.44,151.0,282.0,3.01,27.0,28.0,130.0,105.0,44.0,10.13,3.56,75.0,387.0,48.0,27.0,5.4,7.0,109.0,638.0,,,,,,,,,,,,,1.53,9.6,8.85,,粟粒状, 无, p1泛(M1 PER),H0, 未做,CK+， Vimentin+， VEGF-， CMET-,,,,,54.204993429697765,1505083
1505185,李静,583391,女,55,T3,N1,M0, ⅡB,1,2,2.0,0.0,0.0,1.0, 肠化生+,1.0,32,髓样型（med）,INFc,0.0,,1.0,,,,,2.0,2015-02-26,2022-09-01,1,,,SOX,,,,,,6, 低分化腺癌（G3)(por)80 低粘附腺癌20,G3, (1a)02 (1b)01 (3a)16 (3b)02 (4sb)05 (4d)00 (5)00 (6)02 (7)04 (8a)01 (8p)06 (9)02 (11p)01," L（幽门窦部）, 小弯侧Less,",30,25,10, R0 D2,,4.08,1.7,1.94,142.0,213.0,2.54,28.0,33.0,162.0,101.0,11.0,10.02,4.35,79.0,218.0,49.0,30.0,5.4,4.6,79.0,263.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF+， CMET+,,,,,90.14454664914585,1505185
1505423,杨冬来,590285,男,35,T3,N0,M0, ⅡA,1,4,2.0,0.0,0.0,1.0, 肠化生+,0.0,21,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-02-28,2021-06-21,1,,,SOX,,,,,,6, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a)00 (1b)03 (3a)00 (3b)00 (4sb)00 (4d)05 (5)00 (6)01 (7)05 (8a)03 (8p)01 (9)01 (11p)02 (12a)00,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,70,60,5, R0 D2,,7.28,4.13,2.39,153.0,198.0,2.68,27.0,21.0,125.0,129.0,24.0,14.6,6.35,71.0,257.0,76.0,25.0,4.8,7.2,100.0,461.0,,,,,,,,,,,,,10.83,7.7,1.86, 未做,无, , P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+) CD34(+)， S100(+),,,,,75.7227332457293,1505423
1505438,常淑清,589263,女,57,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,36,中间型（int）,INFb,0.0,,,,,,,0.0,2015-02-28,2021-05-24,1,,,,,,,,,0,高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)0/3 (1b)0/3 (2)0/4 (3a)0//8 (3b)0/1 (4sa)0/0 (4sb)0/1 (4d)0/6 (5)0/0 (7)0/2 (8a) 0/2(8p)0/1 (9)0/3 (11p)0/2,"前Ant, 后Post, 小弯侧Less, L（幽门窦部）,",55,40,10, R0 D2,,6.84,3.48,2.87,120.0,253.0,1.98,20.0,22.0,133.0,68.0,21.0,8.46,2.65,61.0,283.0,39.0,22.0,5.5,9.0,37.0,259.0,83.6,64.0,12.7,5.04,0.1,10.9,4.9,3.9,1.19,1.42,8.83,146.0,1.86,1.99,1.68, 未做,无, 无, P0,H0, 未做," CK+, Vimentin -,VEGF-, CMET-, CD34(脉管周+)",,,,,74.80289093298292,1505438
1505383,乔志琴,589262,女,52,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 肠化生+,4.0,53,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-02-28,2015-09-15,2,,,SOX,,,,,,1, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a)0/5， (1b)0/2 (3a)0/13 (3b)0/0 (4sb)0/0 (4d)1/15 (5)0/0 (6)2/6 (7)0/5 (8a)1/1 (8p)0/1 (9)0/3 (11p)0/2 (12a)0/0," L（幽门窦部）, 小弯侧Less, 后Post,",70,50,15, R0 D2,,6.26,3.33,2.05,106.0,284.0,2.18,9.0,19.0,179.0,48.0,3.0,3.47,1.92,111.0,178.0,34.0,77.0,5.1,4.1,83.0,350.0,69.9,38.4,25.5,1.51,0.0,5.9,22.1,1.7,0.297,0.474,66.2,144.0,0.2,21.29,1.25, 未做,无, 无, P0,H0, 未做," CK +,Vimentin-, VEGF弱+， CMET-， CD34（脉管+） S-100（神经+）",,,,,6.5374507227332455,1505383
1506123,刘国祥,591580,男,56,T1b,N0,M0,ⅠA,1,0,0.0,1.0,1.0,0.0,,0.0,14,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-05,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)03 (3a)01 (3b)02 (4sb)00 (4d)00 (5)02 (6)00 (7)01 (8a)02 (8p)00 (9)00 (11p)01," L（幽门窦部）, 后Post,",30,25,10, R0 D2,,6.77,4.42,1.77,112.0,233.0,2.01,34.0,21.0,130.0,56.0,15.0,16.06,6.72,65.0,230.0,43.0,22.0,9.5,3.9,82.0,301.0,67.9,47.9,15.8,3.03,0.2,8.1,22.3,3.3,0.789,1.98,10.8,53.7,0.442,19.87,1.77,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,74.63863337713535,1506123
1505614,曲长辉,587720,男,54,T2,N2,M0, ⅡB,1,3,0.0,0.0,0.0,0.0, 肠化生+,4.0,17,中间型（int）,INFb,2.0,,1.0,,,,,2.0,2015-03-02,2020-04-27,0,,,XELOX,,,,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/2 (1b)0/0 (3a)0/3 (3b)0/0 (4sb)0/0 (4d)2/2 (5)0/0 (6)0/2 (7)2/2 (8a)0/1 (8p)0/2 (9)0/2 (11p)0/1," L（幽门窦部）, 前Ant,",30,30,8, R0 D2,,7.96,4.35,2.9,156.0,,3.01,20.0,19.0,138.0,91.0,16.0,5.9,2.53,63.0,231.0,40.0,23.0,5.4,5.4,81.0,449.0,84.4,26.7,50.6,0.53,0.3,7.6,7.2,15.6,0.807,1.72,10.6,90.9,0.493,24.8,1.22, 未做,无, 无, P0,H0, 未做, CMET散在弱+， Vimentin- VEGF弱+ CK +，CD34（脉管周+） S-100（神经+）,,,,,61.859395532194476,1505614
1506471,徐静霞,591443,女,70,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0,,0.0,34,中间型（int）,INFb,1.0,,1.0,,,,,0.0,2015-03-09,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90% 低粘附腺癌10% Lauren肠型,G3, (1a)00 (1b)00 (3a)09 (3b)00 (4sb)00 (4d)03 (5)00 (6)02 (7)04 (8a)04 (8p)06 (9)02 (11p)04," L（幽门窦部）, 前Ant,",40,25,, R0 D2,,4.15,2.2,1.48,137.0,174.0,2.45,22.0,28.0,168.0,75.0,22.0,12.88,3.66,76.0,269.0,47.0,29.0,5.3,7.2,60.0,254.0,66.5,40.6,21.1,1.92,0.1,13.3,18.6,1.7,0.901,2.44,15.6,6.91,0.991,7.88,3.18, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF弱（+）、 CMET（-）、 S-100+、 CD34+,,,,,74.50722733245729,1506471
1505577,胡法竹,588035,男,74,T4b,N2,M0, ⅢB,1,1,0.0,1.0,1.0,1.0, 肠化生+,3.0,8,中间型（int）,INFb,1.0,,1.0,,,,,0.0,2015-03-02,2017-01-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a) 1/1(1b) 0/0(2)1/1 (3a)0/1 (4sa)0/0 (4sb)0/0 (4d)0/1 (7) 0/0(9)0/2 (10)0/0 (11p)1/2 脾脏组织符合囊肿形成," SiewerⅢ, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,17,,R1,5.56,3.54,1.43,118.0,199.0,3.25,18.0,22.0,136.0,91.0,34.0,7.52,2.47,61.0,214.0,37.0,24.0,5.1,6.8,95.0,338.0,74.2,36.7,35.4,1.04,0.1,4.8,20.1,5.3,0.559,1.07,10.7,151.0,54.79,283.9,2.16, 未做,无, 无, P0,H0, 未做, CMET散在弱+， Vimentin -，VEGF-， CK+， S-100(神经+) CD34（脉管+）,,,,,22.503285151116952,1505577
1505609,王其水,591468,男,65,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,30,中间型（int）,INFc,0.0,,1.0,,,,,2.0,2015-03-02,2019-09-06,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)， Lauren肠型,G3,"小弯侧0/10, (1a)0/2 (1b)0/2, (2) 0/1(3b)0/6 (4sb) 0/2(4d)0/2 (5) 0/0(6)0/1 (7)0/1 (8a) 0/1(8p) 0/1(9)0/0 (11p)0/1"," G=E, SiewerⅢ, 小弯侧Less,",25,16,4, R0,,5.32,2.81,2.06,102.0,316.0,2.36,28.0,29.0,154.0,119.0,15.0,8.45,3.25,72.0,232.0,42.0,30.0,5.1,5.6,62.0,258.0,73.4,38.6,19.8,1.95,0.2,8.5,17.8,1.8,0.785,3.39,14.3,154.0,1.23,10.78,1.4, 未做,无, 无, P0,H0, 未做," CK+, Vimentin-, VEGF弱+， CMET弱+， CD34（脉管+）， S-100（神经+）",,,,,54.17214191852825,1505609
1505594,朱宪良,591599,男,73,T3,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 肠化生+,21.0,43,中间型（int）,INFc,0.0,,1.0,,,,,2.0,2015-03-02,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren弥漫型,G3, (1a)00 (1b)01 (2)02 (3a)27 (3b)00 (4sb) 00(4d)45 (5)00 (6)04 (7)04 (8a)01 (8p)01 (9)00 (11p)02 小弯66 大弯9 10,MU 大弯侧Gre  小弯侧Less 后Post ,120,110,12, R0 D2,,5.79,3.33,1.42,101.0,206.0,3.01,17.0,22.0,126.0,62.0,11.0,6.05,2.83,47.0,142.0,28.0,19.0,4.7,3.2,69.0,216.0,80.7,59.1,20.3,2.91,0.1,9.0,7.9,0.5,0.185,2.29,9.45,88.1,0.951,8.04,10.06, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET散在弱(+)  CD34(+)  S100(+),,,,,90.01314060446781,1505594
1505506,钱恩,590394,男,64,T1b,N1,M0, ⅠB,1,0,2.0,0.0,0.0,0.0,,1.0,43,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2015-03-02,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 90低粘附腺癌10 Lauren弥漫型,G3, (1a)03 (1b)04 (3a)16 (3b)00 (4sb) 03(4d)0 13 (5) 05(6)00 (7)03 (8a)02 (8p)01 (9)01 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",20,15,10, R0 D2,,10.49,6.4,2.73,137.0,341.0,4.66,16.0,17.0,114.0,86.0,14.0,6.71,2.77,64.0,121.0,36.0,28.0,5.1,5.1,50.0,241.0,70.0,39.5,28.2,1.4,0.1,11.5,17.2,4.9,0.599,2.99,18.1,369.0,0.648,8.04,1.36, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(-）  CD34(+)  S100(+),,,,,74.73718791064388,1505506
1505367,王树兰,586666,女,63,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,28,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-02-28,2021-05-24,1,,,SOX,替吉奥单药,替吉奥单药,替吉奥单药,替吉奥单药,替吉奥单药,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 粘液腺癌（muc）20 （GIST）Lauren肠型 ,G3, (1a)02 (1b)01 (3a)08 (3b)00 (4sb)01 (4d)04 (5)01 (6)01 (7)01 (8a)01 (9)03 (11p)05 (12a)00,L（幽门窦部） 小弯侧Less ,40,25,2, R0 D2,,4.61,1.88,2.16,132.6,5.0,2.31,29.0,33.0,186.0,79.0,21.0,16.84,5.3,75.0,188.0,42.0,33.0,5.9,5.0,64.0,246.0,50.4,38.7,9.4,4.12,0.0,22.9,25.1,1.9,0.865,5.0,16.6,283.0,1.43,17.88,2.14, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(-) CD34(+)， S100(+),,,,,74.80289093298292,1505367
1512621,王彦江,591677,男,43,T3,N3a,M1, Ⅳ,1,3,2.0,0.0,0.0,0.0, 肠化生+,12.0,21,中间型（int）,INFb,0.0,,1.0,,,,,2.0,2015-04-23,2021-06-21,1,SOX*2,1.0,SOX,SOX,SOX,卡佩他滨单药,,,4,低粘附腺癌  Lauren弥漫型,GX, (3b)44 (4sb)11 (4d)00 (5)00 (6)11 (7)12 (8a)04 (8p)03 (9)01 (11p)11 (12a)00, LMU 前Ant 后Post 大弯侧Gre  ,50,50,10,,R2,6.9,3.67,2.44,141.4,167.0,3.21,63.0,58.0,162.0,89.0,24.0,13.39,3.93,68.0,332.0,41.0,27.0,4.8,6.0,69.0,307.0,,,,,,,,,,,,,1.48,4.93,22.33, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(+)， S100(+)，D2-40（+）,,,,,73.94875164257556,1512621
1505648,李平,588044,男,60,T3,N3a,M0,ⅢB,1,5,2.0,0.0,0.0,1.0, 肠化生+,12.0,22,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2015-03-03,2022-09-01,1,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,多西他赛 奥沙利铂 替吉奥,多西他赛 替吉奥,6, 低分化腺癌（G3)(por)50 低粘附腺癌30 粘液腺癌（muc）20 Lauren弥漫型,G3, (1a)01 (1b)01 (3a)511 (3b)11 (4sb)11 (4d)00 (5)22 (6)22 (7)00 (8a)01 (8p)11 (9)01 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",55,40,8, R0 D2+,,2.77,1.81,0.75,134.2,140.0,2.58,14.0,15.0,133.0,84.0,35.0,5.85,2.41,62.0,226.0,39.0,23.0,4.4,5.2,74.0,233.0,79.3,50.5,23.0,2.2,0.3,9.9,8.0,3.4,2.21,1.89,10.0,6.92,1.36,7.56,2.54,,无,, P0,H0, 未做,CK + Vimentin - VEGF灶+ CMET- CD34(脉管周+)  S-100(神经+),,,,,89.98028909329828,1505648
1506122,王艳春,591008,男,55,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,38,中间型（int）,INFb,0.0,0.85,1.0,,,,,0.0,2015-03-05,2020-04-26,0,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)06 (1b)03 (2)02 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)010 (5)00 (6)05 (7)01 (8a)01 (8p)06 (9)01 (11p)01," LMU 后Post, 大弯侧Gre, 小弯侧Less,",90,70,20, R0 D2+,,9.73,6.9,1.69,147.2,317.0,2.95,16.0,19.0,114.0,74.0,13.0,14.85,6.81,61.0,123.0,36.0,25.0,5.2,4.2,79.0,178.0,82.5,36.6,38.4,0.95,0.1,4.1,9.1,16.7,0.883,1.76,14.0,449.0,2.86,9.98,4.03,,无,, P0,H0, 未做, CK+ Vimentin- VEGF弱+ CMET- CgA- Syn- CD34脉管周+ S-100神经+,,,,,61.727989487516425,1506122
1505925,王云波,540368,女,60,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,0.0, 肠化生+,12.0,30,中间型（int）,INFc,0.0,,1.0,,,,,2.0,2015-03-04,2016-10-21,2,,,SOX,,,,,,6, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)04 (3a)14 (3b)11 (4sb)00 (4d)57 (5)02 (6)11 (7)00 (8a)02 (8p)12 (9)11 (11p)24,L（幽门窦部） 小弯侧Less 后Post ,55,45,9,,R1,7.76,3.96,3.21,147.0,238.0,3.51,22.0,25.0,166.0,85.0,15.0,23.48,5.89,74.0,223.0,45.0,29.0,4.7,5.5,88.0,279.0,74.8,45.0,25.1,1.79,0.1,9.7,14.6,2.2,0.351,2.96,15.6,5.0,1.24,16.4,17.52, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(+)， S100(+),,,,,19.612352168199735,1505925
1506581,吕林友,589897,男,57,T3,N1,M0, ⅡB,1,3,2.0,0.0,0.0,0.0, 肠化生+,1.0,13,硬型（sci）,INFc,0.0,,,,,,,0.0,2015-03-10,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a) (1b)04 (3a) (3b)14 (4sb)03 (4d)00 (5)01 (6)00 (7)00 (8a)00 (9)00 (10)01 (12a)00," L（幽门窦部）, 小弯侧Less,",40,30,6, R0 D2,,8.84,5.43,2.51,146.0,298.0,16.0,26.0,10.0,138.0,80.0,22.5,15.86,4.16,68.4,267.19,46.0,22.4,5.4,4.18,87.0,325.0,70.0,40.6,23.8,1.71,0.5,12.1,12.9,0.7,1.04,1.18,11.8,572.0,1.51,7.65,2.56, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,74.47437582128778,1506581
1505655,贾桂荣,584361,女,59,T1a,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+,0.0,38,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2015-03-03,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren弥漫型,G3, (1a)02 (1b)00 (3a) 0 15(3b)00 (4sb)05 (4d)04 (5)00 (6)05 (7)01 (8a)01 (8p)00 (9)02 (11p)03," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,15,, R0 D2,,5.76,3.21,2.12,119.2,230.0,2.73,28.0,29.0,142.0,75.0,20.0,5.36,1.97,62.0,263.0,37.0,25.0,5.0,4.6,81.0,344.0,69.9,40.7,24.2,1.68,0.2,15.3,13.9,3.0,1.15,2.32,13.8,34.4,1.08,11.35,30.06, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF灶(+)  cMET(-)  CD34(+)  ,,,,,74.70433639947437,1505655
1506156,袁淑荣,591535,女,62,T4a,N1,M0, ⅢA,1,3,2.0,0.0,0.0,1.0, 肠化生+,2.0,20,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2015-03-05,2020-04-26,0,,,,,,,,,0, 低粘附腺癌 70低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a)01 (1b)012 (3a)00 (3b)00 (4sb)00 (4d)00 (5)00 (6)02 (7)00 (8a)23 (8p)00 (9)02 (11p)00 (16a1)00,L（幽门窦部） 前Ant 小弯侧Less 后Post ,85,60,10, R0 D2,,5.0,3.17,1.38,140.4,107.0,1.59,43.0,40.0,175.0,41.0,10.0,14.59,4.73,66.0,178.0,38.0,28.0,5.8,6.8,49.0,298.0,66.8,48.7,15.7,3.1,0.2,17.5,13.8,0.5,0.642,2.15,19.4,20.5,0.747,23.46,15.22, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(-)  CD34(+)  S100(+),,,,,61.727989487516425,1506156
1506675,高英廷,591567,男,62,T3,N0,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+,0.0,29,中间型（int）,INFc,0.0,,,,,,,0.0,2015-03-10,2019-03-31,0,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/2 (1b)0/2 (3a)0/6 (3b)0/1(4sb)0/0 (4d)0/7 (5)0/0 (6)0/1(7) 0/0(8a) 0/1(8p)0/6 (9)0/1 (11p)0/1 (12a) 0/1," L（幽门窦部）, 后Post,",55,40,15, R0,,7.35,4.81,1.88,131.4,200.0,3.11,17.0,24.0,114.0,67.0,11.0,12.77,4.27,65.0,212.0,40.0,25.0,4.9,5.4,60.0,252.0,70.3,52.9,12.3,4.3,0.1,11.0,16.2,2.0,2.0,3.11,10.0,49.4,4.67,2.03,1.51, 未做,无,, P0,H0, 未做," CK+ Vimentin-, CMET -,VEGF-, CD34(脉管+) S-100（神经+）",,,,,48.68593955321945,1506675
1506449,张伟旭,588082,女,58,T3,N1,M0, ⅡB,1,3,2.0,1.0,1.0,1.0, 肠化生+,1.0,40,中间型（int）,INFc,2.0,,1.0,,,,,0.0,2015-03-09,2020-04-27,1,,,XELOX,,,,,,4, 低分化腺癌（G3)(por)55 管状腺癌（中分化【G2】【tub2】30 粘液腺癌（muc）15 Lauren弥漫型,G3, (1a)04 (1b)07 (3a)17 (3b)02 (4sb)00 (4d) 09(5) 00(6)04 (7)01 (8a) 03(8p)00 (9) 02(11p)01,L（幽门窦部） 小弯侧Less ,40,25,12, R0 D2,,6.68,3.75,2.27,130.8,275.0,2.09,52.0,44.0,174.0,118.0,8.0,8.38,2.48,71.0,234.0,40.0,31.0,4.8,3.1,60.0,221.0,69.2,45.0,17.9,2.51,0.0,15.3,13.6,4.4,0.662,2.27,21.4,22.0,8.45,26.18,300.0, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(-)  CD34(+)  S100(+),,,,,61.629434954007884,1506449
1506128,马金山,590343,男,68,T4b,N3a,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 肠化生+,9.0,27,硬型（sci）,INFc,0.0,,1.0,,,,,0.0,2015-03-05,2017-12-05,2,,,,,,,,,0, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren弥漫型,G3, (1a)01 (1b)13 (3a)12 (3b)11 (4sb)02 (4d)36 (5)00 (6)02 (7)03 (8a)01  (8p)03 (12a)00, L（幽门窦部） 小弯侧Less 后Post ,60,50,15,,R2,5.37,3.81,0.86,83.5,204.0,2.85,9.0,18.0,225.0,44.0,68.0,2.68,1.3,53.0,97.0,31.0,22.0,5.6,5.2,75.0,238.0,69.0,30.8,35.7,0.86,0.1,11.9,13.7,1.4,0.587,1.67,12.4,51.8,3.8,7.18,1.4, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(-)，CD34(+)， S100(+),,,,,33.04862023653088,1506128
1506652,韩喜太,590384,男,63,T4b,N3b,M0, ⅢC,1,5,0.0,1.0,1.0,1.0, 肠化生+,16.0,50,中间型（int）,INFc,3.0,,1.0,,,,,1.0,2015-03-10,2016-09-30,2,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 低粘附腺癌30% Lauren肠型,G3,大弯58 (1a)11 (1b)13 (2)01 (3a)12 (3b)00 (4sb) (4d)23 (5)00 (6)38 (7)00 (8a)12 (8p)02 (9)013 (11p)00," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",70,60,10,,R1,4.15,2.0,1.69,128.0,132.0,2.18,22.0,30.0,166.0,59.0,8.0,8.97,3.48,59.0,178.0,38.0,21.0,4.6,7.7,70.0,196.0,58.6,38.4,19.4,1.98,0.1,15.6,24.3,0.3,0.482,2.47,10.5,21.2,0.877,9.3,1.7, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF灶（+）、 CMET灶（+）、 CD34+、 S-100+,,,,,18.725361366622863,1506652
1506470,于淑霞,590391,女,48,T1a,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+,0.0,56,中间型（int）,INFc,0.0,,,,,,,0.0,2015-03-09,2022-09-01,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)02 (1b)03 (3a)011 (3b)00(4sb)01 (4d)018 (5)01 (6)03 (7)02 (8a)01 (8p) 04(9)03 (11p)01 小弯06," L（幽门窦部）, 小弯侧Less,",30,20,4, R0 D2,,8.67,5.19,3.12,133.6,194.0,1.62,16.0,21.0,156.0,29.0,12.0,16.37,5.65,69.0,185.0,40.0,29.0,4.5,4.6,64.0,249.0,66.6,45.5,17.7,2.57,0.3,6.5,25.1,1.0,1.35,2.39,17.9,5.0,1.53,20.65,0.964, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+),,,,,89.7831800262812,1506470
1506582,崔清礼,590454,男,73,T3,N1,M1, Ⅳ,1,5,0.0,0.0,0.0,0.0, 肠化生+,2.0,25,中间型（int）,INFc,2.0,0.25,,,,,,0.0,2015-03-10,2016-03-09,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】70 粘液腺癌（muc）20 乳头状癌（G1）（pap）10 Lauren肠型,G2,小弯24 (1a)05 (1b)02 (2)02 (3a)03 (3b)00 (4sb)05 (4d)01 (5)01 (6)00 (7)02," LMU 前Ant, 后Post, 小弯侧Less,",95,75,5,,R2,9.89,6.8,2.28,56.1,446.0,2.78,18.0,18.0,192.0,67.0,32.0,7.58,2.85,67.0,228.0,41.0,26.0,7.8,4.8,69.0,171.0,52.9,36.1,14.1,2.56,0.1,10.2,33.1,0.3,0.955,3.51,11.5,545.0,2.92,13.16,24.33,,无,, P0,H1多（M1 HEP), 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,11.990801576872535,1506582
1506762,姜海,590622,男,63,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0,,0.0,29,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-11,2021-05-24,1,,,,,,,,,0," 管状腺癌（高分化【G1】【tub1】）90%, 粘液腺癌（muc）10%. Lauren肠型",G1, (1a)0/3 (1b) 0/6(3a)0/9 (3b)0/1 (4sb)0/0 (4d)0/2 (5)0/0 (6)0/2 (7)0/0 (8a)0/1 (8p)0/1 (9)0/1 (11p)0/3," L（幽门窦部）, 后Post,",20,20,3, R0 D2,,8.01,4.96,2.43,152.0,252.0,3.21,22.0,26.0,173.0,59.0,19.0,17.63,5.39,66.0,286.0,43.0,23.0,6.5,7.0,68.0,354.0,68.9,41.7,25.5,1.64,0.0,12.0,18.2,0.7,0.777,2.45,10.5,55.4,0.88,5.75,3.45, 未做,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-， CD34（脉管+） S-100（神经+）,,,,,74.44152431011827,1506762
1506670,宋建华,590572,女,51,T2,N0,M0, ⅠB,1,2,0.0,1.0,1.0,0.0, 肠化生+,0.0,24,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-10,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 粘液腺癌（muc）15 Lauren肠型,G3, (1a)02 (1b)00 (2)03 (3a)010 (3b)01 (4sb)02 (4d)00 (5)00 (6)01 (7)01 (8a)02 (8p)01 (9)01," MU 前Ant,",20,15,3, R0 D2,,7.38,3.5,3.31,118.0,227.0,2.63,16.0,19.0,143.0,69.0,7.3,5.93,2.08,71.0,182.0,42.0,29.0,5.2,5.3,69.0,184.0,83.1,45.0,38.0,1.18,3.5,8.4,7.5,9.1,1.08,2.75,17.9,10.3,0.2,12.99,16.97,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,74.47437582128778,1506670
1507089,王忠环,590632,男,60,T2,N2,M0, ⅡB,1,3,0.0,1.0,1.0,0.0, 肠化生+,3.0,27,中间型（int）,INFb,3.0,,1.0,,,,,0.0,2015-03-12,2021-06-21,1,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 低粘附腺癌15 Lauren肠型,G3, (1a)00 (1b) 06(3a) 03(3b)00 (4sb)00 (4d)00 (5)00 (6) 00(7)01 (8a)00 (8p)00 (9) 00(11p)00大弯26 大网 1 11,L（幽门窦部） 后Post 大弯侧Gre  ,35,30,4, R0 D2,,5.11,3.21,0.95,145.0,146.0,2.27,16.0,20.0,149.0,58.0,15.0,5.69,2.16,56.0,187.0,36.0,20.0,4.6,6.9,75.0,221.0,78.3,60.2,14.8,4.07,0.1,2.9,18.3,2.2,0.489,0.593,9.6,54.2,1.58,7.24,5.51, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(-)  CD34(+)  S100(+),,,,,75.32851511169514,1507089
1506685,孙衍成,588127,男,63,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+,2.0,16,中间型（int）,INFc,1.0,,1.0,,,,,1.0,2015-03-10,2019-08-06,0,,,FOLFOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)12 (3b)00 (4sb)00 (4d)01 (5)00 (6)03 (7)02 (8a)11 (8p)03 (9)01 (11p)03," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,12, R0 D2+,,8.94,5.63,1.96,145.9,212.0,3.97,8.6,16.3,164.3,73.3,14.9,9.5,5.6,74.0,195.0,48.1,25.9,4.9,3.88,88.1,218.3,63.8,34.8,22.2,1.57,0.1,9.4,26.5,1.8,1.14,0.73,14.2,111.0,1.2,6.08,2.26,,无,, P0,H0, 未做,CK + Vimentin - VEGF弱+ CMET散在+ CD34(脉管周+)  S-100(神经+),,,,,52.890932982917214,1506685
1507046,胡国军,590662,男,62,T3,N0,M0, ⅡA,1,2,2.0,0.0,0.0,1.0, 肠化生+,0.0,22,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2015-03-12,2020-04-26,0,,,,,,,,,0, 低粘附腺癌60%， 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40%， Lauren肠型,G3, (1a)0/2 (1b)0/2 (3a)0/6 (3b)0/1 (4sb)0/0 (4d)0/10 (5)0/0 (6)0/3 (7)0/3 (8a)0/1 (8p)0/2 (9)0/1 (11p)0/1 (12a)0/0 (14v)0/0," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",70,70,5, R0 D2,,8.03,6.36,0.96,117.0,248.0,4.08,20.0,19.0,117.0,62.0,12.0,14.13,5.81,59.0,192.0,38.0,21.0,4.9,6.3,53.0,224.0,65.2,45.0,17.4,2.59,0.0,11.3,22.5,0.3,0.507,1.78,9.55,997.0,2.63,5.9,3.33, 未做,无, 无, P0,H0, 未做," CK+, Vimentin -,CMET- VEGF弱+ CD34（脉管+） S-100（神经+）",,,,,61.498028909329825,1507046
1518453,毕书江,590806,男,48,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 肠化生+,6.0,31,中间型（int）,INFb,1.0,,,,,,,0.0,2015-06-15,2021-05-17,1,,,SOX,,,,,,2, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)05 (1b)01 (2)02 (3a)25 (3b)00 (4sa)03 (4sb)00 (4d)01 (5)00 (6)02 (7)11 (8a)02 (8p)02 (9)02 (11p)01 (12a)00 (16a1)01肿物旁33," M（胃体部）, 小弯侧Less,",50,30,9,,R1,4.93,2.97,1.24,119.0,205.0,3.28,49.0,36.0,196.0,125.0,37.0,12.27,4.3,71.0,399.0,39.0,32.0,4.2,5.8,93.0,378.0,,,,,,,,,,,,,1.02,7.42,10.33, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,71.05781865965834,1518453
1507332,赵凤昌,590505,男,59,T1a,N0,M0,ⅠA,1,5,1.0,0.0,0.0,0.0, 未观察,0.0,55,硬型（sci）,INFc,0.0,,1.0,,,,,0.0,2015-03-16,2017-07-31,0,,,,,,,,,0," 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60%, 低粘附腺癌40%， Lauren混合型",G3,"大弯侧0/5， (1a) 0/1(1b)0/0 (3a)0/15 (3b)0/1 (4sb)0/4 (4d)0/5 (5)0/0 (6)0/10 (7)0/1 (8a)0/2 (8p)、（9）0/6, (11p)0/5, (12a)0/0, (12p)0/0"," L（幽门窦部）, 小弯侧Less,",30,30,5, R0 D2,,5.5,2.57,2.19,136.0,240.0,2.39,24.0,22.0,163.0,54.0,14.0,11.2,4.36,58.0,237.0,37.0,21.0,5.6,9.2,51.0,253.0,50.5,27.5,18.2,1.51,0.3,5.4,40.6,1.4,1.04,1.19,10.4,601.0,3.1,14.52,1.25, 未做,无, 无, P0,H0, 未做," CMET-, Vimentin- VEGF弱+， CK+",,,,,28.515111695137975,1507332
1508306,蔡丽,590701,女,48,T4a,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,4.0,55,中间型（int）,INFb,3.0,,,,,,,0.0,2015-03-23,2022-09-01,1,,,XELOX,XELOX,XELOX,紫杉醇联合替吉奥,紫杉醇联合替吉奥,替吉奥单药,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90%， 粘液腺癌（muc）10%， Lauren肠型,G3, (1a)0/0 (1b)0/0 (3a)0/23 (3b)1/2 (4sb)0/7 (4d)2/8 (5)0/0 (6)0/3 (7)0/3 (8a)1/2 (8p)0/5 (9)0/0 (11p) 0/2(12a)0/0," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,50,10,,R1,16.72,14.72,1.49,127.7,275.0,3.46,15.0,23.0,149.0,70.0,4.0,7.89,3.41,67.0,116.0,41.0,26.0,7.8,7.5,72.0,378.0,58.5,27.1,27.3,0.99,0.1,6.8,32.8,3.0,2.31,2.55,19.6,120.0,41.49,1000.0,25.81, 未做,无, 无, P0,H0, 未做," CK+, Vimentin-, VEGF-,CMET-, CD34(脉管+) S-100（神经+）",,,,,89.32325886990802,1508306
1507543,由信文,592403,男,38,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,20,中间型（int）,INFc,2.0,,1.0,,,,,0.0,2015-03-17,2021-05-24,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)05 (3a)03 (3b)00 (4sb)00 (4d)00 (5)00 (6)05 (7)02 (8a)01 (8p)01 (9)03 (12a)00 (14v)00," L（幽门窦部）, 小弯侧Less,",50,30,5, R0 D2,,8.44,4.5,3.34,168.2,236.0,2.15,49.0,32.0,188.0,77.0,44.0,17.86,6.09,75.0,372.0,48.0,27.0,4.5,4.8,86.0,435.0,73.5,29.7,26.3,1.13,0.2,7.3,17.4,7.4,0.937,2.95,20.2,100.0,0.902,20.69,1.26, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF弱（+）、 CMET（-）,,,,,74.24441524310117,1507543
1507415,李相臣,592393,男,57,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,10.0,45,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-03-16,2021-06-21,1,,,替吉奥,,,,,,1, 管状腺癌（中分化【G2】【tub2】65 乳头状癌（G1）（pap）35 Lauren肠型,G2, (1a)14 (1b)17(2)01 (3a) 22(3b)02 (4sb) 01(4d)17 (5)23 (6)28 (7)01 (8a)03 (8p)00 (9)00 (11p)12大弯04  6组软组织可见癌,L（幽门窦部） 小弯侧Less 前Ant 后Post ,80,70,16, R0 D2,,6.17,2.87,2.43,93.0,258.0,3.59,9.0,16.0,132.0,72.0,8.0,7.17,3.29,64.0,231.0,37.0,27.0,5.4,5.3,91.0,269.0,54.8,30.0,22.0,1.36,0.1,4.6,37.8,1.4,0.487,1.95,16.3,2410.0,61.28,6.32,1.52, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(-)  CD34(+)  S100(+),,,,,75.19710906701708,1507415
1507346,相克勤,592398,男,67,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,25,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2015-03-16,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b) 01(2) 02(3a)08 (3b) 03(4sa)00 (4sb)00 (4d)02 (5)00 (6)00 (7)01 (8a)04 (8p)02 (9)00 (11p)01,ML 小弯侧Less ,20,20,5, R0 D2,,9.91,6.64,2.36,140.9,308.0,5.16,26.0,27.0,165.0,105.0,39.0,25.31,8.31,72.0,236.0,46.0,26.0,5.4,4.0,77.0,388.0,70.5,35.0,26.6,1.32,0.1,18.3,9.8,5.5,0.757,2.12,12.6,291.0,4.94,20.53,4.14, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(-)  CD34(+)  S100(+),,,,,89.55321944809461,1507346
1507726,雷德春,592435,男,61,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,9.0,40,中间型（int）,INFb,2.0,,1.0,,,,,0.0,2015-03-18,2017-09-06,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (2)01 (3a)313 (3b)24 (4sa)13 (4sb)00 (4d)111 (5)00 (6)01 (7)01 (8a)02 (8p)01 (9)11 (11p)11 3a，5 软组织可见癌," M（胃体部）, 小弯侧Less,",60,50,20, R0 D2,,7.48,4.66,2.22,157.0,227.0,3.59,24.0,25.0,175.0,95.0,14.0,8.67,3.63,65.0,198.0,39.0,26.0,4.5,6.3,71.0,217.0,73.2,34.5,35.6,0.97,0.1,7.9,16.3,1.3,1.47,3.2,18.3,224.0,0.745,7.38,2.66, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(-)，CD34(+)， S100(+),,,,,29.664914586070957,1507726
1507453,赵学增,590895,男,63,T4b,N1,M0, ⅢB,1,4,0.0,1.0,1.0,1.0, 肠化生+,2.0,10,中间型（int）,INFc,3.0,,,,,,,0.0,2015-03-16,2021-01-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌20 粘液腺癌（muc）10 Lauren肠型,G3, (1a)01 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)00 (5)01 (6)01 (7)22 (8a)03 (8p)00 (9)00 (11p)01," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",,,,,R1,7.48,4.89,2.01,151.0,268.0,2.8,16.0,25.0,189.0,77.0,11.0,16.29,5.18,76.0,287.0,46.0,30.0,5.2,7.2,62.0,284.0,64.0,23.7,34.2,0.69,0.1,6.9,27.7,2.7,5.51,3.8,18.2,28.4,0.685,16.21,1.55,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF- ，CMET-,,,,,69.57950065703022,1507453
1507443,刘士林,592751,男,63,T4b,N3a,M0, ⅢC,1,4,0.0,0.0,0.0,1.0,肠化生+,9.0,26,中间型（int）,INFc,2.0,,1.0,,,,,0.0,2015-03-16,2017-08-15,2,,,,,,,,,0,浸润型混合性癌（低粘附性癌为主，中低分化管状腺癌30%）,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,60,20, D2+,R1,5.7,3.52,1.65,157.8,178.0,2.9,22.0,23.0,136.0,78.0,6.0,5.77,3.33,63.0,208.0,39.0,24.0,5.6,7.7,72.0,294.0,56.5,27.2,15.5,1.75,1.0,8.4,32.0,0.6,0.921,2.04,20.4,5.0,1.24,14.5,3.68,,无, 无, P0,H0, 未做,,,,,,29.00788436268068,1507443
1507672,管成仁,592437,男,70,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+,5.0,23,硬型（sci）,INFc,1.0,,1.0,,,,,2.0,2015-03-17,2021-05-17,1,,,奥沙利铂联合替加氟,,,,,,1, 低粘附腺癌 80管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)20,G3, (1a)01 (1b)04 (3a) 11(3b)02 (4sb)03 (4d)12 (5)22 (6)11 (7)02 (8a)00 (8p)00 (9) 02(11p)02 (12a)01,L（幽门窦部） 小弯侧Less 前Ant 后Post ,30,15,10, R0 D2,,7.82,5.78,1.45,154.8,334.0,5.16,12.0,11.0,143.0,98.0,25.0,7.3,3.0,66.0,228.0,36.0,30.0,4.3,4.5,71.0,284.0,64.6,56.4,6.7,8.42,0.1,10.8,20.2,1.0,1.42,4.09,16.7,115.0,1.42,58.54,3.5, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF灶(+)  cMET散在弱(+)  CD34(+)  S100(+),,,,,74.01445466491458,1507672
1507523,孔宪君,592731,男,59,T2,N3a,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+,9.0,51,中间型（int）,INFa,0.0,,1.0,,,,,0.0,2015-03-17,2019-05-03,0,,,SOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)07 (3a)213 (3b)06 (4sb)00 (4d)611 (5)11 (6)00 (7)03 (8a)02 (8p)02 (9)00 (11p)03 (12a)00 (14v)00," L（幽门窦部）, 大弯侧Gre,",30,25,8, R0 D2,,5.48,3.42,1.42,119.7,369.0,3.28,22.0,20.0,153.0,61.0,32.0,4.86,2.09,70.0,418.0,40.0,30.0,5.1,8.6,94.0,396.0,,,,,,,,,,,,,1.25,7.36,3.1, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF弱（+）、 CMET（-）、 CD34+、 S-100+,,,,,49.5400788436268,1507523
1508364,白景芝,588163,女,58,T4b,N2,M0, ⅢB,1,4,0.0,1.0,1.0,1.0, 肠化生+,4.0,50,中间型（int）,INFb,2.0,,,,,,,0.0,2015-03-23,2016-03-15,2,,,,,,,,,0, 低粘附腺癌80% 低分化腺癌（G3)(por)20% Lauren肠型,G3,肿物旁47 (1a)02 (1b)06 (3a)06 (3b)00 (4sb)01 (4d)06 (5)09 (6)00 (7)02 (8a)01 (8p)08 (9)01 (11p)01 (12a)00," L（幽门窦部）,  M（胃体部）, U（胃底部）, 前Ant, 后Post, 小弯侧Less,",80,70,10,,R1,3.55,1.37,1.78,138.7,185.0,2.01,13.0,19.0,194.0,115.0,21.0,11.81,4.61,66.0,267.0,41.0,25.0,5.2,7.2,61.0,201.0,,,,,,,,,,,,,69.58,17.94,1.24, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,11.76084099868594,1508364
1507621,高泽民,592827,男,63,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+,1.0,28,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-03-17,2018-06-06,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)55 乳头状癌（G1）（pap）45 Lauren肠型,G3, (1a)00 (1b)02 (3a)12 (3b)01 (4sb)00 (4d)010 (5)00 (6)03 (7)01 (8a)00 (8p)05 (9)01 (11p)02 大弯01," L（幽门窦部）, 小弯侧Less,",60,60,10, R0 D2,,5.92,3.94,1.47,102.3,264.0,4.9,22.0,21.0,118.0,88.0,10.0,6.82,2.22,65.0,144.0,40.0,25.0,6.5,6.8,54.0,207.0,60.0,43.2,13.7,3.5,0.1,13.5,24.9,1.1,1.15,3.21,15.8,11.5,1.39,33.91,2.39, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(-)  CD34(+)  S100(+),,,,,38.66622864651774,1507621
1507745,李胜作,593215,男,69,T2,N0,M0, ⅠB,1,2,0.0,1.0,1.0,0.0, 肠化生+,0.0,16,中间型（int）,INFb,2.0,,1.0,,,,,0.0,2015-03-18,2018-10-05,2,,,SOX,,,,,,1," 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por), Lauren肠型",G3, (1a)0/0 (1b)0/0 (2)0/1 (3a)0/0 (3b)0/4 (4sa)0/0 (4sb)0/0 (4d)0/4 (5)0/0 (6)0/0 (7)0/1 (8a)0/0 (8p)0/2 (9)0/0 (11p)0/4,"小弯侧Less, M（胃体部）,",70,60,20, R0 D2,,5.53,3.08,1.83,148.0,279.0,2.24,62.0,68.0,183.0,181.0,33.0,14.33,5.61,66.0,202.0,39.0,27.0,5.0,4.1,59.0,250.0,48.5,26.1,21.5,1.21,0.2,8.1,41.2,2.1,1.01,1.77,23.7,114.0,0.948,9.19,5.39, 未做,无, 无, P0,H0, 未做," CK+, VEGF弱+， Vimentin-， CMET-， CD34（脉管+） S-100（神经+）Syn灶+ CgA灶+",,,,,42.60840998685939,1507745
1507830,张文彬,590827,男,64,T1b,N1,M0, ⅠB,1,0,0.0,0.0,0.0,0.0,,1.0,29,中间型（int）,INFb,2.0,,1.0,,,,,2.0,2015-03-18,2021-05-24,1,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)03 (3b)01 (4sb)01 (4d)05 (5)03 (6)02 (7)00 (8a)11 (8p)03 (9)02 (11p)05 (12a)00 (14v)01," L（幽门窦部）, 小弯侧Less,",25,20,10, R0 D2,,4.67,2.31,1.9,155.0,203.0,2.09,32.0,30.0,133.0,53.0,21.0,20.69,7.85,67.0,341.0,40.0,27.0,5.2,5.4,79.0,370.0,79.8,49.2,24.0,2.05,0.2,7.9,11.2,4.1,1.17,1.36,16.8,16.7,0.493,8.42,1.24, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF弱（+）、 CMET散在弱（+）,,,,,74.21156373193166,1507830
1508495,吕树东,590803,男,58,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,10.0,38,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-24,2016-07-14,2,,,XELOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/6 (1b）2/6 (3a）2/4(3b）0/0 (4sb)0/0 (4d)1/3 (5)0/0 (6)4/6 (7)0/5 (8a)1/2 (8p)0/1 (9)0/2 (11p)0/3 (12a)0/03b组 4d组可见4枚癌结节," L（幽门窦部）, 前Ant,",30,25,6, R0 D2,,5.12,2.76,1.76,150.5,197.0,2.33,13.0,17.0,114.0,73.0,3.0,21.97,8.93,70.0,220.0,43.0,27.0,4.3,8.5,90.0,362.0,65.2,34.5,23.2,1.49,0.1,8.1,22.8,4.7,0.979,2.0,14.5,5.0,0.771,11.65,1.87, 未做,无, 无, P0,H0, 未做," CMET-, Vimentin-, VEGF-, CK+, CD34(  脉管+） S-100（神经+）",,,,,15.703022339027594,1508495
1507997,张百文,592365,男,68,T3,N1,M0, ⅡB,1,1,0.0,1.0,1.0,1.0, 肠化生+,2.0,27,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-03-19,2015-08-02,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3,小弯17  (1a)01 (1b)04 (3a)00 (3b)00 (4sb)00 (4d)04 (5)00 (6)01 (7)00 (8a)00 (8p)01 (9)05 (11)00 (11p)03 (17)11," UM 小弯侧Less,",60,50,15, R0 D2+,,6.43,4.47,1.47,134.0,242.0,4.23,10.0,11.0,129.0,87.0,20.0,5.14,2.18,66.0,173.0,41.0,25.0,5.3,5.4,76.0,298.0,79.5,29.2,21.2,1.38,0.1,3.1,15.5,14.1,1.05,1.64,13.1,7.64,1.15,9.2,1.08,,无,, P0,H0, 未做,CK + Vimentin (- VEGF(灶+) CMET(散在+) CD34(脉管周+)  S-100(神经+),,,,,4.467805519053877,1507997
1508554,高雪松,591147,男,44,T4a,N1,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,1.0,24,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-24,2021-06-21,1,,,SOX,,,,,,5, 管状腺癌（中分化【G2】【tub2】90% 乳头状癌（G1）（pap）10% Lauren肠型,G2, (1a)01 (1b)13 (3a)01 (3b)01 (4sb)00 (4d)06 (5)00 (6)01 (7)01 (8a)03 (8p)04 (9)01 (11p)02 (12a)00," L（幽门窦部）, 后Post,",60,50,20, R0 D2,,3.47,1.49,1.66,142.0,242.0,1.68,19.0,22.0,132.0,75.0,30.0,13.78,4.47,64.0,338.0,39.0,25.0,4.6,5.3,72.0,290.0,65.5,39.2,21.9,1.79,0.3,7.1,25.0,1.3,1.21,1.51,14.6,7.8,1.68,2.03,18.68, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,74.93429697766096,1508554
1508363,郑宝才,592230,男,46,T4a,N3a,M0, ⅢB,1,1,2.0,1.0,1.0,1.0, 肠化生+,15.0,44,中间型（int）,INFc,1.0,,,,,,,0.0,2015-03-23,2019-04-13,0,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por) 30 Lauren弥漫型,G3, (1a)01 (1b)13 (3a)2 13 (3b)00 (4sb)01 (4d)11 12 (5)00 (6)00 (7)01 (8a)03 (8p)03 (9) 14(11p)02 (12p)01," L（幽门窦部）, 大弯侧Gre,",50,40,10, R0 D2,,6.09,3.09,2.29,143.9,187.0,2.68,11.0,16.0,99.0,59.0,14.0,17.76,7.42,58.0,219.0,36.0,22.0,4.5,9.1,85.0,287.0,72.7,40.8,25.5,1.6,0.2,14.3,9.5,1.0,1.49,1.33,13.9,82.5,0.999,7.43,1.17, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,48.68593955321945,1508363
1508606,宋庆开,593038,男,62,T4b,N0,M0, ⅢA,1,4,2.0,1.0,1.0,1.0,,0.0,19,中间型（int）,INFc,0.0,,,,,,,0.0,2015-03-24,2016-09-02,2,,,DX,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)04 (1b)02 (2)04 (3a)01 (3b)01 (4sa)00 (4sb)00 (4d)05 (5)00 (6)00 (7)00 (8a)00 (8p)01 (9)00 (11p)01," LMU 前Ant, 后Post, 小弯侧Less,",40,40,10, R0 D2,,6.23,3.92,1.74,151.8,167.0,2.17,15.0,15.0,156.0,84.0,18.0,12.38,4.45,66.0,282.0,42.0,24.0,5.4,6.4,61.0,169.0,64.1,41.3,20.5,2.01,0.4,16.3,17.4,1.6,0.475,1.78,15.2,18.9,,,,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,17.345597897503286,1508606
1508698,于留兰,592237,女,63,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0,肠化生+,0.0,14,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-25,2016-11-17,2,,,,,,,,,0, 低粘附腺癌90 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10 Lauren肠型,G3, (1a)01 (1b)01 (3a)04 (3b)00 (4sb)00 (4d)00 (5)00 (6)02 (7)00 (8a)01 (8p)03 (9)02 (11p)00,L（幽门窦部） 小弯侧Less 后Post,55,40,10, D2 R0,,5.9,3.17,2.14,138.5,230.0,2.42,11.0,15.0,158.0,63.0,6.0,7.43,2.79,57.0,233.0,39.0,18.0,6.3,4.5,72.0,448.0,61.0,38.4,20.5,1.87,0.7,10.3,25.9,0.7,0.583,1.73,9.92,10.6,0.947,5.99,2.07,,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)，CD34(+)， S100(+),,,,,19.80946123521682,1508698
1508398,吕占林,592883,男,45,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,42,中间型（int）,INFa,0.0,,,,,,,0.0,2015-03-23,2019-08-12,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】65 低粘附腺癌35 Lauren肠型,G2, (1a)01 (1b)09 (3a)00 (3b)00 (4sb)00 (4d)00 (5)00 (6)011 (7)07 (8a) (8p)01 (9)02 (11p)05 (12a)00 (14v)02 (16a1)04," LM 小弯侧Less,",35,25,8, R0 D2,,5.46,2.55,2.16,138.0,177.0,1.56,15.0,17.0,152.0,57.0,24.0,11.27,3.68,59.0,300.0,38.0,21.0,4.8,7.1,77.0,285.0,73.0,51.5,18.8,2.74,0.1,14.3,10.4,0.9,0.596,1.51,8.45,15.0,1.4,5.65,1.8,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,52.660972404730614,1508398
1507944,徐丽萍,592624,女,41,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,4.0,26,中间型（int）,INFc,0.0,,,,,,,0.0,2015-03-19,2021-05-24,1,,,SOX,,,,,,5, 低粘附腺癌70% 低分化腺癌（G3)(por)30% Lauren肠型,G3, (1a)00 (1b)00 (3a)18 (3b)25 (4sb)01 (4d)04 (5)11 (6)00 (7)01 (8a)01 (11p)04 (12a)01 (12p)00," L（幽门窦部）,  小弯侧Less,",25,25,6, R0 D2,,7.35,3.29,3.53,141.2,278.0,2.21,14.0,22.0,138.0,60.0,7.0,17.85,5.36,71.0,243.0,45.0,26.0,4.4,4.6,51.0,241.0,79.4,21.9,15.4,1.42,0.2,7.2,11.2,16.2,0.927,2.22,13.9,127.0,0.334,18.74,5.34, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34+、 S-100+,,,,,74.17871222076215,1507944
1508583,崔鹏洲,590778,男,62,T3,N2,M0, ⅢA,1,2,0.0,0.0,0.0,1.0, 肠化生+,3.0,31,中间型（int）,INFb,0.0,,,1.0,,,,0.0,2015-03-24,2020-05-18,0,,,替吉奥单药,替吉奥单药,SOX,SOX,,,4, 管状腺癌（中分化【G2】【tub2】60 粘液腺癌（muc）40,G2, (1a)02 (1b)00 (3a)26 (3b)00 (4sb)01 (4d)07 (5)12 (6)03 (7)01 (8a)03 (8p)02 (9)00 (11p)04," LM 前Ant, 后Post, 小弯侧Less,",70,60,20, R0 D2,,5.68,3.68,1.32,130.7,136.0,2.54,30.0,30.0,123.0,92.0,10.0,5.34,2.38,59.0,177.0,34.0,25.0,4.7,4.7,62.0,334.0,72.5,51.4,16.9,3.04,0.2,10.9,13.1,1.3,0.897,3.44,16.4,174.0,,86.47,1.95,,无,, P0,H0, 未做,CK + Vimentin + VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,61.826544021024965,1508583
1508590,张桂兰,592242,女,58,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0, 正常,0.0,29,,,2.0,,,,,,,0.0,2015-03-24,2021-05-24,1,,,,,,,,,0, 高级别上皮内瘤变 管状腺癌（高分化【G1】【tub1】）,G1, (1a) 0/0  (1b) 0/0(3a)0/4 (3b)0/0 (4sb)0/0 (4d)0/15 (5)0/0 (6)0/3 (7)0/2 (8a)0/2  (9)0/1 (11p)0/1 (12a)0/1," L（幽门窦部）, 后Post,",70,50,, R0 D2,,7.23,3.87,2.9,136.9,311.0,2.6,13.0,19.0,147.0,95.0,14.0,21.13,5.3,67.0,242.0,38.0,29.0,5.1,5.4,65.0,253.0,50.1,40.4,23.8,1.7,0.5,0.5,21.1,2.0,1.17,2.77,19.4,5.0,0.969,18.57,4.11, 未做,无, 无, P0,H0, 未做," CK +,Vimentin -,CMET-, VEGF-",,,,,74.01445466491458,1508590
1508830,钱宏利,593403,男,58,T4b,N0,M0, ⅢA,1,5,0.0,1.0,1.0,1.0, 肠化生++,0.0,31,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-25,2021-05-24,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/0 (1b)0/0 (3a)0/6 (3b)0/4 (4sb)0/0 (4d)0/0 (5)0/0 (6)0/5 (7)0/2 (8a)0/10 (8p)0/2 (9)0/1 (12a)0/1," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,45,25, R0 D2,,7.67,4.63,2.09,137.7,209.0,2.97,40.0,32.0,126.0,81.0,12.0,9.48,3.76,68.0,197.0,42.0,26.0,4.9,4.0,62.0,346.0,65.6,42.2,19.4,2.18,0.7,19.0,11.4,2.5,0.735,1.95,13.4,16.6,0.972,7.14,1.14, 未做,无, 无, P0,H0, 未做, CMET-， Vimentin-， VEGF-， CK+， S-100（神经+） CD34（脉管+）,,,,,73.98160315374507,1508830
1508608,钱富起,592939,男,61,T4b,N2,M0, ⅢB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 鳞状上皮,4.0,28,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-24,2017-08-09,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (2)17 (3a)29 (3b)01 (4sa)01 (4sb) 00(4d)01 (5)00 (6)03 (7)04 (8a)01 (8p)11 (9)00 (11p)00,GE SiewerⅢ型 后Post 大弯侧Gre ,35,30,10,,R1,5.04,1.82,2.64,188.2,46.0,1.93,37.0,39.0,300.0,87.0,52.0,17.24,5.14,65.0,183.0,41.0,24.0,6.1,5.5,70.0,285.0,76.9,33.2,42.6,0.78,0.8,4.2,17.9,0.9,1.01,2.79,12.8,177.0,35.95,2.24,2.51, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,28.54796320630749,1508608
1509297,姜桂廷,593621,男,61,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,45,中间型（int）,INFa,2.0,,,,,,,0.0,2015-03-30,2020-04-26,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,"大网淋巴结0/0 ,小弯侧0/1(1a)0/4 (1b)0/3 (3a)0/15 (3b)0/0 (4sb)0/1 (4d)0/10 (5)0/1 (6)0/1 (7)0/4 (8a)0/1 (8p)0/1 (9)0/0 (11p)0/3 (12)0/0"," L（幽门窦部）, 小弯侧Less,",25,20,15, R0,,4.32,1.77,1.98,149.3,266.0,4.45,12.0,18.0,197.0,120.0,36.0,14.16,5.4,70.0,206.0,38.0,32.0,5.3,4.6,78.0,266.0,62.5,35.4,22.0,1.61,0.2,6.4,29.1,0.8,0.651,3.93,16.5,6.91,2.16,9.41,1.51, 未做,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF- CK+,,,,,60.906701708278575,1509297
1509377,吕凤云,593682,女,66,T4a,N3a,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,13.0,25,中间型（int）,INFb,1.0,,,,,,,0.0,2015-03-30,2019-04-13,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)24 (1b)00 (2)11 (3a)34 (3b)33 (4sa)00 (4sb)00 (4d)05 (5)00 (6) 11(7)00 (8a)03 (8p)00 (9)01 (11p)00 (12a)11 (10)11  胃旁11," GE, SiewerⅢ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,20, R0 D2,,6.91,3.4,1.89,129.3,390.0,2.58,18.0,22.0,143.0,71.0,14.0,7.46,2.6,63.0,178.0,37.0,26.0,4.8,4.5,52.0,261.0,64.6,31.7,29.0,1.09,0.2,10.8,22.6,3.1,0.596,2.71,17.0,294.0,2.88,14.18,1.53, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,48.45597897503285,1509377
1508672,杨洪英,593467,女,47,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,25.0,41,中间型（int）,INFb,1.0,,,,,,,0.0,2015-03-25,2015-10-21,2,,,SOX,,,,,,6, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren肠型,G3, (1b)13 (3a)614 (3b)01 (4sb)00 (4d)55 (5)11 (6)1010 (7)12 (8a)11 (8p)01 (9)00 (11p)02 (12a)01 (14v)00," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,35,5,,R1,9.63,6.81,2.12,117.0,428.0,4.03,17.0,24.0,175.0,71.0,24.0,6.27,2.24,69.0,202.0,43.0,26.0,4.9,2.5,53.0,237.0,59.9,36.7,19.2,3.49,0.1,13.8,22.0,1.2,1.13,1.74,14.5,35.1,0.579,461.2,15.81,,无, 无, P0,H0, 未做,CK+， Vimentin-，VEGF-， CMET-,,,,,6.898817345597897,1508672
1508773,贺宝林,593734,男,59,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,0.0, 肠化生+,4.0,44,中间型（int）,INFa,3.0,,,,,,,0.0,2015-03-25,2021-05-24,1,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】75 乳头状癌（G1）（pap）15 粘液腺癌（muc）10 Lauren肠型,G2,小弯02 (1a)01 (1b)04 (3a)25 (3b)00 (4sb)00 (4d)015 (5)11 (6)04 (7)02 (8a、8p、12a)11 (9)06 (11p)03," ML 小弯侧Less,",40,32,5, R0 D2,,6.69,3.83,2.19,156.9,173.0,3.33,22.0,23.0,178.0,69.0,21.0,6.15,2.46,62.0,252.0,39.0,23.0,5.3,5.1,69.0,276.0,69.2,44.3,15.2,2.91,0.1,12.5,13.1,6.9,0.812,1.43,13.3,17.9,14.65,2.04,9.43,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,73.98160315374507,1508773
1508974,贾名师,594028,男,73,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+,3.0,26,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-26,2016-11-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】70 粘液腺癌（muc）30 Lauren肠型,G2,小弯14 (1a)00 (1b)01 (2)02 (3a)01 (3b)17 (4sa)11 (4sb)00 (4d)05 (5)00 (6)02 (7)00 (8a)00 (8p)00 (9)00 (11p)03 (12a)00," UM 前Ant, 后Post, 小弯侧Less,",80,70,8, R0 D2,,6.05,4.1,1.21,83.8,256.0,2.45,17.0,17.0,152.0,75.0,13.0,6.09,2.47,62.0,138.0,35.0,27.0,7.1,6.7,77.0,239.0,,,,,,,,,,,,,42.85,963.1,6.69,,无,, P0,H0, 未做, CK+ Vimentin— VEGF- CMET- CD34脉管+ S-100神经+,,,,,19.54664914586071,1508974
1508894,彭华,591186,男,57,T4b,N0,M0, ⅢA,1,2,0.0,0.0,0.0,0.0, 肠化生+,0.0,41,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-26,2019-08-12,0,,,SOX,,,,,,4, 粘液腺癌（muc）85 管状腺癌（中分化【G2】【tub2】15 Lauren肠型,G2, (1a)03 (1b)07 (3a)08 (3b)03 (4sb)00 (4d)00 (5)00 (6)03 (7)06 (8a)04 (8p)04 (9)01 (11)02 (12a)00," L（幽门窦部）, 前Ant,",40,30,12, R0 D2,,6.45,2.69,3.2,144.0,223.0,2.41,39.0,32.0,132.0,57.0,71.0,12.12,4.49,62.0,300.0,43.0,19.0,4.1,7.5,75.0,569.0,67.1,35.2,28.0,1.26,0.1,4.9,25.5,11.0,0.56,1.63,11.0,16.6,2.02,47.13,7.81,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- ,,,,,52.562417871222074,1508894
1509552,韩继侠,592642,女,64,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,29,中间型（int）,INFb,2.0,,,,,,,0.0,2015-03-31,2016-08-01,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03(1b)00(2)03 (3a)00 (3b)02(4sa)01(4sb)00(4d)02 (5)00 (6)03 (7)01 (8a)01 (8p)01 (9)03 (10)00 (11p)03(11d)05 (12a)00 (16a2)01   1b 4d 结肠壁 软组织可见癌," GE, SiewerⅢ,",70,65,15, R0 D2+,,5.87,2.57,2.89,127.1,256.0,2.49,15.0,24.0,158.0,104.0,9.0,11.77,3.99,79.0,187.0,49.0,30.0,4.7,3.7,53.0,243.0,55.0,35.1,17.4,2.02,0.1,5.9,37.6,0.2,1.4,11.3,17.9,13.5,1.91,339.6,5.79, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,16.064388961892245,1509552
1509296,王春莲,593615,女,66,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,40,,,0.0,,,,,,,0.0,2015-03-30,2020-04-26,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)08 (1b)03 (3a)06 (3b)04 (4sb)02 (4d)01 (5)04 (6)06 (7)00 (8a)00 (8p)02 (9)03 (11p)01,L（幽门窦部） 前Ant ,10,10,, D2 R0,,4.48,1.51,2.56,143.2,194.0,2.22,20.0,22.0,176.0,67.0,6.0,15.58,4.53,70.0,252.0,43.0,27.0,4.7,5.0,47.0,252.0,67.8,43.1,21.5,2.0,0.2,5.2,26.0,1.4,2.13,2.6,15.3,55.9,1.01,6.95,5.01, 未做,无,无,P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-),,,,,60.906701708278575,1509296
1509594,陈美玲,594172,女,30,T3,N3b,M0, ⅢC,1,2,2.0,1.0,1.0,1.0, 肠化生++,35.0,42,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-31,2017-02-08,2,,,XELOX,,,,,,6, 低粘附腺癌 Lauren弥漫型,GX,大弯1/1 (1a)0/1 (1b)0/0 (3a)10/12 (3b)0/1 (4sb)0/0 (4d)8/11 (5)0/0 (6)3/3 (7)6/6 (8a)1/1 (8p)2/2 (9)2/2 (11p)2/2 (12a)0/0 (12p)0/0," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,45,10, R0 D2,,9.68,7.62,1.41,84.1,333.0,2.99,18.0,22.0,153.0,63.0,8.0,11.32,4.33,73.0,150.0,43.0,30.0,5.6,3.3,61.0,229.0,79.9,34.9,29.5,1.18,0.0,7.6,11.6,1.6,2.84,9.83,12.9,42.8,1.51,16.32,6.09, 未做,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF- CK+ CD34（脉管+） S-100（神经+）,,,,,22.339027595269382,1509594
1509298,王洪芝,593417,女,69,T4b,N2,M0, ⅢB,1,3,2.0,0.0,0.0,1.0, 肠化生+,3.0,8,中间型（int）,INFc,1.0,,,,,,,0.0,2015-03-30,2017-12-07,2,,,口服替吉奥,口服替吉奥,口服替吉奥,,,,3, 低粘附腺癌 Lauren弥漫型,GX, (1a)11 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)13 (5)00 (6)00 (7)00 (8a)00 (8p)11 (9)00 (11p)00 (12a)01," ML 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,30,7,,R1,6.14,5.08,0.56,107.4,307.0,1.98,18.0,20.0,156.0,63.0,8.0,14.34,5.42,62.0,117.0,35.0,27.0,6.0,25.3,127.0,741.0,,,,,,,,,,,,,1.06,14.88,2.8,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET- CD34脉管+ S-100神经+,,,,,32.29303547963206,1509298
1509411,王德兰,593643,女,50,T3,N1,M0, ⅡB,1,2,2.0,0.0,,1.0, 肠化生+,1.0,7,中间型（int）,INFb,0.0,,,1.0,,,,1.0,2015-03-30,2020-12-17,1,,,,,,,,,0, 低粘附腺癌70 粘液腺癌（muc）30 Lauren弥漫型,GX, (1a)01 (1b)00 (3b)12 (4sb)00 (4d)02 (5)00 (6)00 (7)01 (8a)00 (8p)01 (12a)00 (11p)00 (14v)00," LM 前Ant, 小弯侧Less,",40,30,5, R0 D2,,8.89,7.05,1.43,126.7,246.0,2.4,22.0,24.0,161.0,70.0,22.0,8.32,3.15,71.0,280.0,42.0,29.0,5.6,4.4,78.0,269.0,,,,,,,,,,,,,1.12,23.52,27.28,,无, 无, P0,H0, 未做, CK+， Vimentin部分+， VEGF-， CMET+,,,,,68.62680683311432,1509411
1509590,王立学,594054,男,60,T3,N0,M0, ⅡA,1,1,2.0,1.0,1.0,1.0, 肠化生+,0.0,54,中间型（int）,INFb,1.0,,,,,,,1.0,2015-03-31,2021-05-17,1,,,,,,,,,0, 低粘附腺癌85 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)05 (1b)05 (2)04 (3a)014 (3b)00 (4sa)01 (4sb)00 (4d)012 (5)00 (6)02 (7)01 (8a)02 (8p)01 (9)01 (11p)05 (12a)01," LM 前Ant, 后Post, 小弯侧Less,",55,55,10, R0 D2,,4.92,2.71,1.8,155.4,241.0,1.98,31.0,25.0,151.0,92.0,17.0,9.33,3.08,64.0,234.0,44.0,20.0,4.4,7.7,57.0,249.0,80.0,49.9,27.9,1.79,0.1,7.6,10.9,2.3,0.844,1.19,8.47,10.2,3.35,8.01,13.45,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+ CD34(脉管周+)  S-100(神经+),,,,,73.5545335085414,1509590
1509774,刘顺石,594114,男,57,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,1.0, 肠化生+,0.0,57,中间型（int）,INFb,0.0,,,,,,,0.0,2015-04-01,2022-09-01,1,,,XELOX,,,,,,1, 粘液腺癌（muc）70 低粘附腺癌30 Lauren肠型,GX, (1a)01 (1b)00 (3a)02 (3b)023 (4sb)00 (4d)04 (5)00 (6)00 (7)04 (8a)02 (8p)03 (9)02 (11p)02 (12a)05, M（胃体部） 后Post ,30,30,5, D2 R0,,7.79,4.89,2.32,148.9,241.0,3.58,33.0,28.0,181.0,102.0,20.0,14.31,4.82,67.0,220.0,41.0,26.0,4.9,5.7,58.0,241.0,65.9,22.5,39.4,0.57,0.2,7.3,25.4,2.3,0.659,3.38,15.9,8.92,0.856,8.07,31.09, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)，CD34(+)， S100(+),,,,,89.02759526938239,1509774
1510111,王中清,594126,男,62,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,16.0,40,中间型（int）,INFb,0.0,,,,,,,0.0,2015-04-04,2015-11-13,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)1/1(1b)1/1 (2)0/0 (3a)1/1 (3b)0/1 (4sa)0/2 (4sb)4/8 (4d)0/10 (5) 0/1(6)0/2 (7)0/0 (8a)0/1 (8p)1/1 (9)5/7 (11p)3/4 (12p)0/0，3a，3b，4sa 软组织可见癌6枚癌结节," U（胃底部）, 前Ant, 后Post, 大弯侧Gre,",80,60,10,,R1,7.92,5.03,1.99,131.3,282.0,3.11,17.0,22.0,127.0,79.0,13.0,12.44,4.8,59.0,219.0,38.0,21.0,4.5,6.4,68.0,230.0,71.2,45.9,19.6,2.34,0.6,16.1,7.4,2.1,0.608,2.04,11.6,19.3,9.1,1000.0,4.21, 未做,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF- CK+ CD34(脉管+) S-100(神经+),,,,,7.3258869908015765,1510111
1509404,李桂秋,592719,男,55,T3,N0,M0, ⅡA,1,3,1.0,0.0,0.0,1.0, 肠化生+,0.0,19,中间型（int）,INFb,0.0,,,,,,,0.0,2015-03-30,2017-04-01,2,,,XELOX,,,,,,3, 低粘附腺癌70% 粘液腺癌（muc）30% Lauren混合型,GX, (1a)02 (1b)00 (2)03 (3a)03 (3b)00 (4sb)02 (4d)02 (5)00 (6)00 (7)02 (8a)02 (8p)01 (9)01 (11p)01," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",30,30,5,,R1,4.35,1.57,2.16,141.0,128.0,1.98,254.0,187.0,160.0,73.0,41.0,6.59,3.66,72.0,112.0,38.0,34.0,4.4,4.0,71.0,295.0,80.3,45.7,30.1,1.52,0.2,10.3,8.3,2.2,1.34,1.63,30.9,29.6,3.55,304.7,4.5, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34D2-40+、 S-100+,,,,,24.080157687253614,1509404
1510053,汤晓明,593791,男,47,T4b,N2,M0, ⅢB,1,1,0.0,0.0,0.0,1.0, 肠化生+,4.0,28,中间型（int）,INFb,2.0,,,,,,,0.0,2015-05-04,2021-06-21,1,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)05 (1b)00 (3a)02 (3b)01 (4sb)00 (4d)310 (5)01 (6)00 (7)02 (8a)11 (8p)01 (9)03 (11p)02 (12a)00 (16a1)00," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",80,70,25,,R1,11.41,64.6,25.2,127.0,434.0,2.44,20.0,22.0,186.0,71.0,13.0,6.43,2.47,67.0,208.0,42.0,25.0,4.9,5.2,63.0,246.0,72.1,43.4,24.9,1.74,0.1,9.3,14.7,5.7,1.46,1.47,15.9,269.0,1.41,12.39,9.75, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 CD34D2-40+、 S-100+,,,,,73.58738501971091,1510053
1509592,王希文,593798,女,65,T4b,N2,M0, ⅢB,1,3,0.0,0.0,0.0,0.0, 肠化生+,3.0,45,中间型（int）,INFb,1.0,,,,,,,0.0,2015-03-31,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)05 (3a)09 (3b)06 (4sb)00 (4d)06 (5)03 (6)11 (7)12 (8a)01 (8p)00 (9)01 (11p)03 (12a)01,L（幽门窦部） 前Ant 小弯侧Less 后Post ,50,40,20,,R1,5.84,4.06,1.26,97.0,421.0,3.68,14.0,22.0,10.0,72.0,10.0,12.7,4.34,71.0,178.0,43.0,28.0,4.7,8.6,58.0,231.0,57.9,32.7,19.8,1.65,0.0,16.1,23.7,1.2,2.34,2.97,12.9,12.0,1.22,124.2,2.44, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)，CD34(+)， S100(+),,,,,89.0604467805519,1509592
1510052,祁海涛,594080,男,52,T4b,N2,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,3.0,17,中间型（int）,INFb,0.0,,,,,,,1.0,2015-04-04,2018-03-08,2,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren肠型,G3, (1a)03 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)14 (5)01 (6)01 (7)01 (8a)01 (8p)01 (12a)12 (11p)11," ML 前Ant, 后Post, 小弯侧Less,",80,70,15, R0 D2,,8.78,6.3,1.92,124.5,350.0,1.86,17.0,26.0,139.0,58.0,13.0,10.34,3.96,69.0,236.0,43.0,26.0,5.7,4.0,82.0,273.0,,,,,,,,,,,,,3.61,17.88,1.53,,无,, P0,H0, 未做,CK + Vimentin –  VEGF- CMET+ CD34(脉管周+)  S-100(神经+),,,,,35.11826544021025,1510052
1509818,汪子娟,594257,女,50,T3,N1,M0, ⅡB,1,2,2.0,0.0,0.0,1.0, 肠化生+,1.0,26,中间型（int）,INFb,0.0,,,,,,,0.0,2015-04-01,2018-04-23,0,,,奥沙利铂,,,,,,1, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,小弯11 (1a)01 (1b)01 (2)02 (3a)02 (3b)01 (4sa)01 (4sb)00 (4d)05 (5)00 (6)04 (7)02 (8a)00 (8p)01 (9)03 (11p)02 (12a)00," M（胃体部）, 大弯侧Gre,",40,35,8, R0 D2+,,7.66,5.19,1.85,122.0,422.0,3.61,21.0,23.0,191.0,171.0,18.0,8.6,2.97,74.0,208.0,46.0,28.0,5.5,6.6,59.0,242.0,,,,,,,,,,,,,2.6,28.13,1.75,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,36.727989487516425,1509818
1510090,王云鼎,591210,男,86,T4b,N2,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,4.0,12,中间型（int）,INFb,0.0,,,,,,,0.0,2015-04-04,2017-11-07,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)01 (3a)00 (3b)11 (4sb)00 (4d)34 (5)02 (6)02 (7)00," ML 后Post, 大弯侧Gre, 小弯侧Less,",60,60,10,,R1,8.17,4.96,2.51,115.0,149.0,3.08,14.0,24.0,154.0,71.0,15.0,14.95,5.85,59.0,113.0,31.0,28.0,5.4,5.4,69.0,297.0,,,,,,,,,,,,,2.06,7.1,1.41,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,31.143232588699078,1510090
1510285,许振国,594880,男,55,T2,N0,M0, ⅠB,1,1,0.0,0.0,0.0,0.0, 肠化生+,0.0,21,中间型（int）,INFb,0.0,,,,,,,0.0,2015-04-07,2021-05-24,1,,,,,,,,,0, 粘液腺癌（muc） Lauren肠型,GX, (1a)00 (1b)02 (3a)05 (3b)00 (4sb)00 (4d)08 (5)00 (6)01 (7)01 (8a)02 (8p)01 (9)00 (11p)00 (12a)01," ML 后Post, 小弯侧Less,",70,50,20, R0 D2,,7.82,5.29,1.7,167.2,315.0,3.28,42.0,35.0,136.0,103.0,25.0,13.93,4.72,72.0,293.0,44.0,28.0,4.8,7.8,90.0,419.0,68.4,43.1,16.7,2.58,0.5,11.6,16.8,1.2,0.519,3.31,15.3,37.3,2.68,1.61,67.77, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  S100(+),,,,,73.5545335085414,1510285
1511104,刘灿军,594309,男,61,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,19.0,22,中间型（int）,INFb,1.0,,,,,,,1.0,2015-04-13,2015-07-16,2,,,,,,,,,0, 低分化腺癌（G3)(por)65%， 乳头状癌（G1）（pap）35%  Lauren肠型,G3, 小弯侧4/4(1a)0/1 (1b)0/0 (2)1/1 (3a)1/1 (3b)4/4 (4sa)0/0 (4sb)0/0 (4d)2/2 (5)1/1 (6)3/3 (7)0/0 (8a) (8p)1/3 (9)0/0 (11p)0/0 (12p)2/2," ML 前Ant, 后Post, 小弯侧Less,",50,50,15,,R2,8.34,5.67,1.81,118.0,316.0,4.9,17.0,23.0,188.0,93.0,17.0,8.47,3.37,67.0,190.0,40.0,27.0,5.0,8.2,77.0,302.0,68.7,36.7,26.2,1.4,0.2,12.0,15.5,8.1,1.13,1.33,11.9,37.0,1000.0,28.93,11.01, 未做,无,  无, P0,H0, 未做, CK+ Vimentin- CMET+ VEGF+ CD34、D2-40(脉管+) S-100（神经+）,,,,,3.088042049934297,1511104
1510199,张兴堂,594839,女,56,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,12,,,0.0,,,,,,,0.0,2015-04-07,2021-05-21,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)01 (1b)02 (3a)06 (3b)00 (4sb)00 (4d)00 (5)02 (6)00 (7)01 (8a)00 (8p)00 (9)00 (11p)00," L（幽门窦部）, 后Post,",8,5,, R0 D2,,4.53,2.16,1.89,142.0,258.0,2.34,33.0,36.0,181.0,86.0,11.0,8.7,2.63,71.0,218.0,40.0,31.0,5.0,6.8,61.0,279.0,70.3,50.0,15.8,3.16,0.1,11.8,15.5,5.6,0.692,4.05,16.8,11.5,1.16,4.74,6.56, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-) ,,,,,73.45597897503285,1510199
1510561,汪世录,591250,男,71,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 肠化生+,5.0,31,中间型（int）,INFb,1.0,,,,,,,0.0,2015-04-09,2017-08-13,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】70 乳头状癌（G1）（pap）30 Lauren肠型,G2, (1a)01 (1b)04 (3a)03 (3b)01 (4sb)24 (4d)00 (5)23 (6)00 (7)03 (8a)11 (8p)03 (9)00 (11p)02 (12a)04 (14v)02 12a 软组织可见癌, L（幽门窦部） D(十二指肠) 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,60,10, D2 R0,,5.95,3.7,1.56,66.0,320.0,1.93,26.0,27.0,169.0,74.0,14.0,11.2,4.8,62.0,185.0,40.0,22.0,7.3,6.9,85.0,475.0,60.9,42.2,16.6,2.54,0.0,8.4,27.8,2.0,0.934,1.84,10.6,36.4,8.23,10.25,1.53,,无,,P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)，CD34(+)， S100(+),,,,,28.153745072273324,1510561
1510391,高印德,595175,男,49,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,23,,,1.0,,,,,,,2.0,2015-04-08,2020-04-26,1,,,,,,,,,0, 低粘附腺癌,GX,小弯0/2 (1a)0/1 (1b)0/4 (3a)0/7 (3b)0/1 (4sb)0/0 (4d)0/1 (5)0/2 (6)0/1 (7)0/1 (8a)0/1 (8p)0/0 (9)0/0 (11p)0/1 (12a)0/1," LM 前Ant, 后Post, 小弯侧Less,",30,20,5, R0 D2,,3.95,1.95,1.62,112.7,341.0,32.4,25.0,25.0,164.0,77.0,7.0,12.53,4.8,67.0,309.0,42.0,25.0,5.5,5.6,72.0,334.0,64.4,37.4,25.4,1.47,0.1,5.4,28.0,1.6,0.638,2.06,11.8,90.5,1.07,7.04,1.24, 未做,无, 无, P0,H0, 未做, CMET（弱+） Vimentin-， VEGF-， CK+,,,,,60.611038107752954,1510391
1510051,朱凤和,586116,男,59,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 肠化生+,10.0,26,中间型（int）,INFb,2.0,,,,,,,0.0,2015-04-04,2021-06-21,1,,,SOX,,,,,,6, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren弥漫型,G3, (1a)01 (1b)02 (3a)23 (3b)00 (4sb)00 (4d)44 (5)22 (6)04 (7)01 (8a)23 (8p)02 (9)00 (11p)04, L（幽门窦部） 前Ant ,50,40,15, D2 R0,,9.72,7.17,1.97,150.3,263.0,2.49,24.0,28.0,180.0,56.0,10.0,10.75,3.55,70.0,261.0,44.0,26.0,5.7,7.6,76.0,274.0,75.6,62.9,11.1,5.67,0.2,6.3,13.9,0.9,0.722,1.45,7.05,19.7,2.74,53.75,5.1, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(+),,,,,74.57293035479631,1510051
1510408,焉玉山,594848,男,43,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,16,,,0.0,,,,,,,0.0,2015-04-08,2021-05-24,1,,,,,,,,,0, 低粘附腺癌85 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)15,G3, (1a)01 (1b)03 (3a)00 (3b)02 (4sb)00 (4d)02 (5)00 (6)06 (7)00 (8a)01 (9)00 (11p)01," LM 小弯侧Less,",50,50,3, R0 D2,,8.05,4.98,1.97,160.0,249.0,2.56,19.0,17.0,166.0,54.0,14.0,10.71,4.64,61.0,164.0,36.0,25.0,6.8,4.7,68.0,150.0,63.0,35.7,20.6,1.73,0.2,12.2,21.6,0.7,1.26,3.06,17.6,93.8,1.46,7.12,1.14,,无, 无, P0,H0, 未做,CK+， Vimentin-，VEGF-， CMET+,,,,,73.52168199737187,1510408
1511393,于杰,595395,男,59,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,30,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-15,2017-09-06,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (2)02 (3a)05 (3b)01 (4sa)01 (4sb)01 (4d)04 (5)00 (6)02 (7)04 (8a)01 (8p)01 (9)00 (11p)05 (12a)01,M（胃体部） 小弯侧Less ,10,8,3, D2 R0,,6.82,3.6,2.66,161.1,267.0,2.45,24.0,23.0,141.0,80.0,29.0,17.99,6.83,72.0,196.0,46.0,26.0,9.4,4.1,72.0,280.0,49.7,30.3,18.3,1.66,0.1,18.9,27.9,1.0,1.79,3.1,17.2,5.0,2.79,22.27,1.61, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+),,,,,28.74507227332457,1511393
1510593,李太峰,586128,男,37,T4a,N3b,M1, Ⅳ,1,4,0.0,1.0,1.0,1.0, 肠化生+,29.0,35,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-04-09,2016-08-18,2,,,XELOX,XELOX,AZS2281,,,,3, 低粘附腺癌85 低分化腺癌（G3)(por)15 Lauren肠型,G3, (1a)11 (1b)11 (3b)33 (4sb)00 (4d)510 (5)11 (6)67 (7)33 (8a)11 (9)44 (11p)44, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,50,10,,R2,8.91,7.08,0.93,157.0,423.0,2.54,25.0,24.0,155.0,75.0,23.0,13.45,6.4,80.0,185.0,50.0,30.0,6.3,7.2,80.0,315.0,,,,,,,,,,,,,1.78,14.02,14.49,,粟粒状, 无, p1盆(M1 PER),H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(+)， S100(+),,,,,16.327201051248355,1510593
1511017,吴兴华,594342,男,66,T4a,N0,M0, ⅡB,1,5,0.0,0.0,0.0,1.0, 肠化生+,0.0,41,中间型（int）,INFb,3.0,,,,,,,2.0,2015-04-13,2021-06-21,1,,,,,,,,,0, 粘液腺癌（muc）85 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)15 Lauren肠型,G3, (1a)05 (1b)03 (3a)05 (3b)02 (4sb)01 (4d)08 (5)00 (6)06 (7)04 (8a)00 (8p)01 (9)01 (11p)04 (12a)01," ML 前Ant, 后Post, 小弯侧Less,",90,60,20, R0 D2+,,4.19,2.88,0.85,82.9,246.0,2.63,25.0,11.0,95.0,100.0,18.7,3.37,3.21,55.6,172.26,34.3,21.3,9.0,4.75,66.0,225.0,,,,,,,,,,,,,1.85,13.95,3.01,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET点灶弱+ CD34(脉管周+)  S-100(神经+),,,,,74.2772667542707,1511017
1510704,张秀萍,595342,女,56,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,16.0,41,中间型（int）,INFb,0.0,,,,,,,0.0,2015-04-09,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/2 (1b)0/6 (3a)4/5 (3b)1/1 (4sb)0/2 (4d)0/3 (5)4/4 (6)5/7 (7)0/4 (8a)1/2 (8p)0/2 (9)0/1 (11p)1/2," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,30,10,,R1,6.77,3.72,2.63,152.0,290.0,,7.0,14.0,141.0,77.0,11.0,17.33,4.77,72.0,257.0,46.0,26.0,7.5,6.5,82.0,219.0,69.3,53.2,13.3,4.0,0.1,24.5,5.0,0.5,0.893,1.69,9.4,688.0,15.98,5.63,2.25, 未做,无, 无, P0,H0, 未做," CMET-, Vimentin-, VEGF-, CK-, CD34、D2-40(脉管+)  S-100（神经+）",,,,,74.40867279894874,1510704
1510691,刘月霞,594902,女,65,T1a,N1,M0, ⅠB,1,0,,,,,,2.0,26,,,1.0,,1.0,,,,,1.0,2015-04-09,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)04 (3b)12 (4sb)00 (4d)02 (5)01 (6)04 (7)17 (8a)01 (8p)01 (9)02 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",15,10,, R0 D2,,4.57,2.44,1.45,151.5,168.0,2.19,25.0,33.0,176.0,74.0,22.0,20.91,7.33,77.0,215.0,46.0,31.0,5.4,5.9,61.0,266.0,87.3,43.2,43.0,1.0,0.1,2.6,8.3,2.5,0.99,4.41,12.8,76.5,2.62,12.11,1.83,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET+,,,,,88.76478318002627,1510691
1510594,张凤霞,595591,女,55,T3,N2,M0, ⅢA,1,2,2.0,0.0,0.0,1.0, 肠化生+,4.0,18,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-09,2022-09-01,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,肿物旁11 大弯02 小弯11 (1a)01 (1b)02 (3a)15 (3b)11 (4sb)01 (4d)00 (5)01 (6)00 (7)00 (8a)00 (8p)00 (9)00 (11p)03," L（幽门窦部）, 后Post,",50,40,10, R0 D2+,,5.63,2.15,3.0,129.2,326.0,2.06,19.0,20.0,107.0,97.0,23.0,8.44,2.72,68.0,341.0,41.0,27.0,8.0,6.3,49.0,378.0,78.3,42.8,33.5,1.28,0.2,10.3,98.0,0.1,1.19,2.77,12.9,7.18,0.888,10.83,3.45,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF点灶+ CMET点灶+ CD34(脉管周+)  S-100(神经+),,,,,88.76478318002627,1510594
1511125,高俊清,595195,男,64,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,14,中间型（int）,INFb,2.0,,1.0,,,,,1.0,2015-04-13,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/0 (1b)0/0 (3a)0/7 (3b)0/0 (4sb)0/0 (4d)0/0 (5)0/0 (6)0/0 (7) 0/0(8a)0/0 (8p)0/3 (9)0/1 (11p)0/3," LM 小弯侧Less,",20,20,, R0 D2,,6.46,4.03,1.93,172.3,187.0,2.33,24.0,25.0,185.0,92.0,67.0,23.74,7.06,71.0,402.0,42.0,29.0,6.1,6.2,87.0,380.0,60.4,31.5,25.9,1.22,0.2,9.5,28.2,1.8,1.95,2.32,13.5,80.6,2.19,17.04,1.25, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF+ CK+,,,,,88.63337713534823,1511125
1511103,张满金,595240,男,62,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,5.0,40,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-13,2016-01-26,2,,,,,,,,,0, 低粘附腺癌85% 低分化腺癌（G3)(por)15% Lauren肠型,G3, (1a)25 (1b)00 (2)01 (3a)03 (3b)00 (4sa)01 (4sb)00 (4d)112 (5)00 (6)16 (7)14 (8a)02 (8p)03 (9)02 (11p)01 (12a)00," L（幽门窦部）, M（胃体部）, U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,10, R0,,4.53,2.32,1.77,139.0,199.0,2.24,22.0,21.0,114.0,71.0,6.0,13.22,4.78,54.0,263.0,36.0,18.0,5.8,6.7,62.0,180.0,61.5,46.5,12.9,3.6,0.2,21.8,14.0,0.3,0.529,2.07,6.8,293.0,1.59,7.75,1.45, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（弱+）、 CMET（+）、 CD34D2-40+、 S-100+,,,,,9.461235216819974,1511103
1511561,乔华烈,595128,男,59,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,17,中间型（int）,INFb,0.0,,1.0,,,,,2.0,2015-04-16,2016-07-06,2,,,,,,,,,0, 乳头状癌（G1）（pap）70% 管状腺癌（中分化【G2】【tub2】30% Lauren肠型,G2, (1a)00 (1b)01 (3a)02 (3b)01 (4sb)00 (4d)00 (5)00 (6)03 (7)04 (8a)02 (8p)01 (9)02 (11p)00 (12p)00 (14v)01," M（胃体部）, L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",90,70,30, R0,,3.79,2.01,1.2,93.0,247.0,2.21,40.0,41.0,146.0,46.0,12.0,6.76,2.93,54.0,127.0,33.0,21.0,4.5,3.2,63.0,301.0,82.6,41.6,36.2,1.15,0.2,9.1,6.1,5.9,0.326,1.24,8.86,13.8,0.518,4.75,1.02, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（小区弱+）、 CMET（小区弱+）、 CD34D2-40+、 S-100+,,,,,14.684625492772668,1511561
1511265,孙敬诚,594702,男,64,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,8,,,1.0,,,,,,,1.0,2015-04-14,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (3a)07 (3b)00 (4sb)00 (4d)00 (5)00 (6)00 (7)00 (8a)04 (8p)01 (9)03 (11p)00 (12a)00," L（幽门窦部）, M（胃体部）, 前Ant,",20,5,, R0,,7.54,4.98,1.67,147.9,156.0,2.34,18.0,21.0,131.0,67.0,12.0,13.27,5.13,57.0,328.0,36.0,21.0,5.0,6.6,79.0,327.0,72.1,47.6,17.2,2.77,0.1,11.3,11.1,2.8,0.356,1.88,9.68,8.07,3.96,12.31,1.18, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,88.60052562417872,1511265
1511088,潘海东,595561,男,29,T3,N3a,M0,ⅢB,1,5,0.0,1.0,1.0,1.0, 肠化生+,11.0,36,中间型（int）,INFb,2.0,,,,,,,1.0,2015-04-13,2019-01-16,2,,,SOX,,,,,,6, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren肠型,G3, (1a)00 (1b)15 (3a)814 (3b)11 (4sb)03 (4d)14 (5)00 (6)03 (7)02 (8a)03 (8p)01 (9)00 (11p)00," LM 前Ant,",25,20,8, R0 D2+,,5.44,3.04,1.7,134.5,325.0,2.49,8.0,18.0,181.0,83.0,9.0,8.77,3.73,73.0,317.0,47.0,26.0,5.5,5.5,106.0,338.0,,,,,,,,,,,,,3.62,10.57,0.9,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+ CD34(脉管周+)  S-100(神经+),,,,,45.137976346911955,1511088
1511191,曲振友,595530,男,59,T3,N0,M0, ⅡA,1,5,0.0,1.0,1.0,1.0, 肠化生+,0.0,27,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-04-14,2021-05-17,1,,,XELOX,,,,,,4, 粘液腺癌（muc）70 低粘附腺癌30 Lauren肠型,GX, (1a)00 (1b)04 (3a)00 (3b)011 (4sb)01 (4d)09 (5)00 (6)02 (7)00 (8a)00 (8p)00 (9)00 (11p)00," LD 前Ant, 后Post, 小弯侧Less,",30,30,10, R0 D2+,,3.88,2.22,1.2,112.0,249.0,2.31,25.0,25.0,151.0,110.0,12.0,11.03,4.23,64.0,232.0,44.0,20.0,5.0,8.1,61.0,221.0,44.3,34.3,7.9,4.34,0.1,10.3,40.2,0.6,0.79,1.55,7.72,7.22,0.773,25.28,2.52,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,73.0946123521682,1511191
1511116,张宝才,595572,男,55,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,1.0, 肠化生+,1.0,22,中间型（int）,INFb,2.0,,1.0,,,,,2.0,2015-04-13,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)04 (1b)03 (3a)04 (3b)00 (4sb)03 (4d)12 (5)00 (6)03 (7)13 (8a)00 (8p)00 (9)00 (11p)00," LD 小弯侧Less,",25,25,10, R0 D2+,,7.69,4.0,2.93,140.6,350.0,2.58,34.0,26.0,151.0,55.0,27.0,6.06,2.68,74.0,341.0,45.0,29.0,7.0,5.9,98.0,220.0,,,,,,,,,,,,,1.9,29.99,2.99,,无,, P0,H0, 未做,CK + Vimentin - VEGF弱+ CMET弱+ CD34(脉管周+)  S-100(神经+),,,,,74.2772667542707,1511116
1511118,邹德安,586177,男,34,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,8.0,56,中间型（int）,INFb,3.0,,1.0,,,,,1.0,2015-04-13,2015-09-18,2,,,XELOX,,,,,,3, 低分化腺癌（G3)(por)60 粘液腺癌（muc）30 低粘附腺癌10 Lauren肠型,G3, (1b)00 (3a)04 (3b)25 (4sb)01 (4d)00 (5)01 (6)08 (7)617 (8a) (8p)03 (9)04 (11p)04 (12a)00 软组织可见癌3A," LM 前Ant,",30,30,10, R0 D2,,5.88,2.42,2.83,159.0,250.0,2.24,21.0,21.0,123.0,60.0,18.0,14.62,5.61,71.0,273.0,42.0,29.0,4.4,6.0,76.0,231.0,69.9,41.5,19.4,2.14,0.0,11.3,16.4,0.9,0.617,2.99,15.2,18.7,1.38,2.25,14.35,,无, 无, P0,H0, 未做,CK+， Vimentin-，VEGF-， CMET+,,,,,5.19053876478318,1511118
1511470,吴志斌,594807,男,59,T2,N0,M0, ⅠB,1,2,0.0,1.0,1.0,0.0, 肠化生+,0.0,48,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-04-15,2021-05-24,1,,,SOX,,,,,,4, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)06 (1b)09 (3a)010 (3b)00 (4sb)02 (4d)03 (5)00 (6) (14v)00 (7)011 (8a) (8p)04 (11p)02 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,20,15, R0 D2+,,10.07,5.86,2.96,170.0,205.0,3.21,31.0,27.0,171.0,86.0,105.0,9.71,3.46,74.0,345.0,45.0,29.0,9.9,5.0,80.0,147.0,70.9,38.9,28.0,1.39,0.6,10.7,15.2,0.5,0.463,1.85,12.4,34.4,4.22,13.66,8.91,,无, 无, P0,H0, 未做,CK+， Vimentin-，VEGF+， CMET+,,,,,73.29172141918528,1511470
1511388,李继平,596254,男,70,T4a,N3a,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,9.0,37,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-15,2016-03-15,2,,,,,,,,,0, 粘液腺癌（muc）50 低粘附腺癌30 低分化腺癌（G3)(por)20 Lauren肠型,G3, (1a)02 (1b)05 (3a)05 (3b)01 (4sb)00 (4d)812 (5)11 (6)01 (7)03 (8a)05 (9)01 (11p)01 (12a)00," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,70,12, R0 D2,,4.66,3.23,0.87,138.7,195.0,29.8,19.0,6.0,93.0,76.0,14.7,14.69,4.95,59.3,165.56,37.8,21.5,11.8,5.21,99.0,238.0,70.2,33.7,31.6,1.07,0.2,7.4,18.9,2.7,1.78,1.85,8.29,58.7,208.8,8.23,14.92,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF+， CMET+,,,,,11.005256241787121,1511388
1511266,程鹤岩,590606,男,57,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+,2.0,20,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-04-14,2017-11-01,2,,,SOX,,,,,,7, 低分化腺癌（G3)(por)60 粘液腺癌（muc）30 低粘附腺癌10 Lauren肠型,G3,大弯02 (1a)01 (1b)03 (3a)02 (3b)06 (4sb)00 (4d)04 (5)11 (6)00 (7)00 (8a、8p、9)11 (11p)00," LD 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,8, R0 D2+,,10.15,6.21,2.82,136.6,301.0,3.51,7.0,12.0,149.0,69.0,15.0,16.52,6.32,68.0,248.0,41.0,27.0,5.6,7.1,88.0,447.0,73.2,35.7,32.1,1.11,0.2,8.5,15.1,3.0,0.673,1.89,11.7,65.5,4.84,74.33,6.13,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,30.617608409986858,1511266
1511192,姜丹,594986,女,33,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,37,中间型（int）,INFb,2.0,,1.0,,,,,1.0,2015-04-14,2019-08-12,0,,,XELOX,XELOX,XELOX,XELOX,SOX,SOX,6, 低粘附腺癌 Lauren肠型,GX, (1a)03 (1b)02 (3a)07 (3b)01 (4sb)01 (4d)014 (5)01 (6)02 (7)00 (8a)01 (8p)01 (11p)04 (12a)00 (14v)00," L（幽门窦部）, M（胃体部）, 大弯侧Gre,",25,25,8, R0,,4.16,2.42,1.36,103.0,292.0,2.58,12.0,16.0,159.0,66.0,15.0,7.13,3.04,73.0,231.0,43.0,30.0,5.6,4.2,62.0,285.0,67.7,44.2,20.6,2.15,0.1,9.3,20.1,1.4,1.32,2.75,13.4,8.35,1.16,17.28,2.61, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）、 CD34D2-40+、 S-100+,,,,,51.93823915900131,1511192
1511688,康秀贤,595583,女,37,T4b,N0,M0, ⅢA,1,5,0.0,0.0,0.0,1.0, 肠化生+,0.0,16,中间型（int）,INFb,1.0,,1.0,,,,,0.0,2015-04-16,2021-05-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)02 (2)00 (3a)00 (3b)01 (4sa)00 (4sb)00 (4d)00 (5)00 (6)00 (7)01 (8a)03 (8p)03 (10)01 (11d)03 (11p)02," MU 前Ant, 后Post, 小弯侧Less,",70,70,30, R0 D2+,,7.53,4.98,1.64,108.0,342.0,3.08,16.0,19.0,127.0,57.0,8.0,5.38,2.09,60.0,149.0,36.0,24.0,4.8,4.5,52.0,284.0,,,,,,,,,,,,,0.861,195.0,7.53,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF+ CMET- CD34(脉管周+)  S-100(神经+),,,,,73.02890932982918,1511688
1511581,朱爱华,592803,女,77,T4b,N3b,M1, Ⅳ,1,5,2.0,1.0,1.0,1.0, 肠化生+,24.0,24,中间型（int）,INFb,1.0,,1.0,,,,,2.0,2015-04-16,2015-07-13,2,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,小弯88 (1a)11 (1b)11 (3a)00 (3b)00 (4sb)00 (4d)44 (5)66 (6)33 (7)11," LMU 小弯侧Less,",90,60,20,,R2,8.35,6.37,1.2,123.0,275.0,3.35,17.0,23.0,188.0,51.0,11.0,4.48,2.38,71.0,183.0,38.0,33.0,,7.0,95.0,241.0,,,,,,,,,,,,,2.68,9.97,3.81,,粟粒状, 无, p1泛(M1 PER),H0, 未做,CK + Vimentin - VEGF弱+ CMET弱+ CD34(脉管周+)  S-100(神经+),,,,,2.890932982917214,1511581
1511082,袁长江,595307,男,61,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+,1.0,24,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-04-13,2021-05-17,1,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren肠型,G3, (1a)07 (1b)03 (3a)00 (3b)011 (4sb)04 (4d)01 (5)00 (6)02 (7)02 (8a)00 (8p)00 (9)01 (11p)02 小弯11," L（幽门窦部）, 前Ant, 小弯侧Less,",35,35,10, R0 D2,,4.59,2.32,1.82,132.0,202.0,3.08,20.0,22.0,166.0,41.0,18.0,14.26,5.85,68.0,267.0,40.0,28.0,5.3,4.6,77.0,211.0,65.0,28.7,31.0,0.93,0.3,4.8,26.9,8.1,1.87,3.62,16.9,166.0,3.75,7.42,1.05, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  S100(+),,,,,73.12746386333771,1511082
1511658,秦文富,596601,男,73,T3,N0,M0, ⅡA,1,1,0.0,0.0,0.0,0.0, 肠化生+,0.0,26,中间型（int）,INFb,0.0,,1.0,,,,,2.0,2015-04-16,2021-05-17,1,,,,,,,,,0, 乳头状癌（G1）（pap）85 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)15 Lauren肠型,G3, (1a)00 (1b)00 (2)00 (3a)07 (3b)03 (4sa)01 (4sb)01 (4d)00 (5)00 (6)02 (7)02 (8a)02 (8p)03 (9)00 (11p)03 (12a)00," UM 前Ant, 后Post, 小弯侧Less,",100,80,40, R0 D2+,,9.03,6.53,1.42,92.0,481.0,2.78,15.0,19.0,110.0,71.0,22.0,5.16,2.04,56.0,186.0,33.0,23.0,4.8,9.7,71.0,31.0,,,,,,,,,,,,,12.78,31.04,2.6,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET弱+ CD34(脉管周+)  S-100(神经+),,,,,73.02890932982918,1511658
1512244,张淑芬,596459,女,61,T3,N0,M0, ⅡA,1,1,2.0,1.0,1.0,1.0, 肠化生+ 异型增生+,0.0,15,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-04-22,2017-10-12,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)03 (1b)01 (3a)02 (3b)00 (4sb)00 (4d)02 (5)01 (6)01 (7)00 (8a)00 (8p)01 (9)00 (11p)03 (12a)01," ML 前Ant, 后Post, 小弯侧Less,",50,40,10, R0 D2+,,7.97,4.9,2.22,139.9,223.0,2.68,21.0,23.0,200.0,91.0,32.0,14.92,3.78,71.0,295.0,43.0,28.0,6.5,5.8,76.0,406.0,,,,,,,,,,,,,1.06,17.9,2.96,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF弱+ CMET- CD34(脉管周+)  S-100(神经+),,,,,29.69776609724047,1512244
1512093,李士兰,596452,女,62,T2,N3a,M0, ⅢA,1,5,0.0,0.0,0.0,1.0, 肠化生+,10.0,24,中间型（int）,INFa,1.0,,1.0,,,,,1.0,2015-04-20,2018-11-23,0,,,,,,,,,0, 乳头状癌（G1）（pap）80 低分化腺癌（G3)(por)20 Lauren肠型,G3, (1a)00 (1b)11 (3a)79 (3b)11 (4sb)00 (4d)05 (5)02 (6)01 (7)00 (8a)00 (8p)02 (9)00 (11p)02 (11)11 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",35,30,5, R0 D2+,,8.17,3.61,2.67,136.3,230.0,2.27,28.0,29.0,219.0,108.0,10.0,10.66,3.7,68.0,197.0,42.0,26.0,,5.8,52.0,205.0,,,,,,,,,,,,,30.54,11.7,1.93,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,43.13403416557161,1512093
1512266,孙显军,596410,男,41,T3,N2,M0, ⅢA,1,3,1.0,0.0,0.0,1.0, 肠化生+,4.0,26,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-21,2021-05-17,1,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G2,大网04 (1a)11 (1b)02 (3a)12 (3b)11 (4sb)01 (4d)02 (5)02 (6)11 (7)01 (8a)02 (8p)00 (9)00 (11p)03 (12a)04," L（幽门窦部）, 后Post,",30,30,15, R0 D2+,,7.38,3.05,3.71,148.5,228.0,3.21,19.0,12.0,171.0,106.0,34.4,16.84,4.2,76.2,222.96,46.0,30.2,4.5,4.94,100.0,220.0,,,,,,,,,,,,,3.23,20.69,1.06,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,72.8646517739816,1512266
1512622,温秀,596608,男,64,T4b,N3a,M1, Ⅳ,1,5,1.0,1.0,1.0,0.0, 肠化生+,14.0,19,中间型（int）,INFa,1.0,,1.0,,,,,1.0,2015-04-23,2016-07-12,2,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren混合型,G3, (1a)45 (1b)22 (3a)01 (3b)00 (4sb)00 (4d)11 (5)00 (6)00 (7)66 (8a)01 (8p)13 (9)00 (11p)00," LM 前Ant, 后Post, 大弯侧Gre,",50,35,10,,R2,7.06,4.6,1.82,150.4,192.0,2.27,20.0,14.0,108.0,79.0,46.0,10.23,5.53,68.0,322.0,41.0,27.0,4.9,5.8,66.0,223.0,,,,,,,,,,,,,2.44,17.07,1.16,,无,, p1局腹膜(M1 PER),H0, 未做,CK + Vimentin - VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,14.651773981603153,1512622
1511779,谢丽华,594757,女,57,T1b,N1,M0, ⅠB,1,0,0.0,0.0,0.0,0.0, 肠化生+,1.0,17,中间型（int）,INFb,1.0,,1.0,,,,,2.0,2015-04-17,2021-05-24,1,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)00 (3a)01 (3b)01 (4sb)04 (4d)01 (5)00 (6)02 (7)01 (8a)02 (8p)01 (9)11 (11p)01," LM 前Ant, 后Post, 小弯侧Less,",50,35,1, R0 D2+,,5.6,2.57,2.23,133.0,234.0,2.18,24.0,28.0,145.0,59.0,15.0,16.76,6.09,78.0,211.0,46.0,32.0,4.6,6.2,58.0,346.0,66.1,50.7,14.2,3.57,0.2,14.3,16.9,0.3,0.914,3.36,14.8,179.0,0.72,5.2,1.52,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF+ CMET弱+ CD34(脉管周+)  S-100(神经+),,,,,73.22601839684626,1511779
1511659,张海波,594708,男,45,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,14.0,26,中间型（int）,INFb,1.0,,1.0,,,,,2.0,2015-04-16,2020-05-14,0,,,奥沙利铂,,,,,,1," 低粘附腺癌80%, 低分化腺癌（G3)(por)20%, Lauren肠型",G3, (1a)0/1 (1b)0/1 (3a)0/3 (3b)1/1 (4sb)0/0 (4d)3/4 (5)3/3 (6)3/8 (7)0/0 (8a)1/1 (8p)0/1 (9)2/2 (11p)1/1 9组软组织可见癌," LM 后Post, 前Ant, 小弯侧Less,",50,50,20,,R1,10.73,6.08,3.57,104.3,456.0,3.25,22.0,25.0,131.0,79.0,10.0,5.54,2.16,67.0,372.0,40.0,27.0,5.4,8.4,108.0,344.0,82.1,36.4,44.2,0.82,0.4,2.7,10.8,2.3,2.24,2.67,16.0,52.5,3.11,88.28,5.82, 未做,无, 无, P0,H0, 未做, CMET(弱+) Vimentin（弱+） VEGF- CK+ S-100（神经+） CD34，D2-40(脉管+),,,,,60.939553219448094,1511659
1512147,李树民,594480,男,72,T4a,N3a,M1, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,9.0,15,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-21,2016-10-28,2,,,,,,,,,0, 低分化腺癌（G3)(por)70% 低粘附腺癌30% Lauren肠型,G3, 小湾46 (1a)11 (1b)22 (2)00 (3a)00 (3b)00 (4sb)00 (4d)00 (5)00 (7)00 (8a)03 (9)12 (11p)11," SiewerⅢ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,15,,R2,7.43,4.79,2.05,141.0,231.0,4.03,18.0,27.0,196.0,77.0,18.0,16.07,6.44,77.0,263.0,47.0,30.0,3.8,3.2,62.0,294.0,54.3,33.4,19.3,1.73,0.2,10.0,33.3,2.0,1.14,2.12,12.3,8.7,2.3,12.56,7.41, 未做,无, 无, p1盆(M1 PER),H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）、 CD34D2-40+、 S-100+,,,,,18.265440210249672,1512147
1511950,尤秀艳,596346,女,52,T1b,N1,M0, ⅠB,1,0,0.0,1.0,1.0,1.0, 肠化生+,1.0,22,中间型（int）,INFb,0.0,,1.0,,,,,2.0,2015-04-20,2021-05-24,1,,,SOX,,,,,,2, 低粘附腺癌70% 低分化腺癌（G3)(por)30% Lauren肠型,G3, (1a)01 (1b)03 (3a)15 (3b)01 (4sb)00 (4d)02 (5)01 (6)01 (7)01 (8a) (8p)05 (9)01 (11p)01 (12a)00," M（胃体部）, 小弯侧Less,",30,20,1, R0 D2,,8.13,5.59,1.9,147.1,239.0,2.15,17.0,29.0,155.0,75.0,9.0,11.43,3.98,73.0,215.0,45.0,28.0,5.3,5.7,74.0,250.0,40.6,23.5,13.1,1.79,0.0,10.3,46.0,1.4,3.6,1.86,11.5,56.7,0.82,8.63,3.32, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（弱+）、 CMET（弱+）、 CD34D2-40+、 S-100+,,,,,73.12746386333771,1511950
1512232,王景兰,596398,女,61,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,9.0,27,中间型（int）,INFb,1.0,,1.0,,,,,0.0,2015-04-21,2021-06-21,1,,,卡培他滨,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) 0/1(1b)2/4 (3a)2/3 (3b) 0/0(4sb)0/0 (4d)0/4 (5)0/0 (6) 4/6(7) 0/2(8a) 0/1(8p)0/2 (9)1/1 (11p)0/3 (12a)0/0," LM 前Ant, 后Post, 小弯侧Less,",60,40,15, R0 D2,,7.57,4.48,2.57,129.8,327.0,4.44,20.0,29.0,228.0,67.0,4.0,10.2,5.3,64.0,275.0,41.0,23.0,6.2,3.0,58.0,172.0,73.5,50.4,21.1,2.39,0.1,10.9,11.2,2.1,0.784,2.05,10.4,8.47,1.19,7.82,4.18, 未做,无, 无, P0,H0, 未做, CMET- Vimentin -VEGF+ CK+ S-100(神经+) CD34、D-2-40(脉管+),,,,,74.01445466491458,1512232
1512332,宋学民,596458,男,50,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,3.0,41,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-22,2018-12-04,2,,,,,,,,,0, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren肠型,G3, (1a)01 (1b)00 (3a)26 (3b)01 (4sb)17 (4d)011 (5)00 (6)02 (7)06 (8a)01 (8p)01 (9)01 (11p)04 (12a)00 (14v)00," M（胃体部）, 小弯侧Less, 后Post,",65,60,10, R0 D2,,7.21,3.55,2.25,143.0,247.0,3.53,20.0,26.0,174.0,97.0,29.0,13.92,5.37,68.0,296.0,42.0,26.0,4.5,6.2,65.0,430.0,65.4,46.2,18.4,2.51,0.4,17.3,12.3,0.3,0.501,1.41,11.7,698.0,0.758,4.77,10.47,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF+， CMET+,,,,,43.42969776609724,1512332
1511951,武凤兰,594775,女,60,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,0.0, 肠化生+ 异型增生+,5.0,26,中间型（int）,INFb,0.0,,1.0,,,,,2.0,2015-04-20,2021-05-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)00 (3a)02 (3b)01 (4sb)01 (4d)23  (6)25 (5) (7) (8a) (9) (11p) (12a)1 10," M（胃体部）, 后Post,",30,25,12, R0 D2,,4.74,2.34,1.93,134.8,218.0,3.21,21.0,28.0,193.0,84.0,9.0,20.7,6.92,69.0,235.0,43.0,26.0,4.6,3.0,49.0,229.0,73.5,43.9,26.4,1.66,0.0,9.2,15.4,2.3,0.594,2.83,9.77,5.0,0.754,8.08,1.29, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(小区弱+)  cMET(小区弱+)  CD34(+)  D2-40(+) S100(+),,,,,72.89750328515112,1511951
1512062,赵永林,596461,男,57,T3,N3b,M0, ⅢC,1,3,0.0,0.0,0.0,0.0, 肠化生+,57.0,84,中间型（int）,INFb,1.0,,1.0,,,,,2.0,2015-04-20,2021-06-21,1,,,XELOX,,,,,,1, 低粘附腺癌55 低分化腺癌（G3)(por)35 粘液腺癌（muc）10 Lauren肠型,G3, (1a)00 (1b)14 (3a)9 13 (3b)910 (4sa)01 (4sb)23 (4d)3034 (5)01 (6)01 (7)01 (8a)01 (8p)03 (9)03 (11p) 01(12a)02 大网66," ML 后Post, 小弯侧Less,",55,40,10, R0 D2,,7.46,4.62,1.66,137.2,263.0,3.43,14.0,24.0,211.0,58.0,8.0,11.49,4.49,55.0,177.0,32.0,23.0,4.3,4.2,69.0,207.0,73.1,56.4,12.3,4.59,0.1,12.8,9.2,2.7,1.04,2.15,9.5,313.0,2.59,5.7,3.98, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(若+)  cMET(弱+)  CD34(+)  D2-40（+）S100(+),,,,,74.04730617608409,1512062
1511697,刘国林,595198,男,52,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,22,,,0.0,,,,,,,1.0,2015-04-16,2019-05-03,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)01 (1b)02 (3a)04 (3b)02 (4sb)00 (4d)04 (5)00 (6)00 (7)05 (8a)01 (8p)02 (9)00 (11p)01 (12a)00 (14v)00," LM 大弯侧Gre,",25,15,2, R0 D2+,,5.44,2.13,2.85,162.0,211.0,2.49,18.0,25.0,153.0,84.0,13.0,31.65,9.91,67.0,286.0,42.0,25.0,4.2,5.6,76.0,406.0,74.9,35.4,23.1,1.53,0.1,4.3,18.2,9.0,1.71,1.66,11.2,25.1,0.575,7.56,1.13,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET+,,,,,48.55453350854139,1511697
1512077,赵君,596388,男,52,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,33,中间型（int）,INFa,1.0,,1.0,,,,,0.0,2015-04-20,2019-07-06,0,,,,,,,,,0, 低分化腺癌（G3)(por)70% 低粘附腺癌30% Lauren肠型,G3, (1a)01 (1b)02 (3a)04 (3b)03 (4sb)00 (4d)07 (5)01 (6)07 (7)01 (8a)01 (8p)01 (9)02 (11p)01 (12a)00 (12p)02," L（幽门窦部）, 前Ant,",10,10,5, R0,,6.91,4.74,1.59,151.6,288.0,2.84,25.0,27.0,146.0,100.0,41.0,8.96,3.65,65.0,278.0,40.0,25.0,4.8,7.2,83.0,329.0,71.3,51.2,16.7,3.07,0.2,17.2,8.5,2.4,1.83,3.98,17.7,34.5,1.27,8.2,1.75, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（弱+）、 CMET（-）、 S-100+、 （CD34、D2-40）+,,,,,50.52562417871222,1512077
1511978,刘天福,596510,男,53,T2,N2,M0, ⅡB,1,3,0.0,1.0,1.0,0.0, 肠化生+,4.0,24,中间型（int）,INFb,3.0,,1.0,,,,,0.0,2015-04-20,2019-08-06,0,,,奥沙利铂,,,,,,1, 低分化腺癌（G3)(por)70%， 低粘附腺癌30%。 Lauren肠型,G3, (1a)0/0 (1b)0/0 (3a)0/6 (3b)0/0 (4sb)0/1 (4d)2/4 (5)0/0 (6)1/3 (7)0/1 (8a)1/2 (8p)0/1 (9)0/1 (11p)0/4 (12p)0/1," L（幽门窦部）, 小弯侧Less,",20,12,4, R0,,8.01,4.46,2.83,158.0,275.0,3.76,9.0,22.0,175.0,81.0,29.0,14.22,5.1,75.0,337.0,45.0,30.0,4.4,5.9,89.0,420.0,67.5,38.1,24.7,1.54,0.4,5.0,25.6,3.7,2.84,3.03,19.1,5.0,3.44,1.63,1.45, 未做,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF+ CK+ S-100(神经+) CD34、D2-40(脉管+),,,,,51.544021024967144,1511978
1512457,丁惠林,594720,男,68,T3,N0,M0, ⅡA,1,5,0.0,1.0,1.0,1.0, 肠化生+,0.0,20,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-22,2017-08-03,2,,,替吉奥单药,替吉奥单药,,,,,2, 低分化腺癌（G3)(por)80 低粘附腺癌20,G3,小弯06 (1a)02  (1b)02 (2)02 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)00," MU SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",80,50,15, R0 D2+,,9.87,7.39,17.42,99.0,566.1,3.59,23.0,14.0,123.0,175.0,36.0,15.09,4.86,65.3,,41.5,23.8,5.86,6.08,91.0,279.0,,,,,,,,,,,,,7.45,1.35,,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET小区+ CgA- CD56- CD34(脉管周+)  S-100(神经+),,,,,27.398160315374508,1512457
1512220,薛大发,593899,男,64,T3,N1,M0, ⅡB,1,3,1.0,0.0,0.0,1.0, 肠化生+,2.0,19,中间型（int）,INFb,1.0,,1.0,,,,,2.0,2015-04-21,2021-06-21,1,,,XELOX,,,,,,6, 粘液腺癌（muc）60 低粘附腺癌40 Lauren混合型,GX,小弯12 (1a)05 (1b)00 (2)01 (3a)13 (3b)00 (4sb)00 (4d)00 (4)01 (5)00 (6)03 (7)02 (8a)00 (8p)00 (9)01 (11d)01," U（胃底部）, GE, SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",40,30,8, R0 D2+,,9.03,4.81,3.22,147.0,240.0,3.43,36.0,26.0,189.0,88.0,49.0,9.22,3.49,76.0,313.0,44.0,32.0,5.6,9.3,96.0,275.0,,,,,,,,,,,,,2.78,22.24,1.95,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET弱+ CD34(脉管周+)  S-100(神经+),,,,,74.01445466491458,1512220
1512544,官美芳,595136,女,86,T4b,N3b,M0, ⅢC,1,4,0.0,0.0,0.0,1.0, 肠化生+,29.0,29,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-04-23,2015-07-01,2,,,,,,,,,0, 低粘附腺癌 Lauren肠型,GX,小弯00 (1a)00 (1b)11 (2)00 (3a)00 (3b)00 (4sb)55 (4d)99 (5)33 (6)99 (7)22," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,6,,R1,7.84,5.53,1.34,113.4,266.0,3.18,9.0,19.0,167.0,79.0,7.0,13.6,4.21,66.0,149.0,39.0,27.0,4.3,6.8,74.0,417.0,,,,,,,,,,,,,3.13,2.15,13.97,,无, 无, P0,H0, 未做,CK + Vimentin – VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,2.266754270696452,1512544
1512146,李立刚,596676,男,47,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,16.0,29,中间型（int）,INFb,2.0,,1.0,,,,,1.0,2015-04-21,2018-01-09,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90 粘液腺癌（muc）10 Lauren肠型,G2, (1a)00 (1b)03 (3a)02 (3b)00 (4sb)01 (4d)57 (5)45 (6)12 (7)14 (8a)00 (8p)00 (9)00 (11p)00小弯55 1a，3a，3b软组织可见癌,ML MU 小弯侧Less 前Ant 后Post ,60,40,15, R0 D2,,6.86,4.34,1.75,125.8,406.0,3.86,47.0,33.0,150.0,86.0,5.0,7.05,3.22,64.0,154.0,39.0,25.0,4.4,5.2,60.0,276.0,62.1,26.7,30.3,0.88,0.1,7.9,25.9,1.2,0.888,2.06,9.22,22.6,3.37,6.83,3.1, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,32.65440210249671,1512146
1512659,史国文,596360,男,55,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 肠化生+,0.0,12,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-04-23,2021-05-24,1,,,SOX,SOX,SOX,SOX,XELOXX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)00 (3a)01 (3b)00 (4sb)01 (4d)01 (5)00 (6)00 (7)00 (8a)00 (8p)03 (9)02 (11p)01 (12a)00," M（胃体部）, 小弯侧Less,",40,30,8, R0 D2,,6.1,2.96,2.73,152.0,285.0,3.86,25.0,18.0,130.0,130.0,69.0,15.62,4.12,73.0,260.0,41.0,32.0,8.2,9.9,76.0,352.0,67.9,42.1,24.5,1.72,0.2,15.0,14.5,1.6,1.2,6.81,12.6,13.2,2.35,20.82,2.29,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF+， CMET+,,,,,73.02890932982918,1512659
1513518,闫永林,596861,男,70,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,1.0,16,中间型（int）,INFb,1.0,,1.0,,,,,0.0,2015-04-30,2015-10-15,2,,,,,,,,,0, 低分化腺癌（G3)(por)60% 低粘附腺癌40% Lauren肠型,G3,小湾12 (1a)01 (1b)03 (2)02 (3a)00 (3b)00 (4sb)01 (4d)04 (5)02 (6)00 (7)00 (8a)00 (9)01 (11p)00," SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",15,15,3, R0 D2,,6.3,3.65,1.88,112.0,151.0,3.21,12.0,20.0,153.0,57.0,10.0,8.13,3.69,68.0,149.0,36.0,32.0,7.7,6.5,75.0,231.0,79.4,22.1,56.5,0.39,0.2,5.0,12.1,2.4,1.99,2.87,17.7,1840.0,4.61,48.07,3.42, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（-）、 CD34D2-40+、 S-100+,,,,,5.519053876478318,1513518
1512545,金应哲,596831,男,63,T4b,N0,M0, ⅢA,1,3,2.0,0.0,0.0,0.0, 肠化生+,0.0,43,中间型（int）,INFb,0.0,,1.0,,,,,2.0,2015-04-23,2017-09-11,0,,,,,,,,,0, 低粘附腺癌  Lauren弥漫型,GX, (1a)00 (1b)04 (3a)04 (3b)02 (4sb)00 (4d)09 (5)00 (6)07 (7)00 (8a)08 (9)04 (11p)05,LD LM  前Ant 后Post  大弯侧Gre  ,100,100,30, R0 D2,,9.02,5.83,2.24,149.1,394.0,35.1,17.0,29.0,168.0,104.0,35.0,7.59,2.8,70.0,231.0,42.0,28.0,4.6,3.6,74.0,322.0,74.4,39.3,27.0,1.46,0.5,1.9,20.7,8.3,0.368,1.49,12.1,134.0,4.24,1000.0,132.8, 未做,无,, P0,H0, 未做,"ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(+)， S100(+),D2-40(+)",,,,,28.64651773981603,1512545
1512437,李春梅,596765,女,61,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 肠化生+,0.0,30,中间型（int）,INFa,3.0,,,,,,,0.0,2015-04-22,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)00 (3b)00 (4d)015 (5)02 (6)02 (7)01 (8a)01 (8p)02 (9)05 (11p)02 (12a)00 (14v)00," L（幽门窦部）, 后Post,",25,15,6, R0 D2,,5.1,2.8,1.82,139.6,231.0,2.33,17.0,18.0,159.0,75.0,7.0,10.78,4.2,68.0,292.0,40.0,28.0,4.8,7.0,46.0,225.0,67.4,40.5,24.9,1.63,0.1,13.7,14.5,1.2,1.45,2.07,16.6,18.7,1.74,7.21,1.61,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,73.98160315374507,1512437
1513375,秦洪岩,598078,男,51,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,9.0,51,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-04-29,2021-06-21,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3, (1a)03 (1b)01 (3a)310 (3b)11 (4sb)03 (4d)04 (5)11 (6)15 (7)13 (8a)11 (8p)01 (9)04 (11p)05 (12a)00 (12p)01 软组织可见癌大网18," LM 前Ant, 后Post, 小弯侧Less,",70,60,10, R0 D2,,7.62,6.15,0.9,146.2,138.0,,14.0,24.0,132.0,70.0,17.0,9.97,3.82,58.0,156.0,34.0,24.0,4.3,6.2,81.0,180.0,57.7,41.0,14.6,2.81,0.1,13.5,27.5,1.4,0.435,2.06,10.1,35.9,3.51,11.55,2.59,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF+， CMET+,,,,,73.75164257555848,1513375
1512383,郭淑香,581806,女,57,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,0.0, 肠化生+,0.0,31,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2015-04-22,2016-08-18,2,紫杉醇联合替吉奥*4,1.0,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)05 (2)06 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)07 (5)02 (6)02 (7)02 (8a)02 (8p)04 (9)00 (11p)00 (12a)00,M（胃体部） L（幽门窦部） 小弯侧Less ,25,20,2, D2 R0,,5.87,3.62,1.64,143.5,165.0,2.58,29.0,34.0,197.0,90.0,18.0,19.26,5.08,68.0,250.0,42.0,26.0,7.7,8.3,67.0,310.0,,,,,,,,,,,,,2.25,19.23,11.45,,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(-)，CD34(+)， S100(+),,,,,15.900131406044677,1512383
1512925,谭丽红,597732,女,40,T4b,N0,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,0.0,47,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-04-27,2018-04-24,0,,,XELOX,,,,,,4, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren肠型,G3,下切旁01 (1a)01 (1b)00 (2)06 (3a)07 (3b)01 (4sa)00 (4sb)00 (4d)011 (5)00 (6)05 (7)02 (8a、8p、9)08 (11p)05," U（胃底部）, 前Ant, 后Post, 大弯侧Gre,",50,50,10, R0 D2+,,10.2,8.36,1.5,127.8,344.0,4.03,12.0,17.0,177.0,64.0,13.0,7.01,2.37,75.0,297.0,44.0,31.0,6.4,4.2,73.0,268.0,,,,,,,,,,,,,1.26,24.2,7.78,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,35.90670170827858,1512925
1513996,张政河,596905,男,71,T4a,N1,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,1.0,24,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-07,2015-09-28,2,,,口服替吉奥,,,,,,2, 管状腺癌（中分化【G2】【tub2】70 乳头状癌（G1）（pap）30,G2, (1a)02 (1b)01 (2)05 (3a)04 (3b)00 (4sb)02 (4d)15 (5)00 (6)00 (7)02 (8a)00 (8p)02 (9)00 (11p)01," LMU 前Ant, 后Post, 小弯侧Less,",150,130,20, R0 D2+,,15.2,12.13,1.82,94.2,693.0,5.44,9.0,13.0,120.0,82.0,32.0,9.12,3.59,64.0,64.0,36.0,28.0,6.0,4.9,75.0,184.0,,,,,,,,,,,,,4.2,11.85,,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET灶+ CD34(脉管周+)  S-100(神经+),,,,,4.730617608409987,1513996
1513002,赵克友,597238,男,62,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,8.0,17,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-27,2016-01-03,0,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren肠型,G3,小弯22 (1a)00 (1b)03 (3a)12 (3b)22 (4sb)00 (4d)00 (5)00 (6)33 (7)03 (8a)00 (8p)01 (9)00 (11p)00," LM 前Ant, 后Post, 小弯侧Less,",70,55,10, R0 D2+,,6.18,3.61,1.87,92.1,358.0,3.68,25.0,24.0,132.0,115.0,22.0,13.02,5.32,76.0,190.0,41.0,35.0,5.2,6.3,85.0,303.0,,,,,,,,,,,,,1.35,5.4,3.39,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,8.245729303547963,1513002
1512451,尹淑友,596750,男,52,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,15.0,24,中间型（int）,INFb,0.0,,,,,,,1.0,2015-04-15,2017-05-01,2,,,,,,,,,0, 低分化腺癌（G3)(por)80% 低粘附腺癌20% Lauren肠型,G3, (1a)13 (1b)11 (2)06 (3a)33 (3b)11 (4sb)01 (4d)33 (5)11 (6)11 (7)00 (8a)22 (8p)00 (9)22 软组织可见癌," L（幽门窦部）, M（胃体部）, U（胃底部）, 前Ant, 后Post, 小弯侧Less,",70,60,15,,R1,5.49,2.98,1.91,87.3,215.0,,15.0,18.0,92.0,62.0,13.0,7.01,3.39,54.0,152.0,33.0,21.0,5.2,4.8,52.0,259.0,,,,,,,,,,,,,1.3,6.61,3.01, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 CD34/D2-40+、 S-100+、 VEGF（-）、 CMET（小区点灶+）,,,,,24.540078843626805,1512451
1513019,肖井兰,596951,女,53,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,22,中间型（int）,INFa,0.0,,1.0,,,,,1.0,2015-04-27,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren肠型,G3, (1a)05 (1b)02 (3a)02 (3b)01 (4sb)00 (4d)010 (5)00 (6)00 (7)01 (8a) (8p)01 (9)00 (11p)00," ML 前Ant,",20,20,2, R0 D2,,5.78,2.63,2.87,139.5,256.0,2.6,14.0,17.0,162.0,87.0,30.0,10.87,2.98,69.0,273.0,42.0,27.0,4.5,3.6,80.0,217.0,71.0,48.9,19.7,2.48,0.1,9.8,18.1,4.2,2.16,2.24,16.0,5.0,1.5,12.07,2.26, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+) CD117（—） ,,,,,72.89750328515112,1513019
1512980,王德珍,596898,女,64,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,0.0, 肠化生++ 慢性炎症（+）,7.0,39,中间型（int）,INFc,1.0,,1.0,,,,,1.0,2015-04-27,2021-06-21,1,,,XELOX,,,,,,3, 粘液腺癌（muc）50%， 低粘附腺癌40%， 低分化腺癌（G3)(por)10%， Lauren肠型,G3, (1a)0/1 (1b)0/0 (3a)5/14 (3b)1/3 (4sb)0/0 (4d)0/0 (5)0/0 (6)0/3 (7)0/3 (8a)1/2 (8p)0/3 (9)0/4 (11p)0/4 (12a)0/0 (12p)0/2，3b见一癌结节," LM 前Ant, 后Post, 小弯侧Less,",70,70,8,,R1,5.03,2.08,2.55,121.7,218.0,2.44,20.0,31.0,157.0,102.0,7.0,9.35,3.51,64.0,160.0,38.0,26.0,5.2,7.6,68.0,201.0,60.8,37.0,21.4,1.73,2.1,9.0,27.8,0.3,0.461,3.06,10.9,59.5,8.48,378.0,2.96, 未做,无, 无, P0,H0, 未做,Vimentin -VEGF+ CK+ S-100（神经+） CD34、D2-40(脉管+) CMET+,,,,,73.8173455978975,1512980
1513076,于志华,597167,男,55,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,3.0,31,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-28,2017-07-27,0,,,XELOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)0/2 (1b)0/1 (3a)0/4 (3b)0/0 (4sb)0/1 (4d)1/9 (5)0/0 (6) (14v) 2/2(7)0/4 (8a)0/1 (8p)0/2 (9)0/1 (11p)0/4 (12a)0/0，6、14组见一枚癌结节," LD 前Ant, 后Post, 小弯侧Less,",60,50,12,,R1,7.54,3.33,3.27,156.9,160.0,3.33,27.0,30.0,167.0,97.0,9.0,14.2,5.04,74.0,204.0,45.0,29.0,4.0,4.3,89.0,314.0,52.2,37.9,11.0,3.45,0.1,7.9,37.9,0.4,1.43,4.02,10.8,59.9,3.11,8.68,12.51, 未做,无, 无, P0,H0, 未做," CMET+, Vimentin-, VEGF+ CK+ S-100（神经+） CD34、D2-40（脉管+）",,,,,26.971090670170828,1513076
1513077,张国军,597140,男,60,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,5.0,40,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-04-28,2018-11-14,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)08 (1b)02 (2)03 (3a)14 (3b)05(4sb)01 (4d)36 (5)04 (6)06 (7)00 (8a)00 (8p)00 (9)00 (11p)00小弯11,LMU 小弯侧Less 前Ant 后Post ,90,70,18, R0 D2,,7.94,4.78,2.36,124.9,492.0,3.46,33.0,27.0,105.0,100.0,30.0,4.19,1.6,63.0,282.0,39.0,24.0,4.6,5.4,76.0,371.0,73.9,45.8,24.7,1.85,0.1,9.3,13.0,51.6,0.747,1.1,10.3,132.0,62.36,36.49,12.27, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,42.57555847568988,1513077
1513195,莫长有,596117,男,59,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,22,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-28,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)04 (3b)02 (4sb)01 (4d)00 (5)03 (6)00 (7)03 (8a)06 (8p)00 (9)00 (11p)01 (12a)01," L（幽门窦部）, 后Post,",8,6,2, R0 D2+,,4.87,2.86,1.67,146.6,212.0,2.08,25.0,30.0,181.0,56.0,76.0,9.43,3.54,61.0,304.0,39.0,22.0,4.8,6.6,63.0,367.0,,,,,,,,,,,,,3.03,25.71,7.6,,无,, P0,H0, 未做,CK + Vimentin – VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,73.78449408672799,1513195
1509782,刘继武,591233,男,77,T4b,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,0.0, 肠化生+,27.0,38,中间型（int）,INFb,0.0,,,,,,,0.0,2015-04-01,2016-05-04,2,,,,,,,,,0, 低粘附腺癌60%， 低分化腺癌（G3)(por)20%， 粘液腺癌（muc）20%， Lauren弥漫型,G3,小弯侧2/4， (1a) 22(1b)22 (2) 911(3a) (3b)57 (4sb) 01(4d) 01(5)00 (7)56 (8a) 01(8p)00 (9)11 (11p)01," U（胃底部）, 前Ant, 后Post, 小弯侧Less,",80,80,15,,R1,6.14,4.03,1.55,79.7,289.0,3.21,28.0,31.0,187.0,83.0,31.0,4.63,2.54,59.0,104.0,35.0,24.0,4.6,7.3,56.0,250.0,71.7,27.7,40.9,0.68,0.1,3.7,20.0,0.5,0.476,2.49,14.1,76.6,99.23,14.23,7.4, 未做,无, 无, P0,H0, 未做, CK+  Vimentin_  CMET_  CD34 脉管+  S-100神经+,,,,,13.107752956636006,1509782
1513150,刘国玉,597708,男,64,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,1.0,26,中间型（int）,INFb,2.0,,1.0,,,,,1.0,2015-04-28,2020-04-26,0,,,SOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,,5, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)06 (1b)13 (3a)06 (3b)00(4sa)02 (4sb)03 (4d)00 (5)00 (6)02 (7)00 (8a)03 (8p)01 (9)00 (11p)00 ," LM 小弯侧Less,",30,30,8, R0 D2,,8.08,4.26,3.02,159.7,199.0,2.68,28.0,32.0,160.0,86.0,61.0,8.4,3.3,74.0,271.0,44.0,30.0,4.9,5.2,71.0,281.0,65.2,30.6,33.9,0.9,0.6,9.2,24.1,5.4,1.36,3.38,13.8,15.2,1.35,7.98,0.956, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,59.95400788436268,1513150
1512924,霍云芳,596128,女,82,T4b,N2,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+,4.0,18,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-27,2016-08-19,2,,,,,,,,,0," 管状腺癌（中分化【G2】【tub2】80%， 低粘附腺癌20%, Lauren肠型",G2," (1a)0/0 (1b)0/0 (3a)1/4 (3b)0/0 (4sb)0/1 (4d)1/3 (5)0/0 (6) 0/2(7)0/6 (8a)2/2,3b,5组见两枚癌结节"," M（胃体部）, 大弯侧Gre,",40,30,30,,R2,4.48,3.02,1.05,108.6,250.0,6.18,12.0,17.0,167.0,101.0,10.0,11.03,4.18,75.0,195.0,43.0,32.0,5.2,7.2,102.0,411.0,57.4,31.3,24.9,1.26,0.1,5.7,34.8,0.3,1.03,3.75,14.7,280.0,1.43,10.83,2.93, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF+ CK+ S-100(神经+) CD34、D2-40(脉管+),,,,,15.768725361366622,1512924
1513176,高占海,597686,男,66,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,16,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-28,2021-06-21,1,,,FOLFOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) 0/1(1b)0/3 (3a)0/3 (3b)0/0 (4sb)0/1 (4d)0/1 (5)0/1 (6)0/0 (7)0/0 (8a)0/1 (8p)0/2 (9)0/0 (11p)0/3 (12a)0/0," L（幽门窦部）, 大弯侧Gre,",60,50,10,,R1,9.08,5.47,2.5,107.0,323.0,3.85,14.0,20.0,135.0,56.0,12.0,3.51,1.54,61.0,167.0,34.0,27.0,4.6,4.9,60.0,256.0,74.5,25.3,44.9,0.56,0.4,5.7,15.7,2.5,0.994,2.89,12.0,149.0,3.16,14.79,3.77, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF+ CK+ S-100(神经+) CD34、D2-40(脉管+),,,,,73.78449408672799,1513176
1513187,柴文涛,597193,男,61,T4b,N1,M0, ⅢB,1,3,0.0,0.0,0.0,0.0, 肠化生+,1.0,22,中间型（int）,INFb,3.0,,1.0,,,,,1.0,2015-04-28,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)12 (2)04 (3a)02 (3b)06 (4sa)00 (4sb)00 (4d)00 (5)01 (6)02 (7)00 (8a)02 (8p)01 (9) 01(11p)00 (12a)01,U（胃底部） SiewerⅢ型 小弯侧Less 后Post ,90,80,10, R0 D2,,7.72,5.17,1.97,157.0,300.0,3.4,22.0,24.0,171.0,73.0,21.0,19.9,6.54,68.0,243.0,38.0,30.0,5.5,5.2,83.0,289.0,72.2,42.3,22.7,1.86,0.2,14.7,9.6,4.0,1.97,2.91,9.99,44.3,1.96,14.69,1.67, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,88.14060446780552,1513187
1513432,于永和,596519,男,55,T4b,N3b,M1, Ⅳ,1,4,2.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,19.0,30,中间型（int）,INFb,3.0,,1.0,,,,,0.0,2015-04-30,2016-01-05,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,小弯1516 (1a)14 (1b)11 (2)00 (3a)00 (3b)00 (4sb)23 (4d)05 (5)00 (6)00 (7)00 (8a)00 (8p)00 (9)00 (11p)00 (14v)01," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,25,5,,R2,5.44,2.27,2.59,145.6,333.0,2.9,19.0,18.0,134.0,118.0,12.0,21.33,6.72,68.0,317.0,44.0,24.0,5.7,5.5,83.0,302.0,,,,,,,,,,,,,1.31,2.09,2.7,,无,, p1局腹膜(M1 PER),H0, 未做,CK + Vimentin –  VEGF+ CMET- CD34(脉管周+)  S-100(神经+),,,,,8.21287779237845,1513432
1513546,于德胜,597250,男,59,T4b,N0,M0, ⅢA,1,5,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,34,中间型（int）,INFb,0.0,,,,,,,1.0,2015-04-30,2021-06-21,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por)70%， 乳头状癌（G1）（pap）30%， Lauren肠型,G3, (1a) 0/0(1b)0/2 (3a)0/8 (3b)0/0 (4sb)0/0 (4d)0/12 (5)0/0 (6)0/0 (7)0/1 (8a)0/1 (8p)0/3 (9)0/1 (11p)0/6 (12a)0/0," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",80,70,25,,R1,6.47,4.23,1.68,102.5,303.0,3.49,17.0,21.0,184.0,98.0,9.0,5.17,2.42,56.0,161.0,36.0,20.0,5.0,7.0,77.0,228.0,79.1,45.1,29.0,1.56,0.0,5.9,13.2,1.6,0.643,1.31,6.06,16.6,2.87,7.75,1.27, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ S-100(神经+) CD34、D2-40(脉管+),,,,,73.71879106438895,1513546
1513433,娄术君,597237,男,60,T2,N2,M0, ⅡB,1,5,0.0,0.0,0.0,1.0, 肠化生+,3.0,30,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-04-30,2020-04-29,1,,,SOX,,,,,,3, 低分化腺癌（G3)(por)60% 低粘附腺癌40% Lauren肠型,G3,肿物旁11 (1a)01 (1b)01 (3a)14 (3b)01 (4sb)11 (4d)06 (5)00 (6)05 (7)03 (8a)01 (8p)01 (9)03 (11p)01 (12a)00 (12p)01," M（胃体部）, L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",20,10,8, R0 D2,,7.82,4.62,2.68,155.1,223.0,3.53,18.0,19.0,128.0,64.0,16.0,15.49,4.8,67.0,322.0,44.0,23.0,5.6,5.1,69.0,249.0,,,,,,,,,,,,,2.09,24.17,2.5, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）、 S-100+、 CD34D2-40+,,,,,59.98685939553219,1513433
1513646,迟忠昌,598146,男,66,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,12,中间型（int）,INFa,1.0,,1.0,,,,,1.0,2015-05-04,2020-04-26,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)02 (5)00 (6)00 (7)02 (8a)(9)02(8p)00 (11p)01 (12a)03,ML 大弯侧Gre  ,5,,, R0 D2,,6.34,3.35,2.33,153.0,173.0,2.94,22.0,24.0,146.0,30.0,30.0,10.94,3.48,68.0,338.0,41.0,27.0,5.0,6.4,100.0,490.0,48.4,30.6,12.5,2.45,0.1,11.3,36.7,0.6,0.855,2.95,11.1,475.0,4.31,17.24,1.36, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,59.75689881734559,1513646
1513578,王继祥,597062,男,60,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,4.0,28,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-04,2016-05-03,2,,,,,,,,,0, 粘液腺癌（muc）80% 低粘附腺癌20% Lauren肠型,GX, (1a)01 (1b)00 (3a)08 (3b)01 (4sb)00 (4d)38 (5)00 (6)00 (7)01 (8a)11 (8p)02 (9)03 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,30,8, R0 D2,,6.13,3.69,1.66,145.9,210.0,3.53,19.0,21.0,180.0,97.0,12.0,8.4,3.1,67.0,262.0,44.0,23.0,5.5,3.7,90.0,366.0,73.4,42.0,27.8,1.51,0.2,10.0,10.7,2.4,0.941,2.61,7.98,108.0,3.86,6.76,14.17, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）、 S-100+、 CD34D2-40+,,,,,11.990801576872535,1513578
1513647,周春秀,586220,女,69,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,22,中间型（int）,INFb,1.0,,,,,,,0.0,2015-05-04,2021-05-17,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型 Lauren弥漫型,G2, (1a)01 (1b)00 (3a)09 (3b)01 (4sb)00 (4d)02 (5)01 (6)00 (7)01 (8a)01 (8p)01 (9)02 (11p)02 (12a)01," M（胃体部）, 小弯侧Less,",30,20,4, R0 D2,,6.25,3.46,1.98,122.2,236.0,3.16,28.0,28.0,171.0,112.0,22.0,5.38,1.98,65.0,219.0,40.0,25.0,5.1,10.6,70.0,245.0,75.1,45.2,22.1,2.05,0.2,9.4,13.4,1.6,1.05,1.3,10.1,123.0,2.26,6.56,0.915, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 S-100+、 CD34D2-40+,,,,,72.43758212877792,1513647
1513709,李洪春,488441,男,68,T1b,N0,M0,ⅠA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,6,中间型（int）,INFa,1.0,,,,,,,,2015-05-05,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 乳头状癌（G1）（pap）20 Lauren肠型,G2, (2)00 (3a)00 (4sb)04 肠旁01 肿物旁01," U（胃底部）, 前Ant, 后Post, 小弯侧Less,",40,30,10, R0,,5.56,3.89,1.11,142.1,130.0,2.12,17.0,23.0,156.0,93.0,44.0,16.19,6.76,69.0,290.0,43.0,26.0,4.9,8.8,111.0,548.0,,,,,,,,,,,,,2.9,17.55,1.13,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,73.5545335085414,1513709
1513252,邹玉田,597674,男,60,T4b,N3a,M0, ⅢC,1,3,1.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,10.0,28,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-04-29,2016-11-30,2,,,SOX,,,,,,5, 低粘附腺癌80 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)20 Lauren混合型,G3, (1a)03 (1b)14 (3a)22 (3b)11 (4sb)01 (4d)34 (5)01 (6)00 (7)12 (8a)22 (8p)02 (9)03 (11p)13 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,20, R0 D2,,10.0,6.57,2.74,135.0,236.0,3.84,38.0,34.0,141.0,103.0,16.0,9.92,5.51,67.0,242.0,40.0,27.0,5.3,6.9,93.0,265.0,76.7,31.5,20.1,1.57,0.2,12.1,6.6,5.8,0.702,1.27,13.8,59.7,1.26,3.99,,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF+， CMET+,,,,,19.086727989487514,1513252
1514512,刘永军,597759,男,52,T3,N3a,M0,ⅢB,1,1,0.0,0.0,0.0,0.0, 肠化生+,7.0,47,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-05-12,2021-06-21,1,,,替吉奥单药,,,,,,6, 粘液腺癌（muc） Lauren肠型,GX, (1a)02 (1b)15 (3a)07 (3b)00 (4sb)01 (4d)28 (5)00 (6)39 (7)02 (8a)11 (8p)01 (9)03 (11p)06 (12a)00 (14v)02," L（幽门窦部）M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",,,, R0 D2+,,4.66,2.69,1.58,123.9,332.0,2.15,30.0,30.0,147.0,128.0,25.0,7.6,2.93,69.0,283.0,45.0,24.0,5.2,4.9,95.0,328.0,74.4,43.6,17.6,2.48,0.0,4.1,19.4,3.2,1.05,3.03,7.3,76.5,5.06,2.53,24.29, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）、 S-100+、 CD34D2-40+,,,,,73.32457293035479,1514512
1516985,陈卫晶,599997,女,50,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 肠化生+,3.0,35,中间型（int）,INFb,3.0,,,,,,,1.0,2015-06-02,2021-05-17,1,,,赫赛汀 多西他赛 奥沙利铂 卡佩他滨,,,,,,6, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren肠型,G3, (1a)15 (1b)01 (3a)02 (3b)00 (4sb)03 (4d)013 (5)01 (6)22 (7)01 (8a、8p、9)03 (11p、11d)03 (12a)01," L（幽门窦部）, 后Post,",15,12,7, R0 D2+,,6.28,3.51,2.22,149.5,243.0,2.48,40.0,36.0,195.0,65.0,34.0,9.75,2.35,71.0,265.0,42.0,29.0,4.9,7.0,58.0,330.0,67.4,45.2,17.6,2.57,0.4,17.2,8.4,0.5,0.921,1.81,14.7,209.0,1.1,16.88,7.17,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET+ ,,,,,71.48488830486203,1516985
1513761,欧阳志芳,598043,男,66,T4b,N3b,M0, ⅢC,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,39.0,49,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-05,2021-01-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren肠型,G3, (1a)23 (1b)24 (3a)69 (3b)22 (4sb)99 (4d)1011 (5)11 (6)13 (7)23 (8a)22 (8p)22,LD 前Ant 小弯侧Less 后Post ,30,20,10,,R1,4.05,2.4,1.0,133.0,191.0,3.27,40.0,56.0,166.0,76.0,32.0,8.78,3.82,62.0,190.0,34.0,28.0,5.0,5.1,105.0,221.0,64.0,42.5,20.0,2.13,0.2,19.3,12.6,0.3,1.28,2.84,14.1,41.1,1.03,63.62,3.64, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)，CD34(+)， S100(+)D2-40（+）,,,,,67.93692509855452,1513761
1513785,霍永林,596132,男,72,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,14.0,34,中间型（int）,INFb,3.0,,1.0,,,,,1.0,2015-05-05,2015-11-30,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)55 (3b)77 (4sb)00 (4d)06 (5)00 (6)00 (7)02 (8a)14 (8p)03 (9)03 (11p)02肿物旁11, GE SiewerⅢ型 前Ant 后Post 大弯侧Gre  小弯侧Less,60,50,20,,R1,7.71,4.5,2.26,131.0,180.0,3.05,18.0,20.0,171.0,53.0,18.0,6.33,2.34,75.0,270.0,45.0,30.0,3.6,7.8,105.0,357.0,54.4,28.7,22.1,1.3,0.1,7.1,35.7,5.6,0.709,1.94,13.7,76.7,1.64,30.73,2.34, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,6.865965834428383,1513785
1513662,鲁彦飞,597285,男,53,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,14,中间型（int）,INFb,1.0,,,,,,,0.0,2015-05-04,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)00 (5)00 (6)07 (7)01 (8a)03 (8p)02 (9)00 (11p)01,L（幽门窦部） 后Post ,15,15,6, R0 D2,,6.68,4.06,2.2,148.0,276.0,2.33,29.0,21.0,143.0,66.0,21.0,19.31,12.73,68.0,352.0,43.0,25.0,4.7,7.8,87.0,286.0,70.5,38.3,30.1,1.27,0.6,8.6,18.1,4.5,0.813,1.53,9.46,10.2,3.64,11.12,1.31, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  D2-40(+) S100(+),,,,,72.66754270696451,1513662
1514120,董长运,597306,男,72,T3,N3a,M0,ⅢB,1,1,2.0,1.0,1.0,1.0, 肠化生+,11.0,15,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-05-07,2021-01-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)50 低粘附腺癌50 Lauren弥漫型,G3, (1a)00 (1b)00 (2)01 (3a)11 (3b)01 (4sa)01 (4sb)00 (4d)00 (5)00 (6)00 (7)00 (8a)23 (8p)00 (9)00 (11p)00 (12a)00 肿物旁88," MU 后Post, 大弯侧Gre, 小弯侧Less,",90,80,20, R0 D2+,,4.91,2.38,1.77,109.0,218.0,2.85,19.0,26.0,130.0,92.0,39.0,7.34,3.0,58.0,132.0,33.0,25.0,5.2,7.1,75.0,252.0,,,,,,,,,,,,,2.94,10.01,4.07,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,67.8712220762155,1514120
1514106,李兰英,597426,女,56,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,3.0,29,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-07,2015-10-18,0,,,SOX,,,,,,6, 粘液腺癌（muc） Lauren肠型,GX, (1a)00 (1b)01 (2)04 (3a)25 (3b)00 (4sb)00 (4d)02 (5)00 (6)01 (7)01 (8a)03 (8p)05 (9)02 (11p)01,ML 前Ant 小弯侧Less ,50,30,20, D2 R0,,4.06,1.15,2.31,124.7,272.0,2.34,19.0,23.0,146.0,76.0,11.0,11.31,4.17,67.0,156.0,38.0,29.0,4.9,3.3,64.0,218.0,53.9,34.9,17.4,2.01,0.2,9.5,32.4,0.6,1.19,2.99,14.8,6.65,1.32,7.33,1.39, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(+)，D2-40(+),,,,,5.387647831800263,1514106
1513847,吴跃忠,598906,男,62,T1b,N1,M0, ⅠB,1,0,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,1.0,20,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-06,2021-05-24,1,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/0 (1b)0/3 (3a) 0/3(3b)1/1 (4sb)0/1 (4d)0/0 (5)0/0 (6)0/1 (7)0/0 (8a)0/2 (8p)0/1 (9)0/4 (11p)0/4," L（幽门窦部）, 小弯侧Less,",15,10,3, R0 D2,,9.91,6.2,2.56,150.0,338.0,2.22,38.0,30.0,167.0,83.0,29.0,9.39,3.1,66.0,350.0,40.0,26.0,4.8,6.4,92.0,495.0,61.4,32.5,27.7,1.17,0.2,11.7,24.5,5.9,1.97,2.91,9.99,44.3,3.38,2.37,0.594, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF+ CK +S-100(神经+) CD34、D2-40(脉管+),,,,,72.60183968462549,1513847
1514458,王纯军,599254,男,66,T4a,N3a,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,8.0,41,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-11,2016-10-01,2,,,,,,,,,0, 粘液腺癌（muc）60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren肠型,G3, (1a)03 (1b)23 (3a)2 11 (3b)00 (4sb)01 (4d)13 (5)03 (6)26 (7)13 (8a) (8p)06 (9)02 (11p)00,L（幽门窦部） LM 大弯侧Gre  前Ant 后Post 小弯侧Less ,80,60,12, R0 D2,,8.04,4.03,3.37,124.9,202.0,3.46,20.0,22.0,161.0,88.0,6.0,7.78,3.42,64.0,249.0,40.0,24.0,5.0,5.9,96.0,403.0,47.2,27.9,14.6,1.91,0.1,10.4,36.0,1.4,1.11,1.84,11.0,248.0,7.44,9.61,9.13, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(灶+)  CD34(+)  D2-40(+) S100(+),,,,,16.72141918528252,1514458
1514262,张汝河,598177,男,54,T4b,N2,M0, ⅢB,1,2,2.0,0.0,0.0,0.0, 慢性炎症（+）,5.0,21,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-08,2016-01-26,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)01 (3a)04 (3b)00 (4sb)04 (4d)14 (5)00 (6)11 (7)00 (8a)14 (8p)13 (9)00 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",28,20,8,,R1,5.37,2.57,2.29,154.0,152.0,3.4,34.0,33.0,175.0,90.0,13.0,9.82,3.34,74.0,260.0,45.0,29.0,4.8,8.2,84.0,310.0,,,,,,,,,,,,,2.53,404.7,2.58,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+ CD34(脉管周+)  S-100(神经+),,,,,8.639947437582128,1514262
1514811,孔庆连,596973,女,75,T4a,N1,M0, ⅢA,1,1,0.0,0.0,0.0,1.0, 肠化生+,2.0,17,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-13,2016-12-08,2,,,替吉奥单药,,,,,,2, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)0/2 (1b)0/0 (2)0/1 (3a)0/0 (3b)2/5 (4sa)0/0 (4sb)0/0 (4d)0/0 (5)0/0 (7)0/1 (8a)0/2 (8p)0/3 (9)0/0 (11p)0/3," U（胃底部）, 小弯侧Less, 后Post, 前Ant,",30,30,15,,R1,7.29,4.55,2.13,112.8,298.0,1.52,44.0,53.0,195.0,86.0,14.0,13.56,4.02,67.0,258.0,40.0,27.0,5.2,7.3,56.0,369.0,70.5,44.2,20.9,2.11,0.3,13.0,12.0,1.3,1.46,8.68,13.2,24.7,2.72,63.28,3.37, 未做,无, 无, P0,H0, 未做, CMET +Vimentin -VEGF -CK+ S-100（神经+） CD34、D2-40（脉管+）,,,,,18.889618922470433,1514811
1514617,冯秋芝,597651,女,72,T1b,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,24,中间型（int）,INFb,1.0,,,,,,,1.0,2015-05-12,2020-04-26,0,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)0/2 (1b)0/0 (3a)0/3 (3b)0/1 (4sb)0/0 (4d)0/3 (5)0/3 (6)0/4 (7)0/0 (8a)0/1 (8p)0/1 (9) 0/2(11p)0/4 (12a) 0/0(12b)0/0," M（胃体部）, 小弯侧Less,",30,30,, R0,,5.9284,3.9,1.44,137.0,253.0,2.99,28.0,24.0,158.0,78.0,30.0,9.04,2.57,66.0,217.0,41.0,25.0,5.5,6.0,58.0,318.0,66.8,45.2,10.9,4.15,0.2,12.6,17.1,11.0,0.901,1.14,16.9,120.0,0.828,8.44,2.09, 未做,无,,,, 未做, CMET(+灶) Vimentin- VEGF- CK+ S-100(神经+) CD34、D2-40(脉管+),,,,,59.49408672798948,1514617
1515310,孙凤玲,599225,女,54,T1b,N3a,M0, ⅡB,1,0,2.0,0.0,0.0,0.0, 慢性炎症（+）,12.0,41,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-18,2021-06-21,1,,,XELOX,,,,,,1, 低粘附腺癌80% 低分化腺癌（G3)(por)20% Lauren弥漫型,G3, (1a)02 (1b)00 (2)38 (3b)45 (4sb)00 (4d)07 (5)11 (6)02 (7)01 (8a)03 (8p)01 (9)01 (11p)02 (12a)00 (14a)01 (14v)03 (16a1)肿物旁44," M（胃体部）, 小弯侧Less,",30,20,10, R0 D2+,,4.5,2.24,1.7,131.0,308.0,2.85,22.0,23.0,185.0,73.0,23.0,13.7,4.94,71.0,288.0,42.0,29.0,6.3,6.8,69.0,291.0,68.4,45.7,23.0,1.99,1.0,10.5,18.9,0.9,1.16,2.88,14.8,632.0,2.13,32.19,2.96, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（灶+）,,,,,73.12746386333771,1515310
1514459,许建成,598996,男,63,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,7,中间型（int）,INFb,3.0,,,,,,,1.0,2015-05-11,2021-05-24,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a) 00(1b) 01(3a)02 (3b)00 (4sb)00 (4d)01 (5)01 (6)00 (7)00 (8a)01 (8p)01 (9)00 (11p)00 (12a)00 (12b)00," L（幽门窦部）, 后Post,",20,10,15, R0,,6.14,2.23,3.27,136.0,136.0,1.82,26.0,27.0,178.0,48.0,24.0,13.56,5.65,65.0,249.0,40.0,25.0,6.1,5.3,71.0,278.0,56.3,34.0,20.1,1.69,0.1,11.7,30.4,3.2,0.555,1.94,11.8,401.0,2.19,10.32,4.59, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ S-100(神经+) CD34、D2-40(脉管+),,,,,72.43758212877792,1514459
1514087,徐小栋,597596,男,44,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,8.0,31,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-07,2021-05-17,1,,,FOLFOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)39 (1b)03 (3a)17 (4sb)00 (4d)02 (5)00 (6)01 (7)27 (7、8、9)11 膜样组织旁11," LD 前Ant, 后Post, 小弯侧Less,",50,30,10, R0 D2+,,9.4,6.2,2.38,126.4,458.0,3.85,21.0,20.0,39.0,59.0,8.0,6.32,1.23,68.0,239.0,41.0,27.0,6.1,4.0,81.0,316.0,72.2,42.3,22.7,0.86,0.2,14.7,9.6,4.0,1.55,0.918,12.5,62.8,4.64,7.24,17.03,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,72.33902759526939,1514087
1514331,郭来新,599393,男,50,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,17,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-11,2021-06-21,1,,,,,,,,,0, 低粘附腺癌 Lauren肠型,GX, (1a)03 (1b)02 (3a)00 (3b)00 (4sb)00 (4d)07 (5)00 (6)03 (7)02,M（胃体部） 小弯侧Less ,15,,, R0 D1+,,5.5,2.62,2.12,155.1,224.0,2.17,25.0,25.0,142.0,70.0,15.0,11.7,4.26,62.0,233.0,41.0,21.0,5.4,5.9,75.0,312.0,72.1,33.5,20.8,1.61,0.2,13.2,10.1,2.4,0.851,0.964,9.06,13.2,2.82,15.7,1.5, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(灶+)  CD34(+)  D2-40(+) S100(+),,,,,73.3574244415243,1514331
1515835,张玉莲,598729,女,51,T1b,N2,M0, ⅡA,1,0,0.0,0.0,0.0,1.0, 肠化生+,3.0,19,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-21,2021-06-21,1,,,XELOX,,,,,,3, 低粘附腺癌90% 低分化腺癌（G3)(por)10% Lauren肠型,G3, (1a)02 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)03 (5)11 (6)24 (7)02 (8a)03 (8p)01 (9)00 (11p)01 (12a)01 (12p)00," L（幽门窦部）, D(十二指肠), 前Ant, 后Post, 小弯侧Less, 大弯侧Gre,",15,15,5, R0 D2,,5.42,3.45,1.6,123.0,229.0,2.52,19.0,22.0,158.0,74.0,36.0,10.79,3.74,63.0,206.0,38.0,25.0,5.4,6.6,52.0,199.0,77.8,50.0,21.5,2.33,0.2,13.0,6.0,2.5,1.9,1.94,10.5,5.89,0.848,4.16,1.46, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）,,,,,73.02890932982918,1515835
1514798,张良玉,598821,男,51,T2,N1,M0, ⅡA,1,2,0.0,1.0,1.0,0.0, 肠化生+,1.0,40,中间型（int）,INFb,1.0,,,,,,,1.0,2015-05-13,2021-07-01,1,,,FOLFOX,FOLFOX,卡佩他滨,,,,3," 管状腺癌（中分化【G2】【tub2】80%， 粘液腺癌（muc）20%, Lauren肠型",G2, (1a)0/4 (1b)0/0 (3a)0/10 (3b) 1/2(4sb)0/2 (4d)0/9 (5)0/2 (6)0/1 (7)0/2 (8a)0/1 (8p)0/1 (9)0/2 (11p)0/2 (12a)0/1 (12p)0/1," M（胃体部）, 小弯侧Less,",30,20,10, R0 D2,,7.37,4.87,1.99,130.0,225.0,2.89,29.0,25.0,116.0,62.0,26.0,11.79,4.12,64.0,319.0,40.0,24.0,6.7,5.0,73.0,366.0,73.1,44.5,24.6,1.81,0.3,18.9,5.0,1.3,6.49,2.35,9.19,242.0,3.12,6.32,1.48, 未做,无,,,H0, 未做, CMET(+灶) Vimentin- VEGF- CK+ S-100（神经+） CD34、D2-40(脉管+),,,,,73.62023653088042,1514798
1514544,孙成发,597484,男,50,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,31,中间型（int）,INFb,2.0,,1.0,,,,,1.0,2015-05-12,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)07 (3a)05 (3b)02 (4sb)02 (4d)02 (5)00 (6)03 (7)02 (8a) (8p) (9)03 (11p) 00(12a)02 (16a1)01," L（幽门窦部）, 小弯侧Less,",30,30,6, R0 D2,,3.74,1.84,1.28,155.0,161.0,2.76,54.0,36.0,184.0,45.0,137.0,17.28,5.28,65.0,327.0,40.0,25.0,4.0,7.6,85.0,282.0,73.1,47.8,20.1,2.38,0.2,12.3,12.6,1.0,1.39,3.29,12.7,5.0,1.31,7.55,1.22, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,72.40473061760841,1514544
1514623,高远振,598809,男,57,T4a,N3a,M0, ⅢB,1,3,1.0,0.0,0.0,0.0, 慢性炎症（+）,15.0,43,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-05-12,2021-03-01,1,,,XELOX,,,,,,6, 粘液腺癌（muc）60 低分化腺癌（G3)(por)20 低粘附腺癌20 Lauren混合型,G3, (1a)37 (1b)25 (2)04 (3a)24 (3b)04 (4sa)00 (4sb)01 (4d) 25(5)11 (6)44 (7)01 (8a)11 (8p)01 (9)01 (11p)00 (12a)02 肿物旁02,M（胃体部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,80,80,15, R0 D2,,7.06,4.07,2.23,150.7,200.0,2.36,9.0,18.0,111.0,38.0,6.0,9.89,4.28,65.0,191.0,40.0,25.0,4.5,7.6,84.0,302.0,77.5,42.4,33.2,1.28,1.2,14.6,5.2,1.6,2.21,1.9,31.8,486.0,5.98,105.1,101.8, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,69.64520367936925,1514623
1514589,谢永久,599419,男,76,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,16,,,3.0,,1.0,,,,,1.0,2015-05-12,2021-05-17,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)02 (1b)03 (3a)01 (3b)03 (4sb)02 (4d)02 (5)01 (6)00 (7)00 (8a)02 (8p)00 (9)00 (11p)00," LM ML 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",130,110,35, R0 D1+,,7.96,4.45,2.64,101.0,274.0,2.52,12.0,21.0,175.0,45.0,8.0,7.7,2.76,48.0,155.0,29.0,19.0,5.0,5.3,83.0,260.0,39.5,20.6,17.7,1.16,0.9,7.3,48.7,0.7,1.05,2.19,10.9,5.0,0.23,5.45,2.95,,无,, P0,H0, 未做,CK + Vimentin –  VEGF灶+ CMET+,,,,,72.17477003942182,1514589
1514482,李罡,597836,男,58,T4b,N3b,M1, Ⅳ,1,4,0.0,0.0,0.0,1.0, 慢性炎症（+）,19.0,19,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-11,2015-07-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren肠型,G3, (1a)00 (1b)00 (3a)00 (3b)11 (4sb)11 (4d)55 (5)00 (6)00 (7)00 大弯11 小弯1111 大弯侧另见三枚癌结节," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,20,,R2,7.48,6.14,0.82,94.0,189.0,3.21,20.0,30.0,171.0,46.0,34.0,5.9,3.56,47.0,178.0,31.0,16.0,4.8,6.7,72.0,158.0,,,,,,,,,,,,,,,,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+ CD34(脉管周+)  S-100(神经+),,,,,1.6754270696452036,1514482
1514643,黄文有,598831,男,62,T2,N0,M0, ⅠB,1,1,0.0,0.0,0.0,0.0, 肠化生+,0.0,23,中间型（int）,INFb,2.0,,,,,,,1.0,2015-05-12,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)02 (2)02 (3a)04 (3b)01 (4sa)00 (4sb)00 (4d)00 (5)00 (6)00 (7)00 (8a、8p)01 (9)01 (11p)01 (12a)01," U（胃底部）, 后Post, 大弯侧Gre,",40,25,10,R0 D2,,8.35,5.74,1.86,150.0,235.0,3.4,21.0,23.0,132.0,75.0,18.0,8.16,2.94,67.0,344.0,344.0,26.0,5.9,7.4,83.0,274.0,53.0,31.6,18.8,1.68,0.2,10.0,31.2,1.4,1.02,3.04,13.2,54.0,1.29,11.63,3.8,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET灶+ CD34(脉管周+)  S-100(神经+),,,,,72.40473061760841,1514643
1514993,张国臣,599228,男,60,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,22,中间型（int）,INFb,1.0,,,,,,,1.0,2015-05-14,2022-09-01,1,,,SOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)04 (3a)01 (3b)00 (4sb)04 (4d)00 (5)00 (6)03 (7)02 (8a)01 (8p)00 (9)02 (11p)01 (12a)01 小弯01," LM 前Ant, 后Post, 小弯侧Less,",40,35,10, R0 D2+,,5.81,3.14,2.07,163.0,234.0,2.53,14.0,25.0,147.0,68.0,11.0,14.27,4.64,72.0,226.0,43.0,29.0,4.9,6.6,73.0,327.0,65.7,42.3,17.3,2.45,0.4,10.5,21.0,1.8,1.3,1.37,13.2,120.0,1.95,27.22,3.26,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+,,,,,87.6149802890933,1514993
1515026,葛永德,599211,男,69,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,11.0,29,中间型（int）,INFb,0.0,,,,,,,2.0,2015-05-14,2017-12-29,2,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)00 (2)00 (3a)37 (3b)22 (4sa)00 (4sb)00 (4d)01 (5)00 (6)01 (7)00 (8a)02 (8p)01 (9)02 (11p)02 (12a)11 小弯46 肿物旁12," LMU 前Ant, 小弯侧Less,",90,50,15, R0 D2+,,9.24,6.94,1.66,140.3,241.0,3.49,31.0,34.0,136.0,81.0,30.0,11.74,4.88,65.0,269.0,38.0,27.0,5.6,5.9,102.0,293.0,41.0,24.9,13.6,4.04,0.2,6.0,44.2,1.7,0.674,2.73,13.8,10.1,6.72,540.1,1.5,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET灶弱+,,,,,31.537450722733244,1515026
1515511,胡双波,597537,男,54,T4b,N2,M0, ⅢB,1,3,2.0,0.0,0.0,0.0, 肠化生+,6.0,20,中间型（int）,INFb,3.0,,,,,,,1.0,2015-05-19,2015-10-22,2,,,FOLFOX,FOLFOX,卡佩他滨,,,,3, 低粘附腺癌 Lauren弥漫型,GX, (1a)22 (1b)08 (3a)11 (3b)22 (4sb)00 (4d)02 (5)01 (6)11 (7)03," ML 前Ant, 后Post, 小弯侧Less,",100,50,30,,R2,6.11,4.64,0.98,75.0,222.0,3.53,23.0,28.0,171.0,62.0,11.0,7.29,2.88,69.0,236.0,42.0,27.0,6.0,5.9,70.0,274.0,,,,,,,,,,,,,18.89,95.88,32.87,,无,, P0,H0, 未做,CK + Vimentin –  VEGF- CMET+,,,,,5.124835742444152,1515511
1515135,张喜财,597561,男,45,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,3.0,41,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-15,2018-04-20,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,胰腺旁11 肿物旁22 (1a)00 (1b)06 (2)02 (3a)02 (3b)01 (4sa)03 (4sb)01 (4d)03 (5)00 (6)07 (7)01 (8a)00 (8p)02 (9)00 (10)00 (11p)00," LMU 前Ant, 后Post, 小弯侧Less,",120,80,15, R0 D2+,,7.27,3.87,2.79,106.7,325.0,5.16,19.0,26.0,171.0,81.0,12.0,6.81,2.56,73.0,172.0,40.0,33.0,5.7,6.1,67.0,317.0,,,,,,,,,,,,,2.64,1.28,4.61,,无,, P0,H0, 未做,CK+ Vimentin- VEGF- CMET+,,,,,35.183968462549274,1515135
1514929,潘立玲,599519,女,45,T1b,N0,M0,ⅠA,1,0,1.0,0.0,0.0,0.0, 肠化生+,0.0,17,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-14,2021-05-24,1,,,XELOX,,,,,,4, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3, (1a)00 (1b)01 (3a)02 (3b)01 (4sb)00 (4d)03 (5)02 (6)00 (7)01 (8a)03 (8p)01 (9)01 (11p)02,LD 小弯侧Less ,25,10,2,R0 D2,,5.27,3.19,1.61,119.0,281.0,3.04,16.0,22.0,136.0,57.0,7.0,8.58,3.44,64.0,223.0,41.0,23.0,4.2,5.0,51.0,194.0,73.6,49.8,21.8,2.28,0.9,11.2,13.0,1.9,0.867,1.36,10.7,154.0,20.97,0.6,1.55, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(+) D2-40（+）,,,,,72.33902759526939,1514929
1515322,邹云君,599530,男,62,T2,N2,M0, ⅡB,1,2,0.0,0.0,0.0,0.0, 肠化生+,5.0,66,中间型（int）,INFb,1.0,,,,,,,0.0,2015-05-18,2021-06-21,1,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,(1a)0 12 (1b)03 (3a)19 (3b)01 (4sb)01 (4d)219 (5)27 (6)02 (8a)04 (8p)02 (9)01 (11p)02 (12a)01 (2)03," L（幽门窦部）, 前Ant,",40,40,10, R0 D2,,6.62,3.1,2.79,148.0,269.0,3.25,23.0,27.0,160.0,84.0,29.0,11.0,3.89,63.0,303.0,39.0,24.0,5.8,7.5,64.0,401.0,60.8,36.6,19.6,1.87,0.5,10.9,26.7,12.4,2.37,4.18,15.1,32.7,1.65,11.25,2.73, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  D2-40(+) S100(+),,,,,73.12746386333771,1515322
1514797,于桂茹,597401,女,60,T4a,N2,M0, ⅢA,1,3,1.0,0.0,0.0,1.0, 慢性炎症（+）,6.0,18,中间型（int）,INFb,2.0,,1.0,,,,,1.0,2015-05-13,2019-09-02,0,,,,,,,,,0, 低粘附腺癌75 低分化腺癌（G3)(por)20 粘液腺癌（muc）5 Lauren混合型,G3, (1a)00 (1b)00 (3a)11 (3b)22 (4sb)00 (4d)13 (5)11 (6)01 (7)15 (8a)02 (8p)03 (9)00 (12a)00 软组织可见癌7," LM 前Ant, 后Post, 小弯侧Less,",80,60,20, R0 D2,,4.52,1.92,2.08,125.4,232.0,3.11,12.0,15.0,136.0,75.0,6.0,8.27,3.08,62.0,146.0,36.0,26.0,5.5,4.2,60.0,166.0,,,,,,,,,,,,,0.642,9.07,8.14,,无, 无, P0,H0, 未做, CK+， Vimentin- VEGF灶+， CMET灶+,,,,,51.6754270696452,1514797
1515217,惠春芳,597495,男,54,T1b,N0,M0,ⅠA,1,0,1.0,0.0,0.0,1.0, 肠化生+,0.0,15,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-16,2021-05-25,1,,,,,,,,,0, 低分化腺癌（G3)(por)70 低粘附腺癌30,G3, (1a)00 (1b)01 (3a)02 (3b)00 (4sb)00 (4d)02 (5)00 (6) (14v)03 (7)03 (8a) (8p)03 (9)00 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",20,15,, R0 D2,,5.71,3.08,1.92,158.0,181.0,1.67,38.0,27.0,161.0,76.0,29.0,7.79,3.23,66.0,320.0,42.0,24.0,7.0,7.9,76.0,264.0,61.3,42.3,17.8,2.38,1.0,20.2,13.7,0.9,0.632,2.81,8.61,7.67,1.99,10.15,2.38,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF灶+， CMET灶+,,,,,72.30617608409986,1515217
1515216,李越峰,599456,男,47,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,9.0,25,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-16,2017-10-15,2,,,替吉奥联合多西他赛,,,,,,5, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)13 (3b)00 (4sb)01 (4d)00 (5)00 (6) (14v)33 (7)26 (8a)11 (8p) (9)03 (11p)01 (12a)00 (16a1)03," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,15, R0 D2,,9.56,5.62,2.81,141.0,367.0,3.97,32.0,22.0,185.0,84.0,12.0,3.94,1.61,61.0,278.0,40.0,21.0,4.7,3.7,84.0,244.0,71.1,42.9,17.4,2.47,0.7,10.5,14.4,1.3,0.859,1.38,6.67,66.6,6.17,4.85,26.89,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET灶+,,,,,29.00788436268068,1515216
1515499,刘廷文,599481,男,69,T3,N3a,M0,ⅢB,1,4,0.0,0.0,0.0,1.0, 肠化生+,7.0,29,中间型（int）,INFb,1.0,,,,,,,0.0,2015-05-18,2019-09-02,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a)02 (1b)00 (3a)05 (3b)11 (4sb)00 (4d)611 (5)01 (6)02 (7)01 (8a) (8p)02 (9)02 (11p)02 (12a)00," ML 后Post, 大弯侧Gre, 小弯侧Less,",70,60,10, R0 D2,,7.12,4.18,2.31,117.6,268.0,2.48,9.0,14.0,150.0,56.0,14.0,3.63,1.48,50.0,258.0,32.0,18.0,5.2,6.9,83.0,274.0,,,,,,,,,,,,,0.834,7.33,2.13,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,51.51116951379763,1515499
1515340,杨利国,599096,男,57,T4a,N3a,M0, ⅢB,1,4,2.0,0.0,0.0,1.0, 肠化生+,9.0,49,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-05-18,2017-05-28,2,,,SOX,,,,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)02 (1b)22 (2)01 (3a)22 (3b)22 (4sb)13 (4d)016 (5)00 (6)00 (7)01 (8a)04 (8p)01 (9)01 (11p)03肿物旁12贲门旁19," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,15, R0 D2,,9.33,6.14,2.09,138.6,295.0,4.03,10.0,20.0,150.0,75.0,14.0,16.83,5.48,64.0,242.0,39.0,25.0,4.9,4.2,94.0,404.0,58.9,46.4,11.7,3.97,0.1,9.5,25.0,1.4,0.68,8.09,11.0,54.4,1.92,7.27,6.24,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF灶+， CMET+,,,,,24.342969776609724,1515340
1515341,鄂明芹,599574,女,50,T4b,N3a,M0, ⅢC,1,3,2.0,0.0,0.0,1.0, 肠化生+,13.0,22,中间型（int）,INFb,1.0,,,,,,,1.0,2015-05-18,2017-01-22,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)0/0 (1b)3/3 (3a)0/3 (3b)0/1 (4sb)0/1 (4d)2/3 (6)1/1 (7)0/1 (8a)1/1 (8p)2/2 (9)1/1 (11p)1/1 (12a)2/2 (12p)0/1 (16a1)0/0，肿物旁0/1," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,20,,R1,9.23,7.13,1.35,128.0,172.0,4.45,19.0,28.0,142.0,50.0,8.0,28.39,10.72,59.0,130.0,38.0,21.0,3.5,6.2,60.0,434.0,71.3,46.8,16.0,2.93,0.3,17.9,5.5,2.1,0.74,1.72,7.2,115.0,1.63,242.2,2.4, 未做,无,,,H0,," CMET+,Vimentin-, VEGF-, CK+ S-100(神经+) CD34、D2-40(脉管+)",,,,,20.203679369250985,1515341
1515977,王志祥,591439,男,59,T4b,N0,M0, ⅢA,1,2,0.0,0.0,0.0,1.0, 肠化生+,0.0,24,中间型（int）,INFb,1.0,,,,,,,,2015-05-21,2020-10-16,1,,,,,,,,,0," 管状腺癌（中分化【G2】【tub2】60%, 低粘附腺癌40%, Lauren肠型",G2, (1a)04 (1b)07 (2)01 (3a)00 (4sb)01 (4d)01 (5)00 (6)00 (8a)01 (8p)04 (9)01 (11p)03，肿物旁01," M（胃体部）, 后Post, 大弯侧Gre,",45,35,8,,R1,6.92,2.4,2.62,138.7,181.0,1.9,14.0,16.0,149.0,63.0,9.0,11.67,4.78,65.0,239.0,39.0,26.0,4.6,8.0,78.0,276.0,56.0,34.1,18.9,1.8,0.3,15.0,25.0,1.8,1.05,8.19,12.5,275.0,2.64,9.17,1.14, 未做,无,,,H0,," CMET(灶+) Vimentin-, VEGF-， CK+ ",,,,,64.88173455978975,1515977
1515353,刘猛杰,599571,男,45,T2,N3a,M0, ⅢA,1,3,0.0,1.0,1.0,0.0, 肠化生+,8.0,23,中间型（int）,INFb,3.0,,,,,,,1.0,2015-05-18,2018-02-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)04 (3a)26 (3b)00 (4sb)00 (4d)22 (5)00 (6)33 (7)01 (8a)11 (8p)00 (9)02 (11p)04 (12a)00 (12p)00 (14v)00 (16a1)00," L（幽门窦部）, D(十二指肠), 大弯侧Gre,",40,40,18, R0 D2+,,7.39,4.19,2.67,179.0,190.0,1.88,67.0,39.0,175.0,96.0,142.0,6.26,2.22,64.0,466.0,41.0,23.0,5.2,5.4,86.0,335.0,,,,,,,,,,,,,6.08,24.21,2.02, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（灶+）、 S-100+、 CD34D2-40+,,,,,32.52299605781866,1515353
1516628,宁宪才,598799,男,55,T4b,N1,M0, ⅢB,1,2,1.0,0.0,0.0,1.0, 肠化生+,1.0,24,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-28,2016-02-08,2,,,,,,,,,0, 低粘附腺癌80% 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)20% Lauren混合型,G3, (1a)01 (1b)02 (2)03 (3a)12 (4sa)01 (4sb)01 (7)04 (8a)01 (8p)06 (9)00 (11p)01 (16a1)02," U（胃底部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre,",80,70,20,,R1,7.02,5.04,1.44,66.8,479.0,4.2,19.0,23.0,125.0,96.0,26.0,5.84,2.6,70.0,120.0,38.0,32.0,5.2,6.0,71.0,310.0,73.3,33.3,27.8,1.2,0.1,6.2,18.1,1.4,1.42,4.13,13.0,33.1,1.63,5.06,4.82, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）,,,,,8.409986859395532,1516628
1515513,吴国民,599601,男,56,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,1.0,24,中间型（int）,INFb,1.0,,,,,,,0.0,2015-05-19,2020-12-17,1,,,卡佩他滨,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)01 (3a)17 (3b)03 (4sb)00 (4d)02 (5)00 (6)01 (7)01 (8a)02 (8p)01 (9)01 (11p)01 (12a)02," L（幽门窦部）, 小弯侧Less,",35,30,6, R0 D2,,5.85,2.19,3.16,157.0,140.0,2.68,63.0,41.0,183.0,104.0,27.0,6.61,2.75,70.0,192.0,43.0,27.0,6.7,8.9,79.0,212.0,65.8,45.0,14.6,3.08,0.4,24.1,8.2,1.6,1.51,1.84,12.0,69.2,7.18,103.8,4.02,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,66.98423127463863,1515513
1515129,闫怀,599529,男,73,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,0.0, 肠化生+,0.0,14,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-15,2018-05-16,2,,,,,,,,,0, 管状腺癌（高中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)02 (5)00 (6)00 (7)05 (8a)01 (8p)02 (9)00 (11p)00 小弯02," LD 前Ant, 后Post, 小弯侧Less,",40,40,8, R0 D2,,8.1,4.4,2.64,114.0,258.0,3.18,15.0,25.0,132.0,69.0,8.3,6.32,2.12,60.0,144.0,36.0,24.0,2.8,5.9,66.0,224.0,52.0,39.0,11.8,3.31,0.2,12.1,31.7,2.6,1.54,7.79,11.5,27.4,3.32,6.15,4.63,,无,, P0,H0, 未做,CK + Vimentin – VEGF灶+ CME灶T+,,,,,36.038107752956634,1515129
1515489,闻金庆,599121,女,65,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0,,0.0,28,,,0.0,,,,,,,1.0,2015-05-19,2019-07-11,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)05 (1b)05 (3a)01 (3b)05 (4sb)01 (4d)01 (5)03 (6)02 (7)01 (8a、8p、9)01 (11p、12a)03," LD 后Post, 小弯侧Less,",25,15,4, R0 D2+,,5.32,3.48,1.47,125.4,223.0,3.14,32.0,36.0,184.0,74.0,,8.81,2.29,76.0,268.0,42.0,34.0,5.2,7.4,54.0,193.0,,,,,,,,,,,,,0.786,8.33,2.43,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET灶+,,,,,49.73718791064389,1515489
1515751,申宝发,597957,男,61,T1b,N1,M0, ⅠB,1,0,0.0,0.0,0.0,0.0, 肠化生+,1.0,34,中间型（int）,INFb,3.0,,1.0,,,,,1.0,2015-05-21,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren肠型,G2, (1a)04 (1b)04 (3a)16 (3b)00 (4sb)02 (4d)01 (5)00 (6)06 (7)00 (8a)00 (8p)02 (9)02 (11p)03 (12a)04,L（幽门窦部） 小弯侧Less ,25,20,, R0 D2,,8.08,5.98,1.54,163.0,282.0,2.63,20.0,20.0,160.0,70.0,33.0,9.88,3.01,69.0,334.0,45.0,24.0,5.9,5.5,74.0,234.0,44.5,30.2,9.9,3.05,0.1,10.6,36.6,0.6,0.446,2.24,9.98,74.9,4.91,1.32,6.42,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,73.02890932982918,1515751
1515646,王景生,600352,男,46,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,28,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-20,2020-12-17,1,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren肠型,G3, (1a)03 (1b)00 (3a)03 (3b)03 (4sb)02 (4d)00 (5)01 (6)02 (7)06 (8a)03 (8p) (9)04 (11p)00 (12a)01 (14v)00," L（幽门窦部）, 前Ant, 小弯侧Less,",15,15,, R0 D2+,,6.31,4.34,1.47,154.7,203.0,3.67,25.0,21.0,164.0,75.0,24.0,19.1,5.93,69.0,376.0,45.0,24.0,4.7,4.6,71.0,345.0,64.9,31.0,23.3,1.33,0.5,13.6,15.7,5.5,1.02,1.33,9.54,43.2,2.53,14.15,1.04,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET灶+,,,,,66.95137976346912,1515646
1515752,李恒昌,599631,男,63,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,1.0, 肠化生+,0.0,27,中间型（int）,INFb,0.0,,,,,,,1.0,2015-05-21,2021-05-21,1,,,XELOX,,,,,,2, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)03 (3a)013 (3b)00 (4sb)01 (4d)01 (5)00 (6)01 (7)02 (8a)01 (8p)02 (9)02 (11p)01,LM 小弯侧Less ,13,,, R0 D2,,5.93,4.4,1.19,159.9,347.0,2.73,15.0,16.0,129.0,74.0,23.0,24.1,6.4,70.0,365.0,43.0,27.0,5.9,6.3,75.0,379.0,71.0,29.4,35.9,0.82,1.2,13.9,9.5,7.9,0.691,1.45,12.8,56.6,0.943,10.03,7.67, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(灶+)  CD34(+)  D2-40(+) S100(+),,,,,72.01051248357425,1515752
1516034,赵庆友,598836,男,73,T3,N3a,M0,ⅢB,1,5,0.0,0.0,0.0,1.0, 肠化生+,7.0,46,中间型（int）,INFb,1.0,,,,,,,1.0,2015-05-25,2017-03-16,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】60%， 低粘附腺癌40%， Lauren肠型,G2, (1a)00 (1b)00 (3a) 27(3b)25 (4sb) 02(4d)016 (5)00 (6)23 (7)03 (8a)12 (8p)01 (9)03 (11p)04 (12a)00," LD 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,45,10, R0 D2,,4.74,2.72,1.56,86.0,300.0,3.49,18.0,17.0,142.0,89.0,18.0,8.12,2.32,62.0,215.0,34.0,28.0,4.9,7.2,74.0,203.0,49.3,23.5,22.7,1.04,0.2,4.7,37.4,0.5,1.28,4.38,12.2,32.4,2.23,17.02,22.02, 未做,无,,,H0,, CMET+， Vimentin-， VEGF-， CK +，S-100（神经侵犯） CD34、D2-40(未见脉管瘤栓),,,,,21.71484888304862,1516034
1515852,冯延君,599621,男,49,T4b,N2,M0, ⅢB,1,3,2.0,1.0,1.0,0.0, 肠化生+,5.0,22,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-05-21,2019-07-06,0,,,,,,,,,0, 低粘附腺癌 印戒细胞癌(sig) Lauren弥漫型,GX, (1a)00 (1b)04 (3a)01 (3b)12 (4d) (6)36 (4sb)00 (5)01 (7)02 (8a) (8p)13 (11p)02 (12a)01," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,80,20,,R2,5.34,2.93,1.53,149.5,251.0,4.2,11.0,19.0,169.0,44.0,12.0,11.55,3.99,69.0,237.0,42.0,27.0,4.8,5.2,92.0,246.0,61.0,34.6,17.3,2.0,0.3,7.2,23.5,1.9,1.22,1.52,10.5,80.7,2.83,319.4,207.1,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF灶+， CMET灶+,,,,,49.50722733245729,1515852
1515482,李英春,599700,女,47,T3,N3b,M0, ⅢC,1,3,1.0,0.0,0.0,1.0, 肠化生+,22.0,37,中间型（int）,INFb,1.0,,,,,,,1.0,2015-05-19,2021-05-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren混合型,G2, (1a)01 (1b)02 (3b)22 (4sb)01 (4d)45 (5)33 (6)810 (7)01 (8a)22 (8p)01 (9)00 (11p)05, L（幽门窦部） 前Ant 后Post 大弯侧Gre  ,80,40,20, R0 D2,,5.5,2.77,2.04,111.0,256.0,2.29,19.0,23.0,161.0,77.0,4.0,5.21,1.31,54.0,223.0,35.0,19.0,5.6,6.0,49.0,273.0,55.2,31.0,19.6,1.58,0.1,10.9,28.6,0.7,0.729,1.12,6.4,28.3,2.44,17.05,2.12, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(+) D2-40（+）,,,,,71.94480946123521,1515482
1515846,崔景环,599890,女,68,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,16,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-21,2021-06-21,1,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30,G3, (1a)08 (1b)00 (3a)00 (3b)02 (4sb)00 (4d)01 (5)00 (6)04 (7)01 (8a)00 (8p)00 (9)00 (11p),LD 前Ant 小弯侧Less 后Post ,40,30,10, R0 D2,,6.42,3.52,2.21,157.0,227.0,2.49,18.0,23.0,135.0,87.0,7.0,8.38,3.18,68.0,211.0,40.0,28.0,6.8,3.7,63.0,164.0,46.0,27.9,15.3,1.82,0.4,16.1,30.9,1.2,1.03,2.3,14.9,84.7,1.3,45.14,1.18, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(+)， S100(+) D2-40（+）,,,,,73.02890932982918,1515846
1516205,王晓旭,600004,女,51,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,27,,,1.0,,1.0,,,,,1.0,2015-05-26,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por)35% 低粘附腺癌65%,G3, (1a)01 (1b)03 (3a)06 (3b)01 (4sb)00 (4d)00 (5)00 (6)06 (7)02 (8a)03 (8p)01 (9)00 (11p)04 (12a)00," L（幽门窦部）, D(十二指肠), 后Post,",20,20,10, R0 D2,,5.48,3.27,1.71,125.9,216.0,2.12,27.0,25.0,156.0,57.0,12.0,9.64,3.26,38.0,280.0,38.0,25.0,4.6,6.9,53.0,220.0,72.2,39.9,26.5,1.51,0.2,9.3,14.3,1.7,0.753,1.41,12.7,713.0,1.62,5.67,54.65, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（灶+）、 CMET（+）、,,,,,71.94480946123521,1516205
1516593,董庄,599147,男,80,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,7,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-05-28,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (3b)00 (4d)06 (5)01 (6)00 (7)00小湾00," L（幽门窦部）, D(十二指肠), 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,15,10, ,R2,3.33,1.45,1.3,90.0,272.0,2.68,36.0,27.0,180.0,100.0,25.0,7.37,2.64,68.0,216.0,34.0,34.0,4.9,5.4,106.0,265.0,58.6,20.5,30.3,0.68,0.4,9.2,0.8,0.0,1.35,6.02,15.4,131.0,31.84,25.3,1.51, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（灶+）、 CMET（+）,,,,,87.1550591327201,1516593
1516594,刘金利,599129,女,78,T3,N2,M0, ⅢA,1,1,0.0,1.0,1.0,1.0, 肠化生+,3.0,20,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-28,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 00(1b)00 (3a)28 (3b)12 (4sb)00 (4d)04 (5)00 (6) 01(7)00 (8a)00 (8p)00 (9)02 (11p)02 (12a)00，肿物旁01," LM 前Ant, 后Post, MU 小弯侧Less,",60,50,15, R0 D2,,7.2,3.18,3.16,122.4,362.0,3.76,17.0,24.0,135.0,88.0,10.0,12.3,4.3,69.0,154.0,40.0,29.0,4.4,2.7,58.0,215.0,46.7,28.1,14.8,1.9,0.7,9.4,39.8,1.8,0.813,2.58,12.7,1230.0,44.31,76.32,92.5, 未做,无,,,H0, 未做, CMET+ Vimentin -VEGF+ CK+ S-100 （神经侵犯）CD34，D2-40（可见脉管瘤栓）,,,,,72.79894875164257,1516594
1516313,雷桂芝,600015,女,61,T3,N0,M0, ⅡA,1,2,,0.0,0.0,0.0,,0.0,16,,,2.0,,1.0,,,,,1.0,2015-05-26,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)05 (3b)00 (4sb)00 (4d)02 (5)00 (6)03 (7)00 (8a)03 (8p)01 (9)01 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",20,15,5, R0 D2,,7.88,5.06,2.33,142.0,236.0,2.73,19.0,20.0,172.0,138.0,,13.49,4.22,71.0,316.0,43.0,28.0,6.5,6.0,68.0,274.0,64.8,48.6,14.0,3.47,1.1,5.1,11.7,0.2,1.14,2.01,12.9,24.9,0.848,7.23,3.02, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（灶+）、 CMET（+）,,,,,71.94480946123521,1516313
1515824,刘颖,600394,女,50,T4b,N2,M0, ⅢB,1,3,1.0,0.0,0.0,1.0, 肠化生+,5.0,28,中间型（int）,INFb,1.0,,,,,,,1.0,2015-05-21,2016-11-08,2,,,,,,,,,0, 低粘附腺癌85 管状腺癌（中分化【G2】【tub2】15 Lauren混合型,G2, (1a)02 (1b)02 (3a)13 (4sb)00 (4d)110 (5)11 (6)11 (7)01 (8a)00 (8p)01 (9)02 (11p)02," LD LM ML 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,30,10, R0 D2+,,5.34,2.52,2.4,140.7,240.0,3.43,12.0,20.0,192.0,67.0,6.0,6.11,2.02,68.0,180.0,39.0,29.0,4.7,3.0,70.0,180.0,,,,,,,,,,,,,0.781,6.23,1.97,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET+,,,,,17.641261498028907,1515824
1515750,肖春,599287,男,56,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,27,中间型（int）,INFb,1.0,,,,,,,1.0,2015-05-21,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)01 (3b)011 (4d)00 (4sb)00 (5)04 (6)04 (7)05 (8a)00," ML 前Ant,",,,, R0 D1+,,5.26,2.58,2.46,123.2,260.0,2.01,18.0,26.0,126.0,90.0,8.0,8.35,5.21,67.0,347.0,44.0,23.0,6.5,4.5,75.0,236.0,57.1,36.2,16.9,2.14,0.3,10.9,13.6,0.5,1.17,0.984,9.24,133.0,1.12,9.18,1.01,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET灶+,,,,,87.3850197109067,1515750
1515901,王玉芝,599736,女,62,T4b,N0,M0, ⅢA,1,4,2.0,0.0,0.0,1.0, 肠化生+,0.0,37,中间型（int）,INFb,0.0,,,,,,,0.0,2015-05-22,2017-09-09,2,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren弥漫型,G3, (1a)04 (1b)04 (3a)04 (3b)01 (4sa)00 (4d)017 (5)02 (6)00 (7)01 (8)01 (9)01 (11p)01 (12)01," LD LM ML 前Ant,",60,50,15, R0 D2+,,9.41,6.69,2.26,106.3,426.0,4.66,11.0,17.0,164.0,74.0,19.0,6.77,2.55,71.0,226.0,41.0,30.0,5.0,4.5,69.0,196.0,,,,,,,,,,,,,46.88,0.798,4.0,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CD34(脉管周+)  S-100(神经+),,,,,27.628120893561103,1515901
1516177,刘启业,599725,男,57,T3,N3a,M0,ⅢB,1,1,2.0,1.0,1.0,1.0, 慢性炎症（+）,7.0,16,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-05-25,2017-12-15,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)00 (3a)01 (3b)13 (4sb)00 (4d)24 (5)33 (6)00 (7)00 (8a、8p)01 (9)12 (11p)00 (12a)01," ML MU 小弯侧Less,",90,50,10, R0 D2+,,5.6,2.73,2.33,120.0,274.0,2.84,10.0,17.0,127.0,70.0,,9.21,2.54,66.0,278.0,39.0,27.0,5.5,8.5,73.0,253.0,,,,,,,,,,,,,1.95,4.17,0.922,,无,, P0,H0, 未做,CK + Vimentin - VEGF灶+ CMET- CD34、D2-40(脉管周+)  S-100(神经+),,,,,30.716162943495398,1516177
1515858,李兆国,598896,男,70,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+,7.0,11,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-05-21,2019-07-06,0,,,替吉奥单药,替吉奥单药,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren混合型,G3, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)02 (4d)11 (5)11 (6)00 (7)11 (8a)22 (8p)00 (9)00 (11p)22 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",40,35,20, R0 D2+,,6.38,3.29,2.66,137.9,144.0,4.03,24.0,13.0,113.0,65.0,19.1,6.08,2.47,65.5,170.3,38.7,26.8,6.0,2.94,77.0,212.0,64.4,42.5,18.3,2.32,0.3,12.9,16.3,1.3,0.677,2.23,14.5,89.7,2.81,577.5,3.5,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+ CD34(脉管周+)  S-100(神经+),,,,,49.50722733245729,1515858
1516170,朴春玉,599314,女,51,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,27,,,0.0,,,,,,,0.0,2015-05-25,2021-05-24,1,,,,,,,,,0, 腺癌,GX, (1a)02 (1b)02 (3a)08 (3b)00 (4sb)00 (4d)06 (5)00 (6)02 (7)02 (8a)01 (8p)02 (9)01 (11p)01," ML 大弯侧Gre,",10,8,5, R0 D1+,,8.69,4.88,2.76,136.7,255.0,2.45,13.0,20.0,210.0,59.0,10.0,7.81,2.08,67.0,305.0,41.0,26.0,4.8,5.0,61.0,167.0,68.7,46.7,15.1,3.09,1.7,14.1,5.0,0.3,1.77,1.84,11.3,89.5,,,,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET-,,,,,71.97766097240472,1516170
1515753,李金江,600174,男,66,T4b,N3a,M0, ⅢC,1,1,0.0,1.0,1.0,1.0, 肠化生+,11.0,39,中间型（int）,INFb,3.0,,1.0,,,,,1.0,2015-05-21,2016-03-24,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3," (1a)13 (1b)33 (2)03 (3a)33 (3b)00 (4sb)00 (4d)08 (5)00 (6)06 (7)01 (8a)11 (8p)12 (9)04 (11p)11 (12a)00，小弯侧12,1b见癌结节一枚", LM ML,80,80,15,,R1,8.73,6.27,1.6,89.7,586.0,4.44,10.0,13.0,146.0,109.0,59.0,8.18,3.99,68.0,134.0,39.0,29.0,6.8,85.0,85.0,308.0,43.6,23.6,14.9,1.58,0.1,10.8,18.1,0.7,0.377,2.39,13.6,12.8,2.95,8.53,9.86, 未做,无,, P0,H0,, CMET+， Vimentin-， VEGF+， CK+， S-100 （神经侵犯）CD34、D2-40(脉管瘤栓),,,,,10.11826544021025,1515753
1516529,李桂芝,599274,女,67,T3,N3b,M0, ⅢC,1,3,1.0,0.0,0.0,1.0, 肠化生+,18.0,43,中间型（int）,INFb,2.0,,1.0,,,,,1.0,2015-05-28,2018-04-22,2,,,SOX,,,,,,2, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3, (1a)02 (1b)02 (3a)56 (3b)66 (4sb)04 (4d)314 (5)11 (6)11 (7)11 (8a)11 (8p)02 (9)01 (11p)01 (12a)00 (16a1)01,L（幽门窦部） 前Ant 后Post 小弯侧Less  ,,,,R0 D2,,3.48,1.96,1.21,120.9,157.0,2.63,16.0,26.0,195.0,98.0,11.0,10.17,7.82,72.0,159.0,41.0,31.0,4.3,6.0,42.0,206.0,72.2,29.1,39.2,0.74,0.6,10.0,15.2,1.6,1.35,5.94,12.1,44.9,12.96,1000.0,5.59,,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(-)， S100(+) D2-40（-）,,,,,34.82260183968462,1516529
1517909,黄淑霞,599267,女,67,T4b,N2,M0, ⅢB,1,5,1.0,0.0,0.0,0.0, 慢性炎症（+）,3.0,24,中间型（int）,INFb,0.0,,,,,,,1.0,2015-06-09,2017-08-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90%， 粘液腺癌（muc）10%， Lauren混合型,G2, (1a) 00(1b)00 (3a)02 (3b)00 (4sb)00 (4d)02 (5)00 (6)34 (7)02 (8a)04 (8p)04 (9)03 (11p)03," LD 前Ant, 后Post, 小弯侧Less,",90,40,10,,R1,19.21,17.1,1.12,79.0,450.0,5.74,12.0,19.0,127.0,89.0,10.0,21.86,14.78,56.0,86.0,32.0,24.0,6.0,6.7,55.0,295.0,51.0,37.8,9.5,3.98,0.5,34.4,12.1,0.9,0.844,2.43,10.0,350.0,1.36,6.83,17.22, 未做,无,,,H0,, Vimentin-， VEGF-， CK+， CMET+， S-100（未见明确神经侵犯） CD34、D2-40(未见明确脉管瘤栓),,,,,26.05124835742444,1517909
1516140,王桂森,599268,男,75,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,7.0,19,中间型（int）,INFb,0.0,,,,,,,0.0,2015-05-25,2016-10-14,2,,,口服替吉奥,,,,,,1, 粘液腺癌（muc） Lauren肠型,GX, (1a)00 (1b) 01(3a) 05(3b)35 (4sb)00 (4d)23 (5)00 (6)22 (7)00 (8a)01 (8p)01 (9)01 (12a)00," LD 前Ant, 后Post, 小弯侧Less,",50,45,8, R0 D2,,11.46,10.63,0.5,137.0,153.0,3.18,14.0,22.0,178.0,73.0,12.0,21.41,11.12,66.0,167.0,39.0,27.0,5.3,5.4,69.0,337.0,50.5,23.1,25.4,0.91,2.8,3.9,41.8,7.4,0.879,1.09,13.6,18.1,2.44,6.28,286.3, 未做,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF- CK+ S-100（神经侵犯） CD34、D2-40(+),,,,,16.68856767411301,1516140
1516167,薛居明,600275,男,47,T4a,N1,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+,1.0,21,中间型（int）,INFb,2.0,,1.0,,,,,1.0,2015-05-25,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 02(1b)01 (3a)010 (3b)00 (4sb)00 (4d)02 (5)00 (6)02 (7)01 (8a)11 (8p)01 (9) 01(11p)02 (12a)00 (12p)00," LD 小弯侧Less,",20,20,8, R0 D2,,6.4,4.33,1.53,149.6,283.0,1.56,12.0,14.0,126.0,51.0,22.0,15.66,5.76,61.0,339.0,41.0,20.0,5.5,4.5,82.0,240.0,67.7,36.1,16.2,2.23,1.0,7.9,21.3,6.5,1.14,1.21,9.02,11.7,4.22,6.77,1.29, 未做,无,, P0,H0, 未做, CMET+ Vimentin- VEGF（灶+） CK+ S-100（神经侵犯） CD34、D2-40(可见脉管瘤栓),,,,,72.89750328515112,1516167
1515825,马保财,599563,男,51,T4a,N0,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,27,中间型（int）,INFb,1.0,,,,,,,1.0,2015-05-21,2019-09-02,0,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)04 (2)01 (3a)07 (4sb)01 (4d)00 (5)02  (6)01 (7)01 (8a)01 (9)01 (11p)05肿物旁01," U（胃底部）, 小弯侧Less,",30,30,10, R0 D2,,6.55,2.32,3.69,156.2,239.0,2.15,12.0,16.0,106.0,86.0,14.0,6.63,2.26,66.0,275.0,43.0,23.0,4.4,5.3,87.0,234.0,,,,,,,,,,,,,3.19,13.54,1.44,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,51.41261498028909,1515825
1516033,谭兆云,599911,男,61,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,1.0, 肠化生+,0.0,31,中间型（int）,INFb,1.0,,,,,,,0.0,2015-05-26,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)80 粘液腺癌（muc）20 Lauren肠型,G3, (1a)03 (1b)02 (3a) 03(3b)01 (4sb)00 (4d)012 (5)01 (6)02 (7)00 (8a)03 (8p)01 (9)01 (11p)01 (14v)01,LM,25,20,8, R0 D2,,6.2,3.11,2.03,150.0,237.0,1.73,25.0,26.0,152.0,76.0,16.0,14.39,4.64,68.0,324.0,42.0,26.0,5.4,6.9,79.0,309.0,71.1,46.7,19.4,2.41,0.3,13.9,9.9,0.6,1.35,1.99,10.9,17.9,0.834,10.05,1.82, 未做,无,,,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  D2-40(+) S100(+),,,,,87.22076215505913,1516033
1516471,张福君,599795,男,52,T3,N1,M0, ⅡB,1,2,1.0,0.0,0.0,1.0, 肠化生+,2.0,22,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-05-27,2018-08-23,0,,,XELOX,,,,,,1, 低粘附腺癌88%， 粘液腺癌（muc）10%， 管状腺癌（中分化【G2】【tub2】2%， Lauren混合型,G2, (1a)00 (1b) 00(2)02 (3a)03 (3b)24 (4sb)01 (4d)02 (5)01 (6)01 (7)02 (8a)01 (8p)02 (9)02 (11p)01 (12a)00," LM 小弯侧Less,",20,20,8, R0 D2,,6.95,4.51,1.84,156.9,234.0,2.33,26.0,25.0,141.0,61.0,61.0,5.2,2.08,60.0,396.0,40.0,20.0,4.5,6.9,75.0,350.0,59.6,29.0,27.6,1.05,0.3,11.1,26.1,4.1,0.374,1.01,7.18,5.0,10.0,243.8,2.87, 未做,无,, P0,H0, 未做, CMET+ Vimentin- VEGF（灶+） CK+ S-100（神经侵犯） CD34、D2-40（未见脉管瘤栓）,,,,,38.89618922470434,1516471
1516232,于宝龙,599779,男,51,T1a,N0,M0,ⅠA,1,5,0.0,0.0,0.0,0.0, 肠化生+,0.0,15,中间型（int）,INFb,3.0,,1.0,,,,,1.0,2015-05-26,2021-05-24,1,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)02 (3a)05 (3b)01 (4sb)00 (4d)00 (5)00 (6)00 (7)04 (8a)02 (8p)01 (9)00 (11p)00, LM 后Post ,20,20,10, R0 D2,,11.42,7.11,3.08,132.3,349.0,3.01,28.0,28.0,206.0,127.0,24.0,5.8,1.92,78.0,287.0,50.0,28.0,4.8,9.0,74.0,389.0,76.8,33.8,27.9,1.21,0.1,6.8,13.2,6.5,0.565,0.943,12.0,103.0,9.43,12.11,1.37, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,71.94480946123521,1516232
1516903,高福荣,599784,女,64,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,39,中间型（int）,INFb,2.0,,,,,,,1.0,2015-06-01,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)07 (3a)03 (3b)02 (4sb)04 (4d) 03(5)05 (6)05 (7)02 (8a)04 (8p)03 (11p)00, LD 大弯侧Gre  ,30,25,12, R0 D2,,7.01,4.15,2.27,118.0,273.0,1.43,18.0,24.0,159.0,170.0,47.0,4.65,1.79,69.0,252.0,43.0,26.0,5.7,6.2,52.0,149.0,61.8,26.9,26.5,1.02,0.5,10.9,24.5,3.3,0.997,1.73,10.8,51.2,1.9,7.62,4.0, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+),,,,,72.66754270696451,1516903
1516355,刘志刚,600305,男,53,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,33,,,1.0,,,,,,,1.0,2015-05-27,2021-06-21,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)08 (3a)011 (3b)00 (4sb)00 (4d)07 (5)00 (6)02 (7)02 (8a)00 (8p)01 (9)00 (11p)01," MU 大弯侧Gre,",15,6,1, R0 D2+,,11.57,7.74,3.18,164.2,267.0,3.85,17.0,22.0,144.0,166.0,54.0,9.17,2.76,72.0,254.0,46.0,26.0,5.1,7.2,74.0,271.0,,,,,,,,,,,,,2.9,9.56,1.16,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+ ,,,,,72.83180026281208,1516355
1516528,李树财,599982,男,72,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,14,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-05-28,2018-04-24,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)04 (3a)010 (3b)00 (4sb)00 (4d)00 (5)00 (6)00 (7)00 (8a)00 (8p)00 (9)00 (11p)00," UM SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",45,30,8, R0 D2+,,6.17,4.32,1.17,142.4,193.0,3.85,12.0,26.0,161.0,81.0,17.0,13.54,3.7,64.0,245.0,37.0,27.0,4.6,7.2,88.0,267.0,,,,,,,,,,,,,2.03,7.64,15.29,,无,, P0,H0, 未做,CK + Vimentin - VEGF灶+ CMET-,,,,,34.88830486202365,1516528
1517023,张喜国,599954,男,45,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,34,,,1.0,,,,,,,2.0,2015-06-02,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)05 (1b)02 (3a)00 (3b)00 (4sb)00 (4d)03 (5)08 (6)00 (7)06 (8a)01 (8p)03 (9)02 (11p)01 (12a)00 (12p)03," L（幽门窦部）, 小弯侧Less,",10,10,, R0 D2+,,6.36,2.99,2.77,150.0,282.0,2.15,19.0,23.0,173.0,68.0,11.0,29.62,7.48,66.0,256.0,44.0,22.0,5.0,7.2,82.0,241.0,,,,,,,,,,,,,7.46,21.73,1.29,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET弱+,,,,,86.99080157687253,1517023
1516940,曲锡权,600231,男,54,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,8.0,62,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-01,2021-06-21,1,,,XELOX,,,,,,4, 低粘附腺癌 Lauren肠型,GX, (1a)04 (1b)116 (2)00 (3a)12 (3b)16 (4sa)13 (4sb)01 (4d)010 (5)00 (6)115 (7)00 (8a)01 (8p)22 (9)11 (11p)00 (11d)01 (12a)00," LM 大弯侧Gre,",100,50,15, R0 D2,,10.36,6.3,2.91,128.0,331.0,3.61,16.0,20.0,166.0,76.0,14.0,7.47,2.58,66.0,261.0,41.0,25.0,5.0,5.5,76.0,343.0,56.6,35.5,11.5,3.09,0.3,16.9,21.9,6.9,0.837,2.07,12.2,23.7,37.68,4.23,1.94, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(灶+)  cMET(+) S100(+),,,,,72.66754270696451,1516940
1516624,吴广兴,601321,男,64,T4b,N0,M0, ⅢA,1,5,0.0,0.0,0.0,1.0, 肠化生+,0.0,29,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-05-28,2021-06-21,1,,,,,,,,,0, 粘液腺癌（muc）,GX, (1a) 00(1b)00 (3a)013 (3b)00 (4sb)00 (4d)01 (5)00 (6)01 (7)00 (8a)02 (8p)04 (9)03 (11p)05 (12a)00," LD 前Ant, 后Post, 小弯侧Less,",40,40,8,,R1,11.33,7.1,3.03,133.0,161.0,29.8,37.0,42.0,205.0,108.0,32.0,22.44,9.09,70.0,158.0,40.0,30.0,4.8,5.0,89.0,248.0,79.2,41.7,29.5,1.41,2.2,3.4,15.6,2.6,1.09,2.97,15.0,122.0,1.75,32.78,2.01, 未做,无, 无, P0,H0, 未做, CMET+， Vimentin-， VEGF+ CK+ S-100（神经侵犯） CD34、D2-40(未见),,,,,72.79894875164257,1516624
1517176,徐凤琴,599827,女,63,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,34,,,2.0,,1.0,,,,,1.0,2015-06-03,2021-05-24,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)03 (1b)01 (3a)03 (3b)02 (4sb)05 (4d)04 (5)00 (6)02 (7)01 (8a)02 (8p)03 (9)03 (11p)03 (12a)01,ML 小弯侧Less ,40,30,20,R0 D2,,7.47,4.33,2.59,125.0,347.0,2.85,26.0,25.0,187.0,158.0,32.0,10.61,2.8,69.0,227.0,43.0,26.0,5.6,5.1,53.0,242.0,58.4,39.4,12.7,3.1,0.2,14.5,25.3,2.3,1.045,3.72,13.0,16.1,6.86,27.49,10.45, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)，CD34(-)， S100(-) D2-40（-）,,,,,71.6819973718791,1517176
1517151,韩志敏,600056,男,60,T4b,N3a,M1, Ⅳ,1,1,0.0,0.0,0.0,0.0, 肠化生+,15.0,51,中间型（int）,INFb,3.0,,1.0,,,,,1.0,2015-06-03,2016-01-18,2,,,XELOX,XELOX,紫杉醇联合替吉奥,,,,8, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (3a)01 (3b)111 (4sb)01 (4d)924 (5)00 (6)24 (7)310," LM 后Post,",80,70,40,,R2,4.91,2.56,1.82,56.0,314.0,2.91,16.0,25.0,152.0,59.0,11.0,17.71,6.48,66.0,149.0,38.0,28.0,4.9,5.3,56.0,208.0,74.6,34.3,30.9,1.11,0.1,7.2,13.7,17.7,0.475,3.06,12.3,22.3,1.3,10.1,3.35,,无, 无, p1局腹膜(M1 PER),H0, 未做, CK+， Vimentin-， VEGF灶+， CMET+,,,,,7.522996057818659,1517151
1516817,徐德荣,600656,女,77,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,2,,,1.0,,1.0,,,,,1.0,2015-06-01,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)02 (3b)00 (5)00 (6)00 (7)00," LD 大弯侧Gre,",10,,, R0 D2,,4.32,2.3,1.52,98.8,233.0,2.8,15.0,23.0,168.0,90.0,10.0,12.84,3.68,69.0,197.0,39.0,30.0,5.2,3.8,63.0,180.0,72.3,33.6,37.8,0.89,0.4,5.2,17.5,1.8,2.73,4.32,12.9,488.0,4.64,29.4,1.73, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(灶+)  cMET(+) ,,,,,71.74770039421813,1516817
1517088,王志田,601326,男,42,T4b,N0,M0, ⅢA,1,3,2.0,0.0,0.0,1.0, 肠化生+,0.0,26,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-02,2021-06-21,1,,,XELOX,,,,,,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)03 (1b)01 (3a)00 (3b)01 (4sb)01 (4d)09 (5)00 (6)01 (7)02 (8a、8p、9)04 (11p)03 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,20, R0 D2+,,4.24,2.36,1.54,63.8,376.0,2.52,27.0,25.0,144.0,53.0,8.0,6.19,1.95,58.0,217.0,37.0,21.0,4.9,2.5,61.0,206.0,,,,,,,,,,,,,2.16,7.26,1.23,,无,, P0,H0, 未做,CK + Vimentin - VEGF灶+ CMET+,,,,,72.634691195795,1517088
1517002,周凤鸣,601362,男,65,T4b,N1,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,1.0,46,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-06-02,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (2)04 (3a)114 (3b)02 (4sa)01 (4sb)00 (4d)05 (5)01 (6)03 (7)01 (8a) 02(8p)01 (9)04 (11p)01 (12b)03 肿物旁01," UM 小弯侧Less,",50,40,8, R0 D2,,4.83,2.85,1.25,93.8,158.0,2.74,15.0,18.0,142.0,58.0,16.0,6.58,2.3,57.0,249.0,36.0,21.0,4.3,5.4,75.0,242.0,72.9,40.7,32.0,1.27,0.3,9.7,12.3,1.0,1.21,0.736,7.95,304.0,1.05,90.22,2.56, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-) S100(+),,,,,72.634691195795,1517002
1517874,董文廷,600672,男,61,T4b,N0,M0, ⅢA,1,1,0.0,0.0,0.0,1.0, 肠化生+,0.0,27,中间型（int）,INFb,1.0,,,,,,,1.0,2015-06-09,2018-07-07,2,,,XELOX,XELOX,XELOX,XELOX,SOX,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70%， 粘液腺癌（muc）30%， Lauren肠型,G3, 1组00(1a) 00(1b)01 (3a)01 (3b)03 (4sb)00 (4d)04 (5)01 (6) 08(7)02 (8a)02 (8p)01 (9)00 (11p)04," LM 前Ant, 后Post, 小弯侧Less,",90,80,10,,R1,8.01,5.57,1.51,118.0,277.0,4.73,19.0,20.0,143.0,88.0,35.0,13.85,3.38,63.0,160.0,40.0,13.0,5.8,5.3,67.0,349.0,57.5,40.2,14.8,2.72,0.1,7.7,27.6,2.5,0.494,1.07,6.97,113.0,3.37,5.83,14.78, 未做,无,, P0,H0,, CMET+ Vimentin- VEGF- CK+ S-100（可见神经侵犯） CD34、D2-40(未见),,,,,36.925098554533506,1517874
1517805,崔义武,602788,男,62,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+,2.0,25,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-09,2021-07-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)90% 低粘附腺癌10% Lauren肠型,G3, (1a)03 (1b)01 (3a)03 (3b)01 (4sb)00 (4d)04 (5)00 (6)26 (7)01 (8a)01 (8p)02 (9)02 (11p)01," L（幽门窦部）, D(十二指肠), 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,16,5, R0 D2,,5.34,3.45,1.44,166.4,214.0,2.52,26.0,29.0,191.0,108.0,16.0,11.1,3.76,74.0,51.0,44.0,30.0,9.1,6.2,85.0,305.0,60.9,39.6,19.9,1.99,0.2,9.7,15.7,3.9,1.52,2.63,13.3,57.8,5.33,32.45,33.23, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（灶+）、 CMET（+）,,,,,72.73324572930355,1517805
1517314,田立冬,602110,男,51,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,31,,,2.0,,1.0,,,,,1.0,2015-06-04,2020-05-11,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)75 低粘附腺癌25,G3, (1a)00 (1b)00 (3a)011 (3b)01 (4sb)00 (4d)03 (5)00 (6)06 (7)00 (8a)01 (8p)00 (9)08 (11p)01,LD 小弯侧Less ,30,30,10,,R2,9.84,5.78,2.98,103.0,312.0,3.97,16.0,19.0,127.0,69.0,11.0,3.8,1.2,62.0,223.0,37.0,25.0,1.8,6.8,58.0,181.0,55.4,30.0,22.4,1.34,0.0,7.1,31.2,0.4,1.24,1.7,10.5,10.7,2.71,15.9,10.3, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,59.23127463863337,1517314
1517513,王善波,601244,男,47,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,37,,,0.0,,,,,,,1.0,2015-06-05,2021-05-25,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)03 (3a)01 (3b)01 (4sb)01 (4d)00 (5)01 (6)012 (7)010 (8a) (8p)03 (9)05 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",10,10,3, R0 D2,,8.58,4.43,3.21,152.0,247.0,2.36,44.0,36.0,206.0,79.0,19.0,4.81,2.3,66.0,261.0,42.0,24.0,5.2,6.0,74.0,307.0,67.5,41.6,24.1,1.73,0.2,19.4,10.0,2.5,0.6,1.05,11.2,56.7,1.47,6.64,1.43,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,71.6491458607096,1517513
1518131,孙绪宏,599777,男,50,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,22,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-11,2021-06-21,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)02 (1b)05 (2)00 (3a)01 (3b)00 (4sb)00 (4d)03 (5)02 (6)00 (7)04 (8a) (8p)05,LD  大弯侧Gre  ,45,40,30,,R2,15.41,11.18,2.25,141.0,383.0,6.87,26.0,23.0,158.0,63.0,41.0,8.35,3.26,71.0,124.0,38.0,33.0,4.3,4.1,78.0,231.0,56.2,35.4,19.6,1.81,0.4,9.6,30.0,4.5,1.53,2.04,16.8,28.4,6.04,29.3,2.15, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,72.33902759526939,1518131
1518080,李加军,600694,男,32,T4b,N3b,M0, ⅢC,1,4,0.0,0.0,0.0,1.0, 慢性炎症（+）,19.0,49,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-10,2016-04-20,2,,,,,,,,,0, 低粘附腺癌 Lauren肠型,GX, (1a)05 (1b)66 (2)01 (3a)25 (3b)01 (4sa)00 (4sb)00 (4d)610 (5)11 (6)14 (7)03 (8a)14 (8p)03 (9)01 (11p)23 (12b)01 (14v)01," M（胃体部）, L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",140,150,,,R1,5.02,2.56,1.99,144.4,230.0,1.54,15.0,18.0,131.0,43.0,5.0,11.76,4.51,66.0,248.0,43.0,23.0,4.9,6.5,88.0,340.0,68.1,36.6,27.6,1.33,0.4,9.6,17.8,1.5,0.598,0.995,10.8,28.8,1.3,14.54,1.97, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）,,,,,10.348226018396845,1518080
1518053,冯志刚,600908,男,56,T1b,N0,M0,ⅠA,1,0,,1.0,1.0,0.0,,0.0,16,,,1.0,,1.0,,,,,1.0,2015-06-10,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)04 (1b)01 (2)03 (3a)03 (3b)03 (4sa)00 (4sb)00 (5)00 (7)00 (8a)00 (8p)00 (9)02 (11p)00," U（胃底部）, 后Post,",20,20,, R0 D2,,8.53,4.56,3.07,159.0,198.0,2.34,26.0,23.0,197.0,72.0,24.0,16.99,6.25,74.0,303.0,45.0,29.0,6.8,7.1,68.0,341.0,62.2,39.0,18.3,2.13,0.3,9.0,23.6,5.6,0.855,2.42,13.1,48.1,2.39,7.48,2.18, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（灶+）、 CMET（+）,,,,,71.4520367936925,1518053
1517964,李奉山,602892,男,73,T2,N0,M0, ⅠB,1,2,2.0,0.0,0.0,0.0, 肠化生+,0.0,40,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-10,2021-05-24,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)014 (3b)00 (4sb)00 (4d)07 (5)00 (6)03 (7)04 (8a)07 (8p)02 (9)00 (11p)01 (12a)00 (14v)02," L（幽门窦部）, 小弯侧Less,",35,25,8, R0 D2+,,3.94,2.09,1.32,126.8,179.0,2.9,16.0,17.0,127.0,77.0,15.0,11.17,4.12,71.0,308.0,42.0,29.0,4.8,6.1,99.0,407.0,69.2,44.9,20.8,2.16,0.6,10.6,16.4,3.4,0.982,2.19,12.4,104.0,1.9,12.67,1.27, 未做,无, 无, P0,H0, 未做, CK（+） Vimentin（-） VEGF（-） CMET（+）,,,,,71.4520367936925,1517964
1518397,王承建,598360,男,58,T4b,N2,M0, ⅢB,1,4,0.0,0.0,0.0,0.0, 肠化生+,3.0,15,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-12,2021-05-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)03 (4sb)00 (4d)14 (5)01 (6)12 (7)04 (8a)00 (9)00 (11p)00 (12a)00 (3b)11," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",110,110,35,,R1,5.26,3.95,0.58,88.7,376.0,3.43,22.0,32.0,135.0,93.0,15.0,9.77,5.26,69.0,84.0,31.0,38.0,4.6,5.3,47.0,208.0,,,,,,,,,,,,,1.6,18.02,12.53,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+ ,,,,,71.15637319316689,1518397
1517315,李杰,602274,男,68,T3,N0,M0, ⅡA,1,4,0.0,0.0,0.0,0.0, 肠化生+,0.0,32,中间型（int）,INFb,0.0,,,,,,,1.0,2015-06-04,2021-02-08,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren肠型,G3, (1a)00 (1b)00 (2)04 (3a)010 (3b)01 (4sb)01 (4d)07 (5)05 (6)03 (7)00 (8a)01 (8p)00 (9)0," LD LM ML 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",55,50,10, R0 D2+,,9.71,7.24,1.66,123.9,385.0,,14.0,16.0,151.0,82.0,48.0,6.44,2.32,72.0,398.0,46.0,26.0,5.6,6.6,128.0,412.0,62.5,42.7,15.8,2.7,0.2,9.1,22.8,1.6,0.631,1.55,10.2,6.79,0.882,16.53,3.52,,无,, P0,H0, 未做,CK + Vimentin –  VEGF- CMET+,,,,,68.19973718791064,1517315
1517359,刘文,600914,男,55,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,38,,,1.0,,,,,,,1.0,2015-06-04,2018-04-05,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)03 (3a)010 (3b)00 (4sb)00 (4d)016 (5)00 (6)02 (7)01 (8a)00 (8p)01 (9)01 (11p)02 (12a)00," LD 小弯侧Less,",15,15,, R0 D2+,,5.16,2.39,1.89,154.5,146.0,1.81,29.0,30.0,148.0,74.0,17.0,16.96,6.35,72.0,297.0,44.0,28.0,5.2,6.9,78.0,281.0,32.1,16.9,10.0,1.69,0.2,8.2,54.2,5.2,0.939,2.07,18.7,11.6,2.3,1.64,8.25,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+ ,,,,,34.03416557161629,1517359
1517806,李纯林,601181,男,74,T3,N1,M0, ⅡB,1,2,,0.0,0.0,0.0,,2.0,20,,,2.0,,1.0,,,,,1.0,2015-06-09,2021-05-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)03 (1b)00 (3a)02 (3b)11 (4sb)00 (4d)010 (5)00 (6)12 (7)00 (8a)00 (8p)00 (9)01 (11p)01," LD 小弯侧Less,",15,10,1, R0 D2+,,6.26,3.95,1.6,95.3,392.0,2.85,35.0,29.0,199.0,59.0,12.0,7.8,3.16,39.0,253.0,39.0,23.0,5.2,5.1,66.0,238.0,78.5,39.0,35.4,1.1,0.4,7.1,10.7,3.8,0.899,1.46,9.01,49.6,,,,,无,, P0,H0, 未做,CK + Vimentin –  VEGF灶+ CMET+ ,,,,,71.25492772667542,1517806
1517836,王刚,601252,男,67,T4b,N3b,M0, ⅢC,1,4,2.0,0.0,0.0,1.0, 慢性炎症（+）,28.0,34,中间型（int）,INFc,1.0,,1.0,,,,,1.0,2015-06-09,2016-07-20,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)45 (1b)22 (2)66 (3a)44 (3b)01 (4sb)12 (4d)01 (5)00 (6)01 (7)11 (8a)11 (8p)11 (9)11 (11p)11 小弯56 肿物旁11," UM SiewerⅢ, 小弯侧Less,",60,50,10, R0 D2+,,6.31,4.43,1.39,157.9,230.0,1.99,28.0,27.0,263.0,86.0,15.0,20.87,6.73,68.0,336.0,43.0,25.0,5.4,6.5,102.0,347.0,62.4,34.5,24.1,1.43,0.2,5.0,28.4,2.8,0.702,1.71,9.57,42.5,,,,,无,, P0,H0, 未做,CK + Vimentin –  VEGF灶+ CMET+ ,,,,,13.370565045992116,1517836
1518166,杨青云,598678,男,62,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,1.0,,0.0,18,,,2.0,,1.0,,,,,1.0,2015-06-11,2021-06-21,1,,,SOX,,,,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)01 (1b)00 (2)03 (3a)03 (3b)03 (4sb)00 (4d)01 (5)00 (6)02 (7)00 (8a)02 (8p)00 (9)00 (11p)00 肿物旁03," MU 小弯侧Less,",15,10,8, R0 D2+,,8.48,5.72,2.0,148.0,233.0,2.68,28.0,30.0,171.0,101.0,46.7,14.11,5.61,77.2,474.13,46.5,30.7,5.5,4.54,104.0,409.0,,,,,,,,,,,,,0.571,7.62,,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+ ,,,,,72.33902759526939,1518166
1517724,张军,601187,男,73,T1b,N0,M0,ⅠA,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,17,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-08,2017-02-25,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)03 (2)03 (3a)08 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)00 (6)00 (7、8a、8p、9、11p、12a)00," U（胃底部）, 小弯侧Less,",25,15,8, R0 D2+,,6.34,2.72,3.09,142.6,197.0,,28.0,28.0,194.0,61.0,12.0,6.49,2.9,64.0,289.0,40.0,24.0,4.7,8.4,106.0,457.0,81.4,44.4,35.1,1.26,0.4,3.3,13.1,4.7,1.64,2.84,10.2,237.0,1.34,7.96,3.65,,无,, P0,H0, 未做,CK + Vimentin –  VEGF灶+ CMET+ ,,,,,20.630749014454665,1517724
1517751,沈春艳,602849,女,41,T3,N3a,M0,ⅢB,1,2,0.0,0.0,0.0,1.0, 肠化生+,11.0,33,中间型（int）,INFb,2.0,,1.0,,,,,1.0,2015-06-08,2021-05-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)24 (2)02 (3a)66 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)00 (6)04 (7)01 (8a)22 (8p)14 (9)04 (11p)01 (12a)01," M（胃体部）, 小弯侧Less,",30,20,8, R0 D2+,,6.06,4.06,1.48,115.1,223.0,2.3,20.0,20.0,168.0,67.0,7.0,11.72,4.11,60.0,188.0,37.0,23.0,4.8,6.3,57.0,189.0,60.9,30.4,26.5,1.15,0.1,11.1,22.9,6.0,0.27,1.25,10.5,8.66,7.91,1.55,2.02,,无, 无, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+ ,,,,,71.28777923784494,1517751
1517389,谷庆国,602298,男,37,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,36,,,1.0,,1.0,,,,,1.0,2015-06-04,2021-05-21,1,,,XELOX,,,,,,1, 低粘附腺癌,GX, (1a)00 (1b)04 (3a)03 (3b)01 (4sb)00 (4d)04 (5)00 (6)04 (7)02 (8a)02 (8p) (9)06 (11p)03,L（幽门窦部） 小弯侧Less ,20,10,1,R0 D2,,11.62,6.33,4.59,180.9,197.0,2.54,31.0,33.0,219.0,108.0,22.0,7.91,2.35,76.0,400.0,50.0,26.0,5.0,7.2,88.0,307.0,56.7,36.5,17.2,2.12,0.2,14.6,26.1,0.9,1.8,0.845,8.66,41.8,6.76,20.93,1.14,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,71.55059132720105,1517389
1519608,邢文忠,601217,男,55,T4b,N3a,M0, ⅢC,1,3,0.0,0.0,0.0,0.0, 肠化生+,11.0,20,中间型（int）,INFb,1.0,,,,,,,1.0,2015-06-25,2016-03-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80%， 粘液腺癌（muc）20%， Lauren肠型,G3, (1a)02 (1b)00 (3a)33 (3b)00 (4sb)00 (4d)23 (5)11 (6)14 (7)01 (8a)11 (8p)34 (12a)00 (14v)01，（7）软组织可见癌," LD 大弯侧Gre, 后Post, 小弯侧Less,",50,40,10,,R2,4.14,2.25,1.5,137.4,186.0,2.74,152.0,93.0,846.0,58.0,22.0,14.94,4.51,54.0,247.0,34.0,20.0,4.1,5.2,53.0,305.0,62.7,39.2,21.8,1.8,0.5,1.7,32.4,3.6,0.687,0.809,6.84,221.0,4.11,20.25,5.08, 未做,无,,,H0,, CMET+ Vimentin-， VEGF-， CK+ S-100（未见） CD34、D2-40(未见),,,,,8.508541392904073,1519608
1517895,刘艳霞,602283,女,37,T4b,N2,M0, ⅢB,1,4,0.0,0.0,0.0,1.0, 肠化生+,3.0,34,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-09,2020-06-01,1,,,SOX,SOX,SOX,口服替吉奥,口服替吉奥,,5, 低粘附腺癌 Lauren肠型,GX, (1a)03 (1b)01 (2)02 (3a)01 (3b)14 (4sb)00 (4d)05 (5)01 (6)09 (7)24 (8a)01 (8p)01 (9)02 (11p)00," LM ML 前Ant, 后Post, 小弯侧Less,",60,50,10, R0 D2+,,4.63,2.87,1.41,125.0,234.0,2.38,14.0,19.0,154.0,49.0,8.0,7.6,2.63,65.0,241.0,39.0,26.0,,6.0,78.0,274.0,72.6,48.8,19.5,2.5,0.1,9.7,17.0,2.0,1.62,1.96,14.2,275.0,,,,,无, 无, P0,H0,已冲,CK + Vimentin –  VEGF灶+ CMET+,,,,,59.75689881734559,1517895
1518085,赵连民,599013,男,40,T1b,N2,M0, ⅡA,1,0,,0.0,0.0,0.0,,3.0,16,,,1.0,,1.0,,,,,1.0,2015-06-10,2021-06-21,1,,,FOLFOX,,,,,,3, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30,G3, (1a)12 (1b)00 (3a)13 (3b)00 (4sb)00 (4d)00 (5)00 (6)13 (7)00 (8a)01 (8p)00 (9)01 (11p)04 (12a)02,L（幽门窦部） 小弯侧Less ,15,15,,R0 D2,,8.29,5.62,1.9,159.2,332.0,3.53,41.0,24.0,125.0,100.0,44.0,33.86,12.28,70.0,299.0,44.0,26.0,4.6,5.5,61.0,597.0,63.8,41.5,18.4,2.26,1.3,13.2,17.7,4.4,0.805,2.39,12.5,22.8,0.673,3.79,1.48,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,72.3718791064389,1518085
1518130,刘兴海,602237,男,71,T4b,N2,M1, ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,13,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-11,2016-10-12,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)00 (2)03 (3a)00 (3b)22 (4sb)00 (4d)24 (5)00 (7)00 (8a)01 (8p)00 (9)11 (11p)00," LM 小弯侧Less,",40,35,8,,R2,3.57,1.74,1.49,76.7,280.0,4.23,8.0,16.0,166.0,70.0,8.0,7.17,2.97,63.0,199.0,35.0,28.0,4.9,6.1,89.0,261.0,61.8,28.8,30.9,0.93,0.1,4.8,31.0,3.4,0.652,2.06,11.5,56.2,1.09,843.8,3.71,,无,, p1局腹膜(M1 PER),H0, 未做,CK + Vimentin –  VEGF+ CMET+ ,,,,,16.064388961892245,1518130
1518245,罗万珍,600562,女,56,T4b,N3a,M0, ⅢC,1,5,2.0,1.0,1.0,1.0, 肠化生+,12.0,33,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-11,2021-07-01,1,,,XELOX,,,,,,4, 低粘附腺癌50 低分化腺癌（G3)(por)50 Lauren弥漫型,G3, (1a)48 (1b)33 (3a)34 (3b)211 (4sb)01 (4d)03 (5)00 (6)01 (7)00 (8a)00 (8p)00 (9)01 (11p)01," UM GE, SiewerⅢ, 前Ant, 后Post, 大弯侧Gre,",100,60,30, R0 D2+,,8.06,4.84,2.4,102.0,321.0,3.46,15.0,20.0,140.0,88.0,11.0,7.14,2.69,66.0,201.0,38.0,28.0,4.7,6.2,68.0,234.0,82.8,32.0,47.8,0.67,0.2,4.7,10.1,1.9,0.813,1.58,12.2,17.4,1.59,4.1,,,无, 无, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+ ,,,,,72.66754270696451,1518245
1518290,许惠民,602797,男,67,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,3.0,16,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-12,2017-07-13,2,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren肠型,G3, (1a)06 (1b)01 (3b)00 (4sb)00 (4d)12 (5)00 (6)00 (7)03 (8a、8p、11p、12a)22 (9)00 (11p)01 3a软组织内可见癌," LD 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",33,25,5,,R1,9.69,8.08,1.04,122.0,231.0,4.2,19.0,22.0,169.0,66.0,15.0,13.04,5.15,66.0,276.0,42.0,24.0,11.3,5.5,86.0,227.0,,,,,,,,,,,,,1.76,113.3,6.29,,无,, P0,H0, 未做,CK + Vimentin- VEGF+ CMET+,,,,,25.03285151116951,1518290
1517637,张长斌,602820,男,49,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,28,中间型（int）,INFb,2.0,,1.0,,,,,1.0,2015-06-08,2020-04-26,1,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】60 粘液腺癌（muc）40 Lauren肠型,G2, (1a)03 (1b)03 (3a)03 (4sb)05 (4d)01 (5)01 (6)02 (7)02 (8a)01 (8p)01 (9)06 (11p)00,M（胃体部） 小弯侧Less ,40,30,20,R0 D2,,5.18,3.16,1.56,127.3,152.0,2.49,14.0,21.0,144.0,82.0,14.0,7.06,3.23,64.0,241.0,37.0,27.0,4.2,6.8,92.0,316.0,61.5,37.8,20.3,1.86,0.2,17.8,16.7,1.5,0.999,0.849,12.7,57.6,2.15,61.29,4.46, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(-)， S100(+) D2-40（-）,,,,,58.60709592641261,1517637
1518154,张兴,602369,男,74,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+,2.0,46,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-06-11,2021-06-21,1,,,,,,,,,0, 粘液腺癌（muc）60 管状腺癌（中分化【G2】【tub2】40 Lauren肠型,G2, (1a)04 (1b)010 (2)00 (3a)01 (3b)25 (4sb)00 (4d)012 (5)04 (6)01 (7)01 (8a) 02(8p)03 (9)00 (11p)02肿物旁01,ML 小弯侧Less 前Ant 后Post ,80,60,30, R0 D2,,6.72,4.12,1.9,106.5,436.0,3.85,15.0,17.0,139.0,131.0,20.0,5.22,2.07,65.0,164.0,40.0,25.0,5.6,6.0,81.0,264.0,54.8,33.4,13.6,2.88,1.3,2.9,40.2,6.1,0.708,1.66,10.2,15.1,6.58,16.66,53.61, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+) S100(+),,,,,72.33902759526939,1518154
1518613,贺信德,600721,男,69,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,0.0, 肠化生+,6.0,18,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-16,2016-07-06,2,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)00 (1b)04 (2)02 (3a)14 (3b)44 (4sb)00 (4d)11 (5)00 (6)00 (7)00 (8a)03 (8p)00 (9)00 (11p)00," LM 小弯侧Less,",35,30,10,,R1,7.71,5.2,2.0,95.6,345.0,2.15,3.0,4.0,,52.0,13.0,4.5,1.8,54.5,,34.0,20.5,5.06,10.0,79.9,186.3,,,,,,,,,,,,,0.72,6.91,,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+,,,,,12.680683311432325,1518613
1518687,杨晓峰,600736,男,49,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,33,,,1.0,,1.0,,,,,1.0,2015-06-16,2018-04-22,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)010 (3a)05 (3b)00 (4sb)05 (4d)00 (5)00 (6)05 (7)02 (8a)01 (8p)01 (9)00 (11p)01 (12a)01," LD 小弯侧Less,",15,15,10, R0 D2+,,7.94,4.41,2.84,154.0,258.0,3.08,29.0,24.0,151.0,63.0,41.6,9.4,2.58,66.8,366.28,45.2,21.6,5.6,4.55,74.0,331.0,,,,,,,,,,,,,8.98,1.45,3.9,,无,, P0,H0, 未做, CK + Vimentin - VEGF 灶+ CMET+,,,,,34.19842312746386,1518687
1518555,孙自金,602131,男,47,T3,N2,M0, ⅢA,1,2,0.0,0.0,0.0,0.0, 肠化生+,5.0,35,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-15,2021-05-17,1,,,FOLFOX,,,,,,5, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)06 (3a)26 (3b)00 (4sb)01 (4d)16 (5)00 (6)13 (7)11 (8a、8p)05 (9)02 (11p)01 (12a)01," L（幽门窦部）, 后Post,",20,15,8, R0 D2+,,6.31,2.56,3.21,141.8,280.0,2.38,24.0,20.0,132.0,34.0,21.0,5.99,2.17,70.0,368.0,42.0,28.0,4.9,4.7,91.0,278.0,,,,,,,,,,,,,1.52,7.24,6.23,,无,, P0,H0, 未做,CK + Vimentin– VEGF+ CMET+,,,,,71.05781865965834,1518555
1518255,杨秀艳,602600,女,52,T3,N1,M0, ⅡB,1,4,,0.0,0.0,1.0,,2.0,10,,,1.0,,1.0,,,,,1.0,2015-06-08,2016-12-30,2,,,XELOX,,,,,,3, 低粘附腺癌,GX, (1a)01 (1b)01 (2)02 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)11 (6)00 (7)01  (8p) 00(9) 00(11p)00肿瘤旁12 (8a) 软组织可见癌, LMU 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,30,, R0 D2,,6.28,3.19,2.5,101.0,326.0,3.28,13.0,20.0,169.0,88.0,7.0,7.22,2.56,67.0,199.0,41.0,26.0,5.1,5.3,67.0,261.0,67.0,27.9,31.2,0.89,0.8,4.0,26.6,4.3,1.3,1.91,10.9,30.4,1.24,9.42,4.45, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(灶+)  cMET(+) S100(+),,,,,18.758212877792378,1518255
1518228,李相顺,601381,男,52,T3,N3a,M0,ⅢB,1,2,1.0,1.0,1.0,1.0, 慢性炎症（+）,7.0,20,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-11,2020-04-26,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80% 低粘附腺癌20% Lauren混合型,G3, (1a)22 (1b)03 (2)00 (3a)57 (3b)00 (4sb)01 (4d)00 (5)00 (6)00 (7)01 (9)03 (11p)01肿物旁02," U（胃底部）, 小弯侧Less,",30,20,10, R0 D2,,6.92,4.38,1.67,84.0,385.0,3.16,18.0,20.0,128.0,73.0,18.0,8.99,2.4,63.0,314.0,38.0,25.0,4.8,9.2,158.0,467.0,70.6,42.7,24.3,1.76,0.3,12.7,15.2,2.4,0.951,2.56,12.6,5.0,1.49,10.54,1.34, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）,,,,,58.50854139290407,1518228
1518454,刘尚岩,600112,男,62,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,7.0,30,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-15,2021-05-17,1,,,SOX,,,,,,4, 低粘附腺癌 Lauren肠型,GX, (1a)02 (1b)00(2)03 (3a)04 (4sa)00 (4sb)03 (4d)48 (5)12 (6)00 (7)00 (8a)11 (8p)01 (9)01 (11p)02 (12a)02 (3b) 软组织可见癌 肿物旁11," M（胃体部）, 前Ant, 小弯侧Less,",80,65,7, R0 D2,,7.15,3.75,2.91,154.7,264.0,2.95,18.0,23.0,177.0,52.0,18.0,38.47,12.09,67.0,359.0,42.0,25.0,7.6,4.8,98.0,282.0,50.0,28.7,17.3,1.66,0.5,8.9,39.4,0.9,0.608,2.71,8.75,5.0,2.71,36.21,0.632, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+) S100(+),,,,,71.05781865965834,1518454
1519456,杨建军,600957,男,66,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,23,,,1.0,,,,,,,1.0,2015-06-24,2021-05-24,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)01 (3a)02 (3b)00 (4sb)00 (4d)08 (5)00 (6)01 (7)02 (8a)01 (8p)02 (9)01 (11p)04 (12a)00 (14v)00," M（胃体部）, 小弯侧Less,",25,20,, R0 D2,,6.97,4.49,1.92,139.1,216.0,2.9,15.0,14.0,139.0,77.0,18.0,6.84,2.26,68.0,399.0,42.0,26.0,7.3,8.9,103.0,265.0,67.0,49.2,16.1,3.06,0.4,7.3,23.1,0.5,0.87,2.91,11.2,474.0,2.56,13.07,1.19,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,70.99211563731932,1519456
1518530,李国仁,600745,男,49,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,31,,,1.0,,1.0,,,,,1.0,2015-06-15,2020-12-17,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)00 (3a)05 (3b)01 (4sb)01 (4d)07 (5)01 (6)04 (7)05 (8a)01 (8p)02 (9)02 (11p)02," L（幽门窦部）, 前Ant,",25,15,5, R0 D2,,9.67,5.06,3.89,160.0,227.0,2.09,43.0,37.0,155.0,67.0,24.0,9.66,4.39,66.0,390.0,43.0,23.0,4.3,7.8,64.0,250.0,,,,,,,,,,,,,2.93,15.66,4.16,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF灶+， CMET+,,,,,66.09724047306176,1518530
1518479,刘广君,602715,男,69,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,3.0,25,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-15,2016-08-20,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren肠型,G3, (1a)04 (1b)05 (3a)01 (3b)00 (4sb)01 (4d)01 (5)00 (6)03 (7)01 (8a、8p、9)36 (11p)02 (12a)01," L（幽门窦部）, 后Post,",35,30,10, R0 D2+,,8.34,5.27,2.22,140.6,251.0,,22.0,23.0,131.0,69.0,9.0,7.55,5.79,64.0,181.0,38.0,26.0,5.2,7.7,71.0,287.0,,,,,,,,,,,,,1.41,7.08,6.69,,无,, P0,H0, 未做,CK + Vimentin- VEGF+ CMET+ ,,,,,14.19185282522996,1518479
1518532,邢有吉,597882,男,61,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,12,,,1.0,,1.0,,,,,1.0,2015-07-15,2021-05-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)02 (3a)02 (3b)00 (4sb)00 (4d)04 (5)01 (6)00 (7)00 (8a)01  (9)01 (12a)01," M（胃体部）, 小弯侧Less,",25,25,2, R0 D2,,6.16,3.13,2.55,102.8,278.0,3.86,20.0,22.0,141.0,71.0,20.0,12.06,7.62,69.0,245.0,40.0,29.0,5.3,5.0,61.0,255.0,64.3,34.3,28.7,1.2,1.5,5.2,28.8,6.2,0.379,2.6,15.0,41.0,3.68,9.85,1.24, 未做,无,,,H0, 未做, CMET+ Vimentin- VEGF+ CK+ S-100(未见) CD34、D2-40（未见）,,,,,70.30223390275953,1518532
1518562,张桂芬,604048,女,74,T3,N2,M0, ⅢA,1,2,0.0,0.0,0.0,1.0, 肠化生+,6.0,19,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-15,2021-06-21,1,,,,,,,,,0, 低分化腺癌（G3)(por)60%， 粘液腺癌（muc）40%， Lauren肠型,G3, (1a) 01(1b)01 (3a) 33(3b)33 (4sb)00 (4d) 00(5)01 (6)04 (7)05 (8a) (8p) (11p)01 (14v)00 (9)00," M（胃体部）, 小弯侧Less,",15,10,5, R0 D2,,5.52,3.76,1.4,145.0,233.0,2.98,15.0,33.0,168.0,84.0,7.0,8.33,3.92,71.0,243.0,43.0,28.0,5.0,6.9,65.0,272.0,63.4,30.5,30.6,1.0,1.9,3.6,28.3,2.6,1.02,1.79,11.6,36.5,5.02,11.07,3.31, 未做,无,,,H0,, CK+ Vimentin- VEGF+ CMET+， S-100可见神经侵犯，cd34.d2-40未见,,,,,72.20762155059133,1518562
1518531,李云节,600753,男,66,T3,N3b,M0, ⅢC,1,4,2.0,0.0,0.0,1.0, 肠化生+,26.0,47,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-15,2018-04-18,2,,,SOX,,,,,,3, 低粘附腺癌 Lauren弥漫型,GX, (1a)14 (1b)44 (2)01 (3a)66 (3b)03 (4sa)02 (4sb)00 (4d)811 (5)33 (6)11 (7)11 (8a)01 (8p)01 (9) 02(11p)01 (12a)00 (17)11 小弯22 肿物旁23," ML 小弯侧Less, 前Ant, 后Post,",50,50,10, R0 D2,,6.56,2.71,3.1,119.0,442.0,4.03,21.0,18.0,129.0,108.0,57.0,5.15,1.57,72.0,322.0,39.0,33.0,8.8,6.2,86.0,257.0,37.3,23.4,12.8,1.83,0.8,14.8,44.2,0.9,1.03,3.97,14.2,401.0,1.03,9.64,2.23, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(灶+)  cMET(+) S100(+),,,,,34.09986859395532,1518531
1518863,曾凡斌,602675,男,60,T3,N3b,M1, Ⅳ,1,3,0.0,1.0,1.0,1.0, 肠化生+,23.0,32,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-17,2021-06-21,1,,,FOLFOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)12 (3a)33 (3b)12 (4sb)00 (4d)00 (5)11 (6)11 (7)23 (8a)55 (8p)11 (9)02 (11p)01 (12b)77 (13)11,L（幽门窦部） 小弯侧Less ,30,25,8,,R1,6.94,4.02,2.38,147.6,255.0,4.66,37.0,27.0,127.0,137.0,159.0,13.83,5.84,75.0,264.0,44.0,31.0,5.6,5.6,106.0,457.0,68.0,35.4,28.6,1.24,0.7,10.1,20.5,3.8,1.17,2.54,14.8,133.0,0.895,5.89,1.14, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,72.14191852825229,1518863
1519070,汤潞汗,600093,男,58,T4b,N2,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,4.0,23,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-06-18,2021-06-21,1,,,SOX,SOX,紫杉醇联合替吉奥,紫杉醇联合替吉奥,紫杉醇联合替吉奥,,5, 管状腺癌（中分化【G2】【tub2】60% 粘液腺癌（muc）40% Lauren肠型,G2, (1a)00 (1b)03 (3a)03 (3b)00 (4sb)00 (4d)15 (5)03 (7)35 (8a)00 (8p)01 (9)01 (11p)02," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",60,35,10,,R1,6.78,4.02,2.07,103.9,280.0,2.99,15.0,17.0,132.0,70.0,11.0,14.93,6.56,54.0,248.0,35.0,19.0,4.2,5.1,66.0,310.0,54.7,39.9,12.5,3.19,0.3,15.5,27.4,1.0,0.603,1.26,6.09,21.2,2.62,1.08,3.84, 未做,无, 无, P0,H0, 未做, CK（+） Vimentin（-） VEGF（灶+） CMET（+）,,,,,72.10906701708278,1519070
1519374,张世福,604086,男,63,T4b,N1,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,2.0,31,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-23,2016-03-08,2,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)06 (3a)17 (3b)00 (4sb)00 (4d)16 (5)01 (6)00 (7)03 (8a)01 (8p)02 (9)02 (11p)02 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",30,15,5,,R1,7.36,5.61,1.11,142.2,191.0,4.44,14.0,23.0,173.0,62.0,9.0,13.09,5.49,66.0,248.0,40.0,26.0,4.7,5.7,65.0,218.0,51.0,22.1,26.5,0.83,0.5,6.5,40.4,4.5,0.805,2.44,11.2,10.7,4.86,53.75,3.5, 未做,无, 无, P0,H0, 未做,,,,,,8.508541392904073,1519374
1519375,班德琴,600775,女,67,T3,N0,M0, ⅡA,1,1,0.0,0.0,0.0,0.0, 肠化生+,0.0,20,中间型（int）,INFb,1.0,,,,,,,1.0,2015-06-23,2018-11-23,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)3 (1b)01 (3a)01 (3b)02 (4sb)00 (4d)00 (5)01 (6)04 (7)01 (8a)01 (8p)02 (9)01 (11p)01 (12a)02," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",70,50,10, R0 D2+,,8.52,6.64,1.14,94.5,287.0,2.9,11.0,16.0,227.0,58.0,20.0,8.26,3.19,57.0,151.0,30.0,27.0,5.1,6.4,80.0,278.0,,,,,,,,,1.34,1.42,14.3,74.8,1.03,5.09,2.37,,无, 无, P0,H0, 未做,CK + Vimentin –  VEGF- CMET+,,,,,41.03153745072273,1519375
1518883,王英华,600642,男,62,T2,N2,M0, ⅡB,1,2,,0.0,0.0,1.0,,4.0,25,,,3.0,,,,,,,1.0,2015-06-17,2021-05-21,1,,,XELOX,XELOX,XELOX,XELOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)05 (3a)00 (3b)22 (4sb)00 (4d)16 (5)00 (6)02 (7)07 (8a)11 (8p)00 (9)01 (11p)01 (12a)00," M（胃体部）, 前Ant,",18,15,5, R0 D2,,8.21,4.52,2.89,152.0,287.0,3.16,24.0,27.0,192.0,61.0,22.0,16.26,6.05,72.0,316.0,44.0,28.0,4.9,7.6,80.0,311.0,56.9,36.2,11.1,3.26,1.3,12.7,24.8,1.9,1.51,2.82,12.3,123.0,3.49,,1.04,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,71.12352168199737,1518883
1519042,韩建芹,602426,女,60,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,25,,,1.0,,,,,,,1.0,2015-06-18,2021-07-23,1,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30,G3, (1a)00 (1b)03 (3a)07 (3b)03 (4sb)00 (4d)01 (5)00 (6)02 (7)05 (8a)01 (8p)02 (9)01 (11p)00,L（幽门窦部） 小弯侧Less ,20,20,8,R0 D2,,6.55,2.95,2.99,147.0,254.0,4.32,17.0,23.0,144.0,97.0,14.0,16.0,4.73,73.0,274.0,44.0,29.0,5.2,5.7,65.0,274.0,51.1,33.6,22.7,1.48,0.7,20.1,16.9,6.2,1.03,1.76,13.5,13.1,6.6,30.59,3.19, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,73.16031537450722,1519042
1518962,张艳福,602397,男,45,T4b,N3a,M0, ⅢC,1,4,2.0,1.0,1.0,0.0, 肠化生+,13.0,18,中间型（int）,INFb,1.0,,,,,,,1.0,2015-06-18,2017-04-10,2,,,,,,,,,0, 粘液腺癌（muc）60 低粘附腺癌40 Lauren弥漫型,GX," (1a)22 (1b)12 (3a)33 (4sb)11 (4d)22 (5)00 (7)22 (8a)02 (8p)11 (9)13 8a，3a，6,7,5 软组织可见癌",LM LD 前Ant 后Post 大弯侧Gre  小弯侧Less ,130,120,30,,R2,6.07,3.72,1.54,140.0,288.0,2.91,18.0,21.0,139.0,69.0,9.0,9.68,3.71,53.0,206.0,30.0,23.0,5.4,6.7,69.0,6.7,70.1,42.9,25.5,1.68,0.2,9.9,17.3,1.2,0.687,2.76,8.82,597.0,2.83,35.22,55.44, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(-) D2-40（+）,,,,,21.747700394218132,1518962
1519076,郑殿文,601059,男,67,T2,N3a,M0, ⅢA,1,2,,0.0,0.0,0.0,,9.0,9,,,3.0,,,,,,,2.0,2015-06-18,2016-07-07,2,,,,,,,,,0, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】30,G2, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)00 (5)11 (6)44 (7、8a、8p、9)44," LD 前Ant, 后Post, 小弯侧Less,",20,20,10,,R2,6.87,4.4,2.06,147.2,217.0,2.63,10.0,19.0,187.0,78.0,3.0,8.11,3.17,79.0,178.0,43.0,36.0,5.0,7.7,89.0,229.0,46.7,30.3,12.4,2.44,0.2,9.8,37.7,0.6,1.52,2.15,17.8,16.4,253.0,26.21,5.41,,无,, P0,H0, 未做,CK + Vimentin –  VEGF- CME弱T+,,,,,12.64783180026281,1519076
1519040,霍春友,600790,男,63,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,16,,,1.0,,1.0,,,,,1.0,2015-06-18,2021-07-22,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)05 (1b)00 (3a)07 (3b)00 (4sb)00 (4d)00 (5)00 (6)00 (7)03 (8a)01 (8p)00 (9)00 (11p)00," UM SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",35,30,5, R0 D2+,,6.41,4.13,1.66,152.6,159.0,3.01,22.0,29.0,181.0,87.0,19.0,22.28,6.99,70.0,261.0,42.0,28.0,5.0,8.8,70.0,247.0,48.8,27.6,24.8,1.11,0.5,14.3,24.4,0.9,0.995,2.86,1.7,12.0,1.81,11.92,9.26,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+,,,,,73.12746386333771,1519040
1519513,马洪春,603989,男,64,T3,N3b,M0, ⅢC,1,3,0.0,0.0,0.0,1.0, 肠化生++,20.0,34,中间型（int）,INFb,2.0,,,,,,,1.0,2015-06-24,2016-08-01,2,,,力朴素联合替吉奥,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 乳头状癌（G1）（pap）20 Lauren肠型,G3, (1a)13 (1b)22 (3a、3b)47 (4sa、4sb)00 (2、19)916 (110)02 (7、2、3a、3b、111)44," U（胃底部）, E（食道）, G=E, SiewerⅡ, 后Post, 大弯侧Gre, 小弯侧Less,",90,60,20, R0 D2+,,10.88,8.42,1.41,127.9,245.0,3.61,23.0,28.0,167.0,98.0,27.0,11.62,4.33,76.0,241.0,41.0,35.0,4.4,7.0,76.0,297.0,,,,,,,,,,,,,3.26,31.5,16.69,,无,, P0,H0, 未做,CK + Vimentin –  VEGF- CMET+,,,,,13.272010512483574,1519513
1519075,关丙龙,604194,男,51,T1b,N1,M0, ⅠB,1,0,,0.0,0.0,0.0,,1.0,15,,,0.0,,,,,,,1.0,2015-06-18,2020-04-26,0,,,,,,,,,0, 低粘附腺癌55 低分化腺癌（G3)(por)45,G3, (1a)01 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)00 (5)01 (6)11 (7)01 (8a)05(9)01 (11p)00 (12a)01(15)01,L（幽门窦部） 前Ant 小弯侧Less ,25,20,6, R0 D2,,6.25,3.56,2.14,169.0,233.0,1.75,18.0,20.0,140.0,64.0,9.0,17.41,6.59,69.0,367.0,43.0,26.0,4.8,7.7,75.0,365.0,59.4,48.4,22.9,2.11,0.3,10.4,14.1,3.9,0.941,3.0,11.5,143.0,0.884,3.39,3.23, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+) ,,,,,58.27858081471747,1519075
1519285,何双林,603692,男,67,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,24,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-06-23,2016-06-20,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80% 粘液腺癌（muc）20% Lauren肠型,G3, (1a)00 (1b)06 (3a)02 (3b)00 (4sb)00 (4d)04 (5)01 (6)03 (7)00 (8a)01 (8p)01 (9)03 (11p)01 (14v)02," L（幽门窦部）, D(十二指肠), 前Ant, 后Post, 大弯侧Gre,",50,50,23, R0 D2,,7.02,4.51,1.38,145.0,320.0,3.68,21.0,25.0,177.0,75.0,11.0,6.68,2.33,62.0,283.0,38.0,24.0,4.8,9.6,84.0,387.0,51.0,39.1,20.3,1.93,0.3,7.5,25.9,5.9,0.325,4.16,9.68,8.89,1.16,4.85,5.5, 未做,无, 无, P0,H0, 未做, CK（+） Vimentin（-） VEGF（+） CMET（+）,,,,,11.925098554533507,1519285
1519663,汪凤兰,603572,女,78,T3,N1,M0, ⅡB,1,5,0.0,0.0,0.0,0.0, 肠化生+,2.0,34,中间型（int）,INFb,2.0,,,,,,,1.0,2015-06-25,2020-05-11,0,,,,,,,,,0, 低分化腺癌（G3)(por)80% 粘液腺癌（muc）20% Lauren肠型,G3, (1a)00 (1b)00 (3a)09 (3b)12 (4sb)00 (4d)010 (5)01 (6)13 (7)03 (8p)02 (9)01 (11p)01 (12a)00肿物旁02," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,40,15, R0 D2,,5.26,2.2,2.71,120.3,374.0,4.44,20.0,25.0,176.0,91.0,11.0,6.99,2.43,65.0,171.0,40.0,25.0,5.7,5.9,65.0,293.0,48.9,28.3,30.2,0.94,0.1,4.8,34.2,0.5,0.316,2.17,9.11,5.0,9.27,12.64,45.83, 未做,无, 无, P0,H0, 未做, CK（+） Vimentin（-） VEGF（-） CMET（+）,,,,,58.54139290407358,1519663
1519367,刘建刚,603436,男,55,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,36,,,1.0,,1.0,,,,,1.0,2015-06-23,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)03 (3a)08 (3b)00 (4sb)00 (4d)07 (5)01 (6)00 (7)01 (8a)02 (8p)01 (9)06 (11p)06 (12a)00," L（幽门窦部）, 小弯侧Less,",20,20,15, R0 D2,,5.1,2.72,1.95,172.4,261.0,3.33,55.0,38.0,166.0,74.0,16.0,11.73,4.22,62.0,404.0,41.0,21.0,5.3,6.3,75.0,362.0,55.0,39.9,23.1,1.73,0.5,17.0,15.8,5.5,0.668,0.921,6.73,18.0,2.2,8.13,3.18,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF灶+， CMET+,,,,,65.83442838370564,1519367
1519537,郑海贤,604258,女,55,T4b,N2,M0, ⅢB,1,1,0.0,0.0,0.0,0.0, 慢性炎症（+）,4.0,26,中间型（int）,INFb,1.0,,1.0,,,,,2.0,2015-06-24,2015-12-20,2,,,,,,,,,0, 低粘附腺癌 Lauren肠型,GX, (1a)03 (1b)00 (3a)05 (3b)13 (4sb)00 (4d)00 (5)00 (6)14 (7)01 (8a)22 (8p)00 (9)03 (11p)05," LD 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,12,,R1,6.5,4.53,1.37,142.0,161.0,2.68,16.0,22.0,193.0,56.0,17.0,12.76,6.29,67.0,172.0,39.0,28.0,6.8,4.1,101.0,429.0,64.0,31.2,41.4,0.75,0.4,11.9,8.9,7.1,1.13,3.51,10.9,228.0,80.32,16.87,5.17, 未做,无,,,H0, 未做, CMET（弱+） Vimentin-， VEGF（弱+） CK+ S-100（未见） CD34，D2-40(未见),,,,,5.88042049934297,1519537
1518614,魏波,602804,男,51,T1b,N0,M0,ⅠA,1,3,,0.0,0.0,0.0,,0.0,29,,,1.0,,,,,,,1.0,2015-06-16,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)03 (3a)02 (3b)01 (4sb)00 (4d)07 (5)00 (6)04 (7)06 (8a)02 (8p) (9)01 (11p)03 (12a)00," LD 小弯侧Less,",20,20,10, R0 D2,,10.95,8.86,0.86,135.5,209.0,2.79,29.0,28.0,179.0,75.0,44.0,14.56,7.03,74.0,376.0,44.0,30.0,5.0,6.6,90.0,367.0,,,,,,,,,,,,,1.19,5.67,1.22,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,66.06438896189225,1518614
1519522,张国良,604216,男,71,T3,N2,M0, ⅢA,1,1,0.0,1.0,1.0,0.0, 肠化生+,6.0,26,中间型（int）,INFb,2.0,,,,,,,1.0,2015-06-24,2021-06-21,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)01 (1b)06 (3a)04 (3b)00 (4sb)01 (4d)69 (5)00 (6)00 (7)02 (8a)01 (8p)01 (9)00 (11p)00 (12a)01胃壁结节符合胃肠道间质瘤，极低侵袭危险性，梭形细胞型，病灶直径0.8cm," M（胃体部）, 小弯侧Less, 前Ant,",70,50,20, R0 D2,,7.65,5.01,1.95,105.5,286.0,3.21,17.0,16.0,162.0,61.0,19.0,40.29,20.48,51.0,95.0,30.0,21.0,6.5,4.9,55.0,135.0,70.4,36.2,21.1,1.71,0.5,8.1,20.5,3.4,0.653,3.87,13.5,69.0,1.11,9.9,9.81, 未做,无, 无,,H0, 未做, CMET（灶+） Vimentin-， VEGF-， CK+ S-100（未见） CD34、D2-40(可见),,,,,71.9119579500657,1519522
1519609,何兰恒,604220,男,67,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,21,,,1.0,,,,,,,0.0,2015-06-25,2021-05-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20,G2, (1a)01 (1b)04 (3a)02 (3b)03 (4sb)01 (4d)04 (5)02 (6)01 (7)01 (8a)00 (8p)00 (9)01 (11p)00肿物旁01,LM 小弯侧Less 前Ant 后Post ,20,15,1, R0 D2,,7.34,3.79,3.04,157.5,280.0,3.33,22.0,21.0,157.0,94.0,22.0,7.54,2.43,72.0,370.0,43.0,29.0,8.3,9.1,90.0,335.0,53.0,27.8,31.7,0.88,0.2,7.4,29.5,5.3,0.762,2.36,12.7,10.7,,,, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,70.86070959264126,1519609
1519286,赵玉华,603744,女,44,T4b,N3b,M1, Ⅳ,1,4,2.0,1.0,1.0,1.0, 肠化生+,23.0,23,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-06-23,2015-08-01,2,,,,,,,,,0, 低粘附腺癌80 乳头状癌（G1）（pap）20 Lauren弥漫型,G1, (1a)11 (1b)11 (3a)33 (3b)33 (4sb)55 (4d)44 (5)22 (6)33 (7)11," LD LM ML 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",130,90,15,,R2,9.1,6.56,1.77,95.0,433.0,3.4,17.0,23.0,211.0,59.0,22.0,5.84,2.53,64.0,262.0,40.0,24.0,4.4,5.2,47.0,88.0,,,,,,,,,,,,,,,,,粟粒状, 无, p1泛(M1 PER),H0, 未做,CK + Vimentin –  VEGF灶+ CMET+,,,,,1.281208935611038,1519286
1519352,王广生,603646,男,63,T2,N0,M0, ⅠB,1,3,,0.0,0.0,1.0,,0.0,24,,,2.0,,1.0,,,,,1.0,2015-06-23,2021-05-24,1,,,,,,,,,0, 粘液腺癌（muc）60 低分化腺癌（G3)(por)40,G3, (1a)04 (1b)02 (3a)00 (3b)00 (4sb)01 (4d)04 (5)01 (6)01 (7)06 (8p)01 (9)01 肿物旁03," LM 小弯侧Less,",10,6,6, R0 D2+,,7.74,5.24,1.68,116.9,318.0,3.85,17.0,21.0,138.0,88.0,11.0,8.08,2.99,67.0,280.0,40.0,27.0,4.7,6.7,77.0,257.0,53.1,35.6,21.3,1.67,0.3,10.5,21.7,1.6,1.22,2.29,12.5,59.0,2.97,26.35,1.67,,无,, P0,H0, 未做,CK + Vimentin –  VEGF灶+ CMET+ ,,,,,71.02496714848883,1519352
1519365,李永海,603501,男,60,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 肠化生+,0.0,39,中间型（int）,INFb,1.0,,,,,,,0.0,2015-06-23,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)04 (1b)08 (2)00 (3a)01 (3b)05 (4sa)00 (4sb)00 (4d)06 (5)00 (6)02 (7)01(8a)02(8p)02 (9)01 (11p)02 (12a)05, U（胃底部） 前Ant ,10,10,6, R0 D2,,8.06,4.12,3.15,139.0,304.0,2.56,18.0,23.0,145.0,62.0,21.0,18.73,6.06,68.0,294.0,42.0,26.0,4.7,6.7,68.0,284.0,35.1,28.4,14.2,2.0,0.7,4.9,49.3,2.5,0.502,2.15,11.4,48.0,2.71,3.98,1.3, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-) ,,,,,86.30091984231274,1519365
1519072,吴秀红,600570,女,50,T1b,N2,M0, ⅡA,1,0,,1.0,1.0,0.0,,3.0,28,,,0.0,,,,,,,2.0,2015-08-18,2021-06-07,1,,,XELOX,,,,,,5, 低分化腺癌（G3)(por)70 低粘附腺癌30,G3, (1a)00 (1b)02 (3a)02 (3b)00 (4sb) 00 (4d)216 (5)00 (6)01 (7)02 (8a)11 (8p)01 (9)01 (11p)02 (12a)00," L（幽门窦部）, 前Ant,",25,15,8, R0 D2,,8.15,5.56,1.78,129.0,275.0,2.63,37.0,48.0,183.0,51.0,9.0,11.31,4.36,57.0,162.0,33.0,24.0,8.2,2.5,64.0,310.0,61.8,34.4,18.2,1.89,1.5,7.7,26.1,35.7,1.74,3.6,13.7,196.0,0.482,5.55,8.02,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET弱+,,,,,69.64520367936925,1519072
1519689,曲国云,603510,女,51,T3,N0,M0, ⅡA,1,2,,0.0,0.0,0.0,,0.0,33,,,0.0,,,,,,,1.0,2015-06-25,2021-06-21,1,,,SOX,,,,,,6, 低粘附腺癌,GX, (1a)03 (1b)07 (3a)04 (3b)01 (4sb)02 (4d)04 (5)00 (6)06 (7)01 (8a)01 (8p)01 (9)01 (11p)01 (12a)01," M（胃体部）, 小弯侧Less,",15,15,8, R0 D2,,6.25,3.15,2.55,125.2,181.0,2.56,12.0,16.0,169.0,103.0,13.0,16.84,5.49,66.0,214.0,40.0,26.0,5.1,6.1,88.0,192.0,51.2,34.4,11.8,2.92,0.2,12.6,34.8,1.3,1.41,1.9,12.4,5.0,1.31,1.13,6.11, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+) ,,,,,71.87910643889619,1519689
1519428,鲁永明,600649,男,61,T2,N1,M0, ⅡA,1,2,2.0,0.0,0.0,0.0, 肠化生+,2.0,18,中间型（int）,INFb,0.0,,,,,,,1.0,2015-06-24,2018-04-05,0,,,,,,,,,1, 粘液腺癌（muc）60 低粘附腺癌40 Lauren弥漫型,GX, (1a)02 (1b)00 (2)04 (3a)05 (3b)00 (4sa)01 (4sb)00 (4d)01 (5)00 (7)00 (8a)12 (8p)01 (9)12 (11p)00 (12a)00," U（胃底部）, 后Post,",25,25,8, R0 D2,,9.41,6.19,2.65,144.3,260.0,3.85,16.0,16.0,157.0,79.0,22.0,13.1,4.5,66.0,251.0,40.0,26.0,4.4,7.4,99.0,347.0,62.0,33.9,33.2,1.02,0.3,9.3,13.5,10.9,0.743,1.54,12.9,20.7,5.23,8.28,5.4,,无,, P0,H0, 未做,CK + Vimentin –  VEGF- CMET+,,,,,33.37713534822602,1519428
1520007,钟决标,598575,男,57,T4b,N2,M0, ⅢB,1,2,0.0,0.0,0.0,0.0, 肠化生+,3.0,15,中间型（int）,INFb,1.0,,,,,,,1.0,2015-06-29,2020-07-02,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)03 (3b)02 (4sb)00 (4d)00 (5)00 (6)00 (7)01 (8a)14 (8p)00 (9)00 (11p)01 (12a)00 小弯01 大弯23," LM 前Ant, 后Post, 小弯侧Less,",45,35,10, R0 D2+,,5.58,3.5,1.41,137.0,188.0,2.3,21.0,24.0,131.0,65.0,35.0,19.72,6.52,66.0,315.0,38.0,28.0,5.2,8.7,64.0,250.0,74.4,31.2,27.9,1.12,0.2,5.6,16.9,7.9,1.7,1.93,12.7,158.8,2.78,0.79,4.17,,无,, P0,H0, 未做,CK + Vimentin –  VEGF- CMET+,,,,,60.118265440210244,1520007
1519429,闫玉玲,604148,女,50,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,10,,,1.0,,,,,,,1.0,2015-06-24,2021-05-25,1,,,,,,,,,0, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】30,G2, (1a)00 (1b)01 (3a)00 (3b)01 (4sb)00 (4d)02 (5)00 (6)01 (7)01 (8a)01 (8p)01 (9)01 (11p)01, M（胃体部） 小弯侧Less ,30,30,,R0 D2,,4.93,2.38,2.26,150.1,317.0,2.68,30.0,29.0,159.0,48.0,15.0,9.67,3.27,70.0,287.0,43.0,227.0,4.8,4.8,62.0,336.0,65.9,29.9,27.3,1.1,0.6,7.7,24.4,3.9,0.77,2.65,11.4,33.9,1.23,11.45,1.93, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,71.02496714848883,1519429
1519893,施春志,603758,男,61,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0, 慢性炎症（+）,0.0,33,髓样型（med）,INFb,1.0,,,,,,,1.0,2015-06-29,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)07 (2)07 (3a)07 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)02 (6)01 (7)01 (8a)02 (8p)02 (9)00 (11p)01 (12a)01 (11d)00, U（胃底部） 后Post ,15,10,,R0 D2,,7.86,5.38,1.78,146.0,258.0,2.72,28.0,25.0,137.0,71.0,18.0,24.05,7.88,72.0,293.0,44.0,28.0,5.5,11.0,82.0,335.0,53.2,25.1,23.3,1.08,0.3,10.6,33.8,1.5,0.77,1.56,13.9,5.0,2.34,10.63,3.89, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(-)，CD34(-)， S100(-) D2-40（-）,,,,,86.10381077529566,1519893
1519664,刘玉芹,604224,女,65,T1a,N1,M0, ⅠB,1,0,,0.0,0.0,0.0,,2.0,18,,,0.0,,,,,,,2.0,2015-06-25,2021-05-11,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (3a)01 (3b)13 (4sb)00 (4d)02 (5)00 (6)01 (7)13 (8a)03 (8p)01 (9)02 (11p)01 (12a)00," M（胃体部）, 后Post, 大弯侧Gre,",15,15,, R0 D2,,4.14,1.82,1.74,127.0,275.0,2.41,17.0,26.0,175.0,64.0,10.0,13.47,4.18,75.0,195.0,43.0,32.0,4.3,7.6,68.0,244.0,63.4,42.4,16.0,2.65,0.4,17.5,17.4,1.9,2.09,2.96,12.8,22.3,0.911,12.66,1.18,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET弱+,,,,,70.53219448094612,1519664
1519992,曲琦,604330,女,35,T3,N3b,M0, ⅢC,1,5,2.0,0.0,,1.0, 肠化生+,24.0,35,中间型（int）,INFb,0.0,,,,,,,0.0,2015-06-29,2018-04-01,2,,,XELOX,,,,,,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)12 (3b)11 (4sb)01 (4d)512 (5)00 (6)66 (7)33 (8a)11 (8p)35 (9)00 (11p)44 (12a)00 (14v)00," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,30,10, R0 D2+,,6.42,3.09,2.58,75.0,396.0,2.58,16.0,20.0,99.0,54.0,6.0,12.05,5.59,66.0,195.0,43.0,23.0,5.0,8.7,58.0,235.0,64.2,36.6,24.3,1.51,0.4,7.6,26.3,2.3,0.524,1.7,9.49,7.18,1.96,8.58,4.77,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,33.08147174770039,1519992
1519696,李太荣,603926,男,69,T2,N1,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,2.0,18,中间型（int）,INFb,0.0,,,,,,,1.0,2015-06-25,2020-04-26,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)04 (2)23 (3a)06 (3b)01 (4sa)00 (4sb)00 (4d)02 (5)00 (7)00 (8a)00 (9)01 (11p)01 (12a)00," SiewerⅡ, 前Ant,",30,20,10, R0 D2,,5.59,2.85,2.27,126.5,244.0,2.28,21.0,22.0,123.0,68.0,11.0,13.72,5.55,63.0,273.0,38.0,25.0,5.6,6.6,69.0,302.0,71.6,58.8,9.7,6.06,0.2,10.6,14.4,0.6,0.415,3.7,10.4,68.6,2.98,10.68,1.32, 未做,无, 无, P0,H0, 未做, CK（+） Vimentin（-） VEGF（-） CMET（+）,,,,,58.04862023653088,1519696
1519987,李淑兰,603981,女,65,T1b,N1,M0, ⅠB,1,0,,0.0,0.0,0.0,,1.0,18,,,0.0,,,,,,,0.0,2015-06-29,2018-04-05,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)04 (1b)13 (3a)03 (3b)00 (4sb)00 (4d)01 (5)00 (6)02 (7)01 (8a)03 (8p)00 (9)00 (11p)01," LM 前Ant, 后Post, 小弯侧Less,",40,30,, R0 D2+,,4.64,2.67,1.35,112.6,165.0,2.78,15.0,19.0,131.0,55.0,5.0,14.36,4.67,57.0,246.0,36.0,21.0,4.6,7.6,72.0,272.0,,,,,,,,,,,,,0.56,5.73,6.32,,无, 无, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+,,,,,33.21287779237845,1519987
1520321,张余扬,604498,男,23,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 异型增生+,0.0,19,中间型（int）,INFc,0.0,,,,,,,1.0,2015-07-01,2021-05-17,1,,,XELOX,,,,,,6, 低粘附腺癌60% 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40% Lauren弥漫型,G3, (1a)02 (1b)03 (2)01 (3a)02 (4sa)00 (5)00 (7)05 (8a)01 (8p)01 (9)02 (10)01 (11p)01 (12a)00," M（胃体部）, U（胃底部）, 前Ant,",40,30,3, R0 D2,,6.3,3.14,2.74,140.9,308.0,2.01,17.0,23.0,134.0,77.0,10.0,8.59,4.06,70.0,220.0,45.0,25.0,4.5,3.9,73.0,289.0,66.9,30.4,27.9,1.09,0.4,4.2,26.8,1.2,0.838,1.82,9.85,46.6,0.809,5.15,3.75, 未做,无, 无, P0,H0, 未做, CK（+） Vimentin（-） VEGF（-） CMET（+）,,,,,70.53219448094612,1520321
1520464,葛恩锁,603527,男,49,T4b,N2,M0, ⅢB,1,3,2.0,0.0,0.0,0.0, 肠化生+,6.0,49,中间型（int）,INFc,2.0,,,,,,,1.0,2015-07-02,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)01 (3a)216 (3b)00 (4sb)00 (4d)38 (5)00 (6)16 (7)05 (8a)03 (8p)02 (9)04 (11p)03 (12a)00," L（幽门窦部）, M（胃体部）, 前Ant,",40,40,9, R0 D2,,8.66,6.12,1.88,156.8,329.0,3.59,19.0,23.0,147.0,68.0,9.0,10.61,3.9,65.0,210.0,40.0,25.0,4.4,9.2,82.0,289.0,83.1,40.2,39.1,1.03,0.8,6.2,7.5,3.4,1.21,1.66,11.0,28.2,2.1,16.74,18.04, 未做,无, 无, P0,H0, 未做, CK（+） Vimentin（-） VEGF（-） CMET（+）,,,,,86.00525624178712,1520464
1520379,范文学,598161,男,62,T4b,N3a,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,13.0,47,中间型（int）,INFc,2.0,,,,,,,2.0,2015-07-02,2021-05-17,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren弥漫型,G3, (1a)03 (1b)14 (3a)417 (3b)33 (4sb)00 (4d)211 (5)11 (6)12 (7)01 (8a)11 (8p)02 (9)01 (11p)00 (12a)00 (19)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,10,,R1,7.83,4.5,2.86,131.4,288.0,5.44,16.0,21.0,131.0,59.0,5.0,8.34,3.16,69.0,192.0,37.0,32.0,5.4,6.5,95.0,405.0,54.1,27.0,24.9,1.08,0.9,3.0,41.0,0.5,0.795,3.15,16.5,12.5,1.71,23.28,14.59, 未做,无, 无, P0,H0, 未做, CK（+） Vimentin（-） VEGF（-） CMET弱（+）,,,,,70.4993429697766,1520379
1519988,于凤飞,602671,男,58,T4b,N1,M0, ⅢB,1,5,0.0,0.0,0.0,1.0, 肠化生+,2.0,22,中间型（int）,INFb,2.0,,,,,,,0.0,2015-06-29,2021-05-17,1,,,SOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)04 (1b) 01(3a)01 (3b)00 (4sb)24 (4d)02 (5)02 (6)01 (7) 01(8a)00 (8p)02 (9)02 (11p)02 (12a)00 (12p)00," MU 前Ant, 后Post, 小弯侧Less,",60,50,45,,R1,5.86,4.2,1.08,131.0,288.0,3.51,25.0,20.0,124.0,119.0,26.0,12.15,4.38,70.0,304.0,42.0,28.0,13.8,5.8,84.0,237.0,70.4,36.2,21.1,1.71,0.2,7.5,20.5,3.4,0.653,3.37,12.1,68.8,7.76,15.14,2.3, 未做,无,, P0,H0, 未做, CMET-， Vimentin-， VEGF-， S-100（神经侵犯） CD34、D2-40(未见),,,,,70.59789750328515,1519988
1519961,陈小凤,603688,女,42,T3,N2,M0, ⅢA,1,3,2.0,0.0,0.0,0.0, 慢性炎症（+）,4.0,30,中间型（int）,INFb,0.0,,,,,,,2.0,2015-06-29,2021-06-21,1,,,XELOX,,,,,,6, 低粘附腺癌70%， 管状腺癌（中分化【G2】【tub2】20%， 粘液腺癌（muc）10%， Lauren弥漫型,G2, (1a)02 (1b)00 (3a)313 (3b)11 (4sb)00 (4d)08 (5)00 (6)01 (7)00 (8a)01 (8p)01 (9)01 (11p)01 (12a)00 (14v)00 (19)01," M（胃体部）, 小弯侧Less,",30,25,10, R0 D2,,13.15,11.36,1.03,138.0,258.0,2.91,15.0,25.0,167.0,84.0,4.0,12.03,4.46,68.0,275.0,44.0,24.0,4.9,4.7,60.0,159.0,68.5,54.4,11.9,4.57,0.2,9.7,19.5,0.8,0.935,1.17,9.39,86.2,4.34,24.93,2.27, 未做,无, 无, P0,H0, 未做, CMET（弱+） Vimentin-， VEGF-， CK+， S-100（未见） CD34、D2-40(未见),,,,,71.74770039421813,1519961
1519949,王运锋,604486,男,70,T3,N2,M0, ⅢA,1,3,,0.0,0.0,0.0,,4.0,19,,,1.0,,,,,,,2.0,2015-06-29,2018-01-18,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)01 (2)02 (3a)25 (3b)11 (4sa)00 (4sb)00 (4d)00 (5)00 (6)02 (7)01 (8a)01 (8p)00 (9)02 (11p) 11(12a)01," M（胃体部）, 小弯侧Less,",55,40,10, R0 D2,,10.37,6.03,1.96,143.0,243.0,3.61,18.0,25.0,154.0,102.0,25.0,11.16,4.37,73.0,302.0,42.0,31.0,5.6,6.0,88.0,269.0,64.4,40.1,21.0,1.91,1.0,7.5,24.7,2.6,0.633,6.42,13.2,30.6,10.75,41.07,1.24, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(弱+),,,,,30.683311432325887,1519949
1519986,杨井义,603416,男,63,T2,N1,M0, ⅡA,1,3,0.0,1.0,1.0,0.0, 肠化生+,1.0,18,中间型（int）,INFb,1.0,,,,,,,1.0,2015-06-29,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)04(3a)02 (3b) 11(4sb)02 (4d)00 (5)01 (6)07 (7) (8a) (8p) (9)01,LM 小弯侧Less 前Ant ,60,50,15, R0 D2,,6.53,3.24,2.69,151.0,238.0,2.12,35.0,33.0,182.0,82.0,53.0,13.46,4.74,67.0,302.0,41.0,26.0,4.6,5.1,85.0,512.0,79.0,33.0,43.4,0.76,0.5,6.05,13.7,2.1,1.83,1.29,11.9,42.4,1.99,14.79,1.12, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+) CD34(+)  D2-40(+),,,,,71.74770039421813,1519986
1519866,田永春,603781,男,48,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,14.0,30,中间型（int）,INFb,0.0,,,,,,,1.0,2015-06-29,2018-12-20,2,,,,,,,,,0, 乳头状癌（G1）（pap）50 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】50 Lauren肠型,G3, (1a)01 (1b)01 (3a)15 (3b)00 (4sb) 11(4d)1014 (5)22 (6)00 (7)00 (8a)01 (8p)01 (9)00 (11p)03(12a)01,L（幽门窦部） 前Ant 后Post ,50,35,10, R0 D2,,8.61,4.98,2.92,154.3,231.0,3.68,29.0,28.0,196.0,72.0,26.0,7.1,2.27,43.0,146.0,43.0,22.0,5.3,3.8,67.0,278.0,77.3,48.7,23.0,2.12,3.7,16.7,5.0,9.3,0.664,1.26,6.94,88.4,5.59,13.88,7.88, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+)  S100(+),,,,,41.72141918528252,1519866
1519584,曲振芳,603677,男,63,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+,4.0,24,中间型（int）,INFb,1.0,,,,,,,1.0,2015-06-25,2020-12-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren肠型,G2, (1a)00 (1b)04 (3a)01 (3b)01 (4sb)00 (4d)14 (5)01 (6)34 (7)06 (8a)00 (8p)00 (9)02 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,50,10, R0 D2,,5.95,3.72,1.7,146.2,228.0,3.4,15.0,21.0,249.0,78.0,11.0,9.81,3.17,67.0,214.0,39.0,28.0,4.8,5.5,80.0,150.0,,,,,,,,,,,,,5.17,27.79,1.43,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,65.76872536136662,1519584
1520140,程力军,603700,男,63,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,8.0,20,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-06-30,2017-08-09,2,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren混合型,G3, (11p)00 (9)00 (8p)00 (7)02 (6)23 (5)01 (4d)12 (4sb)00 (1a)22 (3b)00 (3a)310 (1b)00," LM 小弯侧Less,",50,50,10, R0 D2+,,4.15,1.81,1.71,129.0,80.0,2.27,29.0,47.0,155.0,101.0,24.0,18.31,8.4,65.0,106.0,32.0,33.0,5.0,6.8,71.0,402.0,66.1,393.0,17.4,2.26,0.6,10.7,21.1,0.5,1.88,3.82,16.9,17.3,3.89,25.25,2.62,,无,, P0,H0, 未做,CK + Vimentin+  VEGF+ CMET+,,,,,25.328515111695136,1520140
1520193,王绅福,604883,男,57,T1b,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,33,中间型（int）,INFa,2.0,,,,,,,1.0,2015-07-01,2021-05-25,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (5)02 (8a)01 (7)01 (8p)01 (6)01 (9)01 (11p)05 (1a)01 (1b)01 (3a)011 (3b)00 (4d)08 (4sb)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",20,20,0.4, R0 D2,,4.27,2.36,1.47,146.7,119.0,2.8,20.0,24.0,150.0,78.0,9.0,23.78,9.94,59.0,328.0,39.0,20.0,4.5,5.9,62.0,370.0,73.1,25.4,45.2,0.56,0.3,9.5,15.4,3.1,0.652,1.14,6.08,23.9,2.51,7.05,0.998,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,70.79500657030223,1520193
1520192,许财,603459,男,77,T3,N2,M0, ⅢA,1,2,,1.0,1.0,0.0, 正常,3.0,9,中间型（int）,INFa,1.0,,,,,,,0.0,2015-07-01,2021-06-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2,肿物旁24 (1a)01 (1b)00 (3a)01 (4sb)00 (4d)0 (5)00 (6)13 (7)00 (8a)00 (9)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,35,12, R0 D1+,,8.81,5.85,2.01,134.0,202.0,2.85,16.0,24.0,130.0,82.0,12.0,17.14,7.3,65.0,196.0,37.0,28.0,5.0,9.5,92.0,330.0,68.9,33.1,32.3,1.02,0.2,1.5,26.7,2.4,2.09,0.844,12.7,68.5,1.37,6.26,8.69,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+,,,,,71.1892247043364,1520192
1520391,张国明,603618,男,68,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,24,中间型（int）,INFa,1.0,,1.0,1.0,,,,1.0,2015-07-02,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)08 (3b)02 (4sb)00 (4d)05 (5)00 (6)01 (7)01 (8a)02 (8p)01 (9)01 (11p)01 (12a)01,L（幽门窦部） 小弯侧Less 前Ant 后Post ,60,50,15, R0 D2,,6.19,3.23,2.29,115.0,205.0,4.23,21.0,28.0,162.0,62.0,10.0,5.98,2.11,66.0,182.0,40.0,26.0,5.4,6.4,85.0,252.0,69.5,31.1,28.5,1.09,0.6,20.6,7.6,1.3,0.848,2.4,10.5,12.2,1.83,6.21,1.37, 未做,无,, P0,H0, 未做,ck(+)  vimentin(部分+)  VEGF(弱+)  cMET(+)  S100(+),,,,,71.6491458607096,1520391
1520967,马子萍,604558,女,53,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,26,中间型（int）,INFa,0.0,,1.0,,,,,1.0,2015-07-07,2021-05-25,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a)03 (1b)04 (3a)00 (3b)00 (4sb)02 (4d)04 (5)00 (6)03 (7)01 (8a)02 (8p)03 (9)01 (11p、12a)03," M（胃体部）, 小弯侧Less,",10,10,2, R0 D2+,,5.71,3.99,1.02,80.0,373.0,5.7,46.0,53.0,275.0,76.0,16.0,6.97,3.53,83.0,80.0,39.0,44.0,4.6,2.7,50.0,124.0,77.6,53.3,20.2,2.64,0.1,6.2,14.7,2.6,2.11,3.78,26.3,47.0,2.31,3.21,0.855,,无, 无, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+,,,,,70.59789750328515,1520967
1521650,王树英,603831,女,73,T3,N2,M1, Ⅳ,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,3.0,14,中间型（int）,INFc,1.0,,,,,,,1.0,2015-07-14,2017-02-08,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】45 粘液腺癌（muc）30 乳头状癌（G1）（pap）25 Lauren混合型,G2, (1a)00 (1b)00 (3a)29 (3b)00 (4d)03 (4sb)01 (5)00 (6)00 大网旁11 3b软组织内可见一枚癌结节," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,80,20,,R2,4.25,2.26,1.37,92.0,236.0,3.16,16.0,22.0,129.0,133.0,41.0,4.48,2.12,53.0,183.0,33.0,20.0,4.1,4.8,66.0,305.0,67.3,25.1,36.0,0.7,1.7,7.7,21.1,0.6,0.688,0.926,7.3,84.4,1.77,34.53,33.78,,粟粒状, 无, p1盆(M1 PER),H0, 未做,CK + Vimentin (-) VEGF(-) CMET(+) ,,,,,18.889618922470433,1521650
1520522,周荫祥,604399,男,75,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,3.0,31,中间型（int）,INFa,0.0,,1.0,,,,,1.0,2015-07-03,2017-09-01,2,,,奥沙利铂 雷替曲塞,,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,肿物旁316 (1a)06 (1b)06 (2)01 (3a)00 (3b)00 (4sa)00 (4sb)00 (5)00 (6)00 (7)02 (8p)00 (9)00 (11p)00," UM 前Ant, 后Post, 小弯侧Less, SiewerⅢ,",60,60,10, R0 D2+,,6.1,2.7,2.82,99.0,188.0,2.94,13.0,19.0,160.0,72.0,10.0,7.07,2.94,63.0,125.0,35.0,28.0,5.1,6.9,84.0,371.0,48.3,23.3,23.4,0.99,0.2,11.5,38.5,2.2,0.615,3.6,12.3,121.0,5.05,15.6,2.09,,无,, P0,H0, 未做,CK + Vimentin - VEGF部分+ CMET+,,,,,25.985545335085412,1520522
1520465,郭洪海,604955,男,59,T4b,N2,M1, Ⅳ,1,4,2.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,14,中间型（int）,INFb,0.0,,,,,,,0.0,2015-07-02,2016-05-18,2,,,,,,,,,0, 粘液腺癌（muc）85 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)15 Lauren弥漫型,G3, (1a)00 (1b)00 (2)11(3a)05 (3b)00 (4sb)11 (4d)37 (5)00 (6)00 (7)00  (3a、3b)可见2枚癌结节," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,90,10,,R2,6.22,3.92,1.56,146.0,186.0,2.68,18.0,23.0,158.0,100.0,10.0,11.84,4.9,70.0,211.0,40.0,30.0,4.4,4.7,80.0,344.0,72.9,39.0,32.5,1.2,0.2,12.4,12.2,7.1,1.22,2.52,15.8,59.6,3.67,22.68,6.42,,无,, p1局腹膜(M1 PER),H0, 未做,CK + Vimentin - VEGF- CMET-,,,,,10.545335085413928,1520465
1522543,李占东,604606,男,75,T4b,N3a,M0, ⅢC,1,3,0.0,0.0,0.0,1.0, 肠化生+,7.0,55,中间型（int）,INFa,1.0,,,,,,,1.0,2015-07-22,2016-11-25,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)13 (1b)03 (3a)00 (3b)01 (4d)312 (4sb)02 (5)12 (6)28 (7)05 (8a)03 (8p)05 (9)06 (11p)03 (12a)02, L（幽门窦部） 小弯侧Less 大弯侧Gre  后Post ,50,40,10,R0 D2,,4.04,2.81,0.92,92.5,299.0,3.1,24.0,31.0,107.0,58.0,10.0,5.66,3.58,53.0,142.0,33.0,20.0,8.9,8.3,87.0,218.0,71.0,50.9,16.6,3.07,0.5,10.5,13.0,2.3,0.618,1.71,7.23,72.5,38.69,9.62,1.21, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(-)， S100(+) D2-40（-）,,,,,16.16294349540079,1522543
1521106,陈发葵,602226,男,66,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,15,,,3.0,,,,,,,0.0,2015-07-08,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 （GIST）,G2, (8a)01 (3a)03 (1b)00 (12a)01 (5)02 (1a)02 (4sb)01 (8p)02 (6)00 (3b)00 (4d)02 (7)01," L（幽门窦部）, M（胃体部）, 小弯侧Less,",20,20,20, R0 D2,,12.51,8.62,2.65,145.0,433.0,2.63,23.0,29.0,188.0,65.0,24.0,15.21,6.15,69.0,235.0,38.0,31.0,4.3,4.8,64.0,273.0,50.9,31.4,17.0,1.85,2.2,8.1,37.5,1.8,1.03,3.44,16.0,50.0,2.49,17.99,0.99,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,71.4520367936925,1521106
1520853,蒋宜萍,606404,女,48,T1a,N2,M0, ⅡA,1,2,1.0,0.0,0.0,0.0, 慢性炎症（+）,3.0,14,硬型（sci）,INFb,1.0,,,,,,,1.0,2015-07-07,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)00 (1b)00 (3a)06 (3b)11 (4sb)00 (4d)11 (5)01 (6)12 (7)02 (8a)00 (8p)00 (9)01 (11p)00," LM 前Ant, 后Post, 小弯侧Less,",15,10,8, R0 D2+,,5.87,3.07,2.28,110.0,268.0,2.38,12.0,18.0,187.0,59.0,8.0,12.37,3.64,65.0,255.0,40.0,25.0,5.5,4.9,74.0,258.0,71.4,46.3,21.6,2.14,0.7,7.3,19.5,2.5,2.44,1.96,8.68,18.4,1.8,1.57,3.4,,无, 无, P0,H0, 未做,CK + Vimentin –  VEGF- CMET+,,,,,71.48488830486203,1520853
1520811,齐连升,604590,男,56,T4b,N3a,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+,12.0,24,中间型（int）,INFb,0.0,,,,,,,1.0,2015-07-06,2017-01-04,2,,,XELOX,XELOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3," (1a)01 (1b)01 (3a) 00(3b)11 (4sb)01 (4d)11 (5)00 (6) 79(7)00 (8a)12 (8p)01 (9)01 (11p)26 (12p)00,3b可见2枚癌结节"," LM 小弯侧Less, 前Ant,",45,35,15,,R1,7.75,4.02,3.11,108.0,247.0,3.35,22.0,18.0,174.0,65.0,18.0,25.81,8.6,67.0,309.0,41.0,26.0,6.7,4.8,94.0,260.0,39.1,31.6,30.1,1.05,0.2,9.6,20.5,4.0,0.498,2.1,10.7,72.4,2.62,53.79,3.19, 未做,无, , P0,H0, 未做, CMET+， Vimentin-， VEGF-， CK+ S-100 （神经染色）CD34，D2-40(脉管染色),,,,,18.00262812089356,1520811
1520675,邓文库,604261,男,51,T3,N2,M0, ⅢA,1,1,1.0,0.0,0.0,1.0, 慢性炎症（+）,4.0,46,中间型（int）,INFc,3.0,,,,,,,1.0,2015-07-06,2021-05-21,1,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】60 粘液腺癌（muc）40,G2, (1a) (1b)17 (3a)01 (3b)16 (4sb)01 (4d)110 (5) 12(6)06 (7)01 (8a)04 (8p)01 (9)01 (11p)01 (12a)02,LM 前Ant 大弯侧Gre  ,130,100,15, R0 D2,,8.2,4.13,3.28,155.3,282.0,2.78,17.0,18.0,147.0,61.0,27.0,9.61,3.34,65.0,420.0,41.0,24.0,4.6,7.4,88.0,358.0,72.9,41.7,21.7,1.92,0.1,11.3,14.4,3.6,0.793,1.52,10.3,40.7,3.7,16.24,69.87, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+) S100(+),,,,,70.4993429697766,1520675
1521621,周彩艳,604579,女,42,T2,N0,M0, ⅠB,1,2,,0.0,,1.0, 慢性炎症（+）,0.0,34,中间型（int）,INFc,1.0,,,,,,,1.0,2015-07-13,2021-06-21,1,,,,,,,,,0, 低分化腺癌（G3)(por)65%， 低粘附腺癌35%， Lauren混合型,G3, (12b)00 (10)04 (11d)02 (11p)01 (4sb)00 (2)04 (6)00 (3b)00 (12a)00 (8a)02 (5)00 (8p)02 (9)00(7)01 (3a)00 (1a)06 (1b)05 (4d)07 (19)00 ," U（胃底部）, 前Ant,",25,20,8, R0 D2,,6.45,4.84,1.05,101.7,294.0,2.33,8.0,27.0,262.0,38.0,8.0,10.1,2.52,71.0,249.0,41.0,30.0,4.5,5.3,59.0,125.0,63.9,46.3,12.0,3.86,0.8,14.0,19.6,15.8,2.45,2.18,14.7,1316.0,1.01,4.67,1.5, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin-， VEGF-， CK+ S-100（见神经侵犯） CD34、D2-40(未见),,,,,71.28777923784494,1521621
1528839,许武德,605022,男,61,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,0.0, 异型增生+,3.0,37,中间型（int）,INFa,0.0,,,,,,,2.0,2015-09-15,2022-09-01,1,,,SOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)05 (1b)01 (9)01 (6)34 (8a)03 (4sb)00 (7)02 (8p)04 (3a)04 (4d)02 (11p)03 (14v)03 (5)03 (3b)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,20,5, R0 D2+,,5.58,4.12,0.77,73.6,184.0,6.06,24.0,27.0,158.0,89.0,18.0,12.86,6.4,54.0,74.0,30.0,24.0,5.9,5.4,58.0,216.0,59.3,26.3,23.4,1.12,0.1,23.5,16.7,8.7,1.04,0.896,8.35,8.8,6.59,24.09,1.44, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET弱（+）,,,,,83.54139290407359,1528839
1521129,王树林,605017,男,45,T3,N2,M0, ⅢA,1,4,2.0,1.0,,1.0, 肠化生+,6.0,23,中间型（int）,INFc,1.0,,,,,,,1.0,2015-07-08,2017-05-24,2,,,,,,,,,0, 低粘附腺癌85 低分化腺癌（G3)(por)15,G3, (1a)01 (1b)03 (2)03 (3a)12 (3b)00 (4sa)00 (4sb)00 (4d)33 (5)00 (6)00 (7)24 (8a) (9)03 (8p)01 (11p)03," LMU 前Ant, 大弯侧Gre, 小弯侧Less,",80,80,20, R0 D2,,4.33,2.14,1.82,129.8,253.0,2.68,16.0,22.0,144.0,59.0,9.0,18.68,6.73,62.0,291.0,39.0,23.0,4.8,4.2,90.0,365.0,71.9,43.3,20.7,2.09,0.6,6.1,18.4,3.4,0.535,1.25,9.66,11.7,0.2,25.59,1.45,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF- CMET+,,,,,22.536136662286463,1521129
1521183,李宝珍,606459,男,72,T4b,N3b,M0, ⅢC,1,4,2.0,1.0,,1.0, 慢性炎症（+）,19.0,39,中间型（int）,INFb,1.0,,,,,,,1.0,2015-07-09,2016-06-07,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (5) 11(6)37 (7)11 (8a)01 (8p)22 (9)24 (11p)07 (1a)00 (1b)15 (3a)56 (4sb)01 (4d)44," LMU 小弯侧Less, 后Post, 前Ant,",90,70,20, R0,,8.57,5.03,2.75,166.3,298.0,3.21,23.0,26.0,212.0,64.0,14.0,8.93,2.99,60.0,215.0,37.0,23.0,4.7,5.7,60.0,213.0,59.0,30.8,23.3,1.32,1.3,5.4,33.0,3.1,0.754,2.45,9.05,341.0,2.51,17.12,11.54, 未做,无, 无, P0,H0,, CMET+ Vimentin- VEGF- CK+ S-100 CD34 D2-40(可见脉管瘤栓和神经侵犯),,,,,10.972404730617608,1521183
1521321,李贵彬,604847,男,50,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,21,中间型（int）,INFa,1.0,0.7,,,,,,1.0,2015-07-09,2021-05-17,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)08 (4d)06 (5)00 (6)03 (7)00 (8a)03 (9)00 (11p)01, L（幽门窦部） 前Ant ,15,12,8, R0 D2,,9.12,4.97,3.21,151.1,203.0,1.95,30.0,21.0,130.0,66.0,77.0,8.33,2.34,71.0,416.0,43.0,28.0,4.9,6.7,91.0,303.0,53.7,39.8,10.7,3.72,0.3,24.1,20.2,2.0,0.802,3.08,12.3,7.07,4.43,16.49,1.12, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+),,,,,70.26938239159001,1521321
1521233,杨成安,606193,男,63,T2,N0,M0, ⅠB,1,2,0.0,0.0,,0.0, 异型增生+,0.0,14,中间型（int）,INFb,0.0,,,,,,,0.0,2015-07-09,2021-05-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)， Lauren肠型,G3, (1a)03 (1b)00 (3a)00 (3b)00 (4sb)04 (4d)01 (5)01 (6) 00(7)01 (8a)01 (9)01 (11p)02 (12a)00," SiewerⅡ,",20,15,15, R0 D2,,7.01,3.45,3.15,163.0,283.0,2.15,31.0,26.0,146.0,68.0,27.0,8.38,2.8,74.0,356.0,43.0,31.0,5.7,3.14,78.0,339.0,69.3,40.0,23.1,1.73,0.1,8.6,20.7,5.6,1.12,3.5,11.1,59.4,2.11,15.65,0.879, 未做,无, 无, P0,H0, 未做," CMET-, Vimentin-, VEGF-, CK+, S-100(神经染色) CD34、D2-40(脉管染色)",,,,,70.40078843626806,1521233
1521284,胡德兰,607139,女,51,T4b,N2,M0, ⅢB,1,1,1.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,24,中间型（int）,INFc,0.0,,,,,,,1.0,2015-07-09,2016-06-07,2,,,XELOX,,,,,,6, 粘液腺癌（muc）60 低粘附腺癌40 Lauren混合型,GX,大弯00 (5)11 (7)00 (6)34 (4d)00 (1a)01 (1b)00 (3a)013 (4sb)00 (3b)01 (8a)11 (8p)01 (9)02 (11p)00," LD 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,45,10,,R1,8.25,4.94,2.39,122.0,381.0,2.68,19.0,26.0,170.0,138.0,14.0,7.43,2.75,64.0,226.0,41.0,23.0,4.9,3.8,55.0,254.0,,,,,,,,,,,,,34.53,6.79,79.5,,无, 无, P0,H0, 未做,CK + Vimentin –  VEGF- CMET+,,,,,10.972404730617608,1521284
1521299,王林,600833,男,60,T3,N3a,M0,ⅢB,1,4,2.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,7.0,19,中间型（int）,INFc,0.0,,1.0,1.0,,,,1.0,2015-07-09,2019-05-01,0,,,,,,,,,0, 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren弥漫型,G3, (1a)00 (1b)00 (2)01 (3a)00 (3b)01 (4sa)03 (4sb)34 (4d)22 (5)00 (6)01 (7)00 (8a)00 (8p)02 (9)01 (11p)01 小弯12 肿物旁11,MU 小弯侧Less 前Ant 后Post ,55,55,5, R0 D2,,5.75,3.1,1.97,147.7,231.0,2.38,23.0,26.0,176.0,100.0,15.0,18.66,7.1,68.0,240.0,43.0,25.0,4.4,5.8,79.0,296.0,52.6,32.2,17.4,1.85,0.7,6.6,37.5,1.9,0.895,0.724,10.1,61.7,5.14,0.918,6.69, 未做,无,, P0,H0, 未做,ck(+)  vimentin(+)  VEGF(部分弱+)  cMET(+),,,,,45.729303547963205,1521299
1521596,杨振芳,606432,男,68,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+） 异型增生+,0.0,29,中间型（int）,INFa,0.0,,1.0,,,,,0.0,2015-07-13,2018-10-20,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (3a)010 (6)01 (7)01 (8a)00 (8p)03 (9)03 (11p)00 (4sb)01 (12a)00 (12b)00 (3b)03 (5)00 (4d)05," M（胃体部）, 小弯侧Less,",60,40,2, R0 D2,,5.85,3.15,1.93,135.5,188.0,3.59,21.0,20.0,155.0,86.0,20.0,10.48,3.91,72.0,198.0,30.0,30.0,7.0,4.5,71.0,164.0,67.1,35.5,25.7,1.38,0.4,8.2,23.6,4.4,1.91,2.92,13.9,71.6,5.34,36.7,2.35, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（部分+）、 CMET（-）,,,,,39.25755584756899,1521596
1522239,王殿军,604688,男,44,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,30.0,39,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-07-20,2021-05-21,1,,,替吉奥单药,,,,,,4, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)02 (1b)12 (2)02 (3a)11 11 (3b)11 (4sa)00 (4sb)00 (4d)44 (5)11 (6)23 (7)22 (8a)11 (8p)11 (9) 11(11p)14 (12a)33 (16a2)11, LM 后Post 小弯侧Less 大弯侧Gre  ,18,10,8, R0 D2,,6.08,1.8,3.66,105.0,262.0,2.91,25.0,45.0,195.0,38.0,5.0,20.24,4.53,68.0,160.0,40.0,28.0,4.3,4.9,84.0,216.0,52.7,39.1,11.6,3.37,0.2,20.7,22.9,0.2,1.09,2.99,13.1,10.4,20.31,49.67,144.8, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,70.03942181340341,1522239
1521617,张成兰,603465,女,69,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,21,中间型（int）,INFa,0.0,,,,,,,1.0,2015-07-13,2020-10-06,1,,,卡佩他滨,XELOX,XELOX,XELOX,,,4, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)00 (3a)02 (3b)01 (4sb)02 (4d)01 (6)15 (7)05 (8a)01 (8p)00 (9)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,50,10, R0 D2,,7.08,4.93,1.42,90.9,270.0,2.8,14.0,21.0,150.0,85.0,8.0,4.73,1.66,60.0,190.0,34.0,26.0,5.4,3.3,82.0,140.0,74.0,44.6,25.4,1.76,0.1,11.0,10.9,2.5,1.24,2.04,10.5,147.2,3.3,16.56,0.975,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,62.81208935611038,1521617
1521417,赵明明,607174,女,36,T1b,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,27,中间型（int）,INFb,0.0,,,,,,,,2015-07-10,2021-07-22,1,,,SOX,,,,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)03 (1b)01 (3a)04 (3b)00 (4sb)00 (4d)03 (5)00 (6)01 (7)03 (8a)03 (8p)04 (9)02 (11p)02 (12a)00,L（幽门窦部） 小弯侧Less 后Post ,18,15,5,R0 D2,,5.81,3.79,1.55,121.2,262.0,2.41,10.0,15.0,135.0,69.0,13.0,8.53,2.96,64.0,260.0,40.0,24.0,4.5,5.1,76.0,209.0,81.5,56.7,20.6,2.75,0.4,10.6,6.6,4.3,1.46,1.04,10.2,5.81,1.85,33.74,0.7444, 未做,无,无, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,72.40473061760841,1521417
1521517,李树林,606719,男,73,T3,N2,M0, ⅢA,1,5,0.0,0.0,,0.0, 肠化生+,3.0,16,硬型（sci）,INFa,2.0,,,,,,,0.0,2015-07-13,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)00 (3b)01 (4sb)00 (4d)15 (5)00 (6)11 (7)00 (8a)00 (8p)04 (9)0 (11p)01 (12a)00 (14v)12," L（幽门窦部）, 前Ant,",80,65,6,,R1,14.34,13.01,0.94,111.4,293.0,3.51,16.0,18.0,143.0,83.0,9.0,8.64,3.49,60.0,209.0,34.0,26.0,4.0,5.3,69.0,351.0,63.7,27.2,32.9,0.83,0.5,21.2,11.5,2.2,0.675,2.09,10.3,25.7,1.02,5.08,1.42, 未做,无, 无, P0,H0, 未做, CMET-， Vimentin- VEGF- CK+ S-100（神经染色） CD34、D2-40(脉管染色),,,,,71.28777923784494,1521517
1521718,王世和,605019,男,54,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+） 异型增生+,0.0,23,中间型（int）,INFa,2.0,,,,,,,0.0,2015-07-14,2018-10-15,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)02 (3a)02 (3b)00 (4sb)00 (4d)00 (5)00 (6)00 (7)04 (8a) 02(8p)01 (9) 02(11p)04 (12a) 00(14v)02肿物旁03," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",40,30,10, R0 D2,,6.62,67.3,1.66,165.0,296.0,2.9,18.0,21.0,161.0,77.0,7.0,22.49,7.56,75.0,289.0,42.0,33.0,3.8,7.1,90.0,361.0,52.8,33.1,14.1,2.35,0.3,12.6,33.2,2.6,0.825,2.42,15.4,28.9,5.37,1.58,1.32, 未做,无,,,H0, 未做, CMET- Vimentin- VEGF- CK+ S-100 CD34、D2-40（未见）,,,,,39.060446780551906,1521718
1521595,胡志学,606396,男,59,T3,N3a,M0,ⅢB,1,2,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,7.0,16,中间型（int）,INFa,0.0,,,1.0,,,,2.0,2015-07-13,2016-04-01,2,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】,G2,(3a)02 (3b)12 (4sb)03 (4d)00 (5)22 (6)12(8a)11 (7)  (8p) (9) (11p)24," L（幽门窦部）, 小弯侧Less,",50,50,15,,R2,8.88,6.23,1.96,147.9,248.0,3.43,17.0,24.0,158.0,65.0,12.0,12.16,4.17,68.0,369.0,40.0,28.0,4.9,7.6,81.0,368.0,71.2,24.7,43.6,0.57,0.2,3.9,22.4,6.3,0.809,1.42,10.3,51.3,9.38,50.44,1.47, 未做,无,, P0,H0, 未做,ck(+)  vimentin(部分+)  VEGF(-)  cMET(弱+),,,,,8.639947437582128,1521595
1521746,赵连春,607205,男,65,T3,N2,M0, ⅢA,1,3,1.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,3.0,41,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-07-14,2020-04-27,1,,,,,,,,,0, 低粘附腺癌90% 低分化腺癌（G3)(por)10% Lauren混合型,G3, (1a)00 (1b)06 (3a)07 (3b)11 (4sb)01 (4d)06 (5)02 (6)28 (7)00 (8a)06 (9)01 (11p)03," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",30,30,10, R0 D2,,7.95,5.29,1.82,146.6,225.0,2.73,29.0,29.0,161.0,53.0,15.0,9.31,3.84,72.0,324.0,39.0,33.0,4.5,6.8,112.0,408.0,83.9,42.1,32.5,1.3,0.4,5.4,9.1,16.6,0.629,1.06,16.3,30.9,1.77,11.33,1.32, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）,,,,,57.45729303547963,1521746
1521666,高淑珍,600804,女,67,T4b,N0,M0, ⅢA,1,3,1.0,1.0,1.0,0.0, 异型增生+,0.0,13,硬型（sci）,INFa,1.0,,,,,,,1.0,2015-07-14,2021-06-21,1,,,,,,,,,0, 低分化腺癌（G3)(por)90% 粘液腺癌（muc）10% Lauren混合型,G3, (1a)00 (1b)00 (3a)06 (3b)00 (4sb)00 (4d)00 (5)00 (6)01 (7)01 (8a)01 (8p)03 (9)00 (11p)00 (12a)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",70,50,20, R0 D2,,6.69,3.57,2.36,90.0,572.0,2.68,15.0,18.0,133.0,129.0,13.0,5.81,2.19,58.0,256.0,34.0,24.0,4.6,6.7,70.0,421.0,71.5,47.6,19.9,2.39,0.1,16.9,9.2,1.3,0.887,1.73,6.91,5.0,0.704,4.02,3.06, 未做,无, 无, P0,H0, 未做, CK（+） Vimentin（-） VEGF（-） CMET（+）,,,,,71.25492772667542,1521666
1521719,孙焱,604811,女,40,T1b,N0,M0,ⅠA,1,0,1.0,1.0,1.0,0.0, 肠化生+,0.0,31,中间型（int）,INFa,3.0,,,,,,,1.0,2015-07-14,2021-05-25,1,,,XELOX,,,,,,6, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)01 (1b)01 (3a)02 (3b)00 (4sb)03 (4d)05 (5)00 (6)04 (7)02 (8a)00 (8p)01 (9)01 (10)05 (11p)01 (14a)02 (14v)03," L（幽门窦部）, 小弯侧Less,",30,15,, R0 D2+,,4.76,2.74,1.66,121.4,190.0,2.45,15.0,23.0,140.0,44.0,7.0,17.96,6.78,74.0,231.0,39.0,35.0,5.3,4.1,46.0,231.0,,,,,,,,,,,,,1.02,11.05,0.976,,无, 无, P0,H0, 未做,CK + Vimentin (-) VEGF(-) CMET(+) ,,,,,70.36793692509855,1521719
1521858,丛宝金,607300,男,58,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,23,中间型（int）,INFa,0.0,,1.0,1.0,,,,1.0,2015-07-15,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (5)00 (6)00 (7、8a、8p、9、11p)07 (4d)01 (1a)00 (1b)00 (3a)011 (4sb)00 (3b)00 肿物旁04," LM 前Ant, 大弯侧Gre, 小弯侧Less,",60,60,20, R0 D2+,,3.55,2.21,0.93,59.5,286.0,3.43,18.0,20.0,87.0,64.0,29.0,10.67,4.7,63.0,187.0,36.0,27.0,5.4,6.0,69.0,363.0,71.1,38.5,27.7,1.39,0.2,11.8,15.2,2.7,0.466,2.39,10.8,29.4,2.44,3.02,9.28,,无,, P0,H0, 未做,CK + Vimentin (灶+) VEGF(部分弱+) CMET(+) ,,,,,85.57818659658344,1521858
1521737,孙日久,607153,男,75,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 异型增生+,5.0,41,中间型（int）,INFc,1.0,,1.0,,,,,1.0,2015-07-14,2015-09-18,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】50 低粘附腺癌50 Lauren混合型,G3, (1a)03 (1b)03 (3a)00 (3b)03 (4sb)00 (4d)03 (5)411 (6)01 (7)01 (8a)12 (8p)05 (9)06 (11p)03 (12a)00,LD 前Ant 后Post 大弯侧Gre  小弯侧Less ,30,50,8,R0 D2,,4.56,2.21,0.85,147.0,142.0,2.09,21.0,26.0,182.0,58.0,11.0,13.56,5.63,65.0,245.0,34.0,31.0,4.0,3.9,56.0,91.0,57.3,41.0,14.9,2.75,0.6,9.1,24.1,,1.1,1.82,16.3,108.0,1.64,5.91,1.73, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(+)， S100(+) D2-40（+）,,,,,2.1681997371879107,1521737
1521857,许向丽,607165,女,50,T3,N0,M0, ⅡA,1,3,2.0,0.0,,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,73,中间型（int）,INFb,0.0,,1.0,1.0,,,,1.0,2015-07-15,2018-01-31,2,,,XELOX,,,,,,3, 低粘附腺癌 Lauren弥漫型,GX, (4sb)03 (11p)04 (9)07 (8a)03 (8p)01 (1b)00 (1a)04 (3a)021 (15)01 (14v)02 (12a)00 (7)00 (5)01 (3b)02 (6)08 (4d)015," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,25,8, R0 D2+,,4.44,1.86,2.18,110.0,266.0,2.53,10.0,16.0,160.0,55.0,7.0,11.87,3.86,74.0,198.0,38.0,36.0,5.2,4.6,75.0,243.0,63.5,31.3,13.3,2.35,0.2,10.4,24.2,2.3,1.01,2.9,18.1,38.7,0.916,257.9,1.77,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF部分弱+， CMET+,,,,,30.584756898817343,1521857
1521932,陈丽红,607348,女,41,T4b,N1,M1, Ⅳ,1,4,2.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,2.0,11,中间型（int）,INFb,0.0,,1.0,1.0,,,,1.0,2015-07-16,2016-06-17,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (2)00 (3a)11 (3b)11 (4sb)00 (4sa)00 (4d)03 (5)00 (6)03 (7)00 (8a)03 24sa 软组织可见癌,LMU 小弯侧Less 大弯侧Gre  后Post ,130,120,18,,R2,5.81,4.05,1.26,128.0,339.0,4.58,11.0,12.0,126.0,67.0,14.0,9.51,3.21,66.0,264.0,37.0,29.0,4.9,4.0,76.0,242.0,,,,,,,,,0.713,3.94,9.25,5.4,15.27,4.24,14.24, 未做,无, 无,p1局腹膜(M1 PER),H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(+)，CD34(-)， S100(+) D2-40（-）,,,,,11.070959264126149,1521932
1521810,苏江,606526,男,60,T4b,N3b,M1, Ⅳ,1,3,2.0,0.0,,1.0, 慢性炎症（+）,24.0,38,硬型（sci）,INFc,0.0,,,,,,,1.0,2015-07-15,2019-09-02,0,,,TFP,紫杉醇联合替吉奥,紫杉醇联合替吉奥,紫杉醇联合替吉奥,紫杉醇联合替吉奥,紫杉醇联合替吉奥,6, 粘液腺癌（muc） Lauren弥漫型,GX, (1a)02 (1b)00 (3a)29 (3b)22 (4sb)00 (4d)11 (5)00 (6)11 (7)34 (8a)22 (8p)11 (9)01 (11p)34 小弯911," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,80,20,,R2,7.07,4.11,2.16,121.2,296.0,4.66,17.0,19.0,128.0,59.0,9.0,6.48,2.73,59.0,149.0,33.0,26.0,4.2,7.6,71.0,270.0,77.0,48.2,26.7,1.81,0.0,17.0,5.5,3.5,0.417,1.08,10.2,353.0,17.25,0.6,300.0,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET灶+,,,,,49.60578186596583,1521810
1523998,王玉莉,607366,女,55,T1b,N0,M0,ⅠA,1,0,0.0,1.0,,0.0, 异型增生+,0.0,17,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-08-03,2020-10-06,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)04 (3b)00 (4sb)00 (4d)00 (5)01 (6) 03(7) 01(8a)01 (8p)03 (9)02 (11p)01 (12a)00," M（胃体部）, 小弯侧Less,",40,25,10, R0 D2,,6.08,3.17,2.19,125.7,227.0,2.03,19.0,20.0,155.0,67.0,12.0,12.61,5.07,61.0,195.0,35.0,26.0,6.6,4.5,48.0,290.0,76.4,36.1,33.0,1.09,0.2,13.3,9.1,0.6,0.422,2.5,10.9,67.0,1.47,8.43,0.68, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF灶+ CK +S-100（神经染色） CD34、D2-40(脉管染色),,,,,62.12220762155059,1523998
1521931,尹玉和,606331,男,51,T2,N1,M0, ⅡA,1,2,1.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,22,中间型（int）,INFc,0.0,,1.0,1.0,,,,1.0,2015-07-16,2020-10-06,1,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3, (1a)01 (1b)00 (3a)00 (3b)01 (4sb)01 (4d)14 (5)00 (6)04 (7)03 (8a)02 (8p)03 (9)03," L（幽门窦部）, 前Ant, 小弯侧Less,",50,40,8, R0 D2+,,8.41,5.75,1.41,147.3,206.0,1.96,17.0,21.0,160.0,56.0,13.0,19.3,6.4,60.0,263.0,35.0,25.0,6.3,6.3,60.0,314.0,77.0,45.6,28.4,1.61,0.4,9.6,10.3,1.8,1.15,2.8,8.14,10.6,1.3,3.12,1.22,,无,, P0,H0, 未做,CK + Vimentin (部分+) VEGF(部分弱+) CMET(+) ,,,,,62.71353482260184,1521931
1522332,杨洪丽,607213,女,43,T1b,N0,M0,ⅠA,1,2,2.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,22,中间型（int）,INFb,0.0,,,1.0,,,,0.0,2015-07-20,2018-04-23,0,,,,,,,,,0, 低粘附腺癌75 低分化腺癌（G3)(por)25 Lauren弥漫型,G3, (3a)00 (3b)00 (4sb)01 (4d)05 (5)00 (6)00 (7)05 (8a)04 (8p)02 (9)01 (11p)02," L（幽门窦部）, 后Post, 小弯侧Less,",30,20,2, R0 D2+,,7.14,4.84,1.72,136.0,251.0,2.4,25.0,21.0,175.0,73.0,14.0,22.55,7.52,79.0,297.0,43.0,36.0,6.6,5.3,74.0,206.0,,,,,,,,,,,,,0.944,19.31,1.68,,无, 无, P0,H0, 未做,CK + Vimentin+ VEGF- CMET- ,,,,,33.11432325886991,1522332
1522059,梁凤有,606340,男,65,T4b,N1,M0, ⅢB,1,3,1.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,22,中间型（int）,INFc,0.0,,,,,,,0.0,2015-07-16,2020-10-06,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren混合型,G2, (1a)01 (1b)11 (2)07 (3a)04 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)00 (6)00 (7)00 (8a)00 (8p)00 (9)05 (11p)02 肿物旁02," U（胃底部）, 前Ant, 后Post, 小弯侧Less,",30,20,10, R0 D2+,,6.28,3.83,1.85,132.0,255.0,3.97,19.0,22.0,129.0,66.0,25.0,7.61,3.42,67.0,282.0,40.0,27.0,5.5,6.1,98.0,397.0,74.9,36.6,33.1,1.11,0.3,5.0,19.1,4.9,0.932,2.38,10.6,22.1,2.76,15.59,1.35,,无,, P0,H0, 未做,CK + Vimentin (-) VEGF(-) CMET(-) ,,,,,62.71353482260184,1522059
1522240,文亚芹,607234,女,53,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,41.0,67,中间型（int）,INFc,1.0,,,,,,,1.0,2015-07-20,2017-03-01,2,,,,,,,,,0, 粘液腺癌（muc）70% 低粘附腺癌30% Lauren弥漫型,GX,小湾33 (1a)34 (1b)55 (2)79 (3a)78 (3b)00 (4sa)01 (4sb)11 (4d)614 (5)00 (6)01 (7)67 (8a)0203 (9)13 (11p)02 (12a)00 (8p)03 (12p)01 (14v)00 (19)23," SiewerⅡ, 前Ant, 后Post, 小弯侧Less,",40,20,8, R0 D2+,,6.76,4.16,1.64,133.0,236.0,3.35,30.0,28.0,163.0,70.0,9.0,6.44,2.42,67.0,269.0,40.0,27.0,4.5,5.0,63.0,285.0,57.7,43.9,11.6,3.78,0.4,15.9,24.9,0.8,1.85,1.97,9.44,48.0,0.818,138.5,7.96, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,19.38239159001314,1522240
1522153,阚学民,606352,男,50,T4a,N3a,M0, ⅢB,1,2,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,7.0,10,中间型（int）,INFa,2.0,,,,,,,1.0,2015-07-17,2016-03-18,2,,,FOLFOX,FOLFOX,多西他赛 奥沙利铂 替吉奥,卡佩他滨单药,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,肿物旁69 (5)00 (6)00 (7)00 (8a)00 (8p)00 (9)11 (11p)00 (1a)00 (1b)00 (2)00 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)00," U（胃底部）, SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",30,30,6, R0 D2+,,7.39,4.81,2.12,141.0,248.0,4.9,25.0,23.0,167.0,139.0,33.0,10.86,4.18,65.0,230.0,43.0,22.0,4.9,5.7,75.0,446.0,67.9,31.5,29.9,1.05,0.3,5.9,24.6,3.7,0.298,0.598,7.32,5.0,11.33,18.99,4.51,,无,, P0,H0, 未做,CK + Vimentin (-) VEGF(-) CMET(+) ,,,,,8.04862023653088,1522153
1522403,郑海玉,607001,男,56,T4b,N2,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,6.0,27,中间型（int）,INFa,2.0,,,,,,,1.0,2015-07-21,2016-12-08,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,肿物旁11 (1a)01 (1b)00 (3a)13 (3b)17 (4sb)00 (4d)13 (5)00 (6)25 (7)02 (8a)01 (8p)02 (9)01 (11p)01 (14v)00," LM 前Ant, 后Post, 小弯侧Less,",55,50,12, R0 D2+,,5.76,3.78,1.27,118.7,266.0,4.03,11.0,14.0,116.0,93.0,13.0,7.13,2.29,57.0,191.0,35.0,22.0,6.3,6.2,77.0,336.0,,,,,,,,,,,,,626.4,5.12,1.41,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+ ,,,,,16.62286465177398,1522403
1522029,陈文江,604720,男,55,T2,N0,M0, ⅠB,1,1,0.0,0.0,,1.0, 肠化生+ 慢性炎症（+） 异型增生+,0.0,18,中间型（int）,INFa,0.0,,,1.0,,,,0.0,2015-07-16,2020-10-06,1,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) 01(1b)02 (2)03 (3a)02 (3b)02 (4sa)00 (4sb)01 (4d) 00(5) 00(6) 00(7)01 (8a)01 (8p)00 (9)02 (11p)03 (12a)00," U（胃底部）, 前Ant, 小弯侧Less,",25,20,10, R0 D2,,7.61,4.33,2.22,130.7,216.0,3.8,22.0,43.0,165.0,59.0,38.0,10.95,3.9,61.0,243.0,37.0,24.0,5.6,1.72,67.0,338.0,58.4,43.7,13.3,3.29,0.2,10.6,28.2,1.7,0.737,1.43,9.09,90.6,2.46,4.67,0.511, 未做,无, 无, P0,H0, 未做, CMET- Vimentin（部分+） VEGF- CK+ S-100（可见神经侵犯) CD34、D2-40(未见),,,,,62.71353482260184,1522029
1522341,吴美明,606732,男,43,T4b,N3a,M1, Ⅳ,1,3,2.0,1.0,,1.0, 异型增生+,11.0,32,中间型（int）,INFc,1.0,,,,,,,1.0,2015-07-20,2016-10-15,2,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)01 (3a)44 (3b)00 (4sb)00 (4d)24 (5)00 (6)22 (7)35 (8a)03 (8p)03 (9)01 (11p)05 (12a)00 (16a1)03," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",35,30,10, D2,R1,7.75,4.21,2.74,160.2,309.0,2.39,18.0,20.0,133.0,79.0,11.0,8.1,2.88,62.0,317.0,40.0,22.0,4.1,5.3,72.0,305.0,76.3,49.2,24.4,2.02,0.1,12.1,10.2,0.8,0.672,1.17,8.3,27.96,6.64,136.0,2.26,,无, 无, P0,H1单（M1 HEP), 未做, CK+， Vimentin- VEGF- CMET+,,,,,14.88173455978975,1522341
1522505,牛海清,607258,男,63,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,16,中间型（int）,INFa,0.0,,,,,,,1.0,2015-07-21,2018-04-19,0,,,SOX,XELOX,SOX,SOX,,,4, 管状腺癌（中分化【G2】【tub2】60 乳头状癌（G1）（pap）40 Lauren肠型,G2, (11p)01 (9)01 (8a)01 (8p)01 (7)01 (6)06 (5)00 (4d)03 (4sb)00 (3b)00 (3a)00 (2)00 (1b)02 (1a)00," UM 后Post,",50,40,10, R0 D2+,,5.58,3.11,1.95,127.1,291.0,3.53,23.0,22.0,122.0,100.0,52.0,16.64,6.26,74.0,287.0,40.0,34.0,6.1,4.9,109.0,360.0,,,,,,,,,,,,,2.96,23.55,3.51,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+ ,,,,,32.95006570302234,1522505
1522748,王在全,606860,男,73,T3,N1,M0, ⅡB,1,1,0.0,1.0,1.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,23,中间型（int）,INFa,2.0,,,,,,,1.0,2015-07-23,2016-10-07,2,,,XELOX,TX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)02 (3a)04 (3b)00 (4sb)00 (4d)00 (5)02 (6)06 (7)05(9) (11p)12 (8a) (12a) (9) (11p) 软组织可见癌, L（幽门窦部） 前Ant 小弯侧Less 后Post ,65,80,10, D2,R2,8.36,5.41,2.08,121.5,303.0,2.85,21.0,25.0,191.0,100.0,19.0,9.94,3.88,61.0,189.0,37.0,24.0,4.4,6.4,88.0,314.0,68.3,43.2,22.0,1.96,0.1,8.9,18.7,2.3,0.524,1.81,7.56,16.2,2.3,4.38,19.58, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(-) D2-40（+）,,,,,14.520367936925098,1522748
1523973,那秀朋,607810,男,61,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 异型增生+,7.0,30,中间型（int）,INFc,1.0,,,,,,,1.0,2015-08-03,2017-03-03,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70%， 低粘附腺癌30%， Lauren混合型,G3, (1a)00 (3a)33 (3b)11 (4sb)00 (4d)00 (5)00 (6)36 (7)08 (8a)04 (8p)03 (9)00 (11p)05 (12a)00 (1b)00," U（胃底部）, 后Post, 大弯侧Gre, 小弯侧Less,",40,50,10, R0 D2 ,,4.97,3.0,1.37,161.0,198.0,2.94,9.0,18.0,143.0,58.0,6.0,19.65,8.87,59.0,147.0,32.0,27.0,3.2,7.0,109.0,359.0,53.4,25.0,23.2,1.08,0.1,11.1,25.3,5.3,1.03,1.88,13.8,10.1,2.31,24.72,3.37, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ S-100（神经染色） CD34、D2-40( 脉管染色）,,,,,18.988173455978973,1523973
1522542,汪恒飞,606870,男,41,T1b,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,14,中间型（int）,INFa,1.0,,,,,,,1.0,2015-07-22,2020-10-06,1,,,口服替吉奥,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)04 (3b)00 (4sa)01 (4sb)00 (5)00 (6)01 (8a)01 (8p)01 (9)03 (4d)02 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",15,15,, R0 D2,,8.5,3.79,3.01,163.9,208.0,3.58,37.0,24.0,206.0,67.0,63.0,19.69,6.84,69.0,421.0,42.0,27.0,4.8,4.9,95.0,491.0,77.7,40.4,34.1,1.18,0.4,16.0,4.3,3.6,1.72,0.99,9.74,513.6,3.61,12.99,16.5,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,62.516425755584756,1522542
1522867,韩贵林,606606,男,51,T1b,N1,M0, ⅠB,1,0,1.0,0.0,,0.0, 肠化生+,2.0,18,中间型（int）,INFc,0.0,,,,,,,0.0,2015-07-23,2020-10-06,1,,,XELOX,,,,,,6," 管状腺癌（中分化【G2】【tub2】80%, 低粘附腺癌15%, 粘液腺癌（muc）5%, Lauren混合型",G2, (1a) (1b)02 (3a)02 (3b)02 (4sb)00 (4d) 05(5)01 (6)23 (7)02 (8a) (8p)01 (9)01 (11p)00," L（幽门窦部）, 前Ant,",20,15,5, R0 D2,,7.14,4.22,2.0,157.0,247.0,3.27,22.0,22.0,159.0,66.0,23.0,9.5,2.7,68.0,318.0,41.0,27.0,4.4,5.7,91.0,346.0,68.9,35.0,26.9,1.3,0.2,10.1,18.2,5.4,1.51,1.51,7.64,23.1,2.72,7.31,8.72, 未做,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF -CK+ S-100 CD34、D2-40(未见),,,,,62.48357424441524,1522867
1522852,刘明华,606901,女,62,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,29,中间型（int）,INFa,1.0,,,,,,,1.0,2015-07-23,2019-05-01,0,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)08 (3b)00 (4sb)02 (4d)16 (5)01 (6)00 (7)(9)08 (8a)00 (8p)01(11p)00 (13)02, LM 前Ant 后Post 大弯侧Gre  小弯侧Less ,100,90,20,RO D2,,8.38,5.64,2.09,111.0,267.0,4.66,20.0,22.0,151.0,74.0,19.0,6.72,2.38,66.0,171.0,36.0,30.0,6.4,5.4,55.0,30.4,72.2,33.3,29.3,1.14,0.1,13.7,13.4,4.8,0.509,3.18,13.7,7.31,1.01,11.17,1.7, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+) ,,,,,45.269382391590014,1522852
1522859,王福,607403,男,57,T1b,N1,M0, ⅠB,1,0,2.0,0.0,0.0,0.0, 肠化生+,2.0,25,硬型（sci）,INFc,0.0,,1.0,,,,,1.0,2015-07-23,2022-09-01,1,,,,,,,,,0, 低粘附腺癌80% 低分化腺癌（G3)(por)20% Lauren弥漫型,G3, (1a)04 (1b)04 (3a)00 (3b)00 (4sb)00 (4d)00  (5)00  (6)24 (7)02 (8a)01 (8p)07 (12a)03," L（幽门窦部）, 前Ant, 小弯侧Less,",30,20,10, R0 D2,,6.6,4.48,1.33,151.7,167.0,2.73,37.0,53.0,153.0,71.0,216.0,11.98,4.24,78.0,501.0,47.0,31.0,5.4,6.7,79.0,744.0,55.7,34.0,16.3,2.09,0.4,4.5,38.0,5.3,0.944,3.33,11.8,592.0,2.29,0.6,3.67, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）,,,,,85.31537450722733,1522859
1523108,付守芹,606903,女,65,T3,N2,M0, ⅢA,1,2,0.0,0.0,0.0,0.0, 肠化生+,3.0,26,中间型（int）,INFa,0.0,,,,,,,0.0,2015-07-27,2020-10-06,1,,,SOX,,,,,,4, 管状腺癌（高中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)01 (3a)02 (3b)00 (4sb)11 (4d)00 (5)16 (6)15 (7)01 (8a)02 (8p)03 (9) 00(11p)01(14v)02," LM 小弯侧Less,",35,35,6, R0 D2,,5.52,3.51,1.35,136.6,271.0,2.54,17.0,24.0,186.0,78.0,12.0,23.43,7.74,65.0,237.0,38.0,27.0,4.7,4.9,47.0,229.0,64.2,34.8,20.9,1.67,0.3,7.1,24.5,2.7,0.869,2.56,12.5,88.7,2.18,8.3,12.15, 未做,无,, P0,, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-),,,,,62.352168199737186,1523108
1522749,于仁祥,607283,男,66,T3,N0,M0, ⅡA,1,4,2.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,38,中间型（int）,INFb,0.0,,,,,,,0.0,2015-07-23,2016-11-15,2,,,替吉奥单药,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)04 (1b)00 (2)07 (3a)05 (3b)04 (4sa)00 (4sb)00 (4d)02 (5)00 (6)02 (7)04 (8a)00 (8p)06 (9)02 (11p)01," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,80,10, R0 D2,,9.33,6.81,1.57,132.2,234.0,2.95,48.0,30.0,209.0,192.0,98.0,14.03,5.25,65.0,252.0,37.0,28.0,4.4,7.9,69.0,351.0,76.7,44.3,26.6,1.67,0.1,8.4,12.4,2.4,1.74,2.39,13.0,53.6,2.27,0.6,8.77,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET-,,,,,15.801576872536137,1522749
1522784,吴绍宽,607272,男,62,T1b,N0,M0,ⅠA,1,0,1.0,1.0,,0.0, 肠化生+ 慢性炎症（+） 异型增生+,0.0,25,中间型（int）,INFa,0.0,,1.0,,,,,0.0,2015-07-23,2021-05-25,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】75 低粘附腺癌25,G3, (3a)01 (7)02 (6)00 (1b)01 (3b)01 (4sb)00 (1a)03 (4d)09 (5)00 (9)02 (8p)06," M（胃体部）, 前Ant,",35,30,, R0 D2,,6.7,3.57,2.37,155.8,227.0,2.68,20.0,25.0,147.0,78.0,18.0,13.47,5.29,66.0,340.0,39.0,27.0,5.8,9.7,82.0,254.0,69.6,41.2,25.2,1.63,0.2,10.7,18.6,2.5,1.04,2.7,13.2,364.0,2.25,4.51,1.31,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF部分弱+ CMET-,,,,,70.07227332457293,1522784
1522851,赵守卫,607237,男,55,T2,N2,M0, ⅡB,1,3,0.0,0.0,,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,5.0,21,中间型（int）,INFa,0.0,,1.0,,,,,1.0,2015-07-23,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 低分化腺癌（G3)(por)20 Lauren肠型,G3, (1a)02 (1b)00 (3a)25 (3b)00 (4sb)01 (4d)25 (5)11 (6)03 (7)00 (8a)02 (8p)01 (9)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,40,10, R0 D2,,7.22,4.71,2.0,134.1,246.0,2.63,17.0,20.0,175.0,65.0,14.0,10.05,3.92,57.0,219.0,36.0,21.0,5.0,6.5,64.0,236.0,64.5,38.6,21.6,1.79,0.2,11.6,21.2,4.5,0.738,1.88,9.14,11.7,1.93,6.37,2.61,,无, 无, P0,H0, 未做, CK+， Vimentin- VEGF部分弱+ CMET+,,,,,70.9592641261498,1522851
1522911,王福全,607326,男,67,T4b,N3b,M0, ⅢC,1,3,1.0,1.0,,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,20.0,34,中间型（int）,INFb,1.0,,,,,,,0.0,2015-07-24,2016-10-15,2,,,,,,,,,0, 低粘附腺癌80 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)15 粘液腺癌（muc）5 Lauren混合型,G3, (1a)02 (1b)11 (3a)01 (3b)00 (4sb)01 (4d)1414 (5)11 (6)36 (7)01 (8a)12 (8p)02 (9)00 (11p)01 (12a)02," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,60,10, R0 D2,,7.64,5.06,1.68,148.0,251.0,4.03,23.0,23.0,158.0,109.0,8.0,6.57,3.62,60.0,165.0,36.0,24.0,5.5,7.1,84.0,251.0,53.5,38.8,9.9,3.92,0.2,15.4,27.9,1.8,0.846,2.68,10.6,30.6,0.726,32.6,7.35,,无, 无, P0,H0, 未做, CK+ Vimentin- CMET- VEGF-,,,,,14.750328515111695,1522911
1524106,郑绪亮,607901,男,75,T3,N2,M0, ⅢA,1,1,1.0,1.0,1.0,1.0, 异型增生+,4.0,25,中间型（int）,INFb,1.0,,,,,,,1.0,2015-08-04,2017-02-03,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)75%， 粘液腺癌（muc）20%， 低粘附腺癌5%， Lauren混合型,G3,小弯03 (1a) 02(1b)00 (3a) 02(3b)00 (4sb)03 (4d)02 (6)12 (7)00(5.12a)22 (8a)14 (8p)02 (9)03 (11p)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,23,3, R0 D2,,5.93,3.95,1.4,135.5,157.0,2.41,10.0,17.0,175.0,60.0,7.0,7.47,3.26,66.0,216.0,39.0,27.0,4.7,3.8,83.0,279.0,76.4,36.1,33.0,1.09,0.2,13.0,9.1,0.5,0.422,2.5,10.9,67.0,4.71,7.81,2.78, 未做,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+ S-100(神经染色) CD34、D2-40(脉管染色),,,,,18.035479632063073,1524106
1523189,赵作成,607077,男,58,T2,N1,M0, ⅡA,1,3,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,1.0,40,中间型（int）,INFa,1.0,,1.0,,,,,1.0,2015-07-27,2021-06-21,1,,,,,,,,,0, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）30 Lauren肠型,G2, (1a) (1b) (3a) (3b)121 (4sb) (4d)016 (9)02 (16a1)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,25,5, R0 D2,,6.02,3.69,1.76,152.3,263.0,2.34,23.0,21.0,145.0,65.0,15.0,6.43,3.12,66.0,195.0,37.0,29.0,4.7,4.4,79.0,286.0,67.9,44.5,20.7,2.15,0.5,10.3,21.6,5.5,1.12,2.54,14.3,116.0,3.9,15.09,5.68,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF+ CMET+,,,,,70.82785808147175,1523189
1523283,李军,606952,男,67,T1b,N2,M0, ⅡA,1,0,0.0,0.0,0.0,0.0, 肠化生+,3.0,18,中间型（int）,INFc,2.0,,,,,,,1.0,2015-07-28,2020-10-06,1,,,SOX,SOX,SOX,SOX,替吉奥单药,,5, 管状腺癌（中分化【G2】【tub2】90 粘液腺癌（muc）10 Lauren肠型,G2, (1a)01 (1b)02 (3a)00 (3b)13 (4sb)00 (4d)01 (5)12 (6)01 (7)12 (8a)00 (8p) 01(9)03 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",50,45,3, R0 D2,,8.37,4.4,2.98,158.1,184.0,3.21,22.0,23.0,194.0,74.0,18.0,31.21,8.11,69.0,261.0,41.0,28.0,5.9,6.2,93.0,320.0,43.0,26.3,10.5,2.5,0.2,6.7,47.0,2.6,0.925,2.41,10.7,83.3,2.13,51.85,1.05, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+),,,,,62.319316688567675,1523283
1523203,于留全,607945,男,48,T2,N0,M0, ⅠB,1,3,2.0,0.0,0.0,0.0, 肠化生+,0.0,42,中间型（int）,INFc,1.0,,1.0,,,,,1.0,2015-07-27,2020-10-06,1,,,,,,,,,0, 粘液腺癌（muc）75 低粘附腺癌 15低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)02 (1b)03(3a)011(3b)01(4sb)01(4d)012(5)00(6)04(7)03(8a)01(8p)02(9)00 (11p)02,L（幽门窦部） 大弯侧Gre  前Ant 后Post ,70,50,10, R0 D2,,6.48,3.28,2.76,169.8,233.0,2.38,24.0,24.0,169.0,54.0,12.0,22.47,9.35,65.0,267.0,40.0,25.0,4.0,5.4,57.0,270.0,63.4,42.7,14.2,3.01,0.1,8.0,27.1,1.9,1.09,1.11,11.8,12.9,7.56,6.33,17.71, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+),,,,,62.352168199737186,1523203
1523889,王勤,607957,男,61,T3,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 肠化生+,6.0,28,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-08-03,2020-05-18,0,,,XELOX,,,,,,6," 低分化腺癌（G3)(por)80%, 低粘附腺癌20% Lauren弥漫型",G3, (1a) 00(1b)01 (3a)15 (3b)22 (4sb)03 (4d)04 (5)00 (6)14 (7)03 (8a)11 (8p)02 (9)01 (11p)01 (12a)11," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,80,10, R0 D2,,3.69,2.29,0.99,88.8,214.0,4.23,17.0,20.0,130.0,62.0,9.0,7.89,3.35,60.0,187.0,35.0,25.0,4.6,6.8,86.0,322.0,66.7,43.2,21.8,1.98,0.0,12.3,20.4,4.7,0.763,1.66,10.7,146.0,10.17,28.97,1.05, 未做,无, 无, P0,H0, 未做, CK +CMET+ Vimentin- VEGF灶+ S-100（神经染色） CD34、D2-40(脉管染色),,,,,57.49014454664914,1523889
1523640,黄振权,607118,男,61,T3,N1,M0, ⅡB,1,1,0.0,0.0,0.0,1.0, 异型增生+,1.0,47,中间型（int）,INFc,1.0,,,,,,,1.0,2015-07-30,2017-09-08,0,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)03 (1b)03 (3a)18 (3b)00 (4sb)02 (4d)06 (5)01 (6)05 (7)04 (8a)06 (8p)02 (9)03 (11p)01 (12p)03,M（胃体部） 前Ant 小弯侧Less ,40,25,6,R0 D2,,6.99,4.2,2.7,151.3,269.0,20.03,12.0,15.0,156.0,123.0,18.0,4.56,2.0,65.0,256.0,42.0,23.0,6.3,4.5,88.0,236.0,,,,,,,,,,,,,,,, 未做,, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(-)， S100(+) D2-40（-）,,,,,25.328515111695136,1523640
1523379,韩广荣,607819,男,56,T3,N3b,M0, ⅢC,1,3,0.0,1.0,,1.0, 肠化生+,29.0,37,中间型（int）,INFa,1.0,,,,,,,1.0,2015-07-28,2016-12-18,2,,,DP,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)12 (1b)01 (2)01 (3a)22 (3b)00 (4sa)00 (4sb)00 (4d)2224 (5)00 (6)12 (7)12 (8a)11 (8p)01 (9)00 (11p)00 (12a)11 软组织可见癌3911," LMU 前Ant, 后Post, 小弯侧Less, 大弯侧Gre,",80,50,10, R0 D2,,10.94,7.13,3.14,142.5,214.0,3.41,20.0,25.0,216.0,63.0,18.0,9.4,3.27,63.0,270.0,35.0,28.0,4.4,7.2,116.0,502.0,,,,,,,,,,,,,0.539,548.8,7.78,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,16.72141918528252,1523379
1523531,马金山,608109,男,63,T3,N0,M0, ⅡA,1,2,0.0,0.0,,0.0, 肠化生+,0.0,34,中间型（int）,INFa,0.0,,1.0,,,,,1.0,2015-07-29,2019-09-02,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)014 (3b)00 (4sb)00 (4d)03 (5)00 (6)07 (7)02 (8a) (8p)01 (9)02 (11p)00," LM 前Ant, 后Post, 大弯侧Gre,",60,45,15, R0 D2,,6.05,4.85,0.72,110.0,173.0,3.11,15.0,20.0,121.0,55.0,12.0,8.04,2.85,56.0,174.0,33.0,23.0,5.5,7.4,84.0,237.0,,,,,,,,,,,,,1.81,3.97,2.53,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF部分弱+ CMET+,,,,,49.14586070959264,1523531
1524432,张宜兰,605322,女,78,T1b,N0,M0,ⅠA,1,2,,,,,,0.0,25,,,,0.2,,,,,,,2015-08-06,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60%， 低粘附腺癌40%，,G3, (1a)01 (1b)03 (2)04 (3a)08 (3b)03 (4sa)00 (4sb) 00(7)00 (8a) 01(8p)03 (9)00 (10)00 (11p)02," SiewerⅢ, 后Post, 小弯侧Less,",30,20,8, R0 D2,,5.26,2.63,2.16,126.0,206.0,3.05,20.0,28.0,153.0,62.0,9.0,9.36,2.83,70.0,267.0,41.0,29.0,4.6,4.2,51.0,212.0,,,,,,,,,,,,,1.81,24.18,, 未做,无, 无, P0,H0, 未做," CK上皮+,CK8/18上皮+,EMA上皮+，villin上皮+,cyclinD1上皮+，CD20滤泡及部分滤泡间细胞+，CD3滤泡间细胞+，CD21示增生FDC网，CD10、BCL6生发中心+，BCL2滤泡生发中心-，Kappa，Lambda散在+，CD30散在+，",,,,,84.85545335085413,1524432
1523109,刘文华,606631,女,42,T3,N0,M0, ⅡA,1,2,2.0,0.0,,0.0, 肠化生+,0.0,31,中间型（int）,INFb,0.0,,,1.0,,,,0.0,2015-07-27,2020-10-06,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)00 (3a)08 (3b)02 (4sb)02 (4d)00 (5)01 (6)02 (7)03 (8a) (8p)03 (9)04 (11p)02 (12a)01 (14v)02," LM 前Ant, 后Post, 小弯侧Less,",40,40,12, R0 D2,,11.78,9.77,1.51,135.6,351.0,6.18,19.0,19.0,161.0,59.0,8.0,18.03,5.68,74.0,190.0,43.0,31.0,5.0,5.3,56.0,221.0,,,,,,,,,,,,,1.67,16.71,5.65,,无, 无, P0,H0, 未做, CK+， Vimentin部分+， VEGF-， CMET-,,,,,62.352168199737186,1523109
1523765,尹鹏竹,607843,男,63,T3,N3b,M1, Ⅳ,1,2,2.0,0.0,,1.0, 异型增生+,17.0,17,中间型（int）,INFc,0.0,,,,,,,1.0,2015-07-31,2015-12-29,2,,,SOX,,,,,,3, 低粘附腺癌 Lauren弥漫型,GX, (1a)44 (1b)11 (3a)11 (3b)00 (4sb)22 (4d)22 (5)11 (6)00 (7)22 (8a)00 (8p)22 (9)11 (11p)11," L（幽门窦部）, 前Ant, 小弯侧Less,",20,18,10,,R2,6.24,4.54,1.12,105.2,287.0,4.73,13.0,18.0,116.0,274.0,14.0,12.1,5.7,74.0,150.0,32.0,42.0,4.6,2.8,44.0,287.0,,,,,,,,,,,,,2.24,17.6,27.1,,粟粒状, 无, p1泛(M1 PER),H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,4.9605781865965834,1523765
1523639,苑学文,607861,男,65,T3,N3b,M0, ⅢC,1,3,2.0,1.0,,1.0, 肠化生+,23.0,27,硬型（sci）,INFc,2.0,,1.0,,,,,1.0,2015-07-30,2019-09-02,0,,,SOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren弥漫型,G3, (1a)22 (1b)22 (2)12 (3a)11 (3b)22 (4sa)11 (4sb)33 (4d)22 (5)11 (6)01 (7)22 (8a)33 (8p)01 (9)22 (11d)00 (12a)01小弯11," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,70,10, R0 D2,,6.0,2.63,2.92,131.3,168.0,2.63,15.0,15.0,157.0,91.0,11.0,19.21,6.2,67.0,275.0,40.0,27.0,6.6,4.3,100.0,274.0,,,,,,,,,,,,,7.48,971.9,9.59,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF弱+ CMET+,,,,,49.11300919842313,1523639
1520361,崔彬,600896,男,53,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,31,髓样型（med）,INFb,2.0,,,,,,,1.0,2015-07-02,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,大弯04 (1a)06 (1b)06 (3a)04 (3b)02 (4sb)01 (4d)03 (5)01 (6)00 (7)04 (8a)00 (9)00," L（幽门窦部）, 小弯侧Less,",20,15,5, R0 D1+,,7.2,3.25,3.08,157.0,300.0,2.6,21.0,21.0,152.0,64.0,22.0,14.94,4.89,67.0,337.0,42.0,25.0,4.7,5.9,96.0,291.0,67.1,43.4,19.2,2.26,0.9,9.4,19.8,1.0,1.13,2.38,10.9,16.8,1.62,10.71,1.17,,无,,,H0, 未做,CK + Vimentin –  VEGF- CMET弱+,,,,,63.17345597897503,1520361
1523686,王金友,608145,男,62,T4b,N1,M0, ⅢB,1,3,0.0,1.0,,0.0, 肠化生+,2.0,14,硬型（sci）,INFa,1.0,,1.0,,,,,1.0,2015-07-30,2016-05-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)03 (3b)01 (4sb)00 (4d)11 (5)00 (6)12 (7)01 (8a)02 (8p)01 (9)02 (11p)01 软组织可见癌6," LD 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,30,,R2,8.01,4.62,2.93,138.2,332.0,2.38,21.0,21.0,155.0,83.0,10.0,10.8,3.15,68.0,327.0,44.0,24.0,5.3,9.3,76.0,286.0,,,,,,,,,,,,,3.48,7.32,4.62,,无, 无, P0,H0, 未做, CK+， Vimentin- VEGF灶+ CMET+,,,,,9.526938239159001,1523686
1524191,王会臣,607884,男,51,T3,N1,M0, ⅡB,1,3,0.0,0.0,,0.0, 肠化生+ 异型增生+,2.0,33,中间型（int）,INFb,2.0,,1.0,,,,,2.0,2015-08-05,2021-07-23,1,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】50 乳头状癌（G1）（pap）30 粘液腺癌（muc）20 Lauren肠型,G2, (1a)00 (1b)00 (3a)03 (3b)00 (4sb)00 (4d)04 (5)01 (6)04 (7)07 (8a)02 (8p)26 (9)03 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,40,6, R0 D2,,7.83,4.61,2.06,139.0,226.0,2.63,44.0,30.0,160.0,67.0,24.0,12.18,3.7,61.0,436.0,41.0,20.0,4.2,5.8,79.0,434.0,66.8,43.7,17.8,2.46,0.3,12.4,19.2,1.5,0.446,0.698,7.89,178.0,8.59,127.3,6.17,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF局灶弱+ CMET弱+,,,,,71.58344283837056,1524191
1523706,丛丽贤,607832,女,58,T3,N2,M0, ⅢA,1,2,2.0,1.0,,1.0, 肠化生+ 异型增生+,4.0,38,中间型（int）,INFc,1.0,,1.0,,,,,1.0,2015-07-30,2020-12-17,1,,,,,,,,,0, 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren弥漫型,G3, (1a)02 (1b)03 (3a)213 (3b)00 (4sb)00 (4d)04 (5)00 (6)07 (7)00 (8a)03 (8p)04 (9)00 (11p)00," LM 前Ant, 后Post, 小弯侧Less,",40,40,10, R0 D2,,8.22,5.18,2.28,158.0,231.0,2.41,18.0,21.0,211.0,179.0,133.0,11.49,3.29,67.0,311.0,42.0,25.0,5.9,6.3,82.0,228.0,,,,,,,,,,,,,6.4,9.87,5.25,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF+ CMET+,,,,,64.61892247043363,1523706
1524229,吕淑芹,608432,女,54,T3,N1,M0, ⅡB,1,3,0.0,0.0,,0.0, 肠化生+,2.0,23,中间型（int）,INFa,1.0,,,,,,,0.0,2015-08-05,2020-10-06,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)04 (3b)00 (4sb)01 (4d)00 (5)00 (6)28 (7)03 (8a)01 (8p)04 (9)00 (11p)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,10, R0 D2,,4.62,3.07,1.21,66.5,235.0,2.78,15.0,19.0,149.0,83.0,5.0,5.05,2.03,62.0,142.0,39.0,23.0,5.4,4.2,55.0,189.0,,,,,,,,,,,,,12.8,7.7,2.46, 未做,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF- CK+ S-100（神经染色） CD34、D2-40(脉管染色),,,,,62.056504599211564,1524229
1524144,张月英,608279,女,59,T4a,N3a,M0, ⅢB,1,4,2.0,0.0,,1.0, 异型增生+,8.0,24,硬型（sci）,INFc,1.0,,,,,,,1.0,2015-08-04,2021-05-21,1,,,SOX,SOX,SOX,SOX,替吉奥单药,,5, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)22 (2)35 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)04 (5)02 (6)03 (7)22 (8a)01 (8p)01 (9)11 (10)00 (11p)02 (12a)00," SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",90,80,18, R0 D2,,6.4,4.12,1.75,106.0,342.0,3.28,17.0,23.0,172.0,61.0,4.0,7.38,2.1,76.0,256.0,44.0,32.0,5.2,3.9,56.0,286.0,68.4,31.7,32.7,0.97,0.3,4.3,25.0,5.8,0.935,2.72,11.3,135.0,0.898,6.45,1.5, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ S-100(神经染色) CD34、D2-40(脉管染色),,,,,69.54664914586071,1524144
1524034,张福良,608620,男,64,T2,N1,M0, ⅡA,1,3,1.0,0.0,,0.0, 异型增生+,1.0,24,硬型（sci）,INFa,0.0,,,,,,,1.0,2015-08-04,2020-10-06,1,,,XELOX,,,,,,6, 低粘附腺癌90%， 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10%， Lauren混合型,G3, (1a)00 (1b)00 (3a)12 (3b)02 (4sb)00 (4d)03 (5)00 (6)02 (7)02 (8a)06 (8p)02 (9)02 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",30,30,15, R0 D2,,8.34,4.2,3.22,150.0,300.0,2.95,22.0,24.0,192.0,113.0,24.0,24.47,7.77,72.0,273.0,40.0,32.0,5.4,4.5,84.0,345.0,66.9,36.5,26.7,1.37,0.1,12.2,17.9,5.6,0.714,3.67,9.77,112.0,0.72,15.83,88.35, 未做,无, 无, P0,H0, 未做, CK+ VEGF- Vimentin- CMET+ S-100（神经染色） CD34、D2-40(脉管染色),,,,,62.089356110381075,1524034
1523827,王殿起,609712,男,52,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,34,,,,,,,,,,,2015-07-31,2016-08-15,2,,,,,,,,,0, 低粘附腺癌,GX, (11p)04 (9)04 (8p)01 (8a)02 (6)05 (5)00 (4d)05 (7)04 (3b)00 (3a)03 (1a)01 (1b)05 (4sb)00,L（幽门窦部） 前Ant ,15,15,,R0 D2,,5.43,3.3,1.77,153.0,137.0,1.91,29.0,25.0,180.0,79.0,33.0,21.34,6.68,74.0,378.0,43.0,31.0,5.4,6.6,67.0,365.0,73.3,44.3,25.1,1.76,0.2,16.9,8.6,0.5,1.0,2.64,11.7,12.7,1.83,14.62,1.69, 未做,无,, P0,H0, 未做,ck（+）,,,,,12.516425755584756,1523827
1523753,李纪献,608445,男,59,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+,2.0,35,中间型（int）,INFa,1.0,,1.0,1.0,,,,1.0,2015-07-31,2020-05-11,0,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)08 (3b)00 (4sb)01 (4d)13 (5)00 (6)04 (7)11 (8a)02 (8p)06 (9)08 (11p)01, MU 前Ant 后Post ,55,40,8,R0 D2,,,,,,,,11.0,16.0,146.0,80.0,5.0,12.79,5.17,66.0,220.0,39.0,27.0,5.3,5.9,90.0,271.0,52.3,31.0,17.7,1.75,0.1,7.3,35.3,0.6,3.49,1.63,13.1,34.2,,,, 未做,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,57.35873850197109,1523753
1523828,于桂华,609677,女,68,T1b,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+,0.0,44,中间型（int）,INFa,0.0,,1.0,1.0,,,,1.0,2015-07-31,2020-12-17,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (8p)03 (5)00 (8a)03 (11p)06 (9)04 (1b)06 (3a)01 (3b)00 (4sb)04 (6)02 (1a)05 (7)01 (4d)08大网01," L（幽门窦部）, 大弯侧Gre,",18,15,4, R0 D2,,5.72,2.98,1.97,117.0,251.0,2.06,16.0,21.0,159.0,69.0,10.0,4.9,1.76,63.0,200.0,34.0,29.0,4.4,5.1,60.0,284.0,,,,,,,,,,,,,0.977,7.56,1.58,,无, 无, P0,H0, 未做, CK+ Vimentin部分+ VEGF部分弱+ CMET+,,,,,64.58607095926412,1523828
1523840,刘刚,608168,男,65,T2,N2,M0, ⅡB,1,3,0.0,0.0,,0.0, 肠化生+,6.0,20,中间型（int）,INFa,2.0,,,,,,,1.0,2015-08-01,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) (1b)12 (3a) (3b)08 (4sb)13 (4d)00 (6)24 (7)23 (5) (12a)00 (11p)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,25,14, R0 D2,,9.55,5.38,3.09,148.0,257.0,3.28,20.0,21.0,156.0,130.0,18.0,13.28,4.91,68.0,226.0,41.0,27.0,4.8,7.1,85.0,252.0,,,,,,,,,,,,,1.2,8.48,2.35,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,85.0197109067017,1523840
1523910,陈淑英,608306,女,59,T3,N3a,M0,ⅢB,1,2,2.0,1.0,1.0,0.0, 异型增生+,15.0,31,中间型（int）,INFc,1.0,,,,,,,1.0,2015-08-03,2020-10-06,1,,,SOX,SOX,XELOX,XELOX,XELOX,卡佩他滨,6, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren弥漫型,G3, (1a)00 (1b)58 (2)00 (3a)44 (3b)11 (4sa) 01(4sb)00 (4d)06 (5）00(6)06 (7)11 (8a)00 (8p)11 (9)11 (11p)00 (12a)00 小弯22,M（胃体部） 小弯侧Less 前Ant 后Post ,40,40,, R0 D2,,5.03,3.38,1.19,139.3,147.0,2.49,20.0,23.0,160.0,84.0,7.0,16.62,4.93,76.0,280.0,41.0,35.0,5.3,3.8,65.0,258.0,54.8,39.6,13.3,2.98,0.3,21.5,22.3,1.0,0.961,4.25,10.7,54.2,0.759,5.55,2.19, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+)  CD34(+)  D2-40(+) ,,,,,62.12220762155059,1523910
1523841,车志新,608231,男,49,T1a,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+,0.0,35,中间型（int）,INFa,1.0,,,,,,,1.0,2015-08-01,2021-05-25,1,,,,,,,,,0, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren肠型,G3, (1a) (1b)04 (3a) (3b)06 (4sb)07 (6) (4d)04 (5) (12a)01 (7) (8a) (8p) (9) (11p)013," L（幽门窦部）, 后Post,",35,35,, R0 D2,,9.22,4.63,3.28,158.0,275.0,,28.0,25.0,200.0,90.0,54.0,5.64,2.65,71.0,231.0,44.0,27.0,5.3,5.6,86.0,371.0,69.2,40.2,18.0,2.23,0.2,17.3,9.9,5.2,,,,,2.21,8.48,1.83,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,69.7766097240473,1523841
1523888,杨德年,609748,男,75,T1b,N1,M0, ⅠB,1,0,1.0,1.0,1.0,0.0, 异型增生+,1.0,36,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-08-03,2020-10-06,1,,,口服替吉奥,,,,,,1,中低分化 粘液10 低黏附10,G3, (1a)01 (1b)01 (3a)18 (3b)00 (4sb)00 (4d) 07 (5)02 (6)02 (7)00 (8a)04 (8p)03 (9)02 (11p)06,L（幽门窦部） 前Ant 小弯侧Less 后Post ,70,70,,R0 D2,,6.82,4.27,1.97,145.0,201.0,3.28,19.0,26.0,218.0,91.0,17.0,12.27,4.04,65.0,350.0,38.0,27.0,4.4,4.9,68.0,243.0,62.9,33.0,26.8,1.23,0.1,19.3,12.8,0.2,0.406,2.05,11.6,386.0,2.09,3.07,1.59, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(+)， S100(-) D2-40（+）,,,,,62.12220762155059,1523888
1524343,杨凤英,608314,女,48,T2,N0,M0, ⅠB,1,3,2.0,0.0,0.0,0.0, 异型增生+,0.0,22,中间型（int）,INFc,1.0,,1.0,,,,,1.0,2015-08-06,2021-05-25,1,,,多西他赛 卡铂,,,,,,6, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)00 (3a)02 (3b)00 (4sb)03 (4d)08 (5)00 (6)03 (7)00 (8a)01 (8p)01 (9)02 (11p)01 (12a)00,U（胃底部） 前Ant 大弯侧Gre  后Post ,30,25,5,R0 D2,,6.42,3.06,2.83,141.8,207.0,2.27,24.0,24.0,124.0,49.0,12.0,8.74,3.5,69.0,300.0,39.0,30.0,4.9,3.2,56.0,289.0,68.8,41.6,24.3,1.71,0.2,13.4,15.6,1.4,0.907,2.21,13.8,81.8,0.76,5.73,0.858, 未做,无, 无, P0,H0,,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,69.61235216819973,1524343
1523974,李国民,609689,男,53,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+,0.0,35,中间型（int）,INFa,2.0,,,,,,,1.0,2015-08-03,2020-10-06,1,,,奥沙利铂联合替加氟,奥沙利铂联合替加氟,,,,,2, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)05 (3a)01 (3b)01 (4sb)00 (4d)06 (5)00 (6)00 (7)06 (8a)03 (8p)05 (9)01 (11p)04,L（幽门窦部） 小弯侧Less ,60,50,, R0 D2,,7.41,5.15,1.63,158.3,211.0,1.79,25.0,26.0,202.0,78.0,21.0,13.04,4.15,68.0,408.0,42.0,26.0,5.1,4.8,84.0,342.0,77.9,46.1,24.4,1.89,0.1,8.2,9.4,3.8,0.566,1.88,9.63,12.1,3.32,7.8,1.98, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,62.12220762155059,1523974
1524051,苗国义,608309,男,52,T1b,N0,M0,ⅠA,1,0,0.0,1.0,1.0,0.0, 肠化生+ 异型增生+,0.0,20,中间型（int）,INFa,2.0,,,,,,,1.0,2015-08-04,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】  Lauren肠型,G2, (1a)00 (1b)02 (3a)01 (3b)00 (4sb)02 (4d)01 (5)00 (6)04 (7)00 (8a)02 (8p)03 (9)03 (11p)02 (12a)00,L（幽门窦部） 前Ant 小弯侧Less ,35,25,8,R0 D2,,8.23,5.31,2.2,155.8,217.0,2.85,27.0,29.0,207.0,50.0,23.0,9.51,3.31,69.0,408.0,42.0,27.0,4.9,3.8,65.0,309.0,56.5,41.7,13.0,3.21,10.5,0.1,28.8,0.4,2.21,3.4,10.8,44.8,4.32,10.44,1.38, 未做,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(-) D2-40（+）,,,,,62.089356110381075,1524051
1524129,徐福祥,608202,男,55,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,1.0, 肠化生+,2.0,46,中间型（int）,INFb,0.0,,,,,,,1.0,2015-08-04,2020-10-06,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren肠型,G3, (1a)02 (1b)04 (3a)06 (3b)19 (4sb)03 (4d)08 (5)00 (6)00 (7)05 (8a)01 (8p)01 (9)06 (11p)11 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",55,50,10,R0 D2,,4.83,2.18,2.33,139.8,189.0,2.28,21.0,21.0,165.0,53.0,6.0,11.89,4.51,54.0,234.0,34.0,20.0,4.4,6.7,61.0,200.0,55.6,35.4,17.2,2.06,0.2,13.3,28.4,1.8,0.791,1.56,7.67,132.0,1.54,6.21,1.8, 未做,无,, P0,H0,,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(+) ,,,,,62.089356110381075,1524129
1524863,张树娟,608456,女,41,T3,N1,M0, ⅡB,1,2,2.0,1.0,1.0,1.0, 慢性炎症（+）,2.0,42,中间型（int）,INFc,1.0,,,1.0,,,,2.0,2015-08-11,2021-07-23,1,,,XELOX,,,,,,6, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren弥漫型,G3, (1a)01 (1b)03 (3a)04 (3b)01 (4sb)02 (4d)012 (5)23 (6)03 (7)02 (8a)00 (8p)00 (9)00 (11p)06 (12a)05,L（幽门窦部） 小弯侧Less 后Post ,30,20,10, R0 D2,,9.61,7.21,1.76,127.9,278.0,3.05,18.0,23.0,192.0,58.0,6.0,9.55,3.82,66.0,253.0,39.0,27.0,3.9,4.6,56.0,270.0,78.8,43.6,25.2,1.73,0.2,11.3,7.7,1.8,1.72,1.7,11.7,38.6,1.86,9.99,4.09, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(+)，CD34(+)， S100(+) D2-40（+）,,,,,71.38633377135348,1524863
1524138,李太,608258,男,56,T4a,N2,M0, ⅢA,1,4,2.0,1.0,1.0,1.0, 肠化生+,6.0,45,中间型（int）,INFc,0.0,,,,,,,0.0,2015-08-04,2020-10-06,1,,,紫杉醇联合替吉奥,SOX,,,,,2, 低粘附腺癌 Lauren弥漫型,GX, (1a)11 (1b)00 (2)05 (3a)11 (3b)00 (4sa)01 (4sb)02 (4d)010 (5)00 (6)017 (7)00 (8a)11 (8p)00 (9) 14(10) 00(11p)22 (11d) 01(12a)00,LMU 小弯侧Less 前Ant 后Post ,70,65,10, R0 D2,,8.38,5.55,2.28,148.2,267.0,3.14,10.0,17.0,163.0,85.0,9.0,9.82,3.19,68.0,188.0,40.0,28.0,3.8,6.2,136.0,443.0,41.5,27.7,11.1,2.5,0.1,8.8,43.7,1.3,1.15,2.47,12.2,30.2,3.95,4.49,1.31, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+) S100(+),,,,,62.089356110381075,1524138
1524277,吕莉,609797,女,62,T3,N0,M0, ⅡA,1,2,1.0,1.0,1.0,1.0, 异型增生+,0.0,32,硬型（sci）,INFb,0.0,,1.0,,,,,1.0,2015-08-05,2021-06-21,1,,,口服替吉奥,,,,,,1, 粘液腺癌（muc）90 低分化腺癌（G3)(por)10 Lauren混合型,G3, (1a)00 (1b)01 (3a)07 (3b)01 (4sb)00 (4d)06 (5)00 (6)04 (7)06 (8a)01 (8p)01 (9)02 (11p)01 (12a)01 (14v)01，5 软组织可见癌,L（幽门窦部） 前Ant 小弯侧Less 后Post  ,60,50,8, R0 D2,,7.67,4.25,2.62,133.2,234.0,2.27,24.0,31.0,195.0,79.0,15.0,22.54,7.63,70.0,174.0,38.0,32.0,5.6,6.7,63.0,202.0,56.0,32.9,18.7,1.76,0.2,14.9,22.7,1.6,0.96,3.55,12.2,12.3,1.65,91.1,34.13, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(+)， S100) D2-40（+）,,,,,70.53219448094612,1524277
1524433,周凤芝,609844,女,51,T1b,N1,M0, ⅠB,1,0,0.0,0.0,0.0,0.0, 肠化生+,2.0,23,中间型（int）,INFa,0.0,,,,,,,2.0,2015-08-06,2021-07-12,1,,,XELOX,,,,,,6,中低分化管状腺癌,G3, (1a)02 (1b)04 (3a)14 (3b)00 (4d)12 (4sb)00 (5)00 (6)02 (7)02 (8a)01 (8p) (9)03 (11p)02 (12p)01,L（幽门窦部） 前Ant 小弯侧Less ,20,20,5,R0 D2,,6.72,3.53,2.66,142.0,429.0,2.49,11.0,17.0,14.0,110.0,14.0,12.97,3.25,68.0,340.0,41.0,27.0,4.9,4.1,75.0,234.0,73.6,40.7,28.4,1.43,0.2,8.8,14.2,3.0,1.46,0.772,11.4,63.1,2.67,15.84,0.906, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,71.1892247043364,1524433
1524214,何江,607910,男,62,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,28,,,3.0,,1.0,,,,,2.0,2015-08-05,2020-10-06,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)03 (1b)00 (3a)03 (3b)04 (4sa)03 (4sb)01 (4d)04 (5)00 (6)03 (7)02 (8a)02 (8p)02 (9)01 (11p)00,L（幽门窦部） 前Ant ,25,15,3, R0 D2,,4.41,2.03,1.79,155.7,218.0,1.84,21.0,25.0,168.0,75.0,12.0,13.13,4.46,67.0,259.0,40.0,27.0,4.5,4.7,74.0,367.0,,,,,,,,,,,,,3.37,18.0,1.14,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,62.056504599211564,1524214
1524681,马振芹,608182,女,63,T3,N2,M0, ⅢA,1,1,2.0,0.0,0.0,0.0, 慢性炎症（+）,4.0,32,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-08-10,2019-06-01,2,,,FOLFOX,,,,,,5, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a)00 (1b)03 (3a)03 (3b)11 (4sb)01 (4d)08 (5)11 (6)12 (7)11 (8a)03 (8p)03 (9)04 (11p)02 (12a)00, L（幽门窦部） 前Ant 后Post 大弯侧Gre  ,80,50,20, R0 D2,,9.57,6.88,1.15,116.0,423.0,2.84,27.0,25.0,182.0,70.0,23.0,3.93,1.55,49.0,302.0,28.0,21.0,5.4,4.3,51.0,217.0,74.0,43.2,26.8,1.61,0.2,15.9,8.2,5.6,0.713,3.94,9.25,5.4,0.956,15.25,1.04, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-)，CD34(-)， S100(-) D2-40（-）,,,,,45.69645203679369,1524681
1524984,于凤兰,609713,女,47,T3,N0,M0, ⅡA,1,4,0.0,0.0,0.0,0.0, 肠化生+,0.0,30,中间型（int）,INFa,0.0,,1.0,1.0,,,,1.0,2015-08-12,2020-10-06,1,,,XELOX,,,,,,3, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)02 (3b)02 (4sb)00 (4d)012 (5)00 (6)05 (7)04 (8a、8p)02 (9)01 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",60,55,8, R0 D2+,,8.83,5.46,2.73,135.1,338.0,3.97,42.0,29.0,165.0,105.0,13.0,16.52,5.82,70.0,191.0,43.0,27.0,5.1,5.7,45.0,224.0,65.0,33.2,27.0,1.23,0.8,9.9,23.7,13.6,1.72,2.3,10.4,72.8,3.19,18.56,2.04,,无, 无, P0,H0, 未做,CK + Vimentin部分+ VEGF+ CMET+,,,,,61.826544021024965,1524984
1524441,罗志明,607517,男,63,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+,2.0,22,硬型（sci）,INFc,1.0,,1.0,,,,,1.0,2015-08-06,2020-10-06,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)00 (3a)19 (3b)00 (4sb)00 (4d)02 (5) 00(6)02 (7)01 (8a)01 (8p)01(9)01(11p)00 (12a)01, L（幽门窦部） 小弯侧Less 后Post ,45,45,10, R0 D2,,7.33,3.92,2.57,168.0,222.0,2.58,24.0,23.0,162.0,111.0,18.0,17.06,5.53,65.0,305.0,43.0,22.0,5.5,4.6,63.0,335.0,50.0,30.4,13.7,2.22,0.4,4.4,43.4,2.4,0.259,1.32,8.5,468.0,0.818,17.68,1.95, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,62.023653088042046,1524441
1524469,林焕礼,609893,男,55,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,17,,,1.0,,,,,,,1.0,2015-08-06,2020-10-06,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)02 (1b)01 (3a)02 (3b)04 (4sb)00 (4d)00 (5)00 (6)04 (7)00 (8a)00 (8p)01 (9)01 (11p)00 (12a)01," L（幽门窦部）, 后Post, 小弯侧Less,",50,40,10, R0 D2,,8.85,5.21,2.78,166.0,267.0,2.31,34.0,27.0,191.0,58.0,16.0,14.7,4.43,65.0,405.0,43.0,22.0,5.5,4.5,81.0,482.0,76.4,35.0,36.8,0.95,0.8,10.6,9.6,2.2,0.468,1.97,6.58,7.37,1.78,11.05,1.33, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+)  CD34(+) S100(+),,,,,62.023653088042046,1524469
1524361,张全顺,608618,男,61,T1b,N3a,M0, ⅡB,1,0,1.0,1.0,1.0,0.0, 异型增生+,7.0,32,中间型（int）,INFa,1.0,,,,,,,1.0,2015-08-06,2016-06-05,2,,,XELOX,,,,,,3, 低分化腺癌（G3)(por)75 低粘附腺癌25 Lauren混合型,G3, (1a)00 (1b)12 (3a)03 (3b)03 (4sb)00 (4d)010 (5)02 (6)34 (7)34 (8a) 01(8p)02 (9)00(11p)01 (12a)00, L（幽门窦部） 小弯侧Less 前Ant ,40,20,, R0 D2,,8.27,5.36,2.05,132.6,285.0,3.59,20.0,21.0,158.0,69.0,10.0,7.39,3.09,68.0,175.0,42.0,26.0,5.3,5.6,75.0,374.0,72.1,35.1,26.4,1.33,0.3,7.2,17.3,3.3,0.447,3.73,11.3,72.3,5.13,29.02,46.09, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+)  CD34(+)  D2-40(+) ,,,,,9.986859395532194,1524361
1524461,张玉春,608327,男,78,T3,N1,M0, ⅡB,1,3,1.0,1.0,,1.0,肠化生 异型增生+,2.0,31,中间型（int）,INFc,2.0,,1.0,,,,,1.0,2015-08-06,2017-01-16,2,,,,,,,,,0," 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)55%, 低粘附腺癌40%, 粘液腺癌（muc）5% Lauren混合型",G3, (1a) 00(1b)00 (3a)213 (3b)00 (4sb)00 (4d)04 (5)00 (6)08 (7) 01(8a)03 (8p)01 (9)00 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less, 后Post,",70,60,8, R0 D2,,4.79,2.75,1.64,125.0,218.0,3.14,23.0,27.0,178.0,87.0,14.0,5.57,2.62,60.0,238.0,39.0,21.0,4.4,7.8,87.0,332.0,57.9,36.2,19.0,1.91,0.5,8.9,31.7,2.1,0.79,1.82,6.32,511.0,3.71,20.86,3.25, 未做,无, 无, P0,H0, 未做, CMET(部分+) Vimentin- VEGF+ CK+ S-100(神经+) CD34、D2-40(脉管+),,,,,17.378449408672797,1524461
1524781,邓树佰,607523,男,47,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,20.0,45,硬型（sci）,INFc,0.0,,,,,,,1.0,2015-08-10,2016-10-13,2,,,,,,,,,0, 低粘附腺癌80%， 低分化腺癌（G3)(por)20%， Lauren弥漫型,G3,"小弯侧11 (1a)68 (1b)00 (2) 00(3a)11 (3b)12 (4sa)22 (4sb)00 (4d)12 (5)11 (6)05 (7)44 (8a)12 (8p)07 (9)16 (11p)13 (12a)01 (10)00,1a见3枚癌结节，1b见1枚癌结节，3a组见2枚癌结节，4sa组见2枚癌结节"," SiewerⅢ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,70,10, R0 D2,,5.48,2.89,1.93,175.0,285.0,2.24,32.0,32.0,226.0,88.0,25.0,38.41,14.42,71.0,356.0,44.0,27.0,4.7,5.0,64.0,354.0,68.4,31.7,32.7,0.97,0.3,4.3,25.0,5.8,0.935,2.72,11.3,135.0,1.18,2.71,1.26, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF-， CK+ S-100（神经侵犯） CD34、D2-40(脉管瘤栓),,,,,14.126149802890932,1524781
1524832,李彦华,609630,男,57,T3,N1,M0, ⅡB,1,3,0.0,1.0,,1.0, 肠化生+,1.0,22,中间型（int）,INFa,0.0,,1.0,1.0,,,,1.0,2015-08-11,2021-07-23,1,,,XELOX,,,,,,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (6)01 (7)04 (8a)01 (8p)03 (9)02 (11p)01 (1a) 01(1b)00 (3a)06 (3b)00 (4sb)02 (4d)11 (5)00 4sb组软组织内1枚结节内见癌+," L（幽门窦部）, 前Ant,",45,45,10, R0 D2,,8.82,5.85,2.07,137.0,330.0,2.63,16.0,21.0,176.0,63.0,19.0,4.35,1.69,63.0,267.0,40.0,23.0,5.2,4.2,54.0,320.0,73.2,49.9,18.8,2.65,0.2,12.9,12.2,2.5,0.585,1.78,9.66,5.0,2.77,19.1,1.95, 未做,无, 无, P0,H0, 未做, VEGF+ Vimentin（部分+） CMET+ CK+ S-100（神经侵犯） CD34、D2-40(见脉管瘤栓),,,,,71.38633377135348,1524832
1524928,徐华永,608613,男,46,T1b,N0,M0,ⅠA,1,0,0.0,1.0,1.0,0.0, 肠化生+,0.0,25,中间型（int）,INFa,0.0,,,,,,,2.0,2015-08-11,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)02 (3a)03 (3b)00 (4sb)00 (4d)06 (5)01 (6)03 (7)02 (8a)00 (8p)00 (9)00 (11p)00 (12a)00,L（幽门窦部） 小弯侧Less ,25,20,5, R0 D2,,8.9,5.25,2.78,157.0,256.0,2.58,21.0,23.0,172.0,75.0,19.0,13.6,3.87,72.0,300.0,46.0,26.0,5.2,3.3,83.0,377.0,78.8,43.6,25.2,1.73,0.2,11.3,7.7,1.8,1.72,1.7,11.7,38.6,2.8,6.1,1.47,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(-) D2-40（+）,,,,,70.33508541392904,1524928
1524691,宋新河,609603,男,59,T3,N2,M0, ⅢA,1,2,2.0,1.0,1.0,1.0, 肠化生+,6.0,63,中间型（int）,INFc,2.0,,1.0,,,,,1.0,2015-08-10,2016-01-01,2,,,,,,,,,0,中低分化管状腺癌,G3, (1a)00 (1b)12 (3a)03 (3b)16 (4sb)02 (4d)015 (5)04 (6) 07(7)24 (8a)01 (8p)05 (9)06 (11p)05 (12a)12小弯11," M（胃体部）, 小弯侧Less,",20,15,6, R0 D2,,8.4,4.72,3.02,147.0,293.0,3.59,18.0,20.0,148.0,111.0,19.0,7.28,2.8,72.0,261.0,45.0,27.0,5.2,6.0,94.0,315.0,,,,,,,,,,,,,26.32,0.732,1.33, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,4.730617608409987,1524691
1525172,王明春,608642,男,57,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 肠化生+,3.0,20,中间型（int）,INFa,3.0,,,,,,,1.0,2015-08-13,2017-06-01,2,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (2)01 (3a)23 (4sb)00 (4d)01 (5)00 (6)01 (7)02 (8p)02 (9)03 (11p)04 (12a)11 (12p)01 软组织可见癌," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",45,25,10, R0 D2,,6.96,4.44,1.81,168.3,168.0,3.68,27.0,22.0,142.0,95.0,14.0,11.27,3.53,74.0,301.0,44.0,30.0,5.8,4.9,75.0,247.0,72.1,35.5,32.4,1.1,0.3,8.0,16.8,0.8,1.36,1.36,15.6,47.2,16.47,5.99,3.68, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,21.616294349540077,1525172
1524833,许淑琴,609872,女,61,T3,N1,M0, ⅡB,1,3,2.0,0.0,0.0,1.0, 肠化生+,1.0,20,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-08-11,2021-05-21,1,,,XELOX,,,,,,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)02 (3a)02 (3b)01 (4sb)01 (4d)03 (5)01 (6)14 (7)01 (8a、8p、9)05 (11p)00 (12a)00," L（幽门窦部）, 后Post, 大弯侧Gre,",50,50,10, R0 D2+,,6.69,4.02,2.24,138.4,333.0,3.08,20.0,20.0,138.0,12.0,11.0,7.54,2.11,61.0,247.0,39.0,22.0,5.4,3.3,59.0,279.0,,,,,,,,,,,,,1.15,4.44,10.17,,无, 无, P0,H0, 未做,CK + Vimentin –  VEGF部分+ CMET+,,,,,69.3166885676741,1524833
1525815,苏君臣,607500,男,64,T3,N0,M0, ⅡA,1,2,2.0,0.0,0.0,1.0, 肠化生+,0.0,30,中间型（int）,INFb,0.0,,,1.0,,,,0.0,2015-08-19,2019-06-01,0,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)04 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)07 (5)00 (6)03 (7)01 (8a)05 (8p)06 (9)01 (11p)00 (14v)02,L（幽门窦部） 前Ant 小弯侧Less 后Post ,45,20,5, R0 D2,,4.17,2.62,1.21,110.9,223.0,3.85,15.0,41.0,132.0,101.0,56.0,5.44,2.24,64.0,295.0,39.0,25.0,4.8,7.0,90.0,397.0,59.8,39.4,17.7,2.23,0.2,14.8,20.1,0.9,0.592,1.5,11.1,75.7,2.12,4.87,2.13,,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(-)，CD34(-)， S100(+) D2-40（-）,,,,,45.400788436268066,1525815
1525078,纪术平,609867,女,47,T4b,N3a,M0, ⅢC,1,4,0.0,1.0,1.0,0.0, 肠化生+,8.0,15,中间型（int）,INFa,3.0,,,1.0,,,,0.0,2015-08-12,2017-07-07,2,,,TX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 乳头状癌（G1）（pap）15 Lauren肠型,G3, (1b)01 (2)03 (3a)01 (3b)11 (4sa)00 (4sb)11 (4d)22 (5)01 (6)11 (7、8a、8p、9)23 (10)23 (12a)11," LMU 后Post, 大弯侧Gre, 小弯侧Less,",120,120,20,,R2,5.43,4.57,0.61,63.1,288.0,4.66,14.0,15.0,168.0,58.0,12.0,14.88,4.18,44.0,156.0,25.0,19.0,6.4,6.89,62.0,174.0,76.6,44.8,27.7,1.62,0.1,4.7,17.8,3.9,0.448,1.07,6.21,24.8,51.03,13.67,1.42,,无, 无, P0,H0, 未做,CK + Vimentin+ VEGF- CMET-,,,,,22.831800262812088,1525078
1524862,杨树春,608334,男,55,T4b,N2,M0, ⅢB,1,3,1.0,0.0,0.0,1.0, 肠化生+,3.0,25,中间型（int）,INFa,1.0,,1.0,,,,,1.0,2015-08-11,2016-07-29,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3, (1a)01 (1b)00 (3a)06 (3b)01 (4sb)00 (4d)310 (5)02 (6)01 (7)00 (8a)01 (8p)02 (9)01 (11p)00 (12a)00," L（幽门窦部）, 后Post, 大弯侧Gre,",50,50,10, R0 D2+,,6.56,3.46,2.3,153.5,150.0,3.14,17.0,26.0,228.0,87.0,20.0,10.37,3.53,68.0,307.0,38.0,30.0,4.4,6.3,80.0,270.0,52.2,22.1,15.6,1.42,0.0,6.2,33.7,0.3,1.21,2.82,13.9,5.31,3.6,25.07,1.9,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+,,,,,11.59658344283837,1524862
1524903,高秀玲,609926,女,49,T3,N3a,M0,ⅢB,1,2,1.0,1.0,,1.0, 肠化生+,7.0,46,中间型（int）,INFc,2.0,,,1.0,,,,1.0,2015-08-11,2021-05-21,1,,,XELOX,,,,,,1, 低粘附腺癌65%， 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30%， 粘液腺癌（muc）5%， Lauren混合型,G3, (1a) 01(1b)02 (3a)214 (3b)01 (4sb)02 (4d)111 (5)00 (6)16 (7)00 (8a)11 (8p)22 (9)02 (11p)01 (12a)01 (14v)02," L（幽门窦部）, 后Post,",60,60,20, R0 D2,,7.03,4.23,1.86,117.3,287.0,3.21,15.0,21.0,200.0,54.0,8.0,11.5,3.48,61.0,151.0,36.0,25.0,2.2,3.3,67.0,472.0,68.5,41.3,19.8,2.09,0.1,11.8,18.8,0.7,0.714,3.67,9.77,112.0,0.382,31.71,8.36, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin（部分+） VEGF- CK+ S-100（神经侵犯） CD34、D2-40(脉管瘤栓),,,,,69.3166885676741,1524903
1525101,刘学良,604794,男,66,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,17.0,33,中间型（int）,INFa,3.0,,1.0,,,,,1.0,2015-08-12,2021-07-01,1,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)22 (1b)13 (3a)55 (3b)00 (4sb)00 (4d)14 (5)00 (6)57 (7)23 (8a)11 (8p)03 (9)04 (11p)01 (12a)00肠系膜前叶00," M（胃体部）, L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",90,60,10, R0 D2,,6.0,3.26,1.92,107.3,370.0,3.41,14.0,16.0,223.0,70.0,11.0,5.08,1.85,58.0,189.0,33.0,25.0,4.9,4.2,79.0,216.0,56.2,43.7,10.4,4.2,2.7,8.0,23.3,0.1,0.636,2.5,9.77,311.0,8.97,132.8,2.81, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（弱+）、 CMET（+）,,,,,70.63074901445466,1525101
1524925,于宝初,610004,男,52,T4b,N0,M0, ⅢA,1,3,2.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,58,髓样型（med）,INFa,1.0,0.8,,,,,,1.0,2015-08-11,2021-07-23,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, 小弯侧07(1a)01 (1b)01 (3a)01 (3b)00 (4sb)03 (4d)020 (5)02 (6)08 (7)03 (8a)01 (8p)03 (9)02 (11p)04 (12a)00 (14v)02," L（幽门窦部）, 后Post,",100,70,30,,R2,7.86,5.66,1.75,126.0,265.0,5.27,13.0,17.0,127.0,170.0,99.0,7.22,2.97,71.0,173.0,39.0,32.0,4.4,4.8,104.0,291.0,75.5,45.1,25.1,1.8,1.2,11.2,11.9,5.4,0.49,7.09,12.0,20.6,2.24,4.28,3.1, 未做,无, 无, P0,H0, 未做, CMET +Vimentin-  CK+ S-100（神经+） CD34（脉管+）、D2-40,,,,,71.38633377135348,1524925
1525116,李世芝,609933,女,58,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,29,中间型（int）,INFa,0.0,,,1.0,,,,1.0,2015-08-12,2021-07-23,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (2)02 (3a)06 (3b)03 (4sb)00 (4d)02 (5)01 (6)04 (7)01 (8p)01 (9)01 (11p)03 (12a)03 (12p)01,L（幽门窦部） 小弯侧Less ,35,25,, R0 D2,,8.61,5.86,2.27,135.2,241.0,2.4,16.0,20.0,230.0,74.0,12.0,18.19,5.27,72.0,278.0,43.0,29.0,4.2,4.9,93.0,297.0,77.7,49.6,21.5,2.31,3.7,10.4,8.5,1.0,0.741,3.04,10.8,10.2,1.89,5.86,2.54, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,71.35348226018397,1525116
1525266,赵宝山,609992,男,48,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,35,中间型（int）,INFa,0.0,,1.0,1.0,,,,1.0,2015-08-13,2020-10-06,1,,,TPF,,,,,,3, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)05 (1b)02 (3a)02 (3b)00 (4sb)00 (4d)02 (5)00 (6)02 (7)00 (8a)012 (8p)05 (9)03 (11p)02,L（幽门窦部） 大弯侧Gre  ,35,35,8, R0 D2,,5.61,2.7,2.31,144.9,283.0,2.9,19.0,18.0,164.0,87.0,23.0,13.11,6.04,65.0,300.0,41.0,24.0,4.8,6.2,82.0,306.0,59.4,42.3,11.6,3.65,3.1,16.8,21.6,0.2,1.51,1.37,9.56,39.4,1.52,6.94,1.34, 未做,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(+)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,61.793692509855454,1525266
1527479,王国芝,612158,女,47,T4b,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+,27.0,28,中间型（int）,INFb,2.0,,,,,,,2.0,2015-09-02,2016-07-14,2,,,XELOX,,,,,,2, 低中分化腺癌（G3)(por)70 粘液腺癌（muc）20 低粘附腺癌10 Lauren混合型,G3, (3b)22 (6)66 (3a)44 (1a)56 (11p)22 (8a) (8p)11 (1b)11 (9)22 (4d)22 (7)11 (5)11 (4sb)00, L（幽门窦部） 小弯侧Less ,60,40,8,,R1,5.67,3.42,1.52,102.3,293.0,2.73,17.0,23.0,146.0,55.0,10.0,6.36,2.16,65.0,190.0,41.0,24.0,4.3,4.8,56.0,271.0,69.7,36.6,26.0,1.41,0.3,23.0,6.0,4.0,1.0,0.726,8.48,35.4,36.2,1000.0,7.21, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,10.38107752956636,1527479
1525651,宁国太,609990,男,73,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+,0.0,38,中间型（int）,INFa,0.0,,,1.0,,,,1.0,2015-08-18,2021-05-21,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3,肿物旁01 小弯03 (1a)00 (1b)07 (2)06 (3a)06 (3b)00 (4sa)03 (4sb)00 (4d)05 (5)00 (6)1 (7)01 (8a)02 (8p)01 (9)01 (10)00 (11p)01 (12a)00," U（胃底部）, 前Ant, 后Post, 小弯侧Less,",95,80,8, R0 D2+,,11.52,7.53,2.79,108.0,382.0,5.7,34.0,23.0,150.0,101.0,20.0,13.11,5.83,72.0,134.0,42.0,30.0,5.8,3.1,52.0,193.0,,,,,,,,,,,,,0.715,7.87,12.9,,无,, P0,H0, 未做,CK + Vimentin部分+ VEGF- CMET+,,,,,69.08672798948751,1525651
1525454,肖永清,610326,男,50,T4b,N3a,M0, ⅢC,1,4,1.0,0.0,0.0,0.0, 慢性炎症（+）,10.0,21,硬型（sci）,INFa,0.0,,1.0,,,,,0.0,2015-08-14,2020-05-12,0,,,,,,,,,0, 粘液腺癌（muc） Lauren混合型,GX,小弯413  (6)、14)68、大小弯各见一枚癌结节," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,20,,R2,6.25,2.99,2.29,145.0,265.0,2.49,18.0,19.0,158.0,67.0,21.0,11.09,3.96,72.0,266.0,44.0,28.0,5.6,5.2,71.0,275.0,,,,,,,,,,,,,2.72,12.9,84.52,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET-,,,,,56.93166885676741,1525454
1525529,王伟,608383,男,52,T1b,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+,0.0,9,髓样型（med）,INFc,0.0,,,,,,,1.0,2015-08-17,2020-10-06,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3, (1a)00 (1b)00 (2)02 (3a)04 (3b)00 (4sa)00 (4sb)00 (7)00 (8a)00 (8p)00 (9)01 (11p)02 (10)00," U（胃底部）, 后Post,",,,, R0 D1+,,5.29,2.85,1.97,132.9,160.0,2.54,18.0,21.0,134.0,76.0,13.0,11.6,4.47,62.0,252.0,41.0,21.0,4.7,4.9,73.0,444.0,,,,,,,,,,,,,3.4,5.73,4.0,,无,, P0,H0, 未做,CK + Vimentin–VEGF- CMET+,,,,,61.662286465177395,1525529
1526006,宋文库,608347,男,62,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,18,中间型（int）,INFa,1.0,,1.0,1.0,,,,1.0,2015-08-20,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (4sb)00 (11p)00 (4d)03 (3b)02 (6)04 (5)01 (8p)00 (9)03 (8a)01 (1a)00 (1b)00 (3a)03 (7)01 (12a)00," L（幽门窦部）, 小弯侧Less,",20,20,2, R0 D2,,7.44,3.61,2.34,132.7,169.0,2.95,25.0,21.0,148.0,66.0,37.0,14.03,4.42,71.0,282.0,44.0,27.0,5.2,3.9,73.0,273.0,,,,,,,,,,,,,2.52,9.78,3.51, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（部分+）、 VEGF（部分+）、 CMET（+）,,,,,70.03942181340341,1526006
1527376,任鸾凤,610001,女,61,T3,N1,M0, ⅡB,1,4,2.0,1.0,1.0,1.0, 肠化生+,1.0,10,中间型（int）,INFc,0.0,,,1.0,,,,2.0,2015-09-01,2017-03-30,2,,,FOLFOX,,,,,,5, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)03 (2)01 (3a)02 (3b)00 (4sa)00 (4sb)01 (4d)01 (8a)01 (5)00 (6)00 (7)00 (12a)00 (11p)11 (10)00 (9)00 (8p)00," M（胃体部）, L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,35,10, R0 D2,,9.85,7.05,1.97,123.0,293.0,2.49,27.0,28.0,185.0,68.0,15.0,7.4,2.61,61.0,363.0,39.0,22.0,5.7,4.6,58.0,281.0,83.3,28.5,45.3,0.63,1.2,6.0,8.3,6.6,1.07,6.2,7.29,38.0,0.617,11.09,4.73, 阳性+++,无, 无, P0,H0, 未做, CK（+）、 Vimentin（部分+）、 VEGF（-）、 CMET散在弱（+）,,,,,18.922470433639948,1527376
1526684,刘秀梅,608341,女,38,T4a,N3a,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,8.0,23,髓样型（med）,INFc,0.0,,1.0,,,,,1.0,2015-08-26,2019-06-01,2,,,SOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3,小湾22 (1a)01 (1b)00 (3a)04 (3b)00 (4sb)01 (4d)610 (5)00 (6)00 (7)01 (8a)01 (8p)01 (9)01 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,15, R0 D2,,6.74,4.51,1.84,90.8,247.0,3.51,17.0,22.0,188.0,71.0,11.0,9.83,3.42,73.0,318.0,45.0,28.0,5.3,3.6,72.0,276.0,56.5,30.5,24.1,1.27,0.5,10.0,31.1,0.4,,,,,1.31,18.02,2.57, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）,,,,,45.170827858081466,1526684
1525494,季晓峰,608738,男,53,T2,N3a,M0, ⅢA,1,2,1.0,0.0,0.0,1.0, 肠化生+,10.0,18,中间型（int）,INFc,1.0,,,,,,,1.0,2015-08-17,2021-07-23,1,,,XELOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 粘液腺癌（muc）30% Lauren混合型,G3, (1a)01 (1b)00 (3a)66 (3b)00 (4sb)00 (4d)24 (5)00 (6)00 (7)11 (8p)02 (9)01 (8a)12 (11p)01 (12a)00 (12p)00 (14v)00 (19)00," M（胃体部）, 前Ant,",15,10,6, R0 D2,,9.31,5.36,2.86,140.1,350.0,2.34,20.0,22.0,165.0,73.0,17.0,5.75,2.12,62.0,310.0,41.0,21.0,4.8,2.5,78.0,286.0,73.3,31.3,32.1,0.98,0.9,9.1,15.6,3.8,0.62,5.17,8.2,7.25,3.05,19.61,4.3, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,71.1892247043364,1525494
1525345,宋桂芹,608406,女,70,T3,N0,M0, ⅡA,1,3,2.0,1.0,1.0,1.0, 异型增生+,0.0,6,中间型（int）,INFc,1.0,,,,,,,1.0,2015-08-14,2016-12-07,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren弥漫型,G3,大弯02 小弯0 (8a)04," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,18,10, R0 D2+,,5.68,3.87,1.39,122.0,159.0,2.9,14.0,21.0,156.0,107.0,10.0,8.7,2.86,67.0,324.0,39.0,28.0,5.6,9.8,187.0,369.0,74.4,40.7,30.3,1.34,1.2,11.3,13.3,4.4,0.84,8.89,13.4,39.1,2.96,20.86,4.16,,无, 无, P0,H0, 未做,CK + Vimentin–VEGF- CMET+,,,,,15.801576872536137,1525345
1525603,战玉杰,608972,男,58,T2,N1,M0, ⅡA,1,3,0.0,1.0,1.0,0.0, 肠化生+,2.0,17,中间型（int）,INFa,2.0,,,,,,,1.0,2015-08-17,2016-12-01,2,,,卡佩他滨,,,,,,3, 管状腺癌（中分化【G2】【tub2】90 乳头状癌（G1）（pap）10 Lauren肠型,G2, (1a)00 (1b)01 (3a)09 (3b)00 (4sb)00 (4d)02 (5)00 (6)13 冰冻(6)11 (7)00 (8a)00 (8p)00 (9)00 (11p)01," L（幽门窦部）, 前Ant, 小弯侧Less,",25,15,7,,R1,8.35,6.41,1.28,135.7,200.0,2.8,6.0,12.0,151.0,58.0,9.0,7.47,2.82,60.0,249.0,37.0,23.0,5.7,2.7,81.0,231.0,,,,,,,,,,,,,24.31,18.06,21.85,,无,, P0,H0, 未做,CK + Vimentin –  VEGF- CMET+,,,,,15.505913272010512,1525603
1525493,宋桂芝,607558,女,47,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 异型增生+,7.0,43,硬型（sci）,INFb,1.0,,1.0,,,,,1.0,2015-08-17,2017-01-26,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)02 (1b)04 (3a)112 (3b)13 (4sb)00（4d）311 (5)01 (6)02 (7) 01(8a)22 (8p)00 (9)01 (11p)00 (12a)00 (12p)01 (14v)03 (4d) 软组织可见癌,L（幽门窦部） 小弯侧Less 前Ant 后Post ,60,60,10, R0 D2,,4.87,3.15,1.39,65.4,384.0,2.95,7.0,9.0,155.0,55.0,6.0,12.0,4.03,57.0,170.0,34.0,23.0,5.1,5.4,74.0,139.0,56.5,30.5,24.1,1.27,0.5,10.0,31.1,0.4,0.489,3.64,10.7,5.0,0.952,5.16,6.07, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF灶(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,17.345597897503286,1525493
1525794,迟桂文,607563,男,50,T3,N2,M1, Ⅳ,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,4.0,56,硬型（sci）,INFb,1.0,,1.0,,,,,0.0,2015-08-19,2019-05-01,0,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3,小弯310 (1a)00 (1b)00 (2)01 (3a)00 (3b)01 (4sa)02 (4sb)03 (4d)013 (5)02 (6)01 (7)02 (8a)04 (8p)13 (9)010 (11p)02 (12a)02 (10)00," UM 前Ant, 后Post, 小弯侧Less,",90,70,5,,R2,4.61,2.86,1.04,114.1,330.0,3.58,14.0,21.0,115.0,54.0,14.0,8.39,3.03,58.0,253.0,35.0,23.0,4.0,5.0,63.0,314.0,,,,,,,,,,,,,1.01,3.02,1.33,,无,, P0,H1单（M1 HEP), 未做,CK + Vimentin –  VEGF+ CMET-,,,,,44.382391590013135,1525794
1525895,董顺波,608549,男,62,T3,N2,M0, ⅢA,1,3,1.0,0.0,,1.0, 肠化生+,3.0,12,中间型（int）,INFc,0.0,,,1.0,,,,1.0,2015-08-19,2019-04-24,0,,,SOX,,,,,,1," 粘液腺癌（muc）60%, 低分化腺癌（G3)(por)20%, 低粘附腺癌20%, Lauren混合型",G3, (1a)01 (1b)00 (3a)04 (3b)11 (4sb)00 (4d)00 (5)01 (6)11 (7)01 (8a)11 (8p)01 (9)01 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,30,10, R0 D2,,7.26,4.27,2.11,142.3,175.0,2.25,24.0,22.0,151.0,62.0,26.0,6.33,2.9,73.0,197.0,44.0,29.0,6.9,2.8,65.0,277.0,68.1,41.8,25.6,1.63,0.1,10.1,20.9,1.0,0.742,4.29,13.0,457.0,2.09,0.6,1.37, 未做,无, 无, P0,H0, 未做, CMET +Vimentin(部分+) VEGF- CK+ S-100（神经侵犯） CD34、D2-40(未见),,,,,44.15243101182654,1525895
1526294,齐光信,401943,男,62,T4b,N3a,M0, ⅢC,1,4,0.0,0.0,,1.0, 异型增生+,7.0,34,硬型（sci）,INFa,0.0,,,,,,,1.0,2015-08-24,2021-07-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,小弯28 (1a)02 (1b)01 (2)00 (3a)35 (3b)00 (4sa) 00(4sb)01 (4d)26 (5)00 (6)00 (7)02 (8a)01 (8p)02 (9)06 (10)00 (11p)00 (12a)00，12组00," ML 前Ant, 小弯侧Less,",90,60,20, R0 D2,,10.44,7.82,1.74,78.0,603.0,5.44,27.0,26.0,127.0,64.0,26.0,6.15,2.9,63.0,119.0,38.0,25.0,5.0,2.9,63.0,312.0,52.8,28.4,20.0,1.42,0.2,17.2,28.3,1.2,1.11,2.29,10.2,272.0,0.87,2.95,1.28, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin -VEGF- CK +S-100（神经侵犯） CD34、D2-40(未见),,,,,70.2365308804205,1526294
1526421,韩其君,609765,男,72,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+,29.0,40,中间型（int）,INFc,3.0,,,1.0,,,,1.0,2015-08-24,2016-09-01,2,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren混合型,G3,小弯33 (1a)01 (5)33 (3b)1415 (12a)00 (4sb)00 (6)00 (7)58 (4d)14 (9)11 (8a)12 (8p)11 (3a)02 (11p)00 (1b)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",70,45,15, R0 D2+,,5.23,3.04,1.65,134.0,226.0,4.2,15.0,20.0,146.0,55.0,17.0,11.49,5.47,67.0,125.0,38.0,29.0,4.3,5.8,104.0,260.0,,,,,,,,,,,,,186.6,8.64,35.15,,无,, P0,H0, 未做, CK + Vimentin部分+ VEGF- CMET+,,,,,12.28646517739816,1526421
1526076,周铠,608925,男,52,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 肠化生+,0.0,18,硬型（sci）,INFb,0.0,,,,,,,0.0,2015-08-20,2021-06-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)01 (3b)00 (4sb)01 (4d)00 (5)01 (6)02 (7)02 (8a)02 (8p)05 (9)00 (11p)04 (12a)00," L（幽门窦部）, 前Ant,",20,15,5, R0 D2,,7.9,5.41,1.67,162.9,209.0,2.12,39.0,28.0,179.0,83.0,23.0,15.34,5.59,66.0,306.0,43.0,23.0,3.9,4.9,64.0,360.0,78.3,50.3,23.2,2.17,0.3,7.7,11.1,4.7,0.772,1.79,10.1,53.3,17.56,14.65,1.01, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,70.03942181340341,1526076
1525898,付文彬,610359,男,45,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,41,中间型（int）,INFa,0.0,,,1.0,,,,0.0,2015-08-19,2021-06-21,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01(8p)00 (3a)04 (4d)07 (9)02 (8a)01 (3b)01 (11p)04 (7)01 (5)01 (6)019 (4sb)00," L（幽门窦部）, 后Post,",30,30,8, R0 D2+,,7.41,3.42,3.23,121.0,270.0,2.58,19.0,21.0,122.0,60.0,16.0,7.03,2.82,54.0,307.0,34.0,20.0,3.7,5.3,79.0,250.0,,,,,,,,,,,,,,10.6,1.26,,无,, P0,H0, 未做,CK + Vimentin部分+ VEGF- CMET-,,,,,70.07227332457293,1525898
1525976,王国恩,610149,男,53,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,13,髓样型（med）,INFa,0.0,,1.0,,,,,1.0,2015-08-20,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)03 (3a)01 (3b)00 (4sb)00 (4d)03 (5)01 (6)00 (7)03 (8a)01 (8p)00 (9)00 (11p)00 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",20,15,3, R0 D1+,,9.47,6.04,2.72,167.3,223.0,2.01,37.0,24.0,159.0,80.0,36.0,7.09,2.24,67.0,427.0,45.0,22.0,4.6,4.6,90.0,441.0,,,,,,,,,,,,,3.98,1.04,21.04,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+,,,,,84.39553219448094,1525976
1526295,文广山,605760,男,59,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,24,中间型（int）,INFa,0.0,,1.0,1.0,,,,1.0,2015-08-24,2016-12-17,0,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)01 (3a)014 (3b)00 (4sb)00 (4d)03 (5)02 (6)01 (7)00 (8a)00 (8p)（12a）01 (9)00 (11p)00,L（幽门窦部） 小弯侧Less ,25,25,8, R0 D2,,6.82,4.59,1.83,136.5,306.0,2.29,25.0,24.0,136.0,71.0,28.8,14.29,3.39,72.2,313.22,46.1,26.1,5.7,5.0,76.0,319.0,,,,,,,,,,,,,6.4,19.04,, 未做,无,, P0,H0, 未做,ck(+)  vimentin(部分+)  VEGF(部分弱+)  cMET(+) ,,,,,15.801576872536137,1526295
1526635,徐秀洁,610768,女,62,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,1.0,异型增生+,0.0,24,中间型（int）,INFc,1.0,,,,,,,2.0,2015-08-26,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)05 (1b)01 (3a)00 (3b)01 (4sb)00 (4d)00 (5)01 (6)05 (7)01 (8a)01 (8p)04 (9)04 (11p)01,L（幽门窦部） 前Ant 小弯侧Less 后Post ,40,35,10, R0 D2,,7.3,3.1,3.56,148.0,283.0,3.28,22.0,31.0,190.0,91.0,22.0,6.63,1.9,77.0,344.0,47.0,30.0,5.1,5.3,66.0,189.0,70.4,52.0,14.4,3.61,0.2,13.7,14.1,0.21,1.71,1.63,11.9,52.0,2.93,49.45,4.3, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(-)， S100(+) D2-40（-）,,,,,61.366622864651774,1526635
1526388,刘守本,608551,男,74,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,26,中间型（int）,INFa,2.0,,,1.0,,,,1.0,2015-08-24,2017-06-07,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (2)06 (3a)04 (3b)00 (4sa)00 (4sb)01 (7)00 (8a)01 (8p)02 (9)04 (11p)07 (12a)00 (12p)01," M（胃体部）, U（胃底部）, 后Post, 前Ant,",20,20,, R0 D2,,12.4,9.84,1.63,133.4,200.0,2.78,18.0,22.0,142.0,73.0,44.0,25.46,10.05,67.0,257.0,39.0,28.0,5.0,7.0,114.0,29.7,60.3,34.8,23.5,1.48,0.1,11.5,25.9,2.2,0.701,2.82,15.7,1241.6,2.12,8.16,1.87, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（部分+）、 VEGF（-）、 CMET（+）,,,,,21.45203679369251,1526388
1526493,王伟,610852,男,41,T4b,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 异型增生+,21.0,21,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-08-25,2015-12-09,2,,,,,,,,,0, 低分化腺癌（G3)(por)（）90% 粘液腺癌（muc）10% Lauren弥漫型,G3, (1a)00 (1b)00 (2)66 (3a)22 (3b)22 (4sa)00 (4sb)44 (4d)22 (5)11 (6)11 (7)00 (8a)11 (8p)00 (9)00 (10)11 (11p)00 (11d)11 (12a)00 软组织可见癌," L（幽门窦部）, M（胃体部）, U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",140,100,20, R0 D2,,4.52,2.83,1.09,164.0,210.0,2.21,22.0,25.0,126.0,91.0,14.0,16.49,5.86,69.0,316.0,45.0,24.0,4.8,3.9,81.0,408.0,50.6,28.5,20.4,1.4,0.1,11.4,33.6,0.7,0.841,1.93,10.5,115.6,2.87,1000.0,17.04, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）,,,,,3.4822601839684624,1526493
1526573,刘淑琴,609072,女,59,T3,N1,M0, ⅡB,1,1,2.0,1.0,1.0,1.0, 肠化生+,2.0,17,中间型（int）,INFb,0.0,,,1.0,,,,2.0,2015-08-25,2020-04-02,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)01 (3a)02 (4sb)00 (4d)00 (5)00 (6)25 (7)01 (8a)01 (8p)01 (9)02 (11p)03," L（幽门窦部）, 大弯侧Gre,",15,15,6, R0 D2,,11.41,8.49,2.25,145.0,259.0,2.73,67.0,62.0,208.0,120.0,31.0,9.93,3.0,77.0,292.0,48.0,29.0,5.4,3.9,64.0,274.0,54.8,39.6,13.3,2.98,0.3,21.5,22.3,1.0,0.961,4.25,10.7,54.2,1.39,10.73,1.1, 未做,无, 无, P0,H0, 未做, CK+ Vimentin（部分+） VEGF- CMET（部分弱+）,,,,,55.25624178712221,1526573
1526634,赵维兴,610877,男,42,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+,18.0,41,髓样型（med）,INFc,0.0,,1.0,,,,,1.0,2015-08-26,2016-04-21,2,,,XELOX,,,,,,5, 低分化腺癌（G3)(por)80% 低粘附腺癌20% Lauren混合型,G3, (1a)01 (1b)00 (3a)28 (3b)11 (4sb)00 (4d)05 (5)01 (6)1013 (7)23 (8a)33 (8p)01 (9)04 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,60,15, R0 D2,,5.73,2.74,2.12,114.4,252.0,2.24,19.0,20.0,143.0,54.0,34.0,7.66,3.52,63.0,277.0,41.0,22.0,4.9,3.8,71.0,397.0,56.4,41.5,12.5,3.32,0.1,13.0,27.6,1.6,0.499,2.48,8.48,11.8,0.905,3.68,1.31, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）,,,,,7.851511169513797,1526634
1526231,杨秀芝,610895,女,75,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,1.0, 肠化生+,1.0,20,中间型（int）,INFa,3.0,,,1.0,,,,2.0,2015-08-21,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)07 (1b)00 (3a)11 (3b)00 (4sb)00 (4d)02 (5)00 (6)02 (7)03 (8a)00 (8p)00 (9)00 (11p)05 4d软组织可见癌,L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre  ,50,40,9, R0 D2,,7.15,4.5,1.83,108.8,268.0,3.08,14.0,19.0,151.0,77.0,22.0,11.91,4.44,66.0,137.0,42.0,24.0,5.4,3.6,60.0,319.0,55.4,37.5,15.3,2.45,0.1,14.1,29.5,0.5,1.06,2.11,12.9,5.0,5.01,6.5,5.62, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(部分+)  VEGF(-)  cMET(弱+) S100(+),,,,,61.530880420499344,1526231
1525827,汪国义,608489,男,68,T1b,N1,M0, ⅠB,1,0,1.0,1.0,1.0,0.0, 肠化生+,2.0,19,中间型（int）,INFc,0.0,,,,,,,0.0,2015-08-19,2020-03-01,2,,,希罗达,希罗达,,,,,2, 粘液腺癌（muc）70 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1b)00 (9)03 (11p)01 (3a)24 (7)01 (4sb)00 (6)03 (4d)01 (5)01 (3b)00 (8a)00 (8p)05 (1a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,2, R0 D2+,,6.87,3.98,2.12,131.5,258.0,3.33,13.0,16.0,150.0,67.0,14.0,9.23,3.62,57.0,297.0,36.0,21.0,,4.2,93.0,312.0,,,,,,,,,,,,,2.34,,,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET-,,,,,54.402102496714846,1525827
1526636,孙凤国,610773,男,43,T3,N3a,M0,ⅢB,1,2,1.0,1.0,1.0,1.0, 肠化生+,8.0,37,中间型（int）,INFc,1.0,,,1.0,,,,1.0,2015-08-26,2020-10-06,1,,,SOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G3, (1a)13 (1b)00 (3a)59 (3b)01 (4sb)02 (4d)04 (5)00 (6)02 (7)01 (8a)01 (8p)03 (9)14 (11p)11 (12a)06," M（胃体部）, 前Ant, 小弯侧Less,",50,40,10, R0 D2+,,10.45,7.46,1.7,98.0,240.0,,54.0,28.0,147.0,69.0,40.0,7.8,2.96,67.0,417.0,42.0,25.0,4.5,5.7,114.0,451.0,,,,,,,,,,,,,1.5,3.4,2.07,,无,, P0,H0, 未做,CK + Vimentin部分+  VEGF- CMET+,,,,,61.366622864651774,1526636
1526478,杜臣,610905,男,56,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,4.0,29,中间型（int）,INFa,1.0,,,,,,,2.0,2015-08-25,2019-05-01,0,,,SOX,SOX,SOX,SOX,FOLFOX,希罗达,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)03 (3b)01 (4sb)01 (4d)06 (5)01 (6)48 (7)01 (12a)00 (8a)01 (8p)04 (9)00 (11p)02," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,20, R0 D2+,,8.63,5.01,2.62,134.0,275.0,2.79,34.0,24.0,177.0,69.0,27.0,7.38,2.91,68.0,366.0,44.0,24.0,,5.6,102.0,437.0,,,,,,,,,,,,,1.12,8.12,12.3,,无,, P0,H0, 未做,CK + Vimentin– VEGF- CMET弱+,,,,,44.185282522996054,1526478
1526776,肖吉山,610729,男,59,T1b,N0,M0,ⅠA,1,0,1.0,1.0,1.0,1.0,,0.0,12,中间型（int）,INFb,1.0,,1.0,,,,,2.0,2015-08-27,2021-07-23,1,,,FOLFOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3, (1a)00 (1b)00 (2)04 (3a)06 (3b)00 (4sa)00 (4sb)00 (7)00 (8a)00 (8p)00 (9)00 (10)00 (11p)02," U（胃底部）, 后Post,",50,70,10, R0 D1+,,8.125,5.73,1.62,69.5,619.0,4.44,15.0,23.0,157.0,73.0,30.2,7.25,1.28,74.5,163.55,40.2,34.3,5.2,6.73,94.0,336.0,,,,,,,,,,,,,134.2,14.2,6.84,,无,, P0,H0, 未做,CK + Vimentin –  VEGF弱+ CMET弱+,,,,,70.86070959264126,1526776
1526422,卢景水,608757,男,60,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 异型增生+,0.0,10,中间型（int）,INFa,1.0,,1.0,,,,,2.0,2015-08-24,2018-05-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (2)00 (3a)05 (3b)00 (4sa)00 (4sb)00 (7)01 (9)01 (11p)01," U（胃底部）, 前Ant,",10,8,, R0 D1+,,8.26,4.52,2.95,143.7,208.0,2.18,28.0,29.0,188.0,75.0,29.3,8.56,1.33,73.9,222.53,45.2,28.7,5.2,6.56,96.0,279.0,,,,,,,,,,,,,1.32,7.28,24.72,,无,, P0,H0, 未做,CK + Vimentin –  VEGF+ CMET+,,,,,32.22733245729303,1526422
1526403,陈望贤,610749,男,66,T3,N2,M0, ⅢA,1,2,2.0,1.0,1.0,1.0, 肠化生+,5.0,22,中间型（int）,INFb,0.0,,,1.0,,,,2.0,2015-08-24,2016-10-25,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)02 (1b)00 (3a)312 (3b)12 (4sb)02 (4d)00 (5)00 (6)00 (7)00 (8a)（12a）13 (8p)00 (9)01 (11p)00,L（幽门窦部） 小弯侧Less 前Ant 后Post ,35,25,10, R0 D2,,5.03,2.93,0.95,154.0,147.0,2.73,16.0,17.0,159.0,36.0,9.0,26.6,10.51,65.0,302.0,40.0,25.0,4.3,4.1,97.0,416.0,56.3,33.8,19.1,1.77,0.1,6.4,35.2,3.9,1.08,1.0,12.3,5.0,1.82,11.41,1.91, 未做,无,, P0,H0, 未做,ck(+)  vimentin(部分+)  VEGF(-)  cMET(弱+)  CD34(+)  D2-40(+) S100(+),,,,,14.060446780551905,1526403
1526581,房玉林,610725,男,61,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 肠化生,0.0,26,中间型（int）,INFa,2.0,,,,,,,2.0,2015-08-25,2021-07-23,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," L（幽门窦部）, 小弯侧Less,",30,25,3, R0 D2,,7.8,4.55,2.61,172.4,272.0,2.21,22.0,19.0,187.0,77.0,16.0,12.49,4.09,71.0,397.0,46.0,25.0,4.4,4.0,104.0,,60.2,38.0,19.5,1.95,0.1,10.6,27.1,1.2,0.799,1.51,10.3,71.6,2.06,3.69,1.44, 未做,无, 无, P0,H0, 未做, Vimentin（-） VEGF（-） CK（+）cMET(弱阳）,,,,,70.92641261498028,1526581
1527066,杨景荣,610891,男,63,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,0.0, 肠化生+,0.0,32,中间型（int）,INFa,1.0,,,,,,,1.0,2015-08-31,2021-07-23,1,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)04 (2)08 (3a)00 (3b)09 (4sb)01 (4d)01 (5)00 (7)00 (8a)02 (8p)00 (9)03 (11p)02," U（胃底部）, 前Ant, 小弯侧Less,",30,25,8, R0 D2,,5.2,2.74,1.94,117.0,223.0,3.28,11.0,13.0,114.0,63.0,11.0,9.39,3.5,68.0,218.0,39.0,29.0,4.5,4.7,108.0,458.0,37.7,20.9,15.6,1.34,0.3,6.2,53.6,2.4,0.71,5.85,11.9,76.2,2.2,3.84,2.35, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,70.7293035479632,1527066
1526727,刘桂英,611180,女,58,T1b,N0,M0,ⅠA,1,0,1.0,0.0,,0.0, 肠化生+,0.0,25,中间型（int）,INFc,0.0,,,1.0,,,,2.0,2015-08-26,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90%， 低粘附腺癌10%， Lauren混合型,G3, (4sb)01 (1a)02 (1b)00 (8p)05 (3b)00 (4d)04 (5)01 (6)04 (9)02 (7) 02(8a)01 (11p)03 (12a)00," M（胃体部）, 小弯侧Less,",25,25,2, R0 D2,,3.85,1.87,1.48,140.0,193.0,1.86,88.0,67.0,162.0,145.0,262.0,10.47,3.98,69.0,211.0,40.0,29.0,4.6,4.1,59.0,250.0,64.6,37.8,25.2,1.5,0.3,11.1,20.1,1.0,6.8,1.6,10.9,5.0,1.28,22.44,4.71, 未做,无, 无, P0,H0, 未做, Vimentin(部分+) VEGF- CK+ S-100 CD34、D2-40(未见明确脉管瘤栓及神经侵犯) CMET（部分弱+）,,,,,61.366622864651774,1526727
1526559,孟祥文,611002,男,51,T3,N0,M1, Ⅳ,1,3,1.0,1.0,1.0,1.0,肠化生+,0.0,1,中间型（int）,INFc,1.0,,1.0,,,,,1.0,2015-08-20,2017-04-27,2,,,XELOX,,,,,,8, 管状腺癌（中分化【G2】【tub2】70 粘液腺癌（muc）30 Lauren混合型,G2,,L（幽门窦部） 后Post 小弯侧Less ,70,70,12,,R2,5.31,3.14,1.65,87.1,248.0,3.35,23.0,21.0,119.0,50.0,15.0,5.63,2.05,60.0,166.0,35.0,25.0,5.0,3.8,76.0,236.0,64.6,37.8,25.2,1.5,0.3,11.1,20.1,1.0,6.8,1.6,10.9,5.0,0.259,5.16,12.64, 未做,无,, p1局腹膜(M1 PER),H0, 未做,ck(+)  vimentin(-)  VEGF(部分弱+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,20.2365308804205,1526559
1526550,王发礼,611352,男,58,T4b,N3a,M0, ⅢC,1,4,1.0,1.0,1.0,1.0, 肠化生+,10.0,12,中间型（int）,INFc,1.0,,1.0,1.0,,,,0.0,2015-08-25,2015-10-07,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G3, (7)00 (1b)34 (4d)11 (8p)00 (3b)12 (8a)00 (6)55 (9)00 (11p)00," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,50,10,,R2,5.68,3.79,1.45,138.4,286.0,5.74,16.0,20.0,160.0,82.0,14.0,9.6,3.44,70.0,177.0,41.0,29.0,9.5,4.5,75.0,245.0,,,,,,,,,,,,,2.05,30.05,5.22,,无,, P0,H0, 未做,CK + Vimentin散在+  VEGF弱+ CMET-,,,,,1.4126149802890933,1526550
1526709,王殿义,611996,男,55,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,28,中间型（int）,INFa,2.0,,,,,,,2.0,2015-08-26,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,小弯07 (1a)02 (1b)04 (2)04 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)01 (5)00 (7)02 (8a)01 (8p)01 (9)04 (10)00 (11p)02," U（胃底部）, 小弯侧Less,",40,25,, R0 D1+,,7.52,4.74,2.12,167.0,254.0,2.53,13.0,19.0,158.0,75.0,19.0,16.27,6.05,71.0,349.0,43.0,349.0,5.2,2.8,85.0,269.0,,,,,,,,,,,,,1.19,,,,无,, P0,H0, 未做,CK + Vimentin –  VEGF- CMET弱+,,,,,61.366622864651774,1526709
1526844,王廷达,611206,男,44,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 肠化生+,7.0,29,中间型（int）,INFb,0.0,,,1.0,,,,0.0,2015-08-27,2020-10-06,1,,,XELOX,XELOX,紫杉醇联合替吉奥,紫杉醇联合替吉奥,紫杉醇联合替吉奥,紫杉醇联合替吉奥,6, 低粘附腺癌,GX, (1a)01 (1b)22 (3a)37 (3b)11 (4sb)03 (4d)010 (5)00 (6) 00(7)12(8a)01 (8p)00(9)01 (11p)00 (12a) 00(12b)01,L（幽门窦部） 小弯侧Less 前Ant 后Post ,50,30,10, R0 D2,,3.53,1.83,1.35,140.6,223.0,2.27,17.0,18.0,125.0,87.0,21.0,7.28,2.73,65.0,282.0,40.0,25.0,4.8,4.1,93.0,353.0,66.0,34.4,24.2,1.42,0.2,13.8,18.5,1.0,0.673,2.19,11.3,522.0,1.43,16.21,1.48, 未做,无,, P0,H0, 未做,ck(+)  vimentin部分(+)  VEGF(-)  cMET(-)  CD34(+)  D2-40(+) S100(+),,,,,61.333771353482256,1526844
1527616,盛国恩,612022,男,57,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,0.0, 肠化生+,0.0,44,中间型（int）,INFa,0.0,,,,,,,,2015-09-06,2020-10-06,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)02 (3a)06 (3b)08 (4sb)00 (4d)06 (5)03 (6)05 (7)01 (8a)02 (8p)03 (9)05 (11p)00 (12a)01,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less,90,80,15, R0 D2,,7.87,5.15,1.48,128.0,313.0,4.44,11.0,13.0,130.0,59.0,47.0,8.06,2.78,67.0,246.0,41.0,26.0,6.0,5.1,81.0,403.0,,,,,,,,,,,,,6.59,9.8,42.54, 未做,无,, P0,H0, 未做,ck（+），ck8/18（+），p63(-)，ck5/6(-)，CD34(+)， S100(-) D2-40（+）,,,,,61.00525624178712,1527616
1527205,由福成,608348,男,65,T1a,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+,0.0,29,中间型（int）,INFa,0.0,,,,,,,1.0,2015-08-31,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)06 (1b)01 (3a)04 (3b)01 (4sb)00 (4d)05 (5)03 (6)01 (8a)01 (8p)05 (9)01 (11)01," L（幽门窦部）, 前Ant,",40,20,5, R0 D2,,5.65,3.09,1.62,150.8,254.0,2.06,23.0,21.0,198.0,101.0,48.0,18.03,5.64,68.0,349.0,42.0,26.0,5.4,5.3,98.0,274.0,,,,,,,,,,,,,5.4,2.43,1.13, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ S-100 CD34、D2-40(未见),,,,,61.202365308804204,1527205
1527254,苏道君,612010,男,59,T4b,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+,31.0,36,中间型（int）,INFb,1.0,,,1.0,,,,2.0,2015-09-01,2016-07-29,2,,,SOX,SOX,奥沙利铂,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren混合型,G3, (1a)11 (1b)33 (2)33 (3a)58 (3b)56 (4sa)00 (4sb)22 (4d)55 (5)00 (6)33 (7)12 (8a)00 (8p)11 (9)11 (11p)00 肿物旁11," U（胃底部）, 前Ant, 后Post, 大弯侧Gre,",100,60,30,,R1,7.13,4.78,1.39,138.4,257.0,2.8,16.0,19.0,149.0,63.0,63.0,13.26,5.01,70.0,282.0,39.0,31.0,4.9,5.0,89.0,348.0,,,,,,,,,,,,,2.37,65.61,7.01,,无,, P0,H0, 未做,CK + Vimentin散在+ VEGF- CMET弱+,,,,,10.90670170827858,1527254
1534912,孙玉喜,609003,男,52,T2,N1,M0, ⅡA,1,3,2.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,1.0,27,中间型（int）,INFb,0.0,,,,,,,0.0,2015-11-11,2021-07-01,1,替吉奥*3,1.0,SOX,,,,,,3, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)00 (1b)01 (3a)110 (3b)01 (4sb)00 (4d)04 (5)00 (6)00 (7)02 (8a)01 (8p)01 (9)06 (11d)00 (11p)01 (12a)00 (19)00," L（幽门窦部）, 小弯侧Less,",25,15,10, R0 D2,,6.51,2.11,3.39,143.1,237.0,1.91,50.0,49.0,174.0,63.0,21.0,21.34,8.47,59.0,319.0,35.0,24.0,4.2,2.9,78.0,317.0,60.6,29.6,25.2,1.17,0.5,10.3,28.3,8.8,1.08,1.36,15.5,96.8,1.68,5.74,2.17, 未做,无, 无, P0,H0, 未做,灶（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）、 S-100（-）、CK18/18部分（+）、CK20（+）,,,,,67.64126149802891,1534912
1527349,张占富,611834,男,64,T3,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 肠化生+,4.0,22,中间型（int）,INFc,2.0,,1.0,,,,,0.0,2015-09-01,2019-04-17,0,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60  低粘附腺癌 40 Lauren弥漫型,G3, (1a)00 (1b)01 (2)03 (3a)36 (3b)00 (4sa)01 (4sb)00 (4d)02 (5)00 (6)02 (7)11 (8a)02 (8p)00 (9)02 (11p)02, ML 小弯侧Less ,45,30,10, R0 D2,,9.66,5.5,3.13,158.0,293.0,2.49,33.0,25.0,159.0,99.0,30.0,15.07,4.78,70.0,450.0,43.0,27.0,4.6,4.0,83.0,316.0,52.7,27.7,24.3,1.14,2.6,8.8,35.7,2.8,1.09,1.67,10.4,56.5,1.91,10.71,31.94,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(+)，cMET(-)，CD34(+)， S100(+) D2-40（+）,,,,,43.495400788436264,1527349
1527190,秦玉华,611394,女,59,T4b,N3a,M0, ⅢC,1,3,2.0,1.0,,1.0, 慢性炎症（+）,11.0,15,中间型（int）,INFc,0.0,,1.0,,,,,0.0,2015-08-31,2016-07-14,2,,,XELOX,,,,,,3, 低粘附腺癌 Lauren弥漫型,GX," (1a)01 (1b)11 (3a)55 (3b)00 (4sb)00 (5)00 (6)00 (7)11 (8a)11 (8p)02 (9)12 (11p)22 (12a)00,3b、5、6组可见癌组织"," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,60,40,,R2,7.33,3.23,3.21,129.1,207.0,4.08,16.0,24.0,169.0,66.0,12.0,4.84,1.92,65.0,102.0,39.0,26.0,5.8,4.2,59.0,196.0,59.7,34.5,22.3,1.55,0.1,34.1,4.9,1.6,1.39,0.798,6.4,13.0,3.39,284.1,53.91, 未做,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF弱+ CK+ S-100、 CD34、D2-40(可见脉管瘤栓，神经侵犯),,,,,10.446780551905388,1527190
1527105,高翠娥,611407,女,57,T2,N0,M0, ⅠB,1,3,1.0,0.0,0.0,0.0, 肠化生+,0.0,55,中间型（int）,INFb,2.0,,1.0,,,,,2.0,2015-08-31,2019-05-03,0,,,XELOX,,,,,,6, 粘液腺癌（muc）70% 管状腺癌（中分化【G2】【tub2】20% 乳头状癌（G1）（pap）10% Lauren混合型,G2, (1a)02 (1b)02 (3a)015 (3b)01 (4sb)00 (4d)010 (5)00 (6)05 (7)03 (8a)07 (8p)06 (9)02 (11p)01 (12a)01," L（幽门窦部）, 后Post,",50,50,12, R0 D2,,6.87,4.51,1.71,128.2,238.0,2.52,12.0,20.0,160.0,62.0,11.0,12.85,3.54,59.0,257.0,37.0,22.0,5.9,5.5,60.0,317.0,,,,,,,,,,,,,3.35,273.1,15.5, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF局灶弱（+）、 CMET部分弱（+）,,,,,44.053876478318,1527105
1527087,张巨林,611238,女,61,T3,N1,M0, ⅡB,1,2,1.0,1.0,1.0,1.0, 肠化生+,2.0,31,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-08-31,2020-10-06,1,,,,,,,,,0, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)02 (1b)02 (3a)12 (3b) 01(4sb)02 (4d)011 (5)00 (6)01 (7)12 (8a) 01(8p)03 (9)03 (11p)00 (12a)01, L（幽门窦部） 小弯侧Less 前Ant 后Post ,30,30,10, R0 D2,,5.58,2.74,2.29,121.0,158.0,3.27,31.0,40.0,147.0,63.0,21.0,12.61,4.42,67.0,215.0,37.0,30.0,7.1,6.3,60.0,343.0,76.0,48.9,24.8,1.97,0.4,14.0,8.3,4.0,1.38,1.5,13.2,16.5,2.34,0.6,7.52, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF弱(+)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,61.202365308804204,1527087
1527325,佟桂兰,611023,女,64,T2,N1,M0, ⅡA,1,2,0.0,1.0,1.0,0.0, 肠化生+,2.0,14,中间型（int）,INFa,0.0,,,,,,,0.0,2015-09-01,2021-07-01,1,,,奥沙利铂,,,,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) 02(1b) 00(3a)12 (3b)11 (4sb)00 (7)00 (8a)01 (8p)01 (9) 01(11p)02 (6)04 (12a)00 (5)00 (4d)00," L（幽门窦部）, 小弯侧Less,",35,30,10, R0 D2,,6.42,3.78,2.04,130.4,187.0,2.58,20.0,22.0,182.0,69.0,25.0,9.99,3.65,59.0,216.0,38.0,21.0,5.7,5.0,52.0,257.0,70.9,47.4,20.0,2.37,0.1,13.9,11.5,0.9,1.08,0.99,7.47,260.4,3.89,20.45,1.16, 未做,无, 无, P0,H0, 未做, CMET- Vimentin -VEGF- CK+ S-100（未见神经侵犯） CD34、D2-40(可见脉管瘤栓),,,,,69.97371879106439,1527325
1527347,吕秀莲,609039,女,57,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+,2.0,31,中间型（int）,INFa,0.0,,,,,,,0.0,2015-09-01,2021-07-23,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,肿物旁11 (11p)02 (8p)02 (9)03 (8a)06 (3b)00 (6)12 (5)00 (12a)00 (7)03 (1b)00 (14v)06 (1a)00 (3a)01 (4sb)01 (4d)04," L（幽门窦部）, D(十二指肠), 前Ant,",25,20,10, R0 D2,,7.88,4.49,2.61,126.7,498.0,4.9,17.0,24.0,151.0,86.0,21.0,7.34,2.81,71.0,248.0,42.0,29.0,4.7,6.1,54.0,395.0,71.2,39.8,28.0,1.42,0.2,16.1,11.2,1.4,0.314,3.2,11.0,104.9,0.589,6.63,1.12, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,70.69645203679369,1527347
1527180,于国华,611427,男,55,T2,N1,M0, ⅡA,1,1,1.0,0.0,0.0,0.0, 异型增生+,1.0,27,中间型（int）,INFb,0.0,,1.0,,,,,2.0,2015-08-31,2020-10-06,1,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3, (1a)01 (1b)00 (3a)02 (3b)11 (4sb)01 (4d)08 (5)00 (6)02 (7)07 (8a)01 (8p)02 (9)01 (11p)01 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",40,30,, R0 D2+,,5.3,2.95,2.12,151.0,230.0,2.49,20.0,23.0,165.0,76.0,6.0,14.81,5.02,67.0,276.0,44.0,23.0,5.0,4.8,75.0,279.0,,,,,,,,,,,,,0.868,7.81,2.48,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET+,,,,,61.202365308804204,1527180
1527326,张桂珍,611857,女,71,T4b,N1,M0, ⅢB,1,1,2.0,0.0,0.0,1.0, 肠化生+,1.0,24,中间型（int）,INFc,1.0,,1.0,1.0,,,,1.0,2015-09-01,2020-10-06,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)02 (1b)06 (2)12 (3a)06 (3b)03 (4sa)00 (4sb)00 (5)00 (8a)00 (8p)03 (9)01 (7)01 (10)00 (12a)00," U（胃底部）, 后Post, 大弯侧Gre,",40,20,20, R0 D2+,,4.27,2.57,1.36,54.0,220.0,3.11,22.0,24.0,185.0,74.0,10.0,5.32,1.93,64.0,241.0,36.0,28.0,5.7,7.2,70.0,359.0,,,,,,,,,,,,,0.587,4.58,1.8,,无, 无, P0,H0, 未做,CK + Vimentin散在+  VEGF部分+  CMET部分+,,,,,61.169513797634686,1527326
1527357,王振玲,611403,女,65,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,13,中间型（int）,INFa,0.0,,,,,,,0.0,2015-09-01,2018-04-24,0,,,SOX,SOX,XELOX,XELOX,奥沙利铂,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)01 (3b)00 (4sb00 (4d)04 (5)00 (6)00 (7)02 (8a)02 (8p、9)01 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",50,50,10, R0 D2+,,7.69,4.58,2.4,100.0,338.0,4.45,30.0,36.0,189.0,91.0,58.0,8.6,3.61,68.0,240.0,41.0,27.0,7.2,4.1,92.0,373.0,79.0,36.5,39.7,0.92,0.8,8.4,21.3,8.0,0.724,1.63,9.16,60.2,7.85,15.81,2.29,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET-,,,,,31.734559789750328,1527357
1527448,王丽英,611889,女,51,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+,27.0,33,中间型（int）,INFb,0.0,,1.0,1.0,,,,0.0,2015-09-02,2016-12-01,2,,,XELOX,XELOX,SOX,SOX,SOX,,5, 低粘附腺癌80% 低分化腺癌（G3)(por)20% Lauren混合型,G3, (1b)00 (6)02 (3b)77 (4d)00 (4sb)00 (5)00 (3a)66 (7)11 (14v)12 (1a)02 (8a)01 (9)55 (12a)00 (11p)44 (8p)33," M（胃体部）, L（幽门窦部）, 小弯侧Less,",20,15,10, R0 D2+,,6.3,4.27,1.51,135.0,315.0,3.68,16.0,21.0,180.0,88.0,12.0,15.27,6.05,71.0,239.0,43.0,28.0,4.9,6.1,57.0,265.0,73.1,55.2,15.5,3.56,0.1,10.1,13.2,0.3,1.01,2.06,10.3,65.0,1.22,6.39,20.43, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin个别散在（+）、 VEGF灶弱（+）、 CMET（-）,,,,,14.98028909329829,1527448
1527373,李海燕,611877,女,43,T1a,N0,M0,ⅠA,1,0,2.0,0.0,,0.0, 肠化生+,0.0,31,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-09-01,2020-10-06,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (8p) 05(9) 03(7)04 (12a)00 (11p)02 (8a)02 (3a) 04(1a)00 (1b)00 (3b)01 (5)00 (6)03 (4d)07 (4sb)00," L（幽门窦部）, 小弯侧Less,",40,25,5, R0 D2,,6.52,65.57,1.63,140.6,288.0,2.34,24.0,28.0,171.0,54.0,10.0,15.66,5.69,67.0,199.0,39.0,28.0,4.3,3.7,56.0,240.0,71.2,39.1,27.3,1.43,0.2,10.9,15.4,2.8,0.659,3.17,11.1,5.0,0.958,4.56,1.45, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF部分弱+ CK+ S-100 CD34、D2-40(未见),,,,,61.169513797634686,1527373
1528602,朱玉焕,611597,女,70,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,13.0,23,中间型（int）,INFa,0.0,,,1.0,,,,2.0,2015-09-14,2017-08-04,2,,,替吉奥单药,,,,,,3, 低分化腺癌（G3)(por) Lauren肠型,G3,  (5)00 (11d)33 (7)01 (3a)44 (4d)06 (1b)00 (3b)00 (11p)11 (1a)00 (4sb)00 (10)00 (8a)01 (2)55 (8p)01 (6)01 (12a)00," U（胃底部）, 小弯侧Less,",80,60,15, R0 D2,,8.86,6.56,1.53,121.0,285.0,3.11,11.0,24.0,168.0,77.0,19.0,8.78,3.36,63.0,120.0,35.0,28.0,4.7,5.1,53.0,320.0,75.7,44.5,25.5,1.75,0.2,10.1,11.9,2.0,0.369,2.67,10.8,10.4,2.58,1000.0,3.77, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（部分+）、 VEGF（-）、 CMET弱（+）,,,,,22.667542706964518,1528602
1528001,范维东,611490,男,48,T1b,N0,M0,ⅠA,1,0,1.0,0.0,0.0,0.0, 肠化生+,0.0,24,中间型（int）,INFb,0.0,,,,,,,1.0,2015-09-08,2021-07-23,1,,,,,,,,,0,低黏附性癌 80 中低分化20,G3,," L（幽门窦部）, 后Post, 小弯侧Less,",25,10,,R0 D2,,6.36,3.18,2.28,152.0,170.0,2.24,33.0,29.0,137.0,50.0,55.0,10.55,4.78,64.0,342.0,41.0,23.0,5.1,5.6,81.0,,,,,,,,,,,,,,0.94,8.17,1.36,,,,,,,,,,,,70.4664914586071,1528001
1528180,王德柱,611618,男,59,T4b,N2,M0, ⅢB,1,3,1.0,0.0,0.0,1.0, 肠化生+,4.0,25,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-09-09,2021-07-23,1,,,XELOX,,,,,,2,低黏附性癌80 中分化管状腺癌20,G2, (3a) (3b) (8a)," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,10,,R1,6.38,3.81,1.75,98.0,403.0,4.03,16.0,19.0,146.0,94.0,12.0,6.3,1.85,67.0,316.0,43.0,24.0,5.2,9.3,87.0,,,,,,,,,,,,,,1.81,6.21,6.67,,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF+ CK+,,,,,70.43363994743758,1528180
1527750,徐玉琴,608054,女,56,T4b,N1,M1, Ⅳ,1,4,0.0,0.0,0.0,1.0, 异型增生+,1.0,14,中间型（int）,INFa,1.0,,,,,,,2.0,2015-09-07,2018-02-01,2,,,SOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)03 (2)02 (3a)01 (3b)00 (4sa)00 (4sb)00 (4d)03 (5)00 (6)00 (7)01 (8a)00 (8p)01 (9)01 (10)00 (11p)00 (12a)00小湾11 软组织可见癌," M（胃体部）, 前Ant, 小弯侧Less,",50,40,10,,R2,5.33,2.6,1.85,110.0,353.0,3.01,48.0,45.0,209.0,197.0,127.0,45.02,33.85,62.0,272.0,35.0,27.0,4.7,5.0,52.0,298.0,,,,,,,,,,,,,1.73,28.2,1.65, 未做,无, 无, p1局肠缘(M1 PER),H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET弱（+）,,,,,28.843626806833115,1527750
1527606,崔玉臣,611210,男,74,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+,2.0,33,中间型（int）,INFa,0.0,,1.0,,,,,1.0,2015-09-06,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)04 (1b)02 (3a)05 (3b)00 (4sb)00 (4d)19 (5)00 (6)11 (7)06 (8a)01 (8p)01 (9)02 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",70,50,10, R0 D2+,,4.95,2.58,1.56,109.1,259.0,2.8,19.0,27.0,185.0,77.0,21.0,5.9,2.71,59.0,241.0,36.0,23.0,5.5,8.5,67.0,335.0,75.6,38.6,27.6,1.4,0.1,5.8,14.7,0.5,0.617,3.03,8.91,13.0,3.44,33.6,1.15,,无,, P0,H0, 未做,CK + Vimentin –  VEGF弱+ CMET部分+,,,,,83.8370565045992,1527606
1527889,徐德恩,611635,男,71,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,1.0, 肠化生+,0.0,27,中间型（int）,INFa,0.0,,,,,,,2.0,2015-09-08,2020-03-06,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)06 (3a)05 (3b)01 (4sb)00 (4d)07 (5)00 (6)02 (7)01 (8a)01 (8p)00 (9)00 (11p)00 (12a)01," LM 小弯侧Less,",40,35,12, R0 D2,,6.87,4.04,2.15,125.0,254.0,3.46,18.0,21.0,172.0,80.0,45.0,8.48,3.6,58.0,171.0,36.0,22.0,4.3,5.9,51.0,205.0,69.5,47.4,19.2,2.47,0.6,10.5,16.3,1.0,0.814,1.95,9.93,5.0,6.84,7.76,2.3,,无,, P0,H0, 未做,CK + Vimentin– VEGF- CMET弱+,,,,,53.90932982917214,1527889
1535754,周淑娥,612048,女,62,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,31,,,3.0,,,,,,,0.0,2015-11-18,2018-06-01,2,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)01 (3a)06 (3b)00 (4sb)00 (4d)010 (5)00 (6) 03(7)04 (8a)02 (8p)02 (9)02 (11p)01,L（幽门窦部） 大弯侧Gre  ,20,20,5, R0 D2,,3.96,1.03,2.23,135.5,181.0,3.43,32.0,39.0,231.0,98.0,26.0,7.14,2.3,59.0,148.0,38.0,21.0,4.4,5.9,65.0,269.0,,,,,,,,,,,,,4.09,47.96,2.5, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  ,,,,,30.420499342969777,1535754
1529695,赵彦祯,610630,男,79,T4b,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,23.0,45,中间型（int）,INFb,0.0,,,,,,,1.0,2015-09-22,2019-05-03,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 低粘附腺癌30% Lauren混合型,G3, (1a)04 (1b)23 (2)01 (3a)89 (3b)11 (4sa)01 (4sb)11 (4d)46 (5)11 (6)44 (7)00 (8a)00 (8p)01 (9)01 (10)00 (11p)00 (12a)00肿物旁22," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,45,15,,R2,9.02,71.27,19.88,119.2,358.0,18.9,19.0,26.0,148.0,72.0,18.0,7.46,3.35,64.0,186.0,34.0,30.0,5.6,4.6,91.0,369.0,61.8,39.6,19.6,2.02,0.0,8.5,26.8,0.4,0.275,5.81,13.0,292.4,1.98,62.96,4.19, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,43.331143232588694,1529695
1527686,赵万华,611103,女,64,T4b,N3a,M1, Ⅳ,1,4,2.0,1.0,1.0,1.0, 肠化生+,12.0,12,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-09-06,2016-08-15,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a、1b)11 (5)00 (3a、3b)00 (4d)22 (4sb)00 (6)88 (7)00 (8a)11," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,60,10,,R2,4.8,3.22,1.15,92.1,191.0,5.27,10.0,12.0,147.0,87.0,12.0,5.38,1.91,63.0,158.0,37.0,26.0,4.6,4.5,77.0,415.0,76.1,31.8,42.8,0.74,0.1,7.8,14.7,0.3,1.3,2.61,9.55,15.5,0.784,8.3,1.48,,粟粒状, 无, p1盆(M1 PER),H0, 未做,CK + Vimentin部分+ VEGF- CMET-,,,,,11.300919842312746,1527686
1527960,康殿孝,611280,男,75,T3,N2,M0, ⅢA,1,2,1.0,1.0,,1.0, 肠化生+,5.0,18,中间型（int）,INFb,0.0,,,1.0,,,,1.0,2015-09-08,2021-07-23,1,,,S1,,,,,,6,低黏附性癌80 低中分化管状腺癌20,G2, (1b) 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,30,15,R0 D2,,4.6,1.98,1.79,138.0,184.0,2.25,13.0,20.0,172.0,54.0,22.0,13.04,5.57,69.0,337.0,40.0,29.0,4.5,7.8,96.0,,,,,,,,,,,,,,2.89,159.0,4.08,,,,,,,,,,,,70.4664914586071,1527960
1528340,黄德军,613450,男,56,T3,N2,M0, ⅢA,1,5,1.0,1.0,,0.0, 慢性炎症（+）,3.0,51,中间型（int）,INFa,2.0,,1.0,,,,,2.0,2015-09-10,2021-07-23,1,,,FOLFOX6,,,,,,8, 低中分化腺癌（G3)(por) 乳头状癌30（G1）（pap）,G3, (7) (8a)," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",110,50,10,R0 D2,,5.43,3.38,1.48,98.3,301.0,3.61,12.0,18.0,154.0,44.0,11.0,9.17,3.5,53.0,234.0,28.0,25.0,3.9,5.2,67.0,,,,,,,,,,,,,,3.82,3.09,6.03,,,,,,,,,,,,70.40078843626806,1528340
1527890,汤顺华,611273,女,56,T3,N3b,M0, ⅢC,1,3,2.0,1.0,,1.0, 慢性炎症（+）,17.0,26,中间型（int）,INFc,0.0,,,,,,,2.0,2015-09-08,2020-05-11,0,,,DP,,,,,,3, 低分化腺癌（G3)(por),G3, (3a) (3b) (4d) (6) (8a) (11p)," L（幽门窦部）, 小弯侧Less,",40,40,20,R0 D2,,6.6,4.04,2.13,128.0,255.0,2.9,57.0,41.0,179.0,74.0,22.0,13.55,5.21,69.0,289.0,46.0,23.0,6.0,5.1,59.0,,,,,,,,,,,,,,1.43,16.11,3.92,,,,,,,,,,,,56.07752956636005,1527890
1527840,蔵艳,611279,女,51,T2,N0,M0, ⅠB,1,2,2.0,0.0,0.0,0.0, 异型增生+,0.0,48,中间型（int）,INFb,0.0,,,,,,,1.0,2015-09-07,2022-09-01,1,,,FOLFOX,,,,,,2, 低分化腺癌（G3)(por)60% 低粘附腺癌40% Lauren弥漫型,G3, (1a)00 (1b)03 (3a)05 (3b)02 (4sb)01 (4d)023 (5)01 (6)01 (7)01 (8a)06 (8p)01 (9)01 (11p)00 (12a)00 (14v)03," L（幽门窦部）, 前Ant,",30,20,10, R0 D2,,3.63,2.28,1.01,103.0,251.0,2.76,11.0,16.0,168.0,71.0,9.0,11.6,4.19,67.0,218.0,41.0,26.0,4.4,4.3,72.0,235.0,,,,,,,,,,,,,0.549,6.36,1.07, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,83.80420499342969,1527840
1527961,马兰,612178,女,43,T3,N3a,M0,ⅢB,1,4,2.0,1.0,,1.0, 肠化生+,9.0,31,中间型（int）,INFc,0.0,,,1.0,,,,1.0,2015-09-08,2017-07-15,2,,,XELOX,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)03 (1b)33 (2)00 (3a)03 (3b)00 (4sb)00 (4d)510 (5)00 (6)01 (7)00 (8a)01 (8p)03 (9)04 (11d)01 (14v)01小弯11," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,50,10, R0 D2,,11.53,10.15,0.79,110.9,196.0,,9.0,14.0,138.0,58.0,11.0,20.01,6.2,74.0,305.0,45.0,29.0,4.8,6.5,72.0,215.0,,,,,,,,,,,,,0.758,10.17,1.16,,无, 无, P0,H0, 未做, CK+ Vimentin部分+ VEGF- CMET+,,,,,22.207621550591327,1527961
1528079,蔡桂云,608875,女,69,T3,N2,M0, ⅢA,1,2,2.0,1.0,1.0,1.0, 异型增生+,5.0,26,中间型（int）,INFc,0.0,,,,,,,1.0,2015-09-09,2016-09-01,2,,,口服替吉奥,,,,,,1, 低粘附腺癌70 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30 Lauren弥漫型,G3, (1a)00 (1b)01 (3a)01 (3b)11 (4sb)00 (4d)00 (5)00 (6)11 (7)24 (8a)16 (8p)05 (9)06 (11p)01(12a)00, LM 前Ant 小弯侧Less ,40,35,15, R0 D2,,10.5,7.13,2.24,135.1,211.0,2.68,22.0,18.0,154.0,137.0,20.0,4.51,1.38,62.0,187.0,37.0,25.0,8.3,8.2,77.0,169.0,,,,,,,,,,,,,3.03,21.36,2.23, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+)  CD34(+)  D2-40(+) S100(+),,,,,11.76084099868594,1528079
1527607,王玉祥,611150,男,64,T3,N2,M0, ⅢA,1,2,2.0,1.0,1.0,1.0, 肠化生+,4.0,32,中间型（int）,INFc,0.0,,,,,,,1.0,2015-09-06,2018-05-27,2,,,XELOX,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)03 (3a)33 (3b)00 (4sb)00 (4d)05 (5)00(6)03(7)00 (8a)12(8p)05(9)06(11p)04,L（幽门窦部） 小弯侧Less 前Ant 后Post ,60,50,5,,R1,8.8,5.36,2.52,147.0,256.0,2.15,32.0,36.0,201.0,92.0,11.0,10.12,3.13,66.0,271.0,39.0,27.0,4.0,6.5,87.0,297.0,45.9,32.4,10.6,3.06,0.2,13.3,36.7,0.7,1.45,2.62,12.0,37.5,2.42,37.88,5.22, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+) ,,,,,32.65440210249671,1527607
1527959,吴忠起,612177,男,51,T1b,N0,M0,ⅠA,1,0,1.0,1.0,1.0,0.0, 肠化生+,0.0,23,中间型（int）,INFb,1.0,,1.0,1.0,,,,1.0,2015-09-08,2021-06-21,1,,,XELOX,,,,,,2, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren混合型,G3, (1a)00 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)06 (5)00 (6)05 (7)04 (8a)03 (8p)00 (9)00 (11p)02 (14v)02," L（幽门窦部）, 大弯侧Gre,",25,20,18, R0 D2+,,8.28,5.97,1.81,170.0,229.0,3.1,39.0,33.0,150.0,72.0,35.0,14.68,4.67,76.0,409.0,50.0,26.0,6.8,6.1,93.0,518.0,,,,,,,,,,,,,2.01,3.45,2.68,,无,, P0,H0, 未做,CK + Vimentin部分+ VEGF+ CMET+,,,,,69.41524310118265,1527959
1528260,徐爱民,610918,男,49,T2,N1,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+,1.0,27,中间型（int）,INFa,0.0,,,,,,,1.0,2015-09-10,2020-10-06,1,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)08 (3b)00 (4sb)00 (4d)04 (5)01 (6)01 (7)01 (8a)04 (8p)01 (9)04 (11p)00,L（幽门窦部） 小弯侧Less 后Post ,30,30,5, R0 D2,,8.97,4.33,3.67,141.3,339.0,2.4,20.0,16.0,129.0,67.0,29.0,9.97,3.34,60.0,311.0,38.0,22.0,5.2,6.5,101.0,343.0,,,,,,,,,,,,,1.46,9.51,2.27,,无,, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(+) D2-40（+）,,,,,60.873850197109064,1528260
1528373,王俊生,613829,男,63,T2,N0,M0, ⅠB,1,2,2.0,0.0,0.0,1.0, 肠化生+,0.0,13,中间型（int）,INFc,0.0,,,,,,,1.0,2015-09-10,2020-10-06,1,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)02 (1b)02 (3a)01 (4sb)00 (4d)00 (5)01 (6)00 (7)02 (8a、8p)02 (9)00 (11p)03 (12a)00," L（幽门窦部）, 前Ant,",25,25,6, R0 D2+,,5.09,2.55,2.07,158.9,144.0,2.16,18.0,22.0,174.0,72.0,38.0,25.3,9.3,68.0,211.0,43.0,25.0,5.4,6.5,71.0,337.0,,,,,,,,,,,,,1.49,6.05,2.5,,无,, P0,H0, 未做,CK + Vimentin– VEGF- CMET+,,,,,60.873850197109064,1528373
1528154,李相阳,612076,男,44,T4b,N3a,M0, ⅢC,1,3,2.0,1.0,,1.0, 慢性炎症（+）,8.0,12,中间型（int）,INFb,0.0,,,,,,,1.0,2015-09-09,2016-02-14,2,,,SOX,,,,,,5, 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren弥漫型,G3, (1a) (1b) (3a)34 (4sb)00 (14v) (4d) (6)47 (5) (12a) (7) (8a) (8p) (9) (11p) (3b)11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,55,10, D2+,R1,6.14,4.03,1.44,76.8,279.0,2.78,13.0,17.0,183.0,71.0,9.0,7.86,2.34,66.0,250.0,43.0,23.0,4.3,6.0,77.0,472.0,,,,,,,,,,,,,1.95,6.38,9.4,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,5.19053876478318,1528154
1528327,王杰,608867,男,59,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,20.0,31,中间型（int）,INFa,1.0,,1.0,,,,,1.0,2015-09-10,2019-05-03,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)813 (3b)11 (4sb)03 (4d)00 (5)00 (6)56 (7)00 (9)44 (11p)22 (8a) (8p) (12a)01," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,45,10, R0 D2,,8.77,5.79,1.57,65.0,714.0,6.43,19.0,21.0,142.0,75.0,25.0,6.32,3.24,64.0,95.0,35.0,29.0,4.8,4.4,84.0,358.0,,,,,,,,,,,,,3.37,6.36,135.6, 未做,无, 无, P0,H0, 未做,/ CK（+）、 Vimentin（-）、 VEGF（部分+）、 CMET（+）、CK5/6小灶（+）、P63小灶（+）,,,,,43.72536136662286,1528327
1528259,张恒,611940,男,79,T4b,N3a,M0, ⅢC,1,4,1.0,1.0,1.0,1.0, 异型增生+,7.0,18,中间型（int）,INFb,1.0,,,,,,,1.0,2015-09-10,2016-05-18,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70% 低粘附腺癌20% 粘液腺癌（muc）10% Lauren混合型,G3, (1a)00 (1b)44 (2)05 (3a)22 (3b)11 (4sb)00 (4d)24 (5)00 (6)00 (7)02," L（幽门窦部）, M（胃体部）, U（胃底部）, LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,70,20,,R2,4.99,3.3,1.04,116.3,239.0,4.9,8.0,12.0,118.0,75.0,26.0,6.08,3.04,57.0,112.0,29.0,28.0,5.5,9.3,107.0,194.0,,,,,,,,,,,,,2.26,43.32,2.63, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,8.245729303547963,1528259
1528863,张万发,613553,男,63,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,11,中间型（int）,INFa,1.0,,,,,,,1.0,2015-09-15,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,25,8, D2 R0,,6.66,3.57,2.38,128.0,289.0,2.94,20.0,24.0,158.0,52.0,6.0,11.75,4.05,62.0,321.0,42.0,20.0,5.0,10.6,76.0,,,,,,,,,,,,,,5.75,0.6,6.6,,,,,,,,,,,,60.709592641261494,1528863
1528620,李忠国,611281,男,61,T1b,N1,M0, ⅠB,1,2,2.0,1.0,,1.0, 肠化生+,1.0,46,中间型（int）,INFc,0.0,,,1.0,,,,2.0,2015-09-14,2020-10-06,1,,,SOX,,,,,,3, 低粘附腺癌 Lauren弥漫型,GX, (8p)04 (4sb)03 (3a)012 (4d)011 (6)04 (1b)02 (1a)04 (8a)04 (7)11 (3b)00 (5)01 (11p)00 (9)00," L（幽门窦部）, 前Ant,",30,25,3, R0 D2,,6.62,3.55,2.36,134.2,221.0,2.6,18.0,23.0,182.0,57.0,14.0,18.74,8.08,71.0,314.0,40.0,31.0,4.6,6.6,82.0,255.0,,,,,,,,,,,,,0.958,3.42,1.38,,无, 无, P0,H0, 未做, CK+， Vimentin部分+， VEGF-， CMET弱+,,,,,60.74244415243101,1528620
1528080,陈芳清,608837,男,65,T3,N1,M0, ⅡB,1,2,1.0,1.0,,1.0, 肠化生+,2.0,37,中间型（int）,INFc,0.0,,,,,,,1.0,2015-09-09,2020-10-06,1,,,口服替吉奥,,,,,,5, 低粘附腺癌90 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10 Lauren混合型,G3, (1a)03 (1b)02 (3a)15 (3b)12 (4sb)02 (4d)011 (5)01 (6)03 (7)03 (8a)01 (8p)01 (9)01 (11p)01 (12a)01," LM 前Ant, 后Post, 小弯侧Less,",80,70,20, R0 D2,,9.1,6.62,1.49,74.1,490.0,5.44,11.0,22.0,214.0,60.0,27.0,4.24,1.64,64.0,199.0,34.0,30.0,5.5,6.7,79.0,233.0,,,,,,,,,,,,,5.57,46.08,80.76,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,60.906701708278575,1528080
1528790,李国忠,613871,男,52,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 异型增生+,3.0,31,硬型（sci）,INFa,1.0,,,,,,,2.0,2015-09-15,2018-04-21,0,,,XELOX,SOX,SOX,SOX,,,4, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)04 (1b)11 (2)02 (3a)23 (3b)00 (4sb)04 (5)01 (7)00 (8a)01 (8p)03 (9)05 (11p)07 (10)00," U（胃底部）, 前Ant, 后Post, 小弯侧Less,",40,30,10, R0 D2+,,6.53,3.43,2.5,120.2,309.0,2.97,26.0,23.0,130.0,54.0,29.0,9.77,3.0,71.0,281.0,45.0,26.0,5.7,5.0,78.0,317.0,,,,,,,,,,,,,3.41,692.3,3.23,,无,, P0,H0, 未做,CK + Vimentin–VEGF- CMET弱+,,,,,31.176084099868593,1528790
1528371,刘士峰,611829,男,43,T2,N0,M0, ⅠB,1,2,1.0,0.0,0.0,1.0, 肠化生+,0.0,25,中间型（int）,INFb,0.0,,,1.0,,,,2.0,2015-09-10,2021-06-21,1,,,,,,,,,0, 低粘附腺癌90% 低分化腺癌（G3)(por)10% Lauren混合型,G3, (1a)06 (1b)02 (3a)07 (3b)00 (4d)00 (5)00 (6)04 (7)04 (8a)02 (8p)00 (9)00 (4sb)00," M（胃体部）, 小弯侧Less,",13,9,, R0 D2,,7.56,4.17,2.42,160.0,280.0,2.29,32.0,24.0,120.0,86.0,20.0,14.38,5.47,75.0,344.0,45.0,30.0,5.0,4.1,83.0,375.0,,,,,,,,,,,,,1.96,4.36,6.64, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（部分+）、 VEGF（-）、 CMET（+）,,,,,69.34954007884362,1528371
1536649,吴洪民,613609,男,63,T4b,N1,M0, ⅢB,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,1.0,44,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-11-25,2021-07-01,1,SOX*3,1.0,SOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)06 (1b)00 (2)07 (3a)03 (3b)00 (4sa)00 (4sb)01 (4d)05 (5)00 (6)01 (7)03 (8a)02 (8p)04 (9) 03(11p) 02(12a)12 大网05,GE 后Post 小弯侧Less ,40,40,10, R0 D2,,6.61,2.59,2.86,155.8,107.0,2.15,59.0,63.0,235.0,79.0,26.0,17.05,5.77,68.0,308.0,43.0,25.0,4.1,6.0,71.0,240.0,,,,,,,,,,,,,1.9,7.68,1.25, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF部分(+)  cMET(+) S100(+),,,,,67.18134034165571,1536649
1529619,曲兴芳,610625,女,77,T3,N0,M0, ⅡA,1,2,0.0,1.0,,0.0, 肠化生++,0.0,21,中间型（int）,INFa,1.0,,1.0,,,,,2.0,2015-09-22,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)06 (1b)05 (3a)00 (3b)00 (4sb)00 (4d)01 (5)00 (6)06 (7)00 (8a)01 (8p)00 (9)01 (11p)00 (12a)01," L（幽门窦部）, 小弯侧Less,",20,15,3, R0 D2,,7.95,4.46,2.99,141.6,222.0,3.11,16.0,24.0,189.0,88.0,12.0,11.62,4.15,68.0,213.0,44.0,24.0,7.1,4.4,58.0,192.0,,,,,,,,,,,,,3.68,33.23,,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF+ CMET弱+,,,,,60.51248357424441,1529619
1529897,张怀悦,613901,男,78,T3,N2,M0, ⅢA,1,3,1.0,1.0,,1.0, 慢性炎症（+）,3.0,18,硬型（sci）,INFc,0.0,,1.0,,,,,1.0,2015-09-23,2021-01-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)50 粘液腺癌（muc）30 低粘附腺癌20 Lauren混合型,G3, (1a)03 (1b)11 (2)03 (3a)24 (3b)00 (4sa)00 (4d)02 (5)00 (6)00 (7)00 (8a)04 (8p)01 (9)01 (11p)00 (12a)00," GE, SiewerⅢ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,45,13, R0 D2,,5.25,3.12,1.56,146.0,282.0,1.98,22.0,25.0,181.0,54.0,13.0,16.84,5.3,70.0,252.0,44.0,26.0,6.7,4.8,75.0,328.0,,,,,,,,,,,,,3.33,,,,无, 无, P0,H0, 未做,CK+ Vimentin- VEGF+ CMET+,,,,,63.30486202365309,1529897
1528778,李伟,611991,男,56,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+,19.0,27,中间型（int）,INFb,0.0,,,,,,,1.0,2015-09-15,2018-04-28,2,,,SOX,,,,,,6,低黏附性癌70 低分化管状腺癌30,G3, (7) (3a) (4d) (6) (11p) (8a) (8p) (9)," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,50,12,,R2,7.42,5.23,1.45,143.8,277.0,3.01,22.0,27.0,156.0,60.0,12.0,7.22,3.1,71.0,328.0,45.0,26.0,5.6,4.6,75.0,,,,,,,,,,,,,,63.88,382.2,3.78,,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+,,,,,31.40604467805519,1528778
1528681,朱士军,612207,男,62,T3,N0,M0, ⅡA,1,0,2.0,0.0,0.0,1.0, 肠化生++,0.0,27,中间型（int）,INFb,0.0,,,1.0,,,,1.0,2015-09-14,2021-05-24,1,,,SOX,,,,,,1, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)00 (12a)00 (3a)017 (3b)00 (4d)05 (4sb)00 (5)00 (6)00 (8a)01 (8p)00 (9)00 (4sa)00 (2)01 (11p)01 (7)00肿物旁01," U（胃底部）, 前Ant,",30,15,2, R0 D2,,4.99,2.78,1.5,86.7,262.0,2.18,16.0,22.0,134.0,53.0,24.0,5.63,2.4,48.0,264.0,31.0,17.0,5.3,6.9,110.0,363.0,,,,,,,,,,,,,1.24,3.59,0.897, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（部分+）、 VEGF（-）、 CMET（+）,,,,,68.29829172141918,1528681
1528716,王勤,612070,男,68,T3,N2,M0, ⅢA,1,3,0.0,1.0,,1.0, 肠化生+,3.0,8,中间型（int）,INFb,3.0,,,,,,,1.0,2015-09-14,2019-09-02,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3,小弯38," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",30,30,8, R0 D2,,11.17,9.78,0.68,110.0,190.0,,27.0,44.0,174.0,46.0,32.0,8.34,3.76,50.0,244.0,31.0,19.0,6.6,4.2,76.0,280.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,47.60183968462549,1528716
1528939,陈子滨,614084,男,53,T1b,N0,M0,ⅠA,1,1,0.0,0.0,0.0,0.0, 异型增生+,0.0,15,中间型（int）,INFa,1.0,,1.0,,,,,1.0,2015-09-16,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)05 (3a)06 (3b)00 (4sb)00 (4d)01 (5)00 (6)00 (7)01 (8a)01 (8p)00 (9)01 (11p)00," L（幽门窦部）, 后Post,",20,15,5, R0 D2,,5.14,3.24,1.37,150.2,175.0,2.27,29.0,31.0,193.0,71.0,24.0,15.31,5.66,66.0,296.0,42.0,24.0,4.7,6.7,79.0,344.0,,,,,,,,,,,,,3.9,16.9,, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(+)  cMET(+) ,,,,,60.709592641261494,1528939
1528883,马志君,614048,男,56,T1b,N0,M0,ⅠA,1,3,0.0,0.0,0.0,0.0, 异型增生+,0.0,60,中间型（int）,INFa,3.0,,,,,,,1.0,2015-09-15,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",20,20,12, R0 D2,,7.19,4.53,2.2,152.7,237.0,3.14,17.0,28.0,224.0,58.0,14.0,8.98,3.08,63.0,184.0,40.0,23.0,5.7,7.6,65.0,,,,,,,,,,,,,,3.42,23.22,6.85,,,,,,,,,,,,60.74244415243101,1528883
1528711,周延军,610967,男,46,T4b,N0,M0, ⅢA,1,3,2.0,0.0,,1.0, 慢性炎症（+）,0.0,16,中间型（int）,INFb,0.0,,,,,,,1.0,2015-09-14,2020-10-07,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren弥漫型,G3, (4sb) (4d)06 (3a) (3b) (1a) (1b) (5) (7)09 (11p) (11d)01 软组织可见癌N11," UM 前Ant, 后Post, 大弯侧Gre,",40,18,10, R0 D2,,13.13,10.54,1.52,90.4,407.0,5.74,37.0,35.0,231.0,217.0,302.0,7.06,5.45,47.0,46.0,25.0,22.0,4.5,4.2,50.0,112.0,,,,,,,,,,,,,1.21,4.49,0.932,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF- CMET+,,,,,60.775295663600524,1528711
1538049,闫淑芬,611813,女,52,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,17,中间型（int）,INFc,0.0,,,,,,,1.0,2015-12-08,2021-06-21,1,SOX*3,1.0,SOX,SOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)00 (3b)01 (4sb)00 (4d)06 (6)03 (7)01 (8a)01 (8p)01 (9)02 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",30,30,8, R0 D2,,4.18,2.18,1.62,124.9,110.0,1.63,58.0,70.0,187.0,73.0,20.0,26.64,9.7,72.0,323.0,45.0,27.0,4.9,3.3,62.0,263.0,,,,,,,,,,,,,5.58,4.77,2.47, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+) ,,,,,66.4257555847569,1538049
1529620,程桂杰,613784,女,44,T4b,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 慢性炎症（+）,36.0,52,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-09-22,2018-08-06,2,,,XELOX,,,,,,3,低黏附性癌70 低分化管状腺癌30,G3, (1b)66 (2)22 (3a)11 (3b)57 (4sa)88 (4sb)44 (4d)24 (5) 11(8a)25 (10)12 (11p)45," MU 前Ant, 后Post, 大弯侧Gre,",150,120,5,,R1,10.53,7.86,2.01,118.1,297.0,3.18,10.0,14.0,114.0,54.0,20.0,11.56,5.35,68.0,253.0,41.0,27.0,4.3,5.3,60.0,,,,,,,,,,,,,,1.5,6.57,1.91,,无, 无, P0,H0, 未做, CK +Vimentin- VEGF+ CMET-,,,,,34.46123521681997,1529620
1529017,王海英,612222,女,35,T3,N1,M0, ⅡB,1,2,2.0,0.0,0.0,1.0, 肠化生+,1.0,57,中间型（int）,INFc,2.0,,1.0,1.0,,,,1.0,2015-09-16,2022-09-01,1,,,XELOX,,,,,,6, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)02 (1b)01 (3a)16 (3b)08 (4sb)08 (4d)05 (5)00 (6)010 (7)03 (8a)03 (8p)04 (9)04 (11p)00 (12a)03,L（幽门窦部） 小弯侧Less 后Post ,40,35,8, R0 D2,,6.56,3.29,2.71,140.6,303.0,2.09,8.0,13.0,148.0,48.0,16.0,12.94,4.88,64.0,317.0,38.0,26.0,4.0,4.7,65.0,219.0,,,,,,,,,,,,,1.12,2.59,2.7, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(部分+)  VEGF(部分+)  cMET(+)  S100(+),,,,,83.50854139290406,1529017
1529340,隋胜江,611577,男,51,T2,N0,M0, ⅠB,1,2,2.0,0.0,0.0,1.0, 肠化生+,0.0,25,中间型（int）,INFc,0.0,,,,,,,1.0,2015-09-18,2021-06-21,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,卡佩他滨,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b) 011(3a)00 (3b)00 (4sb)00 (4d)00 (5)00（6）05 (7)01 (8a)01 (8p)05 (9)01 (11p)00 (6) 软组织可见癌," L（幽门窦部）, 大弯侧Gre,",35,25,5, R0 D2,,8.04,3.88,3.13,171.0,262.0,2.53,38.0,30.0,208.0,80.0,31.0,8.96,2.73,62.0,311.0,36.0,26.0,4.9,6.2,82.0,361.0,,,,,,,,,,,,,0.759,5.98,3.34, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+) S100(+),,,,,69.08672798948751,1529340
1529925,李凤英,612707,女,74,T3,N3a,M0,ⅢB,1,2,1.0,1.0,,1.0, 肠化生+,7.0,23,中间型（int）,INFb,1.0,,,,,,,1.0,2015-09-23,2018-09-24,2,,,SOX,SOX,SOX,SOX,口服替吉奥,口服替吉奥,6, 粘液腺癌（muc）70 低粘附腺癌30 Lauren混合型,GX, (1a) (1b) (3a) (3b) (5)411 (4sb) (4d) (6)210 (8a)12," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,35,7, R0 D2,,11.66,7.21,2.94,117.8,390.0,4.73,30.0,27.0,172.0,80.0,21.1,7.57,1.97,79.3,173.83,43.0,36.3,7.0,4.15,62.0,271.0,,,,,,,,,,,,,49.98,10.74,2.91,,无, 无, P0,H0, 未做,CK+， Vimentin-， VEGF-， CMET部分+,,,,,36.038107752956634,1529925
1530108,康凤云,614075,女,63,T2,N3a,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 肠化生+,7.0,23,中间型（int）,INFa,0.0,,,,,,,2.0,2015-09-24,2015-12-10,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)00 (3a)09 (7)12 (6)02 (8p)00 (3b)22 (12a)01 (4d)01 (4sb)00 (9)11 (5)01 (11p)34 (8a)00,L（幽门窦部） 前Ant 后Post 小弯侧Less ,50,50,6, R0 D2,,8.65,4.47,3.42,138.5,239.0,2.68,30.0,29.0,158.0,58.0,19.0,9.99,4.11,72.0,268.0,44.0,28.0,6.7,5.8,50.0,298.0,,,,,,,,,,,,,1.54,69.69,25.5, 未做,无, 无, P0,H0, 未做,ck（+），vimentin（-），VEGF(-)，cMET(+)，CD34(+)， S100(+) D2-40（+）,,,,,2.5295663600525624,1530108
1529448,徐亚东,610952,男,57,T3,N0,M0, ⅡA,1,2,2.0,1.0,,1.0, 肠化生+,0.0,31,中间型（int）,INFc,1.0,,,1.0,,,,1.0,2015-09-21,2020-10-07,1,,,FOLFOX,,,,,,6,低黏附性癌80 低分化管状腺癌20,G3,," ML 前Ant,",30,25,3,R0 D2,,6.21,3.41,1.75,149.5,240.0,,15.0,24.0,225.0,73.0,17.0,11.38,3.66,67.0,282.0,44.0,23.0,4.5,6.8,74.0,,,,,,,,,,,,,,2.15,9.97,0.952,,无, 无, P0,H0, 未做,,,,,,60.545335085413925,1529448
1529538,宋桂英,611802,女,55,T1b,N0,M0,ⅠA,1,0,1.0,1.0,,0.0, 肠化生+,0.0,29,中间型（int）,INFb,3.0,,,1.0,,,,1.0,2015-09-21,2020-10-07,1,,,,,,,,,0, 低分化腺癌80 低黏附20,G3,," L（幽门窦部）, 前Ant,",9,,,R0 D2,,9.1,5.72,2.67,138.0,253.0,2.42,22.0,21.0,157.0,61.0,7.0,41.25,13.93,68.0,310.0,44.0,24.0,5.9,9.1,51.0,,,,,,,,,,,,,,3.33,14.72,3.9,,无, 无, P0,H0, 未做,,,,,,60.545335085413925,1529538
1529467,崔云飞,611329,女,50,T3,N3b,M1, ⅢC,1,4,2.0,1.0,1.0,1.0, 慢性炎症（+）,37.0,40,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-09-21,2016-03-27,2,,,FOLFOX,FOLFOX,FOLFOX,替吉奥联合多西他赛联合奥沙利铂,,,4, 低分化管状腺癌（G3)(por)70% 低粘附腺癌30%,G3, (1b)11 (2)11 (3a) 33(4sa) 22(4d) 1314(6)12 (7)66 (8a)11 (8p)22 (9)11 (11p)66 (4sb)00," 后Post, 小弯侧Less, LMU",110,50,8,,R2,5.01,3.13,1.37,114.0,256.0,2.52,15.0,22.0,182.0,67.0,23.0,13.81,4.45,72.0,189.0,43.0,29.0,4.6,4.7,59.0,,,,,,,,,,,,,,0.66,35.7,8.7,,无, 无, p1局肠缘(M1 PER),H0, 未做, CK+ VEGF+ CMET+ Vimentin-,,,,,6.176084099868594,1529467
1529707,张喜林,613484,男,61,T3,N3b,M0, ⅢC,1,4,1.0,1.0,1.0,1.0, 肠化生+,24.0,46,中间型（int）,INFb,2.0,,1.0,,,,,2.0,2015-09-22,2019-09-04,2,,,XELOX,,,,,,4, 低分化腺癌（G3)(por) 乳头状癌20（G1）（pap） 低黏附20 Lauren混合型,G3, (9)16 (11p)13 (8a)11 (7)33 (6)67 (4sb)48 (3a)46 (3b)11 (1b)23," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,30,10,,R1,5.7,3.35,1.67,138.0,170.0,3.46,22.0,26.0,176.0,45.0,7.0,10.59,3.25,54.0,311.0,34.0,20.0,5.1,5.6,70.0,,,,,,,,,,,,,,1.63,539.9,5.19,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF+ CMET+,,,,,47.40473061760841,1529707
1529553,刘成林,611697,男,63,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+,0.0,15,中间型（int）,INFa,0.0,,1.0,,,,,1.0,2015-09-21,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)01 (3b)00 (4sb)01 (4d)05 (5)00 (6)02 (7)02 (8a)01 (8p)00 (9)02 (11p)01 (12a)," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,35,10, R0 D2,,7.0,62.5,28.0,147.0,271.0,3.76,19.0,25.0,156.0,99.0,26.0,8.06,3.0,70.0,222.0,45.0,25.0,4.8,4.5,74.0,392.0,67.6,32.0,31.8,1.01,0.2,5.8,23.0,3.5,1.11,1.99,10.4,38.5,2.5,3.63,3.85, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）,,,,,83.3442838370565,1529553
1530103,李艳江,614098,男,60,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,1.0, 异型增生+ 慢性炎症（+）,0.0,13,中间型（int）,INFa,0.0,,,,,,,0.0,2015-09-24,2019-02-01,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】50% 粘液腺癌（muc）50% Lauren肠型,G2, 大弯04小湾06 (8a) (8p)02 (9)01," L（幽门窦部）, 小弯侧Less,",40,35,5, R0 D2,,13.51,51.1,42.49,120.5,434.0,4.44,6.0,14.0,116.0,95.0,12.0,6.44,2.49,35.0,178.0,35.0,30.0,4.3,4.8,75.0,279.0,81.4,16.1,63.0,0.26,0.2,3.2,15.8,2.9,1.15,5.71,11.2,26.5,3.11,38.88,7.81,,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,40.27595269382392,1530103
1529540,李凤荣,613875,女,59,T3,N3a,M0,ⅢB,1,3,2.0,1.0,,0.0, 肠化生++,8.0,31,中间型（int）,INFc,0.0,,,,,,,1.0,2015-09-21,2018-09-19,2,,,XELOX,,,,,,6, 低粘附腺癌 Lauren弥漫型,GX, (4sb)00 (1a)01 (12a)00 (6)37 (9)00 (11p)34 (4d)17 (3a)06 (3b)01 (8p)02 (8a)00 (7)00 (5)11 (1b)02," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",70,85,20, R0 D2,,4.81,2.56,1.7,106.1,231.0,3.1,11.0,16.0,178.0,59.0,17.0,14.88,5.22,65.0,220.0,40.0,25.0,4.3,5.0,61.0,196.0,,,,,,,,,,,,,33.66,80.5,237.8,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET+,,,,,35.939553219448094,1529540
1529466,王淑云,611691,女,67,T1a,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+,0.0,20,中间型（int）,INFa,0.0,,1.0,,,,,1.0,2015-09-21,2020-10-07,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (4d)01 (4sb)00 (1b)00 (7)00 (11p)00 (6)01 (5)00 (8a)02 (12a)00 (3a)013 (9)01 (1a)01 (8p)00 (3b)00," L（幽门窦部）, 小弯侧Less,",22,15,3, R0 D2,,7.44,3.03,3.73,124.0,269.0,3.76,18.0,20.0,156.0,85.0,24.0,11.62,4.11,64.0,251.0,38.0,26.0,4.9,5.6,80.0,347.0,,,,,,,,,,,,,2.43,8.14,1.25,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF部分+ CMET+,,,,,60.545335085413925,1529466
1529550,崔德春,612136,男,57,T4b,N1,M0, ⅢB,1,3,2.0,1.0,,1.0, 慢性炎症（+）,2.0,19,中间型（int）,INFb,1.0,,,,,,,1.0,2015-09-21,2021-07-01,1,,,XELOX,,,,,,4, 低分化腺癌（G3)(por),G3, (11p) (11d)," LMU 前Ant, 后Post, 小弯侧Less,",110,110,15,,R1,13.77,10.27,2.55,100.5,513.0,5.16,9.0,9.0,107.0,87.0,18.0,5.77,2.51,65.0,154.0,36.0,29.0,4.1,8.6,99.0,,,,,,,,,,,,,,1.18,4.63,6.24,,无, 无, P0,H0, 未做,,,,,,69.3166885676741,1529550
1529523,王亚杰,613485,女,60,T3,N3a,M0,ⅢB,1,4,2.0,1.0,1.0,1.0, 慢性炎症（+）,10.0,16,中间型（int）,INFc,1.0,,,,,,,1.0,2015-09-21,2016-09-15,2,,,,,,,,,0, 低粘附腺癌80%， 低分化腺癌（G3)(por)20%， Lauren弥漫型,G3, (1a)34 (1b)00 (2)11 (3a)44 (3b)00 (4sa)01 (4sb)00 (4d)01 (5)00 (6)01 (7)00 (8a)01 (8p)23 (9)00 (11p) 00(12a)00，1b、2组见癌组织," SiewerⅡ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,150,10, R0 D2,,4.53,2.74,1.44,130.0,325.0,2.42,16.0,23.0,209.0,62.0,10.0,9.77,3.33,72.0,234.0,43.0,29.0,5.2,6.8,59.0,309.0,,,,,,,,,,,,,2.68,15.58,10.01, 未做,无, 无, P0,H0, 未做, Vimentin- VEGF- CK+ CMET + S-100 CD34 D2-40(可见脉管瘤栓、神经侵犯),,,,,11.826544021024967,1529523
1529554,吴文明,612143,男,42,T2,N0,M0, ⅠB,1,3,1.0,0.0,0.0,1.0, 肠化生+,0.0,30,中间型（int）,INFb,0.0,,,,,,,1.0,2015-09-21,2021-06-21,1,,,XELOX,,,,,,2, 低粘附腺癌90 管状腺癌（中分化【G2】【tub2】10 Lauren混合型,G2, (1a)02 (1b)01 (3a)02 (3b)01 (4sb)00 (4d)08 (5) 00(6)01 (7）04(8a) 01(8p)04 (9)03 (11p)02 (12a)00 (12p)01, L（幽门窦部） 后Post 小弯侧Less ,35,30,6, R0 D2,,5.7,2.44,2.72,152.3,199.0,2.36,15.0,20.0,158.0,52.0,12.0,14.22,4.53,67.0,291.0,47.0,20.0,4.9,6.9,69.0,270.0,,,,,,,,,,,,,2.48,18.65,33.3, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-) S100(+),,,,,68.98817345597897,1529554
1529868,马学成,614050,男,56,T3,N3b,M0, ⅢC,1,3,1.0,1.0,,1.0, 肠化生+,16.0,37,硬型（sci）,INFb,1.0,,,,,,,1.0,2015-09-23,2019-04-02,2,,,SOX,,,,,,6,低黏附性癌70% 中低分化管状腺癌30%,G3, (4d) (6) (8a) (9) (11p)," L（幽门窦部）,",50,45,12,R0 D2,,5.05,2.72,1.89,83.6,312.0,2.03,15.0,21.0,155.0,50.0,7.0,13.99,4.06,59.0,287.0,41.0,18.0,5.3,7.5,63.0,,,,,,,,,,,,,,4.57,369.4,1.93,,无, 无, P0,H0, 未做,,,,,,42.27989487516425,1529868
1529962,魏景玉,612966,男,62,T2,N1,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,1.0,28,中间型（int）,INFa,0.0,,,,,,,2.0,2015-09-24,2019-05-03,0,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60% 乳头状癌（G1）（pap）40% Lauren肠型,G3, (1a)01 (1b)04 (3a)011 (3b)00 (4sb)00 (4d)02 (5)00 (6)16 (7)02 (8a)01 (8p)01 (9)00 (11p)00 (12a)00网膜左根部00," L（幽门窦部）, 小弯侧Less,",25,20,6, R0 D2,,7.47,49.68,41.98,158.5,270.0,2.34,34.0,26.0,160.0,69.0,46.0,21.69,7.4,70.0,329.0,47.0,23.0,4.7,5.8,76.0,432.0,65.5,41.3,18.2,2.27,0.1,6.9,24.9,1.7,0.745,2.54,8.61,27.04,6.58,1.07,26.96, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET弱（+）,,,,,43.26544021024967,1529962
1529896,戴秀珠,614007,男,54,T2,N0,M0, ⅠB,1,3,0.0,0.0,,0.0, 异型增生+,0.0,30,中间型（int）,INFa,0.0,,,,,,,1.0,2015-09-23,2020-04-07,0,,,,,,,,,0, 低分化腺癌（G3)(por),G3,," L（幽门窦部）,",30,20,3,R0 D2,,12.42,8.63,2.69,155.6,362.0,3.33,16.0,22.0,201.0,87.0,15.0,13.03,3.72,70.0,346.0,47.0,23.0,4.1,6.8,82.0,,,,,,,,,,,,,,5.24,8.26,1.78,,无, 无, P0,H0, 未做,,,,,,54.467805519053876,1529896
1529771,张东生,613373,男,60,T3,N1,M0, ⅡB,1,2,2.0,1.0,1.0,1.0, 肠化生+,1.0,32,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-09-23,2020-10-07,1,,,XELOX,,,,,,5,低黏附性癌70% 低中分化管状腺癌30%,G2, (1a)01 (1b)00 (3a)05 (3b)00 (4sb)01 (4d)07 (5)01 (6)12 (7)04 (8a)02 (8p)05 (9)01 (11p)03 (12a)00 (14v)00," L（幽门窦部）,",50,30,10,R0 D2,,5.61,3.47,1.63,140.0,200.0,2.68,19.0,20.0,149.0,51.0,9.0,24.51,8.4,66.0,289.0,45.0,21.0,6.9,5.8,88.0,,,,,,,,,,,,,,1.77,31.99,1.46,,无, 无, P0,H0, 未做, CK+ VEGF+ Vimentin -CMET-,,,,,60.4796320630749,1529771
1529918,陈国文,612972,男,64,T3,N3b,M0, ⅢC,1,3,2.0,1.0,,1.0, 肠化生+,20.0,55,中间型（int）,INFc,0.0,,,,,,,0.0,2015-09-23,2016-08-16,2,,,XELOX,XELOX,紫杉醇 卡佩他滨,紫杉醇 卡佩他滨,紫杉醇 卡佩他滨,紫杉醇 卡佩他滨,7,低黏附性癌,GX, (7) (3a) (4d)," L（幽门窦部）, 前Ant,",70,60,8,R0 D2,,10.52,7.02,2.14,148.4,381.0,6.18,13.0,17.0,142.0,77.0,41.0,7.66,3.07,62.0,278.0,41.0,21.0,4.5,5.1,90.0,,,,,,,,,,,,,,4.06,17.34,300.0,,无, 无, P0,H0, 未做,,,,,,10.775295663600525,1529918
1530400,郭忠发,614484,男,74,T1a,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+,0.0,21,中间型（int）,INFa,1.0,,,,,,,0.0,2015-09-28,2021-07-23,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2,," L（幽门窦部）, 小弯侧Less,",10,6,1,R0 D2,,7.85,6.39,0.79,125.0,200.0,2.16,27.0,52.0,354.0,64.0,16.0,28.33,11.38,75.0,188.0,48.0,27.0,7.0,10.4,71.0,,,,,,,,,,,,,,8.1,8.29,34.92,,无, 无, P0,H0, 未做,,,,,,69.80946123521682,1530400
1529674,徐丽,613973,女,56,T1b,N0,M0,ⅠA,1,0,1.0,1.0,1.0,0.0, 肠化生+,0.0,31,中间型（int）,INFb,0.0,,,1.0,,,,2.0,2015-09-22,2021-07-23,1,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3, (1a)00 (1b)05 (8a)05 (4d)09 (4sb)00 (12a)00 (3a)04 (3b)01 (5)00 (6)04 (7)02 (8p)00 (9)01 (11p)00," M（胃体部）, 后Post,",15,15,5, R0 D2+,,4.46,1.92,2.1,126.4,220.0,2.12,22.0,22.0,158.0,86.0,25.0,7.0,1.74,68.0,268.0,40.0,28.0,5.2,4.9,78.0,252.0,,,,,,,,,,,,,,,,,无,, P0,H0, 未做,,,,,,70.0065703022339,1529674
1529996,赵忠臣,613711,男,58,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,28,中间型（int）,INFa,0.0,,,1.0,,,,2.0,2015-09-24,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (4d)02 (6)05 (5)00 (4sb)00 (3a)011 (1b)00 (12a)00 (11p)00 (3b)03 (7)00 (8a)01 (8p)01 (9)03,LM 前Ant 小弯侧Less ,25,25,, R0 D2,,6.87,3.81,2.29,148.1,272.0,2.58,18.0,25.0,159.0,79.0,17.0,13.63,5.24,75.0,254.0,48.0,27.0,4.5,9.6,89.0,474.0,,,,,,,,,,,,,2.36,0.965,1.03,,无,, P0,H0, 未做,ck（+），vimentin（+），VEGF(-)，cMET(+)，CD34(-)， S100(-) D2-40（-）,,,,,60.446780551905384,1529996
1530326,于新洲,613391,男,74,T3,N1,M0, ⅡB,1,3,1.0,1.0,,1.0, 慢性炎症（+） 异型增生+,1.0,46,中间型（int）,INFa,0.0,,,,,,,1.0,2015-09-28,2017-07-13,2,,,,,,,,,0, 低分化管状腺癌（G3)(por)70% 低粘附腺癌30%,G3, (3a)," MU 后Post,",85,50,13, R0,,5.86,3.06,2.04,59.5,307.0,3.14,16.0,20.0,123.0,90.0,8.0,8.01,2.91,59.0,170.0,38.0,21.0,4.8,6.1,61.0,,,,,,,,,,,,,,0.95,4.83,0.817,,无, 无, P0,H0, 未做,,,,,,21.48488830486202,1530326
1530122,李淑贤,615130,女,50,T3,N0,M0, ⅡA,1,3,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,16,硬型（sci）,INFc,1.0,,,,,,,0.0,2015-09-24,2020-10-07,1,,,,,,,,,0, 乳头状癌60（G1）（pap） 管状腺癌（中分化40【G2】【tub2】,G2,," L（幽门窦部）, 前Ant,",40,30,20,R0 D2,,4.05,1.87,1.73,100.0,143.0,2.24,13.0,24.0,177.0,85.0,11.0,10.45,3.75,69.0,219.0,43.0,26.0,4.5,8.5,68.0,,,,,,,,,,,,,,1.84,18.99,0.95,,无, 无, P0,H0, 未做,,,,,,60.446780551905384,1530122
1530325,初培杰,614148,男,70,T1a,N0,M0,ⅠA,1,0,1.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,26,髓样型（med）,INFa,1.0,,,,,,,0.0,2015-09-28,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren混合型,G2, (1a)01 (1b)02 (3a)07 (3b)03 (4sb)00 (4d)05 (5)00 (6)02 (7)03 (8a)00 (8p)01 (9)02 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",30,20,2, R0 D2,,6.19,3.9,4.99,157.0,186.0,2.31,12.0,19.0,176.0,68.0,14.0,18.37,7.76,66.0,263.0,39.0,27.0,3.9,9.5,86.0,316.0,,,,,,,,,,,,,3.38,19.84,2.69,,无, 无, P0,H0, 未做,CK+ Vimentin- VEGF- CMET-,,,,,60.31537450722733,1530325
1530282,王凤云,613323,女,56,T3,N0,M0, ⅡA,1,3,1.0,0.0,,1.0, 肠化生+,0.0,46,中间型（int）,INFa,0.0,,1.0,,,,,1.0,2015-09-25,2020-12-17,1,,,XELOX,,,,,,5, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40 Lauren混合型,G3, (1a) (1b) (3a) (3b) (5) (7) (8a) (8p) (9)019 (4sb) (4d) (6) (11p)020," LM 前Ant, 后Post, 小弯侧Less, 大弯侧Gre,",70,70,7, R0 D2,,13.13,11.67,1.17,101.2,75.0,3.14,22.0,27.0,180.0,61.0,13.0,7.11,2.5,67.0,209.0,27.0,,5.1,5.1,62.0,270.0,,,,,,,,,,,,,1.15,12.56,13.26,,无, 无, P0,H0, 未做,CK+ Vimentin- VEGF+ CMET部分+,,,,,62.74638633377135,1530282
1530416,张含玺,613037,男,66,T2,N3b,M0, ⅢB,1,2,1.0,1.0,1.0,1.0, 异型增生+,18.0,45,中间型（int）,INFb,0.0,,,,,,,0.0,2015-09-28,2020-10-07,0,,,卡佩他滨,,,,,,2,中低分化 80 低黏附20,G3, (3a) (3b) (4d) (6) (9) (12a)," L（幽门窦部）, 前Ant,",40,30,12,R0 D2,,4.84,2.28,1.87,105.5,207.0,,7.0,17.0,138.0,40.0,8.0,8.96,3.81,53.0,108.0,27.0,26.0,4.3,4.3,86.0,,,,,,,,,,,,,,2.62,30.22,1.29,,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF- CK +,,,,,60.31537450722733,1530416
1530037,刘恒荣,614787,男,66,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+,5.0,41,中间型（int）,INFa,1.0,,1.0,,,,,1.0,2015-09-24,2017-08-13,2,,,FOLFOX,,,,,,5, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)017 (3b)01 (9)04 (11p)00 (12a)00 (4sb)00 (4d)311 (5)00 (6)25 (7)02 (8a) (8p)01," L（幽门窦部）, 前Ant,",70,45,15, R0 D2,,4.4,55.05,33.59,134.2,226.0,3.14,14.0,20.0,127.0,79.0,11.0,12.62,4.55,69.0,266.0,42.0,27.0,5.0,5.0,87.0,204.0,51.1,27.1,18.6,1.46,0.1,17.3,29.2,2.9,0.798,3.98,10.5,5.0,1.02,17.0,2.12, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（+）、 CMET（+）、CK5/6(-)P63(-),,,,,22.634691195795007,1530037
1530413,张道红,611736,男,49,T3,N3a,M0,ⅢB,1,3,2.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,14.0,45,髓样型（med）,INFa,0.0,,,,,,,0.0,2015-09-28,2019-05-03,0,,,,,,,,,0, 粘液腺癌（muc）60% 低粘附腺癌40% Lauren弥漫型,GX, (1a)02 (1b)02 (3a)411 (3b)00 (4sb)08 (4d)12 (5)11 (6)89 (7)00 (8a)01 (8p)00 (9)02 (11p)01 (12a)03 (15)03," L（幽门窦部）, 后Post,",70,50,10, R0 D2,,3.33,1.85,1.22,147.0,172.0,2.3,17.0,21.0,145.0,40.0,8.0,14.79,6.41,68.0,298.0,44.0,24.0,4.6,4.0,60.0,347.0,,,,,,,,,,,,,0.582,10.63,12.18, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,43.13403416557161,1530413
1530466,马桂珍,613375,女,80,T2,N0,M0, ⅠB,1,2,1.0,0.0,0.0,0.0, 异型增生+ 慢性炎症（+）,0.0,16,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-09-29,2021-07-23,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren混合型,G2, (1a)02 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)02 (5)01 (6)01 (7)02 (8a)03 (8p)03 (9)01 (11p)00," ML 小弯侧Less,",15,10,8, R0 D2+,,7.25,4.86,1.81,123.6,212.0,2.19,7.0,15.0,145.0,75.0,22.0,20.06,6.56,66.0,192.0,41.0,25.0,7.1,12.1,144.0,480.0,,,,,,,,,,,,,3.27,19.81,1.06,,无,, P0,H0, 未做,CK + Vimentin - VEGF+ CMET- ,,,,,69.7766097240473,1530466
1530405,李艳芹,612436,女,74,T3,N2,M1, Ⅳ,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,3.0,23,中间型（int）,INFa,2.0,,,,,,,0.0,2015-09-28,2021-07-23,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,(1b)01 (3a)16 (3b)01 (4sb)01 (4d)07 (5)11 (6)00 (8a) 01(8p)11 (9)01 (11p) 03(12a)00 胰腺被膜可见癌,L（幽门窦部） 小弯侧Less 后Post ,50,50,20,,R1,5.94,3.76,1.47,115.0,268.0,2.38,16.0,22.0,165.0,61.0,12.0,9.3,3.95,64.0,167.0,34.0,30.0,6.7,9.7,72.0,405.0,,,,,,,,,,,,,4.15,341.8,2.73, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  D2-40(+) S100(+),,,,,69.80946123521682,1530405
1530565,于春云,487260,女,59,T3,N0,M0, ⅡA,1,3,1.0,0.0,0.0,0.0, 肠化生+,0.0,28,中间型（int）,INFc,0.0,,,,,,,0.0,2015-09-29,2021-05-24,1,,,XELOX,,,,,,3, 粘液腺癌（muc）90 低粘附腺癌10 Lauren混合型,GX, (1a)02 (1b)01 (3a)02 (3b)00 (4sb)0 (4d)05 (5)00 (6)01 (7)09 (8a)02 (9)04 (11p)00," ML 小弯侧Less,",35,30,10, R0 D2+,,5.62,3.41,1.66,118.0,267.0,5.27,40.0,39.0,189.0,124.0,42.0,4.57,1.53,63.0,198.0,38.0,25.0,4.9,7.6,71.0,187.0,,,,,,,,,,,,,1.25,22.91,36.07,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET- ,,,,,67.80551905387648,1530565
1530539,苍景民,613393,男,42,T3,N3a,M0,ⅢB,1,4,2.0,1.0,1.0,1.0, 异型增生+,11.0,23,中间型（int）,INFc,0.0,,,,,,,2.0,2015-09-29,2016-06-10,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)01 (2)03 (3a)33 (3b)00 (4sb)00 (4d)25 (5)00 (6)22 (7)11 (8a)11 (8p、9)02 (10)00 (11p)24 (12a)01," UM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,,, R0 D2+,,7.55,4.78,2.21,168.0,284.0,2.53,21.0,21.0,142.0,93.0,24.0,17.37,6.34,76.0,346.0,45.0,31.0,5.5,4.8,77.0,357.0,,,,,,,,,,,,,8.36,19.44,5.88,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET弱+,,,,,8.377135348226018,1530539
1530538,杨明春,613119,男,56,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+,2.0,27,中间型（int）,INFa,1.0,,1.0,,,,,0.0,2015-09-29,2021-07-01,1,,,SOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (6)13 (12a) 12(1a)01 (1b)00 (3a)05 (3b)03 (4sb) 01(4d)00 (5)00 (7)01 (9)04 (11p)07," L（幽门窦部）, 前Ant, 后Post,",80,50,10,,R1,5.48,2.88,1.77,94.0,224.0,4.08,16.0,20.0,155.0,88.0,31.0,5.94,1.84,67.0,264.0,35.0,32.0,4.4,5.1,82.0,,,,,,,,,,,,,,1.53,0.6,5.68,,无, 无, P0,H0, 未做, CK+ VEGF+ CMET- Vimentin-,,,,,69.053876478318,1530538
1530561,史桂芝,614831,女,47,T3,N3b,M0, ⅢC,1,2,0.0,1.0,,1.0, 异型增生+ 慢性炎症（+）,32.0,43,中间型（int）,INFb,2.0,,1.0,,,,,2.0,2015-09-29,2018-04-08,2,,,XELOX,,,,,,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1b) (3a) (3b) (4d) (6) (7) (8a) (8p) (9)," L（幽门窦部）, 后Post,",20,20,8, R0 D2,,4.02,2.3,1.29,73.0,255.0,2.09,16.0,23.0,138.0,64.0,24.0,8.83,3.13,66.0,237.0,39.0,27.0,4.2,4.9,56.0,,,,,,,,,,,,,,5.31,9.84,1.44,,无,,,,,,,,,,30.28909329829172,1530561
1530467,任万香,614843,男,62,T3,N0,M0, ⅡA,1,2,0.0,1.0,,1.0, 肠化生+,0.0,30,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-09-29,2019-05-03,2,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 粘液腺癌10（muc）,G2,," ML 大弯侧Gre, 前Ant,",40,35,10,R0 D2,,4.66,2.4,1.66,157.0,197.0,3.11,44.0,34.0,155.0,80.0,34.0,9.79,3.73,71.0,194.0,44.0,27.0,4.9,6.7,71.0,,,,,,,,,,,,,,2.31,23.9,3.41,,无, 无, P0,H0, 未做,,,,,,43.1011826544021,1530467
1530556,孙树全,613107,男,71,T1a,N0,M0,ⅠA,1,0,1.0,0.0,0.0,0.0, 异型增生+,0.0,26,中间型（int）,INFb,0.0,,1.0,,,,,0.0,2015-09-29,2019-05-03,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60% 低粘附腺癌40% Lauren混合型,G3, (1a)02 (1b)01 (3a)07 (3b)00 (4sb)00 (4d)06 (5)00 (6)02 (7)03 (8a)01 (8p)04 (9)00 (12a)00 (11p)00," L（幽门窦部）, 小弯侧Less,",35,20,4, R0 D2,,6.26,3.78,1.78,171.0,235.0,1.93,27.0,29.0,163.0,59.0,44.0,26.04,8.5,67.0,366.0,40.0,27.0,5.7,5.7,66.0,366.0,,,,,,,,,,,,,1.78,7.72,4.62,,无, 无, P0,H0, 未做, CK（+）、 Vimentin（0-）、 VEGF（+）、 CMET（-）,,,,,43.1011826544021,1530556
1530584,杨占山,614781,男,65,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,20,中间型（int）,INFa,3.0,,1.0,,,,,0.0,2015-09-30,2019-08-30,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)00 (3a)07 (3b)02 (4sb)00 (4d)04 (5)00 (6)01 (7)01 (8a)00 (8p)01 (9)01 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less, 前Ant,",30,25,1, R0 D1,,5.01,2.53,1.84,144.0,74.0,1.6,41.0,43.0,187.0,148.0,258.0,18.86,7.76,65.0,192.0,34.0,31.0,4.9,6.8,68.0,247.0,,,,,,,,,,,,,2.97,44.47,2.12, 未做,无, 无, P0,H0, 未做," Vimentin-, VEGF+, CK+, CMET-, CD34、D2-40(未见明确脉管瘤栓) S-100（未见明确神经侵犯）",,,,,46.97766097240473,1530584
1530708,尹国学,614139,男,63,T2,N0,M0, ⅠB,1,3,2.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,18,中间型（int）,INFa,1.0,,,,,,,0.0,2015-10-08,2021-07-23,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3,," M（胃体部）, 前Ant, 大弯侧Gre,",30,28,8,R0 D2,,4.67,3.26,0.86,139.0,165.0,2.68,11.0,19.0,144.0,76.0,8.0,7.69,2.15,62.0,215.0,37.0,25.0,5.0,5.3,80.0,,,,,,,,,,,,,,2.51,42.17,4.62,,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF- CK+,,,,,69.48094612352168,1530708
1530703,杨忠发,615113,男,35,T3,N3a,M0,ⅢB,1,2,2.0,1.0,,1.0, 肠化生+,13.0,32,中间型（int）,INFc,0.0,,,,,,,0.0,2015-10-06,2020-05-18,0,,,,,,,,,0,低黏附性癌60% 低分化管状腺癌40%,G3, (1a)02 (3a)45 (3b)00 (4sb)00 (4d)28 (5)11 (6) 11(7)22 (8a) 34(8p)02 (9)00 (11p)07 (12a)00," L（幽门窦部）, 小弯侧Less,",30,16,15,R0 D2,,13.64,9.67,3.04,108.2,233.0,2.18,34.0,26.0,97.0,51.0,16.0,4.3,1.65,47.0,118.0,28.0,19.0,5.5,8.2,90.0,252.0,,,,,,,,,,,,,1.02,3.85,1.28,,无, 无, P0,H0, 未做, CK+ VEGF- Vimentin -CMET-,,,,,55.38764783180026,1530703
1531310,丛旭日,615109,男,60,T3,N1,M1, Ⅳ,1,3,0.0,1.0,1.0,1.0, 肠化生+,2.0,29,中间型（int）,INFc,2.0,,,,,,,0.0,2015-10-13,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (4d)," L（幽门窦部）,",80,60,20,,R2,8.91,6.76,1.15,59.9,239.0,2.63,31.0,36.0,178.0,84.0,14.0,8.95,4.06,76.0,222.0,39.0,37.0,6.1,6.0,90.0,,,,,,,,,,,,,,2.21,9.34,2.58,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET-,,,,,82.62155059132719,1531310
1530970,王慧,615115,女,55,T1b,N0,M0,ⅠA,1,0,1.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,29,中间型（int）,INFa,0.0,,,,,,,0.0,2015-10-10,2020-10-14,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低粘附腺癌20 Lauren混合型,G2,," L（幽门窦部）, 小弯侧Less,",50,40,5,R0 D2,,3.91,1.81,1.84,133.4,249.0,2.27,11.0,19.0,165.0,64.0,10.0,25.04,8.43,72.0,322.0,44.0,28.0,5.5,3.6,68.0,,,,,,,,,,,,,,1.2,6.98,6.29,,无, 无, P0,H0, 未做, CK + Vimentin- VEGF- CMET-,,,,,60.15111695137976,1530970
1531091,贾连忠,615125,男,59,T3,N1,M0, ⅡB,1,2,1.0,0.0,0.0,1.0, 肠化生+,1.0,13,中间型（int）,INFb,1.0,,,,,,,0.0,2015-10-12,2018-11-02,2,,,XELOX,,,,,,6, 低黏附75 低分化腺癌20（G3)(por) 粘液腺癌5（muc） Lauren混合型,G3, (3a)," U（胃底部）,",30,30,10,R0 D2,,7.49,4.72,2.23,155.0,256.0,3.01,15.0,17.0,146.0,98.0,58.0,15.88,6.96,71.0,355.0,43.0,28.0,5.9,6.6,75.0,,,,,,,,,,,,,,6.61,21.97,1.12,,无, 无, P0,H0, 未做, CK + Vimentin- VEGF- CMET-,,,,,36.69513797634691,1531091
1530729,雷恩语,614886,男,61,T3,N1,M0, ⅡB,1,3,2.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,2.0,39,中间型（int）,INFa,0.0,,,,,,,2.0,2015-10-08,2020-10-07,1,,,,,,,,,0, 低粘附腺癌70 低分化腺癌30（G3)(por) Lauren弥漫型,G3, (3b)," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,10,R0 D2,,4.07,2.22,1.47,69.6,362.0,1.7,10.0,15.0,134.0,51.0,7.0,5.47,2.65,53.0,149.0,30.0,23.0,4.9,4.3,73.0,,,,,,,,,,,,,,2.81,181.7,1.5,,无, 无, P0,H0, 未做, Vimentin— VEGF-CK+ CMET 弱,,,,,59.98685939553219,1530729
1531421,胡秀明,616084,男,63,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,8.0,26,中间型（int）,INFa,0.0,,,,,,,0.0,2015-10-13,2016-05-16,2,,,,,,,,,0, 低中分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)22 (2)01 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)00 (7)14 (8a)06 (9)26 (11d)02 (11p)33," U（胃底部）,",50,40,30,,R2,8.11,5.06,1.97,121.0,241.0,2.53,19.0,21.0,133.0,84.0,29.0,24.81,7.71,69.0,263.0,42.0,27.0,5.0,6.0,85.0,,,,,,,,,,,,,,36.9,823.5,2.38,,无, 无, P0,H0, 未做, CK +VEGF- Vimentin- CMET-,,,,,7.09592641261498,1531421
1530790,董忠胜,615095,男,51,T1a,N0,M0,ⅠA,1,0,1.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,25,中间型（int）,INFa,0.0,,,,,,,0.0,2015-10-08,2021-06-21,1,,,,,,,,,0, 低粘附腺癌60% 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40% Lauren混合型,G3, (1a)05 (1b)01 (3a)02 (3b)00 (4sb)03 (4d)02 (5)01 (6)02 (7)01 (8a)01 (8p)03 (9)01 (11p)02 (12a)01," L（幽门窦部）, 小弯侧Less,",40,30,, R0 D2,,5.41,2.19,2.59,146.0,189.0,1.98,19.0,22.0,128.0,80.0,18.0,8.13,3.3,70.0,265.0,45.0,25.0,5.2,7.8,78.0,347.0,,,,,,,,,,,,,1.3,4.97,2.94,,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,68.42969776609723,1530790
1531090,张洪杰,615227,女,43,T2,N0,M0, ⅠB,1,1,2.0,0.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,34,中间型（int）,INFa,0.0,,,,,,,0.0,2015-10-12,2016-10-15,0,,,XELOX,,,,,,3, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren弥漫型,G3, (1a)02 (1b)01 (3a)015 (3b)00 (4sb)00 (4d)06 (5)01 (6)03 (7)04 (8a)01 (8p)00 (9)01 (11p)00," M（胃体部）, 大弯侧Gre,",15,15,6, R0 D2,,5.96,3.97,1.29,123.0,355.0,2.16,16.0,23.0,166.0,57.0,16.0,14.25,5.63,76.0,266.0,47.0,29.0,5.3,4.2,63.0,201.0,,,,,,,,,,,,,2.1,0.6,1.32,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,12.12220762155059,1531090
1531245,王忠德,615138,男,66,T4b,N2,M0, ⅢB,1,2,0.0,1.0,,0.0, 肠化生+,3.0,16,中间型（int）,INFb,,,,,,,,,2015-10-12,2016-03-15,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】神经内分泌瘤 Lauren肠型,G3, (1a) (1b)11 (2)02 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)05 (5)00 (6)00 (7)00 (8a)03 (8p)02 (9)11 (10)01," U（胃底部）, 后Post,",50,50,8, R0 D2,,7.49,5.28,1.39,113.0,282.0,2.58,22.0,19.0,148.0,72.0,33.0,12.95,3.96,64.0,329.0,40.0,24.0,4.4,6.4,79.0,370.0,40.8,21.6,16.9,1.28,0.1,16.6,39.6,0.4,,2.12,9.25,36.6,2.57,11.18,11.26,,无, 无, P0,H0, 未做, Syn+ CD56部分+ CK+ CgA部分+,,,,,5.091984231274639,1531245
1531239,李金库,615179,男,50,T3,N2,M1, Ⅳ,1,3,1.0,1.0,1.0,1.0, 异型增生+ 慢性炎症（+）,6.0,16,中间型（int）,INFb,1.0,,,,,,,0.0,2015-10-12,2018-01-15,2,,,卡佩他滨,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40%， 粘液腺癌（muc）30%， 低粘附腺癌30%， Lauren混合型,G3, (1a) 02(1b)00 (3a)34 (3b)00 (4sb)00 (4d)35 (5)00 (6)04 (7)01，肝右叶内见中-低分化腺癌," ML 后Post,",45,30,6,,R1,7.32,4.17,2.26,161.7,199.0,3.33,30.0,35.0,505.0,91.0,39.0,13.3,4.85,75.0,343.0,48.0,27.0,7.8,8.3,80.0,425.0,,,,,,,,,,,,,2.6,72.47,1.68, 未做,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF- CK+ S-100（神经侵犯） CD34、D2-40(脉管瘤栓),,,,,27.135348226018397,1531239
1531482,马万春,612465,男,80,T2,N0,M0, ⅠB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,0.0,21,中间型（int）,INFa,0.0,,,,,,,0.0,2015-10-14,2017-08-11,2,,,,,,,,,0, 低粘附腺癌 70 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)00 (1b)02 (3a)05 (3b)00 (4sb)00 (4d)01 (5)00 (6)02 (7) 02(8a)01 (8p)03(9)02(11p)03(12a)00, L（幽门窦部） 前Ant ,50,22,2, R0 D2,,7.8,5.58,1.64,143.7,303.0,3.21,21.0,28.0,195.0,70.0,38.0,12.66,4.56,67.0,380.0,48.0,19.0,6.3,5.5,69.0,367.0,,,,,,,,,,,,,2.94,14.17,2.9, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  D2-40(+) S100(+),,,,,21.911957950065702,1531482
1532802,王立平,614858,男,67,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 异型增生+,29.0,30,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-10-26,2017-05-10,2,,,,,,,,,0, 管状腺癌（中低分化60【G2】【tub2】 低粘附腺癌40,G3, (1a)0/0 (1b)3/3 (3a)12/13 (3b)0/0 (4sb)0/0 (4d)2/2 (5)1/1 (6)6/6 (7)1/1 (8a)1/1 (8p)(9)3/3," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,15,,R2,6.74,3.57,2.55,116.4,174.0,2.45,26.0,33.0,146.0,52.0,16.0,9.67,5.48,60.0,184.0,39.0,21.0,6.1,5.8,74.0,377.0,,,,,,,,,,,,,1.36,4.64,53.66,,无,, P0,H0, 未做, CMET+ Vimentin- VEGF+ CK+ CD34+ S-100+,,,,,18.462549277266753,1532802
1531398,赵凤臣,616147,男,46,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,31,髓样型（med）,INFa,0.0,,,,,,,0.0,2015-10-13,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)02 (3b)08 (4sb)00 (4d)02 (5)01 (6)04 (7)08 (8a)01 (9)01 (11p)03," L（幽门窦部）, 小弯侧Less,",8,5,5, R0 D2+,,5.05,2.76,1.66,164.0,218.0,2.94,72.0,94.0,179.0,102.0,4092.0,22.33,6.57,65.7,442.18,45.4,20.3,4.9,2.01,56.0,304.0,,,,,,,,,,,,,5.08,11.87,0.846,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET-,,,,,82.62155059132719,1531398
1531225,沈成,613285,男,67,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,2.0,9,中间型（int）,INFa,2.0,,,,,,,0.0,2015-10-12,2017-03-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (5) (8a)," L（幽门窦部）,",45,45,15,R0 D2,,6.0,3.51,1.93,132.7,223.0,2.9,19.0,32.0,193.0,90.0,28.0,13.08,5.08,70.0,277.0,48.0,22.0,6.3,7.2,78.0,334.0,,,,,,,,,,,,,3.41,1.05,28.2,,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF -CK +,,,,,17.082785808147175,1531225
1531506,李艳清,611118,女,56,T3,N3a,M0,ⅢB,1,3,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,8.0,41,硬型（sci）,INFa,0.0,,,,,,,1.0,2015-10-14,2020-02-01,2,替吉奥*2,1.0,SOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)00 (2)00 (3a)04 (3b)13 (4sa)00 (4sb)00 (4d)110 (5)00 (6)02 (7)11 (8a) (8p) (9)210 (11p)23," LM 小弯侧Less,",30,25,5, R0 D2,,6.79,4.09,1.85,98.4,283.0,2.9,24.0,18.0,209.0,79.0,12.0,12.7,5.34,55.0,86.0,28.0,27.0,12.4,6.2,41.0,82.0,,,,,,,,,,,,,0.689,15.01,5.4,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF- CMET+,,,,,51.60972404730617,1531506
1531309,马玉琴,613271,女,61,T3,N0,M0, ⅡA,1,1,2.0,0.0,0.0,0.0, 肠化生+,0.0,23,中间型（int）,INFc,0.0,,,,,,,0.0,2015-10-13,2020-05-18,0,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)02 (1b)01 (3a)03 (3b)00 (4sb)03 (4d)00 (5)00 (6)05 (7)00 (8a)00 (8p)01 (9)04 (11p)04," M（胃体部）, 后Post, 小弯侧Less,",25,25,10, R0 D2+,,6.03,3.43,1.97,144.1,291.0,2.74,18.0,26.0,179.0,68.0,6.0,12.47,3.3,70.0,224.0,46.0,24.0,4.6,6.8,53.0,230.0,,,,,,,,,,,,,1.71,4.91,2.83,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET-,,,,,55.157687253613666,1531309
1531777,王洪生,616545,男,79,T2,N2,M0, ⅡB,1,1,0.0,1.0,,0.0, 肠化生+,3.0,37,中间型（int）,INFa,0.0,,,,,,,2.0,2015-10-15,2020-10-07,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)12 (1b)00 (2)03 (3a)012 (3b)01 (4sa)00 (4sb)01 (4d)29 (5)00 (6)03 (7)02 (8a)02 (8p)02 (9)00 (11p)00 (12a)00," L（幽门窦部）, U（胃底部）, 后Post, 大弯侧Gre,",50,30,10, R0 D2,,8.52,4.44,3.12,140.9,304.0,2.63,17.0,21.0,151.0,55.0,15.0,7.69,2.67,57.0,272.0,37.0,20.0,4.1,7.0,87.0,331.0,,,,,,,,,,,,,1.84,14.67,1.83,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF- CMET弱+,,,,,59.75689881734559,1531777
1532141,冯亚秋,616591,女,66,T4b,N3a,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 异型增生+,10.0,12,中间型（int）,INFc,3.0,,,,,,,0.0,2015-10-19,2015-12-27,2,,,口服替吉奥,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60% 低粘附腺癌40% Lauren混合型,G3, (1a)33 (1b)34 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)01 (5)00 (6)00 (7)01," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,50,10,,R2,9.93,7.13,1.87,150.0,264.0,3.43,11.0,15.0,206.0,89.0,13.0,18.92,6.58,64.0,209.0,43.0,21.0,6.5,4.8,65.0,266.0,60.6,23.7,33.6,0.71,0.0,14.4,22.5,0.6,1.09,1.19,7.81,7.45,74.91,1000.0,300.0, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,2.266754270696452,1532141
1532024,宫有财,615560,男,55,T2,N3a,M0, ⅢA,1,1,1.0,1.0,1.0,1.0, 肠化生+,8.0,46,中间型（int）,INFb,0.0,,,,,,,0.0,2015-10-19,2020-10-27,1,,,SOX,奥沙利铂 卡佩他滨多西他赛,奥沙利铂 卡佩他滨多西他赛,奥沙利铂 卡佩他滨多西他赛,奥沙利铂 卡佩他滨多西他赛,奥沙利铂 卡佩他滨多西他赛,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60% 低粘附腺癌40% Lauren混合型,G3,小湾02 (1a)03 (1b)00 (3a)118 (3b)00 (4sb)01 (4d)15 (5)01 (6)36 (7)00 (8a)22 (8p)14 (9)00 (11p)04," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,10,10, R0 D2,,4.9,51.6,1.45,155.7,254.0,2.78,18.0,18.0,151.0,41.0,9.0,8.46,2.96,57.0,390.0,39.0,18.0,5.3,5.7,71.0,270.0,77.5,53.8,20.2,2.66,0.6,5.6,13.9,2.2,0.826,1.34,5.73,45.2,1.01,6.77,25.02, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,60.282522996057814,1532024
1532025,孙云,616554,女,43,T1a,N1,M0, ⅠB,1,0,1.0,0.0,0.0,0.0, 肠化生+,1.0,27,中间型（int）,INFb,1.0,,1.0,1.0,,,,0.0,2015-10-19,2020-10-07,1,,,替吉奥单药,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 低黏附40 Lauren混合型,G3, (1a)00 (1b)00 (3a)15 (3b)02 (4sb)00 (4d)05 (5)00 (6)08 (7)02 (8a)01 (8p)01 (9)03," L（幽门窦部）, 小弯侧Less,",25,10,2,R0 D2,,7.06,4.92,1.4,111.0,240.0,1.84,18.0,21.0,120.0,44.0,7.0,9.8,3.57,64.0,255.0,42.0,22.0,3.9,3.9,64.0,,,,,,,,,,,,,,0.94,4.86,2.56,,无, 无, P0,H0, 未做, CK+ Vimentin+ VEGF+ CMET-,,,,,59.62549277266754,1532025
1532114,孙胜利,616630,男,62,T3,N0,M0, ⅡA,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+） 肠化生+,0.0,17,中间型（int）,INFa,2.0,,,,,,,0.0,2015-10-19,2017-02-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60% 低粘附腺癌40% Lauren混合型,G3, (1a)00 (1b)02 (3a)02 (3b)00 (4sb)01 (4d)02 (5)01 (6)00 (7)03 (8a)01 (8p)02 (9)01 (11p)01 (12a)01," L（幽门窦部）, 小弯侧Less,",30,30,10, R0 D2,,4.84,2.33,1.97,137.1,234.0,4.2,24.0,21.0,133.0,103.0,15.0,7.53,2.75,64.0,166.0,41.0,23.0,5.0,6.3,63.0,231.0,63.2,50.7,10.4,4.88,0.2,16.4,18.5,0.2,0.978,1.36,9.6,62.9,1.03,3.86,8.05, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（-）,,,,,15.473061760840999,1532114
1532273,魏兴成,616436,男,46,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 肠化生+,0.0,31,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-10-20,2021-05-24,1,,,SOX,,,,,,4, 粘液腺癌（muc）80 低粘附腺癌20 Lauren弥漫型,GX, (1a)00 (1b)02 (3a)011 (3b)01 (4sb)01 (4d)08 (5)00 (6)01 (7)01 (8a)01 (8p)02 (9)02 (11p)00 (12a)01 (14v)00," L（幽门窦部）, 前Ant,",30,27,10, R0 D2+,,8.44,5.35,2.72,169.2,193.0,2.45,51.0,35.0,178.0,63.0,25.0,20.71,6.74,73.0,273.0,51.0,22.0,6.0,5.4,72.0,485.0,,,,,,,,,,,,,1.09,11.36,2.83,,无,, P0,H0, 未做,CK + Vimentin部分+ VEGF- CMET-,,,,,67.11563731931669,1532273
1533080,刘瑞梅,615959,女,43,T2,N0,M0, ⅠB,1,2,2.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,19,髓样型（med）,INFa,0.0,,1.0,,,,,0.0,2015-10-27,2021-05-17,1,,,,,,,,,0, 低分化腺癌（G3)(por) 低粘附腺癌10,G3, (1a)0/3 (1b)0/2 (3a)0/6 (3b)0/0 (4sb)0/1 (4d)0/2 (5)0/0 (6)0/3 (7)0/2 (12a)0/0," L（幽门窦部）, 前Ant, 小弯侧Less,",38,20,10, R0 D2,,5.65,3.54,1.83,103.0,235.0,2.68,14.0,23.0,138.0,64.0,4.0,11.86,3.52,73.0,232.0,46.0,27.0,5.1,3.9,54.0,159.0,,,,,,,,,,,,,5.12,19.04,0.956,,无, 无, P0,H0, 未做, Vimentin- CK+ S-100+ VEGF+ CMET- CD34-,,,,,66.65571616294349,1533080
1532151,刘德胜,616674,男,52,T1b,N0,M0,ⅠA,1,0,1.0,0.0,,0.0, 异型增生+,0.0,26,中间型（int）,INFb,0.0,,,,,,,0.0,2015-10-19,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3, (1a)01 (1b)01 (3a)00 (3b)02 (4sb)00 (4d)010 (5)01 (6)01 (7)03 (8a)00 (8p)02 (9)02 (11p)03," L（幽门窦部）, 前Ant,",20,10,, R0 D2,,9.07,4.68,3.53,154.1,199.0,2.79,19.0,17.0,173.0,78.0,34.0,16.07,6.07,71.0,367.0,47.0,24.0,4.8,5.7,92.0,366.0,,,,,,,,,,,,,1.82,5.21,5.07,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF- CMET-,,,,,59.62549277266754,1532151
1532208,芦竟春,613237,男,60,T3,N1,M0, ⅡB,1,3,1.0,1.0,1.0,0.0, 肠化生+,1.0,38,中间型（int）,INFa,1.0,,,,,,,0.0,2015-10-20,2021-07-23,1,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)04 (1b)04 (3a)06 (3b)01 (4sb)00 (4d)15 (5)02 (6)04 (7)05 (8a)01 (8p)01 (9)00 (11p)05 (12a)00 (16a1)00," L（幽门窦部）, 前Ant,",65,50,13, R0 D2+,,5.42,3.32,1.29,82.1,316.0,2.29,13.0,16.0,132.0,72.0,13.0,9.28,3.75,62.0,227.0,37.0,25.0,,5.1,71.0,272.0,,,,,,,,,,,,,1.19,9.77,1.4,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET- CgA- Syn- CD56- lca-,,,,,69.08672798948751,1532208
1532545,桑秀花,616810,女,56,T4a,N1,M0, ⅢA,1,3,2.0,0.0,0.0,1.0, 肠化生+,1.0,27,中间型（int）,INFc,0.0,,,,,,,1.0,2015-10-22,2020-10-07,1,,,XELOX,,,,,,6, 低粘附腺癌55 粘液40 中低分化5,G3," (1b)0/0, (3a)0/7, (3b)0/0, (4d)0/8, (4sa)0/0, (4sb)0/0, (5)0/0, (6)1/7, (7)0/0, (8a)0/1, (8p)0/1, (9)0/2, (11p)0/1"," L（幽门窦部）, 前Ant, 小弯侧Less, 后Post, 大弯侧Gre,",60,40,20, R0 D2,,4.56,2.78,1.28,99.9,323.0,3.4,11.0,14.0,156.0,46.0,12.0,4.5,1.68,57.0,197.0,38.0,19.0,6.3,5.4,83.0,209.0,,,,,,,,,,,,,108.1,1.23,88.73,,无, 无, P0,H0, 未做, CD34未见明确瘤栓， S-100免疫酶标显示可见神经侵犯。 CMET 部分+， VEGF -，Vimentin-， CK+，Lauren分型弥漫型，CerbB-2 0分,,,,,59.526938239159,1532545
1532444,尹建世,616017,女,68,T3,N1,M0, ⅡB,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+） 肠化生+,1.0,50,中间型（int）,INFa,0.0,,,,,,,0.0,2015-10-21,2020-10-07,1,,,XELOX,,,,,,4,低黏附性癌70 中低分化管状腺癌30%,G3, (1a)02 (1b) 00(3a)011 (3b) 11(4sb)07 (4d) 010(5)02 (6)04 (7) 02(8a)01 (8p)05 (9)02 (11p) 01(12a)00 (19)02," M（胃体部）, 后Post, 小弯侧Less,",40,40,15,R0 D2,,5.06,2.34,2.0,124.0,174.0,2.58,10.0,19.0,159.0,68.0,45.0,5.79,2.13,68.0,287.0,44.0,24.0,6.5,4.5,76.0,,,,,,,,,,,,,,3.94,38.28,0.953,,无, 无, P0,H0, 未做, CK+ VEGF- Vimentin- CMET-,,,,,59.55978975032851,1532444
1532887,刘本义,615981,男,78,T4b,N1,M0, ⅢB,1,2,1.0,0.0,,1.0, 肠化生+,1.0,17,中间型（int）,INFb,0.0,,,1.0,,,,0.0,2015-10-26,2018-01-25,0,,,,,,,,,0, 低分化腺癌（G3)(por)90 粘液腺癌（muc）10 腺瘤,G3, (1a)01 (1b)02 (3a)11 (3b)00 (4sb)00 (4d)06 (5)00 (6)00 (7)03 (8a)03 (8p)01 (9)00 (11p)00 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",55,50,12, R0 D2,,4.16,2.63,1.02,67.0,185.0,2.97,11.0,16.0,136.0,51.0,11.0,6.59,3.04,54.0,196.0,33.0,21.0,6.5,7.5,75.0,280.0,76.0,23.5,49.1,0.48,0.1,2.9,20.3,0.2,0.424,1.66,9.79,37.2,5.36,10.99,5.43,,无, 无, P0,H0, 未做, CK+， Vimentin灶+ VEGF- CMET-,,,,,27.003942181340342,1532887
1532279,张淑霞,616715,女,50,T3,N0,M1, Ⅳ,1,4,,0.0,0.0,1.0, 肠化生+,0.0,20,中间型（int）,INFc,0.0,,,1.0,,,,1.0,2015-10-20,2017-01-01,2,,,FOLFOX,,,,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (2)01 (3a)05 (3b)00 (4sa)00 (4sb)00 (4d)09 (5)00 (6)04 (7)01 (8a)00 (8p)00 (9)00 (11p)00 (12a)00 软组织可见癌," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,17,4,,R2,14.08,12.12,1.5,150.0,165.0,2.27,21.0,18.0,155.0,62.0,20.0,8.14,3.76,69.0,237.0,46.0,23.0,6.1,5.7,69.0,102.0,69.3,45.7,21.5,21.3,0.4,16.8,8.0,0.1,1.09,1.75,9.41,24.2,0.868,12.05,1.43, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin部分（+）、 VEGF（-）、 CMET（部分+）,,,,,14.421813403416557,1532279
1532451,李钦福,616697,男,52,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,,1.0, 肠化生+,12.0,56,中间型（int）,INFc,0.0,,,,,,,0.0,2015-10-21,2015-12-15,2,,,,,,,,,0, 低粘附腺癌40 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30 粘液腺癌（muc）30 Lauren混合型,G3, (1a)01 (1b)010 (3a)00 (3b)00 (4d)35 (4sb)04 (5)29 (6)47 (7)28 (8a)00 (8p)01 (9)09 (11p)00大网边缘12," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",60,50,10, R0 D2,,7.43,4.9,1.9,148.1,258.0,2.91,19.0,17.0,124.0,68.0,20.0,10.08,4.14,61.0,248.0,43.0,18.0,5.6,6.4,75.0,274.0,53.0,39.1,10.1,3.87,0.1,10.5,33.0,0.2,0.743,1.74,6.55,28.6,4.95,42.97,7.87,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,1.8068331143232588,1532451
1532619,万淑贤,616305,女,64,T3,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 肠化生+,36.0,43,中间型（int）,INFc,0.0,,,,,,,2.0,2015-10-22,2020-10-07,1,,,SOX,,,,,,6,低黏附性癌90% 低分化管状腺癌10%,G3, (1a)11 (1b) 23(2)23 (3a)44 (3b) 00(4sa) 00(4sb) 00(4d) 1112(5)00 (6) 77(7)12(8a)12 (8p)02 (9)00 (11p)55 (12a)00 (14v)22, LMU,60,40,5,R0 D2,,4.92,2.16,2.32,116.8,338.0,2.95,15.0,22.0,189.0,83.0,20.0,14.47,4.2,84.0,274.0,48.0,36.0,6.0,6.6,68.0,257.0,,,,,,,,,,,,,1.07,19.76,1.72,,无, 无, P0,H0, 未做, CK+ VEGF -Vimentin -CMET+,,,,,59.526938239159,1532619
1532609,孙双,616232,男,52,T4a,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 异型增生+,30.0,42,中间型（int）,INFb,0.0,,,,,,,2.0,2015-10-22,2016-04-13,2,,,,,,,,,0, 低粘附腺癌70% 低分化腺癌（G3)(por)30% Lauren混合型,G3, (1a)11 (1b)11 (3a)610 (3b)22 (4sb)00 (4d)28 (5)00 (6)1214 (7)11 (8a)11 (8p)22 (9)22," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",35,25,7, R0 D2,,7.0,5.1,1.34,163.2,140.0,2.09,16.0,16.0,137.0,75.0,12.0,6.7,3.41,62.0,212.0,40.0,22.0,7.9,5.1,74.0,106.0,59.5,41.0,12.8,3.2,0.1,12.1,27.3,0.5,1.34,2.23,10.0,43.2,12.92,16.73,2.85, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET部分（弱+）,,,,,5.716162943495401,1532609
1532878,魏振军,613207,男,51,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+） 肠化生+,0.0,17,中间型（int）,INFa,0.0,,,,,,,0.0,2015-10-26,2020-10-07,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 02(1b)00 (3a) 02(3b)00 (4sb)00 (4d)02 (5)02 (6)06 (7)00 (8a)01 (9)03 (11p)00," L（幽门窦部）, 大弯侧Gre,",13,12,5, R0 D2,,5.49,3.28,1.7,148.2,360.0,2.84,23.0,23.0,155.0,67.0,33.0,13.46,4.88,71.0,366.0,47.0,24.0,5.7,5.4,76.0,,,,,,,,,,,,,,0.93,4.99,1.15,,无, 无, P0,H0, 未做, CK+ VEGF -Vimentin- CMET-,,,,,59.39553219448094,1532878
1532384,刘金山,616846,男,53,T3,N0,M0, ⅡA,1,2,1.0,0.0,0.0,1.0, 肠化生+,0.0,34,中间型（int）,INFa,0.0,,,1.0,,,,0.0,2015-10-21,2019-05-03,0,,,XELOX,,,,,,4, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3, (1a)03 (1b)010 (2)03 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)00 (6)01 (7) 00(8a)04 (8p)03 (9)03 (10)00 (11p)01 (11d)02 (12a)00, M（胃体部） 小弯侧Less ,40,35,10, R0 D2,,8.57,4.83,2.7,154.0,228.0,2.9,17.0,20.0,170.0,94.0,12.0,7.9,3.75,67.0,240.0,45.0,22.0,5.5,5.1,90.0,274.0,56.2,19.9,34.3,0.58,0.1,4.5,39.2,0.2,0.829,7.02,8.89,18.6,2.71,6.17,1.01, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(部分+)  VEGF(-)  cMET(-)  S100(+),,,,,42.3784494086728,1532384
1532829,杨万民,613212,男,57,T3,N1,M0, ⅡB,1,3,2.0,0.0,,1.0, 肠化生+ 慢性炎症（+）,2.0,54,中间型（int）,INFa,0.0,,,,,,,0.0,2015-10-26,2020-10-07,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3, (1a)010 (1b)012 (2)03 (3a)08 (3b)00 (4sa)01 (4sb)02 (4d)02 (5)13 (6)04 (7)02 (8a)02 (8p)01 (9)03 (11p)00 (12a)11," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,70,10, R0 D2,,12.0,7.85,3.16,126.5,352.0,4.66,19.0,21.0,130.0,74.0,20.0,8.58,4.08,65.0,202.0,41.0,24.0,5.1,7.1,73.0,310.0,,,,,,,,,,,,,3.31,4.75,2.73,,无, 无, P0,H0, 未做, CK+， Vimentin-， VEGF-， CMET-,,,,,59.39553219448094,1532829
1533652,张淑艳,616728,女,53,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,38,中间型（int）,INFb,0.0,,,,,,,2.0,2015-11-02,2016-11-15,2,,,XELOX,,,,,,5, 低分化腺癌（G3)(por) 低粘附腺癌20,G3, (1a)0/3 (1b)0/0 (3a)4/0 (3b)0/1 (4sb)0/0 (4d)2/5 (5)0/0 (6)0/7 (7)1/3 (8a)0/1 (8p)0/3 (9)0/5 (11p)0/1 (12a)0/0," L（幽门窦部）, 后Post, 小弯侧Less,",35,30,10, R0 D2,,2.76,1.25,1.12,132.5,99.0,2.12,29.0,47.0,220.0,107.0,25.0,21.14,8.69,62.0,101.0,35.0,27.0,4.6,5.9,47.0,213.0,,,,,,,,,,,,,1.28,23.22,1.43, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ CD34+ S-100+,,,,,12.450722733245728,1533652
1532896,曹焕志,613218,男,52,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 异型增生+,5.0,46,中间型（int）,INFc,0.0,,,,,,,0.0,2015-10-26,2019-05-01,0,,,SOX,SOX,SOX,SOX,SOX,多西他噻+卡佩他滨,6,低中分化,G2, (1a)0/0； (1b)1/4； (3a)2/13； (3b)0/0； (4sb)0/2 (4d)0/8 (5)0/2 (6)1/8 (7)0/1 (8a)1/1 (8p)0/1 (9)0/1 (11p)0/5," L（幽门窦部）, 后Post, 小弯侧Less, 前Ant,",50,40,10, R0 D2,,6.33,3.85,2.01,126.0,207.0,2.34,31.0,30.0,152.0,60.0,8.0,6.33,2.52,49.0,200.0,34.0,15.0,5.9,7.4,68.0,335.0,,,,,,,,,,,,,2.69,99.63,1.52, 未做,无, 无, P0,H0, 未做, CD34脉管瘤栓 S-100神经侵犯 CK+ VEGF- Vimentin-,,,,,42.1484888304862,1532896
1532877,张锡珍,613616,女,47,T4b,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+,18.0,28,中间型（int）,INFb,0.0,,,,,,,2.0,2015-10-26,2019-04-24,0,,,XELOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)55%， 低粘附腺癌45%， Lauren混合型,G3, (1a)12 (1b)23 (2)07 (3a)11 (3b)11 (4sa)00 (4sb) 01(4d) 44(5) 00(6)44 (7)33 (11p)22," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,80,15,,R2,3.8,2.12,1.18,79.9,433.0,3.33,15.0,17.0,124.0,38.0,6.0,9.46,3.81,46.0,151.0,31.0,15.0,5.2,2.3,46.0,182.0,,,,,,,,,,,,,3.11,0.936,4.84, 未做,无, 无, P0,H0, 未做, CMET部分（弱+） Vimentin- VEGF- CK+ S-100（神经侵犯） CD34、D2-40(脉管瘤栓）,,,,,41.9185282522996,1532877
1532970,李国志,382453,男,70,T3,N2,M0, ⅢA,1,3,1.0,1.0,,0.0, 慢性炎症（+） 肠化生+,5.0,34,中间型（int）,INFb,0.0,,,,,,,0.0,2015-10-27,2017-03-12,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 乳头状癌30（G1）（pap） Lauren混合型,G2, (1a) (1b) (3a) (3b) (4sb) (4d) (5) (6) (7) (8a) (9) (11p)," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,10,,R1,7.8,3.92,3.06,141.0,200.0,2.85,28.0,36.0,173.0,84.0,26.0,11.47,4.71,70.0,155.0,43.0,27.0,4.9,6.0,57.0,,,,,,,,,,,,,,4.31,21.86,2.42,,无, 无, P0,H0, 未做, CK +VEGF -Vimentin -CMET-,,,,,16.491458607095925,1532970
1533651,周永林,613155,男,63,T2,N0,M0, ⅠB,1,1,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,30,中间型（int）,INFa,0.0,,,,,,,2.0,2015-11-02,2020-10-07,1,,,SOX,,,,,,2, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】30 Lauren肠型,G2, (1a)00 (1b)03 (2)05 (3a)00 (3b)013 (4sa)00 (4sb)01 (4d)00 (7)04 (8a)02 (8p)01 (9)01 (11p)00," U（胃底部）, 后Post, 小弯侧Less,",30,25,8, R0 D2,,4.83,2.4,1.81,120.2,322.0,2.4,25.0,25.0,154.0,56.0,18.0,22.66,7.09,66.0,280.0,46.0,2.0,5.5,7.4,85.0,513.0,,,,,,,,,,,,,0.916,0.916,3.78,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET弱+,,,,,59.16557161629435,1533651
1533197,伊文才,613682,男,64,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,0.0,17,中间型（int）,INFb,0.0,,,,,,,2.0,2015-10-28,2020-10-07,1,,,,,,,,,0, 低分化腺癌（G3)(por) 低黏附20 Lauren肠型,G3, (1a)00 (1b)00 (3a)06 (3b) 01(4sb)00 (4d)05 (5)00 (6)00 (7)00 (8a)01 (9)03 (11p)01," LM 前Ant, 后Post, 小弯侧Less,",55,50,8, R0 D2,,10.49,7.06,2.65,168.9,209.0,5.27,21.0,26.0,160.0,82.0,51.0,22.39,7.65,74.0,235.0,45.0,29.0,5.3,4.3,61.0,,,,,,,,,,,,,,29.4,14.6,62.6,,无, 无, P0,H0, 未做, CK+ VEGF- Vimentin- CMET+,,,,,59.32982917214191,1533197
1533905,刘军,612854,男,46,T2,N0,M0, ⅠB,1,1,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,19,中间型（int）,INFa,2.0,,,,,,,1.0,2015-11-03,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 乳头状癌30（G1）（pap）,G2, (1a)0/0 (1b)0/2 (3a)0/2 (3b)0/0 (4sb)0/2 (4sa)0/6 (4d)0/1 (7)0/1 (8a)0/1 (9)0/0 (11p)0/3," U（胃底部）,",35,30,12, R0 D2,,5.64,3.18,1.89,154.0,194.0,2.04,18.0,17.0,152.0,49.0,22.0,14.64,4.98,68.0,346.0,44.0,24.0,5.4,5.2,86.0,356.0,,,,,,,,,,,,,1.24,10.08,12.77, 未做,无,, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ CD34- S-100-,,,,,81.9316688567674,1533905
1534241,田耀忠,609341,男,67,T3,N1,M0, ⅡB,1,2,2.0,,,, 肠化生+ 慢性炎症（+）,2.0,29,中间型（int）,,0.0,,,,,,,2.0,2015-11-05,2021-07-23,1,,,SOX,,,,,,6, 低分化腺癌（G3)(por) 低粘附腺癌30 Lauren弥漫型,G3, (1a) 00(1b) 00(2)04 (3a)010 (3b)01 (4sa)02 (4sb)00 (4d)01 (7)22 (8a)01 (8p) 00(9)04 (11d)00 (11p)04," U（胃底部）, SiewerⅡ, 小弯侧Less,",35,30,5,R0 D2,,7.06,5.48,0.82,123.0,218.0,2.44,13.0,19.0,177.0,73.0,18.0,12.28,4.46,72.0,294.0,42.0,30.0,6.6,6.5,84.0,211.0,,,,,,,,,,,,,1.41,7.97,1.41, 未做,无, 无, P0,H0, 未做, CK+ VEGF- Vimentin- CMET+ LCA+ CK8/18+,,,,,68.5611038107753,1534241
1533224,龚大范,616240,男,59,T3,N2,M0, ⅢA,1,1,0.0,1.0,,1.0, 慢性炎症（+）,6.0,37,中间型（int）,INFa,0.0,,,,,,,0.0,2015-10-23,2020-10-07,0,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b) 04(3a)410 (3b) 01(4sb)00 (4d)03 (5)00 (6)00 (7)00 (8a)03 (8p)03 (9)25 (11p)01 (12a)01 (14v)03," L（幽门窦部）, 前Ant, 小弯侧Less,",15,15,5, R0 D2,,6.54,4.02,1.79,119.0,273.0,2.09,18.0,19.0,136.0,59.0,15.0,17.04,6.18,63.0,256.0,41.0,22.0,7.1,5.3,77.0,341.0,,,,,,,,,,,,,2.07,49.12,2.07,,无, 无, P0,H0, 未做, VEGF- Vimentin- CMET- CK+,,,,,59.49408672798948,1533224
1533835,许淑珍,613149,女,71,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,13.0,36,中间型（int）,INFc,0.0,,,1.0,,,,1.0,2015-11-03,2016-07-05,2,,,,,,,,,0, 低粘附腺癌55 低分化腺癌（G3)(por)30 粘液腺癌（muc)15 Lauren肠型,G3, (1a)02 (1b)22 (3a)02 (3b)02 (4sb)00 (4d)16 (5)33 (6)36 (7)510 (8a)00 (8p)23 (9)00 (11p)00 (12a)00," 后Post, 大弯侧Gre, 小弯侧Less,",50,40,12, R0 D2+,,8.47,5.1,2.46,120.0,295.0,4.08,16.0,22.0,142.0,71.0,48.0,9.2,3.14,67.0,162.0,38.0,29.0,8.2,6.9,66.0,193.0,,,,,,,,,,,,,180.4,1000.0,6.19,,无, 无, P0,H0, 未做,CK + Vimentin部分+ VEGF- CMET部分+,,,,,8.04862023653088,1533835
1533123,刘德斌,613659,男,61,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,1.0,15,中间型（int）,INFb,0.0,,,,,,,1.0,2015-10-28,2020-10-07,1,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)01 (3b)11 (4sb)00 (4d)00 (5)00 (6)02 (7)02 (8a)03 (8p)03 (9)02 (11p)01 (12a)00 癌结节1枚,L（幽门窦部） 小弯侧Less 后Post,30,20,10, R0 D2,,7.4,3.56,2.94,144.0,219.0,2.4,36.0,32.0,151.0,104.0,37.0,12.47,3.87,74.0,360.0,44.0,30.0,4.7,7.1,65.0,463.0,,,,,,,,,,,,,3.25,5.14,1.11, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+)  CD31(+)  D2-40(+) ,,,,,59.32982917214191,1533123
1533730,吴莉娜,616283,女,56,T1a,N0,M0,ⅠA,1,0,1.0,0.0,0.0,0.0, 慢性炎症（+） 肠化生+,0.0,16,中间型（int）,INFa,1.0,,,,,,,2.0,2015-11-02,2021-05-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低粘附腺癌20 Lauren混合型,G2, (1a)0/0； (1b)0/2； (3a)0/2； (3b)0/1； (4sb)0/0； (4d)0/3； (5)0/0； (6)0/2 (7)0/2； (8a)0/3； (11p)0/2； (12a)0/0," L（幽门窦部）, 后Post,",40,20,5, R0 D2,,5.22,3.31,1.37,145.0,237.0,1.88,36.0,29.0,168.0,62.0,25.0,15.59,4.67,73.0,351.0,50.0,23.0,5.2,5.7,64.0,264.0,,,,,,,,,,,,,4.7,36.46,1.35,,无, 无, P0,H0, 未做, CK+; Vimentin-; VEGF-; CMET 弱,,,,,66.45860709592641,1533730
1533762,宋景德,617728,男,58,T4b,N3b,M0, ⅢC,1,4,0.0,1.0,1.0,1.0, 肠化生+,56.0,62,中间型（int）,INFb,0.0,,,,,,,0.0,2015-11-02,2019-05-01,0,,,SOX,,,,,,4, 低分化腺癌（G3)(por),G3, (1a)0/2 (3a)11/11 (3b)1/1 (4sb)0/0 (4d)19/19 (5)0/0 (6)3/3 (7)1/3 (8a)3/3 (9)7/7 (14v)6/7 (15)0/0," L（幽门窦部）, M（胃体部）, U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,10,,R1,8.21,4.94,2.19,105.7,273.0,4.9,28.0,38.0,235.0,72.0,10.0,5.5,2.69,49.0,167.0,29.0,20.0,7.8,4.2,82.0,288.0,,,,,,,,,,,,,2.31,4.34,2.27, 未做,无,, P0,H0, 未做, VEGF- Vimentin- CK+ CMET-,,,,,41.9185282522996,1533762
1533580,金建伟,615693,男,54,T1b,N1,M0, ⅠB,1,0,2.0,0.0,,0.0, 异型增生+,2.0,26,中间型（int）,INFc,1.0,,1.0,,,,,1.0,2015-10-30,2020-10-07,1,,,奥沙利铂,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)04 (1b)06 (3a)05 (3b)00 (4sb)00 (4d)00 (5)00 (6)00 (7)01 (8a)01 (8p)28 (9)01 (11p)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,15,2, R0 D2,,9.23,5.47,2.87,142.0,240.0,2.53,18.0,20.0,125.0,66.0,12.0,7.88,3.19,67.0,288.0,46.0,21.0,4.9,5.5,73.0,382.0,,,,,,,,,,,,,2.5,3.21,1.13, 未做,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF+ CMET+ S-100（未见神经侵犯） CD34、D2-40(未见脉管瘤栓),,,,,59.26412614980289,1533580
1533751,孙建东,617716,男,55,T3,N1,M0, ⅡB,1,4,1.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,1.0,51,中间型（int）,INFb,0.0,,1.0,,,,,1.0,2015-11-02,2020-10-07,1,,,XELOX,,,,,,2, 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)05 (1b)01 (2)08 (3a)17 (3b)00 (4sa)00 (4sb)04 (4d)09 (5)00 (6)05 (7)01 (8a)01 (8p)01 (9)00 (10)09 (11p)00," M（胃体部）, 后Post,",20,20,10, R0 D2,,7.68,3.83,3.26,146.9,295.0,2.19,28.0,28.0,135.0,66.0,22.0,9.34,3.33,69.0,378.0,45.0,24.0,51.0,7.2,77.0,288.0,,,,,,,,,,,,,2.9,10.6,2.39,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF+CMET+,,,,,59.16557161629435,1533751
1533731,王荣,617380,女,49,T1b,N3a,M0, ⅡB,1,2,0.0,1.0,,0.0, 肠化生+,7.0,30,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-11-02,2020-10-07,1,,,紫杉醇联合希罗达,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)11 (1b)13 (3a)02 (3b)00 (4sb)00 (4d)515 (5)00 (6)01 (7)03 (8a)00 (8p)01 (9)04 (11p)00," L（幽门窦部）, 前Ant, 小弯侧Less,",50,40,5, R0 D2,,3.87,1.41,1.94,130.1,175.0,2.53,17.0,16.0,186.0,53.0,6.0,8.53,2.86,59.0,214.0,41.0,18.0,4.8,7.4,64.0,12.4,,,,,,,,,,,,,0.499,3.95,6.42,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF部分+ CMET+,,,,,59.16557161629435,1533731
1533821,赵洪成,613084,男,64,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,12.0,35,中间型（int）,INFc,0.0,,,,,,,0.0,2015-11-03,2017-02-27,2,,,SOX,,,,,,6,低黏附70 粘液30,GX, (1a)01 (1b) 03(2)02 (3a)68 (3b)15 (4sa)00 (4sb)00 (4d)04 (5)00 (6)03 (7)00 (8a)12 (8p)23 (9) 11(11p)12 (12a)01 (14v)00," 前Ant, 后Post, 小弯侧Less, ML",80,70,10,R0 D2,,5.63,2.07,2.92,158.0,214.0,2.45,21.0,20.0,163.0,89.0,30.0,16.22,6.13,70.0,320.0,44.0,26.0,4.4,7.3,95.0,286.0,54.7,36.5,16.4,2.23,0.2,9.7,34.6,1.2,1.0,1.68,12.1,5.38,22.86,2.8,180.6,,无, 无, P0,H0, 未做, CK+ VEGF- Vimentin- CMET-,,,,,15.83442838370565,1533821
1533578,高现江,618473,男,50,T3,N1,M0, ⅡB,1,4,1.0,0.0,0.0,1.0, 慢性炎症（+）,1.0,22,中间型（int）,INFc,0.0,,1.0,1.0,,,,0.0,2015-10-30,2020-05-20,2,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)01 (1b)01 (2)04 (3a)00 (3b)00 (4sa) 00(4sb)00 (4d)00 (5)00 (6)06 (7)00 (8a)01 (8p)00 (9)02 (11p)02 小弯15, LMU 小弯侧Less ,75,50,4, R0 D2,,5.91,2.58,2.84,157.0,205.0,2.27,21.0,27.0,144.0,107.0,25.0,8.67,2.01,71.0,483.0,48.0,23.0,6.4,4.6,76.0,535.0,75.2,32.2,31.2,1.03,0.3,10.4,13.3,0.7,0.988,2.95,10.1,5.87,1.43,14.05,6.35, 未做,无,, P0,H0, 未做,ck(+)  vimentin部分(+)  VEGF弱(+)  cMET(-) S100(+),,,,,54.66491458607096,1533578
1533982,赵玉军,617407,男,50,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+,0.0,19,中间型（int）,INFb,0.0,,,1.0,,,,1.0,2015-11-04,2020-10-07,1,,,替吉奥单药,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 乳头状癌（G1）（pap）15 Lauren肠型,G3, (1a)01 (1b)00 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)01 (6)05 (7)05 (8a)01 (8p)00 (9)02 (11p)00 (12a)00,M（胃体部） 小弯侧Less 前Ant 后Post ,50,40,10, R0 D2,,8.43,5.43,2.43,146.3,287.0,3.14,41.0,30.0,167.0,86.0,85.0,7.77,2.99,74.0,352.0,51.0,23.0,7.4,5.9,87.0,398.0,60.8,31.2,23.0,1.36,0.1,5.7,31.0,0.5,1.28,3.5,12.5,15.8,3.49,11.45,1.77, 未做,无,, P0,H0, 未做,ck(+)  vimentin散在(+)  VEGF(-)  cMET(+)  CD31(+)  D2-40(+) S100(+),,,,,59.09986859395532,1533982
1533906,刘玉民,617837,男,54,T3,N0,M0, ⅡA,1,4,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,0.0,38,中间型（int）,INFa,0.0,,,,,,,1.0,2015-11-03,2022-09-01,1,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)05 (1b)02 (3a)03 (3b)02 (4sb)00 (4d)07 (5)00 (6)012 (7)06 (8a)01 (9)00 (11p)00 (12a)00," LM 前Ant, 大弯侧Gre, 小弯侧Less,",110,90,12, R0 D2+,,5.12,2.63,1.79,106.4,314.0,4.45,13.0,16.0,120.0,85.0,12.0,4.08,1.43,57.0,267.0,39.0,8.0,4.6,5.9,79.0,205.0,62.1,38.8,21.6,1.8,0.1,11.7,23.3,0.4,0.843,1.37,13.7,305.0,0.839,5.19,9.85,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+,,,,,81.9316688567674,1533906
1534266,唐伟硕,617742,男,61,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,33,中间型（int）,INFb,0.0,,,1.0,,,,1.0,2015-11-05,2021-05-17,1,,,,,,,,,0,中低分化,G3, (1a)0/0 (1b)0/2 (3a)0/5 (3b)0/2 (4sb)0/0 (4d)0/8 (5)0/1 (6)0/5 (7)0/1 (8a)0/2 (9)0/1 (11p)0/6 (12a)0/0," L（幽门窦部）, 小弯侧Less,",20,15,4, R0 D2,,6.16,3.71,1.9,161.0,237.0,2.09,21.0,28.0,175.0,51.0,13.0,23.81,8.14,76.0,294.0,52.0,24.0,5.3,8.1,80.0,241.0,,,,,,,,,,,,,1.96,10.08,12.77, 未做,无,, P0,H0, 未做, CMET+ Vimentin+ VEGF- CK+ S100-,,,,,66.36005256241786,1534266
1534164,王庆杰,618864,男,54,T4b,N3a,M0, ⅢC,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,8.0,37,中间型（int）,INFc,0.0,,,1.0,,,,2.0,2015-11-05,2018-05-09,2,,,奥沙利铂 氟尿嘧啶,奥沙利铂 氟尿嘧啶,艾坦联合替吉奥4,口服替吉奥2,,,10, 低粘附腺癌 90低分化腺癌（G3)(por)10 Lauren肠型,G3, (1a)03 (3a)39 (3b)06 (4sb)03 (4d)29 (5)11 (6)01 (7)11 (8a)01 (8p)02 (9)11 (11p) 00(12a)02,L（幽门窦部） 后Post ,50,40,10, R0 D2,,9.04,5.63,2.81,140.1,263.0,2.63,20.0,24.0,140.0,67.0,12.0,14.14,4.63,65.0,254.0,46.0,19.0,4.7,6.2,61.0,273.0,63.5,45.9,15.0,3.06,0.1,14.5,20.0,0.4,0.687,1.92,15.7,93.2,2.55,15.27,2.32, 未做,无,, P0,H0, 未做,ck(+)  vimentin部分(+)  VEGF(-)  cMET弱(+)  CD31(+)  D2-40(+) ,,,,,30.091984231274637,1534164
1533904,刘善泰,617743,男,63,T1b,N1,M0, ⅠB,1,0,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+,2.0,39,中间型（int）,INFa,2.0,,,,,,,2.0,2015-11-03,2019-05-03,0,,,卡佩他滨,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)02 (3a)01 (3b)01 (4sb)01 (4d)19 (5)02 (6)08 (7)06 (8a)02 (8p)02 (9)00 (11p)00 (12a)15," L（幽门窦部）, M（胃体部）, 前Ant, 小弯侧Less,",20,20,6, R0 D2,,8.33,5.07,2.37,138.0,247.0,2.01,30.0,30.0,173.0,57.0,26.0,24.57,8.34,62.0,301.0,43.0,19.0,5.2,4.7,46.0,285.0,70.9,43.5,21.3,2.04,0.1,8.7,17.9,0.8,0.769,1.84,11.0,80.1,3.26,5.73,4.9, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（弱+）,,,,,41.95137976346912,1533904
1534233,孙晓清,617851,男,68,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+,2.0,30,中间型（int）,INFc,0.0,,,,,,,0.0,2015-11-05,2020-10-07,1,,,,,,,,,0, 低粘附腺癌 Lauren肠型,GX, (1a)05 (1b)03 (3a)011 (3b)22 (4sb)00 (4d)05 (5)00 (6)01 (7)01 (8a)00 (8p)00 (9)01 (11p)01,L（幽门窦部） 后Post 小弯侧Less ,70,50,8, R0 D2,,5.62,3.52,1.46,170.0,169.0,3.49,14.0,26.0,239.0,82.0,11.0,18.05,6.36,66.0,302.0,44.0,22.0,3.9,9.0,100.0,411.0,,,,,,,,,,,,,27.42,137.7,285.5, 未做,无, , P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD34(+)  D2-40(+) S100(+),,,,,59.0670170827858,1534233
1533935,王新志,616363,男,67,T2,N2,M0, ⅡB,1,2,1.0,1.0,1.0,1.0, 肠化生+,3.0,22,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-11-03,2021-07-23,1,,,,,,,,,0, 管状腺癌（高中分化【G1】【tub1】）90% 低粘附腺癌10% Lauren混合型,G2, (1a)00 (1b)28 (2)12 (3a)01 (3b)00 (4sa)00 (4sb)00 (4d)05 (5)00 (6)01 (7)01 (8a)01 (8p)01 (9)02 (11p)00," U（胃底部）, 小弯侧Less,",15,15,, R0 D2,,6.29,4.34,1.3,155.0,182.0,2.85,18.0,19.0,158.0,75.0,13.0,19.64,8.18,11.46,281.0,45.0,25.0,4.3,5.0,91.0,302.0,76.8,41.4,32.1,1.29,0.1,7.5,8.6,0.5,0.975,1.73,13.0,14.3,1.4,5.4,29.82, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF灶（+）、 CMET（+）,,,,,68.62680683311432,1533935
1534064,曲梅静,529496,女,55,T1a,N0,M0,ⅠA,1,0,2.0,0.0,0.0,, 慢性炎症（+）,0.0,18,中间型（int）,INFc,0.0,,,,,,,0.0,2015-10-04,2020-10-07,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)04 (3a)05 (3b)00 (4sb)01 (4d)03 (5)00 (6)01 (7) 01(8a)01 (9)00 (11p)01," L（幽门窦部）, 小弯侧Less,",25,15,,R0 D2,,4.8,3.05,1.32,129.0,168.0,2.85,25.0,21.0,144.0,71.0,30.0,10.31,3.41,70.0,356.0,44.0,26.0,5.1,7.6,60.0,358.0,66.1,34.9,25.5,1.37,0.1,18.1,14.4,1.7,,1.02,12.7,92.3,0.55,3.46,3.19,,无, 无, P0,H0, 未做, CK+ VEGF- Vimentin- CMET-,,,,,60.118265440210244,1534064
1533921,连世胜,615386,男,66,T2,N0,M0, ⅠB,1,1,0.0,,,, 肠化生+ 慢性炎症（+）,0.0,41,中间型（int）,INFa,1.0,,,,,,,2.0,2015-11-03,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,大弯侧01 (1a)04(1b)08(3a)02 (3b)01 (4sb)00 (4d) 06(5)00 (6)05 (7)00 (8a)01 (8p)05 (9) 01(11p)03 (12a)04," L（幽门窦部）, 小弯侧Less,",25,20,3, R0 D2,,9.74,6.16,2.58,125.0,479.0,3.97,26.0,25.0,176.0,52.0,17.0,7.03,2.28,66.0,307.0,45.0,21.0,4.5,7.8,77.0,300.0,,,,,,,,,,,,,4.88,10.8,7.75, 未做,无, 无, P0,H0, 未做, CMET 弱+Vimentin- VEGF- CK+ ,,,,,59.13272010512483,1533921
1534607,许加库,618151,男,65,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,19,,,0.0,,,,,,,0.0,2015-11-09,2022-09-01,1,,,,,,,,,0, 高级别上皮内瘤变 管状腺癌（高分化【G1】【tub1】）,G1, (1a) (1b)02 (3a)03 (4sb)07 (4d)02 (5) (12a)02 (7) (8a) (8p) (9) (11p)02," L（幽门窦部）, 小弯侧Less,",18,18,4, R0 D2,,5.06,2.91,1.65,145.0,217.0,2.91,20.0,14.0,157.0,66.0,7.0,8.6,2.69,69.3,256.0,44.0,25.3,5.2,7.0,68.0,243.0,,,,,,,,,,,,,3.08,7.28,19.61,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET-,,,,,81.73455978975032,1534607
1535489,王培安,617561,男,70,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,4.0,20,髓样型（med）,INFb,0.0,,,,,,,0.0,2015-11-17,2016-07-01,2,,,XELOX,XELOX,,,,,2, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)04 (3a)36 (3b)11 (4sb)02 (4d)02 (5)01 (6)01 (7)03 (8a)00 (11p)00," L（幽门窦部）, 小弯侧Less,",40,38,10, R0 D2,,4.61,2.08,1.89,104.0,240.0,3.33,20.0,24.0,162.0,42.0,19.0,8.69,3.24,64.0,301.0,44.0,20.0,3.8,3.7,100.0,344.0,66.3,42.5,25.5,1.67,1.1,11.4,17.6,0.4,0.567,1.35,9.42,20.3,1.79,5.66,1.43, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD31(+)  D2-40(+),,,,,7.457293035479632,1535489
1534508,李志娟,612992,女,50,T3,N3b,M0, ⅢC,1,3,1.0,1.0,,1.0, 慢性炎症（+）,16.0,21,中间型（int）,INFc,0.0,,,1.0,,,,1.0,2015-11-09,2017-07-24,2,,,XELOX,,,,,,3, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3, (1a)00 (1b)02 (3a)45 (3b)11 (4sb)00 (4d)22 (5)11 (6)44 (7)01 (8a)33 (8p)00 (9)01 (11p)00 (11d)00 (14v)11," L（幽门窦部）, 小弯侧Less,",50,40,4, R0 D2,,5.6,3.15,1.53,126.0,227.0,2.42,25.0,28.0,147.0,81.0,14.0,12.91,3.61,68.0,336.0,42.0,26.0,4.9,3.4,69.0,253.0,71.1,34.7,34.1,1.02,0.3,11.7,15.5,0.8,2.45,4.68,11.0,78.6,382.3,8.13,3.85,,无, 无, P0,H0, 未做, CK+ Vimentin部分+ VEGF- CMET+,,,,,20.466491458607095,1534508
1534600,梁国辉,617583,女,59,T1b,N2,M0, ⅡA,1,0,2.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,3.0,24,中间型（int）,,0.0,,,,,,,2.0,2015-11-09,2020-06-02,2,,,SOX,,,,,,2, 低分化腺癌（G3)40(por) 低粘附腺癌60 Lauren弥漫型,G3, (1a)02 (1b)02 (3a)02 (3b)00 (4sb)00 (4d)14 (5)01 (6)24 (7)02 (8a)01 (8p)04 (9)02 (11p)00,L（幽门窦部） 前Ant 小弯侧Less,45,40,8, R0 D2,,5.08,2.83,1.69,132.0,202.0,2.31,12.0,17.0,167.0,48.0,7.0,10.7,3.48,48.0,337.0,35.0,13.0,4.0,4.4,70.0,240.0,63.0,43.3,15.2,2.85,0.1,17.8,17.8,0.2,1.02,0.835,4.07,110.0,1.18,6.92,1.14, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET弱(+) S100(+),,,,,54.7634691195795,1534600
1534230,王力华,617571,男,59,T4b,N1,M0, ⅢB,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,2.0,30,中间型（int）,INFb,1.0,,,,,,,2.0,2015-11-05,2021-07-23,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)01 (3a)08 (3b)00 (4sb)01 (4d)213 (5)00 (6)04 (7)00 (8a)00 (8p)01 (9)00 (11p)01," L（幽门窦部）, 小弯侧Less,",30,20,5, R0 D2,,7.44,4.63,2.11,147.8,321.0,3.97,15.0,17.0,170.0,60.0,17.0,7.07,2.74,68.0,284.0,43.0,25.0,4.2,6.8,79.0,301.0,74.4,47.1,18.0,2.62,0.2,14.3,9.3,0.7,0.91,2.03,11.8,143.0,0.96,2.45,4.38, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET弱（+）,,,,,68.5611038107753,1534230
1534104,魏相茹,617803,女,58,T2,N2,M0, ⅡB,1,3,0.0,1.0,,0.0, 异型增生+,6.0,9,硬型（sci）,INFa,0.0,,,,,,,1.0,2015-11-04,2022-09-01,1,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)01 (3a)34 (3b)00 (4sb)00 (4d) (6)11 (5)00 (7) (8a) (8p) (9) (11p)22 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",55,50,10, R0 D2,,,,,,,2.76,7.0,13.0,168.0,93.0,8.0,5.03,1.87,58.0,235.0,39.0,19.0,4.0,2.7,60.0,300.0,80.7,42.7,24.2,1.76,0.1,7.3,10.8,0.9,1.07,2.6,7.41,5.19,26.83,32.06,0.921,,无, 无, P0,H0, 未做, CK+， Vimentin- VEGF- CMET部分+,,,,,81.89881734559789,1534104
1534588,仲伟日,613081,男,68,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,9,,,1.0,,,,,,,1.0,2015-11-09,2020-10-07,1,,,,,,,,,0, 高级别上皮内瘤变 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)01 (3a)02 (3b)00 (4sb)04 (4d)02 (5)00 (6)01 (7)00 (8a)00 (8p)00 (9)00 (11p)00," L（幽门窦部）, 小弯侧Less,",40,30,, R0 D2,,6.55,3.78,2.18,146.0,208.0,2.45,26.0,19.0,186.0,45.0,34.0,21.52,7.66,65.0,380.0,44.0,21.0,6.4,5.1,81.0,354.0,53.7,38.5,14.3,2.69,0.0,16.3,27.8,0.7,1.02,2.32,8.34,5.0,1.1,6.75,19.25,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,58.93561103810775,1534588
1534095,冯淑兰,616005,女,59,T4b,N1,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,1.0,36,中间型（int）,INFa,0.0,,,,,,,1.0,2015-11-04,2021-05-17,1,,,XELOX,,,,,,7, 管状腺癌（中分化70【G2】乳头30【tub2】,G2, (1a)0/3 (1b)0/2 (2)0/2 (3a)0/3 (3b)0/1 (4sa)0/1 (4sb)0/0 (4d)0/7 (5)0/3 (6)0/7 (7)0/2 (8a)0/1 (8p)0/3 (12a)0/0 (12p)0/1," ML 前Ant, 小弯侧Less,",50,70,10,,R1,4.81,2.71,1.68,85.1,357.0,3.33,9.0,10.0,116.0,72.0,9.0,3.33,1.25,65.0,169.0,36.0,29.0,6.6,5.9,55.0,206.0,,,,,,,,,,,,,15.6,10.87,135.4,,无, 无, P0,H0, 未做, CMET +Vimentin- VEGF- CK+ CD34+ S-100+,,,,,66.39290407358739,1534095
1534651,侯玉英,618484,女,67,T3,N3a,M0,ⅢB,1,1,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,9.0,27,中间型（int）,INFb,1.0,,,1.0,,,,2.0,2015-11-10,2020-10-07,1,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)01 (3b)12 (4sb)00 (4d)49 (5)00 (6)46 (7)02 (8a)02 (9)03 (11p)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",50,50,9, R0 D2+,,6.77,4.76,1.37,69.8,475.0,3.49,10.0,12.0,154.0,115.0,9.0,8.45,2.82,68.0,183.0,40.0,28.0,7.9,6.4,71.0,245.0,78.4,49.3,23.6,2.09,0.1,14.9,5.9,0.1,0.847,4.41,13.3,364.0,7.79,25.6,1.03,,无, 无, P0,H0, 未做,CK + Vimentin部分+  VEGF- CMET弱+,,,,,58.90275952693823,1534651
1534493,佟庆功,618910,男,65,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+） 肠化生+,0.0,38,中间型（int）,,0.0,,,,,,,0.0,2015-11-09,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 01(1b)01 (3a) 010(3b)01 (4sb)00 (4d)010 (5)02 (6)03 (7)03 (8a)01 (9)01 (11p)02 (12a) 02(12p)01," L（幽门窦部）, 小弯侧Less,",35,25,1,R0 D2,,5.02,3.27,1.3,123.4,202.0,2.12,9.0,19.0,167.0,69.0,13.0,26.24,8.53,59.0,301.0,40.0,19.0,5.1,6.9,83.0,245.0,43.9,32.6,10.2,3.2,0.3,15.2,37.9,1.2,0.485,1.69,8.04,156.0,3.04,511.0,0.954,,无, 无, P0,H0, 未做, CK+ VEGF- Vimentin- CMET-,,,,,58.93561103810775,1534493
1534492,安春清,618928,男,42,T4b,N3a,M0, ⅢC,1,2,0.0,0.0,,1.0, 慢性炎症（+）,8.0,28,中间型（int）,INFc,0.0,,,,,,,1.0,2015-11-09,2020-10-07,1,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,卡佩他滨,6, 低粘附腺癌70%， 低分化腺癌（G3)(por)30% Lauren肠型,G3, (1a)01 (1b)01 (3a)26 (3b)00 (4sb)00 (4d)26 (5)11 (6)13 (7)03 (8a)12 (8p)02 (9)11 (11p)00 (14v)02前系膜前叶00," LM 前Ant, 后Post, 小弯侧Less,",70,45,10, R0 D2,,4.23,2.41,1.45,88.7,242.0,3.49,22.0,24.0,153.0,81.0,20.0,6.92,2.39,54.0,251.0,38.0,16.0,4.9,4.6,64.0,309.0,71.6,38.9,27.0,1.44,0.1,8.7,18.7,0.5,0.719,2.06,5.38,12.7,44.24,169.6,9.58, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ S-100（神经侵犯） CD34、D2-40(未见),,,,,58.93561103810775,1534492
1534519,刘建国,619134,男,80,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0, 腺体萎缩+ 慢性炎症（+）,0.0,13,中间型（int）,INFb,0.0,,1.0,1.0,,,,1.0,2015-11-09,2021-05-17,1,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】,G3, (1a)0/1 (1b)0/0 (3a)0/0 (3b)0/0 (5)0/0 (6)0/1 (4sb)0/0 (4d)0/0 (7)0/0 (8a)0/2 (8p)0/0 (9)0/4," L（幽门窦部）,",32,22,1, R0 D2,,8.12,4.89,2.51,159.0,167.0,3.43,17.0,24.0,184.0,50.0,27.0,13.68,5.12,72.0,329.0,72.0,27.0,5.3,6.6,97.0,430.0,,,,,,,,,,,,,2.31,11.53,5.68,,无,, P0,H0, 未做, CK+ Vimentin+ CMET+,,,,,66.22864651773982,1534519
1534582,赵国忠,613009,男,72,T3,N1,M0, ⅡB,1,2,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,2.0,39,中间型（int）,INFb,0.0,,,,,,,1.0,2015-11-09,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,大弯01小弯24； (1a)00 (1b) 00(3a)05 (3b)03 (4sb)02 (4d)08 (5)00 (6)04 (7)01 (8a)01 (8p)02 (9) 02(11p)04 (12a)00 (14v)02," L（幽门窦部）, 小弯侧Less,",30,30,10,R0 D2,,6.39,4.87,1.28,84.0,307.0,2.54,12.0,20.0,119.0,43.0,20.0,7.15,3.32,55.0,198.0,34.0,21.0,5.8,4.9,71.0,349.0,48.3,30.3,16.8,1.8,0.1,8.0,42.0,0.5,0.679,3.09,11.7,86.6,1.1,10.5,0.8, 未做,无, 无, P0,H0, 未做, CK+ CMET+ Vimentin- VEGF-,,,,,58.93561103810775,1534582
1534652,张守志,613039,男,58,T1a,N0,M0,ⅠA,1,0,0.0,,,, 慢性炎症（+）,0.0,31,中间型（int）,INFb,2.0,,1.0,1.0,,,,2.0,2015-11-10,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)01 (3a)05 (3b)00 (4sb)01 (4d)08 (6)06 (7)01 (8a) 02(8p)02 (9)01 (11p)01," L（幽门窦部）, 后Post,",30,30,3,R0 D2,,6.31,3.08,2.2,147.0,228.0,1.64,36.0,41.0,204.0,96.0,21.0,7.49,2.83,65.0,257.0,46.0,19.0,5.4,7.7,62.0,250.0,58.5,29.4,24.3,1.21,1.5,4.7,34.6,0.7,1.32,2.94,9.43,5.0,1.73,10.94,3.12,,无, 无, P0,H0, 未做, Vimentin+ CMET+ CK+ VEGF+,,,,,58.90275952693823,1534652
1534755,王颖,618948,女,41,T1a,N1,M0, ⅠB,1,0,1.0,,,, 肠化生+ 慢性炎症（+）,1.0,28,中间型（int）,,0.0,,,,,,,2.0,2015-11-10,2020-10-07,1,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3," (1a)01, (1b)01 (3a)02 (3b)00 (4sb)01 (4d)04 (5)00 (6)17 (7)03 (8a)01 (8p)02 (9)01 (11p)05"," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,40,10, R0 D2,,7.96,4.99,2.49,135.5,258.0,3.58,17.0,25.0,142.0,90.0,12.0,11.94,3.75,66.0,208.0,45.0,21.0,8.8,5.2,56.0,200.0,69.3,45.2,20.1,2.25,0.2,14.6,14.8,0.3,0.698,3.56,7.61,8.32,1.67,10.01,1.49,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF-CMET弱+,,,,,58.90275952693823,1534755
1534650,张孝,619148,男,64,T3,N2,M0, ⅢA,1,2,,0.0,0.0,1.0, 肠化生+,3.0,33,中间型（int）,INFb,1.0,,,,,,,1.0,2015-11-10,2021-07-23,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)04 (5)00 (6)00 (7)38 (8a)00 (8p)02 (9)01 (11p)04," L（幽门窦部）, 后Post, 大弯侧Gre,",40,30,8, R0 D2,,9.72,3.66,5.22,157.0,290.0,2.38,19.0,26.0,141.0,89.0,19.0,10.52,3.71,69.0,302.0,47.0,22.0,4.5,5.5,57.0,294.0,75.9,26.0,21.8,1.19,0.3,8.2,13.6,3.0,0.854,1.36,10.5,114.8,3.3,10.27,1.3, 未做,无, 无, P0,H0, 未做,CK(+)、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,68.39684625492772,1534650
1534806,王淑兰,618525,女,64,T4b,N2,M0, ⅢB,1,3,1.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,5.0,41,中间型（int）,INFb,0.0,,,,,,,2.0,2015-11-11,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3," (1a)01 (1b)12 (2)01 (3a)111 (3b)02 (4sa)03 (4sb)04 (4d)00 (7)11 (8a)04 (8p)13 (9)13 (10)06 软组织可见癌3a,7"," U（胃底部）, 后Post, 小弯侧Less,",40,35,12, R0 D2,,15.32,11.21,2.66,123.6,277.0,6.35,15.0,23.0,164.0,91.0,23.0,6.84,2.24,66.0,136.0,43.0,23.0,5.4,4.6,55.0,253.0,68.9,29.5,32.8,0.9,0.1,9.7,20.3,4.8,,3.75,10.3,14.6,0.929,20.84,2.23,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET弱+,,,,,58.86990801576872,1534806
1534878,何志国,618879,男,62,T3,N2,M0, ⅢA,1,3,0.0,1.0,,1.0, 慢性炎症（+）,4.0,41,中间型（int）,INFb,0.0,,,,,,,1.0,2015-11-11,2016-11-15,2,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)14 (1b)07 (3a)27 (4sb)010 (4d)01 (5)00 (6)00 (7)05 (8a)02 (8p)02 (9)01 (11p)00," L（幽门窦部）, 小弯侧Less,",18,12,10, R0 D2,,5.7,3.24,1.78,153.2,163.0,3.33,29.0,25.0,166.0,93.0,33.0,8.22,3.27,66.0,201.0,41.0,25.0,4.5,6.5,69.0,236.0,53.5,29.0,21.7,1.34,0.1,7.7,35.8,6.5,1.28,2.25,13.5,76.7,1.76,5.6,20.24,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF-CMET+,,,,,12.155059132720105,1534878
1534721,何殿忠,617984,男,71,T4b,N2,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,6.0,17,中间型（int）,INFb,0.0,,,,,,,2.0,2015-11-10,2016-05-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a、1b)01 (3a)00 (3b)33 (4sb)00 (4d)03 (5)00 (6)25 (7)12 (8、9)01 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,50,15,,R1,6.32,3.18,2.65,97.8,315.0,3.33,9.0,18.0,124.0,82.0,11.0,7.06,2.79,73.0,235.0,41.0,32.0,5.5,5.1,100.0,326.0,55.3,21.5,27.8,0.77,0.5,5.0,36.7,0.4,2.58,4.69,18.2,380.0,4.08,119.3,8.43,,无,, P0,H0, 未做,CK + Vimentin– VEGF- CMET弱+,,,,,5.683311432325887,1534721
1534877,张喜琳,619461,女,64,T1b,N2,M0, ⅡA,1,0,0.0,1.0,,0.0, 慢性炎症（+）,3.0,22,中间型（int）,INFb,2.0,,,,,,,2.0,2015-11-11,2018-06-15,2,,,SOX,吉西他滨,阿帕替尼,,,,3, 管状腺癌（中低分化【G2】【tub2】 Lauren肠型；胰腺： 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (3a)07 (3b)02 (4sb)00 (4d)06 (5)01 (6)01 (7)11 (8a)01 (9)00 (11p)22 (12a)00," L（幽门窦部）, 小弯侧Less,",25,15,10,,R2,5.0,3.35,1.33,137.0,253.0,2.68,22.0,22.0,322.0,77.0,25.0,14.84,4.92,72.0,278.0,49.0,23.0,7.4,3.1,74.0,296.0,76.6,32.0,38.6,0.83,0.0,4.1,17.7,3.1,0.775,2.21,9.57,282.0,2.84,26.11,20.4,,无, 无, P0,H0, 未做, CK+ Vimentin -VEGF- CMET+,,,,,31.110381077529563,1534877
1534736,尹淑红,618903,女,50,T4b,N3b,M0, ⅢC,1,4,1.0,1.0,1.0,1.0, 慢性炎症（+）,28.0,38,中间型（int）,INFc,0.0,,,1.0,,,,1.0,2015-11-10,2019-01-01,2,,,XELOX,XELOX,XELOX,卡佩他滨,,,4, 低分化腺癌（G3)(por) 低粘附腺癌40,G3, (1a)1/4 (1b)3/4 (2)1/1 (3a)4/5 (3b)0/0 (4sa)0/1 (4sb)0/0 (4d)9/12 (5)1/1 (6)1/2 (7)2/2 (8a)1/1 (8p)4/4 (9)0/0 (11p)0/0 (12a)1/1," L（幽门窦部）, M（胃体部）, U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,50,15,,R1,3.69,1.51,1.82,125.0,250.0,17.2,6.0,13.0,138.0,53.0,3.0,9.33,2.66,65.0,42.0,42.0,23.0,260.0,4.3,74.0,217.0,,,,,,,,,,,,,0.928,4.58,2.98, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin+ VEGF- CK+ CD34+ S-100+,,,,,37.71353482260184,1534736
1534910,张树海,619463,男,52,T3,N0,M0, ⅡA,1,3,0.0,0.0,,0.0, 慢性炎症（+）,0.0,17,中间型（int）,INFb,0.0,,1.0,1.0,,,,1.0,2015-11-11,2019-09-02,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (2)01 (3a)06 (3b)00 (4sa)00 (4sb)00 (4d)00 (7)01 (8a)02 (8p)01 (9)05 (11p)01," UM 后Post, 小弯侧Less,",15,10,8, R0 D2,,4.51,2.77,1.37,104.3,172.0,2.84,18.0,17.0,135.0,39.0,76.0,7.15,2.69,59.0,402.0,40.0,,5.8,3.56,62.0,,70.1,49.9,18.6,2.68,0.1,9.6,16.4,1.1,0.87,1.99,6.68,17.0,2.04,6.98,1.04,,无, 无, P0,H0, 未做, CK+ Vimentin部分+ VEGF散在+ CMET+,,,,,45.69645203679369,1534910
1535505,曹金海,618708,男,58,T1b,N0,M0,ⅠA,1,0,1.0,,,, 肠化生+ 慢性炎症（+）,0.0,25,中间型（int）,INFa,2.0,,,,,,,2.0,2015-11-17,2020-10-07,1,,,,,,,,,0, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)03 (1b)01 (3a)05 (3b)00 (4sb)00 (4d)01 (5)01 (6)08 (7)03 (8a)01 (9)00 (11p)02 (12a)00," L（幽门窦部）, 前Ant,",25,20,2, R0 D2+,,7.7,4.77,1.99,138.9,320.0,2.91,79.0,78.0,221.0,119.0,87.0,5.1,1.92,74.0,423.0,50.0,24.0,,4.8,61.0,403.0,,,,,,,,,,,,,1.81,6.65,9.07,,无,, P0,H0, 未做,CK + Vimentin– VEGF- CMET弱+,,,,,58.67279894875164,1535505
1535103,邹本凯,619492,男,63,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,13.0,27,中间型（int）,INFb,2.0,,,1.0,,,,1.0,2015-11-12,2017-02-15,2,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】,G3, (1a)0/1， (1b)1/2， (3a)2/2， (3b)0/0， (4sa)0/0， (4sb)0/1， (2)0/5， (4d)2/3， (5)3/3， (6)2/2， (7)1/1， (8p)0/1， (9)0/2， (11p)1/3," ML 前Ant, 后Post, 小弯侧Less,",60,40,10,,R1,7.37,4.61,2.1,107.0,268.0,3.4,83.0,29.0,135.0,126.0,17.0,6.07,0.98,70.9,272.22,46.8,24.1,7.7,5.73,88.0,288.0,,,,,,,,,,,,,2.17,15.61,5.48, 未做,无,, P0,H0, 未做, CMET+ Vimentin+ VEGF- CK+ CD34+ S-100+,,,,,15.14454664914586,1535103
1535321,孙玉河,619439,男,68,T1a,N0,M0,ⅠA,1,0,0.0,,,, 肠化生+ 慢性炎症（+）,0.0,17,中间型（int）,,1.0,,,,,,,0.0,2015-11-16,2020-10-07,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a) 00(1b)01 (3a)05 (3b)01 (4sb)00 (4d)01 (5) 01(6)02 (7)01 (8a)01 (9)01 (11p)03 (12a)00,L,8,5,5,R0 D2,,6.69,3.5,2.54,163.0,144.0,2.03,13.0,17.0,164.0,70.0,11.0,15.79,5.88,68.0,336.0,45.0,23.0,5.0,5.6,88.0,208.0,67.2,39.5,9.4,4.2,0.0,12.9,17.7,5.7,0.172,2.22,10.7,5.0,1.24,9.86,2.2,,,,,,, CK+ VEGF- Vimentin -CMET-,,,,,58.70565045992115,1535321
1535428,李海淑,615415,女,60,T3,N3a,M0,ⅢB,1,3,0.0,1.0,,1.0, 慢性炎症（+）,13.0,20,中间型（int）,INFc,0.0,,,1.0,,,,1.0,2015-11-16,2016-04-15,2,,,XELOX,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90%， 粘液腺癌（muc）10%。 Lauren肠型,G3," (1a)03 (1b)22 (3a)23 (3b)22 (4sb)22 (4d)11 (5)00 (6)22 (7)11 (8a)01 (8p)01 (9) 01(11p)11,5组可见1枚癌结节"," L（幽门窦部）, 前Ant, 小弯侧Less, 大弯侧Gre,",50,40,10, R0 D2,,6.52,3.08,2.87,102.9,439.0,3.01,16.0,21.0,217.0,67.0,57.0,6.18,2.47,71.0,186.0,41.0,30.0,6.8,4.4,66.0,232.0,,,,,,,,,,,,,1.66,52.25,3.39, 未做,无, 无, P0,, 未做, CMET +Vimentin部分+ VEGF- CK+ S-100(可见神经侵犯) CD34、D2-40(脉管瘤栓),,,,,4.9605781865965834,1535428
1535643,张万祥,615404,男,61,T4b,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,17.0,37,硬型（sci）,INFc,0.0,,,,,,,0.0,2015-11-18,2018-03-11,2,,,卡佩他滨,XELOX,奥沙利铂 雷替曲塞,,,,3, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)02 (1b)13 (3a)00 (3b) 55(4sb)01 (4d)45 (5)00 (6)13 (7)33 (8a)02 (8p)04 (9)00 (11p)05 (12p)01," LM 后Post,",50,40,10,,R1,4.33,2.05,1.94,164.9,258.0,3.85,41.0,32.0,149.0,55.0,37.0,7.42,3.6,73.0,465.0,48.0,25.0,4.9,8.5,92.0,499.0,43.9,29.9,10.8,2.77,0.0,9.1,44.9,1.8,0.726,2.73,11.6,79.8,0.2,7.71,12.11, 未做,无,, P0,H0, 未做,,,,,,27.726675427069644,1535643
1535331,赵淑杰,619679,女,54,T4b,N3b,M0, ⅢC,1,4,2.0,0.0,,1.0, 肠化生+ 慢性炎症（+）,27.0,39,中间型（int）,INFc,0.0,,,,,,,2.0,2015-11-16,2016-10-07,2,,,,,,,,,0, 低粘附腺癌 70管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)44 (1b)33 (2)33 (3a)11 (3b)00 (4sa)14 (4sb)00 (4d) 37(5)02 (6)45 (7)00 (8a)12 (8p)12 (9)11 (11p)33 (12a)00 (19)00," LMU 后Post, 大弯侧Gre, 小弯侧Less, 前Ant,",50,40,10,,R1,3.74,1.93,1.56,144.5,160.0,2.03,18.0,24.0,158.0,25.0,7.0,27.67,9.84,64.0,191.0,43.0,21.0,3.7,2.7,46.0,264.0,64.5,47.5,14.8,3.21,0.2,17.3,15.6,0.4,0.879,1.35,10.7,5.0,2.0,5.92,1.14,,无, 无, P0,H0, 未做, CK+ Vimentin- CMET+ VEGF-,,,,,10.709592641261498,1535331
1535399,刘桂芬,612258,女,60,T2,N2,M0, ⅡB,1,3,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,4.0,15,中间型（int）,INFb,0.0,,,1.0,,,,0.0,2015-11-16,2016-05-15,2,SOX*2,1.0,SOX,SOX,紫杉醇 卡佩他滨,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)11 (1b)01 (3a)13 (3b)01 (4sb)00 (4d)02 (5)01 (6)12 (7)11 (8a) (8p) (9)02 (11p)01," L（幽门窦部）, 前Ant, 小弯侧Less,",30,20,3, R0 D2,,7.71,3.68,2.98,118.6,227.0,2.4,22.0,26.0,212.0,124.0,10.0,14.43,4.38,71.0,298.0,44.0,27.0,5.2,5.4,45.0,273.0,,,,,,,,,,,,,3.5,13.06,5.97,,无, 无, P0,H0, 未做, CK+ Vimentin部分+ VEGF- CMET-,,,,,5.946123521681997,1535399
1600364,吕永生,618190,男,60,T2,N0,M0, ⅠB,1,3,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,40,中间型（int）,INFc,3.0,,,,,,,,2016-01-06,2020-12-01,2,替吉奥*2,1.0,SOX,SOX,SOX,,,,3, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b) 01(3a)05 (3b)01 (4sb)01 (4d)08 (5)01 (6)07 (7)04 (8a)01 (8p)02 (9)05 (11p) 03(12a)00 (12p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,10,,R1,4.15,1.41,2.13,107.0,107.0,2.79,25.0,30.0,200.0,88.0,18.0,9.4,3.54,62.0,205.0,35.0,27.0,5.0,5.4,70.0,349.0,,,,,,,,,,,,,3.39,11.57,5.1, 未做,无, 无, P0,H0, 未做,,,,,,58.83705650459921,1600364
1535757,朱俊礼,619687,男,52,T3,N2,M1, Ⅳ,1,2,0.0,1.0,,1.0, 慢性炎症（+）,5.0,23,中间型（int）,INFb,0.0,,,,,,,2.0,2015-11-18,2018-11-07,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a)12 (1b)01 (2) 01(3a)01 (3b)11 (4sb)01 (4d)29 (5)00 (6)00 (7)02 (8a)11 (9)01 (11p)01 (12p)00," L（幽门窦部）, 前Ant, 小弯侧Less,",35,30,10,,R2,14.54,10.14,2.49,125.0,193.0,4.03,18.0,23.0,169.0,47.0,19.0,9.17,4.6,56.0,125.0,34.0,22.0,3.2,5.8,77.0,288.0,73.4,57.0,13.8,4.13,0.1,10.4,10.5,1.8,1.33,3.79,9.84,69.5,49.76,7.59,1.04,,无, 无, P0,H1单（M1 HEP), 未做, CK+ CMET+ Vimentin- VEGF-,,,,,35.64388961892247,1535757
1536490,丛树芳,620302,男,54,T4b,N1,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,2.0,38,中间型（int）,INFa,0.0,,,,,,,0.0,2015-11-24,2017-04-08,2,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)04 (3a)03 (3b)00(4sb)06 (4d)13 (5)01 (6)16 (7)05 (8a)03 (8p)01 (9)03 (11p)02 ,LM 前Ant 后Post 大弯侧Gre  小弯侧Less ,100,80,20, R0 D2,,7.18,4.73,1.91,94.0,325.0,3.85,5.0,12.0,138.0,75.0,15.0,16.24,6.47,66.0,197.0,40.0,26.0,4.1,7.6,78.0,269.0,77.3,55.1,21.5,2.56,0.1,7.3,7.3,1.2,1.19,3.36,10.2,,0.655,11.81,1.75, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD31(+)  D2-40(+) S100(+),,,,,16.45860709592641,1536490
1536726,徐相智,613786,男,66,T3,N0,M0, ⅡA,1,2,0.0,0.0,,0.0, 慢性炎症（+）,0.0,22,中间型（int）,INFc,0.0,,,,,,,1.0,2015-11-26,2020-10-07,0,SOX*3,1.0,替吉奥单药,SOX,SOX,SOX,SOX,,5, 低分化腺癌（G3)(por)60%， 低粘附腺癌40%， Lauren混合型,G3, (1a)01 (1b)01 (3a)05 (3b)00 (4sb)03 (4d)09 (5)00 (6)00 (7)02 (8a) (8p)01 (9)00 (11p)00," L（幽门窦部）, 小弯侧Less,",40,40,10, R0 D2,,11.36,10.41,0.56,110.0,125.0,5.7,13.0,18.0,132.0,50.0,12.0,7.12,3.35,62.0,152.0,38.0,24.0,5.3,8.4,57.0,203.0,,,,,,,,,,,,,1.96,9.71,3.59, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ S-100(未见) CD34、D2-40(未见),,,,,58.37713534822601,1536726
1536454,叶茂森,620386,男,77,T2,N1,M0, ⅡA,1,1,2.0,1.0,,0.0, 肠化生+ 慢性炎症（+）,1.0,10,髓样型（med）,INFb,3.0,,,,,,,0.0,2015-11-24,2020-10-07,1,,,,,,,,,0, 低分化腺癌（G3)(por) 70低粘附腺癌30 Lauren弥漫型,G3, (1a)00 (1b)02 (3a)00 (3b)00 (4sb)00 (4d)00 (5)00 (6)12 (7)01 (8a)01 (8p)02 (9)00 (11p) 02(12a)00," L（幽门窦部）, 大弯侧Gre,",40,40,10,R0 D2,,5.59,2.8,2.18,132.0,230.0,1.91,6.0,15.0,158.0,48.0,19.0,9.4,3.62,55.0,240.0,36.0,19.0,4.3,4.6,87.0,,54.6,25.4,27.0,0.94,0.2,5.4,35.0,0.5,0.306,1.78,9.89,5.0,2.85,6.24,2.57,,无, 无, P0,H0, 未做, CK+ VEGF- Vimentin- CMET-,,,,,58.44283837056504,1536454
1536314,文丽平,619248,女,46,T3,N1,M0, ⅡB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+） 肠化生+,2.0,18,中间型（int）,INFc,2.0,,,,,,,2.0,2015-11-23,2020-06-01,2,,,XELOX,,,,,,1,低黏附性癌70% 低分化管状腺癌30%,G3, (1a)0/2 (1b)0/0 (3a)0/2 (3b)0/1 (4sb)0/0 (4d)0/0 (5)0/3 (6)1/1 (7)0/1 (8a)0/2 (8p)0/1 (9)0/2 (11p)0/0," L（幽门窦部）, 大弯侧Gre,",30,30,10, R0 D2,,3.66,1.7,1.48,125.0,300.0,1.77,25.0,29.0,134.0,35.0,17.0,10.29,3.46,66.0,337.0,46.0,20.0,4.6,5.8,81.0,266.0,,,,,,,,,,,,,2.17,7.17,6.78, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ CD34+ S-100+,,,,,54.270696452036795,1536314
1536289,陈宝库,620242,男,66,T3,N2,M0, ⅢA,1,2,2.0,1.0,,1.0, 慢性炎症（+） 肠化生+,5.0,18,中间型（int）,INFb,0.0,,,,,,,0.0,2015-11-23,2018-01-23,2,,,SOX,,,,,,3, 低分化腺癌（G3)10(por) 粘液腺癌（muc）30 低粘附腺癌60 Lauren弥漫型,G3,小弯11 (1a)00 (1b) 01(3a) 36(3b)00 (4sb)00 (4d)02 (5) 11(6)00 (7)01 (8a)01 (8p)01 (9) 02(11p)02 (12a) 00(14v)00," L（幽门窦部）, 小弯侧Less, 后Post,",60,60,10,R0 D2,,6.25,4.68,1.42,130.9,232.0,4.66,12.0,17.0,134.0,69.0,24.0,6.6,2.33,61.0,301.0,41.0,20.0,5.1,5.0,76.0,305.0,76.5,45.2,24.4,1.85,0.3,12.7,7.2,1.9,0.917,2.31,9.0,86.2,1.05,5.8,95.9,,无, 无, P0,H0, 未做, CK+ VEGF -Vimentin -CMET-,,,,,26.018396846254927,1536289
1536325,温德臣,620092,男,62,T4b,N1,M0, ⅢB,1,3,0.0,1.0,,0.0, 慢性炎症（+）,1.0,11,中间型（int）,INFc,0.0,,,,,,,0.0,2015-11-23,2017-06-15,2,,,,,,,,,0, 粘液腺癌（muc）60 乳头状癌（G1）（pap）40 Lauren肠型,G1, (1a) 00(1b)02 (3a) 01(3b)00 (4sb) 00(4d)15 (5) 02(6)00 (7) 018组00 9组00 689组各见一枚癌结节," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,80,20,,R2,6.15,4.06,1.52,82.8,377.0,3.04,17.0,19.0,170.0,70.0,18.0,3.99,1.86,56.0,182.0,33.0,23.0,3.7,5.6,83.0,231.0,,,,,,,,,,,,,2.68,4.75,70.54, 未做,无, 无, P0,H0, 未做, CK+ Vimentin —VEGF— CMET—,,,,,18.725361366622863,1536325
1536633,苏江河,620746,男,67,T3,N1,M0, ⅡB,1,3,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,2.0,22,中间型（int）,INFa,3.0,,,,,,,0.0,2015-11-25,2021-07-01,1,,,SOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap）20% Lauren肠型,G2, (1a)00 (3a)06 (3b)01 (4sb)00 (4d)04 (5) 00(6)03 (7)24 (8a)01 (8p)02 (9) 01(11p)00 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",75,60,10,R0 D2,,8.93,5.55,2.53,109.0,420.0,16.3,13.0,20.0,150.0,83.0,10.0,7.19,2.54,68.0,307.0,44.0,24.0,4.8,6.4,88.0,303.0,67.3,36.1,30.2,1.2,0.2,9.7,20.7,9.9,,2.2,11.4,,2.89,15.33,5.33, 未做,无, 无, P0,H0, 未做,,,,,,67.18134034165571,1536633
1536453,魏景芳,618963,男,60,T3,N2,M0, ⅢA,1,1,0.0,1.0,1.0,1.0, 慢性炎症（+）,3.0,39,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-11-24,2022-09-01,1,,,SOX,,,,,,6, 低粘附腺癌 Lauren肠型,GX, (1a)05 (1b)06 (3a)00 (3b)00 (4sb)22 (4d)110 (5)00 (6)02 (7)03 (8a)03 (8p)00 (9)04 (11p)04," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",60,50,15, R0 D2,,7.06,2.23,3.81,118.0,297.0,3.97,7.0,11.0,92.0,70.0,14.0,4.78,1.41,63.0,234.0,39.0,24.0,4.6,9.7,92.0,249.0,,,,,,,,,,,,,1.75,22.64,19.22, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin部分（+）、 VEGF（-）、 CMET（-）,,,,,81.24178712220761,1536453
1536484,闫秀军,619899,男,52,T2,N2,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,4.0,26,中间型（int）,INFa,1.0,,,,,,,2.0,2015-11-24,2020-10-07,1,,,XELOX,,,,,,4, 管状腺癌（中分化90【G2】【tub2】 低粘附腺癌10,G2, (1a)0/0 (1b)0/0 (3a)1/6 (3b)0/0 (4sb)0/2 (4d)3/4 (5)0/0 (6)0/3 (7)0/4 (8a)0/2 (8p)0/1 (9)0/2 (11p)0/2 (12a)0/0 (14v)0/0," L（幽门窦部）, 大弯侧Gre,",15,12,5, R0 D2,,6.55,1.73,3.59,152.0,203.0,1.435,27.0,20.0,133.0,102.0,213.0,14.11,4.75,59.0,440.0,41.0,18.0,3.9,4.1,95.0,285.0,,,,,,,,,,,,,3.83,6.82,3.21, 未做,无,, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ CD34+ S-100+,,,,,58.44283837056504,1536484
1537122,刘继承,620110,男,54,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+） 肠化生+,0.0,22,中间型（int）,,0.0,,,,,,,2.0,2015-11-30,2022-09-01,1,,,,,,,,,0,高中分化管状腺癌,G2, (1a)0/0 (1b)0/0 (2)0/4 (3a)0/0 (3b)0/0 (4sa)0/1 (4sb)0/1 (7)0/2 (8a)0/2 (8p)0/3 (9)0/4 (11p)0/5," M（胃体部）, 前Ant, 小弯侧Less,",65,25,10, R0 D2,,4.73,2.36,1.61,91.0,418.0,2.45,22.0,29.0,132.0,51.0,13.0,5.12,2.26,62.0,204.0,39.0,23.0,4.8,4.8,77.0,258.0,,,,,,,,,,,,,1.29,8.83,0.93, 未做,无,, P0,H0, 未做, CD34- S-100-,,,,,81.04467805519053,1537122
1537265,彭志臣,620116,男,63,T3,N0,M0, ⅡA,1,1,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,32,髓样型（med）,INFa,1.0,,,,,,,1.0,2015-12-01,2020-10-07,1,,,XELOX,,,,,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 乳头状癌（G1）（pap）10 Lauren肠型,G3, (1a)00 (1b)01 (2)05 (3a)04 (3b)00 (4sa)03 (4sb)01 (4d)00 (7)04 (8a)01 (8p)01 (9)02 (11d)02 (11p)01 (12a)01," GE, SiewerⅢ, 后Post, 小弯侧Less,",40,40,15, R0 D2,,5.78,3.97,1.2,131.0,234.0,3.67,7.0,15.0,133.0,72.0,9.0,13.21,4.71,61.0,194.0,39.0,22.0,4.2,4.6,71.0,219.0,,,,,,,,,,,,,3.64,13.24,1.08,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,58.21287779237845,1537265
1536386,李明宇,613827,男,47,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,21,,,3.0,,1.0,,,,,1.0,2015-11-24,2021-06-21,1,SOX*3,1.0,SOX,,,,,,3,低中分化,G2, (1a)00 (1b)01 (3a)05 (3b)00 (4sb)00 (4d)02 (5)01 (6)00 (7)01 (8a)03 (8p)01 (11p)07 (12a)00," L（幽门窦部）, 小弯侧Less,",50,15,3,,R1,4.42,1.91,1.71,109.0,151.0,1.93,22.0,36.0,189.0,65.0,21.0,14.28,6.56,72.0,216.0,43.0,29.0,6.0,8.1,78.0,331.0,80.3,48.3,29.2,1.65,0.3,9.6,8.4,1.3,1.09,5.09,14.0,,4.38,7.1,1.38,,无, 无, P0,H0, 未做, CMET +Vimentin+ CK+ VEGF+,,,,,66.88567674113008,1536386
1536681,金玉财,618973,男,65,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,,1.0, 慢性炎症（+）,25.0,42,中间型（int）,INFc,1.0,,,,,,,0.0,2015-11-25,2016-05-01,2,,,XELOX,,,,,,2, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren肠型,G3, (1a)00 (1b)22 (2)22 (3b)00 (4sa)00 (4sb)00 (4d)06 (5)00 (6)01 (7)22 (8a)11 (8p)33 (9)18 (10)810 (10a)11 (11p)45 (12a)11," UM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,90,20, R0 D2,,6.77,3.76,2.3,150.0,231.0,3.25,26.0,32.0,187.0,56.0,21.0,7.49,2.42,68.0,342.0,43.0,25.0,4.4,8.6,76.0,372.0,,,,,,,,,,1.31,11.2,1550.0,2.65,11.38,8.6,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET-,,,,,5.19053876478318,1536681
1535583,陈胜光,617539,男,47,T1a,N0,M0,ⅠA,1,3,2.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,41,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-11-17,2021-05-17,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)0/0 (1b)0/0 (3a)0/10 (3b)0/0 (4sb)0/0 (4d)0/5 (5)0/0 (6)0/10 (7)0/4 (8a)0/6 (8p)0/3 (9)0/1 (11p)0/1 (12a)0/0 (14v)0/1 (2)0/0," L（幽门窦部）, M（胃体部）,",30,25,5,,R1,7.12,4.33,2.2,167.9,301.0,3.59,25.0,23.0,160.0,81.0,16.0,10.59,3.95,75.0,316.0,47.0,28.0,4.2,5.5,80.0,314.0,,,,,,,,,,,,,3.25,15.75,1.14, 未做,无,, P0,H0, 未做, CMET- Vimentin+ VEGF- CK+ CD34- S-100-,,,,,65.9658344283837,1535583
1536841,张淑菊,620263,女,71,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,10,中间型（int）,INFc,0.0,,,,,,,1.0,2015-11-26,2020-10-07,1,,,,,,,,,0, 低粘附腺癌 Lauren肠型,GX, (1a)12 (1b)01 (2)22 (3a)00 (3b)23 (4sa)00 (4sb)00 (5)00 (7)00 (8a)01 (8p)00 (9)00 (11p)01," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,55,10, R0 D2+,,3.54,1.23,1.84,128.1,536.0,3.11,17.0,27.0,134.0,62.0,14.0,6.1,1.96,58.0,226.0,39.0,19.0,5.2,4.7,51.0,230.0,69.2,40.8,20.5,1.99,0.0,14.3,14.0,0.8,0.53,1.89,8.35,16.5,0.921,17.42,2.27,,无, 无, P0,H0, 未做,CK- Vimentin - VEGF- CMET+,,,,,58.37713534822601,1536841
1536823,王山,620304,男,53,T2,N0,M0, ⅠB,1,2,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,28,中间型（int）,INFb,0.0,,,,,,,2.0,2015-11-26,2020-10-07,1,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】 Lauren肠型,G3, (1a)01 (1b)04 (3a)013 (3b)00 (4sb)01 (4d)00 (5)00 (6)02 (7)03 (8a)01 (8p)00 (9)02 (11p)01," L（幽门窦部）, 小弯侧Less, 前Ant,",15,15,5, R0 D2,,6.06,2.28,3.1,140.0,249.0,2.33,29.0,26.0,143.0,73.0,42.0,12.47,5.36,64.0,306.0,41.0,23.0,4.8,8.2,83.0,546.0,80.8,54.3,23.1,2.35,0.0,8.1,8.5,1.1,0.725,2.35,13.8,20.4,0.816,3.51,1.13, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET局灶弱(+)  CD31(+)  D2-40(+) S100(+),,,,,58.37713534822601,1536823
1536860,陈静,615723,女,39,T3,N3b,M0, ⅢC,1,3,0.0,1.0,,1.0, 慢性炎症（+）,39.0,39+1,中间型（int）,INFc,0.0,,,,,,,0.0,2015-11-26,2019-03-13,2,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)11 (1b)00 (2)22 (3a)44 (3b)22 (4sa)01 (4sb)00 (4d)88 (5)00 (6)66 (7) (8a)11 (8p)11 (9)22 (10)11 (11d)11 (11p)66 (12a)11.5组见癌团," LMU 小弯侧Less, 后Post,",95,70,10,R0 D2,,4.57,3.2,0.84,96.0,240.0,2.91,16.0,22.0,106.0,53.0,14.0,10.42,3.35,55.0,160.0,36.0,19.0,4.5,5.9,50.0,200.0,70.3,48.0,18.1,2.65,0.1,8.8,16.4,3.9,1.07,2.24,14.0,,0.689,71.22,22.44,,无, 无, P0,H0, 未做, CK+ VEGF- Vimentin -CMET-,,,,,39.5203679369251,1536860
1536822,陈淑莲,620105,女,60,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,18.0,21,中间型（int）,INFc,0.0,,1.0,1.0,,,,1.0,2015-11-26,2017-02-02,2,,,口服替吉奥,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60% 低粘附腺癌40% Lauren肠型,G3,小湾55 (1a)11 (1b)00 (2)22 (3a)33 (3b)00 (4sa)01 (4sb)00 (4d)79 (5)00 (6)11 (7)00 软组织可见癌," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",55,55,8,,R2,6.31,3.52,2.3,112.8,313.0,3.11,21.0,21.0,137.0,57.0,9.0,6.72,2.45,57.0,213.0,40.0,17.0,4.9,3.6,43.0,253.0,85.8,58.8,24.5,2.4,0.2,7.7,6.1,1.1,0.559,2.31,7.44,485.0,2.33,1000.0,63.86, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin散在（+）、 VEGF散在弱（+）、 CMET部分（+）,,,,,14.257555847568987,1536822
1537336,白学礼,618225,男,72,T3,N3b,M0, ⅢC,1,3,0.0,1.0,,1.0, 慢性炎症（+）,42.0,50,中间型（int）,INFc,0.0,,1.0,1.0,,,,0.0,2015-12-01,2018-03-15,2,,,XELOX,,,,,,5, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren肠型,G3, (1a)02 (1b)33 (3a)1517 (3b)11 (4sb)34 (4d)55 (5)13 (6)45 (7)11 (8a)66 (8p)11 (9)22 (11p)00," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",70,55,10, R0 D2,,4.85,2.69,1.77,150.5,193.0,3.33,26.0,26.0,195.0,70.0,5.0,21.6,9.22,65.0,243.0,45.0,20.0,4.8,4.7,69.0,245.0,,,,,,,,,,,,,30.33,6.29,4.12,,无, 无, P0,H0, 未做, CK+， Vimentin部分+ VEGF散在+ CMET-,,,,,27.43101182654402,1537336
1536401,李淑华,611536,女,63,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,0.0, 慢性炎症（+）,3.0,24,中间型（int）,INFc,0.0,,,,,,,0.0,2015-11-24,2020-10-07,1,,,紫杉醇联合希罗达,紫杉醇联合希罗达,紫杉醇联合希罗达,紫杉醇联合希罗达,卡佩他滨,卡佩他滨,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 乳头状癌（G1）（pap）20 Lauren肠型,G3, (1a)04 (1b)00 (3a)11 (3b)02 (4sb)00 (4d)12 (5)00 (6)14 (7)02 (8a)04 (8p)01 (9) 01(11p)00 大网01, L（幽门窦部） 前Ant 后Post 小弯侧Less ,80,50,10, R0 D2,,8.91,6.59,1.76,127.0,331.0,2.38,10.0,15.0,187.0,109.0,18.0,9.59,2.94,65.0,355.0,44.0,21.0,8.5,4.2,61.0,168.0,69.2,37.9,28.1,1.35,0.1,5.1,20.5,0.5,0.563,4.71,5.3,28.7,13.73,10.05,6.21, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD31(+)  D2-40(+) ,,,,,58.44283837056504,1536401
1537058,刘福堂,619592,男,50,T4b,N1,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,2.0,35,中间型（int）,INFb,0.0,,,,,,,2.0,2015-11-30,2017-11-17,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)06 (1b)01 (3a)02 (3b)00 (4sb)01 (4d)012 (5)00 (6)12 (7)04 (8a)01 (8p)00 (8a、8p)01 (9)04 (11p)00 肿物旁11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,20,10, R0 D2+,,4.15,2.23,1.38,130.0,204.0,2.52,15.0,19.0,145.0,52.0,13.0,8.75,3.79,73.0,223.0,48.0,25.0,5.8,3.8,74.0,240.0,68.2,31.3,32.9,0.95,0.2,12.7,11.5,1.4,1.89,2.51,11.1,178.0,2.64,10.57,4.59,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET弱+,,,,,23.587385019710904,1537058
1536861,付晓峰,619770,男,57,T3,N1,M0, ⅡB,1,4,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,2.0,47,髓样型（med）,INFa,1.0,,,,,,,2.0,2015-11-26,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,小弯旁02 (1a)01 (1b)00 (3a)17 (3b)00 (4sb)01 (4d)111 (5)01 (6)09 (7)06 (8a)02 (9)03 (11p)03 (12a)01," LM 前Ant, 大弯侧Gre, 小弯侧Less,",110,70,15, R0 D2+,,5.89,3.45,1.84,118.3,248.0,2.68,19.0,25.0,155.0,96.0,12.0,15.51,5.35,61.0,201.0,41.0,20.0,4.4,5.9,64.0,220.0,67.6,30.2,30.9,0.98,0.4,7.9,23.6,3.7,0.654,3.17,9.21,424.0,1.09,2.84,4.79,,无,, P0,H0, 未做,CK + Vimentin– VEGF- CMET弱+,,,,,58.37713534822601,1536861
1537123,张桂林,619594,男,58,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,26,中间型（int）,INFa,1.0,,,,,,,1.0,2015-11-30,2020-10-07,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)03 (3a)00 (3b)00 (4sb)00 (4d)012 (5)00 (6)04 (7)02 (8a)01 (8p、9)04 (12a)00," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",65,50,10, R0 D2+,,13.17,6.96,5.09,140.2,287.0,3.33,13.0,18.0,147.0,70.0,19.0,7.23,2.68,60.0,309.0,38.0,22.0,4.4,7.3,82.0,368.0,,,,,,,,,,,,,1.92,5.76,1.31,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET+,,,,,58.24572930354796,1537123
1537150,任学清,621076,男,52,T2,N0,M0, ⅠB,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,20,中间型（int）,INFb,0.0,,,,,,,1.0,2015-11-30,2020-10-07,1,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren肠型,G3, (1a)03 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)04 (5)00 (6)04 (7)03 (8a、8p)01 (9)03 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",70,40,5, R0 D2+,,5.6,3.05,2.04,139.8,227.0,2.19,10.0,19.0,136.0,59.0,16.0,15.69,5.13,63.0,410.0,43.0,20.0,4.7,8.4,89.0,266.0,,,,,,,,,,,,,1.41,11.84,1.57,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET散在+,,,,,58.24572930354796,1537150
1536858,李亚英,620160,女,63,T3,N3a,M1, Ⅳ,1,3,0.0,1.0,,1.0, 慢性炎症（+）,9.0,31,中间型（int）,INFc,0.0,,1.0,1.0,,,,0.0,2015-11-26,2017-04-15,2,,,FOLFOX,FOLFOX,FOLFOX,卡佩他滨,卡佩他滨,卡佩他滨,6, 低粘附腺癌80%， 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20%， Lauren肠型,G3,小弯00， (1a）01 (1b)01 (3a)38 (3b)00 (4sb)04 (4d)38 (5)01 (6)36 (7)02，小弯及7组可见一枚癌结节," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,18,4,,R2,5.75,3.38,1.92,103.9,447.0,4.88,27.0,27.0,120.0,44.0,7.0,7.1,2.18,66.0,207.0,44.0,22.0,5.5,6.7,57.0,307.0,,,,,,,,,,,,,1.55,308.0,32.6, 未做,无, 无, P0,H0, 未做, CMET- Vimentin部分+ VEGF弱+ CK+ S-100（可见神经侵犯） CD34、D2-40(可见脉管瘤栓),,,,,16.62286465177398,1536858
1537059,吕仁杰,620759,男,54,T2,N1,M0, ⅡA,1,3,0.0,1.0,,1.0, 慢性炎症（+）,2.0,31,中间型（int）,INFb,2.0,,,,,,,1.0,2015-11-30,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a) 08(3b)00 (4sb)02 (4d)04 (5) 00(6)14 (7)01 (8a)02 (8p)02 (9) (11p) 01(12a)05 (14v)00," L（幽门窦部）, 前Ant,",20,15,10,R0 D2,,4.69,2.33,1.81,133.3,220.0,1.77,16.0,17.0,141.0,68.0,13.0,6.04,2.56,61.0,221.0,37.0,24.0,4.2,5.8,72.0,246.0,71.7,51.3,19.6,2.62,0.3,18.3,7.5,0.3,1.25,3.51,11.6,,0.87,4.59,1.72,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,58.24572930354796,1537059
1537160,王凤华,615536,女,50,T2,N0,M0, ⅠB,1,3,0.0,0.0,,1.0, 慢性炎症（+）,0.0,26,中间型（int）,INFc,0.0,,,1.0,,,,0.0,2015-11-30,2020-10-07,1,,,XELOX,,,,,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b) 00(2)03 (3a)02 (3b)00 (4sa)00 (4sb) 02(4d01(5)00 (6)05 (7)02 (8a)03 (8p)03 (9)02 (11p)01 (12a)01 (11d)02," UM 小弯侧Less,",60,55,10,R0 D2,,6.42,2.45,3.24,75.1,407.0,2.9,16.0,23.0,142.0,61.0,12.0,5.66,2.07,63.0,124.0,36.0,27.0,4.0,6.2,75.0,202.0,78.0,45.5,30.4,1.5,0.1,5.8,15.1,3.0,1.85,3.25,12.4,,1.16,6.7,1.74, 未做,无, 无, P0,H0, 未做, CK +Vimentin+ VEGF- CMET-,,,,,58.24572930354796,1537160
1537241,于友全,618589,男,61,T4a,N1,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,1.0,40,中间型（int）,INFc,0.0,,,,,,,1.0,2015-12-01,2019-05-01,0,,,XELOX,XELOX,紫杉醇联合替吉奥,紫杉醇联合替吉奥,,,5, 低分化腺癌（G3)(por) 低粘附腺癌50,G3, (1a)0/6 (1b)0/3 (2)0/3 (3a)1/4 (3b)0/1 (4sa)0/5 (4sb)0/3 (8a)0/1 (8p)0/1 (9)0/1 (11p)," U（胃底部）, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,18, R0 D2,,4.75,2.54,1.58,136.0,183.0,1.93,9.0,17.0,137.0,54.0,19.0,11.11,4.56,56.0,194.0,37.0,19.0,3.4,5.0,80.0,273.0,,,,,,,,,,,,,2.18,1.29,1.59, 未做,无,, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+ CD34+ S-100+,,,,,40.9658344283837,1537241
1537335,于全江,620208,男,83,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,,1.0, 慢性炎症（+）,20.0,27,中间型（int）,INFc,0.0,,,,,,,0.0,2015-12-01,2016-12-21,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)23 (2)01 (3a) 00(3b)01 (4sa)00 (4sb)22 (4d)44 (5)00 (6)66 (7)00 (8a)11 (11p)33 (12a)00小弯23," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,85,15,,R1,11.16,8.93,1.82,65.2,448.0,4.88,7.0,10.0,110.0,59.0,11.0,3.5,1.79,48.0,74.0,30.0,18.0,7.1,5.6,47.0,171.0,49.0,30.1,18.2,1.65,0.6,10.5,37.8,2.3,1.38,2.8,7.92,,2.54,5.08,1.98, 未做,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET-,,,,,12.680683311432325,1537335
1537655,郭龙,618471,男,51,T2,N1,M0, ⅡA,1,2,0.0,0.0,,1.0, 慢性炎症（+）,2.0,16,中间型（int）,INFc,0.0,,1.0,1.0,,,,1.0,2015-12-03,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren肠型,G3, (1a)01 (1b)01 (3a)03 (3b)00 (4sb)03 (4d)24 (5)00 (6)00 (7) (8a) (9)01 (8p)01 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",50,40,12, R0 D2,,5.09,3.59,0.95,171.9,157.0,4.2,30.0,34.0,218.0,43.0,49.0,6.94,3.73,52.0,224.0,32.0,20.0,7.0,5.7,82.0,397.0,,,,,,,,,,,,,0.541,18.3,2.18,,无, 无, P0,H0, 未做, CK+ VEGF+ CMET+ Vimentin+,,,,,80.946123521682,1537655
1537676,王桂英,620361,女,59,T2,N3b,M0, ⅢB,1,5,2.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,22.0,27,中间型（int）,INFc,0.0,,,,,,,0.0,2015-12-03,2016-01-30,2,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】60 低粘附腺癌40 Lauren弥漫型,G3, (1a)23 (1b)11 (3a)77 (3b)33 (4sb)01 (4d)68 (5)00 (6)11 (7)22 (8a)01 (8p)00 (9)00 (11p)00 (12a)00 4d 软组织可见癌,L（幽门窦部） 后Post 大弯侧Gre  小弯侧Less ,60,45,13, R0 D2,,6.83,4.5,1.59,151.2,425.0,3.21,12.0,18.0,178.0,91.0,8.0,9.51,3.2,62.0,275.0,40.0,22.0,6.1,3.5,63.0,219.0,68.8,45.5,21.0,2.17,0.1,5.1,20.9,0.2,0.353,2.56,6.03,,1.26,15.64,8.62, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(-)  CD31(+)  D2-40(+) ,,,,,1.9053876478318001,1537676
1537340,王国有,619010,男,56,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,39,中间型（int）,INFc,1.0,,1.0,1.0,,,,2.0,2015-12-01,2018-04-25,0,,,XELOX,,,,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)02 (3a)01 (3b)00 (4sb)01 (4d)07 (5)00 (6)06 (7)011 (8a、8p)01 (9)04 (11p)00 (12a)05," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",27,20,8, R0 D2+,,7.63,5.45,1.45,132.0,296.0,2.58,20.0,24.0,135.0,79.0,11.0,8.88,3.76,73.0,231.0,46.0,27.0,4.2,7.7,94.0,346.0,72.1,35.7,28.0,1.28,0.1,9.7,16.4,2.0,1.71,2.68,10.5,,1.77,0.898,1.14,,无,, P0,H0, 未做,CK + Vimentin+ VEGF+ CMET+,,,,,28.777923784494085,1537340
1537171,董德祥,620228,男,63,T3,N3a,M0,ⅢB,1,3,0.0,1.0,,1.0, 慢性炎症（+）,9.0,37,中间型（int）,INFa,0.0,,,,,,,0.0,2015-11-30,2020-10-07,1,,,,,,,,,0," 粘液腺癌（muc）50%, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30%, 低粘附腺癌20%. Lauren肠型",G3,大弯01 (1a)15 (1b)04 (3a)06 (3b)11 (4sb)00 (4d)17 (5)11 (6)58 (7)00 (8a)00 (8p)02 (9)01 (11p)01 (12a)00," L（幽门窦部）, 后Post, 大弯侧Gre,",55,50,14, R0 D2,,9.47,4.79,3.27,134.0,202.0,5.74,28.0,27.0,186.0,57.0,35.0,4.95,2.32,70.0,187.0,43.0,27.0,5.1,4.9,69.0,176.0,,,,,,,,,,,,,3.07,181.5,19.58, 未做,无, 无, P0,H0, 未做, CMET -Vimentin- VEGF- CK+ S-100（神经侵犯） CD34、D2-40(脉管瘤栓),,,,,58.24572930354796,1537171
1537494,肖志波,620396,男,43,T1b,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 慢性炎症（+）,0.0,25,中间型（int）,INFb,1.0,,1.0,,,,,0.0,2015-12-02,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)04 (1b)00 (3a)04 (5)00 (6)03 (4d)08 (4sb)00 (7) 01(8a)02 (9)00 (11p)02," M（胃体部）, 后Post,",35,25,,R0 D2,,10.87,7.16,2.5,132.0,442.0,2.73,27.0,26.0,167.0,88.0,40.0,8.88,3.09,73.0,426.0,47.0,26.0,4.8,6.3,77.0,369.0,61.1,45.9,12.3,3.73,0.1,12.9,21.9,0.5,1.03,2.0,7.59,,1.87,5.17,2.04,,无, 无, P0,H0, 未做, CK+ VEGF +Vimentin- CMET-,,,,,58.18002628120893,1537494
1537438,王静波,620235,女,41,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,22,,,0.0,,,,,,,1.0,2015-12-02,2020-10-07,1,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】60 低粘附腺癌40,G3, (1a)01 (1b)00 (3a)08 (3b)01 (4sb)00 (4d)01 (5)00 (6)02 (7)01 (8a)01 (8p)01 (9)02 (11p)03 (12a) 01(14v)00,L（幽门窦部） 后Post 大弯侧Gre ,20,10,2, R0 D2,,7.19,3.34,2.98,128.4,276.0,2.18,18.0,23.0,141.0,43.0,7.0,5.16,2.18,77.0,274.0,47.0,30.0,8.1,8.1,61.0,304.0,86.1,41.3,39.5,1.05,0.1,7.3,5.6,1.8,2.4,2.33,12.2,,1.03,12.28,2.94, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+) ,,,,,58.18002628120893,1537438
1537403,刘翠玲,620379,女,66,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,10.0,30,中间型（int）,INFc,0.0,,1.0,1.0,,,,1.0,2015-12-02,2019-10-19,2,,,,,,,,,0, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren肠型,G3, (1a)12 (1b)01 (3a)28 (3b)01 (4sb)01 (4d)46 (5)00 (6)22 (7)02 (8a)13 (8p)02 (9)01 (11p)01 (12a)00,L（幽门窦部） 前Ant 小弯侧Less 后Post 大弯侧Gre  ,50,35,10, R0 D2,,7.82,4.04,2.74,131.5,335.0,3.76,19.0,20.0,182.0,58.0,8.0,7.56,2.9,82.0,263.0,45.0,37.0,6.7,5.3,70.0,443.0,56.7,24.9,31.3,0.8,0.0,6.9,31.5,1.7,0.861,4.96,17.5,,1.74,8.6,1.51, 未做,无, 无, P0,H0, 未做,ck(+)  vimentin部分(+)  VEGF部分(+)  cMET(+)  CD31(+)  D2-40(+) S100(+),,,,,46.55059132720105,1537403
1538363,王景贵,619800,男,66,T4b,N2,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,3.0,38,中间型（int）,INFc,0.0,,,,,,,1.0,2015-12-10,2016-12-01,0,,,XELOX,,,,,,1, Lauren混合型 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30,G3, (1a)00 (1b)02 (3a)116 (3b)01 (4sb)00 (4d)19 (5)11 (6)03 (7)00 (8a) 02(8p)02 (9)01 (11p)01 (12a)00,L（幽门窦部） 后Post 前Ant 大弯侧Gre  ,65,60,15,,R1,6.46,4.31,1.56,109.7,224.0,2.58,16.0,24.0,152.0,53.0,5.0,5.72,2.48,50.0,217.0,33.0,17.0,6.3,11.1,76.0,300.0,61.9,37.8,21.2,1.78,1.8,9.9,25.9,1.2,0.353,3.31,4.28,,1.81,647.0,4.01, 未做,无,, P0,H0, 未做,,,,,,11.727989487516425,1538363
1537677,郭维清,619979,男,61,T2,N3a,M0, ⅢA,1,5,1.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,11.0,27,中间型（int）,INFc,0.0,,,,,,,1.0,2015-12-03,2016-07-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌25 粘液腺癌（muc）5 Lauren混合型,G3, (1a)12 (1b)03 (3a)25 (3b)00 (4sb)00 (4d)22 (5)11 (6)55 (7)04 (8a)02 (8p)02 (9)00 (11p)01," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",75,30,23, R0 D2,,10.5,7.7,2.41,129.8,367.0,3.51,22.0,35.0,212.0,41.0,20.0,29.24,18.92,56.0,97.0,32.0,24.0,4.1,7.9,52.0,436.0,,,,,,,,,,,,,3.1,8.2,6.59,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,7.391590013140604,1537677
1537666,雇丽华,621098,女,42,T2,N1,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,1.0,21,中间型（int）,INFa,0.0,,,,,,,0.0,2015-12-03,2018-05-21,0,,,XELOX,,,,,,6, 管状腺癌（中低分化【G2】【tub2】,G3, (1a)0/0 (1b)0/2 (3a)0/6 (3b)0/1 (4sb)0/0 (4d)0/4 (5)0/1 (6)1/4 (7)0/1 (8a)0/1 (8p)0/0 (9)0/1 (11p)0/0 (12a)0/0," L（幽门窦部）, 小弯侧Less,",20,20,2, R0 D2,,4.3,2.3,1.63,123.0,255.0,2.06,10.0,22.0,253.0,48.0,5.0,10.66,3.66,69.0,188.0,41.0,28.0,5.1,6.6,59.0,224.0,,,,,,,,,,,,,1.5,4.08,1.59, 未做,无, 无, P0,H0, 未做, CMET- Vimentin- VEGF- CK+ CD34- S-100-,,,,,29.566360052562416,1537666
1537650,高有明,620471,男,66,T3,N3a,M0,ⅢB,1,2,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,19,硬型（sci）,INFb,0.0,,1.0,,,,,0.0,2015-12-03,2017-06-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3, (1a)01 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)23 (5)00 (6)57 (7)02 (8a)01 (8p)02 (9)02 (11p)00 (12a)00(3a、3b、4d、11p)组软组织内可见癌+," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",40,35,6, R0 D2+,,7.79,4.42,2.64,154.0,330.0,5.27,22.0,26.0,161.0,76.0,19.0,7.61,3.53,68.0,244.0,41.0,27.0,4.5,7.3,73.0,356.0,,,,,,,,,,,,,2.58,15.61,3.7,,无,, P0,H0, 未做,CK+ Vimentin- VEGF部分+ CMET-,,,,,18.396846254927727,1537650
1537956,韩桂珍,615778,女,53,T4b,N3a,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,8.0,20,中间型（int）,INFc,0.0,,,,,,,2.0,2015-12-07,2017-02-08,2,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,大弯01 小弯12 (1a)01 (1b)11 (2)00 (3a)01 (3b)00 (4sa)33 (4sb)00 (4d)03 (5)00 (6)00 (7)22 (8a)13 (8p)01 (9)02 (12a)00," UM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",110,70,,,R1,6.79,4.5,1.7,109.0,272.0,4.32,22.0,24.0,142.0,73.0,13.0,9.25,3.76,64.0,102.0,37.0,27.0,8.9,4.5,56.0,196.0,73.4,54.8,17.8,3.08,1.6,15.7,8.9,7.2,0.943,3.72,9.67,,2.64,11.68,1.43,,无, 无, P0,H0, 未做,CK + Vimentin– VEGF- CMET弱+,,,,,14.09329829172142,1537956
1537640,那晓丽,619981,女,35,T3,N3b,M1, Ⅳ,1,3,0.0,1.0,1.0,1.0,,23.0,23,中间型（int）,INFc,0.0,,,,,,,2.0,2015-12-03,2017-07-21,2,,,,,,,,,0, 低粘附腺癌,GX, (1a)2/2 (1b)0/0 (3a)4/4 (3b)0/0 (4sb)1/1 (4d)7/7 (5)1/1 (6)5/5 (7)1/1 (8a)2/2 (8p)1 (9)1," LM 前Ant, 后Post, 小弯侧Less,",30,13,10,,R1,5.64,4.13,0.89,86.0,283.0,3.14,12.0,19.0,156.0,281.0,6.0,3.93,1.73,35.0,183.0,35.0,20.0,4.0,4.2,52.0,158.0,,,,,,,,,,,,,0.84,60.0,11.14, 未做,无, 双侧, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ CD34+ S-100+,,,,,19.579500657030223,1537640
1538034,邱正山,620476,男,49,T1a,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,19,中间型（int）,INFc,1.0,,,,,,,1.0,2015-12-08,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 00(1b)03 (3a)00 (3b)04 (4sa)00 (4sb)00 (4d)03 (5) 01(6)02 (7)02 (8a)02 (8p)01 (9)01 (11p)00," L（幽门窦部）, 前Ant,",20,20,2,R0 D2,,6.94,2.99,3.05,149.0,247.0,2.41,74.0,48.0,160.0,66.0,71.0,11.51,4.56,79.0,314.0,47.0,32.0,5.1,6.8,67.0,446.0,70.7,37.8,29.7,1.27,0.1,18.4,8.7,1.3,0.63,2.56,12.3,,,,,,无, 无, P0,H0, 未做, CK+ CMET+ Vimentin- VEGF-,,,,,57.98291721419185,1538034
1537974,关国清,622366,女,59,T3,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,33.0,45,中间型（int）,INFc,0.0,,,,,,,1.0,2015-12-07,2016-12-15,2,,,,,,,,,0, 低分化腺癌20（G3)(por) 低粘附腺癌80,G3, (1a)1/1 (1b)0/3 (2)4/4 (3a)5/6 (3b)0/0 (4sb)0/0 (4d)6/7 (5)2/2 (6)2/4 (7)0/1 (8a)1/1 (8p)1/1 (9)0/1 (11p)0/0 (12a)0/1,LMU,130,100,5,,R1,4.4,2.08,1.85,138.2,276.0,2.24,19.0,23.0,149.0,103.0,9.0,8.4,3.05,68.0,243.0,40.0,28.0,4.6,5.0,62.0,259.0,,,,,,,,,,,,,3.23,7.17,2.55, 未做,无, 无, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ CD34+ S-100+,,,,,12.28646517739816,1537974
1538120,李绪修,622132,男,81,T1a,N0,M0,ⅠA,1,0,1.0,,,, 肠化生+ 慢性炎症（+）,0.0,46,中间型（int）,,3.0,,,,,,,1.0,2015-12-08,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90% 低粘附腺癌10% Lauren混合型,G2, (1a)05 (1b)00 (2)00 (3a)016 (3b)00 (4sa) 00(4sb) 06(4d)04 (5)07 (6)03 (7)03 (8a)01 (9)00 (11p)01," U（胃底部）, SiewerⅢ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",,,,R0 D2,,5.93,4.02,1.42,140.9,220.0,2.45,21.0,24.0,179.0,55.0,8.0,19.59,6.12,72.0,298.0,44.0,28.0,5.0,9.2,74.0,297.0,76.1,45.9,28.3,1.62,0.1,7.2,12.6,1.0,0.51,5.26,11.2,,1.71,1.2,2.95,,无, 无, P0,H0, 未做, CK+ CMET+ Vimentin -VEGF-,,,,,57.98291721419185,1538120
1537501,韩丽娜,477027,女,59,T1b,N0,M0,ⅠA,1,0,0.0,1.0,1.0,0.0, 慢性炎症（+）,0.0,26,中间型（int）,INFb,1.0,,1.0,,,,,1.0,2015-12-02,2020-10-07,1,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】 Lauren肠型,G3, (1a)02 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)04 (5) 00(6)06 (7)02 (8a)02 (8p)04 (9)04 (11p)00 (12a)00," M（胃体部）, 前Ant,",20,18,, R0 D2,,3.83,2.18,1.31,149.3,137.0,2.24,24.0,23.0,148.0,92.0,19.0,9.79,4.04,71.0,299.0,46.0,25.0,6.1,6.5,75.0,353.0,,,,,,,,,,,,,0.557,5.46,1.42, 未做,无, 无, P0,H0, 未做, vimentin(-)  VEGF局灶弱(+)  cMET部分(+)  CD31(+)  D2-40(+) ,,,,,58.18002628120893,1537501
1537876,崔文贵,620749,男,65,T4b,N1,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+） 异型增生+,1.0,26,中间型（int）,INFa,0.0,,,,,,,1.0,2015-12-07,2018-01-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】70% 粘液腺癌（muc）20% 低粘附腺癌10% Lauren肠型,G2,肿物旁12 (1a)00 (1b)01 (2)01 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)011 (5)02 (6)03 (7)01 (8a)02 (8p)01 (9)00," M（胃体部）, U（胃底部）, UM 前Ant, 后Post, 小弯侧Less,",110,80,20, ,R1,6.39,3.92,1.94,62.7,592.0,3.97,17.0,21.0,132.0,56.0,49.0,3.05,1.2,52.0,197.0,32.0,20.0,4.3,7.7,61.0,161.0,73.2,40.0,27.3,1.47,0.1,6.1,17.8,4.8,0.916,2.59,10.5,,1.53,10.37,1.68, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,24.83574244415243,1537876
1537675,韩淑义,622144,男,54,T3,N2,M0, ⅢA,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,5.0,24,中间型（int）,INFc,0.0,,,,,,,2.0,2015-12-03,2016-10-04,0,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,大弯12 (1a)00 (1b)01 (3a)15 (3b)01 (4sb)00 (5)00 (6)25 (7)06 (8a)11 (8p)00 (9)00 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",25,20,12, R0 D2+,,6.02,3.18,2.31,140.8,227.0,2.54,54.0,40.0,181.0,51.0,11.0,9.21,3.38,72.0,355.0,46.0,26.0,5.1,10.1,76.0,227.0,55.1,34.6,18.7,1.85,0.1,12.6,29.3,3.2,0.864,1.56,10.1,,1.28,8.19,1.23,,无,, P0,H0, 未做,CK + Vimentin - VEGF- CMET散在弱+,,,,,10.052562417871222,1537675
1538060,刘成军,622468,男,59,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,24,中间型（int）,INFc,1.0,,,1.0,,,,1.0,2015-12-08,2019-05-01,0,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】 低粘附腺癌20,G3, (1a)0/2 (1b)0/3 (3a)0/3 (3b)0/0 (4sb)0/0 (4d)0/3 (5)0/2 (6)0/5 (7)0/1 (8a)0/1 (8p)0/0 (9)0/3 (11p)0/1 (12a)0/0," L（幽门窦部）, 小弯侧Less,",40,25,15, R0 D2,,8.84,3.91,4.12,162.0,288.0,1.77,32.0,28.0,147.0,79.0,33.0,22.82,8.05,77.0,273.0,46.0,31.0,5.2,6.6,71.0,417.0,,,,,,,,,,,,,1.97,1.07,1.55, 未做,无,, P0,H0,, CMET+ Vimentin+ VEGF- CK+ CD34+ S-100+,,,,,40.73587385019711,1538060
1537964,杨德利,619995,男,73,T2,N1,M0, ⅡA,1,2,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,1.0,19,中间型（int）,INFa,1.0,,,,,,,1.0,2015-12-07,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)12 (3a)08 (3b)05 (4sa)00 (4sb)00 (4d)00 (7)00 (8a)00 (8p)00 (9)00 (11p)02 (12a)01," U（胃底部）, 后Post,",25,22,6, R0 D2,,6.44,4.16,1.75,141.6,137.0,2.63,34.0,25.0,150.0,77.0,112.0,8.78,3.05,66.0,322.0,44.0,22.0,11.6,6.8,81.0,291.0,,,,,,,,,,,,,,11.53,1.95,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,58.01576872536136,1537964
1538053,李树彬,619872,男,61,T3,N1,M0, ⅡB,1,3,0.0,1.0,,1.0, 肠化生+,1.0,19,中间型（int）,INFc,2.0,,,1.0,,,,1.0,2015-12-08,2019-12-06,2,,,,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 粘液腺癌（muc）20 Lauren肠型,G3, (4sb) (4d) (6)08 (1a) (1b) (3a) (3b) (5)17 (7)03 (8a)01," L（幽门窦部）, 小弯侧Less,",50,35,12, R0 D2,,8.41,4.6,2.6,120.9,339.0,3.67,19.0,21.0,119.0,80.0,22.0,7.62,3.16,71.0,201.0,45.0,26.0,5.1,5.7,68.0,324.0,,,,,,,,,,,,,,8.53,5.04,,无, 无, P0,H0, 未做, CK+ Vimentin+ VEGF- CMET+,,,,,47.93035479632063,1538053
1537493,韩春波,620192,女,40,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,,1.0, 慢性炎症（+）,15.0,41,中间型（int）,INFc,0.0,,,,,,,2.0,2015-12-02,2017-06-08,2,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)12 (3a)11 (3b)516 (4sb)00 (4d)48 (5)11 (6)33 (7)00 (8a)01 (8p)01 (9)05 (11p)01," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,10, R0 D2,,9.49,6.59,1.94,125.3,288.0,2.79,17.0,36.0,271.0,49.0,12.0,13.76,5.68,76.0,125.0,45.0,31.0,4.9,9.0,73.0,323.0,,,,,,,,,,,,,,0.921,3.51,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET弱+,,,,,18.199737187910642,1537493
1537877,陈富华,622099,女,64,T3,N0,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,0.0,31,中间型（int）,INFa,2.0,,,,,,,1.0,2015-12-07,2021-05-24,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)05 (3b)00 (4sb)00 (4d)06 (5)02 (6)03 (7)06 (8a)01 (8p)02 (9)02 (11p)03 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",65,50,15, R0 D2+,,6.19,3.25,2.28,95.0,309.0,3.18,18.0,23.0,164.0,86.0,12.0,5.7,2.35,67.0,251.0,40.0,27.0,6.1,7.4,68.0,272.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做,CK + Vimentin - VEGF- CMET+,,,,,65.53876478318003,1537877
1537969,杨雯,619046,女,53,T1b,N0,M0,ⅠA,1,0,0.0,1.0,1.0,0.0, 肠化生+,0.0,11,中间型（int）,INFb,0.0,,1.0,1.0,,,,1.0,2015-12-07,2020-11-30,1,,,XELOX,,,,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)02 (5)02 (6)02 (7)02 (8a)01 (9)00 (11p)00 (12a)00," L（幽门窦部）, 大弯侧Gre,",25,20,5, R0 D2+,,7.12,4.33,2.25,132.8,316.0,3.49,33.0,20.0,187.0,123.0,24.5,10.33,3.34,73.5,261.86,45.0,28.5,5.5,4.09,72.0,245.0,74.1,42.5,25.7,1.65,0.1,8.2,17.1,5.0,0.46,2.73,11.9,,1.81,10.41,3.63,,无, 无, P0,H0, 未做,CK + Vimentin+ VEGF+ CMET+,,,,,59.78975032851511,1537969
1539579,周五俊,620025,男,74,T3,N2,M0, ⅢA,1,2,1.0,1.0,1.0,1.0, 慢性炎症（+） 肠化生+,4.0,14,中间型（int）,INFb,0.0,,,,,,,,2015-12-21,2016-07-14,2,,,,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)01 (1b)00 (2)00 (3a)39 (3b)00 (4sa)00 (4sb)12 (7)00 (8a)00 (8p)00 (9)00 (11p)02," SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",45,40,8,,R1,12.94,10.31,1.72,128.0,160.0,6.18,20.0,18.0,207.0,95.0,73.0,17.15,7.26,72.0,259.0,42.0,30.0,5.7,9.2,167.0,401.0,,,,,,,,,,,,,1.19,0.684,5.79, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,6.767411300919842,1539579
1537938,张祥渠,415357,男,68,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+,0.0,13,中间型（int）,INFb,0.0,,,,,,,1.0,2015-12-07,2020-10-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)02 (5)00 (6)00 (7)03 (8a)03 (8p)02 (9)00 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",18,15,2, R0 D2,,8.19,5.08,2.29,147.2,177.0,3.33,12.0,18.0,150.0,77.0,,13.6,5.61,74.0,301.0,45.0,29.0,4.1,6.8,80.0,332.0,67.8,31.2,35.0,0.89,0.2,10.0,20.7,1.8,0.889,6.16,12.9,,0.725,5.46,25.72, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,57.81865965834428,1537938
1538179,韩鹏飞,622053,女,61,T2,N1,M0, ⅡA,1,2,1.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,2.0,28,中间型（int）,INFb,0.0,,,,,,,1.0,2015-12-09,2020-12-12,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90%， 低粘附腺癌10% Lauren混合型,G3, (1a)00 (1b) 00(3a)09 (3b)00 (4sb)00 (4d)05 (5)00 (6)17 (7)01 (8a)11 (8p)02 (9)03 (12a)00," L（幽门窦部）, 后Post,",35,25,5,R0 D2,,3.67,1.33,2.02,110.0,268.0,2.58,13.0,17.0,159.0,65.0,14.0,14.22,4.6,68.0,294.0,42.0,26.0,5.6,6.5,70.0,252.0,67.4,51.2,15.1,3.39,0.1,7.9,22.0,0.2,1.43,2.23,12.4,,1.9,9.4,3.05, 未做,无, 无, P0,H0, 未做, CK+ CMET+ Vimentin- VEGF-,,,,,60.118265440210244,1538179
1538454,刘凤成,622041,男,73,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,0.0, 肠化生+,2.0,30,中间型（int）,INFc,1.0,,,1.0,,,,1.0,2015-12-11,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren肠型,G3, (1a)02 (1b)07 (3a)04 (3b)00 (4sb)00 (4d)112 (5)00 (6)01 (7)01 (8a)11 (9)02 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,10, R0 D2+,,7.23,5.01,1.61,79.5,349.0,3.41,16.0,22.0,135.0,72.0,9.0,8.11,3.31,66.0,170.0,40.0,26.0,5.3,8.7,63.0,260.0,,,,,,,,,,,,,0.9,4.12,6.76,,无,, P0,H0, 未做,CK + Vimentin部分+ VEGF- CMET+,,,,,80.68331143232588,1538454
1538372,方翠英,620457,女,53,T4b,N0,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,28,中间型（int）,INFc,1.0,,1.0,1.0,,,,1.0,2015-12-10,2020-12-07,1,,,XELOX,XELOX,XELOX,XELOX,卡培他滨,卡培他滨,6, 低粘附腺癌60% 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30% 粘液腺癌（muc）10% Lauren肠型,G3,大网01 (1a)00 (1b)02 (2)04 (3a)03 (3b)00 (4sa)03 (4sb)01 (4d)02 (5)00 (6)02 (7)04 (8a)03 (8p)05 (11p)00 (12a)00 软组织可见癌," L（幽门窦部）, M（胃体部）, U（胃底部）, 前Ant, 后Post, 小弯侧Less,",80,60,12, R0 D2,,4.98,2.79,1.6,151.0,251.0,2.31,168.0,120.0,233.0,217.0,178.0,17.62,7.99,75.0,203.0,46.0,29.0,5.6,7.2,79.0,286.0,,,,,,,,,,,,,1.4,5.86,1.6, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin部分（+）、 VEGF部分（+）、 CMET（+）,,,,,59.92115637319316,1538372
1538591,张同信,622656,男,49,T4b,N1,M0, ⅢB,1,3,1.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,2.0,23,髓样型（med）,INFb,1.0,,,,,,,1.0,2015-12-11,2016-09-07,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3,小弯01 (1a)01 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)01 (5)15 (6)00 (7)111 (8a)01 (9)00 (11p)01 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,70,20,,R1,5.38,4.0,0.98,73.0,403.0,4.32,9.0,12.0,107.0,70.0,21.0,6.19,2.69,60.0,262.0,38.0,22.0,6.3,5.6,86.0,316.0,,,,,,,,,,,,,0.437,29.97,6.15,,无,, P0,H0, 未做,CK + Vimentin– VEGF- CMET+,,,,,8.902759526938238,1538591
1538909,蒋传文,621147,男,60,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,17,中间型（int）,INFc,0.0,,1.0,1.0,,,,2.0,2015-12-15,2019-03-01,2,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)09 (3b)00 (4sb)00 (4d)03 (5)00 (6)00 (8a)01 (8p)02 (9)02 (12a)00 3b组另见两枚癌结节," L（幽门窦部）, 小弯侧Less,",50,50,10, R0 D2+,,8.72,5.21,2.56,142.0,324.0,3.08,37.0,32.0,171.0,85.0,26.0,20.7,8.35,65.0,223.0,42.0,23.0,4.9,8.6,76.0,319.0,,,,,,,,,,,,,15.99,1.44,9.41,,无,, P0,H0, 未做,CK + Vimentin+ VEGF+ CMET+,,,,,38.50197109067017,1538909
1538241,张闻峰,622113,男,46,T1b,N0,M0,ⅠA,1,0,0.0,1.0,,0.0, 肠化生+,0.0,17,中间型（int）,INFb,0.0,,,,,,,1.0,2015-12-09,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3b)00 (4sb)00 (4d)08 (5)00 (6)02 (7)00 (8a)05 (9)00 (11p)02," L（幽门窦部）, 小弯侧Less,",22,15,2,R0 D2,,4.99,2.54,1.54,137.0,227.0,2.54,21.0,24.0,158.0,76.0,14.0,20.08,7.78,70.0,336.0,44.0,26.0,6.6,5.1,63.0,63.0,77.7,40.8,33.8,1.21,0.2,6.0,12.7,1.2,0.69,4.65,8.54,,1.62,4.49,1.35, 未做,无, 无, P0,H0, 未做, CK+ CMET+ Vimentin- VEGF-,,,,,57.95006570302234,1538241
1538958,刘淑琴,615726,女,72,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,25,中间型（int）,INFc,0.0,,,,,,,,2015-12-15,2020-10-07,1,,,,,,,,,0, 低粘附腺癌 Lauren肠型,GX, (1a)01 (1b)01 (3a)03 (3b)02 (4sb)00 (4d)57 (5)00 (6)04 (7)02 (8a)02 (8p)01 (9)02 (11p) 00(12a)00, LM 大弯侧Gre  ,20,15,12, R0 D2,,10.44,5.55,4.24,131.4,305.0,4.03,23.0,25.0,183.0,76.0,15.0,14.21,5.61,80.0,226.0,43.0,37.0,9.7,6.4,68.0,259.0,42.5,29.1,12.3,2.37,0.3,14.7,41.5,0.5,0.964,3.41,15.9,,1.92,10.73,9.28, 未做,无, 无, P0,H0, 未做,ck(+)  CD31(+)  D2-40(+) S100(+),,,,,57.75295663600525,1538958
1538665,王立山,620497,男,55,T3,N0,M0, ⅡA,1,2,0.0,0.0,,1.0, 慢性炎+,0.0,19,中间型（int）,INFc,2.0,,1.0,1.0,,,,1.0,2015-12-14,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)02 (3a)06 (3b)02 (5)00 (6)01 (4d)02 (4sb)01 (7)01 (8a)01 (8p)02 (9)00 (11p)00 (13a)00," L（幽门窦部）, 前Ant,",50,30,6, R0 D2,,6.36,3.51,2.04,151.0,177.0,2.53,34.0,29.0,122.0,104.0,42.0,9.44,3.31,74.0,352.0,46.0,28.0,5.8,5.5,93.0,413.0,67.4,45.1,17.1,2.64,0.3,8.5,21.5,1.4,0.669,2.02,11.9,,3.24,1.22,2.9, 未做,无, 无, P0,H0, 未做, CK+ S-100(可见神经侵犯） CD34、D2-40(未见）,,,,,57.78580814717477,1538665
1539218,李富,622377,男,65,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,23,髓样型（med）,INFc,3.0,,,,,,,1.0,2015-12-17,2020-10-06,1,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap） Lauren肠型,G2, (1a)02 (1b)01 (3a)07 (3b)02 (4sb)00 (4d)02 (5)01 (6)04 (7)00 (8a) 00(8p)00 (9) 03(11p)01,LM 前Ant 小弯侧Less 后Post ,70,70,18, R0 D2,,10.27,8.34,1.0,75.7,402.0,3.43,17.0,20.0,136.0,68.0,24.0,10.96,4.37,63.0,154.0,37.0,26.0,4.9,8.3,66.0,247.0,70.7,49.8,16.8,2.96,0.1,18.3,9.7,3.3,0.462,1.95,11.7,,2.93,30.62,5.39, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET(+) S100(+),,,,,57.65440210249671,1539218
1538775,徐忠宇,622568,男,67,T3,N2,M0, ⅢA,1,3,0.0,0.0,,1.0, 慢性炎症（+）,5.0,28,中间型（int）,INFc,1.0,,,,,,,1.0,2015-12-14,2017-02-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）40（pap） 粘液腺癌10（muc）,G2, (1a)01 (1b)00 (2)00 (3a)512 (3b)00 (4sa)00 (4sb)00 (4d)05 (5)00 (6)03 (7)01 (8a)01 (8p)04 (9)01 (11p)00," SiewerⅢ, 前Ant, 后Post, 小弯侧Less, GE,",70,60,10, R0 D2,,8.86,5.33,2.67,140.0,286.0,3.33,12.0,19.0,181.0,71.0,19.0,14.97,6.61,66.0,204.0,40.0,26.0,7.6,6.0,76.0,189.0,,,,,,,,,,,,,,5.66,7.07,,无, 无, P0,H0, 未做, CK +,,,,,14.09329829172142,1538775
1538614,陈遵学,619069,男,65,T3,N3a,M0,ⅢB,1,3,0.0,0.0,,0.0, 肠化生+,7.0,30,中间型（int）,INFc,1.0,,,,,,,2.0,2015-12-12,2020-06-16,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】60 粘液腺癌（muc）40,G2, (1a)26 (1b)14 (3a)47 (3b)47 (4sb)02 (4d)04 (5)01 (6)00 (7) (8a) (8p) (9)06 (11p)00," LM 后Post,",50,50,5, R0 D2,,10.59,6.98,2.37,75.0,412.0,4.73,16.0,17.0,136.0,56.0,30.0,4.2,2.25,72.0,170.0,37.0,35.0,6.6,6.0,95.0,305.0,,,,,,,,,,,,,,5.67,3.81,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET弱+,,,,,54.139290407358736,1538614
1538294,付义鸣,622227,男,47,T4b,N3a,M0, ⅢC,1,3,2.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,13.0,33,中间型（int）,INFc,0.0,,,,,,,1.0,2015-12-09,2017-02-06,2,,,XELOX,,,,,,5, 低粘附腺癌 Lauren弥漫型,GX, (1a)02 (1b)03 (2)02 (3a)23 (3b)00 (4sa)00 (4sb)00 (4d)711 (5)00 (6)01 (7)02 (8a)03 (8p)01 (9)11 (11p)00 (12a)00 (15)01," LM 前Ant, 后Post, 小弯侧Less,",70,70,20, D2,R1,6.03,3.61,1.77,82.0,342.0,2.9,15.0,19.0,117.0,66.0,9.0,10.08,3.54,63.0,209.0,37.0,26.0,4.5,4.8,72.0,245.0,,,,,,,,,,,,,,4.92,3.79,,无, 无, P0,H0, 未做, CK+ Vimentin- VEGF- CMET+,,,,,13.961892247043364,1538294
1539103,周殿德,622143,男,62,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,3,中间型（int）,INFb,0.0,,,,,,,,2015-12-16,2020-10-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) (3a)00 (3b)00 (4sb)00 (4d)00 (5)01 (6)02 (7)00 (8a)00 (8p)00 (9)00 (11p)00 (12a)00," L（幽门窦部）, 大弯侧Gre,",20,18,, R0 D2,,5.72,3.57,1.72,153.4,228.0,1.93,26.0,28.0,168.0,94.0,30.0,8.84,3.3,73.0,394.0,45.0,28.0,5.2,6.1,65.0,262.0,79.4,51.3,24.2,2.12,0.1,10.3,8.2,1.1,1.03,1.65,12.3,,,10.24,6.47,,无, 无, P0,H0, 未做, CK+,,,,,57.72010512483574,1539103
1538940,韩传有,621153,男,67,T3,N0,M0, ⅡA,1,3,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,19,中间型（int）,INFa,3.0,,,,,,,2.0,2015-12-15,2020-10-06,1,,,,,,,,,0, 乳头状癌（G1）（pap） 管状腺癌（中分化【G2】【tub2】 粘液腺癌（muc） Lauren肠型,G2, (1a)02 (1b)02 (3a)06 (3b)00 (4sb)00 (4d)02 (5)00 (6)02 (7)01 (8a)00 (8p)01 (9)03," L（幽门窦部）, 后Post, 小弯侧Less,",50,50,10, R0 D2,,5.8,3.21,2.05,135.0,212.0,2.56,20.0,22.0,138.0,56.0,5.0,10.73,4.85,65.0,210.0,43.0,22.0,4.7,9.4,71.0,237.0,,,,,,,,,,,,,,10.47,3.53,,无, 无, P0,H0, 未做, CK + Vimentin- VEGF- CMET弱+,,,,,57.72010512483574,1538940
1539128,于海臣,622567,男,51,T3,N2,M0, ⅢA,1,2,0.0,1.0,,1.0, 慢性炎症（+）,5.0,22,中间型（int）,INFc,0.0,,1.0,,,,,1.0,2015-12-16,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 乳头状癌10（G1）（pap）,G2, (1a)00 (1b)01 (3a)12 (3b)01 (4sb)02 (4d)04 (5)01 (6)15 (7)11 (8a)11 (9)14 (11p)00," LM 后Post, 大弯侧Gre, 小弯侧Less,",65,55,12, D2,R1,7.82,5.0,1.68,104.4,359.0,2.33,22.0,24.0,135.0,59.0,6.0,13.44,5.42,71.0,304.0,44.0,27.0,5.5,3.9,71.0,268.0,,,,,,,,,,,,,,76.38,2.33,,无, 无, P0,H0, 未做, CK +,,,,,80.51905387647831,1539128
1539834,王德民,623150,男,41,T1b,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,23,中间型（int）,INFa,0.0,,,,,,,,2015-12-22,2020-10-06,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (3a)02 (3b)00 (4sb)00 (4d)04 (5)00 (6) 02(7)01 (8a)03 (8p)05 (9)03 (11p)00 (14v)01," L（幽门窦部）, 小弯侧Less,",25,25,4, R0 D2,,6.97,3.85,2.37,154.6,230.0,2.19,25.0,29.0,142.0,79.0,57.0,22.73,8.33,83.0,357.0,48.0,35.0,5.6,8.7,69.0,344.0,,,,,,,,,,,,,1.66,9.85,3.09, 阳性+,无, 无, P0,H0, 未做, CK+ S-100未见，D2-40、CD34（未见）,,,,,57.49014454664914,1539834
1538744,潘德廷,622479,男,77,T4b,N3a,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,13.0,15,中间型（int）,INFc,1.0,,,,,,,1.0,2015-12-14,2016-01-14,2,,,,,,,,,0, 低分化腺癌（G3)(por)80% 低粘附腺癌20% Lauren弥漫型,G3, (1a)00 (1b)01 (2)44 (3a)22 (3b)00 (4sa)00 (4sb)11 (4d)33 (5)11 (6)01 (7)00 (8a)00 (8p)22 (9)00 (11p)00 软组织可见癌," U（胃底部）, M（胃体部）, UM 前Ant, 后Post, 小弯侧Less,",60,50,10,,R2,5.35,3.49,1.26,153.0,169.0,3.21,20.0,25.0,137.0,100.0,12.0,18.2,8.59,69.0,201.0,44.0,25.0,5.9,2.8,56.0,210.0,68.7,40.4,26.3,1.54,0.0,5.2,23.1,5.0,0.301,1.23,9.52,,1.84,10.16,0.946, 未做,无, 无, P0,H0, 未做, CK（+）、 Vimentin（-）、 VEGF（-）、 CMET（+）,,,,,1.0183968462549278,1538744
1538910,徐忠礼,622161,男,62,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,,1.0, 慢性炎症（+）,14.0,21,中间型（int）,INFc,0.0,,,1.0,,,,2.0,2015-12-15,2017-11-17,2,,,SOX,,,,,,1, 低分化腺癌（G3)(por) 低粘附腺癌40% Lauren肠型,G3, (1a)00 (3a)33 (3b)11 (4sb)00 (4d)45 (5)00 (6)44 (7)11 (8a) 11(8p)03 (9)01 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,50,10,,R1,6.44,4.22,1.66,139.6,302.0,2.45,22.0,25.0,171.0,75.0,8.0,14.64,6.31,71.0,237.0,42.0,29.0,5.0,5.4,77.0,269.0,45.1,24.5,18.5,,,,45.0,0.4,0.473,3.37,13.1,,1.46,8.45,18.82,,无, 无, P0,H0, 未做, CK+ Vimentin+ CMET+ VEGF-,,,,,23.0946123521682,1538910
1538664,刘福,620039,男,53,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,22,中间型（int）,INFa,0.0,,1.0,,,,,1.0,2015-12-14,2021-05-17,1,,,,,,,,,0, 管状腺癌（低中分化【G2】【tub2】,G2, (3a)0/4 (3b)0/0 (4sb)0/0 (4d)0/1 (6)0/6 (7)0/0 (8a)0/1 (8p)0/0 (9)0/2 (11p)0/2 (12a)0/0 (1a)0/0 (1b)0/5 (5)0/1," L（幽门窦部）, 小弯侧Less,",25,20,3, R0 D2,,4.45,2.33,1.63,143.1,201.0,1.84,13.0,17.0,166.0,60.0,151.0,16.7,6.7,65.0,313.0,42.0,23.0,4.7,7.3,97.0,274.0,,,,,,,,,,,,,2.22,1.31,0.88, 未做,无,, P0,H0, 未做, CMET+ Vimentin- VEGF+ CK+ CD34- S-100-,,,,,65.07884362680683,1538664
1538689,范喜清,622543,男,64,T2,N2,M0, ⅡB,1,3,0.0,1.0,1.0,0.0, 慢性炎症（+）,4.0,16,中间型（int）,INFc,0.0,,,,,,,1.0,2015-12-14,2021-05-17,1,,,SOX,,,,,,6, 低分化腺癌（G3)(por) 低粘附腺癌20,G3, (1a)0/0 (1b)0/1 (3a)0/4 (3b)1/1 (4sb)0/0 (4d)1/2 (5)1/1 (6)1/4 (7)0/1 (8a)0/1 (8p)0/0 (9)0/1 (11p)0/0 (12a)0/0," L（幽门窦部）, 大弯侧Gre,",40,30,3, R0 D2,,7.15,55.56,3.0,147.3,278.0,2.68,13.0,15.0,119.0,63.0,28.0,16.95,5.54,64.0,303.0,42.0,22.0,4.1,5.1,78.0,365.0,,,,,,,,,,,,,2.16,7.03,1.83, 未做,无,, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ CD34+ S-100-,,,,,65.07884362680683,1538689
1538836,杨俊豪,619081,男,64,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,25,中间型（int）,INFc,0.0,,,,,,,1.0,2015-12-15,2019-05-01,0,,,XELOX,,,,,,4,中低分化,G3, (1a)0/0 (1b)0/0 (3a)0/6 (3b)0/0 (4sb)0/7 (4d)0/2 (5)0/0 (6)0/2 (7)0/4 (8a)0/2 (8p)0/1 (9)0/1 (11p)0/0 (12a)0/0," M（胃体部）, 后Post,",50,40,15, R0 D2,,5.11,3.37,1.08,88.0,301.0,2.68,21.0,20.0,170.0,62.0,21.0,10.43,4.18,61.0,203.0,40.0,21.0,7.5,5.4,70.0,258.0,,,,,,,,,,,,,2.5,20.5,1.26, 未做,无,, P0,H0, 未做, CMET+ Vimentin- VEGF- CK+ CD34_ S-100_,,,,,40.50591327201051,1538836
1539692,荣艳辉,622756,女,34,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,38,中间型（int）,INFc,0.0,,,,,,,,2015-12-21,2019-03-01,2,,,XELOX,,,,,,6, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren肠型,G3, (1a)02 (1b)04 (3a)05 (3b)09 (4sb)00 (4d)06 (5)00 (6)02 (7)07 (8a、8p)01 (9、11p)02 (12a)00," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",35,30,8, R0 D2+,,12.67,10.66,1.62,141.0,218.0,1.95,13.0,18.0,163.0,46.0,10.0,38.89,13.02,72.0,226.0,45.0,27.0,5.0,4.5,62.0,212.0,,,,,,,,,,,,,1.03,5.61,4.7,,无, 无, P0,H0, 未做,CK +,,,,,38.30486202365309,1539692
1538764,韩德印,620480,男,62,T3,N1,M0, ⅡB,1,3,1.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,1.0,33,髓样型（med）,INFb,1.0,,,,,,,2.0,2015-12-14,2016-12-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)01(1b)00(2)19(3a)02(3b)00(4sa)02(4sb)00(4d)04 (5)00 (6)04 (7)04 (8a)02 (8p) (9)04 (11p)01, U（胃底部） 后Post 小弯侧Less 大弯侧Gre,60,60,10, R0 D2,,5.35,3.25,1.4,125.0,278.0,3.21,14.0,16.0,122.0,89.0,46.0,12.51,4.78,59.0,228.0,35.0,24.0,4.2,8.8,85.0,315.0,70.8,45.1,26.1,1.73,0.0,10.3,13.1,1.0,0.781,2.07,9.54,,1.77,0.6,2.0, 未做,无,, P0,H0, 未做,ck(+)  vimentin(-)  VEGF(-)  cMET弱(+)  CD31(+)  D2-40(+) ,,,,,11.59658344283837,1538764
1539011,张永利,613441,男,48,T3,N1,M0, ⅡB,1,2,1.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,1.0,29,中间型（int）,INFb,0.0,,,1.0,,,,1.0,2015-12-16,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)04 (3b)12 (4sb) 00(4d)02 (5)00 (6) 01(7)04 (8a)01 (8p)07 (9)04 (11p)03, L（幽门窦部） 小弯侧Less ,30,20,15, R0 D2,,5.54,2.52,2.31,148.0,229.0,2.79,15.0,15.0,122.0,84.0,22.0,5.87,2.34,62.0,281.0,39.0,23.0,4.8,6.5,85.0,325.0,79.6,53.8,21.7,2.48,0.2,6.9,9.7,1.1,0.649,3.0,9.19,,2.78,4.61,8.56, 未做,无,, P0,H0, 未做,ck(+)  vimentin(+)  VEGF(+)  cMET(+)  CD31(+)  D2-40(+),,,,,57.68725361366623,1539011
1539217,胡永智,622988,男,59,T1a,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 慢性炎症（+）,0.0,28,中间型（int）,INFa,0.0,,,,,,,,2015-12-17,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G1】【tub1】） Lauren肠型,G2, (1a)01 (1b)02 (3a)04 (3b)00 (4sb)02 (4d)03 (5)00 (6)01 (7)05 (8a)02 (8p)01 (9)04 (11p)03," L（幽门窦部）, 前Ant,",10,10,2, R0 D2,,5.06,2.58,1.95,144.2,176.0,2.29,23.0,34.0,162.0,62.0,22.0,10.16,4.22,72.0,323.0,46.0,26.0,5.1,8.4,66.0,329.0,,,,,,,,,,,,,1.22,5.89,1.57, 未做,无, 无, P0,H0, 未做,  CK+ S-100(未见) CD34、D2-40(未见）,,,,,57.65440210249671,1539217
1539755,高明松,623207,男,73,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,25,中间型（int）,INFa,0.0,,,,,,,,2015-12-22,2018-04-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3,小弯25 (1a)13 (1b)12 (2)02 (3a)00 (3b)16 (4sa)00 (4sb)00 (7)12 (8a)01 (8p)11 (9)01 (11p)02," U（胃底部）, GE, SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",50,50,7, R0 D2+,,6.18,3.7,1.67,157.0,237.0,3.41,11.0,16.0,145.0,54.0,22.0,20.0,7.16,69.0,351.0,42.0,27.0,6.1,4.5,88.0,293.0,,,,,,,,,,,,,37.69,4.64,1.45,,无,, P0,H0, 未做,Desmin-,,,,,27.75952693823916,1539755
1539321,李德生,623212,男,65,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,5.0,23,中间型（int）,INFb,0.0,,,,,,,,2015-12-17,2018-09-08,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,卡培他滨,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10,G3, (1a)02 (1b)01 (3a)13 (3b)00 (4sb)00 (4d)01 (5)01 (6)24 (7)01 (8a)14 (8p)01 (9)13 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",30,20,8, R0 D2,,7.94,4.84,1.93,166.0,181.0,4.23,27.0,25.0,206.0,77.0,24.0,11.49,4.89,77.0,349.0,46.0,31.0,6.0,7.9,97.0,291.0,59.5,33.5,20.4,1.64,0.3,11.0,23.8,2.1,2.33,2.84,11.4,,6.32,19.34,0.608, 未做,无,, P0,H0, 未做,ck(+) CD31(+)  D2-40(+) S100(+),,,,,32.72010512483574,1539321
1539702,赵丽艳,620996,女,46,T3,N2,M0, ⅢA,1,3,0.0,1.0,,1.0, 慢性炎症（+）,4.0,31,中间型（int）,INFc,0.0,,,,,,,,2015-12-21,2020-12-17,1,,,SOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren肠型,G3, (1a)02 (1b)11 (3a)07 (3b)23 (4sb)00 (4d)03 (5)00 (6)06 (7)12 (8a)02 (8p)04 (9)01 (11p)00," L（幽门窦部）, 前Ant,",40,35,13, R0 D2,,6.81,3.9,2.45,132.0,280.0,2.63,15.0,20.0,143.0,44.0,12.0,11.18,3.8,70.0,362.0,42.0,28.0,6.3,5.1,67.0,203.0,76.9,44.1,31.5,1.4,0.4,8.3,11.1,5.8,1.36,2.31,11.0,,,24.35,11.51,,无, 无, P0,H0, 未做, CK+,,,,,59.88830486202365,1539702
1540203,孙长太,623243,男,71,T2,N1,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,1.0,8,中间型（int）,INFa,1.0,,,,,,,,2015-12-24,2020-10-06,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a)01 (1b)01 (3a)00 (3b)11 (4sb)02 (4d)00 (5)01 (6)00 (7) (8a) (8p) (9)01 (11p)00 (12a)01,LM 后Post 小弯侧Less ,35,30,, R0 D2,,5.67,3.24,1.83,159.7,179.0,1.9,23.0,24.0,130.0,86.0,48.0,21.71,8.05,79.0,333.0,46.0,33.0,17.0,8.3,82.0,289.0,64.4,35.4,23.1,1.53,0.3,10.5,21.2,3.1,1.92,2.33,14.2,,3.45,18.11,1.98, 未做,无, 无, P0,H0, 未做, CK +,,,,,57.42444152431012,1540203
1539527,孟凡华,621005,女,60,T2,N0,M0, ⅠB,1,2,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,32,中间型（int）,INFc,0.0,,,,,,,,2015-12-19,2022-09-01,1,,,XELOX,替吉奥单药,,,,,2, 管状腺癌（中分化【G2】【tub2】80 乳头状癌（G1）（pap）20 Lauren肠型,G2, (1a)01 (1b)01 (2) 00(3a)03 (3b) 00(4sa)00 (4sb)02 (4d)00 (5)04 (6)01 (7)00 (8a)02 (8p)03 (9)09 (11p)06, LM 小弯侧Less ,30,20,15, R0 D2,,4.31,2.16,1.71,113.4,306.0,2.99,11.0,16.0,148.0,71.0,16.0,8.36,3.04,68.0,365.0,42.0,26.0,7.8,5.0,73.0,228.0,62.3,34.7,24.7,1.4,0.0,9.0,26.2,5.2,0.869,3.49,8.51,,1.45,10.76,5.48, 未做,无,, P0,H0, 未做,ck(+)  CD31(+)  D2-40(+) S100(+),,,,,80.42049934296978,1539527
1539278,苗培志,620993,男,52,T3,N0,M0, ⅡA,1,5,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,34,中间型（int）,INFc,0.0,,,,,,,,2015-12-17,2022-09-01,1,,,SOX,,,,,,7, 低粘附腺癌80% 低分化腺癌（G3)(por)20% Lauren肠型,G3, (1a)00 (1b)00 (3a)03 (3b)06 (4sb)01 (4d)01 (5)05 (6)03 (7)01 (8a)01 (8p)09 (9)04 (11p)00," L（幽门窦部）, 小弯侧Less,",50,40,6, R0 D2,,9.37,4.13,3.41,163.0,278.0,2.68,24.0,25.0,143.0,110.0,30.0,10.94,3.36,67.0,374.0,45.0,22.0,5.1,5.1,76.0,395.0,64.7,35.0,27.0,1.3,0.2,11.5,16.9,2.6,0.736,1.05,6.31,,1.42,4.05,1.43, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,80.4862023653088,1539278
1540655,宋敏,623154,女,66,T2,N0,M0, ⅠB,1,1,0.0,1.0,1.0,0.0, 慢性炎症（+）,0.0,14,中间型（int）,INFa,0.0,,,,,,,,2015-12-29,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)00 (2)00 (3a)07 (3b)02 (4sa)00 (4sb)00 (7)02 (8a)00 (8p)00 (9)01," M（胃体部）, 小弯侧Less,",20,15,5, R0 D1+,,8.7,5.66,2.47,129.0,320.0,3.18,24.0,24.0,134.0,75.0,25.0,11.05,3.91,75.0,275.0,43.0,32.0,5.9,5.3,60.0,314.0,,,,,,,,,,,,,0.882,15.73,1.55,,无, 无, P0,H0, 未做, CK+,,,,,57.26018396846255,1540655
1600222,付井春,620523,男,51,T3,N1,M0, ⅡB,1,3,0.0,0.0,,1.0, 肠化生+ 慢性炎症（+）,1.0,19,硬型（sci）,INFa,1.0,,,,,,,,2016-01-05,2018-09-20,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b) 00(2)01 (3a)02 (3b)00 (4sa) 01(4d) 01(5)01 (7)00 (8a)05 (8p)00 (9)02 (11p)11," MU 后Post, 大弯侧Gre, 小弯侧Less,",55,38,7,,R2,6.86,4.12,1.75,155.4,242.0,2.38,37.0,27.0,157.0,66.0,50.0,11.56,4.44,69.0,287.0,44.0,25.0,4.6,6.8,81.0,312.0,55.1,31.4,25.3,1.24,2.9,10.9,28.8,1.0,0.637,2.14,9.66,,2.29,8.67,1.15, 未做,无, 无, P0,H0, 未做, CK+,,,,,32.49014454664914,1600222
1539970,周丽立,622899,女,29,T3,N0,M0, ⅡA,1,4,0.0,0.0,,1.0, 慢性炎症（+）,0.0,29,中间型（int）,INFc,0.0,,,,,,,,2015-12-23,2020-10-06,1,,,XELOX,,,,,,1, 低粘附腺癌,GX, (1a)01 (1b)04 (2)01 (3a)03 (3b)00 (4sa)01 (4sb)00 (4d)04 (5)00 (6)06 (7)04 (8a)03 (8p)00 (9)01 (11p)01 (12a)00," M（胃体部）, 前Ant, 后Post, 大弯侧Gre,",45,35,6, R0 D2,,5.23,3.16,1.76,92.6,351.0,2.12,15.0,18.0,153.0,55.0,8.3,8.37,3.12,66.0,195.0,43.0,23.0,7.0,1.88,50.0,312.0,,,,,,,,,,,,,,11.91,1.03,,无, 无, P0,H0, 未做, CK +,,,,,57.45729303547963,1539970
1540125,程子健,622784,男,39,T4b,N2,M1, Ⅳ,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,6.0,19,中间型（int）,INFb,1.0,,,,,,,,2015-12-24,2016-05-17,2,,,FOLFOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80% 低粘附腺癌20% Lauren混合型,G3, (1a)12 (1b)00 (2)03 (3a)14 (3b)00 (4sa)01 (4sb)00 (4d)33 (5)00 (6)11 (7)00小肠05 软组织可见癌," L（幽门窦部）, M（胃体部）, LM 后Post, 大弯侧Gre, 小弯侧Less,",70,50,20,,R2,6.37,4.16,1.57,129.6,248.0,4.2,10.0,14.0,133.0,51.0,14.0,13.25,5.91,66.0,198.0,42.0,24.0,4.4,5.0,96.0,285.0,,,,,,,,,,,,,1.44,121.7,2.78, 阳性+,无, 无,  p1局肠缘(M1 PER),H0, 未做, CK（+）,,,,,4.763469119579501,1540125
1539610,郑常志,622630,男,69,T2,N2,M0, ⅡB,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,6.0,47,中间型（int）,INFb,0.0,,,,,,,,2015-12-21,2020-10-06,1,,,,,,,,,0, 低分化腺癌（G3)(por) 低粘附腺癌30% Lauren肠型,G3, (1a)02 (1b)01 (3a)619 (3b)00 (4sb)00 (4d)09 (5)01 (6)04 (7)04 (8a)02 (8p)01 (9)03 (12a)01," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",15,10,,R0 D2,,6.52,4.29,1.25,151.0,247.0,2.74,19.0,23.0,152.0,91.0,13.0,9.57,4.23,67.0,249.0,41.0,26.0,4.9,8.2,88.0,170.0,37.1,22.0,13.5,1.63,0.0,7.5,50.5,1.4,0.416,3.13,10.4,,1.27,14.35,1.2, 未做,无, 无, P0,H0, 未做, CK+,,,,,57.52299605781866,1539610
1540024,赵杰,619888,男,68,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,3.0,28,中间型（int）,INFb,0.0,,,,,,,,2015-12-23,2018-11-15,2,,,SOX,,,,,,8, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren混合型,G3, (1a)04 (1b) 01(3a)00 (3b) 05(4sb)00 (4d)07 (5)11 (6)14 (7)01 (8a)00 (8p)00 (9)03 (11p)01 (12a)11,L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre  后Post ,50,40,10, R0 D2,,6.83,4.22,1.53,145.8,321.0,3.18,24.0,28.0,166.0,80.0,13.0,12.94,5.98,74.0,222.0,42.0,32.0,6.0,6.1,84.0,385.0,49.4,31.0,14.5,2.14,0.1,6.0,39.3,0.9,0.401,4.27,13.4,,2.34,6.18,1.37, 未做,无,, P0,H0, 未做,ck(+) CD31(+)  D2-40(+) S100(+),,,,,34.75689881734559,1540024
1539969,张春华,622794,女,61,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,33,中间型（int）,INFb,1.0,,,,,,,,2015-12-23,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】60 粘液腺癌（muc）20 低粘附腺癌20 Lauren肠型,G2, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)023 (5)01 (6)01 (7)01 (8a)02 (8p)01 (9) 00(11p)00 (12p)04," L（幽门窦部）, 前Ant,",30,25,5, R0 D2,,7.16,3.83,2.41,146.5,295.0,1.64,25.0,21.0,171.0,110.0,15.0,6.73,2.33,77.0,378.0,45.0,32.0,5.6,9.5,71.0,214.0,58.9,33.1,24.0,1.38,0.1,13.4,25.1,1.9,1.53,3.72,15.5,,1.13,4.23,4.22, 未做,无, 无, P0,H0, 未做, CK +,,,,,57.45729303547963,1539969
1540093,马增库,623110,男,57,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,2.0,17,中间型（int）,INFc,1.0,,,,,,,,2015-12-24,2020-10-06,1,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)24 (2)02 (3a)01 (3b)00 (4sa)00 (4sb)03 (7)01 (8a)00 (8p)01 (9)00 (11p)02," U（胃底部）, GE, SiewerⅢ, 前Ant, 小弯侧Less,",45,40,10, R0 D2+,,3.79,1.9,1.55,114.0,252.0,2.58,20.0,18.0,142.0,62.0,19.0,5.11,2.2,69.0,280.0,43.0,26.0,7.6,8.3,75.0,294.0,73.4,42.6,28.3,1.51,0.4,8.6,14.1,2.1,1.08,1.55,10.4,,1.59,9.09,3.69,,无,, P0,H0, 未做, CK+,,,,,57.42444152431012,1540093
1540177,王和平,623097,男,51,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,22.0,35,中间型（int）,INFc,0.0,,,,,,,,2015-12-24,2018-05-01,0,,,XELOX,,,,,,4, 低粘附腺癌50 低分化腺癌（G3)(por)45 粘液腺癌（muc）5 Lauren弥漫型,G3, (1a)00 (1b)13 (2)25 (3a)66 (3b)14 (4sa)00 (4sb)00 (4d)1111 (5)00 (6)00 (7)00 (8a)02 (8p、9)02 (11p)12 (12a)00 (14v)00  软组织可见癌," LMU 前Ant, 大弯侧Gre, 小弯侧Less,",30,30,10, R0 D2+,,7.14,4.07,2.28,156.0,247.0,3.58,20.0,26.0,172.0,93.0,14.0,12.25,4.68,79.0,296.0,48.0,31.0,5.3,9.1,84.0,417.0,,,,,,,,,,,,,2.53,86.74,5.89,,无,, P0,H0, 未做, CK+,,,,,28.21944809461235,1540177
1539767,王江,620608,男,53,T1a,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,33,中间型（int）,INFa,1.0,,,,,,,,2015-12-22,2020-12-24,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 03(1b)00 (3a)07 (3b)02 (4sb)02 (4d)06 (5) 00(6)08 (7)01 (9)01 (11p)02 (12a)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,35,,R0 D2,,6.13,4.0,1.34,153.0,200.0,2.91,21.0,26.0,140.0,59.0,28.0,11.34,3.92,68.0,372.0,44.0,24.0,4.9,8.5,86.0,350.0,79.0,50.5,20.2,2.5,0.1,9.2,9.6,1.7,1.61,1.81,7.99,,1.06,4.16,1.1,,无, 无, P0,H0, 未做, CK+,,,,,60.08541392904073,1539767
1540193,唐忠和,623037,男,65,T2,N1,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+） 肠化生+,2.0,33,中间型（int）,INFa,0.0,,,,,,,,2015-12-24,2017-11-30,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)0/1 (1b)0/0 (3a)0/10 (3b)0/1 (4sb)0/0 (4d)0/11 (5)0/0 (6)2/3 (7)0/0 (8a)0/1 (8p)0/3 (9)0/2 (11p)0/1 (12a)0/0," M（胃体部）, 大弯侧Gre,",25,25,15,,R1,7.42,3.71,3.14,155.0,185.0,2.54,22.0,23.0,151.0,68.0,28.0,15.1,6.36,68.0,365.0,45.0,23.0,5.3,9.4,82.0,287.0,,,,,,,,,,,,,4.19,6.76,7.47, 未做,无, 无, P0,H0, 未做, CK+ CD34- S-100-,,,,,23.226018396846253,1540193
1540195,王德林,623069,男,60,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,17.0,24,中间型（int）,INFc,0.0,,,,,,,,2015-12-24,2017-01-01,2,,,奥沙利铂 雷替曲塞,,,,,,1, 粘液腺癌（muc）60% 低分化腺癌（G3)(por)40% Lauren肠型,G3, (1a)02 (1b)00 (3a)35 (3b)23 (4sb)01 (4d)77 (5)00 (6)33 (7)12 (8p)00 (9)00 (11p)00 (12a)11," L（幽门窦部）, M（胃体部）, 后Post, LM 大弯侧Gre, 小弯侧Less,",70,70,20, R0 D2,,6.36,4.22,1.52,165.5,259.0,2.45,24.0,25.0,161.0,83.0,13.7,18.07,4.45,65.7,216.89,43.3,22.4,5.4,5.12,83.0,319.0,70.3,39.8,26.0,1.53,0.3,11.1,16.8,3.6,0.558,1.46,7.4,,340.1,5.11,63.53, 阳性+,无, 无, P0,H0, 未做, CK（+）,,,,,12.28646517739816,1540195
1540092,蒋少山,620641,男,65,T2,N0,M0, ⅠB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,18,中间型（int）,INFb,0.0,,,,,,,,2015-12-24,2020-04-27,0,,,卡培他滨,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)00 (3a)07 (3b)01 (4sb)00 (4d)01 (5)00 (6)01 (7)02 (8a)00 (8p)02 (9)02 (11p)01 (12a)01," L（幽门窦部）, 小弯侧Less,",18,15,5, R0 D2,,5.24,2.28,1.93,157.0,191.0,2.58,26.0,27.0,192.0,78.0,25.0,5.59,2.18,69.0,270.0,43.0,26.0,4.5,7.8,77.0,337.0,68.6,42.5,24.4,1.74,0.3,7.3,22.1,4.7,0.616,2.04,9.98,,2.6,15.03,4.19, 阳性+,无, 无, P0,H0, 未做, CK（+）,,,,,52.10249671484888,1540092
1540414,赵庭凤,623063,男,79,T4a,N3b,M0, ⅢC,1,3,1.0,1.0,,1.0, 慢性炎症（+）,28.0,32,中间型（int）,INFc,0.0,,,,,,,,2015-12-28,2016-10-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) 低粘附腺癌40% 乳头状癌（G1）（pap）10% Lauren混合型,G3, (1a)01 (1b)00 (2)00 (3a)88 (3b)55 (4sa)00 (4sb)00 (4d)36 (5)00 (6)33 (7)55 (8a)11 (8p) 11(9) 11(11p)11 (12a)00," LM 后Post, 小弯侧Less, 前Ant,",90,60,15,,R1,5.1,3.62,0.68,57.0,195.0,3.01,14.0,20.0,126.0,48.0,4.0,5.88,3.07,47.0,189.0,29.0,18.0,5.6,7.3,76.0,238.0,50.0,24.8,22.0,1.13,0.0,2.9,43.8,8.9,0.428,3.34,12.3,,0.859,6.1,168.4, 未做,无, 无, P0,H0, 未做, CK+,,,,,9.132720105124836,1540414
1600548,王凤,614728,女,66,T2,N1,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,2.0,21,中间型（int）,INFa,3.0,,,,,,,,2016-01-07,2019-06-02,0,XELOX*2,1.0,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)04 (5)01 (6)27 (7)01 (8a)01 (8p)01 (9) 00(11p)00 (12a)02,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,30,10, R0 D2,,4.46,2.71,1.31,119.7,200.0,2.01,15.0,20.0,133.0,55.0,10.0,5.91,2.38,64.0,191.0,37.0,27.0,4.8,3.9,69.0,148.0,77.1,47.1,27.8,1.69,0.4,8.6,11.2,1.5,0.95,2.48,10.8,,2.84,8.01,1.32, 未做,无, 无, P0,H0, 未做, CK +,,,,,40.80157687253614,1600548
1540493,宿正厚,620571,男,61,T4b,N1,M0, ⅢB,1,1,0.0,1.0,,1.0, 慢性炎症（+）,1.0,31,中间型（int）,INFc,1.0,,,,,,,,2015-12-28,2019-05-22,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)02 (2)13 (3a)010 (3b)03 (4sa)00 (4sb)04 (4d)01 (7)03 (8a)01 (8p)02 (9)00 (10)01," U（胃底部）, 大弯侧Gre,",30,30,15, R0 D2,,5.29,3.06,1.84,103.0,236.0,2.36,18.0,24.0,155.0,52.0,10.0,11.64,4.24,75.0,306.0,47.0,28.0,6.3,7.3,81.0,266.0,,,,,,,,,,,,,,10.98,1.98,,无, 无, P0,H0, 未做, CK +,,,,,40.76872536136662,1540493
1600046,许卫平,618447,男,58,T3,N0,M0, ⅡA,1,2,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,45,中间型（int）,INFc,0.0,,,,,,,,2016-01-04,2016-07-15,2,MDCF*2,1.0,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)01 (1b)01 (3a)010 (3b)05 (4sb) 018 (5)00 (6)04 (7)03 (8a)01 (8p)01 (9)01 (11p)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",26,20,12, R0 D2,,6.32,3.37,1.29,135.4,234.0,4.44,17.0,22.0,183.0,55.0,11.0,12.23,6.84,54.0,66.0,31.0,23.0,4.8,5.0,62.0,80.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK+,,,,,6.340341655716163,1600046
1540520,盛永兴,621033,男,58,T4b,N3b,M0, ⅢC,1,4,2.0,1.0,,1.0, 慢性炎症（+）,19.0,23,中间型（int）,INFc,0.0,,,,,,,,2015-12-28,2016-12-15,2,,,XELOX,,,,,,1, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren弥漫型,G3, (1a) (1b) (3a) (3b)1314 (5)11 (2) (4sa) (4sb) (4d) (6)57 软组织可见癌小网膜囊 (12a)00," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,10,,R1,5.49,2.53,2.35,180.0,259.0,2.76,20.0,21.0,143.0,92.0,44.0,34.11,11.4,72.0,289.0,46.0,26.0,4.5,6.2,61.0,233.0,70.3,45.6,18.0,2.53,0.2,16.1,11.3,4.4,1.4,2.25,8.5,,,5.73,6.36,,无, 无, P0,H0, 未做, CK+,,,,,11.59658344283837,1540520
1540207,杨双山,620893,男,57,T1b,N0,M0,ⅠA,1,0,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,22,中间型（int）,INFb,0.0,,,,,,,,2015-12-24,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)01 (3a)07 (3b) 00(4sb)00 (4d)02 (5)00 (6) 01(7)03 (8a)01 (8p)01 (9)05 (11p)00 (12a)00," L（幽门窦部）, 后Post,",30,20,10,R0 D2,,5.26,2.77,2.12,150.0,189.0,2.4,14.0,23.0,128.0,89.0,14.0,13.26,5.8,78.0,369.0,48.0,30.0,5.0,4.0,86.0,251.0,,,,,,,,,,,,,3.76,26.98,1.34,,无, 无, P0,H0, 未做, CK+,,,,,57.42444152431012,1540207
1540681,吴立波,623494,男,50,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,30.0,36,中间型（int）,INFc,1.0,,,,,,,,2015-12-29,2018-04-18,0,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 粘液腺癌（muc）10 Lauren肠型,G3, (1a)33 (1b)23 (2)66 (3a)11 (3b)22 (4sa)00 (4sb)11 (5)33 (6)25 (7)22 (8a)11 (8p、9)12 (11d)11 (11p)23 (4d)33," LMU 前Ant, 后Post, 小弯侧Less,",40,20,15,,R1,7.64,4.91,2.09,153.3,252.0,3.1,32.0,25.0,136.0,118.0,31.0,14.25,4.75,71.0,351.0,46.0,25.0,6.2,5.2,87.0,339.0,,,,,,,,,,,,,4.58,40.56,23.35,,无,, P0,H0, 未做, CK+,,,,,27.628120893561103,1540681
1540260,张文德,620074,男,79,T4a,N2,M0, ⅢA,1,3,0.0,1.0,,1.0, 慢性炎症（+）,5.0,31,中间型（int）,INFc,0.0,,,,,,,,2015-12-25,2016-05-15,2,,,,,,,,,0, 粘液腺癌（muc）80 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)20 Lauren肠型,G3, (1a) (1b) (3a) (3b) (5)518 (4sb) (4d) (6)012 (8p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,18, R0 D2,,4.55,3.32,0.77,104.0,116.0,2.01,17.0,21.0,197.0,64.0,17.0,15.8,5.9,69.0,361.0,46.0,23.0,5.4,10.9,75.0,347.0,,,,,,,,,,,,,,163.2,1.99,,无, 无, P0,H0, 未做, CK+,,,,,4.664914586070959,1540260
1540589,关中东,623415,男,47,T4a,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,24.0,35,中间型（int）,INFb,1.0,,,,,,,,2015-12-29,2018-07-11,2,,,奥沙利铂联合S1,,,,,,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)25 (3a)55 (3b)13 (4sb)00 (4d)913 (5)00 (6)22 (7)00 (8a)22 (8p)22 (9)01 (11p)11 (12a)0 (16a1)01," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",80,70,20, R0 D2+,,9.44,7.18,1.28,125.5,293.0,4.2,19.0,17.0,186.0,105.0,9.0,12.6,5.05,68.0,374.0,46.0,22.0,7.1,8.2,100.0,348.0,69.5,39.8,24.0,1.66,0.5,10.7,15.9,5.9,0.725,0.954,6.37,,10.03,5.16,2.3,,无,, P0,H0, 未做, CK+,,,,,30.387647831800262,1540589
1540802,张玉珍,622902,女,68,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,21,中间型（int）,INFa,1.0,,,,,,,,2015-12-30,2020-10-14,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)04 (3b)01 (4sb)01 (4d)07 (5)00 (6)00 (7)05 (8a)01 (8p)00 (9)02 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post,",30,25,, R0 D2+,,5.91,3.04,2.46,107.7,235.0,1.98,17.0,25.0,219.0,101.0,7.0,4.37,1.55,56.0,165.0,33.0,23.0,,3.11,57.0,232.0,,,,,,,,,,,,,2.12,10.23,1.69, 阳性+,无, 无, P0,H0, 未做, CK+,,,,,57.49014454664914,1540802
1540640,胡广庆,620673,男,49,T1b,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,8,中间型（int）,INFb,0.0,,,,,,,,2015-12-29,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (3a)05 (3b)00 (4sb)00 (4d)00 (5)00 (6)00 (7)00 (8a)01 (9)00 (12a)00," L（幽门窦部）, 大弯侧Gre,",20,15,5,R0 D2,,5.02,3.14,1.42,162.0,196.0,2.18,23.0,23.0,162.0,44.0,23.0,20.75,8.45,74.0,449.0,52.0,22.0,4.6,5.7,94.0,560.0,,,,,,,,,,,,,0.68,4.36,5.04, 未做,无, 无, P0,H0, 未做, CK+,,,,,57.26018396846255,1540640
1540503,马良,622719,男,59,T3,N0,M0, ⅡA,1,3,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,44,中间型（int）,INFa,0.0,,,,,,,,2015-12-28,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) 00(1b)00 (3a) 013(3b) 02(4sb)00 (4d)017 (5)01 (6) 05(7)02 (8a)01 (11p) 01(12a00)小弯02," L（幽门窦部）, 前Ant, 小弯侧Less,",40,35,10,R0 D2,,8.86,4.71,3.02,162.0,235.0,3.14,16.0,16.0,194.0,87.0,20.0,9.45,2.81,68.0,328.0,45.0,23.0,8.4,8.0,86.0,287.0,,,,,,,,,0.795,3.27,6.73,,5.08,12.19,1.99, 未做,无, 无, P0,H0, 未做, CK+,,,,,57.29303547963206,1540503
1600018,姚庆祯,623507,男,77,T4a,N3a,M1, Ⅳ,1,3,0.0,1.0,,1.0, 慢性炎症（+）,12.0,18,中间型（int）,INFc,1.0,,,,,,,,2016-01-04,2016-07-21,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (3a)58 (3b)22 (4sb)03 (4d) 22(5)00 (6)11 (7)00 (11p)11 (12a)11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,45,12,,R2,6.27,3.68,1.96,71.0,320.0,2.49,13.0,23.0,159.0,71.0,13.0,7.82,3.32,68.0,166.0,40.0,28.0,6.1,9.1,105.0,295.0,,,,,,,,,,,,,3.37,32.71,4.16, 未做,无, 无, p1局腹膜(M1 PER),H0, 未做, CK+,,,,,6.5374507227332455,1600018
1540470,翟汉宝,623602,男,52,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,6.0,24,硬型（sci）,INFb,0.0,,,,,,,,2015-12-28,2019-05-03,0,,,卡培他滨,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)04 (3b)00 (4sb)00 (4d)04 (5)02 (6)45 (7)00 (8a)11 (8p)01 (9)15 (11p)01 (12a)00 软组织可见癌," L（幽门窦部）, 大弯侧Gre,",45,35,5, R0 D2,,7.29,4.35,2.42,139.8,208.0,2.25,33.0,44.0,215.0,136.0,50.2,9.67,2.81,66.7,294.62,44.8,21.9,5.6,3.42,84.0,243.0,83.3,55.0,20.8,2.64,0.3,5.4,8.8,3.9,1.1,1.33,7.51,,8.07,50.0,2.67, 未做,无, 无, P0,H0, 未做, CK +,,,,,40.14454664914586,1540470
1540665,王静,623584,男,40,T4b,N2,M1, Ⅳ,1,5,2.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,6.0,18,髓样型（med）,INFb,0.0,,,,,,,,2015-12-29,2019-09-02,0,,,紫衫醇联合替吉奥,,,,,,6, 粘液腺癌（muc） 低分化腺癌10（G3)(por),G3, (1a)01 (1b)02 (3a)13 (3b)22 (4sb)01 (4d)03 (5)00 (6)00 (7)01 (8a)01 (8p)01 (9)01 (14v)11 (14a)11," LM 前Ant, 后Post, 大弯侧Gre,",140,100,40,,R1,8.85,4.66,2.47,72.0,707.0,7.15,10.0,19.0,159.0,77.0,21.0,7.0,3.38,64.0,82.0,32.0,32.0,6.6,3.87,81.0,244.0,,,,,,,,,,,,,,55.98,300.0,,无, 无, p1局腹膜(M1 PER),H0, 未做, CK +,,,,,44.119579500657025,1540665
1600569,张希平,623537,男,70,T3,N0,M0, ⅡA,1,3,1.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,31,髓样型（med）,INFb,0.0,,,,,,,,2016-01-07,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)04 (2)011 (3a)00 (3b)05 (4sa)01 (4sb)02 (7)00 (8a)06 (8p)01 (9)00 (11p)00 (12a)00," SiewerⅡ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,30,10, R0 D2,,9.83,6.94,2.22,148.0,227.0,2.33,35.0,35.0,203.0,81.0,27.0,10.49,4.13,81.0,310.0,45.0,36.0,5.6,3.8,83.0,326.0,,,,,,,,,,,,,,15.04,4.69,,无, 无, P0,H0, 未做, CK +,,,,,79.79632063074901,1600569
1600304,王国财,620674,男,60,T4b,N3a,M0, ⅢC,1,5,0.0,1.0,,1.0, 慢性炎症（+）,7.0,9,中间型（int）,INFc,0.0,,,,,,,,2016-01-06,2016-05-15,2,,,,,,,,,0, 低分化腺癌（G3)(por) 粘液腺癌40（muc）,G3, (1a)00 (1b)11 (3a)00 (3b)00 (4sb)01 (4d)23 (5)00 (6)00 (7)22 (8a)00 (8p)00 (9)11," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",95,80,12,,R2,10.68,7.8,1.55,86.0,391.0,3.67,19.0,18.0,127.0,73.0,11.0,4.62,2.03,61.0,131.0,34.0,27.0,6.0,6.8,68.0,330.0,,,,,,,,,,,,,,802.8,136.4,,无, 无, P0,H0, 未做, CK +,,,,,4.270696452036794,1600304
1540668,黄守江,623318,男,60,T1b,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,33,髓样型（med）,INFa,1.0,,,,,,,,2015-12-29,2020-10-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)09 (3b) 00(4sb)02 (4d) 012(5)01 (6)01 (7)01 (8a)01 (8p) 00(9)03 (12a)01," L（幽门窦部）, 大弯侧Gre,",16,10,3,R0 D2,,6.43,4.38,1.52,134.0,108.0,2.24,25.0,28.0,145.0,76.0,10.0,13.62,5.28,73.0,253.0,45.0,28.0,5.7,7.1,68.0,192.0,73.1,37.6,34.3,1.1,10.4,0.3,7.3,1.9,0.91,1.42,10.7,,2.2,5.33,1.98, 未做,无, 无, P0,H0, 未做, CK+,,,,,57.26018396846255,1540668
1600155,张兆敬,623298,男,54,T4b,N3a,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,12.0,19,中间型（int）,INFc,0.0,,,,,,,,2016-01-05,2016-12-07,2,,,,,,,,,0, 低分化腺癌（G3)(por)50 低粘附腺癌50 Lauren混合型,G3,小弯34 (1a)01 (1b)11 (2)03 (3a)55 (3b)00 (4sa)00 (4sb)00 (7)13 (8a)22 (8p)00 (9)00 (11p)00 (12a)00," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",30,30,18, R0 D2+,,7.63,3.93,2.78,157.0,198.0,2.49,19.0,21.0,151.0,85.0,20.0,12.21,4.33,73.0,313.0,46.0,27.0,5.0,5.8,69.0,437.0,,,,,,,,,,,,,1.98,46.07,7.63,,无,, P0,H0, 未做,CK + ,,,,,11.070959264126149,1600155
1600139,侯然军,623926,男,57,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,3.0,15,中间型（int）,INFc,0.0,,,,,,,,2016-01-05,2022-09-01,1,,,XELOX,,,,,,6, 粘液腺癌（muc） 管状腺癌（中低分化40【G2】【tub2】,G3, (1a)0/3 (1b)0/0 (3a)1/4 (3b)0/0 (4sb)0/0 (4d)0/1 (5)0/0 (6)0/0 (7)0/0 (8a)0/1 (8p)0/1 (9)0/2 (11p)0/0 (12a)0/0," L（幽门窦部）, 前Ant,",40,25,3, R0 D2,,4.47,2.61,1.37,139.0,235.0,2.06,21.0,18.0,171.0,84.0,15.0,19.79,7.38,59.0,281.0,39.0,20.0,5.1,6.8,103.0,406.0,,,,,,,,,,,,,4.5,11.34,2.16, 未做,无,, P0,H0, 未做,CK+ CD34+ S-100-,,,,,79.86202365308804,1600139
1600476,于庆有,620829,男,73,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,14.0,22,中间型（int）,INFc,2.0,,,,,,,,2016-01-07,2021-02-06,1,,,SOX,SOX,替吉奥单药,S1,,,4, 粘液腺癌（muc）40 低粘附腺癌40 低分化腺癌（G3)(por)20 Lauren混合型,G3, (1a)01 (1b)12 (3a)23 (3b)00 (4sb)00 (4d)710 (5)11 (6)11 (7)01 (8a)11 (8p)01 (9)11 (11p)00 (12a)00,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,55,45,15, R0 D2,,12.48,10.71,0.91,128.4,265.0,1.62,45.0,43.0,199.0,48.0,5.0,12.03,5.2,48.0,197.0,30.0,18.0,7.1,6.6,72.0,199.0,75.7,48.1,23.5,2.05,0.1,10.7,9.1,0.4,0.296,1.52,6.96,,5.07,31.61,17.0, 未做,无,, P0,H0, 未做, CK （+） CD34(+)  D2-40(+) S100(+),,,,,61.00525624178712,1600476
1608181,李永贵,623586,男,64,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,20.0,37,中间型（int）,INFa,3.0,,,,,,,,2016-03-17,2017-05-01,2,XELOX*3,1.0,XELOX,,,,,,1, 低中分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)33 (3a)44 (3b)00 (4sb)24 (4d)66 (5)11 (6)46 (7)00 (8a)02 (8p)04 (9)02 (11p)00 (12a)01 (12p)02,M（胃体部） 后Post ,80,60,12, R0 D2,,5.71,1.79,2.96,126.0,252.0,2.8,32.0,132.0,188.0,81.0,28.0,14.1,3.68,70.0,330.0,43.0,27.0,4.7,5.6,65.0,360.0,,,,,,,,,,,,,1.66,8.73,1.24, 未做,无,, P0,H0, 未做, CK8/18+  CK5/6部分弱+ P63-,,,,,13.469119579500656,1608181
1540863,胡树和,623931,男,53,T4a,N3a,M0, ⅢB,1,3,0.0,1.0,,1.0, 慢性炎症（+）,8.0,23,中间型（int）,INFc,0.0,,,,,,,,2015-12-31,2021-05-17,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)01 (2)13 (3a)00 (3b)22 (4sb)00 (4d)24 (5)11 (6)04 (7)11 (8a)11 (8p)01 (9)04," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",55,50,12,,R1,7.52,5.13,1.93,135.1,191.0,1.6,13.0,23.0,192.0,86.0,8.0,10.33,3.35,65.0,329.0,39.0,26.0,4.3,5.8,61.0,345.0,,,,,,,,,,,,,1.21,5.35,5.34,,无, 无, P0,H0, 未做, CK+,,,,,64.5203679369251,1540863
1600023,王子文,623891,男,64,T4b,N0,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,47,中间型（int）,INFc,0.0,,,,,,,,2016-01-04,2019-05-03,0,,,XELOX,,,,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (2)05 (3a)013 (3b)01 (4sa)00 (4sb)05 (4d)08 (5)00 (6)04 (7)02 (8a) 01(8p)03 (9)02 (11p)01 (12a)00," U（胃底部）, 后Post, 小弯侧Less,",45,40,10,,R1,5.36,2.49,2.3,152.0,213.0,2.33,26.0,29.0,169.0,84.0,31.0,8.18,3.55,67.0,296.0,44.0,23.0,5.1,5.5,66.0,235.0,,,,,,,,,,,,,0.953,3.53,1.36, 阳性+,无, 无, P0,H0, 未做, CK +,,,,,39.91458607095926,1600023
1600098,任彩学,623438,男,54,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+） 肠化生++,0.0,37,中间型（int）,INFc,0.0,,,,,,,,2016-01-04,2019-05-03,0,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)02 (1b)05 (3a)08 (3b)00 (4sb)01 (4d)06 (5)02 (6)03 (7)05 (8a)01 (8p)01 (9)01 (11p)01 (12a)01," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,35,4, R0 D2,,8.32,5.95,1.67,167.0,156.0,1.93,12.0,12.0,144.0,84.0,5.0,23.3,9.47,61.0,245.0,38.0,23.0,3.9,7.8,74.0,300.0,78.5,52.4,22.9,2.29,0.3,12.2,6.9,0.2,0.92,2.31,9.34,,2.81,5.13,1.25, 阳性+,无, 无, P0,H0, 未做, CK +,,,,,39.91458607095926,1600098
1600097,陈伟萍,623377,男,45,T1b,N0,M0,ⅠA,1,0,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,10,中间型（int）,INFc,0.0,,,,,,,,2016-01-04,2019-05-01,0,,,,,,,,,0, 粘液腺癌（muc）,GX, (1a)0/1 (1b)0/0 (3a)0/0 (3b)0/0 (4sb)0/0 (4d)0/0 (5)0/0 (6)0/4 (7)0/0 (8a)0/1 (9)0/2 (11p)0/0 (12a)0/0," L（幽门窦部）, 小弯侧Less,",35,20,3, R0 D2,,10.11,6.92,1.99,158.0,200.0,2.45,66.0,39.0,209.0,98.0,37.0,10.16,4.41,68.0,317.0,46.0,22.0,6.1,3.9,78.0,356.0,,,,,,,,,,,,,2.91,17.32,1.51, 未做,无,, P0,H0, 未做, CK+ CD34+ S-100+,,,,,39.84888304862024,1600097
1600583,刘福全,623939,男,55,T3,N3a,M0,ⅢB,1,3,0.0,1.0,,1.0, 慢性炎症（+）,7.0,33,中间型（int）,INFc,0.0,,,,,,,,2016-01-07,2019-09-02,0,,,XELOX,,,,,,5, 乳头状癌（G1）（pap） 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】30 Lauren肠型,G2, (4sb) (4d) (6)112 (1a) (1b) (3a) (3b) (5)620 (14v)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,50,10, R0 D2,,6.08,2.28,2.78,132.0,397.0,1.96,17.0,25.0,100.0,96.0,13.0,5.66,2.46,69.0,339.0,40.0,29.0,5.4,5.9,99.0,350.0,,,,,,,,,,,,,567.3,13.82,53.0,,无, 无, P0,H0, 未做, CK+,,,,,43.823915900131404,1600583
1600580,邵宪芝,623413,女,57,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,9.0,30,中间型（int）,INFc,1.0,0.8,,,,,,,2016-01-07,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)02 (3a)26 (3b)03 (4sb)00 (4d)34 (5)00 (6、14v)310 (7)02 (8a)01 (9)00 (11p)11 (12a)00," LM 前Ant, 后Post, 大弯侧Gre,",50,35,12, R0 D2+,,6.33,4.16,1.52,134.0,283.0,2.9,15.0,20.0,162.0,66.0,23.0,16.02,5.26,68.0,349.0,42.0,26.0,5.0,3.8,79.0,353.0,,,,,,,,,,,,,0.883,14.98,3.03, 阳性+,无, 无, P0,H0, 未做, CK+ CK8/18+ CgA- Syn- CD56-,,,,,79.79632063074901,1600580
1600938,张永成,625204,男,49,T4b,N1,M0, ⅢB,1,3,0.0,0.0,,1.0, 肠化生+ 慢性炎症（+）,1.0,41,中间型（int）,INFa,0.0,,,,,,,,2016-01-11,2020-12-18,1,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 粘液腺癌40（muc）,G2, (1a)04 (1b)03 (3a)06 (3b)12 (4sb)00 (4d)03 (5)00 (6)05 (7)09 (8a)00 (8p)01 (9)02 (11p)05 (12a)00," LM 后Post, 小弯侧Less,",60,40,10, R0 D2,,9.06,4.19,3.94,157.0,311.0,2.15,10.0,15.0,167.0,62.0,18.0,9.79,3.2,65.0,447.0,42.0,23.0,5.7,6.5,79.0,311.0,,,,,,,,,,,,,0.794,4.07,1.76,,无, 无, P0,H0, 未做, CK +,,,,,59.23127463863337,1600938
1600377,张文明,625180,女,68,T3,N2,M0, ⅢA,1,3,2.0,1.0,,0.0, 肠化生+ 慢性炎症（+）,3.0,37,髓样型（med）,INFb,1.0,,,,,,,,2016-01-06,2021-06-01,1,,,SOX,,,,,,6, 低分化腺癌（G3)(por) 低粘附腺癌40,G3, (1a)01 (1b)01 (3a)16 (3b)00 (4sb)00 (4d)118 (5)00 (6)11 (7)01 (8a)04 (8p)02 (9)01 (11p)01 (12a)01," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,80,20, R0 D2,,11.57,7.82,3.03,149.0,392.0,3.21,15.0,18.0,147.0,47.0,12.0,10.49,2.97,53.0,269.0,33.0,20.0,4.9,3.5,50.0,245.0,,,,,,,,,,,,,0.746,12.78,18.84, 未做,无, 无, P0,H0, 未做, CK +,,,,,64.81603153745073,1600377
1600951,许书润,623956,男,74,T1b,N0,M0,ⅠA,1,0,1.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,24,髓样型（med）,INFa,0.0,,,,,,,,2016-01-11,2018-04-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)02 (1b)01 (2)01 (3a)01 (3b)00 (4sa) 01(4sb)00 (4d) 05(7)02 (8a)01 (8p)03 (9)04 (11p)03,GE SiewerⅡ型 小弯侧Less ,10,8,5, R0 D2,,5.46,2.22,2.15,156.2,192.0,1.88,12.0,17.0,193.0,86.0,8.0,14.92,6.78,70.0,238.0,43.0,27.0,4.7,6.9,78.0,348.0,70.5,39.0,27.3,1.43,0.4,16.6,11.4,0.8,0.857,2.53,12.1,,2.27,11.08,2.36, 未做,无,, P0,H0, 未做, CK +,,,,,26.938239159001313,1600951
1601026,杨广全,623862,男,68,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,23,中间型（int）,INFc,1.0,,,,,,,,2016-01-12,2020-06-01,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)04 (3a)00 (3b)00 (4sb)00 (4d)05 (5)00 (6)06 (7)02 (8a)02 (8p、9)01 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",40,30,15, R0 D2+,,10.17,6.24,2.45,184.0,304.0,3.11,23.0,25.0,181.0,91.0,19.0,12.46,4.77,69.0,250.0,45.0,24.0,5.8,5.9,93.0,322.0,51.9,26.8,17.8,1.51,0.3,12.1,32.2,7.7,0.961,1.49,8.55,,2.52,5.6,2.26, 阳性+,无,, P0,H0, 未做, CK+,,,,,52.6281208935611,1601026
1600898,于永志,623850,男,45,T3,N3b,M0, ⅢC,1,3,0.0,1.0,,1.0, 慢性炎症（+）,20.0,59,中间型（int）,INFc,2.0,,,,,,,,2016-01-11,2017-12-19,2,,,XELOX,,,,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3,小弯33 (1a)03 (1b)01 (2)59 (3a)38 (3b)11 (4sa)00 (4sb)44 (4d)011 (5)00 (6)04 (7)22 (8a)01 (8p)03 (9)04 (11p)25 (12a)00," UM 前Ant, 大弯侧Gre, 小弯侧Less,",70,50,10,R0 D2,,6.73,3.84,2.24,155.1,243.0,2.27,35.0,27.0,207.0,92.0,27.0,10.66,3.96,64.0,294.0,39.0,25.0,5.2,5.0,85.0,367.0,,,,,,,,,,,,,1.31,5.73,2.35, 未做,无, 无, P0,H0, 未做, CK+,,,,,23.258869908015768,1600898
1600835,毛万春,625320,男,60,T2,N1,M0, ⅡA,1,3,2.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,1.0,19,髓样型（med）,INFa,1.0,,,,,,,,2016-01-11,2021-06-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren弥漫型,G3, (1a)01 (1b)00 (3a)03 (3b)01 (4sb)01 (4d)06 (5)00 (6)02 (7)12 (8a)01 (8p)01 (9)00 (11p)00 (12a)00," M（胃体部）, L（幽门窦部）, 前Ant, 小弯侧Less,",40,30,6, R0 D2,,6.31,3.54,1.84,104.9,233.0,2.73,11.0,15.0,131.0,57.0,12.0,9.01,3.46,65.0,267.0,41.0,24.0,5.1,8.6,73.0,250.0,77.6,53.6,18.0,2.98,0.1,9.8,10.4,2.6,1.26,2.58,8.47,,2.5,8.18,5.31, 阳性+,无, 无, P0,H0, 未做, CK（+）,,,,,64.65177398160316,1600835
1600524,孙立杰,624226,男,47,T2,N2,M0, ⅡB,1,2,1.0,1.0,1.0,1.0, 慢性炎症（+）,3.0,42,中间型（int）,INFc,0.0,,,,,,,,2016-01-07,2019-05-03,0,,,,,,,,,0, 低分化腺癌（G3)(por)60% 低粘附腺癌40% Lauren混合型,G3, (1a)02 (1b)03 (3a)00 (3b)03 (4sb)00 (4d)011 (5)35 (6)02 (7)01 (8a)01 (8p)02 (9)05 (11p)06 (12a)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,30,6, R0 D2,,4.44,2.5,1.54,148.0,190.0,2.22,18.0,20.0,159.0,63.0,6.0,3.99,1.62,58.0,245.0,37.0,21.0,4.4,7.6,69.0,284.0,76.0,59.5,14.9,3.97,0.4,7.7,10.7,0.5,0.618,1.6,8.74,,2.34,3.12,5.18, 阳性+,无, 无, P0,H0, 未做, CK +,,,,,39.81603153745072,1600524
1601199,李文,623859,男,69,T1b,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 慢性炎症（+） 肠化生+,0.0,16,中间型（int）,INFa,3.0,,,,,,,,2016-01-13,2019-08-13,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,小弯01 (1a)00 (1b) 02(2)04 (3a)02 (3b)01 (4sa)00 (4sb)00 (4d)02 (7)00 (8a)01 (8p) 02(9)00 (11p)01 (12a)00," U（胃底部）, SiewerⅢ, 前Ant,",15,12,,R0 D2,,7.07,3.71,2.56,157.4,195.0,2.79,15.0,17.0,166.0,75.0,14.0,9.73,3.59,71.0,290.0,44.0,27.0,11.2,4.7,99.0,375.0,,,,,,,,,,,,,5.88,9.13,0.983, 未做,无, 无, P0,H0, 未做, CK+,,,,,42.96977660972404,1601199
1602023,张宝安,624231,男,57,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,25,中间型（int）,INFa,1.0,,,,,,,,2016-01-19,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)05 (3b)00 (4sb)00 (4d)07 (5)00 (6)06 (7)00 (8a)01 (8p、9)01 (9)02 (11p)01 (12a)00," M（胃体部）, 前Ant, 大弯侧Gre,",20,13,8, R0 D2+,,6.59,5.24,1.24,75.0,159.0,2.15,26.0,26.0,904.0,52.0,11.0,23.6,11.82,61.0,229.0,42.0,19.0,5.1,7.2,57.0,162.0,,,,,,,,,,,,,0.911,6.29,3.03,,无,, P0,H0, 未做, CK+,,,,,79.40210249671485,1602023
1600899,韩香兰,618717,女,71,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,8.0,26,中间型（int）,INFc,2.0,,,,,,,,2016-01-11,2019-01-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型 （GIST）,G3, (1a)02 (1b)00 (2)01 (3a)58 (3b)11 (4sa)01 (4sb)00 (4d)02 (5)03 (6)01 (7)01 (8a)02 (8p)11 (9)02 (11p)00 (12a)11," M（胃体部）, 后Post, 小弯侧Less,",30,30,8, R0 D2,,5.61,2.66,2.5,138.5,181.0,1.98,18.0,20.0,169.0,58.0,11.0,11.14,4.15,68.0,271.0,40.0,28.0,4.6,7.5,56.0,294.0,86.4,48.2,40.0,1.2,3.0,9.0,3.8,5.6,0.769,3.42,12.2,,1.6,12.51,1.3, 阳性+,无, 无, P0,H0, 未做,,,,,,35.67674113009198,1600899
1601859,芦相忠,624133,男,52,T1a,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 慢性炎症（+）,0.0,12,中间型（int）,INFc,0.0,,,,,,,,2016-01-18,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)03 (3b)00 (4sb)00 (4d)01 (5)01 (6)02 (7)01 (8a)02 (8p)01 (9)00 (11p)01 (12a)00," LM 小弯侧Less,",30,30,10, R0 D2,,12.39,6.33,4.6,99.0,421.0,4.45,40.0,31.0,210.0,91.0,108.0,10.89,4.2,79.0,295.0,48.0,31.0,5.9,5.1,77.0,555.0,,,,,,,,,,,,,,13.14,0.781,,无, 无, P0,H0, 未做, CK +,,,,,79.43495400788436,1601859
1602125,王凤海,625599,男,65,T3,N0,M0, ⅡA,1,2,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,13,中间型（int）,INFc,0.0,,,,,,,,2016-01-20,2021-07-13,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (2)00 (3a)04 (3b)00 (4sa)01 (4sb)00 (4d)00 (7)03 (8a)04 (8p)01 (9)00 (11p)00," U（胃底部）, 小弯侧Less,",25,20,8, R0 D2,,5.32,2.74,2.14,159.8,167.0,2.36,40.0,15.0,152.0,73.0,32.0,20.15,7.15,71.0,352.0,45.0,26.0,5.2,6.6,100.0,366.0,,,,,,,,,,,,,,1.18,1.64,,无, 无, P0,H0, 未做, CK +,,,,,65.73587385019711,1602125
1601095,吴跃明,625520,男,67,T2,N3a,M0, ⅢA,1,5,0.0,1.0,1.0,1.0, 慢性炎症（+）,7.0,13,中间型（int）,INFc,1.0,,,,,,,,2016-01-12,2021-05-21,1,,,SOX,,,,,,1, 粘液腺癌（muc）60 管状腺癌（中分化【G2】【tub2】40 Lauren肠型,G2, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)03 (4d)44 (5)00 (6)33 (7)00 (8a)00 (8p)00 (9)00 (11p)00 (12a)03 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,45,18, R0 D2+,,4.73,3.15,1.07,91.0,319.0,2.41,21.0,27.0,150.0,63.0,6.0,11.68,4.53,65.0,258.0,42.0,23.0,5.2,4.34,60.0,171.0,,,,,,,,,,,,,2.11,288.9,3.55,,无,, P0,H0, 未做, CK+,,,,,64.25755584756898,1601095
1601366,王金菊,625377,女,64,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,23,,,0.0,,,,,,,,2016-01-14,2022-09-01,1,,,,,,,,,0, 腺癌,GX, (1a)01 (1b)03 (3a)07 (3b)01 (4sb)01 (4d)04 (5)00 (6)01 (7)03 (8a)00 (8p)01 (9)00(11p)01(12a)00,L（幽门窦部） 小弯侧Less ,20,10,, R0 D2,,7.7,4.68,2.54,152.5,271.0,2.97,51.0,41.0,174.0,114.0,21.0,15.23,5.16,72.0,284.0,46.0,26.0,6.5,4.5,65.0,362.0,59.3,31.2,25.2,1.24,0.1,15.5,22.7,0.6,0.827,2.21,10.2,,1.53,15.0,2.11, 阳性+,无, 无, P0,H0, 未做, CK +,,,,,79.56636005256242,1601366
1601744,张元宝,625583,男,59,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,22.0,30,中间型（int）,INFc,0.0,,,,,,,,2016-01-18,2017-02-14,2,,,XELOX,,,,,,6, 管状腺癌（中低分化【G2】【tub2】50%， 低粘附腺癌50%,G3, (1a)00 (1b)03 (3a)00 (3b)02 (4sb)00 (4d)24 (5)00 (6)33 (7)34 (8a)22 (8p)12 (9)55 (11p)33 (12a)00 (12p)12," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,10,,R1,7.75,4.82,2.14,144.0,232.0,2.15,35.0,28.0,183.0,96.0,10.0,4.43,1.92,71.0,206.0,44.0,27.0,5.4,5.3,83.0,282.0,,,,,,,,,,,,,5.7,18.78,6.72, 未做,,, P0,H0, 未做, CK+ S-100- CD34+,,,,,12.910643889618921,1601744
1601941,房德彦,624014,男,66,T1a,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,22,中间型（int）,INFa,0.0,,,,,,,,2016-01-19,2021-07-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)01 (3a)06 (3b)00 (4sb)01 (4d)06 (5)00 (6)00 (7)05 (8a、8p)02 (9)00 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",10,,, R0 D2+,,8.03,4.54,2.55,162.0,255.0,2.16,29.0,28.0,187.0,59.0,15.0,18.05,7.73,75.0,355.0,48.0,27.0,6.6,5.6,76.0,210.0,59.9,47.3,9.9,4.78,0.1,25.1,13.3,1.2,0.494,4.49,8.87,,2.49,14.05,1.36, 阳性+,无,, P0,H0, 未做, CK+ CD68 CK8/18+ LCA- CD56- CgA- Syn-,,,,,65.37450722733246,1601941
1602310,陈喜和,624157,男,59,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,36,中间型（int）,INFc,1.0,,,,,,,,2016-01-21,2021-06-01,1,,,卡培他滨单药口服,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 粘液腺癌（muc）30 Lauren肠型,G3, (1a)01(1b)00(2)02(3a)011(3b)00 (4sa) 01(4sb)00 (4d)06 (5)00 (6)06 (7)03 (8a)01 (8p)03 (9)02 (11p)00 (12a)00,U（胃底部） SiewerⅢ型 小弯侧Less ,45,25,6, R0 D2,,7.62,3.14,3.39,156.0,326.0,1.91,26.0,30.0,168.0,65.0,13.0,20.45,8.33,67.0,327.0,44.0,23.0,5.3,3.7,77.0,235.0,66.9,55.6,7.5,7.41,0.1,8.1,23.9,1.2,0.853,1.24,8.92,,2.22,5.01,1.19, 阳性+,无, 无, P0,H0, 未做, CK +,,,,,64.32325886990802,1602310
1602545,郭宪宽,614725,男,64,T4b,N2,M0, ⅢB,1,3,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,3.0,5,中间型（int）,INFb,2.0,,,,,,,,2016-01-23,2016-08-16,2,XELOX*2,1.0,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,10,5,,R2,7.17,3.84,2.48,134.0,186.0,2.53,85.0,89.0,208.0,95.0,49.0,11.0,2.79,76.2,236.51,48.1,28.1,8.0,6.3,89.0,106.0,,,,,,,,,,,,,2.94,27.69,,,无, 无, P0,H0, 未做, CK +,,,,,6.767411300919842,1602545
1601452,孙广祥,625571,男,57,T1b,N3a,M0, ⅡB,1,0,0.0,1.0,1.0,0.0,  慢性炎症（+）,10.0,36,中间型（int）,INFc,2.0,,,,,,,,2016-01-14,2020-12-01,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a) 0/0(1b)0/0 (3a)2/14 (3b)0/1 (4sb)0/0 (4d)8/13 (5)0/0 (6)0/1 (7)0/2 (8a)0/2 (8p)0/1 (9)0/1 (11p)0/1 (12a)0/0,"M（胃体部）, 前Ant, 小弯侧Less,",40,20,10, R0 D2,,6.42,3.28,2.09,160.0,200.0,2.06,24.0,27.0,197.0,46.0,9.3,33.29,11.67,50.0,242.0,32.0,18.0,5.2,3.2,62.0,238.0,,,,,,,,,,,,,1.78,19.46,4.7, 阴性,无,, P0,H0, 未做,CK+ S-100- CD34+,,,,,58.5742444152431,1601452
1601998,耿春富,625299,男,76,T3,N0,M0, ⅡA,1,3,2.0,0.0,,1.0, 慢性炎症（+）,0.0,27,中间型（int）,INFc,0.0,,,,,,,,2016-01-19,2020-12-18,1,,,,,,,,,0, 低粘附腺癌 溃疡癌变,GX, (1a)01 (1b)02 (3a)00 (3b)07 (4sb)02 (4d)04 (5)00 (6)05 (7)02 (8a)02 (8p)01 (9)01 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",25,25,8, R0 D2,,6.03,2.91,2.34,147.0,220.0,2.12,18.0,25.0,142.0,82.0,17.0,16.14,6.81,68.0,295.0,39.0,29.0,4.9,5.3,82.0,246.0,,,,,,,,,,,,,,15.49,1.64,,无, 无, P0,H0, 未做, CK +,,,,,58.96846254927726,1601998
1602201,崔凤国,624361,男,50,T4b,N0,M1, Ⅳ,1,3,0.0,0.0,,1.0, 慢性炎症（+）,0.0,27,中间型（int）,INFc,0.0,,,,,,,,2016-01-20,2017-07-15,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】乳头20 腺癌,G2, (1a)01 (1b)02 (2)05 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)04 (5)00 (6)04 (7)04 (8a)02 (8p)02 (9)00 (11p)00," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,90,18,,R2,5.61,3.08,2.02,151.6,194.0,1.95,15.0,15.0,180.0,62.0,27.0,12.56,4.85,65.0,290.0,41.0,24.0,4.7,4.4,84.0,347.0,,,,,,,,,,,,,,3.61,3.55,,无, 无, P0,H0, 未做, CK +,,,,,17.805519053876477,1602201
1601824,曲行选,625912,男,62,T2,N0,M0, ⅠB,1,2,0.0,,,,,0.0,19,,,0.0,,,,,,,,2016-01-18,2019-03-29,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)02 (1b)02 (2)00 (3a)00 (3b)00 (4sa)02 (4sb)02 (4d)00 (5)00 (6)00 (7)04 (8a) 03(8p)01 (9) 01(11p) 01(12p)01," U（胃底部）, SiewerⅢ, 小弯侧Less,",20,10,,R0 D2,,10.01,5.51,3.65,162.3,243.0,2.85,24.0,19.0,173.0,53.0,24.0,15.69,5.43,73.0,385.0,42.0,31.0,4.4,6.9,92.0,346.0,,,,,,,,,,,,,1.59,8.78,0.617, 未做,无, 无, P0,H0, 未做, CK+,,,,,38.30486202365309,1601824
1602375,张国福,625890,男,57,T1b,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 慢性炎症（+）,0.0,14,中间型（int）,INFc,0.0,,,,,,,,2016-01-21,2021-07-12,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)03 (3b)00 (4sb)00 (4d)01 (5)00 (6)04 (7)02 (8a)01 (9)00 (11p)02 (12a)00," L（幽门窦部）, 大弯侧Gre, 后Post,",20,15,2,R0 D2,,6.8,3.23,2.68,167.7,206.0,2.38,36.0,27.0,129.0,81.0,84.0,12.2,4.94,70.0,236.0,42.0,28.0,5.0,4.3,89.0,437.0,77.1,58.1,16.5,3.52,2.6,10.1,9.0,4.8,2.36,2.25,11.8,,1.44,6.87,5.29, 未做,无, 无, P0,H0, 未做, CK+,,,,,65.67017082785807,1602375
1602124,赵树有,625752,男,72,T2,N1,M0, ⅡA,1,3,2.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,2.0,24,髓样型（med）,INFa,0.0,,,,,,,,2016-01-20,2022-09-01,1,,,,,,,,,0, 粘液腺癌（muc）75 低分化腺癌（G3)(por)15 低粘附腺癌10 Lauren弥漫型,G3, (1a)04 (1b)00 (3a)09 (3b)13 (4sb)00 (4d)00 (5)00 (6)12 (7)00 (8a)02 (8p)00 (9)02 (11p)02,L（幽门窦部） 后Post 小弯侧Less 大弯侧Gre  ,40,35,10, R0 D2,,4.9,2.63,1.8,131.7,254.0,2.78,32.0,42.0,206.0,50.0,14.0,8.34,4.2,64.0,257.0,39.0,25.0,5.2,4.8,61.0,263.0,43.1,23.2,12.9,1.8,0.1,7.0,45.0,0.2,0.73,1.98,10.2,,3.67,20.74,3.24, 未做,无,, P0,H0, 未做, CK +,,,,,79.36925098554534,1602124
1601724,任福林,625872,男,59,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,2.0,35,中间型（int）,INFb,1.0,,,,,,,,2016-01-18,2019-01-01,2,,,FOLFOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)12 (1b)01 (3a)09 (3b)00 (4sb)00 (4d)03 (5)01 (6)19 (7)00 (8a)02 (8p)01 (9)05 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",30,20,15, R0 D2,,8.39,4.28,3.08,158.0,279.0,2.58,24.0,25.0,158.0,90.0,15.0,10.48,4.19,78.0,301.0,47.0,31.0,5.4,4.5,81.0,356.0,71.2,40.8,28.4,1.44,1.2,10.6,14.8,1.2,1.09,4.19,12.8,,1.71,9.45,7.43, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,35.446780551905384,1601724
1602534,刘振欣,625667,男,61,T3,N2,M0, ⅢA,1,3,0.0,1.0,,1.0, 慢性炎症（+）,5.0,30,中间型（int）,INFc,2.0,,,,,,,,2016-01-22,2017-07-20,0,,,,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 乳头状癌（G1）（pap）20 Lauren肠型,G3, (1a) (1b) (3a) (3b)522 (4sb) (4d) (4sa)08," UM 前Ant, 后Post, 小弯侧Less,",40,40,10, R0 D2,,8.2,4.45,3.28,147.8,208.0,2.22,10.0,18.0,162.0,88.0,8.0,11.48,4.62,68.0,261.0,45.0,23.0,9.0,6.9,70.0,324.0,,,,,,,,,,,,,38.63,144.3,6.36,,无, 无, P0,H0, 未做, CK+,,,,,17.904073587385017,1602534
1602508,张佰森,624201,男,57,T1a,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,16,,,3.0,,,,,,,,2016-01-22,2021-07-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) (1b) (3a) (3b)09 (4sb) (4d)07," LM 前Ant,",15,13,, R0 D2,,4.91,2.99,1.64,156.0,305.0,3.33,20.0,23.0,135.0,66.0,17.0,11.24,4.05,71.0,256.0,42.0,29.0,4.2,5.6,87.0,324.0,70.3,39.2,22.8,1.72,0.3,7.8,19.2,1.2,0.445,4.88,11.6,,2.87,6.73,1.02,,无, 无, P0,H0, 未做,,,,,,65.27595269382391,1602508
1602302,刘玉环,624202,男,76,T3,N3a,M0,ⅢB,1,5,0.0,1.0,1.0,1.0, 慢性炎症（+）,10.0,13,中间型（int）,INFc,1.0,,,,,,,,2016-01-21,2016-05-13,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 粘液腺癌（muc）30% Lauren肠型,G3, (1a)00 (1b)00 (2)00 (3a)66 (3b)00 (4sa)00 (4sb)00 (4d)44 (5)00 (6)03 (7)00," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",90,70,20,,R2,9.09,6.62,1.61,133.0,264.0,3.41,19.0,21.0,205.0,113.0,79.0,15.25,7.96,60.0,174.0,35.0,25.0,4.8,10.5,68.0,274.0,,,,,,,,,,,,,51.43,2.08,9.22, 阳性+,无, 无, P0,H0, 未做, CK（+）,,,,,3.712220762155059,1602302
1602662,栾永寿,625832,男,78,T3,N2,M0, ⅢA,1,1,0.0,1.0,1.0,1.0, 慢性炎症（+）,6.0,20,中间型（int）,INFc,0.0,,,,,,,,2016-01-25,2017-03-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (2)12 (3a)01 (3b)44 (4sa)01 (4sb)00 (4d)02 (5)00 (6)03 (7)05 (8a)01 (8p)11 (9)00 (12a)00 (11d)00," U（胃底部）, 前Ant, 小弯侧Less,",100,35,15, R0 D1,,12.13,8.05,3.22,106.6,419.0,2.99,15.0,18.0,116.0,59.0,13.0,9.19,4.08,67.0,220.0,37.0,30.0,6.0,8.6,110.0,389.0,71.1,27.4,20.8,1.32,1.4,7.3,16.9,3.8,4.56,13.2,0.576,,3.18,22.37,1.1, 阳性+,无, 无, P0,H0, 已冲, CK（+）,,,,,13.173455978975033,1602662
1602714,刘凯,625416,女,39,T4b,N3a,M0, ⅢC,1,4,2.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,7.0,30,中间型（int）,INFc,0.0,,,,,,,,2016-01-25,2017-09-10,2,,,SOX,SOX,替吉奥,,,,3, 低粘附腺癌 低分化腺癌20（G3)(por),G3, (1a)0/0 (1b)0/2 (3)0/3 (4sa)1/2 (4sb)3/5 (4d)2/3 (5)0/0 (6)0/5 (7)1/3 (8a)0/2 (8p)0/0 (9)0/2 (11p)0/1 (14v)0/0," U（胃底部）,",60,60,, R0 D2,,4.57,2.44,1.75,127.0,171.0,2.03,11.0,17.0,170.0,41.0,8.0,8.41,3.87,67.0,214.0,41.0,26.0,5.3,3.9,93.0,357.0,,,,,,,,,,,,,1.37,31.73,1.37, 未做,无, 无, P0,H0, 未做,,,,,,19.513797634691194,1602714
1602868,刘志国,625911,男,65,T3,N2,M0, ⅢA,1,3,1.0,1.0,,1.0, 慢性炎症（+）,5.0,31,中间型（int）,INFc,0.0,,,,,,,,2016-01-26,2021-05-17,1,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)29 (3b)00 (4sb)01 (4d)15 (5)13 (6)13 (7)01 (8a)01 (8p)02 (9)02 (11p)00 (12a)02 (14)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,15, R0 D2,,5.69,3.1,1.88,142.7,243.0,3.67,22.0,28.0,141.0,81.0,11.0,9.58,4.44,71.0,226.0,41.0,30.0,6.3,3.9,73.0,223.0,,,,,,,,,,,,,1.29,8.16,5.2,,无, 无, P0,H0, 未做, CK +,,,,,63.66622864651774,1602868
1602807,赵义忠,627071,男,62,T3,N3a,M0,ⅢB,1,4,0.0,1.0,,1.0, 慢性炎症（+）,14.0,27,中间型（int）,INFc,0.0,,,,,,,,2016-01-26,2017-12-01,2,,,XELOX,,,,,,5, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren肠型,G3, (1a)22 (1b)11 (2)00 (3a)33 (3b)00 (4sa)01 (4sb)00 (4d)22 (5)00 (6)06 (7)02 (10)00 (8a)01 (8p)23 (9)22 (11p)03 (12p)01," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",150,100,40, R0 D2,,,,,,,2.2,22.0,25.0,128.0,69.0,11.0,12.27,4.7,67.0,303.0,42.0,25.0,5.9,5.9,74.0,254.0,,,,,,,,,,,,,17.28,4.15,3.21,,无, 无, P0,H0, 未做, CK+,,,,,22.174770039421812,1602807
1603070,李长福,627466,男,64,T3,N0,M0, ⅡA,1,3,1.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,0.0,27,中间型（int）,INFb,0.0,,,,,,,,2016-01-28,2021-06-01,1,,,紫衫醇联合顺铂,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)07 (1b)00 (3a)04 (3b)00 (4sb)01 (4d)04 (5)00 (6)03 (7)02 (8a)01 (8p)04 (9)00 (11p)00 (12a)01,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,35,30,10, R0 D2,,7.77,5.94,1.42,145.6,296.0,3.59,24.0,26.0,131.0,73.0,29.0,9.38,4.2,64.0,209.0,38.0,26.0,4.5,4.8,73.0,258.0,79.9,54.8,25.3,2.17,0.8,7.1,10.3,3.1,1.15,2.87,9.43,,1.63,13.55,1.31, 阳性+,无,, P0,H0, 未做, CK +,,,,,64.09329829172141,1603070
1602855,李向有,626813,男,73,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,2.0,15,中间型（int）,INFc,2.0,,,,,,,,2016-01-26,2017-05-31,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)00 (3b)04 (4sb)00 (4d)01 (5)00 (6)22 (7)02 (8a)00 (8p)03 (9)02 (11p)01 (12a)00 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,20, R0 D2,,6.9,2.99,3.34,145.2,242.0,2.21,20.0,17.0,141.0,59.0,21.0,9.41,3.83,72.0,298.0,44.0,28.0,5.4,2.9,83.0,437.0,79.2,42.3,39.3,1.08,2.9,15.2,2.6,35.0,0.709,2.33,12.9,,1.54,19.28,1.56, 阳性+,无, 无, P0,H0, 已冲, CK（+）,,,,,16.130091984231274,1602855
1602719,陶传付,627115,男,48,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,15,中间型（int）,INFc,0.0,,,,,,,,2016-01-25,2021-06-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (2)00 (3a)06 (3b)02 (4sa)00 (4sb)00 (4d)00 (7)06 (8a)00 (8p)00 (9)00 (11p)00," U（胃底部）, 后Post, 小弯侧Less,",22,20,3, R0 D2,,7.44,3.95,2.6,147.0,255.0,2.44,20.0,24.0,138.0,73.0,27.0,9.04,4.37,66.0,299.0,41.0,25.0,4.5,5.0,72.0,380.0,60.1,43.2,17.8,2.43,0.5,26.4,9.7,0.7,0.883,1.74,10.4,,1.6,9.97,3.68, 阳性+,无, 无, P0,H0, 未做,,,,,,64.19185282522996,1602719
1602904,刘连友,624440,男,56,T4b,N3a,M0, ⅢC,1,2,1.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,7.0,37,中间型（int）,INFb,2.0,,,,,,,,2016-01-27,2018-12-12,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)04 (1b)11 (3a)07 (3b)23 (4sb)02 (4d)19 (5)00 (6)01 (7) (8a) (8p) (9)23 (11p)13 (14v)01 (16a1)03," LM 前Ant, 后Post, 小弯侧Less,",70,70,8, R0 D2,,7.22,4.4,2.06,91.6,299.0,2.54,14.0,15.0,94.0,47.0,6.0,5.67,3.0,50.0,173.0,35.0,15.0,7.3,5.7,56.0,200.0,,,,,,,,,,,,,10.4,6.53,13.64,,无, 无, P0,H0, 未做,,,,,,34.49408672798948,1602904
1604956,薛玉德,625988,男,58,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,0.0, 慢性炎症（+）,4.0,29,中间型（int）,INFa,0.0,,,,,,,,2016-02-25,2020-05-19,0,,,SOX,,,,,,3, 低粘附腺癌 80低分化腺癌（G3)(por)20 Lauren混合型,G3, (1a)00 (1b)00 (3a)14 (3b)08 (4sb)00 (4d)212 (5)11 (6) 01(7)00 (8a)00 (8p)01 (9)02 (11p)00 (12a)00, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,50,5, R0 D2,,5.94,3.44,1.67,145.2,151.0,2.53,15.0,20.0,129.0,58.0,7.0,12.07,6.39,64.0,64.0,39.0,25.0,3.5,7.1,70.0,305.0,59.8,34.4,22.8,1.51,0.3,16.5,17.4,3.5,0.944,2.2,11.7,,1.6,8.93,2.35, 未做,无,, P0,H0, 未做, CK +,,,,,50.75558475689881,1604956
1603078,徐金梅,626865,女,60,T3,N3b,M0, ⅢC,1,4,0.0,1.0,1.0,1.0, 慢性炎症（+）,29.0,47,中间型（int）,INFc,0.0,,,,,,,,2016-01-28,2019-06-13,2,,,FOLFOX,,,,,,3, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)06 (2)01 (3a)710 (3b)11 (4sa) 01(4sb)00 (4d)1416 (5) 01(6)33 (7)01 (8a) 01(8p)22 (9) 11(11p)11 (12a)01, ML 前Ant 后Post 大弯侧Gre  小弯侧Less ,30,20,5, R0 D2,,8.12,2.8,4.62,140.2,223.0,3.25,14.0,22.0,173.0,105.0,7.0,5.44,2.34,71.0,252.0,44.0,27.0,5.6,5.9,79.0,299.0,72.5,54.2,16.8,3.23,0.4,14.4,11.6,0.6,0.71,1.61,10.1,,7.4,42.71,10.19, 阳性+,无,, P0,H0, 未做, CK +,,,,,40.473061760841,1603078
1603033,傅殿芳,626271,女,61,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,14.0,21,髓样型（med）,INFb,0.0,,,,,,,,2016-01-28,2016-09-10,2,,,XELOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)12 (1b)00 (3a)11 (3b)00 (4sb)00 (4d)03 (5)01 (6)66 (7)22 (8a)00 (8p)23 (9)22 (11p)01," L（幽门窦部）, 前Ant, 小弯侧Less,",40,30,10, R0 D2,,6.19,3.76,1.76,146.1,204.0,2.22,14.0,18.0,170.0,78.0,10.0,8.22,4.03,67.0,192.0,43.0,24.0,4.6,5.6,61.0,129.0,,,,,,,,,,,,,2.17,8.78,5.89, 阴性,无, 无, P0,H0, 未做,,,,,,7.424441524310118,1603033
1602914,王传财,627407,男,49,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,36,中间型（int）,INFa,0.0,,,,,,,,2016-01-27,2021-07-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren肠型,G3, (1a)00 (1b)01 (3a)07 (3b)01 (4sb)05 (4d)03 (5)00 (6)09 (7)00 (8a)02 (8p)03 (9)01 (11p)04 (12a)00,L（幽门窦部） 前Ant 小弯侧Less 后Post ,20,20,, R0 D2,,6.92,3.47,2.87,159.0,202.0,1.65,17.0,23.0,163.0,62.0,10.0,20.84,9.14,73.0,260.0,46.0,27.0,4.9,5.3,90.0,259.0,71.4,49.8,19.3,2.58,1.4,6.8,18.0,2.4,0.75,2.59,11.8,,0.943,10.48,1.49, 阳性+,无,, P0,H0, 未做, CK +,,,,,65.11169513797634,1602914
1603209,姜长海,626846,男,62,T3,N0,M0, ⅡA,1,3,2.0,0.0,,1.0, 慢性炎症（+）,0.0,37,中间型（int）,INFc,0.0,,,,,,,,2016-02-01,2021-06-01,1,,,XELOX,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)02 (1b)01 (2)01 (3a) 05(3b)02 (4sa) (4sb) (4d)09 (5)00 (6) 02(7)07 (8a)01 (8p)00 (9)00 (11p)01," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",50,40,10, R0,,4.4,2.48,1.44,95.8,220.0,1.45,17.0,15.0,123.0,44.0,15.0,10.27,4.86,51.0,242.0,32.0,19.0,4.6,6.3,84.0,267.0,,,,,,,,,,,,,0.861,6.01,0.732, 阳性+,无, 无, P0,H0, 未做, CK+,,,,,63.96189224704336,1603209
1603193,吴立国,627365,男,45,T3,N3b,M1, Ⅳ,1,3,0.0,1.0,,1.0, 慢性炎症（+）,23.0,25,中间型（int）,INFc,0.0,,,,,,,,2016-02-01,2017-12-15,2,,,XELOX,XELOX,XELOX,SOX,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)11 (1b)00 (2)44 (3a)55 (3b)11 (4sb)01 (4d)77 (5)22 (6)01 (7)22 (9)11," UM 前Ant, 后Post, 小弯侧Less,",100,90,20,,R2,7.92,5.78,1.24,73.8,333.0,3.86,11.0,18.0,119.0,56.0,11.0,7.93,3.63,62.0,225.0,38.0,24.0,4.2,7.1,141.0,391.0,,,,,,,,,,,,,1.21,6.89,6.03, 阳性+,无, 无, P0,H0, 未做, CK+,,,,,22.437582128777922,1603193
1603202,王桂兰,624424,女,79,T2,N0,M0, ⅠB,1,1,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,28,中间型（int）,INFc,0.0,,,,,,,,2016-01-29,2019-09-02,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (3a)06  (4sb)01 (4d)07 (5)01 (6)04 (7)01 (8a)02 (8p)01 (9)01 (11p)01," L（幽门窦部）, 小弯侧Less,",40,30,15, R0 D2,,6.52,3.38,2.38,102.0,224.0,2.56,40.0,38.0,162.0,48.0,19.0,8.02,3.94,58.0,194.0,34.0,24.0,4.9,7.7,90.0,352.0,,,,,,,,,,,,,12.98,9.05,2.28,,无, 无, P0,H0, 未做, CK+,,,,,43.1011826544021,1603202
1603201,杨孟春,626743,男,59,T3,N0,M0, ⅡA,1,2,0.0,0.0,,1.0, 慢性炎症（+）,0.0,28,中间型（int）,INFc,0.0,,,,,,,,2016-01-29,2021-05-11,1,,,XELOX,,,,,,2, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)04 (2)02 (3a)06 (3b)00 (4sa)04 (4sb)02 (4d)01 (5)01 (6)02 (7)04 (8a)00 (8p)01 (9)00 (11p)00," M（胃体部）, 小弯侧Less,",40,30,15, R0 D2,,8.61,51.64,3.28,154.3,211.0,2.68,12.0,14.0,127.0,70.0,25.0,13.17,5.52,63.0,297.0,40.0,23.0,4.7,7.2,91.0,338.0,69.5,44.5,25.2,1.77,2.9,25.0,2.6,0.5,3.02,1.29,9.76,,1.15,8.16,1.01,,无, 无, P0,H0, 未做, CK+,,,,,63.370565045992116,1603201
1603077,郭青吉,627238,男,68,T4b,N3b,M0, ⅢC,1,3,1.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,30.0,53,中间型（int）,INFb,0.0,,,,,,,,2016-01-28,2019-12-04,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)00 (1b)15 (3a)613 (3b)77 (4sb)02 (4d)1115 (5)01 (6)33 (7)01 (8a)12 (8p)00 (9)01 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",80,60,10, R0 D2,,5.13,3.78,0.87,94.2,227.0,2.68,14.0,20.0,125.0,53.0,12.0,4.3,1.37,63.0,237.0,40.0,23.0,6.0,4.48,103.0,251.0,,,,,,,,,,,,,1.79,1.77,55.84,,无, 无, P0,H0, 未做,,,,,,46.1892247043364,1603077
1603242,苏玉峰,627203,男,62,T2,N0,M0, ⅠB,1,2,0.0,0.0,,1.0, 慢性炎症（+）,0.0,29,中间型（int）,INFc,0.0,,,,,,,,2016-02-01,2021-05-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)00 (3a)05 (3b)00 (4d) 03(5)00 (6)03 (7)06 (8a)02 (9)06 (11p)01," M（胃体部）, 小弯侧Less,",18,15,5, R0,,5.16,2.02,2.37,168.0,217.0,2.45,27.0,22.0,165.0,71.0,24.0,15.81,6.06,74.0,302.0,46.0,28.0,6.5,7.2,75.0,248.0,,,,,,,,,,,,,0.723,7.53,3.5, 未做,无, 无, P0,H0, 未做, CK+,,,,,63.60052562417871,1603242
1603311,林义成,627250,男,56,T2,N0,M0, ⅠB,1,3,,0.0,,0.0, 正常,0.0,19,中间型（int）,INFb,1.0,,,,,,,,2016-02-02,2021-07-12,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2,," LM 小弯侧Less,",10,10,5, R0 D2,,3.85,2.16,1.32,128.9,268.0,2.99,24.0,31.0,144.0,87.0,39.0,21.73,7.39,72.0,275.0,48.0,24.0,5.3,5.0,60.0,279.0,,,,,,,,,,,,,2.26,6.68,1.31,,无, 无, P0,H0, 未做,,,,,,65.27595269382391,1603311
1603276,张金才,627063,男,66,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,,1.0, 肠化生+,9.0,33,中间型（int）,INFb,2.0,,,,,,,,2016-02-02,2020-12-18,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren肠型,G3,," LM 前Ant, 后Post, 大弯侧Gre,",70,,15, R0 D2,,9.75,7.22,1.69,126.6,268.0,3.21,42.0,54.0,233.0,62.0,48.0,13.19,4.78,67.0,184.0,37.0,30.0,,6.1,67.0,318.0,,,,,,,,,,,,,5.36,79.06,1.61,,无, 无, P0,H0, 未做, CK+,,,,,58.50854139290407,1603276
1603327,单良,624676,男,29,T1a,N0,M0,ⅠA,1,0,,0.0,,0.0, 肠化生+,0.0,23,中间型（int）,,1.0,,,,,,,,2016-02-03,2021-06-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,30,, R0 D2,,7.0,4.22,2.25,158.9,239.0,2.44,25.0,19.0,138.0,56.0,28.0,16.78,8.0,73.0,378.0,47.0,26.0,4.6,6.8,103.0,466.0,,,,,,,,,,,,,1.99,20.9,0.754, 未做,无, 无, P0,H0, 未做, CK +,,,,,63.89618922470434,1603327
1603395,杨万成,629038,男,46,T4a,N2,M0, ⅢA,1,3,1.0,0.0,0.0,1.0, 慢性炎症（+）,6.0,24,中间型（int）,INFb,1.0,,,,,,,,2016-02-15,2021-04-12,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80% 低粘附腺癌20% Lauren混合型,G2, (1a)01 (1b)24 (3a)01 (3b)01 (4sb)01 (4d)01 (5)01 (6)23 (7)12 (8p)02 (8a)02 (9)12 (11p)03," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,8, R0 D2,,7.47,3.85,2.94,152.2,197.0,2.03,21.0,25.0,170.0,90.0,9.0,8.73,3.55,70.0,251.0,40.0,30.0,4.8,7.0,98.0,330.0,69.1,37.9,30.3,1.25,0.4,7.8,4.5,1.1,2.08,2.67,13.6,,2.29,42.44,1.87, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,61.859395532194476,1603395
1603621,吴德富,629032,男,53,T2,N0,M0, ⅠB,1,2,1.0,0.0,0.0,1.0, 正常,0.0,35,中间型（int）,INFb,2.0,,,,,,,,2016-02-17,2021-06-01,1,,,XELOX,,,,,,1, 粘液腺癌（muc）70  低粘附腺癌15 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)15 Lauren混合型,G3, (1a)00 (1b)01 (2) 01(3a)015 (3b)01 (4sa) 00(4sb) 00(4d)01 (5) 01(6)00 (7)03 (8a)02 (8p)02 (9) (11p)04, GE SiewerⅢ型 后Post ,28,25,3, R0 D2,,6.04,2.91,2.54,137.5,267.0,1.84,24.0,22.0,134.0,49.0,8.0,11.21,3.65,60.0,309.0,39.0,21.0,4.6,7.9,78.0,340.0,,,,,,,,,,,,,0.976,13.96,4.32, 未做,无,, P0,H0, 未做, CK +,,,,,63.43626806833114,1603621
1603438,张英,628909,男,55,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,11,中间型（int）,INFa,0.0,,,,,,,,2016-02-15,2021-07-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,大弯07小湾04," L（幽门窦部）, 小弯侧Less,",18,15,5, R0 D2,,6.93,3.43,2.74,163.0,224.0,3.08,21.0,20.0,121.0,95.0,26.0,15.09,5.12,73.0,308.0,45.0,28.0,5.3,5.3,100.0,436.0,68.8,50.0,16.7,2.99,1.1,14.9,12.5,1.8,2.19,2.68,9.13,,2.64,7.71,5.37, 未做,无, 无, P0,H0, 未做, CK +,,,,,64.48751642575559,1603438
1603703,吕文江,629013,男,55,T3,N1,M0, ⅡB,1,3,1.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+） 异型增生+,2.0,38,中间型（int）,INFa,0.0,,,,,,,,2016-02-17,2021-06-01,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por)60% 低粘附腺癌40% Lauren混合型,G3,大弯019小湾219," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",80,80,10, R0 D2,,8.67,4.82,2.25,140.0,255.0,2.01,20.0,19.0,176.0,106.0,21.0,8.12,3.23,67.0,189.0,42.0,25.0,5.9,6.5,72.0,394.0,64.8,47.4,16.3,2.91,0.4,16.2,13.6,1.9,0.406,3.36,8.17,,45.5,7.75,3.74, 阳性+,无, 无, P0,H0, 未做, CK（+）,,,,,63.43626806833114,1603703
1603624,姜贵军,628908,男,59,T2,N0,M0, ⅠB,1,2,1.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,34,中间型（int）,INFb,0.0,,,,,,,,2016-02-17,2021-07-02,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80% 粘液腺癌（muc）20% Lauren混合型,G3,大弯019小湾015 (8a)01," L（幽门窦部）, 小弯侧Less,",20,20,3, R0 D2,,7.116,2.89,3.3,139.0,284.0,2.41,24.0,24.0,113.0,64.0,19.0,8.61,2.88,63.0,284.0,38.0,25.0,4.9,6.9,68.0,324.0,,,,,,,,,,,,,5.29,3.98,1.71, 阳性+,无, 无, P0,H0, 未做,,,,,,64.45466491458606,1603624
1603563,张继生,629004,男,42,T4a,N0,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,33,中间型（int）,INFa,0.0,,,,,,,,2016-02-16,2019-11-21,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,小弯012 (1a)00 (1b)00 (2)00 (3a)00 (3b)02 (4sa)00 (4sb)00 (4d)02 (5)00 (7)016 (8a)01 (8p)00 (9)00 (11p)00," U（胃底部）, 前Ant, 大弯侧Gre,",40,37,3, R0 D2,,6.49,3.12,2.62,154.0,191.0,3.41,16.0,18.0,163.0,72.0,17.0,7.04,2.57,79.0,372.0,48.0,31.0,6.6,5.4,87.0,261.0,,,,,,,,,,,,,0.694,8.8,3.85, 阳性+,无,, P0,H0, 未做, CK +,,,,,45.137976346911955,1603563
1603548,赵月娟,629010,女,41,T4b,N3a,M1, Ⅳ,1,3,2.0,0.0,0.0,1.0, 正常,14.0,20,中间型（int）,INFc,1.0,,,,,,,,2016-02-16,2016-11-02,2,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren弥漫型,G3, (1a)02 (1b)00 (3a)11 (3b)23 (4sb)00 (4d)00 (5)22 (6)00 (7)12 (8a)22 (9)02 (11p)11 (12a)00 小弯55," LM 前Ant, 后Post, 小弯侧Less,",60,55,8,,R2,6.12,4.47,1.02,129.1,129.1,3.18,11.0,14.0,169.0,45.0,12.0,9.87,4.56,72.0,292.0,43.0,29.0,6.5,3.9,92.0,355.0,,,,,,,,,,,,,1.2,17.64,1.51, 阳性+,无, 无, p1局腹膜(M1 PER),H0, 未做, CK +,,,,,8.541392904073588,1603548
1603929,张悦明,624464,男,54,T3,N2,M0, ⅢA,1,2,0.0,0.0,,1.0, 慢性炎症（+）,6.0,25,中间型（int）,INFa,0.0,,,,,,,,2016-02-18,2021-05-11,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por)50 粘液腺癌（muc）40 低粘附腺癌10 Lauren肠型,G3, (4sb) (4d) (6)19 (1a) (1b) (3a) (3b) (5)516," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,20, R0 D2,,8.05,4.8,2.4,140.0,351.0,4.03,8.0,12.0,131.0,52.0,1.0,15.66,5.93,65.0,242.0,39.0,26.0,4.7,5.2,113.0,530.0,,,,,,,,,,,,,0.742,7.8,2.72,,无, 无, P0,H0, 未做, CK+,,,,,62.71353482260184,1603929
1603873,段学坤,630399,男,60,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,15,中间型（int）,INFa,0.0,,,,,,,,2016-02-18,2017-12-20,2,,,,,,,,,0, 粘液腺癌（muc）80 低粘附腺癌10 低分化腺癌（G3)(por)10 Lauren肠型,G3, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)01 (4d)01 (5)00 (6)02 (7)03 (8a、8p)04 (9)01 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,20, R0 D2+,,4.84,3.1,1.25,151.0,175.0,2.48,27.0,26.0,189.0,79.0,11.0,9.01,2.66,70.0,324.0,45.0,25.0,4.9,8.6,80.0,328.0,63.8,35.7,25.8,1.38,1.1,17.0,22.0,10.0,1.27,1.39,9.7,,40.86,5.77,29.7,,无,, P0,H0, 未做, CK+,,,,,22.043363994743757,1603873
1603876,李艳,627275,男,62,T3,N0,M0, ⅡA,1,3,1.0,0.0,,1.0, 慢性炎症（+）,0.0,21,中间型（int）,INFa,0.0,,,,,,,,2016-02-18,2021-06-01,1,,,XELOX,,,,,,4, 粘液腺癌（muc）80% 低粘附腺癌20% Lauren混合型,GX, (1a)00 (1b)00 (3a)01 (3b)08 (4sb)00 (4d)00 (5)00 (6)04 (7)00 (8a) 02(8p) (9)01 (11p)01 (12a)00," L（幽门窦部）, 前Ant,",60,40,20, R0,,4.89,3.15,1.41,149.0,135.0,2.28,41.0,23.0,158.0,71.0,17.0,6.46,2.5,67.0,297.0,43.0,24.0,5.9,7.7,73.0,250.0,,,,,,,,,,,,,3.82,150.4,32.77, 未做,无, 无, P0,H0, 未做,,,,,,63.40341655716163,1603876
1603928,闫仲元,624612,男,54,T4b,N3b,M0, ⅢC,1,3,1.0,0.0,0.0,1.0, 慢性炎症（+）,34.0,35,髓样型（med）,INFb,0.0,,,,,,,,2016-03-18,2016-05-15,2,,,XELOX,,,,,,2, 管状腺癌（低分化【G2】【tub2】50% 低粘附腺癌30% 粘液腺癌（muc）20%,G3, (1a)44 (1b)11 (2)55 (3a)33 (3b)11 (4sa)00 (4sb)22 (4d)55 (5)01 (6)00 (7)11 (8a)33 (8p)11 (9)11 (11d)22 (11p)33 (12a)11 (12p)11," L（幽门窦部）, M（胃体部）, U（胃底部）, 后Post,",90,60,10,,R1,4.06,1.35,2.12,120.0,232.0,1.98,23.0,30.0,207.0,71.0,5.0,16.49,5.45,64.0,171.0,39.0,25.0,5.3,7.9,70.0,302.0,,,,,,,,,,,,,145.0,1000.0,300.0, 未做,无,, P0,H0, 未做, S-100+ CK+,,,,,1.9053876478318001,1603928
1604227,秦文学,626890,男,50,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,34,,,0.0,,,,,,,,2016-02-22,2021-07-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)05 (1b)01 (3a)06 (3b)02 (4sb)01 (4d)03 (5) 00(6)05 (7)03 (8a)01 (8p)01 (9)01 (11p)05 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",20,15,2, R0,,4.25,2.36,1.47,154.6,154.0,1.64,30.0,26.0,142.0,138.0,9.0,8.77,3.59,71.0,403.0,43.0,28.0,5.5,6.6,100.0,312.0,,,,,,,,,,,,,1.09,14.48,3.5, 未做,无, 无, P0,H0, 未做,,,,,,64.25755584756898,1604227
1604026,高有,626067,男,57,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,27,中间型（int）,INFa,2.0,,,,,,,,2016-02-19,2017-06-15,2,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)06 (3a)01 (3b) 01(4sb)01 (4d)00 (5)00 (6)03 (7)06 (8a)02 (8p)03 (9)01 (11p)02," L（幽门窦部）, 后Post,",45,30,5, R0 D2,,6.4,3.42,2.18,144.7,286.0,2.68,21.0,24.0,128.0,71.0,26.0,9.69,3.18,68.0,371.0,39.0,29.0,5.0,3.6,70.0,350.0,47.9,34.6,12.9,2.68,0.3,11.7,38.5,0.8,1.28,3.06,11.4,,3.73,14.34,6.7, 阴性,无,, P0,H0, 未做, CK +,,,,,15.83442838370565,1604026
1603931,杜克俊,624468,男,51,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,16,中间型（int）,INFa,2.0,,,,,,,,2016-02-18,2021-07-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (2)04 (3a)04 (3b)01 (4sa)00 (4sb)00 (4d)00 (5)01 (6)01 (7)02 (8a)01 (11p)00," M（胃体部）, 小弯侧Less,",22,18,8, R0 D2,,16.4,10.52,4.78,163.5,218.0,5.27,77.0,30.0,535.0,82.0,34.0,19.65,5.09,68.0,367.0,42.0,26.0,4.5,4.8,70.0,330.0,,,,,,,,,,,,,4.26,10.94,14.65, 阳性+,无, 无, P0,H0, 未做,,,,,,64.38896189224704,1603931
1604448,胡文秀,624473,男,69,T4b,N1,M0, ⅢB,1,3,0.0,0.0,,1.0, 肠化生 慢性炎症 异型增生,1.0,26,中间型（int）,INFa,0.0,,,,,,,,2016-02-23,2019-09-02,0,,,XELOX,,,,,,2,低中分化管状腺癌,G2, (1a)03 (1b)02 (3a)11 (3b)03 (4sb)00 (4d)04 (5)00 (6)03 (7)02 (8a)03 (8p)01 (9)04 (11p)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,20,10, R0 D2,,5.16,2.65,1.9,126.4,229.0,3.49,17.0,25.0,130.0,61.0,17.0,11.44,4.08,68.0,164.0,40.0,28.0,4.2,3.7,91.0,336.0,,,,,,,,,,,,,2.77,11.01,2.03,,无, 无, P0,H0, 未做, CK +,,,,,42.27989487516425,1604448
1604151,刘延汉,626066,男,67,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,4.0,41,中间型（int）,INFa,0.0,,,,,,,,2016-02-17,2021-05-17,1,,,XELOX,XELOX,XELOX,XELOX,口服替吉奥,卡培他滨,6, 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌20 粘液腺癌（muc）10 Lauren肠型,G2, (1a)010 (1b)17 (3a)02 (3b)11 (4sb)00 (4d)00 (5)00 (6)29 (7)03 (8a)01 (8p)03 (9)03 (11p)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,30,5, R0 D2,,4.73,1.75,2.28,156.8,183.0,3.68,22.0,26.0,185.0,57.0,7.0,23.39,7.82,66.0,185.0,40.0,26.0,6.4,5.0,88.0,321.0,53.8,34.8,19.9,1.75,0.8,10.2,31.1,4.8,0.428,1.8,9.85,,2.08,13.91,2.9, 阳性+,无,, P0,H0, 未做, CK +,,,,,62.943495400788436,1604151
1604029,史秋娥,624470,女,63,T4b,N2,M0, ⅢB,1,3,,0.0,,0.0,,5.0,29,,,1.0,,,,,,,,2016-02-19,2017-04-15,2,,,多西他赛联合奈达铂,多西他噻,,,,,2, 管状腺癌（中分化【G2】【tub2】,G2,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,25,10,,R2,8.81,5.91,1.97,83.0,463.0,3.76,17.0,22.0,143.0,121.0,15.0,8.93,2.69,70.0,203.0,41.0,29.0,5.9,3.23,72.0,224.0,,,,,,,,,,,,,27.8,12.57,8.82,,无, 无, P0,H0, 未做, CK +,,,,,13.830486202365309,1604029
1604790,石山林,627312,男,58,T4a,N2,M1, Ⅳ,1,3,1.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,4.0,20,髓样型（med）,INFb,0.0,,,,,,,,2016-02-24,2017-10-01,2,,,XELOX,,,,,,2, 粘液腺癌（muc）70% 低粘附腺癌20% 低分化腺癌（G3)(por)10% Lauren混合型,G3, (1a)00 (1b)01 (2)04 (3a)03 (3b)23 (4sa)00 (4sb)00 (4d)13 (6)01 (7)15," L（幽门窦部）, M（胃体部）, U（胃底部）, 后Post, 大弯侧Gre, 小弯侧Less,",90,60,18,,R2,5.56,3.61,1.5,164.2,211.0,2.78,12.0,13.0,112.0,56.0,19.0,17.01,5.63,61.0,287.0,39.0,22.0,4.8,4.4,89.0,278.0,68.3,38.4,26.6,1.44,2.0,10.7,18.6,4.1,0.344,1.46,7.18,,0.945,56.3,151.3, 阳性+,无, 无, P0,H0, 未做, CK（+）,,,,,19.21813403416557,1604790
1603921,符文昌,624631,男,61,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,30,中间型（int）,INFa,1.0,,,,,,,,2016-02-18,2021-04-20,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)09 (2)02 (3a) (3b)00 (4sb)00 (5) 01(7)01 (8a)03 (9)01 (11p)05 (12p)01," U（胃底部）, 小弯侧Less,",50,45,10, R0,,4.07,2.02,1.58,146.0,212.0,3.4,15.0,16.0,149.0,92.0,12.0,13.26,4.0,66.0,284.0,40.0,26.0,5.4,7.5,77.0,448.0,,,,,,,,,,,,,1.23,11.51,6.14, 未做,无, 无, P0,H0, 未做, CK+,,,,,62.023653088042046,1603921
1604398,万桂荣,627282,女,68,T3,N1,M0, ⅡB,1,3,,0.0,0.0,0.0, 正常,1.0,54,中间型（int）,INFb,0.0,,,,,,,,2016-02-23,2021-07-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (3a)013 (3b)03 (4sb)07 (4d)010 (5)01 (6)12 (7)012 (8a)02 (8p)01 (9)02 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",55,45,6, R0 D2+,,8.45,5.36,2.37,92.0,442.0,2.9,7.0,11.0,132.0,71.0,4.0,7.1,2.76,60.0,179.0,37.0,23.0,4.4,7.1,82.0,160.0,69.1,45.4,15.4,2.95,1.0,11.6,12.3,3.9,1.07,0.87,8.84,,0.954,18.26,1.29, 阴性,无, 无, P0,H0, 未做, CK+,,,,,64.22470433639947,1604398
1604542,仲崇君,618745,男,58,T4a,N3a,M0, ⅢB,1,3,0.0,0.0,,1.0, 肠化生+ 慢性炎症（+）,10.0,19,中间型（int）,INFa,3.0,,,,,,,,2016-02-23,2019-09-14,2,,,SOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)12 (3a)78 (3b)22 (4sb)01 (4d)01 (5)00 (6)00 (7)02 (8p)01 (8a)01 (9)01 (11p)00," M（胃体部）, 后Post, 小弯侧Less,",35,30,10, R0 D2,,6.27,3.64,1.75,133.4,309.0,3.18,13.0,16.0,135.0,74.0,21.0,8.94,3.19,66.0,347.0,41.0,25.0,4.2,7.2,100.0,351.0,,,,,,,,,,,,,1.47,14.61,5.15,,无, 无, P0,H0, 未做, CK+,,,,,42.67411300919842,1604542
1604575,乔淑芳,629556,女,63,T3,N1,M0, ⅡB,1,3,2.0,0.0,,0.0, 慢性炎症（+） 异型增生+,1.0,17,中间型（int）,INFa,0.0,,,,,,,,2016-02-23,2018-12-15,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)01 (3a) 02(3b) 12(4sb)00 (4d)02 (5)01 (6)02 (7)01 (8a) 01(8p)02 (9)01 (11p)01 (12a)01," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,15,10,,R2,6.4,4.67,1.25,131.9,186.0,2.8,11.0,18.0,153.0,78.0,5.0,6.36,2.7,62.0,175.0,40.0,22.0,7.6,8.3,69.0,189.0,,,,,,,,,0.974,1.2,8.26,,2.3,10.68,1.77, 未做,无, 无, P0,H0, 未做, CK+CK818+,,,,,33.70565045992115,1604575
1604450,王立春,629559,男,57,T3,N2,M0, ⅢA,1,3,0.0,1.0,,0.0, 肠化生+,5.0,28,中间型（int）,INFa,0.0,,,,,,,,2016-02-23,2016-08-17,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)95% 粘液腺癌（muc）5%,G3, (1a)00 (1b) 00(3a)01 (3b)33 (4sb)00 (4d)00 (6)01 (7)01 (8a)01 (8p)01 (9)13 (11p)03 (12a)00 (12p)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,45,15,,R2,5.42,3.14,1.84,135.6,242.0,3.41,23.0,30.0,113.0,75.0,22.0,13.48,4.66,64.0,225.0,40.0,24.0,4.7,6.4,73.0,200.0,,,,,,,,,0.738,5.62,9.63,,3.15,201.4,2.4, 未做,无, 无, P0,H0, 未做, CK+,,,,,5.781865965834428,1604450
1604144,王振林,629563,男,78,T2,N0,M0, ⅠB,1,3,0.0,0.0,,0.0, 慢性炎症（+）,0.0,20,中间型（int）,INFa,0.0,,,,,,,,2016-02-19,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 粘液腺癌（muc）40 Lauren肠型,G3, (1a)03 (1b)03 (3a)02 (3b)01 (4sb)00 (4d)00 (5)00 (6)00 (7)01 (8a)01 (8p)01 (9)00 (11p)01 (12a)05," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,30,6, R0 D2,,5.43,4.31,0.68,120.0,226.0,,8.0,16.0,133.0,53.0,11.0,8.05,3.9,62.0,168.0,36.0,26.0,11.0,4.9,79.0,185.0,,,,,,,,,,,,,1.63,15.93,0.984,,无, 无, P0,H0, 未做, CK+,,,,,78.38370565045992,1604144
1604641,王玉斌,624482,男,62,T4a,N3a,M1, Ⅳ,1,3,,1.0,1.0,1.0, 慢性炎症（+）,10.0,20,中间型（int）,INFc,1.0,,,,,,,,2016-02-24,2017-02-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)00 (3a)36 (3b)55 (4sb)00 (4d)04 (5)00 (6)11 (7)02 (11p)00 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,35,10,,R2,13.68,12.32,0.82,117.1,268.0,3.67,15.0,17.0,211.0,62.0,9.0,19.87,6.33,70.0,264.0,46.0,24.0,6.3,8.1,114.0,229.0,50.0,34.7,10.1,3.44,1.0,8.4,35.4,2.9,0.567,1.65,6.28,,1.7,13.67,1.82, 阴性,无, 无, P0,H0, 未做, CK（+）,,,,,11.268068331143231,1604641
1607484,刘艳芹,626957,女,53,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,27,中间型（int）,INFa,0.0,,,,,,,,2016-03-14,2021-07-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)02 (3a)02 (3b)01 (4sb)01 (4d)06 (5)03 (6)01 (7)01 (8a)02 (8p)03 (9)01 (11p)01 (12a)01 (14v)00," L（幽门窦部）, 大弯侧Gre,",20,20,10,R0 D2,,7.98,5.19,2.46,88.5,360.0,,9.0,15.0,107.0,161.0,10.0,5.34,1.52,70.0,329.0,44.0,26.0,6.1,3.0,72.0,208.0,,,,,,,,,,,,,4.0,32.46,3.59,,无, 无, P0,H0, 未做, CK +,,,,,63.5676741130092,1607484
1610840,付晓东,626776,男,55,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,1.0,29,中间型（int）,INFa,0.0,,,,,,,,2016-04-06,2017-01-05,2,,,SOX,SOX,SOX,紫衫醇联合卡培他滨,FOLFOX,,5, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)20 低粘附腺癌10,G3, (1a) 02(1b) 02(2) 01(3a) 03(3b) 00(4sa)00 (4sb)00 (4d)00 (5)00 (6) 00(7) 13(8a)01 (8p)04 (9) 03(11p)04 (12a)03," SiewerⅡ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,15,8, R0 D2+,,4.92,1.53,2.62,144.0,111.0,2.65,23.0,26.0,182.0,74.0,20.0,25.43,8.18,70.0,227.0,40.0,30.0,4.2,4.9,81.0,273.0,92.1,44.2,45.1,0.98,1.2,3.3,3.2,7.8,0.412,1.2,11.4,,9.85,91.44,38.95,,,, P0,H0, 未做, CK + CD34+ S-100+,,,,,9.00131406044678,1610840
1604794,何淑英,627216,女,61,T1a,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 慢性炎症（+）,1.0,21,中间型（int）,INFa,0.0,,,,,,,,2016-02-24,2021-06-01,1,,,奥沙利铂联合替加氟,,,,,,1, 低粘附腺癌 Lauren肠型,GX, (1a)01 (1b)03 (3a)02 (3b)00 (4sb)00 (4d)14 (5)00 (6)02 (7)03 (8a)00 (8p)00 (9)02 (11p)04 (12a)00," L（幽门窦部）, 前Ant,",40,30,4, R0 D2,,4.69,2.35,2.05,142.1,236.0,1.75,17.0,22.0,140.0,61.0,9.0,12.74,3.86,68.0,315.0,42.0,26.0,4.8,3.4,63.0,170.0,68.1,43.1,17.6,2.45,0.1,12.1,14.1,2.8,0.824,2.37,9.37,,0.656,7.02,3.7, 阳性+,无, 无, P0,H0, 未做, CK +,,,,,63.206307490144546,1604794
1604996,张建新,630119,男,59,T3,N2,M0, ⅢA,1,3,1.0,1.0,,1.0, 慢性炎症（+）,6.0,26,中间型（int）,INFb,0.0,,,,,,,,2016-02-25,2021-05-01,1,,,SOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】50 低粘附腺癌30 粘液腺癌（muc）20 Lauren混合型,G2, (1a)00 (1b)02 (3a)15 (3b)00 (4sb)03 (4d)12 (5)01 (6)35 (7)01 (8a)12 (8p)01 (9)02 (11p)02 (12a)00 (12p)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",30,30,8, R0 D2,,11.26,5.95,3.86,173.0,233.0,14.7,23.0,26.0,192.0,102.0,81.0,18.07,6.61,68.0,328.0,42.0,26.0,4.1,5.3,80.0,285.0,,,,,,,,,,,,,4.03,253.0,4.09, 未做,无, 无, P0,H0, 未做, CK+,,,,,62.155059132720105,1604996
1604775,赵连祥,626094,男,58,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,29,中间型（int）,INFa,0.0,,,,,,,,2016-02-24,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)02 (3b)03 (4sb)01 (4d)011 (5)00 (6)03 (7)03 (8a)01 (8p)02 (9)02 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",30,20,4, R0 D2,,6.07,1.95,3.03,124.7,344.0,4.08,15.0,16.0,143.0,66.0,10.0,6.97,2.98,64.0,308.0,39.0,25.0,4.7,3.7,74.0,192.0,,,,,,,,,,,,,0.57,11.88,6.01, 阳性+,无, 无, P0,H0, 未做,,,,,,78.21944809461235,1604775
1605356,宋春芝,630029,女,65,T3,N3b,M0, ⅢC,1,3,1.0,0.0,,0.0, 慢性炎症（+）,30.0,49,中间型（int）,INFa,0.0,,,,,,,,2016-02-29,2018-03-15,2,,,SOX,SOX,奥沙利铂 雷替曲塞,奥沙利铂 雷替曲塞,奥沙利铂 雷替曲塞,,5, 低粘附腺癌50% 粘液腺癌（muc）30% 管状腺癌（中分化【G2】【tub2】20%,G2, (1a)00 (1b)00 (3a)610 (3b)33 (4sb) 34(4d)711 (5) 00(6)01 (7)67 (8a)11 (8p)14 (9)59 (11p)00 (12a)00 (14v)00," M（胃体部）, 小弯侧Less,",18,15,3, R0,,5.0,2.96,1.78,150.3,230.0,3.24,9.0,16.0,182.0,93.0,7.0,9.71,2.6,75.0,310.0,44.0,31.0,5.7,4.3,75.0,291.0,,,,,,,,,,,,,3.89,15.2,66.51, 未做,无, 无, P0,H0, 未做, CK+,,,,,24.47437582128778,1605356
1604953,孙彩荣,629987,女,53,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,5.0,32,中间型（int）,INFa,2.0,,,,,,,,2016-02-25,2019-12-17,2,,,SOX,替吉奥单药,SOX,替吉奥单药,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)04 (3b)01 (4sb)03 (4d)16 (5)00 (6)16 (7)06 (8a)11 (8p、9)23 (11p)00 (12a)00小弯01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,35,20, R0 D2+,,5.96,3.66,1.64,126.0,181.0,2.63,25.0,31.0,167.0,80.0,6.0,8.94,2.41,75.0,300.0,44.0,31.0,5.2,7.4,63.0,193.0,73.8,34.7,30.3,1.15,0.2,11.9,10.6,1.9,1.09,2.57,12.3,,,,, 阳性+,无, 无, P0,H0, 未做, CK+,,,,,45.69645203679369,1604953
1605428,邓永全,624531,男,56,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,35,,,0.0,,,,,,,,2016-02-29,2021-06-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20,G3, (1a)02 (1b)02 (3a)010 (3b)00 (4sb)00 (4d)05 (5)00 (6)03 (7)01 (8a)04 (8p)05 (9)02 (11p)00 (12a)00," LM 小弯侧Less,",20,13,5, R0 D2,,7.97,4.74,2.65,155.4,221.0,2.76,19.0,19.0,125.0,87.0,31.0,11.21,3.52,68.0,402.0,44.0,24.0,5.3,9.9,88.0,474.0,,,,,,,,,,,,,1.1,6.81,5.47,,无, 无, P0,H0, 未做, CK+,,,,,63.042049934296976,1605428
1604957,梁继平,630183,男,39,T1b,N0,M0,ⅠA,1,0,0.0,1.0,1.0,0.0, 慢性炎症（+）,0.0,28,中间型（int）,INFa,3.0,,,,,,,,2016-02-25,2021-06-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 01(1b)06 (3a)01 (3b)00 (4sb)00 (4d)04 (5)00 (6)03 (7)04 (8a)01 (8p)01 (9)02 (11p)05 (12a)00," M（胃体部）, 小弯侧Less,",25,20,3, R0 D2,,8.32,5.34,2.42,147.3,182.0,2.12,19.0,21.0,155.0,68.0,13.0,10.73,3.55,83.0,418.0,49.0,34.0,5.7,6.0,82.0,264.0,61.1,35.2,21.7,1.62,1.1,10.9,24.3,0.4,1.24,3.25,12.8,,0.612,6.6,3.04, 阳性+,无,, P0,H0, 未做, CK +,,,,,63.17345597897503,1604957
1606667,曲明友,627278,男,58,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,10.0,28,中间型（int）,INFb,1.0,,,,,,,,2016-03-08,2019-07-23,2,,,XELOX,,,,,,2, 低粘附腺癌80 低分化腺癌（G3)(por)20,G3, (1a)00 (1b) 14(2)01 (3a)710 (3b)00 (4sa) 00(4sb) 01(7)13 (8a)01 (8p) 05(9) 00(11p)02 (12a)00," U（胃底部）, SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",50,40,6, R0 D2+,,6.02,3.28,2.05,164.0,216.0,2.18,129.0,55.0,153.0,115.0,30.0,18.24,6.59,80.0,257.0,46.0,34.0,15.1,6.9,84.0,190.0,,,,,,,,,,,,,1.5,16.81,2.5, 未做,, , P0,H0, 未做, CK+ S-100+ CD34+,,,,,40.473061760841,1606667
1606490,高志强,628775,男,76,T3,N3a,M0,ⅢB,1,3,,0.0,0.0,1.0, 慢性炎症（+）,11.0,35,中间型（int）,INFb,1.0,,,,,,,,2016-03-07,2021-05-10,1,,,,,,,,,0, 粘液腺癌（muc）70 低粘附腺癌30,GX, (1a) 00(1b)01 (3a)815 (3b)00 (4sb) 00(4d) 29(5) 23(6) 03(7) 00(8a) 01(8p)01 (9) 01(11p)00 (12a)00 (14v)2," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,50,10, R0 D2+,,5.08,4.4,0.86,96.2,325.0,2.28,16.0,25.0,191.0,66.0,6.0,12.27,4.85,59.0,268.0,35.0,24.0,6.5,5.4,88.0,325.0,,,,,,,,,,,,,3.84,45.31,,,,,,H0, 未做, CK + CD34- S-100-,,,,,62.089356110381075,1606490
1605003,柳广英,624632,女,58,T4b,N3a,M0, ⅢC,1,3,0.0,0.0,,0.0, 慢性炎症（+）,8.0,20,中间型（int）,INFa,1.0,,,,,,,,2016-02-25,2017-09-15,2,,,SOX,,,,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)01 (1b)02 (3a)34 (3b) 22(4sb) 00(4d) (5)11 (6)11 (7)01 (8a)11 (8p)04 (9)01 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,40,15,,R2,6.03,3.97,1.54,91.3,303.0,3.15,9.0,11.0,123.0,63.0,5.0,3.38,1.18,61.0,189.0,37.0,24.0,5.1,8.0,66.0,221.0,,,,,,,,,,,,,1.13,177.6,7.2, 未做,无, 无, P0,H0, 未做, CK+,,,,,18.659658344283837,1605003
1605471,李权,630244,男,52,T3,N3a,M0,ⅢB,1,3,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,7.0,23,中间型（int）,INFa,0.0,,,,,,,,2016-02-29,2018-05-02,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b) 03(3a) 34(3b) 00(4sb)00 (4d)05 (5)11 (6)12 (7)00 (8a)11 (8p)01 (9)03 (12a)01," L（幽门窦部）, 小弯侧Less,",35,20,8, R0,,4.41,2.81,1.18,160.0,202.0,2.28,13.0,17.0,198.0,127.0,238.0,15.13,4.39,81.0,470.0,49.0,32.0,5.2,8.5,91.0,293.0,,,,,,,,,,,,,3.14,7.02,1.57, 未做,无, 无, P0,H0, 未做, CK+,,,,,26.05124835742444,1605471
1605421,赵允举,630188,男,77,T4b,N0,M0, ⅢA,1,3,0.0,,,, 慢性炎症（+）,0.0,23,中间型（int）,INFa,0.0,,,,,,,,2016-02-29,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)04 (1b)00 (3a)03 (3b)00 (4sb)00 (4d)02 (5)02 (6)02 (7)02 (8a)01 (8p)02 (9)01 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,18,8,,R2,7.7,6.23,1.0,154.2,207.0,3.33,12.0,14.0,141.0,78.0,7.0,15.7,6.84,63.0,206.0,38.0,25.0,5.4,8.0,80.0,290.0,,,,,,,,,,,,,0.786,11.26,1.04,,无, 无, P0,H0, 未做, CK+,,,,,78.05519053876478,1605421
1606770,刘君,628147,男,56,T4b,N1,M0, ⅢB,1,5,2.0,0.0,0.0,0.0, 正常,1.0,22,中间型（int）,INFc,0.0,,,,,,,,2016-03-08,2016-12-30,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,FOFIRI,6, 低粘附腺癌（G3)90(por) 粘液腺癌（muc）10,G3, (1a) 00(1b)00 (3a)05 (4sb)13 (4d)00 (5) 00(6)04 (7)01 (8a) (8p) (9)05 (11p)04 (3b)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,45,15,R0,,11.12,7.28,2.79,189.4,233.0,4.66,64.0,40.0,151.0,84.0,43.0,45.45,18.23,81.0,337.0,49.0,32.0,4.6,6.2,91.0,698.0,,,,,,,,,,,,,3.99,13.91,2.31,,,, P0,H0, 未做, CK+ CD34 - S-100-,,,,,9.756898817345597,1606770
1605350,赵相瑛,624530,男,48,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,28,,,,,,,,,,,2016-02-29,2021-07-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)01 (1b)02 (3a)03 (3b)00 (4sb)02 (4d)04 (5)01 (6)01 (7)05 (8a)06 (8p)01 (9)01 (11p)00 (12a)01," LM 小弯侧Less,",15,10,2, R0 D2,,7.73,4.5,2.1,150.0,279.0,3.21,23.0,28.0,165.0,64.0,11.0,12.25,4.16,70.0,340.0,46.0,24.0,4.8,6.0,75.0,189.0,68.5,37.7,28.6,1.32,1.2,1.9,27.8,1.3,0.61,0.989,7.82,,2.02,5.32,2.57, 阳性+,无,, P0,H0, 未做, CK +,,,,,64.02759526938239,1605350
1605468,刘国忠,615758,男,51,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,9.0,28,中间型（int）,INFa,0.0,,,,,,,,2016-02-29,2020-04-27,0,,,XELOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)01 (3a)16 (3b)01 (4sb)01 (4d)511 (5)00 (6)22 (7)00 (8a)11 (8p)01 (9)01 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 大弯侧Gre,",30,20,12, R0 D2,,4.94,2.04,2.36,148.0,166.0,2.01,21.0,16.0,119.0,58.0,5.0,24.38,7.68,69.0,315.0,45.0,24.0,5.4,7.0,91.0,381.0,78.8,48.3,25.7,1.88,0.4,6.8,11.9,1.9,0.577,1.85,8.54,,2.89,11.89,0.893, 阳性+,无, 无, P0,H0, 未做, CK（+）,,,,,49.90144546649146,1605468
1605871,冯国利,627331,男,60,T4b,N3b,M1, Ⅳ,1,3,2.0,0.0,0.0,0.0, 慢性炎症,65.0,67,中间型（int）,INFa,1.0,,,,,,,,2016-03-02,2017-04-15,2,,,紫衫醇联合替吉奥,紫衫醇联合替吉奥,SOX,SOX,SOX,SOX,6, Lauren弥漫型 低粘附腺癌,GX," (1a)(7)(3a)5,5 (1b)0,0 (3b)2,2 (4sb)0,0 (4d)14,14 (5)3,3 (6)12,12 (8a)(8p)6,7 (9)4,4 (11p)15,15 (12a)2,2 (12p)1,2 (16a1)1,1"," 后Post, 小弯侧Less, L（幽门窦部）, G,",90,75,15,,R2,10.23,7.46,2.18,106.4,466.0,15.2,10.0,34.0,238.0,94.0,23.0,7.6,2.41,71.0,138.0,35.0,36.0,4.4,4.9,83.0,469.0,,,,,,,,,,,,,229.9,8.91,5.43,阴性,无,, p1泛(M1 PER),H0, 未做, CK +,,,,,13.436268068331144,1605871
1605689,方吉祥,627337,男,66,T4b,N0,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,33,中间型（int）,INFa,0.0,,,,,,,,2016-03-01,2021-06-01,1,,,SOX,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)01 (3b)03 (4sb)00 (4d)03 (5)04 (6)012 (7)01 (8a)01 (8p)02 (9)02 (11p)04," L（幽门窦部）, 小弯侧Less,",40,30,7, R0 D2+,,6.8,2.79,3.14,165.0,259.0,4.44,18.0,21.0,122.0,64.0,64.0,12.04,4.96,69.0,213.0,41.0,28.0,7.1,4.8,84.0,315.0,53.2,38.8,10.9,3.56,0.2,11.6,31.4,2.5,0.719,3.09,10.3,,1.39,11.08,1.47, 阴性,无,, P0,H0, 未做, CK+,,,,,63.00919842312746,1605689
1605426,马玉霞,629575,女,48,T1b,N0,M0,ⅠA,1,0,0.0,1.0,1.0,, 慢性炎症（+）,0.0,17,中间型（int）,INFa,0.0,,,,,,,,2016-02-29,2020-09-17,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)01 (1b)01 (3a)03 (3b)00 (4sb)00 (4d)04 (5)00 (6)00 (7)00 (8a)03 (8p)02 (9)02 (11p)00 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,20,7, R0 D2+,,6.98,3.04,3.31,120.5,231.0,4.44,16.0,19.0,152.0,47.0,8.0,10.52,3.45,67.0,232.0,43.0,24.0,6.7,4.2,72.0,205.0,,,,,,,,,,,,,0.579,9.16,1.09,,无,, P0,H0, 未做, CK +,,,,,54.59921156373193,1605426
1605688,邱德思,631006,男,64,T4b,N2,M0, ⅢB,1,1,0.0,0.0,0.0,1.0, 慢性炎症（+）,6.0,13,中间型（int）,INFa,0.0,,,,,,,,2016-03-01,2017-09-21,2,,,XELOX,,,,,,7, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap）,G2, (1a)01 (1b)00 (2)13 (3a)34 (4sa)01 (4sb)00 (7)12 (11p)12," U（胃底部）, 后Post,",60,50,35, R0 D2,,5.89,3.16,2.08,91.7,336.0,2.58,21.0,20.0,135.0,74.0,10.0,7.1,2.81,63.0,289.0,38.0,25.0,5.0,5.9,67.0,307.0,,,,,,,,,,,,,2.66,412.5,17.33,,,, P0,H0, 未做, CK  + S-100+ CD34 -,,,,,18.69250985545335,1605688
1605422,孙强,629571,男,60,T3,N2,M1, Ⅳ,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,4.0,17,中间型（int）,INFa,0.0,,,,,,,,2016-02-29,2016-05-26,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)01 (3a)00 (3b)26 (4sb)01 (5)11 (6)12 (7)02 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,20,10,,R2,6.86,4.04,2.09,126.9,279.0,3.21,13.0,22.0,136.0,77.0,23.0,15.31,5.15,62.0,259.0,40.0,22.0,4.9,4.7,74.0,387.0,,,,,,,,,,,,,0.777,141.9,12.46, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,2.8580814717477003,1605422
1605670,李凤云,624498,女,56,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+） 异型增生+,7.0,19,中间型（int）,INFa,0.0,,,,,,,,2016-03-01,2017-10-26,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)01 (3a)22 (3b)11 (4sb)00 (4d)29 (5)11 (7)12," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,8,,R2,6.76,30.07,2.03,103.4,211.0,2.52,16.0,17.0,193.0,102.0,16.0,5.31,2.16,66.0,156.0,42.0,24.0,6.0,7.3,69.0,340.0,,,,,,,,,,,,,14.99,735.1,25.53, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,19.842312746386334,1605670
1605922,王治利,624516,女,54,T4a,N3b,M0, ⅢC,1,4,1.0,1.0,1.0,1.0, 慢性炎症（+）,20.0,20,中间型（int）,INFb,0.0,,,,,,,,2016-03-02,2016-05-31,2,,,SOX,,,,,,1, 低粘附腺癌80 粘液腺癌（muc）20 Lauren混合型,GX, (1a)00 (1b)22 (2)11 (3a)22 (3b)00 (4sa)00 (4sb)00 (4d)33 (5)11 (6)22 (7)11 (8a)11 (8p)11 (9)44 (11p)11 (12a)00 (14v)11," LM 前Ant, 后Post, 小弯侧Less,",50,30,10, R0 D2+,,6.02,3.22,2.27,134.9,239.0,4.44,32.0,32.0,245.0,83.0,12.0,8.75,2.66,77.0,273.0,46.0,31.0,5.6,7.1,79.0,300.0,,,,,,,,,,,,,3.97,432.6,50.76, 阳性+,无,, P0,H0, 未做, CK+,,,,,2.9566360052562417,1605922
1605604,刘公良,624619,男,60,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,17,中间型（int）,INFa,0.0,,,,,,,,2016-03-01,2019-11-28,2,,,,,,,,,0, 管状腺癌（高中分化【G1】【tub1】） Lauren肠型,G2, (1a)02 (1b)02 (3a)01 (3b)00 (4sb)02 (4d)02 (5)01 (6)02 (7)01 (8a)03 (8p)00 (9)00 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,20,5, R0 D2+,,5.17,2.28,2.49,154.1,162.0,1.88,33.0,30.0,138.0,52.0,15.0,14.67,5.23,74.0,312.0,44.0,30.0,4.9,5.1,85.0,298.0,,,,,,,,,,,,,0.35,3.53,0.956, 阴性,无,, P0,H0, 未做, CK +,,,,,44.908015768725356,1605604
1605921,孔德俊,628973,男,35,T2,N0,M0, ⅠB,1,3,1.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,16,中间型（int）,INFa,0.0,,,,,,,,2016-03-02,2021-09-02,1,,,XELOX,,,,,,4, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren混合型,G3, (3a)09 (3b)00 (4sb)02 (4d)01 (5)00 (6)01 (7)01 (8a)01 (8p)00 (9)00 (11p)00 (12a)01," L（幽门窦部）, 前Ant,",15,12,5, R0,,5.65,3.77,1.32,157.0,205.0,2.49,25.0,25.0,166.0,78.0,19.0,15.85,5.26,73.0,368.0,46.0,27.0,5.1,4.1,82.0,311.0,,,,,,,,,,,,,1.18,2.66,4.65,,无, 无, P0,H0, 未做, CK+,,,,,66.03153745072274,1605921
1606124,田迎春,631144,男,59,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,27,,,0.0,,,,,,,,2016-03-03,2021-07-06,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)02 (1b)09 (3a)03 (3b)00 (4sb)00 (4d)08 (5)01 (6)00 (7)02 (8a)00 (8p)00 (9)02 (11p)00 (12a)00," L（幽门窦部）, 前Ant,",20,20,3, R0 D2,,6.52,3.99,2.02,167.7,158.0,2.09,12.0,16.0,118.0,61.0,17.0,23.37,8.04,71.0,294.0,43.0,28.0,4.9,5.1,86.0,320.0,62.4,30.8,24.5,1.26,2.9,7.7,27.0,4.2,0.648,1.3,9.01,,1.89,7.09,0.684, 阳性+,无, 无, P0,H0, 未做,,,,,,64.09329829172141,1606124
1605596,赵刚,628975,男,36,T3,N1,M0, ⅡB,1,2,1.0,0.0,0.0,1.0, 慢性炎症（+）,2.0,37,中间型（int）,INFc,0.0,,,,,,,,2016-03-01,2021-05-11,1,,,FOLFOX,FOLFOX,FOLFOX,XELOX,XELOX,XELOX,6, 低粘附腺癌70% 低分化腺癌（G3)(por)30% Lauren混合型,G3, (1a)00 (1b)03 (3a)06 (3b)24 (4sb)00 (4d)011(5)00 (6)02 (7)04 (8a)01 (8p)01 (9)02 (11p)02 (12a)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,30,10, R0 D2,,7.19,3.76,2.5,145.0,243.0,2.95,18.0,21.0,138.0,71.0,12.0,21.35,7.49,69.0,314.0,44.0,25.0,4.7,5.8,80.0,531.0,,,,,,,,,,,,,2.85,12.07,1.42, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,62.319316688567675,1605596
1606154,吴建平,631096,男,52,T4b,N3a,M0, ⅢC,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,7.0,13,中间型（int）,INFa,0.0,,,,,,,,2016-03-03,2017-12-11,2,,,,,,,,,0, 粘液腺癌（muc）60 管状腺癌（中分化【G2】【tub2】40,G2, (1a)12 (1b)00 (2)44 (3a)13 (3b) 11(4sa)00 (4sb)02 (4d)00 (7)00 (8a)00 (9) 00(11p)00 大弯01," U（胃底部）, SiewerⅡ, 前Ant, 后Post, 大弯侧Gre,",40,30,15,,R1,5.69,3.53,1.63,125.6,256.0,2.63,25.0,47.0,383.0,59.0,25.0,10.3,2.69,77.0,315.0,47.0,30.0,5.3,7.1,65.0,281.0,,,,,,,,,,,,,4.01,17.08,1.29, 未做,,, P0,H0, 未做, CK+ CD34- S-100-,,,,,21.28777923784494,1606154
1606060,付兢涛,629593,男,44,T2,N0,M0, ⅠB,1,1,1.0,0.0,0.0,0.0, 肠化生+,0.0,11,中间型（int）,INFa,1.0,,,,,,,,2016-03-03,2021-07-05,1,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40,G3, (1a) 00(1b) 00(3a)02 (3b)00 (4sb)00 (4d) 04(5) 00(6)01 (7) 01(8a)02 (9) 01(12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,10,2, R0 D2,,7.83,4.72,2.32,159.0,198.0,2.29,24.0,19.0,183.0,90.0,21.0,16.41,5.06,66.0,355.0,45.0,21.0,4.5,4.6,95.0,339.0,,,,,,,,,,,,,1.69,6.35,5.62, 未做,,, P0,H0, 未做, CD34 - CK + S-100-,,,,,64.0604467805519,1606060
1606769,宋成林,628964,男,78,T4a,N0,M0, ⅡB,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,25,中间型（int）,INFa,0.0,,,,,,,,2016-03-08,2019-10-05,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90 粘液腺癌（muc）10 Lauren肠型,G2, (1a) 01(1b)00 (3a)04 (3b)08 (4sb)01 (4d)07 (5)00 (6)01 (7)01 (8a) 02(8p)00 (9)00 (11p)00 (12a)00 4d及大弯软组织可见癌, L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre  ,80,55,10, R0 D2,,8.03,2.55,4.82,133.0,157.0,3.11,15.0,19.0,158.0,66.0,8.0,9.83,3.85,67.0,202.0,34.0,33.0,4.7,11.2,86.0,272.0,,,,,,,,,,,,,3.67,7.1,1.12, 阴性,无,, P0,H0, 未做, CK +,,,,,42.90407358738502,1606769
1606157,杜荣先,626219,男,57,T2,N2,M0, ⅡB,1,2,2.0,0.0,0.0,, 慢性炎症（+）,5.0,29,中间型（int）,INFc,0.0,,,,,,,,2016-03-03,2019-03-18,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)02 (3a)05 (3b)33 (4sb)12 (4d)05 (5)00 (6)15 (7)02 (8a)01 (9)00 (12a)02 (14v)01," L（幽门窦部）, 后Post, 小弯侧Less,",20,20,3, R0 D2+,,5.3,2.79,2.01,160.0,298.0,2.15,22.0,23.0,131.0,56.0,20.0,8.3,2.74,69.0,317.0,41.0,28.0,5.5,7.9,72.0,338.0,82.6,40.2,38.5,1.04,0.2,5.4,10.0,2.4,0.862,1.64,9.76,,1.48,9.1,2.69, 未做,无,, P0,H0, 未做, CK+,,,,,36.465177398160314,1606157
1607803,公淑琴,623534,女,67,T3,N3a,M0,ⅢB,1,3,2.0,1.0,,1.0, 慢性炎症（+）,15.0,27,中间型（int）,INFc,0.0,,,,,,,,2016-03-15,2019-02-01,2,XELOX*2,1.0,XELOX,,,,,,3, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a)24 (1b)11 (3a)23 (3b)01 (4sb)12 (4d)12 (5)00 (6)46 (7)12 (8a)22 (8p)14 (9)00 (11p)00 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",35,25,10, R0 D2,,5.76,1.83,3.1,128.0,162.0,2.91,30.0,36.0,170.0,90.0,37.0,10.71,2.97,74.0,263.0,38.0,36.0,6.7,6.2,92.0,232.0,,,,,,,,,,,,,2.79,16.04,7.53,,无, 无, P0,H0, 未做, CK+,,,,,34.59264126149803,1607803
1607125,蔡景辉,626207,男,46,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,12,,,0.0,,,,,,,,2016-03-10,2021-07-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a) 00(1b) 00(3a) 01(3b)02 (4sb) 00(4d)02 (5) 00(6) 02(7) 00(8a) 02(9) 01(12a)02," L（幽门窦部）, 前Ant,",10,8,, R0 D2,,6.81,3.64,2.43,172.0,242.0,2.8,51.0,39.0,171.0,72.0,27.0,12.77,4.93,79.0,386.0,44.0,35.0,6.1,5.7,100.0,363.0,,,,,,,,,,,,,0.944,7.61,2.57, 未做,,, P0,H0, 未做, CK +,,,,,63.69908015768725,1607125
1606586,葛文芝,629646,女,66,T4b,N1,M0, ⅢB,1,3,2.0,1.0,1.0,0.0, 慢性炎症（+）,1.0,23,髓样型（med）,INFa,0.0,0.9,,,,,,,2016-03-07,2022-09-01,1,,,XELOX,,,,,,7, 低分化腺癌（G3)60(por) 低粘附腺癌40,G3, (1a)01 (1b)00 (3a)02 (3b)00 (4sb)00 (4d) 04(5) 07(6)02 (7) 00(8a)12 (8p) 01(9)02 (11p)02 (12a)00," LM 前Ant, 后Post, 大弯侧Gre,",80,60,10,,R1,11.19,8.5,1.48,63.0,389.0,3.05,6.0,13.0,122.0,81.0,4.0,6.95,2.86,54.0,92.0,29.0,25.0,6.0,4.8,54.0,332.0,,,,,,,,,,,,,21.28,8.6,6.54,,无, 无, P0,H0, 未做, CK+ CD34+ S-100- CgA- Syn- CD56-,,,,,77.82522996057818,1606586
1606174,金英福,626874,男,59,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,0.0, 慢性炎症（+）,7.0,20,中间型（int）,INFa,0.0,,,,,,,,2016-03-03,2017-04-20,2,,,SOX,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)02 (3a)12 (3b)00 (4sb)00 (4d)14 (5)23 (6)11 (7)12 (8a)12 (8p)01 (9)00 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,30,15, R0 D2,,12.79,11.06,0.99,112.8,292.0,2.76,55.0,65.0,146.0,81.0,19.0,10.78,4.81,61.0,98.0,26.0,35.0,4.9,7.9,59.0,168.0,,,,,,,,,,,,,1.98,11.79,3.64, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,13.567674113009199,1606174
1606447,李淑珍,629268,女,66,T4b,N3a,M0, ⅢC,1,4,0.0,1.0,1.0,0.0, 肠化生+,13.0,22,中间型（int）,INFa,0.0,,,,,,,,2016-03-07,2017-03-15,2,,,奥沙利铂,奥沙利铂,,,,,2, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)22 (1b)13 (3a)04 (3b)00 (4sb)00 (4d)25 (5)33 (6)22 (7)33," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,2,,R1,16.02,14.59,0.77,105.0,234.0,4.66,16.0,18.0,163.0,69.0,7.0,6.03,2.47,71.0,134.0,38.0,33.0,6.0,6.0,76.0,170.0,,,,,,,,,,,,,3.28,36.17,12.91,,无, 无, P0,H0, 未做, CK+ CD34+  D2-40+,,,,,12.253613666228645,1606447
1606155,田亚财,629350,男,61,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,22,,,3.0,,,,,,,,2016-03-03,2021-07-06,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)03 (1b)02 (3a)04 (3b)00 (4sb)00 (4d)05 (5)00 (6)01 (7)01 (8a)01 (9)03 (11p)02," L（幽门窦部）, 后Post,",12,10,2, R0 D2,,7.1,2.34,3.67,149.0,149.0,2.9,22.0,21.0,210.0,87.0,18.0,10.67,3.76,79.0,242.0,39.0,40.0,5.4,5.0,65.0,373.0,,,,,,,,,,,,,1.53,5.86,1.54,,无, 无, P0,H0, 未做, CK+,,,,,64.09329829172141,1606155
1607345,王有,627666,男,75,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,2.0,32,中间型（int）,INFa,0.0,,,,,,,,2016-03-11,2019-06-01,2,,,卡培他滨单药口服,,,,,,1, 管状腺癌（低中分化【G2】【tub2】 Lauren肠型,G2, (1a) (1b)119 (3a) (3b)01 (4sb) (4d)05 (5)00 (6)12 (8a) (8p) (9)05," L（幽门窦部）, 前Ant,",20,20,5, R0 D2,,4.94,2.88,1.72,157.0,214.0,2.12,17.0,24.0,214.0,56.0,10.0,16.0,4.91,71.0,321.0,40.0,31.0,4.3,4.4,84.0,244.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK+ CD34-  D2-40- ,,,,,38.66622864651774,1607345
1606671,赵凤芹,629287,女,44,T3,N1,M0, ⅡB,1,3,2.0,0.0,,1.0, 慢性炎症（+）,1.0,44,中间型（int）,INFa,0.0,,,,,,,,2016-03-08,2017-07-20,0,,,FOLFOX,,,,,,4, 低粘附腺癌 Lauren弥漫型,GX, (4sb) (4d)014 (1a) (1b) (3a) (3b) (5)124 (6)00 (7)01 (8a) (8p)05," M（胃体部）, 前Ant,",55,50,8, R0 D2,,7.81,3.58,3.33,138.0,267.0,2.68,32.0,21.0,106.0,43.0,16.0,9.52,3.48,75.0,205.14,35.0,40.0,4.6,4.7,74.0,291.0,,,,,,,,,,,,,1.34,8.13,1.02,,无, 无, P0,H0, 未做, CK+,,,,,16.392904073587385,1606671
1607748,张存书,626674,男,59,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,31,中间型（int）,INFa,0.0,,,,,,,,2016-03-15,2021-06-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a) 01(1b) 02(2)03 (3a)02 (3b) 01(4sa) 03(4sb)00 (4d) 09(5)00 (6)02 (7) 03(8a)01 (8p) 01(9)03 (11p)00 (12a)00 (11d)00," LMU 前Ant, 后Post, 小弯侧Less,",60,50,15, R0 D2+,,8.68,3.08,4.58,140.0,169.0,3.27,10.0,15.0,126.0,82.0,12.0,9.39,2.95,64.0,323.0,35.0,29.0,4.7,6.6,90.0,414.0,,,,,,,,,,,,,2.59,17.44,2.53, 阳性+,,, P0,H0, 未做, CK + S-100- CD34-,,,,,62.54927726675427,1607748
1607186,葛士学,626426,男,65,T3,N3b,M0, ⅢC,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,22.0,33,中间型（int）,INFa,1.0,,,,,,,,2016-03-10,2019-01-23,2,,,XELOX,,,,,,6, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap） Lauren肠型,G2, (1a)11 (1b)00 (2)22 (3a)912 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)01 (6)02 (7)45 (8a)35 (8p)22 (9)12 (11p)11 (12a)00," EG SiewerⅠ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",55,40,7, R0 D2,,7.59,4.87,1.99,153.0,284.0,3.16,10.0,16.0,168.0,82.0,21.0,13.79,4.54,69.0,295.0,40.0,29.0,4.3,6.1,89.0,348.0,,,,,,,,,,,,,2.36,393.6,4.15,,无, 无, P0,H0, 未做,,,,,,34.46123521681997,1607186
1607424,张艳梅,613164,女,48,T1b,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,27,中间型（int）,INFa,2.0,,,,,,,,2016-03-11,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (4sb) (4d) (6)08 (1a) (1b) (3a) (3b) (5)018 (8a) (8p)01," L（幽门窦部）, 小弯侧Less,",20,20,, R0 D2,,9.28,5.82,2.71,143.0,176.0,1.95,19.0,21.0,145.0,63.0,9.0,7.65,2.86,70.0,246.0,37.0,33.0,5.2,6.3,86.0,239.0,,,,,,,,,,,,,4.17,15.77,7.45,,无, 无, P0,H0, 未做, CK+,,,,,77.69382391590013,1607424
1606768,黄贵玉,631058,男,52,T4b,N0,M0, ⅢA,1,2,2.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,26,中间型（int）,INFc,0.0,,,,,,,,2016-03-08,2021-06-01,1,,,XELOX,XELOX,XELOX,SOX,SOX,,5, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)02 (3b)08 (4sb)00 (4d)06 (5)00 (6)01 (7)02 (8a)01 (8p)02 (9)01 (11p)01 (12a)00 (14v)00 横结肠系膜01," L（幽门窦部）, 小弯侧Less,",35,35,8, R0 D2+,,9.85,7.83,1.25,148.0,235.0,2.85,8.0,13.0,100.0,62.0,13.0,9.65,4.11,65.0,256.0,34.0,31.0,5.8,4.45,89.0,261.0,,,,,,,,,,,,,,,,,无,, P0,H0, 未做, CK +,,,,,62.779237844940866,1606768
1606488,单志勋,629313,男,46,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,27,,,0.0,,,,,,,,2016-03-07,2021-07-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)01 (1b)00 (3a)01 (3b)02 (4sb)00 (4d)02 (5)00 (6)00 (7)05 (8a)04 (8p)02 (9)05 (11p)05 (12a)00," L（幽门窦部）, 小弯侧Less,",20,20,3, R0 D2+,,7.92,5.05,2.22,184.0,296.0,,40.0,31.0,175.0,76.0,87.0,23.92,9.33,82.0,337.0,43.0,39.0,5.5,4.2,95.0,318.0,,,,,,,,,,,,,1.44,19.57,0.75,,无,, P0,H0, 未做, CK +,,,,,63.79763469119579,1606488
1607627,李洪延,632002,男,65,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,5.0,45,中间型（int）,INFa,0.0,,,,,,,,2016-03-14,2018-05-01,0,,,SOX,SOX,SOX,,,,3, 低分化腺癌（G3)(por)80 乳头状癌（G1）（pap）20 Lauren肠型,G3, (1a)02 (1b)00 (3a)00 (3b)26 (4sb)00 (4d)07 (5)00 (6)00 (7)14 (8a)05 (8p)00 (9)08 (11p)210 (12a)00 (14v)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,15,,R1,6.13,4.14,1.2,80.0,405.0,4.03,10.0,15.0,99.0,58.0,7.0,4.93,2.6,59.0,134.0,30.0,29.0,6.3,2.87,85.0,303.0,,,,,,,,,,,,,2.9,28.7,1.67,,无,, P0,H0, 未做, CK +,,,,,25.558475689881732,1607627
1607489,孙德荣,626696,男,67,T2,N0,M0, ⅠB,1,1,0.0,0.0,0.0,0.0, 肠化生+,0.0,22,中间型（int）,INFa,1.0,,,,,,,,2016-03-14,2021-06-15,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)02 (3a) 04(3b)00 (4d) 08(5) 00(6) 00(7) 01(8a)02 (9) 01(11p) 02(12a)00 (12p)02," M（胃体部）, 前Ant,",25,25,8, R0 D2+,,5.56,2.04,2.85,140.0,199.0,1.9,14.0,20.0,169.0,67.0,8.0,19.86,7.77,68.0,296.0,68.0,26.0,4.2,4.8,113.0,289.0,,,,,,,,,,,,,2.38,7.72,1.36, 阳性+,,, P0,H0, 未做, CD34 + CK+ S-100 -,,,,,63.042049934296976,1607489
1608850,李景华,631402,男,56,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,2.0,21,中间型（int）,INFa,0.0,,,,,,,,2016-03-22,2021-06-15,1,,,XELOX,,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) 01(1b)01 (3a)18 (3b)03 (4sb)00 (4d)02 (5)11 (6)01 (7)01 (8a)00 (8p)01 (9)01 (11p)01 (12a)00, L（幽门窦部） 小弯侧Less ,30,25,7, R0 D2,,7.12,4.08,2.16,149.0,307.0,2.63,12.0,19.0,163.0,70.0,25.0,5.3,3.54,74.0,324.0,45.0,29.0,4.6,6.1,93.0,270.0,,,,,,,,,,,,,4.23,17.02,1.38, 阴性,无,, P0,H0, 未做, CK +,,,,,62.779237844940866,1608850
1607163,鞠彦平,631360,男,54,T1a,N1,M0, ⅠB,1,0,,,,,,1.0,18,,,0.0,,,,,,,,2016-03-10,2021-07-13,1,,,替吉奥,?,?,?,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)04 (3a)01 (3b)00 (4sb)13 (4d)01 (5)05 (6)00 (7)00 (8a)00 (8p)02 (9)00 (11p)02," L（幽门窦部）, 前Ant,",25,18,, R0 D2,,6.18,4.24,1.09,146.0,224.0,1.73,11.0,21.0,191.0,128.0,91.0,12.25,5.67,80.0,310.0,46.0,34.0,5.8,5.0,97.0,653.0,,,,,,,,,,,,,2.13,14.02,0.98,,无, 无, P0,H0, 未做, CK+,,,,,64.09329829172141,1607163
1607403,马义,631137,男,59,T4b,N3b,M0, ⅢC,1,3,2.0,1.0,,1.0, 慢性炎症（+）,20.0,33,中间型（int）,INFc,0.0,,,,,,,,2016-03-11,2017-12-30,2,,,奥沙利铂,,,,,,1, 低粘附腺癌95 低分化腺癌（G3)(por)5 Lauren弥漫型,G3, (3a) (3b)22 (4sb) (4d)55 (6)33 (7) (8a) (8p) (9)313 (1a) (1b)44," L（幽门窦部）, 前Ant,",60,55,15, R0 D2,,9.52,5.5,2.64,162.0,241.0,4.43,17.0,28.0,188.0,81.0,10.0,6.68,2.23,71.0,241.0,44.0,27.0,4.9,4.2,80.0,182.0,,,,,,,,,,,,,2.93,6.79,2.31,,无, 无, P0,H0, 未做, CK+,,,,,21.64914586070959,1607403
1607633,金玉华,631468,女,59,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,7.0,30,中间型（int）,INFa,0.0,,,,,,,,2016-03-14,2022-09-01,1,,,卡培他滨单药口服,,,,,,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)03 (3a)36 (3b)00 (4sb)01 (4d)01 (5)00 (6)03 (7)25 (8a)00 (8p)01 (9)01 (11p)01 (12a)23,LM 小弯侧Less 前Ant 后Post ,70,50,15, R0 D2,,7.76,5.01,1.82,102.0,318.0,3.93,23.0,29.0,208.0,105.0,32.0,8.0,2.45,79.0,281.0,47.0,32.0,7.5,3.8,68.0,445.0,59.9,36.0,19.0,1.89,0.1,13.7,23.7,1.1,0.615,4.58,12.2,,12.01,16.03,0.886, 阳性+,无,, P0,H0, 未做, CK +,,,,,77.59526938239159,1607633
1607530,魏畔林,633496,男,63,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,18,,,0.0,,,,,,,,2016-03-14,2021-06-08,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)04 (3a) 00(3b)01 (4sb)00 (4d)02 (5)01 (6)00 (8a)03 (8p)04 (9)01 (11p)00," L（幽门窦部）, 前Ant,",20,20,5, R0 D2,,7.24,3.78,2.57,137.0,181.0,2.61,36.0,34.0,172.0,84.0,108.0,10.34,4.07,72.0,328.0,48.0,24.0,5.7,7.8,102.0,383.0,41.6,24.7,12.0,2.06,0.3,8.1,47.1,4.8,2.05,2.58,8.56,,2.5,7.73,4.41, 阴性,无,, P0,H0,, CK +,,,,,62.81208935611038,1607530
1607708,汪新功,631385,男,68,T1b,N0,M0,ⅠA,1,0,,1.0,1.0,0.0,,0.0,24,,,0.0,,,,,,,,2016-03-15,2021-07-01,1,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30,G3, (1a)02 (1b)02 (3a)03 (3b)00 (4sb)00 (4d)02 (5)00 (6)04 (7)03 (8a)02 (8p)02 (9)02 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",25,25,3, R0 D2+,,4.44,1.86,1.99,132.8,216.0,3.33,9.0,14.0,151.0,78.0,12.0,7.96,3.14,65.0,190.0,40.0,25.0,5.2,8.7,89.0,287.0,,,,,,,,,,,,,1.55,11.56,1.46, 阴性,无,, P0,H0, 未做, CK +,,,,,63.53482260183968,1607708
1607532,曹丽霞,472926,女,57,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,22,,,0.0,,,,,,,,2016-03-14,2020-09-23,0,,,,,,,,,0, 低粘附腺癌,GX, (1a)04 (1b) 02(3a)09 (3b)00 (4sb)05 (4d) 00(5) 00(6)02 (7)00 (8a)00 (8p) 00(9) 00(11p)00 (12a)00," M（胃体部）, 前Ant,",15,15,, R0 D2,,4.91,2.19,2.27,94.2,311.0,2.56,44.0,52.0,168.0,101.0,17.0,8.76,2.64,79.0,260.0,43.0,36.0,5.2,4.6,70.0,329.0,,,,,,,,,,,,,1.56,17.9,8.76, 未做,无, 无, P0,H0, 未做, CK+,,,,,54.33639947437582,1607532
1607635,赵淑仙,633526,女,68,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,31,,,0.0,,,,,,,,2016-03-14,2021-08-11,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20,G3, (1a)01 (1b)01 (3a)012 (3b)00 (4sb)03 (4d)04 (5)00 (6)03 (7)02 (8a)01 (8p)02 (9)01 (11p)00 (12a)01," M（胃体部）, 大弯侧Gre,",20,10,5, R0 D2+,,6.87,4.26,1.89,126.3,221.0,2.36,13.0,23.0,167.0,105.0,71.0,16.82,5.66,71.0,250.0,43.0,28.0,6.3,5.1,84.0,271.0,,,,,,,,,,,,,2.48,30.81,1.65,,无, 无, P0,H0, 未做, CK+,,,,,64.91458607095926,1607635
1607928,邹兴波,631533,男,43,T4b,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,21.0,30,中间型（int）,INFb,0.0,,,,,,,,2016-03-16,2019-03-01,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,小弯55 (1a)03 (1b)00 (3a)11 (3b)00 (4sb)00 (4d)99 (5)00 (6)22 (7)22 (8a)12 (8p)01 (9)02 (11p)12 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",65,50,5, R0 D2+,,7.45,4.44,2.5,157.2,240.0,3.2,14.0,21.0,183.0,113.0,12.0,15.17,4.51,74.0,357.0,46.0,28.0,6.6,7.8,105.0,410.0,,,,,,,,,,,,,1.27,10.73,6.1,,无,, P0,H0, 未做, CK +,,,,,35.4796320630749,1607928
1608551,曹喜路,631481,男,56,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,27,,,,,,,,,,,2016-03-21,2019-09-19,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)05 (1b)01 (2)02 (3a)01 (3b)01 (4sb)00 (4d)05 (5)03 (6)02 (7)00 (8a、8p)01 (9)04 (11p)01 (12a)01 (14v)00," L（幽门窦部）, 小弯侧Less,",25,,, R0 D2+,,4.9,2.1,2.02,110.3,109.0,1.84,28.0,26.0,129.0,81.0,49.0,8.81,3.52,72.0,219.0,42.0,30.0,6.1,6.4,100.0,328.0,,,,,,,,,,,,,3.11,20.76,0.807, 阳性+++,无,, P0,H0, 未做,,,,,,41.95137976346912,1608551
1608060,赵世国,633035,男,61,T1b,N0,M0,ⅠA,1,0,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,30,中间型（int）,INFa,1.0,,,,,,,,2016-03-16,2022-09-01,1,,,,,,,,,0, 粘液腺癌（muc）60 管状腺癌（中分化【G2】【tub2】40 Lauren肠型,G2, (1a)03 (1b)03 (3a)08 (3b)03 (4sb)03 (4d)02 (5)00 (6)11 (7)02 (8a)03 (8p)01 (9)00 (11p)01 (12a)00," L（幽门窦部）, 前Ant,",40,30,15, R0 D2,,9.31,5.36,2.73,121.0,110.0,3.76,20.0,30.0,123.0,129.0,309.0,13.78,6.78,74.0,300.0,44.0,30.0,5.1,5.8,85.0,532.0,68.2,47.4,18.0,2.63,0.2,7.3,21.2,1.8,2.55,3.7,10.7,,1.66,23.68,1.22, 阳性+,无,, P0,H0, 未做, CK +,,,,,77.52956636005256,1608060
1607699,孙忠学,626454,男,62,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,21,,,1.0,,,,,,,,2016-03-15,2021-08-16,1,,,,,,,,,0, 高级别上皮内瘤变 管状腺癌（高分化【G1】【tub1】）,G1, (1a)02 (1b)02 (3a)01 (3b)00 (4sb)00 (4d)06 (5)01 (6)00 (7)03 (8a)02 (8p)00 (9)01 (11p)00 (12a)03," L（幽门窦部）, 小弯侧Less,",15,15,2, R0 D2,,4.91,3.13,1.27,156.6,152.0,2.23,21.0,23.0,154.0,73.0,18.0,19.15,5.25,70.0,312.0,46.0,24.0,5.3,4.5,67.0,442.0,,,,,,,,,,,,,1.09,13.11,0.972,,无, 无, P0,H0, 未做, CK+,,,,,65.04599211563732,1607699
1607709,王威宁,632977,女,56,T3,N0,M0, ⅡA,1,3,2.0,1.0,1.0,0.0, 慢性炎症（+）,0.0,33,中间型（int）,INFb,0.0,,,,,,,,2016-03-15,2021-06-01,1,,,替吉奥单药,,,,,,7, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)03 (3b)01 (4sb)00 (4d)05 (5)00 (6)07 (7)01 (8a)05 (8p)04 (9)03 (11p)04 (12a)00," L（幽门窦部）, 前Ant,",30,30,12, R0 D2,,4.83,3.0,1.42,137.6,228.0,2.95,14.0,20.0,184.0,69.0,15.0,13.75,4.98,74.0,357.0,47.0,27.0,5.1,7.8,65.0,279.0,67.2,42.4,18.8,2.26,0.1,12.8,18.3,1.4,1.95,1.85,9.83,,0.911,9.81,1.14, 未做,无,, P0,H0, 未做, CK +,,,,,62.54927726675427,1607709
1609073,董树林,630951,男,70,T2,N2,M0, ⅡB,1,2,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,4.0,14,中间型（int）,INFa,0.0,,,,,,,,2016-03-23,2017-11-15,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)02 (3a)11 (3b)00 (4sb)00 (4d)14 (5)00 (6)11 (7)01 (8a)11 (8p)00 (9)02 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",30,25,10, R0 D2,,8.2,4.6,2.36,151.4,258.0,4.0,19.0,22.0,162.0,83.0,20.0,12.09,5.65,74.0,227.0,41.0,33.0,6.1,6.6,116.0,365.0,,,,,,,,,,,,,2.48,16.85,2.94,,无, 无, P0,H0, 未做, CK+,,,,,19.776609724047304,1609073
1608355,刘长库,633032,男,73,T3,N2,M0, ⅢA,1,3,0.0,1.0,,1.0, 慢性炎症（+）,4.0,26,中间型（int）,INFa,1.0,,,,,,,,2016-03-18,2019-12-04,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (3a) (3b) (5)09 (4sa)(4sb) (4d) (6)06 (11d)01 (12a)01 (15)00 (1a) (1b) (2)49 ," GE, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,15, R0 D2,,6.36,3.72,2.07,143.7,177.0,3.07,17.0,19.0,156.0,66.0,13.0,9.74,3.23,68.0,232.0,43.0,25.0,5.0,6.5,110.0,228.0,,,,,,,,,,,,,2.7,12.88,1.85, 未做,无, 无, P0,H0, 未做, CK+,,,,,44.546649145860705,1608355
1608132,盛百芹,627205,女,62,T3,N2,M0, ⅢA,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+）,3.0,22,中间型（int）,INFb,0.0,,,,,,,,2016-03-17,2017-02-13,2,XELOX*1,1.0,,,,,,,0, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren弥漫型,G3, (1a)01 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)15 (5)11 (6)12 (7)02 (8a)01 (8p)04 (9)01 (11p)03 (12a)00," L（幽门窦部）, 前Ant,",40,38,15, R0 D2,,5.66,3.24,1.67,109.7,192.0,3.13,18.0,29.0,170.0,67.0,10.0,10.83,4.81,62.0,189.0,39.0,23.0,5.2,5.8,75.0,246.0,,,,,,,,,,,,,6.39,294.6,106.0, 未做,无, 无, P0,H0, 未做, CK+ CD34— S-100+ D2-40 -,,,,,10.939553219448094,1608132
1608184,李宝亮,633027,男,31,T3,N1,M0, ⅡB,1,2,1.0,1.0,,1.0, 慢性炎症（+）,1.0,31,中间型（int）,INFb,0.0,,,,,,,,2016-03-18,2021-06-01,1,,,XELOX,XELOX,,,,,2, 低粘附腺癌70 低分化腺癌（G3)(por)25 粘液腺癌（muc）5 Lauren混合型,G3, (1a)00 (1b)00 (3a)12 (3b)01 (4sb)00 (4d)04 (5)01 (6)01 (7)01 (8a)05 (8p)05 (9)05 (11p)01 (12a)02," L（幽门窦部）, 小弯侧Less,",22,20,8, R0 D2,,6.89,4.17,1.96,159.0,234.0,1.98,58.0,25.0,145.0,125.0,40.0,9.76,3.72,68.0,337.0,45.0,23.0,4.9,6.7,90.0,371.0,,,,,,,,,,,,,1.41,7.16,3.48, 未做,无, 无, P0,H0, 未做, CK+,,,,,62.450722733245726,1608184
1608353,蔡建民,626470,男,47,T3,N0,M0, ⅡA,1,2,0.0,1.0,,1.0, 慢性炎症（+）,0.0,22,中间型（int）,INFa,0.0,,,,,,,,2016-03-18,2021-06-01,1,,,SOX,,,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70%， 粘液腺癌（muc）30% Lauren肠型,G3, (1a)03 (1b)00 (3a)05 (3b)00 (4sb)00 (4d)02 (5)01 (6)01 (7)02 (8a) (8p)02 (9)00 (11p)05，（大网 ）01," L（幽门窦部）, 前Ant, 小弯侧Less,",60,60,20, R0 D2,,6.62,4.23,1.67,131.0,250.0,2.85,30.0,20.0,126.0,101.0,17.3,8.71,2.86,6.9,176.0,40.0,26.9,4.7,5.04,83.0,208.0,68.0,37.4,28.1,1.33,0.1,9.8,21.3,1.5,1.11,2.98,0.154,5.12,1.89,10.19,11.14, 阴性,无, 无, P0,H0, 未做, CK+， CD34，D2-40(脉管染色)， S-100（脉管瘤栓及神经侵犯）,,,,,62.450722733245726,1608353
1608734,程宪美,626652,男,67,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+） 肠化生+,0.0,34,中间型（int）,INFa,0.0,,,,,,,,2016-03-22,2021-06-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a) 01(3a)09 (3b)00 (4sb) (4d)01 (5)00 (6) 02(7) 02(8a)02 (9) 02(11p) 02(12a)00小弯02," M（胃体部）, 小弯侧Less,",30,20,12, R0 D2+,,5.83,2.29,3.03,133.0,213.0,1.72,29.0,29.0,159.0,61.0,16.0,15.07,4.92,70.0,255.0,42.0,28.0,4.3,6.9,86.0,229.0,77.5,69.5,6.8,10.2,0.1,6.0,15.8,0.5,0.766,2.72,13.1,,2.19,7.44,1.09,阴性,,, P0,H0, 未做, CK + CD34- S-100-,,,,,62.516425755584756,1608734
1608732,刘克俭,631440,男,79,T3,N2,M0, ⅢA,1,2,0.0,0.0,,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,3.0,26,中间型（int）,INFa,3.0,,,,,,,,2016-03-22,2017-05-15,2,,,,,,,,,0, 粘液腺癌（muc）70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30,G3, (1a)02 (1b)04 (3a)00 (3b)04 (4sb)00 (4d)04 (5)0 (6)24 (7)03 (8a)14  (9)01 (11p)00 (12a)00 (14v)00," L（幽门窦部）, 前Ant, 小弯侧Less,",40,30,10, R0 D2,,4.29,2.85,0.93,86.0,333.0,2.6,9.0,13.0,115.0,31.0,7.0,6.76,0.0,47.0,131.0,27.0,20.0,4.9,4.4,91.0,210.0,,,,,,,,,,,,,5.01,23.81,3.36, 阴性,无, 无, P0,H0, 未做, CK+,,,,,13.764783180026281,1608732
1608675,宋金铭,631188,男,62,T3,N1,M0, ⅡB,1,3,0.0,0.0,,0.0, 慢性炎症（+）,1.0,66,中间型（int）,INFa,1.0,,,,,,,,2016-03-21,2018-06-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)02 (1b)03 (2)03 (3a)115 (3b)04 (4sa)05 (4sb)03 (4d)05 (5)00 (6)02 (7)03 (8a)03 (8p)01 (9)02 (10)07 (11p)01 (12a)01 (12p)02 (16b1)04," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,60,50, R0 D2+,,8.34,6.18,1.47,92.0,317.0,3.72,13.0,17.0,147.0,61.0,26.0,12.24,5.03,59.0,126.0,32.0,27.0,4.8,7.9,77.0,308.0,,,,,,,,,,,,,0.37,5.95,2.14,,无, 无, P0,H0, 未做, CK+,,,,,26.346911957950066,1608675
1608508,赵万波,626640,男,63,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,24,髓样型（med）,INFa,1.0,,,,,,,,2016-03-21,2021-06-08,1,,,奥沙利铂,,,,,,1, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】30 Lauren肠型,G2, (1a)01 (1b)00 (2)03 (3a)04 (3b)02 (4sa) (4sb) (4d)01 (7)04 (8a)02 (8p)03 (9)02 (11p)02," L（幽门窦部）, 后Post, 大弯侧Gre,",80,50,50, R0 D2,,8.07,5.86,1.46,52.0,309.0,3.33,14.0,15.0,108.0,65.0,18.0,4.75,1.67,61.0,164.0,35.0,26.0,8.1,7.1,70.0,197.0,,,,,,,,,,,,,2.3,738.5,47.66,,无, 无, P0,H0, 未做, CK+ CD34-  D2-40-  S-100-,,,,,62.582128777923785,1608508
1608240,李万金,631553,男,52,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,17,中间型（int）,INFa,0.0,,,,,,,,2016-03-17,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)01 (3a)00 (3b)00 (4sb)02 (4d)05 (5)00 (6)02 (7)02 (8a)01 (8p)01 (9)02 (11p)00 (12a)01," L（幽门窦部）, 前Ant,",40,30,6, R0,,6.3,3.67,2.08,148.0,191.0,3.07,22.0,24.0,151.0,71.0,41.0,11.93,3.92,63.0,341.0,42.0,21.0,4.3,5.6,80.0,484.0,,,,,,,,,,,,,2.34,8.83,0.727, 阴性,无, 无, P0,H0, 未做, CK+ CD34- S-100-,,,,,77.49671484888304,1608240
1608434,孙晓红,633533,女,39,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,17,,,0.0,,,,,,,,2016-03-18,2021-07-20,1,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40,G3, (3a) (3b) (7) (8a) (8p) (9)015 (4sb)01 (5)01 (6)00," L（幽门窦部）, 前Ant,",15,10,, R0 D2,,8.17,5.4,2.12,143.2,265.0,2.72,17.0,22.0,159.0,51.0,25.0,14.5,4.7,75.0,357.0,49.0,26.0,5.6,9.9,69.0,316.0,,,,,,,,,,,,,0.818,25.55,1.18,阴性,无, 无, P0,H0, 未做, CK+,,,,,64.0604467805519,1608434
1608846,闫立波,631205,男,55,T4b,N1,M0, ⅢB,1,2,0.0,0.0,,1.0, 肠化生+,1.0,18,中间型（int）,INFa,1.0,,,,,,,,2016-03-22,2017-07-06,2,,,XELOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)02 (5)00 (6)14 (7)04 (8a) (8p)01 (9)03 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,70,8,,R1,1084.0,7.95,2.07,142.0,320.0,4.43,17.0,22.0,144.0,124.0,14.0,9.16,199.0,60.0,199.0,40.0,20.0,5.4,3.6,81.0,367.0,76.7,50.9,18.3,2.78,1.1,11.9,9.6,2.1,7.1,2.37,9.37,,12.66,8.42,3.21, 阴性,无, 无, P0,H0, 未做, CK+， CD34，D2-40(未见脉管瘤栓)，S-100(可见神经侵犯),,,,,15.473061760840999,1608846
1608554,胡殿武,631363,男,59,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,26,,,1.0,,,,,,,,2016-03-21,2021-07-05,1,,,,,,,,,0, 低分化腺癌（G3)(por)60 低粘附腺癌40,G3, (1a)06 (1b) 01(2)03 (3a)02 (3b) 01(4sa)00 (4sb)0 0(4d)01 (5) 01(7)01 (8a)05 (8p)02 (9) 02(11p)03," U（胃底部）, 小弯侧Less,",15,,, R0 D2+,,9.89,5.97,2.88,142.4,230.0,3.2,15.0,17.0,150.0,88.0,20.0,6.82,2.23,67.0,289.0,41.0,26.0,4.9,6.3,86.0,344.0,62.7,30.6,24.5,1.25,0.1,22.7,13.2,1.8,0.883,1.86,9.57,,2.66,12.24,0.826, 阴性,,,,H0, 未做, CK +,,,,,63.469119579500656,1608554
1608776,徐丽华,631216,女,55,T3,N0,M0, ⅡA,1,3,2.0,0.0,,1.0, 慢性炎症（+）,0.0,22,中间型（int）,INFc,0.0,,,,,,,,2016-03-22,2021-07-12,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,卡培他滨,7, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)02 (3a)03 (3b)02 (4sb)00 (4d)00 (5)00 (6)03 (7)08 (8a)00 (8p)03 (9)01 (11p)00 (12a)00," LM 小弯侧Less,",40,40,15, R0 D2,,6.72,4.55,1.56,105.7,227.0,3.9,11.0,15.0,168.0,85.0,7.0,10.59,3.85,64.0,176.0,38.0,26.0,5.5,2.7,70.0,192.0,,,,,,,,,,,,,0.907,6.54,1.23,,无, 无, P0,H0, 未做, CK+,,,,,63.66622864651774,1608776
1608658,李守荣,631377,男,55,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,16,,,0.0,,,,,,,,2016-03-21,2021-07-06,1,,,,,,,,,0, 高级别上皮内瘤变 管状腺癌（高分化【G1】【tub1】）,G1, (1a)03 (1b)01 (3a)00 (3b)01 (4sb)00 (4d)01 (5)01 (6)03 (7)01 (8a)00 (8p)02 (9)00 (11p)01 (12a)02," L（幽门窦部）, 前Ant,",15,15,3, R0 D2,,5.02,3.13,1.38,153.6,180.0,2.2,49.0,32.0,160.0,74.0,21.0,30.42,8.43,67.0,405.0,41.0,26.0,5.0,5.9,87.0,309.0,,,,,,,,,,,,,0.659,6.04,9.92,,无, 无, P0,H0, 未做, CK+,,,,,63.50197109067017,1608658
1608775,苗长友,631637,男,62,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,13,,,0.0,,,,,,,,2016-03-22,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)02 (1b)00 (2)01 (3a)08 (3b)00 (4sa)00 (4sb)01 (4d)00 (7)01," 前Ant, U（胃底部）,",25,10,, R0 D1,,6.58,3.17,2.13,166.0,213.0,2.7,27.0,27.0,176.0,101.0,30.0,15.61,6.23,81.0,342.0,51.0,30.0,6.4,8.6,92.0,394.0,,,,,,,,,,,,,1.11,7.14,1.21, 阴性,无, 无, P0,H0, 未做, CK+,,,,,77.33245729303547,1608775
1609528,徐道清,626659,男,78,T4a,N1,M0, ⅢA,1,2,0.0,1.0,,1.0, 慢性炎症（+）,2.0,9,中间型（int）,INFa,0.0,,,,,,,,2016-03-25,2017-03-15,2,,,口服替吉奥,,,,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren肠型,G3, (6)00 游离脂肪内淋巴结29," L（幽门窦部）, 大弯侧Gre,",38,20,6, R0 D2,,7.62,4.83,2.19,155.5,258.0,3.75,38.0,27.0,140.0,77.0,14.0,15.78,5.75,72.0,272.0,46.0,26.0,6.1,8.8,70.0,260.0,,,,,,,,,,,,,1.11,33.22,0.92,,无, 无, P0,H0, 未做, CK+,,,,,11.662286465177397,1609528
1609003,王秀芝,632722,女,61,T4b,N3b,M1, Ⅳ,1,3,1.0,1.0,1.0,1.0, 正常,16.0,31,中间型（int）,INFa,0.0,,,,,,,,2016-03-23,2016-09-15,2,,,,,,,,,0, 粘液腺癌（muc）60 低分化腺癌（G3)(por) 20低粘附腺癌20 Lauren混合型,G3, (1a)22 (1b)23 (3a)01 (3b)46 (4sb)00 (4d)111 (6)67 (14v)11 软组织可见癌," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",40,35,8,,R2,8.17,3.78,3.8,122.0,285.0,3.03,24.0,20.0,164.0,80.0,8.0,11.07,4.07,8.0,218.0,42.0,26.0,5.0,3.2,73.0,261.0,68.0,37.4,28.1,1.33,0.1,9.8,21.3,1.5,0.154,1.11,2.98,,19.72,636.1,300.0, 阴性,无, 无, P0,H0, 未做, CK+,,,,,5.781865965834428,1609003
1609815,袁忠泽,626610,男,64,T4b,N1,M0, ⅢB,1,2,1.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,1.0,28,中间型（int）,INFc,0.0,,,,,,,,2016-03-29,2017-05-16,2,,,卡培他滨,,,,,,2, 低粘附腺癌 70低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)01 (1b)00 (3a)16 (4sa)02 (4sb)01 (5)00  (7)03 (8a)02 (8p)02 (9)02 (11p)01 (12a)01 (2)07 (3b)16 (20)00," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",95,80,15, R0 D2,,9.12,4.73,3.68,141.0,271.0,3.48,23.0,23.0,152.0,70.0,31.0,9.52,3.67,72.0,248.0,42.0,30.0,5.7,6.7,89.0,473.0,51.7,32.5,15.7,2.07,0.2,11.9,32.4,1.4,3.33,10.4,1.04,,2.8,2.49,1.01, 阴性,无, 无, P0,H0, 未做, CK+ CD34， D2-40可见脉管瘤栓，  S-100神经染色可见,,,,,13.567674113009199,1609815
1610688,夏传玉,629423,男,70,T2,N0,M0, ⅠB,1,2,,,,,,0.0,29,,,3.0,,,,,,,,2016-04-05,2022-09-01,1,,,口服替吉奥,,,,,,1, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）,G2, (1a)03 (1b)02 (3a)04 (3b)00 (4sb)02 (4d)06 (5)00 (6)00 (7)03 (8a)03 (8p)02 (9)02 (11p)02," M（胃体部）, 后Post,",30,30,10, R0 D2,,7.6,4.26,2.36,146.0,252.0,4.69,22.0,23.0,154.0,98.0,19.0,13.94,4.5,76.0,274.0,44.0,32.0,4.5,7.0,77.0,417.0,71.1,41.5,26.2,1.58,0.3,10.7,14.9,3.6,1.71,3.68,12.9,,11.14,3.63,2.79, 阴性,无, 无, P0,H0, 未做, CK+,,,,,76.87253613666228,1610688
1609689,庞连江,631271,男,69,T3,N3a,M0,ⅢB,1,3,0.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,9.0,25,中间型（int）,INFa,1.0,,,,,,,,2016-03-28,2016-11-11,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 粘液腺癌（muc）30 Lauren肠型,G3, (1a)00 (1b)02 (3a)15 (3b)00 (4sa)01 (4sb)03 (4d)02 (5)00 (6)01 (7)55 (8a)01 (8p)11 (9)22 (11p)02 (12a)00 (14v)00," M（胃体部）, 小弯侧Less,",30,20,15, R0 D2,,5.87,2.65,2.45,128.0,258.0,3.13,25.0,24.0,133.0,71.0,9.0,11.57,3.69,64.0,236.0,41.0,23.0,4.5,6.7,73.0,292.0,,,,,,,,,,,,,55.7,12.21,6.45, 阳性+,无, 无, P0,H0, 未做, CK+,,,,,7.490144546649145,1609689
1610501,张静,632796,女,53,T4b,N2,M0, ⅢB,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,4.0,20,中间型（int）,INFc,0.0,,,,,,,,2016-04-01,2017-08-02,2,,,XELOX,,,,,,6, 粘液腺癌（muc）50 低粘附腺癌50 Lauren弥漫型,GX, (1a)01 (1b)00 (3a)25 (3b)00 (4sb)00 (4d)27 (5)01 (6)00 (7)02 (8a)01 (8p)02 (9)00 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,15, R0 D2+,,6.0,43.8,2.63,129.0,362.0,3.23,13.0,15.0,164.0,76.0,10.0,7.45,2.67,70.0,367.0,40.0,30.0,5.1,3.2,79.0,311.0,84.8,34.7,41.2,41.2,1.9,4.2,9.2,3.8,3.03,2.42,9.97,,2.75,667.6,111.6, 未做,无, 无, P0,H0, 未做, CK +,,,,,16.031537450722734,1610501
1609681,王继善,633360,男,78,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,0.0, 正常,1.0,17,中间型（int）,INFa,0.0,,,,,,,,2016-03-28,2020-05-19,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 粘液腺癌（muc）30 Lauren肠型,G3, (1a)01 (1b)00 (3a)01 (3b)01 (4sb)00 (4d)01 (5)02 (6)01 (7)03 (8a)11 (8p) (9)05 (11p)01 (12a)00 6组 软组织可见癌," L（幽门窦部）, 小弯侧Less, 前Ant,",50,40,10, R0 D2,,6.2,44.7,31.5,111.0,237.0,3.03,33.0,28.0,134.0,74.0,16.0,6.64,2.33,65.0,279.0,39.0,26.0,5.7,7.9,63.0,336.0,71.8,34.0,28.0,1.21,0.5,7.9,17.1,2.9,0.568,2.29,1.9,,1.66,7.36,6.53,阳性+,无,, P0,H0, 未做, CK +,,,,,49.70433639947437,1609681
1609859,赵先瑞,631053,男,63,T2,N0,M0, ⅠB,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,43,中间型（int）,INFb,0.0,,,,,,,,2016-03-29,2021-09-02,1,,,,,,,,,0, 低粘附腺癌,GX, (1a) 02(1b)03 (3a)07 (3b) 00(4sb)03 (4d)08 (5)02 (6) 010(7) 02(8a)01 (8p)02 (9)01 (11p)01 (12a)00小弯01," L（幽门窦部）, 大弯侧Gre, 后Post, 小弯侧Less,",20,20,6, R0 D2+,,7.45,4.33,2.48,149.0,235.0,3.13,26.0,28.0,173.0,64.0,12.0,19.05,6.97,71.0,254.0,43.0,28.0,4.2,7.4,76.0,283.0,67.4,36.2,28.7,1.26,0.1,12.2,17.2,4.6,1.01,1.92,9.9,,2.54,23.45,0.784, 阴性,,, P0,H0, 未做, CK + CD34- S-100-,,,,,65.14454664914585,1609859
1609951,陈全平,629452,男,49,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,3.0,19,中间型（int）,INFa,0.0,,,,,,,,2016-03-29,2021-05-21,1,,,FOLFOX,,,,,,6, 粘液腺癌（muc）70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30,G3, (1a) 00(1b)00 (3a)05 (3b) 01(4sb) 01(4d) 02(5)00 (6)14 (7)01 (8a)12 (9)00 (11p) 02(12a)00 (12p)11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",50,25,5, R0 D2+,,7.59,4.14,2.6,159.0,320.0,2.37,54.0,33.0,184.0,92.0,40.0,13.32,4.22,71.0,345.0,47.0,24.0,5.3,4.5,69.0,374.0,57.5,39.5,14.5,2.72,0.1,9.3,31.2,1.4,0.589,2.39,7.49,,1.28,25.53,7.55, 阳性+,,, P0,H0, 未做, CK + CD34- S-100-,,,,,61.727989487516425,1609951
1610126,李宏伟,626611,男,49,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,2.0,21,中间型（int）,INFa,1.0,,,,,,,,2016-03-30,2018-01-03,2,,,XELOX,,,,,,4, 低分化腺癌（G3)(por),G3, (1a)02 (1b)12 (3a) 02(3b)02 (4sa) 00(4sb)00 (4d) 02(5)00 (6) 04(7)01 (8a) 01(8p)02 (9) 03(11p) 01(12a)00 (2)11," UM 前Ant, 后Post, 小弯侧Less,",50,45,10, R0 D2+,,9.69,6.39,2.34,82.0,630.0,3.33,24.0,22.0,190.0,63.0,42.0,16.27,5.88,58.0,212.0,36.0,22.0,5.5,3.1,67.0,232.0,83.4,45.6,28.0,1.63,1.0,5.3,7.4,0.6,1.79,1.88,11.6,,6.01,15.55,1.35, 阴性,,, P0,H0, 未做, CK + CD34+ S-100+,,,,,21.156373193166885,1610126
1610377,董江东,633984,男,62,T1a,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,36,,,1.0,,,,,,,,2016-03-31,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (3a)06 (3b)00 (4sb)00 (4d)03 (5)01 (6)08 (7)05 (8a)01 (8p)04 (9)03 (11p)01 (12a)01, L（幽门窦部） 小弯侧Less ,18,18,5, R0 D2,,6.95,52.14,33.27,165.3,277.0,2.44,16.0,18.0,151.0,68.0,13.0,17.01,5.85,71.0,399.0,44.0,27.0,4.8,7.9,85.0,347.0,68.2,36.3,22.3,1.63,0.4,10.7,17.2,2.1,1.39,1.55,10.4,,2.02,11.62,0.842, 阴性,无,, P0,H0, 未做, CK +,,,,,77.03679369250985,1610377
1609740,邓忠,633418,男,50,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 异型增生+,13.0,49,中间型（int）,INFa,0.0,,,,,,,,2016-03-29,2018-08-14,2,,,,,,,,,0, 低分化腺癌（G3)(por)75 低粘附腺癌25 Lauren混合型,G3, (1a)01  (3a)77 (3b)00 (4sb)00 (4d)34 (5)00 (6)29 (7)05 (8a)07 (8p)04 (9)03 (11p)03 (12a)00 (12p)13 (14v)03,LM 前Ant 后Post 大弯侧Gre  小弯侧Less ,40,40,5,R0 D2+,,7.36,3.72,2.76,155.0,249.0,3.23,165.0,95.0,139.0,99.0,97.2,16.18,6.2,70.9,144.81,44.0,26.9,4.8,3.72,74.0,306.0,62.6,32.7,26.7,1.22,0.2,17.3,17.3,1.0,1.45,1.94,11.5,,2.66,14.43,0.75, 阴性,无,, P0,H0, 未做, CK+， CD34+ S-100+，D2-40+,,,,,28.515111695137975,1609740
1609917,关秀艳,633558,女,72,T4a,N3a,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,15.0,40,中间型（int）,INFa,0.0,,,,,,,,2016-03-29,2020-06-09,0,,,,,,,,,0, 低中分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)13 (3a)49 (3b)11 (4sb)00 (4d)37 (6)44 (7)01 (8a)11 (8p)02 (9)07 (11p)14,L（幽门窦部） 前Ant 小弯侧Less 后Post ,40,40,13,,R1,4.25,2.7,1.1,111.2,219.0,2.97,8.0,16.0,151.0,64.0,8.0,5.21,2.85,61.0,95.0,39.0,22.0,6.6,8.3,60.0,177.0,50.4,30.4,9.2,3.3,0.2,18.9,28.4,1.1,1.58,2.68,7.03,,3.64,13.06,3.14, 阴性,无, 无, P0,H0, 未做, CK + ，CD34+ S-100+，D2-40+,,,,,50.36136662286465,1609917
1609949,张玉峰,631122,男,53,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,25.0,27,中间型（int）,INFa,0.0,,,,,,,,2016-03-29,2020-02-23,2,,,SOX,,,,,,8, 中低分化腺癌（G3)(por) Lauren肠型,G3, (1a)11 (1b) 11(3a)11 (3b)34 (4d) 67(6)22 (7)33," M（胃体部）, 后Post, 大弯侧Gre, 小弯侧Less,",80,70,10,,R2,8.89,6.98,1.31,125.0,244.0,4.43,26.0,20.0,171.0,106.0,31.0,7.28,2.72,63.0,216.0,39.0,24.0,5.6,3.3,63.0,211.0,,,,,,,,,,,,,0.747,11.69,17.48, 未做,无, 无, P0,H0, 未做, CK +,,,,,46.846254927726676,1609949
1610021,韦天荣,632658,男,59,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,30,中间型（int）,INFa,1.0,,,,,,,,2016-03-30,2022-09-01,1,,,XELOX,,,,,,6, 粘液腺癌（muc）70 管状腺癌（中分化【G2】【tub2】30 Lauren肠型,G2, (1a)00 (1b)00 (3a)06 (3b)00 (4sb)00 (4d)012 (5)00 (6)04 (7)01 (8a)04 (8p)01 (9)01 (11p)00 (14v)01,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,80,45,8, R0 D2,,4.73,58.8,29.8,123.0,278.0,3.48,25.0,15.0,144.0,103.0,16.0,8.1,3.55,65.0,238.0,44.0,21.0,5.6,3.7,59.0,291.0,60.8,46.1,11.2,4.12,0.1,7.5,28.1,1.4,0.275,5.41,4.74,,9.87,1000.0,21.15, 阴性,无,, P0,H0, 未做, CK+， CD34+ S-100-，D2-40+,,,,,77.06964520367937,1610021
1610631,王春红,635398,女,50,T1a,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,51,中间型（int）,INFc,0.0,,,,,,,,2016-04-05,2021-08-18,1,,,,,,,,,0, 低粘附腺癌,GX, (1a) (1b) (3a) (3b) (4sb) (4d) (5) (6) (7) (8a) (8p) (9) (12a) (14v)," L（幽门窦部）, 小弯侧Less,",30,20,6, R0 D2+,,5.6,2.75,2.18,141.5,191.0,2.11,22.0,21.0,200.0,83.0,9.0,20.15,5.4,68.0,336.0,43.0,25.0,4.9,4.5,53.0,328.0,64.1,41.0,20.7,1.98,0.4,12.8,20.5,0.9,1.48,2.79,10.1,,1.07,10.97,6.28,,无, 无, P0,H0, 未做, CK + CD34 -S-100-,,,,,64.42181340341655,1610631
1610225,田泽清,629531,男,66,T4b,N3a,M0, ⅢC,1,2,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,11.0,40,中间型（int）,INFa,1.0,,,,,,,,2016-03-31,2019-07-29,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 00(1b)02 (3a)36 (3b)33 (4sb)00 (4d)34 (5)01 (6)24 (7)07 (8a)07 (8p)02 (9)02 (11p)02 (12a)00, L（幽门窦部） 大弯侧Gre  前Ant 后Post ,50,40,15, R0 D2,,7.77,4.26,2.78,130.9,350.0,3.72,18.0,23.0,146.0,86.0,19.0,5.52,2.46,73.0,259.0,44.0,,4.5,5.0,90.0,472.0,78.4,55.7,20.7,2.69,0.4,8.2,12.2,1.5,1.04,2.65,10.3,,1.88,17.45,1.93, 阳性+,无,, P0,H0, 未做, CK +,,,,,39.91458607095926,1610225
1610766,王玮,635380,男,58,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,25,中间型（int）,INFa,0.0,,,,,,,,2016-04-05,2021-07-13,1,,,口服替吉奥,,,,,,8, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)01 (1b)00 (3a)05 (3b)03 (4sb)00 (4d)01 (5)00 (6)03 (7)01 (8a)02 (8p)03 (9)05 (11p)00 (12a)01," M（胃体部）, 大弯侧Gre,",30,30,8, R0 D2+,,8.36,5.38,1.82,108.0,330.0,4.21,17.0,17.0,197.0,62.0,14.0,7.36,3.16,70.0,238.0,43.0,27.0,6.5,7.4,85.0,528.0,73.5,42.6,21.7,1.96,0.1,8.6,14.6,2.2,0.711,3.31,8.42,,3.24,14.8,0.878, 未做,无,, P0,H0, 未做, CK +,,,,,63.23915900131406,1610766
1609813,宋淑琴,629406,女,75,T4a,N1,M0, ⅢA,1,3,2.0,1.0,,1.0, 异型增生+,1.0,11,中间型（int）,INFc,0.0,,,,,,,,2016-03-29,2018-09-20,2,,,,,,,,,0, 管状腺癌（中分化【G2】10【tub2】 低粘附腺癌90 Lauren弥漫型,G2, (1a)00 (1b)02 (3a)00 (3b)00 (4sb)00 (4d)01 (5)00 (6)02 (7)01 (8a)01 (8p)12 (9)00 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,30,15,,R2,7.16,4.52,2.01,148.0,287.0,2.41,27.0,28.0,189.0,95.0,2.0,7.68,2.96,66.0,261.0,42.0,24.0,6.6,6.8,67.0,141.0,,,,,,,,,,,,,1.2,33.69,0.91, 未做,无, 无, P0,H0, 未做, CK+,,,,,29.730617608409986,1609813
1610226,沈英喜,626551,男,66,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,,1.0, 正常,12.0,15,中间型（int）,INFa,2.0,,,,,,,,2016-03-31,2016-06-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 乳头状癌（G1）（pap）15 Lauren肠型,G3, (1a)00 (1b)11 (2) 25(4sa)00 (4sb)11 (5)22 (7)11 (6)22 (4d)11 (3a)22 (3b)00," M（胃体部）, 后Post, 大弯侧Gre,",40,30,10,,R2,5.57,3.04,1.7,128.0,237.0,3.07,17.0,22.0,151.0,85.0,18.0,11.62,4.07,70.0,208.0,44.0,26.0,4.7,7.8,71.0,214.0,,,,,,,,,,,,,8.39,8.08,4.31, 未做,无, 无, P0,H0, 未做, CK+,,,,,2.3324572930354797,1610226
1610324,王敏,634930,女,41,T4b,N2,M0, ⅢB,1,3,2.0,1.0,1.0,1.0, 慢性炎症,3.0,32,中间型（int）,INFc,0.0,,,,,,,,2016-03-29,2019-02-01,2,,,XELOX,,,,,,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (2) 05(3a) 00(3b)01 (4sa) 00(4sb)00 (4d)018 (5)00 (6) 04(7)01 肿物旁软组织可见癌33," M（胃体部）, 小弯侧Less,",80,60,18,,R2,2.81,1.24,1.29,111.0,307.0,2.75,15.0,23.0,146.0,57.0,8.0,8.75,2.78,76.0,293.0,46.0,30.0,4.5,8.3,69.0,218.0,,,,,,,,,,,,,1.19,22.81,2.2, 未做,无, 无, P0,H0, 未做, CK +,,,,,34.13272010512483,1610324
1621080,字艳,635620,女,46,T3,N0,M0, ⅡA,1,4,2.0,,,,,0.0,15,硬型（sci）,INFc,0.0,,,,,,,,2016-06-22,2021-05-11,1,XELOX*3,1.0,XELOX,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)02 (3a)01 (3b) 00(4sb)00 (4d)01 (5)01 (6)01 (7)01 (8a) 01(8p)01 (9)03 (11p)02 (12a)00 3a软组织可见癌,L（幽门窦部） 前Ant 后Post 大弯侧Gre  ,30,25,, R0 D2,,6.09,4.0,1.42,120.0,307.0,1.82,9.0,10.0,120.0,42.0,8.0,21.7,3.88,61.0,292.0,38.0,23.0,4.1,2.4,59.0,157.0,81.6,51.7,20.5,2.52,0.3,9.3,6.3,6.4,1.62,1.66,9.67,,0.9,12.69,4.86, 阴性,无, 无, P0,H0, 未做, CK +,,,,,58.60709592641261,1621080
1610790,韩坤,635482,男,56,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,8.0,40,髓样型（med）,INFa,1.0,,,,,,,,2016-04-05,2021-05-11,1,,,奥沙利铂,,,,,,1, 粘液腺癌（muc）85 低中分化腺癌（G3)(por)15 Lauren肠型,G3, (1a)00 (1b)00 (3a)210 (3b)56 (4sb)12 (4d)03 (5)01 (6)08 (7)02 (8a)01 (8p)02 (9)03 (11p)01 (14v)01,M（胃体部） 小弯侧Less ,35,35,17, R0 D2,,4.84,1.98,2.27,156.5,217.0,2.56,13.0,14.0,154.0,95.0,18.0,13.59,5.31,65.0,284.0,40.0,25.0,5.1,5.9,75.0,394.0,67.5,37.8,26.4,1.41,0.6,11.2,19.9,3.2,0.909,2.33,8.86,,,12.39,5.0, 未做,无, 无, P0,H0, 未做, S-100- CD34+ D-40+,,,,,61.169513797634686,1610790
1610953,周贵,629438,男,45,T4b,N2,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,6.0,21,中间型（int）,INFb,0.0,,,,,,,,2016-04-06,2018-10-13,2,,,SOX,,,,,,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】50 低粘附腺癌50 Lauren混合型,G3, (1a)01 (1b)00 (2)01 (3a)34 (3b)01 (4sa)00 (4sb)01 (4d)24 (5)01 (6)12 (7)01 (8a)01 (8p)01 (9)02 (11p)01,LMU 前Ant 小弯侧Less 后Post ,60,35,5,,R1,7.07,57.83,31.09,144.9,331.0,3.03,14.0,15.0,134.0,68.0,18.0,8.75,3.56,72.0,261.0,45.0,27.0,4.5,7.4,86.0,320.0,80.0,34.2,41.8,0.82,0.2,10.4,8.4,3.7,0.368,1.93,9.85,,,67.43,0.753, 阳性+,无,, P0,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,30.223390275952692,1610953
1610768,路宏岩,624488,女,47,T3,N3a,M0,ⅢB,1,2,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,9.0,32,中间型（int）,INFa,0.0,,,,,,,,2016-04-05,2019-08-20,0,,,XELOX,,,,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)00 (1b) 00(3a)46 (3b) 01(4sb)01 (4d) 44(5) 02(6) 13(7)02 (8a)01 (8p)01 (9)03 (11p)05 (12a)00 (14v)02大网01," L（幽门窦部）, 大弯侧Gre, 后Post,",40,30,8, R0 D2+,,7.9,3.37,3.96,116.0,251.0,2.76,8.0,14.0,121.0,55.0,6.0,2.8,0.84,64.0,282.0,36.0,28.0,4.6,7.8,85.0,244.0,68.7,52.3,12.2,4.29,0.2,21.7,7.9,1.8,1.17,2.32,11.7,,1.94,8.59,5.87, 阳性+,无, 无, P0,H0, 未做, CK + CD34 +S-100+,,,,,40.473061760841,1610768
1610162,杨海峰,626557,男,39,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,32,,,0.0,,,,,,,,2016-03-30,2021-07-13,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)04 (1b)03 (3a)00 (3b)011 (4sb)01 (4d)03 (5)00 (6)06 (7)01 (8a)01 (9)02 (12a)00," L（幽门窦部）, 小弯侧Less, 后Post,",10,5,2,R0 D2+,,5.4,47.2,36.3,157.0,173.0,2.09,24.0,23.0,159.0,68.0,9.0,28.5,8.82,68.0,315.0,45.0,23.0,4.4,8.4,79.0,258.0,72.3,44.8,26.7,1.68,0.3,14.7,7.7,0.7,0.745,2.3,9.7,,2.7,12.61,0.948, 未做,无,, P0,H0, 未做, CK+,,,,,63.43626806833114,1610162
1610364,李春生,631235,男,54,T3,N3a,M0,ⅢB,1,1,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,11.0,37,中间型（int）,INFa,0.0,,,,,,,,2016-03-31,2018-01-09,2,,,,,,,,,0,乳头状癌（G1）（pap）70 低分化腺癌（G3)(por)20 低粘附腺癌10 Lauren肠型,G3, (1a)22 (1b)01 (3a)34 (3b)22 (4sb)14 (5)01 (6)33 (7)07 (8a)03 (8p)02 (9)07 (11p)01 (12a)00  (4d)软组织可见癌,L（幽门窦部） 前Ant 大弯侧Gre  ,65,45,35,R0 D2+,,4.7,43.4,45.1,88.0,241.0,2.52,32.0,15.0,118.0,46.0,15.0,10.25,5.49,57.0,304.0,35.0,22.0,5.1,5.9,73.0,415.0,85.1,40.0,33.9,1.18,0.7,4.5,7.4,4.8,0.777,2.14,7.81,,2.93,16.15,3.13, 阴性,无,, P0,H0, 未做, CK+， CD34+ S-100+，D2-40+,,,,,21.320630749014455,1610364
1610454,夏忠君,629499,男,48,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+） 异型增生+,4.0,31,中间型（int）,INFa,0.0,,,,,,,,2016-04-01,2022-09-01,1,,,XELOX,,,,,,6, 低分化腺癌（G3)(por)85 乳头状癌（G1）（pap）15 Lauren肠型,G3, (1a)00 (1b)01 (3a)34 (3b)01 (4sb)07 (4d)00 (5)01 (6)05 (7)17 (8a)01 (8p) (9)03 (11p)01 7组 软组织可见癌, L（幽门窦部） 前Ant 小弯侧Less 后Post ,50,45,10, R0 D2,,6.38,4.19,1.65,156.3,212.0,2.75,23.0,24.0,139.0,67.0,25.0,7.0,2.69,65.0,360.0,40.0,25.0,4.8,5.0,75.0,382.0,61.8,40.3,16.0,2.52,0.1,6.5,29.5,2.9,1.36,1.82,11.2,,7.42,35.35,1.62, 阳性+,无,, P0,H0, 未做, CK +,,,,,77.00394218134034,1610454
1610508,宋守文,632886,男,64,T3,N2,M0, ⅢA,1,3,1.0,0.0,,1.0, 肠化生+ 慢性炎症（+）,3.0,21,中间型（int）,INFa,0.0,,,,,,,,2016-04-01,2021-06-14,1,,,SOX,,,,,,4, 低粘附腺癌 80低分化腺癌（G3)(por)20 Lauren混合型,G3, (1a)00 (1b)00 (3a)05 (4sb)01 (4d)26 (5)01 (6)11 (7)04 (8a)00 (8p)01 (9)02 (11p)00 (12a)00 3b软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,15, R0 D2,,6.33,4.03,2.01,179.0,157.0,2.72,43.0,36.0,182.0,75.0,45.0,18.45,7.9,70.0,354.0,47.0,23.0,5.1,5.0,112.0,312.0,,,,,,,,,,,,,8.35,63.7,14.53, 阴性,无, 无, P0,H0, 未做, CK-,,,,,62.417871222076215,1610508
1610565,杨兆林,635047,男,52,T2,N1,M0, ⅡA,1,2,0.0,0.0,,1.0, 慢性炎症（+）,1.0,28,中间型（int）,INFa,0.0,,,,,,,,2016-04-01,2021-06-08,1,,,奥沙利铂 亚叶酸钙 氟尿嘧啶,奥沙利铂 亚叶酸钙 氟尿嘧啶,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)， Lauren肠型,G3, (1a)02 (1b)01 (2)07 (3a)00 (3b)15 (4sa)011 (4sb)00 (4d)00 (5)00 (7)00 (8a)00 (8p)00 (9)01 (11p)01," SiewerⅢ, 后Post,",40,35,4, R0 D2,,8.93,3.49,4.39,163.2,238.0,2.54,55.0,34.0,201.0,82.0,17.0,20.05,7.76,72.0,313.0,43.0,29.0,5.8,5.4,84.0,295.0,51.7,32.5,15.7,2.07,0.2,11.9,32.4,1.4,1.04,3.33,10.4,,10.68,12.72,4.55, 未做,无, 无, P0,H0, 未做, CK+,,,,,62.22076215505913,1610565
1610892,徐殿富,635525,男,70,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,9,中间型（int）,INFa,1.0,,,,,,,,2016-04-06,2021-07-12,1,,,口服替吉奥,口服替吉奥,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (2)01 (3a)00 (3b)03 (4sa)00 (4sb)00 (5)00 (6)02 (7)00 (8a)00 (8p)00 (9)02 (11p)01," U（胃底部）, 前Ant, 小弯侧Less,",30,25,10, R0 D2+,,5.46,2.58,2.18,103.0,315.0,3.93,25.0,26.0,217.0,76.0,23.0,7.38,2.31,62.0,339.0,40.0,22.0,4.9,7.5,93.0,334.0,64.9,35.3,24.5,1.44,0.8,14.3,19.1,6.5,0.617,1.83,7.41,,1.46,9.14,2.94, 未做,无,, P0,H0, 未做, CK +,,,,,63.17345597897503,1610892
1611756,高天霞,634015,女,68,T3,N1,M0, ⅡB,1,3,0.0,1.0,,0.0, 肠化生+ 慢性炎症（+）,1.0,32,中间型（int）,INFa,0.0,,,,,,,,2016-04-12,2019-05-05,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)02 (1b)03 (2)01 (3a)16 (3b)01 (4sa)02 (4sb)00 (4d)04 (5)01 (6)03 (7)01 (8a)01 (8p)02 (9)01 (11p)02 (12a)02," ML 小弯侧Less,",50,30,4, R0 D2,,4.36,3.01,1.11,84.1,293.0,3.26,11.0,15.0,171.0,77.0,11.0,5.39,2.06,59.0,180.0,36.0,23.0,6.5,4.0,66.0,210.0,,,,,,,,,,,,,2.43,5.14,8.4,,无, 无, P0,H0, 未做, CK+,,,,,36.727989487516425,1611756
1610842,毛淑华,626588,女,66,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,14.0,25,中间型（int）,INFa,2.0,,,,,,,,2016-04-06,2017-03-24,0,,,奥沙利铂,奥沙利铂,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70%， 粘液腺癌（muc）30%， Lauren肠型,G3, (1a) 25(1b)22 (3a)00 (3b)11 (4sa)55 (4sb)00 (5)00 (7)01 (8a)01 (8p)12 (9)36 (11p)02," SiewerⅢ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,45,15, R0 D2,,6.27,3.34,2.42,134.9,206.0,3.61,19.0,24.0,164.0,87.0,8.0,12.15,4.37,60.0,193.0,39.0,21.0,4.3,6.5,78.0,293.0,,,,,,,,,,,,,2.72,25.24,5.89, 阴性,无, 无, P0,H0, 未做," CD34、D2-40( 脉管瘤栓)，S-100(神经侵犯),CK+",,,,,11.563731931668856,1610842
1610695,王义福,635442,男,69,T4b,N1,M0, ⅢB,1,3,0.0,1.0,1.0,1.0,  慢性炎症（+）,1.0,25,中间型（int）,INFa,3.0,,,,,,,,2016-04-05,2021-06-14,1,,,XELOX,XELOX,,,,,2, 管状腺癌（高中分化【G2】【tub2】,G2, (1a)02 (1b)00 (2)04 (3a)00 (3b)05 (4sa)00 (4sb)00 (4d)00 (5)01 (6)11 (7)07 (8a)01 (8p)01 (9)03 (11p)00 (12a)00," L（幽门窦部）, M（胃体部）, LM 后Post, 大弯侧Gre, 小弯侧Less,",100,55,10, R0 D2,,12.17,10.87,0.77,125.0,199.0,,13.0,16.0,119.0,84.0,25.0,3.82,1.41,53.0,167.0,31.0,22.0,6.5,4.2,85.0,214.0,,,,,,,,,,,,,14.11,5.48,6.89, 阳性+,无,, P0,H0, 未做, CD34+ S-100+,,,,,62.286465177398156,1610695
1610770,柳金荣,629478,女,65,T1a,N0,M0,ⅠA,1,0,0.0,0.0,,0.0, 慢性炎症（+）,0.0,35,中间型（int）,INFa,1.0,,,,,,,,2016-04-05,2021-08-10,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)00 (3a)03 (3b)01 (4sb)00 (4d)05 (5)02 (6)03 (7)013 (8a)01 (8p)01 (9)03 (11p)01," LM 小弯侧Less,",35,20,5, R0 D2,,6.15,3.07,2.38,127.9,288.0,2.97,10.0,16.0,141.0,79.0,6.0,9.26,3.6,62.0,259.0,39.0,23.0,3.6,3.4,79.0,213.0,,,,,,,,,,,,,1.27,6.41,0.926, 阳性+,无, 无, P0,H0, 未做, CK+,,,,,64.15900131406045,1610770
1610789,赵双玲,629538,女,51,T3,N1,M0, ⅡB,1,3,2.0,0.0,,0.0, 慢性炎症（+）,1.0,31,中间型（int）,INFb,0.0,,,,,,,,2016-04-05,2022-09-01,1,,,XELOX,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)16 (3b)01 (4sb)00 (4d)05 (5)01 (6)04 (7)02 (8a)00 (8p)06 (9)00 (11p)05 (12a)01," L（幽门窦部）, 后Post, 小弯侧Less,",15,15,8, R0 D2,,3.32,1.55,1.44,132.7,147.0,2.48,18.0,24.0,132.0,108.0,28.0,14.97,5.26,73.0,252.0,42.0,31.0,4.4,4.0,68.0,266.0,,,,,,,,,,,,,1.53,2.71,1.46, 未做,无, 无, P0,H0, 未做, CK+,,,,,76.87253613666228,1610789
1612012,刘启军,635923,男,57,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,15,,,,,,,,,,,2016-04-13,2020-09-18,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)00 (1b)00 (2)01 (3a)05 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)00 (7)02 (8、9、11p)05," U（胃底部）, 后Post,",40,30,3, R0 D2,,4.91,2.31,2.22,160.6,369.0,3.52,17.0,22.0,142.0,63.0,53.0,10.44,4.0,66.0,322.0,40.0,26.0,4.5,4.9,84.0,452.0,,,,,,,,,,,,,1.59,6.68,0.863,,无,, P0,H0, 未做,,,,,,53.186596583442835,1612012
1613162,解长英,635616,女,50,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,31,,,0.0,,,,,,,,2016-04-21,2021-09-27,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)01 (1b)01 (2)06 (3a)010 (4sa)02 (4sb)00 (4d)01 (6)00 (7)05 (8a)01 (8p)01 (9)03 (11p)00," MU 小弯侧Less,",30,30,3, R0 D2,,4.22,1.88,1.82,137.0,170.0,3.4,14.0,30.0,177.0,66.0,13.0,9.02,4.02,69.0,192.0,42.0,27.0,4.6,2.6,75.0,283.0,66.1,41.2,22.1,1.86,0.1,11.0,21.0,0.7,0.947,2.12,12.1,,1.1,8.95,0.855, 未做,无, 无, P0,H0, 未做, CK+,,,,,65.21024967148489,1613162
1611467,张超,635383,女,57,T4a,N3b,M0, ⅢC,1,3,1.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,16.0,38,中间型（int）,INFb,1.0,,,,,,,,2016-04-11,2021-04-21,1,,,XELOX,Cape OX ,Cape OX ,,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌 40,G3, (1a)02 (1b)13 (3a)26 (3b)12 (4sb)00 (4d)410 (5)00 (6)811 (7)04 (8a)00 (9)00 (11p)00 (12a)00,"L（幽门窦部）, 小弯侧Less,",18,15,10,,R2,5.21,3.37,1.02,126.0,243.0,3.01,50.0,44.0,229.0,129.0,12.0,11.86,5.27,66.0,195.0,38.0,28.0,4.7,3.5,71.0,212.0,,,,,,,,,,,,,3.21,93.81,0.997, 阳性+,无, 无, P0,H0,, CD34- S-100- D2-40-,,,,,60.31537450722733,1611467
1611754,马素勤,633481,女,63,T2,N0,M0, ⅠB,1,2,0.0,0.0,,,肠上皮化生，慢性炎,0.0,32,中间型（int）,INFa,0.0,,,,,,,,2016-04-12,2021-08-11,1,,,,,,,,,0,浸润溃疡型混合型中分化管状癌 Lauren肠型,G2, (1a) 00(1b)01 (3a)03 (3b)02 (4sb)00 (4d)010 (5)01 (6) 07(7)05 (8a)(8p)01 (11p) 02(12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",30,25,3, R0 D2,,7.63,3.85,3.01,131.0,156.0,4.0,16.0,26.0,149.0,205.0,105.0,2.97,1.35,68.0,150.0,33.0,35.0,11.2,4.8,71.0,326.0,,,,,,,,,,,,,4.32,10.08,2.36, 阴性,无, 无, P0,H0, 未做," CK + CD34,D2-40脉管显示未见明确脉管瘤栓",,,,,63.96189224704336,1611754
1611510,谭生,633622,男,72,T3,N0,M0, ⅡA,1,2,0.0,0.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,21,中间型（int）,INFa,0.0,,,,,,,,2016-04-11,2021-06-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)01 (3a)01 (3b)05 (4sb)00 (4d)01 (5)00 (6)00 (7)05 (8a)00 (8p)01 (9)02 (11p)00 (12a)00," L（幽门窦部）, 后Post,",25,25,3, R0 D2,,6.82,3.87,2.34,124.0,336.0,2.9,28.0,28.0,151.0,55.0,21.0,16.7,5.58,68.0,291.0,43.0,25.0,4.3,6.5,92.0,380.0,,,,,,,,,,,,,2.93,11.91,1.23,,无, 无, P0,H0, 未做, CK+,,,,,62.155059132720105,1611510
1612096,张金宴,635503,男,65,T2,N0,M0, ⅠB,1,3,0.0,0.0,,0.0, 慢性炎症（+）,0.0,20,中间型（int）,INFa,1.0,,,,,,,,2016-04-14,2021-08-18,1,,,SOX  6,替吉奥单药2,紫衫醇 卡培他滨1,甲磺酸阿帕替尼1,,,10, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) (1b) (3a) (3b) (5)012 (4sb) (4d) (6)08," L（幽门窦部）, 后Post,",40,20,5, R0 D2,,7.7,4.5,2.47,147.0,264.0,2.85,21.0,20.0,168.0,66.0,17.0,7.53,2.62,62.0,278.0,39.0,23.0,4.9,7.1,87.0,276.0,,,,,,,,,,,,,1.18,9.04,1.35,,无, 无, P0,H0, 未做, CK+,,,,,64.12614980289094,1612096
1611808,刘国,633451,男,67,T3,N3a,M0,ⅢB,1,2,0.0,1.0,1.0,0.0, 慢性炎症（+）,14.0,27,中间型（int）,INFa,0.0,,,,,,,,2016-04-12,2017-01-05,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)12 (3a)18 (3b)22 (4sb)00 (4d)89 (5)00 (6)12 (7)14 (8a)00 (8p)00 (9)00 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",55,30,8,,R2,6.39,4.21,1.45,145.0,296.0,4.0,31.0,32.0,184.0,71.0,17.8,11.83,7.29,74.5,171.06,43.2,,,,,235.0,,,,,,,,,0.901,3.38,10.6,,32.03,13.02,, 阳性+,无,, P0,H0, 未做, CK +,,,,,8.804204993429698,1611808
1612094,孙庆祥,636871,男,65,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,18,,,0.0,,,,,,,,2016-04-14,2021-08-17,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a) 01(1b) 00(3a) 05(3b) 00(4sb) 00(4d) 00(5) 00(6)00 (7)06 (8a) 01(8p)02 (9) (11p)03 (12a)00," L（幽门窦部）, 小弯侧Less,",12,8,2, R0 D2+,,8.41,6.81,0.77,105.6,177.0,2.79,15.0,20.0,141.0,82.0,28.0,16.82,4.94,68.0,424.0,41.0,27.0,4.9,7.6,83.0,301.0,,,,,,,,,,,,,1.87,5.99,25.0, 阳性+,,, P0,H0, 未做, CK +,,,,,64.09329829172141,1612094
1613218,吕宝福,633630,男,52,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,3.0,16,中间型（int）,INFa,0.0,,,,,,,,2016-04-21,2019-05-28,0,,,XELOX,,,,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)01 (1b)00 (3a) 22(3b) 00(4sb) 00(4d)04 (5) 00(6)03 (7)02 (8a)11 (8p)02 (12a) 00(12p)01," L（幽门窦部）, 小弯侧Less,",30,20,8, R0 D2+,,9.02,5.99,2.32,159.0,326.0,4.0,20.0,25.0,152.0,93.0,20.0,12.6,4.92,68.0,299.0,45.0,23.0,4.5,5.6,71.0,265.0,58.2,35.7,19.8,1.8,0.0,22.1,18.4,1.1,0.412,2.38,7.9,,0.783,31.57,1.61, 阳性+,,, P0,H0, 未做, CK + S-100+,,,,,37.187910643889616,1613218
1611094,姚芹,635391,女,53,T2,N1,M0, ⅡA,1,2,0.0,0.0,,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,27,中间型（int）,INFa,1.0,,,,,,,,2016-04-07,2021-06-16,1,,,XELOX,,,,,,5, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)05 (1b)00 (3a)00 (3b)05 (4sb)00 (4sd)117 (4d)00 (5)00 (6)00 (7)00 (8a)00 (8p)00 (9)00 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",40,25,10, R0 D2,,4.61,1.96,2.08,139.0,226.0,2.7,10.0,15.0,151.0,64.0,12.0,8.92,3.15,65.0,339.0,40.0,25.0,6.4,2.8,65.0,125.0,,,,,,,,,,,,,0.421,13.01,4.3, 阳性+,无, 无, P0,H0, 未做, CK+,,,,,62.286465177398156,1611094
1611597,王秀兰,636514,女,71,T4b,N3b,M0, ⅢC,1,4,1.0,1.0,1.0,1.0, 异型增生,25.0,28,中间型（int）,INFb,0.0,,,,,,,,2016-04-11,2017-09-15,2,,,,,,,,,0, 低粘附腺癌70% 管状腺癌（中低分化【G2】【tub2】30% Lauren混合型,G3, (1a)22 (2)33 (3a) 33(3b)00 (4sa)00 (4sb)00 (4d)57 (5)34 (6)00 (7)11 (8a)44 (8p)33 (9) 11(11p)11 (1b)00," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,30,10, R0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK +,,,,,17.1484888304862,1611597
1612174,王玉山,636942,男,63,T4b,N0,M0, ⅢA,1,3,0.0,1.0,,1.0, 慢性炎症（+）,0.0,9,中间型（int）,INFa,0.0,,,,,,,,2016-04-14,2019-09-02,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (4sa) (4sb) (4d) (6)03 (1a) (1b) (3a) (3b) (5) (7) (8a) (8p) (9) (11p) (11d)06," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,20, R0 D2,,8.39,4.31,3.15,163.0,213.0,4.97,26.0,26.0,215.0,78.0,24.0,8.88,3.41,67.0,278.0,41.0,26.0,4.5,5.2,89.0,318.0,,,,,,,,,,,,,2.19,36.78,3.22,,无, 无, P0,H0, 未做, CK+,,,,,40.60446780551905,1612174
1612488,王顺孝,629401,男,64,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,11,,,0.0,,,,,,,,2016-04-15,2020-09-10,0,,,,,,,,,0, 低粘附腺癌,GX, (4sb) (4d) (6)01 (1a) (1b) (3a) (3b) (5)010," L（幽门窦部）, 小弯侧Less,",20,15,5, R0 D2,,5.31,2.69,2.12,152.0,133.0,2.03,21.0,26.0,173.0,62.0,19.0,15.49,5.62,66.0,296.0,42.0,24.0,4.5,6.3,73.0,252.0,,,,,,,,,,,,,2.81,2.61,5.0,,无, 无, P0,H0, 未做, CK+,,,,,52.858081471747695,1612488
1611714,吴淑芳,637210,女,66,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,10,,,0.0,,,,,,,,2016-04-12,2021-08-11,1,,,,,,,,,0, 低粘附腺癌,GX,病理报告未分组," L（幽门窦部）, 小弯侧Less,",10,5,3, R0 D2,,6.51,3.55,2.5,129.0,257.0,2.48,20.0,31.0,171.0,47.0,9.0,11.84,5.51,52.0,198.0,30.0,22.0,6.1,2.4,62.0,213.0,,,,,,,,,,,,,2.64,21.82,0.758, 阴性,无, 无, P0,H0, 未做, CK+,,,,,63.96189224704336,1611714
1612361,郭庆固,633641,男,56,T2,N0,M0, ⅠB,1,3,0.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,21,中间型（int）,INFa,0.0,,,,,,,,2016-04-15,2021-08-12,1,,,口服替吉奥,,,,,,6, 管状腺癌（低中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)02 (5)01 (6)05 (7)02 (8a)01 (8p)03 (9)03 (11p)00 (12a)01," L（幽门窦部）, 小弯侧Less,",30,20,8, R0 D2,,5.37,2.85,1.9,162.0,147.0,1.93,26.0,29.0,138.0,77.0,15.0,12.94,4.09,65.0,325.0,40.0,25.0,4.7,7.7,90.0,321.0,,,,,,,,,,,,,2.79,7.17,2.06,,无, 无, P0,H0, 未做, CK+,,,,,63.89618922470434,1612361
1612211,刘树江,637246,男,50,T2,N1,M0, ⅡA,1,2,0.0,0.0,,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,26,中间型（int）,INFa,0.0,,,,,,,,2016-04-14,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (4sb) (4d) (6)114 (1a) (1b) (3a) (3b) (5)012," L（幽门窦部）, 大弯侧Gre,",30,30,10, R0 D2,,7.02,3.91,2.33,164.9,195.0,1.93,34.0,28.0,149.0,76.0,28.0,12.19,4.96,63.0,435.0,42.0,21.0,5.7,5.6,95.0,354.0,,,,,,,,,,,,,2.36,9.44,5.42,,无, 无, P0,H0, 未做, CK+,,,,,76.57687253613666,1612211
1612097,孙秀兰,636501,女,63,T1b,N1,M0, ⅠB,1,0,0.0,0.0,0.0,0.0, 慢性炎症,1.0,8,中间型（int）,INFa,0.0,,,,,,,,2016-04-14,2021-09-02,1,,,,,,,,,0, 低中分化腺癌（G3)(por)60% 乳头状癌（G1）（pap）40% Lauren肠型,G3, (1a) 01(1b)02 (3a) 00(3b)01 (4sb) 01(4d)01 (5) 00(6) 01(7) 00(8a)11," L（幽门窦部）, 后Post, 小弯侧Less,",30,20,3, R0 D2,,7.38,3.71,2.56,142.0,186.0,2.03,14.0,17.0,161.0,91.0,21.6,6.11,1.8,72.0,332.0,46.0,26.0,4.9,3.1,71.0,325.0,,,,,,,,,,,,,4.33,8.66,3.37, 未做,无, 无, P0,H0, 未做, CK +,,,,,64.61892247043363,1612097
1612494,吕延平,633572,男,59,T4a,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症,22.0,48,中间型（int）,INFa,1.0,,,,,,,,2016-04-18,2017-04-15,2,,,SOX,,,,,,2, 低分化腺癌60（G3)(por) 粘液腺癌30（muc） 乳头状癌10（G1）（pap） Lauren肠型,G3, (1a) 00(1b)00 (3a) 56(3b)35 (4sb)00 (4d)715 (5)00 (6)610 (7)02 (8a)14 (8p)00 (9)02 (11p)04 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,30,10, R0,,7.58,4.7,1.77,118.9,252.0,2.88,9.0,12.0,140.0,121.0,11.0,9.19,3.49,60.0,285.0,37.0,23.0,4.8,3.9,78.0,471.0,,,,,,,,,,,,,12.42,5.44,19.93, 未做,无, 无, P0,H0, 未做, CK +,,,,,11.892247043363994,1612494
1612626,顾景臣,633578,男,64,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,0.0, 肠化生 异型增生+ 慢性炎症（+）,2.0,20,中间型（int）,INFa,3.0,,,,,,,,2016-04-08,2019-10-01,2,,,,,,,,,0, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】30 Lauren肠型,G2, (1a) 02(1b)00 (2)00 (3a)24 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)00 (7)02 (8a)04 (8p) 03(9)03 (11p)02," U（胃底部）, 后Post,",40,25,7, R0,,6.38,3.85,1.89,163.7,183.0,2.7,32.0,24.0,163.0,74.0,31.0,17.97,4.69,67.0,350.0,43.0,24.0,4.8,5.3,73.0,290.0,,,,,,,,,,,,,2.84,2.3,2.68, 未做,无, 无, P0,H0, 未做, CK +,,,,,41.75427069645203,1612626
1612740,高玉霞,636528,女,62,T3,N2,M0, ⅢA,1,4,2.0,0.0,,0.0, 慢性炎症（+）,4.0,25,中间型（int）,INFc,0.0,,,,,,,,2016-04-19,2017-01-15,2,,,奥沙利铂,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)02 (2)03 (3a)12 (3b)00 (4sa)00 (4sb)02 (4d)01 (5)00 (6)11 (7)01 (8a)04 (8p)01 (9)24 (11p)02 (11d)01," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",130,105,8, R0 D2,,4.57,2.6,1.5,113.3,249.0,3.2,17.0,35.0,164.0,107.0,54.0,11.83,3.83,64.0,283.0,39.0,25.0,4.0,3.6,52.0,267.0,,,,,,,,,,,,,1.53,22.97,1.96,,无, 无, P0,H0, 未做, CK+,,,,,8.902759526938238,1612740
1612702,徐淑芝,633785,女,71,T1b,N0,M0,ⅠA,1,0,0.0,1.0,1.0,0.0,异型增生+,0.0,12,中间型（int）,INFa,1.0,,,,,,,,2016-04-19,2018-10-30,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)00 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)01 (5)00 (6)01 (7)04 (8a)01 (8p)02 (9)02 (11p)00," L（幽门窦部）, 小弯侧Less,",18,15,3, R0 D2,,7.28,3.79,2.81,141.0,213.0,3.28,17.0,17.0,172.0,65.0,16.0,11.25,3.38,72.0,277.0,43.0,29.0,4.2,3.8,76.0,308.0,,,,,,,,,,,,,1.64,24.86,1.67, 阴性,无, 无, P0,H0, 未做, CD34 + S-100 -,,,,,30.354796320630747,1612702
1612845,王永泽,636534,男,53,T3,N3a,M0,ⅢB,1,5,0.0,1.0,,0.0, 慢性炎症（+）,14.0,22,中间型（int）,INFa,0.0,,,,,,,,2016-04-19,2021-05-13,1,,,SOX  6,口服替吉奥2,,,,,8, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 乳头状癌（G1）（pap）15 Lauren肠型,G3, (1a)00 (1b)00 (3a)22 (3b)11 (4sb)11 (4d)35 (5)00 (6)55 (7)03 (8a)12 (8p)01 (9)01 (11p)11 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,20,5, R0 D2,,4.71,1.76,2.01,169.0,227.0,3.02,19.0,23.0,182.0,75.0,24.0,19.78,6.71,62.0,344.0,40.0,22.0,4.8,5.1,84.0,236.0,,,,,,,,,,,,,2.83,8.59,2.64,,无, 无, P0,H0, 未做, CK+,,,,,60.775295663600524,1612845
1613222,曲新友,634119,男,66,T1b,N0,M0,ⅠA,1,3,0.0,0.0,,0.0, 慢性炎症（+）,0.0,20,中间型（int）,INFa,0.0,,,,,,,,2016-04-21,2018-08-19,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)01 (1b)01 (3a)03 (3b)00 (4sb)00 (4d)02 (5)00 (6)00 (7)06 (8a)00 (8p)03 (9)02 (11p)02 (12a)00," M（胃体部）, 大弯侧Gre,",30,25,4, R0 D2,,7.01,4.74,1.88,138.6,290.0,4.43,10.0,15.0,167.0,68.0,12.0,16.57,5.5,71.0,270.0,43.0,28.0,5.2,5.7,87.0,244.0,,,,,,,,,,,,,2.07,20.65,7.36,,无, 无, P0,H0, 未做, CK+,,,,,27.92378449408673,1613222
1612815,孔险峰,637022,女,44,T3,N0,M0, ⅡA,1,3,2.0,0.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,21,中间型（int）,INFc,0.0,,,,,,,,2016-04-19,2021-08-10,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)04 (3a)01 (3b)01 (4sb)00 (4d)05 (5)00 (6)04 (7)01 (8a)02 (8p)02 (9)00 (11p)01 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",30,20,18, R0 D2,,6.24,4.24,1.6,103.0,242.0,2.44,12.0,21.0,211.0,43.0,7.0,13.71,4.69,78.0,240.0,48.0,30.0,4.9,4.0,66.0,176.0,,,,,,,,,,,,,0.858,8.69,0.787, 阴性,无, 无, P0,H0, 未做, CK+ S-100+,,,,,63.69908015768725,1612815
1612947,关振坤,638985,女,58,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0,  慢性炎症（+）,19.0,43,中间型（int）,INFa,1.0,,,,,,,,2016-04-20,2017-08-15,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren肠型,G2,小弯11 (1a)00 (1b)00 (3a)24(3b）56 (4sb)01 (4d)24 (5)00 (6)45 (7)410 (8a)12 (8p)02 (9)02 (11p)06 (12a)00， 3b，横结肠系膜组织内可见癌," L（幽门窦部）,",55,40,10, R0,,7.39,4.81,1.78,96.8,557.0,5.45,11.0,18.0,152.0,101.0,32.0,4.79,2.14,61.0,135.0,38.0,23.0,5.3,9.8,60.0,283.0,,,,,,,,,,,,,25.42,2.93,1.31, 未做,无, 无, P0,H0, 未做, CK +  IHC:C-erB-2(1+) CD34  D2-40 可见脉管瘤栓， S-100可见神经侵犯,,,,,15.83442838370565,1612947
1612844,王福,637257,男,59,T3,N1,M0, ⅡB,1,2,,1.0,1.0,0.0,,2.0,31,,,1.0,,,,,,,,2016-04-19,2021-06-01,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por),G3,," L（幽门窦部）, 小弯侧Less,",50,40,8, R0 D0,,8.0,6.11,1.09,64.0,319.0,2.9,28.0,27.0,155.0,91.0,20.0,6.22,3.12,74.0,171.0,38.0,36.0,5.6,7.3,137.0,633.0,,,,,,,,,,,,,1.53,16.18,1.32, 未做,无, 无, P0,H0, 未做, CK+,,,,,61.399474375821285,1612844
1612900,王作友,633693,男,59,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,26,,,0.0,,,,,,,,2016-04-20,2018-04-03,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (3a)03 (3b)01 (4sb)00 (4d) 02(5)02 (6)05 (7)05 (8a)01 (8p)02 (9)02 (11p)02 (12a)00 (12p)01, L（幽门窦部） 小弯侧Less ,35,35,, R0 D2,,5.89,2.65,2.08,160.3,245.0,2.91,26.0,33.0,154.0,129.0,21.0,4.96,1.97,62.0,295.0,38.0,24.0,4.2,5.5,97.0,335.0,57.4,41.0,14.7,2.79,0.1,5.5,35.9,4.2,0.859,2.07,9.27,,7.1,2.76,1.35,,无,, P0,H0, 未做, CK +,,,,,23.423127463863338,1612900
1613582,徐凤兰,637259,女,70,T4b,N1,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,1.0,19,中间型（int）,INFa,0.0,,,,,,,,2016-04-25,2016-09-15,2,,,口服替吉奥,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (2)13 (3a)02 (3b)00 (4sa)00 (4sb)05 (4d)07 (5)00 (6)00 (7)00 (9)00,"U（胃底部）, 后Post, 大弯侧Gre,",65,60,15,,R1,5.88,4.27,0.93,72.9,102.0,2.33,19.0,39.0,126.0,113.0,22.0,10.43,3.88,59.0,83.0,30.0,29.0,5.2,3.3,56.0,219.0,,,,,,,,,,,,,9.76,254.4,4.99, 阴性,无, 无, P0,H0, 未做, CK+ CD34 + D2-40+  S-100+,,,,,4.697766097240473,1613582
1613844,卢波,623716,男,43,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,0.0, 正常,4.0,22,髓样型（med）,INFa,3.0,,,,,,,,2016-04-26,2020-05-20,0,,,XELOX,,,,,,2, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)0/3 (1b)0/2 (2)0/1 (3a)1/2 (3b)0/2 (4sa)0/0 (4sb)0/0 (4d)1/4 (5)0/1 (6)0/1 (7)0/2 (8a)1/1 (8p)0/1 (9)0/1 (11p)1/1 (12a)0/0," M（胃体部）, 小弯侧Less,",60,60,10, R0,,6.25,45.39,39.73,142.6,410.0,2.79,40.0,36.0,165.0,79.0,20.0,12.04,4.16,69.0,284.0,38.0,31.0,4.5,4.1,82.0,389.0,,,,,,,,,,,,,1.35,5.99,1.11, 未做,无, 无, P0,H0, 未做, CK+,,,,,48.78449408672799,1613844
1613735,李桂春,637128,女,67,T3,N3a,M0,ⅢB,1,2,1.0,1.0,1.0,1.0, 慢性炎症,13.0,52,中间型（int）,INFb,0.0,,,,,,,,2016-04-26,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)80% 低粘附腺癌20% Lauren混合型,G3, (1a) 01(1b)00 (3a)55 (3b) 118(4sb) 00(4d)211 (5)11 (6) 310(7) (8a)11 (8p)00 (9) 01(11p)01 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",120,100,20, R0,,6.62,3.64,2.12,82.7,508.0,4.12,12.0,17.0,160.0,94.0,10.0,8.01,2.67,57.0,219.0,34.0,23.0,4.8,2.6,73.0,283.0,,,,,,,,,,,,,1.83,6.0,15.04, 未做,无, 无, P0,H0, 未做, CK +,,,,,76.1826544021025,1613735
1613642,殷立泉,638703,男,65,T3,N3a,M0,ⅢB,1,2,1.0,1.0,1.0,1.0, 异型增生+ 肠化生+,11.0,22,中间型（int）,INFc,0.0,,,,,,,,2016-04-25,2019-11-01,2,,,XELOX,,,,,,6, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)00 (1b)00 (2)23 (3a)00 (3b)22 (4sa)01 (4sb)00 (4d)13 (5)11 (6)11 (7)24 (8a)02 (8p)00 (9)11 (11p)14," M（胃体部）, U（胃底部）,L（幽门窦部）, 后Post, 小弯侧Less, ",90,50,20, R0 D2,,8.57,5.75,1.88,141.7,282.0,3.52,22.0,26.0,164.0,121.0,33.0,9.13,3.7,66.0,202.0,35.0,31.0,4.7,6.0,100.0,427.0,,,,,,,,,,,,,15.07,28.68,5.12, 阳性+,无, 无, P0,H0, 未做, CK+ CD34+  D2-40+  S-100+,,,,,42.21419185282523,1613642
1613999,左云河,637116,男,61,T3,N3a,M0,ⅢB,1,2,0.0,1.0,,0.0, 慢性炎症（+）,9.0,28,中间型（int）,INFc,0.0,,,,,,,,2016-04-27,2017-04-15,2,,,XELOX,XELOX,SOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)03 (3a)35 (3b)23 (4sb)00 (4d)24 (5)00 (6)14 (7)12 (8a)00 (8p)02 (9)02 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,50,4, R0 D2,,5.53,2.73,1.87,160.9,301.0,2.76,17.0,22.0,200.0,120.0,20.0,26.96,8.03,73.0,349.0,42.0,31.0,4.9,9.9,102.0,293.0,,,,,,,,,,,,,1.26,10.78,1.02, 未做,无, 无, P0,H0, 未做, CK+,,,,,11.59658344283837,1613999
1613836,蔡春艳,637185,女,43,T3,N0,M0, ⅡA,1,3,2.0,0.0,,0.0, 正常,0.0,27,中间型（int）,INFc,0.0,,,,,,,,2016-04-26,2021-06-23,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)02 (1b)04 (3a)05 (3b)00 (4sb)00 (4d)01 (5)01 (6)05 (7)03 (8a)03 (8p)01 (9)00 (11p)01 (12a)00," L（幽门窦部）, 前Ant,",40,30,8, R0 D2,,3.92,2.31,1.18,117.3,234.0,2.17,18.0,22.0,154.0,57.0,4.0,9.02,3.19,62.0,259.0,36.0,26.0,4.2,3.6,71.0,207.0,,,,,,,,,,,,,1.23,5.68,2.11,,无, 无, P0,H0, 未做, CK+ CD34-  D2-40 - S-100-,,,,,61.892247043363994,1613836
1613887,葛富,637146,男,72,T3,N2,M0, ⅢA,1,3,0.0,0.0,,1.0, 慢性炎症（+）,5.0,38,中间型（int）,INFc,1.0,,,,,,,,2016-04-26,2016-10-21,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (8a) (8p)03 (4sb) (4d) (6)16 (1a) (1b) (3a) (3b) (5)429," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,30,8, R0 D2,,4.48,2.01,1.89,130.7,144.0,1.91,37.0,52.0,124.0,74.0,18.0,12.3,5.83,52.0,101.0,27.0,25.0,3.7,4.2,72.0,350.0,,,,,,,,,,,,,5.53,7.51,17.91,,无, 无, P0,H0, 未做, CK+,,,,,5.847568988173456,1613887
1613891,马春国,638826,男,71,T3,N2,M0, ⅢA,1,3,2.0,1.0,,1.0, 肠化生+,3.0,30,髓样型（med）,INFc,0.0,,,,,,,,2016-04-26,2016-12-15,2,,,卡培他滨单药口服,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (2)05 (3a)312 (3b)00 (4sa)01 (4sb)00 (4d)00 (5)00 (6)01 (7)03 (8a)02 (8p)02 (9)00 (11p)04," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,6, R0 D2,,6.6,6.03,1.8,122.1,489.0,4.43,16.0,28.0,201.0,87.0,22.0,10.74,4.98,59.0,184.0,34.0,25.0,4.0,3.6,87.0,327.0,,,,,,,,,,,,,1.8,12.48,2.09,,无, 无, P0,H0, 未做, CK+,,,,,7.654402102496714,1613891
1614218,杨军童,638285,男,59,T3,N1,M0, ⅡB,1,3,0.0,1.0,,1.0, 肠化生+,2.0,30,中间型（int）,INFa,0.0,,,,,,,,2016-04-28,2020-06-17,2,,,XELOX,,,,,,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)01 (3a)08 (3b)14 (4sb)00 (4d)05 (5)00 (6)03 (7)01 (8a)12 (8p)00 (9)02 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,10, R0 D2,,8.18,4.6,3.03,136.0,217.0,3.2,20.0,30.0,155.0,39.0,43.0,14.48,5.57,54.0,362.0,33.0,21.0,3.6,3.3,62.0,292.0,,,,,,,,,,,,,7.02,,17.45,,无, 无, P0,H0, 未做, CK+,,,,,49.63863337713535,1614218
1614259,王秀珍,623682,女,76,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,34,中间型（int）,INFa,1.0,,,,,,,,2016-04-28,2020-05-12,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)03 (3a)02 (3b) 02(4sb)00 (4d)01 (5)02 (6)01 (7)00 (8a)08 (8p)02 (9)05 (11p)02 (12a)03, L（幽门窦部） 前Ant 后Post 小弯侧Less ,60,50,8, R0 D2,,9.21,5.55,2.7,100.2,379.0,4.43,17.0,20.0,151.0,94.0,9.0,3.79,1.03,62.0,190.0,35.0,27.0,6.1,3.8,68.0,225.0,72.3,35.4,31.0,1.14,0.2,9.2,15.7,3.8,0.444,1.2,9.92,,0.706,12.67,7.6, 阴性,无, 无, P0,H0, 未做, CK +,,,,,48.45597897503285,1614259
1614262,孙保久,637274,男,62,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 异型增生+ 慢性炎症（+）,3.0,11,中间型（int）,INFc,0.0,,,,,,,,2016-04-28,2016-12-14,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/0 (1b)0/0 (2)1/4 (3a)0/4 (3b)0/0 (4sa)0/0 (4sb)0/0 (4d)0/0 (5)0/0 (7)1/2 小弯1/1," U（胃底部）, 后Post, 小弯侧Less, 大弯侧Gre,",50,30,8,,R2,8.33,5.74,1.6,156.9,255.0,4.1,11.0,15.0,154.0,79.0,11.0,9.99,4.24,64.0,230.0,41.0,23.0,4.1,4.6,101.0,240.0,66.8,18.6,29.2,0.64,0.4,11.1,19.1,7.8,0.642,1.4,8.38,,5.88,42.07,1.31, 未做,无, 无, P0,H0, 未做, CK + CD34 S-100,,,,,7.555847568988173,1614262
1614612,张凤兰,640523,女,62,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,6.0,29,硬型（sci）,INFb,2.0,,,,,,,,2016-05-03,2021-06-01,1,,,XELOX,,,,,,1, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)27 (3b)00 (4sb)00 (4d)01 (5)11 (6)23 (7)03 (8a)11 (8p)04 (9)04 (11p)04 (14v)01 5 软组织可见癌,L（幽门窦部） 前Ant ,30,30,15, R0 D2,,4.28,2.56,1.52,118.0,287.0,2.76,22.0,29.0,159.0,69.0,9.0,3.53,1.23,69.0,310.0,38.0,31.0,4.5,5.9,89.0,244.0,75.1,25.7,37.8,0.68,0.7,11.6,12.4,3.5,2.04,2.05,14.3,,2.86,42.28,0.97,,无, 无, P0,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,60.939553219448094,1614612
1614339,张宝文,638333,男,59,T2,N2,M0, ⅡB,1,2,0.0,1.0,1.0,0.0, 肠化生+,3.0,17,髓样型（med）,INFa,2.0,,,,,,,,2016-04-29,2018-02-15,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)00 (3a)03 (3b)00 (4sb)00 (4d)00 (5)00 (6)35 (7)01 (8a)00 (8p)00 (9)03 (11p) 02(12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",30,30,8, R0,,5.79,3.45,1.78,173.2,184.0,2.7,12.0,15.0,134.0,64.0,11.0,17.6,5.96,73.0,303.0,42.0,31.0,4.4,8.0,88.0,285.0,,,,,,,,,,,,,1.63,10.59,0.857, 未做,无, 无, P0,H0,, CK +,,,,,21.583442838370566,1614339
1614217,王克文,637283,男,62,T4b,N3a,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 正常,10.0,35,硬型（sci）,INFc,0.0,,,,,,,,2016-04-28,2019-04-13,0,,,SOX,SOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)25 (3b)17 (4sb)00 (4d)13 (5)11 (6)58 (7)03 (8a)03 (8p) (9)04 (11p)01 3a、4d、6 软组织可见癌,L（幽门窦部） 小弯侧Less 后Post 大弯侧Gre  前Ant ,60,50,10,,R2,5.79,3.47,1.5,114.5,290.0,3.52,24.0,25.0,152.0,85.0,19.0,5.93,2.52,56.0,237.0,35.0,21.0,4.8,7.3,88.0,260.0,59.9,36.1,20.2,1.79,0.1,10.9,27.8,2.8,0.369,1.53,6.74,,3.04,9.2,16.93, 未做,无,, P0,H0, 未做, CK +,,,,,35.4796320630749,1614217
1614303,陈振友,640440,男,57,T3,N1,M0, ⅡB,1,2,1.0,0.0,,1.0, 慢性炎症（+）,1.0,30,中间型（int）,INFb,0.0,,,,,,,,2016-04-28,2021-05-24,1,,,XELOX,,,,,,1, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)02 (1b)03 (2)01 (3a)13 (3b)03 (4sa)00 (4sb)01 (4d)00 (5)00 (6)03 (7)03 (8a)03 (8p)01 (9)03 (11p)03 (12a)01," UM 后Post, 小弯侧Less,",60,40,10, R0 D2,,5.2,2.8,1.9,107.5,589.0,3.07,16.0,19.0,113.0,78.0,20.0,5.98,2.06,67.0,377.0,42.0,25.0,4.5,12.2,93.0,404.0,,,,,,,,,,,,,1.83,36.66,2.27,,无, 无, P0,H0, 未做, CK+,,,,,60.84099868593955,1614303
1614614,史文生,637215,男,54,T3,N1,M0, ⅡB,1,3,1.0,1.0,,1.0, 慢性炎症（+）,1.0,29,中间型（int）,INFc,0.0,,,,,,,,2016-05-03,2021-06-07,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por)95 低粘附腺癌5,G3, (1a)03 (1b)02 (2)04 (3a)02 (3b)13 (4sa)00 (4sb)00 (4d)02 (5)00 (6)04 (7)01 (8a)02 (8p)02 (9)01 (11p)03 (12a)00," U（胃底部）, 小弯侧Less,",15,8,8, R0 D2,,7.61,3.94,2.81,138.5,221.0,,15.0,20.0,145.0,61.0,10.0,7.79,1.76,61.0,354.0,40.0,21.0,5.0,6.9,89.0,244.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK+,,,,,61.136662286465175,1614614
1614600,付仁海,637197,男,61,T4b,N3a,M0, ⅢC,1,3,,1.0,1.0,1.0, 正常,11.0,15,髓样型（med）,INFa,2.0,,,,,,,,2016-05-03,2021-05-18,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)22 (1b)12 (2)33 (3a)01 (4sa)00 (4sb)00 (7) (8a) (8p) (9) (11p)23 (3b) (5)23," U（胃底部）, GE, SiewerⅢ, 后Post, 小弯侧Less,",100,75,25, R0 D2,,9.4,6.9,1.75,123.1,285.0,2.47,15.0,19.0,110.0,75.0,19.0,7.57,2.71,64.0,214.0,35.0,29.0,6.7,5.8,105.0,526.0,,,,,,,,,,,,,6.12,2.34,65.43,,无, 无, P0,H0, 未做, CK+ CD34+  D2-40+  S-100+,,,,,60.4796320630749,1614600
1614613,解建勋,637308,男,53,T2,N2,M0, ⅡB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,4.0,24,中间型（int）,INFc,0.0,,,,,,,,2016-05-03,2021-05-25,1,,,,,,,,,0, 低粘附腺癌 管状腺癌60（中分化【G2】【tub2】 低分化腺癌（G3)(por)40,G3, (1a)07 (1b) 00(3b)00 (4sb)01 (4d) 03(5) 25(6) 00(7)01 (8a)23 (8p) 02(9)02 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,20,, R0 D2+,,5.98,3.79,1.48,144.2,304.0,3.07,8.0,11.0,160.0,76.0,41.0,15.21,5.51,72.0,302.0,46.0,26.0,4.9,6.8,83.0,481.0,72.4,41.8,27.4,1.53,0.2,10.2,15.6,7.5,0.545,4.0,9.24,,2.8,12.36,1.36, 阳性+,,, P0,H0, 未做, CK +,,,,,60.709592641261494,1614613
1614546,郑庆复,638349,男,77,T3,N0,M0, ⅡA,1,3,0.0,0.0,,1.0, 肠化生+ 慢性炎症（+）,0.0,22,中间型（int）,INFa,0.0,,,,,,,,2016-05-03,2021-06-09,1,,,口服替吉奥,,,,,,1, 管状腺癌（中分化【G2】【tub2】80 乳头状癌（G1）（pap）15 粘液腺癌（muc）5 Lauren肠型,G2, (1a)03 (1b)03 (2)07 (3a)02 (3b)01 (4sa)00 (4sb)00 (4d)01 (5)00 (6)00 (7)03 (8a)01 (8p)01 (9)00 (12a)00," G=E, SiewerⅡ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,10,3, R0 D2,,6.09,3.63,2.08,158.2,226.0,2.6,30.0,27.0,176.0,63.0,13.0,11.85,4.59,74.0,285.0,45.0,29.0,5.6,4.9,81.0,347.0,,,,,,,,,,,,,2.32,6.08,2.15,,无, 无, P0,H0, 未做, CK+,,,,,61.202365308804204,1614546
1615095,伍贵才,638346,男,61,T4b,N0,M0, ⅢA,1,2,2.0,0.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,64,中间型（int）,INFa,0.0,,,,,,,,2016-05-06,2021-06-07,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)02 (3a)019 (3b)03 (4sb)01 (4d)09 (5)02 (6)012 (7)04 (8a)03 (8p)02 (9)03 (11p)03 (12a)00," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,90,10,,R1,8.73,5.77,2.16,93.7,487.0,4.29,11.0,13.0,181.0,110.0,39.0,4.5,1.37,68.0,260.0,39.0,29.0,4.6,6.1,83.0,257.0,,,,,,,,,,,,,32.93,14.11,69.51,,无, 无, P0,H0, 未做, CK+,,,,,61.038107752956634,1615095
1614601,李忠范,637191,男,59,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,18.0,32,中间型（int）,INFc,0.0,,,,,,,,2016-05-03,2017-12-14,2,,,SOX,SOX,替吉奥单药,,,,3, 低粘附腺癌70 管状腺癌（低分化【G2】【tub2】30 Lauren混合型,G3, (1a)00 (1b)00 (2)34 (3a)912 (3b)00 (4sa)00 (4sb)00 (5)00 (7)23 (8a)01 (8p)02 (9)01 (11d)12 (11p)14 (16a1)00," U（胃底部）, 前Ant, 小弯侧Less, 后Post, 大弯侧Gre, SiewerⅡ,",45,35,10, R0 D2,,6.17,5.12,0.37,151.6,114.0,2.52,19.0,20.0,127.0,102.0,10.0,24.0,8.0,64.0,310.0,42.0,22.0,4.4,6.4,81.0,342.0,37.3,25.3,10.4,2.43,0.1,16.7,36.5,1.5,0.753,0.867,7.26,,1.45,20.81,2.17,,无,, P0,H0, 未做,Ck+、cd34+、d2-40+ s-100+,,,,,19.38239159001314,1614601
1614706,张子才,623739,男,50,T4b,N3a,M1, Ⅳ,1,2,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,29,中间型（int）,INFb,1.0,,,,,,,,2016-05-04,2018-08-17,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (3a)06 (3b)22 (4sb)03 (4d)11 (5)00 (6)00 (7)24 (8a)05 (8p)22 (9)04 (11p)02 3a、3b、4d、6、8a组软组织可见癌, LM 前Ant 小弯侧Less 后Post ,80,50,8,,R2,6.87,5.05,1.13,101.7,322.0,4.69,33.0,24.0,110.0,62.0,13.0,5.74,2.25,63.0,173.0,36.0,27.0,4.9,5.1,80.0,283.0,,,,,,,,,,,,,4.85,16.15,0.824, 未做,无,, P0,H0, 未做, CK +,,,,,27.43101182654402,1614706
1614704,王本忠,640456,男,64,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,5.0,22,中间型（int）,INFa,0.0,,,,,,,,2016-05-04,2018-04-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)03 (3a)00 (3b)02 (4sb)03 (4d)01 (6)33 (7)01 (8a)22 (8p)02 (9)01 (11p)02 (12a)01," L（幽门窦部）, 前Ant,",30,20,10, R0 D2,,9.88,8.25,1.14,150.0,241.0,3.01,25.0,29.0,185.0,64.0,8.0,13.84,5.01,56.0,270.0,32.0,24.0,6.1,4.0,85.0,124.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK+ CD31-  D2-40-  S-100-,,,,,22.897503285151117,1614704
1614518,王晶,626150,男,69,T4a,N2,M0, ⅢA,1,3,1.0,1.0,1.0,0.0, 正常,4.0,29,中间型（int）,INFc,0.0,,,,,,,,2016-05-03,2021-05-19,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90% 低粘附腺癌10% Lauren混合型,G2, (3a)(1/5) (4sa)(1/2) (4sb)(1/1) (11p)(1/5) (1a)(0/3) (1b)(0/1) (2)(0/3) (3b)(0/1) (5)(0/1) (7)(0/2) (8a)(0/2) (8p)(0/2) (9)(0/1)," U（胃底部）, 后Post, 小弯侧Less,",60,40,5,R0,,10.22,7.27,2.32,100.0,271.0,110.3,5.0,10.0,157.0,57.0,33.0,9.75,3.09,63.0,347.0,40.0,23.0,5.6,3.8,97.0,368.0,,,,,,,,,,,,,1.57,23.5,1.41, 阳性+,无, 无, P0,H0, 未做, CK CD34 S-100,,,,,60.51248357424441,1614518
1614739,白生智,639929,男,67,T3,N2,M0, ⅢA,1,2,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+,4.0,19,髓样型（med）,INFa,3.0,,,,,,,,2016-05-04,2021-05-27,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)(0/0) (1b)(0/6) (3a)(0/0) (3b)(2/4) (4sb)(0/0) (4d)(0/1) (5)(1/1) (8a)(1/1) (6)(1/3) (7)(0/2) (8p)(0/1) (9)(0/0) (11p)(0/1) (12a)(0/0)," LM 前Ant, 后Post, 小弯侧Less,",90,70,15, R0,,8.28,5.94,1.63,79.3,271.0,4.82,20.0,20.0,183.0,77.0,22.0,5.94,2.35,60.0,183.0,33.0,27.0,4.5,7.2,77.0,228.0,,,,,,,,,,,,,2.33,17.93,3.57, 未做,无, 无, P0,H0, 未做, CK CD31 S-100,,,,,60.74244415243101,1614739
1614745,孙守杰,637297,男,62,T4b,N2,M0, ⅢB,1,5,0.0,1.0,,1.0, 慢性炎症（+）,4.0,44,中间型（int）,INFb,0.0,,,,,,,,2016-05-04,2019-09-02,0,,,XELOX,,,,,,2, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)01 (1b)01 (2)38 (3a)010 (3b)17 (4sa)06 (4sb)00 (4d)01 (5)00 (6)00 (7)04 (8a)01 (8p)03 (9)02 (11p)00 (12a)00," GE, SiewerⅢ, 后Post, 前Ant, 大弯侧Gre, 小弯侧Less,",80,70,15, R0 D2,,9.88,6.96,1.99,152.0,275.0,4.32,15.0,15.0,147.0,90.0,47.0,12.11,3.8,64.0,273.0,40.0,24.0,6.2,7.5,87.0,383.0,,,,,,,,,,,,,2.74,13.59,7.03,,无, 无, P0,H0, 未做, CK+,,,,,39.94743758212878,1614745
1614945,王海,637220,男,51,T2,N2,M0, ⅡB,1,3,1.0,1.0,,1.0, 肠化生+ 慢性炎症（+）,4.0,15,中间型（int）,INFc,1.0,,,,,,,,2016-05-05,2020-04-14,0,,,XELOX,,,,,,6, 低粘附腺癌55 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 乳头状癌（G1）（pap）5,G3, (1a)00 (1b)01 (3a)01 (3b)01 (4sb)00 (4d)03 (5)00 (6)36 (7)01 (8a)11 (8p)00 (9)00 (11p)00 (12a)01," L（幽门窦部）, 小弯侧Less,",35,35,5,,R1,6.37,3.74,1.9,118.7,398.0,3.13,22.0,28.0,177.0,121.0,61.0,9.61,3.43,70.0,419.0,44.0,26.0,5.2,6.9,91.0,376.0,,,,,,,,,,,,,2.33,138.1,14.34,,无, 无, P0,H0, 未做, CK+,,,,,47.30617608409987,1614945
1614737,吴占山,640733,男,59,T2,N0,M0, ⅠB,1,2,1.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,18,髓样型（med）,INFb,1.0,,,,,,,,2016-05-04,2019-05-01,0,,,XELOX,XELOX,替吉奥单药,,,,3, 低粘附腺癌50 管状腺癌（中低分化【G2】【tub2】50,G3, (1a)01 (1b)03 (3a)01 (3b)00 (4sb)00 (4d)00 (5)01 (6)00 (7)01 (8a)03 (8p)03 (9)00 (11p)02 (12a)00, L（幽门窦部） 前Ant 小弯侧Less ,35,20,10, R0 D2,,5.19,2.4,2.33,146.0,198.0,2.56,45.0,38.0,154.0,135.0,25.0,15.69,5.08,68.0,312.0,40.0,28.0,4.3,7.7,151.0,438.0,75.6,38.1,32.9,1.16,0.1,6.4,17.2,3.2,1.47,1.79,11.8,,8.45,7.9,2.25, 未做,无,, P0,H0, 未做, CK +,,,,,35.873850197109064,1614737
1614943,张树成,633822,男,65,T4a,N1,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,1.0,18,中间型（int）,INFa,0.0,,,,,,,,2016-05-05,2021-05-27,1,,,奥沙利铂,,,,,,3, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)01 (2)07 (3a)17 (3b)00 (4sa)00 (4sb)01 (7)00 (8a)00 (8p)00 (9)00 (11p)00 (12a)00," U（胃底部）, 前Ant, 后Post, 小弯侧Less, 大弯侧Gre,",65,40,5, R0 D2,,6.68,4.47,1.7,128.4,338.0,3.07,17.0,23.0,178.0,77.0,30.0,14.26,4.39,74.0,333.0,40.0,34.0,6.0,6.1,105.0,442.0,,,,,,,,,,,,,2.31,34.91,1.95, 未做,无, 无, P0,H0, 未做, CK+ CD31+  D2-40+  S-100+,,,,,60.709592641261494,1614943
1614823,王忠诚,640572,男,66,T4a,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,3.0,34,中间型（int）,INFb,0.0,,,,,,,,2016-05-05,2022-09-01,1,,,奥沙利铂,,,,,,3, 乳头状癌（G1）（pap）60 管状腺癌（中分化【G2】【tub2】40 Lauren肠型,G2, (1a)01 (1b)01 (3a)16 (3b)13 (4sb)00 (4d)13 (5)01 (6)012 (7)02 (8a)01 (8p)01 (9)01 (11p)02 (12a)00 另3b 5组 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,60,15,,R1,3.63,1.78,1.46,93.0,177.0,2.9,16.0,21.0,145.0,49.0,9.0,10.52,4.16,56.0,205.0,33.0,23.0,4.4,8.2,84.0,274.0,,,,,,,,,,,,,12.05,16.61,1.88, 阳性+,无, 无, P0,H0, 未做, CK + S-100+ CD31+  D2-40+ ,,,,,75.88699080157687,1614823
1614941,平玉江,640240,男,72,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 肠化生++ 慢性炎症（+） 异型增生+,5.0,23,中间型（int）,INFb,1.0,,,,,,,,2016-05-05,2018-03-21,2,,,,,,,,,0, 管状腺癌（低中分化【G2】【tub2】70 低粘附腺癌30 Lauren混合型,G2, (1a)01 (1b)00 (3a)1900 (4sb)00 (4d)01 (5)00 (6)25 (7)01 (8a)22 (9)03 (11p)01 (3b)00 (3b)(8a) 软组织可见癌," L（幽门窦部）, 小弯侧Less,",40,35,12, R0 D2,,5.29,2.33,2.18,160.0,214.0,2.79,24.0,28.0,157.0,80.0,25.0,16.67,5.8,65.0,287.0,36.0,29.0,4.7,6.2,94.0,363.0,,,,,,,,,,,,,85.61,6.4,1.2,,无,, P0,H0, 未做,Ck+、cd34+、d2-40+ s-100+,,,,,22.503285151116952,1614941
1615481,沙文彬,506054,男,50,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 正常,0.0,31,中间型（int）,INFa,0.0,,,,,,,,2016-05-10,2022-09-01,1,,,XELOX,,,,,,4, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)00 (3a)08 (3b)00 (4sb)01 (4d)04 (5)01 (6)03 (7)02 (8a)01 (8p)02 (9)04 (11p)00 (12a)04," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,35,10, R0 D2+,,8.71,6.36,1.8,87.6,427.0,4.1,18.0,19.0,119.0,74.0,8.0,5.72,2.06,59.0,248.0,36.0,23.0,5.4,4.8,85.0,315.0,68.9,38.4,28.0,1.37,1.8,12.0,17.6,1.0,1.88,1.68,9.03,,2.11,2.7,4.35, 未做,无,, P0,H0, 未做, CK +,,,,,75.7227332457293,1615481
1615378,马月菊,640290,男,60,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,36,,,1.0,,,,,,,,2016-05-09,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（低分化【G1】【tub1】）,G3, (1a)01 (1b)00 (3a)08 (3b)02 (4sb)02 (4d)02 (5)01 (6)07 (7)01 (8a)04 (8p)00 (9)03 (11p)05 (12a)00," L（幽门窦部）, 后Post,",20,15,5, R0 D2,,6.79,3.36,2.77,157.0,171.0,1.96,16.0,18.0,140.0,61.0,11.0,20.94,7.52,68.0,399.0,43.0,25.0,4.7,4.0,94.0,262.0,56.4,26.9,24.6,1.09,0.1,11.9,30.6,5.4,0.855,2.52,10.3,,0.964,9.48,2.56,,无,, P0,H0, 未做, CK+,,,,,75.75558475689881,1615378
1615240,曲胜国,640828,男,44,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,10.0,15,中间型（int）,INFc,0.0,,,,,,,,2016-05-09,2018-09-09,2,,,卡培他滨,,,,,,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌35 乳头状癌（G1）（pap）5 Lauren混合型,G3, (1a)00 (1b)00 (3a)01 (3b)46 (4sb)00 (4d)23 (5)12 (6)00 (7)22 (8a)00 (8p)00 (9)11 (11p)00 (12a)00," L（幽门窦部）, 前Ant,",90,80,10, R0 D2,,8.45,5.43,2.52,148.0,325.0,3.28,24.0,18.0,125.0,119.0,42.6,12.52,3.7,63.3,307.77,39.9,23.4,7.4,2.63,73.0,268.0,,,,,,,,,,,,,2.07,458.0,3.62,,无, 无, P0,H0, 未做, CK+ CD31+  D2-40 + S-100+,,,,,28.02233902759527,1615240
1614880,赵振明,626205,男,66,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,28,,,0.0,,,,,,,,2016-05-05,2021-07-07,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (3a)013 (3b)02 (4sb)02 (4d)05 (5)00 (6)02 (7)00 (8a)01 (8p)03 (9)00 (11p)00 (12a)00," L（幽门窦部）, 大弯侧Gre, 小弯侧Less,",20,15,5, R0 D2,,4.65,1.9,2.06,140.1,188.0,2.44,10.0,21.0,131.0,50.0,7.0,13.95,5.77,65.0,190.0,39.0,26.0,4.0,4.7,92.0,364.0,,,,,,,,,,,,,1.23,10.75,0.905, 阳性+,无,, P0,H0, 未做, CK +,,,,,62.056504599211564,1614880
1615482,崔万忠,640577,男,53,T4b,N0,M0, ⅢA,1,2,0.0,0.0,,0.0, 慢性炎症（+）,0.0,36,中间型（int）,INFa,0.0,,,,,,,,2016-05-10,2021-06-14,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)65 乳头状癌（G1）（pap）35 Lauren肠型,G3, (1a)03 (1b)01 (2)00 (3a)01 (3b)02 (4sa)03 (4sb)00 (4d)04 (5)01 (6)06 (7)01 (8a)01 (8p)03 (9)05 (10)01 (11p)02," G=E, SiewerⅡ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",65,60,18, R0 D2,,7.53,4.49,2.0,116.0,423.0,2.79,17.0,19.0,119.0,78.0,12.0,9.45,2.87,60.0,284.0,36.0,24.0,4.4,6.8,84.0,270.0,,,,,,,,,,,,,4.94,6.17,2.71, 未做,无, 无, P0,H0, 未做, CK+,,,,,61.136662286465175,1615482
1615376,郭书林,640576,男,75,T3,N0,M0, ⅡA,1,3,0.0,1.0,,0.0, 肠化生+ 慢性炎症（+）,0.0,25,中间型（int）,INFa,0.0,,,,,,,,2016-05-09,2017-06-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) (1b) (3a) (3b) (5) (7) (9) (11p) (12a)016 (4sb) (4d) (6)09," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,15, R0 D2,,6.2,3.87,1.57,80.0,286.0,4.21,31.0,22.0,135.0,75.0,59.0,4.04,1.91,50.0,166.0,28.0,22.0,4.9,6.3,69.0,154.0,,,,,,,,,,,,,2.01,70.03,6.3,,无, 无, P0,H0, 未做, CK+,,,,,13.206307490144546,1615376
1615259,周福作,640734,男,58,T2,N1,M0, ⅡA,1,3,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+） 异型增生+,1.0,29,中间型（int）,INFa,3.0,,,,,,,,2016-05-09,2022-09-01,1,,,XELOX,,,,,,1, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】30,G2, (1a)00 (1b)02 (3a)02 (3b)03 (4sb)02 (4d) 06(5) 00(6) 03(7)02 (8a)14 (8p)01 (9)02 (11p)02 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",20,20,5, R0 D2+,,4.01,2.35,31.94,164.0,178.0,2.2,28.0,30.0,163.0,61.0,10.0,16.67,5.48,62.0,298.0,39.0,23.0,4.4,7.7,81.0,331.0,71.6,41.7,22.0,1.9,0.1,18.4,8.5,3.0,1.37,3.63,8.3,,2.55,16.61,3.03, 阳性+,,,,H0, 未做, CK + S-100 -,,,,,75.75558475689881,1615259
1615865,任秀财,640759,男,48,T1b,N0,M0,ⅠA,1,0,2.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,28,中间型（int）,INFb,0.0,,,,,,,,2016-05-12,2020-07-08,0,,,,,,,,,0, 低分化腺癌（G3)(por) 90%低粘附腺癌10% Lauren弥漫型,G3,," M（胃体部）, 后Post, 小弯侧Less,",20,10,0, R0,,9.56,7.33,1.31,150.0,124.0,,22.0,15.0,205.0,90.0,26.0,12.93,4.09,60.0,342.0,38.0,22.0,4.5,4.9,75.0,311.0,,,,,,,,,,,,,2.17,6.61,0.887, 未做,无, 无, P0,H0, 未做, CK S-100,,,,,49.86859395532194,1615865
1615485,张显生,640765,男,74,T3,N0,M0, ⅡA,1,2,2.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,40,髓样型（med）,INFa,0.0,,,,,,,,2016-05-10,2021-09-02,1,,,口服卡培他滨,,,,,,1, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)00 (1b)06 (3a)02 (3b)011 (4sb)00 (4d)04 (5)00 (6)02 (7)01 (8a)03 (8p)01 (9)03 (11p)07 (14v)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,15, R0 D2,,6.25,3.86,1.84,134.3,183.0,2.95,33.0,34.0,172.0,60.0,17.0,9.74,4.32,63.0,152.0,33.0,30.0,4.5,8.5,63.0,250.0,36.2,23.5,9.8,2.4,0.1,15.0,39.0,0.4,1.51,3.87,11.7,,21.22,4.38,13.23, 阴性,无, 无, P0,H0, 未做, CK + ，S-100未见神经侵犯，CD31、D2-40未见明确脉管瘤栓,,,,,63.76478318002628,1615485
1615579,王希英,638377,女,55,T3,N0,M0, ⅡA,1,3,,,,,,0.0,25,,,0.0,,,,,,,,2016-05-10,2022-09-01,1,,,XELOX,SOX,SOX,SOX,,,4, 低粘附腺癌,GX, (1a) (1b)05 (3a) (3b)01 (4sb) (4d) (6)09 (5) (12a)01 (7) (8a) (8p) (9) (11p)09," L（幽门窦部）, 小弯侧Less,",23,13,2, R0 D2,,5.67,2.83,2.24,140.3,198.0,2.7,18.0,27.0,152.0,66.0,8.0,20.82,7.5,65.0,270.0,40.0,25.0,4.0,5.1,62.0,304.0,,,,,,,,,,,,,1.03,19.05,3.53, 未做,无, 无, P0,H0, 未做, CK+,,,,,75.7227332457293,1615579
1616414,周君,640155,男,63,T3,N0,M0, ⅡA,1,2,1.0,1.0,1.0,0.0, 肠化生+,0.0,18,髓样型（med）,INFa,0.0,,,,,,,,2016-05-16,2021-05-11,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (4sb) (4d) (6)01 (1a) (1b) (3a) (3b) (5)017," U（胃底部）, 小弯侧Less,",45,40,5, R0 D2,,6.39,3.82,1.82,135.6,216.0,3.9,8.0,21.0,111.0,54.0,41.0,11.1,3.82,64.0,329.0,36.0,28.0,4.8,9.3,78.0,279.0,,,,,,,,,,,,,1.66,5.21,1.99,,无, 无, P0,H0, 未做, CK+,,,,,59.82260183968462,1616414
1615764,刘福金,631315,男,57,T3,N3a,M1, Ⅳ,1,3,2.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,8.0,24,中间型（int）,INFb,0.0,,,,,,,,2016-05-11,2019-01-08,2,,,XELOX,XELOX,XELOX,XELOX,口服替吉奥,多西他赛联合顺铂,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40,G3, (1a) (1b) (3a) (3b) (5)412 (4sb) (4d) (6)13 (8a)15 (8p)01 (13)11 (14v)01 (16b1) (16b2)11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,20,10,,R2,7.99,4.71,2.25,151.0,273.0,3.48,20.0,19.0,182.0,98.0,18.0,13.88,4.6,65.0,353.0,41.0,24.0,4.4,5.8,83.0,360.0,,,,,,,,,,,,,2.75,21.08,6.52,,无, 无, P0,H0, 未做, CK+,,,,,31.93166885676741,1615764
1616466,庄丽英,638138,女,74,T4a,N1,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,2.0,36,中间型（int）,INFa,1.0,,,,,,,,2016-05-17,2019-09-02,0,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)02 (3a)02 (3b)05 (4sb)00 (4d)010 (5)00 (6)110 (7)00 (8a)11 (8p)00 (9)00 (11p)03 (12a)00," L（幽门窦部）, 前Ant,",80,60,10, R0 D2,,8.05,4.27,2.88,140.0,249.0,4.56,26.0,24.0,142.0,152.0,18.6,7.7,2.22,71.1,196.28,39.1,32.0,4.8,4.71,67.0,208.0,,,,,,,,,,,,,1.34,76.8,3.69,,无, 无, P0,H0, 未做, CK+,,,,,39.5203679369251,1616466
1616314,孙启荣,638382,女,54,T1b,N0,M0,ⅠA,1,1,,,,,,0.0,37,,,1.0,,,,,,,,2016-05-16,2017-07-13,0,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)02 (1b)05 (3a)06 (3b)00 (4sb)01 (4d)08 (5)00 (6)02 (7)04 (8a)01 (8p)02 (9)05 (11p)01 (12a)00," M（胃体部）, 小弯侧Less,",20,15,4, R0 D2,,4.75,2.36,1.97,122.4,217.0,2.17,16.0,23.0,187.0,50.0,7.0,11.92,4.56,66.0,207.0,40.0,26.0,4.4,5.4,53.0,167.0,,,,,,,,,,,,,0.361,6.38,1.94,,无, 无, P0,H0, 未做, CK+,,,,,13.896189224704337,1616314
1616715,汪忠臣,640836,男,60,T4a,N3a,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,8.0,33,中间型（int）,INFa,3.0,,,,,,,,2016-05-18,2017-11-27,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】60 乳头状癌（G1）（pap）40 Lauren肠型,G2, (1a)00 (1b)14 (2)28 (3a)35 (3b)01 (4sa)11 (4sb)00 (4d)04 (5)00 (6)02 (7)01 (8a)01 (8p)01 (9)11 (11p)03 (12a)00 (15)01," UM 前Ant, 后Post, 小弯侧Less,",60,40,10, R0 D2,,4.16,2.57,1.04,90.8,279.0,2.85,16.0,18.0,132.0,47.0,11.0,10.55,3.81,55.0,289.0,35.0,20.0,4.7,7.7,90.0,309.0,,,,,,,,,,,,,1.55,27.59,2.02,,无, 无, P0,H0, 未做, CK+,,,,,18.331143232588698,1616715
1615866,战晓伟,640848,女,59,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,12.0,28,中间型（int）,INFc,1.0,,,,,,,,2016-05-10,2021-06-03,1,,,XELOX,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,6, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)00 (1b)00 (3a)05 (3b)68 (4sb)00 (4d)24 (5)11 (6)12 (7)01 (8a)11 (8p)01 (9)04 (11p)11 (12a)00 4d 软组织可见癌, L（幽门窦部） 前Ant 大弯侧Gre  ,80,70,15, R0 D2,,7.32,4.25,2.21,85.5,328.0,3.26,17.0,28.0,163.0,88.0,10.0,7.8,3.26,60.0,295.0,34.0,26.0,4.6,7.0,58.0,257.0,72.1,48.3,24.2,2.0,2.8,10.3,16.2,4.2,1.1,2.6,9.18,,0.666,8.94,2.42,,无, 无, P0,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,60.775295663600524,1615866
1616375,姜贵林,640893,男,66,T4a,N3b,M1, Ⅳ,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,19.0,26,中间型（int）,INFb,0.0,,,,,,,,2016-05-16,2021-07-15,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren混合型,G3, (1a)00 (1b)00 (2)03 (3b)22 (4sa)00 (4sb)57 (4d)00 (5)11 (6)55 (7)00 (8a) (8p) (9) (11p) (12a)66," ML 前Ant, 后Post, 小弯侧Less,",90,80,15, D2,R1,5.5,2.66,2.42,148.5,223.0,2.74,22.0,18.0,125.0,73.0,11.0,6.95,2.48,58.0,288.0,33.0,25.0,6.8,6.2,89.0,375.0,,,,,,,,,,,,,1.94,2.95,76.53, 未做,无, 无, p1局腹膜(M1 PER),H0, 未做, CK+,,,,,61.95795006570302,1616375
1615862,包淑芝,640401,女,67,T4b,N1,M0, ⅢB,1,2,0.0,0.0,0.0,1.0, 肠化生+,2.0,25,中间型（int）,INFa,2.0,,,,,,,,2016-05-12,2021-05-26,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,小弯01 (1a)00 (1b)00 (3a)03 (3b)00 (4sb)00 (4d)23 (5)01 (6)04 (7)04 (8a)05 (8p)02 (9)02 (11p)00 (12a)00," LM 后Post, 大弯侧Gre,",55,50,10, R0 D2,,8.9,6.61,1.72,110.3,314.0,2.3,23.0,30.0,199.0,89.0,10.0,8.49,2.99,50.0,134.0,29.0,21.0,7.1,3.9,69.0,183.0,,,,,,,,,,,,,1.86,12.01,2.86, 未做,无, 无, P0,H0, 未做," CK+ S-100可见神经侵犯，cd31,d2-40(未见)",,,,,60.446780551905384,1615862
1616384,张有富,640609,男,48,T4a,N0,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+,0.0,29,中间型（int）,INFa,0.0,,,,,,,,2016-05-16,2021-05-27,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3,小弯侧03 (1a) 00(1b)05 (2)04 (3a)05 (3b)01 (4sa)00 (4sb)00 (4d)03 (5)00 (6)02 (7)01 (8a)01 (8p)01 (9)03 (11p)00," L（幽门窦部）, 前Ant,",90,70,15, R0 D2,,4.79,3.48,0.89,62.8,451.0,3.13,19.0,14.0,91.0,85.0,6.6,6.32,3.07,59.0,167.96,33.4,25.6,6.2,3.0,71.0,255.0,67.5,42.0,25.1,1.67,0.3,6.9,21.9,2.1,0.322,3.06,10.0,,1.04,7.3,6.29, 阴性,无, 无, P0,H0, 未做, CK+ S-100（可见神经侵犯）CD31/D2-40(脉管瘤栓),,,,,60.34822601839684,1616384
1615629,付彦侠,633751,女,52,T4b,N2,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,4.0,45,中间型（int）,INFb,2.0,,,,,,,,2016-05-11,2018-01-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren混合型,G3, (1a)03 (1b)02 (3a)16 (3b)01 (4sb)00 (4d)07 (5)01 (6)38 (7)02 (8a)02 (8p)03 (9)06 (11p) 03(12a)01,L（幽门窦部） 前Ant 后Post 小弯侧Less ,45,45,15, R0 D2,,7.38,5.07,1.69,119.1,383.0,3.56,16.0,19.0,145.0,989.0,13.0,6.6,2.77,66.0,130.0,38.0,28.0,4.4,5.3,47.0,200.0,68.2,49.7,14.4,3.45,0.3,18.6,6.5,1.1,0.847,2.12,12.0,,8.07,6.85,12.91, 阴性,无, 无, P0,H0, 未做, CK +,,,,,20.006570302233904,1615629
1616187,董宝素,639863,男,59,T4a,N3a,M0, ⅢB,1,3,2.0,1.0,1.0,1.0, 正常,15.0,19,髓样型（med）,INFc,0.0,,,,,,,,2016-05-20,2016-10-13,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,大弯78，小弯811," L（幽门窦部）, 前Ant,",90,55,15,,R1,5.69,2.99,2.08,159.0,176.0,2.6,24.0,17.0,115.0,62.0,11.3,36.87,9.09,68.7,229.38,44.3,24.4,5.9,6.98,101.0,457.0,,,,,,,,,,,,,333.0,17.23,300.0, 阴性,无, 无, P0,H0, 未做, CK+ CD31+  D2-40+  S-100+,,,,,4.7963206307490145,1616187
1615984,张玉春,638167,女,63,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,32,髓样型（med）,INFa,0.0,,,,,,,,2016-05-12,2021-05-27,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)00 (3b)04 (4sb)01 (4d)00 (6)010 (7)03 (8a)01 (8p)06 (9) 01(11p)05 (12a)00," L（幽门窦部）, 小弯侧Less,",60,30,10, R0 D2,,4.46,2.52,1.46,113.0,216.0,2.56,18.0,22.0,184.0,66.0,18.0,10.2,3.72,64.0,256.0,39.0,25.0,4.4,5.9,65.0,229.0,74.2,36.6,32.4,1.13,0.3,11.4,13.4,4.7,0.822,2.14,9.19,,1.58,16.32,0.892, 未做,无,, P0,H0, 未做, CK +,,,,,60.4796320630749,1615984
1615985,郭文栋,639874,男,60,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,3.0,17,中间型（int）,INFb,1.0,,,,,,,,2016-05-12,2021-06-09,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌15 粘液腺癌（muc）5 Lauren混合型,G3, (1a)12 (1b)00 (2)11 (3a)17 (3b)01 (4sa)00 (4sb)02 (4d)01 (5)01 (7)01 (8a)00 (8p)01 (9)00 (11p)00," L（幽门窦部）, 前Ant,",25,25,15,R0,,4.75,2.49,1.81,158.0,172.0,2.48,20.0,26.0,209.0,121.0,8.0,12.34,4.11,66.0,346.0,39.0,27.0,6.6,6.7,85.0,281.0,,,,,,,,,,,,,3.04,38.94,1.15,,无, 无, P0,H0, 未做, CK+ CD34+  D2-40+  S-100+,,,,,60.906701708278575,1615985
1616380,张顺,640885,男,60,T1b,N1,M0, ⅠB,1,2,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,1.0,25,中间型（int）,INFa,0.0,,,,,,,,2016-05-16,2021-09-27,1,,,奥沙利铂单药化疗,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)00 (3a)17 (3b)00 (4sb)00 (4d)01 (5)00 (6)05 (7)01 (8a)01 (8p)02 (9)04 (11p)01 (12a)00," L（幽门窦部）, M（胃体部）, 后Post,",20,25,10, R0 D2,,5.31,2.68,2.09,164.1,152.0,1.92,64.0,53.0,165.0,52.0,99.0,18.45,6.8,68.0,252.0,38.0,30.0,4.7,9.5,72.0,349.0,,,,,,,,,,,,,2.68,23.07,5.56,,无, 无, P0,H0, 未做, CK+ CD34+  D2-40+  S-100-,,,,,64.38896189224704,1616380
1616288,汪金,640748,男,48,T4a,N0,M0, ⅡB,1,3,1.0,0.0,0.0,1.0, 正常,0.0,23,硬型（sci）,INFc,0.0,,,,,,,,2016-05-16,2021-05-18,1,,,,,,,,,0, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)02 (1b)05 (2)00 (3a)02 (3b)00 (4sb)00 (5)00 (7)05 (8a)01 (8p)01 (9)02 (11p)02 (12a)00, U（胃底部） 后Post ,25,22,5, R0,,8.55,5.28,2.52,167.0,231.0,2.64,27.0,25.0,160.0,95.0,73.0,9.53,3.54,63.0,341.0,39.0,24.0,4.2,7.6,89.0,324.0,,,,,,,,,,,,,0.711,4.02,7.54, 阳性+,, 无, P0,H0, 未做, CK +,,,,,60.05256241787122,1616288
1616285,李桂云,633889,女,58,T3,N3a,M0,ⅢB,1,2,0.0,1.0,1.0,1.0, 正常,8.0,25,中间型（int）,INFa,0.0,,,,,,,,2016-05-16,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60%， 乳头状癌（G1）（pap）40%， Lauren肠型,G3, (1a)02 (1b)02 (3a)22 (3b)13 (4sb)00 (4d) 14(5)00 (6)14 (7)13 (8a) (8p)23 (9)02 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",25,20,10, R0 D2,,5.6,3.2,1.7,132.7,225.0,3.8,11.0,13.0,169.0,66.0,13.0,4.44,2.71,65.0,231.0,39.0,26.0,5.3,6.4,62.0,275.0,,,,,,,,,,,,,7.62,572.2,0.851, 未做,无, 无, P0,H0, 未做," CK+, S-100（可见神经侵犯)CD34、D2-40(可见脉管瘤栓)",,,,,75.52562417871222,1616285
1616989,王建生,640919,男,60,T4b,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,18.0,26,硬型（sci）,INFc,0.0,,,,,,,,2016-05-19,2017-02-15,2,,,SOX,SOX,SOX,SOX,替吉奥单药化疗,,5, 低粘附腺癌 Lauren肠型,GX," 小弯22(1a) 11(1b)11 (2)34 (3a) 44(3b)00 (4sa)01 (4sb)00 (4d) 24(5)01 (6)02 (7)22 (8a) (8p) (9)33 (12a)00 (14v)01 另在1a,1b,3a,3b,4sb,7组软组织可见癌"," M（胃体部）,前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,60,7,,R1,4.73,2.82,1.47,149.0,151.0,2.97,25.0,29.0,145.0,65.0,22.0,13.9,3.74,70.0,225.0,37.0,33.0,5.0,4.4,71.0,396.0,,,,,,,,,,,,,3.67,41.87,4.95, 未做,无, 无, P0,H0, 未做, CK + ，S-100可见神经侵犯， CD31、D2-40可见脉管瘤栓,,,,,8.935611038107753,1616989
1616561,方继玲,638173,女,57,T1b,N3b,M0, ⅢB,1,3,0.0,1.0,1.0,, 肠化生+,19.0,34,中间型（int）,INFa,0.0,,,,,,,,2016-05-17,2019-05-06,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)65 乳头状癌（G1）（pap）30 低粘附腺癌5 Lauren肠型,G3, (1a)01 (1b)23 (3a)78 (3b)34 (4sb)00 (4d)24 (5)11 (6)11 (7)12 (8a)11 (8p)04 (9)02 (11p)02 (12a)11," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,40,5, R0 D2,,3.51,1.59,1.46,127.3,191.0,2.5,18.0,27.0,150.0,33.0,7.0,11.27,4.25,62.0,173.0,37.0,25.0,4.1,7.6,51.0,141.0,,,,,,,,,,,,,3.11,6.45,1.58,,无, 无, P0,H0, 未做, CK+,,,,,35.611038107752954,1616561
1616564,刘世荣,626543,女,74,T3,N2,M0, ⅢA,1,2,2.0,0.0,0.0,1.0, 慢性炎症（+）,6.0,16,中间型（int）,INFc,0.0,,,,,,,,2016-05-17,2017-12-01,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)02 (3a)11 (3b)11 (4sb)00 (4d)26 (5)00 (6)13 (7)01 (8a)00 (8p)00 (9)00 (11p)00 (12a)00," L（幽门窦部）, 前Ant,",50,30,10, R0 D2,,3.61,1.8,1.43,127.0,234.0,3.12,17.0,23.0,172.0,98.0,16.0,7.31,2.41,61.0,284.0,35.0,26.0,5.8,4.7,65.0,162.0,,,,,,,,,,,,,1.85,7.48,3.52,,无, 无, P0,H0, 未做, CK+ CD31 - D2-40-  S-100-,,,,,18.495400788436267,1616564
1616563,吴兰健,640392,男,46,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,20.0,26,硬型（sci）,INFc,0.0,,,,,,,,2016-05-17,2018-09-06,2,,,,,,,,,0," 低粘附腺癌90%, 低分化腺癌（G3)(por)10% Lauren混合型",G3, (1a)11 (1b)01 (3a) 44(3b)00 (4sb)00 (4d)56 (5) 11(6)44 (7)01 (8a)34 (8p)01 (9)01 (11p)11 (12a)11 (16a1)00。3a/5软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,55,20, R0 D2,,7.51,3.11,3.79,177.0,312.0,3.48,31.0,38.0,152.0,56.0,30.0,9.79,4.3,63.0,243.0,39.0,24.0,5.3,4.6,76.0,44.0,,,,,,,,,0.858,2.06,7.63,,6.23,145.7,4.36, 阴性,无, 无, P0,H0, 未做, CK+ S-100（可见神经侵犯）CD34、D2-40(可见脉管瘤栓),,,,,27.660972404730618,1616563
1616527,杨宝君,633794,男,57,T1a,N0,M0,ⅠA,1,2,,,,,,0.0,22,,,0.0,,,,,,,,2016-05-17,2021-09-27,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)00 (3a)05 (3b)00 (4sb)00 (4d)03 (5)00 (6)01 (7)02 (8a)01 (8p)03 (9)02 (11p)03 (12a)01," L（幽门窦部）, 小弯侧Less,",20,20,, R0 D2,,5.27,2.73,1.77,156.0,271.0,2.2,19.0,23.0,181.0,67.0,14.0,9.34,3.77,69.0,329.0,40.0,29.0,4.8,6.7,70.0,390.0,,,,,,,,,,,,,3.95,21.94,1.95,,无, 无, P0,H0, 未做, CK+,,,,,64.35611038107753,1616527
1616712,何建民,640880,男,64,T4a,N1,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 肠化生+,2.0,24,髓样型（med）,INFa,2.0,,,,,,,,2016-05-18,2022-09-01,1,,,口服替吉奥,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)17 (3b)00 (4sb)00 (4d)03 (5)00 (6)02 (7)02 (8a)15 (8p)00 (9)02 (11p)02 (12a)003b 软组织可见癌," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",55,50,18, R0 D2,,11.09,8.98,1.27,87.5,434.0,5.1,17.0,20.0,156.0,83.0,16.0,4.63,1.77,65.0,204.0,36.0,29.0,5.8,8.7,124.0,204.0,63.1,25.2,34.8,0.72,0.1,10.6,25.0,4.2,0.796,2.87,10.8,,1.85,28.03,1.7,,无, 无, P0,H0, 未做,Ck（+）CD31(+) D2-40(+)S-100(+),,,,,75.45992115637318,1616712
1616470,邹振江,640653,男,68,T4a,N3a,M0, ⅢB,1,2,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,28,中间型（int）,INFa,0.0,,,,,,,,2016-05-17,2020-06-30,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,紫杉醇联合替吉奥*5,10, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70%， 乳头状癌（G1）（pap）30%， Lauren肠型,G3, (1a)02 (1b)00 (3a)02 (3b)23 (4sb)01 (4d)06 (5)12 (6)11 (7)14 (8a) (8p)24 (9) (11p)03 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,35,8, R0 D2,,4.05,1.92,1.76,138.0,237.0,2.3,18.0,23.0,167.0,73.0,12.0,8.77,3.54,62.0,210.0,35.0,27.0,5.4,5.3,71.0,229.0,82.4,40.5,39.3,1.03,0.2,7.3,8.8,3.3,0.454,2.92,11.1,,1.59,6.21,3.48, 阴性,无, 无, P0,H0, 未做, CK+ S-100（可见神经侵犯）D2-40，cd31（可见脉管瘤栓）,,,,,49.44152431011826,1616470
1617736,吴刚,641376,男,65,T4a,N0,M0, ⅡB,1,3,1.0,0.0,0.0,1.0, 异型增生+ 慢性炎症（+）,0.0,19,硬型（sci）,INFb,1.0,,,,,,,,2016-05-25,2017-12-12,2,,,口服替吉奥,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren混合型,G3, (1a)02 (1b)01 (2)02 (3a)04 (3b)04 (4sa)00 (4sb)00 (5)00 (7)01 (8a)01 (8p)02 (9)01 (11p)01 (12a)00, GE SiewerⅢ型 前Ant 小弯侧Less 后Post ,50,40,15, R0 D2,,6.89,3.41,2.92,143.0,175.0,2.46,55.0,36.0,159.0,86.0,69.0,6.33,2.56,68.0,198.0,35.0,33.0,7.1,7.6,74.0,397.0,,,,,,,,,,,,,3.92,11.98,0.938, 阴性,无,, P0,H0, 未做, CK +,,,,,18.593955321944808,1617736
1616653,刘泽义,641418,男,67,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,1.0,42,硬型（sci）,INFa,0.0,,,,,,,,2016-05-18,2021-06-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)04 (1b)14 (2)04 (3a)04 (3b)02 (4sa)00 (4sb)00 (4d)09 (5)01 (6)06 (7)03 (8a)02 (8p)01 (9)01 (11p)01, U（胃底部） 后Post ,40,30,10, R0 D2,,4.92,2.71,1.48,134.2,239.0,2.7,18.0,21.0,128.0,81.0,10.0,8.9,3.69,63.0,171.0,37.0,26.0,4.4,7.9,68.0,260.0,59.4,43.2,15.1,2.86,0.1,7.9,29.4,1.7,0.755,2.52,11.1,,1.16,8.29,5.31, 未做,无,, P0,H0, 未做, CK +,,,,,60.446780551905384,1616653
1616987,冀殿龙,640929,男,47,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,21,,,1.0,,,,,,,,2016-06-19,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)03 (1b)02 (3a)00 （3b)00 (4sb)00 (4d)00 (5)00 (6)01 (7)01 (8a)01 (8p)03 (9)06 (11p)00 (12a)02," L（幽门窦部）, 小弯侧Less,",30,30,2, R0 D2+,,6.03,3.31,2.08,142.7,189.0,2.17,46.0,36.0,166.0,68.0,44.0,8.27,2.78,61.0,382.0,37.0,24.0,,6.5,81.0,287.0,81.0,37.2,32.4,1.15,0.3,8.0,5.8,2.8,1.73,1.25,8.21,,0.974,9.27,1.73, 未做,无,, P0,H0, 未做, CK +,,,,,74.40867279894874,1616987
1616710,刘树彬,502505,男,57,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,33,,,0.0,,,,,,,,2016-05-18,2021-07-06,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20,G3, (1a)00 (1b)03 (3a)03 (3b)06 (4sb)00 (4d)06 (5)03 (6)02 (7)01 (8a)01 (8p)03 (9)03 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",15,15,, R0 D2,,4.44,1.54,1.99,161.4,173.0,2.13,54.0,35.0,136.0,46.0,69.0,18.68,7.68,60.0,336.0,38.0,22.0,5.0,6.3,88.0,274.0,78.7,49.8,27.1,1.84,0.2,10.0,7.3,1.3,0.647,1.46,7.67,,1.72,13.28,1.01,  阴性,无,, P0,H0, 未做, CK +,,,,,61.596583442838366,1616710
1618184,付连志,633688,男,46,T4b,N3a,M0, ⅢC,1,3,2.0,1.0,1.0,0.0,,7.0,35,中间型（int）,INFc,0.0,,,,,,,,2016-05-27,2021-05-27,1,,,SOX,SOX,SOX,口服替吉奥,口服替吉奥,,5, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (4sb) (4d) (6)77 (1a) (1b) (3a) (3b) (5)03," M（胃体部）, 大弯侧Gre,",55,50,13, R0 D2,,17.97,14.87,1.25,97.0,336.0,3.48,14.0,12.0,123.0,24.0,72.0,13.9,7.93,54.0,104.0,30.0,24.0,6.5,5.4,103.0,348.0,,,,,,,,,,,,,1.07,6.32,2.36,,无, 无, P0,H0, 未做, CK+,,,,,59.98685939553219,1618184
1617397,曲振霞,640934,女,64,T4a,N1,M0, ⅢA,1,4,2.0,1.0,1.0,1.0, 慢性炎症（+）,2.0,20,硬型（sci）,INFc,1.0,,,,,,,,2016-05-23,2021-06-01,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)03 (1b)00 (3a)25 (3b)00 (4sb)01 (4d)00 (5)00 (6)03 (7)04 (8a)01 (8p)00 (9)01 (11p)02 (12a)00," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",40,35,13, R0 D2+,,6.83,3.72,2.58,120.0,302.0,2.95,18.0,24.0,182.0,106.0,12.0,8.64,2.67,72.0,353.0,42.0,30.0,5.6,7.7,69.0,232.0,,,,,,,,,,,,,0.774,6.77,0.814,,无, 无, P0,H0, 未做, CK+,,,,,60.282522996057814,1617397
1617275,张长莉,640951,女,54,T1b,N1,M0, ⅠB,1,3,,1.0,1.0,1.0,,1.0,29,,,0.0,,,,,,,,2016-05-23,2021-09-27,1,,,,,,,,,0, 低粘附腺癌 90低分化腺癌（G3)(por)10,G3, (1a) 01(1b)00 (3a)07 (3b)11 (4sb)01 (4d)07 (5)02 (6)01 (7)03 (8a)01 (9)03 (11p) 01(12a)00 (14v)00," 前Ant, 小弯侧Less, M（胃体部）,",30,25,6, D2+ R0,,22.54,19.69,1.86,87.0,135.0,2.0,14.0,18.0,112.0,63.0,10.0,4.61,1.67,63.0,263.0,37.0,26.0,5.8,7.2,39.0,233.0,48.1,28.6,17.0,1.68,0.2,18.2,24.8,1.8,0.995,2.13,11.4,,0.255,5.79,5.31, 阴性,无, 无, P0,H0, 未做, CK + S-100+,,,,,64.15900131406045,1617275
1617165,姜术伦,358946,男,65,T4a,N3a,M0, ⅢB,1,3,2.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,12.0,38,硬型（sci）,INFc,1.0,,,,,,,,2016-05-20,2019-04-14,2,,,TPF,TPF,TPF,TPF,TPF,TPF,8, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)68 (3b)00 (4sb) 00(4d) 13(5)00 (6)34 (7)24 (8a)03 (8p)03 (9)08 (11p)05 (12a)00, L（幽门窦部） 大弯侧Gre  ,25,20,10, R0 D2,,6.57,3.83,2.15,128.4,248.0,2.46,19.0,21.0,147.0,53.0,23.0,11.38,4.0,69.0,450.0,42.0,27.0,4.7,7.6,107.0,406.0,65.0,36.7,18.3,2.01,0.1,11.9,14.8,0.9,0.515,1.67,9.13,,1.98,2.74,7.5, 阳性+,无,, P0,H0, 未做, CK +,,,,,34.78975032851511,1617165
1617394,王景山,640945,男,61,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,1.0,19,中间型（int）,INFa,0.0,,,,,,,,2016-05-23,2021-06-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)01 (2)01 (3a)03 (4sa)00 (4sb)00 (4d)01 (5)01 (6)01 (7)01 (8a)01 (8p)02 (9)02 (11p)02 (12a)00, M（胃体部） 小弯侧Less ,30,30,8, R0 D2,,5.25,3.02,1.89,157.0,202.0,3.43,17.0,20.0,128.0,52.0,13.0,12.32,3.36,64.0,344.0,40.0,24.0,5.3,4.1,70.0,337.0,81.8,46.3,31.6,1.47,1.0,6.2,9.4,6.3,0.657,0.9,7.87,,1.31,8.48,1.02,,无, 无, P0,H0, 未做,Ck（+）CD31(-) D2-40(+)S-100(+),,,,,60.282522996057814,1617394
1618290,于桂荣,638140,女,72,T4b,N2,M0, ⅢB,1,2,1.0,1.0,1.0,1.0, 慢性炎症（+）,3.0,15,中间型（int）,INFb,0.0,,,,,,,,2016-05-30,2017-12-14,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren混合型,G3, (1a)01 (1b)01 (3a)16 (3b)11 (4sb)01 (4d)01 (5)00 (6)01 (7)02 (8a)11 (8p)00 (9)00 (11p)00 (12a)00, L（幽门窦部） 前Ant 后Post 小弯侧Less ,50,50,10, R0 D2,,7.66,4.89,2.19,100.0,392.0,3.58,17.0,22.0,152.0,114.0,22.0,4.76,1.73,66.0,226.0,35.0,31.0,10.3,7.7,67.0,403.0,65.3,28.0,33.0,0.85,0.4,8.9,18.5,1.7,0.406,4.0,10.9,,2.7,55.79,3.15, 未做,无, 无, P0,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,18.495400788436267,1618290
1617494,那桂新,642946,女,63,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,40,中间型（int）,INFa,1.0,,,,,,,,2016-05-24,2019-05-05,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 乳头状癌（G1）（pap）20 Lauren肠型,G3, (1a)01 (1b)00 (2)05 (3a)06 (4sa)00 (4sb)04 (4d)00 (5)02 (6)09 (7)04 (8a)03 (8p)01 (9)02 (11p)03 (12a)00," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,55,25, R0 D2,,4.08,2.91,0.62,81.0,236.0,2.56,13.0,27.0,174.0,84.0,7.0,8.15,3.14,67.0,218.0,39.0,28.0,5.2,6.6,59.0,241.0,,,,,,,,,,,,,1.38,110.8,2.2,,无, 无, P0,H0, 未做, CK+,,,,,35.34822601839684,1617494
1618817,王学训,642840,男,80,T3,N0,M0, ⅡA,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,0.0,32,中间型（int）,INFc,3.0,,,,,,,,2016-06-02,2019-09-02,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】85 低粘附腺癌15,G2, (1a)02 (1b)01 (3a)02 (3b)02 (4sb)00 (4d)09 (5)00 (6)06 (7)00 (8a)03 (8p)02 (9)03 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,15,6, R0 D2,,6.15,3.74,1.83,137.5,280.0,2.74,10.0,26.0,182.0,54.0,7.0,19.21,6.92,56.0,168.0,31.0,25.0,4.2,8.3,73.0,374.0,,,,,,,,,,,,,0.88,9.05,0.868, 未做,无, 无, P0,H0, 未做, CK+,,,,,38.99474375821288,1618817
1617934,宋海,634878,男,65,T1b,N0,M0,ⅠA,1,3,0.0,,,, 肠化生+ 慢性炎症（+）,0.0,33,中间型（int）,INFb,1.0,,,,,,,,2016-05-26,2019-09-02,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)08 (3b)01 (4sb)02 (4d)07 (5)01 (6)06 (7)01 (8a) (8p)03 (9)02 (11p)01 (12a)01," L（幽门窦部）, 后Post,",15,10,5, R0 D2,,7.9,6.23,0.91,115.0,336.0,6.66,31.0,35.0,171.0,139.0,82.0,7.43,3.3,68.0,178.0,36.0,32.0,4.6,8.0,85.0,276.0,,,,,,,,,,,,,2.27,11.26,1.56, 未做,无, 无, P0,H0, 未做, CK+,,,,,39.22470433639947,1617934
1617543,田立华,633837,男,46,T2,N1,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,1.0,40,髓样型（med）,INFa,0.0,,,,,,,,2016-05-24,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)03 (3a)07 (3b)01 (4sb)01 (4d)05 (5)01 (6)111 (7)01 (8a)01 (8p)02 (9)02 (11p)03 (12a)01," L（幽门窦部）, 后Post, 小弯侧Less,",35,35,7, R0 D2,,4.46,2.61,1.38,163.7,256.0,2.41,21.0,25.0,175.0,71.0,14.0,20.42,6.57,72.0,285.0,44.0,28.0,4.6,9.3,70.0,318.0,,,,,,,,,,,,,1.16,14.02,1.1, 未做,无, 无, P0,H0, 未做, CK+,,,,,75.2628120893561,1617543
1617963,陈树君,638160,男,60,T2,N1,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,2.0,30,中间型（int）,INFb,0.0,,,,,,,,2016-05-26,2021-06-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)09 (5)01 (6)29 (7)01 (8a)01 (8p)02 (9)01 (11p)03 (12a)01," L（幽门窦部）, 后Post,",22,15,4, R0 D2,,,,,,,2.2,19.0,20.0,107.0,85.0,19.0,11.62,3.47,66.0,270.0,37.0,29.0,4.5,5.7,83.0,329.0,,,,,,,,,,,,,2.32,2.81,1.7, 未做,无, 无, P0,H0, 未做, CK+,,,,,60.183968462549274,1617963
1618071,孙玉华,642835,女,42,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,9.0,27,中间型（int）,INFc,0.0,,,,,,,,2016-05-27,2019-09-02,0,,,,,,,,,0, 粘液腺癌（muc）50 低分化腺癌（G3)(por)40 低粘附腺癌10 Lauren弥漫型,G3, (1a)00 (1b)02 (3a)00 (3b)02 (4sb)00 (4d)47 (5)01 (6)24 (7)14 (8a)00 (8p)01 (9)23 (11p)03 (12a)00," L（幽门窦部）, 后Post,",15,10,, R0 D2,,6.28,3.37,2.45,111.0,310.0,2.14,22.0,23.0,127.0,57.0,6.0,11.02,3.37,71.0,262.0,41.0,30.0,5.9,6.9,88.0,305.0,,,,,,,,,,,,,0.689,10.56,1.33, 未做,无, 无, P0,H0, 未做, CK+,,,,,39.19185282522996,1618071
1617643,刘彦平,638429,男,52,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,18,,,0.0,,,,,,,,2016-05-25,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30,G3, (3a)05 (3b)01 (4sb)00 (4d) 02(5)01 (6)03 (7) 04(8a)01 (11p)00 (12a)01," L（幽门窦部）, 小弯侧Less,",30,20,5, R0 D2+,,10.26,5.46,3.76,161.0,300.0,2.48,24.0,23.0,167.0,93.0,16.0,8.07,1.74,69.0,466.0,42.0,27.0,5.1,7.9,92.0,379.0,67.2,48.6,11.8,4.12,0.1,8.5,20.4,1.6,1.49,3.34,15.0,,2.22,14.57,3.45, 阳性+,,, P0,, 未做, CK +,,,,,75.22996057818659,1617643
1618288,李振国,641724,男,56,T3,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+） 腺体萎缩+,4.0,21,中间型（int）,INFc,0.0,,,,,,,,2016-05-30,2017-03-24,0,,,口服卡培他滨,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)00 (1b)25 (2)13 (3a)13 (3b)00 (4sa)01 (4sb)00 (5)00 (7)01 (8a) (8p)06 (9)02 (11p)00 (12a)00," U（胃底部）, 前Ant, 小弯侧Less,",35,28,10, R0 D2,,7.62,3.6,3.52,137.0,239.0,1.77,21.0,25.0,170.0,80.0,9.0,23.4,9.21,64.0,273.0,40.0,24.0,5.3,7.3,75.0,233.0,,,,,,,,,,,,,1.89,9.5,0.881,,无, 无, P0,H0, 未做, CK+,,,,,9.789750328515112,1618288
1617927,王阁忠,626156,男,54,T2,N1,M0, ⅡA,1,3,2.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+） 异型增生+,1.0,35,中间型（int）,INFc,0.0,,,,,,,,2016-05-26,2022-09-01,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌,GX, (1a)00 (1b) 00(3a)014 (3b) 11(4sb) 00(4d)07 (5) 00(6)00 (7)01 (8a)01 (8p) 01(9)02 (11p)03 (12a)00," L（幽门窦部）, 后Post,",20,15,6, R0 D2+,,13.83,11.71,1.05,138.2,170.0,1.88,13.0,17.0,165.0,84.0,23.0,7.21,2.31,60.0,407.0,37.0,23.0,5.2,7.9,90.0,342.0,80.4,62.2,14.8,4.2,0.1,6.5,10.7,0.9,0.665,2.01,7.95,,2.28,100.2,0.854, 阳性+,,, P0,H0, 未做, CK + S-100 -,,,,,75.19710906701708,1617927
1617847,田玉萍,636598,女,59,T4b,N3a,M0, ⅢC,1,2,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,13.0,26,髓样型（med）,INFb,0.0,,,,,,,,2016-05-26,2020-06-01,2,,,口服卡培他滨,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren混合型,G3, (1a)02 (1b)00 (3a)06 (3b)00 (4d)23 (5)1 (6)44 (7)12 (8a)45 (8p)1 (9)01 (11p)003b 软组织可见癌, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,80,60,20, D1,R1,9.52,7.21,1.4,107.2,193.0,3.4,9.0,17.0,131.0,80.0,6.0,4.17,2.31,73.0,153.0,38.0,35.0,4.2,13.7,79.0,438.0,44.4,33.0,9.9,3.33,0.1,23.2,29.1,0.4,2.4,4.07,13.8,,301.7,13.94,7.01,,无, 无, P0,H0, 未做,Ck（+）CD31(+) D2-40(+)S-100(+),,,,,48.19316688567674,1617847
1618289,李秀琴,640423,女,66,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,14,,,0.0,,,,,,,,2016-05-30,2021-07-06,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 高级别上皮内瘤变,G1, (3a)05 (3b)00 (4sb)00 (4d)05 (5)01 (6)01 (7)00 (8a)02,L（幽门窦部） 前Ant ,22,15,, R0 D2,,9.37,6.19,2.46,128.0,286.0,2.65,18.0,16.0,181.0,83.0,14.0,7.19,2.03,64.0,332.0,41.0,23.0,6.5,8.1,70.0,253.0,56.8,26.3,26.4,1.0,0.3,21.4,17.5,2.3,0.89,0.991,8.2,,0.697,5.91,3.7, 未做,无, 无, P0,H0, 未做,SMA(+)DESMN(+),,,,,61.202365308804204,1618289
1617859,赵吉勤,639494,男,58,T3,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 肠化生 慢性炎症,4.0,46,髓样型（med）,INFc,1.0,,,,,,,,2016-05-26,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 粘液腺癌（muc） 低分化腺癌（G3)(por) 低粘附腺癌 Lauren弥漫型,G3,"4,9 (1a) (1b) (2) (3a) (4sa) (4sb) (4d) (5) (6) (7) (8a) (8p) (9) (11p) (12a)0,37"," M（胃体部）, 前Ant, 小弯侧Less,",40,40,4, R0,,7.38,4.95,2.05,152.8,185.0,2.7,16.0,17.0,147.0,91.0,13.0,19.16,6.0,66.0,365.0,39.0,27.0,4.5,6.8,79.0,328.0,,,,,,,,,,,,,1.62,15.48,21.71,,无,, P0,H0, 未做, CK +,,,,,75.19710906701708,1617859
1618292,李春华,623787,女,47,T3,N3b,M0, ⅢC,1,5,2.0,1.0,1.0,1.0, 粘膜萎缩+ 慢性炎症（+）,16.0,16,中间型（int）,INFc,0.0,,,,,,,,2016-05-30,2017-09-01,2,口服替吉奥*3,1.0,SOX,,,,,,1, 低分化腺癌（G3)(por)90% 粘液腺癌（muc）10% Lauren弥漫型,G3, (1a)（1/1） (1b)(1/1) (2)(1/1) (3a)(1/1) (3b)(1/1) (4sa)(1/1) (4sb)(1/1) (4d)(1/1) (5)(1/1) (6)(6/6) (8a) (1/1)(7)(0/0), LM,60,30,10, R0,,6.66,5.03,1.14,100.6,325.0,2.9,39.0,27.0,188.0,57.0,24.0,3.81,1.63,49.0,132.0,28.0,21.0,3.6,6.0,73.0,128.0,,,,,,,,,,,,,3.11,83.68,18.7, 未做,无, 无, P0,H0, 未做, CD34 S-100,,,,,15.078843626806833,1618292
1618448,张泽兴,640473,男,47,T4b,N2,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,4.0,28,中间型（int）,INFb,2.0,,,,,,,,2016-05-31,2017-01-11,2,,,,,,,,,0, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3, (1a)01 (1b)00 (3a)010 (3b)22 (4sb)00 (4d)05 (5)11 (6)00 (7)05 (8a)02 (9)02,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,70,40,12, D1,R2,6.82,4.22,1.66,165.9,192.0,6.35,27.0,25.0,171.0,97.0,49.0,16.89,8.32,66.0,160.0,38.0,28.0,4.2,8.1,114.0,423.0,70.9,50.1,16.3,3.07,0.0,15.1,9.5,1.1,0.652,4.72,9.18,,2.83,28.24,6.51, 阴性,无,, P0,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,7.391590013140604,1618448
1618409,夏凤华,638179,女,57,T1a,N0,M0,ⅠA,1,0,,0.0,,0.0,,0.0,24,,,1.0,,,,,,,,2016-05-31,2019-05-05,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)05 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)01 (5)00 (6)01 (7)04 (8a)03 (8p)02 (9)02 (11p)03 (12a)01," L（幽门窦部）, 小弯侧Less,",40,20,0, R0 D2,,3.34,1.97,1.17,134.0,155.0,2.1,11.0,19.0,186.0,66.0,12.0,10.7,3.74,64.0,230.0,41.0,23.0,4.8,7.9,75.0,217.0,,,,,,,,,,,,,1.97,24.25,0.903,,无, 无, P0,H0, 未做, CK+ ,,,,,35.11826544021025,1618409
1618211,袁德伟,642918,男,42,T4a,N3b,M0, ⅢC,1,5,2.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,17.0,59,中间型（int）,INFc,0.0,,,,,,,,2016-05-30,2017-07-14,0,,,XELOX,XELOX,XELOX,XELOX,口服卡培他滨,紫杉醇联合替吉奥,10, 低粘附腺癌,GX, (1a)02 (1b)00 (2) 01(3a)517 (3b)01 (4sa)12 (4sb) 44(4d) 510(5)00 (6) 07(7)14 (8a)02 (8p)02 (9)16 (12a)01," LMU 后Post, 大弯侧Gre, 小弯侧Less,",45,45,12, R0 D2+,,9.36,6.91,1.8,159.2,179.0,2.09,15.0,17.0,134.0,75.0,16.0,14.74,6.24,59.0,182.0,38.0,21.0,3.9,5.1,97.0,334.0,77.1,45.6,27.1,1.68,0.2,8.6,9.5,0.6,1.31,1.23,7.31,,1.89,7.5,1.29,,,, P0,H0, 未做, CK + S-100+,,,,,13.469119579500656,1618211
1618449,王义,642924,男,56,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,2.0,37,中间型（int）,INFa,0.0,,,,,,,,2016-05-31,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)012 (3b)13 (4sb)00 (4d)14 (5)03 (6)03 (7)03 (8a)02 (8p)01 (9)04 (11p)00 (12a)00 (12p)01," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",40,30,10, R0 D2+,,10.45,5.63,3.48,167.0,318.0,3.12,15.0,23.0,198.0,66.0,13.0,18.79,6.29,64.0,401.0,43.0,21.0,4.7,6.9,113.0,265.0,72.6,35.1,19.5,1.8,0.4,6.9,16.4,2.3,0.563,0.71,7.52,,4.41,39.91,1.22, 未做,无,, P0,H0, 未做, CK +,,,,,75.03285151116951,1618449
1618769,吕忠和,642956,男,52,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,22,,,0.0,,,,,,,,2016-06-02,2022-09-01,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)00 (1b)00 (3a)02 (3b)01 (4sb)00 (4d)01 (5)00 (6)03 (7)01 (8a)01 (8p)03 (9)03 (11p)03 (12a)00 (15)00," L（幽门窦部）, 小弯侧Less,",40,30,3, R0 D2+,,2.79,1.78,0.6,145.6,187.0,2.33,24.0,28.0,216.0,46.0,16.0,24.64,8.1,59.0,346.0,40.0,19.0,4.9,5.8,98.0,407.0,74.2,43.3,0.1,1.84,0.1,9.4,9.3,2.4,0.556,1.09,6.95,,0.914,11.45,0.78, 阴性,无,, P0,H0, 未做, CK +,,,,,74.96714848883049,1618769
1618242,张美芹,642939,女,69,T1b,N0,M0,ⅠA,1,3,,,,,,0.0,29,,,0.0,,,,,,,,2016-05-30,2022-09-01,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)00 (1b)02 (3a) 011(3b) 07(4sb)00 (4d)03 (5)00 (6) 04(7)01 (8a) (8p)01 (9)00 (12a)00," M（胃体部）,",20,20,4, R0 D2,,5.92,3.18,1.98,147.8,314.0,3.81,8.0,18.0,180.0,87.0,8.0,9.44,3.44,65.0,164.0,39.0,26.0,4.8,3.1,81.0,239.0,67.3,27.2,36.3,0.75,0.2,4.2,25.9,2.1,1.02,2.55,8.36,,3.67,13.5,1.66, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,75.06570302233902,1618242
1618400,庄永江,642945,男,62,T3,N1,M0, ⅡB,1,4,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,2.0,28,髓样型（med）,INFb,0.0,,,,,,,,2016-05-31,2017-07-17,2,,,XELOX,XELOX,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,6, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren弥漫型,G3, (1a)02 (1b)00 (2)00 (3b)15 (4sa)01 (4sb)00 (4d)07 (5)11 (6)07 (7)00 (8a)01 (8p)01 (9)02 (11p)01 (12a)00," L（幽门窦部）, D(十二指肠), M（胃体部）, U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,75,10, D2,R1,6.6,4.3,1.55,127.0,312.0,3.48,19.0,21.0,173.0,65.0,13.0,15.99,4.81,59.0,268.0,37.0,22.0,4.3,4.9,97.0,288.0,,,,,,,,,,,,,10.89,10.08,13.14,,无, 无, P0,H0, 未做, CK+ CD34+  D2-40+  S-100+,,,,,13.534822601839684,1618400
1618446,钟明文,638189,男,52,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,25,,,0.0,,,,,,,,2016-05-31,2022-09-01,1,,,,,,,,,0, 高级别上皮内瘤变 管状腺癌（高分化【G1】【tub1】）,G1, (1a)00 (1b)00 (3a)07 (3b)00 (4sb)00 (4d)06 (5)00 (6)06 (7)02 (8a)01 (8p) (9)03 (12a)00," L（幽门窦部）, 前Ant,",25,20,10, R0 D2,,7.1,5.06,1.51,177.0,231.0,3.01,43.0,33.0,164.0,111.0,13.0,14.31,4.96,71.0,354.0,46.0,25.0,5.1,6.7,68.0,270.0,69.4,44.3,21.9,2.02,0.7,20.5,8.8,1.6,1.09,2.87,11.8,,2.44,16.2,1.67, 未做,,,,H0,, CK+,,,,,75.03285151116951,1618446
1618374,张叶红,640519,男,47,T4a,N1,M0, ⅢA,1,4,2.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,2.0,25,硬型（sci）,INFc,0.0,,,,,,,,2016-05-31,2018-01-01,2,,,,,,,,,0, 低粘附腺癌70% 低分化腺癌（G3)(por)30%,G3, (1a) 0/0(1b)0/0 (3a)0/3 (4sb)0/2 (4d)0/2 (6)0/5 (7)0/5 (8a)0/3 (8p)0/0 (9)2/4 (11p)0/0 (12a)0/1 (3b)0/0 (5)0/0 3b、5软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,10, R0,,6.33,3.88,1.13,112.2,326.0,4.56,22.0,32.0,191.0,72.0,42.0,6.6,3.17,63.0,121.0,37.0,26.0,4.6,4.5,59.0,132.0,,,,,,,,,,,,,1.55,19.7,0.79, 未做,无, 无, P0,H0, 未做, CD34 S-100 CK+,,,,,19.053876478318003,1618374
1618767,王景英,642241,女,61,T3,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）粘膜萎缩,5.0,28,中间型（int）,INFc,0.0,,,,,,,,2016-06-02,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)60 低粘附腺癌40,G3, (1a)02 (1b)44 (3a)12 (3b)00 (4sb)00 (4d)03 (5)00 (6)02 (7)03 (8a)00 (8p)03 (9)04 (11p)05 (12a)00," L（幽门窦部）, 小弯侧Less,",40,30,10, R0 D2,,4.93,3.06,1.47,160.1,220.0,3.07,26.0,29.0,179.0,107.0,8.0,13.44,5.84,62.0,185.0,42.0,20.0,5.0,4.1,63.0,236.0,,,,,,,,,,,,,3.47,18.55,0.796,,无, 无, P0,H0, 未做, CK+ CD34+  D2-40+  S-100+,,,,,74.96714848883049,1618767
1618820,李军,638449,男,49,T2,N1,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,2.0,32,硬型（sci）,INFb,0.0,,,,,,,,2016-06-02,2021-05-14,1,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 低粘附腺癌15,G3, (1a)01 (1b)02 (3a)14 (3b)00 (4sb)00 (4d)14 (5)00 (6)05 (7)07 (8a)02 (8p)02 (9)04 (11p)01," L（幽门窦部）, 前Ant,",45,35,10, R0 D2,,7.55,4.32,2.49,144.6,313.0,4.43,51.0,33.0,148.0,103.0,52.0,8.99,2.99,62.0,316.0,40.0,22.0,4.4,7.7,79.0,346.0,,,,,,,,,,,,,1.72,6.91,3.81,,无, 无, P0,H0, 未做, CK+,,,,,59.36268068331143,1618820
1618711,李建国,636624,男,68,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,26.0,33,中间型（int）,INFb,0.0,,,,,,,,2016-06-02,2019-04-17,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren混合型,G3, (1a)44 (1b)22 (2)22 (3a)55 (3b)66 (4sa)11 (4sb)00 (4d)00 (5) (12a)44 (6)01 (7)11 (8a)13 (8p)02 (9)02 (11p)00 3b 软组织可见癌,U（胃底部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,40,10, R0 D2,,4.28,2.25,1.7,129.8,197.0,3.9,23.0,27.0,195.0,50.0,15.0,13.72,5.67,70.0,228.0,42.0,28.0,4.4,3.3,82.0,281.0,61.4,42.0,13.9,3.02,0.0,12.6,21.9,1.0,0.466,2.13,11.0,,1.29,6.29,5.16, 阳性+,无,, P0,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,34.46123521681997,1618711
1618773,刘桂荣,642352,女,54,T2,N0,M0, ⅠB,1,3,1.0,0.0,0.0,1.0, 肠化生+ 异型增生+,0.0,27,中间型（int）,INFb,0.0,,,,,,,,2016-06-02,2021-07-06,1,,,,,,,,,0, 粘液腺癌（muc）50 管状腺癌（中分化【G2】【tub2】15 类癌(神经内分泌癌)35 Lauren混合型,G2, (1a) 03(1b)00 (3a) 06(3b)00 (4sb)00 (4d)05 (5)00 (6)02(7)01 (8a)01 (8p)01 (9)04 (11p)04 (12a)00," L（幽门窦部）, 大弯侧Gre,",30,30,12, R0 D2,,6.4,4.26,1.78,133.9,231.0,4.0,38.0,31.0,254.0,99.0,21.0,12.02,4.66,73.0,315.0,45.0,28.0,5.5,5.2,80.0,245.0,,,,,,,,,,,,,1.33,34.07,11.25, 未做,无,, P0,H0,, CK+ CD56 + Syn+ CgA+ S-100(神经侵犯)， CD31  D2-40 （未见）,,,,,61.10381077529566,1618773
1619059,孙志学,640555,男,59,T1a,N2,M0, ⅡA,1,4,2.0,,,, 慢性炎症（+）,4.0,22,中间型（int）,,0.0,,,,,,,,2016-06-03,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)85 低粘附腺癌15 Lauren弥漫型,G3, (1a)00 (1b)00 (2)01 (3a)28 (3b)12 (4sa)00 (4sb)00 (4d)03 (5)00 (6)03 (7)12 (8a)01 (8p)01 (11p)01 (12a)00," LMU 前Ant, 后Post, 小弯侧Less,",40,40,, R0 D2,,6.66,3.46,2.49,154.6,312.0,2.6,29.0,25.0,150.0,57.0,17.0,12.25,3.42,63.0,417.0,38.0,25.0,6.4,5.4,63.0,235.0,,,,,,,,,,,,,1.93,11.66,4.21,,无, 无, P0,H0, 未做, CK+,,,,,74.93429697766096,1619059
1619103,曹立杰,502530,女,47,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,0.0, 慢性炎症（+）,13.0,26,中间型（int）,INFc,1.0,,,,,,,,2016-06-06,2022-09-01,1,,,,,,,,,0, 低粘附腺癌85 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】15 Lauren弥漫型,G3, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)510 (5)00 (6)57 (7)02 (8a)00 (8p)01 (9)33 (11p)01 (12a)00," M（胃体部）, 大弯侧Gre,",35,30,5, R0 D2,,4.91,2.99,1.43,103.0,246.0,1.78,13.0,19.0,139.0,38.0,7.0,8.89,3.33,68.0,228.0,42.0,26.0,4.3,5.1,65.0,197.0,,,,,,,,,,,,,2.82,4.14,1.08,,无, 无, P0,H0, 未做, CK+,,,,,74.83574244415243,1619103
1619060,刘亚芬,502547,女,53,T3,N1,M0, ⅡB,1,3,2.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,26,中间型（int）,INFb,0.0,,,,,,,,2016-06-03,2019-05-05,0,,,XELOX,,,,,,1, 低粘附腺癌70 低分化腺癌（G3)(por)30,G3, (1a)03 (1b)02 (3a)01 (3b)00 (4sb)04 (4d)03 (5)00 (6)02 (7)01 (8a)01 (8p)02 (9)01 (11p)16 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,15,10, R0 D2+,,4.96,2.21,2.2,126.7,193.0,3.33,20.0,22.0,175.0,84.0,21.0,7.24,2.4,71.0,275.0,40.0,31.0,5.2,4.7,61.0,247.0,,,,,,,,,,,,,1.66,17.85,8.6,,无, 无, P0,H0, 未做, CK+,,,,,35.019710906701704,1619060
1618816,杨绪明,642388,男,63,T3,N3a,M0,ⅢB,1,3,1.0,0.0,0.0,1.0, 慢性炎症（+）,9.0,32,中间型（int）,INFc,0.0,,,,,,,,2016-06-02,2018-04-22,0,,,XELOX,,,,,,1, 低粘附腺癌,GX, (1a) 02(3a)410 (3b)22 (4sb) 00(4d)01 (5) 00(6)04 (7) 11(8a)01 (8p) 03(9)04 (11p)01小弯23," L（幽门窦部）, 小弯侧Less,",40,25,10, R0 D2+,,4.59,2.44,1.61,155.2,198.0,1.74,22.0,22.0,194.0,58.0,10.0,25.17,9.5,65.0,212.0,41.0,24.0,4.9,5.0,79.0,300.0,45.9,30.8,14.9,2.07,0.0,10.7,28.7,0.7,0.609,2.15,9.48,,1.71,5.83,8.45, 阳性+,,, P0,H0, 未做, S-100 +,,,,,22.634691195795007,1618816
1619065,黄艳伟,502548,男,59,T4b,N1,M1, ⅢB,1,3,2.0,0.0,0.0,1.0, 慢性炎症,2.0,22,中间型（int）,INFc,0.0,,,,,,,,2016-06-06,2020-06-16,2,,,奥沙利铂+卡培他滨+多西他赛,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)08 (3b)00 (4sb)01 (4d)04 (6)25 (7)03 (8a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,25,12,,R2,5.96,3.39,1.99,135.3,112.0,2.95,38.0,35.0,182.0,85.0,18.0,10.16,4.67,73.0,225.0,47.0,26.0,4.6,12.3,92.0,239.0,,,,,,,,,,,,,7.17,4.49,3.59, 未做,无, 无, p1盆(M1 PER) p1局腹膜(M1 PER),H0, 未做, CK +,,,,,48.3245729303548,1619065
1618715,刘艳青,643324,女,65,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,1.0,27,髓样型（med）,INFc,0.0,,,,,,,,2016-06-02,2018-06-20,2,,,卡培他滨+顺铂,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)05 (1b)00 (3a)00 (3b)00 (4sb)05 (4d)12 (5)00 (6)03 (7)01 (8a)05 (8p)03 (9)02 (11p)01 (12a)00," L（幽门窦部）, 大弯侧Gre,",25,20,8, R0,,5.62,2.78,2.31,130.7,255.0,2.95,22.0,23.0,210.0,107.0,21.0,10.97,3.14,69.0,235.0,45.0,24.0,4.8,8.8,75.0,312.0,,,,,,,,,,,,,2.44,14.39,1.19, 未做,无, 无, P0,H0, 未做, CK +,,,,,24.57293035479632,1618715
1619156,吕广寅,642301,男,65,T3,N0,M1, Ⅳ,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,41,中间型（int）,INFa,0.0,,,,,,,,2016-06-06,2016-08-17,2,,,,,,,,,0, 粘液腺癌（muc）,GX, (1a)0/7 (1b)0/0 (2)0/0 (3a)0/9(3b)0/0 (4sa)0/0 (4sb)0/3 (4d)0/2 (5)0/0 (6)0/3 (7)0/3 (8a)0/0 (8p)0/3 (9)0/8 (11p)0/2 (12a)0/1," M（胃体部）, 前Ant, 小弯侧Less, 大弯侧Gre,",100,90,20,,R2,8.66,5.2,2.4,137.6,295.0,5.34,224.0,184.0,302.0,67.0,17.0,10.55,4.36,54.0,129.0,29.0,25.0,4.9,6.6,56.0,151.0,,,,,,,,,,,,,10.68,123.9,46.13, 未做,无, 无, P0,H1单（M1 HEP), 未做, CK+ CD31 S-100,,,,,2.3653088042049935,1619156
1619108,孙焕杰,643343,男,58,T1b,N0,M0,ⅠA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,17,中间型（int）,INFa,0.0,,,,,,,,2016-06-06,2021-07-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)06 (3a)01 (3b)02 (4sb)01 (4d)01 (5)00 (6)00 (7)04 (8a)01 (8p)01 (9) 00(11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",20,20,2, R0 D2,,4.77,3.11,0.89,167.2,214.0,2.65,19.0,17.0,133.0,81.0,10.0,39.83,13.88,63.0,322.0,41.0,22.0,4.9,6.5,83.0,255.0,65.4,37.4,23.2,1.61,0.1,6.6,21.6,7.7,1.11,1.13,7.28,,1.66,10.07,0.989, 阳性+,无,, P0,H0, 未做, CK +,,,,,61.465177398160314,1619108
1619520,叶在军,644378,男,66,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,6.0,26,中间型（int）,INFb,0.0,,,,,,,,2016-06-08,2018-05-01,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低粘附腺癌90 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】10 Lauren混合型,G3, (1a)00 (1b)00 (3a)02 (3b)11 (4sb)00 (4d)27 (5)01 (6)00 (7)02 (8a)13 (8p)01 (9)04 (11p)22 (12a)00 (12p)01 (16a1)02, L（幽门窦部） 小弯侧Less ,50,40,15, R0 D2,,4.35,2.44,1.07,147.8,202.0,2.49,22.0,24.0,143.0,70.0,14.0,15.26,5.63,60.0,248.0,36.0,24.0,4.5,6.9,81.0,301.0,,,,,,,,,,,,,1.34,35.02,1.66, 阳性+,无,, P0,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,22.733245729303547,1619520
1619320,杨兴华,638208,男,65,T2,N0,M0, ⅠB,1,2,0.0,1.0,1.0,0.0, 肠化生+,0.0,28,中间型（int）,INFc,0.0,,,,,,,,2016-06-07,2021-09-30,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)03 (3b)04 (4sb)01 (4d)05 (5)02 (6)03 (7)02 (8a)01 (8p)00 (9)02 (11p)04 (12a)01," L（幽门窦部）, 小弯侧Less,",20,15,10, R0 D2,,6.42,3.19,2.35,154.0,173.0,2.61,33.0,31.0,175.0,85.0,19.0,16.69,5.91,74.0,279.0,45.0,29.0,5.3,6.6,81.0,411.0,,,,,,,,,,,,,1.64,7.97,2.74,,无,, P0,H0, 未做, CK+,,,,,63.76478318002628,1619320
1619279,蒋洪滨,635824,男,65,T1b,N0,M0,ⅠA,1,3,1.0,1.0,1.0,0.0, 正常,0.0,21,中间型（int）,INFb,0.0,,,,,,,,2016-06-07,2021-09-02,1,,,口服替吉奥,口服替吉奥,,,,,2, 管状腺癌（中分化【G2】【tub2】50% 粘液腺癌（muc）40% 低粘附腺癌10% Lauren混合型,G2, (1a)02 (1b)02 (3a)01 (3b)03 (4sb)00 (4d)00 (5)00 (6)07 (7)02 (8a)02 (9)02 (11p)00," L（幽门窦部）, 小弯侧Less,",30,20,10, R0 D2,,7.97,5.46,2.02,161.7,261.0,2.6,19.0,22.0,163.0,97.0,15.0,97.0,3.75,75.0,265.0,44.0,31.0,9.8,6.7,88.0,312.0,72.8,39.9,25.2,1.58,0.6,10.2,14.1,1.2,1.57,3.78,10.7,,0.896,16.18,3.55, 未做,无, 无, P0,H0, 未做,ck（+） S-100未见神经侵犯，CD31、D2-40可见脉管瘤栓,,,,,62.844940867279895,1619279
1619325,孙彬,643825,男,55,T4a,N1,M0, ⅢA,1,3,1.0,0.0,0.0,1.0, 慢性炎症（+）,2.0,23,中间型（int）,INFb,0.0,,,,,,,,2016-06-07,2019-06-01,2,,,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,,,4, 粘液腺癌（muc）50% 低粘附腺癌50% Lauren混合型,GX, (1a)01 (1b)00 (3a)13 (3b)00 (4sb)00 (4d)07 (5)00 (6)12 (7)05 (8p)01 (9)01 (11p)03 (12a)00，3b、4d及5软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,10, R0 D2,,6.13,3.03,2.09,139.0,298.0,4.32,17.0,23.0,113.0,82.0,28.0,7.87,2.44,65.0,280.0,39.0,26.0,6.1,5.4,94.0,369.0,69.4,44.3,21.9,2.02,0.7,20.5,8.8,1.56,1.09,2.87,11.8,,1.5,2.83,13.0, 未做,无, 无, P0,H0,, CK +， S-100可见神经侵犯， CD 31、D2-40未见脉管瘤栓,,,,,35.775295663600524,1619325
1619201,吴连芝,643881,女,63,T1b,N2,M0, ⅡA,1,3,1.0,,,, 慢性炎症（+）,3.0,20,中间型（int）,INFb,0.0,,,,,,,,2016-06-06,2021-06-01,1,,,口服卡培他滨,口服卡培他滨,口服卡培他滨,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3, (1a)00 (1b)03 (3a)13 (3b)01 (4sb)00 (4d)00 (5)00 (6)24 (7)04 (8a)01 (8p)01 (9)03 (11p)00 (12a)00," L（幽门窦部）, 后Post,",20,18,5, R0 D2+,,6.61,4.01,1.94,139.6,316.0,3.66,29.0,36.0,176.0,95.0,20.0,11.81,3.89,72.0,262.0,43.0,29.0,4.8,4.1,48.0,227.0,,,,,,,,,,,,,1.91,21.99,1.34,,无, 无, P0,H0, 未做, CK+,,,,,59.82260183968462,1619201
1619472,张桂英,644021,女,61,T3,N1,M0, ⅡB,1,3,1.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,2.0,27,中间型（int）,INFc,0.0,,,,,,,,2016-06-08,2017-07-20,0,,,,,,,,,0, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)02 (1b)02 (3a)03 (3b)11 (4sb)00 (4d)03 (5)00 (6)01 (7)06 (8a)02 (8p)05 (9)11 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",25,20,10, R0 D2,,6.94,5.31,1.03,113.0,203.0,2.6,20.0,30.0,151.0,68.0,27.0,14.8,4.32,69.0,335.0,44.0,25.0,9.2,8.0,52.0,265.0,,,,,,,,,,,,,0.934,11.05,1.75, 未做,无, 无, P0,H0, 未做, CK+,,,,,13.370565045992116,1619472
1619552,许小明,640465,男,36,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,1.0, 正常,0.0,14,中间型（int）,INFa,0.0,,,,,,,,2016-06-08,2021-07-22,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (3a)03 (3b)00 (4sb) 00(4d)03 (5)00 (6)00 (7) 01(8a) 02(8p) 01(9) 02(11p)02 (12a)00大网 软组织可见癌," L（幽门窦部）, 前Ant, 小弯侧Less, 后Post,",30,25,8, R0 D2+,,5.18,2.85,1.85,152.0,262.0,1.99,25.0,27.0,152.0,66.0,44.0,9.18,2.67,78.0,391.0,47.0,31.0,5.2,6.3,73.0,399.0,,,,,,,,,,,,,,,,,,, P0,H0, 未做, CK +,,,,,61.432325886990796,1619552
1619613,周明海,643539,男,56,T4a,N1,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+） 肠化生+,1.0,23,硬型（sci）,INFb,0.0,,,,,,,,2016-06-12,2021-05-10,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10,G3, (1a)00 (1b) 00(3a)08 (3b) 03(4sb)00 (4d)07 (5)01 (6) 01(7)00 (8a)11 (8p)01 (9)01  (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,30,10, R0 D2+,,7.3,4.68,1.77,164.2,236.0,3.5,14.0,18.0,131.0,137.0,14.0,13.05,4.89,67.0,316.0,42.0,25.0,4.5,4.5,74.0,295.0,72.4,53.7,15.4,3.49,0.2,16.3,8.6,0.3,0.671,1.18,9.24,,1.62,11.14,9.41,,,, P0,H0, 未做, CK +,,,,,58.90275952693823,1619613
1619463,孙淑琴,642430,女,63,T3,N1,M0, ⅡB,1,2,1.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,2.0,32,中间型（int）,INFb,0.0,,,,,,,,2016-06-08,2021-05-27,1,,,,,,,,,0, 低粘附腺癌40 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 Lauren混合型,G3, (1a)01 (1b)02 (3a)00 (3b)14 (4sb)00 (4d)02 (5)01 (6)06 (7)05 (8a)03 (8p)04 (9)02 (11p)01 (12a)11," L（幽门窦部）, 小弯侧Less,",50,30,8, R0 D2,,8.66,5.37,2.32,132.0,209.0,3.28,22.0,23.0,178.0,62.0,12.9,14.34,3.49,61.4,256.78,38.6,22.8,5.4,5.29,70.0,155.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK+ CD31-  D2-40-  S-100-,,,,,59.592641261498024,1619463
1620320,洪殿福,643575,男,58,T4b,N3a,M0, ⅢC,1,4,1.0,1.0,1.0,1.0, 肠化生+,14.0,14,中间型（int）,INFb,1.0,,,,,,,,2016-06-19,2016-09-25,2,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3, (1a)11 (1b)00 (2)22 (3a)33 (3b)00 (4sa)00 (4sb)00 (4d)11 (5)00 (6)33 (7)33, LMU  前Ant 后Post 大弯侧Gre  小弯侧Less,200,130,5,,R2,7.37,5.37,1.13,141.2,259.0,3.03,19.0,23.0,333.0,87.0,33.0,7.53,2.15,55.0,248.0,31.0,24.0,8.2,7.4,82.0,269.0,47.1,28.6,17.7,16.2,0.1,3.9,46.7,0.3,0.3555,4.07,8.76,,3.12,130.3,174.5, 阴性,无,, P0,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,3.219448094612352,1620320
1620088,孙占祥,643905,男,61,T1b,N1,M0, ⅠB,1,3,0.0,,,, 慢性炎症（+）,1.0,33,中间型（int）,,3.0,,,,,,,,2016-06-15,2021-09-27,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)03 (3a)02 (3b)00 (4sb)03 (4d)15 (5)00 (6)03 (7)03 (8a)05 (8p)00 (9)04 (11p)02 (12a)01," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",45,30,5, R0 D2,,5.35,2.65,2.05,149.2,225.0,1.9,30.0,27.0,179.0,52.0,13.0,11.71,3.97,63.0,250.0,39.0,24.0,6.5,6.7,71.0,356.0,,,,,,,,,,,,,1.19,6.53,4.62, 未做,无, 无, P0,H0, 未做, CK+,,,,,63.40341655716163,1620088
1620319,井希成,645353,男,61,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 肠化生+,3.0,23,中间型（int）,INFc,3.0,,,,,,,,2016-06-16,2021-05-11,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)11 (3b)15 (4sb)00 (4d)3 (5)00 (6)12 (7)02 (8a)02 (8p)01 (9)01 (11p)01 (12a)05 (14v)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",60,60,10, R0 D2+,,8.37,4.06,3.22,118.0,457.0,1.86,8.0,16.0,131.0,83.0,10.0,5.82,1.84,69.0,285.0,43.0,26.0,6.3,4.4,83.0,246.0,,,,,,,,,,,,,5.26,2.4,3.18, 未做,无,, P0,H0, 未做, CK+,,,,,58.80420499342969,1620319
1620163,张世举,638273,男,53,T3,N2,M0, ⅢA,1,2,2.0,0.0,0.0,1.0, 慢性炎症（+）,6.0,25,中间型（int）,INFc,0.0,,,,,,,,2016-06-15,2019-04-03,0,,,XELOX,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX, (1a)0/1 (1b)0/1 (3a)0/0 (3b)0/0 (4sb)0/0 (4d)6/7 (5)0/1 (6)0/5 (7)0/1 (8a)0/4 (8p)0/2 (9)0/0 (11p)0/1 (12a)0/2," LM 前Ant, 小弯侧Less, 大弯侧Gre,",70,60,10, R0,,10.63,8.95,0.63,156.6,318.0,2.74,17.0,30.0,216.0,66.0,22.0,37.58,13.89,62.0,196.0,38.0,24.0,4.7,5.3,69.0,274.0,,,,,,,,,,,,,1.69,10.65,1.1, 未做,无, 无, P0,H0, 未做, CD31 S-100,,,,,33.5742444152431,1620163
1619973,张丽颖,644293,女,43,T4a,N1,M0, ⅢA,1,3,0.0,1.0,1.0,1.0,,2.0,15,中间型（int）,INFa,1.0,,,,,,,,2016-06-14,2021-06-11,1,,,XELOX,XELOX,XELOX,口服替吉奥,口服替吉奥,口服替吉奥,8, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)02 (2)04 (3a)01 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)00 (7)02 (8a)02 (9)01 2 软组织可见癌,U（胃底部） 前Ant 后Post 大弯侧Gre  ,25,20,10, R0 D2,,6.47,3.64,2.3,157.3,269.0,2.84,14.0,18.0,177.0,74.0,16.0,15.23,4.63,82.0,328.0,53.0,29.0,4.8,4.5,70.0,268.0,74.2,46.6,23.9,1.95,0.3,14.1,9.6,3.0,1.93,1.58,12.4,,1.57,144.7,0.977, 阴性,无, 无, P0,H0, 未做, CK+,,,,,59.88830486202365,1619973
1620269,宋万有,638239,男,74,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,3.0,12,中间型（int）,INFc,2.0,,,,,,,,2016-06-16,2019-04-03,2,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】 90%低粘附腺癌10% Lauren混合型,G3, (1a)0/1 (1b)0/0 (3a)2/3 (3b)0/1 (4sb)0/0 (4d)0/1 (5)0/0 (6)0/1 (7)0/1 (8a)0/1 (8p)0/0 (9)0/1 (11p)0/1 (12a)0/0," L（幽门窦部）,",45,40,8,R0,,5.74,2.94,1.99,87.3,366.0,2.2,23.0,26.0,198.0,61.0,11.0,8.72,3.44,62.0,158.0,36.0,26.0,4.7,6.0,64.0,185.0,,,,,,,,,,,,,4.25,13.66,3.5, 未做,无, 无, P0,H0, 未做, S-100 CD31,,,,,33.54139290407359,1620269
1620404,尹成海,643850,男,69,T3,N0,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,48,髓样型（med）,INFa,0.0,,,,,,,,2016-06-16,2021-06-20,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a) 04(1b)00 (3a)016 (3b)04 (4sb)00 (4d)010 (5)03 (6)08 (8a)01 (8p)01 (9) 00(11p)01 (12a)00 (7)00," L（幽门窦部）, 前Ant, 小弯侧Less,",50,40,5, R0 D2+,,5.81,4.2,1.11,126.7,207.0,2.61,16.0,22.0,178.0,74.0,19.0,10.78,3.17,67.0,274.0,42.0,25.0,5.2,7.0,73.0,241.0,45.8,33.5,11.0,3.05,0.0,9.7,41.8,0.4,0.87,3.98,8.41,,2.63,2.49,2.81,,,,,H0, 未做, CK +,,,,,60.118265440210244,1620404
1621129,张乃学,643855,男,68,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生 慢性炎症,8.0,40,髓样型（med）,INFa,0.0,,,,,,,,2016-06-22,2021-05-18,1,,,,,,,,,0,浸润型中低 管状腺癌 Lauren肠型,GX, (3a)26 (3b)12 (4d)15 (6)28 (11p)12 (12a)12," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,35,14, R0 D2+,,5.96,4.34,1.23,104.0,294.0,5.12,9.0,20.0,186.0,76.0,6.0,8.84,3.85,68.0,136.0,68.0,25.0,5.1,8.3,79.0,182.0,48.2,34.3,12.9,2.66,0.0,14.1,35.6,0.7,1.04,2.76,9.72,,5.45,11.59,99.71, 阳性+++,无,, P0,H0, 未做, CK（+）,,,,,58.83705650459921,1621129
1620364,杜海波,642732,男,47,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,9.0,21,中间型（int）,INFc,1.0,,,,,,,,2016-06-16,2017-04-06,0,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G2, (1a)00 (1b)00 (3a)01 (3b)12 (4sb)00 (4d)22 (5)03 (6)22 (7)11 (8a)12 (8p)05 (9)12 (11p)11 (12a)00," L（幽门窦部）, 前Ant,",40,40,10, R0,,5.21,2.67,1.74,146.0,252.0,3.23,24.0,25.0,172.0,87.0,23.0,6.93,2.57,69.0,355.0,45.0,24.0,4.9,7.4,71.0,333.0,,,,,,,,,,,,,20.07,3.29,4.65, 未做,无, 无, P0,H0, 未做, CK +,,,,,9.658344283837057,1620364
1620754,姜佰臣,636660,男,46,T1b,N0,M0,ⅠA,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,29,髓样型（med）,INFa,1.0,,,,,,,,2016-06-21,2020-08-24,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)02 (2)03 (3a)02 (3b)02 (4sa)01 (4sb)01 (4d)05 (5)00 (6)02 (7)03 (8a)03 (8p)02 (9)02 (11p)01," M（胃体部）, 后Post,",15,15,5, R0 D2,,4.94,2.96,1.61,154.0,197.0,2.21,5.4,5.6,146.0,67.0,22.0,16.95,6.23,65.0,295.0,43.0,22.0,5.4,5.6,90.0,442.0,74.7,52.0,20.9,2.49,0.3,12.8,10.8,1.4,0.596,1.26,9.08,,1.49,18.26,1.45, 阳性+,无,, P0,H0, 未做,ck（+）、cd34（-）、D2-40（-）、s-100（-）,,,,,50.09855453350854,1620754
1621078,王佳运,642751,男,54,T2,N0,M0, ⅠB,1,5,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,45,髓样型（med）,INFa,0.0,,,,,,,,2016-06-22,2020-09-08,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (3a)011 (3b)08 (4sb)00 (4d)03 (5)04 (6)07 (7)01 (8a)03 (8p)01 (9)02 (11p)02 (12a)00, L（幽门窦部） 前Ant 小弯侧Less ,30,30,10, R0 D2,,8.87,5.37,2.7,142.0,208.0,3.28,16.0,22.0,142.0,70.0,12.0,22.29,7.11,65.0,259.0,42.0,23.0,4.0,5.5,80.0,320.0,77.5,41.2,32.3,12.8,0.5,14.0,7.5,2.5,0.685,1.14,8.25,,2.47,3.18,1.44, 阳性+,无,, P0,H0, 未做,ck（+）、cd34（-）、D2-40（-）、s-100（-）,,,,,50.55847568988173,1621078
1620679,李文娟,638008,女,59,T3,N1,M0, ⅡB,1,2,1.0,1.0,1.0,1.0, 慢性炎症（+） 异型增生+,2.0,28,髓样型（med）,INFb,0.0,,,,,,,,2016-06-20,2021-06-01,1,,,奥沙利铂+5-FU,XELOX,,,,,2, 粘液腺癌（muc）60 低粘附腺癌40 Lauren混合型,GX, (1a)02 (1b)02 (3a)210 (3b)01 (4sb)00 (4d)02 (5)00 (6)01 (7)01 (8a)01 (8p)02 (9)03 (11p)03 (12a)00, L（幽门窦部） 前Ant 小弯侧Less ,35,30,12, R0 D2,,7.15,3.52,2.94,129.0,303.0,3.07,16.0,21.0,166.0,81.0,9.0,8.34,2.17,69.0,252.0,43.0,26.0,4.9,5.9,65.0,268.0,68.0,43.8,15.4,2.84,0.1,16.9,13.1,2.3,0.351,2.79,11.0,,0.897,20.11,35.46, 阳性+,无, 无, P0,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,59.36268068331143,1620679
1620930,袁会武,638015,男,63,T2,N2,M0, ⅡB,1,2,1.0,1.0,1.0,0.0, 慢性炎症（+）,6.0,52,中间型（int）,INFb,0.0,,,,,,,,2016-06-21,2021-06-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20,G3, (1a)03 (1b)00(3a)29 (3b) 09(4sb) 01(4d)214 (5)00 (6)05 (7)05 (8a)11 (8p)01 (9)02 (11p) 01(12a)11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",35,25,6, R0 D2+,,8.46,4.29,3.12,123.0,297.0,3.52,27.0,28.0,223.0,75.0,8.0,4.95,1.95,61.0,233.0,41.0,20.0,4.3,8.2,101.0,270.0,62.6,43.5,17.4,2.5,0.1,9.8,23.8,0.6,0.818,1.54,5.25,,4.23,16.27,15.66,,,, P0,H0, 未做, CK +,,,,,59.32982917214191,1620930
1622220,姜平,583351,女,57,T4b,N1,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 正常,2.0,24,中间型（int）,INFb,0.0,,,,,,,,2016-06-30,2021-07-01,1,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)12 (1b)00 (2)00 (3a)05 (3b)00 (4sa)00 (4sb)12 (4d)02 (5)03 (6)01 (7)01 (8a)00 (8p)02 (9)05 (11p)01 (11d)00 (12a)00 软组织可见癌," MU SiewerⅡ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,5, R0 D2+,,5.07,2.55,1.95,128.4,289.0,3.2,21.0,23.0,186.0,101.0,19.0,10.93,3.06,43.0,279.0,43.0,32.0,4.8,5.2,67.0,318.0,40.5,26.7,12.6,2.12,0.4,18.2,36.4,0.5,2.16,3.22,13.4,,2.29,14.43,3.0,,无, 无, P0,H0, 未做, CK +,,,,,60.019710906701704,1622220
1620680,关茂德,643668,男,76,T1b,N0,M0,ⅠA,1,3,,,,,,0.0,17,,,0.0,,,,,,,,2016-06-20,2020-06-16,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)03 (1b)01 (3a)02 (3b)00 (4sb)01 (4d)06 (5)00 (6)02 (7)02," L（幽门窦部）, 小弯侧Less,",18,15,4, R0,,8.26,4.3,3.2,143.0,145.0,3.13,21.0,22.0,161.0,112.0,32.0,15.03,5.31,76.0,310.0,46.0,30.0,8.2,4.4,94.0,461.0,,,,,,,,,,,,,0.977,10.69,2.85,,无, 无, P0,H0, 未做, CK+,,,,,47.8646517739816,1620680
1620523,刘成福,643906,男,64,T2,N0,M0, ⅠB,1,3,0.0,1.0,1.0,0.0, 慢性炎症（+）,0.0,26,中间型（int）,INFa,0.0,,,,,,,,2016-06-17,2021-07-01,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) 00(1b)01 (3a)02 (3b)02 (4sb)00 (4d)03 (5)00 (6)06 (7) 01(8a)02 (8p) 03(9) 02(11p)04 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",25,25,6, R0,,4.8,3.04,1.28,145.0,189.0,2.9,23.0,18.0,157.0,70.0,20.0,15.03,4.53,63.0,241.0,41.0,22.0,5.0,5.0,70.0,187.0,,,,,,,,,,,,,1.55,10.36,1.24, 未做,无, 无, P0,H0, 未做, CK +,,,,,60.446780551905384,1620523
1621220,秦旭东,643029,男,40,T1b,N0,M0,ⅠA,1,3,,,,,,0.0,24,,,0.0,,,,,,,,2016-06-23,2022-09-01,1,,,,,,,,,0, 低粘附腺癌,GX, (1b)00 (3a)08 (3b)00 (4sb)00 (4d)03 (5)00 (6)08 (7)01 (8a)02 (8p)01 (9)00 (11p)01 (12a)00, L（幽门窦部） 小弯侧Less ,25,20,8, R0 D2,,5.94,2.74,2.44,161.5,171.0,2.22,12.0,18.0,171.0,53.0,8.0,10.29,3.01,67.0,431.0,44.0,23.0,4.8,6.0,87.0,345.0,79.6,41.9,32.2,1.3,0.2,9.0,9.4,2.2,0.454,1.85,10.2,,3.5,5.84,1.74, 阳性+,无,, P0,H0, 未做,,,,,,74.2772667542707,1621220
1621251,崔善亭,638009,男,78,T4b,N2,M1, Ⅳ,1,2,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,5.0,14,髓样型（med）,INFa,2.0,,,,,,,,2016-06-23,2017-05-17,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (3a) 06(3b) 13(4sb)00 (4d)23 (5)00 (6)00 (7) 00(8a)22 (12a)00 另外3b 5 12  软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",120,120,40,,R1,10.64,8.63,0.86,88.0,311.0,4.21,9.0,25.0,194.0,68.0,28.0,16.33,9.36,62.0,44.0,36.0,26.0,6.9,5.3,72.0,134.0,79.7,24.8,39.3,0.63,0.1,5.7,13.4,5.6,0.944,3.38,9.46,,24.15,29.54,300.0,,,, P0,H0, 未做, CK +,,,,,10.775295663600525,1621251
1620936,刘继涛,646565,男,52,T2,N1,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,1.0,15,中间型（int）,INFa,2.0,,,,,,,,2016-06-21,2021-06-01,1,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)05 (5)00 (6)01 (7)00 (8a)11 (8p)01 (9)01 (11p)03 (12a)00," L（幽门窦部）, 小弯侧Less,",15,12,6, R0 D2,,6.49,3.31,2.05,99.0,240.0,4.56,18.0,26.0,201.0,123.0,31.0,14.87,4.39,72.0,252.0,45.0,27.0,7.8,4.2,59.0,209.0,,,,,,,,,,,,,7.1,14.69,3.1,,无, 无, P0,H0, 未做, CK+ CD31-  D2-40 - S-100-,,,,,59.32982917214191,1620936
1621134,刘才渭,643378,男,61,T2,N1,M0, ⅡA,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,2.0,38,中间型（int）,INFa,1.0,,,,,,,,2016-06-22,2020-04-13,0,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)02 (3a)26 (3b)02 (4sb)01 (4d)07 (5)00 (6)010 (7)01 (8a)01 (9)02 (11p)06 (12a)00," M（胃体部）, 前Ant,",20,,, R0,,5.95,4.13,0.89,101.0,200.0,2.14,10.0,13.0,154.0,45.0,29.0,10.74,4.3,57.0,192.0,39.0,18.0,5.6,4.6,67.0,218.0,,,,,,,,,,,,,3.57,12.23,0.666, 未做,无, 无, P0,H0, 未做, CK +,,,,,45.69645203679369,1621134
1621257,魏淑香,646907,女,50,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,34,中间型（int）,INFa,0.0,,,,,,,,2016-06-23,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌80 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)20 Lauren肠型,G3, (1a)04 (1b)00 (3a)07 (3b)02 (4sb)00 (4d)03 (5)00 (6)06 (7)01 (8a)01 (8p)03 (9)03 (11p)01 (12a)03," L（幽门窦部）, 前Ant,",35,25,12, R0 D2,,5.79,3.25,2.07,121.0,251.0,3.33,9.0,14.0,157.0,64.0,6.0,26.38,8.83,60.0,185.0,37.0,23.0,4.5,3.4,68.0,322.0,,,,,,,,,,,,,0.909,38.21,1.38,,无, 无, P0,H0, 未做, CK+ CD31+  D2-40+  S-100+,,,,,74.2772667542707,1621257
1621456,邵希全,643053,男,59,T4b,N3a,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,11.0,40,髓样型（med）,INFb,0.0,,,,,,,,2016-06-24,2018-01-26,2,,,SOX,SOX,SOX,SOX,紫杉醇联合卡培他滨,,5, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren混合型,G3, (1a)00 (1b)01 (3a)314 (3b)00 (4sb)00 (4d)39 (5)01 (6)36 (7)02 (8a)11 (8p)02 (9)01 (11p)01 (12p)01 (14v)11 3a 3b 4d 5 6 软组织可见癌, L（幽门窦部） 前Ant 大弯侧Gre  小弯侧Less ,35,20,10, R0 D2,,6.49,3.95,2.07,143.2,209.0,3.09,26.0,26.0,152.0,72.0,40.0,10.35,3.52,73.0,299.0,45.0,28.0,5.2,6.8,98.0,347.0,66.4,31.4,28.5,1.1,0.1,5.8,15.3,8.7,0.655,2.85,11.7,,3.31,25.04,2.95, 未做,无,,,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,19.086727989487514,1621456
1621324,李广海,643383,男,71,T1b,N0,M0,ⅠA,1,3,1.0,1.0,1.0,0.0, 慢性炎症（+）,0.0,24,中间型（int）,,1.0,,,,,,,,2016-06-23,2021-09-02,1,,,,,,,,,0, 粘液腺癌（muc）50 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30 低粘附腺癌20,G3, (1a)01 (1b)03 (3a)08 (3b)00 (4sb)00 (4d)02 (5)01 (6)02 (7)03 (8a)01 (9)01 (11p)02 (12a)00," L（幽门窦部）, 后Post,",30,22,5, R0 D2,,6.81,4.34,1.92,143.3,216.0,2.44,10.0,14.0,157.0,67.0,14.0,13.87,5.48,61.0,273.0,42.0,19.0,5.5,7.6,76.0,286.0,,,,,,,,,,,,,1.37,0.6,1.48, 未做,无, 无, P0,H0, 未做, CK+,,,,,62.319316688567675,1621324
1621555,刘云诚,645026,男,68,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,6.0,14,中间型（int）,INFc,0.0,,,,,,,,2016-06-24,2017-07-13,0,,,SOX,SOX,,,,,2, 粘液腺癌（muc）60 低粘附腺癌20 管状腺癌（中分化【G2】【tub2】20 Lauren混合型,G2, (3a)01 (8p)01大弯侧12小弯侧510," L（幽门窦部）, 小弯侧Less,",90,70,15, R0 D2+,,8.76,6.3,1.63,98.0,324.0,3.9,17.0,21.0,141.0,85.0,14.0,12.34,4.47,65.0,274.0,38.0,27.0,5.9,5.2,92.0,309.0,,,,,,,,,,,,,19.78,10.27,300.0,,无, 无, P0,H0, 未做, CK+,,,,,12.614980289093298,1621555
1621563,尤广全,642777,男,73,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,17,中间型（int）,INFa,1.0,,,,,,,,2016-06-27,2018-04-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)0/0 (1b)0/1 (3a)0/0 (3b)0/1 (4sb)0/0 (4d)0/0 (5)1/1 (6)0/5 (7)0/0 (8a)0/2 (8p)0/2 (9)0/1 (11p)0/2 (12a)0/1 (14v)0/1 5组软组织可见癌," L（幽门窦部）, 小弯侧Less, 后Post,",15,10,8, R0,,9.22,7.73,0.83,147.0,157.0,3.07,12.0,17.0,146.0,63.0,12.0,11.3,3.74,63.0,347.0,38.0,25.0,4.4,6.0,77.0,374.0,,,,,,,,,,,,,2.17,9.56,1.65, 未做,无, 无, P0,H0, 未做, CK + CD31  S-100,,,,,21.583442838370566,1621563
1622248,王凤兰,638091,女,67,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+,0.0,40,髓样型（med）,INFa,1.0,,,,,,,,2016-06-30,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)04 (1b)02 (2) 02(3a) 04(3b)01 (4sa) 01(4sb)01 (4d) 02(5)00 (6) 04(7) 01(8a) 07(8p)02 (9)01 (10)03 (12a)00 (11d)05," U（胃底部）, 小弯侧Less,",40,25,5, R0 D2+,,6.78,3.51,2.77,121.0,277.0,2.85,16.0,22.0,164.0,90.0,28.0,10.23,3.51,59.0,266.0,39.0,20.0,4.5,6.9,70.0,204.0,,,,,,,,,,,,,5.05,9.53,3.78,,无, 无, P0,H0, 未做, CK +,,,,,74.04730617608409,1622248
1621941,吉长录,643926,男,54,T4b,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 正常,23.0,50,髓样型（med）,INFb,0.0,,,,,,,,2016-06-29,2022-09-01,1,,,,,,,,,0, 低粘附腺癌80 粘液腺癌（muc）20 Lauren弥漫型,GX, (1a)01 (1b)22 (2)03 (3a)88 (3b)79 (4sa)11 (4sb)13 (4d)25 (5)00 (6)05 (7)13 (8a)01 (8p)02 (9)13 (11p)03 (11d)01," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",70,50,15, R0 D2+,,7.89,3.97,3.25,150.0,238.0,3.01,13.0,17.0,141.0,65.0,21.0,15.74,4.4,65.0,322.0,45.0,20.0,4.5,6.3,92.0,397.0,66.3,46.7,17.2,2.72,0.1,16.1,13.2,1.0,0.669,1.88,6.08,,8.57,820.2,39.21, 阳性+++,无,, P0,H0, 未做, CK +,,,,,74.08015768725362,1621941
1621828,陈守义,642587,男,67,T4b,N3a,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+,9.0,21,髓样型（med）,INFa,2.0,,,,,,,,2016-06-28,2016-12-07,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3, (1a)22 (1b)12 (2)00 (3a)22 (3b)11 (4sa)00 (4sb)01 (4d)02 (5)00 (6)00 (7)02 (8a)11 (8p)01 (9)05 (10)00 (11p)22 (12a)00," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",30,30,5, R0 D2+,,6.39,3.48,2.12,145.0,221.0,3.2,27.0,33.0,219.0,72.0,29.0,23.69,10.52,69.0,243.0,41.0,28.0,,4.0,99.0,408.0,58.9,35.0,23.0,1.52,0.6,13.6,20.7,0.6,1.96,2.54,12.4,,4.78,804.6,6.54, 阴性,无,, P0,H0, 未做, CK +,,,,,5.321944809461235,1621828
1621786,梁栋双,642438,男,52,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,39,中间型（int）,INFa,0.0,,,,,,,,2016-06-28,2022-09-01,1,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)04 (1b)03 (3a)08 (3b)01 (4sb)00 (4d)06 (5)00 (6)06 (7)00 (8a)01 (8p)02 (9)01 (11p)02 (12a)05," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",40,30,10, R0 D2,,8.04,5.3,1.85,144.9,285.0,3.33,14.0,15.0,130.0,88.0,8.0,7.71,2.3,59.0,245.0,41.0,18.0,5.9,6.8,67.0,289.0,,,,,,,,,,,,,4.23,0.6,9.82,,无, 无, P0,H0, 未做, CK+ CD34-  D2-40-  S-100+,,,,,74.11300919842313,1621786
1621665,徐安平,643914,男,67,T1b,N0,M0,ⅠA,1,3,0.0,1.0,1.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,26,中间型（int）,INFa,0.0,,,,,,,,2016-06-27,2021-09-27,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)02 (3a)06 (3b)01 (4sb)00 (4d)00 (5)00 (6)02 (7)03 (8a)01 (8p)01 (9)03 (11p)05 (12a)01," L（幽门窦部）, 前Ant,",10,10,, R0 D2,,6.78,3.23,2.64,152.0,193.0,2.74,15.0,16.0,169.0,86.0,12.0,14.33,4.07,65.0,294.0,39.0,26.0,5.6,6.7,78.0,308.0,,,,,,,,,,,,,1.42,7.11,1.58,,无, 无, P0,H0, 未做, CK+ CD31 + D2-40+  S-100-,,,,,63.00919842312746,1621665
1622771,刘景俊,643131,男,70,T4b,N3a,M1, Ⅳ,1,3,0.0,1.0,1.0,1.0, 正常,13.0,26,髓样型（med）,INFa,0.0,,,,,,,,2016-07-06,2018-04-06,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,"(3b)11 (4sb)00 (4d)69 (5)00 (6)311 (7)01 (3a)34 另3a,3b,4d,5组 软组织可见癌"," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,45,120, D2,R2,7.8,5.34,1.75,56.9,265.0,4.56,29.0,42.0,195.0,98.0,100.0,13.69,5.26,70.0,276.0,41.0,29.0,,7.41,104.0,344.0,,,,,,,,,,,,,2.31,19.61,12.8,,无, 无, P0,H0, 未做, CK+,,,,,20.992115637319316,1622771
1621758,张春江,644751,男,61,T3,N2,M0, ⅢA,1,2,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,5.0,30,髓样型（med）,INFa,1.0,,,,,,,,2016-06-28,2020-05-20,0,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,,5, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)03 (1b)00 (3a)012 (3b)12 (4sb)02 (4d)05 (5)00 (6) 03(7) 11(8a) (8p)01 (9) 01(12a)00," M（胃体部）, 前Ant, 小弯侧Less,",55,40,10, R0 D2,,9.51,5.57,2.79,137.0,292.0,3.26,20.0,23.0,147.0,38.0,14.0,9.46,3.22,63.0,225.0,38.0,25.0,4.0,7.9,66.0,322.0,69.4,44.3,21.9,2.02,0.7,20.5,8.8,1.6,1.09,2.87,11.8,,1.97,10.27,9.6, 阴性,无, 无, P0,H0, 未做,CD34、D2-40可见脉管侵犯，S-100可见神经侵犯， CK+,,,,,46.71484888304862,1621758
1621942,穆大伟,643686,男,39,T4b,N3a,M0, ⅢC,1,5,2.0,1.0,1.0,1.0, 慢性炎症（++） 异型增生+,12.0,12,硬型（sci）,INFc,0.0,,,,,,,,2016-06-29,2018-04-29,2,,,SOX,SOX,,,,,2, 低粘附腺癌 90低分化腺癌（G3)(por)10,G3, (1a)00 (1b)11 (2) 22(3a)00 (3b)22 (4sa) 00(4sb)22 (4d) 33(5)00 (6)00 (7)22 软组织可见癌," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",150,130,8,,R2,4.29,2.39,1.34,139.4,195.0,3.09,12.0,15.0,143.0,50.0,16.0,14.24,4.25,71.0,331.0,49.0,22.0,5.2,4.5,88.0,387.0,64.9,36.9,25.9,1.42,0.4,11.1,18.5,0.5,0.465,2.7,7.87,,1.05,525.7,31.25,,,,,H0, 未做, CK +,,,,,21.97766097240473,1621942
1622218,张焕芝,642573,女,70,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,6.0,28,髓样型（med）,INFa,0.0,,,,,,,,2016-06-30,2019-10-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (2)46 (3a)00 (3b)00 (4sa)02 (4sb)00 (4d)03 (5)00 (7)26 (8a)05 (8p)05 (9)01," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,30,12, R0 D2,,5.28,3.54,1.39,98.0,176.0,2.6,11.0,14.0,180.0,68.0,9.0,8.1,2.58,63.0,233.0,41.0,22.0,5.8,5.7,81.0,286.0,79.7,40.7,34.5,1.18,1.2,6.7,10.7,2.2,1.38,2.29,8.21,,,,, 阳性+,无, 无, P0,H0, 未做,Ck（+）CD31(+) D2-40(+)S-100(+),,,,,39.02759526938239,1622218
1622004,王月琴,642599,女,73,T2,N2,M0, ⅡB,1,2,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,6.0,45,髓样型（med）,INFa,0.0,,,,,,,,2016-06-29,2017-04-02,2,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】 Lauren肠型,G3, (1a)0/2 (1b)0/3 (3a)2/12 (3b)0/0 (4sb)0/0 (4d)4/15 (5)0/0 (6)0/6 (7)0/1 (8a)0/1 (8p)0/0 (9)0/1 (11p)0/4 (12a)0/0," M（胃体部）, 后Post,",25,20,10, R0,,5.85,3.37,1.83,106.0,234.0,2.33,14.0,19.0,206.0,81.0,9.0,11.14,4.6,54.0,108.0,36.0,18.0,5.4,6.7,50.0,39.0,,,,,,,,,,,,,2.95,17.24,1.25, 未做,无, 无, P0,H0, 未做, CK + CD 31 S-100,,,,,9.099868593955321,1622004
1622048,陈洪印,642529,男,60,T4a,N0,M0, ⅡB,1,2,2.0,1.0,1.0,1.0, 肠化生+,0.0,38,中间型（int）,INFa,0.0,,,,,,,,2016-06-29,2021-07-05,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a) 01(1b)02 (3a)09 (3b) 02(4sb)00 (4d)04 (5)04 (6) 08(7)00 (8a)01 (8p)01 (9) 03(11p)02 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,10, R0 D2+,,8.18,6.16,1.07,71.3,326.0,4.43,19.0,17.0,142.0,64.0,26.0,7.64,3.66,62.0,213.0,40.0,22.0,7.6,5.2,77.0,316.0,69.3,29.9,34.8,0.86,0.0,5.3,22.7,2.4,0.558,1.42,7.21,,0.612,6.57,2.56, 阴性,,, P0,H0, 未做, CK +,,,,,60.183968462549274,1622048
1622149,张延财,642456,男,52,T4b,N3b,M0, ⅢC,1,5,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,34.0,42,中间型（int）,INFb,1.0,,,,,,,,2016-06-30,2018-05-10,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a) 22(1b)12 (2) 14(3a) 1010(3b)00 (4sa)00 (4sb)00 (4d)1011 (5) 11(6)44 (7)00 (8a) 11(8p) (9)11 (11p)25 (12a)11    3b 4d 5 6 7  软组织可见癌," LMU 前Ant, 后Post, 小弯侧Less,",60,40,10,,R1,6.82,4.67,1.59,121.8,309.0,3.33,24.0,21.0,129.0,86.0,19.0,9.55,4.16,69.0,291.0,43.0,26.0,5.9,5.9,82.0,275.0,50.6,34.9,12.9,2.71,0.2,12.5,31.5,0.8,0.63,2.46,9.69,,5.86,568.6,22.9,,,, P0,H0, 未做, CK +,,,,,22.306176084099867,1622149
1621782,刘长江,646769,男,43,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,5.0,24,髓样型（med）,INFa,0.0,,,,,,,,2016-06-28,2017-07-04,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)03 (1b)01 (2)01 (3a)22 (3b)11 (4sa)01 (4sb)00 (4d)06 (5)00 (6)02 (7)12 (8a)11 (8p)00 (9)03 (11p)01 (12a)00," M（胃体部）, 小弯侧Less,",50,30,8, R0 D2,,7.17,3.31,3.26,162.0,312.0,2.79,36.0,28.0,167.0,126.0,69.0,7.65,2.77,73.0,314.0,45.0,28.0,8.5,5.9,58.0,297.0,,,,,,,,,,,,,2.24,14.02,1.03,,无, 无, P0,H0, 未做, CK+ CD31 + D2-40 + S-100+,,,,,12.187910643889618,1621782
1622389,王玉森,642453,男,67,T1a,N0,M0,ⅠA,1,3,,1.0,1.0,,,0.0,21,,,0.0,,,,,,,,2016-07-01,2021-09-27,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20,G3, (1a)02 (1b)00 (3a)00 (3b)00 (4sb)01 (4d)05 (5)4 (6)00 (7)02 (8a)03 (8p)00 (9)04 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",20,15,, R0 D2,,6.18,4.22,1.46,139.2,166.0,2.3,21.0,25.0,192.0,96.0,64.0,14.47,5.1,65.0,317.0,42.0,23.0,6.2,8.2,100.0,316.0,,,,,,,,,,,,,3.24,6.16,2.32,,无, 无, P0,H0, 未做, CK+ CD31+  D2-40 +,,,,,62.877792378449406,1622389
1622118,王加顺,643048,男,64,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,16,,,0.0,,,,,,,,2016-06-30,2022-09-01,1,,,,,,,,,0, 高级别上皮内瘤变 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)00 (5)00 (6)03 (7)00 (8a)00 (8p)05 (9)02 (11p)03 (12a)00," L（幽门窦部）, 小弯侧Less,",40,30,4, R0 D2,,6.04,3.51,1.76,145.2,235.0,2.48,49.0,31.0,154.0,101.0,47.3,6.33,1.67,69.1,326.3,36.7,32.4,5.4,8.11,106.0,478.0,,,,,,,,,,,,,2.5,8.39,1.11,,无, 无, P0,H0, 未做, CK+,,,,,74.04730617608409,1622118
1622342,何亚荣,644754,女,60,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 正常,0.0,30,硬型（sci）,INFc,0.0,,,,,,,,2016-07-02,2021-06-01,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)07 (3b)00 (4sb)00 (4d)05 (5)00 (6)09 (7)01 (8a)01 (8p)03 (9)02 (11p)02 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",35,15,8, R0,,9.65,6.05,2.73,157.7,196.0,3.13,18.0,19.0,179.0,105.0,18.0,10.02,3.11,63.0,285.0,40.0,23.0,7.5,2.8,69.0,239.0,,,,,,,,,,,,,1.38,14.95,1.17,,无, 无, P0,H0, 未做, CK+,,,,,58.96846254927726,1622342
1622298,岳淑芝,644926,女,48,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,13.0,28,硬型（sci）,INFb,0.0,,,,,,,,2016-07-01,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 低粘附腺癌15%,G3, (1a)00 (1b)12 (3a)00 (3b)27 (4sb)00 (4d)23 (5)00 (6)47 (7)23 (8a)11 (8p)02 (9)02 (11p)11 (12a)00 软组织可见癌," L（幽门窦部）, 小弯侧Less,",55,35,13, R0,,5.85,3.8,0.97,129.8,325.0,2.85,7.0,14.0,143.0,82.0,9.0,9.19,1.99,63.0,274.0,42.0,21.0,6.5,3.4,58.0,249.0,,,,,,,,,,,,,1.9,16.83,3.7, 未做,无, 无, P0,H0, 未做, CK +,,,,,74.01445466491458,1622298
1622626,黄国军,644758,男,61,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,12,,,0.0,,,,,,,,2016-07-05,2021-05-24,1,,,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,6, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】40,G2, (1a)00 (1b)00 (3a)00 (3b)01 (4sb)02 (4d)03 (5)01 (6)01 (7)00 (8a)01 (8p)01 (9)01 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",15,10,5, R0,,5.21,3.25,1.52,93.0,279.0,3.01,20.0,20.0,173.0,73.0,29.0,17.22,6.62,63.0,203.0,38.0,25.0,6.9,5.5,92.0,270.0,,,,,,,,,,,,,1.59,2.18,2.05, 未做,无, 无, P0,H0, 未做, CK +,,,,,58.60709592641261,1622626
1622980,逯靖华,646695,女,77,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 正常,20.0,29,髓样型（med）,INFb,0.0,,,,,,,,2016-07-07,2017-07-15,2,,,,,,,,,0, 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren弥漫型,G3,小弯24 (1a)00 (1b)11 (3a)33 (3b)66 (4sa)00 (4sb)00 (4d)01 (5)00 (6)02 (7)00 (8a)01 (8p)22 (9)22 (11p)23 另在3b组及7组 软组织可见癌," MU 前Ant, 后Post, 小弯侧Less,",80,60,8, R0 D2,,6.6,4.6,1.3,76.1,351.0,4.0,13.0,21.0,246.0,64.0,11.0,6.53,1.72,67.0,189.0,40.0,27.0,5.6,4.6,73.0,186.0,,,,,,,,,,,,,10.61,11.77,4.34,,无, 无, P0,H0, 未做, CK + CD31+  D2-40+  S-100+,,,,,12.253613666228645,1622980
1623071,吴忠琴,638109,女,62,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 正常,4.0,22,髓样型（med）,INFa,0.0,,,,,,,,2016-07-07,2016-08-08,2,,,XELOX,XELOX,XELOX,,,,3, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)13 (3a)36 (3b)00 (4sb)09 (4d)01 (5)00 (6)03 (7)00 另1b 3a 3b 4sb 5组可见癌结节12枚," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,8,,R2,4.94,3.21,1.44,62.9,227.0,2.47,11.0,20.0,195.0,82.0,13.0,9.45,3.19,49.0,164.0,30.0,19.0,4.3,6.0,56.0,284.0,,,,,,,,,,,,,1.58,5.55,0.943,,无, 无, P0,H0, 未做, CK+ CD31+  D2-40+  S-100+,,,,,1.0512483574244416,1623071
1622711,元敬芝,642667,女,56,T3,N0,M0, ⅡA,1,3,1.0,0.0,0.0,1.0, 肠化生+,0.0,20,硬型（sci）,INFc,0.0,,,,,,,,2016-07-05,2022-06-12,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)01 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)02 (5)00 (6)04 (7)02 (8a)04 (8p)03 (9)02 (11p)01 (12a)01 (3a)软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,20,5, R0 D2+,,8.69,5.21,2.46,131.0,361.0,4.0,19.0,22.0,224.0,96.0,13.0,12.15,4.01,70.0,253.0,46.0,24.0,5.1,5.9,96.0,220.0,,,,,,,,,,,,,1.49,7.01,1.28, 阳性++,无, 无, P0,H0, 未做, CK +,,,,,71.22207621550591,1622711
1622772,杨国兴,647182,男,57,T1b,N1,M0, ⅠB,1,3,,,,,,1.0,20,,,0.0,,,,,,,,2016-07-06,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a) 06(1b) 03(3a) 00(3b) 01(4sb)02 (4d)00 (5)00 (6)02 (7)14 (8a) (8p)01 (9)01 (11p)00," L（幽门窦部）, 后Post,",10,10,5, R0 D2,,7.52,4.2,2.51,148.0,265.0,2.41,20.0,21.0,171.0,92.0,40.0,14.71,4.33,71.0,399.0,45.0,26.0,4.7,8.7,89.0,545.0,69.4,44.3,21.9,2.02,0.7,20.5,8.8,1.6,1.09,2.87,11.8,,3.0,15.29,0.999, 未做,无, 无, P0,H0, 未做, CK +,,,,,73.85019710906701,1622772
1622710,田俊影,638117,男,62,T2,N2,M0, ⅡB,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,5.0,23,髓样型（med）,INFa,0.0,,,,,,,,2016-07-05,2021-07-10,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低粘附腺癌80% 低分化腺癌（G3)(por)20% Lauren弥漫型,G3, (1a)0/1 (1b)0/0 (3a)1/4 (3b)1/1 (4sb)0/0 (4d)0/1 (5)0/0 (6)0/5 (7)1/3 (8a)0/2 (8p)0/2 (9)2/3 (11p)0/1 (12a)0/0," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,20,10, R0,,8.33,5.0,2.81,147.0,315.0,2.65,24.0,25.0,259.0,75.0,16.0,9.69,4.38,56.0,164.0,31.0,25.0,7.6,6.0,70.0,227.0,,,,,,,,,,,,,1.53,5.12,0.755, 未做,无, 无, P0,H0, 未做, CK + CD 31 S-100,,,,,60.15111695137976,1622710
1623205,王永岐,637975,男,62,T3,N0,M0, ⅡA,1,1,0.0,0.0,0.0,1.0, 正常,0.0,65,中间型（int）,INFa,0.0,,,,,,,,2016-07-08,2021-06-11,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)04 (1b)00 (2)04 (3a)014 (3b)00 (4sa)00 (4sb)00 (4d)05 (5)01 (6)06 (7)08 (8a) 03(8p) 07(9)05 (11p)06 (12a) 01(12p)01,GE SiewerⅢ型 前Ant 后Post 大弯侧Gre  ,45,30,20, R0 D2,,7.77,4.54,2.13,145.0,183.0,2.65,18.0,19.0,157.0,60.0,23.0,10.22,3.53,59.0,295.0,37.0,22.0,5.0,5.7,101.0,392.0,74.4,47.0,32.3,1.46,6.3,12.8,8.2,0.6,0.994,1.29,9.35,,7.47,0.668,0.966, 未做,无,, P0,H0, 未做, CK +,,,,,59.09986859395532,1623205
1622524,张业田,638113,男,71,T1b,N1,M0, ⅠB,1,3,,,,,,2.0,23,,,0.0,,,,,,,,2016-07-04,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a) 00(3a)04 (3b)03 (4sb)00 (4d) 01(5)00 (6) 26(7) 01(8a)05 (8p)00 (9)03 (11p)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",20,15,3, R0 D2+,,5.06,3.09,1.59,136.0,225.0,2.74,19.0,21.0,121.0,86.0,16.0,7.4,2.18,59.0,313.0,37.0,22.0,6.1,6.7,90.0,283.0,73.0,43.8,24.2,1.81,0.1,16.1,8.9,3.7,0.776,1.84,8.98,,0.912,6.89,1.36, 阳性+,,, P0,H0, 未做, CK +,,,,,73.91590013140605,1622524
1622624,陈桂云,647176,女,61,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,13.0,18,硬型（sci）,INFc,0.0,,,,,,,,2016-07-05,2021-08-05,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20 Lauren混合型,G3, (1a)00 (1b)11 (2)01 (3a)33 (3b)11 (4sa)00 (4sb)00 (4d)04 (5)00 (6)22 (7)22 (8a)11 (8p)11 (9)00 (11p)11 (12a)11 另在3a 7 8a 9组 软组织可见癌," M（胃体部）, 小弯侧Less,",35,30,15, R0 D2,,5.81,2.33,2.94,140.2,206.0,2.74,28.0,26.0,204.0,87.0,67.0,8.11,2.46,74.0,334.0,48.0,26.0,4.9,6.7,70.0,289.0,,,,,,,,,,,,,2.14,14.38,1.7,,无, 无, P0,H0, 未做, CK + CD31+  D2-40+  S-100+,,,,,61.00525624178712,1622624
1622831,李翠英,646605,女,67,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 正常,0.0,28,硬型（sci）,INFc,0.0,,,,,,,,2016-07-06,2021-06-01,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)06 (3b)00 (4sb) 00(4d)05 (5) 01(6)06 (7)05 (8a) 02(8p) 01(9)02," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",30,25,5, R0 D2+,,4.25,2.49,1.34,120.9,293.0,1.88,12.0,16.0,159.0,58.0,9.0,12.58,4.52,65.0,294.0,42.0,23.0,4.9,3.9,59.0,216.0,58.5,41.6,15.2,2.74,0.1,10.9,26.3,1.5,0.966,1.68,10.5,,1.29,,1.15,,无, 无, P0,H0, 未做, CK +,,,,,58.83705650459921,1622831
1622878,曲维全,642600,男,66,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,69,硬型（sci）,INFc,0.0,,,,,,,,2016-07-06,2021-06-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)02 (1b)00 (3a)18 (3b)06 (4sb)02 (4d)335 (5)02 (6)28 (7)12 (8a)01 (8p)01 (9)01 (11p)01另在4d组 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,15, R0 D2,,7.49,4.35,2.51,148.9,155.0,2.85,27.0,23.0,149.0,114.0,11.0,26.65,8.75,63.0,297.0,43.0,20.0,5.0,5.2,85.0,371.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK + CD31+  D2-40+  S-100+,,,,,58.83705650459921,1622878
1623169,尹忠,647607,男,49,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 正常,20.0,54,中间型（int）,INFa,0.0,,,,,,,,2016-07-08,2018-04-20,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,SOX,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3,小弯44 (1a)410 (1b)00 (2)11 (3a)66 (3b)00 (4sa)01 (4sb)00 (4d)06 (5)00 (6)07 (7)06 (8a)04 (9)25 (11d)23 (11p)11," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,30,10, R0 D2,,9.55,6.64,1.99,141.7,294.0,,30.0,21.0,182.0,126.0,18.4,12.47,2.69,65.6,222.01,36.1,29.5,4.8,6.91,106.0,252.0,,,,,,,,,,,,,3.88,8.22,2.78,,无, 无, P0,H0, 未做, CK + CD31+  D2-40+  S-100+,,,,,21.38633377135348,1623169
1623429,齐万金,646635,男,73,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+,0.0,24,髓样型（med）,INFa,0.0,,,,,,,,2016-07-11,2021-10-11,1,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】 Lauren肠型,G3, (1a)0/1 (1b)0/4 (3a)0/3 (3b)0/7 (4sb)0/0 (4d)0/5 (5)0/0 (6)0/0 (7)0/0 (8a)0/1 (8p)0/0 (9)0/1 (11p)0/2 (12a)0/0," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",55,30,8, R0,,10.25,8.98,0.68,98.0,178.0,2.37,38.0,51.0,157.0,87.0,30.8,6.09,2.7,71.0,167.64,32.4,39.5,5.7,8.16,85.0,304.0,,,,,,,,,,,,,1.37,242.3,1.62, 未做,无, 无, P0,H0, 未做, CK + CD 31 S-100,,,,,63.00919842312746,1623429
1623504,薛海昌,647046,男,59,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,23,,,2.0,,,,,,,,2016-07-12,2020-07-07,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)01 (3a)04 (3b)01 (4sb)00 (4d)02 (5)00 (6)02 (7)02 (8a)03 (8p)03 (9)04 (11p)00 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",25,15,5, R0,,5.37,2.21,2.22,140.7,330.0,3.33,19.0,22.0,181.0,88.0,24.0,5.96,1.89,60.0,230.0,39.0,21.0,5.3,6.2,74.0,388.0,,,,,,,,,,,,,3.64,19.0,1.11, 未做,无, 无, P0,H0, 未做, CK +,,,,,47.83180026281209,1623504
1623017,温凤军,646641,男,73,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生++,24.0,32,中间型（int）,INFa,1.0,,,,,,,,2016-07-07,2017-01-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)14 (3b)22 (4sb01) (4d)77 (5)22 (6)67 (7)11 (8p) (11p)47 (12a)003b5612a 软组织可见癌," L（幽门窦部）,  前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",75,65,13,,R2,5.87,3.99,1.17,86.0,404.0,5.12,37.0,34.0,169.0,109.0,221.0,7.69,3.91,59.0,138.0,34.0,25.0,4.9,7.1,73.0,172.0,55.0,37.6,15.2,2.47,0.2,9.8,33.4,1.2,0.835,4.0,11.7,,2.59,179.7,300.0,,无, 无, P0,H0, 未做,Ck（+）CD31(+) D2-40(+)S-100(+),,,,,6.14323258869908,1623017
1623790,石玉华,640816,女,63,T4a,N2,M0, ⅢA,1,4,2.0,0.0,0.0,1.0, 慢性炎症（+）,3.0,26,中间型（int）,INFc,0.0,,,,,,,,2016-07-13,2017-12-22,2,SOX*2,1.0,XELOX,XELOX,,,,,2, 低粘附腺癌 70低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a) 01(1b) 00(2)04 (3a)12 (3b)00 (4sa)01 (4sb)00 (4d)22 (5) 02(6)01 (7) 03(8a) 02(8p)04 (9) 04(12a)00," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",,,, R0 D2+,,4.84,2.29,1.97,107.3,178.0,4.1,26.0,29.0,206.0,91.0,51.0,13.7,3.7,59.0,304.0,37.0,22.0,4.7,5.7,65.0,323.0,76.7,57.9,16.2,3.57,0.3,8.9,11.9,0.9,0.558,1.06,6.77,,4.47,21.27,0.97,,无, 无, P0,H0, 未做, CK +,,,,,17.31274638633377,1623790
1623063,马洪武,643434,男,46,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 正常,3.0,38,中间型（int）,INFc,0.0,,,,,,,,2016-07-07,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌 管状腺癌80（中分化【G2】【tub2】 低分化腺癌（G3)(por)20 Lauren混合型,G3, (1b)00 (3a)111 (3b)00 (4sb)02 (4d)04 (5)00 (6)26 (7) 03(8a)05 (8p)01 (9) 01(11p)04 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,18, R0 D2+,,7.57,3.52,3.06,144.7,324.0,2.33,25.0,32.0,202.0,101.0,36.0,6.52,2.35,68.0,425.0,44.0,24.0,6.0,7.4,86.0,376.0,58.6,31.0,24.2,1.28,0.4,8.3,23.3,0.9,0.554,3.75,7.57,,3.58,2.4,3.03, 阳性+,,,,H0, 未做, CK +,,,,,73.8173455978975,1623063
1623207,李树峰,647263,男,64,T3,N3b,M0, ⅢC,1,5,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,29.0,49,硬型（sci）,INFc,1.0,,,,,,,,2016-07-08,2016-11-09,2,,,,,,,,,0, 低粘附腺癌90 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)02 (1b)00 (2) 05(3a)66 (3b) 12(4sa)00 (4sb) 00(4d)28 (5) 44(6)47 (7)44 (8a)22 (8p)01 (9)02 (11p)33 (11d)00 (12a)00 (12p)11 (19)00大弯22," LM 前Ant, 后Post, 小弯侧Less,",50,50,10, R0,,7.44,4.29,2.28,137.0,260.0,3.81,15.0,16.0,173.0,55.0,15.0,12.36,3.64,65.0,373.0,41.0,24.0,5.2,6.9,105.0,281.0,66.1,35.2,27.5,1.28,0.4,10.5,20.6,2.6,0.475,2.46,7.58,,3.47,15.84,1.82,,,, P0,H0, 未做, CK +,,,,,4.073587385019711,1623207
1623422,范金才,644269,男,48,T2,N0,M0, ⅠB,1,2,1.0,0.0,0.0,1.0, 肠化生,0.0,29,硬型（sci）,INFa,0.0,,,,,,,,2016-07-11,2021-08-11,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2," (1a) (1b) (3a) (3b) (4sb) (4d) (5) (6) (7) (8a) (8p) (9) (11p)0,29"," L（幽门窦部）, 前Ant, 小弯侧Less,",40,30,10, R0 D2,,4.88,3.0,1.35,150.6,255.0,2.91,19.0,22.0,163.0,73.0,13.0,13.99,5.56,67.0,300.0,42.0,25.0,5.5,5.7,89.0,203.0,,,,,,,,,,,,,2.01,5.09,2.97,,无,, P0,H0, 未做, CK +,,,,,61.00525624178712,1623422
1623430,李凤春,643079,男,55,T4b,N2,M0, ⅢB,1,3,,1.0,1.0,1.0,,4.0,19,,,0.0,,,,,,,,2016-07-11,2017-07-13,0,,,SOX,SOX,SOX,SOX,SOX,SOX,9, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)01 (1b)00 (2)02 (3a)12 (3b)22 (4sa)00 (4sb)11 (4d)01 (5)01 (6)01 (7)00 (8a)03 (8p)04 (9)00 (11p)01 (12a)00," U（胃底部）, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,20, R0 D2+,,7.41,4.95,1.62,78.1,682.0,3.84,14.0,11.0,161.0,96.0,28.0,5.2,1.48,62.0,235.0,40.0,22.0,9.1,8.6,91.0,294.0,,,,,,,,,,,,,2.21,2.39,2.92,,无, 无, P0,H0, 未做, CK +,,,,,12.056504599211562,1623430
1623519,庄玉花,643576,女,63,T3,N1,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 肠化生+,1.0,28,中间型（int）,INFa,1.0,,,,,,,,2016-07-12,2021-06-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)01 (3a)05 (3b)00 (4sb)00 (4d)07 (5)01 (6)02 (7)03 (8a)00 (8p)12 (9)02 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,20,10, R0,,4.57,2.83,1.25,126.6,167.0,3.64,21.0,24.0,199.0,121.0,14.0,20.11,7.81,76.0,185.0,46.0,30.0,5.1,4.2,77.0,228.0,,,,,,,,,,,,,0.511,12.27,2.07,,无, 无, P0,H0, 未做, CK +,,,,,58.63994743758212,1623519
1624327,孙世民,646607,男,50,T4b,N0,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,0.0,20,髓样型（med）,INFa,0.0,,,,,,,,2016-07-18,2019-05-05,2,,,XELOX,XELOX,XELOX,XELOX,DP,DP,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)06 (3b)01 (4sb)02 (4d)02 (5)00 (6)02 (7)00 (8a)02 (8p)02 (9)00 (11p)01 (12a)01," LM 前Ant, 后Post, 小弯侧Less,",70,70,10,,R2,6.35,4.25,1.4,54.8,251.0,2.3,19.0,21.0,146.0,82.0,20.0,5.08,2.24,57.0,221.0,38.0,19.0,4.9,4.6,61.0,248.0,,,,,,,,,,,,,0.836,7.68,1.44,,无, 无, P0,H0, 未做, CK +,,,,,33.54139290407359,1624327
1632327,高新廷,643435,男,53,T3,N2,M0, ⅢA,1,3,2.0,0.0,0.0,1.0, 肠化生+,6.0,33,中间型（int）,INFc,2.0,,1.0,,1.0,1.0,,,2016-09-21,2018-07-17,2,替吉奥*3,1.0,SOX,,,,,,1, 低分化腺癌（G3)(por)30 低粘附腺癌70 Lauren弥漫型,G3,(1a)08 (1b)02 (3a)02 (3b)02(4sb)00 (4d)01 (5)00 (6)14(7)00 (8a)01(8p)00 (9)03(11p)03 (12a)00 图, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,45,10, R0 D2,,6.79,3.66,1.6,149.0,335.0,2.24,47.0,39.0,178.0,95.0,42.0,15.93,6.41,60.0,232.0,37.0,23.0,5.8,4.1,67.0,324.0,,,,,,,,,,,,,2.81,21.37,2.8, 未做,无,, P0,H0, 未做, CD31（-） D2-40（-）S-100（+)   CD4(+) CD8(+)VEGF(+),40% 弱-中,50% 中,80% 强,60 弱,21.81340341655716,1632327
1623360,李彦萍,548045,女,48,T4b,N2,M0, ⅢB,1,5,2.0,0.0,0.0,1.0, 正常,4.0,25,中间型（int）,INFc,1.0,,,,,,,,2016-07-11,2017-07-21,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌95 低分化腺癌（G3)(por)5 Lauren弥漫型,G3, (1a)01 (1b)00 (3a) 26(3b)01 (4sb)00 (5) 00(6)26 (7)03 (8a)02 (9)02 (11p)02 (12a)01 (8p)01 3b 6软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,50,,,R1,8.27,5.83,2.02,128.7,282.0,3.84,21.0,25.0,210.0,73.0,15.0,17.62,5.33,75.0,343.0,48.0,27.0,4.9,4.3,64.0,227.0,77.3,45.7,25.5,1.79,0.7,7.4,12.3,3.2,1.22,2.27,10.3,,2.86,12.87,1.2,,无, 无, P0,H0,, CK +,,,,,12.319316688567673,1623360
1623364,李长春,647053,男,62,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,19,,,1.0,,,,,,,,2016-07-11,2020-09-09,0,,,,,,,,,0, 高级别上皮内瘤变 管状腺癌（高分化【G1】【tub1】）,G1, (3a)05 (3b)00 (4sb)00 (4d)03 (5)01 (6)05 (7)02 (8a)01 (11p)01 (12p)01," L（幽门窦部）, 前Ant, 小弯侧Less,",30,20,1, R0 D2,,9.27,5.89,2.47,143.8,228.0,3.81,16.0,22.0,158.0,119.0,40.0,10.5,3.32,69.0,331.0,45.0,24.0,5.5,5.7,85.0,370.0,67.1,51.3,11.3,4.54,0.7,8.5,20.6,0.6,0.371,2.73,9.73,,4.74,17.17,1.1,,无, 无, P0,H0, 未做, CK +,,,,,49.96714848883048,1623364
1623601,徐立堂,647192,男,74,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,14.0,41,中间型（int）,INFc,0.0,,,,,,,,2016-07-12,2018-12-23,2,,,,,,,,,0, 低粘附腺癌95 粘液腺癌（muc）5 Lauren弥漫型,GX, (1a)02 (1b)03 (3a)33 (3b)11 (4sb)07 (4d)611 (5)11 (6)26 (7)02 (8a)11 (8p)01 (9)01 (11p)02 (12a)00 另在3a 3b及5组 软组织可见癌," MU 前Ant, 后Post, 小弯侧Less,",50,40,15, R0 D2,,6.6,4.12,1.89,142.0,209.0,2.09,13.0,16.0,182.0,78.0,33.0,12.94,3.58,63.0,255.0,41.0,22.0,5.4,5.8,80.0,260.0,,,,,,,,,,,,,56.37,177.6,31.58,,无, 无, P0,H0, 未做, CK + CD31+  D2-40+  S-100+,,,,,29.369250985545335,1623601
1623710,陈凤兰,647089,女,66,T4a,N3a,M0, ⅢB,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,14.0,28,中间型（int）,INFb,0.0,,,,,,,,2016-07-13,2016-11-24,0,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)00 (3a)33 (3b)00 (4sb)00 (4d)04 (5)00 (6)44 (7)15 (8a) (8p)22 (9)45 (11p)05 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,8, R0 D2,,6.97,4.24,2.25,129.0,240.0,3.48,16.0,19.0,170.0,74.0,9.0,14.78,5.25,71.0,228.0,46.0,25.0,5.0,3.1,62.0,322.0,,,,,,,,,,,,,16.24,160.0,3.35, 阴性,无, 无, P0,H0, 未做, CK+，CD31、D2-40可见脉管瘤栓，S-100可见神经侵犯,,,,,4.402102496714849,1623710
1624064,桂义甫,637993,男,74,T4a,N0,M0, ⅡB,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,31,中间型（int）,INFa,1.0,,,,,,,,2016-07-15,2020-03-01,2,,,口服卡培他滨,,,,,,1, 低分化腺癌（G3)(por),G3, (1a)0/3 (1b)0/2 (2)0/4 (3a)0/10 (3b)0/0 (4sa)0/0 (4sb)0/0 (4d)0/4 (5)0/0 (6)0/0 (7)0/1 (8a)0/1 (8p)0/3 (9)0/2 (11p)0/1 (12a)0/0," L（幽门窦部）, 后Post, 小弯侧Less,",70,60,10, R0,,6.65,4.29,1.47,114.0,225.0,2.41,10.0,25.0,237.0,57.0,10.0,4.95,2.51,46.0,122.0,28.0,18.0,5.3,5.7,67.0,147.0,,,,,,,,,,,,,0.732,7.12,1.39, 未做,无, 无, P0,H0, 未做, CK + CD 31 S-100,,,,,43.52825229960578,1624064
1623684,王月英,644232,女,56,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,47,,,1.0,,,,,,,,2016-07-13,2022-09-01,1,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30,G3, (1a)01 (1b)07 (3a)010 (3b)00 (4sb) 01(4d)09 (5)01 (6)05 (7)04 (8a)04 (8p)02 (9)01 (11p)02 (12a)00," M（胃体部）, 小弯侧Less,",25,20,5, R0 D2,,5.46,1.91,3.17,149.0,181.0,2.03,11.0,16.0,198.0,74.0,10.0,73.0,3.86,73.0,310.0,46.0,27.0,5.0,4.9,87.0,275.0,54.3,39.8,10.7,3.72,0.4,6.7,35.2,0.3,0.732,2.61,11.7,,4.02,0.768,0.883, 阳性+,无, 无, P0,H0, 未做, CK +,,,,,73.62023653088042,1623684
1624519,刘起多,643467,男,67,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 正常,0.0,16,中间型（int）,INFc,0.0,,,,,,,,2016-07-19,2019-06-01,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,大弯08 小弯06  (13)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,30,20, R0 D2+,,8.03,5.14,2.04,146.6,258.0,2.86,64.0,42.0,150.0,86.0,32.0,12.5,5.6,72.0,162.0,43.0,29.0,6.0,7.4,106.0,246.0,,,,,,,,,,,,,2.74,1.07,6.22,,无, 无, P0,H0, 未做, CK +,,,,,34.39553219448094,1624519
1624524,岳桂琴,643477,女,73,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,13,,,0.0,,,,,,,,2016-07-19,2021-07-14,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3,小弯01 大网01 (1a) (1b) (3a) (3b) (12a)06 (4sb) (4d) (5) (7) （8） (9) (11p)00," L（幽门窦部）, 大弯侧Gre,",30,30,5, R0 D2+,,6.41,3.08,2.44,149.0,209.0,3.03,14.0,21.0,212.0,119.0,17.0,14.32,5.43,73.0,204.0,44.0,29.0,4.5,6.9,84.0,240.0,,,,,,,,,,,,,3.05,5.88,2.4,,无, 无, P0,H0, 未做, CK +,,,,,59.82260183968462,1624524
1624520,刘万侠,647055,女,59,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,1.0, 慢性炎症（+）,2.0,22,髓样型（med）,INFa,0.0,,,,,,,,2016-07-19,2017-11-03,2,,,,XELOX,紫杉醇联合替吉奥,紫杉醇联合替吉奥,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)01 (1b)01 (3a)02 (3b)00 (4sb)00 (4d)02 (5)11 (6)08 (7)01 (8a)01 (8p)01 (9)01 (11p)02 (12a)11," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",40,25,7, R0 D2+,,7.59,2.85,4.14,127.1,270.0,3.48,20.0,26.0,206.0,68.0,13.0,8.66,3.63,74.0,219.0,44.0,30.0,4.9,8.4,82.0,322.0,58.6,35.1,20.3,1.73,3.3,19.4,15.0,0.9,1.52,3.07,11.2,,23.0,4.72,0.996, 阴性,无, 无, P0,H0, 未做, CK +,,,,,15.505913272010512,1624520
1623939,王德顺,648346,男,71,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,7.0,38,中间型（int）,INFa,0.0,,,,,,,,2016-07-14,2018-01-30,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】95 低粘附腺癌5 Lauren肠型,G3, (1a)05 (1b)00 (3a)110 (3b)35 (4sb)00 (4d)03 (5)11 (6)07 (8a)11 (8p)00 (9)02 (11p)01 (12a)11, L（幽门窦部） 小弯侧Less ,38,35,5, R0 D2,,6.72,4.04,1.89,127.9,255.0,3.46,16.0,24.0,187.0,77.0,13.0,6.31,2.75,67.0,229.0,42.0,25.0,4.3,4.4,76.0,200.0,83.0,45.9,33.1,1.39,0.2,13.9,1.7,4.3,0.504,2.34,10.0,,9.2,6.98,4.66,,无, 无, P0,H0, 未做,Ck（+）CD31(+) D2-40(+)S-100(+),,,,,18.561103810775293,1623939
1623826,李慎光,643637,男,53,T2,N3a,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,7.0,28,中间型（int）,INFb,0.0,,,,,,,,2016-07-14,2021-05-12,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低分化腺癌（G3)(por) 管状腺癌（高分化【G1】【tub1】）80 低粘附腺癌20 Lauren混合型,G3, (1a)02 (1b)00 (3a)712 (3b)00 (4sb)00 (4d)03 (5)00 (6)01 (7)03 (8a)01 (8p)02 (9)02 (11p)01 (14v)01, L（幽门窦部） 前Ant 后Post 小弯侧Less ,20,20,8, R0 D2,,6.47,3.21,2.88,153.0,215.0,2.0,29.0,27.0,198.0,82.0,56.0,21.28,6.31,66.0,374.0,44.0,22.0,5.6,3.9,81.0,349.0,53.0,33.5,14.8,2.26,0.5,7.9,33.3,0.2,0.446,1.82,8.66,,0.92,5.9,1.02,,无, 无, P0,H0, 未做,Ck（+）CD31(+) D2-40(+)S-100(+),,,,,57.91721419185282,1623826
1624254,倪军,428278,男,61,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 肠化生+,5.0,22,髓样型（med）,INFb,1.0,,,,,,,,2016-07-18,2018-06-12,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌50 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)25 粘液腺癌（muc）15 Lauren混合型,G3, (3a)07 (3b)01 (4sb)01 (4d)02 (5)00 (6)00 (7)02 (8a)11 (8p)23 (9)23 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",40,30,15, R0 D2,,11.78,7.93,2.74,151.0,273.0,3.28,38.0,34.0,183.0,94.0,39.0,11.3,5.28,67.0,259.0,43.0,24.0,5.7,6.8,115.0,422.0,64.6,27.1,34.4,0.78,0.1,4.8,26.8,1.1,0.452,2.36,8.44,,3.09,704.6,1.07, 未做,无,, P0,H0, 未做,Ck（+）CD31(+) D2-40(+)S-100(+),,,,,22.798948751642573,1624254
1624498,丁乃军,647732,男,65,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 肠化生+,0.0,16,髓样型（med）,INFa,1.0,,,,,,,,2016-07-19,2021-07-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b) 00(3a) 03(3b) 02(4sb)00 (4d)01 (5)00 (6)02 (7) 02(8a)01 (8p)02 (9)01 (11p)01(12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",40,40,8, R0 D2+,,5.57,3.37,1.6,158.6,212.0,1.76,17.0,16.0,138.0,63.0,15.0,22.18,7.83,69.0,302.0,43.0,26.0,5.3,5.0,83.0,265.0,69.0,42.7,23.0,1.86,0.3,14.4,15.4,2.2,0.983,2.88,11.5,,0.864,6.65,0.906, 阳性+,,, P0,H0, 未做, CK +,,,,,59.55978975032851,1624498
1624876,屈昌利,647149,男,42,T1b,N0,M0,ⅠA,1,3,,0.0,0.0,0.0,,0.0,19,,,1.0,,,,,,,,2016-07-21,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20,G3, (1a)00 (1b)02 (3a)05 (3b)00 (4sb)01 (4d)01 (5)01 (6)02 (7)01 (8a)02 (8p)00 (9)03 (11p)01 (12a)00," L（幽门窦部）, 后Post,",15,15,5, R0 D2+,,16.15,13.75,1.21,164.5,200.0,2.6,33.0,23.0,198.0,103.0,27.0,7.88,2.77,69.0,355.0,46.0,23.0,5.4,5.3,88.0,456.0,,,,,,,,,,,,,3.15,14.51,1.14,,无, 无, P0,H0, 未做, CK +,,,,,73.3574244415243,1624876
1624252,王永君,648405,男,62,T4a,N1,M0, ⅢA,1,3,2.0,0.0,0.0,1.0, 正常,2.0,14,髓样型（med）,INFc,0.0,,,,,,,,2016-07-18,2021-06-01,1,,,SOX,SOX,,,,,2, 低粘附腺癌95 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)5,G3, (1a)00 (1b)00 (3a)14 (3b)01 (4sb)00 (4d)03 (5)00 (6)00(7)12 (8a)03 (8p)01 (9)00 (11p)00 (12a)00,L（幽门窦部） 前Ant 后Post 小弯侧Less,40,35,15, R0 D2,,7.0,4.0,2.13,163.8,285.0,4.03,22.0,26.0,152.0,99.0,24.0,16.84,6.54,65.0,331.0,44.0,21.0,4.3,9.2,93.0,478.0,63.4,29.3,25.6,1.14,0.8,8.0,27.1,1.7,0.744,0.922,6.37,,1.36,6.94,10.38, 阳性+,无,, P0,H0, 未做, CK +,,,,,58.44283837056504,1624252
1624409,刘广义,648406,男,60,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0,,9.0,13,中间型（int）,INFa,0.0,,,,,,,,2016-07-19,2017-03-09,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,大弯58 小弯45," L（幽门窦部）, 后Post, 小弯侧Less,",70,40,6,,R2,10.07,8.68,1.09,125.0,324.0,3.9,15.0,14.0,190.0,83.0,19.0,6.52,2.11,53.0,162.0,31.0,22.0,5.5,4.8,71.0,149.0,,,,,,,,,,,,,2.8,14.68,1.79, 未做,无, 无, P0,H0, 未做, CK +,,,,,7.654402102496714,1624409
1624497,曲秀玲,643294,女,53,T4b,N3a,M0, ⅢC,1,3,1.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,10.0,18,髓样型（med）,INFb,0.0,,,,,,,,2016-07-19,2016-12-08,2,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3,小弯11脾门12横结肠旁03 (1a)00 (1b)11 (2)03 (3a)11 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)12 (6)22 (7)00 (8a)00 (8p)11 (9)22 (11p)00 (12a)00," LMU 后Post, 大弯侧Gre, 小弯侧Less,",140,100,40,,R1,11.44,9.19,1.28,129.0,624.0,4.97,31.0,24.0,148.0,121.0,105.0,4.54,1.65,64.0,221.0,38.0,26.0,7.8,4.0,72.0,249.0,,,,,,,,,,,,,3.95,1.79,4.23, 未做,无, 无, P0,H0, 未做, CK +,,,,,4.664914586070959,1624497
1624206,王佩岭,641360,男,65,T4a,N3b,M0, ⅢC,1,4,1.0,1.0,1.0,1.0, 异型增生+,25.0,25,髓样型（med）,INFb,0.0,,,,,,,,2016-07-18,2019-04-03,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,9, 低粘附腺癌 低分化腺癌（G3)(por)40%,G3,小弯33 (1a)00 (1b)00 (2)22 (3a)11 (3b)00 (4sa)00 (4sb)00 (4d)55 (5)33 (6)33 (7)11 (8a)33 (8p)11 (9)22 (11p)11 (12a)00 软组织可见癌," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,15,5,,R1,6.5,4.1,1.39,94.0,197.0,2.95,31.0,33.0,176.0,52.0,9.0,7.66,2.63,54.0,288.0,32.0,22.0,5.0,6.7,116.0,279.0,,,,,,,,,,,,,0.479,4.05,3.79, 未做,无, 无, P0,H0, 未做, CK +,,,,,32.49014454664914,1624206
1624328,国玉莲,647161,男,62,T1b,N1,M0, ⅠB,1,3,,1.0,1.0,0.0,,1.0,38,,,2.0,,,,,,,,2016-07-18,2020-09-15,0,,,,,,,,,0, 溃疡病 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 高级别上皮内瘤变,G2, (1a)00 (1b)06 (3a)18 (3b)06 (4sb)00 (4d)08 (5)00 (6)05 (7) 00(8a) (8p) 01(9) 02(11p) 02(12a)00," L（幽门窦部）, 小弯侧Less,",35,25,8, R0 D2,,11.06,7.77,2.17,137.9,363.0,3.33,19.0,19.0,120.0,63.0,19.0,6.99,3.21,62.0,206.0,39.0,23.0,6.0,3.1,72.0,305.0,,,,,,,,,,,,,1.93,11.99,0.69, 阴性,无, 无, P0,H0, 未做,CD31、D2-40见脉管染色，S-100神经染色 CK+，镜下未见明确神经侵犯,,,,,49.93429697766097,1624328
1624319,王宝丰,647755,男,50,T4a,N3b,M0, ⅢC,1,2,0.0,1.0,1.0,1.0, 慢性炎症（+） 肠化生+,18.0,29,髓样型（med）,INFa,0.0,,,,,,,,2016-07-18,2017-04-07,0,,,XELOX,XELOX,,,,,2, 低分化腺癌（G3)(por) Lauren肠型,G3,横结肠系膜前叶01 (1a)02 (1b)00 (3a)22 (3b)22 (4sb)00 (4d)67 (5)01 (6)34 (7)00 (8a)12 (8p)13 (9)13 (11p)11 (12a)11," L（幽门窦部）, 后Post,",40,40,10, R0,,10.41,6.45,3.01,134.0,274.0,3.81,26.0,27.0,178.0,77.0,45.0,11.32,4.65,53.0,189.0,33.0,20.0,6.5,4.1,65.0,165.0,,,,,,,,,,,,,3.29,5.95,6.95, 未做,无, 无, P0,H0, 未做, CK +,,,,,8.639947437582128,1624319
1624688,马吉顺,647426,男,60,T4a,N3b,M0, ⅢC,1,5,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,50.0,50,中间型（int）,INFb,1.0,,,,,,,,2016-07-20,2021-05-11,1,,,口服卡培他滨,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30,G3,胃壁外11 小弯33  (1a)00 (1b)00 (2)1111 (3a)1010 (3b)11 (4sa)00 (4sb)1010 (4d)66 (5)00 (6)66 (7)22 软组织可见癌," LMU 前Ant,",70,60,10,,R1,5.78,4.03,1.13,153.0,226.0,3.15,18.0,23.0,208.0,85.0,22.0,14.26,7.02,65.0,233.0,41.0,24.0,3.8,6.5,63.0,166.0,,,,,,,,,,,,,6.88,111.5,1.42, 未做,无, 无, P0,H0, 未做, CK +,,,,,57.68725361366623,1624688
1624696,马君,648397,男,64,T3,N0,M0, ⅡA,1,2,1.0,1.0,1.0,0.0, 肠化生+,0.0,63,髓样型（med）,INFa,0.0,,,,,,,,2016-07-20,2020-05-21,0,,,,,,,,,0, 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren混合型,G3, (1a) 02(1b) 01(3a)07 (3b)05 (4sb) 02(4d)012 (5)01 (6) 011(7)011 (8a) 02(8p) 04(9)01 (11p)02 (12a)02," LM 前Ant, 小弯侧Less,",40,35,10, R0 D2+,,5.49,3.6,1.38,116.2,233.0,2.49,14.0,18.0,112.0,91.0,12.0,10.61,5.04,57.0,180.0,33.0,24.0,4.7,6.7,80.0,295.0,77.9,58.0,16.6,3.49,0.3,11.7,10.1,0.8,0.952,1.79,11.5,,2.2,5.73,2.42,,,, P0,, 未做, CK +,,,,,46.02496714848883,1624696
1624346,鹿相德,648384,男,60,T1b,N0,M0,ⅠA,1,3,,,,,,0.0,12,,,0.0,,,,,,,,2016-07-18,2021-07-13,1,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30,G3, (1b)00 (3a)01 (3b)00 (4sb)05 (4d)01 (6)00 (7)00 (8a)01 (8p)01 (9)01 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",20,15,5, R0 D2,,9.18,7.36,1.02,148.0,155.0,2.85,45.0,35.0,234.0,89.0,34.0,15.14,6.06,74.0,345.0,45.0,29.0,9.2,4.6,102.0,306.0,78.6,43.5,32.7,1.33,1.1,11.5,9.6,5.5,0.96,2.37,13.2,,5.03,18.39,0.93,,无, 无, P0,H0, 未做, CK +,,,,,59.82260183968462,1624346
1631691,孙明义,648422,男,52,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,32,,,0.0,,,,,,,,2016-09-14,2021-07-01,1,替吉奥*2,1.0,SOX,SOX,SOX,SOX,,,4, 管状腺癌（高分化【G1】【tub1】）,G1, (1b)01 (3a)04 (3b)00 (4sb)00 (4d)04 (5)00 (6)08 (7)02 (8a)03 (8p) (9)03 (11p)00 (11d)01 (12a)00 (12b)02 (12p)02 (13)01 (16a1)01," L（幽门窦部）, 前Ant, 大弯侧Gre,",30,25,10, R0 D2,,5.24,3.4,1.49,147.0,188.0,3.46,19.0,20.0,143.0,124.0,31.0,8.1,2.35,64.0,300.0,42.0,22.0,5.9,6.3,58.0,198.0,79.7,54.1,22.7,2.38,0.2,11.0,7.4,4.7,0.659,1.43,6.4,,5.59,35.03,4.49, 未做,无, 无, P0,H0, 未做,,,,,,57.52299605781866,1631691
1624687,张振禄,643489,男,61,T4b,N1,M0, ⅢB,1,2,0.0,1.0,1.0,1.0, 肠化生+,1.0,29,中间型（int）,INFa,0.0,,,,,,,,2016-07-20,2021-05-12,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1b)00 (3a)07 (3b)00 (4sb)00 (4d)06 (5)00 (6)15 (7)03 (8a)03 (8p)01 (9)00 (11p)04 (12a)00, ML 前Ant 后Post 大弯侧Gre  小弯侧Less ,90,80,12, R0 D2,,4.7,2.56,1.58,112.0,376.0,5.12,16.0,20.0,172.0,113.0,39.0,5.61,2.05,57.0,197.0,39.0,18.0,5.4,6.2,79.0,324.0,63.7,43.5,17.3,2.51,0.1,11.8,23.5,1.4,0.582,1.08,6.9,,2.11,9.65,5.1, 未做,无,, P0,H0, 未做,,,,,,57.72010512483574,1624687
1624256,刘兴凯,648409,男,61,T1b,N0,M0,ⅠA,1,3,0.0,0.0,0.0,0.0, 肠化生+,0.0,25,硬型（sci）,INFa,1.0,,,,,,,,2016-07-18,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)03 (3b)01 (4sb) 00(4d) 05(5)00 (6)06 (7)03 (8a)02 (8p)00 (9)02 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",15,10,4, R0 D2,,7.27,4.8,1.82,153.0,248.0,5.1,21.0,22.0,170.0,61.0,13.0,26.7,9.55,69.0,311.0,41.0,28.0,5.0,6.5,70.0,257.0,,,,,,,,,,,,,1.1,6.43,2.93, 阴性,无, 无, P0,H0, 未做,CD31、D2-40未见脉管瘤栓，S-100未见神经侵犯 CK+,,,,,73.45597897503285,1624256
1624402,高淑莲,648655,女,74,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,0.0, 肠化生+ 异型增生+,0.0,34,髓样型（med）,INFa,3.0,,,,,,,,2016-07-19,2019-01-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)02 (3b)03 (4sb)00 (4d)02 (5)00 (6)04 (7)014 (8a) (8p)02 (9)03 (11p) 02(12a)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,70,10, R0 D2,,6.91,4.54,1.78,126.0,271.0,4.88,15.0,23.0,122.0,53.0,6.0,7.37,3.27,64.0,188.0,36.0,28.0,5.0,7.7,63.0,264.0,,,,,,,,,,,,,2.27,18.67,1.52, 阴性,无, 无, P0,H0, 未做,CD31、D2-40可见脉管瘤栓，S-100未见神经侵犯， CK +,,,,,29.894875164257556,1624402
1623883,梁明山,647171,男,52,T3,N0,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+,0.0,23,髓样型（med）,INFa,1.0,,,,,,,,2016-07-14,2021-06-01,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a) 00(1b)00 (3a)02 (3b)00 (4sb)00 (4d)06 (5)00 (6) 07(7)03 (8a) (8p)01 (9)02 (11p)02," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",20,20,8, R0 D2,,5.24,3.4,1.49,147.0,188.0,3.46,19.0,20.0,143.0,124.0,31.0,8.1,2.35,64.0,300.0,42.0,22.0,5.9,6.3,58.0,198.0,,,,,,,,,,,,,5.59,35.03,4.49, 阴性,无, 无, P0,H0, 未做,CD31、D2-40可见脉管瘤栓，S-100可见神经侵犯 CK +,,,,,58.5742444152431,1623883
1624629,李淑珍,648428,女,79,T1b,N1,M0, ⅠB,1,2,0.0,1.0,1.0,0.0, 慢性炎症（+）,1.0,11,中间型（int）,INFa,1.0,,,,,,,,2016-07-20,2021-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)03 (5)11 (6)00 (7)03 (8a) (8p)01 (9)01 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",25,25,6, R0 D2,,5.98,3.94,1.43,129.0,239.0,2.3,25.0,40.0,148.0,60.0,17.0,4.58,2.22,53.0,186.0,34.0,19.0,6.0,7.7,55.0,110.0,69.4,44.3,21.9,2.02,0.7,20.5,8.8,1.6,1.09,2.87,11.8,,1.57,6.94,1.75, 阴性,无, 无, P0,H0, 未做, CK+，CD31、D2-40可见脉管瘤栓，S-100未见神经侵犯,,,,,61.432325886990796,1624629
1625360,张淑琴,647790,女,71,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,0.0, 异型增生+,1.0,27,髓样型（med）,INFa,2.0,,,,,,,,2016-07-26,2021-06-01,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)00 (3a)05 (3b)01 (4sb)00 (4d)02 (5)00 (6)19 (7)00 (8a)01 (8p)05 (9)02 (11p)02 (12a)00," L（幽门窦部）, 大弯侧Gre,",60,50,50, R0 D2+,,8.67,4.53,2.79,116.8,333.0,5.34,13.0,22.0,223.0,103.0,42.0,11.59,4.44,73.0,156.0,44.0,29.0,5.2,5.4,80.0,271.0,63.0,27.0,31.4,0.86,0.1,10.2,24.6,3.7,0.99,3.0,12.0,,8.01,5.0,1.12, 阴性,无, 无, P0,H0, 未做, CK +,,,,,58.18002628120893,1625360
1625265,荆向彬,643495,男,58,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,21.0,48,中间型（int）,INFa,0.0,,,,,,,,2016-07-23,2017-05-04,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)11 (1b) 22(2) 36(3a)56 (3b)00 (4sa) 00(4sb)02 (4d)012 (5) 11(6)04 (7)22 (8a)11 (8p)23 (11p)13 (11d)13 (12a)22," U（胃底部）, SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",65,60,8,,R1,4.74,3.23,1.11,98.0,287.0,2.7,11.0,16.0,168.0,71.0,15.0,8.47,3.03,56.0,238.0,36.0,20.0,5.1,7.2,64.0,207.0,83.1,41.7,37.5,1.11,0.2,11.2,4.0,1.2,0.774,2.48,7.08,,4.82,192.9,22.37,,,, P0,H0, 未做, CK +,,,,,9.362680683311432,1625265
1625253,张志昌,648227,男,75,T2,N0,M0, ⅠB,1,1,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,23,髓样型（med）,INFa,0.0,,,,,,,,2016-07-25,2021-09-28,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 乳头状癌（G1）（pap）20 Lauren肠型,G3, (1a)02 (1b)00 (2)04 (3a)07 (3b)01 (4sa)00 (4sb)00 (4d)00 (5)00 (7)00 (8)04 (9)03 (11p)02," SiewerⅡ, 前Ant, 后Post, 小弯侧Less,",30,18,7, R0 D2,,4.98,3.12,1.44,94.4,333.0,2.84,29.0,24.0,149.0,81.0,22.2,12.81,3.11,66.2,305.62,37.9,28.3,5.9,3.48,102.0,400.0,,,,,,,,,,,,,,,, 未做,无,, P0,H0, 未做, CK +,,,,,62.12220762155059,1625253
1624689,陈殿荣,648680,男,74,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,0.0, 慢性炎症（+）,3.0,31,髓样型（med）,INFa,2.0,,,,,,,,2016-07-20,2021-05-11,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,小弯01， (1a)02 (1b) 02(3a) 12(3b)03 (4sb)00 (4d)210 (5)00 (6)02 (7)06 (8a) 01(11p)02," LM 前Ant, 后Post, 大弯侧Gre,",80,70,10, R0 D2,,6.02,3.21,2.11,124.0,315.0,2.65,40.0,35.0,181.0,89.0,20.4,11.35,2.14,58.6,177.38,31.0,27.6,5.5,6.69,67.0,210.0,,,,,,,,,,,,,1.56,1.05,3.15, 阴性,无, 无, P0,H0, 未做, CD31、D2-40可见脉管瘤栓，S-100未见神经侵犯 CK+,,,,,57.68725361366623,1624689
1624893,麻绍仁,648728,男,78,T4a,N3b,M1, Ⅳ,1,4,0.0,1.0,1.0,1.0, 异型增生+,27.0,27,髓样型（med）,INFa,0.0,,,,,,,,2016-07-21,2017-01-15,2,,,,,,,,,0, 粘液腺癌（muc） Lauren肠型,GX," (1a)3/3 (1b)2/2 (2)5/5 (3a)7/7 (3b)2/2 (4sa)0/0 (4sb)0/0 (4d)4/4 (5)0/0 (6)3/3 (7)1/1 1a,2,3a,4sa,4sb,4d,5,6 软组织可见癌"," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",210,160,,,R2,9.47,7.04,1.72,142.0,399.0,4.21,12.0,23.0,199.0,83.0,24.0,16.44,5.34,62.0,314.0,39.0,23.0,5.0,7.4,132.0,482.0,,,,,,,,,,,,,0.936,1000.0,300.0, 未做,无, 无, p1局肠缘(M1 PER),H0, 未做, CK + CD 31 S-100,,,,,5.847568988173456,1624893
1624889,王丛恒,648398,男,70,T3,N3a,M0,ⅢB,1,3,1.0,0.0,0.0,1.0, 慢性炎症（+）,12.0,22,中间型（int）,INFc,0.0,,,,,,,,2016-07-21,2017-11-11,2,,,,,,,,,0, 低粘附腺癌75% 管状腺癌（中分化【G2】【tub2】15% 粘液腺癌（muc）10% Lauren混合型,G2, (1a)01 (1b)02 (3a)810 (3b)00 (4sb) 00(4d)11 (5) 00(6) 00(7)22 (8a)11 (8p)02 (9)00 (11p)03," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,30,10, R0 D2,,5.18,3.5,1.23,137.1,159.0,4.03,39.0,29.0,176.0,82.0,24.7,18.38,8.9,64.0,142.77,36.6,27.4,6.0,3.96,83.0,370.0,,,,,,,,,,,,,7.33,804.4,1.88, 阴性,无, 无, P0,H0, 未做,CD31、D2-40未见脉管瘤栓，S-100可见神经侵犯 CK+,,,,,15.703022339027594,1624889
1624782,郑玉芹,648438,女,77,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,42,髓样型（med）,INFa,1.0,,,,,,,,2016-07-21,2019-04-19,0,,,口服替吉奥,,,,,,1, 低分化腺癌（G3)(por)80 乳头状癌（G1）（pap）20,G3, (1a)00 (1b)00 (3a)312 (3b)22 (4sb)00 (4d)014 (5)07 (6)01 (7)04 (8a)00 (8p)01 (9)00 (11p)00 (12a)01 软组织可见癌," LM 前Ant,",105,55,9,,R1,6.21,3.47,1.85,114.0,412.0,2.79,17.0,30.0,180.0,111.0,88.0,9.68,3.68,69.0,171.0,37.0,32.0,5.1,5.5,59.0,315.0,,,,,,,,,,,,,1.6,18.89,11.43, 未做,无, 无, P0,H0, 未做, CK +,,,,,32.91721419185282,1624782
1624875,谢荣财,648646,男,57,T1b,N0,M0,ⅠA,1,2,1.0,1.0,1.0,0.0, 异型增生+ 慢性炎症（++） 肠化生+,0.0,30,中间型（int）,INFa,0.0,,,,,,,,2016-07-21,2021-07-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)75 低粘附腺癌15 Lauren混合型 粘液腺癌（muc）10,G3, (1b) 02(3a) 013(3b) 00(4sb)02 (4d)06 (5) 02(6) 00(7)02 (8a)02 (8p)00 (9)01 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",28,20,3, R0 D2+,,6.05,3.64,1.47,142.4,155.0,2.48,32.0,27.0,145.0,126.0,24.0,23.89,7.7,63.0,301.0,40.0,23.0,4.4,5.7,66.0,327.0,59.8,37.3,23.0,1.62,0.8,10.1,24.8,3.6,1.01,1.44,8.96,,6.41,11.34,1.21, 阳性+,,, P0,H0, 未做, CK +,,,,,59.32982917214191,1624875
1624490,尚德生,647808,男,59,T4a,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,0.0, 慢性炎症,17.0,52,中间型（int）,INFc,1.0,,,,,,,,2016-07-19,2021-07-01,1,,,口服卡培他滨,XELOX,替吉奥联合顺铂,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 低粘附腺癌 粘液腺癌（muc） Lauren混合型,G3," (3a)3,11 (3b)2,2 (4d)4,13 (6)4,7 (7)3,9 (8a)(8p)1,3 (1a) (1b) (4sb) (5) (9) (11p) (12a)0,20",L,40,30,10, R0 D2+,,6.85,3.6,2.3,152.0,216.0,2.65,22.0,24.0,195.0,59.0,16.0,9.14,3.51,70.0,346.0,45.0,25.0,5.4,3.4,97.0,360.0,,,,,,,,,,,,,2.96,7.29,4.84,,无,, P0,H0, 未做, CK +,,,,,59.39553219448094,1624490
1624630,白晓萍,646685,女,53,T2,N0,M0, ⅠB,1,3,,0.0,0.0,0.0,,0.0,32,,,0.0,,,,,,,,2016-07-20,2021-07-07,1,替吉奥*1,1.0,口服替吉奥,,,,,,1, 低分化腺癌（G3)(por),G3, (1a)02 (1b)06 (2)00 (3a)05 (3b)00 (4sa)02 (4sb)02 (4d)00 (5)00 (6)01 (7)05 (8a)06 (8p)00 (9) 01(11p)02," U（胃底部）, 小弯侧Less,",35,15,2, R0 D2,,4.49,3.03,1.14,3.98,276.0,2.27,16.0,22.0,176.0,77.0,25.0,10.3,3.66,73.0,292.0,44.0,29.0,5.6,3.4,85.0,279.0,63.7,39.9,19.0,2.1,0.6,14.0,18.2,0.7,1.19,3.13,11.9,,0.787,7.64,3.02, 未做,无, 无, P0,H0, 未做, CK +,,,,,59.55978975032851,1624630
1625358,王秋杰,643646,女,61,T1a,N2,M0, ⅡA,1,0,,,,,,6.0,26,,,1.0,,,,,,,,2016-07-26,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】65 粘液腺癌（muc）35,G3, (1a) 00(1b) 01(3a) 27(3b)01 1sb00 (4d) 44(5)00 (6)01 (7)01 (8a)02 (8p) 02(9)01 (11p) 05(12a)01," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,, R0 D2,,7.5,6.17,0.76,110.5,280.0,3.56,11.0,18.0,178.0,80.0,14.0,5.84,1.55,61.0,316.0,40.0,21.0,5.8,10.3,65.0,271.0,,,,,,,,,,,,,1.22,11.67,1.04, 未做,无, 无, P0,H0, 未做, CK +,,,,,73.19316688567673,1625358
1624936,王广辉,643486,男,56,T4a,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,4.0,42,中间型（int）,INFc,0.0,,,,,,,,2016-07-21,2018-09-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60 低粘附腺癌40 Lauren混合型,G3,冰冻11p01 冰冻纵膈11 (1a)05 (1b)36 (2)01 (3a)012 (3b)02 (4sa)04 (4sb)00 (5)00 (7)05 (8a)00 (8p)00 (9)01 (11p)04 (20)00 软组织可见癌," EG SiewerⅠ, 前Ant, 后Post, 小弯侧Less,",30,20,10, R0 D2,,5.02,2.4,1.83,141.1,111.0,4.97,45.0,34.0,148.0,88.0,46.0,7.77,3.02,74.0,249.0,40.0,34.0,5.4,6.3,85.0,370.0,,,,,,,,,,,,,3.28,10.95,1.54, 未做,无,, P0,H0, 未做, CK +,,,,,25.36136662286465,1624936
1625198,周玉兰,643687,女,59,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,15.0,31,硬型（sci）,INFc,1.0,,,,,,,,2016-07-25,2017-07-25,2,,,,,,,,,0, 低粘附腺癌75 低分化腺癌（G3)(por)25 Lauren混合型,G3,小弯11 (1a)00 (1b)02 (3a)14 (3b)35 (4sb)00 (4d)44 (5)22 (6)23 (7)11 (8a) (8p)12 (9)00 (11p)07 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",55,35,7, R0 D2,,5.25,2.84,1.99,123.1,297.0,3.12,14.0,13.0,160.0,67.0,21.0,6.01,1.98,67.0,287.0,42.0,25.0,5.4,4.7,61.0,251.0,69.4,44.3,21.9,2.02,0.7,20.4,8.6,1.6,1.06,2.87,11.8,,1.47,79.49,3.01, 阴性,无, 无, P0,H0, 未做, CK（+） S-100可见神经侵犯， CD31  D2-40 可见脉管瘤栓,,,,,11.990801576872535,1625198
1625276,解观玉,643258,男,61,T2,N1,M0, ⅡA,1,2,1.0,1.0,1.0,1.0, 慢性炎症（+）,1.0,23,中间型（int）,INFb,3.0,,,,,,,,2016-07-25,2020-05-21,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)65 低粘附腺癌20 乳头状癌（G1）（pap）15,G3, (1b)00 (3a)08 (3b)00 (4sb) 00(4d)04 (5)11 (6) 03(7) 00(8a) 02(8p) 02(9)02 (12a)00 (12p)01," L（幽门窦部）, 小弯侧Less,",25,25,8, R0 D2+,,8.98,6.08,2.22,153.7,229.0,2.65,18.0,17.0,155.0,98.0,29.0,8.33,2.11,67.0,451.0,45.0,22.0,4.8,6.7,85.0,236.0,79.1,46.4,21.0,2.21,3.5,6.5,11.9,6.2,0.538,1.55,8.25,,2.4,24.04,3.63, 阳性+,,,,H0, 未做, CK +,,,,,45.86070959264126,1625276
1625196,孙百合,648662,男,55,T1a,N0,M0,ⅠA,1,2,,,,,,0.0,20,,,0.0,,,,,,,,2016-07-25,2020-08-01,2,,,,,,,,,0, 低粘附腺癌80% 管状腺癌（低中分化【G2】【tub2】20%,G2,小弯0/2  (1a)0/2 (1b)0/0(3a)0/0 (3b)0/3 (4sb)0/0 (4d)0/2 5)0/2 (6)0/1 (7)0/2 (8a)0/0 (8p)0/1 (9)0/2 (11p)0/2 (12a)0/1," M（胃体部）, 后Post, 小弯侧Less,",15,15,, R0,,9.14,7.13,1.19,129.0,165.0,2.27,23.0,27.0,187.0,56.0,30.0,12.77,4.93,57.0,214.0,37.0,20.0,7.3,3.4,61.0,215.0,,,,,,,,,,,,,2.27,7.4,14.34, 未做,无, 无, P0,H0, 未做, CK +,,,,,48.22601839684625,1625196
1625424,赵铁英,643212,男,59,T2,N0,M0, ⅠB,1,2,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,0.0,37,中间型（int）,INFa,1.0,,,,,,,,2016-07-26,2021-08-09,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 乳头状癌（G1）（pap）40 粘液腺癌（muc） 35Lauren肠型 管状腺癌（中分化【G2】【tub2】25 Lauren肠型,G2, (1a) 03(1b)01 (3a)02 (3b)02 (4sb) 01(4d)011 (5)01 (6) 05(7) 07(8a)(8p)01 (11p)03 (12a)00," L（幽门窦部）, 后Post,",50,40,15, R0 D2,,7.65,4.69,2.2,136.0,157.0,4.56,22.0,30.0,196.0,68.0,6.0,13.63,5.61,51.0,209.0,30.0,21.0,6.1,2.7,67.0,225.0,,,,,,,,,,,,,5.8,5.48,1.91, 未做,无, 无, P0,H0, 未做, CK（+） CD31  D2-40 可见脉管瘤栓， S-100未见明确侵犯,,,,,60.446780551905384,1625424
1625257,张广顺,648483,男,60,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,39,硬型（sci）,INFb,1.0,,,,,,,,2016-07-25,2022-09-01,1,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)07 (2)03 (3a)07 (3b)01 (4sa)00 (4sb)01 (4d)01 (5)00 (7)05 (8a)01 (9)03 (11p)04,U（胃底部） 后Post 大弯侧Gre  小弯侧Less ,40,25,6, R0 D2,,10.58,5.27,4.07,152.0,133.0,3.58,21.0,26.0,248.0,100.0,30.0,62.0,1.46,62.0,301.0,38.0,24.0,4.5,6.7,85.0,323.0,,,,,,,,,,,,,2.5,4.37,2.05, 阳性+,无,, P0,H0, 未做, CD31（+） D2-40（+）S-100（-),,,,,73.22601839684626,1625257
1625199,初长军,643558,男,51,T1b,N0,M0,ⅠA,1,2,0.0,1.0,1.0,0.0, 慢性炎症（+）,0.0,13,硬型（sci）,INFa,2.0,,,,,,,,2016-07-25,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1b)00 (3a)02 (3b)00 (4sb)00 (4d)03 (5)00 (6)00 (7)01 (8a)02 (8p)01 (9)01 (11p)00 (12a)00," L（幽门窦部）, 前Ant,",30,20,10, R0 D2,,5.53,2.85,2.16,171.8,162.0,2.86,49.0,45.0,240.0,45.0,59.0,18.42,6.03,73.0,444.0,47.0,26.0,5.4,7.3,89.0,362.0,70.6,48.8,19.7,2.48,1.0,11.1,17.6,1.9,0.589,0.991,8.71,,2.49,14.76,2.58, 阴性,无,, P0,H0, 未做, CD31（+） D2-40（+）S-100（-),,,,,73.22601839684626,1625199
1625259,毛小媛,643523,女,67,T2,N1,M0, ⅡA,1,2,1.0,0.0,0.0,1.0, 肠化生+,2.0,24,中间型（int）,INFc,1.0,,,,,,,,2016-07-25,2021-06-01,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌80% 管状腺癌（低中分化【G2】【tub2】20% Lauren混合型,G2, (1a)0/3 (1b)1/3 (3a)0/1 (3b)0/2 (4sb)0/0 (4d)1/8 (5)0/0 (6)0/2 (7)0/1 (8a)0/0 (8p)0/0 (9)0/2 (11p)0/2 (12a)0/0," L（幽门窦部）, 大弯侧Gre,",35,30,5, R0,,4.7,2.8,1.46,134.1,151.0,2.95,44.0,38.0,342.0,67.0,8.0,14.12,4.68,66.0,351.0,39.0,27.0,4.8,7.8,100.0,365.0,,,,,,,,,,,,,2.13,7.39,0.924, 阳性+,无, 无, P0,H0, 未做, CK + CD 31 S-100,,,,,58.21287779237845,1625259
1625423,尹成山,643218,男,51,T4b,N1,M1, Ⅳ,1,2,0.0,0.0,0.0,1.0, 正常,2.0,32,硬型（sci）,INFa,0.0,,,,,,,,2016-07-26,2021-06-01,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G2,小弯01 (1a)03 (1b)01 (2)00 (3a)14 (3b)07 (4sa)00 (4sb)00 (4d)05 (5)11 (6)01 (7)01 (8)02 (9)01 (11p)02 (12a)00 (12p)03," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",60,40,15,,R2,5.55,3.51,1.53,100.0,258.0,3.28,24.0,19.0,162.0,83.0,30.0,6.81,3.0,58.0,283.0,40.0,18.0,5.1,6.0,115.0,361.0,,,,,,,,,,,,,1.1,6.53,8.75,,无,, p1泛(M1 PER),H0, 未做, CK +,,,,,58.18002628120893,1625423
1625425,蒋恩久,647318,男,78,T2,N0,M0, ⅠB,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,22,中间型（int）,INFb,1.0,,,,,,,,2016-07-26,2018-10-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 粘液腺癌（muc）15,G3, (1a)05 (1b) 01(2)01 (3a)05 (3b)02 (4sa) 01(4sb)01 (4d)00 (5) 00(7)02 (8a) 03(9)01 (11p)00," SiewerⅢ, 后Post, 小弯侧Less,",25,20,5, R0 D2,,5.44,2.79,1.75,115.0,254.0,3.28,14.0,17.0,181.0,75.0,14.0,10.34,3.42,61.0,274.0,37.0,24.0,5.0,6.4,101.0,356.0,,,,,,,,,,,,,3.78,0.6,14.37, ,,, P0,H0, 未做, CK +,,,,,26.47831800262812,1625425
1625702,孙国军,643045,男,64,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,45,,,1.0,,,,,,,,2016-07-28,2020-01-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)06 (1b)01 (3a)02 (3b)02 (4sb)00 (4d)08 (5)02 (6)01 (7)02 (8a)07 (8p)04 (9) 04(11p)04 (12a)02," L（幽门窦部）, 小弯侧Less,",15,10,2, R0 D2,,6.73,4.22,1.63,113.0,324.0,4.67,11.0,19.0,152.0,83.0,28.0,6.53,2.67,71.0,245.0,39.0,32.0,4.3,7.3,87.0,294.0,80.0,54.2,24.5,2.21,0.5,10.1,9.2,3.1,0.563,5.0,13.1,,2.85,7.84,0.98,,无,, P0,H0, 未做, CK +,,,,,41.13009198423127,1625702
1626814,岳秀红,643665,女,53,T4b,N3b,M0, ⅢC,1,2,1.0,1.0,1.0,1.0, 慢性炎症（+）,28.0,35,硬型（sci）,INFc,0.0,,0.0,,1.0,2.0,,,2016-08-05,2018-12-13,2,,,XELOX,XELOX,XELOX,多西他赛联合雷替曲塞,多西他赛单药,多西他赛单药,7, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3, (1a)00 (1b)00 (3a)58 (3b)55 (4sb)00 (4d)1515 (5)00 (6)11 (7)00 (8a)11 (8p)00 (9)04 (11p)11 (12a)00 (14v)00,LM 前Ant 后Post 大弯侧Gre  小弯侧Less,70,50,10,,R1,7.09,4.39,2.02,95.5,290.0,3.96,10.0,16.0,149.0,91.0,15.0,3.8,1.07,61.0,244.0,34.0,27.0,14.5,7.9,75.0,227.0,,,,,,,,,,,,,1.49,12.47,0.919,,无,, P0,H0, 未做,  CD4(+) CD8(+)VEGF(-),40% 弱-中,75% 中-强,80% 中-强,40% 弱-中,28.252299605781864,1626814
1625784,朱永霞,643199,女,51,T3,N3a,M1, Ⅳ,1,5,,1.0,1.0,1.0,,11.0,19,,,0.0,,,,,,,,2016-07-28,2018-01-29,2,,,SOX,,,,,,1, 低粘附腺癌,GX, (1a)01 (1b)00 (3a) 45(3b) 00(4sa) 00(4sb)00 (4d)44 (5) 01(6) 00(7) 22(8a) 01(8p) 03(9) 12(11p)00 (12a)00  1b组，4sa组，4sb组可见4枚癌结节," UM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,15,5,,R2,3.65,2.02,1.13,112.0,260.0,1.55,11.0,14.0,164.0,45.0,23.0,4.67,1.91,67.0,227.0,41.0,26.0,3.8,5.0,65.0,143.0,69.4,44.3,21.9,2.02,0.7,20.5,8.8,1.6,1.09,2.87,11.8,,0.696,5.6,1.14,,无, 无, P0,H0, 未做, CK +,,,,,18.068331143232587,1625784
1625701,王绍华,649797,女,64,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,14.0,41,中间型（int）,INFb,0.0,,,,,,,,2016-07-28,2019-09-01,2,,,XELOX,,,,,,1, 低粘附腺癌80% 管状腺癌（中低分化【G2】【tub2】20%,G3,大弯1/1 (1a)0/3(1b)0/0 (3a)1/5 (3b)5/8 (4sb)0/2 (4d)0/2 (5)0/0 (6)6/9 (7)0/2 (8a)1/1 (8p)0/3 (9)0/2 (11p)0/2 (12a)0/0," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",75,70,18, R0,,5.89,3.77,1.43,106.0,187.0,2.13,14.0,14.0,187.0,73.0,56.0,7.16,3.22,60.0,250.0,34.0,26.0,6.8,6.3,64.0,119.0,,,,,,,,,,,,,2.57,6.88,3.2, 未做,无, 无, P0,H0, 未做, CK + CD 31 S-100,,,,,37.12220762155059,1625701
1625335,郝丽萍,647305,女,44,T3,N1,M0, ⅡB,1,3,1.0,1.0,1.0,1.0, 正常,1.0,21,中间型（int）,INFc,1.0,,,,,,,,2016-07-26,2020-05-21,0,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌80% 中低分化腺癌（G3)(por)20% Lauren混合型,G3, (1a)0/3 (1b)0/0 (3a)0/2 (3b)0/0 (4sb)0/0 (4d)1/7 (5)0/0 (6)0/1 (7)0/1 (8a)0/0 (8p)0/0 (9)0/1 (11p)0/2 (12a)0/2 (14v)0/2," M（胃体部）, 前Ant, 大弯侧Gre,",25,12,4, R0,,7.88,6.06,1.17,86.0,196.0,2.37,16.0,18.0,146.0,40.0,13.0,5.44,2.53,64.0,221.0,40.0,24.0,5.6,5.0,38.0,62.0,,,,,,,,,,,,,0.585,5.93,1.1, 未做,无, 无, P0,H0, 未做, CK + CD 31 S-100,,,,,45.827858081471746,1625335
1625813,张玉山,490697,男,54,T4b,N0,M0, ⅢA,1,2,,1.0,1.0,1.0,,0.0,39,,,0.0,,,,,,,,2016-07-28,2019-04-28,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,8, 管状腺癌（中分化【G2】【tub2】,G2,大弯015 小弯024 另送肠管浆膜外软组织可见癌," M（胃体部）, L（幽门窦部）, 大弯侧Gre,",35,25,10, R0 D2+,,4.82,2.97,1.45,101.0,362.0,3.07,13.0,13.0,149.0,78.0,27.0,9.31,3.87,63.0,254.0,44.0,19.0,8.1,3.3,66.0,304.0,,,,,,,,,,,,,3.6,33.54,1.08,,无,,,H0, 未做, CK + GYP-3(-) AFP(-) Hepatocyte(-) CK7(部分+) CK19(+) CK20(-) villin(+),,,,,32.98291721419185,1625813
1626095,何敏,647293,男,54,T3,N1,M0, ⅡB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,1.0,34,中间型（int）,INFa,0.0,,,,,,,,2016-08-01,2021-05-18,1,,,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,6, 低粘附腺癌55  低分化腺癌（G3)(por)30 粘液腺癌（muc）15 Lauren混合型,G3, (1a)00 (1b)01 (3a)09 (3b)03 (4sb)00 (4d)08 (5)11 (6)02 (7)01 (8a)01 (8p)02 (9)04 (11p)02 (12a)00 (12p)00,LM 前Ant 后Post 大弯侧Gre  ,85,5,8, R0 D2,,9.72,7.65,1.1,126.0,170.0,4.0,22.0,23.0,145.0,64.0,17.0,13.52,5.6,69.0,233.0,42.0,27.0,10.1,4.0,68.0,301.0,84.6,42.8,34.9,1.23,0.2,8.9,6.3,3.2,0.761,2.96,12.8,,2.15,10.91,31.1, 阳性+,无,, P0,H0, 未做,ck（+）、cd34（+）、D2-40（+）、s-100（+）,,,,,57.52299605781866,1626095
1625606,丁兴奎,647975,男,54,T2,N0,M0, ⅠB,1,3,,,,,,0.0,22,,,0.0,,,,,,,,2016-07-27,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60  低黏附癌25 粘液腺癌（muc）15,G3, (1a) 03(1b) 02(3a)03 (3b)00 (4sb)01 (4d) 01(5)00 (6)05 (7) 03(8a)00 (8p)00 (9)03 (11p)00 (12a)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,30,, R0 D2,,2.84,0.33,1.93,108.1,161.0,2.95,19.0,22.0,140.0,119.0,41.0,11.88,4.38,68.0,368.0,42.0,26.0,6.2,5.2,65.0,273.0,,,,,,,,,,,,,2.98,11.89,0.68, 未做,无, 无, P0,H0, 未做, CK +   ,,,,,73.16031537450722,1625606
1626362,许兰英,647364,女,74,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,9.0,15,髓样型（med）,INFc,0.0,,0.0,,1.0,2.0,,,2016-08-03,2018-07-12,2,,,,,,,,,0, 粘液腺癌（muc）80 低粘附腺癌20 Lauren弥漫型,GX, (3a)26 (3b)11 (4sb)00 (4d)22 (5)00 (6)00 (7)12 (8a)11 (9)01 (11p)00 (12a)00小弯22         4d、5、6、12a 软组织可见癌, LM 前Ant 后Post 大弯侧Gre  小弯侧Less ,140,120,30, R0 D2,,4.18,2.97,0.78,123.7,177.0,2.49,22.0,29.0,237.0,85.0,50.0,4.13,1.82,65.0,233.0,40.0,25.0,7.7,6.1,60.0,165.0,77.1,53.8,21.3,2.53,0.4,4.7,17.4,0.9,1.01,4.8,8.34,,4.4,567.0,300.0, 阳性+,无, 无, P0,H0, 未做, CK + CD 4+ CD8散在+  VEGF -,35% 中,75% 中-强,75% 中-强,20% 弱,23.258869908015768,1626362
1626003,纪文德,649798,男,79,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,28,,,0.0,,,,,,,,2016-08-01,2021-07-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)05 (3a) 06(3b)04 (4sb)00 (4d) 03(5) 01(6)03 (7)03 (8a)01 (8p)00 (9) 02(11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",20,20,3, R0 D2+,,4.97,2.86,1.59,152.1,165.0,2.27,13.0,24.0,208.0,50.0,10.0,14.75,3.68,72.0,303.0,45.0,27.0,5.0,6.1,86.0,304.0,42.3,26.0,13.9,1.87,0.1,5.2,51.4,0.3,1.03,2.67,11.8,,1.82,15.04,0.951, 阳性+,,, P0,H0, 未做, CK +,,,,,59.13272010512483,1626003
1627168,张玉才,647892,男,49,T3,N2,M0, ⅢA,1,3,1.0,0.0,0.0,1.0,,3.0,20,中间型（int）,INFb,0.0,,2.0,,1.0,2.0,,,2016-08-10,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低粘附腺癌60 粘液腺癌（muc）30 低分化腺癌（G3)(por)10 Lauren混合型,G3, (1a)00 (1b)00 (3a)03 (3b)00 (4sb)02 (4d)35 (5)00 (6)05 (7)00 (8a) (9)01 (8p)02 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,25,10, R0 D2,,6.88,3.3,2.68,160.5,237.0,3.07,20.0,19.0,149.0,90.0,15.0,12.33,4.52,76.0,372.0,49.0,27.0,6.4,5.8,89.0,357.0,,,,,,,,,,,,,2.26,22.26,, 未做,无,, P0,H0, 未做, CK+ CD4+ CD8散在+ VEGF局灶弱+,60% 中,70% 中-强,70% 强,80% 中,72.70039421813404,1627168
1626449,杨淑珍,649127,女,60,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,47,中间型（int）,INFa,0.0,,1.0,,1.0,2.0,,,2016-08-03,2021-02-28,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】75 粘液腺癌（muc）25 Lauren肠型,G2, (1b)00 (3a)29 (3b)12 (4sb)00 (4d)114 (5)01 (6)17 (7)00 (8a)02 (8p)04 (9)02 (11p)06 (12a)00, L（幽门窦部） 前Ant 小弯侧Less 后Post ,30,20,10, R0 D2,,7.2,3.48,3.15,89.3,319.0,3.03,16.0,19.0,170.0,63.0,10.0,9.15,2.89,59.0,315.0,35.0,24.0,5.2,5.9,62.0,282.0,84.3,29.7,54.2,0.55,0.1,12.2,2.2,2.0,0.634,2.95,9.05,,12.9,11.25,1.72, 未做,无, 无, P0,H0, 未做, VEGF（+） CD4（+）  CD8（+） ,70% 弱-中,85% 中,85% 中-强,70% 弱-中,54.86202365308804,1626449
1626061,李岚,647332,女,53,T1b,N0,M0,ⅠA,1,3,1.0,0.0,0.0,0.0, 慢性炎症（+）,0.0,50,硬型（sci）,INFb,0.0,,,,,,,,2016-08-01,2022-09-01,1,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren混合型,G3, (1a)00 (1b)01 (3a)012 (3b)05 (4sb)03 (4d)09 (5)02 (6)09 (7)04 (8a)01 (8p)00 (9)03 (11p)00 (12p)01," M（胃体部）, 后Post,",12,6,5, R0 D2,,4.81,1.96,2.22,117.0,265.0,2.21,23.0,30.0,175.0,48.0,9.0,8.99,3.32,59.0,209.0,37.0,22.0,4.1,5.0,59.0,242.0,72.3,45.5,24.2,1.88,0.2,13.9,11.1,2.1,0.724,2.54,7.76,,1.01,19.01,0.806, 阳性+,无, 无, P0,H0, 未做,ck（+）、cd31（-）、D2-40（-）、s-100（-）,,,,,72.99605781865965,1626061
1625786,郭春义,649324,男,73,T2,N0,M0, ⅠB,1,1,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,0.0,24,髓样型（med）,INFa,0.0,,,,,,,,2016-07-28,2020-06-10,0,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)01 (4d)01 (5)01 (6)06 (7)02 (8a)05 (8p)00 (9)02 (11p) 02(12a)02,L（幽门窦部） 后Post 小弯侧Less ,60,55,12, R0 D2,,4.54,2.71,1.17,132.4,266.0,2.21,11.0,16.0,118.0,61.0,6.0,8.62,3.43,57.0,248.0,36.0,21.0,5.4,7.1,38.0,307.0,83.4,42.3,31.7,1.33,0.2,7.1,7.3,5.8,0.47,2.3,8.0,,0.406,16.63,3.03,,无,, P0,H0, 未做, CK + CD56 - CgA- Syn-,,,,,46.419185282522996,1625786
1625868,付淑华,647340,女,66,T3,N1,M0, ⅡB,1,1,2.0,1.0,1.0,1.0, 慢性炎症（+）,2.0,25,硬型（sci）,INFc,0.0,,,,,,,,2016-07-29,2020-05-26,0,,,XELOX,XELOX,,,,,2, 低粘附腺癌 Lauren弥漫型,GX, (1a)0/4 (1b)0/1 (3a)0/3 (3b)0/0 (4sb)0/0 (4d)2/4 (5)0/0 (6)0/5 (7)0/3 (8a)0/0 (8p)0/1 (9)0/2 (11p)0/2 (12a)0/0 4d 软组织可见癌," L（幽门窦部）, 大弯侧Gre,",20,15,3, R0,,6.66,4.1,2.23,123.0,140.0,2.21,34.0,27.0,215.0,57.0,10.0,12.99,4.81,57.0,187.0,36.0,21.0,6.5,4.6,45.0,130.0,,,,,,,,,,,,,3.31,6.97,0.757, 未做,无, 无, P0,H0, 未做, CK + CD 31 S-100,,,,,45.893561103810775,1625868
1626759,王郁彬,648503,女,78,T3,N3a,M0,ⅢB,1,3,,1.0,1.0,1.0,,8.0,16,,,0.0,,0.0,,1.0,2.0,,,2016-08-05,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)85 低粘附腺癌15,G3,小弯23 (1a)02 (1b)01 (3a)44 (3b)12 (4sb)00 (4d)02 (5)11 (6)01 (7)00 (9)00," L（幽门窦部）, 前Ant,",28,10,3, R0,,7.62,4.94,2.09,126.3,434.0,2.93,17.0,22.0,158.0,76.0,19.0,4.31,1.42,71.0,378.0,42.0,29.0,5.5,4.7,65.0,337.0,,,,,,,,,,,,,8.64,38.96,1.43, 未做,无, 无, P0,H0, 未做, CK CD4 CD8 + VEGF -,80% 中-强,60% 中-强,80% 强,60% 弱-中,72.8646517739816,1626759
1626066,赵申才,649329,男,68,T3,N3b,M0, ⅢC,1,5,1.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,21.0,38,硬型（sci）,INFb,0.0,,,,,,,,2016-08-01,2017-01-19,2,,,,,,,,,0, 低粘附腺癌 乳头状癌（G1）（pap） 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G2," (2)2,2 (3a)2,2 (4d)3,8 (5)1,1 (6)1,6 (7)8,8 (8a)4,6 (1a)(1b)(3b)(4sa)(4sb)(8p)(9)(12a)0,5"," LMU 前Ant, 后Post, 小弯侧Less,",35,25,10, R0 D2+,,7.11,4.13,2.04,124.0,266.0,2.8,16.0,21.0,170.0,86.0,11.0,8.58,2.92,60.0,327.0,37.0,23.0,5.5,8.3,82.0,154.0,,,,,,,,,,,,,1.82,14.12,4.51,,无, 无, P0,H0, 未做, CK +,,,,,5.617608409986859,1626066
1626097,杨玉庭,643299,男,59,T4b,N3a,M0, ⅢC,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,13.0,38,髓样型（med）,INFa,1.0,,,,,,,,2016-08-01,2017-04-15,2,,,,,,,,,0, 低粘附腺癌60% 低分化腺癌（G3)(por)40% Lauren肠型,G3, (1a)0/1 (1b)0/2 (2)1/5 (3a)1/1 (3b)3/6 (4sa)0/0 (4sb)0/0 (4d)0/0 (5)0/0 (6)7/7 (7)0/3 (8a)0/1 (8p)1/3 (9)1/3 (11p)2/6 (12a)0/0," LM 前Ant, 小弯侧Less, 后Post,",80,60,10,,R1,8.38,5.64,1.71,90.0,576.0,5.82,12.0,17.0,121.0,79.0,33.0,2.91,1.64,64.0,110.0,35.0,29.0,5.6,5.3,53.0,211.0,,,,,,,,,,,,,1.47,6.09,1.4, 未做,无, 无, P0,H0, 未做, CD 31  S-100 CK +,,,,,8.442838370565045,1626097
1626664,宋杨,648419,女,45,T4a,N3a,M0, ⅢB,1,3,,0.0,0.0,1.0,,13.0,43,,,0.0,,2.0,,1.0,2.0,,,2016-08-04,2017-07-19,0,,,SOX,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,13, 低粘附腺癌,GX,大弯625 小弯516 (8a)22," LM 前Ant, 后Post, 小弯侧Less,",35,3,10, R0 D2,,6.44,4.04,1.95,121.3,196.0,2.74,6.0,14.0,138.0,49.0,9.0,10.6,3.06,69.0,241.0,43.0,26.0,4.6,7.4,78.0,256.0,,,,,,,,,,,,,0.808,9.87,4.22, 未做,无, 无, P0,H0, 未做, CK +,40% 弱,60% 强,60% 中-强,30% 弱,11.465177398160314,1626664
1626395,王洪涛,649967,男,53,T3,N3a,M0,ⅢB,1,3,1.0,0.0,0.0,1.0, 慢性炎症（+）,9.0,28,硬型（sci）,INFc,0.0,,0.0,,1.0,2.0,,,2016-08-03,2019-05-01,2,,,口服替吉奥,SOX,SOX,SOX,SOX,,5, 低粘附腺癌75 低分化腺癌（G3)(por)25,G3, (1a)01 (1b)00 (3a)24 (3b)00 (4sb) 00(4d) 37(5)00 (6)48 (7) 04(8a) 01(8p)01 (9) 00(11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,6, R0 D2+,,4.87,2.33,1.72,117.0,296.0,2.52,13.0,19.0,152.0,49.0,9.0,8.2,2.78,71.0,253.0,45.0,26.0,4.1,5.1,82.0,335.0,,,,,,,,,,,,,1.07,5.79,5.44,,,, P0,H0, 未做, CK + VEGF -,30% 弱,30% 弱,60% 中,0,32.88436268068331,1626395
1626271,张敏杰,651279,女,61,T3,N0,M0, ⅡA,1,2,0.0,1.0,1.0,0.0, 异型增生+,0.0,14,中间型（int）,INFa,0.0,,1.0,,1.0,2.0,,,2016-08-02,2020-04-20,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】85 乳头状癌（G1）（pap）15 Lauren肠型,G2, (1b)00 (3a)00 (3b)00 (4sb)00 (4d)00 (5)01 (6)00 (7)03 (8a)03 (8p)01 (9)01 (11p)02 (12a)00, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,40,10, R0 D2,,7.18,53.15,2.6,72.3,257.0,2.75,10.0,15.0,142.0,56.0,6.0,8.25,3.13,62.0,162.0,39.0,23.0,5.6,3.4,69.0,207.0,55.9,32.7,14.3,2.29,0.2,12.3,31.0,4.3,0.515,2.58,11.0,,1.0,0.6,1.09, 阳性+,无, 无, P0,H0, 未做,cd31（+）、D2-40（+）、s-100（-）,0,80% 中,85% 中-强,0,44.57950065703022,1626271
1626615,路艳杰,649971,女,68,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,16.0,20,硬型（sci）,INFc,0.0,,,,,,,,2016-08-04,2017-02-10,2,,,,,,,,,0, 低粘附腺癌75 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】25 Lauren弥漫型,G3, (1b)00 (3a)34 (3b)33 (4sb)00 (4d)12 (5)00 (6)33 (7)12 (8a)11 (9)12, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less,50,40,12, D2,R1,3.77,1.88,1.58,111.0,257.0,2.52,40.0,27.0,144.0,77.0,19.0,8.16,2.15,69.0,280.0,41.0,28.0,5.4,6.4,77.0,233.0,59.5,29.7,23.5,1.26,0.4,11.8,26.4,2.0,0.855,1.8,14.1,,3.53,8.47,16.91, 未做,无, 无, P0,H0, 未做, VEGF(-) CD8(+) CD4(+) ,40% 中,70% 强,80% 强,40% 中,6.241787122207621,1626615
1626808,赵德有,649342,男,51,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,13.0,34,中间型（int）,INFa,3.0,,0.0,,1.0,2.0,,,2016-08-05,2020-05-21,0,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,冰冻11d01 冰冻15组01  (1a)01 (1b)00 (2)33 (3a)34 (3b)00 (4sa)12 (4sb)01 (4d)02 (5)01 (6)03 (7)55 (8a)01 (8p)05 (9)01 (11p)23," GE, SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",45,35,7, R0 D2,,5.82,3.79,1.44,155.0,210.0,3.56,26.0,28.0,188.0,87.0,33.0,15.05,5.13,66.0,322.0,43.0,23.0,4.9,8.8,73.0,371.0,,,,,,,,,,,,,14.88,6.04,12.58, 未做,无,, P0,H0, 未做, CK + CD4+ CD8散在+ VEGF-,90% 中-强,90% 强,90% 强,80% 弱-中,45.499342969776606,1626808
1626392,艾桂华,649348,女,61,T4a,N0,M0, ⅡB,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,33,中间型（int）,INFa,0.0,,0.0,,1.0,2.0,,,2016-08-03,2019-05-01,2,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1b)02 (3a)06 (3b)02 (4sb)00 (4d)05 (5)02 (6)06 (7)02 (8a)01 (8p)00 (9)02 (11p)02 (12a)03," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,45,16, R0 D2,,5.42,3.03,1.91,124.7,248.0,2.11,14.0,20.0,138.0,48.0,6.0,7.11,2.63,61.0,306.0,40.0,21.0,4.8,10.8,70.0,292.0,,,,,,,,,,,,,8.85,25.23,1.89,,无, 无, P0,H0, 未做, CK+ CD4+ CD8散在+  VEGF-,0,80% 中,85% 中-强,0,32.88436268068331,1626392
1626223,于子荣,649339,男,59,T1b,N0,M0,ⅠA,1,2,,1.0,1.0,0.0,,0.0,17,,,3.0,,0.0,,1.0,,,,2016-08-02,2020-06-11,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)04 (1b)01 (3a)01 (3b)02 (4sb)00 (4d)00 (5)00 (6)00 (7)01 (8a)01 (8p)05 (9)02 (11p)00 (12a)00," L（幽门窦部）, 后Post,",15,8,5, R0 D2,,5.15,2.61,2.08,152.2,180.0,2.65,20.0,17.0,183.0,94.0,16.0,7.22,2.41,70.0,380.0,46.0,24.0,5.8,7.0,80.0,340.0,,,,,,,,,,,,,2.22,14.48,2.69,,无, 无, P0,H0, 未做, CK+ CD4+ CD8散在+ VEGF-,90% 弱-中,90% 弱-中,90% 强,70% 弱,46.28777923784494,1626223
1626001,张云学,648783,男,77,T2,N2,M0, ⅡB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,6.0,33,中间型（int）,INFb,0.0,,,,,,,,2016-08-01,2021-08-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)85 粘液腺癌（muc）15,G3, (1a)03 (1b)00 (3a)11 (3b)00 (4sb)02 (4d)07 (5)00 (6)512 (7)02 (8a)00 (8p)02 (9)01 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",15,15,6, R0,,7.91,5.73,1.48,153.4,178.0,3.28,18.0,19.0,202.0,95.0,12.0,13.94,5.5,65.0,263.0,44.0,21.0,4.4,7.7,93.0,272.0,,,,,,,,,,,,,38.15,8.61,22.15, 未做,无, 无, P0,H0, 未做, CK +,,,,,59.98685939553219,1626001
1626501,王承和,648619,男,59,T2,N0,M0, ⅠB,1,3,2.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,23,硬型（sci）,INFc,0.0,,0.0,,1.0,2.0,,,2016-08-03,2021-08-02,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)01 (3a)04 (3b)00 (4sb)00 (4d)01 (5)01 (6)02 (7)02 (8a)01 (8p)02 (9)03 (11p)03 (12)00 (14v)02," LM 前Ant, 后Post, 小弯侧Less,",30,20,10, R0 D2,,6.37,2.88,2.7,144.0,233.0,2.33,19.0,23.0,161.0,70.0,24.0,15.84,5.6,67.0,340.0,48.0,19.0,4.7,4.6,85.0,309.0,,,,,,,,,,,,,3.74,8.04,2.15, 未做,无,, P0,H0, 未做, CK +,40% 中,70% 中-强,80% 强,50% 中,59.95400788436268,1626501
1626686,严廷德,649817,男,65,T4b,N3a,M1, Ⅳ,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,7.0,28,中间型（int）,INFa,2.0,,0.0,,1.0,2.0,,,2016-08-04,2021-08-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)55 乳头状癌（G1）（pap）30 粘液腺癌（muc）15 Lauren肠型,G3, (1a) 01(1b)14 (2) 02(3a) 13(3b)01 (4sa)11 (4sb)00 (4d) 02(5)22 (6) 04(7)22 (8a)02 (8p)00 (9)04 胰腺结节可见癌," SiewerⅢ, U（胃底部）, 前Ant, 后Post, 小弯侧Less,",80,70,18,,R2,5.67,4.0,1.01,107.1,239.0,4.43,12.0,20.0,179.0,79.0,9.0,15.48,2.78,64.0,135.0,38.0,26.0,4.9,6.8,88.0,305.0,44.6,31.9,11.7,2.73,0.0,15.1,38.8,0.5,0.511,5.08,12.6,,7.93,15.45,18.09, 阳性+,,, P0,H0, 未做, CK + VEGF -,30% 弱,60% 中,70% 中-强,60% 弱,59.92115637319316,1626686
1626226,薛振春,650976,男,66,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 肠化生 异型增生 慢性炎症,6.0,23,中间型（int）,INFa,1.0,,,,,,,,2016-08-02,2019-03-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap） Lauren肠型,G2," (3a)1,1 (4d)1,3 (6)2,5 (7)1,6 (8a)1,1"," L（幽门窦部）, 前Ant, 小弯侧Less,",50,50,7, R0 D2,,10.5,9.02,0.83,138.0,152.0,3.56,11.0,19.0,192.0,65.0,9.0,15.11,5.49,63.0,269.0,44.0,19.0,6.0,6.0,82.0,323.0,66.9,36.6,26.5,1.38,0.1,11.2,20.8,5.3,0.873,0.971,7.36,,7.51,28.01,8.53,,无,, P0,H0, 未做, CK +,,,,,31.373193166885674,1626226
1626445,姜春生,648961,男,60,T4b,N2,M0, ⅢB,1,2,1.0,0.0,0.0,1.0, 慢性炎症（+）,3.0,25,髓样型（med）,INFa,0.0,,0.0,,1.0,2.0,,,2016-08-03,2019-01-07,2,,,XELOX,口服替吉奥,XELOX,XELOX,XELOX,XELOX,6, 粘液腺癌（muc）90 低粘附腺癌10 Lauren混合型,GX, (1a)00 (1b)05 (3a)12 (3b)00 (4sb)00 (4d)05 (5)01 (6)13 (7)03 (8a)12 (8p)02 (9)00 (11p)02 (12a)00, L（幽门窦部） 前Ant 后Post 小弯侧Less ,60,50,20,,R1,6.81,3.43,2.71,156.3,216.0,3.07,18.0,19.0,137.0,78.0,33.0,16.71,5.34,68.0,301.0,45.0,23.0,4.9,6.0,92.0,260.0,85.4,39.9,43.4,0.92,0.2,11.2,2.7,5.6,1.3,1.66,8.73,,24.84,46.77,53.18, 阳性+,无,, P0,H0, 未做,,40% 中,60% 强,60% 强,20% 弱,29.139290407358736,1626445
1626568,郑财,648605,男,56,T3,N0,M0, ⅡA,1,2,2.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,39,硬型（sci）,INFc,0.0,,0.0,,1.0,2.0,,,2016-08-04,2018-01-23,0,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)01 (3a)010 (3b)00 (4sb)02 (4d)04 (5)00 (6)06 (7)05 (8a)01 (8p)01 (9)08 (11p)01 (12a)00 5组 软组织可见癌, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,30,30,10, R0 D2,,8.33,5.41,1.99,104.0,398.0,5.6,15.0,16.0,163.0,82.0,15.0,5.45,1.61,62.0,247.0,38.0,24.0,5.4,5.9,73.0,228.0,80.9,50.7,26.4,1.92,0.2,13.9,4.5,3.4,0.574,2.99,9.31,,6.3,0.971,3.05, 阳性+,无,, P0,H0, 未做, CD 4 + CD8散在+ VEGF-,30% 中,70% 中,80% 中-强,40% 中,17.641261498028907,1626568
1627259,姜淑琴,649819,女,67,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,11,,,0.0,,,,,,,,2016-08-10,2021-08-09,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)0/2 (1b)0/0 (3a)0/0 (3b)0/0 (4sb)0/0 (4d)0/0 (5)0/0 (6)0/1 (7)0/3 (8a)0/0 (8p)0/4 (9)0/0 (11p)0/1 (12a)0/0," L（幽门窦部）, 小弯侧Less,",30,25,, R0,,10.11,6.81,1.97,120.8,214.0,2.7,18.0,25.0,124.0,86.0,43.0,7.93,2.42,68.0,265.0,42.0,26.0,8.4,6.4,79.0,283.0,,,,,,,,,,,,,2.91,7.14,1.17, 未做,无, 无, P0,H0, 未做, CK +,,,,,59.95400788436268,1627259
1627145,车宝军,651308,男,53,T1b,N0,M0,ⅠA,1,0,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,46,硬型（sci）,INFa,2.0,,0.0,,2.0,2.0,,,2016-08-09,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)0/4 (1b)0/1 (3a)0/7 (3b)0/1 (4sb)0/0 (4d)0/10 (5)0/2 (6)0/6 (7)0/1 (8a)0/1 (8p)0/3 (9)0/7 (11p)0/3 (12a)0/0," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",15,15,, R0,,4.87,2.65,1.77,144.4,187.0,1.88,23.0,21.0,189.0,52.0,10.0,9.08,4.04,54.0,185.0,33.0,21.0,5.1,3.7,79.0,165.0,,,,,,,,,,,,,6.09,17.6,0.802, 未做,无, 无, P0,H0, 未做, CK + CD 31 S-100,90% 中,90% 中,90% 中,95% 强,72.73324572930355,1627145
1626610,张剑舟,643214,男,58,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生,7.0,21,中间型（int）,INFb,0.0,,0.0,,1.0,2.0,,,2016-08-04,2018-01-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3," (3a)3,3 (5)2,2 (6)2,3 (1a) (1b) (3b) (4sb) (4d) (7) (8a) (8p) (9) (11p) (12a)0,14"," L（幽门窦部）, 小弯侧Less, 后Post,",30,30,6, R0,,5.74,3.24,1.88,155.0,271.0,2.41,24.0,26.0,182.0,68.0,20.0,21.37,7.03,73.0,425.0,48.0,25.0,5.6,6.1,93.0,237.0,,,,,,,,,,,,,0.994,7.07,1.34,,无,, P0,H0, 未做, CK+ CD31 D2-40 S-100 MLH1弱 PMS2弱,90% 弱,90% 弱-中,90% 中,80% 弱,16.918528252299605,1626610
1626922,杨彩和,643178,男,60,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,51,,,0.0,,,,,,,,2016-08-08,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a) 02(1b)06 (3a)01 (3b)08 (4sb)00 (4d)05 (5)02 (6) 02(7) 05(8a)08 (8p)01 (9) 03(11p) 08(12a)00," L（幽门窦部）, 小弯侧Less,",15,10,, R0 D2,,8.4,6.95,1.23,144.8,143.0,5.12,67.0,45.0,177.0,54.0,121.0,20.59,11.71,67.0,199.0,32.0,35.0,10.6,3.9,55.0,167.0,,,,,,,,,,,,,3.95,28.15,0.85, 未做,无, 无, P0,H0, 未做, CK+,,,,,72.76609724047306,1626922
1626444,刘桂芬,651399,女,57,T3,N1,M0, ⅡB,1,5,2.0,1.0,1.0,1.0, 慢性炎症（+）,2.0,47,中间型（int）,INFc,0.0,0.03,,,,,1.0,,2016-08-03,2021-05-26,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a) 01(1b) 02(3a) 06(3b)04 (4sb)00 (4d)217 (5)02 (6)08 (7) 04(8a) (8p)00 (9)01 (11p)02 (12a)00," L（幽门窦部）, 后Post,",20,15,10, R0 D2,,6.83,4.12,2.11,130.8,126.0,3.34,42.0,32.0,209.0,102.0,36.2,14.89,3.22,68.1,290.08,39.2,28.9,5.2,9.85,80.0,294.0,,,,,,,,,,,,,4.98,4.98,1.52, 未做,无, 无, P0,H0, 未做, CK+ S-100可见， D2-40  CD31 可见，SMA+，,,,,,57.72010512483574,1626444
1627004,李维远,649827,男,69,T1b,N1,M0, ⅠB,1,3,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,1.0,8,硬型（sci）,INFa,0.0,,0.0,,2.0,2.0,,,2016-08-08,2018-04-15,2,,,口服替吉奥,,,,,,1, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a) 01(1b)01 (3a)01 (3b)00 (4sb)00 (4d)00 (5)00 (6) 00(7) 03(8a) (8p)11 (11p)01 (9)00," L（幽门窦部）, 小弯侧Less,",15,10,3, R0 D2,,6.54,4.69,1.38,130.9,237.0,3.72,71.0,72.0,197.0,56.0,10.0,14.86,5.73,56.0,277.0,34.0,22.0,7.4,4.5,50.0,96.0,,,,,,,,,,,,,4.63,13.22,1.34, 未做,无, 无, P0,H0, 未做, CK+， S-100未见。 D2-40  CD31 未见， MLH1-， MLH2，70%，中 MLH6 85%，中-强 PMS2- CD4+  CD8+  VEGF-,0,70% 中,85% 中-强,0,20.203679369250985,1627004
1627009,崔洪涛,649987,男,57,T4a,N3a,M0, ⅢB,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,8.0,18,中间型（int）,INFc,0.0,,2.0,,1.0,2.0,,,2016-08-08,2019-12-12,2,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren弥漫型,G3, (1a)12 (1b)22 (2)00 (3a)59 (3b)00 (4sa)00 (4sb)00 (4d)01 (5)00 (6)01 (7) (8) (9) (11p)02 (10)00 (11d)01 另3b 软组织可见癌," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,30,8, R0 D2,,5.3,2.99,1.71,107.0,358.0,2.85,11.0,17.0,148.0,42.0,10.0,29.8,8.6,73.0,318.0,48.0,25.0,6.8,6.5,81.0,313.0,,,,,,,,,,,,,1.77,390.1,1.34, 未做,无,, P0,H0, 未做, CK +,50% 弱,70% 中,80% 强,40% 弱,40.11169513797635,1627009
1626810,郑玉芳,651154,女,58,T3,N3a,M0,ⅢB,1,3,,1.0,1.0,1.0,,11.0,23,,,1.0,,0.0,,1.0,2.0,,,2016-08-05,2021-05-25,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)02 (1b)00 (3a)13 (3b)00 (4sb) 00(4d)44 (5)00 (6)44 (7) 03(8a)01 (8p)03 (9)00 (11p)23 (12a)00, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,20,18,1, R0 D2,,10.41,4.66,4.89,137.0,349.0,2.42,13.0,16.0,170.0,61.0,13.0,8.75,2.29,71.0,331.0,44.0,27.0,6.4,7.3,91.0,307.0,65.7,41.9,18.4,2.28,0.2,10.4,22.4,1.2,0.796,3.83,11.0,,1.18,6.78,1.18, 阳性+,无, 无, P0,H0, 未做, CK + VEGF - CD 4+ CD8散在+,30% 弱,70% 中,70% 中,30% 弱,57.6215505913272,1626810
1627512,李宝娣,649829,女,30,T1a,N0,M0,ⅠA,1,2,,,,,,0.0,28,,,0.0,,0.0,,0.0,2.0,,,2016-08-11,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20,G3, (1a)02 (1b)05 (3a)06 (3b)00(4sa)00 (4sb)01 (4d)01 (5)02(6)04 (7)01 (8a)01 (8p)01 (9)02 (11p)02 (12a)00 ," M（胃体部）, 小弯侧Less,",15,15,8, R0 D2,,7.15,4.27,2.19,117.0,224.0,2.33,8.0,15.0,159.0,48.0,8.0,26.83,9.61,61.0,237.0,41.0,20.0,4.1,5.2,69.0,307.0,,,,,,,,,,,,,1.01,25.28,0.853, 阳性+,无, 无, P0,H0, 未做, CK + VEGF- CD4-  CD 8散在+,30% 中,60% 中,70% 中-强,30% 中,72.66754270696451,1627512
1627406,姜玉良,651107,男,56,T3,N3a,M0,ⅢB,1,2,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+） 异型增生+,8.0,30,硬型（sci）,INFc,0.0,,0.0,,1.0,2.0,,,2016-08-11,2022-09-01,1,,,,,,,,,0, 粘液腺癌（muc）80 低分化腺癌（G3)(por)20,G3,(1a)00 (1b)00 (3a)04 (3b)24 (4sb)00 (4d)14 (5)11 (6)23 (7)01 (8a)06 (8p)01 (9)00 (11p)13 (12a)13," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,20,10, R0,,6.97,4.01,2.18,139.0,351.0,4.97,15.0,21.0,187.0,78.0,16.0,6.51,1.61,66.0,294.0,47.0,19.0,4.8,6.6,94.0,428.0,,,,,,,,,,,,,0.647,7.67,18.55, 未做,无, 无, P0,H0, 未做, CK CD4 CD8 + VEGF -,10% 弱,30% 弱-中,40% 中,10% 弱,72.66754270696451,1627406
1627774,刘志存,649991,男,84,T3,N0,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+,0.0,9,中间型（int）,INFa,3.0,,0.0,,2.0,2.0,,,2016-08-15,2017-11-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)00 (2)04 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)01 (7)02 (8a)00 (9)01 (12a)00,MU 前Ant 后Post 小弯侧Less ,50,40,8, R0  D2,,5.38,3.07,1.64,86.0,170.0,2.61,12.0,19.0,147.0,50.0,12.0,11.75,4.7,60.0,124.0,37.0,23.0,6.3,4.8,91.0,220.0,83.9,50.8,28.4,1.79,0.2,5.1,9.5,3.7,1.13,3.71,11.2,,0.79,29.69,2.93,  阴性,无,, P0,H0, 未做, CD31（+） D2-40（+）S-100（+)       CD4(+) CD8(+)VEGF(-),40% 中,70% 中,80% 中-强,15% 弱,14.848883048620236,1627774
1627139,邵元会,651262,男,52,T3,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 肠化生 异型增生 慢性炎症,3.0,27,硬型（sci）,INFc,0.0,,0.0,,1.0,2.0,,,2016-08-09,2021-05-19,1,,,XELOX,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX," (3a)2,5 肿物旁1,1"," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",20,15,8, R0 D2,,6.0,,,150.0,180.0,2.85,17.0,20.0,155.0,50.0,14.0,20.36,7.15,63.0,398.0,44.0,19.0,4.7,9.8,85.0,343.0,,,,,,,,,,,,,1.03,0.6,1.86,,无, 无, P0,H0, 未做, CK CD4  CD8  + VEGF - MLH1 MLH2 PMS2 弱 MLH6 强,10% 弱,30% 弱-中,40% 中,10% 弱,57.29303547963206,1627139
1627261,张凤琴,652720,女,69,T4b,N2,M0, ⅢB,1,2,0.0,0.0,0.0,1.0, 肠化生 慢性炎症,6.0,36,中间型（int）,INFa,0.0,,,,,,,,2016-08-10,2017-05-09,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3," (3a)1,5 (4d)2,12 (6)2,10 (7)1,2"," LM 后Post, 大弯侧Gre, 小弯侧Less,",60,60,10,,R1,8.19,5.64,1.89,101.6,495.0,4.7,13.0,16.0,141.0,182.0,30.0,8.43,2.61,65.0,175.0,39.0,26.0,6.0,5.8,83.0,276.0,,,,,,,,,,,,,36.65,6.36,9.6,,无, 无, P0,H0, 未做, CD56 CgA - Syn CK + MLH1 PMS2 弱 MLH2 MLH6中,30% 弱,60% 中,80% 中-强,20% 弱,8.935611038107753,1627261
1628067,代德华,650903,男,61,T3,N3b,M0, ⅢC,1,3,,0.0,0.0,1.0,,26.0,40,,,0.0,,0.0,,2.0,2.0,,,2016-08-16,2017-05-16,2,,,XELOX,XELOX,XELOX,口服卡培他滨,,,4, 低粘附腺癌85 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)15,G3, (1a) 02(1b)22 (2)05 (3a)88 (3b)22 (4sa)00 (4sb)00 (4d)03 (5)22 (6)22 (7)55 (8a)11 (8p)13 (9)22 (11p) 13(12a)00," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",30,25,5, R0 D2,,7.68,4.59,0.47,115.3,127.0,2.95,35.0,36.0,147.0,91.0,39.0,12.03,4.17,63.0,224.0,34.0,29.0,4.3,6.9,67.0,230.0,,,,,,,,,,,,,3.49,53.62,1.42, 未做,无, 无, P0,, 未做, CK+ MLH1，70%，弱 MLH2，80%，中 MLH6 80%，弱 PMS2，30%，弱 CD4 + CD8 + VEGF- S-100可见,70% 弱,80% 中,80% 强,30% 弱,8.968462549277266,1628067
1627439,韩忱,650675,男,48,T4b,N2,M0, ⅢB,1,3,2.0,1.0,1.0,1.0, 慢性炎症,5.0,85,髓样型（med）,INFc,0.0,,0.0,,2.0,2.0,,,2016-08-11,2017-02-24,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX," (1a)1,3 (3a)1,1 (4d)1,25 (3b)1,1 (11p)1,4"," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",95,75,10,,R1,4.88,2.83,1.58,161.5,308.0,3.01,22.0,24.0,211.0,74.0,12.0,13.23,4.64,65.0,332.0,41.0,24.0,4.4,4.8,85.0,408.0,,,,,,,,,,,,,2.1,7.37,11.34,,无, 无, P0,H0, 未做, CK CD4  CD8 + VEGF - MLH1 MLH2 PMS2 弱 MLH6 强,20% 弱,60% 弱-中,80% 中-强,20% 弱,6.471747700394218,1627439
1627441,侯宪顺,651341,男,51,T3,N0,M0, ⅡA,1,2,2.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,39,髓样型（med）,INFc,0.0,,0.0,,2.0,2.0,,,2016-08-11,2022-09-01,1,,,SOX,SOX,SOX,,,,3, 粘液腺癌（muc）70 低粘附腺癌30,GX, (1a)02 (1b)02 (3a)01 (3b)02 (4sb)02 (4d)04 (5) 00(6)05 (7)04 (8a)02 (8p)08 (9)02 (11p)03 (12a)01 (12p)01, M（胃体部） 小弯侧Less 前Ant ,30,30,15, R0 D2,,5.54,3.04,1.9,157.9,194.0,2.42,50.0,45.0,178.0,112.0,45.0,6.29,2.2,67.0,256.0,42.0,25.0,5.0,8.1,85.0,227.0,78.1,41.3,33.0,1.25,1.4,9.8,11.2,1.5,0.935,2.06,8.31,,1.64,25.32,2.41, 阳性+,无, 无, P0,H0, 未做, CK  + VEGF -  CD4散在(+)  CD8散在(+),30% 中,60% 中,80% 中-强,30% 中,72.66754270696451,1627441
1627883,刘孝阁,648810,女,67,T1b,N1,M0, ⅠB,1,0,,1.0,1.0,0.0,,1.0,51,,,0.0,,0.0,,2.0,2.0,,,2016-08-15,2020-09-09,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10,G2,小弯16 (1a) 01(1b) 00(3a) 013(3b)01 (4sb)01 (4d)011 (5)00 (6) 00(7)04 (8a) 03(8p) 00(9)05 (11p)04 (12a)01 (19)01," L（幽门窦部）, 前Ant, 小弯侧Less,",15,15,, R0 D2+,,8.93,5.34,2.67,121.0,313.0,3.13,15.0,30.0,219.0,73.0,17.0,8.9,2.84,65.0,170.0,37.0,2.0,5.0,4.9,66.0,233.0,70.9,48.4,21.4,2.26,0.2,6.4,17.8,0.9,0.475,3.9,11.5,,3.38,36.59,1.08,,无, 无, P0,H0, 未做, CK +,60% 弱,75% 中,80% 强,30% 弱,48.8173455978975,1627883
1627857,明日,649492,男,48,T3,N0,M0, ⅡA,1,3,1.0,1.0,1.0,1.0, 肠化生+,0.0,22,髓样型（med）,INFb,1.0,,0.0,,2.0,2.0,,,2016-08-15,2022-09-01,1,,,XELOX,XELOX,XELOX,SOX,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 65粘液腺癌（muc）20 低粘附腺癌15,G3, (1a) 00(1b)01 (3a) 09(3b)00 (4sb)00 (4d) 04(5)01 (6)01 (7)02 (8a) 01(8p)01 (9)01 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,50,12, R0 D2+,,5.19,2.45,1.94,82.2,497.0,2.9,22.0,18.0,145.0,46.0,18.0,10.99,5.15,68.0,267.0,41.0,27.0,5.9,5.0,85.0,310.0,78.7,49.2,19.4,2.54,0.1,18.8,1.7,2.2,1.5,2.56,11.1,,2.32,0.6,45.26,,,, P0,H0, 未做, CK +,70% 中,70% 中,85% 中-强,60% 弱-中,72.53613666228647,1627857
1627812,张亚军,651311,男,62,T3,N2,M1, ⅢA,1,4,2.0,0.0,0.0,1.0, 慢性炎症（+）,3.0,32,中间型（int）,INFc,0.0,,0.0,,2.0,2.0,,,2016-08-15,2017-01-01,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,1组03  (1b)04 (2)02 (3a)12 (3b)01 (4sa)00 (4sb)02 (4d)11 (5)00 (6)06 (7)14 (8a)01 (8p)02 (9)02 (11p)02 (12a)00," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,8,,R2,6.51,3.92,1.91,134.1,243.0,2.97,18.0,22.0,158.0,74.0,8.0,6.52,2.29,64.0,275.0,39.0,25.0,5.0,3.4,82.0,195.0,,,,,,,,,,,,,0.453,6.58,2.86, 未做,无,, p1局腹膜(M1 PER),H0, 未做,CK+ CD4散在+ CD8散在+ VEGF-,70% 弱,70% 弱-中,90% 强,90% 强,4.566360052562418,1627812
1628385,孔范金,648799,男,51,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,23,,,0.0,,0.0,,2.0,1.0,,,2016-08-18,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)65 低粘附腺癌35,G3, (1a)00 (1b)00 (3a)05 (3b)02 (4sb)02 (4d)02 (5)00 (6)02 (7)02 (8a)01 (8p)01 (9)00 (11p)01 (12a)00,L（幽门窦部） 前Ant 后Post 小弯侧Less ,10,10,5, R0 D2,,3.79,1.43,1.78,68.0,304.0,2.36,21.0,22.0,106.0,68.0,11.0,4.15,1.64,64.0,339.0,40.0,24.0,5.0,5.3,82.0,343.0,,,,,,,,,,,,,0.677,10.17,1.23, 阴性,无,, P0,H0, 未做,  CD4(+) CD8(+)VEGF(-),40% 中,30% 弱,60% 强,20% 中,72.43758212877792,1628385
1628020,丁宝福,648813,男,63,T3,N2,M0, ⅢA,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,5.0,24,中间型（int）,INFb,0.0,,0.0,,2.0,2.0,,,2016-08-16,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)03 (1b)00 (3a)37 (3b)00 (4sb)01 (4d)01 (5)00 (6)00 (7)02 (8a)02 (8p)22 (9)05 (11p)01 (12a)00, L（幽门窦部） 前Ant 小弯侧Less 后Post ,35,25,8, R0 D2,,8.32,4.69,2.67,110.2,257.0,2.7,21.0,20.0,76.0,83.0,28.0,6.66,2.55,60.0,231.0,38.0,22.0,6.1,7.3,74.0,325.0,73.3,48.3,20.8,2.32,0.4,17.9,8.1,3.4,0.382,3.69,6.56,,31.1,21.57,1.52, 阳性+,无,, P0,H0, 未做, CD31（-） D2-40（-）S-100（-)CD4(+) CD8(+)VEGF(-),20% 弱-中,40% 中,80% 中-强,20% 弱,72.50328515111696,1628020
1627775,芦庆森,651271,男,64,T4b,N1,M0, ⅢB,1,2,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,2.0,70,髓样型（med）,INFa,2.0,,,,,,,,2016-08-15,2021-05-25,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)04 (1b)04 (3a)012 (3b)03  (4sb)00 (4d)18 (5)00 (6)16 (7)07 (8a)01 (8p)04 (9)09 (11p)08 (12a)04,LM 小弯侧Less 后Post 大弯侧Gre  前Ant ,70,70,8,,R1,8.45,5.26,2.43,125.4,2.03,4.84,17.0,12.0,189.0,80.0,22.0,7.44,2.96,62.0,178.0,35.0,27.0,4.5,8.8,84.0,63.0,91.7,43.4,32.4,1.34,0.1,4.8,15.3,1.8,0.337,2.56,10.9,,1.42,6.84,2.25, 阳性+,无,, P0,H0, 未做, CK+ CK8/18+ CK5/6- P40- CDX-2+,0,40% 中,60% 中-强,0,57.29303547963206,1627775
1628230,林树滨,649712,男,58,T3,N3a,M0,ⅢB,1,2,0.0,1.0,1.0,1.0, 慢性炎症（+）,11.0,18,中间型（int）,INFa,1.0,,2.0,,2.0,2.0,,,2016-08-17,2021-07-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 00(1b) 11(3a) 22(3b)00 (4sb)00 (4d) 03(5) 00(6)24 (7)11 (8a) 11(8p)01 (9) 34(11p)11 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,35,8, R0 D2+,,8.05,5.49,2.05,142.4,276.0,3.9,15.0,16.0,185.0,50.0,29.0,7.88,2.71,67.0,349.0,39.0,28.0,5.6,5.5,88.0,310.0,71.4,45.9,21.3,2.15,0.2,9.0,16.1,3.0,1.28,2.2,11.6,,4.53,9.86,18.51, 阳性+,,, P0,H0, 未做, CK +,80% 中,70% 弱,80% 中,70% 中,58.44283837056504,1628230
1627610,史宝东,651025,男,46,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,23,,,0.0,,0.0,,0.0,2.0,,,2016-08-12,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)01 (3a)04 (3b)00 (4sb)00 (4d)01 (5)01 (6) 03(7)03 (8a)06 (8p)02 (9)00 (11p)02 (12a)00,L（幽门窦部） 后Post 大弯侧Gre  ,20,15,5, R0 D2,,5.54,61.51,1.57,141.0,182.0,2.86,12.0,16.0,154.0,60.0,18.0,14.78,6.26,65.0,231.0,40.0,25.0,4.3,4.8,76.0,300.0,84.0,38.3,42.8,0.89,0.3,9.7,5.3,12.9,0.858,2.64,10.8,,2.11,11.59,0.798, 阴性,无,, P0,H0, 未做, CK + CD4-  VEGF - CD8散在+ ,0,60% 中,80% 中-强,0,72.634691195795,1627610
1627810,王印武,651391,男,56,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,15.0,32,硬型（sci）,INFb,0.0,,0.0,,2.0,2.0,,,2016-08-15,2019-11-28,2,,,多西他赛+顺铂+替吉奥,SOX,SOX,口服替吉奥,SOX,SOX,27, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85  低粘附腺癌15 Lauren混合型,G3, (1a)00 (1b)00 (3a)68 (3b)00 (4sb)00 (4d)38 (5)23 (6)25 (7)11 (8a)03 (8p)01 (9)02 (11p)11 (12a)00," L（幽门窦部）, 后Post, 大弯侧Gre, 前Ant, 小弯侧Less,",50,50,20, R0 D2,,9.42,7.3,1.21148,148.0,194.0,5.45,23.0,28.0,180.0,98.0,124.0,17.48,8.92,62.0,188.0,35.0,27.0,5.5,6.7,75.0,247.0,,,,,,,,,,,,,2.41,18.33,19.09, 阴性,无, 无, P0,H0, 未做,CD4+ CD8+ VEGF- ck+ s-100见神经侵犯 CD31，D2-40 可见脉管瘤栓， MLH1（80% 中-强） MLH2 （80% 中-强）MLH6 （90% 强）PMS2（70% 中）,80% 中-强,80% 中-强,90% 强,70% 中,39.42181340341656,1627810
1627991,裴莹,650033,女,55,T1b,N1,M0, ⅠB,1,0,,,,,,1.0,14,,,0.0,,,,,,,,2016-08-16,2021-08-11,1,,,XELOX,,,,,,1, 低粘附腺癌,GX, (1a) 00(1b)02 (3a)11 (3b)00 (4sb)00 (4d)02 (5) 00(6)04 (7)02 (8a) (8p)02 (9) 01(12a)00," L（幽门窦部）, 小弯侧Less,",30,30,, R0 D2,,5.66,2.74,2.37,129.8,276.0,2.72,32.0,27.0,182.0,111.0,27.0,10.62,2.62,78.0,371.0,48.0,30.0,4.8,5.6,63.0,243.0,,,,,,,,,,,,,1.63,2.44,1.8, 未做,无, 无, P0,H0, 未做, CK+,,,,,59.82260183968462,1627991
1627943,荣士武,651306,男,67,T3,N2,M0, ⅢA,1,4,,1.0,1.0,1.0,,6.0,54,,,3.0,,0.0,,2.0,2.0,,,2016-08-16,2017-11-11,2,,,XELOX,,,,,,1, 低粘附腺癌 85管状腺癌（中分化【G2】【tub2】15,G2, (1a)02 (1b)01 (2)06 (3a)36 (3b)01 (4sa)12 (4sb)26 (4d)08 (5)00 (6)010 (7)01 (8a)01 (8p)02 (9)05 (11p)00 (12a)00 (12p)03,LM 前Ant 后Post 大弯侧Gre  小弯侧Less ,90,60,, R0 D2,,9.26,4.92,3.64,154.0,258.0,2.56,16.0,24.0,183.0,62.0,13.0,15.4,4.96,71.0,165.0,41.0,30.0,4.3,5.3,98.0,262.0,75.0,61.3,10.6,5.78,0.3,11.0,8.4,1.4,0.807,2.57,8.07,,350.9,5.99,0.973,,无,, P0,H0, 未做, CK （+） VEGF(-) CD4散在(+)  CD8散在(+),60% 弱,80% 中,90% 强,40% 弱,14.848883048620236,1627943
1627862,乔长力,650022,男,69,T3,N3b,M0, ⅢC,1,2,2.0,1.0,1.0,1.0, 慢性炎症（+）,34.0,38,中间型（int）,INFc,0.0,,0.0,,0.0,2.0,,,2016-08-15,2017-03-15,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)22 (1b)11 (2)04 (3a)88 (3b)22 (4sa)00 (4sb)00 (4d)33 (5)33 (6)44 (7)55 (8a)11 (8p)22 (9)11 (11p)11 (12a)11," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",70,60,10, R0 D2,,6.24,4.4,1.44,105.0,186.0,3.01,17.0,22.0,194.0,84.0,20.0,6.66,2.97,59.0,257.0,34.0,25.0,6.7,5.9,98.0,219.0,,,,,,,,,,,,,1.21,9.03,12.19,,无, 无, P0,H0, 未做, CK+ CD4- CD8散在+ VEGF-,60% 弱,60% 弱,80% 弱-中,80% 弱,6.964520367936925,1627862
1628387,杨树丰,651162,男,46,T2,N2,M0, ⅡB,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,6.0,38,硬型（sci）,INFc,0.0,,0.0,,2.0,2.0,,,2016-08-18,2021-06-16,1,,,XELOX,XELOX,XELOX,,,,3, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)00 (1b)01 (3a)07 (3b)12 (4sb)00 (4d)16 (5)00 (6)39 (7)03 (8a)11 (8p)03 (9)01 (11p)04 (12a)00 (17)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",55,55,10, R0 D2,,6.87,4.53,1.46,156.9,285.0,3.4,15.0,15.0,157.0,54.0,49.0,6.34,3.04,66.0,404.0,40.0,26.0,5.8,4.1,90.0,154.0,,,,,,,,,,,,,2.16,7.64,1.13,,无,, P0,H0, 未做, CK+ CD4+ CD8+ VEGF- CD34+  D2-40 + S-100+,25% 弱,65% 弱-中,70% 中,10% 弱,57.91721419185282,1628387
1628173,丁海兵,651288,男,42,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,33,,,1.0,,0.0,,2.0,0.0,,,2016-08-17,2021-07-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)65 粘液腺癌（muc）35,G3, (1a)01 (1b)01 (3a)04 (3b)02 (4sb)00 (4d)05 (5)00 (6)06 (7)01 (8a)07  (8p)02  (9)02 (11p)02 (12a)00, L（幽门窦部） 前Ant 后Post 小弯侧Less ,20,15,10, R0 D2,,9.53,6.37,2.33,142.7,341.0,2.74,18.0,17.0,159.0,88.0,14.0,9.45,3.12,70.0,296.0,44.0,26.0,4.4,6.7,101.0,366.0,69.3,30.7,30.4,1.01,0.1,11.6,16.9,5.0,0.622,2.15,9.64,,0.955,9.51,4.87, 阳性+,无,, P0,H0, 未做, CD31（-） D2-40（-）S-100（-)CD4(+) CD8(+)VEGF(-),80% 强,80% 强,80% 强,60% 中,58.60709592641261,1628173
1627988,李丽新,651530,女,51,T2,N1,M0, ⅡA,1,2,0.0,1.0,1.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,2.0,41,中间型（int）,INFa,0.0,,0.0,,2.0,0.0,,,2016-08-16,2021-06-07,1,,,XELOX,XELOX,XELOX,,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)02 (1b)01 (3a)07 (3b)00 (4sb)00 (4d)06 (5)23 (6)02 (7)07 (8a)01 (8p)07 (9)01 (11p)01 (12a)00 小弯03," L（幽门窦部）, 后Post, 小弯侧Less,",30,20,5, R0 D2,,17.2,15.55,0.63,139.5,392.0,2.85,18.0,18.0,149.0,56.0,13.0,17.58,5.45,70.0,348.0,45.0,25.0,5.8,4.5,57.0,233.0,,,,,,,,,,,,,0.28,5.48,1.65,,无, 无, P0,H0, 未做, CK+ CD4灶+ CD8- VEGF-,0,40% 弱-中,70% 中-强,0,57.68725361366623,1627988
1628168,梁桂荣,649565,女,52,T4b,N3a,M1, Ⅳ,1,4,1.0,1.0,1.0,1.0, 异型增生+ 慢性炎症（+）,7.0,28,中间型（int）,INFb,1.0,,2.0,,2.0,0.0,,,2016-08-17,2017-05-15,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌85 低分化腺癌（G3)(por)15 Lauren混合型,G3, (1a)03 (1b)12 (2)00 (3a)12 (3b)00 (4sa)01 (4sb)00 (4d)25 (5)00 (6)210 (7)01," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",120,60,15,,R2,3.46,1.59,1.37,76.2,431.0,3.96,15.0,19.0,136.0,73.0,9.0,7.82,2.39,57.0,268.0,34.0,23.0,4.6,4.4,78.0,263.0,,,,,,,,,,,,,1.5,6.69,8.36,,无, 无, p1泛(M1 PER),H0, 未做, CK+ CD4灶+ CD8+ VEGF灶+,25% 弱,15% 弱,20% 弱,20% 弱,8.902759526938238,1628168
1631823,刘宝奇,643461,男,50,T3,N3a,M0,ⅢB,1,3,,0.0,0.0,0.0,,7.0,37,,,1.0,,,,,,,,2016-09-14,2021-05-11,0,SOX*2,1.0,SOX,SOX,,,,,2, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)02 (1b)03 (2)25 (3a)37 (3b)00 (4sa)00 (4sb)00 (4d)03 (5)00 (6)01 (7)12 (8a)01 (8p)07 (9)11 (11p)02 (12a)00食管下端旁03," SiewerⅠ, 前Ant, 后Post, 小弯侧Less, GE,",25,25,10, R0 D2,,5.52,1.95,2.74,105.3,357.0,1.98,10.0,16.0,167.0,82.0,16.0,10.91,3.21,70.0,324.0,40.0,30.0,5.1,4.8,117.0,395.0,,,,,,,,,,,,,5.04,4.19,1.12, 未做,无,, P0,H0, 未做, CK（+）,,,,,55.84756898817346,1631823
1628699,宫传文,650029,男,59,T3,N1,M0, ⅡB,1,3,,1.0,1.0,1.0,,1.0,12,,,1.0,,0.0,,2.0,2.0,,,2016-08-22,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (3a)01 (3b) 00(4sb) 00(4d)02 (5) 00(6)13 (7) 00(8a)00 (8p) 01(9)04 (11p)01," L（幽门窦部）, 前Ant, 大弯侧Gre,",25,15,12, R0 D2+,,4.97,2.94,1.6,157.7,209.0,2.74,19.0,22.0,167.0,77.0,12.0,31.24,10.87,71.0,269.0,44.0,27.0,4.9,4.6,75.0,368.0,53.5,25.7,24.0,1.07,0.3,8.2,37.2,1.3,0.451,3.29,10.5,,0.718,11.47,9.92, 阳性+,,,,H0, 未做, CK +,70% 弱,80% 中,80% 中,80% 弱,72.30617608409986,1628699
1628711,康成勋,651505,男,61,T3,N0,M0, ⅡA,1,3,,1.0,1.0,1.0,,0.0,39,,,0.0,,2.0,,2.0,2.0,,,2016-08-22,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 管状腺癌（中分化【G2】【tub2】70 粘液腺癌（muc）30,G2, (3a)021 (3b)02 (4sb)01 (4d)04 (5)01 (6)02 (7)06 (8a)01 (8p)01 (9)00 (12a)00," L（幽门窦部）, 小弯侧Less,",20,15,5, R0 D2,,7.07,3.63,2.44,144.2,212.0,3.04,23.0,24.0,146.0,58.0,13.0,10.31,3.84,68.0,346.0,41.0,27.0,4.7,6.7,77.0,465.0,64.2,50.6,11.4,4.44,0.2,13.5,21.7,0.8,0.466,2.61,11.9,,5.92,2.21,2.93, 阳性+,无,, P0,H0, 未做,VEGF(+)、CD34(+) CD8（+）,70% 弱,80% 中,80% 中,70% 中,72.30617608409986,1628711
1628288,吴宝君,649499,男,44,T4a,N3a,M0, ⅢB,1,3,2.0,1.0,1.0,1.0, 异型增生+,8.0,28,中间型（int）,INFa,1.0,,0.0,,2.0,2.0,,,2016-08-18,2021-06-07,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)01 (2)02 (3a)02 (3b)00 (4sa)33 (4sb)00 (4d)02 (5)00 (6)04 (7)00 (8a)02 (8p)13 (9)01 (11p)13 (12a)01 (12p)01 小弯22," U（胃底部）, 后Post, 大弯侧Gre,",40,30,8, R0 D2,,6.12,3.35,1.76,160.0,308.0,3.07,32.0,24.0,180.0,95.0,35.0,8.08,2.59,61.0,379.0,39.0,22.0,5.0,5.4,82.0,350.0,,,,,,,,,,,,,1.99,6.94,6.54,,无,, P0,H0, 未做, CK+ CD4散在+ CD8局灶+ VEGF- CD31+  D2-40+  S-100+,60% 弱-中,50% 弱-中,80% 中-强,40% 弱,57.6215505913272,1628288
1628583,王英,649855,女,59,T4a,N2,M0, ⅢA,1,2,1.0,0.0,0.0,1.0, 慢性炎症（+）,3.0,37,髓样型（med）,INFa,0.0,,2.0,,2.0,2.0,,,2016-08-22,2020-03-16,2,,,SOX,SOX,SOX,SOX,SOX,SOX,9, 粘液腺癌（muc）85  低粘附腺癌10 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)5  Lauren混合型,G3, (1a)02 (3a)014 (3b)24 (4sb)00 (4d)03 (5)00 (6)03 (7)01 (8a)14 (8p)00 (9)04 (11p)01 (12a)01 (12p)00,LM 前Ant 后Post 大弯侧Gre  ,90,80,20, R0 D2,,5.76,2.92,2.25,71.0,430.0,2.46,8.0,15.0,173.0,70.0,9.0,6.94,2.59,63.0,159.0,37.0,26.0,4.9,4.8,77.0,161.0,60.3,35.9,20.5,1.75,0.1,11.1,25.2,0.2,0.843,3.2,10.4,,2.38,367.5,9.8, 阴性,无, 无, P0,H0, 未做,VEGF(-)、CD34(+) CD8（+）,80% 中,80% 中,80% 强,70% 弱,42.77266754270696,1628583
1629174,李英贤,651484,女,71,T3,N3a,M0,ⅢB,1,3,2.0,0.0,0.0,1.0, 正常,13.0,29,硬型（sci）,INFc,0.0,,0.0,,2.0,2.0,,,2016-08-25,2019-12-01,2,,,口服替吉奥,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a)02 (1b)22 (3a)24 (3b)02 (4d)22 (5)12 (6)44 (7)12 (8a)00 (8p)02 (9)12 (11p)03 (12a)00," L（幽门窦部）, 前Ant,",50,35,15, R0 D2,,9.09,5.97,2.13,145.4,236.0,4.21,9.0,14.0,130.0,89.0,7.0,8.2,2.91,65.0,188.0,38.0,27.0,5.3,4.7,83.0,307.0,,,,,,,,,,,,,1.78,13.39,6.39,,无, 无, P0,H0, 未做, CK+ CD4散在+ CD8散在+ VEGF- CD31-  D2-40 - S-100+,70% 弱-中,80% 中-强,80% 中-强,25% 弱,39.19185282522996,1629174
1628979,郭永利,650117,男,58,T4b,N2,M0, ⅢB,1,2,0.0,0.0,0.0,1.0, 正常,5.0,35,髓样型（med）,INFa,0.0,,0.0,,2.0,2.0,,,2016-08-24,2016-10-26,0,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】,G2," (3a)2,7 (4d)1,1 (6)2,12"," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",55,40,10, R0 D2,,7.02,3.81,2.64,116.1,353.0,4.82,27.0,19.0,167.0,116.0,40.0,5.51,1.68,75.0,431.0,42.0,33.0,5.2,4.5,117.0,544.0,71.3,36.5,28.0,1.3,0.1,4.0,20.4,2.6,1.55,6.37,15.2,,1.81,12.25,1.47,,无, 无, P0,H0, 未做, CK CD4  CD8  + VEGF - MLH1 PMS2 弱-中 MLH2 MLH6中,80% 弱-中,90% 中,55% 中,70% 弱,2.0696452036793693,1628979
1629582,赵金凤,653403,女,54,T3,N0,M0, ⅡA,1,3,,0.0,0.0,1.0,,0.0,21,,,2.0,,0.0,,2.0,2.0,,,2016-08-29,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】,G2, (4sb) (4d) (6)011 (1a) (1b) (3a) (3b) (5)010," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",40,30,10, R0 D2,,8.98,6.49,1.67,110.0,446.0,2.91,18.0,21.0,132.0,71.0,9.0,5.89,1.79,65.0,296.0,39.0,26.0,4.8,4.3,58.0,201.0,,,,,,,,,,,,,177.0,18.25,0.991,,无, 无, P0,H0, 未做, CK+ CD4部分+ CD8部分+ VEGF-,50% 弱-中,60% 弱-中,50% 中-强,40% 弱,72.07621550591327,1629582
1629429,王清,650038,女,58,T4a,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 肠化生+,5.0,25,中间型（int）,INFa,0.0,,0.0,,2.0,2.0,,,2016-08-26,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)00 (3b)11 (4sb)03 (4d)06 (5)22 (6)00 (7)01 (8a)12 (8p)01 (9)03 (11p)14 (12a)00," L（幽门窦部）, 小弯侧Less,",30,30,20, R0 D2,,5.85,3.09,2.08,123.0,305.0,3.48,12.0,15.0,159.0,66.0,14.0,7.16,2.26,66.0,252.0,39.0,27.0,5.1,5.3,83.0,272.0,,,,,,,,,,,,,1.93,37.84,0.725,,无, 无, P0,H0, 未做, CK+ CD4灶+ CD8散在+ VEGF- CD31-  D2-40-  S-100+,,,,,72.17477003942182,1629429
1629758,金明善,653450,男,70,T4b,N1,M0, ⅢB,1,3,0.0,1.0,1.0,0.0, 肠化生+,1.0,49,髓样型（med）,INFa,0.0,,0.0,,2.0,2.0,,,2016-08-30,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】70 乳头状癌（G1）（pap）30,G2, (2)03 (3a)09 (3b)15 (4sb)01 (4d)07 (5) 01(6)010 (7) 04(8a) 03(8p)01 (9)03 (11p)00 (12a)02   4d组见癌结节一枚," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,80,10, R0 D2+,,6.79,5.24,0.92,75.0,532.0,4.67,16.0,17.0,110.0,82.0,12.0,4.19,1.76,55.0,257.0,36.0,19.0,7.9,8.1,58.0,258.0,60.9,44.5,11.1,4.0,0.1,12.4,19.7,2.8,0.45,1.19,5.29,,5.23,5.1,62.21, 阳性+,,,,H0, 未做, CK +,5% 弱,80% 弱,80% 中,5% 弱,72.04336399474376,1629758
1629811,田伯秋,649783,男,70,T4a,N2,M1, Ⅳ,1,2,1.0,1.0,1.0,1.0, 正常,6.0,26,髓样型（med）,INFb,0.0,,0.0,,1.0,2.0,,,2016-08-30,2018-09-06,2,,,SOX,SOX,SOX,SOX,SOX,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌35 粘液腺癌（muc）5 Lauren混合型,G3, (1a) 00(1b)01 (2) 01(3a) 11(3b) 27(4sa)00 (4sb)01 (7)13 (8a)01 (8p)24 (11p)03 (12a)02 (9)02   1a组见癌," SiewerⅢ, U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,10,,R2,5.8,3.53,1.66,152.0,259.0,3.56,10.0,24.0,164.0,181.0,20.0,14.37,4.29,74.0,306.0,42.0,32.0,5.3,5.9,103.0,340.0,66.6,32.4,31.5,1.03,0.1,5.2,25.5,7.5,1.71,1.99,12.2,,4.1,16.66,3.37, 阳性+,,, P0,H0, 未做, CK +,80% 弱-中,90% 中,90% 中-强,70% 弱-中,24.21156373193167,1629811
1629709,李国志,648751,男,68,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,1.0, 正常,5.0,32,髓样型（med）,INFa,2.0,,0.0,,2.0,2.0,,,2016-08-30,2018-05-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)11 (3b)01 (4sa)23 (4sb)03 (4d)09 (5)01 (6)01 (7)01 (8a)212 (8p)00 (9)00 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",45,40,15, R0 D2,,6.54,3.83,2.04,107.6,301.0,3.9,16.0,21.0,170.0,78.0,7.0,9.19,3.02,68.0,181.0,39.0,29.0,3.7,9.2,95.0,597.0,,,,,,,,,,,,,144.0,26.55,2.64,,无, 无, P0,H0, 未做,CD4散在+ CD8散在+ VEGF-,75% 弱-中,80% 弱-中,90% 中-强,75% 弱,20.006570302233904,1629709
1639737,刘桂芬,649594,女,51,T4a,N0,M1, Ⅳ,1,4,2.0,0.0,0.0,1.0, 正常,0.0,22,硬型（sci）,INFc,1.0,,2.0,,2.0,2.0,,,2016-11-14,2017-04-04,2,紫杉醇腹腔热灌注*1、XELOX*2,1.0,,,,,,,0, 低粘附腺癌,GX, (1a)00 (1b)01 (2)01 (3a)01 (3b)03 (4sa)00 (4sb)00 (4d)01 (5)00 (6)03 (7)02 (8a)01 (8p)04 (9)03 (11p)00 (12a)01," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",140,60,10,,R2,6.71,3.1,2.57,133.0,379.0,1.99,15.0,21.0,129.0,70.0,15.0,26.46,7.06,74.0,320.0,43.0,31.0,4.6,4.2,59.0,229.0,,,,,,,,,,,,,1.97,7.09,0.864, 未做,无, 无, p1局肠缘(M1 PER),H0, 未做, CK+ VEGF+ CD4  CD8 + MLH170 MLH260 MLH680 PMS260,70% 弱-中,60% 中-强,80% 中-强,60% 弱-中,4.6320630749014455,1639737
1629764,黄金国,651249,男,71,T4a,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 正常,3.0,18,髓样型（med）,INFa,0.0,,2.0,,1.0,2.0,,,2016-08-30,2019-03-15,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren弥漫型,G3, (1a)13 (1b)01 (2)02 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)04 (5)11 (6)03 (7)01 (8a)00 (8p)00 (9)00 (11p)11 (12a)00," UM 前Ant, 后Post, 小弯侧Less,",90,70,10, R0 D2,,6.63,4.05,1.31,80.7,499.0,3.96,13.0,19.0,128.0,66.0,9.0,5.87,2.41,62.0,195.0,36.0,26.0,4.6,6.3,74.0,274.0,,,,,,,,,,,,,4.83,0.902,2.96,,无, 无, P0,H0, 未做, CK+ CD4小区+ CD8散在+ VEGF局灶+,20% 弱,80% 中,90% 中-强,10% 弱,30.453350854139288,1629764
1628894,张光石,653686,男,68,T3,N3a,M1, Ⅳ,1,4,,0.0,0.0,1.0,,12.0,19,,,1.0,,0.0,,2.0,2.0,,,2016-08-23,2016-11-15,2,,,口服替吉奥,口服替吉奥,,,,,2, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (4sb) (4d) (6)25 (1a) (1b) (3a) (3b) (5)710 冰冻6组34,UM,40,30,8,,R2,24.22,21.9,0.6,97.9,310.0,5.12,40.0,47.0,168.0,60.0,7.0,27.13,12.99,49.0,154.0,27.0,22.0,6.9,7.8,83.0,206.0,,,,,,,,,,,,,,,,,无, 无, P0,H0, 未做, CK+ CD4部分弱+ CD8散在+ VEGF-,60% 弱-中,80% 中,90% 强,45% 弱,2.759526938239159,1628894
1629753,吕秀珍,649944,女,74,T3,N1,M0, ⅡB,1,2,2.0,1.0,1.0,1.0, 肠化生+,1.0,38,髓样型（med）,INFa,0.0,,0.0,,2.0,2.0,,,2016-08-30,2021-06-01,0,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,6, 低分化腺癌（G3)(por),G3, (3a)011 (3b)06 (4sb)00 (4d)03 (5)01 (6)05 (7)04 (8a)11 (8p)02 (9)01 (11p)00 (12a)00 (12p)00 8p 软组织可见癌, L（幽门窦部） 前Ant 后Post 小弯侧Less ,90,60,10, R0 D2+,,5.24,3.33,1.26,101.0,348.0,3.93,19.0,24.0,210.0,49.0,5.0,4.46,1.61,45.0,154.0,27.0,18.0,5.1,3.8,57.0,204.0,75.8,48.7,18.8,2.59,0.2,4.2,17.3,3.2,0.529,1.83,5.69,,0.576,7.15,5.47,,无, 无, P0,H0, 未做," CD4(+),CD8(+),VEGF(+)",0,70% 弱-中,70% 中,0,57.03022339027595,1629753
1629535,鞠忠武,653457,男,52,T3,N2,M0, ⅢA,1,5,,1.0,1.0,1.0,,4.0,33,,,0.0,,0.0,,1.0,2.0,,,2016-08-29,2022-09-01,1,,,XELOX,,,,,,1," 低粘附腺癌70， 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por,30",G3, 大、小弯112(1a)03 (1b)04 (2)00 (3a)01 (3b)00 (4sa)00 (4sb)00 (5)00 (6)05 (7)00 (8a)11 (8p)11 (9)02  (11p)13 (12a)00," L（幽门窦部）, 小弯侧Less,",30,20,10, R0 D2,,11.71,10.09,1.01,118.0,223.0,3.07,19.0,23.0,164.0,64.0,31.0,13.0,4.06,57.0,348.0,36.0,21.0,4.8,4.3,65.0,311.0,,,,,,,,,,,,,3.64,14.07,0.755, 未做,无, 无, P0,H0, 未做," CK+ S-100可见 CD31  D2-40可见  MLH1,40%,弱 MLH2，60%，中 MLH6，60%，中-强 PMS2，25%，弱 CD4 +， CD8 + VEGF-",40% 弱,60% 中,60% 中-强,25% 弱,72.07621550591327,1629535
1630407,张录,653740,男,73,T4b,N2,M0, ⅢB,1,4,2.0,1.0,1.0,1.0, 肠化生+,3.0,23,髓样型（med）,INFa,0.0,,2.0,,1.0,1.0,,,2016-09-05,2018-09-20,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (3a)12 (3b)02 (4sb)00 (4d)03 (5)00 (6)23 (7)01 (8a) (8p)02 (9)05 (11p)05,L（幽门窦部） 前Ant 后Post 小弯侧Less ,70,65,15, D1,R2,7.28,3.99,2.43,84.6,582.0,27.8,9.0,15.0,134.0,112.0,15.0,7.35,2.0,65.0,224.0,36.0,29.0,4.7,4.6,99.0,246.0,63.1,27.3,33.5,0.81,0.4,5.3,27.8,2.0,0.685,1.76,13.4,,0.556,5.71,7.94, 阴性,无,, P0,H0, 未做, CD31（+） D2-40（+）S-100（+)              CD4(+) CD8(+)VEGF(+),0,50% 中,85% 中-强,0,24.47437582128778,1630407
1629877,王乃香,653812,女,65,T3,N1,M0, ⅡB,1,2,2.0,1.0,1.0,1.0, 正常,1.0,19,中间型（int）,INFc,0.0,,0.0,,2.0,2.0,,,2016-08-31,2018-03-16,2,,,SOX,SOX,SOX,SOX,SOX,口服替吉奥,6, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (3a)01 (3b)00 (4sb)00 (4d)12 (5)01 (6)03 (7)04 (8a)02 (8p)02 (9)01 (11p)03," L（幽门窦部）, 大弯侧Gre,",30,25,7, R0 D2,,6.31,4.19,1.41,130.5,244.0,2.61,12.0,16.0,127.0,64.0,12.0,25.62,8.45,67.0,226.0,40.0,27.0,5.2,4.3,80.0,300.0,68.0,46.0,16.3,2.82,0.4,21.1,9.0,1.1,1.32,3.15,12.1,,0.424,11.17,1.04,,无, 无, P0,H0, 未做,ck(+)  VEGF(-) CD4散在(+)  CD8散在(+),80% 弱-中,80% 中,80% 强,30% 弱,18.462549277266753,1629877
1629947,姜全政,652415,男,77,T3,N2,M0, ⅢA,1,4,2.0,0.0,0.0,1.0, 肠化生+,4.0,26,硬型（sci）,INFc,0.0,,1.0,,1.0,2.0,,,2016-08-31,2022-09-01,1,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)02 (3a)45 (3b)00 (4sa)01 (4sb)01 (4d)00 (5)00 (6)00 (7)02 (8a)02 (8p)03 (9)06 (11p)03,U（胃底部） 大弯侧Gre  前Ant 后Post 小弯侧Less ,40,30,, R0 D2,,6.39,3.46,2.21,138.6,222.0,2.27,16.0,24.0,206.0,50.0,25.0,13.56,5.81,65.0,235.0,42.0,23.0,4.6,7.8,93.0,279.0,56.3,35.4,17.3,2.05,0.5,5.3,35.0,0.8,0.486,2.18,9.77,,1.43,1000.0,1.36,,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4(+)  CD8散在(+),20% 弱,40% 中,40% 强,20% 弱,72.01051248357425,1629947
1629514,滕大君,653782,男,67,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,21,,,2.0,,0.0,,1.0,2.0,,,2016-08-29,2021-08-10,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)08 (3a)03 (3b)00 (4sb)01 (4d)02 (5)00 (6)02 (7)03 (8a)00 (8p)00 (9)02 (11p)00 (12a)00," M（胃体部）, 小弯侧Less,",25,25,8, R0 D2,,7.05,4.03,2.25,138.7,192.0,3.01,21.0,23.0,150.0,56.0,12.0,17.22,4.83,74.0,396.0,43.0,31.0,5.0,5.2,86.0,269.0,,,,,,,,,,,,,0.998,14.77,9.33,,无, 无, P0,H0, 未做, CK+ CD4部分+ CD8散在+ VEGF- CD31-  D2-40-  S-100-,0,40% 弱,80% 强,0,59.36268068331143,1629514
1629536,杨海,653461,男,45,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,30,,,0.0,,,,,,,,2016-08-29,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)02 (1b)03 (3a)01 (3b)01 (4sb)00 (4d)03 (5)00 (6)04 (7)00 (8a)03 (8p)03 (9)07 (11p)03," L（幽门窦部）, 小弯侧Less,",20,20,, R0 D2,,4.6,2.59,1.52,122.6,175.0,1.8,16.0,16.0,127.0,67.0,27.0,9.79,4.03,62.0,306.0,41.0,21.0,5.3,4.1,81.0,331.0,77.0,60.7,14.6,4.16,0.2,12.4,4.9,0.9,1.22,0.617,8.1,,1.51,10.06,0.7, 阴性,无, 无, P0,H0, 未做, CK +,,,,,72.07621550591327,1629536
1629765,孟繁荣,624674,男,63,T4b,N3b,M0, ⅢC,1,2,,1.0,1.0,1.0,,25.0,33,,,1.0,,2.0,,1.0,2.0,,,2016-08-30,2017-07-18,0,SOX*2,1.0,SOX,SOX,SOX,SOX,SOX,,5, 低分化腺癌（G3)(por) 低粘附腺癌,G3, (1a)22 (1b)00 (2)22 (3a)24 (3b)12 (4sa)00 (4sb)00 (4d)00 (5)01 (6)22 (7)36 (8a) (8p)55 (9)11 (11p)22 (12p)01 (111)11," UM 后Post, 大弯侧Gre, 小弯侧Less,",100,60,30,,R1,7.78,5.79,1.05,129.8,314.0,4.43,41.0,34.0,246.0,162.0,120.0,10.5,6.3,67.0,158.0,38.0,29.0,12.7,5.76,85.0,111.0,,,,,,,,,,,,,1.71,12.8,5.44,,无, 无, P0,H0, 未做, CK+ CD34+  D2-40+  S-100+,70% 中,80% 中,90% 强,60 弱,10.578186596583443,1629765
1630111,廉登贤,653407,女,61,T4a,N1,M0, ⅢA,1,2,2.0,0.0,0.0,1.0,,2.0,22,中间型（int）,INFb,0.0,,1.0,,1.0,1.0,,,2016-09-01,2019-04-25,0,,,口服卡培他滨,,,,,,1, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)1/2 (1b)1/2," M（胃体部）, U（胃底部）, 后Post, 小弯侧Less,",50,40,20, R0 D2,,9.01,66.14,2.32,129.0,400.0,4.1,11.0,16.0,158.0,87.0,16.0,8.52,2.74,74.0,347.0,45.0,29.0,5.5,9.8,82.0,354.0,,,,,,,,,,,,,0.908,9.28,1.34,,无, 无, P0,H0, 未做,,70% 中,80% 中,90% 强,70% 弱-中,31.734559789750328,1630111
1629699,王文鹏,650105,男,54,T3,N1,M0, ⅡB,1,3,,1.0,1.0,1.0,,2.0,32,,,0.0,,0.0,,2.0,2.0,,,2016-08-30,2018-05-21,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30,G3, (1a)00 (1b)00 (3a)01 (3b)04 (4sb)00 (4d)04 (5)00 (6)03 (7)05 (8a)03 (8p)02 (9)01 (11p)00 (12a)29," L（幽门窦部）, 前Ant,",25,20,3, R0 D2,,6.66,3.06,2.53,152.3,172.0,2.95,52.0,35.0,126.0,50.0,49.0,15.02,6.59,75.0,307.0,41.0,34.0,4.6,6.3,83.0,369.0,,,,,,,,,,,,,0.495,10.78,0.836,,无, 无, P0,H0, 未做, CK+ CD4散在+ CD8散在+ VEGF- CD31+  D2-40+  S-100+,80% 弱-中,80% 中,90% 强,70% 弱-中,20.66360052562418,1629699
1629663,王忠仁,653394,男,59,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 肠化生+,0.0,59,中间型（int）,INFc,0.0,,0.0,,2.0,2.0,,,2016-08-30,2017-07-06,0,,,XELOX,XELOX,XELOX,XELOX,SOX,,5, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)04 (1b)04 (3a)02 (3b)03 (4sb)012 (4d)010 (5)00 (6)00 (7)07 (8a)01 (8p)01 (9)010 (11p)01 (12a)02," L（幽门窦部）, 小弯侧Less,",50,30,10, R0 D2,,7.83,4.55,2.71,126.7,272.0,3.26,13.0,17.0,125.0,47.0,27.0,5.72,2.36,63.0,335.0,41.0,22.0,4.9,3.5,57.0,373.0,,,,,,,,,,,,,1.31,0.6,0.74,,无, 无, P0,H0, 未做, CK+ CD4散在+ CD8散在+ VEGF-,60% 弱-中,70% 弱-中,90% 中-强,40% 弱,10.183968462549277,1629663
1630152,柏键锋,649950,男,57,T2,N0,M0, ⅠB,1,2,2.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,39,中间型（int）,INFa,0.0,,1.0,,1.0,2.0,,,2016-09-01,2022-09-01,1,,,XELOX,SOX,SOX,SOX,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren弥漫型,G3, (1a) 00(1b)00 (3a)02 (3b) 00(4sb)00 (4d) 08(5)01 (6)011 (7)04 (8a) 03(8p)02 (9)05 (11p)03 (12a)00," L（幽门窦部）, 后Post,",25,20,6, R0 D2,,5.44,3.03,1.65,150.0,190.0,3.4,17.0,20.0,144.0,69.0,42.0,13.65,5.41,73.0,437.0,43.0,30.0,4.7,5.8,74.0,371.0,,,,,,,,,,,,,1.97,8.16,1.35, 未做,无, 无, P0,H0, 未做, CK+， S-100可见。 D2-40  CD31 可见 MLH1，40%弱-中 MLH2，60%中-强 MLH6 60% PMS2，30%，弱 CD4+  CD8+  VEGF+,40% 弱-中,60% 中-强,60% 强,30% 弱,71.97766097240472,1630152
1629948,李瑞祥,653753,男,58,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,13,,,1.0,,,,,,,,2016-08-31,2020-06-09,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b) 00(3a) 04(3b) 00(4sb)00 (4d)05 (5)00 (6)01 (8a) 01(7)01 (9)01 (11p) 00(12a)00," L（幽门窦部）, 大弯侧Gre,",30,22,, R0 D2+,,5.43,2.81,1.93,126.0,225.0,2.44,22.0,19.0,151.0,74.0,62.0,10.35,4.17,59.0,338.0,37.0,22.0,5.1,4.3,77.0,465.0,,,,,,,,,,,,,0.617,8.66,1.94,,,, P0,H0, 未做, CK +,,,,,45.269382391590014,1629948
1630406,姜丽艳,653495,女,60,T4b,N2,M0, ⅢB,1,2,1.0,0.0,0.0,1.0, 正常,5.0,21,中间型（int）,INFc,2.0,,1.0,,2.0,2.0,,,2016-09-05,2021-02-24,2,,,,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌 20 Lauren混合型,G3, (1a)24 (1b)12 (2)00 (3a)00 (3b)00 (4sa)02 (4sb)22 (4d)00 (7)00 (8a)04  (9)02 (11p)05   1b软组织可见癌," U（胃底部）, 后Post,",35,30,8, R0 D2,,5.77,1.35,3.7,114.0,346.0,3.56,13.0,21.0,185.0,82.0,16.0,8.42,1.99,70.0,296.0,41.0,29.0,4.9,4.8,68.0,137.0,68.0,42.0,14.3,2.94,1.0,7.1,22.6,6.3,2.55,3.37,9.73,,0.715,11.98,2.96,,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),60% 弱-中,80% 中-强,90% 强,30% 弱-中,53.64651773981603,1630406
1630899,邸文景,649591,男,78,T4b,N2,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,31,中间型（int）,INFb,0.0,,1.0,,1.0,2.0,,,2016-09-08,2020-02-07,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)00 (1b)02 (3a)05 (3b)11 (4sb)00 (4d)04 (5)00 (6)12 (7)05 (8a)14 (8p)01 (9)03 (11p)02 (12a) 00  3、5、6、12a软组织可见癌 肿物旁22,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,40,35,15,,R1,6.06,3.75,1.65,137.0,247.0,2.61,18.0,21.0,187.0,84.0,20.0,8.13,2.84,61.0,240.0,36.0,25.0,4.5,5.6,103.0,586.0,43.9,29.8,10.1,2.95,0.1,6.9,47.1,1.9,1.2,2.77,9.2,,1.02,6.44,1.64, 阴性,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4(+)  CD8散在(+),60% 弱-中,70% 中,90% 强,30% 弱,40.9658344283837,1630899
1630473,杨斌,653508,男,56,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,28,,,0.0,,,,,,,,2016-09-05,2020-06-22,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30,G2, (3a)09 (3b)02 (4sb)00 (4d)02 (5)00 (6)06 (7)02 (8a)01 (8p)02 (9)03 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",25,20,3, R0 D2,,7.94,4.74,2.59,160.0,230.0,2.79,21.0,26.0,178.0,46.0,16.0,17.13,5.86,65.0,301.0,42.0,23.0,4.8,7.0,73.0,247.0,,,,,,,,,,,,,7.58,18.44,0.856, 阴性,无, 无, P0,H0, 未做,,,,,,45.532194480946124,1630473
1630404,吴凤林,655336,男,62,T4b,N3a,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 正常,8.0,62,中间型（int）,INFc,0.0,,2.0,,2.0,2.0,,,2016-09-05,2018-05-23,2,,,XELOX,,,,,,1, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren弥漫型,G3, (1a)01 (1b)01 (2)03 (3a)020 (3b)00 (4sa)01 (4sb)00 (4d)00 (5)04 (6)00 (7)59 (8a)09 (9)05 (11p)36 (12a)03 (7)(9)软组织可见癌," M（胃体部）, 后Post, 小弯侧Less,",40,40,10, R0 D2+,,5.3,3.32,1.53,111.4,271.0,1.87,13.0,18.0,169.0,75.0,14.0,6.23,2.09,64.0,295.0,38.0,26.0,4.9,7.7,75.0,236.0,81.2,43.3,32.1,2.03,0.5,3.1,13.8,2.6,1.87,2.21,7.8,,,,, 阳性+++,无,, P0,H0, 未做, CD4 散在+ CD8散在+ VEGF小区弱+,60% 弱,40% 中,60% 强,30% 弱,20.532194480946124,1630404
1630810,杜茂刚,655313,男,39,T1b,N0,M0,ⅠA,1,3,,,,,,0.0,31,,,1.0,,,,,,,,2016-09-07,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)01 (3a)09 (3b)00 (4sb)03 (4d)00 (5)00 (6)00 (7)02 (8a)03 (8p)01 (9)07 (11p)03 (12a)01," M（胃体部）, 小弯侧Less,",14,12,1, R0 D2+,,8.21,4.35,2.98,155.0,252.0,2.2,13.0,17.0,175.0,88.0,10.0,11.05,4.17,70.0,388.0,43.0,27.0,5.0,6.1,82.0,379.0,72.9,50.0,18.4,2.72,0.3,17.3,8.9,0.9,0.652,2.15,10.4,,1.39,5.19,3.23, 阳性++,无,, P0,H0, 未做, CK +,,,,,71.78055190538764,1630810
1630449,苏国兴,653578,男,48,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,38,,,0.0,,,,,,,,2016-09-05,2022-09-01,1,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30 低粘附腺癌70,G3, (1a)01 (1b)03 (3a)03 (3b)02 (4sb)00 (4d)03 (5)00 (6) 05(7) 04(8a)05 (8p)04 (9)03 (11p)03 (12a)02," L（幽门窦部）, 小弯侧Less,",60,50,, R0 D2,,6.7,2.53,3.11,135.0,318.0,2.42,26.0,20.0,140.0,81.0,40.0,8.31,3.47,66.0,399.0,42.0,24.0,4.9,5.9,75.0,353.0,71.3,46.0,21.3,2.16,0.5,10.4,16.9,2.2,0.987,2.94,6.69,,0.753,8.91,0.747, 阴性,无,, P0,H0, 未做, CK +,,,,,71.84625492772668,1630449
1630454,范洪军,653542,男,46,T1b,N0,M0,ⅠA,1,3,,0.0,0.0,1.0,,0.0,35,,,0.0,,,,,,,,2016-09-05,2022-09-01,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)05 (1b)03 (3a)02 (3b)00 (4sb)00 (4d)02 (5)01 (6)07 (7)03 (8a)03 (8p) (12a)02 (9)01 (11p)05 (16a1)05," L（幽门窦部）, 小弯侧Less, 后Post,",20,20,5, R0 D2,,9.64,8.27,0.7,117.8,136.0,2.37,23.0,18.0,164.0,47.0,10.0,15.99,6.8,54.0,157.0,33.0,21.0,6.9,5.8,72.0,112.0,,,,,,,,,,,,,4.59,14.85,0.8,,无, 无, P0,H0, 未做, CK + CD31-  D2-40 - S-100+,,,,,71.84625492772668,1630454
1631538,许双奎,655354,男,65,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,8.0,33,髓样型（med）,INFa,3.0,,2.0,,2.0,2.0,,,2016-09-13,2018-06-10,2,,,SOX,SOX,SOX,SOX,SOX,SOX,7, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)14 (2)13 (3a)24 (3b)00 (4sa)00 (4sb)00 (4d)04 (5)00 (6)02 (7)24 (8a)03 (8p)03 (9)22 (11p)02 (12a)00," UM 小弯侧Less,",35,25,10, R0 D2,,9.32,6.22,2.3,121.3,376.0,3.07,22.0,19.0,157.0,66.0,26.0,11.52,4.22,70.0,231.0,41.0,29.0,7.9,3.6,76.0,296.0,,,,,,,,,,,,,6.78,27.39,3.26,,无, 无, P0,H0, 未做, CK+ CD4小区+ CD8散在+ VEGF部分弱+,50% 弱,80% 中,80% 强,25% 弱,20.86070959264126,1631538
1630664,史长海,649611,男,62,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0,,0.0,59,中间型（int）,INFa,0.0,,1.0,,1.0,1.0,,,2016-09-18,2018-11-01,2,,,SOX,SOX,多西他赛联合顺铂,多西他赛联合顺铂,,,4, 低分化腺癌（G3)(por),G3,," L（幽门窦部）, 小弯侧Less,",20,18,10, R0 D2,,9.66,6.08,2.72,144.0,210.0,4.12,15.0,19.0,173.0,84.0,12.0,13.52,5.6,72.0,176.0,40.0,32.0,4.3,4.4,91.0,330.0,,,,,,,,,,,,,4.07,17.17,2.62, 未做,无,, P0,H0, 未做,  VEGF+ CD4  CD8 （+）,40% 中,40% 中,70% 强,30% 弱,25.427069645203677,1630664
1630897,贾新明,655378,男,61,T1b,N2,M0, ⅡA,1,3,,1.0,1.0,1.0,,6.0,18,,,0.0,,2.0,,1.0,2.0,,,2016-09-08,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌90 低分化腺癌（G3)(por)10,G3, 小弯11 (1a)00 (1b)00 (3a)01 (3b)11 (4sb)00 (4d)13 (5)02 (6)12 (7)01 (8a)11 (8p)00 (9)01 (11p)03 (12a)12," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,15,5, R0 D2+,,7.02,3.47,2.86,165.0,184.0,2.14,129.0,48.0,159.0,59.0,50.0,18.88,5.96,70.0,298.0,41.0,29.0,5.8,6.5,82.0,380.0,71.1,41.9,27.5,1.52,0.5,6.1,20.2,1.5,0.427,2.45,11.2,,4.51,7.96,0.838, 未做,无,, P0,H0, 未做, CK + CD4 + CD8散在+ VEGF弱+,60% 弱-中,50% 中,50% 强,60% 弱-中,71.74770039421813,1630897
1631012,吴学艳,653638,女,63,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 肠化生+,22.0,33,髓样型（med）,INFa,2.0,,1.0,,1.0,1.0,,,2016-09-08,2016-12-02,2,,,,,,,,,0, 低分化腺癌（G3)(por)65 低粘附腺癌30 粘液腺癌（muc）5 Lauren弥漫型,G3, (1a)33 (1b)01 (2)01 (3a)12 (3b)22 (4sa)00 (4sb)00 (4d)01 (5)11 (6)710 (7)03 (8a)11 (8p)12 (9)00 (12a)11 (12b)11 (12p)22 (13)22," LMU 前Ant, 后Post, 小弯侧Less,",80,45,10,,R2,5.43,3.53,1.15,81.2,202.0,3.52,10.0,17.0,196.0,72.0,16.0,6.09,1.62,56.0,176.0,31.0,25.0,5.1,4.2,67.0,319.0,65.1,42.4,19.0,2.23,0.1,10.4,21.0,0.2,0.665,1.83,10.1,,,,, 未做,无, 无, P0,H0, 未做, CK + CD4 + CD8+ VEGF+,90% 中,90% 中-强,80% 强,70% 弱,2.7923784494086727,1631012
1630759,翟国柱,649732,男,51,T2,N0,M0, ⅠB,1,3,,1.0,1.0,1.0,,0.0,10,,,2.0,,1.0,,1.0,2.0,,,2016-09-07,2021-08-10,1,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)95 粘液腺癌（muc）5,G3, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)02 (5)00 (6)01 (7)01 (8a) (8p) (9)05 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",20,15,, R0 D2,,5.31,2.8,1.72,150.0,194.0,1.86,37.0,36.0,168.0,62.0,16.0,15.8,6.41,61.0,291.0,39.0,22.0,4.8,5.2,79.0,302.0,,,,,,,,,,,,,1.02,6.09,3.29, 未做,无, 无, P0,H0, 未做, CK+ CD4+ CD8散在+ VEGF+,0,90% 中,90% 强,0,59.0670170827858,1630759
1630762,刘淑芳,653690,女,61,T1a,N0,M0,ⅠA,1,0,,,,, 正常,0.0,16,,,1.0,,,,,,,,2016-09-07,2021-07-20,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)01 (1b)03 (3a)01 (3b)00 (4sb)00 (4d)04 (5)00 (6)04 (7)01 (8a)01 (9)01 (12a)00," L（幽门窦部）, 小弯侧Less,",20,20,, R0 D2,,8.07,5.39,1.96,146.0,233.0,2.65,26.0,24.0,221.0,72.0,16.0,15.65,4.69,70.0,309.0,42.0,28.0,4.2,6.7,65.0,252.0,70.4,46.2,21.3,2.17,0.4,8.3,18.8,0.8,1.21,3.03,9.61,,1.02,8.1,0.773,,无, 无, P0,H0, 未做, CK +,,,,,58.37713534822601,1630762
1631011,王淑琴,653991,女,65,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,7.0,38,中间型（int）,INFc,0.0,,1.0,,1.0,1.0,,,2016-09-08,2018-02-17,2,,,口服替吉奥,,,,,,1, 低粘附腺癌 低分化腺癌（G3)(por)40% Lauren肠型,G3, (1a)02 (1b)00 (2)04 (3a)36 (3b)11 (4sb)03 (4d)19 (5)00 (6)01 (7)22 (8a)03 (8p)04 (9)02 (11p)01   3a、3b、5组及7组软组织可见癌," LM 前Ant, 后Post, 小弯侧Less,",50,30,10, D2,,5.67,3.19,2.16,132.0,270.0,2.91,14.0,18.0,149.0,71.0,13.0,9.18,3.0,69.0,196.0,41.0,28.0,5.5,4.6,79.0,197.0,,,,,,,,,,,,,0.856,6.74,5.12, 阳性+,无, 无, P0,H0, 未做, CK+ CD4+ CD8+  VEGF+,40% 弱,70% 中,60% 中-强,20% 弱,17.31274638633377,1631011
1630937,刘养文,654003,男,59,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,31,,,0.0,,2.0,,1.0,1.0,,,2016-09-08,2021-08-10,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2,小弯02 (1a)07 (1b)01 (2)02 (3a)07 (3b)01 (4sa)00 (4sb)00 (5)00 (7)01 (8a)01 (8p)01 (9)04 (11p)04 (12a)00," U（胃底部）, 后Post,",20,20,5, D2,,11.42,7.21,3.16,100.7,231.0,2.91,20.0,22.0,129.0,65.0,28.0,4.03,1.8,59.0,280.0,35.0,24.0,12.2,6.2,73.0,244.0,,,,,,,,,,,,,,10.95,2.25,,无, 无, P0,H0, 未做, CK+ CD4+ CD8+  VEGF弱+,80% 中,70% 中-强,60% 强,30% 弱,59.03416557161629,1630937
1631542,王淑清,654431,女,52,T4b,N2,M1, Ⅳ,1,4,2.0,1.0,1.0,1.0, 正常,6.0,17,硬型（sci）,INFc,0.0,,1.0,,1.0,2.0,,,2016-09-13,2019-05-05,2,,,贝伐珠单抗+多西他赛+替吉奥,贝伐珠单抗+多西他赛+替吉奥,贝伐珠单抗+多西他赛+替吉奥,贝伐珠单抗+多西他赛+替吉奥,贝伐珠单抗+多西他赛+替吉奥,贝伐珠单抗+多西他赛+替吉奥,6, 低分化腺癌（G3)(por) 低粘附腺癌20 Lauren弥漫型,G3,,"前Ant, 后Post, 大弯侧Gre, 小弯侧Less, MU",100,100,10,,R2,7.16,4.15,2.33,132.8,319.0,2.79,29.0,21.0,144.0,51.0,31.0,11.29,2.78,72.0,290.0,41.0,31.0,5.4,6.3,71.0,341.0,,,,,,,,,,,,,,,,,粟粒状, 双侧, p1泛(M1 PER),H0, 未做,,20% 弱,30% 中,30% 中-强,20% 弱-中,31.6688567674113,1631542
1631537,杨明宝,653588,男,38,T1b,N0,M0,ⅠA,1,3,,0.0,0.0,1.0,,0.0,22,,,0.0,,1.0,,2.0,2.0,,,2016-09-13,2021-07-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10 低粘附腺癌90,G3, (3a) 04(3b)02 (4sb)00 (4d)02 (5)01 (6)05 (7)01 (8a)02 (8p)00 (9)01 (11p)02 (12a)00 (12p)00 (14v)02,M（胃体部） 前Ant 后Post 小弯侧Less ,30,25,10, R0 D2,,9.02,6.18,2.05,163.0,267.0,2.54,14.0,14.0,161.0,74.0,37.0,16.34,4.91,66.0,469.0,42.0,24.0,5.1,9.9,80.0,249.0,68.3,41.6,21.7,1.92,0.5,13.8,17.4,1.0,0.659,1.49,6.75,,0.94,4.34,3.15, 未做,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),10% 弱,40% 弱-中,10% 弱,5% 弱,58.21287779237845,1631537
1631102,樊淑丽,655434,女,53,T1a,N0,M0,ⅠA,1,2,,,,,,0.0,20,,,0.0,,,,,,,,2016-09-09,2018-01-23,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)04 (3a)02 (3b)00 (4sb)00 (4d)02 (5)00 (6)02 (7)01 (8a)02 (8p)03 (9)04 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",15,10,1, R0 D2,,6.9,4.13,2.02,137.3,274.0,2.65,19.0,21.0,229.0,86.0,21.0,10.19,3.63,64.0,266.0,38.0,26.0,5.1,4.2,62.0,174.0,,,,,,,,,,,,,1.92,8.66,10.79,,无, 无, P0,H0, 未做, CK+,,,,,16.45860709592641,1631102
1631485,谷晨虹,649756,男,61,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,24,,,0.0,,,,,,,,2016-09-13,2021-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)03 (1b)02 (3a)04 (3b)00 (4sb)00 (4d)04 (5)01 (6)03 (7)01 (8a)02 (8p)01 (9)02 (11p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",18,18,4, R0 D2+,,7.6,4.62,2.16,134.8,396.0,4.48,11.0,15.0,188.0,101.0,16.0,5.73,1.91,63.0,272.0,36.0,27.0,5.5,6.5,81.0,409.0,,,,,,,,,,,,,3.67,11.6,4.85, 阳性++,无,, P0,H0, 未做, CK +,,,,,59.592641261498024,1631485
1631487,王坤,649593,男,41,T3,N1,M0, ⅡB,1,3,2.0,0.0,0.0,1.0, 正常,1.0,16,髓样型（med）,INFc,0.0,,2.0,,1.0,2.0,,,2016-09-13,2020-01-01,2,,,DCX,DCX,DCX,DCX,DCX,DCX,10, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)02 (1b)01 (3b)01 (4sb00) (4d)00 (5)00 (6)03 (14v)00 (7)01 (8a) (8p)01 (9)02 (11p)03 (12a)01," M（胃体部）, 后Post,",35,25,6, R0 D2,,12.97,10.4,1.33,135.7,260.0,2.02,69.0,25.0,177.0,61.0,58.0,36.22,12.18,71.0,463.0,42.0,29.0,4.9,8.3,100.0,513.0,,,,,,,,,,,,,0.221,4.71,0.935,,无, 无, P0,H0, 未做,,60% 弱-中,80% 中,60% 中-强,60 弱,39.58607095926413,1631487
1631539,孙忠琴,653811,女,63,T3,N3b,M0, ⅢC,1,4,1.0,1.0,1.0,1.0, 正常,16.0,34,中间型（int）,INFa,0.0,,1.0,,2.0,2.0,,,2016-09-13,2017-10-19,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1b)00 (3a)1112 (3b)00 (4sb)00 (4d)47 (5)00 (6)03 (7)13 (8a) (8p)09 (9)00 (11p)00 (12a)00 (1a)00, M（胃体部） L（幽门窦部） 前Ant 后Post 大弯侧Gre 小弯侧Less ,40,30,18, R0 D2,,6.23,3.52,2.16,133.0,206.0,2.79,12.0,22.0,174.0,82.0,11.0,12.85,3.75,68.0,239.0,41.0,27.0,4.8,5.2,82.0,262.0,66.2,27.8,22.1,1.26,0.5,16.7,15.0,0.2,0.621,2.12,10.5,,2.72,24.6,1.74, 阴性,无, 无, P0,H0, 未做,Ck（+）CD31(+) D2-40(+)S-100(+),15% 中,60% 中,50% 中-强,15% 弱-中,13.173455978975033,1631539
1631824,倪永军,653647,男,59,T4b,N0,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 正常,0.0,18,硬型（sci）,INFc,0.0,,1.0,,2.0,2.0,,,2016-09-14,2020-05-22,0,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)02 (1b)00 (3a)06 (3b)00 (4sb) 00(4d)03 (5) 00(6) 01(7) 00(8a)01 (8p)01 (9)03 (11p)00 (12a)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,20,10, R0 D2,,9.58,7.35,1.04,144.6,202.0,6.81,15.0,17.0,180.0,52.0,29.0,19.97,5.22,65.0,324.0,37.0,28.0,5.1,6.9,121.0,535.0,,,,,,,,,,,,,0.859,6.71,5.66, 阴性,无, 无, P0,H0, 未做, CK （+）VEGF（+）CD4+ CD8+ S-100神经染色显示可见神经侵犯 CD31、D2-40显示未见明确脉管瘤栓， MLH1 70% 染色强度为中，  MSH2 70% 染色强度为强 ，MSH6 90% 染色强度为强， PMS2 60% 染色强度为弱,70% 中,70% 强,90% 强,60% 弱,44.21813403416557,1631824
1631699,刘吉勇,653823,男,38,T1b,N1,M0, ⅠB,1,3,,1.0,1.0,0.0,,2.0,28,,,0.0,,,,,,,,2016-09-14,2021-07-22,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por),G3, (1a) 02(1b)01 (3a) 111(3b)00 (4sb)00 (4d)04 (5)11 (6)02 (7)01 (8a)02 (8p) (9)02 (11p)02 (12a)00 (14v)00, L（幽门窦部） 小弯侧Less ,12,10,8, R0 D2,,5.13,2.68,2.09,157.0,234.0,2.11,11.0,39.0,190.0,66.0,14.0,12.27,4.56,55.0,232.0,31.0,24.0,4.6,5.6,93.0,323.0,79.3,32.9,36.8,0.89,0.7,7.9,10.4,3.0,1.07,1.74,13.4,,0.239,4.09,12.96, 未做,无,, P0,H0, 未做, CK +,,,,,58.21287779237845,1631699
1631580,张文库,653918,男,62,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 肠化生+,4.0,29,,,0.0,,1.0,,2.0,2.0,,,2016-09-13,2021-10-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 低粘附腺癌20,G3,," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less, 后Post,",40,30,15,,,11.07,8.61,1.78,142.0,307.0,3.58,12.0,15.0,150.0,89.0,14.0,11.29,4.12,62.0,207.0,38.0,24.0,4.7,4.5,79.0,285.0,,,,,,,,,,,,,2.88,62.07,1.04,,无,, P0,H0, 未做, VEGF（+）,80% 中,60% 中-强,70% 强,90% 弱-中,60.57818659658344,1631580
1631825,陶艳芝,653912,女,56,T3,N3a,M1, Ⅳ,1,4,2.0,0.0,0.0,1.0, 正常,13.0,23,中间型（int）,INFc,1.0,,1.0,,1.0,2.0,,,2016-09-15,2017-07-20,2,,,,,,,,,0, 低粘附腺癌 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01（1b)00（2)00（3a)22（3b)02（4sa)00（4sb)00（4d)00（5)02（6)00（7)22（8a)(8p)01（9)37（11p)00（12a)44," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",80,40,15,,R1,5.72,3.44,1.9,145.0,225.0,3.28,14.0,31.0,200.0,55.0,7.0,9.54,4.32,54.0,117.0,31.0,23.0,7.1,4.0,71.0,342.0,,,,,,,,,,,,,0.893,0.709,0.889, 阴性,无, 单侧, P0,H0, 未做,CK+ CD4+ CD8+ VEGF+ CD31  D2-40 未见瘤栓 S-100可见神经侵犯 MLH1（60% 弱-中） MLH2（75% 中） MLH6 （80% 强）PMS2（40% 中）,30% 中,60% 中,60% 强,40% 弱,10.11826544021025,1631825
1631884,郭艳春,654116,男,60,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,1.0, 肠化生+,0.0,29,中间型（int）,INFa,2.0,,2.0,,1.0,2.0,,,2016-09-18,2017-07-23,0,,,口服卡培他滨,口服卡培他滨,,,,,2, 腺癌 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)03 (3a)08 (3b)01 (4sb)00 (4d)04 (5)00 (6)02 (7)02 (8a)01 (8p)01 (9)01 (11p)03 (12a)01,M,15,15,4, R0 D2,,8.78,4.8,2.8,151.0,240.0,2.88,22.0,26.0,162.0,51.0,23.0,16.43,6.27,64.0,320.0,38.0,26.0,4.6,5.6,77.0,283.0,,,,,,,,,,,,,5.05,13.72,1.14, 阴性,无,, P0,H0, 未做, CD31、D2-40未见脉管瘤栓   S-100见神经侵犯 CD8、CD4+ VEGF弱+ MLH1(60%中) msh2（50%中） msh6（40%强）pms2（20%弱） ,60% 中,50% 中,40% 强,20% 弱,10.11826544021025,1631884
1631973,宫润贵,656308,男,63,T3,N0,M0, ⅡA,1,2,,0.0,0.0,1.0,,0.0,44,,,0.0,,2.0,,2.0,2.0,,,2016-09-19,2020-05-26,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌80 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20,G3,小弯03 (1a)02 (1b)00 (3a)09 (3b)03 (4sb)00 (4d)07 (5)01 (6)04 (7)02 (8a)04 (8p)01 (9)04 (11p)03 (12a)01 软组织可见癌," L（幽门窦部）, 小弯侧Less,",15,10,, R0 D2+,,9.46,5.58,2.91,147.5,286.0,3.9,6.0,16.0,181.0,103.0,16.0,11.22,3.93,71.0,293.0,40.0,31.0,4.7,6.7,71.0,392.0,,,,,,,,,,,,,0.672,45.73,2.42, 阳性++,无,, P0,H0, 未做, CK+ CD4 散在+ CD8散在+ VEGF小区弱+,30% 中,20% 中,40% 强,15% 弱-中,44.185282522996054,1631973
1631926,张昌杰,655953,男,61,T4b,N0,M0, ⅢA,1,2,1.0,1.0,1.0,0.0, 肠化生+,0.0,34,中间型（int）,INFa,0.0,,0.0,,2.0,1.0,,,2016-09-19,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3,大弯03 (1a)00 (1b)00 (3a)06 (3b)01 (4sb)00 (4d)03 (5)00 (6)07 (7)01 (8a) (8p)06 (9)01 (11p)04 (12a)02," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",60,50,10, R0 D2+,,10.17,7.2,2.12,156.8,269.0,4.1,64.0,53.0,184.0,162.0,47.6,11.61,2.9,64.5,187.17,35.4,29.1,5.6,4.09,89.0,270.0,,,,,,,,,,,,,0.742,5.83,2.53,,无, 无, P0,H0, 未做, CK +,0,75% 弱,80% 中,0,71.38633377135348,1631926
1632012,赵会波,653604,女,60,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,32,,,0.0,,,,,,,,2016-09-19,2021-07-01,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)01 (1b)02 (3a)05 (3b)01 (4sb)01 (4d)012 (5)01 (6)06 (7)03," M（胃体部）, 小弯侧Less,",15,15,, D1+,,7.47,4.36,2.39,136.0,211.0,3.09,17.0,18.0,171.0,85.0,18.0,19.75,5.2,73.0,370.0,39.0,34.0,4.5,4.4,71.0,264.0,,,,,,,,,,,,,1.31,29.72,0.754, 阴性,无, 无, P0,H0, 未做, CK +,,,,,57.35873850197109,1632012
1632054,丛佩亮,653749,男,61,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,0.0, 肠化生+,1.0,32,髓样型（med）,INFa,0.0,,1.0,,1.0,2.0,,,2016-09-20,2020-05-26,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por) Lauren肠型,G3,," L（幽门窦部）, 大弯侧Gre,",40,25,10, R0,,8.82,6.35,1.41,67.9,530.0,3.36,9.0,13.0,131.0,65.0,14.0,4.31,1.55,63.0,406.0,35.0,28.0,,,,,,,,,,,,,,,,,6.19,10.46,,,无,, P0,H0, 未做, VEGF+,50% 弱,80% 弱-中,90% 中-强,5% 弱,44.15243101182654,1632054
1632328,申振松,653592,男,52,T3,N2,M0, ⅢA,1,3,0.0,0.0,0.0,0.0, 异型增生+,5.0,38,中间型（int）,INFa,2.0,,1.0,,1.0,1.0,,,2016-09-21,2022-08-30,1,,,XELOX,XELOX,SOX,SOX,SOX,SOX,8, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)01 (2)04 (3a)47 (3b)02 (4sa)01 (4sb)01 (4d)06 (5)00 (6)06 (7)00 (8a)01 (8p)01 (9)04 (11p)12 (12a)00," M（胃体部）, 小弯侧Less,",35,25,5, D2,,8.24,4.67,2.59,135.0,347.0,4.1,32.0,23.0,179.0,65.0,37.0,8.42,2.69,67.0,367.0,39.0,28.0,5.2,6.6,80.0,300.0,,,,,,,,,,,,,33.51,22.13,1.62, 未做,无, 无, P0,H0, 未做, CK+ CD4+ CD8+  VEGF+,80% 弱-中,70% 弱-中,70% 强,50% 弱,71.25492772667542,1632328
1632935,张英,656616,女,38,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,47,,,1.0,,,,,,,,2016-09-26,2022-08-30,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)06 (1b)02 (2)03 (3a)06 (3b)02 (4sa)01 (4sb)03 (4d)06 (5)00 (6)05 (7)03 (8a)00 (8p)02 (9)04 (11p)04 (12a)00 (14v)00," M（胃体部）, 小弯侧Less,",20,20,5, R0 D2,,6.27,2.89,2.91,129.0,252.0,2.52,13.0,17.0,150.0,58.0,11.0,11.29,3.82,74.0,366.0,43.0,31.0,5.0,7.0,78.0,271.0,,,,,,,,,,,,,1.55,0.6,0.754, 阴性,无, 无, P0,H0, 未做,CK+,,,,,71.09067017082785,1632935
1631965,孔庆祥,654422,男,54,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,26,,,1.0,,,,,,,,2016-09-19,2022-08-30,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)00 (1b)00 (3a)04 (3b)03 (4sb)00 (4d)04 (5)00 (6)02 (7)01 (8a)03 (8p)02 (9)05 (11p)01 (12a)01," 前Ant, 后Post, 大弯侧Gre, L（幽门窦部）,",30,20,5, R0,,5.19,3.27,1.37,147.5,207.0,3.13,9.0,11.0,165.0,58.0,15.0,8.23,3.5,61.0,334.0,36.0,25.0,5.1,7.8,96.0,348.0,,,,,,,,,,,,,0.972,7.19,0.847,,无,, P0,H0, 未做, CK+,,,,,71.32063074901446,1631965
1632619,于敬国,653549,男,52,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,30.0,38,髓样型（med）,INFa,2.0,,1.0,,2.0,2.0,,,2016-09-22,2017-09-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)11 (1b)11 (2)01 (3a)88 (3b)55 (4sa)00 (4sb)00 (4d)01 (5)00 (6)13 (7)12 (8a)56 (8p)34 (9)22 (11p)23 (12a)00 (16a1)11," M（胃体部）, 小弯侧Less,",30,30,8,,R2,8.92,7.02,1.15,124.6,275.0,4.32,12.0,16.0,131.0,134.0,61.0,15.97,7.17,67.0,157.0,36.0,31.0,3.6,7.6,93.0,398.0,,,,,,,,,,,,,3.94,50.04,10.43, 未做,无,, P0,H0, 未做, CK + VEGF(+) CD4散在(+)  CD8散在(+),70% 中,80% 中-强,90% 强,80% 中,11.76084099868594,1632619
1632324,徐光霞,414146,女,82,T4a,N3a,M0, ⅢB,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,7.0,25,中间型（int）,INFc,1.0,,1.0,,1.0,1.0,,,2016-09-21,2018-03-01,2,,,,,,,,,0, 低粘附腺癌 低分化腺癌（G3)(por) Lauren肠型,G3,小弯01 (1a)00 (1b)00 (3a)34 (3b)00 (4sb)14 (4d)01 (5)00 (6)00 (7)12 (8a)02 (8p)24 (9)02 (11p)05 (12a)00," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",35,35,6, D2,,5.43,2.98,1.78,93.0,362.0,2.42,10.0,15.0,127.0,69.0,11.0,8.18,3.1,63.0,213.0,38.0,25.0,5.0,3.5,71.0,241.0,,,,,,,,,,,,,0.284,7.63,0.751, 阴性,无, 无, P0,H0, 未做, CK+ CD4+ CD8+  VEGF+,70% 中,60% 中,60% 中-强,40% 弱,17.279894875164256,1632324
1632140,王汉岭,655840,男,84,T4b,N0,M0, ⅢA,1,2,1.0,0.0,0.0,1.0, 肠化生+,0.0,58,髓样型（med）,INFa,1.0,,1.0,,2.0,1.0,,,2016-09-20,2022-08-30,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3, (1a)03 (1b)01 (3a)05 (3b)08 (4sb)00 (4d)013 (5)01 (6)04 (7)05 (8a)03 (8p)03 (9)07 (11p)04 (12a)01," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,65,30, D2,,5.95,3.29,1.99,67.0,511.0,3.93,13.0,15.0,116.0,82.0,9.0,4.12,1.89,65.0,95.0,30.0,35.0,5.3,6.6,73.0,204.0,,,,,,,,,,,,,1.85,4.63,3.69, 阳性+,无, 无, P0,H0, 未做, CK VEGF +,80% 中-强,75% 中-强,95% 强,60% 弱-中,71.28777923784494,1632140
1631929,董成范,656261,男,66,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,45,,,3.0,,,,,,,,2016-09-19,2022-08-30,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2,小弯01  (1a)02 (1b)01 (3a)07 (3b)01 (4sb)01 (4d)08 (5)02 (6)06 (7)01 (8a)03 (8p)05 (9)04 (11p)02 (12a)01," L（幽门窦部）, 小弯侧Less,",30,22,5, D2,,6.28,3.25,2.28,126.5,192.0,3.56,11.0,16.0,159.0,83.0,9.0,5.07,1.68,66.0,244.0,39.0,27.0,4.8,7.0,86.0,295.0,,,,,,,,,,,,,0.97,12.26,1.84, 阴性,无, 无, P0,H0, 未做, CK +,,,,,71.32063074901446,1631929
1632571,邹淑云,657252,女,63,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,48,,,2.0,,,,,,,,2016-09-22,2021-10-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2,," M（胃体部）, 小弯侧Less,",60,50,, R0,,5.52,2.36,2.36,138.1,250.0,2.56,14.0,19.0,118.0,86.0,23.0,10.65,3.52,65.0,263.0,40.0,25.0,4.6,5.0,63.0,157.0,,,,,,,,,,,,,3.62,5.52,5.37,,无, 无, P0,H0, 未做, CK+,,,,,60.282522996057814,1632571
1632401,房淑云,657255,女,61,T4b,N2,M0, ⅢB,1,2,1.0,1.0,1.0,1.0, 正常,5.0,24,髓样型（med）,INFa,0.0,,2.0,,1.0,1.0,,,2016-09-21,2022-08-30,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3, (1a)02 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)14 (5)00 (6)00 (7)11 (8a、11p)33 (8p)04 (9)07 (12a)00 (12p)01 软组织可见癌," LM 前Ant, 大弯侧Gre, 小弯侧Less,",55,40,10, D2+,R1,9.72,6.79,2.09,94.0,362.0,5.45,8.0,12.0,171.0,73.0,15.0,8.28,2.82,60.0,175.0,36.0,24.0,4.8,5.0,70.0,155.0,,,,,,,,,,,,,0.644,22.12,6.18, 未做,无, 无, P0,H0, 未做, CK+ CD4+ CD8+ VEGF弱+,70% 弱-中,80% 中-强,95% 强,40% 弱,71.25492772667542,1632401
1632566,武桂梅,656229,男,53,T3,N3b,M0, ⅢC,1,4,2.0,0.0,0.0,1.0, 肠化生+,24.0,46,硬型（sci）,INFc,0.0,,2.0,,2.0,2.0,,,2016-09-22,2022-08-30,1,,,,,,,,,0, 低粘附腺癌 低分化腺癌（G3)(por)5 Lauren弥漫型,G3, (1a)00 (1b) 00(2) 13(3a)66 (3b)11 (4sa)01 (4sb)03 (4d) 46(5)00 (6)44 (7) 13(8a)04 (8p)01 (9)01 (11p)13 (12a)00 (14v) 11(15)02 小弯57," LMU 前Ant,",90,60,15, R0 D2+,,5.98,2.58,2.61,134.2,327.0,2.79,20.0,20.0,170.0,74.0,9.0,5.46,2.05,63.0,319.0,41.0,22.0,4.5,3.1,73.0,227.0,,,,,,,,,,,,,2.05,6.73,6.98,,无, 无, P0,H0, 未做, CK +,25% 中,85% 弱-中,80% 弱-中,40% 弱,71.22207621550591,1632566
1633049,杨顺成,645826,男,64,T4b,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 正常,17.0,25,中间型（int）,INFa,0.0,,2.0,,2.0,2.0,,,2016-09-26,2018-01-08,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,9, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)00 (1b)00 (2)03 (3a)77 (3b)13 (4sa)00 (4sb)00 (4d)11 (5)11 (6)33 (7)00 (8a)11 (8p)13 (9)11 (11p)01 (12a)11," LM 前Ant, 后Post, 小弯侧Less,",50,40,12, R0 D2,,5.91,61.32,31.47,135.6,272.0,3.13,13.0,19.0,161.0,113.0,16.0,13.15,4.07,69.0,319.0,42.0,27.0,5.2,5.8,87.0,329.0,,,,,,,,,,,,,1.23,9.46,, 阴性,无, 无, P0,H0, 未做,CK+ CD4+ CD8+ VEGF弱+ CD31，D2-40 可见脉管瘤栓， S-100可见神经侵犯， MLH1（70% 弱-中） MLH2 （85% 中）MLH6 （85% 中-强）PMS2（85% 弱）,70% 弱-中,85% 中,85% 中-强,85% 弱,15.407358738501971,1633049
1632492,何景云,653586,女,77,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,26,,,2.0,,,,,,,,2016-09-22,2018-01-23,0,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1b)00 (3a)03 (3b)00 (4sb)02 (4d)00 (5)01 (6) 02(7) 06(8a)02 (8p)01 (9)07 (11p)02 (12a)00," L（幽门窦部）, 前Ant,",35,28,5, R0 D2,,8.71,5.91,1.79,128.1,366.0,1.73,15.0,28.0,208.0,73.0,14.0,11.25,3.56,65.0,153.0,36.0,29.0,3.7,3.2,66.0,294.0,,,,,,,,,,,,,2.03,28.67,, 未做,无, 无, P0,H0, 未做, CK +,,,,,16.031537450722734,1632492
1632567,徐功梅,655469,女,66,T3,N2,M0, ⅢA,1,3,1.0,0.0,0.0,1.0, 肠化生+,6.0,28,髓样型（med）,INFc,0.0,,1.0,,2.0,2.0,,,2016-09-22,2017-04-13,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)00 (1b)01 (3a)02 (3b)00 (4sb)00 (4d)34 (5)01 (6)38 (7)02 (8a)02 (8p)01 (9)06 (11p)01 (12a)00," L（幽门窦部）, 大弯侧Gre,",40,30,10, R0 D2+,,5.18,2.41,1.98,125.8,220.0,2.7,16.0,23.0,213.0,51.0,13.0,15.25,5.11,74.0,291.0,45.0,29.0,4.3,8.4,88.0,274.0,,,,,,,,,,,,,1.76,30.46,1.6, 阴性,无, 无, P0,H0, 未做, CK+ CD4散在+ CD8散在+ VEGF+,20% 弱,60% 弱-中,60% 中-强,10% 弱,6.668856767411301,1632567
1632489,李树林,653579,男,55,T2,N2,M0, ⅡB,1,3,1.0,1.0,1.0,1.0, 异型增生+,3.0,22,髓样型（med）,INFa,3.0,,1.0,,2.0,2.0,,,2016-09-22,2022-08-30,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (3a)310 (3b)00 (4sb)00 (4d)00 (5)00 (6)01 (7)00 (8a) (8p)03 (9)02 (11p)05 (12a)01,M（胃体部） 前Ant 后Post 小弯侧Less ,35,35,10, R0 D2,,7.78,4.8,2.28,150.4,245.0,1.82,14.0,14.0,120.0,69.0,13.0,7.2,3.35,58.0,332.0,36.0,22.0,5.6,4.9,88.0,473.0,,,,,,,,,,,,,2.16,13.76,1.11,  阳性+,无,, P0,H0, 未做, CD4(+) CD8(+)VEGF(-),90% 弱-中,80% 弱-中,90% 中-强,70% 弱,71.22207621550591,1632489
1632574,于庆祖,653597,男,51,T3,N1,M0, ⅡB,1,4,2.0,0.0,0.0,1.0, 肠化生+,1.0,29,硬型（sci）,INFc,0.0,,1.0,,2.0,2.0,,,2016-09-22,2018-01-16,2,,,XELOX,,,,,,1, 低粘附腺癌80  低分化腺癌（G3)(por)20 Lauren弥漫型,G3, (1a)02 (1b)01 (3a)12 (3b)02 (4sb)00 (4d)01 (5)00 (6)09 (7)05 (8a) (8p)02 (9)03 (11p)02 (12a)00,LM 前Ant 后Post 大弯侧Gre  小弯侧Less,120,90,12, R0 D2,,6.27,3.72,1.89,136.0,326.0,6.14,16.0,24.0,180.0,106.0,58.0,9.31,3.72,67.0,297.0,42.0,25.0,5.0,6.6,74.0,296.0,,,,,,,,,,,,,4.01,0.6,6.19, 阴性,无, , P0,H0, 未做, CD4(+) CD8(+)VEGF(-),40% 中,50% 中-强,70% 强,70% 弱-中,15.801576872536137,1632574
1632333,张维华,656313,女,61,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,44,,,0.0,,,,,,,,2016-09-21,2022-08-30,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)02 (1b)01 (3a)04 (3b)03  (4sb)00 (4d)02 (5)01 (6)09 (7)06 (8a)02 (8p)02 (9)02 (11p)09 (12a)01," M（胃体部）, 小弯侧Less,",20,15,2, R0 D2,,5.41,3.29,1.72,131.3,241.0,3.33,68.0,79.0,234.0,100.0,36.0,6.77,2.3,65.0,311.0,41.0,24.0,4.0,5.7,67.0,301.0,,,,,,,,,,,,,1.43,7.41,13.91, 阴性,无, 无, P0,H0, 未做,CK+,,,,,71.25492772667542,1632333
1632682,王文丽,653675,女,53,T1b,N0,M0,ⅠA,1,3,,,,,,0.0,37,,,1.0,,,,,,,,2016-09-23,2022-08-30,1,,,,,,,,,0, 低粘附腺癌 75低分化腺癌（G3)(por)25,G3, (1a)00 (1b)02 (3a)04 (3b)02 (4sb)01 (4d)06 (5)00 (6)03 (7)04 (8a)03 (8p)03 (9)04 (11p)04 (12a)01," L（幽门窦部）, 小弯侧Less,",35,30,6, R0 D2,,6.87,4.41,2.01,140.5,191.0,2.75,12.0,19.0,144.0,116.0,12.0,12.85,4.19,66.0,348.0,40.0,26.0,4.9,5.5,73.0,286.0,,,,,,,,,,,,,0.731,23.19,1.48, 未做,无, 无, P0,H0, 未做, CK+,,,,,71.1892247043364,1632682
1633244,张锦刚,657420,男,45,T3,N3a,M0,ⅢB,1,2,1.0,1.0,1.0,1.0, 正常,9.0,21,髓样型（med）,INFa,0.0,,2.0,,2.0,2.0,,,2016-09-27,2022-08-30,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 粘液腺癌（muc）40 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 30低粘附腺癌30 Lauren混合型,G3, (1a)00 (1b)11 (2)02 (3a)12 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)00 (6)33 (7)12 (8a)00 (8p)12 (9)04 (11p)25 (12a)00," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",60,40,10, R0 D2,,7.25,4.35,2.36,92.5,485.0,3.07,10.0,16.0,206.0,54.0,10.0,5.71,2.08,63.0,248.0,41.0,22.0,5.0,4.9,74.0,320.0,,,,,,,,,,,,,30.05,12.39,300.0, 阴性,无, 无, P0,H0, 未做,CK+ CD4+ CD8+ VEGF弱+ S-100见神经侵犯  CD31，D2-40 可见脉管瘤栓， MLH1 （70% 中）MLH2（80% 中） MLH6（60% 中） PMS2（50% 弱）,70% 中,80% 中,60% 中,50% 弱,71.05781865965834,1633244
1633206,肖淑珍,658596,女,67,T1b,N0,M0,ⅠA,1,3,,,,,,0.0,16,,,0.0,,,,,,,,2016-09-27,2022-08-30,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)02 (5)00 (6)01 (7)03 (8a)01 (8p)01 (9)02 (11p)03 (12a)01 (14v)01," L（幽门窦部）, 小弯侧Less,",20,15,,,,5.63,2.99,2.2,139.0,265.0,2.61,16.0,23.0,218.0,100.0,14.0,18.02,6.02,80.0,261.0,48.0,32.0,5.3,4.3,78.0,228.0,,,,,,,,,,,,,0.688,16.25,0.796, 阴性,, 无, P0,H0, 未做, CK +,,,,,71.05781865965834,1633206
1633417,刘国林,655659,男,59,T3,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 正常,30.0,51,中间型（int）,INFb,0.0,,,,,,,,2016-09-28,2018-12-08,2,,,XELOX,XELOX,XELOX,XELOX,SOX,SOX,9, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20,G3, (1a)01 (1b)00 (3a)1315 (3b)04 (4sb)11 (4d)1212 (5)03 (6)01 (7)12 (8a)04 (8p)01 (9)11 (11p)03 (12a)00  4sb 4d 软组织可见癌 大弯22 横结肠系膜01," M（胃体部）, 大弯侧Gre,",60,40,15,,R1,5.64,3.23,1.62,81.6,417.0,2.7,12.0,15.0,162.0,83.0,15.0,7.68,2.63,67.0,293.0,43.0,24.0,5.3,6.0,92.0,209.0,,,,,,,,,,,,,0.339,194.5,3.1, 未做,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),70% 中,70% 中-强,90% 中,80% 弱-中,26.31406044678055,1633417
1633143,杨秀霞,655646,女,49,T1b,N1,M0, ⅠB,1,3,,0.0,0.0,1.0,,1.0,32,,,2.0,,,,,,,,2016-09-27,2022-08-30,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)05 (3a)04 (3b)00 (4sb)00 (4d)02 (5)00 (6)03 (7)05 (8a)12 (8p)03 (9)05 (11p)03 (12a)00, L（幽门窦部） 小弯侧Less ,25,20,5, R0 D2,,3.81,1.56,1.94,137.9,235.0,2.48,12.0,15.0,168.0,55.0,19.0,14.32,4.8,68.0,267.0,43.0,25.0,5.0,4.0,63.0,404.0,,,,,,,,,,,,,0.388,3.88,0.857, 阳性+,无, 无, P0,H0, 未做, CD31（+） D2-40（+）S-100（-)   ,,,,,71.05781865965834,1633143
1633198,张春来,655683,男,67,T3,N3b,M0, ⅢC,1,2,1.0,1.0,1.0,1.0, 肠化生+,23.0,37,髓样型（med）,INFb,1.0,,1.0,,2.0,2.0,,,2016-09-27,2017-12-07,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)55 低粘附腺癌45 Lauren混合型,G3, (1a)00 (1b)01 (3a)03 (3b)00 (4sb)00 (4d)12 (5)00 (6)1313 (7)01 (8a)55 (8p)03 (9)04 (11p)13 (12a)00 (12p)01 (14v)33 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,35,10, R0 D2+,,7.42,4.15,2.42,139.0,257.0,3.23,16.0,19.0,154.0,69.0,36.0,7.42,3.25,64.0,271.0,38.0,26.0,7.5,4.5,96.0,534.0,,,,,,,,,,,,,1.94,9.7,1.17, 阳性++,无,, P0,H0, 未做, CK+ CD4 散在+ CD8散在+ VEGF+,80% 弱-中,80% 中-强,90% 中-强,70% 弱-中,14.323258869908015,1633198
1633385,李文杰,658608,男,56,T4b,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 正常,20.0,63,中间型（int）,INFa,0.0,,2.0,,2.0,2.0,,,2016-09-28,2022-08-30,1,,,SOX,SOX,SOX,SOX,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3,小弯03 (1a)00 (1b)00 (2)57 (3a)11 (3b)35 (4sa)01 (4sb)01 (4d)721 (5)02 (6)14 (7)22 (8a)01 (8p)05 (9)05 (11p)03 (12a)12 (14v)05," LMU 前Ant, 后Post, 小弯侧Less,",60,40,22, D2+,R1,6.16,4.46,1.07,80.1,457.0,5.82,9.0,12.0,128.0,72.0,20.0,3.37,1.5,57.0,228.0,35.0,22.0,4.9,4.8,83.0,149.0,,,,,,,,,,,,,1.25,15.22,2.67, 阴性,无,, P0,H0, 未做,CD4 散在+ CD8散在+ VEGF弱+ CK+,50% 弱-中,60% 中-强,60% 中-强,70% 弱,71.02496714848883,1633385
1633351,苏英杰,655508,女,49,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,36,,,0.0,,,,,,,,2016-09-28,2021-07-15,1,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40,G3, (1a)01 (1b)01 (3a)010 (3b)01 (4sb)00 (4d)08 (5)00 (6)05 (7)02 (8a)01 (8p)02 (9)03 (11p)01 (12a)01," M（胃体部）, 前Ant,",6,5,2, R0 D2+,,7.88,5.01,2.34,132.0,295.0,2.3,11.0,17.0,137.0,71.0,12.0,8.99,2.8,71.0,347.0,45.0,26.0,4.8,3.8,67.0,240.0,,,,,,,,,,,,,0.2,4.13,4.05,,无, 无, P0,H0, 未做, CK +,,,,,57.52299605781866,1633351
1633307,揣凤芝,656496,女,74,T3,N0,M0, ⅡA,1,3,,0.0,0.0,1.0,,0.0,18,,,0.0,,,,,,,,2016-09-28,2021-10-12,1,,,,,,,,,0, 低粘附腺癌,GX, (3a)07 (3b)00 (4sb) 00(4d)02 (5)00 (6)01 (7) 00(8a)03 (8p)01 (9) 01(11p)02 (12a)01,L（幽门窦部） 后Post ,15,10,5, R0 D2,,4.81,2.41,1.89,129.0,290.0,2.85,20.0,15.0,203.0,112.0,20.0,10.41,3.13,70.0,293.0,40.0,30.0,8.8,6.0,72.0,334.0,,,,,,,,,,,,,0.851,15.7,6.79, 未做,无, 无, P0,H0, 未做, CK +,,,,,60.446780551905384,1633307
1633392,沈宝忠,655549,男,57,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,28,,,0.0,,,,,,,,2016-09-28,2022-08-30,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)03 (3a)01 (3b)01 (4sb)00 (4d)05 (5)00 (6)09 (7)04 (8a)01 (8p)00 (9)02 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",26,16,5,,,7.02,2.75,3.64,140.0,340.0,3.01,20.0,19.0,169.0,74.0,29.0,6.87,2.29,69.0,452.0,43.0,26.0,5.5,6.7,97.0,487.0,,,,,,,,,,,,,3.82,14.71,41.08, 阴性,无, 无, P0,H0, 未做, CK +,,,,,71.02496714848883,1633392
1633544,于广林,655718,男,64,T3,N3a,M0,ⅢB,1,2,0.0,1.0,1.0,1.0, 正常,14.0,46,中间型（int）,INFa,2.0,,1.0,,2.0,2.0,,,2016-09-29,2020-09-02,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 粘液腺癌（muc）15 Lauren肠型,G3, (1a)26 (1b)00 (2)02 (3a)45 (3b)00 (4sa)00 (4sb)00 (4d)210 (5)33 (6)04 (7)24 (8a)11 (8p)02 (9)09 (11p)00 (12a)00 5 软组织可见癌,MU 前Ant 后Post 小弯侧Less ,60,50,10, R0 D2,,7.63,3.3,2.78,113.0,291.0,3.72,15.0,20.0,185.0,88.0,26.0,8.85,3.85,70.0,176.0,38.0,32.0,4.4,6.8,104.0,339.0,,,,,,,,,,,,,15.89,6.5,92.13, 阴性,无,, P0,H0, 未做, CD31（+） D2-40（+）S-100（+)   ,90% 中,90% 中-强,90% 中-强,50% 弱-中,47.109067017082786,1633544
1633200,方敏杰,655609,男,53,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,26,,,0.0,,,,,,,,2016-09-27,2022-08-30,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (1a)03 (1b)05 (3a)02  (3b)00 (4sb)00 (4d)02  (5)00  (6)02  (7)05  (8a)01  (8p)00  (9)03 (11p)02 (12a)01, L（幽门窦部） 前Ant ,15,15,3, R0 D2,,5.98,3.14,2.23,130.0,254.0,3.01,14.0,18.0,156.0,121.0,14.0,9.72,2.79,69.0,278.0,39.0,30.0,5.0,4.7,87.0,418.0,,,,,,,,,,,,,0.756,8.73,3.11, 阴性,无, 无, P0,H0, 未做,,,,,,71.05781865965834,1633200
1633414,孙晓奎,657431,男,64,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,0.0,10,中间型（int）,INFa,2.0,,0.0,,2.0,2.0,,,2016-09-28,2022-08-30,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)06 (5)00 (6)03 (7)01 (8a)00 (8p)00 (9)00," L（幽门窦部）, 后Post, 大弯侧Gre,",30,30,12, R0 D2,,10.97,67.58,2.01,124.0,185.0,35.4,8.0,16.0,169.0,82.0,11.0,8.0,3.75,61.0,37.0,37.0,24.0,44.0,5.2,65.0,196.0,,,,,,,,,,,,,1.01,3.77,2.45, 阴性,无, 无, P0,H0, 未做,CD4+ CD8+ VEGF- CK+ S-100神经侵犯 CD31  D2-40 脉管瘤栓 MLH1（60% 弱-中）MLH2（75% 中） MLH6（80% 强） PMS2（40% 中）,60% 弱-中,75% 中,80% 强,40% 中,71.02496714848883,1633414
1633540,林宏雷,657461,男,45,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 正常,18.0,52,中间型（int）,INFa,3.0,,0.0,,2.0,2.0,,,2016-09-29,2019-05-01,2,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)2/4 (1b)1/2 (3a)4/6 (3b)1/1 (4d)2/9 (6)4/9 (7)1/1 (9)2/7," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",45,25,8, R0 D2,,6.03,53.5,2.11,128.0,309.0,2.44,29.0,28.0,120.0,116.0,67.0,16.0,5.33,69.0,332.0,44.0,25.0,5.2,4.8,85.0,326.0,,,,,,,,,,,,,0.722,3.65,1.42,,无, 无, P0,H0, 未做,,90% 中,90% 中-强,90% 中-强,80% 弱-中,31.011826544021023,1633540
1633311,舒桂芳,656262,女,54,T1b,N0,M0,ⅠA,1,3,,1.0,1.0,0.0,,0.0,14,,,0.0,,,,,,,,2016-09-28,2022-08-30,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)00 (5)01 (6)00 (7)01 (8a)03 (8p)02 (9)02 (11p)02 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",40,20,1, D2,,8.25,4.45,3.14,152.0,226.0,3.01,22.0,22.0,209.0,121.0,20.0,18.52,5.33,71.0,321.0,46.0,25.0,5.1,4.8,77.0,291.0,,,,,,,,,,,,,1.32,20.67,0.765, 阳性+,无, 无, P0,H0, 未做, CK +,,,,,71.02496714848883,1633311
1633597,张会武,657440,男,55,T3,N2,M0, ⅢA,1,2,1.0,1.0,1.0,1.0, 肠化生+,4.0,22,中间型（int）,INFc,0.0,,0.0,,2.0,2.0,,,2016-09-29,2022-08-30,1,,,SOX,SOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)02 (1b)23 (3a)02 (3b)00 (4sb)00 (4d)02 (5)00 (6)12 (7)00 (8a)02 (8p)02 (9)02 (11p)03 (12a)00 (14v)12," L（幽门窦部）, 前Ant, 大弯侧Gre,",25,20,20, R0 D2,,12.74,9.91,2.03,155.0,203.0,2.65,49.0,24.0,176.0,77.0,47.0,32.29,12.08,70.0,342.0,44.0,26.0,5.5,4.9,82.0,294.0,,,,,,,,,,,,,2.64,8.43,1.23, 阴性,无, 无, P0,H0, 未做,CK+ CD4+ CD8+ VEGF- CD31，CD34 可见脉管瘤栓， S-100可见神经侵犯， MLH1（30% 弱） MLH2 （30% 中）MLH6（40% 中） PMS2（40% 中）,30% 弱,30% 中,40% 中,40% 中,70.99211563731932,1633597
1633758,徐文华,656448,男,68,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,0.0, 慢性炎症（+）,2.0,29,中间型（int）,INFa,0.0,,0.0,,2.0,2.0,,,2016-10-08,2022-08-30,1,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)04 (3b)00 (4sb)01  (4d)07 (5)04 (6)02  (7)01 (8a)01 (8p)01 (9)03 (11p)04 (12a)00, ML 后Post 小弯侧Less 大弯侧Gre  ,60,40,15, R0 D2,,5.61,3.69,1.09,91.0,356.0,3.4,16.0,18.0,137.0,64.0,18.0,4.77,1.96,66.0,228.0,35.0,31.0,5.4,4.2,77.0,358.0,,,,,,,,,,,,,0.274,51.6,0.867, 阴性,,, P0,H0, 未做, CD31（-） D2-40（-）S-100（-)              CD4(+) CD8(+)VEGF(-),70% 弱,40% 弱,80% 中-强,5% 弱,70.69645203679369,1633758
1633784,王永泉,657452,男,76,T4b,N2,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 正常,5.0,25,髓样型（med）,INFc,0.0,,2.0,,2.0,2.0,,,2016-10-08,2020-04-24,2,,,,,,,,,0, 粘液腺癌（muc）75 低粘附腺癌15 Lauren混合型,GX, (1a)01 (1b)00 (3a)04 (3b)01 (4sb)00 (4d)01 (5)00 (6)58 (7)01 (8a)04 (8p)02 (9)02 (11p)01 (12a)00 (12p)00 软组织可见癌," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",55,30,10, R0 D2+,,5.25,3.11,1.47,132.0,228.0,3.28,18.0,19.0,157.0,67.0,15.0,10.05,4.56,55.0,245.0,38.0,17.0,6.5,6.3,95.0,370.0,,,,,,,,,,,,,0.972,20.47,25.26, 阴性,无,, P0,H0, 未做,CD4 散在+ CD8散在+ VEGF部分弱+ CK+,40% 弱,70% 中,70% 中,60 弱,42.50985545335085,1633784
1633574,郑兰祥,656292,男,58,T1b,N2,M0, ⅡA,1,3,,1.0,1.0,0.0,,3.0,48,,,1.0,,,,,,,,2016-09-29,2022-08-30,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)85 低粘附腺癌15,G3,," L（幽门窦部）, 小弯侧Less,",30,25,10, R0 D2,,6.49,5.02,1.19,140.6,179.0,1.92,13.0,15.0,137.0,69.0,8.0,9.32,3.39,57.0,257.0,38.0,19.0,5.1,4.0,70.0,217.0,,,,,,,,,,,,,2.07,9.73,8.21, 未做,无,, P0,H0, 未做, CK（+）,,,,,70.99211563731932,1633574
1608274,池淑敏,655736,女,63,T2,N1,M0, ⅡA,1,2,,1.0,1.0,0.0,,2.0,32,,,0.0,,0.0,,2.0,2.0,,,2016-10-09,2022-08-30,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3,," L（幽门窦部）, 前Ant, 大弯侧Gre,",40,25,5, R0 D2,,5.81,3.19,2.01,141.1,306.0,2.97,31.0,35.0,185.0,66.0,49.0,13.32,3.62,73.0,349.0,41.0,32.0,5.8,3.8,69.0,260.0,,,,,,,,,,,,,1.76,25.79,1.34, 阴性,无, 无, P0,H0, 未做, VEGF（—） CK（+）,0,60% 中,85% 强,0,70.66360052562418,1608274
1633579,吴智海,656144,男,64,T3,N2,M0, ⅢA,1,3,1.0,0.0,0.0,1.0, 肠化生+,3.0,21,髓样型（med）,INFc,0.0,,,,,,,,2016-09-29,2022-08-30,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren混合型,G3, (1a)00 (1b)00 (3a)05 (3b)00 (4sb)00 (4d)02 (5)11 (6)24 (7)00 (8a)01 (8p)02 (11p)04 (12a)02," L（幽门窦部）, 后Post, 小弯侧Less,",25,20,10, R0 D2+,,6.67,3.31,2.44,149.8,301.0,4.1,23.0,23.0,168.0,88.0,34.0,10.18,3.2,74.0,362.0,43.0,31.0,5.8,7.1,82.0,302.0,,,,,,,,,,,,,0.785,5.73,4.81, 未做,无,, P0,H0, 未做, CK+,,,,,70.99211563731932,1633579
1633664,王淑范,655741,女,55,T1a,N2,M0, ⅡA,1,3,,,,,,3.0,48,,,0.0,,,,,,,,2016-09-30,2021-08-31,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)01 (3a)317 (3b)02 (4sb)00 (4d)05 (5)00 (6)07 (7)01 (8a)06 (8p)04 (9)02 (11p)00 (12a)00," M（胃体部）, 小弯侧Less,",22,16,12, R0 D2,,5.17,2.56,1.99,97.6,305.0,2.68,85.0,41.0,167.0,72.0,45.0,12.83,4.58,69.0,368.0,40.0,29.0,4.8,4.1,70.0,317.0,,,,,,,,,,,,,0.469,5.81,0.62, 阴性,无, 无, P0,, 未做,CK+,,,,,59.00131406044678,1633664
1633542,胡宏伟,655705,男,53,T3,N1,M0, ⅡB,1,1,0.0,1.0,1.0,1.0, 正常,1.0,22,中间型（int）,INFa,1.0,,2.0,,2.0,2.0,,,2016-09-29,2022-08-30,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)13 (1b)02 (3a)05 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)00 (7)02 (8a)02 (8p)01 (9)02 (11p)03 (2)02," U（胃底部）, 后Post, 小弯侧Less,",55,48,15,R0 D2,,4.74,2.57,1.6,152.0,173.0,2.27,21.0,20.0,141.0,78.0,76.0,17.7,6.65,68.0,435.0,42.0,26.0,6.8,3.7,81.0,339.0,,,,,,,,,,,,,0.2,4.11,8.0, 阳性+,无, 无, P0,H0, 未做, CK+ VEGF 弱 +,70% 弱-中,70% 弱-中,95% 强,40% 弱,70.99211563731932,1633542
1633893,唐兴义,658573,男,83,T4b,N0,M0, ⅢA,1,2,0.0,1.0,1.0,0.0, 肠化生+,0.0,36,中间型（int）,INFa,0.0,,1.0,,2.0,2.0,,,2016-10-09,2022-08-30,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)010 (3b)00 (4sb)01 (4d)07 (5)01 (6)04 (7)03 (8a)01 (8p)01 (9)02 (11p) 05(12a)01,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,100,60,10, R0 D2,,7.8,4.63,1.98,72.2,374.0,2.7,11.0,18.0,142.0,71.0,15.0,7.43,3.44,68.0,182.0,37.0,31.0,7.1,4.8,113.0,378.0,,,,,,,,,,,,,1.45,20.43,9.22, 未做,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),40% 弱,20% 弱,70% 中-强,30% 弱,70.66360052562418,1633893
1633646,赵立德,658242,男,51,T1b,N0,M0,ⅠA,1,2,,,,,,0.0,15,,,1.0,,,,,,,,2016-09-30,2022-08-30,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (3a) 06(3b)00 (4sb) 00(4d)03 (5) 00(6)02 (7) 00(8a) 02(8p) 00(9)02 (11p) 00(12a)00," L（幽门窦部）, 小弯侧Less,",15,10,, R0 D2+,,6.59,3.83,2.26,162.0,202.0,3.09,29.0,25.0,166.0,83.0,54.0,13.22,4.31,71.0,472.0,43.0,28.0,4.4,5.3,100.0,447.0,,,,,,,,,,,,,5.42,6.51,6.14,,无,, P0,H0, 未做, CK +,,,,,70.9592641261498,1633646
1633723,毕连清,643756,男,62,T4b,N3b,M1, Ⅳ,1,2,0.0,1.0,1.0,1.0, 异型增生+,16.0,35,髓样型（med）,INFa,0.0,,0.0,,2.0,2.0,,,2016-10-08,2019-01-30,2,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)05 (2)03 (3a)611 (3b)22 (4sa)00 (4sb)00 (4d)66 (5)00 (6)25 (7)03," LM 前Ant, 小弯侧Less,",35,35,8,,R2,8.69,6.05,2.17,153.6,334.0,3.72,27.0,23.0,149.0,151.0,25.9,26.07,4.89,74.3,339.68,41.5,32.8,6.6,4.49,105.0,311.0,,,,,,,,,,,,,1.82,12.02,1.08, 未做,无, 无, p1局腹膜(M1 PER),H0, 未做, VEGF— CK+ CD4 + CD8 + MLH160 MLH285 MLH690 PMS220,60% 弱-中,85% 中,90% 强,20% 弱,27.726675427069644,1633723
1634219,崔秀玉,655722,女,52,T1b,N0,M0,ⅠA,1,2,,0.0,0.0,0.0,,0.0,38,,,0.0,,0.0,,2.0,2.0,,,2016-10-11,2022-08-30,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2,," M（胃体部）, 大弯侧Gre,",15,10,8, R0 D2,,18.63,15.93,1.63,126.7,223.0,3.48,47.0,46.0,160.0,84.0,10.4,7.14,1.56,49.4,202.46,29.2,20.2,7.5,4.5,71.0,,,,,,,,,,,,,,2.35,7.77,4.15, 阴性,无,, P0,H0, 未做, VEGF（—） CK（+）,15% 弱,20% 弱-中,30% 中,5% 中,70.59789750328515,1634219
1634354,张志权,658610,男,50,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,12.0,37,中间型（int）,INFa,1.0,,0.0,,2.0,2.0,,,2016-10-12,2017-07-26,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G2, (1a) 01(1b)02 (3a)713 (3b)22 (4sb) 00(4d)15 (6)15 (7)02 (8a)02 (8p) 11(9)02 (11p)01 (12a)01," LM 前Ant, 后Post, 小弯侧Less,",30,30,15, R0 D2,,8.64,6.65,1.3,142.0,200.0,2.7,29.0,22.0,192.0,77.0,60.0,15.16,7.27,71.0,370.0,39.0,32.0,6.7,4.4,119.0,359.0,,,,,,,,,,,,,1.16,10.14,0.79, 阴性,无, 无, P0,H0, 未做, VEGF— CK（+）,5% 弱,75% 中-强,75% 中-强,60% 弱,9.42838370565046,1634354
1633783,林晓燕,657345,女,52,T4b,N3b,M1, Ⅳ,1,4,1.0,1.0,1.0,1.0, 慢性炎症（+）,17.0,30,中间型（int）,INFc,0.0,,0.0,,2.0,2.0,,,2016-10-08,2020-05-30,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低粘附腺癌85分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】15 Lauren混合型,G3,小弯44 (1a)11 (1b)11 (2)05 (3a)56 (3b)00 (4sa)00 (4sb)12 (4d)16 (5)22 (6)01 (7)11," MU 前Ant,",50,30,10,,R2,6.02,3.56,2.14,127.0,274.0,2.36,31.0,26.0,144.0,58.0,26.0,17.74,5.92,79.0,417.0,43.0,36.0,6.3,3.1,75.0,330.0,,,,,,,,,,,,,0.26,9.55,7.02, 阴性,无, 无,  p1局肠缘(M1 PER),H0, 未做, VEGF- CK+ CD31  D2-40 可见脉管瘤栓 S-100神经侵犯 MLH110 MLH210 MLH630 PMS2- CD4 + CD8 +,10% 弱,10% 弱,30% 中,0,43.69250985545335,1633783
1633904,白秀梅,657469,女,52,T3,N1,M0, ⅡB,1,3,1.0,0.0,0.0,1.0, 慢性炎症（+） 肠化生+,2.0,21,硬型（sci）,INFc,0.0,,,,,,,,2016-10-09,2022-08-30,1,,,,,,,,,0, 低粘附腺癌 低分化腺癌（G3)(por)85  管状腺癌（中分化【G2】【tub2】15 Lauren混合型,G3, (1a)00 (1b)00 (3a)26 (3b)01 (4sb)00 (4d)03 (5)00 (6)02 (7)01 (8a)01 (8p)02 (9)02 (11p)01 (12a)02,M,25,25,6, R0 D2,,6.45,3.12,2.77,134.0,411.0,2.7,10.0,16.0,140.0,104.0,18.0,4.77,1.79,78.0,246.0,44.0,34.0,5.7,5.2,77.0,231.0,,,,,,,,,,,,,0.95,13.03,0.87, 阴性,无, 无, P0,H0, 未做, CK + CD31、D2-40(未见脉管瘤栓)  S-100（见神经侵犯）,,,,,70.66360052562418,1633904
1634295,赵德普,657363,男,74,T2,N0,M0, ⅠB,1,2,0.0,1.0,1.0,0.0, 肠化生+ 异型增生+,0.0,17,中间型（int）,INFa,2.0,,2.0,,0.0,2.0,,,2016-10-12,2021-08-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 60乳头状癌（G1）（pap）25 粘液腺癌（muc）15,G3, (1b)00 (3a)03 (3b) 00(4sb)00 (4d)01 (5)01 (6)03 (7)01 (8a)03 (8p)00 (9)00 (11p)04 (12a)01,L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre  ,40,30,10, R0 D2,,9.4,3.71,4.25,127.0,243.0,2.33,15.0,21.0,139.0,58.0,23.0,6.88,2.77,66.0,256.0,37.0,29.0,11.0,8.7,136.0,379.0,,,,,,,,,,,,,3.08,24.58,0.972, 阳性+,无,, P0,H0, 未做,ck(+)  VEGF(部分弱+) CD4(-)  CD8散在(+),0,55% 弱-中,90% 中-强,0,57.65440210249671,1634295
1634002,邹勇刚,657481,男,60,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,37,,,0.0,,,,,,,,2016-10-10,2020-06-01,2,,,紫杉醇联合替吉奥,,,,,,1, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)00 (3a)05 (3b)00 (4sb)08 (4d)09 (5)00 (6)06 (7)00 (8a)03 (8p)02 (9) 01 (12a)00网膜01, L（幽门窦部） 前Ant ,12,10,, R0 D2,,6.76,3.41,2.07,141.0,263.0,1.65,17.0,20.0,146.0,82.0,10.0,12.75,4.81,70.0,311.0,41.0,29.0,4.9,4.4,90.0,292.0,,,,,,,,,,,,,2.56,12.87,1.02, 未做,无,, P0,H0, 未做, CK +,,,,,43.69250985545335,1634002
1634406,李桂琴,657487,女,62,T3,N1,M0, ⅡB,1,2,,0.0,0.0,1.0,,1.0,38,,,1.0,,1.0,,2.0,2.0,,,2016-10-12,2022-08-30,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】75 粘液腺癌（muc）25,G2, (1a)03 (1b)03 (2)14 (3a)06 (3b)07 (4sa)01 (4sb)00 (4d)00 (5)00 (6)01 (7)02 (8a)02 (8p)02 (9)04 (11p)03 (12a)00," U（胃底部）, 小弯侧Less,",40,25,10, R0 D2+,,5.43,3.13,1.81,138.0,266.0,2.29,13.0,19.0,145.0,122.0,16.0,17.41,6.65,69.0,318.0,38.0,31.0,5.2,5.4,87.0,228.0,,,,,,,,,,,,,0.49,87.34,1.85, 阴性,无, 无, P0,H0, 未做,CD4散在+ CD8散在+ VEGF+ CK+,70% 中,60% 弱-中,70% 中-强,60% 弱-中,70.56504599211563,1634406
1633842,梁友,656027,男,46,T1b,N2,M0, ⅡA,1,1,,1.0,1.0,1.0,,4.0,27,,,1.0,,,,,,,,2016-10-09,2021-10-12,1,,,XELOX,XELOX,,,,,2, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】55 乳头状癌（G1）（pap）35 粘液腺癌（muc）10,G2, (1b)00 (3a)311 (3b)00 (4sb)01 (4d)01 (5)00 (6)15 (7)00 (8a)03 (9)05 (11p)01 (12a)00 (14v)00," L（幽门窦部）, 前Ant, 小弯侧Less,",60,50,5, R0 D2+,,5.63,3.38,1.44,147.0,208.0,2.11,21.0,24.0,177.0,93.0,21.0,17.19,7.28,65.0,278.0,37.0,28.0,5.8,4.6,101.0,367.0,,,,,,,,,,,,,1.24,0.968,2.59, 阳性+,无,, P0,H0, 未做, CK + ,,,,,60.08541392904073,1633842
1633936,邵祥有,659196,男,65,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,28,,,0.0,,,,,,,,2016-10-10,2017-07-06,0,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)03 (3a)09 (3b)01 (4sb)02 (4d)03 (5)00 (6)01 (7)03 (8a)03 (8p)02 (9)00 (11p)01 (12a)00," M（胃体部）, 小弯侧Less,",30,30,5, R0,,8.3,4.63,2.44,138.0,226.0,2.3,14.0,19.0,172.0,64.0,18.0,13.63,4.96,73.0,320.0,41.0,32.0,5.1,7.7,96.0,243.0,,,,,,,,,,,,,1.56,3.83,1.08, 阴性,无, 无, P0,H0, 未做, CK+,,,,,8.83705650459921,1633936
1634403,张晶,380643,女,43,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,9.0,37,硬型（sci）,INFc,0.0,,0.0,,2.0,2.0,,,2016-10-12,2017-07-23,0,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)04   (1b)02 (3a)02 (3b)11 (4sb)03 (4d)03 (5)22 (6)69 (7)04 (8a)00 (8p)00 (9)01 (11p)05 (12a)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",,,, R0 D2,,6.66,3.89,2.33,72.0,386.0,2.9,10.0,13.0,122.0,51.0,5.2,6.71,2.43,61.0,182.0,35.0,26.0,4.7,2.4,64.0,215.0,,,,,,,,,,,,,0.529,7.77,2.54,阴性 ,无, 无, P0,H0, 未做,CD31 D2-40(见脉管瘤栓)  CK+  S-100（神经侵犯） MLH1(40%弱中) MSH2(25%弱中) MSH6(60%中) PMS2(10%弱) ,40% 弱-中,25% 弱-中,60% 中,10% 弱,9.329829172141919,1634403
1634056,石玉春,659308,男,62,T4b,N1,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,1.0,49,中间型（int）,INFb,2.0,,2.0,,2.0,2.0,,,2016-10-10,2022-08-30,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 低粘附腺癌 Lauren混合型,G3, (1a)02 (1b)00 (3a)06 (3b)00 (4sb)00 (4d)05 (5)00 (6)114 (7)04 (8a)02 (8p)05 (9)05 (11p)05 (12a)01," M（胃体部）, 前Ant,",25,20,6, R0 D2,,8.35,5.05,2.73,129.5,430.0,3.13,9.0,21.0,172.0,79.0,7.0,5.26,2.57,47.0,146.0,28.0,19.0,4.3,5.3,82.0,260.0,,,,,,,,,,,,,2.31,26.74,2.18, 阴性,无,, P0,H0, 未做, CK  CD31、D2-40（见脉管瘤栓） S-100（神经侵犯）  CD1+ CD8+ VEGF+ MLH1(15%中) MSH2（30%中） MSH6（35%强）PMS2（5%中）,15% 中,30% 中,35% 强,5% 中,70.63074901445466,1634056
1634058,信飞,656211,男,56,T4a,N1,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 正常,1.0,36,中间型（int）,INFa,0.0,,2.0,,2.0,2.0,,,2016-10-10,2019-03-30,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,7, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)01 (2)04 (3a)14 (3b)00 (4sa) 00(4sb) 00(4d) 00(5)00 (7)04 (8a)05 (8p)02 (9)05 (11p)04 (12a)00 (10)01, ML 前Ant 大弯侧Gre  ,40,30,10, R0 D2,,6.75,4.44,1.54,152.0,380.0,4.58,20.0,19.0,158.0,46.0,23.0,12.7,4.91,66.0,318.0,39.0,27.0,5.3,6.0,84.0,335.0,,,,,,,,,,,,,1.25,9.77,0.796, 未做,无,, P0,H0, 未做,ck(+)  VEGF(弱+) CD4散在(+)  CD8散在(+),70% 弱-中,60% 弱-中,50% 中-强,60 弱,29.59921156373193,1634058
1644387,胡希海,656217,男,52,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,6.0,44,髓样型（med）,INFc,0.0,,1.0,,1.0,2.0,,,2016-12-21,2022-08-30,1,SOX*3,1.0,SOX,SOX,SOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren混合型,G3, (1a)00 (1b)01 (3a)019 (3b)13 (4sb)00 (4d) 58(5)00 (6)01 (7)02 (8a)01 (8p)04 (9)03 (11p)01 (12a)00 (12p)01 (14v)00, M（胃体部） 前Ant 大弯侧Gre  ,35,30,20, R0 D2,,6.59,4.11,1.72,127.5,359.0,2.8,14.0,17.0,137.0,78.0,7.0,8.07,2.75,64.0,370.0,38.0,26.0,5.0,6.9,92.0,362.0,,,,,,,,,,,,,0.523,4.51,1.66, 未做,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+)  MLH1弱 MLH2中 MLH6中 PMS2弱,90% 弱,90% 中,90% 中,70% 弱,68.26544021024966,1644387
1634127,刘吉亭,656062,男,60,T2,N1,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,1.0,34,中间型（int）,INFa,3.0,,0.0,,2.0,0.0,,,2016-10-11,2021-06-01,0,,,XELOX,XELOX,XELOX,SOX,SOX,SOX,8, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)04 (3a)00 (3b)05 (4sb)00 (4d)02 (5)00 (6)14 (7)03 (8a)08 (8p)00 (9)05 (11p)00 (12a)03," L（幽门窦部）, 大弯侧Gre,",50,40,8, R0 D2+,,6.32,3.88,1.65,163.0,246.0,3.4,31.0,18.0,139.0,91.0,28.1,14.03,2.98,61.3,229.71,34.6,26.7,6.2,5.27,86.0,371.0,,,,,,,,,,,,,1.08,5.1,3.47,,无, 无, P0,H0, 未做, CK,0,90% 强,90% 强,0,55.65045992115637,1634127
1634418,马殿双,658381,男,53,T4b,N2,M0, ⅢB,1,2,0.0,1.0,1.0,1.0, 肠化生+,3.0,39,中间型（int）,INFa,2.0,,1.0,,2.0,2.0,,,2016-10-12,2019-05-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 02(1b)00  (3a)22 (3b)00 (4sb)03 (4d)04 (5)01 (6)15 (7)07 (8a)01 (8p)01 (9)04 (11p)08 (12a)01," LM 前Ant, 大弯侧Gre, 小弯侧Less,",55,45,10, R0 D2,,6.68,4.0,2.06,130.0,253.0,2.6,14.0,18.0,117.0,63.0,15.0,7.65,3.93,61.0,234.0,33.0,28.0,5.9,4.4,76.0,301.0,,,,,,,,,,,,,2.66,16.11,18.17, 阴性,无, 无, P0,H0, 未做, S-100（神经侵犯） CD4+   CD8+   VEGF+  CD31 D2-40（脉管瘤栓 ）MSH2(35%中) MSH6(40%中强) PMS2(-),0,35% 中,40% 中-强,0,30.584756898817343,1634418
1634580,王玉华,656187,女,62,T1b,N0,M0,ⅠA,1,2,,0.0,0.0,0.0,,0.0,32,,,0.0,,1.0,,2.0,2.0,,,2016-10-13,2022-08-30,1,,,,,,,,,0, 粘液腺癌（muc） 管状腺癌75（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）25,G2, (1a)05 (1b)02 (3a)05 (3b)00 (4sb)00 (4d)01 (5)02 (6)03 (7)01 (8a)02 (8p)03 (9)04 (11p)01 (12a)00 (16a1)03, L（幽门窦部） 前Ant 小弯侧Less ,25,20,5, R0 D2,,5.1,3.07,1.4,134.2,313.0,2.8,15.0,13.0,149.0,90.0,15.0,12.04,3.86,73.0,414.0,39.0,34.0,6.1,5.9,84.0,343.0,,,,,,,,,,,,,1.95,23.91,0.702, 阳性+,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),20% 弱,80% 中,85% 中-强,60% 弱-中,70.53219448094612,1634580
1635433,吕宝昌,656381,男,62,T3,N3a,M1,ⅢB,1,3,0.0,0.0,0.0,1.0, 异型增生+,10.0,16,中间型（int）,INFa,3.0,,2.0,,2.0,2.0,,,2016-10-20,2018-11-11,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (3a)00 (3b)13 (4sb)00 (4d)25 (5)00 (6)56 (7)22," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,30,10,,R2,6.5,3.61,2.12,135.0,315.0,3.28,20.0,17.0,118.0,84.0,11.0,5.47,2.35,60.0,173.0,35.0,25.0,6.1,4.8,87.0,197.0,,,,,,,,,,,,,2.15,336.5,96.35, 阴性,无, 无, p1局腹膜(M1 PER),H0, 未做, CK + CD4+ CD8+ VEGF+  S-100可见神经侵犯， CD31，D2-40未见明确脉管瘤栓，  MLH1（40% 弱） MLH2（70% 中） MLH6（70% 中） PMS2（25% 弱）,40% 弱,70% 中,80% 中-强,25% 弱,24.704336399474375,1635433
1635809,汪继库,655668,男,50,T2,N0,M0, ⅠB,1,2,0.0,1.0,1.0,0.0, 肠化生+,0.0,27,中间型（int）,INFa,1.0,,0.0,,2.0,2.0,,,2016-10-24,2022-08-30,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap） Lauren肠型,G2, (1a) 00(1b)01 (3a)02 (3b)01 (4sb)00 (4d)02 (5)00 (6)09 (7)07 (8a)01 (8p)01 (9)00 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",50,40,8, D2+,,8.98,5.82,2.2,139.8,274.0,3.15,16.0,21.0,162.0,73.0,15.0,8.48,4.04,63.0,320.0,36.0,27.0,7.0,5.4,87.0,290.0,,,,,,,,,,,,,2.45,17.9,5.35, 未做,无, 无, P0,H0, 未做, VEGF -,0,65% 中,65% 中,0,70.17082785808147,1635809
1634858,张谦,658685,男,67,T4a,N3b,M1, Ⅳ,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,19.0,26,髓样型（med）,INFc,1.0,,2.0,,2.0,2.0,,,2016-10-17,2019-05-05,2,,,XELOX,FOLFOX,FOLFOX,FOLFOX,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G3, (1a)00 (1b)12 (3a)00 (4sa)02 (4sb)15 (4d)88 (5)00 (6)22 (7)66 (8a) (8p) (12a) (12p)11," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,85,8,,R1,8.46,6.31,1.58,103.8,277.0,3.64,11.0,14.0,149.0,64.0,6.0,12.65,5.78,53.0,182.0,29.0,24.0,5.4,4.8,91.0,302.0,,,,,,,,,,,,,1.58,167.6,10.96, 未做,无, 无, p1局腹膜(M1 PER),H0, 未做, CK+  VEGF+  CD4+  CD8 + MLH125 MLH240 MLH660 PMS215,25% 中,40% 中-强,60% 中-强,15% 中,30.55190538764783,1634858
1634933,李景强,656419,男,64,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,12.0,41,髓样型（med）,INFa,2.0,,1.0,,1.0,2.0,,,2016-10-17,2019-09-20,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,13, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,小弯03 (1a)00 (1b)00 (3a)916 (3b)00 (4sb)00 (4d)010 (5)00 (6)02 (7)01 (8a)11 (8p)02 (9)15 (11p)00 (12a)00 (16a1)00 胃壁11," M（胃体部）, 小弯侧Less,",25,20,8, R0 D2+,,7.63,4.46,2.38,164.0,279.0,2.95,10.0,16.0,156.0,98.0,9.0,14.07,3.96,71.0,396.0,41.0,30.0,6.0,5.1,103.0,401.0,,,,,,,,,,,,,2.14,0.6,2.11, 未做,无,, P0,H0, 未做,CD4+ CD8散在+ VEGF+,70% 弱-中,80% 中,90% 中-强,70% 弱-中,35.08541392904073,1634933
1634972,刘洪琦,658637,男,74,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 正常,7.0,20,髓样型（med）,INFc,0.0,,2.0,,2.0,2.0,,,2016-10-17,2021-10-30,1,,,,,,,,,0, 低分化腺癌（G3)(por) 65低粘附腺癌35 Lauren弥漫型,G3, (1a)00 (1b)00 (3a)44 (3b)11 (4sb)00 (4d)14 (5)00 (6)03 (7)11 (8a)02 (8p)01 (9)03 (11p)01 (12a)00  3a、3b软组织可见癌,L（幽门窦部） 前Ant 后Post 小弯侧Less ,40,25,10, R0 D2,,8.64,5.07,2.43,145.5,459.0,3.84,28.0,24.0,182.0,78.0,23.0,13.18,3.77,69.0,346.0,39.0,30.0,8.1,6.0,104.0,312.0,57.0,39.4,16.5,2.39,0.3,10.7,24.9,1.0,0.312,4.03,9.33,,2.22,10.91,1.2, 阴性,无, 无, P0,H0, 未做,ck(+)  VEGF(部分弱+) CD4散在(+)  CD8散在(+),40% 弱-中,20% 弱-中,60% 中-强,40% 中,60.41392904073587,1634972
1634505,陈鲁军,658377,男,65,T3,N2,M0, ⅢA,1,3,1.0,1.0,1.0,1.0, 正常,4.0,27,硬型（sci）,INFb,0.0,,2.0,,1.0,1.0,,,2016-10-13,2019-09-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren混合型,G3, (1a)12 (1b)11 (2)04 (3a)14 (3b)00 (4sa)00 (4sb)00 (4d)04 (5)01 (6)01 (7)01 (8a)14 (8p)02 (9)01 (11p)00 (12a)02," M（胃体部）, 小弯侧Less,",30,30,15, R0 D2+,,8.02,4.32,2.66,137.0,256.0,2.56,19.0,20.0,143.0,69.0,18.0,18.03,8.03,75.0,305.0,43.0,32.0,8.4,6.1,105.0,396.0,,,,,,,,,,,,,0.93,21.0,2.64,,无, 无, P0,H0, 未做, CK +,60% 中,60% 中,75% 中-强,60% 中,34.59264126149803,1634505
1635107,赵之金,656484,男,70,T4a,N3a,M0, ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+,11.0,27,髓样型（med）,INFb,1.0,,2.0,,1.0,1.0,,,2016-10-18,2017-12-11,2,,,SOX,XELOX,,,,,2, 粘液腺癌（muc）75 低粘附腺癌15 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】10 Lauren混合型,G3,下段食管旁01 (1a)11 (1b)00 (2)34 (3a)26 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)00 (6)03 (7)22 (8a)01 (8p)12 (9)14 (11p)11 (12a)00 1b 3a 3b 5软组织可见癌," UM 前Ant, 后Post, 小弯侧Less,",100,80,13, R0 D2+,,5.31,3.39,1.23,66.0,395.0,3.56,14.0,15.0,138.0,84.0,25.0,4.04,1.54,54.0,322.0,30.0,24.0,6.7,5.3,76.0,220.0,,,,,,,,,,,,,,,,,无, 无, P0,H0,, CK +,30% 弱-中,70% 中,85% 中-强,5% 弱,13.764783180026281,1635107
1643625,肖铁滨,660214,男,59,T3,N2,M0, ⅢA,1,4,0.0,0.0,0.0,1.0, 肠化生 异型增生 慢性炎症,4.0,39,硬型（sci）,INFb,0.0,,0.0,,2.0,2.0,,,2016-12-20,2022-08-30,1,SOX*1,1.0,SOX,SOX,SOX,SOX,,,4, 低分化管状腺癌 Lauren肠型,G3, (1a)15 (1b)13 (3b)12 (4d)15," MU 前Ant, 大弯侧Gre, 小弯侧Less,",30,25,15,,R1,7.09,3.8,2.37,131.0,246.0,4.1,12.0,21.0,150.0,64.0,12.0,9.81,4.58,60.0,234.0,36.0,24.0,4.5,7.2,110.0,314.0,76.6,58.1,14.7,3.59,0.0,10.5,10.0,1.4,0.39,2.32,8.34,,2.23,166.0,3.32, 未做,无,, P0,H0, 未做, CK+  VEGF- CD4+  CD8散在+  MLH1阳性细胞约占80%染色强度为弱 MSH2阳性细胞约占90%染色强度为弱-中,80% 弱,90% 弱-中,90% 中-强,80% 弱,68.29829172141918,1643625
1634928,马景宝,658387,男,56,T3,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,4.0,40,中间型（int）,INFc,0.0,,,,,,,,2016-10-17,2017-07-30,2,,,,,,,,,0, 粘液腺癌（muc） 低粘附腺癌 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)00 (3a)04 (3b)48 (4sb)01 (4d)014 (5)00 (6)04 (7)00 (8a)02 (8p)00 (9)04 (11p)02 (12a)00," LM 前Ant,",30,30,10, R0 D2,,7.38,5.0,1.62,99.9,399.0,3.4,24.0,17.0,99.0,86.0,16.0,12.89,3.37,61.4,290.98,32.3,29.1,9.1,8.57,135.0,508.0,,,,,,,,,,,,,4.56,11.6,2.69, 阴性,无,, P0,H0, 未做,CD31、D2-40见脉管瘤栓  S-100见神经侵犯  CK+ mlh1（70%中） msh2（60%中）msh6（75%中-强）pms2（30%弱）,70% 中,60% 中,75% 中-强,30% 弱,9.395532194480946,1634928
1635328,刘玉莲,658454,女,41,T3,N3a,M0,ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,11.0,50,髓样型（med）,INFa,3.0,,1.0,,2.0,2.0,,,2016-11-19,2022-08-30,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 粘液腺癌（muc） 55管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)35 乳头状癌（G1）（pap）10 Lauren肠型,G3, (1a)01 (1b)03 (3a)38 (3b)45 (4sb)03 (4d)012 (5)11 (6)14 (7)12 (8a)12 (8p)05  (11p)03 (11d)01 (12a)00, L（幽门窦部） 前Ant 后Post 小弯侧Less ,40,40,8, R0 D2,,5.71,3.43,1.57,121.4,250.0,2.65,7.0,16.0,124.0,88.0,6.0,12.17,5.09,67.0,233.0,40.0,27.0,5.4,7.3,84.0,208.0,60.9,39.1,16.5,2.37,0.1,8.4,22.0,1.2,1.87,0.904,10.4,,1.59,152.9,1.85, 阴性,无, 无, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),70% 中,70% 中-强,60% 中-强,50% 弱-中,69.3166885676741,1635328
1635437,孙民斋,658367,男,75,T3,N3a,M0,ⅢB,1,2,0.0,1.0,1.0,1.0,,8.0,25,髓样型（med）,INFa,1.0,,0.0,,2.0,2.0,,,2016-10-20,2017-04-03,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (4d)2/6 (5)2/2 (6)4/6," L（幽门窦部）, 大弯侧Gre, 小弯侧Less,",3,15,4, R0 D2,,6.99,72.63,1.34,158.9,194.0,3.56,11.0,14.0,156.0,114.0,13.0,7.55,4.34,60.0,157.0,37.0,23.0,7.2,7.6,104.0,370.0,,,,,,,,,,,,,,7.08,5.99,,无, 无, P0,H0, 未做,,40% 弱,90% 中-强,95% 中-强,20% 弱,5.4204993429697765,1635437
1635298,董荣久,658252,男,76,T3,N0,M0, ⅡA,1,2,2.0,1.0,1.0,1.0, 肠化生+,0.0,33,中间型（int）,INFc,1.0,,,,,,,,2016-10-19,2022-08-30,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (3a)03 (3b)00 (4sb)00 (4d)00 (5)03 (6)018 (7)03 (8a)01  (9)04 (11p)00 (12a)01 (16a1)00,L（幽门窦部） 前Ant 大弯侧Gre  ,55,40,8, R0 D2,,6.75,3.33,2.78,111.0,386.0,2.39,19.0,27.0,248.0,74.0,9.0,7.42,3.19,64.0,162.0,35.0,29.0,5.7,7.5,93.0,263.0,70.0,14.3,53.3,0.27,0.1,0.6,26.3,3.3,0.445,0.807,14.8,,2.22,19.44,12.64, 阴性,无,, P0,H0, 未做, CK +,,,,,70.33508541392904,1635298
1635383,张云发,658296,男,60,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 正常,0.0,47,中间型（int）,INFa,0.0,,2.0,,2.0,2.0,,,2016-11-20,2022-08-30,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)00 (1b)01 (3a)06 (3b)06 (4sb)00 (4d)04 (5)01 (6)09 (7)01 (8a)04 (8p)01 (9)04 (11p)03 (12a)00,LM 前Ant 后Post 小弯侧Less ,30,20,10, R0 D2,,7.28,4.49,2.29,128.2,286.0,3.67,23.0,21.0,133.0,100.0,11.0,9.46,5.01,69.0,202.0,41.0,28.0,7.1,5.2,102.0,268.0,74.5,32.3,33.2,0.97,0.2,9.3,12.6,1.3,0.707,1.61,11.1,,0.709,2.68,1.04, 未做,无,, P0,H0, 未做,ck(+)  VEGF(部分弱+) CD4散在(+)  CD8散在(+),80% 中,80% 强,85% 强,75% 中,69.2838370565046,1635383
1635246,陈玉香,656388,女,56,T1b,N0,M0,ⅠA,1,3,,,,,,0.0,37,,,0.0,,,,,,,,2016-10-19,2021-08-10,1,,,口服替吉奥,,,,,,1, 低分化腺癌（G3)(por) 低粘附腺癌,G3, (1a)09 (1b)02 (3a)02 (3b)00 (4sb)00 (4d)03 (5)00 (6)04 (7)02 (8a)00 (8p)06 (9)04 (11p)00 (12a)00 (14a)04 大网01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",15,12,6, R0 D2,,3.49,53.83,1.31,125.9,232.0,3.28,15.0,22.0,202.0,67.0,8.0,11.6,4.4,73.0,244.0,45.0,28.0,4.9,4.1,89.0,286.0,,,,,,,,,,,,,1.97,12.58,0.701, 阴性,无,,,H0, 未做,CK+,,,,,57.68725361366623,1635246
1635490,刘长胜,658675,男,69,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,67.0,70,髓样型（med）,INFa,3.0,,2.0,,2.0,2.0,,,2016-10-20,2017-10-06,2,,,XELOX,,,,,,1, 乳头状癌（G1）（pap）75 管状腺癌（中分化【G2】【tub2】25 Lauren肠型,G2,(3a)99 (3b)88 (4sb)00 (4d)1717 (5)44 (6)88 (7)12 (8a)22 (8p)33 (9)22 (11p)1113 (12a)22 软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,7,,R2,6.42,4.0,1.62,140.0,229.0,3.34,8.0,11.0,145.0,82.0,14.0,8.9,4.92,69.0,250.0,41.0,28.0,7.4,6.6,92.0,206.0,67.4,37.5,24.1,1.56,0.5,5.7,24.4,3.1,0.717,3.42,10.4,,6.52,65.63,39.07, 阴性,无,, P0,H0, 未做, CK+ CD4散在+ CD8散在+ VEGF部分弱+,45% 中,65% 中,80% 中-强,20% 弱,11.530880420499342,1635490
1635098,李凯,658687,男,67,T2,N1,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,2.0,18,髓样型（med）,INFa,1.0,,2.0,,2.0,2.0,,,2016-10-18,2022-08-30,1,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1b)00 (3a)03 (3b)00 (4sb)01 (4d)03 (5)00 (6)27 (7)00 (8a)01 (8p)00 (9)03 (11p)00 (12a)00," L（幽门窦部）, 后Post, 大弯侧Gre,",40,30,5, R0 D2+,,6.99,3.9,2.37,126.6,193.0,3.23,11.0,15.0,152.0,48.0,12.0,17.49,6.89,66.0,226.0,36.0,30.0,5.2,9.2,98.0,302.0,65.9,41.0,21.7,1.89,0.2,5.5,23.9,1.0,0.739,3.06,11.8,,0.2,5.15,1.58, 阳性++,无,, P0,H0, 未做,CD4 散在+ CD8散在+ VEGF弱+ CK+,80% 中,85% 中-强,90% 强,70% 弱-中,70.36793692509855,1635098
1635436,王波,657643,男,47,T2,N0,M0, ⅠB,1,3,,0.0,0.0,1.0,,0.0,21,,,0.0,,,,,,,,2016-10-20,2021-07-28,1,,,SOX,SOX,SOX,SOX,SOX,SOX,7, 低粘附腺癌,GX,(1a)04 (1b)00 (3a)04 (3b)01 (4sb)00 (4d)05 (5)00 (6)02 (7)01 (8a)01 (8p)02 (9)00 (11p)01 (12a)00," L（幽门窦部）, 前Ant,",20,15,3, R0 D2+,,6.07,3.01,2.35,167.8,226.0,1.99,19.0,19.0,184.0,56.0,43.0,28.42,10.68,71.0,372.0,43.0,28.0,5.5,4.0,76.0,425.0,,,,,,,,,,,,,1.66,6.23,1.08, 未做,无,, P0,H0, 未做, CK+,,,,,57.22733245729303,1635436
1635492,迟洪芹,658294,女,70,T3,N0,M0, ⅡA,1,2,0.0,1.0,1.0,1.0, 肠化生+,0.0,26,髓样型（med）,INFa,2.0,,1.0,,2.0,2.0,,,2016-10-20,2019-12-12,2,,,,,,,,,0, 乳头状癌（G1）（pap）80 管状腺癌（中分化【G2】【tub2】20,G2, (1a)01 (1b)02 (3a)05 (3b)00 (4sb)00 (4d)02 (5)03 (6)05 (7)00 (8a)02 (8p)01 (9)03 (11p)02," L（幽门窦部）, 小弯侧Less, 后Post,",30,25,6, R0 D2,,5.3,2.97,2.01,113.7,207.0,2.91,14.0,20.0,198.0,68.0,17.0,6.71,2.69,67.0,210.0,40.0,27.0,5.9,8.6,102.0,332.0,75.0,39.7,32.7,1.21,0.8,8.6,11.0,1.1,0.442,1.02,9.92,,5.24,16.18,6.71, 阴性,无, 无, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),65% 弱-中,70% 中,80% 强,70% 弱-中,37.71353482260184,1635492
1635142,马小芬,658542,女,56,T3,N0,M1, Ⅳ,1,3,1.0,0.0,0.0,0.0, 正常,0.0,11,髓样型（med）,INFc,0.0,,0.0,,2.0,2.0,,,2016-10-18,2017-04-15,2,,,SOX,SOX,SOX,SOX,,,4, 低分化腺癌（G3)(por)85 低粘附腺癌15 Lauren混合型,G3, (3a)04 (3b)00 (4sb) 00(4d)04 (5) 00(6)01 (7) (8a) (8p)02,L,45,30,10,,R2,4.38,2.82,1.22,133.6,225.0,2.96,10.0,22.0,221.0,90.0,21.0,20.97,8.58,80.0,379.0,48.0,32.0,5.2,6.2,94.0,341.0,,,,,,,,,,,,,1.2,9.51,2.69, 阴性,,,,,, VEGF—,85% 中,85% 中,80% 中,80% 弱-中,5.88042049934297,1635142
1634929,杨建柒,658522,男,62,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,2.0,39,髓样型（med）,INFa,1.0,,0.0,,2.0,2.0,,,2016-10-17,2022-08-30,1,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】85 乳头状癌（G1）（pap）15 Lauren肠型,G3,肿物旁02 (1a)00 (1b)00 (3a)00 (3b)210 (4sb)00 (4d)08 (5)02 (6)09 (7)01 (8a)01 (8p)04 (9)02 (11p)00 (12a)00," M（胃体部）, 小弯侧Less,",30,15,6, R0 D2+,,3.71,2.04,1.21,79.0,193.0,2.27,15.0,18.0,130.0,56.0,22.0,9.42,4.47,67.0,332.0,39.0,28.0,5.8,5.5,118.0,305.0,,,,,,,,,,,,,1.53,4.97,2.51,,无, 无, P0,H0,, CK + ,70% 弱,85% 中,90% 强,20% 弱,70.40078843626806,1634929
1634970,王彦茹,658385,男,61,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,35,中间型（int）,INFa,0.0,,2.0,,2.0,1.0,,,2016-10-17,2021-10-30,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)03 (1b)02 (2)01 (3a)03 (3b)00 (4sb)00 (4d)05 (5)02 (6)01 (7)05 (8a)01 (8p)03 (9)05 (11p)02 (12a)02," M（胃体部）, 小弯侧Less,",40,20,10, R0 D2+,,7.08,3.85,1.86,106.0,311.0,3.9,9.0,15.0,122.0,42.0,10.0,18.53,11.92,53.0,117.0,29.0,24.0,4.6,3.3,71.0,158.0,,,,,,,,,,,,,2.08,4.08,1.44,,无, 无, P0,H0, 未做, CK +,60% 中,60% 中-强,60% 强,30% 弱,60.41392904073587,1634970
1636053,朱德范,658488,女,63,T4a,N3b,M0, ⅢC,1,2,,1.0,1.0,1.0,,29.0,45,,,1.0,,2.0,,2.0,2.0,,,2016-10-25,2017-06-17,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 90低粘附腺癌10,G3, (1a)12 (1b)00 (2) 15(3a)11 (3b)22 (4sa)00 (4sb)00 (4d) 23(5) 22(6) 49(7)11 (8a) (8p) (12a)11 (9)48 (11p) (11d)45 (12p)66," LM 小弯侧Less,",25,20,8,,R2,6.68,4.12,1.74,114.3,120.0,3.56,11.0,18.0,177.0,68.0,43.0,5.2,2.3,68.0,172.0,33.0,35.0,6.0,4.7,82.0,188.0,71.3,44.9,21.8,2.06,0.2,6.3,18.8,3.3,1.11,4.13,16.1,,2.61,23.86,14.01, 阴性,无, 无, P0,H0, 未做,ck(+)  VEGF(弱+) CD4散在(+)  CD8散在(+),0,45% 弱-中,45% 弱-中,0,7.720105124835742,1636053
1635251,宋占江,656707,男,54,T2,N1,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 肠化生+,1.0,42,髓样型（med）,INFa,1.0,,2.0,,1.0,2.0,,,2016-10-19,2022-08-30,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 粘液腺癌（muc） Lauren肠型,G2, (1a)02 (1b)04 (3a)04 (3b)03 (4sb)01 (4d)06 (5)00 (6)07 (7)01 (8a)11 (8p)(12p)04 (9)05 (11p)03 (12a)01," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,5, D2,,6.0,2.64,2.73,145.3,209.0,2.14,47.0,41.0,248.0,83.0,14.0,14.48,5.5,60.0,220.0,36.0,24.0,5.5,4.9,74.0,98.0,,,,,,,,,,,,,5.86,7.76,1.91, 未做,无, 无, P0,H0, 未做, CK + VEGF 弱+,80% 中,75% 中,85% 中-强,80% 弱-中,70.33508541392904,1635251
1635807,范玉森,659445,男,60,T4b,N1,M0, ⅢB,1,5,0.0,1.0,1.0,1.0, 肠化生+,2.0,18,中间型（int）,INFa,3.0,,1.0,,2.0,2.0,,,2016-10-24,2018-01-13,2,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)04 (1b)02 (2)00 (3a)02 (3b)00 (4sa)01 (4sb)00 (4d)00 (5)00 (6)12 (7)01 (8a)11 (8p)03 (9)01 (11p)00 (12a)01," LM 前Ant, 后Post,  小弯侧Less,",40,38,8, R0 D2,,8.99,5.77,2.19,141.0,264.0,3.84,21.0,17.0,158.0,89.0,45.0,8.18,3.33,66.0,323.0,40.0,26.0,8.8,6.3,100.0,279.0,,,,,,,,,,,,,1.37,6.16,1.97, 阴性,无, , P0,, 未做, S-100见神经侵犯 MLH1(85%中) MSH2（80%中-强） MSH6（80% 中-强） PMS2（70%弱） CD4+ CD8+ VEGF+  CD31，D2-40 可见脉管瘤栓,85% 中,80% 中-强,80% 中-强,70% 弱,14.651773981603153,1635807
1635255,范丹婷,659511,女,32,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 正常,4.0,30,中间型（int）,INFa,2.0,,2.0,,2.0,2.0,,,2016-10-19,2021-10-10,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,15, 低分化腺癌（G3)(por)65 低粘附腺癌20 粘液腺癌（muc）15 Lauren肠型,G3, (1a)02 (1b)00 (3a)28 (3b)00 (4sb)00 (4d)13 (5)01 (6)16 (7)02 (8a)01 (8p)03 (9)01 (11p)03 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",50,40,5, R0 D2+,,8.42,6.1,1.81,145.0,276.0,2.39,21.0,20.0,146.0,91.0,16.0,10.98,4.79,79.0,300.0,47.0,32.0,4.8,5.1,91.0,303.0,,,,,,,,,,,,,1.54,15.77,11.88, 未做,无, 无, P0,H0, 未做, CK+ CD4 散在+ CD8散在+ VEGF部分弱+,20% 弱-中,60% 中,85% 强,0,59.69119579500657,1635255
1635965,刘志英,658339,女,61,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,1.0,,0.0,41,,,0.0,,,,,,,,2016-10-25,2017-08-10,0,,,,,,,,,0, 低粘附腺癌,GX,,M（胃体部） 前Ant ,20,15,1, R0 D2,,6.26,4.7,0.69,124.7,207.0,2.42,12.0,17.0,163.0,74.0,41.0,10.3,7.04,67.0,183.0,43.0,24.0,4.9,3.7,73.0,156.0,,,,,,,,,,,,,1.88,67.08,1.44, 未做,无, 无, P0,H0, 未做, CD31（+） D2-40（+）S-100（-),,,,,9.494086727989487,1635965
1635910,于占华,658506,女,50,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,29,,,0.0,,,,,,,,2016-10-24,2022-08-30,1,,,,,,,,,0, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）30,G2, (1a) 05(1b) 01(3a)02 (3b)00 (4sb)00 (4d)01 (5)00 (6) 05(7) 05(8a) 03(8p)03 (9)01 (11p) 03(12a)00," LM 前Ant,",30,25,, R0 D2,,7.37,4.85,1.83,117.2,180.0,2.52,18.0,21.0,175.0,104.0,32.0,14.36,5.11,71.0,339.0,42.0,29.0,4.7,4.4,88.0,212.0,,,,,,,,,,,,,0.354,9.44,3.6, 阴性,无, 无, P0,H0, 未做, CK（+）,,,,,70.17082785808147,1635910
1636087,吕洪君,660977,男,71,T1b,N1,M0, ⅠB,1,0,,1.0,1.0,1.0,,1.0,8,,,0.0,,,,,,,,2016-10-25,2022-08-30,1,,,口服替吉奥,口服替吉奥,口服替吉奥,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)(1b)02 (3a)00 (3b)00 (4sb)00 (4d)14 (5)01 (6)01 (7)00 (8a)00 (8p)00 (9)00 (11p)00 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",40,30,, R0 D2,,6.58,3.39,2.18,154.7,195.0,2.9,34.0,21.0,121.0,126.0,80.9,12.25,3.1,60.7,262.69,34.8,25.9,5.4,4.27,98.0,340.0,,,,,,,,,,,,,1.13,6.07,, 阴性,无, 无, P0,H0, 未做,CK+ CD31 D2-40见脉管瘤栓 S-100见神经侵犯,,,,,70.13797634691196,1636087
1636057,由春霞,658421,女,71,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,1.0, 异型增生+,1.0,21,髓样型（med）,INFa,1.0,,1.0,,2.0,2.0,,,2016-10-25,2022-08-30,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3,(1a)02  (1b)02(3a)02(3b)11 (4sb)00 (4d)01(5)01(6)02 (7)01 (8a)(8p)02 (9)03 (11p)00 (12a)04, L（幽门窦部） 小弯侧Less ,30,30,10, R0 D2,,5.06,3.09,1.4,126.7,329.0,2.7,12.0,17.0,143.0,73.0,21.0,12.15,5.59,80.0,308.0,44.0,36.0,7.1,5.9,78.0,259.0,78.1,41.2,31.4,1.31,0.3,3.8,15.0,1.1,1.57,3.43,17.0,,0.717,11.97,0.846, 阴性,无, 无, P0,H0, 未做, CD31（+） D2-40（+）S-100（+)   CD4(+) CD8(+)VEGF(+),,,,,70.13797634691196,1636057
1635966,张延伟,658438,男,56,T1b,N0,M0,ⅠA,1,2,,1.0,1.0,1.0,,0.0,47,,,0.0,,1.0,,2.0,2.0,,,2016-10-25,2022-08-30,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】85 乳头状癌（G1）（pap）15,G2, (1b)01 (3a)013 (3b) 05(4sb)01 (4d)011 (5)01 (6)03 (7)03 (8a)05 (8p) 01(9)02 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",20,18,6, R0 D2,,8.55,4.98,2.74,166.9,284.0,2.27,14.0,17.0,149.0,86.0,20.0,22.77,9.5,77.0,390.0,46.0,31.0,11.8,6.6,91.0,192.0,71.5,39.0,27.7,1.41,0.8,11.9,13.8,7.3,0.928,2.61,11.8,,2.35,27.32,3.77, 未做,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),70% 中,70% 中,70% 强,50% 弱,70.13797634691196,1635966
1636062,刘海波,660322,男,57,T1b,N0,M0,ⅠA,1,3,,1.0,1.0,0.0,,0.0,10,,,0.0,,,,,,,,2016-10-25,2021-09-09,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】85 乳头状癌（G1）（pap）15,G2, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)01 (5)00 (6)00 (7)00 (8a)01 (8p)02 (9)04 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",30,30,, R0 D2+,,8.55,5.64,1.98,149.1,278.0,5.12,38.0,26.0,209.0,94.0,20.0,13.71,6.7,73.0,220.0,38.0,35.0,4.6,5.6,101.0,334.0,,,,,,,,,,,,,1.2,5.9,0.781, 未做,无,, P0,H0, 未做,,,,,,58.47568988173456,1636062
1635771,孙贵,656317,男,69,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,10.0,31,髓样型（med）,INFa,2.0,,2.0,,2.0,2.0,,,2016-10-24,2021-10-30,1,,,,,,,,,0, 粘液腺癌（muc）75  管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 25 Lauren肠型,G3, (1a)00 (1b)00 (2)01 (3a)24 (3b)34 (4sa)00 (4sb)00 (4d)35 (5)00 (6)24 (7)01 (8a)02 (8p)00 (9)01 (11p)05 (12a)01 (11d)03," LM 前Ant, 后Post, 小弯侧Less,",90,90,18, R0 D2+,,6.75,4.15,1.97,142.1,270.0,3.56,16.0,19.0,154.0,84.0,13.0,10.23,5.41,68.0,158.0,41.0,27.0,6.4,7.5,100.0,253.0,,,,,,,,,,,,,6.37,188.6,9.27,,无, 无, P0,H0, 未做, CD 31 CK,60% 中,80% 中,80% 中-强,60% 弱-中,60.183968462549274,1635771
1635900,王明刚,660962,男,69,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,, 正常,0.0,18,髓样型（med）,INFa,0.0,,2.0,,2.0,2.0,,,2016-10-24,2021-05-11,0,,,口服替吉奥,口服替吉奥,,,,,2, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)01 (4d)02 (5)00 (6)02 (7)02 (8a)01 (8p)01 (9)02 (11p)01 (12a)04," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,40,15, R0,,9.05,8.52,0.31,100.8,160.0,3.22,17.0,24.0,211.0,125.0,52.0,12.76,6.04,75.0,148.0,39.0,36.0,6.5,6.4,77.0,272.0,,,,,,,,,,,,,1.93,30.42,1.97, 未做,无, 无, P0,H0, 未做, VEGF（+） CK+ CD31  D2-40 脉管瘤栓 S-100未见神经侵犯 MLH190 MLH290 MLH690 PMS240,90% 中,90% 强,90% 强,40% 弱,54.533508541392905,1635900
1636266,薛国英,659564,男,54,T3,N2,M0, ⅢA,1,5,2.0,1.0,1.0,1.0, 异型增生+,6.0,30,髓样型（med）,INFa,0.0,,2.0,,2.0,2.0,,,2016-10-26,2018-04-06,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 粘液腺癌（muc）40 低粘附腺癌 50低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】10 Lauren弥漫型,G3, (1a)09（1b)14  (3b)24（4sa)00（4sb)00（4d)01（5)00（6)02（7)23（8a)00（8p)00（9)00（11p)00（12a) 00（2）05 (3a)14,M,45,30,12, R0 D2,,4.95,2.65,1.75,144.0,274.0,3.81,21.0,19.0,103.0,81.0,28.0,9.2,415.0,69.0,349.0,41.0,28.0,4.5,6.2,96.0,367.0,,,,,,,,,,,,,6.56,36.77,34.32, 阴性,无,, P0,H0, 未做, CK + CD31、D2-40(脉管瘤栓）  S-100见神经侵犯 MLH1(60%弱中)PMS2(50%弱）  MLH2（70% 中-强） MLH6（60% 弱）CD4+ CD8-,60% 弱-中,70% 中-强,60% 中,50% 弱,17.31274638633377,1636266
1637105,苏庆学,660186,男,69,T4a,N0,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,0.0,26,中间型（int）,INFa,0.0,,0.0,,2.0,2.0,,,2016-11-12,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)02 (3a)01 (3b)00 (4sb)011 (4d)00 (5)04 (6)01 (7)00 (8a)01 (8p)01 (9)01 (11p)01 (12a)03 (14v)00, ML 后Post 小弯侧Less ,35,30,12, R0 D2,,4.99,3.48,1.09,74.8,276.0,2.13,19.0,19.0,158.0,56.0,11.0,6.39,3.64,54.0,222.0,32.0,22.0,4.5,4.7,82.0,263.0,75.1,41.1,22.7,1.81,0.1,1.7,16.7,1.9,0.458,1.35,8.98,,0.794,4.66,5.88, 阳性+,无,, P0,H0, 未做,ck(+)  VEGF(-) CD4散在(+)  CD8散在(+),60% 弱,60% 弱-中,60% 弱-中,25% 弱,69.61235216819973,1637105
1636881,郭念云,661051,男,59,T2,N0,M0, ⅠB,1,2,1.0,1.0,1.0,0.0, 肠化生+,0.0,21,髓样型（med）,INFa,1.0,,1.0,,1.0,2.0,,,2016-11-01,2022-09-01,1,,,SOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap） Lauren混合型,G3, (1a)03 (1b)01 (3a)01 (3b)00 (4sb)01 (4d)03 (5)00 (6)06 (7)01 (8a)01 (8p)01 (9)02 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 大弯侧Gre,",30,25,8, R0 D2,,4.27,2.56,1.2,138.9,216.0,2.41,47.0,30.0,198.0,91.0,33.0,14.51,5.94,72.0,362.0,45.0,27.0,5.0,52.0,88.0,287.0,,,,,,,,,,,,,1.3,6.24,1.93, 阴性,无,, P0,H0, 未做, S-100未见神经侵犯 MLH1(60%弱中)MSH2(80%中)MSH6(90%中强)PMS2(65%弱中)CD4+CD8+VEGF+ CD31，D2-40 可见脉管瘤栓,60% 弱-中,80% 中,90% 中-强,65% 弱-中,69.97371879106439,1636881
1636744,张壮志,658308,男,45,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,14,,,1.0,,,,,,,,2016-10-31,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01（1b)00（3a)00（3b)02（4sb)00（4d)05（5)00（6)01（7)00（8a)00（8p)02（9)03（11p)00（12a)00," L（幽门窦部）, 小弯侧Less,",30,30,5, R0 D2,,5.57,3.29,1.74,152.7,204.0,2.76,15.0,19.0,149.0,107.0,22.0,10.84,4.53,66.0,420.0,42.0,24.0,4.3,6.4,89.0,235.0,,,,,,,,,,,,,0.855,11.75,6.24, 阴性,无, 无, P0,H0, 未做,CK+,,,,,70.0065703022339,1636744
1636965,董秀娟,649616,女,64,T1b,N2,M0, ⅡA,1,3,,,,,,4.0,21,,,0.0,,,,,,,,2016-11-02,2020-07-15,2,SOX*2,1.0,SOX,,,,,,1, 低分化管状腺癌,G3, (3a)13 (3b)11 (7)27," U（胃底部）, 前Ant,",40,30,8,,R1,3.9,2.02,1.08,116.4,60.0,3.96,18.0,25.0,192.0,124.0,29.0,11.86,4.8,75.0,218.0,38.0,37.0,5.1,5.5,79.0,263.0,,,,,,,,,,,,,2.89,0.6,0.976, 未做,无, 无, P0,H0, 未做,,,,,,44.382391590013135,1636965
1636834,李国荣,660920,男,66,T1b,N2,M0, ⅡA,1,3,,1.0,1.0,1.0,,3.0,48,,,1.0,,,,,,,,2016-11-01,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】65 低粘附腺癌  5乳头状癌（G1）（pap）30,G2, (1a)05 (1b)02 (3a)07 (3b)34 (4sb)00 (4d)05 (5)01 (6)05 (7)07 (8a)01 (8p)02 (9)01 (11p)07 (12a)01," ML 后Post, 小弯侧Less,",30,15,8, R0 D2,,6.42,62.42,1.77,150.0,202.0,3.01,32.0,27.0,171.0,109.0,23.6,15.71,3.28,69.8,295.68,39.2,30.6,6.4,5.59,85.0,274.0,,,,,,,,,,,,,0.863,6.98,4.92, 阴性,无, 无, P0,H0, 未做, S-100见脉管瘤栓 CK+ CD31 D2-40见脉管瘤栓,,,,,69.97371879106439,1636834
1636602,马晓东,661135,女,45,T3,N1,M0, ⅡB,1,1,,0.0,0.0,0.0,,1.0,19,,,0.0,,0.0,,,,,,2016-10-31,2017-07-06,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por) 乳头状癌（G1）（pap）10,G3, (1a)02 (1b)02 (2)02 (3a)01 (4sa)00 (4sb)00 (4d)00 (5)00 (6)00 (7)04 (8a)02 (8p)03 (9)02 (11p)00 (12a)00小弯11," M（胃体部）, 前Ant, 小弯侧Less,",70,60,35, R0,,5.41,2.82,1.93,76.8,414.0,2.57,13.0,14.0,145.0,54.0,9.0,9.25,3.57,72.0,155.0,41.0,31.0,4.7,2.0,72.0,252.0,,,,,,,,,,,,,1.05,11.78,1.53, 阴性,无, 无, P0,H0, 未做, VEGF+ CD31  D2-40 未见脉管瘤栓  MLH180 MLH265 MLH670 PMS270 CD4 + CD8 +,80% 弱-中,65% 弱,70% 中,70% 弱-中,8.147174770039422,1636602
1636660,焦玉霞,676719,女,60,T4a,N2,M1, ⅢA,1,4,2.0,1.0,1.0,1.0, 肠化生+,3.0,30,中间型（int）,INFc,0.0,,2.0,,2.0,2.0,,,2016-10-31,2020-02-25,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)06 (1b)00 (2)04 (3a)35 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)00 (6)05 (7)02 (8a)00 (9)00 (11p)04 (12a)00," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,8, D2,R2,4.66,2.5,1.7,119.0,236.0,2.68,11.0,13.0,130.0,81.0,6.0,15.01,4.9,62.0,237.0,40.0,22.0,4.7,5.6,65.0,198.0,,,,,,,,,,,,,0.992,11.9,1.14, 阴性,无, 无, p1局肠缘(M1 PER),H0, 未做, VEGF弱+,65% 弱-中,70% 中,80% 中,50% 弱,39.81603153745072,1636660
1636723,冯培明,660873,男,58,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,42,,,1.0,,,,,,,,2016-10-31,2017-05-12,2,,,,,,,,,0, 高级别上皮内瘤变 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b) 023(3a)02 (3b) 08(4sb) 00(4d)00 (5)08 (6) 01(7)00 (8a)00 (8p)00 (9) 00(11p) 00(12a)00," LM 前Ant, 大弯侧Gre, 小弯侧Less,",10,7,2, R0 D2+,,11.17,7.01,3.02,154.2,245.0,2.97,16.0,20.0,155.0,100.0,21.0,20.84,8.51,68.0,312.0,44.0,24.0,3.8,4.6,85.0,309.0,,,,,,,,,,,,,1.63,3.14,5.4,,无, 无, P0,H0, 未做, CK  +,,,,,6.340341655716163,1636723
1636601,苏清兰,661130,女,64,T2,N1,M0, ⅡA,1,2,,0.0,0.0,0.0, 正常,2.0,20,中间型（int）,INFa,1.0,,0.0,,0.0,0.0,,,2016-10-31,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1b)00 (3a)13 (3b)12 (4sb)01 (4d)02 (5)00 (6)04 (7)01 (8a)00 (8p)03 (9)03 (11p)00 (12p)01," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",70,60,30, R0 D2+,,7.45,4.66,1.95,98.7,288.0,3.52,8.0,11.0,132.0,89.0,9.0,8.61,3.67,66.0,197.0,37.0,29.0,5.1,4.4,76.0,238.0,,,,,,,,,,,,,0.2,9.79,1.4, 未做,无, 无, P0,H0, 未做,CD4- CD8- VEGF- CK+,0,70% 弱,60% 弱-中,0,70.0065703022339,1636601
1636885,温铁臣,660949,男,64,T4b,N1,M0, ⅢB,1,3,0.0,0.0,0.0,1.0, 肠化生+,1.0,26,中间型（int）,INFa,2.0,,1.0,,2.0,2.0,,,2016-11-01,2022-09-01,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1b)00 (3a)012 (3b)00 (4sb)05 (4d)05 (5)00 (6)01 (7)00 (8a)11 (8p)01 (9) 00(11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,70,10,,R1,3.87,1.99,1.37,95.0,232.0,2.52,31.0,29.0,171.0,130.0,16.0,8.02,4.51,66.0,161.0,40.0,26.0,3.1,3.7,84.0,250.0,74.6,51.3,19.3,2.66,0.0,8.5,13.6,3.5,1.15,1.12,10.1,,57.84,0.747,1.06, 阳性+,无, 无, P0,H0, 未做,ck(+)  VEGF(+) CD8散在(+),80% 弱,70% 弱,70% 中,70% 弱,69.97371879106439,1636885
1636655,赵秀凤,660955,女,65,T3,N1,M0, ⅡB,1,3,2.0,0.0,0.0,1.0,,1.0,17,中间型（int）,INFa,0.0,,0.0,,2.0,2.0,,,2016-10-31,2022-09-01,1,,,XELOX,XELOX,XELOX,口服卡培他滨,口服卡培他滨,口服卡培他滨,9, 低粘附腺癌 低分化腺癌（G3)(por) Lauren弥漫型,G3, (4d)1/6," M（胃体部）, 大弯侧Gre,",40,30,5, R0 D2,,4.05,59.1,1.2,108.0,217.0,3.26,7.0,12.0,118.0,108.0,18.0,8.82,4.05,76.0,235.0,39.0,37.0,4.7,5.1,83.0,257.0,,,,,,,,,,,,,0.2,3.22,0.611,,无, 无, P0,H0, 未做,,5% 弱,20% 弱-中,20% 中-强,5% 弱,70.0065703022339,1636655
1636741,赵克义,676726,女,61,T3,N0,M0, ⅡA,1,3,2.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,22,中间型（int）,INFc,0.0,,1.0,,2.0,2.0,,,2016-10-31,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren弥漫型,G3, (3a)04 (3b)02 (4sb)00 (4d)06 (5)00 (6)02 (7)00 (8a)03 (8p)01 (9)02 (11p)01 (12a)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,35,14, R0 D2+,,5.77,3.39,1.79,125.4,272.0,3.28,28.0,26.0,202.0,98.0,17.0,8.94,3.73,74.0,270.0,42.0,32.0,6.0,6.2,78.0,334.0,,,,,,,,,,,,,0.398,8.69,0.975, 未做,无, 无, P0,H0, 未做, CK+ CD4 散在+ CD8散在+ VEGF+,80% 中,70% 中,80% 中-强,70% 弱,70.0065703022339,1636741
1636722,李广清,676732,男,60,T3,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,5.0,51,硬型（sci）,INFc,1.0,,2.0,,1.0,2.0,,,2016-10-31,2020-04-02,2,,,XELOX,XELOX,,,,,2, 低粘附腺癌 管状腺癌80（中分化【G2】【tub2】 低分化腺癌（G3)(por)20,G3, (1b)00 (3a)014 (3b)01 (4sb)00 (4d)05 (5)12 (6)312 (7)02 (8a)11 (8p)01 (9)04 (11p)06 (12p)02 (12a)00,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,45,15, R0 D2,,6.26,3.45,1.87,116.0,149.0,2.76,14.0,21.0,135.0,68.0,5.0,5.36,2.6,65.0,223.0,38.0,27.0,5.3,5.1,98.0,294.0,70.7,35.2,26.6,1.32,0.4,7.4,20.0,1.2,0.453,1.78,12.5,,1.51,14.06,3.59, 阴性,无,, P0,H0, 未做,ck(+)  VEGF(弱+) CD4散在(+)  CD8散在(+),80% 中,60% 弱-中,70% 中-强,70% 弱,41.03153745072273,1636722
1637646,于华兰,656296,女,72,T2,N1,M0, ⅡA,1,3,0.0,1.0,1.0,0.0,,2.0,40,中间型（int）,INFa,0.0,,2.0,,2.0,2.0,,,2016-11-07,2022-09-01,1,SOX*2,1.0,XELOX,XELOX,XELOX,,,,3,浸润型混合型癌（乳头状癌为主，中分化管状腺癌20%） Lauren肠型,G2, (2)22," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,30,10, D2,,3.89,1.83,1.33,108.0,251.0,2.7,17.0,26.0,195.0,90.0,21.0,7.83,3.76,64.0,171.0,38.0,26.0,5.1,,71.0,170.0,,,,,,,,,,,,,1.38,10.41,2.48, 未做,无, 无, P0,H0, 未做, CK+ MLH1阳性细胞约占70%，染色强度为弱 MSH2阳性细胞约占75%，染色强度为弱-中 MSH6阳性细胞约占80%，染色强度为中 PMS2阳性细胞约占30%，染色强度为弱 CD4散在+  CD8散在+  VEGF弱+,70% 弱,75% 弱-中,80% 中,30% 弱,69.7766097240473,1637646
1637445,古占元,655298,男,79,T4b,N1,M0, ⅢB,1,3,0.0,1.0,1.0,0.0, 肠化生+,1.0,13,中间型（int）,INFa,0.0,,0.0,,2.0,2.0,,,2016-11-04,2019-05-05,2,,,口服替吉奥,口服替吉奥,口服替吉奥,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (3a)03 (3b)02 (4sb)00 (4d)02 (5)11 (6)04小弯01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,70,15,,R2,9.69,7.11,2.02,107.6,197.0,3.43,26.0,34.0,197.0,129.0,25.1,6.54,2.92,63.7,156.73,33.2,30.5,5.4,6.64,98.0,333.0,,,,,,,,,,,,,1.5,9.66,, 阴性,无, 无, P0,H0, 未做, VEGF（—） CK+ CD31  D2-40 可见脉管瘤栓  MLH1- MLH280 MLH635 PMS25 CD4  CD8 +,0,80% 弱-中,35% 弱-中,5% 弱,29.96057818659658,1637445
1636998,郝振东,660216,男,57,T1b,N0,M0,ⅠA,1,3,,0.0,0.0,1.0,,0.0,16,,,0.0,,,,,,,,2016-11-02,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)01 (3a)01 (3b)01 (4sb)00 (4d)00 (5)02 (6)02 (7)02 (8a)02 (8p)00 (9)01 (11p)03 (12a)00,L（幽门窦部） 小弯侧Less ,20,10,, R0 D2,,6.51,3.85,2.01,143.4,299.0,2.75,17.0,17.0,155.0,67.0,47.0,19.23,6.98,76.0,380.0,46.0,30.0,5.1,6.2,93.0,383.0,76.2,42.6,28.8,1.48,2.2,10.5,11.2,2.8,0.968,1.21,12.3,,2.42,15.03,1.03, 未做,无,, P0,H0, 未做, CK +,,,,,69.94086727989487,1636998
1637315,李贵生,661069,男,66,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,14,,,2.0,,,,,,,,2016-11-03,2019-04-25,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1,  (1a0/0) (1b0/8) (3a0/0) (3b0/0) (4sb0/1) (4d0/3) (60/0) (70/0) (8a0/2) (8p0/0) (90/0) (11p0/0) (12a0/0)," L（幽门窦部）, 小弯侧Less,",20,15,, R0 D2,,7.78,57.44,2.79,149.0,225.0,2.35,18.0,20.0,182.0,88.0,31.0,29.01,9.06,71.0,350.0,43.0,28.0,7.1,5.5,,283.0,,,,,,,,,,,,,0.524,11.52,1.52, 未做,无, 无, P0,H0, 未做, CK+,,,,,29.664914586070957,1637315
1637713,赵艳梅,676776,女,46,T3,N2,M0, ⅢA,1,4,,0.0,0.0,1.0,,5.0,22,,,0.0,,2.0,,2.0,2.0,,,2016-11-07,2018-04-15,2,,,,,,,,,0, 低粘附腺癌,GX, (1a) (3b)," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,95,, D2,,5.02,2.62,1.89,136.8,319.0,2.56,23.0,23.0,185.0,77.0,51.0,15.97,5.48,76.0,267.0,43.0,33.0,4.5,2.7,83.0,276.0,67.1,35.8,25.3,1.54,1.4,10.8,13.5,0.7,1.89,4.55,13.9,,0.363,29.02,2.11,,无, 无, P0,H0, 未做, CK+ CD31  D2-40脉管染色未见明确脉管瘤栓  S-100可见神经侵犯 MLH1弱 + MLH2弱+ MLH6弱+ PMS2弱+ CD4+  CD8+  VEGF弱+,10% 弱,15% 弱,25% 弱-中,5% 弱,17.21419185282523,1637713
1637103,张士德,660895,男,75,T4b,N3b,M0, ⅢC,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,16.0,34,硬型（sci）,INFb,0.0,,1.0,,2.0,2.0,,,2016-11-02,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren混合型,G3,大弯22 (1b)00 (2)02 (3a)48 (3b)11 (4sb)00 (4d)39 (5)00 (6)55 (7)02 (8a)11 (8p、9)03 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,12, R0 D2+,,5.86,3.38,1.94,117.0,269.0,4.56,17.0,20.0,173.0,121.0,9.0,9.32,4.34,62.0,207.0,37.0,25.0,4.3,4.6,96.0,271.0,,,,,,,,,,,,,1.46,194.2,2.97, 未做,无,, P0,H0, 未做,CD4 散在+ CD8散在+ VEGF+,70% 弱-中,60% 中,70% 中-强,50% 弱,69.94086727989487,1637103
1637218,唐永,659762,男,54,T3,N0,M0, ⅡA,1,3,2.0,1.0,1.0,1.0, 肠化生+ 异型增生+,0.0,20,髓样型（med）,INFc,0.0,,1.0,,1.0,2.0,,,2016-11-03,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 粘液腺癌（muc）80 低粘附腺癌15 低分化腺癌（G3)(por)5 Lauren弥漫型,G3, (1a)02 (1b)02 (3a)02 (3b)03 (4sb)00 (4d)02 (5)00 (6)04 (7)01 (8a) (8p)01 (9)00 (11p)01 (12a)02," L（幽门窦部）, 小弯侧Less,",40,30,9, R0 D2,,4.26,1.95,1.82,155.0,139.0,29.2,17.0,18.0,181.0,63.0,5.0,21.23,9.44,71.0,265.0,42.0,29.0,4.9,4.5,94.0,235.0,,,,,,,,,,,,,31.12,10.86,5.71, 阴性,无,, P0,H0, 未做, CD4（+） CD8（+） VEGF（+),80% 弱-中,70% 弱-中,90% 中-强,70% 弱,69.90801576872536,1637218
1637547,唐国富,676293,男,81,T3,N3b,M0, ⅢC,1,5,2.0,1.0,1.0,1.0,,17.0,35,中间型（int）,INFc,0.0,,0.0,,2.0,2.0,,,2016-11-05,2017-08-01,2,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (3a)58 (3b)00 (4sb)01 (4d)05 (5)02 (6)55 (7)00 (8a)11 (8p)01 (9)25 (11p)47 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",35,35,15, R0 D2+,,3.75,2.12,1.23,95.9,190.0,2.17,12.0,25.0,151.0,71.0,6.0,4.87,2.47,48.0,115.0,24.0,24.0,4.9,7.2,80.0,244.0,,,,,,,,,,,,,0.496,22.87,1.0, 未做,无,, P0,H0, 未做,CD4散在+ CD8散在+ VEGF-,15% 弱,80% 弱,50% 弱,80% 弱,8.83705650459921,1637547
1637161,王清云,676985,男,45,T2,N2,M0, ⅡB,1,2,1.0,1.0,1.0,1.0, 肠化生+,3.0,22,髓样型（med）,INFa,3.0,,1.0,,2.0,2.0,,,2016-11-03,2022-09-01,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3, (1a)00 (1b) 05(3a)34 (3b)00 (4sb)01 (4d) 03(5)00 (6)04 (7)00 (8a)01 (8p)01 (9) 02(11p)00 (12a)01," L（幽门窦部）, 后Post, 小弯侧Less,",30,30,10, R0 D2+,,8.39,5.34,2.14,163.0,246.0,3.33,29.0,23.0,150.0,81.0,42.0,8.15,3.28,70.0,378.0,43.0,27.0,5.3,4.7,90.0,354.0,,,,,,,,,,,,,2.11,9.69,1.35,,无, 无, P0,H0, 未做, CK VEGF,80% 中,80% 中,80% 中-强,70% 弱,69.90801576872536,1637161
1644899,王延臣,676693,男,60,T4b,N0,M0, ⅢA,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,0.0,21,中间型（int）,INFb,0.0,,1.0,,2.0,2.0,,,2016-12-29,2022-09-01,1,XELOX*2,1.0,SOX,,,,,,1, 低分化腺癌（G3)(por) 低粘附腺癌,G3,小弯01  (1a)00 (1b)01 (3a)06 (3b)01 (4sb)00 (4d)02 (5)01 (6)02 (7)01 (8a) 01(8p)01 (9)02 (11p)02 (12a)00," LM 前Ant, 后Post, 小弯侧Less,",90,60,10,,R1,9.05,5.66,2.42,95.1,270.0,4.69,10.0,11.0,143.0,82.0,24.0,5.44,2.51,61.0,170.0,33.0,28.0,6.0,8.5,107.0,391.0,,,,,,,,,,,,,0.838,8.72,2.03, 未做,无,, P0,H0, 未做,,0,80% 中-强,80% 强,0,68.06833114323258,1644899
1637548,李盛波,661073,男,53,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,26,,,1.0,,,,,,,,2016-11-05,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a) 01(1b)00 (3a)04 (3b)00 (4sb)00 (4d)03 (5)00 (6)06 (7)04 (8a)01 (8p)02 (9)01 (11p)04 (12a)00 (14v)00,M（胃体部） 小弯侧Less ,20,15,5, R0 D2,,8.02,5.27,1.96,145.3,403.0,3.67,41.0,28.0,180.0,84.0,28.0,16.6,6.31,71.0,591.0,44.0,27.0,5.0,4.8,90.0,426.0,,,,,,,,,,,,,1.04,5.82,2.28, 未做,无,, P0,H0, 未做, CK +,,,,,69.84231274638633,1637548
1637319,蔡玉生,676756,男,66,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 正常,51.0,62,中间型（int）,INFb,0.0,,2.0,,1.0,2.0,,,2016-11-03,2017-06-22,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】80 乳头状癌（G1）（pap）10 低粘附腺癌10 Lauren弥漫型,G2, (1a)00 (1b)12 (3a)1316 (3b)22 (4sb)00 (4d)910 (5)11 (6)44 (7) 00(8a)02 (8p)00 (9)03 (11p)23 (12a)00 (14v)44大弯1515, LM 前Ant 后Post 大弯侧Gre  ,70,70,10, R0 D2,,4.33,2.28,1.51,110.0,235.0,2.39,12.0,15.0,146.0,89.0,21.0,6.82,3.84,63.0,220.0,37.0,26.0,6.2,5.2,86.0,283.0,,,,,,,,,,,,,0.384,6.35,3.33, 未做,无, , P0,H0, 未做,ck(+)  VEGF(弱+) CD4(+)  CD8散在(+),90% 弱,90% 中,80% 中-强,70% 弱,7.588699080157687,1637319
1637208,王亚珍,677003,女,64,T2,N0,M0, ⅠB,1,2,1.0,0.0,0.0,0.0, 正常,0.0,11,中间型（int）,INFa,0.0,,1.0,,2.0,2.0,,,2016-11-03,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90% 低粘附腺癌10% Lauren混合型,G2,11," L（幽门窦部）, 小弯侧Less,",25,20,5, R0 D2,,7.81,3.73,3.29,173.7,155.0,3.26,20.0,26.0,201.0,106.0,12.0,9.64,3.24,77.0,445.0,45.0,32.0,5.4,4.3,87.0,277.0,,,,,,,,,,,,,4.29,3.62,9.36,,无, 无, P0,H0, 未做,,70% 弱-中,80% 弱-中,90% 中-强,40% 弱,69.90801576872536,1637208
1638151,杨莉,660213,女,72,T1b,N0,M0,ⅠA,1,0,,0.0,0.0,0.0,,0.0,13,,,1.0,,,,,,,,2016-11-10,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）50 粘液腺癌（muc）40 乳头状癌（G1）（pap）10,G1, (3a)03  (3b)00 (4sb)03  (4d)05  (5)00 (6)02 (12a)00," L（幽门窦部）, 小弯侧Less,",22,18,5, R0 D1+,,7.7,3.91,3.28,135.4,199.0,3.28,17.0,20.0,174.0,138.0,10.0,14.92,3.32,74.0,314.0,41.0,33.0,4.9,3.7,90.0,233.0,,,,,,,,,,,,,0.202,7.23,3.97, 阴性,无, 无, P0,H0, 未做,,,,,,69.67805519053876,1638151
1637723,刘国正,661061,男,64,T4b,N3a,M1, Ⅳ,1,3,2.0,1.0,1.0,1.0, 正常,10.0,21,中间型（int）,INFc,1.0,,1.0,,2.0,2.0,,,2016-11-07,2019-05-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren弥漫型,G3, (3a)34 (3b)01 (4sb)12 (4d)14 (5)22 (6)33 (7)01 (8a)02 (9)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,20,,R2,12.97,10.57,1.43,124.6,197.0,4.23,12.0,21.0,234.0,78.0,13.0,6.41,2.34,62.0,162.0,36.0,26.0,5.3,5.7,105.0,273.0,,,,,,,,,,,,,1.11,9.66,4.78, 未做,粟粒状,, p1泛(M1 PER),H0, 未做,CD4 散在+ CD8散在+ VEGF+,85% 弱-中,70% 弱-中,70% 中,70% 弱,29.730617608409986,1637723
1637885,王振河,661086,男,66,T2,N1,M0, ⅡA,1,2,1.0,1.0,1.0,1.0, 正常,1.0,23,中间型（int）,INFb,2.0,,,,,,,,2016-11-08,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 管状腺癌（中分化【G2】【tub2】 70%低粘附腺癌 30%Lauren混合型,G2, (1a)04 (1b)03 (2)03 (3a)01 (3b)15 (4sa)00 (4sb)00 (8a)01 (8p)00 (9)01 (11d)01 (11p)00 下肺韧带02 隆突下01 下段食管旁01 隔上00," SiewerⅡ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,30,10, R0 D2,,8.62,48.0,3.56,157.0,260.0,2.52,13.0,16.0,163.0,111.0,29.0,8.23,3.0,67.0,304.0,42.0,25.0,5.6,7.4,108.0,226.0,,,,,,,,,,,,,2.75,6.63,10.49, 阴性,无, 无, P0,H0, 未做,CK+  CD31  D2-40 可见瘤栓 S-100可见神经侵犯,,,,,69.7437582128778,1637885
1638585,温国庆,651574,男,69,T4b,N1,M0, ⅢB,1,3,0.0,0.0,0.0,0.0, 正常,2.0,46,中间型（int）,INFa,3.0,,0.0,,1.0,2.0,,,2016-11-14,2018-01-15,2,SOX*3,1.0,XELOX,XELOX,XELOX,紫杉醇联合替吉奥,紫杉醇联合替吉奥,口服替吉奥,6, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap）20 Lauren肠型,G2, (1a)217 (1b)00 (2)04 (3a)17 (3b)09 (4sa)00 (4sb)00 (4d)04 (5)00 (6)02 (7)02 (8a)01 (8p)08 (9)01 (11p)01 (12a)00," U（胃底部）, SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",30,20,20,,R1,15.2,12.97,0.91,139.7,79.0,4.48,43.0,43.0,287.0,80.0,47.0,30.35,8.72,76.0,168.0,37.0,39.0,5.9,5.5,102.0,218.0,,,,,,,,,,,,,2.27,0.6,31.85, 未做,无, 无, P0,H0, 未做, VEGF+ CK+ CD4+  CD8+ ,80% 弱,70% 弱-中,95% 强,80% 弱,14.027595269382392,1638585
1637607,吴承哲,384774,女,61,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,14,,,0.0,,,,,,,,2016-11-07,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】） 低粘附腺癌40,G2, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)00 (4d)01 (5)03 (6)00 (7)01 (8a)03 (8p)02 (9)02 (11p)00," M（胃体部）, 小弯侧Less,",15,15,, R0 D2+,,8.45,5.3,2.27,138.4,360.0,2.6,22.0,21.0,184.0,68.0,12.0,8.77,2.53,74.0,321.0,43.0,31.0,5.6,4.9,84.0,304.0,,,,,,,,,,,,,2.78,4.89,9.88,,无, 无, P0,H0, 未做, CK,,,,,69.7766097240473,1637607
1638513,隋秀民,678142,男,76,T3,N0,M0, ⅡA,1,2,0.0,0.0,0.0,0.0, 肠化生 异型增生,0.0,22,中间型（int）,INFa,2.0,,1.0,,2.0,2.0,,,2016-11-14,2018-01-23,0,,,口服替吉奥,口服替吉奥,,,,,2, 管状腺癌（中分化【G2】【tub2】,G2,22," L（幽门窦部）, 大弯侧Gre,",35,20,5, R0 D2,,5.87,2.45,2.65,138.2,185.0,3.17,17.0,24.0,137.0,89.0,28.0,20.51,6.39,39.0,442.0,39.0,30.0,5.1,6.8,110.0,483.0,,,,,,,,,,,,,0.827,13.43,2.37,,无, 无, P0,H0, 未做,,90% 中,85% 中-强,80% 中-强,85% 弱-中,14.290407358738502,1638513
1638654,杨文志,676383,男,52,T4b,N3a,M0, ⅢC,1,5,2.0,1.0,1.0,1.0, 正常,14.0,22,硬型（sci）,INFc,0.0,,2.0,,2.0,2.0,,,2016-11-14,2019-05-03,0,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌95% 低分化管状腺癌5% Lauren弥漫型,G3,1422 (1a)33 (1b)03 (3a)01 (3b)00 (4sb)01 (4d)11 (5)00 (6)68 (7)01 (8a)22 (8p)00 (9)22," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,10, R0 D1+,,7.83,4.61,2.38,139.0,293.0,4.12,10.0,17.0,163.0,59.0,9.0,6.19,1.81,65.0,278.0,39.0,26.0,4.3,6.9,130.0,410.0,,,,,,,,,,,,,1.43,6.3,1.37,,无, 无, P0,H0, 未做,,70% 中,50% 中,70% 中-强,65% 中,29.566360052562416,1638654
1638582,李丙芝,658760,女,73,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,19,,,0.0,,,,,,,,2016-11-14,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)07 (3b)01 (4sb)00 (4d)02 (5)00 (6)01 (7)01 (8a)01 (8p)03 (9)03 (11p)00 (12a)00," M（胃体部）, 后Post,",15,12,, D2,,6.29,3.91,1.85,137.0,306.0,3.72,14.0,20.0,161.0,89.0,11.0,10.13,2.51,74.0,367.0,42.0,32.0,5.7,4.9,86.0,262.0,,,,,,,,,,,,,0.959,9.3,4.29, 未做,无, 无, P0,H0, 未做, CK +,,,,,69.54664914586071,1638582
1639169,孙运成,676902,男,66,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 慢性炎症（+）,7.0,16,中间型（int）,INFb,2.0,,1.0,,1.0,2.0,,,2016-11-17,2019-04-23,2,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】60% 低粘附腺癌40% Lauren混合型,G3, (1a)0/1 (1b)6/9 (2)1/3 (3a)0/1 (3b)0/0 (4sa)0/0 (4sb)0/0 (7)0/0 (8a)0/0 (8p)0/0 (9)0/1 (11p)0/1," 后Post, U（胃底部）,",45,28,10, D2,,5.25,2.74,1.78,149.0,223.0,2.57,23.0,21.0,185.0,62.0,30.0,9.01,2.41,71.0,232.0,41.0,30.0,5.0,4.2,95.0,300.0,67.7,31.3,33.9,0.92,0.3,8.3,21.4,4.3,0.819,2.67,15.7,,3.29,40.73,2.27, 未做,无, 无, P0,H0, 未做, S-100 CD  VEGF CK + MLH1（阳性细胞约占60%，染色强度为弱） MSH2（阳性细胞约占80%，染色强度为弱-中） MSH6（阳性细胞约占80%，染色强度为中） PMS2（阳性细胞约占50%，染色强度为弱）,60% 弱,80% 弱-中,80% 中,50% 弱,29.139290407358736,1639169
1639663,李文波,678090,男,52,T2,N2,M0, ⅡB,1,3,,0.0,0.0,1.0,,4.0,21,,,1.0,,,,,,,,2016-11-22,2022-09-01,1,,,mDCF,mDCF,多西他赛+奥沙利铂+替吉奥,,,,4, 低粘附腺癌90低分化腺癌（G3)(por)10,G3, (1a)03 (1b)12 (3a)00 (3b)11 (4sb)00 (4d)14 (5)01 (6)11 (7)04 (8a)02," LM 前Ant, 后Post, 小弯侧Less,",55,45,5, R0 D2+,,5.12,2.48,2.12,157.9,234.0,2.27,59.0,35.0,198.0,63.0,90.0,14.55,4.71,76.0,478.0,46.0,30.0,5.6,7.5,127.0,353.0,,,,,,,,,,,,,1.88,12.23,0.855,,无, 无, P0,H0, 未做, CK +,,,,,69.2838370565046,1639663
1638846,刘铁炼,676395,男,66,T2,N0,M0, ⅠB,1,3,0.0,0.0,0.0,1.0, 慢性炎症（+）,0.0,45,中间型（int）,INFa,1.0,,,,,,,,2016-11-15,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)05 (1b)02 (3a)03 (3b)03 (4sb)00 (4d)013 (5)00 (6)013 (7)01 (8a)01 (8p)02 (9)01 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",15,15,12, R0,,6.46,3.87,1.67,143.0,195.0,2.25,15.0,18.0,148.0,76.0,24.0,15.33,4.77,65.0,233.0,40.0,25.0,5.1,5.9,101.0,410.0,,,,,,,,,,,,,2.06,23.94,1.81, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,69.51379763469119,1638846
1638578,姜高棋,678039,男,66,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 正常,30.0,40,髓样型（med）,INFc,0.0,,0.0,,2.0,2.0,,,2016-11-14,2017-07-23,0,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,,,4," 低分化腺癌（G3)(por)80%低粘附腺癌20%, Lauren弥漫型",G3, (1a)04 (1b)55 (2)02 (3b)33 (4sb)01 (4d)55 (5)11 (14v) 33(16a2)11 (3a)11 (4sa)01 (6)55 (7)12 (8a)22 (8p)11 (9)22 (11p)01 (12a)00," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",110,70,7, R0 D2+,,6.32,3.11,2.69,155.4,191.0,2.79,27.0,21.0,171.0,116.0,14.1,15.38,3.41,59.1,233.09,34.7,24.4,5.4,5.89,97.0,381.0,,,,,,,,,,,,,1.31,9.17,300.0, 阴性,无, 无, P0,H0, 未做,CK+ CD4 CD8+ VEGF-CD31 D2-40见脉管瘤栓 S-100见神经侵犯  MLH1（85% 中） MLH2（90% 中） MLH6 （95% 强）PMS2（55% 弱）,85% 中,90% 中,95% 强,55% 弱,8.245729303547963,1638578
1638636,周政,677038,男,53,T3,N2,M0, ⅢA,1,3,2.0,0.0,0.0,1.0, 正常,3.0,27,硬型（sci）,INFc,0.0,,2.0,,2.0,2.0,,,2016-11-14,2018-03-14,2,,,FOLFOX,FOLFOX,XELOX,,,,3, 低粘附腺癌 Lauren弥漫型,GX, (5)22 (6)15 (1a)03 (1b)00 (2)01 (3a)02 (3b)02 (4sa)00 (4sb)00 (4d)03 (7)00 (8a)02 (8p)05 (9)01 (11p)00 (12a)00 (14v)01," L（幽门窦部）, M（胃体部）, LM 前Ant, 后Post, 小弯侧Less,",60,50,10, R0 D2,,6.1,3.33,2.14,110.0,549.0,5.34,23.0,20.0,149.0,58.0,11.0,3.7,1.08,64.0,184.0,39.0,25.0,6.2,5.6,94.0,254.0,,,,,,,,,,,,,0.648,7.54,2.58,,无, 无, P0,H0, 未做,,40% 弱,10% 弱,5% 弱,25% 弱,15.932982917214192,1638636
1638800,聂洪英,677115,女,75,T3,N3a,M0,ⅢB,1,5,1.0,1.0,1.0,0.0, 肠化生+,10.0,35,髓样型（med）,INFa,2.0,,,,,,,,2016-11-15,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】85%低粘附腺癌10 乳头状癌（G1）（pap）5  Lauren混合型,G3, (1a)22 (1b)05 (3a)05 (3b)02 (4sb)00 (4d)00 (5)46 (6)27 (7)00 (8a)15 (8p)02 (9)00 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,55,20, R0 D2,,8.27,4.62,2.93,143.0,282.0,3.52,16.0,24.0,211.0,121.0,33.0,10.82,2.33,69.0,340.0,44.0,25.0,6.8,4.3,82.0,247.0,,,,,,,,,,,,,0.372,7.55,8.87, 阴性,无, 无, P0,H0, 未做, CK(+) S-100未见神经侵犯 CD31 D2-40见脉管瘤栓,,,,,69.51379763469119,1638800
1638627,李文章,676878,男,66,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 正常,16.0,53,髓样型（med）,INFc,0.0,,2.0,,2.0,2.0,,,2016-11-14,2019-04-25,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,SOX,6, 粘液腺癌（muc） 低粘附腺癌20 Lauren弥漫型,GX, (1a)01 (1b)01 (3a)212 (3b)37 (4sb)07 (4d)511 (5)00 (6)45 (7)00 (8a)12 (8p)04 (9)01 (11p)01 (12a)11 5组软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",65,60,15, D2,,4.1,2.64,0.97,76.0,248.0,3.13,13.0,17.0,129.0,90.0,2.0,4.73,1.81,56.0,159.0,37.0,19.0,5.6,5.2,91.0,206.0,61.5,40.9,19.0,2.15,0.2,7.8,27.9,0.9,0.25,2.95,7.05,,0.835,16.52,4.61, 阳性+,无, 无, P0,H0, 未做, VEGF+ CK+ CD4+  CD8 +,80% 中,80% 弱-中,90% 中-强,70% 弱,29.303547963206306,1638627
1639136,韩桂华,663230,女,62,T3,N0,M0, ⅡA,1,3,0.0,1.0,1.0,1.0, 正常,0.0,29,中间型（int）,INFa,2.0,,2.0,,2.0,2.0,,,2016-11-17,2022-09-01,1,,,XELOX,,,,,,1, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】70% 粘液腺癌（muc）30% Lauren肠型,G2, (1a)01 (1b)06 (3a)01 (3b)00 (4sb)00 (4d)04 (5)00 (6)04 (7)(8)(9)06 (11p)03 (12a)00 (13)01 (14v)03," L（幽门窦部）, 后Post,",30,30,10, R0 D2,,6.36,3.18,2.48,136.0,256.0,2.37,14.0,18.0,133.0,101.0,15.0,12.38,3.73,62.0,194.0,37.0,25.0,5.1,2.7,74.0,274.0,,,,,,,,,,,,,10.21,155.3,1.26, 阴性,无, 无, P0,H0, 未做,CK+ CD4+ CD8+ VEGF弱+ S-100见神经侵犯 CD31 D2-40见脉管瘤栓 MLH1（35% 弱） MLH2（60% 弱-强） MLH6 （80% 中-强）PMS2（25% 弱）,35% 弱,60% 弱-中,80% 中-强,25% 弱,69.44809461235216,1639136
1638962,吴希中,661586,男,55,T4b,N3b,M0, ⅢC,1,2,1.0,1.0,1.0,1.0, 异型增生,17.0,20,中间型（int）,INFa,2.0,,1.0,,2.0,2.0,,,2016-11-16,2017-06-07,2,,,XELOX,XELOX,,,,,2, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3,大弯侧33 (3a)45  (3b)45 (4sb)00 (4d)23 (5)11 (6)22 (7)11 3b、4sb、6软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,15,,R2,6.62,4.49,1.68,140.1,232.0,2.39,26.0,25.0,183.0,87.0,8.9,4.49,1.89,23.7,148.36,23.7,22.4,6.3,6.18,68.0,,,,,,,,,,,,,,1.29,119.4,110.7, 阴性,无, 无, P0,H0, 未做, VEGF（+） CK+ CD4+ CD8+ S-100见神经侵犯 CD31，D2-40 可见脉管瘤栓， MLH1（75% 弱-中） MLH2（70% 中） MLH6（80% 中-强） PMS2（60%，弱）,75% 弱-中,70% 中,80% 中-强,60% 弱,6.668856767411301,1638962
1639088,刘丽萍,661580,女,44,T3,N2,M0, ⅢA,1,4,2.0,0.0,0.0,1.0, 异型增生+ 慢性炎症（+）,3.0,35,硬型（sci）,INFb,0.0,,2.0,,2.0,2.0,,,2016-11-17,2021-10-15,1,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)04 (1b)07 (3a)01 (3b) 01(4sb)00 (4d)28 (5)00 (6)15 (7) 01(8a)04 (8p)02 (9)01 (11p) 01(12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,30,10, R0 D2,,7.41,3.77,2.84,142.3,211.0,1.96,10.0,18.0,147.0,46.0,10.0,14.42,4.23,72.0,230.0,42.0,30.0,5.1,3.8,83.0,200.0,,,,,,,,,,,,,1.02,22.95,4.09, 未做,无, 无, P0,H0, 未做, CD4（+） CD8（+） VEGF（+),80% 弱-中,60% 弱,80% 弱-中,60 弱,58.90275952693823,1639088
1639872,李清和,661587,男,56,T3,N3a,M0,ⅢB,1,2,1.0,1.0,1.0,1.0, 正常,8.0,27,中间型（int）,INFa,1.0,,1.0,,2.0,2.0,,,2016-11-23,2018-08-30,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1b)00 (3a)44 (3b)04 (4sb)00 (4d)33 (5)00 (6)00 (7)12 (8a)05 (8p)05 (9)01 (11p)03 (12a)00," M（胃体部）, 小弯侧Less,",60,40,10, R0 D2,,7.53,5.1,1.79,119.9,322.0,3.59,9.0,12.0,148.0,92.0,20.0,7.79,2.45,74.0,278.0,45.0,29.0,9.2,4.4,75.0,286.0,,,,,,,,,,,,,1.1,8.58,1.98, 阳性,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),90% 弱-中,90% 弱-中,90% 中,80% 弱,21.1892247043364,1639872
1639992,刘青,663206,男,77,T1b,N2,M0, ⅡA,1,2,,1.0,1.0,0.0,,3.0,14,,,1.0,,,,,,,,2016-11-24,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (3a)02 (3b)01 (4sb)00 (4d)02 (5)00 (6)34 (7)00 (8a)04 (9)00 (11p)00 (12a)01, L（幽门窦部） 后Post 小弯侧Less ,10,10,3, R0 D2,,4.25,2.89,0.97,122.0,164.0,1.86,15.0,20.0,158.0,70.0,12.0,8.49,2.67,64.0,213.0,38.0,26.0,5.3,7.3,96.0,340.0,70.8,38.1,28.5,1.34,0.2,5.5,19.7,2.8,0.599,3.12,14.0,,1.31,4.55,3.01, 阴性,无,, P0,H0, 未做,,,,,,69.21813403416557,1639992
1639972,张天双,677130,女,61,T3,N2,M0, ⅢA,1,1,,0.0,0.0,1.0,,3.0,22,,,1.0,,1.0,,2.0,2.0,,,2016-11-24,2022-09-01,1,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)01 (2)13 (3a)01 (3b)01 (4sa)00 (4sb)00 (5)00 (7)22 (8a)04 (8p)02 (9)02 (11p)05 (12a)00,U（胃底部） SiewerⅢ型 后Post 小弯侧Less 大弯侧Gre   ,50,40,10, R0 D2,,6.78,4.73,1.68,131.7,275.0,2.85,21.0,24.0,172.0,76.0,11.0,6.83,1.59,72.0,364.0,43.0,29.0,5.0,8.1,84.0,255.0,,,,,,,,,,,,,0.864,20.08,3.37, 未做,无, 无, P0,H0, 未做, CD4（+） CD8（+） VEGF（+),90% 弱-中,85% 弱-中,80% 中-强,85% 弱,69.21813403416557,1639972
1639815,韩桂云,663219,女,64,T3,N1,M0, ⅡB,1,4,2.0,1.0,1.0,1.0, 慢性炎症（+）,2.0,23,硬型（sci）,INFc,0.0,,2.0,,2.0,2.0,,,2016-11-23,2019-12-26,2,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,SOX,XELOX,9, 低粘附腺癌80 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20 Lauren弥漫型,G3, (1a)00 (1b)00 (3a)02 (3b)23 (4sb)00 (4d)04 (5)00 (6)02 (7)04 (8a)02 (8p)00 (9)00 (11p)04 (12a)02," L（幽门窦部）, 后Post, 小弯侧Less,",40,25,15, R0 D2+,,7.11,26.9,1.91,137.0,177.0,2.44,14.0,17.0,200.0,95.0,26.0,9.68,2.76,62.0,247.0,39.0,23.0,,6.0,91.0,263.0,,,,,,,,,,,,,2.96,1.28,1.69, 未做,无, 无, P0,H0, 未做,CK + CD4散在+  CD8散在+ VEGF部分弱+,70% 弱-中,70% 弱-中,70% 强,60% 弱-中,37.056504599211564,1639815
1639167,王振鹏,640679,男,66,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,14,,,2.0,,,,,,,,2016-11-17,2022-09-01,1,,,,,,,,,0, 中低分化腺癌（G3)(por),G3,," M（胃体部）, 大弯侧Gre, 前Ant,",15,10,, R0 D1,,5.31,2.38,2.45,144.9,166.0,1.77,35.0,49.0,164.0,69.0,46.0,25.28,7.26,72.0,341.0,41.0,31.0,5.2,8.4,87.0,290.0,,,,,,,,,,,,,1.68,20.09,4.98,,无, 无, P0,H0, 未做,,,,,,69.44809461235216,1639167
1639560,李成祥,677105,男,56,T4b,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 正常,19.0,38,髓样型（med）,INFb,0.0,,2.0,,2.0,2.0,,,2016-11-21,2018-01-23,0,,,,,,,,,0, 粘液腺癌（muc） 低分化腺癌（G3)(por)35 低粘附腺癌15 Lauren肠型,G3, (1a)05 (1b)02 (3a)12 (3b)12 (4sb)22 (4d)55 (5)11 (6)55 (7)01 (8a)11 (8p)14 (9)02 (11p)00 (12a)00 (12p)01 (14v)00 (17)12 (18)13," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,10, R0 D2,,4.92,2.19,2.04,137.0,206.0,3.48,29.0,37.0,104.0,57.0,13.0,13.15,5.07,60.0,134.0,35.0,25.0,3.4,3.1,77.0,344.0,,,,,,,,,,,,,23.96,1000.0,164.8, 未做,无, 无, P0,H0, 未做, CK+ CD31  D2-40 可见脉管瘤栓 S—100可见神经侵犯 MLH1— MSH2 80%染色强度为中， MSH6 90% 染色强度为强，PMS2- CD4 + CD8 + VEGF+,0,80% 中,90% 强,0,14.060446780551905,1639560
1639540,杨军,676935,男,47,T1b,N0,M0,ⅠA,1,3,1.0,1.0,1.0,0.0, 肠化生+,0.0,22,髓样型（med）,INFa,1.0,,,,,,,,2016-11-21,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 粘液腺癌（muc） 管状腺癌（中分化【G2】【tub2】20 Lauren混合型,G2, (1a)01 (1b)03 (3a)04 (3b)00 (4sb)00 (4d)02 (5)00 (6)03 (7)02 (8a)04 (8p)01 (9)01 (11p)00 (12a)01," L（幽门窦部）, 后Post, 小弯侧Less,",30,20,10, R0,,6.72,3.91,2.23,163.7,194.0,2.39,18.0,17.0,202.0,78.0,59.0,9.14,2.67,71.0,412.0,45.0,26.0,5.6,5.9,96.0,413.0,,,,,,,,,,,,,2.58,15.0,1.94, 未做,无, 无, P0,H0, 未做, CK（+） ,,,,,69.3166885676741,1639540
1639621,王立志,677076,男,65,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+,9.0,31,髓样型（med）,INFb,0.0,,2.0,,1.0,2.0,,,2016-11-22,2019-01-06,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,11, 粘液腺癌（muc）70 低粘附腺癌20 管状腺癌（中分化【G2】【tub2】10  Lauren混合型,G2, (1a)02 (1b)00 (3a) 510(3b) 00(4sb) 03(4d) 48(5) 00(6) 00(7)02 (8a)00 (8p) 02(9)02 (11p)02 (12a)00 , L（幽门窦部）前Ant 小弯侧Less 后Post  ,60,60,10, R0 D2,,7.82,5.06,2.2,139.0,321.0,4.56,30.0,33.0,202.0,104.0,24.0,14.15,4.61,69.0,213.0,41.0,28.0,5.4,5.4,111.0,277.0,,,,,,,,,,,,,3.72,0.6,23.287, 阴性,无,, P0,H0, 未做,,20% 弱,85% 中-强,95% 强,20% 弱,25.45992115637319,1639621
1639703,胡喜琴,676249,女,58,T3,N3b,M0, ⅢC,1,3,0.0,0.0,0.0,1.0, 肠化生+,16.0,30,髓样型（med）,INFa,0.0,,2.0,,1.0,2.0,,,2016-11-22,2018-10-01,2,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)23 (1b)11 (3a)11 (3b)00 (4sb)77 (4d)00 (5)00 (6)12 (7)15 (8a)11 (8p)04 (9)14 (11p)00 (12a)01," L（幽门窦部）, 后Post,",40,40,12, R0,,6.26,4.89,1.02,119.0,260.0,2.97,9.0,17.0,158.0,97.0,6.0,5.47,1.6,58.0,188.0,37.0,21.0,5.4,4.9,80.0,162.0,,,,,,,,,,,,,1.65,12.65,1.03, 未做,无, 无, P0,H0, 未做, CK（+）、,80% 弱,80% 中,80% 强,50% 弱,22.273324572930353,1639703
1639704,王俊红,678089,女,49,T4a,N3b,M0, ⅢC,1,4,2.0,1.0,1.0,1.0, 正常,40.0,44,硬型（sci）,INFc,0.0,,2.0,,2.0,2.0,,,2016-11-22,2019-03-12,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX, (1a)12 (1b) (2)00 (3a)78 (3b)00 (4sa)00 (4sb)00 (4d)1212 (5)00 (6)23 (7)55 (8a)33 (8p)11 (9)55 (11p)33 (12a)00, LM 前Ant 后Post 大弯侧Gre  小弯侧Less  ,70,60,15, R0 D2,,7.19,4.86,1.7,72.4,472.0,3.81,14.0,16.0,198.0,45.0,9.0,8.5,2.38,57.0,332.0,36.0,21.0,4.2,4.7,70.0,228.0,,,,,,,,,,,,,0.833,4.88,1.21, 阴性,无, 无, P0,H0, 未做, CD4（+） CD8（+） VEGF（+),40% 弱,40% 弱,60% 弱-中,40% 弱,27.59526938239159,1639704
1640079,高学文,663204,男,67,T4b,N3a,M0, ⅢC,1,3,1.0,1.0,1.0,0.0, 肠化生+,9.0,37,中间型（int）,INFb,0.0,,1.0,,1.0,2.0,,,2016-11-24,2017-11-15,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 粘液腺癌（muc） Lauren混合型,G2," (2)1/4 (4d)2/3 (5)1/1 (6)2/7 (11p)1/3 (12a)2/3， (1a)01 (1b)01 (3a)01 (3b)01 (4sa)00 (4sb)00 (7)02 (8a)02 (8p)05 (9)00 (11d)03,6组软组织可见癌"," L（幽门窦部）, U（胃底部）, 前Ant, 后Post, 小弯侧Less,",90,80,15,,R2,8.58,69.57,1.58,83.5,366.0,3.75,9.0,17.0,276.0,59.0,9.0,5.04,1.36,67.0,178.0,35.0,32.0,4.4,4.5,97.0,324.0,56.5,33.6,20.2,1.66,0.1,5.4,26.7,1.6,0.739,2.02,,,107.1,636.6,6.33,,无, 无, P0,H0, 未做,,60% 弱,80% 弱-中,80% 弱-中,50% 弱,11.695137976346912,1640079
1639784,崔爱吉,571574,男,58,T1a,N0,M0,ⅠA,1,2,,,,,,0.0,29,,,0.0,,,,,,,,2016-11-22,2022-09-01,1,,,,,,,,,0, 低粘附腺癌,GX, (1a)01 (1b)00 (3a)015 (3b)00 (4sb)00 (4d)02 (5)02 (6)02 (7)02 (8a) (8p)02 (9)02 (12a)01 (14v)00,L（幽门窦部） 小弯侧Less ,20,20,3, R0 D2,,5.21,2.37,2.22,137.1,197.0,2.65,9.0,16.0,151.0,51.0,23.0,17.7,4.74,67.0,375.0,41.0,26.0,5.0,4.4,90.0,382.0,,,,,,,,,,,,,0.429,5.01,4.14, 未做,无,, P0,H0, 未做,,,,,,69.2838370565046,1639784
1640085,王霞,662966,女,67,T1a,N2,M0, ⅡA,1,3,,1.0,1.0,1.0,,6.0,29,,,1.0,,,,,,,,2016-11-24,2019-03-19,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)02 (1b)02 (3a)04 (3b)13 (4sb)00 (4d)17 (5)00 (6)36 (7)00 (8a)11 (8p)01 (9)02 (11p)00 (12a)01," L（幽门窦部）, 前Ant,",15,15,5, D2,,6.57,3.6,2.37,124.0,218.0,3.56,17.0,21.0,240.0,88.0,14.0,8.35,2.38,74.0,318.0,42.0,32.0,6.0,7.7,91.0,392.0,65.7,47.9,15.8,3.03,0.6,10.8,18.6,0.1,1.09,3.01,13.9,,2.27,20.97,0.787, 未做,无, 无, P0,H0, 未做, CK +,,,,,27.75952693823916,1640085
1639971,刘忠还,663192,男,60,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+,1.0,24,髓样型（med）,INFa,2.0,,1.0,,2.0,2.0,,,2016-11-24,2018-11-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (2)01 (3a)14 (3b)01 (4sa)01 (4sb)02 (4d)01 (5)00 (6)04 (7)03 (8a)02 (8p)02 (9)03 (11p)00 (12a)00 软组织可见癌," SiewerⅡ, 前Ant, 后Post, 小弯侧Less,",50,45,10, R0 D2,,9.15,6.13,1.8,119.5,330.0,4.0,20.0,16.0,159.0,28.0,24.6,13.78,2.91,58.3,157.32,30.6,27.7,4.5,4.89,88.0,488.0,,,,,,,,,,,,,1.07,30.46,2.08, 未做,无, 无, P0,H0, 未做,  CD4+、 CD8散在+、 VEGF（+）,80% 弱-中,60% 弱-中,75% 弱-中,80% 弱,23.226018396846253,1639971
1640187,孙可峰,659892,男,63,T3,N3b,M0, ⅢC,1,2,1.0,1.0,1.0,1.0, 肠化生+,22.0,39,髓样型（med）,INFb,1.0,,,,,,,,2016-12-26,2019-09-15,2,,,FOLFOX,FOLFOX,FOLFOX,XELOX,,,4, 粘液腺癌（muc）60% 低粘附腺癌30% 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10% Lauren混合型,G3, (1a)13 (1b)03 (3a)44 (3b)22 (4sb)01 (4d)1212 (5)11 (6)11 (7)14 (8a)03 (8p)03 (9)02 (11p)00 (12a)00 软组织可见癌," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,13,,R1,9.51,7.67,1.0,121.0,334.0,2.93,11.0,15.0,228.0,59.0,16.0,17.07,5.54,72.0,146.0,40.0,32.0,5.3,4.0,65.0,101.0,,,,,,,,,,,,,1.31,460.2,3.81, 未做,无, 无, P0,H0, 未做,,,,,,32.6215505913272,1640187
1639993,李永海,663149,男,59,T3,N0,M0, ⅡA,1,3,,0.0,0.0,0.0,,0.0,30,,,0.0,,,,,,,,2016-11-24,2022-09-01,1,,,,,,,,,0, 低粘附腺癌 90低分化腺癌（G3)(por)10,G3, (1a)03 (1b)01 (3a)07 (3b)01 (4sb)00 (4d)02 (5)01 (6)02 (7)04 (8a)02 (8p)03 (9)03 (11p)00 (12a)01," M（胃体部）,",20,10,, R0  D2,,6.44,3.77,1.91,154.4,140.0,2.01,13.0,20.0,134.0,87.0,9.0,10.97,3.82,65.0,206.0,41.0,24.0,4.5,7.5,85.0,247.0,,,,,,,,,,,,,2.67,1.06,7.29, 阴性,无, 无, P0,H0, 未做, CK +  D2-40 未见脉管瘤栓， S-100未见神经侵犯,,,,,69.21813403416557,1639993
1640372,苏兴一,663173,男,54,T1b,N1,M0, ⅠB,1,1,,1.0,1.0,,,2.0,27,,,0.0,,,,,,,,2016-11-28,2022-09-01,1,,,,,,,,,0, 粘液腺癌（muc）70 管状腺癌（中分化【G2】【tub2】30,G2, (1a)01 (1b)02 (3a)06 (3b)00 (4sb)00 (4d)17 (5)00 (6)00 (7)05 (8a)14 (8p)01 (9)01 (11p)00 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",15,15,3, D2,,6.51,4.24,1.57,152.0,231.0,0.31,33.0,23.0,160.0,73.0,39.0,10.68,3.92,69.0,314.0,41.0,28.0,4.8,4.1,90.0,383.0,68.9,41.5,23.6,1.76,0.5,16.1,9.1,4.5,0.88,2.95,9.02,,1.08,0.6,2.79, 阴性,无, 无, P0,H0, 未做, CK +,,,,,69.08672798948751,1640372
1640373,胡桂莲,659741,女,54,T1b,N2,M0, ⅡA,1,3,,,,,,6.0,43,,,0.0,,,,,,,,2016-11-28,2017-07-18,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌,GX, 小弯01(1a) 02(1b)612 (3a)01 (3b)00 (4sb) 01(4d) 013(5) 01(6) 01(7) (8a) 04(9) 02(11p)00 (12a)00,L,60,40,, R0 D2,,5.66,3.09,2.14,132.5,209.0,2.14,12.0,16.0,138.0,82.0,9.0,10.93,3.41,62.0,254.0,37.0,25.0,4.7,4.8,79.0,310.0,,,,,,,,,,,,,0.619,1.36,3.78, 阴性,无, 无, P0,H0, 未做, CK（+）,,,,,7.621550591327201,1640373
1640777,林长芝,483490,女,82,T3,N1,M0, ⅡB,1,2,1.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,1.0,10,硬型（sci）,INFc,0.0,0.02,0.0,,1.0,2.0,1.0,,2016-11-30,2019-07-24,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G2, (3a)02 (3b)00 (4sb)00 (4d)00 (5)00 (6)13 (7)00 (8a)02  (9)01 (12a)00 (14v)02," L（幽门窦部）, 后Post,",70,30,12, R0 D2,,6.86,4.16,0.53,114.0,149.0,3.84,10.0,20.0,157.0,103.0,30.0,6.01,1.88,41.0,187.0,41.0,32.0,4.9,5.6,83.0,299.0,70.0,53.4,12.3,4.34,0.2,9.7,16.2,1.7,0.811,3.1,14.8,,2.13,0.6,10.26,,无, 无, P0,H0, 未做,ck(+)  VEGF(-) CD4(+)  CD8散在(+),0,80% 弱,80% 弱-中,0,31.734559789750328,1640777
1640214,张宝贵,663131,男,62,T3,N0,M0, ⅡA,1,3,1.0,0.0,0.0,1.0, 肠化生+ 异型增生+,0.0,24,髓样型（med）,INFb,0.0,,,,,,,,2016-11-25,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】85 低粘附腺癌15 Lauren混合型,G3, (1a) 04(1b)04 (3a) 00(3b) 00(4sb)01 (4d) 05(5)00 (6)00 (7) 01(8a) 06(8p) 02(9) 01(11p)00 (12a)00,  LM,25,20,6, R0 D2,,4.78,1.12,1.25,158.4,93.0,2.11,29.0,15.0,87.0,69.0,27.0,18.67,5.44,52.1,103.29,25.2,26.9,13.9,3.63,71.0,128.0,,,,,,,,,,,,,0.308,25.09,6.69, 阴性,无, 无, P0,H0, 未做, CK（+）,,,,,69.18528252299606,1640214
1640083,周凤英,656530,女,64,T3,N2,M0, ⅢA,1,2,,1.0,1.0,0.0,,5.0,31,,,0.0,,,,,,,,2016-11-24,2022-09-01,1,,,,,,,,,0, 粘液腺癌（muc）85 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)15,G3, (1a)01(1b)01(3a)01(3b)23(4sb)00 (4d)19 (5)22 (6)01(7)06(8a)02 (8p)03 (11p)03 (12a)00, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less  ,60,55,15, R0 D2,,4.24,2.04,1.8,127.3,209.0,2.61,14.0,20.0,154.0,103.0,8.0,9.92,3.69,66.0,200.0,39.0,27.0,4.9,7.4,84.0,260.0,,,,,,,,,,,,,0.296,8.7,12.41, 阳性+,无, 无, P0,H0, 未做, CD31（+） D2-40（+）S-100（-) ,,,,,69.21813403416557,1640083
1640183,张所荣,663143,男,64,T1b,N0,M0,ⅠA,1,3,,0.0,0.0,1.0,,0.0,23,,,0.0,,,,,,,,2016-11-25,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3,(1a)00  (1b)00 (3a)03(3b)01(4sb)00 (4d)01 (5)00 (6)05 (7)02(8a)03 (8p)04(9)01 (11p)03 (12a)00,L（幽门窦部） 后Post 小弯侧Less ,15,15,7, R0 D2,,8.01,5.34,2.13,131.3,343.0,2.92,12.0,19.0,172.0,76.0,16.0,12.75,3.87,78.0,269.0,46.0,32.0,5.8,4.2,96.0,424.0,,,,,,,,,,,,,2.23,13.77,1.36, 未做,无,, P0,H0, 未做,,,,,,69.18528252299606,1640183
1641606,赵秀娥,676545,女,49,T1b,N1,M0, ⅠB,1,3,,1.0,1.0,1.0,,2.0,61,,,1.0,,1.0,,1.0,2.0,,,2016-12-06,2022-09-01,1,,,XELOX,XELOX,XELOX,,,,3, 低粘附腺癌75 低分化腺癌（G3)(por)25,G3, (1a)01 (1b)02 (2)04 (3a)118 (3b)15 (4sa)00 (4sb)011 (4d)02 (5)01 (6)01 (7)04 (8a)03 (8p)04 (9)04 (11p)00 (12a)01," LMU 小弯侧Less,",40,40,2, R0 D2,,6.29,3.53,2.16,122.0,246.0,2.13,19.0,17.0,125.0,48.0,12.0,13.82,4.94,58.0,207.0,34.0,24.0,5.5,3.7,70.0,90.0,,,,,,,,,,,,,1.02,0.6,0.8, 阴性,无, 无, P0,H0, 未做, VEGF（+）CD4+ CD8+ VEGF+ s-100见神经侵犯  CD31，D2-40 可见脉管瘤栓， MLH1（70% 弱-中）， MLH2 （60% 中），MLH6 （80% 中-强），PMS2（60% 弱）,70% 弱-中,60% 中,80% 中-强,60 弱,68.8239159001314,1641606
1640379,王俊,663137,男,57,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,1.0, 慢性炎症（+）,2.0,46,中间型（int）,INFb,1.0,,1.0,,1.0,2.0,,,2016-11-28,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)04 (1b)01 (3a)214 (3b)01 (4sb)00 (4d)04 (5)02 (6)05 (7)02 (8a)01 (8p)05 (9)02 (11p)00 (12a)00 (12p)04 (16a1)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,35,5, R0 D2+,,6.58,47.9,2.69,146.0,245.0,3.07,16.0,18.0,130.0,75.0,15.0,6.8,1.81,64.0,266.0,40.0,24.0,,5.3,106.0,257.0,,,,,,,,,,,,,1.58,10.21,0.851, 未做,无,, P0,H0, 未做,CK + CD4+  CD8散在+ VEGF+,90% 中-强,90% 中-强,90% 强,90% 弱,69.08672798948751,1640379
1640478,何志学,663100,男,58,T3,N1,M0, ⅡB,1,3,,1.0,1.0,0.0,,2.0,3,,,2.0,,,,,,,,2016-11-28,2019-05-05,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)75 乳头状癌（G1）（pap）25,G3,大弯23 小弯00," L（幽门窦部）,",30,20,20, R0,R2,8.49,6.17,1.31,133.2,241.0,3.02,61.0,30.0,125.0,106.0,25.2,6.93,2.58,67.0,181.03,39.4,27.6,5.8,3.15,60.0,259.0,,,,,,,,,,,,,1.67,7.67,1.15, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,29.17214191852825,1640478
1640471,马文彬,647081,男,58,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,7.0,13,髓样型（med）,INFa,2.0,,,,,,,,2016-11-28,2019-05-13,0,FOLFOX*6,1.0,口服卡培他滨,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)01 (1b)00 (3a)34 (3b)00 (4sb)01 (4d)35 (5)00 (6)11 (7)00 (8a)01 (8p)00 (9)00," L（幽门窦部）, 大弯侧Gre,",10,8,5,,R2,3.81,1.79,1.43,129.1,92.0,4.23,25.0,49.0,196.0,129.0,172.0,13.07,4.7,80.0,289.0,44.0,36.0,6.9,3.9,93.0,356.0,,,,,,,,,,,,,11.77,9.14,1.35, 未做,无,, P0,H0, 未做,,,,,,29.43495400788436,1640471
1640882,宋彦阁,662864,男,65,T4b,N3a,M1, Ⅳ,1,2,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+） 异型增生+,10.0,26,髓样型（med）,INFb,0.0,,0.0,,1.0,2.0,,,2016-11-30,2018-06-06,2,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)45 粘液腺癌（muc）55 Lauren肠型,G3,(3a)48 (3b)11(4sb)01 (4d)311(5)01(6)24(12a)00 3A 6 软组织可见癌, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,65,50,15, D2,R2,4.28,2.36,1.22,85.2,402.0,2.76,16.0,21.0,120.0,85.0,9.0,10.12,3.85,65.0,170.0,39.0,26.0,6.6,2.5,86.0,208.0,,,,,,,,,,,,,0.286,17.15,6.6, 未做,无,, p1局肠缘(M1 PER),H0, 未做, CD31（+） D2-40（+）S-100（+)   CD4(+) CD8(+)VEGF(-),90% 弱,90% 弱-中,90% 中-强,70% 弱,18.166885676741128,1640882
1640588,吕文义,676999,男,53,T4b,N0,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,0.0,47,中间型（int）,INFa,1.0,,0.0,,1.0,2.0,,,2016-11-29,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)03 (3a) 06(3b)00 (4sb)03 (4d) 09(5)00 (6) 01(7) 06(8a)04 (8p) 07(9) 05(11p) 00(12a)01," LM 小弯侧Less, 后Post,",50,35,10, R0 D2,,11.52,10.16,0.82,128.0,178.0,3.34,18.0,19.0,138.0,95.0,11.0,17.03,5.46,77.0,299.0,44.0,33.0,4.5,8.4,104.0,248.0,,,,,,,,,,,,,1.6,7.15,3.04, 阴性,无, 无, P0,H0, 未做, VEGF（-） CK(+),75% 弱-中,80% 中,95% 中-强,0,69.053876478318,1640588
1640594,王成国,662892,男,55,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,2.0,18,中间型（int）,INFb,1.0,,0.0,,1.0,2.0,,,2016-11-29,2022-09-01,1,,,奥沙利铂+5-FU,奥沙利铂+6-FU,奥沙利铂+7-FU,奥沙利铂+8-FU,奥沙利铂+9-FU,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 粘液腺癌（muc）20 Lauren肠型,G3,(1a)00  (1b)00 (3a)02(3b)04 (4sb)00 (4d)02 (5)00 (6)12(7)00(8a)11 (8p)01 (9)03 (11p)03 (12a)00,LM 后Post 大弯侧Gre  小弯侧Less ,100,60,15, R0 D2,,6.68,3.51,2.21,157.5,165.0,3.64,29.0,23.0,116.0,79.0,38.2,11.86,3.06,64.8,237.97,33.6,31.2,,4.9,82.0,374.0,,,,,,,,,,,,,1.58,9.41,8.62, 未做,无,, P0,H0, 未做, CD31（+） D2-40（+）S-100（-)   CD4(+) CD8(+)VEGF(-),0,80% 弱-中,90% 中,0,69.053876478318,1640594
1640593,佟克霞,662831,女,52,T4b,N1,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+,1.0,31,髓样型（med）,INFa,1.0,,2.0,,2.0,2.0,,,2016-11-29,2017-05-11,0,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型,G3,  (1a)02 (1b)01 (3a)03 (3b)07 (4sb)00 (4d)06 (5)02 (6)12 (7)01 (8a)04," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",50,45,10, R0 D2+,,6.16,4.77,0.9,83.2,276.0,3.9,11.0,14.0,104.0,62.0,16.0,6.97,2.58,75.0,87.0,39.0,36.0,5.2,4.7,79.0,255.0,,,,,,,,,,,,,0.893,13.65,2.1,,无, 无, P0,H0, 未做, CK +,0,30% 弱-中,75% 中,0,5.354796320630749,1640593
1640706,关世波,662825,男,54,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,18,,,0.0,,,,,,,,2016-11-29,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)60 低粘附腺癌40,G3,大弯010 小弯06 (6)02," M（胃体部）, 小弯侧Less, 后Post,",,,, R0 D2,,6.87,3.34,2.49,138.0,251.0,2.33,43.0,22.0,115.0,68.0,110.8,14.33,2.18,60.1,309.6,35.1,25.0,5.4,5.59,85.0,429.0,,,,,,,,,,,,,1.13,3.1,2.1, 阴性,无, 无, P0,H0, 未做, CK（+）,,,,,69.053876478318,1640706
1642346,金寿英,661919,男,68,T3,N3a,M0,ⅢB,1,3,,1.0,1.0,1.0,,10.0,24,,,1.0,,,,,,,,2016-12-12,2021-05-19,0,,,SOX,SOX,口服替吉奥,,,,3, 管状腺癌（中分化【G2】【tub2】,G2, (1a) 01(1b)44 (2)11 (3a)22 (3b)02 (4sa)01 (4sb)00 (4d)00 (5)00 (6)00 (7)12 (8a)02 (8p)03 (9)00 (11p)11 (12a)02 (12p)02 3a，3b，11p软组织可见癌," MU 前Ant, 后Post, 小弯侧Less,",55,50,10, D2,,17.0,14.55,1.18,134.0,210.0,3.58,14.0,24.0,203.0,94.0,7.0,12.39,3.17,69.0,223.0,41.0,28.0,5.2,5.8,118.0,341.0,75.5,42.7,17.7,2.41,0.2,7.7,14.3,2.3,1.58,2.26,12.0,,2.3,0.6,1.74, 未做,无, 无, P0,H0, 未做, CK+ CD56+ CGA— SYN+,80% 弱-中,90% 中,90% 中-强,60 弱,53.186596583442835,1642346
1641497,杨玉杰,676503,女,61,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,15,,,2.0,,2.0,,2.0,2.0,,,2016-12-01,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)03 (1b)01 (3a)01 (3b)01 (4sb)00 (4d)00 (5)01 (6)02 (7)02 (8a)01 (8p)01 (9)02 (11p)00 (12a)00," LM 小弯侧Less,",25,25,, R0,,6.99,3.86,2.57,138.2,223.0,3.86,34.0,25.0,165.0,91.0,30.0,18.79,4.3,78.0,297.0,45.0,78.0,5.9,6.2,80.0,277.0,,,,,,,,,,,,,0.814,9.14,1.08,,无, 无, P0,H0, 未做, CK +,0,70% 中,90% 中-强,0,68.98817345597897,1641497
1641204,王淑珍,676405,女,60,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,13,,,1.0,,,,,,,,2016-12-02,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)01 (3b)03 (4sb)02 (4d)00 (5)00 (6)03 (7)01 (8a)01 (8p)02 (9)00 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",8,,, R0 D2+,,8.13,4.67,2.46,145.3,293.0,2.42,12.0,16.0,156.0,114.0,14.0,16.08,4.09,73.0,280.0,46.0,27.0,4.9,5.5,103.0,261.0,,,,,,,,,,,,,3.11,30.38,1.19, 未做,无, 无, P0,H0, 未做,,,,,,68.95532194480946,1641204
1641576,杨淑敏,631677,男,57,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 正常,11.0,49,髓样型（med）,INFc,0.0,,2.0,,2.0,2.0,,,2016-12-06,2018-04-27,2,,,XELOX,,,,,,1, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)17 (1b)24 (3a)22 (3b)00 (4sb)44 (4d)00 (5)00 (6)211 (7)04 (8a)01 (8p)03 (9)01 (11p)00 (12a)00," LM 大弯侧Gre,",35,25,10, R0 D2+,,6.02,3.8,1.6,140.1,216.0,4.1,17.0,19.0,165.0,87.0,20.0,10.08,2.98,79.0,260.0,47.0,32.0,4.5,3.3,96.0,337.0,,,,,,,,,,,,,0.791,9.28,2.45,,无, 无, P0,H0, 未做, CK +,60% 弱-中,40% 弱-中,35% 弱-中,60% 弱,16.655716162943495,1641576
1641755,孙光军,676440,男,51,T1b,N0,M0,ⅠA,1,1,,0.0,0.0,0.0,,0.0,29,,,0.0,,,,,,,,2016-12-07,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)010 (2)07 (3a)03 (3b)00 (4sa)00 (4sb)00 (7)01 (8a)03 (8p)00 (9)00 (11p)01 (12a)00 (12p)01 (19)00大网02," U（胃底部）, 后Post,",20,10,8, R0 D2+,,12.9,1.52,1.52,144.4,214.0,2.79,54.0,38.0,165.0,96.0,26.0,23.07,7.03,57.0,206.0,35.0,22.0,4.1,5.3,88.0,297.0,81.9,40.2,35.4,1.14,0.4,9.3,5.1,1.5,1.28,1.77,9.19,,2.99,0.6,2.26, 未做,无,, P0,H0, 未做, CK +,,,,,68.79106438896189,1641755
1642039,施文学,664280,男,52,T3,N0,M0, ⅡA,1,1,,1.0,1.0,1.0,,0.0,27,,,0.0,,,,,,,,2016-12-08,2021-10-15,1,,,,,,,,,0, 低粘附腺癌,GX, (3a)04 (3b)00 (4sb)02 (4d)02 (5)02 (6)04 (7)04 (8a)01 (8p)01 (9)06 (11p)00 (12a)01," L（幽门窦部）, 前Ant,",35,20,4, R0 D2+,,8.01,5.82,1.21,132.0,93.0,1.84,59.0,43.0,148.0,45.0,33.0,17.91,6.86,48.0,121.0,29.0,19.0,,5.3,77.0,170.0,,,,,,,,,,,,,1.98,9.03,1.09, 未做,无,, P0,H0, 未做, CK +,,,,,58.21287779237845,1642039
1642040,赵志民,663986,男,54,T4b,N3a,M0, ⅢC,1,2,0.0,1.0,1.0,1.0, 正常,10.0,47,髓样型（med）,INFa,3.0,,2.0,,1.0,2.0,,,2016-12-08,2017-04-12,2,,,,,,,,,0, 乳头状癌（G1）（pap）65 管状腺癌（高分化【G1】【tub1】）35 Lauren肠型,G1, (1a)01 (1b)01 (3a)117 (3b)11 (4sb)00 (4d)410 (5)11 (6)37 (7)02 (8a)04 (8p)01 (9)02 (11p)00 (12a)00," ML 前Ant, 后Post, 小弯侧Less,",80,70,20, R0 D2+,,8.21,3.78,3.71,142.0,422.0,3.4,13.0,16.0,124.0,88.0,11.0,8.79,2.05,72.0,277.0,46.0,26.0,5.2,7.4,98.0,192.0,,,,,,,,,,,,,2.02,963.6,11.662,,无, 无, P0,H0, 未做, CK +,70% 弱-中,60% 弱-中,70% 中-强,65% 弱,4.106438896189225,1642040
1642079,王延忠,676446,男,62,T1b,N0,M0,ⅠA,1,2,,,,,,0.0,27,,,0.0,,,,,,,,2016-12-08,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,大弯010 小弯014 (8a)03," L（幽门窦部）, 前Ant,",18,15,5, R0,,6.89,2.4,3.5,158.9,176.0,1.82,15.0,21.0,166.0,51.0,11.0,12.13,3.95,67.0,223.0,41.0,26.0,4.7,5.0,97.0,336.0,,,,,,,,,,,,,1.2,5.08,1.27, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,68.75821287779237,1642079
1641400,刘福江,663623,男,42,T3,N0,M0, ⅡA,1,2,0.0,1.0,1.0,0.0, 慢性炎症（+）,0.0,18,髓样型（med）,INFb,0.0,,1.0,,2.0,1.0,,,2016-12-31,2022-09-01,1,,,XELOX,XELOX,PS,,,,3, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】80 乳头状癌（G1）（pap）20,G2, (1a)01 (1b)00 (3a)05 (3b)01 (4sb)00 (4d)00 (5)00 (6)01 (7)01 (8a)01 (8p)01 (9)04 (11p)01, L（幽门窦部） 前Ant 后Post 大弯侧Gre  ,45,40,15,,R1,9.08,5.81,2.76,141.0,270.0,2.56,31.0,26.0,178.0,85.0,17.8,20.47,4.5,61.5,264.35,38.1,23.4,,6.2,112.0,309.0,,,,,,,,,,,,,,,,,,, P0,H0,,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+) MLH1弱 MLH2弱-中 MLH6中-强 PMS2弱,90% 弱,90% 弱-中,90% 中-强,80% 弱,68.00262812089356,1641400
1642167,孙家芝,676420,女,73,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 正常,11.0,45,髓样型（med）,INFc,0.0,,2.0,,1.0,2.0,,,2016-12-09,2017-07-23,0,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por)30,G3, (1a)05 (1b)04 (3a)02 (3b)01 (4sb) 03(4d)615 (5)01 (6)49 (7)00 (8a)01 (8p) 01(9) 02(11p) 00(12a)11," LM 前Ant, 后Post, 小弯侧Less,",50,40,10, R0 D2,,6.87,5.33,1.04,92.0,118.0,2.61,13.0,16.0,144.0,47.0,14.0,7.39,3.47,56.0,138.0,36.0,20.0,9.1,8.7,86.0,409.0,,,,,,,,,,,,,0.2,6.4,2.09, 阴性,无, 无, P0,H0, 未做, CK（+） VEGF（—） CD31  D2-40 可见脉管瘤栓 S-100可见神经侵犯  MLH1 70% 染色强度为中， MLH2 70% 染色强度为弱-中，MLH6 70%  染色强度为中-强，PMS2 80% 染色强度为弱-中， CD4 + CD8 +,70% 中,70% 弱-中,70% 中-强,80% 弱-中,7.424441524310118,1642167
1642082,于永才,664047,男,52,T3,N1,M0, ⅡB,1,2,,0.0,0.0,1.0,,2.0,22,,,1.0,,2.0,,2.0,2.0,,,2016-12-08,2019-05-05,2,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）90 低粘附腺癌10,G2, (1a)00 (1b)00 (3a)00 (3b)00 (4sb)00 (4d)06 (5)14 (6)11 (7)01 (8a)00 (8p)04 (9)03 (11p)00 (12a)03 (12b)01," L（幽门窦部）, 小弯侧Less,",10,10,5, R0,,5.73,2.72,1.84,145.0,224.0,2.41,11.0,15.0,133.0,69.0,9.0,8.84,2.8,64.0,276.0,42.0,22.0,5.1,7.9,86.0,303.0,,,,,,,,,,,,,6.23,13.42,2.86, 未做,无, 无, P0,H0, 未做,CK（+） CD4  CD8 散在+ VEGF+ MLH170 MLH280 MLH690 PMS250 ,70% 弱-中,80% 弱-中,90% 中-强,50% 弱,28.843626806833115,1642082
1642080,马利军,676438,男,56,T3,N1,M0, ⅡB,1,3,,1.0,1.0,1.0,,2.0,16,,,1.0,,,,,,,,2016-12-08,2022-09-01,1,,,,,,,,,0, 低粘附腺癌 管状腺癌60（中分化【G2】【tub2】 低分化腺癌（G3)(por)40,G3, (1a)01 (1b)02 (2)02 (3a)13 (3b)01 (4sa)00 (4sb)00 (7)00 (8a)00 (8p)00 (9)01 (11p)04 肿物旁12,UM 小弯侧Less ,50,40,, R0 D2,,13.43,10.57,1.71,122.0,286.0,2.08,16.0,18.0,144.0,57.0,17.0,5.32,3.93,70.0,360.0,44.0,26.0,6.8,4.5,101.0,320.0,53.5,33.8,16.8,2.01,0.3,11.5,31.7,0.5,0.687,3.3,10.9,,2.23,3.07,1.2, 未做,无,, P0,H0, 未做, CK +,,,,,68.75821287779237,1642080
1642452,张俊青,664092,男,66,T1b,N0,M0,ⅠA,1,3,0.0,0.0,0.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,31,中间型（int）,INFa,0.0,,2.0,,1.0,2.0,,,2016-12-12,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） Lauren肠型 溃疡癌变,G1, (1a)01 (1b)00 (3a)08 (3b)00 (4sb)00 (4d)04 (5)01 (6)01 (7)02 (8a)01 (8p)04 (9)03 (11p)04 (12a)00 (12p)02," L（幽门窦部）, 小弯侧Less,",10,8,5, R0 D2+,,6.54,3.08,2.68,160.0,205.0,2.61,14.0,17.0,148.0,49.0,12.0,20.08,5.15,70.0,358.0,42.0,28.0,4.7,7.9,114.0,405.0,,,,,,,,,,,,,1.19,8.47,5.36, 未做,无,, P0,H0, 未做,CK + CD4+  CD8散在+ VEGF弱+,60% 弱,80% 弱-中,80% 中,50% 弱,68.62680683311432,1642452
1642852,王继仁,658189,男,52,T1a,N0,M0,ⅠA,1,2,,,,,,0.0,36,,,1.0,,,,,,,,2016-12-14,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1b)01 (3a)014 (3b)01 (4sb)00 (4d)03 (5)01 (6)05 (7)01 (8a)01 (8p)03 (9)02 (11p)04 (12a)00," M（胃体部）, 小弯侧Less,",12,10,5, R0 D2+,,14.65,11.78,1.94,126.7,144.0,2.44,61.0,48.0,155.0,56.0,13.4,20.05,3.91,50.2,235.03,28.4,21.8,,6.13,94.0,361.0,,,,,,,,,,,,,1.11,10.37,, 未做,无,, P0,H0, 未做, CK +,,,,,68.5611038107753,1642852
1642459,张华廷,676354,男,76,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,1.0, 异型增生+ 慢性炎症（+）,4.0,19,中间型（int）,INFb,0.0,,2.0,,1.0,2.0,,,2016-12-12,2022-09-01,1,,,SOX,SOX,SOX,口服替吉奥,口服替吉奥,,5,浸润型中低分化管状腺癌 Lauren肠型,G3, (1a) 03(1b)01 (3a)01 (3b)01 (4sb)00 (4d)03 (5)22 (6)11 (7)02 (8a)01 (8p)03 (9)11 (11p)00 (12a)00," L（幽门窦部）, 前Ant",30,20,12, D2,,5.91,2.8,2.51,130.0,261.0,2.95,9.0,12.0,137.0,66.0,21.0,10.21,3.01,63.0,281.0,39.0,24.0,6.2,8.0,91.0,361.0,66.1,50.4,13.9,3.63,0.2,11.4,18.9,0.9,1.17,3.59,8.37,,1.69,44.08,4.63,,无,, P0,H0, 未做, CD31  D2-40脉管染色显示可见脉管瘤栓  S-100神经染色可见神经侵犯 MLH1- MLH2+ MLH6+ PMS2-CD4+ CD8散在+  VEGF弱+,0,90% 弱,90% 弱-中,0,68.62680683311432,1642459
1642768,李桂明,622797,男,55,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,47,中间型（int）,INFb,3.0,,2.0,,1.0,2.0,,,2016-12-14,2022-09-01,1,,,XELOX,XELOX,,,,,2, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) 03(1b)02 (2)09 (3a)02 (3b)03 (4sa)010 (4sb)02 (4d)07 (5) 00(6)04 (7)01 (8a) 02(8p)00 (9) 01(11p) 01(12a)00," MU 小弯侧Less,",25,8,8, D2+,,4.65,3.24,0.83,98.1,248.0,2.42,29.0,27.0,189.0,68.0,34.0,11.8,5.41,78.0,165.0,40.0,38.0,5.7,4.8,71.0,265.0,78.8,31.0,27.5,1.13,0.3,6.6,13.3,2.9,0.425,3.36,16.2,,,,, 未做,无, 无, P0,H0, 未做, CK+,80% 弱-中,70% 弱-中,80% 弱-中,70% 弱,68.5611038107753,1642768
1642465,王立东,677096,男,53,T1b,N0,M0,ⅠA,1,4,0.0,0.0,0.0,0.0, 异型增生+ 慢性炎症（+）,0.0,16,中间型（int）,INFa,2.0,,0.0,,1.0,2.0,,,2016-12-12,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (3a)05 (3b)00 (4sb)00 (4d)00 (5)00 (6)02 (7)00 (8a)01 (8p)04 (9)03 (11p)03 (12a)00," LM 前Ant, 后Post, 大弯侧Gre,",20,15,6, R0 D2+,,7.96,4.07,2.86,176.2,183.0,3.34,20.0,17.0,166.0,88.0,43.0,9.6,2.54,66.0,421.0,43.0,23.0,4.8,7.5,116.0,384.0,,,,,,,,,,,,,4.35,24.2,1.57, 未做,无,, P0,H0, 未做,CK + CD4+  CD8散在+ VEGF-,80% 弱,80% 弱-中,90% 中-强,40% 弱,68.62680683311432,1642465
1642950,范昌,664492,男,69,T3,N3a,M0,ⅢB,1,2,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,20,中间型（int）,INFb,1.0,,1.0,,1.0,2.0,,,2016-12-15,2021-05-21,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (3a)15 (3b)00 (4sb)00 (4d)44 (5)00 (6)24 (7)01 (8a)04 (8p)00 (11p)02 (9)00," L（幽门窦部）, 后Post, 小弯侧Less,",30,30,8, R0 D2+,,5.98,3.81,1.54,162.9,168.0,3.07,23.0,22.0,188.0,72.0,15.0,12.41,3.76,60.0,219.0,39.0,21.0,5.0,6.0,91.0,242.0,,,,,,,,,,,,,,,, 未做,无,, P0,H0, 未做,CK + CD4+  CD8散在+ VEGF+,90% 弱,90% 弱,90% 中,90% 弱,53.153745072273324,1642950
1642319,杨秀英,663907,女,62,T4b,N3a,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 慢性炎症（+）,10.0,23,髓样型（med）,INFc,2.0,0.02,2.0,,1.0,2.0,,,2016-12-12,2018-03-07,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 粘液腺癌（muc）30 乳头状癌（G1）（pap）10 Lauren肠型,G3, (1a)00 (1b)00 (3a)25 (3b)11 (4sb)02 (4d)56 (5)00 (6)22 (7)01 (8a)02 (8p)01 (9)03 (11p)00 (12a)00, LM 小弯侧Less 前Ant 后Post ,40,30,15,,R1,3.54,1.51,1.59,90.1,353.0,3.09,9.0,13.0,163.0,55.0,11.0,4.77,1.56,70.0,140.0,38.0,32.0,4.7,3.3,78.0,184.0,68.2,43.4,23.4,1.85,0.2,5.5,24.2,2.0,0.864,3.51,14.8,,0.946,5.68,6.29, 阳性+,无, 无, P0,H0, 未做,ck(+)  VEGF(弱+) CD4(+)  CD8散在(+),30% 弱,90% 弱-中,90% 中,30% 弱,14.783180026281208,1642319
1642850,陈贵,664536,男,66,T4b,N1,M0, ⅢB,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+）,1.0,29,中间型（int）,INFb,0.0,,1.0,,1.0,2.0,,,2016-12-14,2022-09-01,1,,,XELOX,XELOX,XELOX,,,,3, 乳头状癌（G1）（pap） 管状腺癌70（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】30 Lauren肠型,G2, (1a) 06(1b)00 (2)02 (3a)05 (3b)02 (4sa)01 (4sb)02 (4d)02 (5)01 (6)01 (7)11 (8a)01 (8p)03 (9)00 (11p) 00(12a)00,UM 小弯侧Less 前Ant 后Post ,80,50,8,,R1,6.72,3.93,1.86,92.0,327.0,3.93,10.0,16.0,147.0,82.0,23.0,7.54,2.01,58.0,235.0,35.0,23.0,4.4,4.5,88.0,312.0,4.87,29.8,17.0,1.75,0.2,5.7,43.9,0.4,1.11,1.82,8.37,,6.77,0.6,27.35, 阳性+,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),90% 弱-中,90% 弱,90% 中,80% 弱,68.5611038107753,1642850
1642121,刘士栋,664529,男,45,T1a,N0,M0,ⅠA,1,3,,,,,,0.0,32,,,0.0,,,,,,,,2016-12-09,2022-09-01,1,,,,,,,,,0, 低粘附腺癌,GX,(1a)01 (1b)00 (3a)05 (3b)01 (4sb)00 (4d)09 (5)00 (6)00 (7)08 (8a)03(8p) (9)02 (11p)02 (12a)01,M（胃体部） 小弯侧Less ,25,25,, R0 D2,,6.5,4.75,1.07,142.7,216.0,2.06,13.0,13.0,142.0,100.0,34.0,9.95,2.97,71.0,359.0,47.0,24.0,4.4,6.1,83.0,486.0,67.9,36.9,27.5,1.34,0.7,7.3,19.4,1.6,0.871,2.88,8.59,,1.02,12.69,3.79, 未做,无,, P0,H0, 未做,,,,,,68.72536136662286,1642121
1642917,白凤芹,660145,女,61,T1b,N0,M0,ⅠA,1,3,,1.0,1.0,0.0,,0.0,23,,,0.0,,,,,,,,2016-12-15,2022-09-01,1,,,,,,,,,0, 乳头状癌（G1）（pap）50 管状腺癌（中分化【G2】【tub2】30 粘液腺癌（muc）20,G2, (1a)00 (1b)02 (2)04 (3a)04 (3b)02 (4sa)00 (4sb)00 (7)03 (8a)01 (8p)02 (9)04 (11p)01," SiewerⅡ, 后Post, 小弯侧Less,",30,15,5, R0 D2+,,3.72,1.98,1.35,139.0,238.0,2.68,6.0,14.0,171.0,73.0,15.0,14.67,3.73,77.0,275.0,48.0,29.0,5.2,3.9,80.0,214.0,,,,,,,,,,,,,3.45,25.16,0.87,,无, 无, P0,H0, 未做, CK +,,,,,68.52825229960578,1642917
1642616,张国民,664249,男,43,T3,N1,M0, ⅡB,1,2,0.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,2.0,19,髓样型（med）,INFb,1.0,,2.0,,1.0,2.0,,,2016-12-13,2022-09-01,1,,,SOX,SOX,SOX,SOX,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)24 (3b)01 (4sb)00 (4d)00 (5)00 (6)03 (7)01 (8a)01 (8p)02 (9)02 (11p)04 (12a)00 (12p)00," M（胃体部）, 小弯侧Less,",25,15,6, R0 D2+,,7.99,4.05,2.74,172.7,233.0,2.44,27.0,19.0,152.0,54.0,70.0,17.91,6.86,22.39,351.0,50.0,27.0,4.2,8.4,85.0,170.0,,,,,,,,,,,,,2.14,11.47,1.42, 未做,无,, P0,H0, 未做,CK + CD4+  CD8散在+ VEGF弱+,70% 弱,80% 弱,80% 弱-中,40% 弱,68.5939553219448,1642616
1643337,马东英,677042,女,62,T1b,N1,M0, ⅠB,1,3,,1.0,1.0,0.0,,2.0,16,,,1.0,,2.0,,2.0,2.0,,,2016-12-19,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)03 (5)00 (6)25 (7)01 (8a)00 (8p)00 (9)04 (11p)00 (12a)00," L（幽门窦部）, 前Ant,",25,20,10, R0 D2+,,2.52,0.11,0.98,146.7,164.0,2.88,17.0,41.0,179.0,80.0,13.0,13.83,3.34,76.0,294.0,47.0,29.0,5.1,6.9,70.0,223.0,,,,,,,,,,,,,1.61,12.07,2.06,,无, 无, P0,H0, 未做, CK +,0,80% 弱-中,90% 中-强,0,68.39684625492772,1643337
1643133,贾春江,664493,男,54,T3,N0,M0, ⅡA,1,3,,1.0,1.0,1.0,,0.0,37,,,1.0,,2.0,,2.0,2.0,,,2016-12-16,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3,大弯022小弯015," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",25,20,6, R0 D2,,5.07,2.46,2.12,167.4,22.0,2.47,38.0,33.0,234.0,80.0,24.7,12.04,1.88,64.4,285.02,37.4,27.0,5.1,5.53,80.0,276.0,,,,,,,,,,,,,4.17,20.72,1.32, 未做,无,, P0,H0, 未做, CK+ VEGF+ CD4  CD8 +,60% 弱-中,70% 弱-中,80% 弱-中,50% 弱-中,68.49540078843627,1643133
1642763,张福信,664439,男,60,T3,N3a,M0,ⅢB,1,2,0.0,1.0,1.0,1.0, 正常,9.0,56,中间型（int）,INFa,2.0,,2.0,,1.0,2.0,,,2016-12-14,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)011 (1b)06 (3a)112 (3b)11 (4sb)00 (4d)38 (5)00 (6)35 (7)02 (8a)03 (8p)01 (9)05 (11p)00 (12a)12," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",35,30,10, R0 D2+,,7.46,4.56,2.01,147.0,307.0,3.96,24.0,22.0,131.0,127.0,19.5,8.35,3.21,66.8,184.23,35.4,31.4,4.4,2.56,66.0,339.0,,,,,,,,,,,,,1.16,5.01,2.66, 未做,无,, P0,,, CK+ VEGF— CD4  CD8 +,80% 中,70% 弱-中,80% 中-强,80% 弱-中,68.5611038107753,1642763
1642761,王文国,662619,男,48,T3,N3b,M0, ⅢC,1,3,0.0,1.0,1.0,1.0, 肠化生+,20.0,54,中间型（int）,INFa,1.0,,2.0,,1.0,2.0,,,2016-12-14,2018-03-01,2,,,SOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】65% 低分化腺癌（G3)(por)30% Lauren肠型,G3, (1a)17 (1b)11 (3a)39 (3b)35 (4sb)914 (4d)00 (5)01 (6)33 (7)06 (8a)01 (8p)04 (9)02 (11p)00 (12a)01 (15)00," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,50,10, R0 D2+,,9.02,6.1,2.11,169.0,251.0,2.76,16.0,18.0,179.0,71.0,22.0,11.61,3.47,82.0,473.0,53.0,29.0,5.3,6.6,107.0,297.0,,,,,,,,,,,,,1.5,51.63,2.74, 未做,无, 无, P0,H0, 未做, CD4+、 CD8散在+、 VEGF+、 MLH1弱中、 MLH2中、 MLH6中强、 PMS2弱中,80% 弱-中,90% 中,90% 中-强,80% 弱-中,14.520367936925098,1642761
1642948,李锡麟,664457,男,63,T4b,N2,M0, ⅢB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+,6.0,25,中间型（int）,INFb,0.0,,2.0,,1.0,2.0,,,2016-12-15,2017-03-15,2,,,,,,,,,0, 低分化腺癌（G3)(por) 粘液腺癌（muc） Lauren肠型,G3," (4d)2/5 (6)2/2 (8a)1/2 (8p)1/1， (3a,03 (3b)00 (4sb)01 (5)02 (7)07 (9)02 (11p)00 (12a)00 3b，11p软组织可见癌"," L（幽门窦部）, 小弯侧Less,",35,30,20,,R1,3.64,48.29,1.4,137.0,170.0,3.07,20.0,27.0,137.0,60.0,9.0,9.29,2.99,38.0,230.0,38.0,23.0,4.8,6.5,92.0,356.0,79.5,35.1,43.0,0.82,0.3,10.0,7.4,1.3,1.07,2.73,9.57,,0.534,39.5,12.33,,无, 无, P0,H0, 未做, CK+ CD4+  CD8+  VEGF+,90% 中,90% 中,90% 强,90% 弱,2.9566360052562417,1642948
1642915,韩同秀,660103,男,58,T3,N3a,M0,ⅢB,1,2,0.0,0.0,0.0,1.0, 异型增生+ 慢性炎症（+）,9.0,30,中间型（int）,INFc,2.0,,1.0,,1.0,2.0,,,2016-12-15,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,(1a)05(1b)00 (3a)22(3b)12(4sb)11 (4d)15 (5)23 (6)02(7)13 (8a)02 (8p)02 (9)02(11p)00 (12a)11,L（幽门窦部） 前Ant 后Post 小弯侧Less ,40,40,10, R0 D2,,7.88,4.24,2.98,155.0,282.0,4.48,10.0,17.0,145.0,107.0,8.0,21.81,5.78,72.0,169.0,43.0,29.0,4.7,8.1,87.0,326.0,67.9,39.1,23.4,1.67,0.1,6.4,24.5,2.0,1.81,2.06,12.2,,100.7,5.54,2.79, 阳性+++,无,, P0,H0, 未做, CD31（-） D2-40（-）S-100（+)   CD4(+) CD8(+)VEGF(+),90% 弱-中,90% 弱-中,90% 中,90% 弱-中,68.52825229960578,1642915
1643031,于凤梅,676665,女,51,T3,N1,M0, ⅡB,1,3,,1.0,1.0,1.0,,1.0,34,,,1.0,,,,,,,,2016-12-15,2022-09-01,1,,,XELOX,XELOX,XELOX,,,,3, 低粘附腺癌80%， 低分化管状腺癌20%,G3,134，大弯08，小弯123，贲门旁03," M（胃体部）, 后Post, 小弯侧Less,",20,20,10, R0 D2,,4.52,2.58,1.74,136.7,206.0,2.91,18.0,21.0,141.0,86.0,14.0,9.63,2.99,81.0,354.0,45.0,36.0,5.7,7.3,88.0,370.0,,,,,,,,,,,,,0.627,4.98,2.78,,无, 无, P0,H0, 未做,,,,,,68.52825229960578,1643031
1643956,苏万海,660110,男,47,T3,N0,M0, ⅡA,1,3,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+） 异型增生+,0.0,28,髓样型（med）,INFb,0.0,,0.0,,1.0,2.0,,,2016-12-22,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)01 (3a)07 (3b)00 (4sb)00 (4d)08 (5)00 (6) 01(7) 01(8a)04 (8p)03 (9) 02(11p)01 (12a)00, M（胃体部） 小弯侧Less ,20,12,8, R0 D2,,8.14,3.33,4.13,160.2,224.0,2.33,46.0,38.0,150.0,112.0,21.0,13.82,3.65,72.0,356.0,44.0,28.0,3.8,6.3,86.0,394.0,79.4,34.6,32.3,1.07,0.2,13.5,5.4,1.2,1.1,2.48,10.8,,2.77,9.46,1.12, 未做,无,, P0,H0, 未做,ck(+)  VEGF(-) CD4散在(+)  CD8散在(+),90% 中,90% 中-强,90% 强,80% 弱,68.29829172141918,1643956
1643452,王俊英,663936,男,72,T3,N0,M1, Ⅳ,1,2,0.0,0.0,0.0,1.0, 肠化生+ 慢性炎症（+） 异型增生+,0.0,36,髓样型（med）,INFc,0.0,,1.0,,1.0,2.0,,,2016-12-19,2019-05-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a) 02(3a)014 (3b) 00(4sb)00 (4d)010 (5) 01(6) 00(7) 02(8a)01 (8p)03 (11p)03 4d软组织可见癌, L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre  ,60,50,15,,R2,9.06,6.21,1.76,82.7,337.0,4.84,7.0,10.0,153.0,101.0,29.0,4.8,2.1,61.0,135.0,39.0,22.0,4.6,8.0,63.0,137.0,78.4,52.6,23.2,2.27,0.3,5.0,16.0,1.6,0.16,1.11,8.81,,2.62,6.08,1.39, 未做,无,, P0,H1单（M1 HEP), 未做,ck(+)  VEGF(+) CD4散在(+)  CD8散在(+),90% 弱-中,90% 弱-中,90% 强,70% 弱,28.350854139290405,1643452
1644384,郭合义,659905,男,66,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,33.0,46,中间型（int）,INFc,0.0,,1.0,,2.0,2.0,,,2016-12-26,2017-07-06,2,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,小弯01 (1a)05 (1b)00 (3a)810 (3b)11 (4sb)01 (4d)1012 (5)00 (6)44 (8a)11 (8p)22 (9)11 (11p)11 (12a)00 (14v)55 (15)02 (3b)(5)软组织可见癌," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,30,10, D2+,R1,5.68,3.55,1.48,105.6,294.0,2.47,17.0,22.0,115.0,47.0,8.0,5.77,2.38,55.0,190.0,36.0,19.0,5.1,5.8,85.0,172.0,,,,,,,,,,,,,57.63,37.37,6.84, 未做,无,, P0,H0, 未做,CK + CD4散在+  CD8散在+ VEGF+,80% 弱-中,80% 中-强,90% 强,60 弱,6.307490144546649,1644384
1644329,安国华,664427,男,56,T2,N0,M0, ⅠB,1,4,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,24,中间型（int）,INFc,1.0,0.01,,,,,0.0,,2016-12-26,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)07 (3b)01 (4sb)00 (4d)06 (5)01 (6)00 (7)00 (8a)01 (9)04 (11p)00 (12a)03," LM 后Post, 大弯侧Gre,",30,12,3, R0 D2+,,5.37,2.69,1.75,117.5,223.0,2.2,19.0,17.0,125.0,84.0,15.0,12.69,4.15,63.0,244.0,41.0,22.0,4.3,6.4,79.0,216.0,,,,,,,,,,,,,1.78,2.15,0.908, 未做,无,, P0,H0, 未做, CK +,,,,,68.16688567674113,1644329
1643339,刘焕,664440,男,74,T1b,N0,M0,ⅠA,1,2,,0.0,0.0,,,0.0,17,,,2.0,,,,,,,,2016-12-19,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)00 (3a)01 (3b)01 (4sb)01 (4d)04 (5)00 (6)00 (7)01 (8a)03 (8p)00 (9)02 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",25,20,10, R0 D2+,,5.1,3.46,0.88,153.0,113.0,1.88,31.0,27.0,169.0,47.0,32.0,22.01,7.04,70.0,294.0,44.0,26.0,4.9,6.6,91.0,369.0,58.6,32.4,21.0,1.54,0.4,11.4,19.1,2.7,0.623,1.71,13.3,,0.611,7.91,0.81, 未做,无,, P0,H0, 未做, CK +,,,,,68.39684625492772,1643339
1643858,姜长久,664401,男,61,T3,N3b,M0, ⅢC,1,2,1.0,1.0,1.0,0.0, 异型增生+ 慢性炎症（+）,19.0,29,中间型（int）,INFb,0.0,,2.0,,1.0,2.0,,,2016-12-21,2019-07-29,2,,,,,,,,,0, 低粘附腺癌 90低分化腺癌（G3)(por)10 Lauren混合型,G3, (3a) 35(3b)12 (4sb)00 (4d)35 (5)00 (6) 01(7)12 (8a)33 (8p)13 (9)11 (11p)67 (12a)00, L（幽门窦部） 小弯侧Less 前Ant 后Post,50,45,10,,R1,17.81,15.5,1.14,124.0,357.0,4.97,14.0,12.0,146.0,69.0,15.0,7.42,3.14,60.0,84.0,35.0,25.0,15.9,12.2,89.0,235.0,89.8,47.1,23.5,2.0,0.2,14.8,9.3,1.2,0.902,3.89,9.91,,8.56,14.68,0.767, 未做,无,, P0,H0, 未做,ck(+)  VEGF(弱+) CD4散在(+)  CD8散在(+),80% 强,60% 弱-中,90% 强,80% 中,31.208935611038108,1643858
1643627,高亚清,665387,女,54,T3,N2,M0, ⅢA,1,2,,1.0,1.0,1.0,,4.0,24,,,1.0,,0.0,,2.0,2.0,,,2016-12-21,2019-05-01,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)04 (1b)04 (3a)00 (3b)00 (4sb)00 (4d)37 (5)00 (6)12 (7)01 (8a)02 (8p)02 (9)02 (11p)00 (12a)00," L（幽门窦部）, 后Post, 大弯侧Gre,",30,30,8, R0 D2+,,8.4,3.93,3.75,141.1,226.0,2.52,28.0,19.0,176.0,81.0,36.0,7.09,1.72,75.0,301.0,47.0,28.0,5.8,7.9,72.0,328.0,,,,,,,,,,,,,2.64,111.3,2.21, 未做,无, 无, P0,H0, 未做, CD4散在+、 CD8散在+、 VEGF-、 MLH1弱中、 MLH2中、 MLH6中强、 PMS2弱中,80% 弱-中,80% 中,90% 中-强,80% 弱-中,28.28515111695138,1643627
1643834,褚祥忠,660872,男,62,T3,N3a,M0,ⅢB,1,2,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,8.0,29,中间型（int）,INFb,0.0,,,,,,,,2016-12-21,2018-05-09,2,XELOX*2,1.0,,,,,,,0, 乳头状癌（G1）（pap）70 管状腺癌（中分化【G2】【tub2】 30Lauren肠型,G2, (4d)3/5 (6)2/3 (8p)1/2 (12a)1/1 (1a)01 (1b)02 (3a)04 (3b)03 (4sb)01 (5)00 (7)04 (8a)01 (9)00 (12p)01," L（幽门窦部）, 小弯侧Less,",35,30,10,,R2,6.46,50.92,2.19,120.4,131.0,3.8,42.0,54.0,177.0,116.0,19.0,8.87,3.98,59.0,132.0,36.0,23.0,4.3,6.1,76.0,343.0,74.9,38.1,34.6,1.1,0.4,5.8,16.8,2.0,1.11,2.59,19.7,,22.84,10.66,0.854,,无, 无, P0,H0, 未做, CK+CK20+CK7+VILLIN+,90% 弱-中,90% 弱-中,90% 中,70% 弱,16.557161629434955,1643834
1643336,张占仁,664073,男,68,T3,N2,M0, ⅢA,1,2,1.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,3.0,27,中间型（int）,INFc,2.0,,1.0,,1.0,2.0,,,2016-12-09,2022-09-01,1,,,,,,,,,0, 低粘附腺癌 70管状腺癌（中分化【G2】【tub2】30 Lauren混合型,G2, (6)1/2 (8p)2/3， (1a) 00(1b)01 (2)00 (3a)011 (3b)00 (4sa)00 (4sb)00 (4d)01 (5)00 (7)03 (8a)04 (9)02 (11p)00 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",20,20,15, R0 D2,,8.12,57.74,2.55,142.0,252.0,3.66,14.0,14.0,176.0,46.0,20.0,7.09,2.33,62.0,239.0,38.0,24.0,4.9,4.2,107.0,348.0,80.5,56.1,13.6,4.13,2.1,14.4,4.5,7.2,1.08,2.64,10.3,,1.67,5.77,1.05,,无, 无, P0,H0, 未做, CK +VEGF+ CD4+  CD8+ ,90% 弱-中,90% 弱-中,90% 强,90% 弱,68.72536136662286,1643336
1643350,周庭刚,664394,男,36,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,28,,,1.0,,,,,,,,2016-12-19,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌 Lauren肠型40,G3, (1a) 00(1b)00 (3a)04 (3b)02 (4sb)01 (4d)09 (5)00 (6)02 (7)00 (8a)04 (8p)01 (9)03 (11p)02 (12a)01," 小弯侧Less, LM",15,15,, R0 D2,,8.1,59.81,2.83,154.6,289.0,1.96,22.0,20.0,188.0,67.0,36.0,13.84,3.71,75.0,505.0,48.0,27.0,5.0,4.9,94.0,417.0,72.1,42.0,28.1,1.49,0.6,8.4,18.5,0.4,1.83,3.41,10.6,,3.46,9.25,1.19,,无, 无, P0,H0, 未做, CK+,,,,,68.39684625492772,1643350
1643642,史可夫,663893,男,65,T4b,N0,M0, ⅢA,1,2,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,0.0,25,髓样型（med）,INFc,0.0,,,,,,,,2016-12-20,2018-03-10,2,,,紫杉醇联合替吉奥,紫杉醇+雷替曲塞,甲磺酸阿帕替尼+替吉奥,,,,3, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)07 (2)02 (3a)04 (3b)01 (4sb)00 (4d)07 (7)05横结肠旁05,ML 后Post 小弯侧Less ,50,50,20, R0 D1,,4.88,3.07,1.11,103.9,273.0,4.13,21.0,20.0,177.0,197.0,80.0,7.84,2.25,63.0,264.0,41.0,22.0,4.6,5.0,91.0,275.0,,,,,,,,,,,,,28.12,520.5,5.34, 阳性+,无,, P0,H0, 未做,ck(+)  Villin(-) CK7(-)CK20部分(+) MLH1弱 MLH2弱 MLH6 中PMS2弱,70% 弱,90% 弱,90% 中,70% 弱,14.61892247043364,1643642
1643546,韩淑芬,660055,女,62,T4b,N3a,M0, ⅢC,1,3,2.0,0.0,0.0,1.0, 正常,12.0,31,髓样型（med）,INFc,0.0,,2.0,,2.0,2.0,,,2016-12-20,2018-03-08,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,多西他赛+替吉奥+奥沙利铂,6, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)02 (1b)15 (3a)28 (3b)11 (4sb)22 (4d)59 (5)00 (6)00 (7)01 (8a)00 (8p)11 (9)02 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,10, R0 D2+,,6.91,4.33,1.62,1377.0,160.0,3.23,13.0,13.0,159.0,75.0,11.0,5.8,1.67,63.0,149.0,38.0,25.0,13.9,5.3,70.0,236.0,,,,,,,,,,,,,46.0,1000.0,6.45,,无, 无, P0,H0, 未做, CK +,80% 弱-中,60% 弱-中,70% 中-强,40% 弱,14.553219448094612,1643546
1643859,何有,664151,男,64,T3,N3b,M0, ⅢC,1,2,0.0,1.0,1.0,1.0, 慢性炎症（+） 异型增生+,18.0,42,髓样型（med）,INFb,0.0,,1.0,,1.0,2.0,,,2016-12-21,2020-05-25,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)01 (3a)913 (3b)22 (4sb)00 (4d)37 (5)01 (6)11 (7)15 (8a)24 (8p)03 (9)02 (11p)03," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",55,50,10,,R1,6.77,4.73,1.5,131.6,234.0,3.46,10.0,13.0,128.0,63.0,19.0,9.8,3.73,69.0,139.0,43.0,26.0,5.2,5.5,97.0,331.0,53.8,36.6,13.5,2.71,0.2,9.1,34.5,1.0,0.687,1.2,11.3,,7.36,148.4,5.49, 未做,无,, P0,H0, 未做,CK + CD4+  CD8散在+ VEGF+,90% 弱,80% 弱,90% 中-强,90% 弱,41.09724047306176,1643859
1643472,刘云霞,660054,女,35,T1b,N2,M0, ⅡA,1,3,0.0,1.0,1.0,0.0, 肠化生+ 异型增生+ 慢性炎症（+）,4.0,29,中间型（int）,INFb,1.0,,1.0,,1.0,2.0,,,2016-12-19,2022-09-01,1,,,XELOX,,,,,,1, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)29 (3b)11 (4sb)00 (4d)07 (5)01 (6)13 (7)02 (8a)22 (8p)01 (9)01 (11p)03 (12a)00 (14v)00," L（幽门窦部）, 小弯侧Less,",30,20,15, R0 D2+,,6.85,3.52,2.67,138.0,264.0,2.44,27.0,29.0,168.0,86.0,29.0,26.64,7.73,77.0,323.0,46.0,31.0,4.8,6.2,97.0,263.0,72.2,34.1,29.6,1.15,0.8,10.7,14.1,0.8,1.69,3.12,13.4,,1.01,7.78,110.2, 未做,无, 无, P0,H0, 未做,CK + CD4+  CD8散在+ VEGF+,90% 弱-中,90% 弱-中,90% 中,90% 弱-中,68.39684625492772,1643472
1643746,孙九如,664459,男,58,T1b,N0,M0,ⅠA,1,3,,,,,,0.0,37,,,1.0,,,,,,,,2016-12-21,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,大弯013 小弯024 3a00," L（幽门窦部）, 前Ant, 大弯侧Gre,",20,20,20, R0 D2,,5.4,0.34,2.09,167.2,238.0,2.33,16.0,16.0,163.0,60.0,22.0,12.63,3.99,70.0,406.0,49.0,21.0,5.5,6.8,96.0,374.0,,,,,,,,,,,,,2.42,8.35,1.94, 未做,无, , P0,H0, 未做, CK（+）,,,,,68.3311432325887,1643746
1643455,杨术臣,664471,男,63,T2,N2,M0, ⅡB,1,3,0.0,1.0,1.0,0.0,,4.0,27,中间型（int）,INFb,3.0,,2.0,,1.0,2.0,,,2016-12-19,2019-04-25,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 乳头状癌（G1）（pap）20 Lauren肠型,G3, (1a)03 (1b)01 (3a)12 (3b)01 (4sb)00 (4d)00 (5)11 (6)14 (7) 01(8a)03 (8p)03 (9)03 (11p)04 (12a)00 (12p)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",15,15,8, R0 D2,,5.42,59.64,1.73,150.0,180.0,2.01,9.0,15.0,143.0,64.0,13.0,14.83,4.52,62.0,345.0,40.0,22.0,4.3,9.7,97.0,325.0,,,,,,,,,,,,,2.31,27.25,3.15,,无, 无, P0,H0, 未做, CK+,60% 弱,80% 弱-中,80% 中-强,40% 弱,28.153745072273324,1643455
1643544,李凯,666010,男,43,T4b,N0,M0, ⅢA,1,2,1.0,0.0,0.0,1.0, 慢性炎症（+） 异型增生+,0.0,19,髓样型（med）,INFb,0.0,,2.0,,1.0,2.0,,,2016-12-20,2019-04-04,0,,,SOX,SOX,SOX,SOX,SOX,SOX,8, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren混合型,G3, (1a)01 (1b)00 (3a)01 (3b)00 (4sb)00 (4d)00 (5)01 (6)00 (7)00 (8a)02 (9)04 (11p)05," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,35,15,,R1,8.63,5.46,2.4,161.8,279.0,4.0,12.0,16.0,158.0,93.0,18.0,12.06,3.78,72.0,242.0,47.0,25.0,4.8,3.9,87.0,366.0,67.2,28.1,30.8,0.91,0.2,18.8,11.8,5.0,1.18,2.26,9.6,,1.4,4.87,1.79,,无, 无, P0,H0, 未做, MLH1弱 MLH2 弱MLH6强 PMS2弱 VEGF+ CK+ CD8 + CD4 +,90% 弱,90% 弱,90% 强,70% 弱,27.43101182654402,1643544
1643860,许奎权,676645,男,58,T3,N0,M0, ⅡA,1,3,,0.0,0.0,1.0,,0.0,49,,,0.0,,0.0,,2.0,2.0,,,2016-12-21,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20,G3, (1a)06 (1b)012 (3a) 08(3b) 00(4sb)00 (4d)09 (5)01 (6) 08(7)01 (8a) 02(8p) 01(9) 00(11p)00 (12a)01," L（幽门窦部）, 前Ant, 后Post,",20,12,4, R0 D2,,4.93,2.5,1.92,111.0,214.0,2.3,20.0,19.0,112.0,86.0,44.0,7.21,2.02,68.0,281.0,43.0,25.0,4.6,7.6,91.0,376.0,,,,,,,,,,,,,2.53,14.07,4.67, 阴性,无, 无, P0,H0, 未做, CK（+） VEGF（—） CD4+ CD8+ CD31 D2-40显示未见脉管瘤栓 S-100见神经侵犯 MLH1(70% 弱-强） MLH2（60% 弱-强） MLH6（85% 中-强） PMS2（60% 弱）,70% 弱-中,60% 弱-中,85% 中-强,60% 弱,68.3311432325887,1643860
1644025,王清吉,665431,男,75,T3,N2,M0, ⅢA,1,2,0.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+） 异型增生+,3.0,27,髓样型（med）,INFc,1.0,,2.0,,1.0,2.0,,,2016-12-22,2021-05-25,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60% 粘液腺癌（muc）40% Lauren肠型,G3, (1a)00 (1b)00 (3a)05 (3b)27 (4sb)00 (4d)01 (5)02 (6)15 (7)01 (8a)03 (8p)01 (9)01 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,60,15, R0 D2+,,6.5,3.73,2.05,97.6,236.0,3.81,38.0,23.0,112.0,149.0,25.0,8.07,1.03,59.7,126.68,28.0,31.7,4.3,4.55,83.0,234.0,,,,,,,,,,,,,1.65,17.13,18.38, 未做,无, 无, P0,H0, 未做, CD4+、  CD8散在+、  VEGF弱+、 MLH1-、 MLH2弱中、 MLH6弱中、 PMS2-,0,80% 弱-中,70% 弱-中,0,53.05519053876478,1644025
1644110,亓校军,665432,男,51,T3,N0,M0, ⅡA,1,4,1.0,0.0,0.0,0.0, 正常,0.0,29,髓样型（med）,INFc,0.0,,1.0,,2.0,2.0,,,2016-11-23,2022-09-01,1,,,口服替吉奥,口服卡培他滨,口服卡培他滨,,,,3, 低粘附腺癌70% 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30% Lauren混合型,G3, (1a)04 (1b)03 (2)02 (3a)01 (3b)00 (4sa)00 (4sb)00 (4d)09 (5)00 (6)02 (7)03 (8a)00 (8p)02 (9)01 (11p)00 (12a)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,15, R0 D2,,7.46,4.81,2.1,156.1,235.0,2.09,27.0,11.0,131.0,91.0,20.3,35.24,5.1,69.3,233.8,38.9,30.4,5.3,5.11,74.0,271.0,,,,,,,,,,,,,2.6,0.6,3.76, 未做,无, 无, P0,H0, 未做, CD4散在+、  CD8散在+、 VEGF+、 MLH1弱中、 MLH2弱中、 MLH6中强、 PMS2弱中,70% 弱-中,70% 弱-中,70% 中-强,60% 弱-中,69.25098554533508,1644110
1644139,肖涛,666486,男,53,T3,N1,M1, Ⅳ,1,2,0.0,0.0,0.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,2.0,23,髓样型（med）,INFc,2.0,,2.0,,1.0,2.0,,,2016-12-23,2022-09-01,1,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,6, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,(1a)01 (1b)00 (3a)01(3b)13 (4sb)00 (4d)14 (5)00 (6)01(7)02 (8a)02 (8p)04 (9)05 (11p)00 (12a)00,L（幽门窦部） 前Ant 后Post 小弯侧Less ,80,70,10, D2,R2,8.14,5.1,1.82,87.0,369.0,7.19,24.0,15.0,120.0,88.0,10.5,6.59,1.24,61.1,226.86,36.1,25.0,5.3,5.39,84.0,309.0,,,,,,,,,,,,,1.09,0.95,7.57, 阴性,无,,p1盆(M1 PER),H0, 未做, CD31（-） D2-40（-）S-100（+)   CD4(+) CD8(+)VEGF(+),90% 弱,90% 强,90% 强,80% 弱,68.26544021024966,1644139
1644435,孙合国,666142,男,45,T4b,N3a,M0, ⅢC,1,2,0.0,1.0,1.0,1.0, 正常,14.0,24,髓样型（med）,INFa,2.0,,1.0,,1.0,2.0,,,2016-12-26,2022-09-01,1,,,SOX,SOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)15 (3a)78 (3b)00 (4sb)00 (4d)22 (5)11 (6)24 (7)01 (8a)11 (8p)00 (9)00 (11p)00 (12a)00 软组织可见癌," L（幽门窦部）, 后Post, 大弯侧Gre, 前Ant, 小弯侧Less,",40,35,10, D2,R1,9.51,7.67,1.0,121.0,334.0,2.93,11.0,15.0,228.0,59.0,16.0,17.07,5.54,72.0,146.0,40.0,32.0,5.3,4.0,65.0,101.0,,,,,,,,,,,,,1.31,460.2,3.81, 未做,无, 无, P0,H0, 未做, CK+ CD31  D2-40 可见脉管瘤栓 S-100神经侵犯 MLH180 MLH290 MLH680 PMS285 CD4  CD8 + VEGF+,80% 弱-中,90% 中,80% 中-强,85% 中-强,68.16688567674113,1644435
1644044,于坤,663044,男,58,T3,N0,M0, ⅡA,1,2,,1.0,1.0,1.0,,0.0,18,,,0.0,,2.0,,2.0,2.0,,,2016-12-22,2022-09-01,1,,,,,,,,,0, 低粘附腺癌70 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30,G3, (1a)03 (1b)04 (3a)03 (3b)01 (4sb)00 (4d)01 (5)00 (6)00 (7)02 (8a)00 (8p)01 (9)02 (11p)00 (12a)00 14v01," M（胃体部）, 大弯侧Gre,",14,10,2, R0,,5.44,2.51,2.31,146.0,175.0,2.7,33.0,18.0,165.0,125.0,28.6,11.47,2.51,62.0,242.37,37.6,24.4,4.5,6.61,111.0,359.0,,,,,,,,,,,,,4.17,19.9,2.09, 未做,无, 无, P0,H0, 未做, CK+ MLH170 MLH280 MLH690 PMS250 CD4  CD8 +,70% 弱-中,80% 中-强,90% 强,50% 弱-中,68.29829172141918,1644044
1644020,白洪海,666724,男,50,T2,N2,M0, ⅡB,1,2,,1.0,1.0,1.0,,3.0,7,,,0.0,,,,,,,,2016-12-22,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1b)00 (3a)01 (3b)00 (4sb)00 (4d)00 (5)00 (6)11 (7)11 (8a)12 (8p)00 (9)02 (11p)00 (12a)00," L（幽门窦部）, 大弯侧Gre,",12,10,3, R0 D2+,,10.08,8.43,1.23,103.1,197.0,2.37,10.0,13.0,138.0,57.0,14.0,9.85,3.0,64.0,260.0,39.0,25.0,4.4,7.2,100.0,326.0,,,,,,,,,,,,,0.724,0.6,2.89, 未做,无,, P0,H0, 未做, CK +,,,,,68.29829172141918,1644020
1643961,毕建东,659821,男,66,T2,N1,M0, ⅡA,1,2,,,,,,1.0,23,,,1.0,,,,,,,,2016-12-22,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)75 粘液腺癌（muc）15 低粘附腺癌10,G3, (1a)01 (1b)00 (3a)00 (3b)02 (4sb)01 (4d)05 (5)01 (6)12 (7)02 (8a)01 (8p)02 (9)01 (11p)00 (12a)01 (14v)00," L（幽门窦部）, 后Post, 小弯侧Less,",10,10,5, R0 D2+,,6.01,3.52,1.96,133.0,333.0,2.93,13.0,18.0,135.0,69.0,16.0,9.99,2.62,67.0,357.0,41.0,26.0,4.9,5.6,92.0,297.0,,,,,,,,,,,,,2.36,0.6,1.4, 未做,无,, P0,H0, 未做, CK +,,,,,68.29829172141918,1643961
1644803,刘晶敏,666058,女,41,T3,N3a,M0,ⅢB,1,2,2.0,1.0,1.0,0.0, 肠化生+ 慢性炎症（+）,7.0,20,中间型（int）,INFc,0.0,,2.0,,2.0,2.0,,,2016-12-28,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,14,低粘附腺癌60 低分化腺癌（G3)(por)25  粘液腺癌（muc）15 Lauren弥漫型,G3, (1a)00 (1b)00 (3a)49 (3b)00 (4sb)00 (4d)37 (5)00 (6)00 (7)01 (8a)01 (9)01 (11p)01 (12a)00 (14v)00," M（胃体部）, 前Ant,",35,35,10, R0 D2+,,5.68,3.37,1.71,97.8,256.0,2.27,13.0,17.0,197.0,57.0,6.0,14.05,3.81,67.0,192.0,42.0,25.0,4.5,3.7,72.0,193.0,,,,,,,,,,,,,0.628,3.65,2.53, 未做,无, 无, P0,H0, 未做,CD4散在+  CD8散在+ VEGF弱+,80% 弱,80% 中-强,30% 弱,80% 中-强,68.1011826544021,1644803
1644634,唐淑萍,666165,女,68,T4a,N3a,M0, ⅢB,1,3,,1.0,1.0,1.0,,11.0,23,,,1.0,,,,,,,,2016-12-27,2019-05-05,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 低粘附腺癌20 粘液腺癌（muc）30,G3,大弯918 小弯25," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,25,10, R0,,6.2,2.53,3.15,144.0,236.0,3.56,15.0,19.0,182.0,71.0,19.0,30.88,7.49,66.0,219.0,40.0,26.0,5.5,2.6,70.0,,,,,,,,,,,,,,1.84,0.6,6.81, 未做,无, 无, P0,H0, 未做, CK（+）,,,,,28.21944809461235,1644634
1644699,马清文,665944,男,67,T3,N1,M0, ⅡB,1,2,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,2.0,27,中间型（int）,INFb,0.0,,2.0,,2.0,2.0,,,2016-12-28,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】60 乳头状癌（G1）（pap）40 Lauren弥漫型,G2, (1a)03 (1b)00 (3a)06 (3b)01 (4sb)00 (4d)08 (5)00 (6)00 (7)23 (8a)01 (8p)01 (9) 03(11p)00  3b软组织可见癌,L（幽门窦部） 后Post 小弯侧Less ,65,40,6, R0 D2,,4.94,2.62,1.84,152.0,174.0,1.92,4.0,16.0,162.0,74.0,12.0,12.36,3.78,64.0,253.0,41.0,23.0,4.2,6.8,86.0,273.0,,,,,,,,,,,,,1.88,7.95,5.95, 阳性+,无,, P0,H0, 未做, VEGF(部分弱+) CD4散在(+)  CD8散在(+) MLH1 中-强MLH2中-强 MLH6强 PMS2中-强,90% 中-强,90% 中-强,90% 强,90% 中-强,68.1011826544021,1644699
1644614,许志彬,666815,男,57,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 正常,12.0,38,中间型（int）,INFb,0.0,,2.0,,1.0,2.0,,,2016-12-27,2019-04-25,2,,,SOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3, (1a) 12(1b) 11(2) 04(3a)23 (4sa) 00(4sb)03 (4d) 34(5) 00(6)35 (8a) 12(8p)03 (9) 11(11p)01 (12a)05," ML 前Ant, 小弯侧Less,",50,30,5, R0 D2,,5.53,2.75,2.19,128.3,310.0,3.72,29.0,20.0,141.0,148.0,96.0,7.74,2.63,62.0,189.48,34.1,27.9,9.6,5.01,79.0,420.0,,,,,,,,,,,,,,,, 阴性,无, 无, P0,H0, 未做, MLH1 60% 染色强度为弱-中， MLH2 70%染色强度为中， MLH6 70% 染色强度为中-强， PMS2 80% 染色强度为 CD4 + ，CD8 +，CK（+） VEGF（—） ,60% 弱-中,70% 中,70% 中-强,30% 弱,27.890932982917214,1644614
1644323,金志发,666149,男,48,T4b,N0,M0, ⅢA,1,3,0.0,1.0,1.0,1.0,,0.0,51,中间型（int）,INFc,0.0,,0.0,,1.0,2.0,,,2016-12-26,2022-09-01,1,,,XELOX,XELOX,,,,,2, 腺癌 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a) 00(1b)07 (2)03 (3a)010 (3b)01 (4sa)01 (4sb)00 (4d)06 (5)00 (6)02 (7)04 (8a)01 (8p)00 (9)02 (10)01 (11d)012 (11p)00 (12a)00 (12p)01," SiewerⅢ, 前Ant, 后Post, 小弯侧Less, U（胃底部）,",50,45,8, R0,,16.15,12.71,1.68,121.0,655.0,2.86,20.0,20.0,184.0,99.0,16.0,10.15,2.39,78.0,341.0,47.0,31.0,4.4,6.3,93.0,377.0,53.8,32.8,15.6,2.1,0.2,12.8,30.7,0.9,1.12,1.36,13.7,,1.26,4.28,10.13,,无, 无, P0,H0, 未做, Vimentin +CK+ CD4+  CD8+ ,90% 弱,90% 中,90% 中-强,80% 弱,68.16688567674113,1644323
1644615,任利军,665444,男,58,T3,N1,M0, ⅡB,1,3,,1.0,1.0,1.0,,1.0,17,,,0.0,,1.0,,2.0,2.0,,,2016-12-27,2022-09-01,1,,,SOX,SOX,SOX,SOX,SOX,SOX,8, 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)00 (3a)15 (3b)00 (4sb)00 (4d)00 (5)01 (6)00 (7)04 (8a) (8p)03 (9)02 (11p) (12a)00," M（胃体部）, 小弯侧Less,",15,10,5, R0 D2,,9.32,7.71,0.85,120.0,217.0,2.5,30.0,22.0,162.0,45.0,22.0,23.6,6.55,73.0,286.0,45.0,28.0,4.9,4.9,79.0,286.0,,,,,,,,,,,,,1.68,12.27,0.919, 阴性,无, , P0,H0, 未做, CD4（+） CD8（+） VEGF（+),80% 中-强,90% 中-强,90% 强,70% 弱-中,68.13403416557162,1644615
1644534,苑红旗,666574,男,57,T2,N0,M0, ⅠB,1,3,1.0,0.0,0.0,1.0, 异型增生,0.0,35,中间型（int）,INFb,1.0,,2.0,,2.0,2.0,,,2016-12-27,2022-09-01,1,,,SOX,,,,,,1, 管状腺癌（低中分化） 低粘附腺癌,G2,035 (1a)06 (1b)05 (3a)09 (3b)01 (4sb)00 (4d)03 (5)00 (6)05 (7)01 (8a)01 (8p)02 (9)02 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",20,15,8, D2 R0,,6.8,2.91,2.84,151.3,343.0,1.71,23.0,46.0,197.0,60.0,239.0,23.1,9.86,52.0,143.0,36.0,21.0,5.0,3.2,80.0,430.0,,,,,,,,,,,,,1.61,3.4,3.25,,无, 无, P0,H0, 未做,,90% 弱-中,90% 中,90% 中,80% 弱,68.13403416557162,1644534
1644531,边书敏,666189,女,61,T3,N3a,M0,ⅢB,1,3,2.0,1.0,1.0,1.0, 慢性炎症（+）,13.0,53,中间型（int）,INFc,1.0,,2.0,,2.0,2.0,,,2016-12-27,2018-12-24,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren弥漫型,G3, (1a)01 (1b)00 (3a)821 (3b)34 (4sb)00 (4d)07 (5)11 (6)07 (7)02 (8a)05 (8p)02 (9)12 (11p)00 (12a)01," L（幽门窦部）, 小弯侧Less,",30,25,10, R0,,5.21,3.54,1.29,118.2,276.0,3.67,12.0,16.0,168.0,78.0,9.0,10.35,2.17,80.0,318.0,46.0,34.0,4.9,3.4,76.0,,,,,,,,,,,,,,0.663,4.69,1.27, 未做,无, 无, P0,H0, 未做, CK（+） MLH1 MLH270 MLH660 PMS2- CD4  CD8 +,0,70% 中,60% 中-强,0,23.88304862023653,1644531
1644729,薄玉玲,666171,女,57,T3,N2,M0, ⅢA,1,2,2.0,0.0,0.0,1.0, 正常,4.0,39,硬型（sci）,INFc,0.0,,2.0,,2.0,2.0,,,2016-12-28,2020-01-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌 低分化腺癌（G3)(por)10 Lauren弥漫型,G3, (1a)00 (1b)01 (3a)18 (3b)01 (4sb)00 (4d)02 (5)00 (6)02 (7)01 (8a)08 (8p)04 (9)02 (11p)15 (12a)00 14v25," L（幽门窦部）, 后Post,",20,15,8, R0,,3.74,1.72,1.65,143.8,163.0,2.52,17.0,23.0,154.0,68.0,5.0,13.59,3.66,71.0,188.0,44.0,27.0,4.2,4.4,77.0,304.0,,,,,,,,,,,,,2.61,7.74,1.95, 未做,无, 无, P0,H0, 未做, CK（+） MLH130 MLH240 MLH640 PMS210 CD4  CD8 + VEGF+,30% 弱,40% 弱-中,40% 中-强,10% 弱,36.10381077529566,1644729
1644432,邱海丰,666279,男,45,T3,N1,M0, ⅡB,1,3,0.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,2.0,25,中间型（int）,INFb,0.0,,1.0,,1.0,2.0,,,2016-12-26,2022-09-01,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1b)02 (3a)08 (3b)01 (4sb)00 (4d)05 (5)00 (6)22 (7)01 (8a)01 (8p)00 (9)02 (11p)01 (12a)02,L（幽门窦部） 大弯侧Gre  前Ant 后Post ,30,30,18, R0 D2,,6.44,3.94,1.74,156.6,261.0,3.4,34.0,26.0,182.0,102.0,138.0,18.83,4.94,77.0,304.0,49.0,28.0,5.1,7.2,98.0,414.0,68.8,41.2,24.8,1.66,0.0,14.4,14.5,0.6,0.334,1.43,10.6,,4.0,18.11,12.19, 未做,无,, P0,H0, 未做,ck(+)  VEGF(+) CD4(+)  CD8(+),90% 弱,90% 弱-中,90% 中-强,90% 弱,68.16688567674113,1644432
1644622,梁艳利,666261,男,48,T3,N0,M0, ⅡA,1,2,,1.0,1.0,1.0, ,0.0,19,,,1.0,,,,,,,,2016-12-27,2022-09-01,1,,,XELOX,XELOX,,,,,2, 低粘附腺癌70 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)30,G3, (1a)00 (1b)01 (3a)04 (3b)01 (4sb)01 (4d)02 (5)00 (6)01 (7)02 (8a)02 (8p)01 (9)00 (11p)01 (12a)03," L（幽门窦部）, 后Post,",20,20,10, R0 D2,,5.6,2.63,2.26,157.7,199.0,2.65,30.0,24.0,176.0,72.0,47.0,10.22,2.63,77.0,360.0,48.0,29.0,5.0,4.0,80.0,399.0,79.7,51.9,22.5,2.31,0.1,10.0,8.2,4.5,1.06,1.96,10.5,,3.54,0.6,1.24,阳性+,无,, P0,H0, 未做, CK + MLH1弱-中 MLH2中-强 MLH6强 PMS2弱-中,80% 弱-中,80% 中-强,90% 强,80% 弱-中,68.13403416557162,1644622
1644991,韩敬德,666819,男,54,T1a,N0,M0,ⅠA,1,0,,,,,,0.0,13,,,1.0,,,,,,,,2016-12-29,2022-09-01,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）,G1, (3a)03 (3b)00 (4sb)01 (4d)01 (5)00 (6)06 (7)02 (8a)00 (12a)00,L（幽门窦部） 前Ant 后Post ,10,10,, R0 D2,,6.83,3.41,2.49,159.7,252.0,2.24,16.0,19.0,166.0,57.0,15.0,16.28,3.83,76.0,393.0,46.0,30.0,5.1,7.5,93.0,274.0,69.5,33.1,28.1,1.18,0.2,16.8,12.3,3.3,1.36,1.99,13.0,,2.07,11.09,0.744, 阳性+,无,, P0,H0, 未做, CK +,,,,,68.06833114323258,1644991
1644823,赵洁,665933,女,61,T4a,N2,M0, ⅢA,1,3,2.0,1.0,1.0,1.0, 正常,5.0,19,硬型（sci）,INFc,0.0,,1.0,,2.0,2.0,,,2016-12-28,2019-12-06,2,,,SOX,SOX,SOX,SOX,SOX,XELOX,11, 低粘附腺癌 Lauren弥漫型,GX, (1a)11 (1b)03 (3a)11 (3b)00 (4sb)00 (4d)00 (5)04 (6)17 (7)01 (8a)00 (8p)00 (9)22 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",35,20,12, R0 D2,,6.52,3.43,2.1,130.9,307.0,2.68,12.0,16.0,201.0,86.0,9.0,14.14,3.38,65.0,221.0,41.0,24.0,4.9,3.5,72.0,245.0,,,,,,,,,,,,,0.608,13.41,0.786, 阴性,无, 无, P0,H0, 未做,CD4+ CD8+ VEGF+   CD31，D2-40 未见明确脉管瘤栓 S-100见神经侵犯 CK+ MLH1（70% 弱） MLH2（60% 弱-中） MLH6（70% 强） PMS2（40% 弱） ,70% 弱,60% 弱-中,70% 强,40% 弱,35.2496714848883,1644823
1644619,王淑兰,665927,女,63,T1b,N0,M0,ⅠA,1,0,,,,,,0.0,20,,,0.0,,,,,,,,2016-12-27,2021-06-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 低粘附腺癌10,G3, (1a)02 (1b)02 (3a)02 (3b)02 (4sb)00 (4d)03 (5)00 (6)00 (7)02 (8a)06 (8p)00 (9)01 (11p)00 (12a)00," L（幽门窦部）, 后Post,",15,10,, R0 D2+,,7.47,4.17,2.82,150.1,238.0,2.85,17.0,19.0,166.0,69.0,14.0,12.0,3.17,73.0,248.0,49.0,24.0,5.6,5.9,89.0,381.0,,,,,,,,,,,,,1.65,0.6,2.08,,无, 无, P0,H0, 未做, CK +,,,,,53.580814717477004,1644619
1644723,谷宝印,665857,男,57,T1b,N1,M0, ⅠB,1,1,1.0,,,, 肠化生++ 慢性炎症（+）,2.0,31,中间型（int）,INFa,0.0,,,,,,,,2016-12-28,2022-09-01,1,,,XELOX,XELOX,XELOX,,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G3, (1a)01 (1b)02 (3a)05 (3b)01 (4sb)00 (4d)29 (5)01 (6)02  (7)02 (8a)02 (8p)00 (9)04 (11p)02 (12a)00," M（胃体部）, 大弯侧Gre,",40,40,8, R0 D2,,5.8,2.67,2.43,165.9,215.0,1.93,21.0,22.0,169.0,68.0,30.0,18.79,6.31,80.0,366.0,48.0,32.0,5.1,5.8,96.0,390.0,,,,,,,,,,,,,1.3,13.14,1.83, 未做,无,, P0,H0, 未做,CK（+）,,,,,68.1011826544021,1644723
1644725,胡永方,665862,男,60,T3,N1,M0, ⅡB,1,4,,1.0,1.0,1.0,,1.0,23,,,0.0,,1.0,,2.0,2.0,,,2016-12-28,2017-06-30,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 60低粘附腺癌40,G3,(1a)02 (1b)02 (3a)14 (3b)00 (4sb)00 (4d)01 (5)00 (6)02 (7)01 (8a)03 (8p)01 (9)03 (11p)03 (12a)01," ML 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,20,5, R0 D2,,6.78,57.31,2.13,135.1,219.0,2.65,15.0,19.0,150.0,62.0,11.0,9.4,3.76,72.0,153.0,42.0,30.0,4.5,7.0,80.0,315.0,70.1,42.1,23.5,1.79,0.9,17.3,9.7,2.4,0.689,2.91,12.0,,2.68,68.1,2.07,,无, 无, P0,H0, 未做, CK +CD4+  CD8+  VEGF+,70% 弱,80% 弱-中,80% 中-强,70% 弱,6.044678055190539,1644725
1644487,叶占和,666231,男,60,T3,N0,M0, ⅡA,1,3,1.0,1.0,1.0,1.0, 肠化生+ 异型增生+ 慢性炎症（+）,0.0,43,中间型（int）,INFc,1.0,,1.0,,1.0,2.0,,,2016-12-27,2019-04-01,2,,,,,,,,,0, 粘液腺癌（muc）50 低粘附腺癌 30Lauren混合型,GX, 5组软组织可见癌1a（03）1b（08）3a（04）3b（01）4sb（00）4d（03）5（00）6（03）7（08）8a（03）8p（05）9（02）11p（02）12p（01）," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,8, R0 D2,,6.12,2.36,2.99,154.4,332.0,2.42,39.0,38.0,152.0,75.0,14.0,10.98,4.18,78.0,259.0,44.0,34.0,4.3,7.7,95.0,527.0,63.7,29.2,31.9,0.92,0.1,5.4,28.9,3.0,0.977,2.68,15.8,,3.72,128.0,10.19, 阴性,无, 无, P0,H0, 未做, CK+ cd4+ cd8+ vegf+,90% 弱,90% 中-强,90% 强,70% 弱,27.102496714848883,1644487
1644989,付玉田,665480,男,64,T3,N3a,M0,ⅢB,1,3,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,11.0,32,中间型（int）,INFc,0.0,,1.0,,2.0,2.0,,,2016-12-29,2017-09-08,2,,,,,,,,,0, 低粘附腺癌50 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)45 粘液腺癌（muc）5 Lauren混合型,G3, (1a)00 (1b)00 (3a)03 (3b)35 (4sb)02 (4d)613 (5)00 (6)00 (7)03 (8a)11 (8p)02 (9)02 (11p)11 (12a)00 , L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,40,15, R0 D2,,5.28,3.24,1.48,91.0,313.0,2.7,10.0,13.0,150.0,91.0,11.0,10.88,3.54,65.0,150.0,39.0,26.0,6.4,2.8,83.0,239.0,62.9,14.9,45.9,0.32,0.5,4.5,30.9,3.4,0.548,3.24,14.4,,1.96,0.6,2.66,未做,无,, P0,H0, 未做,,70% 弱,80% 中-强,80% 中-强,60% 弱-中,8.31143232588699,1644989
1644987,朱立善,665479,男,77,T4a,N3a,M0, ⅢB,1,1,1.0,1.0,1.0,1.0, 肠化生+ 慢性炎症（+）,7.0,27,中间型（int）,INFb,0.0,,1.0,,2.0,2.0,,,2016-12-29,2017-12-07,2,,,,,,,,,0, Lauren混合型 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)50(por) 低粘附腺癌30 粘液腺癌（muc）20,G3," (3b)2/2 (5)1/1 (6)1/1 (4d)3/5， (1b),03(3a)04 (4sb)09 (7)01 (8a)00 (8p)00 (9)01 (11p)00 (12a)00"," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,15, R0,,8.45,63.42,2.47,159.1,240.0,3.13,54.0,67.0,207.0,79.0,13.0,9.68,3.11,83.0,212.0,47.0,36.0,5.3,8.3,94.0,235.0,47.1,22.5,20.7,1.87,0.3,5.6,36.0,0.8,0.503,3.39,15.0,,1.98,4.84,8.72,,无, 无, P0,H0, 未做, VEGF+ CK+ CD4+  CD8+ ,70% 弱-中,80% 中-强,80% 强,80% 弱-中,11.268068331143231,1644987
1645084,孔繁荣,665911,女,63,T3,N0,M0, ⅡA,1,2,1.0,0.0,0.0,1.0,,0.0,15,中间型（int）,INFb,0.0,,2.0,,2.0,2.0,,,2016-12-30,2022-09-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3, (1a)00  (1b)00 (3a)00 (3b)00 (4sb)00 (4d)02 (5)00 (6)00 (7)08 (8a)02 (8p)01 (9)01 (12a)01,M（胃体部） 前Ant,30,25,8, R0 D2,,9.7,7.21,1.7,120.0,430.0,5.82,19.0,14.0,145.0,86.0,12.0,6.29,1.45,75.0,248.0,47.0,28.0,10.2,11.8,88.0,309.0,,,,,,,,,,,,,0.716,6.06,4.07, 未做,无, 无, P0,H0, 未做, CD31（-） D2-40（-）S-100（+)   CD4(+) CD8(+)VEGF(+),70% 弱-中,80% 中-强,90% 强,60% 弱,68.03547963206307,1645084
1644799,王建民,666725,男,54,T3,N3a,M0,ⅢB,1,4,2.0,1.0,1.0,1.0, 慢性炎症,14.0,24,硬型（sci）,INFc,0.0,,2.0,,2.0,2.0,,,2016-12-28,2017-12-01,2,,,DP,DP,DP,DP,DP,DP,6, 低粘附腺癌,GX,1424，  (1a)00 (1b)03 (2)01 (3a)33 (3b)11 (4sa)11 (4sb)11 (4d)35 (5)00 (6)13 (7)00 (8a)00 (8p)12 (9)12 (11p)00 (12a)00," L（幽门窦部）, M（胃体部）, U（胃底部）, LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",140,90,15, R0 D2,,5.62,3.01,2.09,151.0,199.0,16.7,14.0,18.0,171.0,82.0,17.0,12.4,3.81,71.0,254.0,46.0,25.0,5.7,3.6,102.0,263.0,,,,,,,,,,,,,1.86,7.19,6.52,,无, 无, P0,H0, 未做,,40% 弱,50% 弱,50% 中,50% 弱,11.103810775295663,1644799
1645083,于文秀,666520,男,51,T3,N2,M0, ⅢA,1,3,0.0,1.0,1.0,1.0, 慢性炎症,6.0,38,髓样型（med）,INFb,0.0,,2.0,,2.0,2.0,,,2016-12-30,2018-04-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,(1a)03 (1b)01 (3a)09 (3b)00 (4sb)00 (4d)02 (5)13 (6)46 (7)06 (8a)11 (8p)03 (9)00 (11d)04 (11p)00 (12a)00," L（幽门窦部）, M（胃体部）, LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,70,10, R0 D2,,5.96,4.42,1.16,122.7,226.0,4.1,8.0,15.0,115.0,58.0,7.0,3.97,1.66,60.0,141.0,38.0,22.0,4.4,6.2,79.0,217.0,,,,,,,,,,,,,2.2,12.66,4.53,,无, 无, P0,H0, 未做,,90% 弱-中,80% 弱-中,70% 弱-中,90% 弱,15.013140604467806,1645083
1644932,赵连祥,666218,男,66,T3,N3a,M0,ⅢB,1,3,0.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,10.0,47,中间型（int）,INFa,1.0,,2.0,,1.0,2.0,,,2016-12-29,2019-05-03,0,,,,,,,,,0, 浸润溃疡型中低分化管状腺癌,G3,1047，  (1a)02 (1b)02 (3a)16 (3b)57 (4sb)02 (4d)06 (5)00 (6)413 (7)04 (8a)03 (8p)01 (9)00 (11p)01 (12a)00," L（幽门窦部）, 前Ant,",50,30,10, R0 D2,,9.31,7.92,1.06,96.2,248.0,2.48,18.0,27.0,148.0,51.0,13.0,9.46,3.56,68.0,136.0,39.0,29.0,5.9,7.5,97.0,279.0,,,,,,,,,,,,,44.67,13.8,3.08,,无, 无, P0,H0, 未做,,70% 弱-中,80% 中,90% 中-强,70% 弱,28.088042049934295,1644932
1645155,张德萍,666827,女,37,T3,N3b,M0, ⅢC,1,3,2.0,1.0,1.0,1.0, 正常,23.0,37,硬型（sci）,INFc,0.0,,1.0,,2.0,2.0,,,2016-12-30,2018-05-19,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌 Lauren弥漫型,GX, (1a)01 (1b)35（3a）01软组织可见癌 (3b)810 (4sb)00 (4d)77 (5)01 (6)12 (7)13 (8a)02 (8p)11 (9)13 (11p)11 (12a)00 ," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,15, R0 D2+,,4.65,2.29,1.42,85.1,225.0,3.56,14.0,19.0,152.0,59.0,16.0,11.29,2.99,67.0,209.0,44.0,23.0,4.7,4.5,65.0,204.0,,,,,,,,,,,,,569.0,2.89,3.16,,无, 无, P0,H0, 未做, CK +,50% 弱,70% 强,70% 强,60% 弱,16.590013140604466,1645155
1644937,张文瑞,665991,男,64,T1b,N0,M0,ⅠA,1,3,1.0,0.0,0.0,0.0, 肠化生+ 慢性炎症（+）,0.0,39,中间型（int）,INFb,1.0,,1.0,,2.0,2.0,,,2016-12-29,2019-03-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3,1a（03）1b（05）3a（012）3b（00）4sb（02）4d（03）5（00）6（00）7（00）8a（01）8p（04）9（04）11p（03）12a（02）," M（胃体部）, 小弯侧Less,",50,20,6, R0 D2,,4.04,2.11,1.62,156.3,229.0,2.11,27.0,24.0,131.0,60.0,29.0,7.64,2.29,73.0,406.0,46.0,27.0,5.6,6.5,104.0,209.0,80.1,58.4,19.7,2.96,0.9,,8.9,0.7,1.04,1.66,10.7,,1.36,7.83,2.19,,无, 无, P0,H0, 未做, CK+ VEGF+ CD4 + CD8 +,,,,,26.47831800262812,1644937
1435871,白书生,582131,男,58,T3,N3a,M0,ⅢB,2,3,0.0,0.0,0.0,1.0,,9.0,20,硬型（sci）,INFa,0.0,,0.0,1.0,,,,0.0,2014-12-08,2015-05-15,2,,,,,,,,,0, 低分化腺癌（G3)(por)60% 低黏附腺癌40% Lauren肠型,G3, (1a)01 (1b)00 (2)00 (3a)25 (3b)79 (4sa)01 (4sb)00 (4d)01 (5)00 (6)03 (7)(8a)(8p)(9)(12a)00 (11p)01," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",30,30,15, R0 D2,,9.36,5.69,2.93,157.0,282.0,2.63,27.0,33.0,190.0,50.0,27.0,7.57,3.46,76.0,296.0,45.0,31.0,4.6,6.6,69.0,361.0,71.4,46.2,19.3,2.39,0.2,4.2,21.1,2.8,0.53,0.833,11.7,164.0,2.78,7.83,0.736,,,, P0,H0,,,,,,,5.19053876478318,1435871
1427324,曹文龙,574654,男,48,T3,N2,M0, ⅢA,2,3,1.0,0.0,0.0,1.0,,6.0,34,中间型（int）,INFc,0.0,,2.0,0.0,,,,2.0,2014-09-22,2015-11-01,2,,,XELOX,XELOX,,,,,2, 低粘附腺癌90% 低分化管状腺癌（G3)(por)10%,G3, (1a)00 (1b)00 (3a)23 (3b)00 (4sb)00 (4d)00 (5)11 (6)13 (7)111 (8a)16 (8p)(9)08 (11p)02 (12a)00 (14v)00, L（幽门窦部） 前Ant 小弯侧Less 后Post ,55,50,7, R0 D2+,,7.07,3.85,2.52,142.8,303.0,2.93,32.0,25.0,151.0,73.0,23.0,9.37,2.96,68.0,346.0,43.0,25.0,5.2,5.4,73.0,274.0,,,,,,,,,,,,,4.06,15.1,3.11,,,, P0,H0,,,,,,,13.304862023653088,1427324
1321814,柴恩礼,534818,男,50,T3,N1,M0, ⅡB,2,3,,,,,,2.0,26,中间型（int）,INFc,1.0,0.25,,,,,,,2013-07-30,2015-07-17,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6,中分化腺癌,G2, (1a)01 (1b)03 (3a)05 (3b)13 (4sb)00 (4d)17 (5)00 (6)01 (7)02 (8a)01 (8p)01 (9)01 (12a)00 (14v)01, L（幽门窦部） 大弯侧Gre  前Ant 后Post ,40,40,15, R0 D2+,,8.96,4.16,3.8,137.9,304.0,2.78,29.0,20.0,163.0,84.0,23.0,7.68,1.3,70.1,310.1,41.0,29.1,4.8,4.58,78.0,266.0,,,,,,,,,,,,,6.05,28.26,1.6,,,, P0,H0,,,,,,,23.554533508541393,1321814
1431571,车恒远,576547,男,67,T4b,N3b,M0, ⅢC,2,4,2.0,1.0,1.0,1.0,,19.0,40,中间型（int）,INFc,0.0,,2.0,0.0,,,,2.0,2014-10-30,2016-09-24,2,,,FOLFOX,,,,,,1, 低分化管状腺癌（G3)95%(por) 低黏附腺癌5%,G3, (1a)04 (1b)00 (2)04 (3a)56 (3b)56 (4sa)01 (4sb)07 (4d)67  (6)00 (7)00 (8a)11 (8p)01 (9)01 (11p)11 (11d)00 (12a)00 小弯11    5软组织可见癌,ML 小弯侧Less 前Ant 后Post 大弯侧Gre  ,60,30,10, R0 D2,,7.65,4.12,2.78,164.0,212.0,3.68,35.0,30.0,166.0,78.0,15.0,26.03,8.96,74.0,313.0,48.0,26.0,4.8,7.5,81.0,383.0,71.5,31.7,36.9,0.86,0.7,8.9,17.1,4.7,0.969,1.27,11.2,26.9,1.8,2.77,1.48,,,, P0,H0,,,,,,,22.831800262812088,1431571
1326575,陈万峰,540171,男,71,T3,N2,M0, ⅢA,2,3,,,,1.0,,3.0,27,中间型（int）,INFb,2.0,0.5,,,,,,,2013-09-16,2014-05-17,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)11 (2)01 (3a)11 (3b)11 (4sa)02 (4sb)01 (4d)00 (5)00 (6)02 (7)01 (8a)04 (9)09 (11d)02 (12a)00 (14v)01," L（幽门窦部）, M（胃体部）, LM 前Ant, 后Post, 小弯侧Less,",50,40,10, R0 D2+,,5.75,3.18,1.99,129.0,144.0,3.28,12.0,24.0,152.0,101.0,14.0,12.94,3.03,66.4,178.4,37.9,28.5,5.5,5.94,92.0,193.0,,,,,,,,,,,,,1.85,0.6,0.637,,,, P0,H0,,,,,,,7.982917214191852,1326575
1402743,迟瑞英,552238,女,76,T3,N1,M0, ⅡB,2,3,,1.0,1.0,1.0,,1.0,33,中间型（int）,INFc,0.0,0.6,,,,,,,2014-02-11,2014-12-01,2,,,,,,,,,0, 粘液腺癌（muc）80% 低分化管状腺癌（G3)(por)10% 低粘附腺癌10%,G3, (1a)06 (1b)06 (3a)03 (3b)14 (4sb)00 (4d)00 (5)00 (6)01 (7)02 (8a)03 (8p)02 (9)04 (11p)01 (12a)00 (12p)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,15,5, R0 D2,,4.66,3.06,1.09,113.2,77.0,3.53,10.0,19.0,239.0,37.0,8.0,6.05,2.46,63.0,125.0,37.0,26.0,9.4,5.8,56.0,143.0,,,,,,,,,,,,,25.52,19.43,2.73,,,, P0,H0,,,,,,,9.625492772667542,1402743
1320625,仇得才,534094,男,44,T4a,N3a,M0, ⅢB,2,2,,,,,,8.0,12,中间型（int）,INFc,0.0,0.2,,,,,,,2013-07-18,2015-12-01,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por),G3, (1a)(1b)04 (3a)(3b)11 (4sb)00 (4d)22 (5)(12a)00 (6)22 (8a)11 (7)(11p)22 ," L（幽门窦部）, 前Ant, 小弯侧Less,",40,35,10, R0 D2,,5.95,3.2,2.12,136.0,255.0,2.58,22.8,16.0,151.0,82.0,17.3,8.71,1.93,65.1,241.56,40.1,25.0,3.5,5.55,61.0,335.0,,,,,,,,,,,,,1.97,9.87,0.891,,,, P0,H0,,,,,,,28.44940867279895,1320625
1333175,党树全,545708,男,66,T3,N2,M0, ⅢA,2,3,,0.0,0.0,1.0,,4.0,25,硬型（sci）,INFc,0.0,0.6,,,,,,,2013-11-26,2022-09-01,1,,,XELOX,,,,,,1, 低分化管状腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)00 (1b)00 (2)00 (3a)06 (3b)13 (4sa)00 (4sb)00 (4d)25 (5)00 (6)13 (7)03 (8a)01 (9)01 (11p)03 (11d)00 (19)00," ML 小弯侧Less,",50,40,8, R0 D2+,,7.25,4.54,1.49,139.6,190.0,3.21,14.0,19.0,172.0,67.0,18.0,12.07,2.05,60.7,164.5,34.6,26.1,6.0,4.39,103.0,258.0,,,,,,,,,,,,,1.5,16.78,2.8,,,, P0,H0,,,,,,,105.15768725361366,1333175
1417454,邸凤祥,566337,男,72,T3,N1,M0, ⅡB,2,2,1.0,,,,,1.0,18,中间型（int）,INFc,1.0,,0.0,0.0,,,,2.0,2014-06-24,2019-10-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80% 低粘附腺癌20%,G2, (1a)00 (1b)01 (3a)00 (3b)00 (4sb)04 (4d)12 (5)00 (6)00 (7)06 (8p)02 (9)02 (11p)01,L（幽门窦部） 后Post 大弯侧Gre  ,30,30,10, R0 D2,,5.73,3.56,1.51,117.0,257.0,4.59,8.0,18.0,158.0,63.0,8.0,6.8,2.17,58.0,157.0,36.0,22.0,4.6,7.0,85.0,276.0,,,,,,,,,,,,,0.717,24.58,1.67,,,, P0,H0,,,,,,,63.23915900131406,1417454
1326664,丁志龙,539675,男,70,T4b,N0,M0, ⅢA,2,3,,1.0,1.0,1.0,,0.0,17,中间型（int）,INFb,0.0,0.4,,,,,,,2013-09-17,2022-09-01,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)02 (1b)00 (2)01 (3a)02 (3b)02 (4sa)02 (4sb)00 (5)00 (6)03 (7)03 (11p)02," U（胃底部）, 前Ant,",60,50,10, R0 D2+,,2.83,1.93,0.64,92.8,160.0,3.01,10.0,21.0,157.0,109.0,13.0,13.97,3.67,66.6,138.7,36.9,29.7,5.1,6.09,71.0,398.0,,,,,,,,,,,,,0.996,5.34,6.29,,,, P0,H0,,,,,,,107.45729303547962,1326664
1415213,董万增,562720,男,76,T2,N1,M0, ⅡA,2,3,1.0,,,,,1.0,21,髓样型（med）,INFa,1.0,,0.0,0.0,,,,,2014-06-03,2016-01-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) 溃疡病灶,G3, (1a)02 (1b)03 (2)12 (3a)04 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)00 (6)02 (7)02 (8a)01 (8p)03 (9)00 (11p)00 (12p)00, LMU,20,20,7, R0 D2,,8.07,5.9,1.5,121.3,314.0,3.51,15.0,29.0,151.0,58.0,33.0,11.74,7.71,64.0,216.0,35.0,29.0,5.1,12.6,111.0,357.0,,,,,,,,,,,,,2.12,12.97,1.04,,,, P0,H0,,,,,,,18.95532194480946,1415213
1428940,范嘉泽,562731,男,73,T3,N3a,M0,ⅢB,2,3,0.0,1.0,1.0,1.0,,7.0,16,髓样型（med）,INFa,1.0,,0.0,0.0,,,,0.0,2014-10-09,2015-12-01,2,,,口服替吉奥,口服替吉奥,口服替吉奥,SOX,奥沙利铂+雷替曲塞,,5, 管状腺癌（低分化（G3)(por) 中分化【G2】【tub2】,G3, (1a)00 (1b)11 (2)00 (3a)35 (3b)00 (4sa)00 (4sb)00 (7)34 (8a)(8p)(9)06 (110)00," G=E, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,6, R0 D2,,5.85,3.3,1.85,134.0,206.0,3.11,14.0,19.0,155.0,57.0,24.0,14.38,5.69,72.0,222.0,48.0,24.0,6.4,6.2,75.0,384.0,,,,,,,,,,,,,6.75,11.45,3.58,,,, P0,H0,,,,,,,13.731931668856767,1428940
1424445,范中祥,572052,男,64,T3,N2,M0, ⅢA,2,3,0.0,1.0,1.0,0.0,,4.0,22,髓样型（med）,INFa,0.0,,0.0,0.0,,,,2.0,2014-08-25,2016-01-01,0,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a)02 (1b)03 (3a)11 (3b)00 (4sb)00 (4d)12 (5)00 (6)23 (7)02 (8a)01 (8p)01 (9)04 (11p)01 (12a)00 (12p)02," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",40,30,10, R0 D2,,11.02,7.16,2.92,166.7,174.0,4.08,20.0,25.0,197.0,68.0,22.0,13.51,5.62,71.0,213.0,47.0,24.0,4.7,3.7,85.0,324.0,,,,,,,,,,,,,3.04,9.01,15.77,,,, P0,H0,,,,,,,16.228646517739815,1424445
1433749,冯晓霞,580103,女,71,T4b,N2,M0, ⅢB,2,3,1.0,1.0,1.0,1.0,,6.0,26,硬型（sci）,INFb,1.0,,0.0,2.0,,,,1.0,2014-11-19,2017-07-15,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化（G3)(por) 【G2】【tub2】70% 低黏附腺癌30% Lauren混合型,G3, (1a)00 (1b)00 (2)00 (3a)14 (4sa)01 (4sb)36 (4d)03 (5)11 (6)15 (7)(9)05 (8a)(8p)00 (11p)01 3b、4d、7、9、11p 软组织可见癌, 胃癌 L（幽门窦部） 前Ant 小弯侧Less 后Post,65,60,10, R0 D2+,,16.5,9.27,6.17,55.0,724.0,5.44,15.0,21.0,116.0,84.0,9.0,7.13,2.62,63.0,153.0,36.0,27.0,9.7,5.4,55.0,231.0,67.9,35.0,30.3,1.16,0.5,14.2,16.7,4.8,0.215,2.64,10.5,250.0,0.2,13.91,2.51,,,, P0,H0,,,,,,,31.83311432325887,1433749
1420368,付玉,568691,男,81,T4b,N2,M0, ⅢB,2,3,1.0,,,,,3.0,16,中间型（int）,INFc,1.0,,0.0,0.0,,,,2.0,2014-07-21,2015-03-05,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80% 低粘附腺癌20%,G2, (1a)00 (1b)111 (3a)00 (3b)00 (4sb)01 (4d)22 (5)00 (6)00 (7)00 (8a)(8p)(9)00 (11p)02, L（幽门窦部） 大弯侧Gre  前Ant 后Post 小弯侧Less,50,40,12, R0 D2,,9.65,7.68,1.09,128.0,91.0,3.33,29.0,15.0,219.0,69.0,11.4,14.26,4.47,9.79,161.76,45.7,30.2,3.8,7.87,77.0,277.0,,,,,,,,,,,,,1.7,42.02,3.28,,,, P0,H0,,,,,,,7.457293035479632,1420368
1334653,高万君,544777,男,63,T2,N1,M0, ⅡA,2,3,,0.0,0.0,1.0,,2.0,23,髓样型（med）,INFc,0.0,,,,,,,,2013-12-10,2018-03-14,2,,,,,,,,,0, 低分化管状腺癌（G3)(por) 粘液腺癌（muc）,G3, (1a)03 (1b)02 (2)02 (3a)28 (3b)00 (4sa)01 (4sb)00 (4d)00 (5)01 (6)00 (7)01 (8a)03 (8p)00 (9)02 (11p)00 (12a)00 (12p)00," M（胃体部）, 小弯侧Less,",25,25,3, R0 D2,,7.29,4.78,1.67,149.0,306.0,3.07,26.8,19.0,158.0,80.0,51.7,10.59,1.64,68.3,319.1,40.6,27.7,7.0,5.03,81.0,418.0,,,,,,,,,,,,,1.21,5.15,7.01,,,, P0,H0,,,,,,,51.08409986859395,1334653
1413885,高玉一,562158,女,60,T3,N3a,M0,ⅢB,2,3,1.0,0.0,0.0,1.0,,12.0,36,硬型（sci）,INFb,1.0,,0.0,0.0,,,,0.0,2014-05-20,2019-10-01,1,,,XELOX,XELOX,紫杉醇联合替吉奥,,,,3, 粘液腺癌（muc）70% 管状腺癌（中分化【G2】【tub2】30%,G2, (1a)23 (1b)33 (2)12 (3a)47 (3b01 (4sa)00 (4sb)00 (4d)011 (5)01 (6)01 (7)11 (8a)(8p)13 (9)03," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",65,50,15, R0 D2,,7.06,3.56,2.95,135.0,267.0,4.22,18.0,28.0,146.0,116.0,16.0,6.01,1.66,81.0,278.0,46.0,35.0,5.7,4.7,78.0,325.0,,,,,,,,,,,,,34.99,35.06,2.23,,,, P0,H0,,,,,,,64.38896189224704,1413885
1415275,宫建清,562074,男,60,T2,N3a,M0, ⅢA,2,3,2.0,,,,,8.0,19,髓样型（med）,INFc,0.0,,0.0,0.0,,,,1.0,2014-06-04,2016-01-28,2,,,,,,,,,0, 低粘附腺癌60% 粘液腺癌（muc）40%,GX, (1a)(1b)14 (3a)16 (3b)00 (4sb)01 (4d)11 (5)55 (6)00 (7)00 (8a)01 (8p)00 (9)00 (12a)00 (14v)01," L（幽门窦部）, 小弯侧Less,",30,30,10, R0 D2+,,7.38,4.01,2.47,165.0,260.0,4.2,12.0,15.0,147.0,61.0,60.0,12.56,3.46,77.0,302.0,44.0,33.0,8.9,7.0,84.0,198.0,,,,,,,,,,,,,10.1,211.9,2.05,,,, P0,H0,,,,,,,19.80946123521682,1415275
1317155,郭日明,530274,男,70,T4a,N1,M0, ⅢA,2,3,,,,,,2.0,20,中间型（int）,INFb,0.0,0.7,,,,,,,2013-06-17,2018-11-23,1,,,口服替吉奥,口服替吉奥,口服卡培他滨,,,,3, 中分化腺癌（G3)(por),G3, (1a)03 (1b)04 (3a)01 (3b)11 (4sb)00 (4d)03 (5)01 (6)01 (7)00 (8a)01 (8p)(9)12 (11p)02 (12a)00 ," L（幽门窦部）, 小弯侧Less,",60,50,12, R0 D2,,5.82,3.61,1.7,126.0,222.0,3.59,10.0,13.0,145.0,91.0,22.3,13.59,6.3,74.6,249.25,43.1,31.5,5.0,8.1,102.0,303.0,,,,,,,,,,,,,15.42,337.0,2.89,,,, P0,H0,,,,,,,65.21024967148489,1317155
1323376,郭少海,535960,男,61,T4a,N2,M0, ⅢA,2,3,,1.0,1.0,1.0,,3.0,22,中间型（int）,INFb,1.0,0.3,,,,,,,2013-08-14,2019-04-13,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】55%  类癌(神经内分泌癌)45%,G2, (1a)01 (1b)02 (3a)02 (3b)00 (4sb)01 (4d)01 (5)00 (6)24 (8a)18 (8p)00 (9)03 (11p)01 (12a)00 (19)00," L（幽门窦部）, 大弯侧Gre,",25,25,5, R0 D2+,,5.24,2.93,1.78,150.0,207.0,2.0,18.4,13.0,155.0,47.0,17.2,14.72,3.4,71.4,229.7,47.8,23.6,4.9,3.0,71.0,266.0,,,,,,,,,,,,,2.54,87.95,1.23,,,, P0,H0,,,,,,,67.93692509855452,1323376
1336475,郭伟军,548530,男,57,T2,N1,M0, ⅡA,2,3,,1.0,1.0,1.0,,1.0,24,中间型（int）,INFb,1.0,0.9,,,,,,,2013-12-26,2015-12-12,2,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a)00 (1b)04 (3a)01 (3b)12 (4sb)00 (4d)04 (5)00 (6)01 (7)01 (8a)02 (8p)02 (9)04 (11p)03 (12a)00 (14v)00," L（幽门窦部）, 小弯侧Less,",25,25,10, R0 D2+,,3.81,1.99,1.17,78.0,159.0,2.08,20.0,15.0,102.0,37.0,6.0,7.84,0.48,60.0,242.0,40.0,20.0,5.8,8.7,79.0,251.0,,,,,,,,,,,,,0.979,11.36,0.833,,,, P0,H0,,,,,,,23.52168199737188,1336475
1435983,郭玉清,582431,女,59,T4a,N2,M0, ⅢA,2,2,2.0,1.0,1.0,1.0,,3.0,19,硬型（sci）,INFc,1.0,,2.0,2.0,,,1.0,2.0,2014-12-08,2020-04-14,1,,,,,,,,,0, 低黏附腺癌 Lauren弥漫型,GX, (1a)00 (1b)02 (3a)11 (3b)11 (4sb)00 (4d)04 (5)01 (6)01 (7)02 (8a)(8p)12 (9)03 (11p)01 (16a2)(16a1)01,胃癌 L（幽门窦部） 小弯侧Less,40,30,5, R0 D2,,7.03,4.39,1.84,152.5,151.0,3.01,19.0,21.0,119.0,87.0,21.0,10.83,3.67,72.0,315.0,41.0,31.0,6.3,4.5,53.0,304.0,69.0,49.3,17.2,2.87,0.2,11.7,16.2,1.5,1.47,3.28,9.56,528.0,0.421,6.46,5.34,,,, P0,H0,,,,,,,64.19185282522996,1435983
1332262,韩淑娟,545207,女,51,T4a,N3a,M0, ⅢB,2,3,,0.0,0.0,1.0,,8.0,19,硬型（sci）,INFc,0.0,0.4,,,,,,,2013-11-18,2015-12-04,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌70% 粘液腺癌（muc）30%,GX, (1a)02 (1b)03 (3a)12 (3b)22 (4sb)00 (4d)23 (5)11 (6)11 (7)00 (8a)02 (8p)00 (9)02 (11p)11," L（幽门窦部）, 小弯侧Less,",40,35,8, R0 D2,,6.81,3.18,3.0,142.0,204.0,2.39,53.0,41.0,198.0,57.0,46.0,13.82,3.09,76.0,299.0,44.0,32.0,6.4,5.5,72.0,471.0,,,,,,,,,,,,,0.834,8.6,2.44,,,, P0,H0,,,,,,,24.50722733245729,1332262
1419733,郝靖秋,564791,男,51,T4b,N3b,M0, ⅢC,2,3,2.0,1.0,1.0,1.0,,17.0,20,中间型（int）,INFc,1.0,,0.0,0.0,,,,0.0,2014-07-15,2015-07-16,2,,,XELOX,SOX,SOX,,,,3, 低粘附腺癌,GX, (1a)22 (1b)11 (2)55 (3a)00 (3b)00 (4sa)13 (4sb)45 (4d)00 (5)44 (6)00 (7)(8a)(8p)(9)00 (10)00 (11p)(11d)00, ML 小弯侧Less 后Post 前Ant ,40,40,10, R0 D2,,8.53,6.32,1.52,182.0,253.0,3.39,17.0,17.0,165.0,89.0,30.0,46.38,16.99,74.0,271.0,46.0,28.0,5.4,7.2,96.0,257.0,,,,,,,,,,,,,9.27,0.91,2.46,,,, P0,H0,,,,,,,12.02365308804205,1419733
1411823,何成跃,561721,男,64,T4a,N3a,M0, ⅢB,2,3,0.0,,,,,11.0,38,中间型（int）,INFc,0.0,,0.0,0.0,,,,,2014-04-29,2015-09-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)06 (3a)45 (3b)00 (4sb)02 (4d)416 (5)11 (6)11 (7)11 (8a)(8p)04 (9)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",65,50,12, R0 D2,,5.42,2.76,2.07,129.1,285.0,3.28,19.0,22.0,104.0,55.0,10.0,7.97,2.78,54.0,157.0,40.0,24.0,5.7,5.5,75.0,213.0,,,,,,,,,,,,,2.08,39.53,4.79,,,, P0,H0,,,,,,,16.392904073587385,1411823
1419525,何福海,568392,男,54,T3,N3a,M0,ⅢB,2,3,1.0,1.0,1.0,0.0,,11.0,26,中间型（int）,INFc,1.0,,0.0,0.0,,,,0.0,2014-07-11,2015-11-15,2,,,,,,,,,0, 低分化腺癌（G3)(por)40% 粘液腺癌（muc）40% 低粘附腺癌20%,G3, (1a)00 (1b)02 (2)00 (3a)00 (3b)02 (4sa)13 (4sb)34 (4d)02 (5)00 (6)02 (7)11 (8a)45 (8p)13 (9)01, ML 小弯侧Less ,40,40,5, R0 D2,,5.12,3.03,1.47,135.0,129.0,2.62,23.0,43.0,182.0,150.0,414.0,24.13,8.91,64.0,280.0,39.0,25.0,4.7,6.9,45.0,282.0,,,,,,,,,,,,,2.66,13.93,9.4,,,, P0,H0,,,,,,,16.16294349540079,1419525
1435100,黄立来,580750,男,45,T3,N1,M0, ⅡB,2,3,2.0,0.0,0.0,0.0,,2.0,30,硬型（sci）,INFc,0.0,,0.0,2.0,,,,0.0,2014-12-01,2018-12-01,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,8, 低分化管状腺癌（G3)(por)60% 低黏附腺癌40%,G3, (1a)01 (1b)01 (3a)00 (3b)00 (4sb)01 (4d)010 (5)11 (6)17 (7)(8a)(8p)(9)(11p)(12a)09," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,50,8, R0 D2,,5.54,2.81,1.77,95.1,304.0,2.58,21.0,31.0,119.0,43.0,19.0,7.2,2.97,63.0,271.0,36.0,27.0,4.5,5.1,62.0,302.0,64.5,44.5,19.4,2.29,0.2,15.8,17.7,0.1,0.854,3.47,11.9,12.8,0.623,9.96,6.71,,,, P0,H0,,,,,,,47.99605781865966,1435100
1421441,纪德君,569215,男,67,T3,N2,M0, ⅢA,2,2,0.0,,,,,5.0,29,中间型（int）,INFa,3.0,,0.0,0.0,,,,0.0,2014-07-29,2016-02-10,2,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,,5, 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)26 (3a)04 (3b)00 (4sb)00 (4d)05 (5)00 (6)35 (7)00 (8a)(8p)(9)03 (11p)04 (12a)00 4d，6组可见3枚癌结节，5组软组织内可见癌," L（幽门窦部）, 前Ant, 小弯侧Less, 大弯侧Gre,",50,40,8, R0 D2,,7.07,4.37,1.84,124.0,229.0,3.33,21.0,26.0,165.0,78.0,12.0,7.04,2.12,61.0,268.0,38.0,23.0,4.9,8.3,66.0,242.0,,,,,,,,,,,,,4.49,82.97,1.4,,,, P0,H0,,,,,,,18.429697766097238,1421441
1325334,江仁秀,539450,女,55,T4a,N3b,M0, ⅢC,2,3,,1.0,1.0,1.0,,16.0,23,中间型（int）,INFc,2.0,0.4,,,,,,,2013-09-03,2014-04-15,2,,,,,,,,,0, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】30% 低黏附性癌70%,G3, (1a)01 (1b)11 (3a)34 (3b)11 (4sa)00 (4sb)00 (4d)46 (5)12 (6)00 (7)11 (8a)23 (8p)22 (9)11 (11p)01 (12a)00," L（幽门窦部）, 大弯侧Gre,",30,20,8, R0 D2,,6.73,3.04,3.12,123.6,293.0,2.73,17.9,21.0,227.0,103.0,14.0,15.35,2.87,79.7,229.92,46.2,33.5,5.6,2.69,54.0,240.0,,,,,,,,,,,,,0.962,11.01,50.88,,,, P0,H0,,,,,,,7.35873850197109,1325334
1419669,江树友,568370,男,58,T1b,N1,M0, ⅠB,2,3,1.0,,,,,1.0,18,中间型（int）,INFb,0.0,,0.0,0.0,,,,0.0,2014-07-14,2019-10-01,1,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,6, 管状腺癌（低分化（G3)(por) 中分化【G2】【tub2】50% 粘液腺癌（muc）50%,G3, (1a)02 (1b)02 (2)00 (3a)03 (3b)00 (4sb)00 (4d)01 (5)00 (6)02 (7)02 (8a)01 (8p)02 (9)01 (11p)11 (12a)00 (12p)00 (14v)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,25,4, R0 D2+,,5.6,2.58,2.26,149.0,223.0,3.75,8.0,14.0,145.0,78.0,22.0,16.17,6.93,75.0,390.0,45.0,30.0,5.2,6.9,70.0,326.0,,,,,,,,,,,,,1.57,4.93,2.6,,,, P0,H0,,,,,,,62.582128777923785,1419669
1322662,姜成民,535258,男,65,T4b,N1,M0, ⅢB,2,3,,0.0,0.0,0.0,,2.0,19,硬型（sci）,INFc,0.0,0.8,,,,,,,2013-08-07,2018-04-22,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)04 (2)03 (3a)13 (3b)00 (4sa)00 (4sb)01 (4d)01 (5)00 (6)01 (8a)01 (9)00 (11p)02 (12p)00," M（胃体部）, 后Post,",90,90,25, R0 D2,,6.47,4.7,1.21,96.0,248.0,4.66,18.0,18.0,116.0,90.0,45.0,7.77,2.83,63.5,144.8,33.5,30.0,5.2,5.41,77.0,370.0,,,,,,,,,,,,,1.27,3.51,1.52,,,, P0,H0,,,,,,,56.47174770039422,1322662
1422514,姜美华,570995,女,58,T3,N2,M0, ⅢA,2,1,2.0,,,,,5.0,29,髓样型（med）,INFa,0.0,,,,,,,,2014-08-07,2020-09-08,1,,,,,,,,,0, 低分化腺癌（G3)(por) 类癌(神经内分泌癌),G3, (1a)02 (1b)01 (3a)01 (3b)04 (4sb)16 (4d)03 (5)00 (6)47 (7)02 (8a)00 (8p)02 (9)00 (11p)01,L（幽门窦部） 后Post 大弯侧Gre  小弯侧Less ,50,50,13, R0 D2,,9.26,6.56,1.72,91.4,284.0,5.38,20.0,23.0,169.0,90.0,21.0,8.44,2.77,54.0,187.0,34.0,20.0,4.7,4.6,60.0,258.0,,,,,,,,,,,,,1.13,14.93,3.91,,,, P0,H0,,,,,,,73.06176084099869,1422514
1422187,姜廷昌,569524,男,65,T3,N3b,M0, ⅢC,2,4,1.0,0.0,0.0,1.0,,20.0,27,中间型（int）,INFa,0.0,,0.0,0.0,,,,,2014-08-05,2018-04-01,2,,,多西他赛+亚叶酸钙+奈达铂,盐酸表柔比星+依托泊苷+奈达铂,,,,,2, 低粘附腺癌50% 管状腺癌（中分化【G2】【tub2】30% 粘液腺癌（muc）20%,G2, (1a)00 (1b)02 (3a)02 (3b)44 (4sb)00 (4d)44 (5)11 (6)57 (7)01 (8a)22 (8p)11 (9)11 (11p)11 (12a)00 (12p)00, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less,50,50,5, R0 D2,,10.9,7.43,2.63,183.4,302.0,3.86,11.0,19.0,219.0,95.0,24.0,9.16,3.9,69.0,280.0,41.0,28.0,5.9,4.32,109.0,389.0,,,,,,,,,,,,,24.92,13.38,6.12,,,, P0,H0,,,,,,,43.856767411300915,1422187
1421397,金贞贤,567383,男,70,T3,N1,M0, ⅡB,2,3,1.0,0.0,0.0,1.0,,2.0,8,中间型（int）,INFa,1.0,,0.0,0.0,,,,2.0,2014-07-29,2019-04-20,2,,,SOX,SOX,SOX,,,,3, 管状腺癌（中分化【G2】【tub2】90% 低粘附腺癌10% ,G2," (1a)01 (1b)00 (2)12 (3a)12 (3b)00 (4sa)00 (4sb)00 (7)00 (8a)(8p)03 2,3a组软组织内可见癌", GE 大弯侧Gre  前Ant 后Post,50,35,8, R0 D2,,5.56,2.75,2.06,138.0,241.0,3.52,18.0,25.0,166.0,70.0,12.0,8.93,2.4,6.53,291.0,41.0,32.0,4.8,3.2,74.0,308.0,,,,,,,,,,,,,7.06,136.9,1.54,,,, P0,H0,,,,,,,56.70170827858081,1421397
1429191,李宝全,574808,男,45,T4b,N3a,M0, ⅢC,2,3,1.0,1.0,1.0,1.0,,8.0,34,髓样型（med）,INFb,0.0,,1.0,0.0,,,,2.0,2014-10-10,2016-04-14,2,,,,,,,,,0, 低黏附腺癌70% 管状腺癌（低分化（G3)(por)中分化【G2】【tub2】30% Lauren混合型,G3, (1a)01 (1b)12 (2)28 (3a)515 (3b)03 (4sa)01 (4sb)00 (7)00 (8a)00 (8p)02 (9)01 (11p)00  大弯01,GE SiewerⅠ型 SiewerⅡ型 SiewerⅢ型 前Ant 后Post 大弯侧Gre  小弯侧Less,70,35,12, R0 D2,,5.28,3.45,1.26,84.0,348.0,2.96,19.0,28.0,245.0,67.0,8.0,7.87,3.04,57.0,176.0,39.0,18.0,5.9,5.5,92.0,272.0,,,,,,,,,,,,,1.14,4.76,31.58,,,, P0,H0,,,,,,,18.134034165571617,1429191
1423803,李春艳,571994,女,59,T3,N1,M0, ⅡB,2,3,2.0,,,,,1.0,51,中间型（int）,INFc,0.0,,2.0,0.0,,,,1.0,2014-08-19,2019-10-01,1,,,XELOX,XELOX,,,,,2, 低粘附腺癌,GX, (1a)02 (1b)01 (3a)017 (3b)13 (4sb)00 (4d)06 (5)01 (6)05 (7)05 (8a)05 (8p)01 (9)02 (11p)02 (12a)00 (14v)01,L（幽门窦部） 前Ant 小弯侧Less 后Post ,30,20,8, R0 D2+,,7.15,3.18,3.19,133.3,260.0,3.46,15.0,17.0,159.0,70.0,19.0,10.57,3.34,73.0,239.0,47.0,26.0,4.9,5.7,72.0,334.0,,,,,,,,,,,,,3.16,0.863,1.86,,,, P0,H0,,,,,,,61.399474375821285,1423803
1418328,李广才,566681,男,65,T3,N2,M0, ⅢA,2,2,2.0,0.0,0.0,1.0,,4.0,29,髓样型（med）,INFc,0.0,,0.0,0.0,,,,0.0,2014-07-01,2016-03-16,2,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)16 (3b)13 (4sb)00 (4d)010 (5)00 (6)00 (7)17 (8a)(8p)12 (9)00 (11p)00 (12a)01, L（幽门窦部） 前Ant 小弯侧Less 后Post ,55,50,10, R0 D2,,5.24,3.21,1.51,136.0,302.0,2.15,55.0,62.0,181.0,100.0,34.0,8.44,3.18,62.0,230.0,39.0,23.0,4.9,7.0,58.0,278.0,,,,,,,,,,,,,43.3,4.49,16.01,,,, P0,H0,,,,,,,20.49934296977661,1418328
1431114,李海波,577383,男,67,T4b,N2,M0, ⅢB,2,3,2.0,1.0,1.0,1.0,,5.0,23,中间型（int）,INFc,2.0,,0.0,0.0,,,,0.0,2014-10-27,2016-11-13,2,,,SOX,SOX,SOX,SOX,SOX,SOX,8,黏液腺癌（muc）60% 低粘附腺癌40% Lauren弥漫型,GX, (1a)01 (1b)00 (3a)310 (3b)11 (4sb)00 (4d)05 (5)00 (6)02 (7)01 (8a)00 (8p)00 (9)01 (11p)01 (14v)11," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",55,40,6, R0 D2+,,5.04,3.6,0.98,152.7,213.0,3.35,34.0,28.0,137.0,56.0,19.0,14.0,6.26,64.0,229.0,39.0,25.0,5.5,3.6,72.0,183.0,,,,,,,,,0.675,3.54,12.6,145.0,24.12,6.45,75.34,,,, P0,H0,,,,,,,24.57293035479632,1431114
1419057,李海波,566863,男,74,T3,N1,M0, ⅡB,2,2,1.0,,,,,1.0,21,中间型（int）,INFc,0.0,,2.0,0.0,,,,1.0,2014-07-08,2016-03-09,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80% 乳头状癌（G1）（pap）20%,G3, (1a)03 (1b)05 (3a)15 (3b)00 (4sb)00 (4d)00 (5)00 (6)00 (7)02 (8a)01 (8p)00 (9)04 (11p)01," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",40,35,8, R0 D2,,6.1,3.62,1.81,139.0,212.0,3.75,11.0,19.0,156.0,122.0,25.0,22.89,9.69,68.0,211.0,39.0,29.0,5.3,6.9,108.0,419.0,,,,,,,,,,,,,1.82,21.2,2.9,,,, P0,H0,,,,,,,20.039421813403415,1419057
1401308,李怀志,551937,男,65,T3,N3a,M0,ⅢB,2,1,,,,,,7.0,28,髓样型（med）,INFc,0.0,0.7,,,,,,,2014-01-14,2019-07-19,0,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (2)00 (3a)03 (3b)25 (4sa)01 (4sb)44 (4d)11 (5)00 (6)02 (7)03 (8a)01 (8p)02 (9)02 (10)02 (11p)01 (11d)00 (12)00     ," L（幽门窦部）, M（胃体部）, U（胃底部）, LMU 前Ant,",70,60,20, R0 D2,,5.45,3.91,1.11,157.0,218.0,3.43,10.5,11.0,122.0,100.0,21.3,9.89,3.05,66.3,182.39,38.1,28.2,5.4,4.98,67.0,224.0,,,,,,,,,,,,,1.89,7.67,3.34,,,, P0,H0,,,,,,,66.09724047306176,1401308
1334502,李惠英,546193,女,68,T4a,N3a,M0, ⅢB,2,3,,1.0,1.0,1.0,,9.0,52,硬型（sci）,INFb,0.0,,,,,,,,2013-12-09,2019-04-13,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低分化腺癌（G3)(por),G3, (1a)02 (1b)00 (3a)17 (3b)04 (4sb)01 (4d)813 (5)03 (6)00 (7)07 (8a)01 (8p)02 (9)02 (11p)07 (12a)00 (12p)03," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",80,60,30, R0 D2,,15.44,12.08,2.0,91.0,345.0,3.35,13.0,24.0,114.0,68.0,13.0,7.73,1.52,52.0,102.0,30.0,22.0,4.3,3.2,52.0,145.0,,,,,,,,,,,,,2.11,6.29,2.45,,,, P0,H0,,,,,,,64.09329829172141,1334502
1318111,李皲,532133,男,51,T4a,N2,M0, ⅢA,2,4,,0.0,0.0,1.0,,4.0,16,中间型（int）,INFc,1.0,0.6,,,,,,,2013-06-25,2014-08-29,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,7, 管状腺癌（低分化腺癌（G3)(por)  中分化【G2】【tub2】,G3, (1a)02 (1b)00 (2)04 (3a)11 (3b)12 (4sa)00 (4sb)00 (4d)12 (6)00 (7)00 (8a)02 (8p)13 (9)00 (11p)00, MU 后Post ,35,60,8, R0 D2,,4.85,2.95,1.45,139.9,197.0,2.09,18.5,18.0,188.0,89.0,22.4,20.34,4.01,76.0,212.92,46.7,29.3,4.2,5.46,88.0,458.0,,,,,,,,,,,,,2.17,20.21,2.4,,,, P0,H0,,,,,,,14.126149802890932,1318111
1416964,李庆福,565367,男,71,T4a,N2,M0, ⅢA,2,3,0.0,,,,,5.0,22,中间型（int）,INFb,1.0,,0.0,0.0,,,,0.0,2014-06-19,2016-12-03,2,,,,,,,,,0, 中分化管状腺癌【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)08 (3b)12 (4sb)00 (4d)24 (5)01 (6)12 (7)02 (8a)11 (9)02 (11p)00 (14v)00  ," L（幽门窦部）, 后Post,",50,40,6, R0 D2+,,7.34,4.36,2.29,108.0,259.0,2.93,20.0,23.0,124.0,53.0,8.3,5.32,2.36,68.0,145.0,37.0,31.0,4.8,3.2,79.0,309.0,,,,,,,,,,,,,2.18,20.4,2.08,,,, P0,H0,,,,,,,29.50065703022339,1416964
1332695,李仁明,535789,男,59,T4a,N3b,M0, ⅢC,2,3,,1.0,1.0,1.0,,17.0,51,髓样型（med）,INFb,1.0,0.6,,,,,,,2013-11-21,2015-04-08,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化（G3)(por),G3, (1a)24 (1b)00 (3a)(3b)313 (5)(12a)17 (6)(4d)66 (4sb)26 (7)00 (11p)02 (8a)(12p)(9)13 (8p)01 (17)11 (16a2)02 (14v)11," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,14, R0 D2+,,12.43,10.36,1.59,109.8,182.0,2.78,11.0,19.0,166.0,57.0,14.0,6.9,1.93,58.4,174.3,34.0,24.4,4.4,8.89,73.0,228.0,,,,,,,,,,,,,3.72,106.4,6.78,,,, P0,H0,,,,,,,16.52431011826544,1332695
1418383,李秀菊,566625,女,44,T3,N3a,M0,ⅢB,2,3,1.0,,,,,10.0,26,中间型（int）,INFc,0.0,,0.0,0.0,,,,1.0,2014-07-02,2019-10-01,1,,,多西他赛+氟尿嘧啶,多西他赛+氟尿嘧啶,多西他赛+氟尿嘧啶,多西他赛+氟尿嘧啶,多西他赛+氟尿嘧啶,多西他赛+氟尿嘧啶,11, 低粘附腺癌90% 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10%,G3, (1a)02 (1b)22 (2)02 (3a)23 (3b)00 (4sa)00 (4sb)01 (4d)04 (5)00 (6)14 (7)11 (8a)11 (9)36," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",40,35,3, R0 D2,,7.44,4.92,1.92,125.2,255.0,3.33,27.0,17.0,147.0,62.0,37.0,10.02,2.62,63.0,186.0,40.0,23.0,5.2,5.4,67.0,247.0,,,,,,,,,,,,,1.43,11.78,1.54,,,, P0,H0,,,,,,,62.97634691195795,1418383
1435696,李艳丰,582355,男,36,T3,N1,M0, ⅡB,2,4,2.0,0.0,0.0,0.0,,2.0,44,硬型（sci）,INFc,1.0,,0.0,,,,,0.0,2014-12-04,2015-09-25,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)0/0 (1b)0/0 (3a)00 (3b)15 (4sb)0/2 (4d)0/0 (5)0/7 (6)0/0 (7)0/10 (8a)0/5 (8p)0/4 (11p)0/4 (11d)1/3 (12a)0/0., L（幽门窦部）,60,40,, R0 D2,,4.4,2.72,1.15,147.8,92.0,2.6,29.0,34.0,154.0,76.0,18.0,10.56,4.57,54.0,203.0,35.0,19.0,6.6,4.0,51.0,244.0,75.2,44.2,28.9,1.53,0.2,10.0,12.6,6.0,1.07,0.973,6.02,14.4,0.557,8.44,0.979,,,, P0,H0,,,,,,,9.69119579500657,1435696
1432195,李耀忠,576694,男,69,T3,N1,M0, ⅡB,2,3,0.0,0.0,0.0,1.0,,2.0,22,硬型（sci）,INFa,1.0,,0.0,0.0,,,,0.0,2014-11-05,2020-04-15,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)02 (3a)02 (3b)02 (4d)01 (4sb)00 (5)11 (6)01 (7)01 (8a)11 (8p)03 (9)00 (11p)03 (12a)00 (12p)00 (14v)00 小弯02 大网边缘01," L（幽门窦部）, 后Post, 小弯侧Less,",50,30,8, R0 D2+,,6.33,4.13,1.63,125.0,190.0,2.68,10.0,17.0,160.0,56.0,9.0,5.42,1.82,57.0,201.0,39.0,18.0,5.6,6.0,82.0,262.0,,,,,,,,,,,,,1.65,33.58,2.31,,,, P0,H0,,,,,,,65.30880420499342,1432195
1403544,梁化昌,549608,男,65,T3,N2,M0, ⅢA,2,3,,0.0,0.0,0.0,,5.0,52,中间型（int）,INFc,0.0,0.7,,,,,,,2014-02-18,2020-09-08,1,,,XELOX,,,,,,1, 粘液腺癌（muc） 低分化腺癌（G3)(por),G3, (1a)03 (1b)05 (3a)18 (3b)02 (4sb)04 (4d)07 (5)25 (6)26 (7)07 (8a)01 (8p)01 (9)00 (11p)03 (12a)00," L（幽门窦部）, 前Ant,",50,40,10, R0 D2,,7.53,5.42,1.44,113.4,227.0,2.24,20.0,26.0,100.0,40.0,16.0,8.01,2.96,55.0,300.0,33.0,22.0,4.4,5.1,89.0,316.0,,,,,,,,,,,,,1.21,5.55,300.0,,,, P0,H0,,,,,,,78.64651773981603,1403544
1412971,林生玉,561071,女,74,T4b,N3a,M0, ⅢC,2,4,0.0,1.0,1.0,1.0,,11.0,44,中间型（int）,INFc,1.0,,0.0,0.0,,,,,2014-05-12,2015-08-12,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80% 低粘附腺癌20% Lauren肠型,G2," 小弯46 大弯11 (1a)02 (1b)01 (2)02 (3a)39 (3b)22 (4sa)01 (4sb)01 (4d)03 (5)00 (6)14 (7)01 (8a)01 (8p)01 (9)08 (10,11p11d)02 (14v)01 "," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,70,10, R0 D2+,,5.78,3.42,1.45,142.0,279.0,4.22,20.0,28.0,197.0,116.0,21.0,8.02,2.95,73.0,201.0,41.0,32.0,6.2,8.7,78.0,247.0,,,,,,,,,,,,,1.44,14.47,3.61,,,, P0,H0,,,,,,,15.013140604467806,1412971
1335339,刘彬,541917,男,63,T4a,N3a,M0, ⅢB,2,3,,0.0,0.0,0.0,,14.0,35,硬型（sci）,INFb,0.0,,,,,,,,2013-12-17,2015-02-06,2,奥沙利铂*2,1.0,SOX,,,,,,1, 粘液腺癌（muc） 印戒细胞癌(sig),GX, (1a)02 (1b)02 (3a)48 (3b)22 (4sb)00 (4d)25 (5)00 (6)48 (7)13 (8a)12 (9)01 (11p)02 (14v)00," L（幽门窦部）, 前Ant, 后Post,",65,40,15, R0 D2+,,4.11,2.08,1.5,132.3,138.0,2.33,22.0,24.0,207.0,63.0,15.0,18.6,6.3,53.5,193.4,37.1,16.4,5.5,7.66,94.0,437.0,,,,,,,,,,,,,2.56,60.54,142.1,,,, P0,H0,,,,,,,13.66622864651774,1335339
1423447,刘彩霞,571100,女,61,T3,N3a,M0,ⅢB,2,3,1.0,,,,,8.0,35,中间型（int）,INFa,1.0,,2.0,0.0,,,,0.0,2014-08-15,2017-05-12,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】60% 乳头状癌（G1）（pap）30% 低粘附腺癌10%,G2, (1a)01 (1b)01 (3b)15 (4sb)00 (4d)57 (5)00 (6)00 (7)(11p)110 (8a)02 (8p)01 (9)03 (12a)00 (14v)00," L（幽门窦部）, 前Ant, 大弯侧Gre, 后Post,",50,40,11, R0 D2+,,5.31,2.18,2.38,138.0,242.0,3.53,14.0,18.0,180.0,106.0,15.0,12.77,4.5,72.0,230.0,47.0,25.0,4.9,5.4,72.0,266.0,,,,,,,,,,,,,101.9,4.47,6.18,,,, P0,H0,,,,,,,32.88436268068331,1423447
1316663,刘冬梅,529812,女,45,T4a,N3a,M0, ⅢB,2,4,,1.0,1.0,0.0,,9.0,34,硬型（sci）,INFc,0.0,0.6,,,,,,,2013-06-09,2014-08-13,2,,,XELOX,XELOX,,,,,2, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)03 (1b)11 (2)13 (3a)23 (3b)00 (4sa)00 (4d)06 (5)00 (6)04 (7)510 (8a)01 (9)00 (11p)03, GE 前Ant 后Post 大弯侧Gre  小弯侧Less  SiewerⅢ,70,50,10, R0 D2,,6.96,4.59,1.78,136.8,217.0,1.77,30.6,24.0,230.0,74.0,29.4,10.25,1.96,70.3,253.5,43.7,26.6,4.3,7.11,79.0,248.0,,,,,,,,,,,,,57.7,8.84,9.74,,,, P0,H0,,,,,,,14.126149802890932,1316663
1320449,刘桂英,534272,女,70,T4a,N3a,M0, ⅢB,2,2,,,,,,7.0,30,硬型（sci）,INFb,1.0,0.7,,,,,,,2013-07-17,2019-10-01,1,,,口服替吉奥,口服替吉奥,口服替吉奥,,,,3, 粘液腺癌（muc） 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, 小湾01 (1a)02 (1b)03 (3a)22 (3b)44 (4d)02 (4sb)01 (5)01 (6)17 (7)07 (8a)(8p)00," L（幽门窦部）, 小弯侧Less,",35,30,8, R0 D2,,4.4,2.51,1.34,115.0,164.0,3.21,13.7,12.0,202.0,63.0,18.6,7.03,2.8,76.0,309.4,45.4,30.6,5.5,10.02,65.0,344.0,,,,,,,,,,,,,4.39,36.12,4.29,,,, P0,H0,,,,,,,74.47437582128778,1320449
1402342,刘汉胜,552678,男,65,T3,N0,M0, ⅡA,2,2,,0.0,0.0,1.0,,0.0,65,中间型（int）,INFc,0.0,0.8,,,,,,,2014-01-24,2019-04-20,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1)01 (2)04 (3)020 (4)011 (5)04 (6)05 (7)05 (8)08 (9)04 (11)02," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,6, R0 D2,,5.78,3.36,1.65,130.4,278.0,2.76,12.0,23.0,104.0,64.0,13.0,10.94,5.67,60.0,186.0,39.0,21.0,4.9,6.1,90.0,245.0,,,,,,,,,,,,,1.38,7.97,1.97,,,, P0,H0,,,,,,,62.81208935611038,1402342
1332559,刘宏福,544999,男,60,T4a,N3a,M0, ⅢB,2,3,,0.0,0.0,1.0,,11.0,45,中间型（int）,INFc,0.0,0.4,,,,,,,2013-11-20,2018-06-22,0,,,,,,,,,0, 低粘附腺癌% 低分化腺癌（G3)(por)%,G3, (1a)03 (1b)03 (3a)113 (3b)00 (4sb)00 (4d)03 (5)58 (6)01 (7)48 (8a)11 (8p)00 (9)02 (11p)03," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,35,6, R0 D2,,4.8,2.3,1.3,120.0,221.0,2.3,18.0,32.0,150.0,61.0,8.0,8.72,1.23,54.0,203.0,29.0,25.0,5.1,6.4,81.0,295.0,,,,,,,,,,,,,2.0,12.88,0.964,,,, P0,H0,,,,,,,55.02628120893561,1332559
1435399,刘继仁,579855,男,72,T4b,N1,M0, ⅢB,2,3,1.0,0.0,0.0,0.0,,2.0,40,髓样型（med）,INFc,1.0,,0.0,0.0,,,,0.0,2014-12-03,2016-08-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)95% 低粘附腺癌5%,G3, (1a)16 (1b)01 (3a)00 (3b)01 (4sb)01 (4d)09 (5)06 (6)12 (7)(8a)(8p)(9)014 (11p)00," LM 后Post, 小弯侧Less,",50,50,13, R0 D2,,8.21,4.67,2.18,127.0,279.0,4.44,21.0,20.0,114.0,43.0,16.0,20.25,7.69,55.0,170.0,33.0,22.0,5.2,4.4,69.0,273.0,70.0,33.0,34.2,0.96,0.4,7.7,19.8,4.7,0.618,2.61,7.27,49.0,1.2,5.95,1.67,,,, P0,H0,,,,,,,20.40078843626807,1435399
1410296,刘闰,556781,男,71,T4a,N2,M0, ⅢA,2,3,,1.0,1.0,0.0,,4.0,25,中间型（int）,INFb,1.0,0.75,,,,,,,2014-04-15,2014-10-24,2,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)02 (3a)06 (3b)11 (4sb)00 (4d)02 (5)02 (6)14 (7)00 (8a)11 (8p)01 (9)00 (11p)15 3组，五组可见5枚癌结节," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,50,15, R0 D2,,5.33,3.22,1.59,156.0,239.0,3.61,19.0,41.0,189.0,60.0,14.0,13.57,4.82,74.0,193.0,43.0,31.0,6.1,5.7,87.0,283.0,,,,,,,,,,,,,1.81,348.2,1.33,,,, P0,H0,,,,,,,6.307490144546649,1410296
1422107,刘树合,571216,男,66,T2,N1,M0, ⅡA,2,3,1.0,0.0,0.0,0.0,,1.0,33,中间型（int）,INFa,1.0,,0.0,0.0,,,,0.0,2014-08-05,2019-10-01,1,,,,,,,,,0, 粘液腺癌（muc）60% 管状腺癌（中分化【G2】【tub2】 30% 低粘附腺癌10%,G2, (1a)01 (1b)01 (3a)05 (3b)09 (4sb)01 (4d)112 (5)00 (6)01 (7)01 (8a)01 (8p)00 (9)01, L（幽门窦部） 前Ant 后Post 大弯Gre ,3,3,0.3, R0 D2,,4.7,2.44,1.97,147.6,207.0,2.78,12.0,17.0,138.0,30.0,6.0,17.08,5.77,73.0,219.0,43.0,30.0,4.7,4.6,90.0,266.0,,,,,,,,,,,,,2.11,22.24,1.86,,,, P0,H0,,,,,,,61.859395532194476,1422107
1318898,刘万林,531746,男,64,T4b,N3b,M0, ⅢC,2,4,,1.0,1.0,1.0,,18.0,33,中间型（int）,INFc,1.0,0.2,,,,,,,2013-07-02,2015-02-11,2,,,,,,,,,0, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 印戒细胞癌(sig),G3, 大弯56 小弯00 (1a)(1b)01 (3a)(3b)710 (5)(12a)00 (6)(4d)05 (4sa)(4sb)33 (7)(8a)(8p)(9)(11p)(10)(11d)38 ," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",,,, R0 D2,,6.33,3.56,2.14,145.4,235.0,3.61,13.0,17.0,147.0,68.0,13.0,9.04,1.83,68.0,230.0,41.0,27.0,3.6,5.6,75.0,248.0,,,,,,,,,,,,,3.84,4.6,4.44,,,, P0,H0,,,,,,,19.349540078843624,1318898
1325329,刘秀芬,538646,女,61,T4a,N3a,M0, ⅢB,2,3,,1.0,1.0,1.0,,11.0,30,中间型（int）,INFc,0.0,0.6,,,,,,,2013-09-03,2019-04-13,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (3a)57 (3b)23 (4sb)00 (4d)23 (5)22 (6)02 (7)03 (8a)01 (8p)01 (9)02 (11p)03 (12a)02," L（幽门窦部）, 小弯侧Less,",35,30,6, R0 D2,,6.62,4.42,1.66,143.5,166.0,2.73,11.0,18.0,216.0,77.0,14.0,13.65,2.8,64.0,210.0,38.5,25.5,4.4,4.37,50.0,184.0,,,,,,,,,,,,,1.01,4.0,2.62,,,, P0,H0,,,,,,,67.27989487516426,1325329
1417403,刘义,565689,男,45,T3,N2,M0, ⅢA,2,2,1.0,0.0,0.0,0.0,,3.0,39,中间型（int）,INFc,0.0,,0.0,0.0,,,,0.0,2014-06-23,2019-10-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化（G3)(por)80% 低粘附腺癌20%,G3, (1a)03 (1b)03 (3a)18 (3b)03 (4sb)00 (4d)15 (5)01 (6)16 (7)02 (8a)02 (9)04 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",20,20,5, R0 D2,,4.49,1.88,1.94,117.0,293.0,4.36,16.0,18.0,142.0,86.0,8.0,4.41,1.92,70.0,191.0,42.0,28.0,4.7,6.8,69.0,238.0,,,,,,,,,,,,,1.42,14.83,1.83,,,, P0,H0,,,,,,,63.27201051248357,1417403
1417723,刘玉忠,566550,男,49,T3,N1,M0, ⅡB,2,3,2.0,0.0,0.0,1.0,,1.0,26,中间型（int）,INFc,0.0,,0.0,0.0,,,,0.0,2014-06-25,2019-10-01,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌60% 粘液腺癌（muc）40%,GX, (1a)03 (1b)03 (2)05 (3a)14 (3b)00 (4sa)00 (4sb)00 (4d)03 (5)00 (6)01 (7)01 (8a)(8p)03 (9)03 (11p)00 (12a)00 (12b)00," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",50,30,8, R0 D2,,7.07,3.8,2.05,140.0,182.0,2.12,9.0,15.0,160.0,70.0,18.0,11.16,3.7,65.0,235.0,41.0,24.0,4.9,8.0,85.0,261.0,,,,,,,,,,,,,3.87,7.56,40.45,,,, P0,H0,,,,,,,63.206307490144546,1417723
1317943,娄廷彦,531318,男,54,T4a,N2,M0, ⅢA,2,3,,0.0,0.0,1.0,,6.0,23,中间型（int）,INFc,2.0,0.4,,,,,,,2013-06-24,2015-01-18,2,,,,,,,,,0, 管状腺癌（低分化腺癌（G3)(por)  中分化【G2】【tub2】,G3, 大弯35 (1a)02 (1b)00 (3)01 (4sb)00 (4d)02 (5)00 (6、14)12 (7)07 (8a、8p)02 (9)22," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,45,10, R0 D2+,,7.93,4.71,2.61,116.4,283.0,2.3,13.0,14.0,143.0,113.0,43.5,7.1,2.22,61.6,180.71,36.6,25.0,4.1,3.45,67.0,326.0,,,,,,,,,,,,,4.56,4.48,1.21,,,, P0,H0,,,,,,,18.823915900131404,1317943
1417114,卢亚琴,565192,女,68,T3,N2,M0, ⅢA,2,5,1.0,,,,,4.0,39,中间型（int）,INFc,0.0,,1.0,0.0,,,,1.0,2014-06-19,2016-11-09,2,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】60% 乳头状癌（G1）（pap）25% 低粘附腺癌15% Lauren混合型,G2, (1a)12 (1b)00 (3a)02 (3b)011 (4sb)00 (4d)03 (5)23 (6)12 (7)01 (8a)04 (8p)04 (9)04 (11p)02 (12a)01 3b组内可见1枚癌结节，3a组软组织内可见癌," L（幽门窦部）, 前Ant, 小弯侧Less,",50,35,10, R0 D2,,5.27,2.72,2.11,152.1,188.0,1.94,14.0,15.0,173.0,114.0,7.0,20.67,6.39,62.0,181.0,40.0,22.0,4.0,7.4,68.0,263.0,,,,,,,,,,,,,1.57,64.75,1.56,,,, P0,H0,,,,,,,28.71222076215506,1417114
1438567,吕长山,584163,男,48,T3,N1,M0, ⅡB,2,2,0.0,0.0,0.0,1.0,,2.0,15,硬型（sci）,INFc,2.0,,0.0,2.0,,,,2.0,2014-12-31,2022-09-01,1,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】低分化（G3)(por)  Lauren肠型,G3, (1a)03 (1b)03 (3a)12 (3b)00 (4sb)01 (4d)13 (5)00 (6)00 (7)00 (8a)03 (8p)00 (9)00 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",15,10,20, R0 D2,,7.35,4.59,2.08,154.1,177.0,1.86,36.0,28.0,148.0,66.0,44.0,19.98,5.34,68.0,366.0,46.0,22.0,5.2,6.1,64.0,411.0,61.4,37.6,20.8,1.81,0.1,14.5,19.3,2.0,0.587,0.71,14.5,21.4,2.8,15.97,1.18,,,, P0,H0,,,,,,,92.01708278580814,1438567
1321306,马胜利,531438,男,67,T4a,N3a,M0, ⅢB,2,2,,,,,,8.0,19,中间型（int）,INFb,0.0,,,,,,,,2013-07-24,2019-04-14,1,替吉奥*1,1.0,,,,,,,0, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 Lauren肠型,G3, (1a)13 (1b)14 (3a)00 (3b)00 (4sb)00 (4d)12 (5)11 (6)22 (7)00 (8a)11 (8p)05 (9)11 (11p)00," L（幽门窦部）, 后Post",20,20,10, R0 D2,,5.4,2.63,1.87,127.8,133.0,2.41,13.2,14.0,194.0,92.0,15.8,11.6,2.88,68.7,298.55,43.8,24.9,5.3,7.83,94.0,342.0,,,,,,,,,,,,,14.4,17.75,12.95,,,, P0,H0,,,,,,,68.65965834428384,1321306
1333785,马兴亚,525611,男,68,T4a,N1,M0, ⅢA,2,3,,1.0,1.0,1.0,,1.0,33,髓样型（med）,INFc,0.0,0.8,,,,,,,2013-12-03,2015-06-24,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化（G3)(por),G3, (1a)02 (1b)00 (3a)08 (3b)00 (4sb)00 (4d)01 (5)00 (6)01 (7)03 (8a)03 (8p)05 (9)01 (11p)05 (12a)01 (12p)12 (14v)01," L（幽门窦部）, 前Ant, 大弯侧Gre,",30,30,5, R0 D2+,,4.6,2.8,0.9,125.0,171.0,5.44,10.0,27.0,137.0,47.0,9.0,17.27,4.72,58.0,177.0,33.0,25.0,4.8,6.5,121.0,25.7,,,,,,,,,,,,,2.12,10.01,1.01,,,, P0,H0,,,,,,,18.659658344283837,1333785
1433391,蒙桂英,579464,女,50,T4a,N3a,M0, ⅢB,2,3,2.0,1.0,1.0,1.0,,8.0,40,中间型（int）,INFc,1.0,,0.0,2.0,,,,,2014-11-17,2019-10-01,1,,,奥沙利铂+5-FU,奥沙利铂+5-FU,奥沙利铂+5-FU,奥沙利铂+5-FU,奥沙利铂+5-FU,紫杉醇+卡培他滨,7, 低分化管状腺癌（G3)(por)60% 低黏附腺癌40% Lauren弥漫型,G3, (1a)35 (1b)25 (3a)13 (3b)00 (4sa)00 (4sb)00 (4d)01 (5)06 (6)28 (7)01 (8a)02 (8p)04 (9)02 (10)00 (11d)02  (11p)01 (12a)00," U（胃底部）, 前Ant, 后Post, 小弯侧Less",60,45,15, R0 D2,,3.09,1.58,1.12,137.0,93.0,2.15,31.0,38.0,149.0,42.0,12.0,9.46,3.73,66.0,227.0,37.0,29.0,4.4,3.5,55.0,239.0,70.4,42.2,15.8,2.67,0.0,12.9,10.3,0.9,3.24,1.92,12.2,41.1,2.51,29.74,15.23,,,, P0,H0,,,,,,,58.44283837056504,1433391
1316954,孟繁森,530152,男,53,T4a T3,N2,M0, ⅢA,2,3,,0.0,0.0,1.0,,3.0,18,中间型（int）,INFb,0.0,0.5,,,,,,,2013-06-14,2019-09-02,1,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,6, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】,G3, 小湾01 (1a)01 (1b)22 (2)01 (3a)02 (3b)12 (4sb)00 (4d)01 (5)00 (6)04 (7)01 (8a)00 (8p)02 (9)01     ," L（幽门窦部）, U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45 45,40 35,10 12, R0 D2,,6.49,5.01,0.95,91.2,409.0,2.52,13.0,11.0,127.0,75.0,66.0,17.51,6.49,56.0,195.0,35.0,21.0,4.3,2.6,68.0,130.0,,,,,,,,,,,,,1.51,0.6,0.585,,,, P0,H0,,,,,,,74.60578186596584,1316954
1323276,孟广孝,535511,男,77,T4a,N1,M0, ⅢA,2,1,,1.0,1.0,0.0,,2.0,34,中间型（int）,INFb,1.0,0.7,,,,,,,2013-08-14,2018-06-12,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)02 (3b)04 (4sb)01 (4d)13 (5)06 (6)11 (7)06 (8a)(8p)01 (9)03 (11p)04 (12a)00 (12p)01 (14v)01 (19)01,L（幽门窦部） 后Post 小弯侧Less ,40,30,10, R0 D2+,,5.32,2.91,1.7,123.5,181.0,2.09,10.0,23.0,208.0,54.0,16.0,24.17,6.91,59.0,249.0,37.0,22.0,4.5,3.7,72.0,174.0,,,,,,,,,,,,,10.03,6.47,2.23,,,, P0,H0,,,,,,,57.91721419185282,1323276
1333982,孟锁柱,548042,男,66,T4a,N2,M0, ⅢA,2,3,,0.0,0.0,0.0,,5.0,48,硬型（sci）,INFb,0.0,0.9,,,,,,,2013-12-04,2019-10-01,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】,G2," (3a)(3b)110 (4sb)00 (4d)011 (5)22 (6)111 (7)01 (8a)05 (8p)00 (9)03 (11p)01 (12a)00 大网结节14 3b,5组内可见4枚癌结节"," LM 前Ant, 后Post, 小弯侧Less,",90,90,12, R0 D2,,9.32,6.65,1.26,86.8,359.0,2.6,12.0,16.0,119.0,43.0,29.0,10.77,2.35,50.2,167.9,31.1,19.1,6.2,10.37,87.0,183.0,,,,,,,,,,,,,8.41,20.24,0.845,,,, P0,H0,,,,,,,69.87516425755584,1333982
1334205,孟宪桂,546021,女,75,T4b,N1,M0, ⅢB,2,2,,1.0,1.0,1.0,,1.0,30,中间型（int）,INFc,2.0,0.1,,,,,,,2013-12-05,2015-07-10,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)03 (3a)01 (3b)02 (4sb)00 (4d)011 (5)00 (6)00 (7)01 (8a)11 (8p)01 (9)04 (11p)01 (12a)00 (19)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,20,6, R0 D2+,,10.48,6.87,2.5,131.2,290.0,4.9,13.0,24.0,118.0,82.0,13.0,10.07,2.38,59.0,166.0,38.0,21.0,4.6,5.4,59.0,174.0,,,,,,,,,,,,,44.54,0.6,2.9,,,, P0,H0,,,,,,,19.11957950065703,1334205
1318680,牟彦有,531749,男,46,T4b,N3a,M0, ⅢC,2,4,,0.0,0.0,0.0,,11.0,16,中间型（int）,INFc,1.0,0.7,,,,,,,2013-07-01,2014-05-15,2,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,8, 低分化腺癌（G3)(por),G3, (1a)11 (1b)00 (2)00 (3a)11 (3b)55 (4sa)00 (4sb)00 (4d)00 (5)00 (6)22 (11p)01 (7)00 (8a)(8p)(9)(12a)(12p)25, LMU,90,9,1.2, R0 D2+,,7.86,5.07,2.24,138.5,236.0,3.68,22.6,15.0,131.0,97.0,33.3,13.0,2.89,75.7,314.34,47.8,27.9,4.9,8.59,83.0,423.0,,,,,,,,,,,,,1.06,5.8,2.42,,,, P0,H0,,,,,,,10.446780551905388,1318680
1334228,慕德英,548180,女,67,T4a,N3b,M0, ⅢC,2,3,,1.0,1.0,1.0,,18.0,62,硬型（sci）,INFc,0.0,,,,,,,,2013-12-05,2014-08-16,2,,,XELOX,,,,,,1, 低分化管状腺癌（G3)(por),G3, (1a)08 (1b)03 (3a)48 (3b)59 (4sb)00 (4d)620 (5)00 (6)36 (7)00 (8a)01 (8p)01 (9)03 (11p)02 (12p)00 (14v)01, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less,35,45,10, R0 D2+,,7.07,5.36,1.23,115.8,264.0,2.99,7.1,15.0,123.0,72.0,13.3,10.61,1.96,59.4,159.62,37.0,22.4,6.8,3.89,60.0,268.0,,,,,,,,,,,,,1.23,5.61,2.47,,,, P0,H0,,,,,,,8.344283837056505,1334228
1400388,聂凤云,549773,女,60,T3,N3a,M0,ⅢB,2,4,,1.0,1.0,1.0,,7.0,56,中间型（int）,INFb,0.0,,,,,,,,2014-01-06,2019-05-08,1,,,,,,,,,0, 低粘附腺癌50% 粘液腺癌（muc）30% 低分化腺癌（G3)(por)20%,G3, 大弯22 (1a、1b)08 (2)03 (3a、3b)514 (4sa)01 (4sb)00 (4d)011 (6)03 (5、12a)00 (7、8a、9)00 (11p)0 (10)014," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",60,60,8, R0 D2,,10.08,6.56,2.93,119.5,334.0,3.59,12.0,21.0,143.0,92.0,21.0,10.69,4.35,71.0,174.0,41.0,30.0,5.6,4.6,69.0,282.0,,,,,,,,,,,,,2.36,14.88,300.0,,,, P0,H0,,,,,,,63.99474375821288,1400388
1327955,蒲文荣,541499,男,47,T4a,N1,M0, ⅢA,2,3,,0.0,0.0,1.0,,1.0,47,中间型（int）,INFc,2.0,0.7,,,,,,,2013-10-08,2019-10-11,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por),G3, (1a、1b)03 (3a、3b)119 (5、12a)00 (4d)01 (4sb)05 (6)05 (7、8、9、11)09 (11)01 (14)04 ," L（幽门窦部）, M（胃体部）, LM 前Ant, 小弯侧Less,",25,25,15, R0 D2+,,4.9,3.09,1.34,139.0,197.0,1.88,30.0,39.0,138.0,101.0,58.0,11.68,1.91,70.0,232.0,43.0,27.0,5.7,6.8,99.0,524.0,,,,,,,,,,,,,1.16,4.9,2.41,,,, P0,H0,,,,,,,72.07621550591327,1327955
1336476,朴相秀,548726,男,57,T3,N2,M0, ⅢA,2,2,,0.0,0.0,0.0,,3.0,21,硬型（sci）,INFb,3.0,0.8,,,,,,,2013-12-26,2016-05-01,0,,,XELOX,SOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap）,G2, (1a)12 (1b)00 (2)01 (3a)04 (3b)01 (4sa)00 (4sb)00 (4d)04 (5)01 (6)00 (7)11 (8a)(8p)01 (9)02 (11p)00 (11d)13 (12a)01,"  U（胃底部）, 前Ant,",45,45,9, R0 D2,,6.39,3.56,2.23,115.6,257.0,2.36,16.1,10.0,108.0,93.0,14.4,7.76,2.13,65.7,282.27,40.0,25.7,5.1,6.1,79.0,219.0,,,,,,,,,,,,,2.48,8.9,4.89,,,, P0,H0,,,,,,,28.153745072273324,1336476
1431244,齐义东,577807,男,56,T4a,N3a,M0, ⅢB,2,5,1.0,1.0,1.0,0.0,,10.0,23,硬型（sci）,INFb,3.0,,0.0,0.0,,,,1.0,2014-10-28,2015-11-11,2,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,6, 管状腺癌（中分化【G2】【tub2】75% 低黏附腺癌25%,G2, (1a)01 (1b)00 (3a)14 (3b)22 (4sb)00 (4d)35 (5)11 (6)22 (7)04 (8a)(8p)01 (9)02 (11p)11 (12a)00 (14v)11,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,35,10, R0 D2+,,6.31,3.74,2.08,143.0,230.0,2.48,25.0,34.0,154.0,43.0,8.0,9.89,3.63,64.0,249.0,41.0,23.0,5.1,9.0,83.0,195.0,,,,,,,,,,,,,4.12,81.62,11.95,,,, P0,H0,,,,,,,12.450722733245728,1431244
1323073,曲安,535940,男,43,T4a,N2,M0, ⅢA,2,3,,0.0,0.0,1.0,,6.0,18,硬型（sci）,INFc,1.0,0.3,,,,,,,2013-08-12,2015-11-17,2,,,,,,,,,0, 粘液腺癌（muc） 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】,G3, (1a)(1b)02 (3a)(3b)12 (4sb)(4d)02 (5)(12a)02 (6)44 (7)(8a)(8p)(9)(11p)16 ," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,10, R0 D2,,5.71,3.32,1.73,114.0,275.0,3.61,10.0,14.0,141.0,63.0,7.0,2.95,1.35,52.0,219.0,34.0,18.0,3.1,4.6,73.0,206.0,,,,,,,,,,,,,4.82,33.05,18.82,,,, P0,H0,,,,,,,27.16819973718791,1323073
1414643,曲法智,560731,男,68,T3,N2,M0, ⅢA,2,3,2.0,,,,,5.0,24,中间型（int）,INFc,0.0,,0.0,0.0,,,,0.0,2014-05-27,2014-09-15,2,,,口服替吉奥,,,,,,1, 低分化管状腺癌（G3)(por)60% 低粘附腺癌40%,G3, (1a)00 (1b)13 (2)02 (3a)28 (3b)00 (4sa)01 (4sb)00 (4d)12 (5)00 (6)03 (7)00 (8a)02 (8p)00 (9)13 (11p)(11d)00 ," M（胃体部）, 前Ant, 小弯侧Less,",25,25,2, R0 D2,,6.93,3.85,1.93,146.9,270.0,4.32,12.0,15.0,178.0,103.0,28.0,6.32,2.45,77.0,167.0,40.0,37.0,5.0,5.4,90.0,306.0,,,,,,,,,,,,,2.45,8.3,18.27,,,, P0,H0,,,,,,,3.6465177398160313,1414643
1323212,曲杰,536008,男,46,T3,N2,M0, ⅢA,2,3,,,,,,5.0,37,中间型（int）,INFc,1.0,0.3,,,,,,,2013-08-13,2016-09-15,2,,,,,,,,,0, 低分化腺癌（G3)(por) 印戒细胞癌(sig) 息肉,G3, (1a)(1b)02 (2)01 (3a)(3b)412 (4sa)(4sb)(4d)06 (5)(12a)01 (6)04 (7)(8a)(8p)(9)(11p)12 (10)01 (14v)08 ," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",45,40,5, R0 D2+,,5.99,4.11,19.77,137.4,287.0,2.85,7.0,23.0,168.0,94.0,13.0,18.06,4.99,72.0,258.0,41.0,31.0,4.6,4.3,79.0,302.0,,,,,,,,,,,,,2.12,6.7,37.94,,,, P0,H0,,,,,,,37.089356110381075,1323212
1333677,任传玉,546111,男,72,T4a,N1,M0, ⅢA,2,3,,0.0,0.0,1.0,,1.0,19,硬型（sci）,INFc,0.0,0.4,,,,,,,2013-12-02,2019-10-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)02 (3a)04 (3b)12 (4sb)01 (4d)01 (5)01 (6)01 (7)01 (8a)02 (8p)00 (9)02 (11p)00," L（幽门窦部）, 小弯侧Less,",40,30,8, R0 D2,,3.2,1.2,1.5,131.0,145.0,2.24,13.0,15.0,139.0,79.0,12.0,10.77,2.03,59.0,225.0,36.0,23.0,4.8,4.7,78.0,190.0,,,,,,,,,,,,,1.31,10.85,2.4,,,, P0,H0,,,,,,,69.94086727989487,1333677
1321889,任凤春,534795,女,65,T4a,N3b,M0, ⅢC,2,3,,,,1.0,,18.0,25,中间型（int）,INFc,0.0,0.4,,,,,,,2013-07-31,2016-03-17,2,,,,,,,,,0, 低分化腺癌（G3)(por) 印戒细胞癌(sig) 粘液腺癌（muc）,G3, (1a)01 (1b)00 (3a)00 (3b)28 (4sb)33 (4d)00 (6)00 (7)11 (8a)11 (12a)11   ," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",70,40,13, R0 D2,,5.06,3.4,1.2,101.0,195.0,3.1,10.0,21.0,121.0,63.0,9.0,15.16,3.76,62.0,235.0,38.0,24.0,4.8,8.6,73.0,269.0,,,,,,,,,,,,,3.54,394.3,6.05,,,, P0,H0,,,,,,,31.537450722733244,1321889
1425854,阮付,573424,男,55,T3,N2,M0, ⅢA,2,3,0.0,,,,,3.0,39,髓样型（med）,INFa,3.0,,0.0,0.0,,,,0.0,2014-09-09,2020-06-08,1,,,SOX,SOX,,,,,2, 管状腺癌（高分化【G1】【tub1】 中分化【G2】【tub2】 乳头状癌（G1）（pap） 粘液腺癌（muc） Lauren肠型,G2, (1a)03 (1b)01 (3a)01 (3b)00 (4sb)01 (4d)19 (5)01 (6)11 (7)05 (8a)15 (8p)02 (9)03 (11p)07 (12a)00 3a软组织可见癌," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,8, R0 D2,,4.34,3.12,0.75,73.5,143.0,3.06,21.0,25.0,158.0,74.0,19.0,11.82,3.86,51.0,292.0,30.0,21.0,5.2,8.1,64.0,230.0,,,,,,,,,,,,,2.81,1.27,8.59,,,, P0,H0,,,,,,,68.95532194480946,1425854
1403558,邵奎文,543044,男,42,T3,N3a,M0,ⅢB,2,1,,,,,,8.0,19,中间型（int）,INFc,0.0,0.7,,,,,,,2014-02-18,2015-05-05,2,TS*3,1.0,TS,TS,TS,口服替吉奥,,,4, 粘液腺癌（muc）60% 低分化管状腺癌（G3)(por)40%,G3, (1a)02 (1b)01 (2)01 (3a)36 (3b)01 (4sa)02 (4sb)00 (4d)01 (5)00 (6)22 (7、8、9)22 (8p)11 (11p)00 (12a)00," L（幽门窦部）, M（胃体部）, U（胃底部）, LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",120,90,8, R0 D2,,4.95,3.0,1.2,127.0,184.0,2.45,25.0,29.0,171.0,61.0,22.0,19.41,6.08,62.0,321.0,38.0,24.0,4.4,4.8,69.0,251.0,,,,,,,,,,,,,2.31,1.86,4.18,,,, P0,H0,,,,,,,14.487516425755585,1403558
1412546,邵立军,560386,男,45,T4a,N2,M0, ⅢA,2,3,2.0,0.0,0.0,1.0,,3.0,41,硬型（sci）,INFc,0.0,,0.0,0.0,,,,,2014-05-07,2016-12-04,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌,GX, (1a)02 (1b)12 (2)07 (3a)13 (3b)02 (4sa)00 (4sb)00 (4d)07 (5)00 (7)11 (8a)(8p)05 (9)01 (12a)01 大网03, LM 小弯侧Less 前Ant 后Post ,20,20,2, R0 D2,,3.63,1.6,1.56,91.8,240.0,3.43,13.0,19.0,115.0,53.0,7.0,9.61,3.58,77.0,256.0,44.0,33.0,5.5,5.7,85.0,259.0,,,,,,,,,,,,,1.29,15.0,0.883,,,, P0,H0,,,,,,,30.946123521681997,1412546
1430316,宋悦磊,574802,男,58,T3,N1,M0, ⅡB,2,3,0.0,1.0,1.0,1.0,,2.0,24,中间型（int）,INFa,3.0,,0.0,0.0,,,,2.0,2014-10-20,2021-07-01,1,,,SOX,SOX,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,6, 管状腺癌（高分化【G1】【tub1】 中分化【G2】【tub2】50% 乳头状癌（G1）（pap）45% 低粘附腺癌5 %Lauren肠型,G2, (1a)02 (1b)11 (2)04 (3a)00 (3b)03 (4sb)00 (4d)01 (7)05 (8a)12 (8p)02 (9)02 (11d)00 (11p)01 (12a)01   (1b)组软组织可见癌," MU SiewerⅡ, 后Post,",60,60,10, R0 D2,,12.36,9.09,1.86,94.0,333.0,4.45,13.0,21.0,132.0,82.0,12.0,17.18,6.66,67.0,133.0,43.0,24.0,4.8,5.8,84.0,242.0,,,,,,,,,,,,,3.59,145.2,2.57,,,, P0,H0,,,,,,,80.35479632063074,1430316
1402844,宋增法,552339,男,69,T3,N3a,M0,ⅢB,2,2,,0.0,0.0,1.0,,9.0,17,中间型（int）,INFc,1.0,0.6,,,,,,,2014-02-11,2020-09-08,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por),G3, (1a)00 (1b)11 (3a)67 (3b)00 (4sb)01 (4d)01 (5)12 (6)11 (7)01 (8a)02 (8p) 00(9)01 (11p)00," L（幽门窦部）, 小弯侧Less,",30,30,8, R0 D2,,6.62,4.15,1.88,167.1,195.0,3.46,25.0,21.0,160.0,87.0,90.0,25.87,7.08,75.0,285.0,48.0,27.0,6.9,5.5,91.0,404.0,,,,,,,,,,,,,4.22,10.9,3.43,,,, P0,H0,,,,,,,78.87647831800263,1402844
1437591,苏静,583247,女,73,T3,N1,M0, ⅡB,2,4,0.0,1.0,1.0,0.0,,1.0,4,硬型（sci）,INFa,0.0,,0.0,0.0,,,,0.0,2014-12-22,2017-07-18,2,,,多西他赛+替吉奥,,,,,,1,浸润溃疡型低黏附腺癌伴粘液分泌,GX, (3a)0/0 (3b)0/0 (4sb)0/0 (4d) 0/0(7)0/0 (8a)0/0 (8p)0/1 (9)0/0 (11p)1/3," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,20, R0 D2,,11.23,7.6,2.58,127.0,295.0,5.16,28.0,29.0,153.0,84.0,18.0,7.83,3.06,78.0,165.0,41.0,37.0,6.1,6.0,64.0,353.0,54.0,34.7,16.4,2.12,0.2,7.5,36.1,3.3,1.13,3.3,16.2,28.3,14.0,66.34,65.51,,,, P0,H0,,,,,,,30.847568988173453,1437591
1425257,孙凤,570949,女,55,T3,N1,M0, ⅡB,2,3,0.0,1.0,1.0,1.0,,2.0,20,髓样型（med）,INFa,0.0,,0.0,0.0,,,,2.0,2014-09-02,2018-06-23,2,,,XELOX,紫杉醇+替加氟+卡铂,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)00 (3b)24 (4sb)00 (4d)00 (5)00 (6)04 (7)05 (8a)(8p)03 (9)01 (11p)03 (12a)00 (14v)00 (16a1)00,L（幽门窦部） 小弯侧Less ,50,50,15, R0 D2+,,9.17,4.39,3.64,134.0,313.0,3.46,25.0,34.0,228.0,89.0,12.0,8.39,2.06,72.0,282.0,41.0,31.0,4.7,4.7,62.0,245.0,,,,,,,,,,,,,8.32,0.915,4.22,,,, P0,H0,,,,,,,45.663600525624176,1425257
1425943,孙凤双,573463,男,50,T4a,N3b,M0, ⅢC,2,3,1.0,1.0,1.0,1.0,,18.0,23,髓样型（med）,INFc,3.0,,0.0,0.0,,,,2.0,2014-09-09,2015-10-15,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌60% 粘液腺癌（muc）30% 低分化管状腺癌（G3)(por)10% Lauren混合型,G3, (1a)22 (1b)12 (3a)11 (3b)01 (4sb)00 (4d)33 (5)00 (6)55 (7)46 (8a)22 (9)00 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,30,18, R0 D2,,6.7,3.81,2.2,149.8,209.0,3.16,27.0,25.0,179.0,87.0,17.0,8.04,3.1,68.0,336.0,43.0,25.0,5.3,6.7,76.0,354.0,,,,,,,,,,,,,21.55,285.2,3.4,,,, P0,H0,,,,,,,13.173455978975033,1425943
1326746,孙国良,540571,男,56,T2,N1,M0, ⅡA,2,3,,,,,,2.0,22,,,0.0,0.8,,,,,,,2013-09-17,2019-10-01,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (3a)07 (4sb)00 (4d)24 (5)01 (6)00 (7)00 (8a)01 (8p)02 (9)05 (11p)01 (12a)00," L（幽门窦部）, 前Ant,",35,30,4, R0 D2,,6.86,3.9,2.59,146.6,297.0,3.21,22.2,25.0,183.0,108.0,24.0,7.5,1.42,71.6,297.5,41.6,30.0,5.1,6.69,65.0,376.0,,,,,,,,,,,,,3.31,17.19,1.43,,,, P0,H0,,,,,,,72.43758212877792,1326746
1401224,孙国志,551938,男,53,T4b,N3b,M0, ⅢC,2,3,,1.0,1.0,1.0,,26.0,36,中间型（int）,INFc,3.0,0.8,,,,,,,2014-01-13,2015-08-17,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】中分化【G2】【tub2】,G2, (1a)00 (1b)11 (2)05 (3a)22 (3b)57 (4sa)00 (4sb)45 (4d)01 (5)44 (6)44 (7)01 (8a)(8p)00 (9)00, G（胃底部部） 小弯侧Less,80,55,10, R0 D2,,5.38,3.85,1.02,126.0,205.0,3.07,12.0,22.0,109.0,76.0,10.0,14.11,6.45,59.0,148.0,39.0,20.0,4.2,3.0,74.0,194.0,,,,,,,,,,,,,2.36,17.47,30.01,,,, P0,H0,,,,,,,19.086727989487514,1401224
1325135,孙克生,538939,男,71,T4a,N3b,M0, ⅢC,2,3,,,,,,16.0,43,中间型（int）,INFb,2.0,0.5,,,,,,,2013-09-02,2016-11-01,2,,,替吉奥+阿帕替尼,,,,,,1, 管状腺癌（中分化【G2】【tub2】30% 低黏附性癌60% 粘液腺癌10%,G2, 大弯02 (3a)410 (3b)22 (5)35 (6)12 (7)(8a)(8p)(9) (14v)03," LM 前Ant, 后Post, 大弯侧Gre,",65,55,12, R0 D2,,7.58,4.64,1.97,124.4,199.0,3.68,25.0,16.0,128.0,86.0,25.0,5.17,2.3,63.0,170.0,34.0,29.0,4.8,6.9,60.0,200.0,,,,,,,,,,,,,1.62,149.5,6.31,,,, P0,H0,,,,,,,37.97634691195795,1325135
1322099,孙茂和,534806,男,71,T4a,N1,M0, ⅢA,2,3,,,,,,2.0,24,中间型（int）,INFc,1.0,0.5,,,,,,,2013-08-01,2014-08-02,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 粘液腺癌（muc）,G3, (1a)00 (1b)02 (3a)02 (3b)00 (4sb)00 (4d)02 (5)00 (6)27 (7)04 (8a)01 (9)06 (12a)00," L（幽门窦部）, 前Ant,",35,25,8, R0 D2,,4.4,2.44,1.58,129.0,230.0,1.79,17.0,15.0,161.0,56.0,13.8,12.33,2.68,65.6,158.59,43.7,21.9,4.4,5.37,65.0,242.0,,,,,,,,,,,,,2.9,13.72,1.42,,,, P0,H0,,,,,,,12.02365308804205,1322099
1417397,孙佩龙,565200,男,47,T3,N2,M0, ⅢA,2,2,1.0,0.0,0.0,1.0,,3.0,27,中间型（int）,INFc,0.0,,0.0,0.0,,,,2.0,2014-06-23,2015-01-15,2,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,6, 低粘附腺癌50% 管状腺癌（中分化【G2】【tub2】 低分化（G3)(por)30%  粘液腺癌（muc）20%,G3, (1a)02 (1b)01 (2)01 (3a)24 (3b)02 (4sa)01 (4sb)01 (4d)02 (5)00 (6)01 (7)13 (8a)01 (8p)01 (9)03 (11p)04, U（胃底部） 前Ant 后Post 小弯侧Less,25,15,5, R0 D2,,7.72,4.75,2.01,154.0,153.0,2.38,49.0,25.0,146.0,94.0,21.0,12.56,4.53,72.0,297.0,42.0,30.0,4.8,4.5,74.0,319.0,,,,,,,,,,,,,3.34,14.55,4.48,,,, P0,H0,,,,,,,6.767411300919842,1417397
1412983,孙淑兰,558748,女,66,T3,N2,M0, ⅢA,2,2,0.0,0.0,0.0,0.0,,3.0,33,髓样型（med）,INFb,0.0,,0.0,0.0,,,,,2014-05-12,2015-04-03,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, 小弯侧12 (1a)00 (1b)02 (2)02 (3a)16 (3b)22 (4sa)00 (4sb)00 (4d)04 (5)00 (6)05 (7)01 (8a)04 (8p)01 (9)02 (11p)04 (12a)00," M（胃体部）, 小弯侧Less,",30,30,10, R0 D2,,5.31,2.36,2.61,131.0,225.0,3.07,15.0,21.0,186.0,98.0,19.0,9.21,2.93,70.0,163.0,40.0,30.0,5.0,3.6,78.0,205.0,,,,,,,,,,,,,4.37,41.32,1.08,,,, P0,H0,,,,,,,10.709592641261498,1412983
1417334,孙喜珍,566317,女,49,T3,N1,M0, ⅡB,2,2,1.0,0.0,0.0,1.0,,2.0,26,中间型（int）,INFc,0.0,,0.0,0.0,,,,2.0,2014-06-23,2015-11-20,2,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,6, 管状腺癌（中分化【G2】【tub2】 低分化（G3)(por)90% 低粘附腺癌10%,G3, (1a)01 (1b)00 (3a)03 (3b)15 (4sb)00 (4d)17 (5)00 (6)03 (7)02 (8a)01 (8p)02 (9)01 (11p)01 (12a)00 (14v)00 (15)00,L（幽门窦部） 前Ant 小弯侧Less 后Post,30,30,8, R0 D2+,,6.15,3.82,1.57,132.0,296.0,4.04,14.0,21.0,148.0,91.0,22.0,13.57,5.99,70.0,225.0,41.0,29.0,4.4,6.5,53.0,247.0,,,,,,,,,,,,,2.08,6.74,1.5,,,, P0,H0,,,,,,,16.918528252299605,1417334
1437669,孙宪波,582079,男,63,T3,N3a,M0,ⅢB,2,3,0.0,1.0,1.0,1.0,,7.0,32,硬型（sci）,INFa,2.0,,0.0,0.0,,,,0.0,2014-12-23,2020-04-14,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1,小弯03 (1a)01 (1b)13 (3a)33 (3b)01 (4sb)00 (4d)18 (5)00 (6)24 (7)02 (8a)02 (8p)02 (9)01 (11p)02 (12a)00  (3b)软组织见有一枚癌结节," L（幽门窦部）, 小弯侧Less,",25,25,7, R0 D2+,,6.37,3.68,2.05,135.6,202.0,3.53,19.0,24.0,166.0,47.0,17.0,10.83,3.99,72.0,185.0,43.0,29.0,6.1,7.5,59.0,256.0,49.1,27.7,16.4,1.69,0.1,7.0,38.5,2.4,0.798,1.65,11.0,25.33,0.94,6.56,1.19,,,, P0,H0,,,,,,,63.69908015768725,1437669
1319127,孙志家,531480,男,58,T2,N1,M0, ⅡA,2,2,,,,,,1.0,26,,,0.0,0.7,,,,,,,2013-07-04,2019-06-02,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】,G3, (1a)01 (1b)01 (3a)01 (3b)03 (4sb)04 (4d)15 (5)02 (6)02 (7)01 (8a)04 (8p)01 (9)01 (11p)00 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",40,35,5, R0 D2,,4.66,2.85,1.24,126.7,164.0,3.14,11.0,15.0,188.0,73.0,8.0,14.02,2.97,72.5,159.1,39.4,33.1,4.9,5.32,53.0,221.0,,,,,,,,,,,,,1.24,2.47,1.82,,,, P0,H0,,,,,,,70.92641261498028,1319127
1316105,塔春海,529699,男,66,T4a,N1,M0, ⅢA,2,2,,,,,,2.0,51,髓样型（med）,INFb,0.0,0.8,,,,,,,2013-06-05,2019-10-01,1,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 ,G3, (1a)01 (1b)05 (3a)04 (3b)11 (4sb)00 (4d)01 (5)11 (6)011 (7)09 (8a)02 (8p)05 (9)05 (11p)03 (16a1)03     ," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,55,10, R0 D2,,9.77,6.5,2.44,135.0,255.0,3.68,11.0,16.0,138.0,79.0,14.0,14.7,3.58,71.0,194.0,41.0,30.0,4.8,6.5,86.0,265.0,,,,,,,,,,,,,6.16,32.04,2.36,,,, P0,H0,,,,,,,75.85413929040736,1316105
1412552,唐丽香,561015,女,73,T4a,N3a,M0, ⅢB,2,3,0.0,0.0,0.0,0.0,,11.0,30,中间型（int）,INFc,0.0,,0.0,0.0,,,,,2014-05-07,2015-06-18,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)04 (1b)00 (3a)25 (3b)00 (4sb)00 (4d)33 (6)56 (7)15 (8a)03 (8p)01 (9)01 (11p)02 , LM 前Ant 后Post 大弯侧Gre,35,45,3, R0 D2,,10.54,6.08,3.75,128.0,432.0,5.16,17.0,23.0,169.0,102.0,27.0,6.37,1.73,84.0,205.0,46.0,38.0,7.0,6.3,84.0,230.0,,,,,,,,,,,,,1.58,65.7,2.1,,,, P0,H0,,,,,,,13.370565045992116,1412552
1414181,唐同茂,561580,男,49,T3,N3a,M0,ⅢB,2,2,0.0,0.0,0.0,1.0,,7.0,26,硬型（sci）,INFc,0.0,,0.0,0.0,,,,0.0,2014-05-22,2019-04-15,0,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】70% 粘液腺癌（muc）30%,G2, (1a)(1b)16 (3a)(3b)11 (4sb)00 (4d)36 (5)00 (6)24 (7)02 (8a)(8p)06 (14v)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,50,8, R0 D2,,6.43,3.8,1.92,93.7,388.0,4.44,16.0,15.0,110.0,47.0,12.0,3.02,1.41,57.0,132.0,34.0,23.0,3.3,5.2,53.0,92.0,,,,,,,,,,,,,20.24,8.36,5.53,,,, P0,H0,,,,,,,58.77135348226018,1414181
1434752,陶长义,580640,男,67,T3,N1,M0, ⅡB,2,3,0.0,0.0,0.0,0.0,,1.0,23,硬型（sci）,INFa,1.0,,0.0,0.0,,,,0.0,2014-11-27,2019-10-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)01 (3b)00 (4sb)02 (4d)06 (5)11 (6)07 (7)01 (8a)01 (8p)03 (9)00 (11p)00 (12a)00 (16)01, 胃癌 L（幽门窦部） 后Post 大弯Gre,40,30,20, R0 D2,,9.72,6.34,2.43,126.3,258.0,2.76,41.0,20.0,144.0,90.0,95.0,12.45,6.43,76.0,247.0,43.0,33.0,4.9,7.0,129.0,377.0,82.1,33.2,44.6,0.74,0.0,6.8,9.3,0.5,0.621,4.01,15.2,287.0,2.59,3.28,1.16,,,, P0,H0,,,,,,,58.1143232588699,1434752
1421682,田惠兰,565603,女,54,T3,N3a,M0,ⅢB,2,3,1.0,0.0,0.0,0.0,,10.0,26,中间型（int）,INFa,2.0,,0.0,0.0,,,,2.0,2014-07-31,2017-01-16,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,紫杉醇联合替吉奥,8, 管状腺癌（低分化（G3)(por)  中分化【G2】【tub2】50% 低粘附腺癌50%,G3, (1a)26 (1b)14 (3a)11 (3b)00 (4sb)00 (4d)01 (5)(11p)00  (6)33 (7)03 (8a)13 (8p)23 (9)01 (12a)01,L（幽门窦部） 前Ant 小弯侧Less 后Post 大弯侧Gre  ,35,35,9, R0 D2,,6.46,4.14,1.92,123.1,196.0,2.1,19.0,24.0,251.0,69.0,8.0,115.55,10.05,79.0,398.0,49.0,30.0,6.7,4.0,31.0,210.0,,,,,,,,,,,,,2.14,28.28,1.41,,,, P0,H0,,,,,,,29.566360052562416,1421682
1415246,佟贵宝,563269,男,64,T3,N1,M0, ⅡB,2,3,1.0,0.0,0.0,0.0,,1.0,33,中间型（int）,INFb,0.0,,0.0,0.0,,,,0.0,2014-06-04,2019-10-01,1,,,口服卡培他滨,,,,,,1, 低分化管状腺癌（G3)(por),G3, (1a)(1b)01 (3a)01 (3b)05 (4sb)00 (4d)02 (5)01 (6)010 (7)06 (8a) (8p)13 (9)04 (12a)00, L（幽门窦部） 前Ant ,50,50,10, R0 D2+,,7.69,4.23,2.7,130.3,305.0,2.76,10.0,18.0,172.0,64.0,11.0,5.35,9.27,67.0,236.0,38.0,29.0,5.5,9.5,82.0,287.0,,,,,,,,,,,,,5.4,35.64,11.8,,,, P0,H0,,,,,,,63.89618922470434,1415246
1432116,汪秋海,578988,男,50,T3,N1,M0, ⅡB,2,3,0.0,0.0,0.0,1.0,,2.0,11,中间型（int）,INFa,2.0,,0.0,0.0,,,,0.0,2014-11-05,2019-10-01,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】低分化( G3)(por)  Lauren肠型,G3, (1a)(1b)13 (2)12 (3a)(3b)00 (4d)00 (4sa)00 (4sb)01 (5)00 (6)02 (7)(8a)(9)(11p)03 (10)00 （11p）00(11d)00 (12a)00, U 大弯侧Gre  ,50,40,10, R0 D2,,5.18,2.36,2.33,152.7,245.0,2.45,14.0,16.0,138.0,61.0,47.0,14.11,4.86,68.0,323.0,49.0,20.0,5.7,5.6,102.0,364.0,58.3,41.2,17.0,2.42,2.0,8.3,31.4,1.2,0.718,1.23,8.57,167.0,2.7,11.71,1.84,,,, P0,H0,,,,,,,58.83705650459921,1432116
1329450,王百坤,542822,男,69,T4a,N3b,M0, ⅢC,2,5,,0.0,0.0,1.0,,16.0,48,中间型（int）,INFb,1.0,0.4,,,,,,,2013-10-22,2015-05-08,2,,,,,,,,,0, 粘液腺癌（muc）60% 低粘附腺癌30% 管状腺癌（中分化【G2】【tub2】低分化（G3)(por)10%,G3, (1a)02 (1b)04 (3a)(3b)14 (4sb)02 (4d)1221 (5)00 (6)38 (7)00 (8a)02 (8p)02 (9)02 (11p)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,20, R0 D2,,5.08,3.17,1.4,86.3,200.0,2.41,37.0,34.0,114.0,57.0,8.0,3.38,0.07,47.0,107.0,28.0,19.0,9.5,3.6,66.0,217.0,,,,,,,,,,,,,3.92,131.0,108.6,,,, P0,H0,,,,,,,18.495400788436267,1329450
1432707,王炳仁,579701,男,55,T3,N1,M0, ⅡB,2,3,2.0,1.0,1.0,1.0,,1.0,21,髓样型（med）,INFc,0.0,,0.0,0.0,,,,0.0,2014-11-10,2020-04-16,1,,,XELOX,XELOX,,,,,2, 粘液腺癌（muc）80% 低黏附腺癌20% Lauren弥漫型,GX, (1a)00 (1b)01 (3a)14 (3b)00 (4d)04 (4sb)00 (5)00 (6)01 (7)02 (8a)02 (8p)01 (9)00 (11p)03 (12a)00 (12p)00 (14v)03 (19)00," L（幽门窦部）, 小弯侧Less,",30,30,10, R0 D2+,,6.16,3.15,2.43,152.2,238.0,2.63,17.0,18.0,156.0,67.0,24.0,16.35,5.37,67.0,239.0,46.0,21.0,4.3,6.3,85.0,232.0,68.8,52.2,13.7,3.81,0.0,22.7,7.3,0.1,0.918,2.55,10.7,56.1,1.82,2.9,6.65,,,, P0,H0,,,,,,,65.17739816031538,1432707
1436923,王福君,583262,男,65,T4a,N2,M0, ⅢA,2,2,0.0,1.0,1.0,1.0,,5.0,37,硬型（sci）,INFa,2.0,,0.0,0.0,,,,2.0,2014-12-16,2017-03-24,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】低分化（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)08 (4d)06 (5)00 (6)46 (7)05 (8a)13 (8p)02 (9)03 (11p)00 (12a)00 小弯01 大弯01,L（幽门窦部） 前Ant 小弯侧Less ,50,40,10, R0 D2,,6.69,3.01,2.97,119.2,259.0,3.05,22.0,25.0,115.0,67.0,11.0,8.9,4.16,64.0,187.0,37.0,27.0,5.4,7.1,68.0,253.0,53.9,33.2,19.6,1.69,0.1,11.0,29.6,2.0,0.492,2.22,9.52,122.0,1.74,8.6,31.97,,,, P0,H0,,,,,,,27.233902759526938,1436923
1319459,王国祥,533467,男,66,T2,N1,M0, ⅡA,2,2,,,,,,1.0,13,,,2.0,0.6,,,,,,,2013-07-08,2018-07-05,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (3a)01 (3b)03 (4sb)00 (4d)01 (5)01 (6)00 (7)02 (8a)13 (8p)01 (9)01 (11p)00 (12a)00," L（幽门窦部）, 大弯侧Gre,",20,15,10, R0 D2,,5.94,3.07,2.31,131.0,190.0,2.24,26.5,20.0,157.0,77.0,23.9,15.27,2.89,68.8,341.99,42.4,26.4,5.0,4.55,111.0,363.0,,,,,,,,,,,,,1.76,5.82,1.52,,,, P0,H0,,,,,,,59.88830486202365,1319459
1334424,王海霞,547912,女,34,T4a,N2,M0, ⅢA,2,3,,0.0,0.0,1.0,,3.0,27,中间型（int）,INFb,0.0,0.8,,,,,,,2013-12-09,2019-09-02,1,,,SOX,,,,,,1, 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (2)01 (3a)00 (3b)06 (4sa)04 (4sb)01 (4d)01 (5)00 (6)03 (7)12 (8a)02 (8p)(9)23 (11p)02 (11d)00 (12a)00 (14v)01," U（胃底部）, 小弯侧Less,",30,30,15, R0 D2+,,4.56,2.75,1.37,138.0,297.0,2.45,7.3,13.0,163.0,66.0,21.2,9.25,3.59,79.8,176.86,43.9,35.9,4.7,3.65,69.0,337.0,,,,,,,,,,,,,5.09,12.83,2.72,,,, P0,H0,,,,,,,68.75821287779237,1334424
1414505,王鸿君,562873,男,48,T3,N1,M0, ⅡB,2,4,1.0,,,,,2.0,45,中间型（int）,INFb,0.0,,0.0,0.0,,,,0.0,2014-05-26,2019-10-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化管状腺癌（G3)(por),G3, (1a)02 (1b)00 (2)13 (3a)04 (3b)05 (4sa)00 (4sb)17 (4d)012 (5)00 (6)02 (7)00 (8a)01 (8p)04 (9)00 (11p)(11d)03 (12a)03, L（幽门窦部）前Ant,60  40,40 40,15 10, R0 D2,,7.09,4.13,2.33,135.8,366.0,3.01,10.0,13.0,113.0,101.0,23.0,7.99,2.69,60.0,286.0,37.0,23.0,4.6,5.9,74.0,340.0,,,,,,,,,,,,,0.717,6.17,1.57,,,, P0,H0,,,,,,,64.19185282522996,1414505
1334526,王纪荣,547692,女,68,T4a,N2,M0, ⅢA,2,3,,1.0,1.0,1.0,,4.0,27,硬型（sci）,INFc,0.0,0.05,,,,,,,2013-12-09,2017-05-15,2,,,口服替吉奥,口服替吉奥,,,,,2, 管状腺癌（中分化【G2】【tub2】 胃肠道间质瘤,G2, (1a)03 (1b)02 (3a)00 (3b)03 (4sb)22 (4d)03 (5)00 (6)00 (7)211 (8a)00 (9)02 (11p)01 (12a)00," L（幽门窦部）, 大弯侧Gre, 胃底大弯间质瘤",25,20,10, R0 D2,,6.33,3.23,2.64,156.0,113.0,2.41,20.0,20.0,179.0,82.0,18.0,20.58,3.34,69.3,169.3,40.8,28.5,4.4,5.76,100.0,535.0,,,,,,,,,,,,,2.56,8.06,0.934,,,, P0,H0,,,,,,,41.16294349540079,1334526
1324626,王嘉勉,535683,男,76,T3,N1,M0, ⅡB,2,1,,0.0,0.0,0.0,,1.0,32,中间型（int）,INFb,3.0,0.6,,,,,,,2013-08-27,2016-03-20,2,,,,,,,,,0, 粘液腺癌（muc） 管状腺癌（高分化【G1】【tub1】）,G1, (1a)02 (1b)03 (3a)02 (3b)00 (4sb)01 (4d)04 (5)00 (6)15 (7)06 (8a)01 (8p)01 (9)02 (11p)04 (12a)00 (19)00," L（幽门窦部）, 后Post,",70,50,20, R0 D2+,,6.08,3.6,1.83,102.0,204.0,2.58,9.5,12.0,129.0,58.0,13.7,7.29,1.52,55.8,194.01,33.8,22.0,4.6,4.87,61.0,284.0,,,,,,,,,,,,,6.35,6.37,1.34,,,, P0,H0,,,,,,,30.749014454664913,1324626
1413736,王杰,562124,男,57,T4a,N2,M0, ⅢA,2,2,0.0,,,,,5.0,23,中间型（int）,INFb,0.0,,0.0,0.0,,,,,2014-05-19,2018-06-06,2,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)16 (1b)00 (3a)00 (3b)00 (4sb)01 (4d)02 (5)11 (6)34 (7)01 (8a)(8p)03 (9)02 (12a)(12b)03 , L（幽门窦部） 小弯侧Less 前Ant 后Post ,30,20,10, R0 D2,,8.74,3.28,4.09,147.0,323.0,3.07,22.0,25.0,190.0,63.0,7.0,8.73,3.0,75.0,226.0,41.0,34.0,6.6,5.0,83.0,296.0,,,,,,,,,,,,,0.667,7.45,1.5,,,, P0,H0,,,,,,,48.58738501971091,1413736
1315044,王仁成,528623,男,74,T2,N3a,M0, ⅢA,2,2,,,,,,11.0,28,,,1.0,0.7,,,,,,,2013-06-27,2020-04-16,1,,,,,,,,,0, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, 小弯11 (1a)00 (1b)00 (3a)26 (3b)46 (4sb)00 (4d)00 (5)11 (6)04 (7)33 (8a)(8p)(9)06 (12a)01 ," L（幽门窦部）, 小弯侧Less,",40,35,4, R0 D2,,5.69,3.15,1.86,115.0,197.0,3.4,16.9,21.0,217.0,80.0,22.8,16.27,4.57,74.6,163.1,39.8,34.8,4.6,5.66,89.0,267.0,,,,,,,,,,,,,5.16,84.09,7.07,,,, P0,H0,,,,,,,81.63600525624179,1315044
1410669,王世德,560261,男,52,T3,N3a,M0,ⅢB,2,4,,1.0,1.0,0.0,,14.0,24,硬型（sci）,INFc,0.0,0.4,,,,,,,2014-04-17,2016-04-20,2,,,口服替吉奥,,,,,,1, 低粘附腺癌,GX, (1a)02 (1b)00 (2)00 (3a)00 (3b)00 (4sa)01 (4sb)01 (4d)00 (6)77 (7)00 (8a)36 (8p)01 (9)33 (11p)11 (12a)00 (19)02," LMU 后Post, 前Ant",100,90,25, R0 D2,,4.68,2.24,1.93,151.0,197.0,3.85,18.0,27.0,260.0,92.0,14.0,4.53,2.04,66.0,145.0,38.0,28.0,5.0,5.0,95.0,268.0,,,,,,,,,,,,,3.21,7.5,4.43,,,, P0,H0,,,,,,,24.113009198423125,1410669
1416198,王淑杰,563773,女,68,T3,N1,M0, ⅡB,2,3,0.0,0.0,0.0,1.0,,1.0,10,硬型（sci）,INFb,1.0,,0.0,0.0,,,,1.0,2014-06-12,2019-10-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)(1b)03 (3a)(3b)13 (4sb)02 (4d)00 (5)00 (6)00 (7)01 (8a)(8p)01 (9)00 (11p)00, L（幽门窦部） 小弯侧Less 前Ant ,25,20,6, R0 D2,,4.46,1.89,2.19,121.0,192.0,2.91,10.0,17.0,165.0,63.0,10.0,14.24,4.18,66.0,185.0,39.0,66.0,4.6,5.5,83.0,275.0,,,,,,,,,,,,,1.42,22.95,1.13,,,, P0,H0,,,,,,,63.633377135348226,1416198
1332932,王树军,546344,男,45,T4a,N2,M0, ⅢA,2,3,,0.0,0.0,1.0,,3.0,50,中间型（int）,INFc,2.0,0.4,,,,,,,2013-11-25,2019-05-08,1,,,XELOX,,,,,,1, 低分化管状腺癌（G3)(por),G3, (1a)01 (1b)00 (3a)113 (3b)04 (4sb)02 (4d)03 (5)00 (6)29 (7)010 (8a)02 (8p)02 (9)02 (11p)02 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,10, R0 D2,,6.54,3.2,2.43,125.5,243.0,1.95,11.2,13.0,121.0,43.0,14.0,10.27,2.45,54.9,221.95,36.2,18.7,4.4,4.91,93.0,222.0,,,,,,,,,,,,,4.03,49.01,1.16,,,, P0,H0,,,,,,,65.37450722733246,1332932
1321851,王喜山,534388,男,52,T2,N1,M0, ⅡA,2,3,,,,,,1.0,35,,,0.0,0.6,,,,,,,2013-07-30,2014-01-15,2,,,XELOX,,,,,,1, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】,G3, (1a)(1b)03 (3a)(3b)017 (4sb)18 (6)(4d)05 (5)(12a)00 (7)(8a)(8p)(9)(11p)02," LM 大弯侧Gre,",30,30,10, R0 D2,,6.7,3.31,2.8,157.8,180.0,2.9,18.0,17.0,147.0,83.0,25.0,15.76,2.97,69.0,310.0,40.0,29.0,2.9,4.9,82.0,343.0,,,,,,,,,,,,,1.01,7.75,0.996,,,, P0,H0,,,,,,,5.551905387647832,1321851
1323558,王兴元,537240,男,53,T4a,N1,M0, ⅢA,2,3,,,,,,2.0,30,中间型（int）,INFc,1.0,0.4,,,,,,,2013-08-16,2015-12-18,0,,,FOLFOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 粘液腺癌（muc）,G3, (1a)(1b)03 (3a)(3b)210 (6)(4d)06 (4sb)03 (5)(12a)00 (7)(8a)(8p)(9)(11p)08," L（幽门窦部）, 小弯侧Less,",40,30,20, R0 D2,,4.8,2.43,41.9,128.0,184.0,2.18,10.0,21.0,148.0,69.0,10.0,7.64,1.78,67.0,248.0,42.0,25.0,5.1,4.4,83.0,217.0,,,,,,,,,,,,,91.55,60.98,3.42,,,, P0,H0,,,,,,,28.055190538764784,1323558
1432232,王秀华,578978,女,41,T3,N3a,M0,ⅢB,2,3,0.0,1.0,1.0,1.0,,7.0,18,中间型（int）,INFa,2.0,,0.0,0.0,,,,2.0,2014-11-05,2019-10-01,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)22 (3b)13 (4sb)02 (4d)12 (5)00 (6)33 (7)02 (8a)04 (8p)00 (9)00 (11p)00,L（幽门窦部） 前Ant 大弯侧Gre  后Post ,50,50,7, R0 D2,,4.87,2.78,1.66,125.3,303.0,2.24,11.0,16.0,157.0,62.0,8.0,10.81,4.24,74.0,203.0,47.0,27.0,4.7,5.0,81.0,311.0,72.2,40.0,25.4,1.57,0.2,8.9,14.3,0.6,2.92,2.35,13.3,312.0,4.32,10.35,6.96,,,, P0,H0,,,,,,,58.83705650459921,1432232
1424582,王秀琴,572083,女,58,T2,N1,M0, ⅡA,2,3,,,,,,2.0,35,,,0.0,,0.0,0.0,,,,,2014-08-26,2019-10-01,1,,,XELOX,XELOX,,,,,2, 管状腺癌（高分化【G1】【tub1】） 管状腺癌（中分化【G2】【tub2】,G2, (1a)06 (1b)02 (2)04 (3a)29 (3b)00 (4sb)00 (4d)01 (5)00 (6)04 (7)02 (8a)01 (8p)01 (9)01 (11p)04 (12a)00 (12p)00," M（胃体部）, 前Ant, 小弯侧Less,",30,20,8, R0 D2,,5.52,2.32,2.73,136.0,295.0,3.27,10.0,19.0,231.0,104.0,8.0,16.65,5.33,73.0,238.0,47.0,26.0,5.6,2.8,82.0,244.0,,,,,,,,,,,,,0.742,5.6,0.956,,,, P0,H0,,,,,,,61.169513797634686,1424582
1423066,王艳玲,571360,女,45,T4b,N3b,M0, ⅢC,2,4,2.0,1.0,1.0,0.0,,22.0,42,中间型（int）,INFb,1.0,,0.0,0.0,,,,2.0,2014-08-13,2014-11-29,2,,,XELOX,,,,,,1, 低分化腺癌（G3)(por),G3,胰腺旁02 (1a)03 (1b)11 (2)12 (3a)12 (3b)33 (4sa)02 (4sb)56 (4d)78 (5)01 (6)36 (7)02 (8a)(8p)01 (9)01 (10)12," M（胃体部）, 前Ant, 后Post, 大弯侧Gre,",80,80,20, R0 D2,,10.39,7.42,2.07,104.0,403.0,3.66,18.0,21.0,265.0,54.0,26.0,5.66,1.91,67.0,184.0,38.0,29.0,5.9,3.3,56.0,219.0,,,,,,,,,,,,,1.33,76.03,29.6,,,, P0,H0,,,,,,,3.54796320630749,1423066
1436247,王永德,575181,男,66,T3,N1,M0, ⅡB,2,3,0.0,0.0,0.0,1.0,,2.0,39,硬型（sci）,INFa,2.0,,0.0,2.0,,,,0.0,2014-12-10,2016-04-13,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化（G3)(por) Lauren肠型,G3, (1a)01 (1b)02 (3a)18 (3b)00 (4sb)00 (4d)014 (5)01 (6)11 (7)03 (8a)01 (8p)05 (9)02 (11p)01," LM 前Ant, 后Post, 小弯侧Less,",50,45,15, R0 D2,,4.84,3.29,1.18,64.4,418.0,4.9,19.0,18.0,116.0,95.0,12.0,7.28,3.47,60.0,104.0,32.0,28.0,5.6,6.5,65.0,221.0,44.9,34.0,12.4,2.74,0.0,12.4,34.9,0.4,1.05,1.88,12.5,107.0,0.645,5.25,5.0,,,, P0,H0,,,,,,,16.09724047306176,1436247
1316189,王友成,529050,男,57,T4a,N3a,M0, ⅢB,2,3,,,,,,9.0,46,硬型（sci）,INFc,1.0,0.2,,,,,,,2013-06-05,2015-02-23,2,,,,,,,,,0, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 ,G3, (1a)05 (1b)04 (3a)310 (3b)13 (4sb)00 (4d)09 (5)00 (6)36 (7)14 (8a)11 (8p)02 (9)01 (11p)01 (14v)00," L（幽门窦部）, 前Ant,",50,45,10, R0 D2,,7.23,5.14,1.68,118.0,205.0,3.61,11.1,3.0,89.0,55.0,12.8,7.18,2.58,55.0,189.99,35.4,19.6,5.0,5.8,62.0,198.0,,,,,,,,,,,,,2.35,14.89,14.83,,,, P0,H0,,,,,,,20.630749014454665,1316189
1328699,王玉荣,472329,女,68,T4a,N2,M0, ⅢA,2,4,,1.0,1.0,1.0,,6.0,21,中间型（int）,INFc,1.0,0.1,,,,,,,2013-10-15,2014-12-01,2,,,,,,,,,0, 低粘附腺癌,GX, (1a)00 (1b)01 (2)45 (3a)01 (3b)01 (4sa) 00(4sb)11 (4d) 12(5)00 (6)02 (7)00 (8a)01 (8p)02 (9)02 (11p)03 (12a)00," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,55,3, R0 D2,,2.79,1.66,0.61,126.3,113.0,2.41,,,,51.0,20.0,,,,178.0,42.0,34.0,,,,,,,,,,,,,,,,,1.92,7.61,4.48,,,, P0,H0,,,,,,,13.534822601839684,1328699
1326907,王玉武,538746,男,57,T4a,N1,M0, ⅢA,2,3,,1.0,1.0,1.0,,2.0,15,中间型（int）,INFb,2.0,0.5,,,,,,,2013-09-18,2018-02-14,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 低黏附性癌30%,G3, (1a)00 (1b)12 (2)02 (3a)00 (3b)01 (4sa)00 (4sb)00 (4d)01 (5)11 (6)01 (7)05 (8a)01 (9)00 (11p)00," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",40,40,12, R0 D2,,6.06,3.55,2.09,126.0,212.0,2.63,15.8,12.0,129.0,79.0,18.9,4.1,1.03,75.7,317.32,43.3,32.4,6.2,5.84,58.0,347.0,,,,,,,,,,,,,3.26,11.73,61.81,,,, P0,H0,,,,,,,52.890932982917214,1326907
1320611,王占山,534070,男,68,T4a,N3a,M0, ⅢB,2,3,,,,,,7.0,23,中间型（int）,INFb,2.0,0.5,,,,,,,2013-07-18,2015-04-30,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, 小弯33 (1a)01 (1b)03 (2)00 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)17 (7)36 (6、14v)01 (7、8、9)02          ," L（幽门窦部）, M（胃体部）, LM 小弯侧Less,",60,40,10, R0 D2+,,6.78,3.86,2.4,101.7,296.0,4.03,12.9,20.0,171.0,86.0,20.8,6.87,1.81,64.4,158.21,37.6,26.8,4.2,5.89,72.0,305.0,,,,,,,,,,,,,134.2,5.68,2.39,,,, P0,H0,,,,,,,21.38633377135348,1320611
1436094,王志民,581814,男,52,T3,N1,M0, ⅡB,2,3,0.0,0.0,0.0,1.0,,1.0,45,硬型（sci）,INFa,2.0,,0.0,2.0,,,,2.0,2014-12-09,2020-04-14,1,,,口服替吉奥,,,,,,1, 管状腺癌（中分化【G2】【tub2】低分化（G3)(por) Lauren肠型,G3, (1a)01 (1b)01 (3a)05 (3b)00 (4sb)00 (4d)010 (5)00 (6)03 (7)114 (8a)03 (8p)02 (9)02 (11p)04 (12a)00,L（幽门窦部） 前Ant 小弯侧Less 后Post 大弯侧Gre  ,100,70,10, R0 D2,,9.07,6.18,2.1,95.0,231.0,4.66,18.0,18.0,85.0,63.0,5.0,7.72,3.37,55.0,118.0,35.0,20.0,4.9,3.6,51.0,200.0,61.7,41.0,18.2,2.25,0.2,5.1,30.3,1.5,0.44,0.916,5.49,84.5,0.942,6.82,25.47,,,, P0,H0,,,,,,,64.15900131406045,1436094
1425949,吴宝军,573250,男,57,T4b,N3b,M0, ⅢC,2,3,1.0,1.0,1.0,1.0,,26.0,37,中间型（int）,INFb,3.0,,0.0,0.0,,,,0.0,2014-09-09,2016-10-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80% 低粘附腺癌20% Lauren混合型,G3, (1a)11 (1b)23 (3a)25 (3b)01 (4sb)00 (4d)22 (5)00 (6)33 (7)34 (8a)55 (8p)01 (9)46 (11p)12 (12a)22 (14v)11 (19)01,胃癌 L（幽门窦部）M 后Post 小弯侧Less,45,40,12, R0 D2+,,5.96,3.31,2.06,104.7,348.0,2.35,27.0,30.0,150.0,64.0,23.0,9.23,3.58,75.0,283.0,42.0,33.0,4.9,3.6,82.0,446.0,,,,,,,,,,,,,1.56,63.06,2.0,,,, P0,H0,,,,,,,25.19710906701708,1425949
1318158,吴德臣,517014,男,69,T4a,N3a,M0, ⅢB,2,3,,1.0,1.0,0.0,,12.0,24,中间型（int）,INFc,1.0,0.8,,,,,,,2013-06-26,2015-03-12,2,,,,,,,,,0, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 粘液腺癌（muc） 乳头状癌（G1）（pap）,G3, 小湾35 (1a)33 (1b)11 (2)33 (3a)00 (3b)22 (4sa)01 (4sb)00 (4d)00 (5)00 (6)03 (7)01 (8a)01 (8p)02 (9)02 (11p)00 (14v)00 ," M（胃体部）, 小弯侧Less,",90,90,25, R0 D2,,5.74,3.48,1.63,104.0,249.0,3.61,11.0,15.0,176.0,70.0,18.0,6.89,1.01,60.0,198.0,33.0,27.0,6.6,5.6,77.0,272.0,,,,,,,,,,,,,4.48,10.47,165.1,,,, P0,H0,,,,,,,20.49934296977661,1318158
1437501,吴凤云,579413,男,78,T3,N2,M0, ⅢA,2,2,0.0,0.0,0.0,0.0,,3.0,12,硬型（sci）,INFa,1.0,,0.0,0.0,,,,0.0,2014-12-22,2020-04-14,1,,,,,,,,,0, 管状腺癌（低分化（G3)(por)中分化【G2】【tub2】 Lauren肠型,G3, (1a)00 (1b)00 (2)00 (3a)22 (3b)00 (4sb)00 (4d)00 (5)01 (6)01 (7)00 (8a) (8p)03 (9)02 (11p)00 (11d)00 (12a)11," M（胃体部）, 小弯侧Less,",30,28,5, R0 D2,,4.82,2.67,1.57,159.0,192.0,3.01,29.0,27.0,175.0,54.0,15.0,19.3,6.2,72.0,262.0,43.0,29.0,5.4,6.0,71.0,294.0,65.6,49.2,14.4,3.42,0.3,11.1,20.1,0.3,0.885,1.97,9.47,57.4,1.29,16.59,10.98,,,, P0,H0,,,,,,,63.73193166885677,1437501
1435887,吴永昌,363696,男,67,T3,N1,M0, ⅡB,2,2,0.0,0.0,0.0,1.0,,2.0,33,硬型（sci）,INFa,2.0,,0.0,2.0,,,,0.0,2014-12-08,2019-10-01,0,,,口服卡培他滨,,,,,,1, 管状腺癌（高分化【G1】【tub1】中分化【G2】【tub2】 Lauren肠型,G2, (1a)06 (1b)02 (2)02 (3a)210 (3b)01 (4sb)01 (4d)03 (6)00 (7)00 (8a)02 (9)02 (11p)03 (12a)01 (19)00," MU 后Post, 小弯侧Less,",30,25,5, R0 D2+,,5.45,3.55,1.39,141.4,191.0,3.08,21.0,22.0,145.0,80.0,13.0,9.05,4.2,64.0,237.0,38.0,26.0,4.6,6.1,76.0,317.0,72.5,45.6,20.9,2.18,0.5,9.2,14.9,3.5,1.97,1.07,9.92,39.5,1.1,8.89,33.39,,,, P0,H0,,,,,,,57.75295663600525,1435887
1334068,吴云龙,545816,男,67,T4b,N0,M0, ⅢA,2,1,,0.0,0.0,0.0,,0.0,16,硬型（sci）,INFa,0.0,0.6,,,,,,,2013-12-04,2019-04-20,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)00 (3a)01 (3b)04 (4sb)00 (4d)01 (5)00 (6)00 (7)00 (8a)01 (8p)02 (9)03 (11p)02," L（幽门窦部）, 后Post,",70,60,10, R0 D2,,4.74,2.53,1.34,125.0,230.0,2.63,13.0,18.0,155.0,71.0,24.0,10.62,6.25,56.9,211.3,37.5,19.4,5.0,7.0,90.0,224.0,,,,,,,,,,,,,1.74,3.66,6.7,,,, P0,H0,,,,,,,64.48751642575559,1334068
1323776,吴志海,537287,男,76,T4a,N1,M0, ⅢA,2,2,,0.0,0.0,0.0,,2.0,50,髓样型（med）,INFa,0.0,0.85,,,,,,,2013-08-19,2018-06-30,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)02 (2)04 (3a)02 (3b)08 (4sb)00 (4d)09 (5)29 (6)04 (7)04 (8a)04 (8p)01 (9)02 (11p)00," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",110,90,10, R0 D2,,9.92,6.41,2.49,79.0,481.0,4.43,9.1,14.0,162.0,82.0,18.6,9.33,2.82,69.4,153.01,36.5,32.9,6.8,5.53,70.0,312.0,,,,,,,,,,,,,1.13,2.95,1.86,,,, P0,H0,,,,,,,58.3442838370565,1323776
1316584,肖海峰,529974,男,76,T4b,N3a,M0, ⅢC,2,4,,0.0,0.0,1.0,,14.0,26,中间型（int）,INFc,0.0,0.6,,,,,,,2013-07-08,2013-11-11,2,,,,,,,,,0, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 ,G3, 小湾33 肿物旁12 (1a)01 (1b)11 (2)44 (3a)22 (3b)00 (4sb)00 (4d)11 (5)00 (6)02 (7)22 (8a)01 (11d)01 (12a)06," M（胃体部）, U（胃底部）, 前Ant, 后Post, 小弯侧Less,",60,50,8, R0 D2,,4.68,2.53,1.51,125.4,146.0,3.05,16.0,25.0,139.0,78.0,20.0,16.82,1.89,62.4,134.0,38.4,24.0,5.2,3.74,59.0,234.0,,,,,,,,,,,,,28.16,15.53,9.7,,,, P0,H0,,,,,,,4.139290407358739,1316584
1424579,肖景兰,570956,女,66,T3,N1,M0, ⅡB,2,4,0.0,,,,,2.0,31,髓样型（med）,INFa,2.0,,0.0,0.0,,,,2.0,2014-08-26,2015-08-01,2,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)03 (1b)04 (3a)26 (3b)00 (4sb)00 (4d)06 (5)02 (6)06 (7)02 (8a)00 (8p)01 (9)00 (11p)01,L（幽门窦部） 小弯侧Less 后Post 大弯侧Gre  前Ant ,50,45,12, R0 D2,,3.76,2.47,0.7,118.0,161.0,3.29,11.0,17.0,143.0,51.0,6.0,7.99,2.74,66.0,132.0,42.0,24.0,5.8,5.7,75.0,287.0,,,,,,,,,,,,,10.3,1.09,2.19,,,, P0,H0,,,,,,,11.169513797634691,1424579
1325195,肖志芳,539242,男,59,T3,N1,M0, ⅡB,2,3,,1.0,1.0,1.0,,1.0,67,中间型（int）,INFb,3.0,0.6,,,,,,,2013-09-02,2019-09-02,1,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】70% 乳头状癌（G1）（pap）30%,G2, (1a)01 (1b)17 (2)05 (3a)09 (3b)00 (4sa)04 (4sb)04 (4d)08 (5)02 (6)05 (7)03 (8a)05 (8p)00 (9)06 (11p)05 (12p)03 (12a)00," U（胃底部）, 小弯侧Less,",30,30,5, R0 D2,,6.81,4.17,2.15,152.0,127.0,2.73,11.1,15.0,162.0,168.0,123.8,10.64,2.51,73.3,338.12,45.9,27.4,5.1,5.5,70.0,379.0,,,,,,,,,,,,,10.14,5.46,4.02,,,, P0,H0,,,,,,,71.97766097240472,1325195
1336847,辛福全,550191,男,68,T3,N3a,M0,ⅢB,2,2,,1.0,1.0,1.0,,12.0,35,硬型（sci）,INFb,1.0,,,,,,,,2013-12-31,2014-11-01,2,,,XELOX,XELOX,XELOX,XELOX,口服卡培他滨,,5, 低分化管状腺癌（G3)(por),G3, (1a)00 (1b)00 (2)00 (3a)00 (3b)210 (4sa)01 (4sb)03 (4d)34 (5)14 (6)00 (7)(8a)(8p)(12a)35 (9)01 (11p)11 (14v)12," M（胃体部）, 大弯侧Gre,",60,60,10, R0 D2+,,5.96,3.63,1.63,69.0,418.0,3.43,19.0,24.0,137.0,70.0,13.0,11.15,4.02,63.0,217.0,40.0,23.0,4.7,5.2,71.0,194.0,,,,,,,,,,,,,1.65,4.96,6.433,,,, P0,H0,,,,,,,10.019710906701707,1336847
1415396,辛惠平,560792,女,56,T3,N2,M0, ⅢA,2,3,2.0,0.0,0.0,0.0,,4.0,20,硬型（sci）,INFc,0.0,,0.0,2.0,,,,0.0,2014-06-05,2019-09-01,1,,,SOX,SOX,SOX,SOX,SOX,SOX,7, 低粘附腺癌60% 低分化管状腺癌（G3)(por)40% Lauren弥漫型,G3, (1a)00 (1b)04 (3a)23 (3b)00 (4sb)00 (4d)12 (5)00 (6)03 (7)00 (8a)12 (8p)05 (9)00 (11p)01 (12a)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,10, R0 D2,,9.69,6.06,3.06,130.0,366.0,3.97,16.0,17.0,157.0,102.0,16.0,14.82,4.86,73.0,323.0,41.0,32.0,5.2,3.4,91.0,310.0,,,,,,,,,,,,,0.842,6.28,0.92,,,, P0,H0,,,,,,,62.877792378449406,1415396
1429454,辛颜权,574039,男,67,T3,N3b,M0, ⅢC,2,5,2.0,1.0,1.0,1.0,,41.0,46,硬型（sci）,INFc,1.0,,2.0,0.0,,,,0.0,2014-10-13,2016-08-15,2,,,FOLFOX,FOLFOX,FOLFOX,SOX,奥沙利铂+雷替曲塞,口服卡培他滨,6, 低黏附腺癌95% 粘液腺癌（muc）5,GX," (1a)22 (1b)89 (2)36 (3a)33 (3b)11 (4sa)00 (4sb)00 (4d)77 (5)(12a)00 (6)56 (7)(8a)(9)88 (8p)(12p)11 (11p)22 (14v)11 软组织可见癌3a,3b"," M（胃体部）,  前Ant, 后Post, 小弯侧Less,",100,90,8, R0 D2+,,4.93,2.36,1.92,130.5,193.0,3.52,16.0,17.0,136.0,72.0,11.0,10.2,3.33,59.0,189.0,38.0,21.0,5.5,6.3,97.0,344.0,,,,,,,,,,,,,2.88,17.95,1.57,,,, P0,H0,,,,,,,22.07621550591327,1429454
1401318,邢桂英,545531,女,55,T3,N3a,M0,ⅢB,2,3,,1.0,1.0,1.0,,10.0,26,硬型（sci）,INFc,1.0,0.8,,,,,,,2014-01-14,2020-09-08,1,,,SOX,SOX,SOX,SOX,SOX,口服替吉奥,6, 低分化管状腺癌（G3)(por)95% 低粘附腺癌5%,G3, (1a)12 (1b)01 (3a)12 (3b)22 (4sb)11 (4d)13 (5)02 (6)45 (7)01 (8p)02 (8a)00 (9)01 (11p)04 (12a)00," L（幽门窦部）, 小弯侧Less,",50,35,5, R0 D2,,4.69,2.68,1.49,140.0,166.0,2.48,12.1,8.0,182.0,114.0,15.1,3.69,8.52,70.0,207.64,42.9,27.1,5.6,6.29,65.0,220.0,,,,,,,,,,,,,0.364,5.68,1.62,,,, P0,H0,,,,,,,79.79632063074901,1401318
1429470,徐振国,574701,男,43,T4b,N3a,M0, ⅢC,2,3,2.0,1.0,1.0,1.0,,9.0,37,髓样型（med）,INFc,1.0,,0.0,0.0,,,,0.0,2014-10-13,2016-07-18,2,,,SOX,SOX,SOX,SOX,SOX,,5, 低黏附腺癌90% 黏液腺癌（muc）10% Lauren弥漫型,GX, (1a)02 (1b)02 (2)13 (3a)45 (3b)00 (4sb)00 (4d)36 (5)00 (6)15 (7)02 (8a)03 (8p)03 (9)01 (10)02 (11d)00 (11p)01 (12a)01 (14v)00 (19)01  (3b、4sb、10)软组织均见癌," LMU 前Ant, 后Post, 小弯侧Less,",70,60,10, R0 D2+,,3.95,1.78,1.82,117.0,313.0,2.41,26.0,26.0,148.0,104.0,57.0,9.51,3.69,67.0,193.0,45.0,22.0,5.0,5.8,82.0,320.0,69.9,48.4,16.3,2.97,0.1,9.7,19.0,1.0,0.633,3.31,10.8,5.0,0.93,6.28,1.44,,,, P0,H0,,,,,,,21.156373193166885,1429470
1320464,许会娟,534557,女,66,T4a,N1,M0, ⅢA,2,3,,0.0,0.0,0.0,,1.0,20,中间型（int）,INFc,0.0,0.5,,,,,,,2013-07-17,2019-05-15,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)01 (3a)06 (4sb)00 (4d)14 (5)00 (6)03 (7)02 (8a、8p)02 (9)01 (11p)00 (11a)00," L（幽门窦部）, 小弯侧Less,",70,60,20, R0 D2,,11.54,7.69,2.9,111.2,430.0,4.03,9.0,12.0,171.0,63.0,12.0,7.95,1.4,57.2,194.0,35.2,22.0,5.2,4.44,50.0,293.0,,,,,,,,,,,,,2.53,8.59,21.71,,,, P0,H0,,,,,,,69.90801576872536,1320464
1432708,许丽娜,579638,女,28,T4a,N2,M0, ⅢA,2,3,2.0,1.0,1.0,1.0,,3.0,23,中间型（int）,INFc,0.0,,0.0,0.0,,,,0.0,2014-11-10,2016-08-07,2,,,XELOX,XELOX,,,,,2, 低黏附腺癌 低分化腺癌（G3)(por) Lauren弥漫型,G3, (1a)01 (1b)03 (3a)00 (3b)00 (4sb)02 (4d)02 (5)24 (6)13 (7)01 (8a)03 (8p)04 (11p)00,L（幽门窦部） 前Ant 后Post 小弯侧Less  ,35,30,15, R0 D2,,5.91,3.16,2.24,97.6,253.0,2.45,21.0,22.0,126.0,48.0,16.0,9.39,3.76,71.0,281.0,44.0,27.0,5.3,7.3,62.0,289.0,78.7,35.2,35.5,0.99,0.1,10.7,9.9,0.2,1.17,2.05,11.5,5.0,0.545,6.62,1.3,,,, P0,H0,,,,,,,20.893561103810775,1432708
1327870,许兆华,542036,男,62,T4b,N3b,M0, ⅢC,2,4,,1.0,1.0,1.0,,18.0,31,髓样型（med）,INFc,,,,,,,,,2013-09-30,2014-12-03,2,,,奥沙利铂+替加氟,奥沙利铂+替加氟,奥沙利铂+替加氟,奥沙利铂+替加氟,奥沙利铂+替加氟,奥沙利铂+替加氟,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80%  低粘附腺癌20%,G3, (1a)13 (1b)11 (2)33 (3a)910 (3b)00 (4sa)01 (4sb)22 (4d)13 (5)01 (6)02 (7)11 (8a)02 (8p)00 (9)01 (11p)01 (11d)00 (12a)00 (19)00," UM 小弯侧Less, 前Ant, 后Post, 大弯侧Gre,",45,30,8, R0 D2+,,3.62,1.6,1.32,123.0,180.0,3.28,11.0,25.0,125.0,69.0,9.0,6.32,2.14,72.0,176.0,39.0,33.0,4.7,5.9,59.0,288.0,,,,,,,,,,,,,1.47,5.11,1.22,,,, P0,H0,,,,,,,14.09329829172142,1327870
1317167,宣兆龙,530147,男,52,T4a,N2,M0, ⅢA,2,3,,0.0,0.0,0.0,,3.0,21,硬型（sci）,INFb,0.0,0.8,,,,,,,2013-06-17,2017-03-04,2,,,,,,,,,0, 粘液腺癌（muc） 印戒细胞癌(sig),GX, (1a)01 (1b)01 (3a)01 (3b)00 (4d)02 (5)00 (6)38 (7)02 (8a)02 (8p)00 (9)01 (11p)03, L（幽门窦部） 小弯侧Less 前Ant 后Post ,65,65,10, R0 D2,,7.06,3.74,2.86,134.0,269.0,3.53,20.0,18.0,177.0,95.0,29.0,8.18,0.58,74.1,246.2,43.1,31.0,5.1,9.97,70.0,393.0,,,,,,,,,,,,,1.27,6.59,56.39,,,, P0,H0,,,,,,,44.546649145860705,1317167
1331613,闫吉利,544061,男,71,T4b,N0,M0, ⅢA,2,1,,1.0,1.0,0.0,,0.0,22,中间型（int）,INFb,1.0,0.6,,,,,,,2013-11-12,2016-06-01,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap）,G2, (1a)00 (1b)03 (2)00 (3a)02 (3b)01 (4sb)02 (4d)01 (5)00 (6)01 (7)02 (8a)04 (8p)01 (12a)00 (14v)01 (19)03," M（胃体部）, 后Post, 大弯侧Gre, 小弯侧Less,",95,60,10, R0 D2+,,15.1,12.39,1.45,123.1,200.0,1.81,5.0,14.0,156.0,107.0,34.0,9.1,2.46,52.0,182.0,37.0,15.0,3.8,8.8,54.0,159.0,,,,,,,,,,,,,2.86,6.5,1.81,,,, P0,H0,,,,,,,30.617608409986858,1331613
1415493,阎祥,564026,男,72,T3,N1,M0, ⅡB,2,3,0.0,1.0,1.0,0.0,,1.0,11,中间型（int）,INFb,0.0,,0.0,0.0,,,,1.0,2014-06-05,2014-11-20,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (2)01 (3a)02 (3b)00 (4sb)02 (4d)01 (5)00 (6)11 (7)00 (8a)01 (8p)00 (9)00 (11p)02 (12a)01 (12p)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,35,10, R0 D2,,5.75,3.48,1.6,163.0,286.0,2.66,16.0,19.0,188.0,69.0,17.0,20.7,6.3,73.0,237.0,43.0,30.0,5.4,7.1,104.0,378.0,,,,,,,,,,,,,1.16,10.91,2.87,,,, P0,H0,,,,,,,5.519053876478318,1415493
1418309,杨锦,563037,男,65,T3,N2,M0, ⅢA,2,4,1.0,0.0,0.0,1.0,,3.0,30,中间型（int）,INFc,,,0.0,0.0,,,,2.0,2014-07-01,2015-10-14,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低粘附腺癌90 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10,G3, (1a)00 (1b)01 (2)00 (3a)07 (3b)16 (4sa)02 (4sb)00 (4d)02 (5)00 (6)01 (7)11 (8a)01 (8p)03 (9)01 (10)00 (11p)04 (11d)00 (12a)00 (14v)00," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",52,45,7, R0 D2+,,11.54,7.64,3.3,141.8,251.0,3.46,,,,77.0,26.0,,,,256.0,45.0,29.0,,,,,,,,,,,,,,,,,2.9,6.5,4.25,,,, P0,H0,,,,,,,15.440210249671484,1418309
1432726,杨宪宏,579136,女,41,T4a,N2,M0, ⅢA,2,3,0.0,1.0,1.0,1.0,,3.0,41,中间型（int）,INFa,2.0,,0.0,0.0,,,,0.0,2014-11-10,2016-07-31,2,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,6, 管状腺癌（中分化【G2】【tub2】70% 粘液腺癌（muc）30% Lauren肠型,G2, (1a)02 (1b)03 (3a)07 (3b)00 (4sb)00 (4d)22 (5)01 (6)06 (7)19 (8a)01 (11p)010," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,45,20, R0 D2,,9.0,6.55,1.61,103.0,319.0,3.14,9.0,13.0,118.0,56.0,7.0,9.86,4.15,60.0,171.0,40.0,20.0,3.7,4.6,69.0,194.0,59.7,36.3,12.5,2.9,0.0,15.7,18.9,0.9,1.02,1.4,10.4,15.5,0.809,46.85,0.947,,,, P0,H0,,,,,,,20.66360052562418,1432726
1319098,杨晓春,533536,男,50,T4a,N3b,M0, ⅢC,2,4,,0.0,0.0,1.0,,27.0,74,中间型（int）,INFc,0.0,0.8,,,,,,,2013-07-04,2014-07-10,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, 小弯1018 (1a、1b、3a、3b、7)36 (2)11 (4sa、4sb)912 (4d)418 (5、12)00 (6)09(8a)01 (8p)03 (9)03 (14v)02 (11p)01   ," M（胃体部）, 前Ant,",35,20,5, R0 D2+,,5.23,1.89,2.82,138.0,167.0,2.1,14.0,14.0,157.0,69.0,18.0,32.16,6.51,69.3,190.1,42.3,27.0,4.5,5.13,77.0,290.0,,,,,,,,,,,,,0.705,3.46,1.18,,,, P0,H0,,,,,,,12.187910643889618,1319098
1436353,杨秀兰,583161,女,69,T3,N0,M0, ⅡA,2,4,0.0,1.0,1.0,1.0,,0.0,10,硬型（sci）,INFa,2.0,,0.0,2.0,,,,2.0,2014-12-11,2017-03-09,2,,,,,,,,,0, 低分化管状腺癌（G3)(por) Lauren肠型,G3, (1a)0/2 (1b)0/1 (2)0/2 (3a)0/0 (3b)0/0 (4sb)0/0 (4d)0/0 (5)00 (6)0/0 (7)0/0 (8a)0/1 (8p)0/3 (9)0/2 (11p)0/0 (12a)0/0 (14v)0/0," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,23,2, R0 D2,,7.44,2.52,4.08,137.0,183.0,2.39,21.0,29.0,162.0,76.0,12.0,10.92,3.58,80.0,253.0,44.0,36.0,5.9,5.5,56.0,212.0,79.1,26.8,48.0,0.56,0.2,6.9,12.1,6.8,1.04,2.07,15.2,25.6,0.427,14.99,1.2,,,, P0,H0,,,,,,,26.905387647831798,1436353
1434753,杨洋,581871,男,23,T4a,N2,M0, ⅢA,2,3,0.0,1.0,1.0,1.0,,3.0,19,硬型（sci）,INFa,1.0,,0.0,1.0,,,,0.0,2014-11-27,2018-01-10,2,,,,,,,,,0, 低分化腺癌（G3)(por)40% 低黏附腺癌30% 粘液腺癌（muc）30 Lauren肠型,G3, (1a)00 (1b)03 (3a)26 (3b)00 (4sb)00 (4d)16 (5)00 (6)00 (7)01 (8a)01 (8p)01 (9)00 (11p)01 (12a)00,M（胃体部） 前Ant ,70,50,20, R0 D2,,4.63,1.97,1.98,155.3,233.0,2.28,18.0,25.0,145.0,72.0,7.0,5.6,2.58,59.0,209.0,36.0,23.0,4.4,5.3,82.0,415.0,,,,,,,,,,,,,0.899,5.18,3.69,,,, P0,H0,,,,,,,37.450722733245726,1434753
1323979,杨长友,536320,男,78,T4a,N2,M0, ⅢA,2,4,,0.0,0.0,0.0,,4.0,25,硬型（sci）,INFc,0.0,0.05,,,,,,,2013-08-21,2019-05-15,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)34 (3a)00 (3b)00 (4sb)00 (4d)04 (5)00 (6)19 (7)00 (8a)02 (8p)01 (9)01 (11p)02 (12a)01 ," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,35,10, R0 D2,,7.11,4.05,2.46,148.0,141.0,2.89,36.0,34.0,222.0,67.0,24.0,14.89,3.39,72.0,241.1,52.2,29.8,5.4,7.53,68.0,293.0,,,,,,,,,,,,,3.27,18.34,4.18,,,, P0,H0,,,,,,,68.75821287779237,1323979
1328985,姚义元,541817,男,69,T4a,N1,M0, ⅢA,2,2,,0.0,0.0,1.0,,2.0,8,中间型（int）,INFb,1.0,0.4,,,,,,,2013-10-17,2014-12-24,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化（G3)(por) 粘液腺癌（muc）,G3, (1a)00 (1b)11 (2)00 (3a)11 (3b)00 (4sa)00 (4sb)00 (6)00 (7)01 (8a)01 (8p)01 (9)00 (11p)03 (19)00 ," U（胃底部）, 前Ant, 后Post, 大弯侧Gre,",60,50,10, R0 D2+,,12.84,9.23,2.29,75.0,256.0,3.85,9.3,15.0,103.0,53.0,17.6,6.9,2.09,52.7,243.96,32.7,20.0,7.5,14.82,294.0,453.0,,,,,,,,,,,,,59.04,7.66,7.36,,,, P0,H0,,,,,,,14.224704336399475,1328985
1431154,于明志,578026,男,71,T4a,N3a,M0, ⅢB,2,5,1.0,1.0,1.0,1.0,,9.0,13,髓样型（med）,INFb,0.0,,0.0,2.0,,,,0.0,2014-10-28,2018-11-17,2,,,,,,,,,0, 低黏附腺癌 80% 管状腺癌（中分化【G2】【tub2】20% Lauren混合型,G2, (1a)11 (1b)02 (3a)11 (3b)11 (4sb)00 (4d)软组织 (5)11 (6)11 (7)35 (8a)11 (9)00 (11p)00 (12a)00 (14v)00 3 6软组织内可见4枚癌结节可见癌 4d软组织内可见癌, 胃癌 L（幽门窦部） 前Ant ,130,100,20, R0 D2+,,7.1,4.93,1.66,145.5,296.0,4.1,20.0,27.0,128.0,68.0,13.0,9.29,4.35,59.0,200.0,35.0,24.0,5.5,9.2,78.0,198.0,,,,,,,,,,,,,1.1,5.44,71.17,,,, P0,H0,,,,,,,48.65308804204993,1431154
1400776,于培刚,549989,男,58,T2,N2,M0, ⅡB,2,1,,1.0,1.0,0.0,,6.0,95,,,2.0,,,,,,,,2014-01-09,2019-10-01,1,,,SOX,SOX,SOX,SOX,SOX,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)05 (1b)05 (3a)010 (3b)217 (4sb)04 (4d)016 (5)37 (6)114 (7)01 (8a)01 (8p)01 (9)04 (11p)08 (12p)01 (14v)01," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,10, R0 D2+,,5.12,2.89,1.65,117.6,192.0,2.28,13.0,30.0,109.0,51.0,8.0,11.31,5.13,55.0,203.0,33.0,22.0,5.5,4.9,74.0,202.0,,,,,,,,,,,,,1.06,3.7,10.56,,,, P0,H0,,,,,,,68.69250985545335,1400776
1321512,于胜权,534753,男,56,T4b,N3a,M0, ⅢC,2,3,,1.0,1.0,0.0,,7.0,16,中间型（int）,INFc,2.0,0.6,,,,,,,2013-07-26,2014-12-04,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, 大弯26 小湾510," M（胃体部）, 后Post, 小弯侧Less,",40,30,10, R0 D2,,8.09,5.16,2.21,125.1,288.0,5.44,20.0,8.0,149.0,68.0,30.0,7.14,0.62,64.0,195.0,35.0,29.0,,3.63,65.0,253.0,,,,,,,,,,,,,5.29,893.1,3.58,,,, P0,H0,,,,,,,16.294349540078844,1321512
1323011,于树财,536232,男,57,T1b,N3a,M0, ⅡB,2,2,,,,,,11.0,16,,,3.0,,,,,,,,2013-08-12,2016-06-18,0,,,SOX,,,,,,1, 低分化腺癌（G3)(por),G3, (1a)01 (1b)01 (2)00 (3a)11 (3b)12 (4sa)00 (4sb)00 (4d)22 (5)00 (6)33 (7)00 (8p)46 (11d)00," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",35,30,8, R0 D2,,3.5,2.2,1.0,126.9,196.0,2.49,11.0,25.0,265.0,59.0,22.0,11.13,1.83,68.0,270.0,43.0,25.0,5.4,5.9,78.0,321.0,,,,,,,,,,,,,0.746,5.27,9.29,,,, P0,H0,,,,,,,34.19842312746386,1323011
1415151,于占文,563086,男,53,T4a,N3a,M0, ⅢB,2,3,1.0,1.0,1.0,1.0,,8.0,25,中间型（int）,INFc,0.0,,0.0,1.0,,,,0.0,2014-06-03,2016-05-29,2,,,奥沙利铂+替加氟,奥沙利铂+替加氟,,,,,2, 低粘附腺癌 70% 粘液腺癌（muc）30%,GX, (1a)(1b)01 (2)00 (3a)22 (3b)00 (4sa)01 (4sb)57 (4d)01 (5)00 (6)01 (7)00 (8a)01 (8p)02 (9)19 (11p)00 (12a)00, UM SiewerⅢ型 后Post 小弯侧Less ,60,50,18, R0 D2,,6.03,3.23,2.12,121.3,288.0,4.32,12.0,15.0,102.0,60.0,29.0,8.34,2.62,64.0,197.0,38.0,26.0,4.8,6.3,69.0,356.0,,,,,,,,,,,,,0.644,13.05,8.46,,,, P0,H0,,,,,,,23.850197109067015,1415151
1412693,于长祯,561918,男,57,T3,N3a,M0,ⅢB,2,4,1.0,0.0,0.0,1.0,,13.0,45,中间型（int）,INFc,0.0,,0.0,0.0,,,,,2014-05-08,2019-10-01,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 60% 低粘附腺癌40%,G3, (1a)(1b)(7)012 (3a)(3b)35 (4sb)00 (4d)27 (5)11 (6)66 (7)03 (8a)13 (8p)(9)02 (11p)03 (12a)00 (14v)00 (16a1)03, L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre  ,40,30,10, R0 D2+,,3.87,1.88,1.62,141.0,245.0,1.93,40.0,24.0,121.0,108.0,15.0,6.46,7.41,72.0,250.0,43.0,29.0,4.7,5.8,88.0,301.0,,,,,,,,,,,,,2.44,87.42,1.17,,,, P0,H0,,,,,,,64.7831800262812,1412693
1427508,于哲财,575332,男,61,T4b,N1,M0, ⅢB,2,3,0.0,1.0,1.0,1.0,,1.0,24,髓样型（med）,INFa,1.0,,0.0,0.0,,,,2.0,2014-09-24,2019-10-01,1,,,口服卡培他滨,,,,,,1, 管状腺癌（低分化（G3)(por)中分化【G2】【tub2】 Lauren肠型,G3, (1a)02 (1b)02 (3a)13 (3b)01 (4sb)00 (4d)02 (5)00 (6)01 (7)03 (8a)01 (8p)03 (9)03 (11p)03,胃癌 L（幽门窦部） 前Ant 后Post 小弯侧Less,40,35,5, R0 D2,,9.2,5.98,2.52,156.4,268.0,3.06,10.0,20.0,139.0,95.0,21.0,16.03,5.81,73.0,238.0,50.0,23.0,6.0,8.4,90.0,340.0,,,,,,,,,,,,,2.38,12.0,4.67,,,, P0,H0,,,,,,,60.21681997371879,1427508
1420692,张德军,569096,男,51,T3,N3b,M0, ⅢC,2,1,0.0,0.0,0.0,0.0,,19.0,30,中间型（int）,INFa,0.0,,0.0,0.0,,,,1.0,2014-07-23,2017-09-02,2,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】60% 低粘附腺癌40%,G2, (1a)11 (1b)01 (3a)88 (3b)01 (4sb)01 (4d)01 (5)00 (6)02 (7)04 (8a)(8p)11 (9)99 (14v)01," L（幽门窦部）, 前Ant,",90,60,50, R0 D2+,,4.68,2.86,1.27,69.0,239.0,2.44,18.0,17.0,129.0,42.0,10.0,7.94,1.95,46.0,411.0,27.0,19.0,5.9,5.8,71.0,213.0,,,,,,,,,,,,,0.73,4.07,1.07,,,, P0,H0,,,,,,,37.352168199737186,1420692
1416608,张德祥,565378,男,78,T3,N3b,M0, ⅢC,2,4,0.0,0.0,0.0,1.0,,20.0,41,中间型（int）,INFb,1.0,,0.0,0.0,,,,1.0,2014-06-16,2015-10-06,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】）80% 乳头状癌（G1）（pap）20%,G1, (1a)02 (1b)00 (3a)33 (3b)11 (4sb)01 (4d)29 (5)00 (6)67 (7)11 (8a)12 (8p)11 (9)24 (11p)22 (12a)00 (14v)18 (19)00," LM 前Ant, 后Post, 小弯侧Less,",60,40,8, R0 D2+,,3.99,2.57,0.97,133.0,164.0,3.29,14.0,18.0,147.0,66.0,29.0,5.56,6.44,56.0,162.0,35.0,21.0,4.8,7.0,76.0,358.0,,,,,,,,,,,,,1.1,69.83,2.29,,,, P0,H0,,,,,,,15.670170827858081,1416608
1421534,张凤有,569758,男,71,T3,N3a,M0,ⅢB,2,5,1.0,0.0,0.0,0.0,,8.0,20,中间型（int）,INFa,1.0,,0.0,0.0,,,,2.0,2014-07-30,2015-07-01,2,,,,,,,,,0, 管状腺癌（低分化（G3)(por) 中分化【G2】【tub2】 Lauren肠型,G3, (1a)02 (1b)04 (3a)35 (3b)00 (4sb)00 (4d)11 (5)11 (6)11 (7)01 (8p)02 (8a)01 (9)22 3a软组织内可见癌," L（幽门窦部）, 前Ant, 后Post,  小弯侧Less,",40,30,16, R0 D2,,12.7,7.88,3.21,106.0,486.0,5.38,24.0,22.0,133.0,88.0,37.0,7.03,2.06,76.0,259.0,38.0,38.0,6.6,7.0,83.0,424.0,,,,,,,,,,,,,2.22,53.04,3.85,,,, P0,H0,,,,,,,11.038107752956636,1421534
1323013,张桂荣,536464,女,71,T4a,N2,M0, ⅢA,2,3,,1.0,1.0,0.0,,6.0,28,中间型（int）,INFb,1.0,0.5,,,,,,,2013-08-12,2014-02-05,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 乳头状癌（G1）（pap）,G3, (1a)(1b)010 (3a)(3b)05 (4sb)(4d)27 (5)(12a)00 (6)11 (7)(8a)(8p)(9)(11p)35," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,25, R0 D2,,5.99,3.74,1.73,137.3,250.0,2.95,15.0,28.0,219.0,58.0,19.0,7.35,2.26,78.1,181.6,46.3,31.8,5.1,9.8,65.0,164.0,,,,,,,,,,,,,8.29,1000.0,11.78,,,, P0,H0,,,,,,,5.814717477003942,1323013
1423982,张继双,571161,男,51,T3,N3a,M0,ⅢB,2,4,1.0,0.0,0.0,0.0,,10.0,32,中间型（int）,INFa,1.0,,0.0,0.0,,,,0.0,2014-08-20,2019-10-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60% 低粘附腺癌40%,G3, (1a)01 (1b)58 (2)11 (3a)01 (3b)00 (4sa)00 (4sb)11 (4d)22 (5)01 (6)05 (7)17 (8a)01 (9)02 (11p)01 (12a)01," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,50,8, R0 D2,,5.12,2.87,1.84,130.5,218.0,2.41,21.0,21.0,134.0,44.0,11.0,8.52,2.87,65.0,337.0,39.0,26.0,5.1,4.7,72.0,208.0,,,,,,,,,,,,,1.9,5.1,7.35,,,, P0,H0,,,,,,,61.366622864651774,1423982
1418916,张建国,567015,男,46,T4b,N1,M0, ⅢB,2,2,1.0,0.0,0.0,1.0,,1.0,28,中间型（int）,INFc,0.0,,0.0,1.0,,,,0.0,2014-07-07,2019-10-01,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低分化管状腺癌（G3)(por)50% 低粘附腺癌40% 粘液腺癌（muc）10%,G3, 小弯01 (1a)01 (1b)00 (2)00 (3a)14 (3b)04 (4sb)00 (4d)02 (5)01 (6)03 (7)04 (8a)02 (8p)02 (9)01 (11p)01 (12a)00 (12b)00 (12p)01 (14v)01 (14a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,40,9, R0 D2+,,7.53,2.99,3.59,167.0,198.0,3.01,13.0,17.0,123.0,71.0,19.0,16.75,6.7,77.0,250.0,44.0,33.0,4.8,8.2,96.0,380.0,,,,,,,,,,,,,0.834,7.2,5.9,,,, P0,H0,,,,,,,62.81208935611038,1418916
1425485,张俊才,572073,男,74,T4a,N2,M0, ⅢA,2,5,1.0,0.0,0.0,1.0,,5.0,33,髓样型（med）,,1.0,,0.0,0.0,,,,2.0,2014-09-03,2015-12-03,2,,,,,,,,,0, 粘液腺癌（muc）,GX, (1a)01 (1b)37 (2)00 (3a)13 (3b)02 (4sa)01 (4sb)04 (5)00 (7)02 (8a)05 (8p)01 (9)01 (10)00 (11p)04 (11b)00 (12a)11 (12p)01,胃癌 U（胃底部） SiewerⅢ型 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,45,8, R0 D2,,6.37,4.15,1.69,127.1,152.0,2.96,17.0,21.0,145.0,75.0,15.0,8.2,3.08,71.0,234.0,47.0,24.0,6.3,4.6,81.0,274.0,,,,,,,,,,,,,18.19,577.4,1.62,,,, P0,H0,,,,,,,14.98028909329829,1425485
1433571,张明杰,579970,女,60,T4a,N3b,M0, ⅢC,2,3,1.0,1.0,1.0,1.0,,28.0,31,中间型（int）,INFa,0.0,,0.0,2.0,,,,0.0,2014-11-18,2015-07-01,2,,,,,,,,,0, 低分化管状腺癌（G3)(por)75% 低黏附腺癌 25% Lauren肠型,G3, (1a)00 (1b)00 (3a)01 (3b)44 (4sb)00 (4d)67 (5)00 (6)55 (7)44 (8a)(8p)11 (9)33 (11p)11 (12a)00 (14v)00 小弯45,L（幽门窦部） 小弯侧Less 前Ant 后Post ,65,60,10, R0 D2+,,6.69,3.88,2.0,83.8,483.0,5.44,8.0,12.0,140.0,77.0,7.0,9.31,3.01,63.0,201.0,41.0,22.0,7.2,3.8,79.0,257.0,73.1,33.9,25.9,1.31,0.1,9.3,16.6,1.2,0.679,1.66,9.61,15.3,0.526,6.71,7.6,,,, P0,H0,,,,,,,7.391590013140604,1433571
1411169,张儒志,560083,男,66,T4b,N0,M0, ⅢA,2,3,0.0,0.0,0.0,0.0,,0.0,17,中间型（int）,INFc,0.0,,,,,,,,2014-04-23,2019-04-22,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)02 (3b)05 (4sb)01 (4d)00 (5)01 (6)01 (7)02 (8a)(8p)02 (9)03 (12a)00   , G 前Ant 小弯侧Less 后Post ,35,30,10, R0 D2,,5.64,4.3,0.9,98.9,175.0,2.73,26.0,26.0,146.0,67.0,12.0,9.36,3.67,64.0,183.0,41.0,23.0,6.1,7.0,83.0,190.0,,,,,,,,,,,,,1.15,28.04,2.96,,,, P0,H0,,,,,,,59.95400788436268,1411169
1332488,张书朋,544808,女,65,T4a,N3a,M0, ⅢB,2,3,,0.0,0.0,1.0,,10.0,31,中间型（int）,INFc,1.0,0.1,,,,,,,2013-11-19,2019-08-14,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (3a)02 (3b)01 (4sb)00 (4d)46 (5)00 (6)37 (7)13 (8a)24 (8p)01 (9)04 (11p)02 (12a)01 (12p)00 (14v)00," L（幽门窦部）, 后Post,",50,40,8, R0 D2+,,7.67,5.26,1.9,134.0,354.0,3.07,7.0,22.0,194.0,66.0,5.0,8.81,1.54,66.0,244.0,37.0,21.0,5.2,5.3,65.0,242.0,,,,,,,,,,,,,0.744,9.6,3.21,,,, P0,H0,,,,,,,68.79106438896189,1332488
1335261,张淑媛,547957,女,72,T4a,N1,M0, ⅢA,2,3,,0.0,0.0,1.0,,1.0,25,硬型（sci）,INFc,0.0,,,,,,,,2013-12-16,2019-04-13,1,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a)00 (1b)00 (3a)13 (3b)03 (4sb)01 (4d)04 (5)03 (6)01 (7)02 (8a)01 (8p)01 (9)00 (11p)04 (12a)01 (12b)01," L（幽门窦部）, 前Ant, 小弯侧Less,",55,60,8, R0 D2+,,6.88,5.05,1.1,60.0,238.0,3.46,15.0,14.0,131.0,44.0,9.0,3.91,1.2,57.0,170.0,30.0,27.0,8.6,4.4,76.0,338.0,,,,,,,,,,,,,0.916,5.64,2.48,,,, P0,H0,,,,,,,63.86333771353482,1335261
1336828,张万海,545399,男,64,T3,N2,M0, ⅢA,2,2,,0.0,0.0,1.0,,5.0,38,硬型（sci）,INFc,0.0,,,,,,,,2013-12-31,2019-09-30,1,,,XELOX,XELOX,,,,,2, 印戒细胞癌(sig),GX, (1a)06 (1b)03 (3a)17 (3b)15 (4sb)00 (4d)18 (5)01 (6)00 (7)01 (8a)04 (8p)01 (9)01 (11p)01 (12a)00 (14v)00," LM 后Post,",80,80,10, R0 D2+,,8.47,4.66,2.78,122.1,280.0,3.51,10.3,13.0,137.0,78.0,22.0,13.46,2.5,64.2,157.83,37.8,26.4,5.0,5.15,87.0,275.0,,,,,,,,,,,,,4.03,3.38,1.13,,,, P0,H0,,,,,,,68.95532194480946,1336828
1425937,张文武,573203,男,61,T3,N1,M0, ⅡB,2,3,2.0,1.0,1.0,1.0,,1.0,32,中间型（int）,INFc,1.0,,0.0,0.0,,,,2.0,2014-09-09,2019-10-01,1,,,口服替吉奥,,,,,,1, 低粘附腺癌,GX, (1a)06 (1b)03 (2)06 (3a)06 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)00 (6)00 (7)02 (8a)00 (8p)01 (9) 02(11p)01 (12a)01,M（胃体部） 小弯侧Less ,65,50,13, R0 D2,,7.74,4.72,2.34,171.1,229.0,3.86,31.0,30.0,160.0,155.0,42.0,6.33,1.82,69.0,377.0,41.0,28.0,21.6,7.7,75.0,237.0,,,,,,,,,,,,,3.53,25.85,13.35,,,, P0,H0,,,,,,,60.709592641261494,1425937
1327044,张晓影,540307,女,38,T3,N2,M0, ⅢA,2,3,,0.0,0.0,1.0,,4.0,15,中间型（int）,INFb,1.0,0.3,,,,,,,2013-09-23,2014-11-20,2,,,DP,DP,DP,DP,DP,DP,6, 低粘附腺癌60% 低分化腺癌（G3)(por)40%,G3, (1a)01 (1b)00 (3a)24 (3b)12 (4sb)00 (4d)00 (5)01 (6)02 (7)12 (8a)00 (9)01 (12p)02," L（幽门窦部）, 小弯侧Less,",45,45,10, R0 D2,,4.61,2.07,2.25,114.0,218.0,2.2,9.3,9.0,125.0,71.0,17.1,5.96,1.26,67.1,211.85,40.8,26.3,5.7,4.71,41.0,205.0,,,,,,,,,,,,,0.757,13.18,13.18,,,, P0,H0,,,,,,,13.896189224704337,1327044
1319944,张永芝,533083,女,63,T4a,N3b,M1, Ⅳ,2,4,,1.0,1.0,0.0,,19.0,22,硬型（sci）,INFc,0.0,0.2,,,,,,,2013-07-11,2015-07-15,2,,,,,,,,,0, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)00 (1b)00 (3a)23 (3b)11 (4sb)01 (4d)11  (5)00 (6)88 (7)00 (8a)22 (8p)22 (9)33 (11p)01    ," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,10,,R2,9.56,6.76,1.84,120.0,190.0,2.34,10.0,14.0,187.0,50.0,10.0,9.92,2.78,60.0,171.0,37.0,23.0,4.4,4.3,54.0,107.0,,,,,,,,,,,,,6.13,108.1,16.42,,,, P0,H0,,,,,,,24.113009198423125,1319944
1431892,张玉军,573879,男,51,T2,N0,M0, ⅠB,2,2,0.0,0.0,0.0,1.0,,0.0,41,中间型（int）,INFa,1.0,,0.0,0.0,,,,2.0,2014-11-03,2020-04-16,1,,,SOX,SOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)01 (1b)00 (3a)015 (3b)00 (4sb)00 (4d)07 (5)00 (6)06 (7)04 (8a)01 (8p)01 (9)01 (11p)05 (12a)00 (12p)00," L（幽门窦部）, 小弯侧Less,",35,30,5, R0 D2+,,4.9,2.69,1.73,154.7,213.0,3.59,22.0,20.0,140.0,57.0,45.0,11.82,4.37,84.0,358.0,55.0,29.0,6.9,7.6,94.0,303.0,,,,,,,,,,,,,0.714,5.29,2.31,,,, P0,H0,,,,,,,65.40735873850197,1431892
1326657,张云峰,539398,男,40,T3,N2,M0, ⅢA,2,3,,1.0,1.0,1.0,,4.0,34,中间型（int）,INFb,1.0,0.3,,,,,,,2013-09-17,2016-08-18,2,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,XELOX,,5, 低分化腺癌（G3)(por)10% 低黏附性癌90%,G3, (1a)(1b)05 (2)02 (3a)03 (3b)01 (4sa)00 (4sb)01 (4d)09 (5)00 (6)03 (7)00 (8a)(8p)02 (9)12 (11p)11 小弯侧25 5组，9组内可见癌结节," M（胃体部）, 小弯侧Less,",50,45,6, R0 D2,,5.48,3.24,1.72,161.0,246.0,2.54,18.0,23.0,202.0,80.0,16.0,20.84,4.1,71.1,263.1,43.7,27.4,5.6,6.87,106.0,295.0,,,,,,,,,,,,,2.1,6.34,14.5,,,, P0,H0,,,,,,,35.019710906701704,1326657
1413151,张兆吉,560117,男,56,T3,N1,M0, ⅡB,2,3,2.0,0.0,0.0,1.0,,1.0,11,硬型（sci）,INFc,0.0,,0.0,0.0,,,,,2014-05-13,2015-10-01,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低粘附腺癌,GX, (1a)02 (1b)02 (2)11 (3a)00 (3b)02 (4sa)00 (4sb)00 (4d)00 (5)(12a)00 (6)01 (7)01 (8a)(8p)00 (9)00 (10)00 (11p)02 ," U（胃底部）, M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,25,10, R0 D2,,7.34,4.1,2.15,138.4,341.0,2.89,11.0,18.0,174.0,93.0,14.0,15.78,4.48,68.0,243.0,40.0,28.0,5.2,3.4,78.0,291.0,,,,,,,,,,,,,0.707,5.42,1.28,,,, P0,H0,,,,,,,16.62286465177398,1413151
1322101,张志信,535877,男,61,T4a,N2,M0, ⅢA,2,4,,0.0,0.0,1.0,,5.0,15,中间型（int）,INFc,0.0,0.4,,,,,,,2013-08-01,2014-06-17,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, 小弯33 (1a)(1b)01 (3b)45 (6)01 (4sa)00 (4d)12 (4sb)03 (7) (8a)(8p)(9)(11p)03 (12a)00," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,45,15, R0 D2,,6.83,4.96,1.28,118.9,245.0,3.61,10.0,8.0,128.0,68.0,13.0,3.53,0.55,69.0,191.0,37.0,32.0,5.7,3.53,68.0,343.0,,,,,,,,,,,,,0.618,10.64,1.02,,,, P0,H0,,,,,,,10.512483574244415,1322101
1325794,赵春喜,538674,男,67,T4b,N1,M0, ⅢB,2,3,,0.0,0.0,1.0,,2.0,12,中间型（int）,INFb,1.0,0.4,,,,,,,2013-09-09,2014-12-14,2,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,多西他赛单药,8, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 粘液腺癌（muc）20% 低粘附腺癌10%,G3, (1a)(1b)(3a)04 (2)00 (3b)00 (4sa)00 (4sb)01 (5)00 (7)04 (11p)23 (11d)00," U（胃底部）, 大弯侧Gre, 后Post, 小弯侧Less,",50,40,10, R0 D2,,7.37,4.22,2.61,128.6,222.0,3.68,8.1,10.0,146.0,74.0,17.7,15.42,2.99,74.7,181.59,42.7,32.0,5.6,3.42,63.0,289.0,,,,,,,,,,,,,1.66,5.47,7.32,,,, P0,H0,,,,,,,15.14454664914586,1325794
1427128,赵德林,574509,男,65,T3,N3a,M0,ⅢB,2,4,0.0,0.0,0.0,1.0,,7.0,24,髓样型（med）,INFa,3.0,,0.0,0.0,,,,0.0,2014-09-19,2019-10-01,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 粘液腺癌（muc）70% 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)25% 乳头状癌（G1）（pap）5% Lauren肠型,G3, (1a)02 (1b)00 (2)610 (3a)11 (3b)00 (4sa)00 (4sb)01 (4d)01 (5)00 (6)00 (7)02 (8a)04 (8p)01 (9)01 (11p)01 (12a)00," M（胃体部）, U（胃底部）, 前Ant, 后Post, 小弯侧Less,",90,70,15, R0 D2,,6.78,4.27,2.06,126.0,261.0,3.59,29.0,33.0,144.0,114.0,34.0,10.55,4.48,70.0,301.0,41.0,29.0,7.5,5.4,72.0,360.0,,,,,,,,,,,,,2.12,56.66,12.6,,,, P0,H0,,,,,,,60.381077529566355,1427128
1327187,赵德贤,540615,女,62,T3,N2,M0, ⅢA,2,3,,1.0,1.0,1.0,,5.0,22,中间型（int）,INFb,0.0,0.4,,,,,,,2013-09-24,2019-04-13,1,,,,,,,,,0, 低分化腺癌（G3)(por)70% 粘液腺癌（muc）30%,G3, (1a)16 (3a)22 (3b)00 (4sb)01 (4d)00 (5)01 (6)14 (7)00 (8a)11 (8p)01 (9)04 (11p)02 (12a)00 (12p)00," L（幽门窦部）, 后Post,",40,30,10, R0 D2,,11.37,6.51,4.14,133.6,333.0,3.14,9.0,13.0,169.0,134.0,10.0,14.11,3.14,68.0,246.0,44.0,24.0,4.7,4.5,69.0,363.0,,,,,,,,,,,,,1.58,8.85,6.63,,,, P0,H0,,,,,,,66.59001314060447,1327187
1434667,赵淑荣,581536,女,63,T4a,N2,M0, ⅢA,2,3,2.0,0.0,0.0,0.0,,5.0,39,硬型（sci）,INFc,0.0,,0.0,1.0,,,,0.0,2014-11-26,2017-03-15,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,7,浸润型 低黏附性癌 Lauren弥漫型,GX, (1a)00  (1a)(1b)(3a)310 (3b)00 (4sb）00 （4d）010 (5)11 (6)11 (7)05 (8a)03 （8p）03 (9）01 （11p）05 （12a）00 （14v）00," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,60,20, R0 D2+,,24.91,22.9,1.05,107.3,380.0,5.44,22.0,24.0,188.0,71.0,27.0,3.18,0.49,65.0,133.0,34.0,31.0,15.8,3.9,248.0,50.0,70.2,45.6,19.3,2.36,0.1,10.8,17.0,0.3,0.638,3.53,12.2,480.0,2.31,3.33,1.2,,,, P0,H0,,,,,,,27.59526938239159,1434667
1332058,赵玉友,543933,男,53,T4a,N1,M0, ⅢA,2,3,,0.0,0.0,1.0,,2.0,28,中间型（int）,INFc,0.0,0.4,,,,,,,2013-11-14,2020-05-14,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)(1b)01 (3a)(3b)24 (5)(12a)01 (6)(4d)01 (4sb)02 (7)(11d)08 (8a)(8p)(9)04 (10)01 (11p)01 (19)04," U（胃底部）, 前Ant, 后Post, 小弯侧Less,",20,15,5, R0 D2+,,4.13,1.64,1.75,132.0,191.0,1.9,12.0,15.0,140.0,59.0,22.0,18.34,15.52,65.9,233.3,40.6,25.3,5.2,5.02,81.0,259.0,,,,,,,,,,,,,1.84,30.36,1.21,,,, P0,H0,,,,,,,77.95663600525624,1332058
1402259,赵作仁,549484,男,69,T3,N1,M0, ⅡB,2,3,,1.0,1.0,1.0,,1.0,13,中间型（int）,INFc,1.0,,,,,,,,2014-01-23,2017-01-15,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (2)12 (3a)02 (3b)00 (4sa)00 (4sb)00 (4d)02 (5)00 (6)00 (7)01 (8a)(8p)02 (9)00 (11p)03," U（胃底部）, 小弯侧Less,",40,35,10, R0 D2,,5.59,3.02,2.09,150.3,233.0,2.89,11.0,13.0,139.0,78.0,16.0,11.0,3.82,64.0,214.0,39.0,25.0,5.5,8.3,61.0,257.0,,,,,,,,,,,,,0.956,12.55,0.941,,,, P0,H0,,,,,,,35.74244415243101,1402259
1325255,郑会莉,536903,女,79,T4b,N3a,M0, ⅢC,2,3,,1.0,1.0,1.0,,13.0,25,髓样型（med）,INFc,0.0,0.5,,,,,,,2013-09-03,2016-12-30,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)44 (1b)13 (2)13 (3a)00 (3b)36 (7)46 (8a)02 (8p)00 (9)01 (4sb)00 另在3d软组织内可见癌," UM 后Post,",50,50,7, R0 D2,,5.12,3.6,0.95,87.2,327.0,3.05,15.0,24.0,211.0,69.0,40.0,7.72,1.53,76.1,280.1,41.4,34.7,5.4,4.08,54.0,249.0,,,,,,,,,,,,,0.687,15.89,6.87,,,, P0,H0,,,,,,,39.88173455978975,1325255
1423712,郑鑫刚,571392,男,46,T2,N2,M0, ⅡB,2,3,1.0,0.0,0.0,0.0,,3.0,33,中间型（int）,INFa,1.0,,0.0,0.0,,,,0.0,2014-08-19,2019-10-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 管状腺癌（高分化【G1】【tub1】）90% 粘液腺癌（muc）10%,G2, (1a)01 (1b)12 (3a)07 (3b)12 (4sb)01 (4d)09 (5)11 (6)02 (7)01 (8a)01 (8p)01 (9)04 (11p)01 (12a)00," L（幽门窦部）M（胃体部）, 后Post, 小弯侧Less,",60,50,10, R0 D2,,5.85,3.25,2.02,150.5,245.0,2.54,24.0,20.0,184.0,69.0,16.0,9.91,3.04,64.0,269.0,45.0,19.0,4.8,3.9,75.0,214.0,,,,,,,,,,,,,8.44,8.23,7.23,,,, P0,H0,,,,,,,61.399474375821285,1423712
1438513,周文,584604,男,51,T3,N2,M0, ⅢA,2,2,2.0,0.0,0.0,1.0,,3.0,19,中间型（int）,INFc,0.0,,0.0,2.0,,,,0.0,2014-12-31,2020-09-08,1,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a)11 (1b)11 (2)01 (3a)13 (3b)02 (4sa)00 (4sb)00 (4d)00 (5)00 (6)03 (7)02 (8a)(9)05 (10)01 (11p)00,L 前Ant 后Post 小弯侧Less ,40,30,20, R0 D2,,6.31,3.51,1.98,150.0,226.0,3.04,31.0,31.0,154.0,109.0,43.0,7.87,2.86,73.0,292.0,46.0,27.0,6.6,4.6,66.0,366.0,70.2,43.9,16.7,2.63,0.5,4.7,22.7,3.1,2.31,1.97,19.3,125.0,0.2,5.49,5.36,,,, P0,H0,,,,,,,68.26544021024966,1438513
1402885,周砚田,553887,男,78,T3,N2,M0, ⅢA,2,3,,1.0,1.0,1.0,,6.0,22,中间型（int）,INFc,3.0,0.5,,,,,,,2014-02-12,2014-12-11,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)95% 粘液腺癌（muc）5%,G3, (1a)01 (1b)01 (3a)17 (3b)00 (4sb)00 (4d)11 (5)33 (6)01 (7)00 (8a)14 (8p)02 (9)01 (11p)01 (12a)00 ," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,10, R0 D2+,,9.63,6.15,2.23,145.0,246.0,2.84,19.0,28.0,175.0,66.0,41.0,21.68,10.29,66.0,273.0,39.0,27.0,4.9,8.0,87.0,162.0,,,,,,,,,,,,,1.02,23.69,1.18,,,, P0,H0,,,,,,,9.921156373193167,1402885
1323366,周忠义,535987,男,51,T3,N2,M0, ⅢA,2,1,,0.0,0.0,0.0,,4.0,26,中间型（int）,INFb,3.0,0.5,,,,,,,2013-08-14,2019-05-15,1,,,奥沙利铂单药化疗,奥沙利铂单药化疗,,,,,2, 管状腺癌（中分化【G2】【tub2】 乳头状癌（G1）（pap）,G2, 大弯00 小弯16 (1a)01 (1b)00 (3)02 (4sb)02 (4d)12 (5)02 (6)22 (7)02 (8p)01 (8、9)04 (11)02 (12a)00 (14)00," L（幽门窦部）, 小弯侧Less,",60,30,6, R0 D2+,,4.47,3.07,0.99,145.7,265.0,2.58,27.0,21.0,184.0,60.0,17.0,20.48,67.4,41.3,301.8,41.3,26.1,5.8,5.9,57.0,233.0,,,,,,,,,,,,,30.55,6.24,6.7,,,, P0,H0,,,,,,,68.98817345597897,1323366
1325465,宗绪尧,536807,男,59,T3,N3a,M0,ⅢB,2,2,,0.0,0.0,1.0,,9.0,29,中间型（int）,INFb,1.0,0.5,,,,,,,2013-09-04,2019-04-13,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)01 (3a)01 (3b)47 (4sb)00 (4d)34 (5)00 (6)14 (7)00 (8a)01 (8p)13 (9)05 (11p)01," L（幽门窦部）, 小弯侧Less,",40,40,7, R0 D2,,7.21,4.33,2.23,150.0,235.0,3.85,17.2,13.0,154.0,90.0,20.3,10.37,2.93,75.3,296.54,42.7,32.6,5.2,3.41,92.0,421.0,,,,,,,,,,,,,8.27,12.49,7.52,,,, P0,H0,,,,,,,67.24704336399473,1325465
1302943,刘长河,516586,男,60,T2,N0,M0, ⅠB,2,2,,0.0,0.0,0.0,,0.0,29,,,1.0,0.4,,,,,,,2013-01-29,2016-07-01,2,,,,,,,,,0, 低分化腺癌（G3)(por) 粘液腺癌（muc） 印戒细胞癌(sig),G3, (1)03 (3a)09 (3b)00 (4sb)01 (4d)04 (5)02 (6)04 (7)03 (8a)01 (8p 9)01 (11p)01      ," L（幽门窦部）, 小弯侧Less,",35,20,10, R0 D2,,5.13,2.68,1.97,150.5,302.0,2.33,13.5,15.0,190.0,85.0,20.0,18.24,6.8,76.1,303.54,45.7,30.4,4.6,6.8,77.0,283.0,,,,,,,,,,,,,1.98,16.26,1.17,,,,P0,H0,,,,,,,41.03153745072273,1302943
1302307,孙广文,516441,男,57,T1a,N0,M0,ⅠA,2,2,,,,,,0.0,53,,,1.0,0.6,,,,,,,2013-01-23,2018-05-07,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, 小弯04 (1)05 (3、7)019 (4sa、4sb)00 (5)00 (6、14v)016 (8a、8p、9)08 (11p)01 (12a)00 ," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,8,3, R0 D2+,,6.23,4.09,1.66,135.0,165.0,2.33,12.3,11.0,145.0,71.0,17.8,9.97,2.7,62.8,195.27,41.5,21.3,4.0,11.44,89.0,197.0,,,,,,,,,,,,,1.73,6.81,1.66,,,,P0,H0,,,,,,,63.40341655716163,1302307
1303024,刘维国,514127,男,62,T4a,N0,M0, ⅡB,2,3,,0.0,0.0,0.0,,0.0,34,中间型（int）,INFc,2.0,0.7,,,,,,,2013-01-30,2019-04-20,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)(1b)01 (3a)07 (3b)01 (4sb)00 (4d)01 (5)00 (6)010 (7)02 (8a)02 (9)02 (11p)05 (12a)03 (16a1)00 ," L（幽门窦部）, 小弯侧Less,",46,35,10, R0 D2+,,5.07,3.44,1.13,73.2,259.0,2.3,10.0,11.0,119.0,55.0,13.0,3.18,1.2,52.4,184.8,37.3,15.1,5.3,4.56,66.0,281.0,,,,,,,,,,,,,0.978,6.75,7.41,,,, P0,H0,,,,,,,74.60578186596584,1303024
1300400,韩天玲,514782,女,74,T1a,N0,M0,ⅠA,2,0,,,,,,0.0,24,,,,,,,,,,,2013-01-07,2018-06-17,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1)02 (3a)00 (3b)00 (4sb)00 (4d)04 (5)00 (6)02 (7)06 (8a)05 (9)03 (11p)02," L（幽门窦部）, 小弯侧Less,",25,20,3, R0 D2,,7.07,3.91,2.09,133.9,235.0,2.86,10.1,13.0,126.0,105.0,13.6,7.43,1.54,71.3,229.97,39.5,31.8,4.9,4.18,82.0,233.0,,,,,,,,,,,,,1.2,8.06,1.72,,,,P0,H0,,,,,,,65.27595269382391,1300400
1303501,李连芳,517415,男,68,T1b,N0,M0,ⅠA,2,1,,,,,,0.0,21,,,,0.07,,,,,,,2013-03-06,2018-06-27,1,,,,,,,,,0, 腺癌 低级别上皮内瘤变,GX, (1a)(1b)00 (3a)02 (3b)00 (4sb)00 (4d)01 (5)00 (6)02 (7)06 (8a)04 (8p)00 (9)02 (11p)04, L（幽门窦部） 前Ant,25,22,5, R0 D2,,6.23,3.03,2.62,125.7,248.0,2.0,28.4,24.0,150.0,87.0,51.3,12.94,5.0,62.1,213.24,40.3,21.8,4.5,4.19,97.0,306.0,,,,,,,,,,,,,1.98,9.78,1.17,,,, P0,H0,,,,,,,63.69908015768725,1303501
1303462,刘德胜,516854,男,49,T4a,N0,M0, ⅡB,2,2,,0.0,0.0,0.0,,0.0,13,中间型（int）,INFb,1.0,,,,,,,,2013-02-05,2018-06-27,1,,,奥沙利铂+替加氟,奥沙利铂+替加氟,,,,,2, 低分化腺癌（G3)(por),G3, (1a)(1b)00 (3a)00 (3b)02 (4sb)00 (4d)02 (5)00 (6)04 (7)01 (8a)00 (8p)03 (9)00 (11p)01 (12a)00," L（幽门窦部）, 后Post,",35,25,9, R0 D2,,4.87,2.7,1.69,123.3,233.0,2.68,28.0,18.0,149.0,119.0,49.0,9.01,1.3,69.4,229.7,42.4,27.0,5.5,3.36,92.0,253.0,,,,,,,,,,,,,2.45,5.68,0.974,,,, P0,H0,,,,,,,64.65177398160316,1303462
1305573,姜守志,518248,男,74,T4b,N0,M0, ⅢA,2,1,,0.0,0.0,0.0,,0.0,16,髓样型（med）,INFb,0.0,0.3,,,,,,,2013-03-06,2013-11-15,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (3a)03 (3b)03 (4sb)00 (4d)02 (5)00 (6)00 (7)01 (8a)02 (8p)02 (9)00 (11p)02 横结肠系膜00      ," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",70,55,8, R0 D2,,6.86,4.66,1.54,54.0,248.0,4.87,5.1,6.0,94.0,87.0,27.9,8.43,4.0,62.9,175.17,37.0,25.9,5.9,6.75,124.0,341.0,,,,,,,,,,,,,2.54,1.33,2.67,,,, P0,H0,,,,,,,8.344283837056505,1305573
1305670,孙世春,518677,男,70,T1b,N0,M0,ⅠA,2,1,,,,,,0.0,34,,,3.0,0.9,,,,,,,2013-03-06,2018-06-27,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3, (1a)02 (1b)00 (3a)07 (3b)01 (4sb)00 (4d)08 (5)02 (6)06 (7)01 (8a)01 (8p)02 (9)02 (11p)02," L（幽门窦部）, 大弯侧Gre,",30,20,8, R0 D2,,4.41,2.84,1.32,122.0,226.0,2.49,9.0,12.0,143.0,52.0,17.0,8.22,1.2,59.0,201.5,36.0,23.0,5.0,5.72,72.0,274.0,,,,,,,,,,,,,1.54,4.39,1.46,,,, P0,H0,,,,,,,63.69908015768725,1305670
1119965,黄一山,467491,男,50,T4a,N0,M0, ⅡB,2,1,,,,,,0.0,31,,,1.0,,,,,,,,2012-09-13,2013-04-30,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) ,G3, 大弯01 小弯012 (2)02 (12)00 (7、8、9、11)012," M（胃体部）, 后Post, 小弯侧Less,",30,30,10, R0 D2,,5.65,4.73,0.76,70.6,156.0,3.3,19.0,26.0,242.0,71.0,13.0,12.78,5.33,32.0,25.0,17.0,15.0,1.3,15.1,73.0,234.0,,,,,,,,,,,,,5.58,16.96,1.75,,,, P0,H0,,,,,,,7.522996057818659,1119965
1307433,姜亚芝,520964,女,62,T1a,N0,M0,ⅠA,2,1,,,,,,0.0,27,,,,,,,,,,,2013-03-21,2018-05-06,1,,,,,,,,,0, 高级别上皮内瘤变,GX, (3)04 (4sa)00 (4sb)00 (5)00 (6)00 (7)01 (8a)04 (9)04 (10)06 (11)05 (12a)00 (12b)02 (14v)01," L（幽门窦部）, 前Ant,",50,10,, R0 D2,,5.6,2.38,2.55,101.0,359.0,2.42,10.0,19.0,130.0,88.0,8.0,5.69,1.02,61.0,189.0,36.0,25.0,7.7,2.7,79.0,237.0,,,,,,,,,,,,,1.84,27.12,1.13,,,, P0,H0,,,,,,,61.498028909329825,1307433
1308060,马树斌,520781,男,59,T4a,N0,M0, ⅡB,2,3,,,,,,0.0,9,髓样型（med）,INFc,,,,,,,,,2013-03-26,2018-06-27,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)01 (1b)00 (3a)00 (3b)01 (4sb)03 (4d)00 (5)00 (6)00 (7)00 (8a)02 (8p)00 (9)01 (11p)01, L（幽门窦部） 前Ant 小弯侧Less 后Post 大弯侧Gre,50,30,10, R0 D2,,5.38,2.62,2.27,143.3,226.0,3.16,17.0,17.0,124.0,51.0,24.0,10.63,1.2,64.9,293.7,38.6,26.3,5.7,6.81,76.0,348.0,,,,,,,,,,,,,1.16,6.09,0.989,,,, P0,H0,,,,,,,63.042049934296976,1308060
1308198,郝成树,521070,男,57,T4a,N0,M0, ⅡB,2,3,,,,,,0.0,28,硬型（sci）,INFc,1.0,0.25,,,,,,,2013-03-27,2018-11-21,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 粘液腺癌（muc）,G2, 大网01 (1、3、7、11)010 (2)05 (4sa)00 (4d)01 (4sb)00 (5)00 (6)01 (8a、8p、9)09 (12p)01 (12a)00 (14v)00," M（胃体部）, U（胃底部）, MU 前Ant, 后Post, 小弯侧Less,",60,45,7, R0 D2+,,5.19,2.14,2.17,140.0,185.0,2.28,107.8,56.0,176.0,102.0,17.0,7.95,4.7,77.7,190.95,44.3,33.4,4.7,5.65,85.0,240.0,,,,,,,,,,,,,4.9,18.78,7.4,,,, P0,H0,,,,,,,67.83837056504599,1308198
1311211,张军付,524328,男,52,T1b,N0,M0,ⅠA,2,1,,,,,,0.0,18,,,1.0,0.3,,,,,,,2013-04-22,2019-02-15,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1)04 (3a、3b)03 (4sa)00 (4sb)00 (6)00 (7)02 (8a)06 (8p)03 (11p)00 ," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",20,10,15, R0 D2,,5.05,2.18,2.26,164.5,197.0,2.48,36.0,25.0,205.0,76.0,31.0,13.48,5.3,69.9,304.0,42.6,27.3,5.3,4.43,68.0,221.0,,,,,,,,,,,,,2.57,22.14,13.09,,,, P0,H0,,,,,,,69.80946123521682,1311211
1311565,吴兆铭,523694,男,63,,,,癌前病变,2,1,,,,,,0.0,9,,,,,,,,,,,2013-04-24,2018-05-17,1,,,,,,,,,0, 高级别上皮内瘤变,GX, (1)03 (3b、7)02 (4sb)00 (4d)00 (5)00 (6)00 (8a)01 (8p、9)02 (11p)00 (11d)00 (14v)01 (16a1)00       ," L（幽门窦部）, 小弯侧Less,",25,20,5, R0 D2+,,6.42,3.68,2.03,139.0,199.0,2.22,16.0,12.0,142.0,97.0,44.0,11.56,6.5,68.2,290.9,42.5,25.7,8.9,6.03,64.0,379.0,,,,,,,,,,,,,2.69,5.96,9.12,,,, P0,H0,,,,,,,60.74244415243101,1311565
1311671,陈继和,525803,男,52,T1a,N0,M0,ⅠA,2,0,,,,,,0.0,19,,,1.0,0.7,,,,,,,2013-04-25,2018-06-17,1,,,,,,,,,0, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 ,G3, (1a)00 (1b)00 (2)01 (3a)07 (3b)03 (4sa)00 (4sb)00 (4d)01 (5)00 (6)01 (7)01 (8a)03 (8p)00 (9)01 (11p)01, L（幽门窦部） 小弯侧Less ,15,,, R0 D2,,7.0,3.63,2.55,159.4,154.0,2.1,39.0,31.0,135.0,53.0,29.0,22.87,5.88,75.0,223.0,43.0,32.0,4.5,8.1,96.0,417.0,,,,,,,,,,,,,0.936,9.41,15.52,,,, P0,H0,,,,,,,61.727989487516425,1311671
1313485,王桂珍,526227,女,70,T4b,N0,M0, ⅢA,2,3,,,,,,0.0,16,中间型（int）,INFc,1.0,0.3,,,,,,,2013-05-13,2018-12-19,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1、3、7)03 (3)00 (4sa)00 (4sb)00 (4d)04 (5)00 (6)03 (7)05 (8a、8p、9)00 (11p)01 (12a)00 (14v)00 ," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",100,60,10, R0 D2+,,7.38,5.03,1.85,121.3,304.0,4.9,11.1,10.0,137.0,114.0,54.6,10.3,1.66,69.1,237.88,41.2,27.9,7.0,6.0,72.0,238.0,,,,,,,,,,,,,3.8,6.83,7.57,,,, P0,H0,,,,,,,67.21419185282522,1313485
1314162,程贵昌,526775,男,65,T2,N0,M0, ⅠB,2,3,,,,,,0.0,30,,,1.0,0.8,,,,,,,2013-05-17,2016-03-31,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)03 (1b)05 (3a)06 (3b)02 (4sb)00 (4d)02 (5)00 (6)05 (7)02 (8a)01 (8p)03  (9)01 , L（幽门窦部） 前Ant,20,15,10, R0 D2,,7.78,5.07,2.13,137.1,186.0,3.14,13.3,14.0,152.0,65.0,25.4,6.74,3.03,67.7,240.34,41.2,26.5,4.8,7.68,83.0,391.0,,,,,,,,,,,,,1.16,58.36,2.92,,,, P0,H0,,,,,,,34.46123521681997,1314162
1315193,杨宝君,528193,男,56,T2,N0,M0, ⅠB,2,2,,,,,,0.0,16,,,0.0,0.7,,,,,,,2013-05-28,2020-04-16,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)02 (1b)03 (2)02 (3a)01 (3b)00 (4sb)00 (4d)00 (5)00 (6)02 (7)02 (8a)02 (8p)01 (9)00 (11p)01," U（胃底部）, 后Post,",30,30,7, R0 D2,,7.7,5.0,2.13,131.0,170.0,2.14,20.0,18.0,129.0,80.0,16.0,8.19,1.09,69.0,242.0,42.0,27.0,4.8,4.5,89.0,287.0,,,,,,,,,,,,,3.35,15.19,6.72,,,, P0,H0,,,,,,,82.62155059132719,1315193
1315266,任佰彪,527944,男,57,T4b,N1,M0, ⅢB,2,3,,,,,,1.0,24,中间型（int）,INFc,1.0,0.3,,,,,,,2013-06-28,2015-07-01,2,,,FOLFOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】,G2, 小弯02 (1a)02 (1b)03 (2)01 (3a)01 (3b)01 (4sb)00 (4d)04 (5)11 (6)01 (7)06 (8a)02 ," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",45,30,10, R0 D2,,10.4,6.59,2.87,127.0,262.0,3.51,9.0,9.0,172.0,145.0,17.0,10.36,0.96,73.5,171.2,41.1,32.4,5.8,9.19,83.0,319.0,,,,,,,,,,,,,2.32,9.1,0.947,,,, P0,H0,,,,,,,24.080157687253614,1315266
1316023,杨树彬,529242,男,70,T2,N2,M0, ⅡB,2,1,,,,,,4.0,24,,,1.0,0.2,,,,,,,2013-06-04,2019-04-20,1,,,SOX,SOX,,,,,2, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)01 (1b)01 (3a)14 (3b)00 (4sb)00 (4d)15 (5)00 (6)04 (7)02 (8a)24 (8p)02 (9)00 (10)01 (11p)00 (12a)00," L（幽门窦部）, 小弯侧Less,",30,22,5, R0 D2,,4.25,1.8,1.93,138.0,213.0,2.99,18.0,18.0,148.0,53.0,18.0,10.33,1.63,67.0,259.0,42.0,25.0,4.4,4.4,84.0,247.0,,,,,,,,,,,,,4.2,20.97,1.66,,, , P0,H0,,,,,,,70.4993429697766,1316023
1313662,吴金巍,526477,男,49,T4b,N1,M0, ⅢB,2,3,,,,,,1.0,18,中间型（int）,INFc,2.0,0.2,,,,,,,2013-05-14,2018-06-28,1,,,SOX,SOX,SOX,SOX,SOX,SOX,12, 管状腺癌（高分化【G1】【tub1】 中分化【G2】【tub2】 乳头状癌（G1）（pap） 粘液腺癌（muc） Lauren肠型,G2, (1a)(1b)03 (3a)07 (3b)00 (4sb)00 (4d)01 (5)01 (6)00 (7)01 (8a)00 (8p)02 (9)01 (11p)01 (12a)00 (14v)01, M（胃体部） 后Post 大弯侧Gre  U（胃底部）,60,50,20, R0 D2+,,5.34,3.06,1.8,131.0,335.0,3.16,22.0,24.0,185.0,80.0,38.0,11.89,2.05,82.0,309.0,49.0,33.0,6.8,3.9,91.0,287.0,,,,,,,,,,,,,1.09,2.95,3.05,,,, P0,H0,,,,,,,61.465177398160314,1313662
1316273,常建萍,529324,女,43,T1a,N0,M0,ⅠA,2,5,,,,,,0.0,27,,,1.0,,,,,,,,2013-06-06,2018-06-06,1,,,,,,,,,0, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)00 (1b)00 (3a)07 (3b)04 (4sb)00 (4d)01 (5)02 (6)01 (7)04 (8a)02 (8p)02 (9)00 (11p)02 (14v)02," L（幽门窦部）, 小弯侧Less,",22,22,, R0 D2+,,5.47,3.03,1.95,127.5,209.0,2.09,19.4,20.0,229.0,67.0,20.0,21.89,4.07,76.1,182.37,46.3,29.8,4.2,4.87,71.0,228.0,,,,,,,,,,,,,0.2,1.25,0.989,,,, P0,H0,,,,,,,59.98685939553219,1316273
1316501,李桂英,529009,女,67,T1b,N1,M0, ⅠB,2,0,,,,,,2.0,26,,,1.0,0.5,,,,,,,2013-06-07,2018-06-27,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (3a)05 (3b)14 (4sb)00 (4d)05 (5)12 (6)02 (7)02 (8a)01 (8p)01 (9)02 (11p)00 (12a)00 (14v)01," L（幽门窦部）, 小弯侧Less, 前Ant, 后Post,",15,15,6, R0 D2+,,5.55,3.27,1.86,125.3,148.0,2.6,17.0,19.0,207.0,84.0,20.0,20.43,5.17,69.0,238.9,41.5,27.5,5.5,6.07,77.0,254.0,,,,,,,,,,,,,1.38,7.19,2.28,,,, P0,H0,,,,,,,60.643889618922465,1316501
1317872,孙峰春,530320,男,72,T2,N0,M0, ⅠB,2,2,,,,,,0.0,17,,,2.0,,,,,,,,2013-05-24,2018-05-06,1,,,,,,,,,0, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)03 (1b)01 (3a)00 (3b)01 (4sb)00 (4d)00 (5)01 (6)02 (7、8)07 (9)02 (12a)00," L（幽门窦部）, 前Ant,",20,20,3, R0 D2,,5.33,2.51,2.33,123.7,132.0,2.72,28.5,18.0,108.0,60.0,13.9,10.18,2.2,62.1,289.75,42.3,19.8,4.4,5.77,109.0,443.0,,,,,,,,,,,,,3.17,10.83,1.76,,,, P0,H0,,,,,,,59.39553219448094,1317872
1318362,常云山,532232,男,62,T1a,N0,M0,ⅠA,2,3,,,,,,0.0,27,,,0.0,,,,,,,,2013-06-27,2018-06-07,1,,,,,,,,,0, 高级别上皮内瘤变,GX, (1a)00 (1b)02 (3a)05 (3b)00 (4sb)00 (4d)010 (5)00 (6)03 (7)01 (8p)02 (9)01 (11p)01 (12a)02 结肠中动脉00, LM,20,18,5, R0 D2,,5.41,3.32,1.57,128.0,153.0,3.27,23.0,18.0,199.0,82.0,24.0,8.61,1.31,64.8,288.9,38.2,26.6,4.9,6.87,88.0,244.0,,,,,,,,,,,,,2.15,5.87,1.89,,,, P0,H0,,,,,,,59.32982917214191,1318362
1319864,孙长有,532014,男,68,T2,N0,M0, ⅠB,2,1,,,,,,0.0,25,,,0.0,0.2,,,,,,,2013-07-11,2017-04-03,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)00 (2)02 (3a)02 (4sa)04 (4d)02 (5)00 (7)01 (8a)01 (9)02 (11p)02 (11d)00 (14v)00,"后Post U（胃底部）,",15,15,6, R0 D2+,,6.07,3.55,2.11,138.0,173.0,2.56,21.8,15.0,173.0,74.0,22.5,18.16,5.05,44.1,274.88,44.1,29.1,4.3,7.21,77.0,308.0,,,,,,,,,,,,,0.2,7.82,1.17,,,, P0,H0,,,,,,,44.74375821287779,1319864
1319961,赵志敏,531627,女,43,T4a,N0,M0, ⅡB,2,4,,,,,,0.0,15,硬型（sci）,INFc,0.0,0.2,,,,,,,2013-07-11,2016-06-15,2,,,,,,,,,0, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)(1b)05 (2)00 (3a)(3b)01 (4sa)(4sb)(4d)00 (5)(12a)00 (6)06 (7)(8a)(8p)(9)(11p)03," LM 前Ant, 后Post, 小弯侧Less,",65,60,8, R0 D2,,3.43,1.87,1.28,62.3,352.0,2.73,14.0,14.0,156.0,37.0,7.0,8.95,1.78,77.0,214.0,43.0,34.0,5.3,5.16,58.0,167.0,,,,,,,,,,,,,1.1,8.05,2.58,,,, P0,H0,,,,,,,35.15111695137976,1319961
1319792,赵德祥,533624,男,63,T4a,N0,M0, ⅡB,2,2,,,,,,0.0,16,中间型（int）,INFc,2.0,0.4,,,,,,,2013-07-10,2017-03-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)00 (3a)04 (3b)00 (4sb)00 (4d)05 (5)00 (6)02 (7)01 (8a)02 (8p)00 (9)01  ," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,7, R0 D2,,5.65,3.22,1.93,131.0,165.0,2.54,14.8,10.0,138.0,68.0,22.4,18.3,4.51,66.1,298.06,40.7,25.4,4.4,3.03,89.0,338.0,,,,,,,,,,,,,1.4,147.6,1.05,,,, P0,H0,,,,,,,44.15243101182654,1319792
1320167,齐艳明,533150,男,56,T2,N0,M0, ⅠB,2,2,,,,,,0.0,23,,,0.0,0.6,,,,,,,2013-07-15,2018-04-22,1,,,,,,,,,0, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】 印戒细胞癌(sig) 粘液腺癌（muc）,G3, 大弯03 (1a)02 (1b)01 (3)06 (4sb)00 (4d)02 (5)00 (6)01 (7)03 (8a、8p)01 (9)02 (11p)01 (12a)00 (14v)01    ," L（幽门窦部）, 小弯侧Less,",10,10,3, R0 D2+,,4.49,3.23,0.61,138.0,174.0,2.78,27.8,21.0,159.0,79.0,15.5,10.12,2.87,69.3,320.57,42.3,27.0,4.2,5.5,73.0,367.0,,,,,,,,,,,,,2.31,7.21,2.23,,,, P0,H0,,,,,,,57.22733245729303,1320167
1320561,金万秋,534256,男,53,T1a,N0,M0,ⅠA,2,3,,,,,,0.0,16,,,1.0,,,,,,,,2013-07-17,2018-07-31,1,,,,,,,,,0, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)02 (1b)02 (3a)02 (3b)02 (4sb)00 (4d)03 (5)00 (6)00 (7)02 (8a)01 (8p)00 (9)00 (11p)02 , L（幽门窦部） 前Ant ,15,15,3, R0 D2,,5.21,2.63,2.34,149.0,185.0,2.45,29.5,20.0,127.0,75.0,66.9,9.6,1.91,70.9,478.96,41.4,29.5,4.5,3.57,69.0,374.0,,,,,,,,,,,,,3.5,0.97,1.09,,,, P0,H0,,,,,,,60.446780551905384,1320561
1321341,刘喜玲,534658,女,56,T4a,N0,M0, ⅡB,2,3,,,,,,0.0,19,中间型（int）,INFc,1.0,0.25,,,,,,,2013-07-25,2018-07-31,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)02 (3a)04 (3b)00 (4sb)00 (4d)03 (5)01 (6)03 (7)00 (8a)01 (8p)03 (9)00 (11p)02," L（幽门窦部）, 后Post,",40,40,18, R0 D2,,7.68,4.02,3.02,116.0,207.0,2.34,18.0,13.0,145.0,115.0,17.6,5.63,1.98,63.6,205.32,38.4,25.2,4.5,6.53,43.0,250.0,,,,,,,,,,,,,3.21,0.684,1.02,,,, P0,H0,,,,,,,60.183968462549274,1321341
1322012,石万富,534151,男,64,T4a,N0,M0, ⅡB,2,3,,,,,,0.0,28,中间型（int）,INFc,1.0,0.25,,,,,,,2013-08-01,2019-01-15,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 粘液腺癌（muc）,G3, 大网08 (1a)00 (1b)00 (3a、3b)02 (4sb)00 (4d)02 (5)00 (6、14)01 (7)09 (8a、8p)01 (9)02 (11d)00 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",40,30,12, R0 D2+,,6.54,2.64,3.28,139.0,227.0,2.94,5.7,11.0,110.0,77.0,13.2,9.21,5.98,66.5,223.55,41.5,25.0,4.3,4.24,91.0,306.0,,,,,,,,,,,,,3.5,32.63,1.58,,,, P0,H0,,,,,,,65.47306176084099,1322012
1322316,王丽娟,536104,女,52,T4a,N0,M0, ⅡB,2,3,,0.0,0.0,1.0,,0.0,14,中间型（int）,INFc,0.0,0.1,,,,,,,2013-08-05,2015-05-30,2,,,奥沙利铂单药化疗,奥沙利铂单药化疗,,,,,2, 低分化腺癌（G3)(por),G3, (1b)00 (3)05 (3b)02 (4sb)00 (4d)00 (5)00 (6)00 (7)00 (8a、8p、9)03 (11p)01 (12a)00 (14v)03   ," L（幽门窦部）, 后Post, 小弯侧Less,",30,20,10, R0 D2+,,5.47,3.2,1.84,138.9,178.0,2.41,21.5,15.0,180.0,91.0,100.2,11.68,2.61,69.4,458.61,45.4,24.0,5.0,5.94,54.0,343.0,,,,,,,,,,,,,2.5,11.5,1.14,,,, P0,H0,,,,,,,21.780551905387647,1322316
1324308,高德江,535544,男,84,T1a,N0,M0,ⅠA,2,0,,,,,,0.0,37,,,3.0,0.4,,,,,,,2013-08-23,2017-11-20,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)03 (1b)02 (2)03 (3a)00 (3b)04 (4sa)04 (4sb)02 (4d)06 (5)00 (6)00 (7)03 (8a)02 (8p)04 (9)02 (12a)02," M（胃体部）, 大弯侧Gre,",30,30,, R0 D2,,5.83,3.22,2.49,134.5,165.0,2.09,21.2,20.0,181.0,62.0,18.8,29.45,5.43,74.7,244.43,43.0,31.7,4.4,5.49,78.0,343.0,,,,,,,,,,,,,0.907,6.73,24.12,,,, P0,H0,,,,,,,50.91984231274638,1324308
1324233,赵兴实,535631,男,75,T4a,N0,M0, ⅡB,2,3,,0.0,0.0,1.0,,0.0,21,中间型（int）,INFc,0.0,0.4,,,,,,,2013-08-22,2014-04-01,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (2)00 (3a)06 (3b)04 (4sa)01 (4sb)01 (4d)06 (5)00 (6)01 (7)00 (8a)01 (8p)00 (9)00," M（胃体部）, 后Post, 小弯侧Less,",40,35,7, R0 D2,,6.32,3.82,1.96,136.0,270.0,3.14,19.4,20.0,151.0,117.0,40.2,16.27,4.44,72.2,227.0,43.5,28.7,,4.79,64.0,294.0,,,,,,,,,,,,,3.24,7.08,1.57,,,, P0,H0,,,,,,,7.293035479632063,1324233
1325137,朱道武,539389,男,46,T1a,N0,M0,ⅠA,2,0,,,,,,0.0,34,,,0.0,0.6,,,,,,,2013-09-02,2018-08-31,1,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a、1b)015 (3a、3b)00 (4sb)00 (4d)03 (5)00 (7)02 (7、8a、8p)03 (9)02 (6、14v)09 (12a)00," L（幽门窦部）, 后Post, 大弯侧Gre,",70,40,, R0 D2+,,6.82,3.6,2.6,140.3,194.0,2.24,22.0,22.0,185.0,70.0,27.0,6.31,1.38,67.5,338.3,41.8,25.7,5.0,6.38,56.0,376.0,,,,,,,,,,,,,6.06,14.36,0.743,,,, P0,H0,,,,,,,59.92115637319316,1325137
1325617,李加印,538814,女,61,T3,N0,M0, ⅡA,2,4,,,,,,0.0,58,,,0.0,0.6,,,,,,,2013-09-05,2018-02-04,2,,,XELOX,XELOX,,,,,2, 粘液腺癌（muc）,GX, (1a)01 (1b)01 (2)03 (3a)03 (3b)02 (4sa)00 (4sb)00 (4d)04 (5)02 (6)012 (7)05 (8a)06 (8p)03 (9)03 (11p)011 (11d)02," ML 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,8, R0 D2,,3.91,2.57,1.07,114.0,234.0,2.12,11.6,12.0,132.0,48.0,13.2,10.97,2.44,77.8,351.58,47.2,30.6,5.6,4.03,51.0,217.0,,,,,,,,,,,,,0.551,3.33,0.992,,,, P0,H0,,,,,,,52.989487516425754,1325617
1326179,项录清,539525,男,61,T3,N0,M0, ⅡA,2,3,,,,,,0.0,13,中间型（int）,INFb,1.0,0.3,,,,,,,2013-09-11,2019-06-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)01 (3a)02 (3b)00 (4sb)00 (4d)00 (5)00 (6)04 (7)03 (8a)00 (8p)01 (9)01 (11p)01," M（胃体部）, 后Post,",30,25,8, R0 D2,,3.86,1.47,1.88,149.7,161.0,1.75,23.2,32.0,170.0,61.0,15.2,16.88,6.3,70.8,225.21,42.9,27.9,4.8,3.77,61.0,315.0,,,,,,,,,,,,,1.17,8.32,1.27,,,, P0,H0,,,,,,,68.65965834428384,1326179
1325774,李明全,539069,男,56,T1b,N0,M0,ⅠA,2,2,,,,,,0.0,8,,,2.0,0.6,,,,,,,2013-09-09,2018-06-19,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)00 (5)00 (6)01 (7)00 (8a)03 (9)00 (11p)03 (12a)00," L（幽门窦部）, 小弯侧Less,",15,10,4, R0 D2,,9.07,5.89,1.94,151.7,264.0,5.44,33.0,23.0,179.0,69.0,41.0,22.88,7.21,74.0,245.8,44.1,29.9,5.0,7.84,48.0,260.0,,,,,,,,,,,,,2.49,0.714,1.17,,,, P0,H0,,,,,,,57.29303547963206,1325774
1325885,王维臣,538671,男,55,T2,N0,M0, ⅠB,2,3,,,,,,0.0,21,,,0.0,0.4,,,,,,,2013-09-09,2017-11-08,0,,,,,,,,,0, 乳头状癌（G1）（pap）70%  管状腺癌（中分化【G2】【tub2】30%,G2, 大弯09 (1a)00 (1b)03 (3)01 (4sb)00 (4d)00 (5)00 (6、14v)00 (7、8a、8p)08 (9)00 (11p、11d)00 (12a)00," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,8, R0 D2+,,6.23,3.73,1.95,95.1,206.0,2.78,15.0,7.0,132.0,65.0,31.0,8.74,1.22,61.0,204.0,41.0,20.0,5.9,8.8,87.0,195.0,,,,,,,,,,,,,1.29,36.76,1.01,,,, P0,H0,,,,,,,49.96714848883048,1325885
1326235,刘凯,540400,男,50,T4b,N0,M0, ⅢA,2,3,,1.0,1.0,1.0,,0.0,10,中间型（int）,INFb,3.0,0.4,,,,,,,2013-09-12,2019-04-20,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (3a)01 (3b)01 (4sb)00 (4d)00 (5)01 (6)02 (7)00 (8a)01 (8p)01 (9)01 (11p)01 (12a)00, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,40,20, R0 D2,,5.05,2.6,2.04,99.1,279.0,3.61,17.6,14.0,158.0,102.0,28.8,5.53,1.33,70.2,221.61,40.6,29.6,6.1,5.61,73.0,355.0,,,,,,,,,,,,,1.61,4.94,1.2,,粟粒状,, P0,H0,,,,,,,67.21419185282522,1326235
1327398,韩维成,471389,男,62,T1b,N0,M0,ⅠA,2,0,,,,,,0.0,24,,,1.0,0.8,,,,,,,2013-09-25,2019-04-09,1,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,10, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 乳头状癌（G1）（pap）30% ,G3, (1a)00 (1b)00 (3a)06 (3b)02 (4sb)00 (4d)00 (5)00 (6)01 (7)00 (8a)01 (8p)05 (9)04 (11p)03 (12a)00 (12p)02," L（幽门窦部）, 小弯侧Less,",18,15,4, R0 D2,,6.17,3.83,1.93,154.5,168.0,2.09,29.0,19.0,169.0,60.0,24.0,17.3,4.21,75.0,401.0,48.0,27.0,5.2,7.9,82.0,481.0,,,,,,,,,,,,,3.17,17.32,1.19,,,, P0,H0,,,,,,,66.4257555847569,1327398
1327453,赵玉琴,542025,女,76,T3,N0,M0, ⅡA,2,2,,0.0,0.0,1.0,,0.0,37,中间型（int）,INFb,1.0,0.6,,,,,,,2013-09-26,2019-06-02,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, (1a)00 (1b)03 (3a)011 (3b)00 (4sb)00 (4d)03 (5)00 (6)03 (7)01 (8a)08 (8p)04 (9)03 (11p)01 (12a)00 (12p)00 (19)00," L（幽门窦部）, 前Ant, 小弯侧Less,",30,30,4, R0 D2,,5.99,2.71,2.78,123.5,243.0,3.21,9.0,22.0,159.0,88.0,22.0,8.11,2.49,75.0,253.0,40.0,35.0,4.6,4.1,69.0,272.0,,,,,,,,,,,,,1.52,15.48,26.13,,,, P0,H0,,,,,,,68.16688567674113,1327453
1327983,杨凤友,541516,男,64,T3,N1,M0, ⅡB,2,3,,,,,,1.0,19,中间型（int）,INFc,1.0,0.7,,,,,,,2013-10-08,2019-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化（G3)(por),G3, (1a)01 (1b)03 (2)02 (3a)03 (3b)19 (4d)00 (4sa)01 (7)00," U（胃底部）, 后Post, 大弯侧Gre, 小弯侧Less, 前Ant,",50,40,15, R0 D2,,5.29,3.39,1.44,145.0,207.0,3.59,15.8,10.0,155.0,99.0,19.1,21.35,3.54,73.8,319.0,28.4,28.4,6.0,4.75,72.0,442.0,,,,,,,,,,,,,91.79,10.94,27.57,,,, P0,H0,,,,,,,70.79500657030223,1327983
1328040,周洪波,541247,男,42,T1b,N0,M0,ⅠA,2,3,,,,,,0.0,32,,,0.0,,,,,,,,2013-10-09,2022-09-02,1,,,,,,,,,0, 低粘附腺癌,GX, (1a、1b)02 (3a、3b)011 (4sb)00 (4d)013 (5)01 (6)01 (7、9)01 (8)00 (11p)02  (12a)01   ," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,30,5, R0 D2,,5.99,3.27,2.18,139.0,163.0,2.12,10.0,20.0,167.0,59.0,14.0,10.55,1.77,74.0,234.0,46.0,28.0,5.0,7.5,94.0,338.0,,,,,,,,,,,,,1.45,2.28,1.18,,,, P0,H0,,,,,,,106.76741130091983,1328040
1328471,闵德君,313005,男,64,T1b,N0,M0,ⅠA,2,5,,,,,,0.0,28,,,2.0,0.2,,,,,,,2013-10-12,2013-11-19,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90% 低粘附腺癌10%,G2, (1a)00 (1b)03 (2)01 (3a)04 (3b)(8p)02 (4sa)00 (4sb)00 (4d)02 (5)00 (6)03 (7)04 (8a)02 (9)02 (11p)03 (12a)00 (19)02," U（胃底部）, 小弯侧Less,",40,30,4, R0 D2+,,6.16,3.86,1.7,148.1,111.0,2.72,16.0,15.0,133.0,72.0,21.2,9.61,1.56,63.1,247.48,40.9,22.2,4.7,7.62,81.0,409.0,,,,,,,,,,,,,2.92,8.7,2.94,,,, P0,H0,,,,,,,1.2483574244415243,1328471
1329582,刘方喜,541953,男,45,T4a,N0,M0, ⅡB,2,4,,,,,,0.0,19,,,0.0,0.2,,,,,,,2013-10-23,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por)50% 低粘附腺癌50%,G3, (1a)00 (1b)03 (3a)04 (3b)00 (4sb)00 (4d)07 (5)00 (6)02 (7)01 (8a)01 (9)01 (11p)00 (12a)00," L（幽门窦部）, 后Post, 小弯侧Less,",20,20,7, R0 D2,,8.14,4.76,2.53,137.0,342.0,3.85,39.0,26.0,139.0,92.0,73.8,5.39,2.1,69.9,260.08,42.8,27.1,5.6,3.84,64.0,290.0,,,,,,,,,,,,,2.22,11.01,8.44,,,, P0,H0,,,,,,,106.30749014454665,1329582
1329724,丁焕久,542949,男,69,T2,N0,M0, ⅠB,2,2,,0.0,0.0,1.0,,0.0,29,,,1.0,0.4,,,,,,,2013-10-24,2020-01-01,1,,,,,,,,,0, 低分化管状腺癌（G3)(por)60% 低粘附腺癌40%,G3, (1a)02 (1b)01 (2)00 (3a)06 (3b)01 (4sa)00 (4sb)00 (4d)01 (5)04 (6)00 (7)05 (8a)06 (8p)01 (9)00 (11p)02 (12a)00 ," M（胃体部）, 小弯侧Less,",15,15,8, R0 D2,,3.43,2.0,1.05,126.5,225.0,3.05,57.0,54.0,167.0,95.0,62.0,3.05,7.13,64.0,222.0,39.0,25.0,6.1,3.1,97.0,372.0,,,,,,,,,,,,,3.43,12.27,0.972,,,, P0,H0,,,,,,,74.24441524310117,1329724
1329974,高文明,542933,男,59,T1b,N0,M0,ⅠA,2,2,,,,,,0.0,18,,,0.0,0.5,,,,,,,2013-10-28,2018-06-13,0,,,,,,,,,0, 低粘附腺癌60% 低分化管状腺癌（G3)(por)40%,G3, (1a)05 (1b)02 (3a)02 (3b)01 (4sb)00 (4d)00 (5)02 (6)01 (7)01 (8a)01 (8p)02 (9)00 (11p)01," L（幽门窦部）, 后Post, 小弯侧Less,",15,15,3, R0 D2,,6.4,3.7,2.0,155.0,188.0,1.95,16.0,22.0,175.0,67.0,17.0,16.78,2.18,70.3,251.6,41.6,28.7,5.7,7.49,71.0,326.0,,,,,,,,,,,,,1.09,5.09,4.0,,,, P0,H0,,,,,,,55.4862023653088,1329974
1330780,王振民,535788,男,50,T2,N0,M0, ⅠB,2,2,,0.0,0.0,0.0,,0.0,19,中间型（int）,INFb,3.0,0.25,,,,,,,2013-11-05,2018-06-17,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)01 (3a)03 (3b)01 (4sb)00 (4d)01 (5)01 (6)01 (7)03 (8a)03 (8p)00 (9)02 (11p)00 (12a)00 (12b)02 (14v)00," L（幽门窦部）, 后Post,",35,30,8, R0 D2+,,4.5,2.2,1.7,134.0,241.0,2.41,20.0,33.0,204.0,52.0,15.0,6.11,0.68,64.0,235.0,41.0,23.0,5.5,4.7,71.0,399.0,,,,,,,,,,,,,1.68,38.83,7.39,,,, P0,H0,,,,,,,55.35479632063075,1330780
1332029,明喜,543944,男,69,T4a,N0,M0, ⅡB,2,2,,0.0,0.0,0.0,,0.0,31,中间型（int）,INFb,0.0,0.5,,,,,,,2013-11-14,2019-04-20,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)02 (1b)01 (3a)01 (3b)00 (4sb)00 (4d)00 (5)00 (6)010 (7)01 (8a)03 (8p)02 (9)01 (11p)08 (14v)02," L（幽门窦部）, 后Post, 小弯侧Less,",40,35,10, R0 D2+,,6.14,1.99,2.98,124.0,255.0,2.41,13.0,18.0,174.0,50.0,28.0,11.51,2.17,64.2,242.2,39.1,25.1,5.7,5.3,87.0,210.0,,,,,,,,,,,,,1.45,5.37,300.0,,,, P0,H0,,,,,,,65.14454664914585,1332029
1331961,姜爱国,544113,男,61,T3,N1,M0, ⅡB,2,3,,,,,,2.0,24,硬型（sci）,INFc,0.0,0.8,,,,,,,2013-11-14,2019-04-20,1,,,口服卡培他滨,,,,,,1, 低分化腺癌（G3)(por),G3, (1a)02 (1b)05 (3a)12 (3b)12 (4sb)00 (4d)01 (5)00 (6)01 (7)01 (8a)01 (8p)04 (9)02 (11p)03," L（幽门窦部）, 小弯侧Less,",40,40,10, R0 D2,,4.77,2.1,2.0,143.3,281.0,3.46,59.0,37.0,173.0,90.0,35.0,27.57,8.91,69.0,275.0,42.0,27.0,5.3,4.3,76.0,345.0,,,,,,,,,,,,,1.12,8.23,1.68,,,, P0,H0,,,,,,,65.14454664914585,1331961
1332404,卢海峰,545005,男,64,T3,N0,M0, ⅡA,2,4,,,,,,0.0,20,,,0.0,0.6,,,,,,,2013-11-19,2022-09-02,1,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a)(1b)05 (2)05 (3a)(3b)00 (4sa)(4sb)00 (7)02 (8a)05 (11p)03 (11d)00," L（幽门窦部）, 大弯侧Gre,",100,60,18, R0 D2,,4.01,2.1,1.15,71.7,281.0,3.07,9.0,19.0,85.0,74.0,14.9,7.76,2.23,50.0,167.2,33.0,17.0,5.2,7.09,70.0,268.0,,,,,,,,,,,,,1.16,12.02,4.78,,,, P0,H0,,,,,,,105.42049934296978,1332404
1332157,王旭新,545075,男,59,T4a,N0,M0, ⅡB,2,3,,0.0,0.0,0.0,,0.0,30,硬型（sci）,INFc,0.0,0.4,,,,,,,2013-11-15,2019-04-22,1,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a)00 (1b)06 (2)01 (3a)04 (3b)03 (4sa)00 (4sb)00 (4d)02 (5)00 (6)03 (7)02 (8a)02 (9)05 (10)01 (12a)01," U（胃底部）, 后Post,",40,35,10, R0 D2,,7.9,4.1,2.8,146.0,152.0,2.18,28.5,28.0,129.0,102.0,19.8,6.35,1.8,65.1,191.0,40.0,24.6,5.3,8.6,83.0,321.0,,,,,,,,,,,,,4.28,6.98,23.4,,,, P0,H0,,,,,,,65.17739816031538,1332157
1332520,姜有和,545201,男,55,T3,N0,M0, ⅡA,2,3,,1.0,1.0,1.0,,0.0,24,中间型（int）,INFb,2.0,0.4,,,,,,,2013-11-20,2020-05-14,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】95% 粘液腺癌（muc）5%,G2, (1a)04 (1b)01 (2)01 (3a)02 (3b)00 (4sa)01 (4sb)00 (4d)00 (5)00 (6)00 (7)01 (8a)02 (8p)01 (9)01 (11d)01 (11p)09 (19)00," U（胃底部）, 小弯侧Less,",30,28,6, R0 D2,,5.91,2.66,2.42,128.2,175.0,1.96,17.0,22.0,156.0,54.0,17.0,4.74,0.93,60.0,207.7,37.0,23.0,5.3,8.51,66.0,238.0,,,,,,,,,,,,,2.95,22.66,5.57,,,, P0,H0,,,,,,,77.75952693823916,1332520
1333382,徐利华,546474,女,36,T2,N0,M0, ⅠB,2,2,,0.0,0.0,0.0,,0.0,21,髓样型（med）,INFc,0.0,0.3,,,,,,,2013-11-28,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)01 (1b)02 (3a)05 (3b)01 (4sb)00 (4d)05 (5)00 (6)01 (7)01 (8a)02 (8p)01 (9)00 (11p)01 (12a)01," LM 后Post, 小弯侧Less,",22,20,5, R0 D2+,,5.9,3.2,2.2,91.0,290.0,2.84,6.0,12.0,128.0,88.0,13.0,5.61,1.36,72.2,154.6,39.2,33.0,5.1,2.6,62.0,223.0,,,,,,,,,,,,,1.09,22.73,1.46,,,, P0,H0,,,,,,,105.12483574244415,1333382
1333431,王玉霞,546369,女,58,T2,N0,M0, ⅠB,2,1,,0.0,0.0,0.0,,0.0,25,髓样型（med）,INFc,1.0,0.3,,,,,,,2013-11-28,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低分化管状腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)01 (1b)00 (3a)02 (3b)01 (4sb)00 (4d)05 (5)00 (6)02 (7)03 (8a)04 (8p)02 (9)02 (11p)03," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,8, R0 D2,,5.6,3.7,1.3,125.0,197.0,2.78,9.0,19.0,163.0,80.0,9.0,8.3,5.22,58.6,170.8,37.8,20.8,6.5,4.84,72.0,229.0,,,,,,,,,,,,,0.484,5.22,2.24,,,, P0,H0,,,,,,,105.12483574244415,1333431
1334141,江玉珍,548017,女,66,T3,N0,M0, ⅡA,2,3,,0.0,0.0,0.0,,0.0,31,硬型（sci）,INFb,1.0,0.8,,,,,,,2013-12-05,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化（G3)(por),G3, (1a)01 (1b)00 (3a)02 (3b)04 (4sb)03 (4d)03 (5)00 (6)06 (7)03 (8a)03 (8p)01 (9)00 (11p)04 (12a)00 (14v)01 (19)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",90,80,5, R0 D2+,,8.14,5.86,1.46,90.0,381.0,3.5,9.4,18.0,97.0,79.0,16.4,7.61,1.1,60.5,155.63,33.9,26.6,7.4,4.41,61.0,331.0,,,,,,,,,,,,,0.535,7.23,3.16,,,, P0,H0,,,,,,,104.89487516425756,1334141
1334589,赵桂兰,548205,女,75,T4a,N0,M0, ⅡB,2,2,,0.0,0.0,1.0,,0.0,58,硬型（sci）,INFb,0.0,,,,,,,,2013-12-10,2019-06-02,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3, 小弯 05 (1a)04 (1b)01 (2)05 (3a)012 (3b)03 (4sa)00 (4sb)01 (4d)09 (5)04 (6)00 (7)03 (8a)02 (8p)01 (9)02 (10)02 (11p)03 (11d)01 (12a)00," ML 前Ant, 后Post, 小弯侧Less,",110,115,5, R0 D2,,10.96,6.98,2.86,112.0,269.0,3.28,13.0,24.0,157.0,72.0,14.0,5.34,1.4,59.0,125.0,31.0,28.0,4.1,4.0,48.0,169.0,,,,,,,,,,,,,0.831,4.33,5.16,,,, P0,H0,,,,,,,65.7030223390276,1334589
1335571,张凤英,547654,女,53,T3,N1,M0, ⅡB,2,3,,0.0,0.0,1.0,,1.0,27,硬型（sci）,INFb,0.0,,,,,,,,2013-12-18,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)02 (3a)01 (3b)15 (4sb)00 (4d)01 (5)00 (6)05 (7)03 (8a)02 (8p)01 (9)00 (11p)07," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,8, R0 D2,,7.53,3.88,3.05,131.2,376.0,2.41,19.6,16.0,177.0,107.0,41.5,10.76,3.42,83.8,315.72,44.7,39.1,5.4,3.82,79.0,312.0,,,,,,,,,,,,,2.14,17.91,3.36,,,, P0,H0,,,,,,,104.46780551905387,1335571
1335736,石桂珍,545342,女,63,T3,N1,M0, ⅡB,2,2,,0.0,0.0,1.0,,2.0,23,硬型（sci）,INFb,0.0,,,,,,,,2013-12-19,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)00 (3a)00 (3b)01 (4sb)00 (4d)16 (5)13 (6)01 (7)05 (8a)03 (8p)03 (9)00 (12a)00 (12p)01," L（幽门窦部）, 后Post, 小弯侧Less,",50,40,10, R0 D2,,6.98,3.51,2.81,67.0,407.0,2.68,20.0,15.0,151.0,70.0,4.0,10.99,1.67,68.0,206.0,40.0,28.0,5.3,3.8,66.0,140.0,,,,,,,,,,,,,1.42,9.23,1.18,,,, P0,H0,,,,,,,104.43495400788436,1335736
1336002,丁继生,547604,男,61,T1b,N0,M0,ⅠA,2,2,,,,,,0.0,5,,,0.0,,,,,,,,2013-12-23,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a、1b)02 (3a、3b)00 (4sa)00 (4sb、4d)00 (5、12)00 (6)00 (7)03 (8a、9)00 (11p)00," L（幽门窦部）, 小弯侧Less,",60,50,, R0 D2,,5.65,3.98,1.02,136.0,248.0,2.54,9.0,22.0,133.0,68.0,19.0,11.21,2.36,60.0,207.0,37.0,23.0,5.0,5.2,65.0,280.0,,,,,,,,,,,,,1.72,11.42,4.24,,,, P0,H0,,,,,,,104.3035479632063,1336002
1336128,宋廷三,547778,男,62,T1b,N0,M0,ⅠA,2,2,,,,,,0.0,34,,,2.0,0.8,,,,,,,2013-12-24,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】90% 粘液腺癌（muc）10%,G2, (1a)02 (1b)05 (3a)03 (3b)01 (4sb)00 (4d)07 (5)00 (6)04 (7)01 (8a)03 (8p)02 (9)00 (11p)02 (12a)00 (14v)00 (19)04 ," L（幽门窦部）, 后Post,",35,25,5, R0 D2+,,6.2,3.57,2.26,154.1,141.0,2.45,27.0,17.0,130.0,63.0,14.0,23.7,7.64,61.0,362.0,38.0,23.0,6.1,7.6,83.0,260.0,,,,,,,,,,,,,2.19,7.39,1.76,,,, P0,H0,,,,,,,104.27069645203679,1336128
1336399,王雁,545384,女,41,T3,N0,M0, ⅡA,2,2,,0.0,0.0,1.0,,0.0,34,中间型（int）,INFc,0.0,0.9,,,,,,,2013-12-26,2019-04-20,1,,,,,,,,,0, 低分化管状腺癌（G3)(por)60% 粘液腺癌（muc）30% 低粘附腺癌10%,G3, (1a)01 (1b)00 (2)01 (3a)03 (3b)04 (4sa)00 (4sb)01 (4d)08 (5)01 (6)00 (7)04 (8a)01 (8p)02 (9)01 (11p)05 (12a)02," ML 小弯侧Less,",35,25,5, R0 D2,,3.81,2.44,0.95,117.0,209.0,2.45,14.0,18.0,177.0,70.0,17.0,10.87,5.3,79.7,266.6,38.8,40.9,4.6,5.77,85.0,341.0,,,,,,,,,,,,,0.2,8.42,1.82,,,, P0,H0,,,,,,,63.76478318002628,1336399
1400469,姜桂云,550454,女,57,T3,N0,M0, ⅡA,2,3,,0.0,0.0,1.0,,0.0,23,中间型（int）,INFc,0.0,0.6,,,,,,,2014-01-07,2022-09-02,1,,,FOLFOX,FOLFOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)00 (3a)05 (3b)01 (4sb)00 (4d)05 (5)01 (6)03 (7)02 (8a)03 (9)01 (11p)00 (12p)00," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,8, R0 D2,,5.58,2.76,2.09,105.4,210.0,2.58,16.0,30.0,155.0,87.0,16.0,5.37,2.17,62.0,188.0,38.0,24.0,4.4,4.9,58.0,207.0,,,,,,,,,,,,,1.78,34.64,7.41,,,, P0,H0,,,,,,,103.81077529566359,1400469
1401391,张继春,551641,男,63,T3,N0,M0, ⅡA,2,1,,,,,,0.0,46,中间型（int）,INFc,3.0,0.6,,,,,,,2014-01-14,2018-10-01,2,,,,,,,,,0, 乳头状癌（G1）（pap）,G1, (1a)04 (1b)00 (2)03 (3a)012 (3b)00 (4sa)02 (4sb)00 (4d)06 (5)01 (6)05 (7)04 (8a)01 (8p)01 (9)04 (11p)03 (12a)00," L（幽门窦部）, 后Post,",50,45,10, R0 D2,,4.12,1.88,1.9,65.0,259.0,2.09,11.0,36.0,147.0,53.0,11.0,12.78,5.45,65.0,201.0,44.0,21.0,4.8,7.7,84.0,312.0,,,,,,,,,,,,,0.913,5.02,1.02,,,, P0,H0,,,,,,,56.53745072273324,1401391
1402104,王文民,550579,男,63,T3,N1,M0, ⅡB,2,2,,1.0,1.0,0.0,,1.0,57,中间型（int）,INFc,0.0,,,,,,,,2014-01-21,2016-08-01,2,,,,,,,,,0, 腺鳞癌,GX, (1a)04 (1b)02 (2)00 (3a)012 (3b)14 (4sa)00 (4sb)016 (4d)05 (5)02 (6)00 (7)01 (8a)02 (8p)02 (9)07," M（胃体部）, 前Ant,",50,40,7, R0 D2,,6.66,4.38,1.55,108.8,330.0,3.68,7.0,20.0,142.0,95.0,13.0,17.98,7.11,68.0,180.0,43.0,25.0,5.3,6.1,78.0,304.0,,,,,,,,,,,,,1.01,11.42,2.59,,,, P0,H0,,,,,,,30.321944809461232,1402104
1402225,王福,552203,男,60,T1b,N0,M0,ⅠA,2,3,,,,,,0.0,27,,,1.0,,,,,,,,2014-01-22,2020-10-10,1,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a)01 (1b)06 (3a)08 (3b)00 (4sb)00 (4d)00 (5)00 (6)05 (7)02 (8a)01 (8p)02 (9)01 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",30,30,4, R0 D2,,4.65,3.13,0.76,115.3,170.0,3.68,14.8,9.0,110.0,72.0,24.6,7.43,2.11,61.8,204.13,37.4,24.4,5.6,4.28,93.0,206.0,,,,,,,,,,,,,0.902,10.67,1.76,,,, P0,H0,,,,,,,80.58475689881735,1402225
1402296,张金生,537769,男,64,T1b,N1,M0, ⅠB,2,2,,0.0,0.0,1.0,,1.0,21,,,2.0,,,,,,,,2014-01-23,2020-10-10,1,,,XELOX,XELOX,,,,,2, 低分化管状腺癌（G3)(por)90% 低粘附腺癌10%,G3, (1a)00 (1b)01 (3a)01 (3b)00 (4sb)01 (4d)00 (5)01 (6)19 (7)00 (8a)03 (8p)02 (9)02 (11p)01 (12a)00 (12p)00," L（幽门窦部）, 大弯侧Gre,",5,3,2, R0 D2,,5.25,2.76,1.83,141.6,239.0,2.54,14.0,18.0,131.0,44.0,18.0,15.67,6.55,63.0,225.0,39.0,24.0,4.4,3.7,79.0,273.0,,,,,,,,,,,,,1.77,6.39,1.16,,,, P0,H0,,,,,,,80.55190538764784,1402296
1402319,孙叶松,551331,男,77,T3,N0,M0, ⅡA,2,2,,0.0,0.0,1.0,,0.0,7,中间型（int）,INFc,1.0,,,,,,,,2014-01-24,2019-04-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)04 (1b)00 (2)00 (3a)02 (3b)01 (4sb)00 (4d)00 (7)00 (9)00 (11p)00," U（胃底部）, 后Post, 小弯侧Less,",30,30,15, R0 D2,,5.17,3.36,1.11,116.2,149.0,1.83,12.0,16.0,111.0,46.0,19.0,8.52,3.94,61.0,213.0,36.0,25.0,6.0,7.6,87.0,310.0,,,,,,,,,,,,,3.75,18.41,20.74,,,, P0,H0,,,,,,,62.352168199737186,1402319
1405352,袁长江,555274,男,55,T3,N0,M0, ⅡA,2,3,,,,,,0.0,45,髓样型（med）,INFb,2.0,0.9,,,,,,,2014-03-03,2019-04-20,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】80% 乳头状癌（G1）（pap）20%,G2,(1a)00 (1b)04 (2)03 (3a)016 (3b)04 (4sa)04 (4sb)01 (4d)01 (5)00 (7)05 (8a)01 (8p)00 (9)05 (20)00,胃癌 GE 前Ant,70,50,10, R0 D2,,6.74,4.31,1.77,147.0,242.0,3.68,31.4,19.0,146.0,109.0,87.4,14.34,6.82,69.5,174.95,41.5,28.0,,,,,,,,,,,,,,,,,5.37,157.5,9.48,,无, 无, P0,H0,,,,,,,61.563731931668855,1405352
1406048,齐成辉,553975,男,71,T3,N0,M0, ⅡA,2,3,,0.0,0.0,1.0,,0.0,31,中间型（int）,INFb,3.0,0.75,,,,,,,2014-03-10,2019-11-06,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2,(1a)03 (1b)01 (2)06 (3a)00 (3b)00 (4sa)00 (4sb)01 (4d)00 (5)00 (6)07 (7)04 (8a)03 (8p)01 (9)02 (11p)04," GE, 前Ant, 后Post, 小弯侧Less,",25,25,15, R0 D2,,9.21,4.96,3.19,143.0,125.0,1.93,12.0,20.0,221.0,60.0,10.0,20.25,6.61,65.0,174.0,42.0,23.0,,,,,,,,,,,,,,,,,37.99,1000.0,6.92,,无, 无, P0,H0,,,,,,,67.90407358738501,1406048
1407742,黄子良,553966,男,73,T3,N1,M0, ⅡB,2,3,,1.0,1.0,0.0,,1.0,45,髓样型（med）,INFb,3.0,0.9,,,,,,,2014-03-24,2019-05-01,1,,,,,,,,,0, 管状腺癌（低分化（G3)(por)）,G3, (1a)03 (1b)02 (3a)09 (3b)00 (4sb)04 (4d)09 (5)11 (6)01 (7)01 (8a、8p)02 (9)06 (11p)03 (12a、12b)02 (14v)02," L（幽门窦部）, 后Post,",20,20,3, R0 D2,,6.49,3.14,2.16,136.0,225.0,3.85,13.0,22.0,126.0,91.0,25.0,14.93,5.27,63.0,138.0,39.0,24.0,,,,,,,,,,,,,,,,,1.13,31.74,2.51,,无,, P0,H0,,,,,,,61.235216819973715,1407742
1407526,高景芳,557598,男,57,T3,N0,M0, ⅡA,2,3,,,,,,0.0,72,髓样型（med）,INFa,0.0,0.55,,,,,,,2014-03-20,2022-09-02,1,,,,,,,,,0, 管状腺癌 （低分化（G3)(por)）,G3,(1a)08 (1b)010 (3a)02 (3b)07 (4sb)08 (4d)07 (5)00 (6)03 (7)014 (8a)00 (8p)04 (9)01 (11p)01 (12a)00 (14v)05,L（幽门窦部） 后Post 小弯侧Less 大弯侧Gre  ,40,25,5, R0 D2,,6.64,4.89,1.18,150.8,268.0,3.21,24.0,19.0,150.0,68.0,7.0,18.4,6.86,68.0,314.0,43.0,25.0,,,,,,,,,,,,,,,,,1.45,5.12,2.57,,无,, P0,H0,,,,,,,101.4454664914586,1407526
1409704,李艳华,557545,女,56,T1a,N0,M0,ⅠA,2,2,,,,,,0.0,34,,,1.0,0.65,,,,,,,2014-04-10,2022-09-02,1,,,,,,,,,0,高级别上皮内瘤变,GX, (1a)07 (1b)01 (3a)02 (3b)01 (4sb)00 (4d)02 (5)00 (6)08 (7)02 (8a、8p)08 (9)01 (11p)02 (12a、12b)00 (14v)00," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",25,25,1, R0 D2,,7.34,5.41,1.39,128.9,248.0,2.54,15.0,18.0,150.0,60.0,7.0,12.53,4.31,66.0,332.0,44.0,22.0,,,,,,,,,,,,,,,,,2.18,0.6,1.31,,无, 无, P0,H0,,,,,,,100.75558475689881,1409704
1408697,丁玉春,557557,女,44,T2,N0,M0, ⅠB,2,2,,1.0,1.0,0.0, 正常,0.0,15,髓样型（med）,INFa,3.0,0.45,,,,,,,2014-03-31,2019-02-14,1,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】中分化【G2】【tub2】）70% 乳头状癌（G1）（pap）30%,G2, (1a)03 (1b)00 (2)01 (3a)00 (3b)00 (4sa)00 (4sb)00 (4d)00 (5)00 (6)00 (7)01 (8a)01 (8p)02 (9)05 (11p)02 (12a)00 (14v)00,"胃癌 U（胃底部） E（食道） GE SiewerⅢ型, 后Post 小弯侧Less Borrmann2型",40,25,10, R0 D2,,3.95,1.9,1.44,149.0,215.0,2.54,18.0,26.0,162.0,72.0,9.0,17.63,5.94,74.0,221.0,42.0,32.0,,,,,,,,,,,,,,,,,0.737,6.26,1.35,,无, 无, P0,H0,,,,,,,58.50854139290407,1408697
1408876,张志荣,557552,男,72,T3,N1,M0, ⅡB,2,3,,,,,,1.0,7,髓样型（med）,INFb,1.0,0.15,,,,,,,2014-04-02,2016-05-01,2,,,,,,,,,0,黏液腺癌（muc）90% 乳头状癌（G1）（pap）5% 管状腺癌（中分化【G2】【tub2】)5%,G2, (1a)(1b)03 (2)00 (3a)(3b)00 (4sa)00 (4sb)01 (4d)00 (7)(8a)(8p)(9)01 (11p)12 (12a)00,胃癌 GE 前Ant  小弯侧Less,90,70,15, R0 D2,,3.64,2.06,1.21,135.0,140.0,1.95,10.0,20.0,116.0,52.0,16.0,16.36,5.36,60.0,210.0,36.0,24.0,,,,,,,,,,,,,,,,,22.0,25.97,1.8,,无,, P0,H0,,,,,,,24.967148488830485,1408876
1409355,姜洪有,558611,男,80,T4a,N0,M0, ⅡB,2,4,,0.0,0.0,1.0,,0.0,28,硬型（sci）,INFc,0.0,0.15,,,,,,,2014-04-08,2017-07-05,2,,,,,,,,,0, 低分化腺癌（G3)(por) 低粘附腺癌,G3, (1a)02 (1b)02 (3a)01 (7)07 (8a)01 (8p、9)01 (11p)05 (12a)01 (4d)03 (3b)00 (5)00 (6)04 (4sb)01," L（幽门窦部）, 小弯侧Less,",30,25,5, R0 D2,,7.29,4.37,2.03,139.8,171.0,2.68,10.0,16.0,158.0,57.0,4.0,16.31,5.36,61.0,187.0,38.0,23.0,,,,,,,,,,,,,,,,,1.47,9.25,3.29,,无,, P0,H0,,,,,,,38.89618922470434,1409355
1414385,夏秀珍,558864,女,74,T3,N0,M0, ⅡA,2,3,,0.0,0.0,1.0,,0.0,21,中间型（int）,INFb,2.0,,0.0,0.0,,,,2.0,2014-05-26,2019-09-02,1,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,14, 管状腺癌（中分化【G2】【tub2】70 乳头状癌（G1）（pap）30 Lauren肠型,G2, (1a)00 (1b)04 (2)03 (3a)06 (4sa)00 (4sb)00 (4d)00 (8a)02 (8p)01 (9)00 (7)01 (11d)00 (11p)04," U（胃底部）, 小弯侧Less,",50,40,20, R0 D2,,4.97,63.44,25.34,134.4,233.0,2.27,,,,65.0,15.0,,,,234.0,44.0,27.0,,,,,,,,,,,,,,,,,0.6,46.57,12.56,,,, P0,H0,,,,,,,63.23915900131406,1414385
1410056,宗瑞鹏,559223,男,60,T2,N0,M0, ⅠB,2,3,,1.0,1.0,0.0,,0.0,45,硬型（sci）,INFb,1.0,0.2,,,,,,,2014-04-14,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)01 (1b)04 (3a)016 (3b)01 (4sb)00 (4d)02 (5)02 (6)07 (7)01 (8a、8p)04 (9)04 (11p)00 (12a、12b)02 (14v)01," L（幽门窦部）, 前Ant, 小弯侧Less,",35,30,8, R0 D2+,,5.03,3.23,1.45,142.0,170.0,2.94,17.0,18.0,143.0,60.0,8.0,23.56,8.23,68.0,231.0,45.0,23.0,5.8,8.0,101.0,270.0,,,,,,,,,,,,,2.22,6.94,5.03,,,, P0,H0,,,,,,,100.62417871222075,1410056
1410162,宁长海,560495,男,61,T2,N0,M0, ⅠB,2,2,,1.0,1.0,0.0,,0.0,37,中间型（int）,INFb,0.0,0.6,,,,,,,2014-04-14,2022-09-02,1,,,口服卡培他滨,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)04 (3a)011 (3b)00 (4sb)00 (4d)02 (5)01 (6)06 (7)04 (8a)(8p)02 (9)02 (11p)03, L（幽门窦部） 小弯侧Less 前Ant ,30,20,8, R0 D2,,6.09,3.82,1.65,157.9,295.0,2.84,16.0,18.0,168.0,64.0,11.0,10.76,3.33,71.0,214.0,44.0,27.0,6.3,8.0,92.0,225.0,,,,,,,,,,,,,2.26,1.13,1.61,,,, P0,H0,,,,,,,100.62417871222075,1410162
1410879,彭桂琴,557194,女,75,T2,N1,M0, ⅡA,2,2,,1.0,1.0,0.0,,1.0,19,中间型（int）,INFa,1.0,,,,,,,,2014-04-21,2019-05-01,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)02 (3a)03 (3b)00 (4sb)00 (4d)01 (5)00 (6)12 (7)02 (8a、8p)07 (9)00 (12a)00 (12p)01," L（幽门窦部）, 大弯侧Gre,",25,25,10, R0 D2,,7.18,3.68,2.87,129.0,258.0,3.46,15.0,28.0,199.0,77.0,13.0,7.71,2.81,73.0,239.0,43.0,30.0,5.4,7.5,84.0,300.0,,,,,,,,,,,,,2.82,34.91,,,,, P0,H0,,,,,,,60.31537450722733,1410879
1411168,刘志,560233,男,67,T3,N0,M0, ⅡA,2,3,2.0,0.0,0.0,1.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,0.0,22,硬型（sci）,INFc,0.0,,,,,,,,2014-04-23,2016-10-01,2,,,,,,,,,0, 低粘附腺癌,GX, (1a)00 (1b)00 (2)03 (3a)04 (3b)00 (4sa)00 (4sb)04 (4d)02 (5)00 (6)00 (7)05 (8a)(8p)(9)03 (11p)01 (11d)00, MU 小弯侧Less 前Ant 后Post,35,30,8, R0 D2,,6.57,3.97,1.94,154.0,241.0,2.58,17.0,23.0,114.0,77.0,16.0,8.41,3.47,65.0,216.0,41.0,24.0,4.8,7.2,79.0,235.0,,,,,,,,,,,,,0.961,5.37,1.22,,,, P0,H0,,,,,,,29.303547963206306,1411168
1411024,刘洪九,560996,男,70,T3,N0,M0, ⅡA,2,2,,1.0,1.0,1.0, 正常,0.0,22,中间型（int）,INFb,1.0,0.55,,,,,,,2014-04-22,2019-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)02 (2)02 (3a)04 (3b)00 (4sb)00 (4d)00 (5)01 (6)02 (7)04 (8a)03 (8p)01 (9)01 (12a)00 (12p)00," U（胃底部）, 小弯侧Less,大弯侧Gre ",30,25,5, R0 D2,,7.18,4.22,2.41,160.0,231.0,4.66,20.0,26.0,178.0,69.0,10.0,18.67,5.5,70.0,250.0,42.0,28.0,9.6,6.0,79.0,205.0,,,,,,,,,,,,,2.13,11.58,1.36,,,, P0,H0,,,,,,,64.35611038107753,1411024
1412195,丛淑芳,560038,女,75,T3,N0,M0, ⅡA,2,1,1.0,,,, 正常,0.0,33,髓样型（med）,INFb,0.0,,0.0,0.0,,,,,2014-05-05,2015-07-30,2,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a)03 (1b)00 (2)00 (3a)06 (3b)05 (4sa)00 (4sb)03 (4d)01 (5)00 (6)03 (7)04 (8a)02 (8p、9)03 (10)02 (11)01    ," U（胃底部）, M（胃体部）,MU 后Post,",60,50,15, R0 D2,,5.61,3.65,1.19,128.0,254.0,2.0,15.0,24.0,181.0,79.0,12.0,16.72,7.05,68.0,166.0,39.0,29.0,4.7,4.0,75.0,308.0,,,,,,,,,,,,,1.3,4.68,0.878,,,, P0,H0,,,,,,,14.816031537450723,1412195
1412267,宁树忠,561238,男,63,T2,N0,M0, ⅠB,2,3,0.0,1.0,1.0,0.0,肠上皮化生，慢性炎,0.0,22,中间型（int）,INFb,1.0,,0.0,0.0,,,,,2014-05-05,2022-09-02,1,,,口服替吉奥,口服替吉奥,口服替吉奥,,,,3, 管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】50% 粘液腺癌（muc）50%,G3, (1a)00 (1b)04 (3a)03 (3b)01 (4sb)00 (4d)04 (5)00 (6)00 (7)01 (8a)01 (8p)03 (9)02 (12a)00 (11p)03 ," L（幽门窦部）, 后Post, 大弯侧Gre,",60,50,15, R0 D2,,4.25,2.58,1.36,87.3,114.0,4.22,32.0,44.0,215.0,88.0,45.0,6.04,3.2,58.0,231.0,37.0,21.0,4.7,5.8,85.0,280.0,,,,,,,,,,,,,1.89,0.6,1.39,,,, P0,H0,,,,,,,99.93429697766096,1412267
1411904,赵春江,561436,男,63,T3,N0,M0, ⅡA,2,2,0.0,0.0,0.0,0.0, 肠化生,0.0,18,硬型（sci）,INFb,0.0,,0.0,0.0,,,,,2014-04-29,2019-05-01,1,,,,,,,,,0, 浸润型伴有淋巴样间质的癌 Lauren肠型,GX, (1a)00 (1b)02 (3a)02 (3b)05 (4sb)00 (4d)01 (5)00 (6)00 (7)02 (8a)01(8p)01 (9)00 (11p)04 (12a)00 ," L（幽门窦部）, M（胃体部）, 后Post, 大弯侧Gre,",35,15,31, R0 D2,,7.31,4.13,2.4,162.6,169.0,2.94,12.0,18.0,177.0,78.0,5.0,23.26,8.36,79.0,239.0,46.0,33.0,4.8,9.1,110.0,409.0,,,,,,,,,,,,,1.24,9.44,2.6,,,, P0,H0,,,,,,,60.05256241787122,1411904
1412003,徐丽芬,561802,女,52,T2,N1,M0, ⅡA,2,3,2.0,,,, 正常,1.0,19,硬型（sci）,INFc,0.0,,0.0,0.0,,,,,2014-04-30,2019-04-20,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低粘附腺癌,GX, (1a)02 (1b)01 (3a)02 (3b)00 (4sb)00 (4d)13 (5)00 (6)05 (7)05 (8a)(8p)00 (9)01 , L（幽门窦部） 前Ant 大弯侧Gre ,30,25,5, R0 D2,,4.86,2.58,1.79,138.3,218.0,2.94,14.0,17.0,187.0,91.0,24.0,7.9,2.22,69.0,228.0,44.0,25.0,5.6,7.0,74.0,368.0,,,,,,,,,,,,,0.392,2.35,5.67,,,, P0,H0,,,,,,,59.65834428383705,1412003
1414673,梁若丹,561945,男,60,T3,N0,M0, ⅡA,2,3,0.0,,,, 肠化生 异型增生,0.0,14,中间型（int）,INFb,0.0,,0.0,0.0,,,,,2014-05-27,2019-06-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)01 (2)02 (3a)00 (3b)00 (4sa)02 (4sb)00 (4d)01 (5)01 (6)01 (7)00 (8a)02 (8p)01 (9)01 (11p)(11d)01 (12a)00," ML 小弯侧Less, 后Post,",22,7,2, R0 D2,,8.43,4.61,3.01,146.0,255.0,2.7,23.0,24.0,178.0,92.0,30.0,16.46,5.51,74.0,292.0,43.0,31.0,5.7,5.4,88.0,322.0,,,,,,,,,,,,,1.24,4.5,6.52,,,, P0,H0,,,,,,,60.183968462549274,1414673
1415221,徐连义,563572,男,51,T1a,N0,M0,ⅠA,2,2,,,,,,0.0,40,,,2.0,,0.0,0.0,,,,1.0,2014-06-03,2022-09-02,1,,,,,,,,,0, 管状腺癌（低分化腺癌（G3)(por)  中分化【G2】【tub2】,G3, (1a)09 (1b)06 (3a)02 (3b)01 (4sb)00 (4d)07 (5)00 (6)00 (7)02 (8a)00 (9)03 (11p)00 (8p、12p)010," L（幽门窦部）, 小弯侧Less,",25,20,5, R0 D2,,6.15,3.55,1.92,168.0,282.0,3.06,14.0,19.0,175.0,74.0,18.0,15.98,4.57,75.0,280.0,44.0,31.0,5.9,9.0,89.0,456.0,,,,,,,,,,,,,1.51,14.61,2.29,,,, P0,H0,,,,,,,98.98160315374507,1415221
1416643,杨波,563121,女,35,T2,N0,M0, ⅠB,2,2,2.0,,,, 肠化生,0.0,30,中间型（int）,INFc,0.0,,0.0,0.0,,,,1.0,2014-06-17,2019-09-02,1,,,XELOX,XELOX,SOX,SOX,,,4, 低粘附腺癌 Lauren弥漫型,GX, (1a)03 (1b)01 (2)04 (3a)00 (3b)02 (4sa)02 (4sb)03 (4d)02 (5)01 (6)01 (7)04 (8a)01 (8p)02 (9)03 (11p)01 (12a)00," U（胃底部）, 小弯侧Less, 后Post,",12,,, R0 D2,,5.8,2.67,2.56,120.0,267.0,2.65,19.0,27.0,174.0,41.0,8.0,17.44,6.58,77.0,304.0,43.0,34.0,4.5,4.9,65.0,237.0,,,,,,,,,,,,,0.995,5.3,2.23,,,, P0,H0,,,,,,,62.516425755584756,1416643
1416936,刘长云,565783,女,50,T1b,N0,M0,ⅠA,2,3,2.0,,,,,0.0,30,中间型（int）,INFa,1.0,,0.0,0.0,,,,0.0,2014-06-18,2022-09-02,1,,,口服替吉奥,口服替吉奥,,,,,2, 低分化管状腺癌（G3)(por)60% 低粘附腺癌40% Lauren弥漫型,G3, (1a)02 (1b)02 (3a)00 (3b)00 (4sb)01 (4d)04 (5)00 (6)03 (7)04 (8a)02 (8p)02 (9)08 (11p)01 (12a)00 (12p)01      ," L（幽门窦部）, 后Post, 小弯侧Less,",25,22,10, R0 D2,,9.1,5.92,2.39,161.9,160.0,2.78,13.0,25.0,148.0,41.0,9.0,11.2,5.18,73.0,248.0,41.0,32.0,5.3,5.6,73.0,264.0,,,,,,,,,,,,,2.21,9.97,1.03,,,, P0,H0,,,,,,,98.48883048620236,1416936
1417856,戴伟明,566408,男,62,T3,N0,M0, ⅡA,2,1,2.0,1.0,1.0,0.0,,0.0,21,中间型（int）,INFc,0.0,,0.0,0.0,,,,0.0,2014-06-26,2020-10-11,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化（G3)(por)85% 乳头状癌（G1）（pap）15%,G3, (1a)01 (1b)03 (2)03 (3a)00 (3b)01 (4sa)01 (4sb)01 (4d)(10)01 (5)00 (7)03 (8a)03 (8p)02 (9)01 (11p)(11d)01,L（幽门窦部） M（胃体部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,35,30,8, R0 D2,,4.18,3.05,0.72,92.7,252.0,2.32,12.0,13.0,122.0,73.0,22.0,11.2,4.66,64.0,237.0,39.0,25.0,5.3,6.9,86.0,280.0,,,,,,,,,,,,,14.23,5.31,1.56,,,, P0,H0,,,,,,,75.52562417871222,1417856
1418232,黄兴太,566761,男,59,T3,N0,M0, ⅡA,2,3,1.0,1.0,1.0,0.0,,0.0,24,中间型（int）,INFc,0.0,,0.0,0.0,,,,1.0,2014-07-01,2019-04-20,1,,,,,,,,,0, 低分化管状腺癌（G3)(por),G3, (1a)01 (1b)02 (3a)01 (3b)00 (4sb)00 (4d)08 (5)00 (6)04 (7)00 (8a)03 (8p)00 (9)02 (11p)03 (12a)00,胃癌 L（幽门窦部）前Ant,60,60,10, R0 D2,,5.1,3.01,1.35,84.0,377.0,4.2,10.0,15.0,151.0,72.0,9.0,9.88,2.81,71.0,222.0,43.0,28.0,5.2,6.7,92.0,187.0,,,,,,,,,,,,,3.12,6.84,1.29,,,, P0,H0,,,,,,,57.6215505913272,1418232
1419415,刘克新,568211,男,56,T2,N0,M0, ⅠB,2,3,1.0,,,,,0.0,23,中间型（int）,INFb,2.0,,0.0,0.0,,,,2.0,2014-07-11,2022-09-02,1,,,,,,,,,0, 管状腺癌（低分化（G3)(por) 中分化【G2】【tub2】,G3, (1a)01 (1b)01 (3a)01 (4sb)00 (4d)06 (5)00 (6)05 (7)01 (8a)00 (8p)01 (9)06 (11p)00 (12a)00 结肠系膜01, L（幽门窦部） 前Ant ,30,30,8, R0 D2,,5.97,3.16,2.42,152.0,210.0,2.66,12.0,21.0,167.0,52.0,12.0,10.77,4.07,70.0,373.0,41.0,29.0,5.2,9.8,74.0,410.0,,,,,,,,,,,,,2.85,13.15,1.32,,,, P0,H0,,,,,,,97.73324572930355,1419415
1420712,刘清明,568990,男,41,T2,N0,M0, ⅠB,2,2,1.0,,,,,0.0,14,中间型（int）,INFa,1.0,,0.0,0.0,,,,2.0,2014-07-23,2019-09-02,1,,,,,,,,,0, 乳头状癌（G1）（pap）60%  管状腺癌（中分化【G2】【tub2】40%,G2, (1a)02 (1b)02 (2)03 (3a)00 (3b)01 (4sa)00 (4sb)00 (4d)00 (5)00 (7)02 (8a)00 (9)01 (11p)00," U（胃底部）, 小弯侧Less,",28,20,3, R0 D2,,6.61,4.87,1.29,152.4,150.0,3.07,35.0,32.0,202.0,72.0,35.0,18.32,6.47,73.0,271.0,44.0,29.0,4.9,4.3,81.0,324.0,,,,,,,,,,,,,5.37,52.23,0.993,,,, P0,H0,,,,,,,61.333771353482256,1420712
1421218,李伟,569591,女,39,T1a,N0,M0,ⅠA,2,0,,,,,,0.0,25,,,0.0,,0.0,0.0,,,,0.0,2014-07-28,2022-09-02,1,,,,,,,,,0, 管状腺癌 管状腺癌（低分化（G3)(por) 中分化【G2】【tub2】 Lauren肠型,G3, (1a)05 (1b)07 (3a)00 (3b)01 (4sb)03 (4d)01 (5)01 (6)01 (7)06 (8a)(8p)00 (9)00, L（幽门窦部） 小弯侧Less ,15,10,4, R0 D2,,6.88,3.68,2.6,122.0,286.0,2.58,26.0,29.0,217.0,65.0,14.0,12.89,3.3,75.0,266.0,42.0,33.0,4.8,7.0,66.0,346.0,,,,,,,,,,,,,0.858,10.98,0.797,,,, P0,H0,,,,,,,97.17477003942182,1421218
1423214,姚洪英,567531,女,54,T2,N0,M0, ⅠB,2,2,0.0,,,, 肠化生,0.0,22,中间型（int）,INFa,1.0,,1.0,0.0,,,,0.0,2014-08-14,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)02 (1b)04 (3a)00 (3b)00 (4sb)02 (4d)05 (5)01 (6)04 (7)00 (8a)00 (8p)(9)00 (11p)04," L（幽门窦部）, 后Post,",35,30,6, R0 D2,,4.58,2.72,1.54,133.0,197.0,2.32,18.0,25.0,157.0,98.0,19.0,14.65,5.14,73.0,253.0,43.0,30.0,4.3,6.9,58.0,326.0,,,,,,,,,,,,,1.64,19.8,2.14,,,, P0,H0,,,,,,,96.61629434954007,1423214
1424043,梁世延,572250,男,62,T3,N0,M0, ⅡA,2,2,0.0,,,, 肠化生,0.0,31,中间型（int）,INFa,1.0,,0.0,0.0,,,,2.0,2014-08-21,2022-09-02,1,,,FOLFOX,FOLFOX,FOLFOX,,,,3, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)03 (2)01 (3a)04 (3b)02 (4sa)00 (4sb)00 (4d)05 (5)(11p)02 (6)07 (7)03 (8a)01 (8p)01 (9)00 小弯02,M（胃体部） 小弯侧Less 后Post ,25,18,3, R0 D2,,7.06,4.18,2.17,159.9,215.0,3.53,14.0,18.0,176.0,75.0,18.0,14.55,4.49,76.0,275.0,50.0,26.0,5.6,5.4,91.0,352.0,,,,,,,,,,,,,2.41,6.67,1.78,,,, P0,H0,,,,,,,96.38633377135348,1424043
1424500,张玉萍,572278,女,41,T3,N0,M0, ⅡA,2,2,0.0,,,, 肠化生 异型增生,0.0,43,髓样型（med）,INFa,1.0,,0.0,0.0,,,,0.0,2014-08-26,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（低分化（G3)(por) 中分化【G2】【tub2】 Lauren肠型,G3, (1a)01 (1b)00 (3a)01 (3b)016 (4sb)00 (4d)07 (5)00 (6)05 (7)05 (8a)03 (8p)00 (9)00 (11p)03 (12a)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,40,10, R0 D2,,6.09,3.45,2.03,128.4,250.0,3.33,14.0,22.0,187.0,85.0,13.0,12.71,3.57,74.0,249.0,43.0,31.0,4.5,6.1,57.0,301.0,,,,,,,,,,,,,0.89,17.69,7.43,,,, P0,H0,,,,,,,96.22207621550591,1424500
1425121,吴世杰,570541,男,57,T1b,N1,M0, ⅠB,2,3,,,,,,1.0,24,,,2.0,,1.0,0.0,,,,1.0,2014-09-01,2022-09-02,1,,,SOX,口服替吉奥,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)01 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)01 (5)01 (6)02 (7) 04(8a)02 (8p)12 (9)00 (11p)01,L（幽门窦部） 小弯侧Less ,30,30,1, R0 D2,,6.89,4.2,1.96,154.5,189.0,3.27,22.0,20.0,139.0,89.0,16.0,9.55,2.71,64.0,365.0,41.0,23.0,6.1,7.1,74.0,246.0,,,,,,,,,,,,,1.27,12.54,2.79,,,, P0,H0,,,,,,,96.02496714848883,1425121
1425269,王喜英,572456,女,64,T1a,N0,M0,ⅠA,2,3,,,,,,0.0,27,,,0.0,,0.0,0.0,,,,2.0,2014-09-02,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)03 (1b)05 (3a)00 (3b)02 (4sb)00 (4d)01 (5)00 (6)03 (7)05 (8a)04 (9)01 (11p)02," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,25,3, R0 D2,,9.71,5.56,3.18,144.8,178.0,18.1,20.0,20.0,168.0,80.0,42.0,10.5,3.24,77.0,329.0,49.0,28.0,5.5,6.5,88.0,546.0,,,,,,,,,,,,,2.83,6.32,3.16,,,, P0,H0,,,,,,,95.99211563731932,1425269
1425350,王金权,571785,男,58,T4b,N0,M0, ⅢA,2,3,1.0,1.0,1.0,0.0, 正常,0.0,18,髓样型（med）,INFb,1.0,,0.0,0.0,,,,2.0,2014-09-02,2020-10-12,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化管状腺癌（G3)(por)80% 低粘附腺癌20%,G3, (1a)02 (1b)06 (3a)00 (3b)00 (4sa)02 (4sb)01 (4d)00 (5)00 (6)01 (7)06 (8a)00 (8p)00 (9)00 (11p)00 (12a)00,M（胃体部） 后Post ,45,45,15, R0 D2,,6.67,3.36,2.6,149.4,322.0,3.34,16.0,18.0,144.0,100.0,28.0,21.77,8.89,72.0,246.0,46.0,26.0,4.7,4.8,89.0,377.0,,,,,,,,,,,,,0.818,5.11,1.32,,,, P0,H0,,,,,,,73.32457293035479,1425350
1425457,杜俊芹,573652,女,60,T2,N0,M0, ⅠB,2,3,0.0,,,, 肠化生 异型增生,0.0,19,髓样型（med）,INFa,0.0,,0.0,0.0,,,,1.0,2014-09-03,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)01 (4d)01 (5)00 (6)01 (7)04 (8a)04 (8p)01 (9)02 (11p)03," L（幽门窦部）, 后Post,",30,20,5, R0 D2,,6.27,3.88,1.9,142.1,272.0,3.53,15.0,19.0,140.0,147.0,26.0,8.33,2.32,76.0,266.0,47.0,29.0,5.8,6.9,83.0,315.0,,,,,,,,,,,,,0.703,5.93,4.21,,,, P0,H0,,,,,,,95.9592641261498,1425457
1425855,谭坤,573683,男,53,T3,N0,M0, ⅡA,2,2,1.0,0.0,0.0,1.0, 肠化生 异型增生,0.0,43,髓样型（med）,INFb,0.0,,0.0,0.0,,,,0.0,2014-09-09,2020-04-16,1,,,,,,,,,0, 低粘附腺癌60% 粘液腺癌（muc）30%  管状腺癌（低分化腺癌（G3)(por) 中分化【G2】【tub2】10 Lauren混合型,G3, (1a)02 (1b)04 (3a)09 (3b)01 (4sb)00 (4d)05 (5)01 (6)06 (7)03 (8a)02 (8p)02 (9)05 (11p)02 (12a)00 (14v)01," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,18, R0 D2+,,7.1,4.51,1.9,148.4,279.0,2.72,13.0,16.0,163.0,58.0,15.0,8.72,2.82,67.0,289.0,46.0,21.0,5.0,9.1,73.0,279.0,,,,,,,,,,,,,1.58,8.04,15.09,,,, P0,H0,,,,,,,67.21419185282522,1425855
1427675,郝君,573033,男,66,T2,N0,M0, ⅠB,2,3,1.0,0.0,0.0,0.0, 腺体萎缩+ 肠化生+ 慢性炎症（+）,0.0,39,髓样型（med）,INFa,0.0,,0.0,0.0,,,,2.0,2014-09-25,2020-04-16,1,,,SOX,SOX,SOX,奥沙利铂单药化疗,,,4, 粘液腺癌（muc）80% 低粘附腺癌10% 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)10% Lauren混合型,G3, (1a)00 (1b)03 (3a)06 (3b)00 (4sb)00 (4d)011 (5)00 (6)03 (7)03 (8a)03 (8p)02 (9)03 (11p)04 (12a)00 (12p)01 (14v)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",20,20,2, R0 D2+,,7.19,4.89,1.55,133.1,386.0,3.66,14.0,19.0,183.0,71.0,8.0,1.61,1.02,61.0,136.0,39.0,22.0,5.9,5.4,88.0,231.0,,,,,,,,,,,,,2.19,10.0,7.91,,,, P0,H0,,,,,,,66.688567674113,1427675
1427766,唐占清,574405,男,61,T1a,N0,M0,ⅠA,2,0,,,,,,0.0,14,,,0.0,,0.0,0.0,,,,0.0,2014-09-25,2020-04-16,1,,,,,,,,,0,伴肠上皮化生及高级上皮内瘤变 粘膜内癌,GX, (1a)00 (1b)00 (3a)08 (3b)00 (4sb)00 (4d)01 (5)00 (6)02 (7)01 (8a)01 (9)01 (12a)00," M（胃体部）, 小弯侧Less,",15,15,, R0 D2,,5.95,3.99,1.4,141.2,126.0,2.76,54.0,33.0,191.0,57.0,23.0,19.41,8.28,81.0,362.0,47.0,34.0,6.0,7.2,73.0,442.0,,,,,,,,,,,,,1.7,14.86,1.54,,,, P0,H0,,,,,,,66.688567674113,1427766
1428217,王国栋,577030,男,52,T3,N1,M0, ⅡB,2,3,2.0,0.0,0.0,1.0, 肠化生 慢性炎症,1.0,24,硬型（sci）,INFc,0.0,,2.0,2.0,,,,0.0,2014-09-29,2020-04-16,1,,,SOX,SOX,SOX,SOX,替吉奥单药化疗,,5, 低粘附性癌 Lauren弥漫型,GX, (1a)01 (1b)114 （2）02 (3a)08 (3b)02 (4sa)00 (4sb)00 （4d）04 (5)00 (6)01 (7)01 (8a)01 (9)00 (11p)00 ,胃癌 L（幽门窦部） 前Ant,35,20,5, R0 D2,,5.51,2.75,2.3,143.0,167.0,3.18,25.0,25.0,170.0,76.0,5.0,13.43,4.93,71.0,367.0,43.0,28.0,5.7,10.3,80.0,365.0,,,,,,,,,,,,,0.775,10.53,3.02,,,, P0,H0,,,,,,,66.55716162943496,1428217
1430583,崔峰,576465,男,64,T2,N0,M0, ⅠB,2,3,0.0,1.0,1.0,1.0,,0.0,22,髓样型（med）,INFa,1.0,,0.0,2.0,,,,2.0,2014-10-22,2018-06-07,0,,,XELOX,XELOX,,,,,2, 低分化管状腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)00 (3a)03 (3b)00 (4sb)02 (4d)00 (5)00 (6)05 (7)07 (8a)(8p)01 (9)03 (11p)01 (12a)00 (14v)00,L（幽门窦部） 大弯侧Gre  前Ant 后Post ,60,50,5, R0 D2+,,8.77,5.84,1.95,158.5,405.0,4.74,11.0,13.0,141.0,85.0,12.0,13.06,4.97,71.0,202.0,43.0,28.0,5.8,5.7,66.0,372.0,69.0,48.9,18.7,2.61,0.1,10.2,19.5,1.9,1.01,2.32,16.0,138.0,2.11,60.15,1.79,,,, P0,H0,,,,,,,43.495400788436264,1430583
1430850,刘军,577842,男,56,T3,N0,M0, ⅡA,2,3,0.0,1.0,1.0,1.0, 肠化生 异型增生 慢性炎症,0.0,25,中间型（int）,INFa,1.0,,2.0,0.0,,,,2.0,2014-10-23,2020-04-16,1,,,SOX,SOX,SOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)02 (1b)02 (3a)02 (3b)01 (4sb)00 (4d)01 (5)00 (6)02 (7)05 (8a)03 (8p)02 (9)02 (11p)03 (12a)00,L（幽门窦部）小弯侧Less 前Ant 后Post 大弯侧Gre  ,50,40,10, R0 D2,,9.45,6.86,1.36,130.0,238.0,2.67,16.0,27.0,109.0,70.0,7.0,4.47,2.18,58.0,202.0,36.0,22.0,3.9,6.7,73.0,222.0,77.8,44.1,32.1,1.37,0.3,5.8,13.3,0.5,0.6,2.04,9.58,6.28,9.14,543.8,4.77,,,, P0,H0,,,,,,,65.76872536136662,1430850
1431119,王凤臣,576445,男,51,T1a,N0,M0,ⅠA,2,5,,0.0,0.0,0.0,,0.0,39,,,0.0,,0.0,0.0,,,,0.0,2014-10-27,2020-04-16,1,,,,,,,,,0, 低黏附腺癌,GX, (1a)01 (1b)00 (3a)012 (3b)00 (4sb)01 (4d)05 (5)01 (6)010 (7)02 (8a)02 (8p)00 (9)01 (11p)02 (12a)00 (14a)01 (14v)01," L（幽门窦部）, 前Ant,",15,15,3, R0 D2+,,9.09,5.34,2.84,141.7,259.0,3.58,17.0,24.0,132.0,68.0,29.0,32.6,10.83,68.0,281.0,42.0,26.0,5.6,3.4,53.0,229.0,87.2,57.6,27.2,2.11,0.2,4.9,6.2,0.6,0.479,5.06,8.71,171.0,3.78,5.35,1.08,,,, P0,H0,,,,,,,65.63731931668856,1431119
1430891,吕民奎,577389,男,47,T2,N0,M0, ⅠB,2,2,0.0,1.0,1.0,0.0, 肠化生 异型增生,0.0,21,髓样型（med）,INFa,2.0,,0.0,0.0,,,,0.0,2014-10-24,2020-04-16,1,,,SOX,SOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 黏液腺癌30% Lauren肠型,G3, (1a)01 (1b)00 (3a)03 (3b)01 (4sb)01 (4d)00 (5)01 (6)02 (7)06 (8a)00 (8p)03 (9)01 (11p)02 (12a)00 (14v)00 (15)00,L（幽门窦部） 小弯侧Less 后Post ,45,40,20, R0 D2+,,8.21,4.68,2.86,172.0,245.0,2.35,25.0,28.0,163.0,86.0,22.0,15.92,6.37,70.0,317.0,47.0,23.0,4.1,6.7,74.0,306.0,72.5,30.3,22.7,1.33,0.2,11.0,13.8,1.7,0.773,3.27,8.39,28.1,2.63,9.02,4.04,,,, P0,H0,,,,,,,65.73587385019711,1430891
1431481,丛秀珍,575760,女,67,T3,N0,M0, ⅡA,2,4,2.0,1.0,1.0,1.0,异型增生+,0.0,25,硬型（sci）,INFc,0.0,,0.0,2.0,,,,0.0,2014-10-30,2016-09-15,2,,,,,,,,,0, 低黏附腺癌 Lauren弥漫型,GX, (1a)01 (1b)02 (2)03 (3a)03 (3b)00 (4sa)00 (4sb)01 (4d)04 (5)01 (6)00 (7)04 (8a)02 (8p)00 (9)02 (11p)01 (12a)01," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",25,15,5, R0 D2,,4.02,2.04,1.67,140.8,228.0,2.97,25.0,31.0,188.0,94.0,12.0,19.15,6.48,71.0,242.0,46.0,25.0,5.4,3.3,59.0,246.0,,,,,,,,,,,,,4.04,8.43,1.31,,,, P0,H0,,,,,,,22.536136662286463,1431481
1432104,张喜连,579011,男,61,T1a,N0,M0,ⅠA,2,0,,,,,,0.0,21,,,0.0,,0.0,0.0,,,,0.0,2014-12-05,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3, (1a)00 (1b)01 (3a)01 (3b)00 (4d)03 (4sb)01 (5)00 (6)02 (7)04 (8a)03 (8p)04 (9)00 (11p)02 (12a)00," L（幽门窦部）, 小弯侧Less,",15,15,, R0 D2,,5.86,2.5,2.87,142.3,258.0,2.84,8.0,20.0,153.0,62.0,12.0,16.27,5.01,69.0,258.0,46.0,23.0,5.0,6.1,82.0,269.0,58.3,37.4,19.0,1.97,0.1,7.8,33.3,1.4,0.526,2.04,12.2,13.1,2.16,10.61,1.13,,,, P0,H0,,,,,,,64.35611038107753,1432104
1432865,王维江,579149,男,54,T1a,N0,M0,ⅠA,2,2,,0.0,0.0,0.0,,0.0,38,,,0.0,,0.0,0.0,,,,0.0,2014-11-11,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2, (1a)00 (1b)03 (3a)01 (3b)00 (4sb)01 (4d)00 (5)00 (6)09 (7)03 (8a)01 (8p)03 (9)04 (11p)04 (12a)00 (14v) 02大网边缘07,L（幽门窦部） 前Ant 小弯侧Less ,13,10,2, R0 D2,,3.97,1.88,1.71,140.0,160.0,1.88,17.0,18.0,141.0,71.0,16.0,14.23,5.97,65.0,216.0,40.0,25.0,5.0,8.7,83.0,287.0,77.7,56.6,14.7,3.85,0.1,8.0,13.4,0.6,0.91,1.56,13.2,22.0,0.309,11.74,1.15,,,, P0,H0,,,,,,,65.14454664914585,1432865
1433831,赵月柱,579430,男,63,T1a,N0,M0,ⅠA,2,0,0.0,0.0,0.0,0.0, 肠化生 异型增生 慢性炎症,0.0,21,中间型（int）,INFa,0.0,,0.0,0.0,,,,0.0,2014-11-19,2019-01-15,2,,,,,,,,,0, 管状腺癌（高分化【G1】【tub1】） Lauren肠型,G1, (1a)01 (1b)01 (3a)07 (3b)00 (4d)01 (4sb)00 (5)00 (6)01 (7)02 (8a)01 (9)02 (11p)04 (12a)00 (12p)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",40,30,, R0 D2,,7.83,4.91,1.82,168.3,150.0,2.6,62.0,57.0,208.0,64.0,80.0,16.55,6.04,79.0,380.0,48.0,31.0,11.4,6.3,92.0,383.0,65.1,39.8,15.7,2.54,0.1,8.1,23.8,0.5,0.723,2.88,12.5,557.0,5.01,3.08,2.01,,,, P0,H0,,,,,,,49.86859395532194,1433831
1433939,梁桂芝,577572,女,78,T3,N1,M0, ⅡB,2,1,0.0,0.0,0.0,0.0, 肠化生,2.0,19,硬型（sci）,INFa,0.0,,0.0,0.0,,,,0.0,2014-11-20,2017-03-24,0,,,,,,,,,0, 低分化管状腺癌（G3)(por) Lauren肠型,G3, (1a)02 (1b)01 (3a)23 (3b)00 (4sb)01 (4d)03 (5)00 (6)06 (7)01 (8a)02 (8p)00 (9)00 (11p)00 (14v)00," LM 后Post, 小弯侧Less,",50,40,12, R0 D2+,,12.62,9.42,2.12,102.0,372.0,3.85,13.0,19.0,141.0,65.0,21.0,7.23,3.73,63.0,164.0,31.0,32.0,5.9,5.7,101.0,353.0,70.7,52.6,14.3,3.68,0.1,10.7,14.9,0.8,0.621,4.12,15.8,334.0,1.63,16.0,1.17,,,, P0,H0,,,,,,,28.088042049934295,1433939
1434282,丛淑凤,580164,女,58,T1b,N0,M0,ⅠA,2,2,0.0,0.0,0.0,0.0, 肠化生,0.0,21,硬型（sci）,INFa,2.0,,0.0,0.0,,,,0.0,2014-11-24,2020-04-15,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)04 (1b)01 (3a)00 (3b)03 (4sb)00 (4d)03 (5)00 (6)00 (8a)03 (8p)00 (9)03 (11p)04 (12a)00," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,15,5, R0 D2+,,4.63,1.84,2.05,114.0,180.0,2.95,19.0,27.0,147.0,47.0,6.0,6.2,2.06,71.0,204.0,33.0,38.0,4.3,4.8,53.0,271.0,,,,,,,,,,,,,0.348,3.03,2.02,,,, P0,H0,,,,,,,64.68462549277267,1434282
1433503,庞军,580474,男,59,T2,N2,M0, ⅡB,2,5,0.0,0.0,0.0,0.0, 正常,4.0,21,中间型（int）,INFa,2.0,,0.0,2.0,,,,0.0,2014-11-17,2017-09-15,2,,,,,,,,,0, 低分化管状腺癌（G3)(por) Lauren肠型,G3, (1a)(1b)01 (2)01 (3a)(3b)22 (4sa)00 (4sb)12 (4d)(6)07 (5)(12a)00 (8a)01 (8p)(11p)(11d)15 (10)02," ML 前Ant, 后Post, 小弯侧Less,",65,50,10, R0 D2,,5.98,3.01,2.3,127.0,230.0,2.72,24.0,26.0,206.0,65.0,11.0,9.69,3.62,63.0,291.0,37.0,26.0,4.6,5.5,69.0,203.0,,,,,,,,,,,,,2.06,11.11,2.43,,,, P0,H0,,,,,,,33.93561103810775,1433503
1434447,李淑珍,581884,女,62,T1b,N0,M0,ⅠA,2,3,0.0,0.0,0.0,0.0,  慢性炎症（+）,0.0,22,硬型（sci）,INFa,1.0,,2.0,2.0,,,,2.0,2014-11-25,2021-07-22,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】60% 粘液腺癌（muc）40% Lauren肠型,G2, (1a)02 (1b)00 (3a)03 (3b)02 (4sb)00 (4d)01 (5)01 (6)03 (7)02 (8a)01 (8p)(9)05 (11p)02 (12a)00 (14v)00,L（幽门窦部） 后Post ,13,10,2, R0 D2+,,9.18,5.02,3.01,134.0,192.0,2.9,20.0,31.0,205.0,92.0,82.0,13.53,4.82,77.0,211.0,42.0,35.0,6.6,3.7,63.0,220.0,67.8,43.6,18.2,2.39,0.1,14.9,14.1,0.3,3.94,2.89,16.7,5.0,1.55,11.74,1.46,,,, P0,H0,,,,,,,79.86202365308804,1434447
1435089,李亚彬,581898,女,49,T1b,N0,M0,ⅠA,2,1,0.0,0.0,0.0,0.0, 肠化生,0.0,30,硬型（sci）,INFa,0.0,,0.0,1.0,,,,0.0,2014-12-01,2016-11-19,0,,,,,,,,,0, 低分化管状腺癌（G3)(por) （GIST） Lauren肠型,G3,大弯08 (1a)00 (1b)02 (3a)05 (3b)00 (4sb)00 (5)00 (6)01 (7)01 (8a)02 (8p)01 (9)03 (11p)07," M（胃体部）, 后Post,",45,30,10, R0 D2+,,7.94,5.03,2.25,146.2,286.0,3.01,12.0,18.0,236.0,69.0,30.0,9.25,3.11,68.0,209.0,42.0,26.0,5.5,5.5,81.0,394.0,76.7,32.4,30.3,1.07,0.2,11.9,9.7,2.6,0.873,1.05,10.5,18.4,0.754,9.15,2.81,,,, P0,H0,,,,,,,23.62023653088042,1435089
1434841,李长海,581575,男,39,T1b,N0,M0,ⅠA,2,2,0.0,0.0,0.0,0.0,  慢性炎症（+）,0.0,11,硬型（sci）,INFa,1.0,,0.0,2.0,,,,0.0,2014-11-27,2020-04-16,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3, (1a)00 (1b)01 (3a)00 (3b)00 (4sb)00 (4d)02 (5)00 (6)02 (7)00 (8a)03 (8p)01 (9)01 (11p)01 (12a)00," L（幽门窦部）, 小弯侧Less,",25,20,3, R0 D2+,,6.08,3.46,1.68,170.0,240.0,2.78,50.0,36.0,198.0,92.0,60.0,16.65,5.36,77.0,364.0,45.0,32.0,,5.8,101.0,561.0,71.1,46.5,16.2,2.87,0.3,12.2,14.2,1.8,1.98,2.78,11.9,8.45,0.762,2.92,0.985,,,, P0,H0,,,,,,,64.61892247043363,1434841
1434754,李铁,581906,男,53,T1b,N0,M0,ⅠA,2,0,,,,,,0.0,11,,,1.0,,0.0,2.0,,,,0.0,2014-11-27,2020-04-16,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90% 低粘附腺癌10%,G3, (3a)03 (3b)00 (4sb)00 (4d)04 (5)00 (6)00 (7)01 (8a)01 (9)01 (11p)01," L（幽门窦部）, 小弯侧Less,",30,20,5, R0 D2,,10.1,2.84,2.01,162.2,291.0,2.34,17.0,23.0,203.0,74.0,11.0,13.52,5.22,69.0,284.0,41.0,28.0,4.2,5.0,70.0,204.0,66.8,44.3,14.1,3.14,0.2,14.3,13.0,0.5,0.457,2.54,12.4,7.06,0.2,8.02,1.08,,,, P0,H0,,,,,,,64.61892247043363,1434754
1436285,李明先,582300,男,58,T2,N2,M0, ⅡB,2,3,0.0,0.0,0.0,0.0, 肠化生,4.0,27,硬型（sci）,INFa,0.0,,0.0,2.0,,,,0.0,2014-12-10,2020-04-14,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2, (1a)00 (1b)02 (3a)06 (3b)01 (4sb)00 (4d)00 (6)34 (7)07 (8a)12 (8p)01 (9)01 (11p)03 (12a)00,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,20,13,10, R0 D2,,4.16,1.71,2.02,118.0,208.0,2.72,32.0,31.0,155.0,80.0,12.0,7.92,3.28,76.0,247.0,41.0,35.0,6.5,3.7,75.0,244.0,55.2,38.6,15.5,2.49,0.1,9.2,27.4,1.1,0.918,3.15,18.0,29.5,0.247,7.16,3.66,,,, P0,H0,,,,,,,64.12614980289094,1436285
1500249,王富,579766,男,76,T3,N1,M0, ⅡB,2,3,0.0,1.0,1.0,1.0,  慢性炎症（+）,1.0,11,中间型（int）,INFb,1.0,,0.0,0.0,,,,0.0,2015-01-06,2020-04-14,1,,,,,,,,,0, 管状腺癌（低分化（G3)(por) 中分化【G2】【tub2】80 乳头状癌（G1）（pap）20 Lauren肠型,G3, (1a)02 (1b)01 (3a)03 (3b)00 (4sb)00 (4d)00 (5)00 (6)00 (7)13 (8a)00 (8p)02 (9)00 (11p)00 (12a)00,L（幽门窦部） 小弯侧Less 前Ant 后Post,40,35,10, R0 D2,,7.46,4.21,2.55,148.0,240.0,2.34,20.0,25.0,140.0,92.0,16.0,13.88,5.66,72.0,189.0,45.0,27.0,5.4,7.0,46.0,287.0,53.6,37.7,14.3,2.64,0.1,11.2,30.4,0.9,0.774,3.23,13.0,31.8,2.96,26.68,2.36,,,, P0,H0,,,,,,,63.23915900131406,1500249
1437634,李国有,584141,男,44,T1b,N0,M0,ⅠA,2,2,0.0,0.0,0.0,0.0,  慢性炎症（+）,0.0,25,硬型（sci）,INFa,0.0,,0.0,2.0,,,,0.0,2014-12-23,2018-06-19,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】低分化（G3)(por) 低粘附腺癌 Lauren肠型,G3, (1a)00 (1b)00 (3a)02 (3b)00 (4sb)01 (4d)02 (5)03 (6)01 (7)06 (8a)06 (8p)02 (9)02 (11p)00 (12a)00 (14v)00, L（幽门窦部） 小弯侧Less ,20,20,5, R0 D2+,,10.0,6.81,2.4,155.8,208.0,3.18,20.0,25.0,165.0,82.0,43.0,9.15,3.47,72.0,297.0,47.0,25.0,5.3,5.7,65.0,354.0,46.8,27.5,17.2,1.6,0.1,6.1,44.3,1.5,1.35,2.99,10.8,231.0,2.08,25.84,3.83,,,, P0,H0,,,,,,,41.85282522996058,1437634
1500029,张春芝,579755,女,57,T1b,N0,M0,ⅠA,2,3,2.0,0.0,0.0,0.0, 肠化生,0.0,29,硬型（sci）,INFc,0.0,,0.0,0.0,,,,0.0,2015-01-04,2020-04-14,1,,,,,,,,,0, 低黏附腺癌90% 低分化管状腺癌（G3)(por)10% Lauren弥漫型,G3, (1a)01 (1b)01 (3a)012 (3b)00 (4sb)05 (4d)00 (5)00 (6)00 (7)02 (8a)02 (8p)02 (9)02 (11p)02," LM 后Post,",20,20,5, R0 D2,,2.96,1.51,1.06,107.0,250.0,2.63,22.0,25.0,164.0,93.0,18.0,7.09,2.98,71.0,210.0,43.0,28.0,5.3,5.0,55.0,172.0,75.2,40.6,28.6,1.42,0.2,5.9,16.0,3.0,1.98,4.13,14.2,120.0,0.242,5.67,0.92,,,, P0,H0,,,,,,,63.30486202365309,1500029
1438501,蒋继军,584972,男,57,T1b,N0,M0,ⅠA,2,5,0.0,0.0,0.0,1.0, 肠化生,0.0,17,硬型（sci）,INFb,3.0,,0.0,0.0,,,,2.0,2014-12-31,2018-05-07,0,,,,,,,,,0,管状腺癌（ 低分化（G3)(por) 中分化【G2】【tub2】60% 乳头状癌（G1）（pap）40% Lauren肠型,G3, (1a)04 (1b)00 (3a)03 (3b)01 (4sb)00 (4d)01 (5)00 (6)01 (7)02 (8a)02 (8p)00 (9)01 (11p)03 (12a)00," L（幽门窦部）, 前Ant, 小弯侧Less,",20,18,, R0 D2,,7.75,5.31,1.6,158.0,180.0,2.9,29.0,25.0,110.0,68.0,12.0,12.05,5.56,72.0,235.0,43.0,29.0,5.1,4.9,82.0,335.0,84.0,26.8,50.6,0.53,0.2,6.6,7.8,10.3,1.33,2.47,20.6,19.3,0.414,5.44,1.2,,,, P0,H0,,,,,,,40.17739816031537,1438501
1500333,张世东,583432,男,62,T3,N0,M0, ⅡA,2,1,0.0,0.0,0.0,1.0, 肠化生,0.0,24,中间型（int）,INFb,0.0,,0.0,2.0,,,,0.0,2015-01-06,2022-09-02,1,,,,,,,,,0, 低分化管状腺癌（G3)(por)90 低粘附腺癌10 Lauren肠型,G3, (1a)02 (1b)01 (2)04 (3a)01 (3b)00 (4sb)00 (4d)07 (5)00 (6)01 (7)02 (8a)02 (8p)01 (9)01 (11d)00 (11p)00 (12a)02 (19)00," LMU 前Ant, 后Post, 小弯侧Less,",80,70,20, R0 D2+,,6.07,3.56,1.69,104.1,353.0,3.14,23.0,24.0,114.0,72.0,8.0,5.77,2.35,71.0,167.0,42.0,29.0,5.0,9.4,81.0,277.0,72.1,49.0,18.2,2.69,0.1,11.4,12.3,6.1,0.972,2.07,26.4,8.5,0.654,5.02,2.1,,,, P0,H0,,,,,,,91.85282522996057,1500333
1315864,李淑兰,529108,女,64,T1a,N0,M0,ⅠA,2,0,,,,,,0.0,22,,,,,,,,,,,2013-06-03,2018-05-09,1,,,,,,,,,0, 低分化腺癌（G3)(por) 印戒细胞癌(sig),G3, (1a)03 (1b)01 (3a)05 (3b)00 (4d)05 (5)00 (6)02 (7)00 (8a)01 (8p)(9)03 (11p)01 (14v)01, L（幽门窦部） 小弯侧Less ,15,10,3, R0 D2+,,7.34,4.25,2.47,126.6,225.0,2.95,10.6,9.0,143.0,121.0,17.0,10.29,1.84,70.3,139.15,39.5,30.8,4.8,4.08,57.0,176.0,,,,,,,,,,,,,1.59,3.86,1.53,,,, P0,H0,,,,,,,59.16557161629435,1315864
1738114,安海臣,701636,男,61,T3,N2 ,M0, ⅢA,3,4,2.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,6.0,28,髓样型（med）,INFc,0.0,,,,,,,,2017-10-19,2020-05-12,0,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌 Lauren弥漫型,GX,," ML 前Ant, 后Post, 小弯侧Less,",90,70,18,R0 D2+,,6.1,3.82,1.65,140.8,246.0,3.1,10.0,14.0,137.0,54.0,12.0,8.6,4.5,64.0,279.0,41.7,22.5,5.0,5.8,96.0,306.0,,,,,,,,,,,,,2.89,46.11,52.35, 阳性+,无,无,无,无,,MLH1+ MSH2+ MSH6+ PMS2+,1,1,1,1,30.749014454664913,1738114
1616284,白鸿,640643,女,38,T4b,N2 ,M0, ⅢB,3,3,2.0,1.0,1.0,1.0,肠上皮化生，慢性炎,6.0,17,中间型（int）,INFc,0.0,,,,,,,,2016-05-16,2020-05-19,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌85 粘液腺癌（muc）15 Lauren弥漫型,GX,," L（幽门窦部）, 前Ant,",40,40,4,R0,,5.98,3.43,2.01,108.0,336.0,2.88,15.0,21.0,156.0,58.0,8.0,11.39,3.51,83.0,290.0,47.0,36.0,4.3,4.0,72.0,251.0,,,,,,,,,,,,,1.87,10.93,1.73,,无,无,无,无,,,,,,,48.0946123521682,1616284
1644826,毕建华,666248,男,56,T3,N3a ,M0,ⅢB,3,3,1.0,1.0,1.0,1.0,肠上皮化生，慢性炎,12.0,25,中间型（int）,INFb,1.0,,2.0,,2.0,2.0,,,2016-12-28,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 50粘液腺癌（muc）40 低粘附腺癌10 Lauren混合型,G3,," GE, SiewerⅢ, 小弯侧Less,",40,35,10,R0 D2,,5.52,2.86,2.11,155.0,212.0,3.07,13.0,22.0,170.0,64.0,14.0,20.4,6.4,72.0,184.0,45.0,27.0,4.4,6.1,94.0,234.0,65.0,41.8,19.6,2.13,1.1,14.5,18.3,1.9,0.56,1.83,10.1,,3.38,15.43,2.9, 阳性++,无,无,无,无,,MLH1+80%弱-中 MSH2+70%中-强 MSH6+80%中-强 PMS2+60%弱-中  CD4散在+ CD8散在+ VEGF弱+,80% 弱-中,70% 中-强,80% 中-强,60% 弱-中,68.13403416557162,1644826
1621561,蔡凤祥,643685,男,40,T4b,N3b ,M1, Ⅳ,3,4,1.0,1.0,1.0,1.0,  慢性炎症（+）,22.0,25,硬型（sci）,INFc,0.0,,,,,,,,2016-06-27,2017-02-22,2,,,XELOX,XELOX,,,,,2, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren混合型,G3,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",200,150,10, D2,R2 ,3.09,1.79,1.02,156.2,276.0,2.86,13.0,15.0,142.0,94.0,13.0,15.45,5.67,71.0,328.0,44.0,27.0,5.5,4.2,84.0,297.0,67.2,37.1,21.6,1.72,0.3,13.5,13.4,4.2,2.29,2.76,11.1,,0.999,7.97,2.43, 阴性,无,无, p1局肠缘(M1 PER),H0,,,,,,,7.884362680683311,1621561
1732168,曹德财,698235,男,63,T2,N0 ,M0, ⅠB,3,3,0.0,1.0,1.0,1.0,异型增生+,0.0,54,中间型（int）,INFa,0.0,,,,,,,,2017-08-29,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,,,4, 低分化腺癌（G3)(por) Lauren肠型,G3,," SiewerⅢ, 前Ant, 小弯侧Less,",60,40,10,R0,,7.65,4.18,2.85,138.9,237.0,3.25,34.0,27.0,213.0,126.0,45.0,10.19,4.24,66.4,186.0,39.5,26.9,4.5,7.1,86.0,235.0,,,,,,,,,,,,,3.91,6.26,0.933, 未做,无,无,无,无,,,,,,,60.118265440210244,1732168
1627711,车玉学,651359,男,61,T3,N3b ,M0, ⅢC,3,3,2.0,1.0,1.0,1.0,,22.0,28,中间型（int）,INFb,0.0,,0.0,,2.0,2.0,,,2016-08-12,2016-11-15,2,,,XELOX,XELOX,,,,,2, 低粘附腺癌80 管状腺癌（中分化【G2】【tub2】20 Lauren弥漫型,G2,," LMU 前Ant, 后Post, 小弯侧Less,",60,30,8,R0 D2,,7.03,4.99,1.33,129.3,235.0,5.1,27.0,27.0,140.0,79.0,33.0,6.59,2.99,70.0,199.0,38.0,32.0,6.4,5.8,77.0,295.0,,,,,,,,,,,,,12.6,81.24,273.5,,无,无,无,无,,MLH1+90%中 MSH2+85%中 MSH6+90%中 PMS2+70%中 ,90% 中,85% 中,90% 中,70% 中,3.1208935611038107,1627711
1708517,陈柏茂,672167,男,67,T3,N1 ,M0, ⅡB,3,2,,0.0,0.0,0.0,,1.0,24,,,2.0,,2.0,,2.0,2.0,,,2017-03-13,2017-12-20,2,,,XELOX,XELOX,XELOX,XELOX,,,5, 低分化腺癌（G3)(por),G3,,LM 小弯侧Less 大弯侧Gre  前Ant 后Post ,25,20,10,R0 D2,,8.16,5.32,2.03,145.0,357.0,4.13,19.0,19.0,185.0,82.0,16.0,9.77,3.05,66.0,280.0,41.0,25.0,4.7,2.1,80.0,254.0,81.2,50.8,26.0,1.95,0.8,5.2,12.7,3.3,2.14,1.8,18.3,,2.99,50.38,0.734, 阴性,无,无,无,无,,MLH1- MSH2+30%弱 MSH6+70%弱 PMS2- CD4散在+ CD8散在+ VEGF灶+,0,30% 弱,70% 弱,0,9.264126149802891,1708517
1708309,陈福顺,670856,男,69,T1b,N0 ,M0,ⅠA,3,4,,0.0,0.0,0.0,,0.0,10,,,0.0,,,,,,,,2017-03-10,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por),G3,," L（幽门窦部）, 小弯侧Less,",20,15,8,R0 D2+,,5.55,3.05,2.1,152.0,179.0,3.07,14.0,21.0,173.0,51.0,22.0,14.04,4.53,75.0,235.0,45.0,30.0,4.5,4.7,99.0,251.0,,,,,,,,,,,,,2.47,15.7,3.69, 未做,无,无,无,无,,,,,,,65.76872536136662,1708309
1725457,陈巍妮,694215,女,35,T3,N0 ,M0, ⅡA,3,3,2.0,0.0,0.0,0.0, 慢性炎症（+） 异型增生+,0.0,20,硬型（sci）,INFc,0.0,,,,,,,,2017-07-11,2021-04-28,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,, U（胃底部） 后Post ,25,25,10,R0 D2,,6.91,4.34,1.93,123.3,227.0,2.23,17.0,11.0,145.0,48.0,8.0,7.91,2.15,68.0,279.0,39.0,29.0,4.3,6.4,82.0,268.0,74.1,39.8,28.8,1.38,0.0,16.7,7.5,3.4,1.22,2.67,12.6,,1.72,0.796,0.767, 阳性+,无,无,无,无,,,,,,,45.565045992115635,1725457
1701091,陈锡真,666381,男,65,T3,N3a ,M0,ⅢB,3,3,1.0,1.0,1.0,0.0, 肠化生 慢性炎症,11.0,29,中间型（int）,INFc,0.0,,2.0,,2.0,2.0,,,2017-01-10,2020-05-01,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,15, 低粘附腺癌65 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30 粘液腺癌（muc）5 Lauren混合型,G3,," M（胃体部）, 小弯侧Less,",50,20,10,R0 D2,,6.82,3.91,2.08,148.3,208.0,2.85,16.0,17.0,180.0,63.0,9.0,14.41,3.89,69.0,282.0,40.0,29.0,4.6,3.9,101.0,352.0,,,,,,,,,,,,,2.27,76.06,5.16, 阴性,无,无,无,无,,MLH1+70%弱-中 MSH2+80%中-强 MSH6+80%中-强 PMS2+10%弱  CD4+ CD8+ VEGF+,70% 弱-中,80% 中-强,80% 中-强,10% 弱,39.65177398160315,1701091
1809970,陈玉梅,718615,女,54,T4b,N0 ,M1, Ⅳ,3,4,2.0,,,,异型增生+,0.0,26,髓样型（med）,INFc,,,,,,,,,2018-03-19,2019-03-27,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌 Lauren弥漫型,GX,," MU 前Ant, 大弯侧Gre,",30,20,7,,R2,5.08,2.12,2.35,130.0,270.0,2.52,20.4,25.0,215.0,92.0,14.0,12.8,5.2,69.3,308.0,44.7,24.6,4.9,6.4,63.0,169.0,,,,,,,,,,,,,2.62,3.73,1.41, 阳性+,无,无,p1局腹膜(M1 PER),无,,,,,,,12.253613666228645,1809970
1743311,陈宗和,708379,男,59,T3,N0 ,M0 , ⅡA,3,3,1.0,0.0,0.0,1.0, 肠化生,0.0,33,中间型（int）,INFb,0.0,,,,,,,,2017-11-23,2020-05-01,2,,,,,,,,,0, 低分化腺癌（G3)10(por) 低粘附腺癌90,G3,," L（幽门窦部）, 小弯侧Less,",30,30,5,R0 D2,,6.61,3.71,2.27,136.0,201.0,2.84,19.6,20.0,154.0,94.0,23.0,19.4,6.3,66.0,377.0,41.6,24.4,4.5,5.3,76.0,365.0,,,,,,,,,0.682,1.64,8.73,,4.16,139.2,1.44,,无,无,无,无,,MLH1+80%弱 MSH2+85%强 MSH6+85强 PMS2+60%弱,80% 弱,85% 强,85% 强,60% 弱,29.23784494086728,1743311
1739478,程锡忱,701783,男,67,T3,N3a ,M0,ⅢB,3,3,1.0,1.0,1.0,1.0,  慢性炎症（+）,12.0,43,中间型（int）,INFc,2.0,,,,,,,,2017-10-30,2022-09-02,1,,,SOX,SOX,SOX,SOX,SOX,口服替吉奥,7, 低粘附腺癌 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,," L（幽门窦部）, 后Post,",25,20,,R0 D2,,6.05,3.25,2.12,157.0,155.0,3.17,12.1,19.0,165.0,88.0,25.0,15.0,6.3,67.0,277.0,35.4,32.4,4.9,5.3,79.0,410.0,,,,,,,,,,,,,1.64,3.17,6.73, 未做,无,无,无,无,,MLH1+80%弱-中 MSH2+90%中 MSH6+90%中-强 PMS2+80%弱-中,80% 弱-中,90% 中,90% 中-强,80% 弱-中,58.08147174770039,1739478
1710906,程永泉,679679,男,56,T2,N0 ,M0, ⅠB,3,2,0.0,0.0,0.0,0.0,  慢性炎症（+）,0.0,18,中间型（int）,INFb,1.0,,,,,,,,2017-03-23,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 粘液腺癌（muc） Lauren肠型,G2,," L（幽门窦部）, 后Post, 大弯侧Gre,",20,17,3,R0 D2,,6.44,3.62,2.4,157.0,208.0,2.79,19.0,20.0,160.0,67.0,15.0,12.01,3.34,72.0,327.0,45.0,27.0,4.7,8.1,104.0,343.0,,,,,,,,,,,,,2.39,21.74,1.02, 未做,无,无,无,无,,,,,,,65.34165571616295,1710906
1623458,崔传恩,637982,男,68,T4b,N3b ,M0, ⅢC,3,2,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,21.0,55,髓样型（med）,INFb,1.0,,,,,,,,2016-07-11,2016-12-15,2,,,口服卡培他滨,口服卡培他滨,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren混合型,G3,," LM 前Ant, 后Post, 小弯侧Less,",60,50,10,R0 D2+,,9.35,6.5,1.92,113.0,271.0,3.07,10.0,16.0,151.0,76.0,8.0,4.27,1.62,60.0,173.0,40.0,20.0,5.9,5.0,71.0,169.0,,,,,,,,,,,,,15.67,1000.0,4.48,,无,无,无,无,,,,,,,5.157687253613666,1623458
1637996,崔善明,677844,男,59,T3,N2 ,M0, ⅢA,3,3,0.0,0.0,0.0,1.0, 正常,3.0,20,中间型（int）,INFa,3.0,,1.0,,2.0,2.0,,,2016-11-09,2022-09-02,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," U（胃底部）, 小弯侧Less,",40,40,5,R0 D2,,5.38,2.99,1.85,156.6,197.0,2.97,18.0,21.0,198.0,46.0,23.0,14.64,4.17,69.0,432.0,42.0,27.0,4.8,4.9,117.0,362.0,,,,,,,,,,,,,2.84,15.85,1.41, 阴性,无,无,无,无,,MLH1+65%弱-中 MSH2+60%弱 MSH6+50%弱-中 PMS2+45%弱,65% 弱-中,60% 弱,50% 弱-中,45% 弱,69.7437582128778,1637996
1620860,崔秀霞,642434,女,38,T4a,N3a ,M0, ⅢB,3,3,2.0,1.0,1.0,1.0,  慢性炎症（+）,12.0,24,中间型（int）,INFc,0.0,,,,,,,,2016-06-21,2019-04-25,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌 Lauren弥漫型,GX,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",45,30,12,R0 D2,,4.15,2.55,1.19,100.0,480.0,2.95,21.0,23.0,152.0,72.0,5.0,9.76,4.04,65.0,250.0,40.0,25.0,5.8,3.0,56.0,259.0,69.4,44.3,21.9,2.02,0.7,20.5,8.8,1.6,1.09,2.87,11.8,,0.784,3.08,0.805, 阳性+,无,无,无,无,,,,,,,34.09986859395532,1620860
1637552,戴建立,660206,男,63,T3,N3a ,M0,ⅢB,3,3,2.0,1.0,1.0,1.0, 肠化生,8.0,21,硬型（sci）,INFc,0.0,,,,,,,,2016-11-05,2020-05-25,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,8, 低粘附腺癌 90低分化腺癌（G3)(por)10 Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,45,8,R0 D2,,6.15,2.51,2.92,140.0,249.0,1.79,18.0,20.0,155.0,65.0,9.0,8.09,2.68,62.0,248.0,36.0,26.0,4.7,5.9,83.0,270.0,,,,,,,,,,,,,0.385,9.06,2.34, 未做,无,无,无,无,,MLH1+5%弱 MSH2+50%弱 MSH6+5%中 PMS2+30%弱-中,5% 弱,50% 弱,5% 中,30% 弱-中,42.60840998685939,1637552
1629533,翟贵友,653444,男,53,T3,N3b ,M0, ⅢC,3,2,2.0,1.0,1.0,1.0,  慢性炎症（+）,17.0,52,硬型（sci）,INFc,0.0,,0.0,,2.0,2.0,,,2016-08-29,2019-05-05,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,7, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3,," U（胃底部）, 前Ant, 小弯侧Less,",45,40,12,R0,,8.58,4.99,2.71,176.9,191.0,2.97,31.0,19.0,148.0,105.0,16.0,15.19,4.66,63.0,363.0,38.0,25.0,6.9,5.8,75.0,257.0,,,,,,,,,,,,,0.463,6.61,0.736,,无,无,无,无,,MLH1+50%弱-中 MSH2+70%中-强 MSH6+80%强 PMS2+30%弱  CD4+散在+ CD8散在+  VEGF-,50% 弱-中,70% 中-强,80% 强,30% 弱,32.16162943495401,1629533
1741759,翟树林,704545,男,67,T4b,N3b ,M0, ⅢC,3,3,2.0,1.0,1.0,1.0,肠上皮化生，慢性炎,17.0,33,中间型（int）,INFc,1.0,,,,,,,,2017-11-14,2021-04-28,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",55,45,10,,R1,8.1,4.25,3.01,151.0,313.0,4.32,9.2,15.0,160.0,128.0,19.0,12.0,5.4,67.7,187.0,38.6,29.1,3.6,7.9,105.0,388.0,64.8,25.7,35.9,0.72,0.1,2.8,30.6,1.4,1.97,1.12,9.86,,297.9,10.88,1.44, 未做,无,无,无,无,,MLH1+60%弱-中 MSH2+40%弱 MSH6+70%中 PMS2+40%弱,60% 弱-中,40% 弱,70% 中,40% 弱,41.4257555847569,1741759
1607804,丁琳琳,578002,女,24,T3,N0 ,M0, ⅡA,3,3,2.0,0.0,0.0,1.0,  慢性炎症（+）,0.0,42,中间型（int）,INFc,0.0,,,,,,,,2016-03-15,2017-09-21,2,,,SOX,SOX,SOX,SOX,XELOX,XELOX,9, 低粘附腺癌 Lauren弥漫型,GX,," L（幽门窦部）, 前Ant,",20,15,10,R0,,20.03,18.39,0.67,123.0,155.0,1.6,6.0,13.0,111.0,42.0,8.0,14.27,5.33,65.0,238.0,44.0,21.0,4.5,3.2,69.0,211.0,,,,,,,,,,,,,1.49,20.47,0.801,,无,无,无,无,,,,,,,18.232588699080157,1607804
1935165,董桂琴,790354,女,65,T4b,N0 ,M0, ⅢA,3,2,,0.0,0.0,1.0,,0.0,23,,,2.0,,,,,,,,2019-08-08,2020-08-24,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3,," U（胃底部）, 后Post, 小弯侧Less,",30,20,20,R0 D2+,,5.6,2.93,2.1,142.0,215.0,3.1,11.0,17.0,147.0,90.0,17.0,10.1,1.6,59.6,234.0,36.0,23.6,,6.0,73.0,331.0,,,,,,,,,,,,,,,, 未做,无,无,无,无,,,,,,,12.54927726675427,1935165
1827043,董淑华,737539,女,53,T4a,N1 ,M0, ⅢA,3,4,2.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,1.0,24,中间型（int）,INFc,0.0,,,,,,,,2018-07-05,2020-12-29,2,,,SOX,SOX,SOX,SOX,SOX,SOX,8, 低粘附腺癌 Lauren弥漫型,GX,, MU,50,30,,R0 D2+,,8.39,5.33,2.53,126.0,255.0,2.41,9.9,15.0,155.0,71.0,16.0,27.8,3.5,70.7,274.0,43.1,27.6,5.2,4.4,62.0,301.0,,,,,,,,,,,,,0.508,13.95,2.93, 未做,无,无,无,无,,,,,,,29.829172141918527,1827043
1714010,樊学媛,680275,女,54,T3,N3a ,M0,ⅢB,3,3,2.0,0.0,0.0,0.0,  慢性炎症（+）,15.0,63,硬型（sci）,INFb,0.0,,,,,,,,2017-04-18,2022-09-02,1,,,多西他赛+替吉奥,多西他赛+替吉奥,SOX,SOX,SOX,口服替吉奥,7, 低粘附腺癌 Lauren弥漫型,GX,," M（胃体部）, 后Post,",50,40,10,R0 D2,,7.61,5.47,1.69,105.0,351.0,3.48,38.0,33.0,248.0,111.0,22.0,6.75,2.15,67.2,237.0,35.6,31.6,4.0,5.1,72.0,248.0,,,,,,,,,,,,,10.55,5.69,11.85, 未做,无,无,无,无,,,,,,,64.48751642575559,1714010
1708758,范春琴,670488,女,63,T3,N2 ,M0, ⅢA,3,2,,0.0,0.0,1.0,,5.0,24,,,0.0,,,,,,,,2017-03-14,2022-01-12,2,,,,,,,,,0, 低粘附腺癌 粘液腺癌（muc）,GX,," M（胃体部）, 小弯侧Less,",30,25,4,R0 D2,,5.58,3.54,1.48,121.5,261.0,3.52,8.0,18.0,192.0,107.0,9.0,14.05,3.78,41.0,151.0,41.0,25.0,3.8,6.2,66.0,177.0,,,,,,,,,,,,,,,, 未做,无,无,无,无,,,,,,,57.98291721419185,1708758
1708908,范春芝,672368,女,59,T3,N3a ,M0,ⅢB,3,3,2.0,0.0,0.0,1.0, 肠化生 慢性炎症 异型增生,15.0,36,中间型（int）,INFc,0.0,,0.0,,0.0,0.0,,,2017-03-14,2019-09-02,2,,,XELOX,XELOX,口服卡培他滨,,,,3, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,20,R0 D2,,5.17,3.62,1.24,141.2,216.0,4.0,4.0,14.0,167.0,82.0,8.0,10.31,2.72,68.0,285.0,41.0,27.0,5.2,5.8,66.0,183.0,,,,,,,,,,,,,0.798,2.83,3.0, 未做,无,无,无,无,,MLH1- MSH2- MSH6- PMS2- CD4- CD8- VEGF-,0,0,0,0,29.632063074901446,1708908
1804074,费立志,714299,男,69,T4b,N3a ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0,  慢性炎症（+）,13.0,19,中间型（int）,INFc,0.0,,,,,,,,2018-01-16,2018-06-13,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,," MU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,25,15, D2,R2,5.34,2.28,2.41,131.0,258.0,3.31,8.0,17.0,155.0,65.0,27.0,16.6,6.1,61.0,218.0,41.2,19.8,5.3,5.8,83.0,346.0,,,,,,,,,,,,,67.64,27.43,15.06, 阴性,无,无,无,无,,MLH1+80%中 MSH2+90%中-强 MSH6+90%强 PMS2+70%弱,80% 中,90% 中-强,90% 强,70% 弱,4.862023653088042,1804074
1644984,冯丽萍,665864,女,51,T3,N3a ,M0,ⅢB,3,2,2.0,1.0,1.0,1.0, 肠化生,7.0,27,硬型（sci）,INFc,1.0,,1.0,,1.0,1.0,,,2016-12-29,2019-05-01,0,,,XELOX,XELOX,XELOX,SOX,SOX,SOX,6, 低粘附腺癌 60%低中分化腺癌（G3)(por)40% Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,25,7,R0 D2,,4.42,2.04,1.96,116.2,310.0,2.5,8.0,10.0,131.0,48.0,5.0,4.04,1.48,60.0,123.0,35.0,25.0,4.5,3.5,54.0,100.0,,,,,,,,,,,,,0.865,23.58,5.72, 阴性,无,无,无,无,,MLH1+80%中 MSH2+70%中-强 MSH6+70%强 PMS2+70%中 CD4+ CD8+ VEGF+,80% 中,70% 中-强,70% 强,70% 中,28.02233902759527,1644984
1736375,冯卫东,699831,男,49,T4a,N3a ,M0, ⅢB,3,3,1.0,1.0,1.0,1.0,肠化生+,8.0,29,髓样型（med）,INFb,0.0,,,,,,,,2017-09-29,2022-09-02,1,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren混合型,G2,," L（幽门窦部）, 小弯侧Less,",40,40,40,R0 D2,,9.52,5.18,3.51,143.0,293.0,3.27,22.0,15.0,168.0,101.0,57.0,13.54,3.93,71.0,330.0,43.0,28.0,6.5,4.2,85.0,371.0,,,,,,,,,,,,,0.997,7.16,3.95, 未做,无,无,无,无,,MLH1+ MSH2+ MSH6+ PMS2+,1,1,1,1,59.09986859395532,1736375
1830315,付宪武,741829,男,73,T4b,N0 ,M0, ⅢA,3,3,,,,,,0.0,25,,,0.0,,,,,,,,2018-07-30,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2,," L（幽门窦部）,",40,50,20,D2+,R1,5.05,2.14,2.19,88.0,280.0,2.64,9.2,20.0,288.0,110.0,14.0,5.3,1.0,65.6,147.0,34.4,31.2,5.5,5.1,75.0,209.0,,,,,,,,,,,,,3.27,1.1,1.35,,无,无,无,无,,,,,,,49.11300919842313,1830315
1619551,付志和,642436,男,73,T3,N2 ,M0, ⅢA,3,3,0.0,0.0,0.0,1.0,,5.0,15,中间型（int）,INFa,0.0,,,,,,,,2016-06-08,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," M（胃体部）, 后Post,",35,20,8,R0,,6.26,4.43,1.39,105.3,279.0,2.25,26.0,34.0,147.0,44.0,11.0,4.83,2.14,58.0,222.0,35.0,23.0,7.2,4.9,64.0,295.0,,,,,,,,,,,,,1.16,5.53,1.05,,无,无,无,无,,,,,,,74.80289093298292,1619551
1701907,高福华,666529,男,61,T3,N1 ,M0, ⅡB,3,2,0.0,0.0,0.0,1.0,异型增生+,1.0,31,中间型（int）,INFa,0.0,,1.0,,1.0,2.0,,,2017-01-16,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por) Lauren肠型,G3,,L（幽门窦部） 前Ant 小弯侧Less ,60,60,10,R0 D2,,6.57,3.94,1.42,127.3,237.0,4.32,15.0,17.0,146.0,86.0,15.0,8.05,2.19,66.0,234.0,40.0,26.0,5.3,7.9,98.0,296.0,52.0,38.9,11.0,3.54,0.1,4.2,36.4,0.2,1.48,1.29,6.82,,2.49,8.44,1.17, 未做,无,无,无,无,,,,,,,67.50985545335085,1701907
1826411,高加富,737873,男,75,T3 T1a,N3b ,M0,,3,3,,0.0,0.0,0.0,,16.0,29,,,2.0,,,,,,,,2018-07-03,2019-07-01,2,,,口服替吉奥,,,,,,1, 管状腺癌（中分化【G2】50%【tub2】 低粘附腺癌50%,G2,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",60 20,50 20,20,,R2,4.65,2.32,1.88,115.0,312.0,3.18,14.9,25.0,195.0,92.0,15.0,6.0,1.3,55.8,108.0,32.6,23.2,5.1,8.4,81.0,304.0,,,,,,,,,,,,,21.6,9.05,4.14, 未做,无,无,无,无,,,,,,,11.925098554533507,1826411
1619975,高亚珍,642797,女,59,T3,N2 ,M0, ⅢA,3,3,2.0,0.0,0.0,1.0,  慢性炎症（+）,3.0,17,中间型（int）,INFa,0.0,,,,,,,,2016-06-14,2021-07-29,1,,,SOX,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX,," M（胃体部）, 小弯侧Less,",40,30,5,R0,,3.89,2.13,1.34,84.0,280.0,3.13,26.0,26.0,178.0,112.0,17.0,8.48,2.53,73.0,299.0,44.0,29.0,5.3,6.1,63.0,192.0,,,,,,,,,,,,,2.82,26.18,,,无,无,无,无,,,,,,,61.465177398160314,1619975
1606489,高玉和,630020,男,71,T3,N3b ,M0, ⅢC,3,3,1.0,1.0,1.0,1.0,  慢性炎症（+）,18.0,40,中间型（int）,INFa,0.0,,,,,,,,2016-03-07,2019-02-22,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 粘液腺癌（muc）50 低粘附腺癌30 低分化腺癌（G3)(por)20 Lauren混合型,G3,, LM 前Ant 后Post 大弯侧Gre  小弯侧Less ,90,80,18,R0 D2,,4.44,2.91,1.11,96.0,275.0,3.58,12.0,17.0,116.0,51.0,24.0,11.5,6.47,61.0,141.0,36.0,25.0,6.5,7.0,96.0,384.0,56.1,31.0,23.1,1.34,0.1,7.2,34.8,0.6,0.289,5.12,6.24,,13.68,77.16,30.22, 阳性+,无,无,无,无,,,,,,,35.545335085413925,1606489
1609694,公智强,629477,男,46,T4b,N1 ,M0, ⅢB,3,3,0.0,1.0,1.0,1.0, 正常,1.0,31,中间型（int）,INFa,1.0,,,,,,,,2016-03-28,2021-07-29,1,,,SOX,SOX,SOX,SOX,XELOX,XELOX,8, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 粘液腺癌（muc）30 Lauren肠型,G3,,U（胃底部） 前Ant 小弯侧Less ,90,60,30,,R1,10.35,6.28,2.57,128.0,484.0,4.67,25.0,21.0,178.0,90.0,21.0,8.71,2.86,70.0,230.0,41.0,29.0,8.2,6.9,65.0,219.0,72.1,40.7,29.1,1.4,0.3,10.6,12.8,9.9,1.18,3.26,10.2,,1.98,9.76,44.36,阳性+,无,无,无,无,,,,,,,64.02759526938239,1609694
1746373,宫兆凡,711874,男,61,T3,N1 ,M0, ⅡB,3,3,0.0,1.0,1.0,1.0, 肠化生,1.0,34,中间型（int）,INFb,1.0,,,,,,,,2017-12-15,2020-11-01,2,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,10,R0,,6.09,4.41,1.26,86.1,267.0,2.84,7.5,14.0,120.0,82.0,9.0,8.1,4.6,58.8,221.0,36.3,25.5,5.2,3.9,77.0,351.0,,,,,,,,,,,,,3.12,18.49,2.08, 未做,无,无,无,无,,MLH1+80%弱-中 MSH2+70%弱-中 MSH6+50%中 PMS2+80%弱-中,80% 弱-中,70% 弱-中,50% 中,80% 弱-中,34.55978975032851,1746373
1633203,顾惠红,655614,女,46,T4b,N3a ,M0, ⅢC,3,4,2.0,0.0,0.0,1.0, 肠化生 慢性炎症,9.0,19,硬型（sci）,INFc,1.0,,2.0,,2.0,2.0,,,2016-09-27,2020-08-22,2,,,XELOX,XELOX,,,,,2, 低粘附腺癌 低分化腺癌（G3)(por)40 Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,20,,R2,5.68,26.72,1.52,103.8,238.0,2.8,12.0,18.0,146.0,41.0,17.0,4.35,2.35,58.0,164.0,37.0,31.0,6.8,8.8,51.0,128.0,,,,,,,,,,,,,1.68,8.91,3.41, 阴性,无,无,无,无,,MLH1+70%弱-中 MSH2+55%中 MSH6+60%强 PMS2+30%弱  CD4散在+ CD8散在+  VEGF散在弱+,70% 弱-中,55% 中,60% 强,30% 弱,46.81340341655716,1633203
1704694,郭宝红,671691,女,37,T2,N2 ,M0, ⅡB,3,2,2.0,1.0,1.0,1.0, 异型增生 慢性炎症,6.0,44,硬型（sci）,INFc,0.0,,,,,,,,2017-02-16,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por)10 低粘附腺癌 Lauren弥漫型,G3,," M（胃体部）, 后Post,",22,10,5,R0,,7.69,5.1,2.03,138.0,314.0,2.7,9.0,17.0,152.0,53.0,9.0,14.28,4.18,79.0,178.0,47.0,32.0,4.3,4.5,75.0,191.0,,,,,,,,,,,,,0.556,7.24,3.53, 未做,无,无,无,无,,,,,,,66.49145860709592,1704694
1747958,郭淑芝,712338,女,64,T3,N2 ,M0, ⅢA,3,4,2.0,0.0,0.0,1.0,,4.0,10,中间型（int）,INFc,0.0,,,,,,,,2017-12-27,2018-10-11,2,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80% 低粘附腺癌20% Lauren弥漫型,G3,," MU  前Ant,后Post, 大弯侧Gre, 小弯侧Less,",10 15,10 10,5 5,R0,,4.79,4.18,0.28,146.0,83.0,2.74,15.0,40.0,203.0,59.0,9.0,8.1,4.7,57.7,134.0,33.0,24.7,,1.9,71.0,80.0,,,,,,,,,,,,,2.36,14.54,2.96, 未做,无,无,无,无,,,,,,,9.461235216819974,1747958
1743271,郭新友,708700,男,57,T4b,N2,M0, ⅢB,3,3,1.0,1.0,1.0,0.0,,6.0,21,中间型（int）,INFb,0.0,,,,,,,,2017-11-23,2018-08-15,2,,,SOX,SOX,紫杉醇+Ramucirumab,紫杉醇+Ramucirumab,紫杉醇+Ramucirumab,,6, 低分化腺癌（G3)80(por) 粘液腺癌（muc）20,G3,," M（胃体部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,70,12,R0 D2+,,11.99,8.95,2.1,142.6,331.0,4.46,26.1,26.0,239.0,113.0,35.0,13.4,5.2,80.1,305.0,46.6,33.5,4.3,7.0,100.0,364.0,57.9,29.6,20.3,1.46,0.1,3.6,38.3,3.9,0.547,2.08,6.3,,1.85,162.5,12.77,,无,无,无,无,,MLH1+50%弱 MSH2+80%中-强 MSH6+80%强 PMS2+60%弱,50% 弱,80% 中-强,80% 强,60 弱,8.705650459921156,1743271
1633352,郭秀龙,655503,女,55,T4b,N2 ,M0 , ⅢB,3,3,0.0,1.0,1.0,1.0,肠上皮化生，慢性炎,4.0,11,中间型（int）,INFa,0.0,,2.0,,2.0,2.0,,,2016-09-28,2021-07-29,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," L（幽门窦部）,前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,30, D2,R2,4.78,3.41,1.06,54.8,343.0,2.52,14.0,12.0,170.0,50.0,15.0,5.05,2.09,58.0,188.0,35.0,23.0,5.6,4.2,62.0,,,,,,,,,,,,,,2.45,12.56,2.01, 未做,无,无,无,无,,MLH1+60%中 MSH2+25%弱 MSH6+75%中 PMS2+30%弱 CD4散在+ CD8散在+ VEGF弱+,60% 中,25% 弱,75% 中,30% 弱,57.98291721419185,1633352
1713957,郭亚芬,683721,女,63,T3,N3b ,M0, ⅢC,3,5,1.0,1.0,1.0,1.0,  慢性炎症（+）,23.0,28,中间型（int）,INFc,1.0,,,,,,,,2017-04-18,2018-02-01,2,,,,,,,,,0, 低粘附腺癌 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,50,15,R0 D2,,7.45,4.28,2.69,75.5,435.0,2.22,21.0,21.0,182.0,95.0,11.0,4.94,1.9,48.2,184.0,23.6,24.6,4.0,4.8,57.0,134.0,,,,,,,,,,,,,1.91,15.18,4.58, 未做,无,无,无,无,,,,,,,9.494086727989487,1713957
1806130,胡双军,719829,男,46,T3,N3b ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0,  慢性炎症（+）,23.0,41,中间型（int）,INFc,0.0,,,,,,,,2018-02-23,2019-08-01,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren弥漫型,G3,," LMU 前Ant, 后Post, 小弯侧Less,",75,70,15,R0 D2,,8.18,5.13,2.32,168.8,241.0,2.56,31.3,24.0,150.0,113.0,41.0,29.9,8.8,72.1,382.0,42.1,30.0,5.0,5.9,78.0,330.0,,,,,,,,,,,,,1.37,11.07,2.92, 未做,无,无,无,无,,MLH1+80%中 MSH2+85%强 MSH6+80%强 PMS2+70%弱-中,80% 中,85% 强,80% 强,70% 弱-中,17.21419185282523,1806130
1739964,胡永杰,701730,男,59,T3,N2 ,M0, ⅢA,3,3,0.0,1.0,1.0,1.0,  慢性炎症（+）,3.0,44,中间型（int）,INFa,1.0,,,,,,,,2017-11-01,2019-10-11,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," UM SiewerⅢ, 前Ant, 小弯侧Less,",80,80,20,R0 D2+,,4.96,2.99,1.58,98.0,217.0,2.97,8.9,15.0,132.0,83.0,11.0,7.8,4.5,62.2,269.0,40.3,21.9,5.3,9.2,94.0,329.0,,,,,,,,,,,,,3.32,3.51,9.99, 阴性,无,无,无,无,,MLH1+60%弱 MSH2+70%中 MSH6+80%中-强 PMS2+60%弱-中,60% 弱,70% 中,80% 中-强,60% 弱-中,23.291721419185283,1739964
1712041,胡振芳,682671,女,34,T3,N3a ,M0,ⅢB,3,4,2.0,1.0,1.0,1.0,  慢性炎症（+）,12.0,39,髓样型（med）,INFc,0.0,,,,,,,,2017-04-05,2021-07-29,0,,,XELOX,XELOX,XELOX,口服卡培他滨,口服卡培他滨,,5, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren弥漫型,G3,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,50,7,R0 D2,,5.63,3.61,1.69,127.5,232.0,2.52,8.0,10.0,116.0,35.0,8.0,13.04,4.04,64.0,242.0,38.0,26.0,4.7,3.1,74.0,176.0,81.5,55.0,17.7,3.11,0.6,8.7,6.6,1.2,1.78,1.44,7.9,,1.32,0.6,4.92, 阳性+,无,无,无,无,,,,,,,51.77398160315374,1712041
1619348,吉占林,642365,女,58,T4b,N3a ,M0, ⅢC,3,2,1.0,1.0,1.0,1.0,  慢性炎症（+）,11.0,37,中间型（int）,INFc,0.0,,,,,,,,2016-06-07,2017-01-15,2,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,50,10,R0,,16.2,14.48,0.61,121.1,189.0,3.28,16.0,19.0,168.0,95.0,9.0,6.04,2.26,59.0,232.0,36.0,23.0,5.7,5.1,72.0,349.0,,,,,,,,,,,,,164.0,7.57,23.42,,无,无,无,无,,,,,,,7.293035479632063,1619348
1604538,贾桂芝,624460,女,38,T4a,N3b ,M0, ⅢC,3,4,0.0,1.0,1.0,0.0, 慢性炎症（+） 异型增生+,46.0,48,中间型（int）,INFa,2.0,,,,,,,,2016-02-23,2016-11-10,2,,,XELOX,XELOX,紫杉醇联合替吉奥,紫杉醇联合替吉奥,紫杉醇联合替吉奥,,5, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren肠型,G3,,LM 小弯侧Less 前Ant 后Post 大弯侧Gre  ,45,35,10, D2,R1,5.74,3.11,1.98,94.0,425.0,2.18,15.0,14.0,211.0,65.0,9.0,7.92,2.17,67.0,188.0,38.0,29.0,5.1,5.6,60.0,229.0,,,,,,,,,,,,,1.79,287.6,33.99, 阴性,无,无,无,无,,,,,,,8.5742444152431,1604538
1811819,姜春龙,718784,男,36,T3,N3a ,M0,ⅢB,3,3,1.0,,,, 肠化生 慢性炎症 异型增生,10.0,22,中间型（int）,INFb,,,,,,,,,2018-03-29,2021-07-29,0,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低分化腺癌（G3)(por)40 粘液腺癌（muc）20 低粘附腺癌440,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,30,10,R0 D2+,,5.13,2.27,1.59,124.0,2888.0,2.41,62.6,34.0,131.0,99.0,67.0,9.7,2.1,63.8,321.0,40.5,23.3,5.4,2.9,80.0,370.0,,,,,,,,,,,,,1.64,13.49,1.95, 未做,无,无,无,无,,,,,,,40.01314060446781,1811819
1710331,姜继兴,674241,男,68,T3,N3a ,M0,ⅢB,3,3,0.0,1.0,1.0,1.0,,13.0,45,硬型（sci）,INFc,1.0,,2.0,,2.0,2.0,,,2017-03-23,2019-05-03,0,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】80 低粘附腺癌20 Lauren肠型,G3,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,10,R0,,8.79,7.32,1.05,108.0,239.0,3.4,29.0,30.0,188.0,58.0,9.3,21.16,6.01,44.6,203.92,23.5,21.1,4.4,3.86,94.0,181.0,,,,,,,,,,,,,2.81,14.03,13.76, 未做,无,无,无,无,,MLH1+80%中-强 MSH2+80%中-强 MSH6+80%强 PMS2+80%弱-中,80% 中-强,80% 中-强,80% 强,80% 弱-中,25.328515111695136,1710331
1803262,姜路,711215,男,66,T3,N3a ,M0,ⅢB,3,4,2.0,0.0,0.0,0.0,,8.0,38,中间型（int）,INFc,0.0,,,,,,,,2018-01-22,2020-07-15,2,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】 Lauren弥漫型,G2,," ML 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35,30,6,R0 D2+,,13.03,93.2,3.4,67.0,323.0,3.58,7.1,8.0,116.0,76.0,19.0,16.5,6.3,69.7,229.0,40.1,29.6,4.9,4.7,77.0,294.0,,,,,,,,,,,,,1.7,0.6,10.09,,无,无,无,无,,MLH1+70%弱-中 MSH2+80%弱-中 MSH6+80%中-强 PMS2+60%弱,70% 弱-中,80% 弱-中,80% 中-强,60% 弱,29.730617608409986,1803262
1602191,姜有洲,625902,男,45,T4b,N1 ,M0, ⅢB,3,2,0.0,1.0,1.0,1.0,  慢性炎症（+）,2.0,17,中间型（int）,INFc,0.0,,,,,,,,2016-01-20,2021-09-01,1,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," U（胃底部）, 后Post,",70,60,15,R0 D2+,,11.07,8.21,1.98,162.0,327.0,2.63,14.0,20.0,173.0,94.0,14.0,8.39,3.68,70.0,331.0,44.0,26.0,,7.8,85.0,315.0,77.1,41.3,31.8,1.3,3.4,11.0,7.0,4.8,0.66,1.63,9.22,,1.81,0.6,21.17, 阴性,无,无,无,无,,,,,,,67.3784494086728,1602191
1734473,蒋丽萍,698048,女,52,T3 T1a,N0 ,M0,,3,3,0.0,1.0,1.0,1.0, 肠化生 异型增生 慢性炎症,0.0,50,中间型（int）,INFa,0.0,,,,,,,,2017-09-14,2022-09-15,1,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," LM 小弯侧Less,",55 5,50,10,R0 D2+,,5.2,3.34,1.27,109.0,363.0,,7.0,14.0,156.0,44.0,28.0,5.2,3.9,62.2,189.0,34.6,27.6,4.4,4.1,62.0,352.0,,,,,,,,,,,,,1.53,0.755,1.47, 未做,无,无,无,无,,,,,,,60.019710906701704,1734473
1621320,鞠强,644579,男,46,T3,N3a ,M0,ⅢB,3,5,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,15.0,38,硬型（sci）,INFb,2.0,,,,,,,,2016-06-23,2021-07-01,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌 管状腺癌85（中分化【G2】【tub2】 低分化腺癌（G3)(por)15 Lauren混合型,G3,, MU 前Ant 后Post 小弯侧Less ,35,25,5,R0 D2,,8.91,6.78,1.19,132.0,237.0,2.18,55.0,58.0,181.0,98.0,110.0,9.85,4.76,60.0,172.0,35.0,25.0,5.4,2.4,65.0,196.0,63.2,32.2,25.8,1.25,0.0,11.9,19.1,1.2,0.466,1.38,14.1,,3.57,3.1,1.14, 阳性+,无,无,无,无,,,,,,,60.2496714848883,1621320
1632490,康东旭,654091,男,46,T4a,N2 ,M0, ⅢA,3,2,2.0,1.0,1.0,1.0, 正常,4.0,27,髓样型（med）,INFb,1.0,,2.0,,1.0,1.0,,,2016-09-22,2021-07-29,1,,,XELOX,XELOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌 60管状腺癌（中分化【G2】【tub2】 10粘液腺癌（muc）30 Lauren弥漫型,G2,," LM 前Ant, 后Post, 小弯侧Less,",50,45,18,R0,,6.26,3.91,1.57,140.0,198.0,2.86,17.0,17.0,190.0,83.0,21.0,9.56,4.22,67.0,300.0,40.0,27.0,5.2,8.4,81.0,396.0,,,,,,,,,,,,,1.21,6.57,1.32, 未做,无,无,无,无,,MLH1+70%中 MSH2+60%中-强 MSH6+90%中-强 PMS2+75%中 CD4小区+ CD8小区+ VEGF弱+,70% 中,60% 中-强,90% 中-强,75% 中,58.18002628120893,1632490
1631448,孔祥发,652443,男,79,T2,N1 ,M0, ⅡA,3,3,,1.0,1.0,1.0,,1.0,28,,,1.0,,0.0,,1.0,2.0,,,2016-09-13,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,," M（胃体部）, GE, SiewerⅢ, 小弯侧Less,",18,10,3,R0,,7.78,4.43,2.63,139.0,240.0,1.63,10.0,20.0,191.0,61.0,12.0,12.6,5.09,64.0,255.0,37.0,27.0,4.5,6.0,94.0,272.0,,,,,,,,,,,,,3.65,12.11,3.42,,无,无,无,无,,MLH1+70%弱 MSH2+60%弱-中 MSH6+60%中-强 PMS2+60%弱-中 CD4+ CD8散在+  VEGF+,70% 弱,60% 弱-中,60% 中-强,60% 弱-中,71.61629434954007,1631448
1744727,寇建英,706766,女,81,T3,N0 ,M0, ⅡA,3,2,0.0,0.0,0.0,0.0, 肠化生,0.0,37,中间型（int）,INFb,1.0,,,,,,,,2017-12-05,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,40,10,R0 D2,,10.58,9.15,0.77,102.0,266.0,3.14,12.9,24.0,273.0,82.0,20.0,6.9,4.6,51.0,97.0,23.8,27.2,,11.5,86.0,246.0,,,,,,,,,,,,,32.09,135.0,0.841,,无,无,无,无,,MLH1+90%中-强 MSH2+90%中-强 MSH6+90%中-强 PMS2+80%弱,90% 中-强,90% 中-强,90% 中-强,80% 弱,56.8988173455979,1744727
1710062,李臣,674327,男,71,T3,N3a ,M0,ⅢB,3,3,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,8.0,26,中间型（int）,INFb,0.0,,1.0,,2.0,2.0,,,2017-03-21,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por)50 粘液腺癌（muc）30 低粘附腺癌20 Lauren混合型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",35,25,10,R0 D2,,5.8,3.13,2.23,156.2,157.0,1.8,12.0,15.0,151.0,99.0,18.0,19.97,7.47,68.0,286.0,43.0,25.0,6.0,6.6,94.0,,,,,,,,,,,,,,18.94,0.6,7.43, 未做,无,无,无,无,,MLH1+70%弱-中 MSH2+80%中 MSH6+80%强 PMS2+40%弱 CD4散在+ CD8散在+ VEGF+,70% 弱-中,80% 中,80% 强,40% 弱,65.40735873850197,1710062
1609919,李春杰,631093,女,37,T3,N3b ,M0, ⅢC,3,3,2.0,0.0,0.0,1.0,  慢性炎症（+）,35.0,50,中间型（int）,INFb,0.0,,,,,,,,2016-03-29,2019-04-02,2,,,XELOX,XELOX,XELOX,XELOX,氟尿嘧啶+卡培他滨,甲磺酸阿帕替尼,6, 低粘附腺癌 Lauren弥漫型,GX,," M（胃体部）, 前Ant,",80,30,16,R0,,6.31,4.11,1.47,73.0,286.0,4.0,13.0,17.0,101.0,54.0,13.0,3.62,1.49,58.0,193.0,36.0,22.0,6.0,6.7,40.0,248.0,,,,,,,,,,,,,0.527,248.0,22.28, 未做,无,无,无,无,,,,,,,36.10381077529566,1609919
1807951,李殿福,717570,男,79,T4b,N3b ,M0, ⅢC,3,3,2.0,1.0,1.0,1.0,,17.0,17,髓样型（med）,INFc,,,,,,,,,2018-03-07,2019-05-01,2,,,,,,,,,0, 低粘附腺癌 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren弥漫型,G3,," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,50,20,R0 D2,,7.36,5.74,0.96,121.2,265.0,4.78,14.9,19.0,176.0,107.0,30.0,11.6,5.0,67.7,303.0,38.1,29.6,5.1,7.3,109.0,452.0,,,,,,,,,,,,,3.71,13.91,,,无,无,无,无,,,,,,,13.797634691195794,1807951
1610504,李芳斌,631627,男,71,T4a,N3a ,M0, ⅢB,3,4,1.0,1.0,1.0,1.0,,14.0,29,中间型（int）,INFb,2.0,,,,,,,,2016-04-01,2016-09-15,2,,,口服卡培他滨,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3,," LMU 前Ant,",70,70,20,R0 D2,,5.95,3.63,1.43,118.0,247.0,3.64,18.0,19.0,140.0,53.0,9.0,8.81,3.9,58.0,165.0,34.0,24.0,5.1,8.4,74.0,299.0,,,,,,,,,,,,,0.459,1000.0,2.88,,无,无,无,无,,,,,,,5.486202365308804,1610504
1821463,李国,732797,男,56,T3,N3a,M0,ⅢB,3,3,,1.0,1.0,1.0,,15.0,21,,,0.0,,,,,,,,2018-05-31,2020-04-02,2,,,,,,,,,0, 印戒细胞癌(sig),GX,," L（幽门窦部）, 小弯侧Less,",30,30,8,R0 D2+,,8.73,6.75,1.41,126.0,204.0,4.34,7.6,14.0,218.0,84.0,84.0,34.7,4.7,74.6,336.0,50.2,24.4,2.5,7.2,96.0,178.0,,,,,,,,,,,,,1.16,9.78,22.18,,无,无,无,无,,,,,,,22.07621550591327,1821463
1705517,李海君,666924,男,45,T3,N3b ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0,,21.0,63,硬型（sci）,INFc,1.0,,0.0,,2.0,1.0,,,2017-02-21,2021-05-21,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌 90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",65,65,15,R0 D2,,5.34,3.04,2.0,144.2,213.0,2.11,31.0,27.0,149.0,67.0,16.1,11.93,2.39,57.5,232.57,37.1,20.4,4.1,5.05,116.0,380.0,,,,,,,,,,,,,2.54,29.21,1.32, 未做,无,无,无,无,,MLH1+80%弱-中 MSH2+80%强 MSH6+80%强 PMS2+70%强 CD4散在+ CD8+ VEGF-,80% 弱-中,80% 强,80% 强,70% 弱,50.91984231274638,1705517
1748046,李海生,706253,男,70,T1a,N0 ,M0,ⅠA,3,1,0.0,0.0,0.0,0.0,,0.0,45,,,,,,,,,,,2017-12-28,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," L（幽门窦部）, 后Post,",50,50,20,R0,,8.4,6.14,1.77,71.1,326.0,3.0,19.0,20.0,116.0,73.0,23.0,4.6,3.7,54.8,268.0,31.4,23.4,6.5,5.3,90.0,356.0,,,,,,,,,,,,,0.73,3.83,1.45, 阴性,无,无,无,无,,MLH1+80%弱 MSH2+60%弱-中 MSH6+80%中-强 PMS2+70%弱,80% 弱,60% 弱-中,80% 中-强,70% 弱,56.14323258869908,1748046
1730990,李宏伟,697912,男,56,T3,N0 ,M0, ⅡA,3,2,,1.0,1.0,1.0,,0.0,26,,,0.0,,,,,,,,2017-09-21,2019-07-01,0,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,9, 低分化腺癌（G3)(por)60 低粘附腺癌40,G3,," L（幽门窦部）, 后Post, 小弯侧Less,",40,30,7,R0 D2,,7.77,4.4,2.77,154.0,251.0,3.15,37.0,27.0,164.0,64.0,30.0,13.73,3.31,75.0,360.0,45.0,30.0,4.6,5.2,101.0,495.0,,,,,,,,,,,,,26.2,17.43,3.42, 未做,无,无,无,无,,,,,,,21.28777923784494,1730990
1636179,李景波,658331,男,55,T3,N3a ,M0,ⅢB,3,5,,0.0,0.0,1.0,,7.0,32,,,0.0,,2.0,,2.0,2.0,,,2016-10-26,2018-08-16,2,,,核糖核酸Ⅱ,,,,,,1, 低粘附腺癌,GX,,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,35,35,12,R0 D2,,4.06,1.52,2.0,120.0,225.0,2.79,12.0,18.0,89.0,52.0,24.0,11.67,4.7,65.0,321.0,37.0,28.0,5.1,4.3,85.0,366.0,79.3,45.2,30.6,1.48,0.2,13.9,5.9,1.4,0.799,4.59,9.31,,0.591,4.79,4.18, 未做,无,无,无,无,,MLH1+65%中 MSH2+50%中 MSH6+50%中-强 PMS2+50%弱-中 CD4散在+ CD8散在+ VEGF弱+,65% 中,50% 中,50% 中-强,50% 弱-中,21.64914586070959,1636179
1707877,李军,674019,男,63,T3 T3,N3a ,M1, Ⅳ,3,3,,1.0,1.0,1.0,,7.0,32,,,1.0,,1.0,,1.0,2.0,,,2017-03-07,2022-09-02,1,,,多西他赛+卡培他滨,多西他赛+卡培他滨,多西他赛+卡培他滨,多西他赛+卡培他滨,多西他赛+卡培他滨,多西他赛+卡培他滨,6, 低分化腺癌（G3)(por) 低粘附腺癌20/ 管状腺癌（中分化【G2】【tub2】,G3,," L（幽门窦部）, U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60 30,60 30,5 10,,R2,5.61,2.88,2.1,111.0,325.0,3.96,11.0,16.0,154.0,74.0,14.0,8.81,1.79,60.0,173.0,35.0,25.0,5.1,4.6,81.0,160.0,,,,,,,,,,,,,4.29,0.6,1.95, 未做,无,无,无,H1单（M1 HEP),,MLH1+80%中 MSH2+85%中-强 MSH6+85%强 PMS2+75%弱-中 CD4+ CD8散在+ VEGF+,80% 中,85% 中-强,85% 强,75% 弱-中,65.86727989487517,1707877
1739579,李林春,694591,男,69,T1b,N0 ,M0,ⅠA,3,3,2.0,1.0,1.0,0.0,,0.0,23,髓样型（med）,INFa,0.0,,,,,,,,2017-10-30,2022-09-02,1,,,口服替吉奥,,,,,,1, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren弥漫型,G3,," ML 前Ant, 后Post, 小弯侧Less,",15,10,4,R0 D2+,,4.91,2.58,1.95,152.6,200.0,2.53,26.0,20.0,155.0,59.0,12.0,14.9,5.08,69.0,289.0,42.0,27.0,5.7,3.9,80.0,179.0,,,,,,,,,,,,,2.58,0.6,5.34, 未做,无,无,无,无,,,,,,,58.08147174770039,1739579
1808665,李美英,720175,女,62,T3,N3b ,M0, ⅢC,3,3,1.0,1.0,1.0,1.0,,21.0,27,中间型（int）,INFb,,,,,,,,,2018-03-12,2021-07-06,2,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20 Lauren混合型,G3,," LMU 前Ant, 后Post, 小弯侧Less,",50,40,10,R0 D2,,7.92,6.71,0.81,80.0,193.0,4.34,11.3,29.0,178.0,92.0,13.0,7.3,4.2,68.0,228.0,38.0,30.0,4.5,5.5,59.0,225.0,,,,,,,,,,,,,2.25,28.39,3.59, 阳性+,无,无,无,无,,,,,,,39.81603153745072,1808665
1705916,李伟,670921,男,53,T3,N3b ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0,异型增生+,22.0,42,中间型（int）,INFc,0.0,,1.0,,2.0,2.0,,,2017-02-23,2017-10-31,2,,,XELOX,XELOX,,,,,2, 低粘附腺癌 管状腺癌（中分化【G2】【tub2】10 Lauren弥漫型,G2,," LMU 前Ant,",40,30,30,R0,,15.9,14.3,0.93,148.8,170.0,2.02,40.0,26.0,132.0,79.0,7.9,13.5,3.66,52.2,163.0,32.6,19.6,,2.32,58.0,124.0,,,,,,,,,,,,,2.34,22.97,1.83, 未做,无,无,无,无,,MLH1+80%弱-中 MSH2+70%中 MSH6+90%强 PMS2+40%弱  CD4散在+ CD8散在+ VEGF部分+,80% 弱-中,70% 中,90% 强,40% 弱,8.21287779237845,1705916
1615354,李宪玉,631261,男,71,T4b T1a,N2 ,M0,,3,3,0.0,0.0,0.0,1.0, 肠化生,5.0,30,中间型（int）,INFa,3.0,,,,,,,,2016-05-09,2017-04-15,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 高级别上皮内瘤变 Lauren肠型,G2,," L（幽门窦部）, M（胃体部）, 前Ant, 后Post, 小弯侧Less,",35 20,25 15,5, D2,R1,7.35,4.05,1.95,163.0,327.0,2.8,19.0,23.0,230.0,93.0,16.0,19.56,6.55,64.0,240.0,39.0,25.0,4.1,6.9,84.0,322.0,,,,,,,,,,,,,5.77,14.84,5.18, 未做,无,无,无,无,,,,,,,11.202365308804204,1615354
1741041,李雪亭,706823,女,71,T3 T3,N1 ,M0,,3,3,0.0,0.0,0.0,1.0,  慢性炎症（+）,1.0,25,中间型（int）,INFb,0.0,,,,,,,,2017-11-08,2019-05-05,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",200 80,190 70,50 10,,R1,8.05,5.43,1.66,73.8,348.0,4.08,9.0,14.0,134.0,109.0,25.0,7.7,4.3,70.3,183.0,35.3,35.0,5.9,3.4,67.0,225.0,,,,,,,,,,,,,1.84,28.07,9.76,,无,无,无,无,,MLH1+60%弱 MSH2+70%弱 MSH6+80%弱+ PMS2+70%弱,60% 弱,70% 弱,80% 弱,70% 弱,17.83837056504599,1741041
1620521,李占山,642326,男,67,T4a,N3b ,M0, ⅢC,3,2,1.0,0.0,0.0,1.0, 肠化生 慢性炎症,22.0,30,中间型（int）,INFc,0.0,,,,,,,,2016-06-17,2020-06-30,2,,,SOX,SOX,SOX,SOX,SOX,口服替吉奥,6, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren混合型,G3,," L（幽门窦部）, 小弯侧Less,",20,15,8,R0 D2,,8.74,6.87,0.94,129.6,199.0,5.97,28.0,21.0,239.0,100.0,25.0,14.07,5.58,58.0,88.0,35.0,23.0,7.0,6.8,63.0,117.0,76.0,40.9,31.7,1.29,0.2,12.6,9.5,14.6,0.574,2.08,9.87,,0.971,6.62,2.49, 阳性+,无,无,无,无,,,,,,,48.42312746386334,1620521
1701102,李忠良,668847,男,55,T4b,N3a ,M0, ⅢC,3,2,0.0,1.0,1.0,1.0, 肠化生,7.0,26,中间型（int）,INFb,1.0,,1.0,,2.0,2.0,,,2017-01-10,2022-09-02,1,,,XELOX,口服卡培他滨,,,,,2, 管状腺癌（中分化【G2】【tub2】 低粘附腺癌,G2,," M（胃体部）, 小弯侧Less,",40,30,10,R0,,8.32,5.96,1.58,148.0,237.0,2.79,47.0,31.0,169.0,101.0,29.5,6.03,1.05,69.7,316.9,38.7,31.0,5.9,9.66,106.0,414.0,,,,,,,,,,,,,1.37,3.56,16.51, 阳性+,无,无,无,无,,MLH1+80%中 MSH2+80%中-强 MSH6+80%强 PMS2+80%弱-强 CD4散在+ CD8散在+ VEGF+,80% 中,80% 中-强,80% 强,80% 弱-中,67.70696452036793,1701102
1628389,梁凤霞,651439,女,70,T3,N1 ,M0, ⅡB,3,3,0.0,0.0,0.0,1.0,  慢性炎症（+）,1.0,34,髓样型（med）,INFa,0.0,,0.0,,2.0,1.0,,,2016-08-18,2021-06-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,70,10,R0,,8.18,5.33,2.12,115.2,343.0,4.0,17.0,22.0,169.0,81.0,12.0,9.33,3.8,69.0,228.0,41.0,28.0,6.7,5.2,53.0,207.0,,,,,,,,,,,,,2.27,51.84,3.19,,无,无,无,无,,MLH1- MSH2+30%弱-中 MSH6+65%弱-中 PMS2- CD4散在+ CD8+ VEGF-,0,30% 弱-中,65% 弱-中,0,57.42444152431012,1628389
1068957,林德忠,631200,男,56,T3,N0 ,M0, ⅡA,3,3,0.0,0.0,0.0,1.0,  慢性炎症（+）,0.0,26,中间型（int）,INFa,0.0,,,,,,,,2016-03-23,2021-01-28,1,,,,,,,,,0,低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】  Lauren肠型 ,G3,," U（胃底部）, 前Ant,",30,25,5,R0,,8.03,4.59,2.77,156.2,261.0,2.97,29.0,26.0,153.0,95.0,153.0,9.76,3.76,72.0,379.0,47.0,25.0,4.7,7.0,89.0,472.0,66.2,49.1,15.3,3.21,0.4,11.6,18.4,0.4,0.842,2.89,10.1,,4.53,11.57,2.48, 阴性,无,无,无,无,,,,,,,58.21287779237845,1068957
1735379,刘春艳,449582,女,42,T4a,N3a ,M0, ⅢB,3,4,2.0,0.0,0.0,1.0,肠上皮化生，慢性炎,11.0,35,硬型（sci）,INFb,0.0,,,,,,,,2017-09-21,2020-08-27,2,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,," ML 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",65,40,6,R0 D2,,3.78,2.19,1.14,64.1,290.0,2.88,18.0,12.0,132.0,46.0,5.0,3.28,0.91,58.0,161.0,32.0,26.0,4.6,3.3,77.0,234.0,66.7,48.3,12.1,3.99,0.1,14.2,17.4,0.6,0.725,2.31,8.72,,0.297,9.68,0.891, 未做,无,无,无,无,,,,,,,35.183968462549274,1735379
1734035,刘凤,700608,女,44,T2,N0 ,M0, ⅠB,3,3,0.0,1.0,1.0,1.0, 异型增生 慢性炎症,0.0,23,中间型（int）,INFa,2.0,,,,,,,,2017-09-12,2022-09-02,1,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,," L（幽门窦部）, 前Ant,",35,25,4,R0 D2,,7.84,4.28,2.86,138.0,314.0,2.26,7.5,14.0,142.0,77.0,15.0,5.7,3.9,63.5,192.0,40.5,23.0,4.7,5.7,73.0,203.0,,,,,,,,,,,,,2.34,19.45,3.07, 未做,无,无,无,无,,,,,,,59.65834428383705,1734035
1636086,刘光艳,626686,女,48,T3,N3a ,M0,ⅢB,3,4,,0.0,0.0,1.0,,7.0,33,,,1.0,,2.0,,2.0,2.0,,,2016-10-25,2019-05-01,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低粘附腺癌60 低分化腺癌（G3)(por)40,G3,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",130,120,,R0 D2,,3.85,2.07,1.48,129.2,165.0,2.23,24.0,21.0,167.0,62.0,11.2,10.07,3.2,50.5,128.49,26.2,24.3,5.2,3.02,53.0,57.0,,,,,,,,,,,,,0.2,4.95,1.13, 阴性,无,无,无,无,,MLH1+80%弱 MSH2+60%弱-中 MSH6+90%中 PMS2+20%弱 CD4散在+ CD8散在+ VEGF弱+,80% 弱,60% 弱-中,90% 中,20% 弱,30.157687253613666,1636086
1637398,刘桂荣,676735,女,75,T3,N3a ,M0,ⅢB,3,3,0.0,1.0,1.0,1.0,,8.0,22,中间型（int）,INFa,2.0,,2.0,,2.0,2.0,,,2016-11-04,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," L（幽门窦部）, 前Ant,",28,15,3,R0,,4.49,2.009,1.97,140.0,173.0,2.95,10.0,17.0,147.0,76.0,8.0,10.2,3.21,63.0,241.0,38.0,25.0,4.6,3.9,98.0,299.0,,,,,,,,,,,,,31.18,13.14,1.49,,无,无,无,无,,MLH1+40%弱 MSH2+30%弱 MSH6+45%弱 PMS2+60%弱  CD4散在+ CD8散在+ VEGF部分弱+,40% 弱,30% 弱,45% 中,60% 弱,69.90801576872536,1637398
1710333,刘国胜,674326,男,64,T3,N1 ,M0, ⅡB,3,2,1.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,2.0,14,中间型（int）,INFa,1.0,,2.0,,2.0,2.0,,,2017-03-23,2022-09-02,1,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) Lauren肠型 Lauren弥漫型,G3,,L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre  ,40,25,8,R0 D2,,3.62,1.79,1.3,97.0,502.0,3.09,11.0,18.0,181.0,86.0,15.0,21.33,6.19,64.0,274.0,40.0,24.0,5.2,6.1,82.0,260.0,,,,,,,,,,,,,1.75,0.6,4.58, 阳性+++,无,无,无,无,,MLH1+80%弱-中 MSH2+80%中 MSH6+80%弱-中 PMS2+80%弱 CD4点灶+ CD8散在+ VEGF弱+,80% 弱-中,80% 中,80% 弱-中,80% 弱,65.34165571616295,1710333
1633384,刘加春,655493,男,65,T3,N2 ,M0, ⅢA,3,3,0.0,1.0,1.0,1.0, 肠化生 异型增生,5.0,15,中间型（int）,INFa,2.0,,2.0,,2.0,2.0,,,2016-09-28,2018-11-06,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," UM 前Ant, 后Post, 小弯侧Less,",45,25,10,R0,,6.96,3.77,1.96,147.0,293.0,2.9,36.0,21.0,153.0,66.0,30.0,10.06,3.78,71.0,274.0,43.0,28.0,5.2,6.2,79.0,367.0,,,,,,,,,,,,,0.579,4.1,2.77,,无,无,无,无,,MLH1+70%中 MSH2+80%中-强 MSH6+80%强 PMS2+40%弱 CD4散在+ CD8散在+ VEGF弱+,70% 中,80% 中-强,80% 强,40% 弱,25.26281208935611,1633384
1710252,刘庆祥,674120,男,62,T3,N1 ,M0, ⅡB,3,2,0.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,2.0,45,中间型（int）,INFa,0.0,,2.0,,2.0,1.0,,,2017-03-22,2018-03-06,2,,,XELOX,XELOX,,,,,2, 低分化腺癌（G3)(por) Lauren肠型,G3,,MU 小弯侧Less 前Ant 后Post ,70,50,10,R0 D2,,9.31,6.04,2.39,151.0,262.0,4.03,11.0,15.0,168.0,73.0,20.0,5.66,1.56,67.0,309.0,38.0,29.0,4.5,8.4,106.0,368.0,,,,,,,,,,,,,2.32,15.99,18.23, 未做,无,无,无,无,,MLH1+90%中 MSH2+90%中 MSH6+90%中-强 PMS2+90%弱-中  CD4点灶+ CD8+ VEGF弱+,90% 中,90% 中,90% 中-强,90% 弱-中,11.465177398160314,1710252
1629094,刘淑兰,649531,女,66,T3,N3a ,M0,ⅢB,3,3,0.0,0.0,0.0,1.0,  慢性炎症（+）,12.0,46,中间型（int）,INFa,1.0,,2.0,,2.0,2.0,,,2016-08-24,2020-08-21,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,10,R0 D2+,,5.95,3.78,1.67,115.7,299.0,3.2,17.0,24.0,159.0,96.0,11.0,12.65,4.74,66.0,220.0,39.0,27.0,6.5,7.7,79.0,320.0,,,,,,,,,,,,,1.5,0.76,1.09, 阳性++,无,无,无,无,,MLH1+60%弱-中 MSH2+70%弱-中 MSH6+80%弱-中 PMS2+40%弱 CD4散在+ CD8散在+ VEGF小区弱+,60% 弱-中,70% 弱-中,80% 弱-中,40% 弱,47.89750328515112,1629094
1715500,刘树弟,680685,男,52,T3,N3a ,M0,ⅢB,3,3,2.0,1.0,1.0,0.0, 正常,7.0,30,中间型（int）,INFc,0.0,,,,,,,,2017-04-27,2021-07-29,0,,,XELOX,,,,,,1, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,35,10,R0 D2,,5.42,3.02,1.98,139.4,127.0,2.61,10.0,11.0,116.0,49.0,9.0,11.22,4.04,56.0,319.0,35.0,21.0,4.8,10.0,100.0,260.0,69.4,34.2,31.3,1.09,0.1,7.1,21.0,1.8,0.772,0.701,6.22,,0.497,4.29,0.999, 未做,无,无,无,无,,,,,,,51.05124835742444,1715500
1640710,刘喜良,661520,男,52,T4b,N3a ,M0, ⅢC,3,2,1.0,1.0,1.0,1.0,异型增生+,9.0,22,硬型（sci）,INFc,2.0,,1.0,,1.0,2.0,,,2016-12-06,2022-09-02,1,,,SOX,SOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren混合型,G3,,M（胃体部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,80,80,10,R0 D2,,10.72,8.25,1.43,2.12,563.0,5.34,15.0,11.0,104.0,67.0,11.0,3.65,1.4,57.0,101.0,32.0,25.0,5.9,5.5,84.0,212.0,,,,,,,,,,,,,0.47,0.6,6.96, 未做,无,无,无,无,,MLH1+9%弱 MSH2+90%弱-中 MSH6+90%中-强 PMS2+90%弱 CD4+ CD8散在+ VEGF+,90% 弱,90% 弱-中,90% 中-强,90% 弱,68.85676741130092,1640710
1644936,刘亚琴,665898,女,68,T3,N0 ,M0, ⅡA,3,2,0.0,0.0,0.0,0.0, 肠化生 慢性炎症,0.0,20,中间型（int）,INFb,0.0,,1.0,,2.0,2.0,,,2016-12-29,2021-06-01,0,,,XELOX,口服卡培他滨,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,,LM 前Ant 后Post 小弯侧Less ,60,50,10,R0 D2,,2.95,1.81,0.8,82.3,223.0,2.01,13.0,18.0,156.0,80.0,23.0,7.89,1.89,63.0,187.0,42.0,21.0,4.7,5.0,60.0,322.0,,,,,,,,,,,,,2.98,20.23,0.696, 未做,无,无,无,无,,MLH1+80%弱-中 MSH2+80%中-强 MSH6+90%强 PMS2+60%弱  CD4散在+ CD8散在+ VEGF+,80% 弱-中,80% 中-强,90% 强,60% 弱,53.05519053876478,1644936
1734568,刘亚茹,699673,女,62,T3,N3a ,M0,ⅢB,3,3,1.0,0.0,0.0,1.0, 肠化生 慢性炎症,14.0,28,中间型（int）,INFb,0.0,,,,,,,,2017-09-15,2022-09-02,1,,,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)50 低粘附腺癌50,G3,," 后Post, 大弯侧Gre,",35,30,10,R0 D2+,,5.66,3.74,1.53,120.0,320.0,2.91,20.0,20.0,186.0,63.0,11.0,13.54,2.86,68.0,279.0,39.0,29.0,5.4,6.0,79.0,312.0,66.8,38.3,44.9,0.85,17.4,4.2,28.2,1.1,0.817,1.2,9.25,,1.25,14.61,3.03,,无,无,无,无,,,,,,,59.55978975032851,1734568
1632494,刘艳波,655448,女,40,T4a,N3a,M0, ⅢB,3,3,2.0,0.0,0.0,0.0, 正常,9.0,47,髓样型（med）,INFa,0.0,,,,,,,,2016-09-22,2021-07-29,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 粘液腺癌（muc） 低粘附腺癌20%  Lauren弥漫型,GX,," MU 前Ant, 后Post, 小弯侧Less,",100,65,15, R0  D2,,3.84,1.93,1.42,85.0,198.0,2.3,10.0,14.0,176.0,31.0,7.0,7.37,3.02,57.0,129.0,37.0,20.0,4.7,3.3,60.0,279.0,,,,,,,,,,,,,0.2,433.5,29.38, 阴性,无,无,无,无,,,,,,,58.18002628120893,1632494
1732578,刘艳华,698076,女,60,T4b,N0 ,M0, ⅢA,3,3,0.0,1.0,1.0,1.0, 肠化生,0.0,9,中间型（int）,INFa,1.0,,,,,,,,2017-08-31,2021-07-29,0,,,XELOX,XELOX,XELOX,XELOX,口服替吉奥,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,, ML 小弯侧Less,35,20,15,,,7.27,4.27,2.4,124.0,377.0,4.71,22.0,22.0,103.0,42.0,14.0,14.71,3.95,68.0,211.0,39.0,29.0,3.7,4.4,82.0,267.0,,,,,,,,,,,,,17.06,7.39,17.58, 未做,无,无,无,无,,,,,,,46.9119579500657,1732578
1627311,刘艳爽,649386,女,30,T3,N3b ,M0, ⅢC,3,4,,1.0,1.0,1.0,,16.0,26,,,0.0,,0.0,,2.0,2.0,,,2016-08-10,2019-05-01,0,,,SOX,口服替吉奥,SOX,SOX,SOX,口服替吉奥,6, 低粘附腺癌 管状腺癌（中分化【G2】【tub2】,G2,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",200,110,,R0 D2,,4.98,2.68,1.89,99.1,317.0,2.41,14.6,21.0,152.0,51.0,6.0,5.89,1.87,65.0,291.0,42.0,23.0,4.8,4.3,79.0,279.0,,,,,,,,,,,,,1.55,11.62,0.765,,无,无,无,无,,MLH1+20%弱 MSH2+40%弱 MSH6+70%中-强 PMS2+10%弱 CD4散在+ CD8散在+ VEGF-,20% 弱,40% 弱,70% 中-强,10% 弱,32.65440210249671,1627311
1627860,刘玉杰,651431,女,41,T3,N3a ,M0,ⅢB,3,3,1.0,0.0,0.0,1.0,  慢性炎症（+）,9.0,28,中间型（int）,INFc,0.0,,0.0,,0.0,2.0,,,2016-08-15,2021-07-29,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3,, L（幽门窦部） 小弯侧Less 后Post 大弯侧Gre  前Ant ,55,30,12,R0 D2,,7.17,3.88,2.7,91.2,317.0,3.5,14.3,13.0,162.0,59.0,18.0,11.61,3.98,72.0,292.0,44.0,28.0,6.9,5.1,79.0,239.0,62.3,34.4,23.4,1.47,0.1,12.5,22.0,3.0,1.79,1.44,11.8,,1.17,4.94,6.34, 阳性+,无,无,无,无,,MLH1+30%弱 MSH2+80%中 MSH6+80%强 PMS2+60%弱-中 CD4- CD8散在+ VEGF-,30% 弱,80% 中,80% 强,60% 弱-中,59.42838370565046,1627860
1710530,刘玉兰,680140,女,67,T2,N0 ,M0, ⅠB,3,1,0.0,1.0,1.0,0.0,  慢性炎症（+）,0.0,81,髓样型（med）,INFa,0.0,,1.0,,2.0,2.0,,,2017-03-24,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren肠型,G3,," M（胃体部）, 前Ant, 小弯侧Less,",45,45,35,R0,,11.34,10.29,0.47,103.1,212.0,5.1,11.0,13.0,154.0,85.0,20.0,7.58,3.18,68.0,175.0,33.0,35.0,,5.1,59.0,75.0,,,,,,,,,,,,,0.644,3.24,0.87, 未做,无,无,无,无,,MLH1+60%弱-中 MSH2+80%中 MSH6+70%中 PMS2+40%弱-中 CD4散在+ CD8散在+ VEGF部分+,60% 弱-中,80% 中,70% 中,40% 弱-中,65.30880420499342,1710530
1747012,刘玉梅,712331,女,52,T3,N3b ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0, 肠化生,17.0,48,硬型（sci）,INFc,1.0,,,,,,,,2017-12-20,2018-02-01,2,,,奥沙利铂单药化疗,,,,,,1, 低粘附腺癌 Lauren弥漫型,GX,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,20,6,D2+,,7.81,5.78,1.37,143.0,282.0,3.52,11.4,15.0,159.0,149.0,17.0,12.1,5.0,74.8,294.0,47.3,27.5,5.5,6.9,77.0,237.0,,,,,,,,,,,,,4.23,8.76,5.58,,无,无,无,无,,,,,,,1.4126149802890933,1747012
1711421,刘志恒,681785,男,66,T4b,N2 ,M0, ⅢB,3,3,2.0,0.0,0.0,0.0,  慢性炎症（+）,3.0,47,中间型（int）,INFb,0.0,,,,,,,,2017-03-30,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren弥漫型,G3,," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",18,12,10,R0 D2+,,5.91,3.96,1.43,141.6,232.0,3.15,14.0,16.0,197.0,85.0,39.0,8.05,2.18,73.0,268.0,43.0,30.0,5.5,5.2,100.0,385.0,,,,,,,,,,,,,1.28,1.25,0.873, 未做,无,无,无,无,,,,,,,65.11169513797634,1711421
1730957,刘作台,697651,女,60,T3,N3b ,M0, ⅢC,3,3,1.0,1.0,1.0,1.0, 肠化生 异型增生 慢性炎症,19.0,38,髓样型（med）,INFb,0.0,,,,,,,,2017-08-21,2020-12-25,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 粘液腺癌（muc）30 低粘附腺癌10 Lauren混合型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",55,50,15,R0 D2+,,6.49,4.87,0.9,85.0,259.0,2.68,19.0,13.0,156.0,88.0,59.0,31.7,16.31,53.0,91.0,29.0,24.0,,4.6,62.0,101.0,,,,,,,,,,,,,1.86,20.77,14.73,,无,无,无,无,,,,,,,40.14454664914586,1730957
1627310,柳德仁,649825,男,44,T4b,N2 ,M0, ⅢB,3,3,1.0,1.0,1.0,1.0,  慢性炎症（+）,4.0,28,中间型（int）,INFc,2.0,,0.0,,2.0,2.0,,,2016-08-10,2021-07-29,1,,,XELOX,XELOX,XELOX,,,,3, 低分化腺癌（G3)(por) Lauren弥漫型 Lauren肠型,G3,," U（胃底部）, 前Ant, 后Post, 小弯侧Less,",65,50,30,R0,,8.6,4.8,2.37,136.0,390.0,3.4,17.0,17.0,137.0,76.0,17.0,6.15,1.82,65.0,261.0,42.0,23.0,4.4,4.6,78.0,278.0,,,,,,,,,,,,,2.12,6.62,18.29, 未做,无,无,无,无,,MLH1+30%弱 MSH2+80%弱 MSH6+80%强 PMS2+70%弱,30% 弱,80% 弱,80% 强,70% 弱,59.592641261498024,1627310
1731612,栾伟,699028,男,62,T3,N3a ,M0,ⅢB,3,3,,1.0,1.0,1.0,,8.0,32,,,2.0,,,,,,,,2017-08-24,2019-07-20,2,,,XELOX,XELOX,,,,,2, 粘液腺癌（muc）40 低粘附腺癌60,GX,," M（胃体部）, 小弯侧Less,",40,20,18,R0 D2+,,7.73,5.36,1.48,98.3,222.0,2.41,23.0,26.0,146.0,58.0,48.0,19.6,7.44,73.0,140.0,36.0,37.0,4.6,4.4,113.0,365.0,,,,,,,,,,,,,51.96,12.73,2.3, 未做,无,无,无,无,,,,,,,22.831800262812088,1731612
1617367,栾永,640655,男,74,T3,N2 ,M0, ⅢA,3,3,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,5.0,19,中间型（int）,INFb,0.0,,,,,,,,2016-05-23,2021-01-27,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70% 低粘附腺癌30% Lauren混合型,G3,," U（胃底部）, 后Post, 小弯侧Less,",40,25,8,R0,,4.81,2.12,1.88,144.8,134.0,2.41,7.0,14.0,195.0,59.0,25.0,19.4,7.63,66.0,139.0,41.0,25.0,4.8,6.2,94.0,236.0,,,,,,,,,,,,,3.87,60.25,6.56, 未做,无,无,无,无,,,,,,,56.17608409986859,1617367
1642168,吕凤霞,664041,女,35,T3,N3b ,M0, ⅢC,3,4,2.0,0.0,0.0,1.0, 异型增生 慢性炎症,41.0,48,中间型（int）,INFb,0.0,,1.0,,1.0,2.0,,,2016-12-09,2018-12-30,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,口服卡培他滨,8, 低粘附腺癌90 粘液腺癌（muc）10 Lauren弥漫型,GX,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,50,15,R0 D2+,,4.88,0.38,1.1,75.3,346.0,3.48,11.0,15.0,133.0,59.0,14.0,7.46,2.09,55.0,173.0,34.0,21.0,5.5,4.1,70.0,275.0,,,,,,,,,,,,,0.2,43.75,1.16,,无,无,无,无,,MLH1+90%弱-中 MSH2+90%中 MSH6+90%强 PMS2+80%弱 CD4+ CD8散在+ VEGF+,90% 弱-中,90% 中,90% 强,80% 弱,24.67148488830486,1642168
1736399,吕娜,704208,女,37,T3,N2 ,M0, ⅢA,3,2,2.0,0.0,0.0,1.0, 肠化生 慢性炎症 异型增生,6.0,20,中间型（int）,INFb,0.0,,,,,,,,2017-09-29,2020-07-01,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por) Lauren弥漫型,G3,," M（胃体部）, 前Ant,",15,10,3,R0 D2,,6.33,4.59,1.35,119.0,328.0,2.37,9.9,16.0,173.0,60.0,14.0,11.8,5.4,66.7,269.0,40.3,26.4,4.4,3.9,62.0,198.0,73.7,42.3,23.0,1.84,0.1,13.1,12.1,0.7,1.47,1.5,12.8,,0.45,7.49,1.04, 未做,无,无,无,无,,,,,,,33.04862023653088,1736399
1734345,吕喜君,701174,男,53,T1a,N0 ,M0,ⅠA,3,2,1.0,0.0,0.0,0.0, 肠化生 慢性炎症,0.0,15,中间型（int）,INFb,0.0,,,,,,,,2017-09-14,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3,," L（幽门窦部）, 小弯侧Less,",30,20,5,R0 D2,,9.85,6.09,2.65,155.0,288.0,3.58,27.3,21.0,145.0,82.0,31.0,12.4,4.8,76.2,264.0,41.9,34.3,12.3,5.1,61.0,340.0,80.2,47.5,26.5,1.79,0.2,8.8,10.4,5.6,1.2,5.16,16.2,,2.0,17.1,6.89,,无,无,无,无,,,,,,,59.592641261498024,1734345
1639816,吕颜奇,661872,男,32,T3 T1b T1a,N0 ,M0,,3,3,,0.0,0.0,1.0,,0.0,24,,,1.0,,,,,,,,2016-11-23,2022-09-02,1,,,SOX,SOX,SOX,,,,3, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3,," 大弯侧Gre, 小弯侧Less, LM",35 37 15,25 30 7,3 2 1, D2,,7.58,4.13,2.62,172.1,283.0,2.84,41.0,25.0,136.0,66.0,43.0,11.47,3.19,69.0,418.0,45.0,24.0,5.1,4.8,89.0,338.0,74.1,47.9,15.6,3.07,0.2,10.8,10.6,1.2,1.38,1.33,6.7,,1.72,19.79,1.43, 未做,无,无,无,无,,,,,,,69.2838370565046,1639816
1812711,马尚海,718754,男,58,T4b,N3b ,M0, ⅢC,3,3,0.0,0.0,0.0,1.0, 肠化生 慢性炎症,19.0,32,中间型（int）,INFb,,,,,,,,,2018-04-04,2018-12-28,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",40,30,15,D2+,R1,9.76,4.98,2.94,162.0,264.0,3.59,21.1,22.0,172.0,122.0,48.0,13.1,5.6,63.7,303.0,41.0,22.7,5.8,8.5,98.0,251.0,,,,,,,,,,,,,2.15,95.84,3.5, 未做,无,无,无,无,,,,,,,8.804204993429698,1812711
1628063,马文玉,643215,女,39,T2,N2 ,M0, ⅡB,3,2,2.0,0.0,0.0,0.0,  慢性炎症（+）,6.0,23,硬型（sci）,INFc,0.0,,0.0,,2.0,2.0,,,2016-08-16,2021-07-29,1,,,XELOX,,,,,,1, 低粘附腺癌85 低分化腺癌（G3)(por)15 Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",40,30,15,R0 D2+,,9.72,5.98,2.76,151.0,311.0,2.65,23.0,16.0,158.0,82.0,17.0,28.34,10.54,75.0,362.0,42.0,33.0,4.9,3.9,81.0,334.0,,,,,,,,,,,,,0.409,23.85,0.642,,无,无,无,无,,MLH1+30%弱 MSH2+30%弱 MSH6+30%中-强 PMS2+40%弱  CD4散在+ CD8散在+ VEGF-,30% 弱,30% 弱,30% 中-强,40% 弱,59.39553219448094,1628063
1622146,马忠山,643463,男,46,T3,N1 ,M1, Ⅳ,3,4,2.0,0.0,0.0,1.0, 正常,2.0,20,硬型（sci）,INFc,1.0,,,,,,,,2016-06-30,2017-05-15,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,," LMU 后Post, 大弯侧Gre, 小弯侧Less, 前Ant,",170,150,18, D2,R1,6.18,3.28,2.35,163.0,252.0,2.27,24.0,21.0,143.0,93.0,25.0,8.38,3.23,64.0,347.0,41.0,23.0,5.0,6.7,107.0,394.0,69.4,44.3,21.9,2.02,0.7,20.5,8.8,1.6,1.09,2.87,11.8,,3.16,19.8,1.0, 阴性,无,无,P0,H0,,,,,,,10.4796320630749,1622146
1707188,孟繁奎,671017,男,70,T4b,N2 ,M0, ⅢB,3,3,0.0,0.0,0.0,0.0, 正常,3.0,17,髓样型（med）,INFa,0.0,,,,,,,,2017-03-02,2019-05-01,2,,,,,,,,,0, 粘液腺癌（muc） 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30 Lauren肠型,G3,," UM SiewerⅢ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,60,10,R0 D2,,8.74,5.63,2.41,102.0,299.0,4.29,23.0,20.0,166.0,167.0,16.6,10.44,2.16,70.1,150.0,34.7,35.4,6.1,4.86,76.0,327.0,,,,,,,,,,,,,36.89,10.94,66.56, 未做,无,无,无,无,,,,,,,25.952693823915897,1707188
1734346,孟晖,698060,女,47,T2,N0 ,M0, ⅠB,3,3,,0.0,0.0,0.0,,0.0,16,,,0.0,,,,,,,,2017-09-14,2022-09-02,1,,,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,口服替吉奥,8, 低粘附腺癌60 低分化腺癌（G3)(por)40,G3,," MU SiewerⅢ, 小弯侧Less,",40,30,,R0 D2+,,7.23,4.7,1.91,126.0,358.0,3.04,9.0,13.0,133.0,75.0,10.0,9.3,4.4,66.0,147.0,37.7,28.3,4.8,4.6,69.0,217.0,,,,,,,,,,,,,0.718,12.36,0.923, 未做,无,无,无,无,,,,,,,59.592641261498024,1734346
1814861,孟祥燕,725319,女,46,T3,N3a ,M0,ⅢB,3,3,,1.0,1.0,0.0,,8.0,28,,,,,,,,,,,2018-04-18,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20,G3,," L（幽门窦部）, 后Post, 大弯侧Gre,",30,20,4,R0 D2,,14.69,12.38,1.05,104.0,238.0,2.44,29.7,20.0,139.0,144.0,88.0,15.36,3.5,56.0,241.0,36.1,19.9,4.7,5.0,63.0,298.0,,,,,,,,,,,,,2.59,1.16,1.06, 未做,无,无,无,无,,,,,,,52.496714848883045,1814861
1632400,莫艳菊,656269,女,41,T4b,N3b ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0, 正常,24.0,25,中间型（int）,INFb,1.0,,1.0,,1.0,2.0,,,2016-09-21,2019-06-15,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低分化腺癌（G3)(por)40% 低粘附腺癌 Lauren弥漫型,G3,," LMU 后Post, 小弯侧Less, 大弯侧Gre, 前Ant,",90,60,10,,R1,8.16,4.51,2.71,104.0,545.0,3.36,58.0,64.0,277.0,88.0,82.3,13.16,3.38,53.9,239.45,27.2,26.7,5.7,3.58,62.0,76.0,,,,,,,,,,,,,1.7,21.31,46.64, 未做,无,无,无,无,,MLH1+70%弱-中 MSH2+80%中 MSH6+80%中-强 PMS2+80%弱 CD4+ CD8散在+ VEGF+,70% 弱-中,80% 中,80% 中-强,80% 弱,32.75295663600526,1632400
1631850,牟金波,656290,女,37,T1b,N0 ,M0,ⅠA,3,3,,0.0,0.0,0.0,,0.0,31,,,,,,,,,,,2016-09-18,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 90低粘附腺癌10,G3,, L（幽门窦部） 前Ant 后Post 小弯侧Less,35,20,8,R0 D2,,12.13,10.06,1.18,124.4,176.0,2.76,52.0,57.0,212.0,61.0,11.5,9.45,1.96,50.9,156.92,28.4,22.5,5.8,7.51,60.0,107.0,66.5,36.9,25.4,1.45,0.4,5.5,26.2,0.6,0.882,3.01,11.4,,0.597,6.58,2.6, 未做,无,无,无,无,,,,,,,71.4520367936925,1631850
1610365,穆清林,633483,男,64,T4a,N3a ,M0, ⅢB,3,3,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,11.0,27,髓样型（med）,INFb,0.0,,,,,,,,2016-03-31,2017-07-12,2,,,紫杉醇+顺铂,,,,,,1, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren混合型,G3,," L（幽门窦部）, 小弯侧Less, 后Post,",30,30,10,R0 D2,,4.99,68.35,23.69,91.4,308.0,3.28,13.0,20.0,141.0,85.0,16.0,6.33,2.32,59.0,262.0,36.0,23.0,4.9,5.6,84.0,355.0,73.5,48.9,23.5,2.08,0.3,5.2,18.5,14.3,,2.53,9.77,,1.97,318.8,1.77, 阳性+,无,无,无,无,,,,,,,15.374507227332456,1610365
1641433,倪宝东,662887,男,54,T4b,N0 ,M0, ⅢA,3,2,0.0,1.0,1.0,1.0, 正常,0.0,20,中间型（int）,INFa,0.0,,2.0,,2.0,2.0,,,2016-12-05,2021-07-29,0,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," U（胃底部）, 后Post,",30,30,8,R0,,10.31,6.03,3.34,148.3,229.0,2.91,32.0,19.0,149.0,84.0,18.6,9.88,2.38,62.5,287.86,36.1,26.4,7.2,4.71,91.0,291.0,,,,,,,,,,,,,1.94,0.6,1.91, 未做,无,无,无,无,,MLH1+70%弱-中 MSH2+70%中 MSH6+85%中-强 PMS2+70%弱-中 CD4+ CD8散在+ VEGF部分弱+,70% 弱-中,70% 中,85% 强,70% 弱-中,55.74901445466491,1641433
1607805,潘日盛,631463,男,61,T4a,N1 ,M0, ⅢA,3,3,2.0,0.0,0.0,1.0,  慢性炎症（+）,1.0,38,中间型（int）,INFc,0.0,,,,,,,,2016-03-15,2020-12-01,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,8, 低粘附腺癌,GX,," LM 前Ant, 后Post, 小弯侧Less,",50,40,15,R0 D2+,,7.54,4.6,2.51,137.0,294.0,4.69,20.0,21.0,139.0,61.0,20.0,10.13,3.19,64.0,321.0,42.0,22.0,6.0,4.8,82.0,207.0,68.1,43.0,23.4,1.84,0.8,12.8,18.2,1.5,0.68,1.04,8.44,,1.59,8.23,1.53, 阴性,无,无,无,无,,,,,,,56.57030223390276,1607805
1615791,裴在奉,640846,男,82,T4b,N1 ,M0 , ⅢB,3,2,0.0,1.0,1.0,1.0, 正常,2.0,21,中间型（int）,INFa,0.0,,,,,,,,2016-05-11,2021-06-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】85 乳头状癌（G1）（pap）15 Lauren肠型,G2,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,60,6,R0 D2,,7.26,4.79,1.71,78.0,356.0,3.59,12.0,16.0,130.0,100.0,18.0,4.71,1.96,49.0,169.0,27.0,22.0,4.6,5.8,89.0,338.0,,,,,,,,,,,,,17.5,226.9,2.62, 未做,无,无,无,无,,,,,,,60.67674113009198,1615791
1635491,齐淑琴,658683,女,71,T4b,N3a ,M0, ⅢC,3,5,1.0,1.0,1.0,1.0, 肠化生 异型增生,11.0,28,硬型（sci）,INFb,0.0,,2.0,,2.0,2.0,,,2016-10-20,2017-03-16,2,,,SOX,SOX,SOX,SOX,SOX,,5, 低粘附腺癌 90低分化腺癌（G3)(por) 10Lauren混合型,G3,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",30,20,2,R0 D2,,9.25,4.98,3.46,119.0,430.0,3.02,31.0,34.0,234.0,81.0,9.0,9.54,2.86,61.7,278.25,34.3,27.4,5.8,3.42,72.0,154.0,,,,,,,,,,,,,0.584,6.61,1.9, 阴性,无,无,无,无,,MLH1+25%弱 MSH2+75%中-强 MSH6+80%强 PMS2+20%弱  CD4散在+ CD8散在+ VEGF弱+,25% 弱,75% 中-强,80% 强,20% 弱,4.829172141918528,1635491
1712950,齐长凤,682252,女,60,T4a,N3a ,M0, ⅢB,3,3,2.0,0.0,0.0,1.0, 肠化生 异型增生,12.0,42,髓样型（med）,INFc,0.0,,,,,,,,2017-04-11,2019-08-01,2,,,,,,,,,0, 低粘附腺癌 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,," LMU 前Ant, 后Post, 小弯侧Less,",90,50,15,R0 D2,,5.52,2.84,2.15,125.5,381.0,3.13,12.0,16.0,118.0,82.0,16.0,5.75,1.61,70.0,308.0,38.0,32.0,5.9,7.3,76.0,261.0,,,,,,,,,,,,,3.85,22.05,, 未做,无,无,无,无,,,,,,,27.660972404730618,1712950
1704330,秦淑英,667130,女,64,T3,N2 ,M0, ⅢA,3,2,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,6.0,15,中间型（int）,INFc,2.0,,0.0,,2.0,2.0,,,2017-02-14,2017-07-26,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80  低粘附腺癌20 Lauren混合型,G3,, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,30,20,10,R0 D2,,5.14,2.74,1.93,117.0,350.0,3.58,26.0,17.0,163.0,132.0,14.0,8.37,2.45,60.0,207.0,37.0,23.0,3.8,4.4,60.0,270.0,,,,,,,,,,,,,3.67,54.61,9.2, 未做,无,无,无,无,,MLH1+80%强 MSH2+90%强 MSH6+90%强 PMS2+70%中  CD4散在+ CD8散在+ VEGF-,80% 强,90% 强,90% 强,70% 中,5.321944809461235,1704330
1617370,任玉秋,640965,女,60,T3,N2 ,M0, ⅢA,3,3,2.0,0.0,0.0,1.0,  慢性炎症（+）,3.0,40,硬型（sci）,,0.0,,,,,,,,2016-05-23,2021-07-29,1,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,," M（胃体部）, 小弯侧Less,",50,40,10,R0 D2+,,5.97,3.12,2.04,138.3,268.0,2.6,30.0,29.0,230.0,62.0,17.0,10.35,3.34,65.0,352.0,38.0,27.0,4.8,4.2,57.0,290.0,,,,,,,,,,,,,2.13,2.88,1.18, 未做,无,无,无,无,,,,,,,62.187910643889616,1617370
1700881,石井成,659733,男,63,T4b,N2 ,M0, ⅢB,3,2,2.0,0.0,0.0,0.0, 肠化生,3.0,25,髓样型（med）,INFb,0.0,0.5,,,,,,,2017-01-09,2017-12-08,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren弥漫型,G3,, LM 大弯侧Gre ,110,100,60,,R1,6.75,4.18,1.73,116.0,456.0,4.97,26.0,20.0,201.0,197.0,202.0,8.83,4.08,64.0,151.0,37.0,27.0,4.9,5.3,66.0,319.0,48.3,31.0,15.1,2.05,0.5,4.4,46.5,3.0,1.07,1.35,8.4,,3.89,0.6,0.845, 未做,无,无,无,无,,,,,,,10.939553219448094,1700881
1732452,石淑媛,697743,女,50,T4a,N3a ,M0, ⅢB,3,3,0.0,0.0,0.0,1.0, 肠化生,9.0,44,硬型（sci）,INFa,0.0,,,,,,,,2017-08-31,2020-03-01,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,11, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3,,L（幽门窦部） 后Post 小弯侧Less ,40,35,15,R0 D2,,4.47,2.83,1.25,107.4,267.0,2.44,19.0,20.0,196.0,66.0,8.0,15.02,4.22,78.0,258.0,43.0,35.0,4.4,5.0,83.0,266.0,,,,,,,,,,,,,1.79,8.49,1.78, 未做,无,无,无,无,,,,,,,29.993429697766096,1732452
1826678,史桂芝,735685,女,55,T3,N3a ,M0,ⅢB,3,2,2.0,0.0,0.0,1.0, 肠化生 慢性炎症 异型增生,10.0,28,中间型（int）,INFc,2.0,,,,,,,,2018-07-04,2022-09-02,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌 低分化腺癌（G3)(por)30 Lauren弥漫型,G3,," L（幽门窦部）, 小弯侧Less,",30,20,6,R0 D2+,,7.96,5.09,2.18,137.0,362.0,3.96,9.2,16.0,164.0,108.0,47.0,8.4,1.6,70.3,201.0,41.5,28.8,4.3,232.0,64.0,232.0,,,,,,,,,,,,,4.27,29.46,1.37, 未做,无,无,无,无,,,,,,,49.96714848883048,1826678
1736704,宋宏贵,702710,男,30,T1a,N0 ,M0,ⅠA,3,2,1.0,,,,,0.0,31,中间型（int）,INFc,0.0,,,,,,,,2017-10-11,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3,," L（幽门窦部）, 小弯侧Less,",15,12,5,R0 D2,,6.57,2.61,3.33,140.0,280.0,2.14,20.0,14.0,165.0,63.0,18.0,15.86,4.52,74.0,300.0,42.0,32.0,4.2,5.3,103.0,321.0,72.0,31.6,33.3,0.95,0.3,12.6,13.9,1.2,0.988,2.85,11.9,,2.26,9.43,0.969, 阳性+,无,无,无,无,,,,,,,58.70565045992115,1736704
1710014,苏荣,669427,男,74,T2,N0 ,M0, ⅠB,3,3,0.0,0.0,0.0,0.0,异型增生+,0.0,27,中间型（int）,INFa,3.0,,,,,,,,2017-03-12,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," U（胃底部）, 小弯侧Less,",25,20,10,R0 D2,,6.14,3.9,1.56,87.3,237.0,3.22,42.0,34.0,141.0,47.0,25.0,6.56,2.71,52.0,160.0,29.0,23.0,7.5,8.1,84.0,209.0,,,,,,,,,,,,,1.62,7.69,0.797,,无,无,无,无,,,,,,,65.7030223390276,1710014
1803757,孙桂云,711591,女,51,T3,N2 ,M0, ⅢA,3,4,1.0,1.0,1.0,1.0,  慢性炎症（+）,5.0,11,中间型（int）,INFc,3.0,0.01,,,,,1.0,,2018-01-25,2019-06-01,2,,,SOX,SOX,SOX,SOX,,,4, 低分化腺癌（G3)(por) 低粘附腺癌 Lauren混合型,G3,," LMU 前Ant, 后Post, 小弯侧Less,",60,30,6,R0 D2,,13.64,91.53,3.52,92.8,165.0,3.67,143.8,91.0,232.0,135.0,8.0,5.1,2.36,46.3,171.0,26.2,20.1,,3.9,53.0,103.0,,,,,,,,,,,,,0.66,8.82,,,无,无,无,无,,MLH1+60%弱-中 MSH2+80%弱-中 MSH6+80%中-强 PMS2+70%弱-中 ,60% 弱-中,80% 弱-中,80% 中-强,70% 弱-中,16.16294349540079,1803757
1742678,孙立镝,701791,男,65,T3,N0 ,M0, ⅡA,3,3,0.0,0.0,0.0,1.0,  慢性炎症（+）,0.0,33,中间型（int）,INFb,1.0,,,,,,,,2017-11-20,2019-05-05,0,,,SOX,SOX,SOX,口服替吉奥,SOX,SOX,7, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,," L（幽门窦部）, 大弯侧Gre,",55,50,20,D2+,,6.78,3.96,2.17,143.0,260.0,3.24,16.7,21.0,146.0,78.0,19.0,16.0,6.6,67.8,235.0,38.7,29.1,6.7,5.1,91.0,331.0,,,,,,,,,,,,,4.76,8.79,1.48,,无,无,无,无,,MLH1- MSH2+90%中 MSH6+80%中-强 PMS2-,0,90% 中,80% 中-强,0,17.444152431011826,1742678
1745937,孙丽伟,711610,女,43,T1a,N0 ,M0,ⅠA,3,2,1.0,,,, 肠化生,0.0,27,中间型（int）,,0.0,,,,,,,,2017-12-13,2022-09-02,1,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por)10 Lauren混合型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,30,,R0 D2+,,9.74,5.16,3.77,93.0,526.0,2.45,12.3,15.0,120.0,82.0,20.0,6.7,4.3,4.5,260.0,42.1,32.9,4.5,5.6,72.0,259.0,,,,,,,,,,,,,1.67,0.6,1.73, 阳性+,无,无,无,无,,,,,,,56.63600525624179,1745937
1636424,孙龙,661003,男,32,T1a,N0 ,M0,ⅠA,3,0,,,,,,0.0,28,,,1.0,,,,,,,,2016-10-27,2022-09-02,1,,,,,,,,,0, 低粘附腺癌,GX,," L（幽门窦部）, 小弯侧Less, 后Post,",15,10,,,,5.3,2.17,2.5,148.0,325.0,2.18,49.0,26.0,139.0,71.0,38.0,14.7,6.05,67.0,380.0,42.0,25.0,4.0,5.6,98.0,320.0,64.1,29.3,22.7,1.29,0.3,8.3,25.1,1.6,0.84,0.515,9.63,,0.518,1.04,2.84, 未做,无,无,无,无,,,,,,,70.17082785808147,1636424
1623598,孙盛琳,643243,男,57,T4a,N1 ,M0, ⅢA,3,2,2.0,1.0,1.0,1.0,  慢性炎症（+）,1.0,31,中间型（int）,INFc,0.0,,,,,,,,2016-07-12,2017-03-08,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",50,40,10,R0 D2+,,5.19,3.06,1.58,137.0,293.0,4.32,14.0,19.0,200.0,78.0,53.0,14.83,4.58,70.0,319.0,48.0,22.0,6.7,7.3,76.0,402.0,68.8,55.3,13.2,4.19,0.1,13.0,17.1,0.6,0.789,2.22,7.28,,5.03,48.21,16.83, 阳性++,无,无,无,无,,,,,,,7.851511169513797,1623598
1741461,孙守冬,708434,男,26,T3,N1 ,M0, ⅡB,3,3,2.0,1.0,1.0,1.0,  慢性炎症（+）,1.0,15,硬型（sci）,INFc,0.0,,,,,,,,2017-11-13,2019-03-08,0,,,XELOX,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,SOX,8, 低粘附腺癌 低分化腺癌（G3)(por),G3,," M（胃体部）, 后Post, 小弯侧Less,",30,20,6,R0,,12.72,10.57,0.78,132.1,194.0,2.27,20.0,13.0,155.0,77.0,17.0,15.3,3.2,77.0,288.0,44.0,33.0,4.6,4.7,100.0,282.0,,,,,,,,,,,,,2.02,0.6,10.84,,无,无,无,无,,MLH1+80%弱-中 MSH2+80%中 MSH6+80%强 PMS2+70%弱-中,80% 弱-中,80% 中,80% 强,70% 弱-中,15.768725361366622,1741461
1642341,孙淑梅,676512,女,73,T4b,N1 ,M0, ⅢB,3,3,1.0,0.0,0.0,1.0, 正常,2.0,12,髓样型（med）,INFb,1.0,,,,,,,,2016-12-12,2019-10-01,2,,,,,,,,,0, 粘液腺癌（muc）80 管状腺癌（中分化【G2】【tub2】20 Lauren混合型,G2,," M（胃体部）, 前Ant, 后Post, 小弯侧Less,",60,40,20, D1,R2 ,4.95,3.099,1.5,96.2,404.0,4.88,10.0,16.0,122.0,53.0,45.0,8.25,2.64,61.0,115.0,30.0,31.0,4.6,3.8,78.0,188.0,,,,,,,,,,,,,0.718,1.99,109.1,,无,无,无,无,,MLH1+60%弱-中 MSH2+70%弱-中 MSH6+70%中-强 PMS2+30%弱 CD4散在+ CD8散在+ VEGF+,60% 弱-中,70% 弱-中,70% 中-强,30% 弱,33.60709592641261,1642341
1615987,孙文,633748,男,56,T3,N3b ,M0, ⅢC,3,2,0.0,1.0,1.0,1.0, 正常,25.0,42,中间型（int）,INFa,2.0,,,,,,,,2016-05-12,2020-05-20,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】95 低粘附腺癌5 Lauren肠型,G2,," MU GE, SiewerⅡ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,10,R0 D2+,,10.62,7.13,2.28,172.0,294.0,4.97,36.0,45.0,204.0,95.0,126.0,36.36,9.36,46.0,457.0,46.0,31.0,5.7,7.1,83.0,242.0,64.3,33.4,27.6,1.21,0.1,8.3,25.4,4.4,0.665,4.63,7.99,,1.78,12.4,4.97, 阳性+++,无,无,无,无,,,,,,,48.25886990801577,1615987
1940937,孙一秋,794635,男,50,T4b,N3b ,M1, Ⅳ,3,2,1.0,1.0,1.0,1.0,  慢性炎症（+）,58.0,62,中间型（int）,INFc,1.0,,,,,,,,2019-09-12,2019-11-22,2,,,信迪利单抗+XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3,," M（胃体部）,",30,20,10,D2+,R2,10.65,7.74,1.57,142.0,182.0,3.15,12.0,14.0,170.0,84.0,24.0,14.3,2.8,62.0,175.0,34.6,27.4,4.5,5.6,105.0,308.0,,,,,,,,,,,,,2.33,0.94,1.95, 未做,无,无,p1泛(M1 PER),无,,,,,,,2.3324572930354797,1940937
1641096,孙玉林,659730,男,52,T3,N3a ,M0,ⅢB,3,3,1.0,1.0,1.0,1.0,  慢性炎症（+）,15.0,41,中间型（int）,INFb,1.0,,2.0,,2.0,2.0,,,2016-12-01,2017-03-15,2,,,XELOX,XELOX,,,,,2, 低粘附腺癌60 低分化腺癌（G3)(por) 40Lauren混合型,G3,,LM 前Ant 小弯侧Less 后Post 大弯侧Gre  ,55,50,15,R0,,5.79,2.79,2.02,131.5,338.0,2.36,30.0,30.0,173.0,68.0,21.0,5.79,1.98,72.0,278.0,44.0,28.0,6.4,7.5,135.0,461.0,65.5,42.9,18.8,2.28,0.2,9.6,21.1,1.2,1.19,4.33,10.1,,3.44,12.13,3.49,,无,无,无,无,,MLH1+80%弱 MSH2+60%弱-中 MSH6+70%弱-中 PMS2+80%弱 CD4散在+ CD8散在+ VEGF弱+,80% 弱,60% 弱-中,70% 弱-中,80% 弱,3.416557161629435,1641096
1625430,孙兆合,643396,男,52,T3,N3a ,M0,ⅢB,3,3,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,14.0,63,中间型（int）,INFb,0.0,,,,,,,,2016-07-26,2021-07-29,1,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（低中分化【G2】【tub2】60% 低粘附腺癌30% 粘液腺癌（muc）10%  Lauren混合型,G2,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,20,10,R0,,7.61,4.1,1.99,142.0,211.0,3.17,19.0,24.0,182.0,44.0,8.0,9.52,3.31,60.0,316.0,40.0,20.0,5.6,7.6,75.0,280.0,,,,,,,,,,,,,1.28,3.65,13.57, 未做,无,无,无,无,,,,,,,60.08541392904073,1625430
1811494,唐艳霞,722393,女,35,T3,N3b ,M0, ⅢC,3,3,2.0,1.0,1.0,0.0,  慢性炎症（+）,32.0,63,硬型（sci）,INFc,,,,,,,,,2018-03-28,2021-07-06,2,,,,,,,,,0, 低分化腺癌（G3)(por) 20低粘附腺癌80,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,25,10,R0 D2+,,6.04,3.02,2.49,132.0,207.0,2.25,9.2,17.0,190.0,88.0,12.0,12.7,4.2,68.2,287.0,43.3,24.9,5.2,6.6,75.0,199.0,,,,,,,,,,,,,0.684,8.65,0.77, 未做,无,无,无,无,,,,,,,39.2904073587385,1811494
1643026,田大力,663922,男,48,T4b,N3b ,M0, ⅢC,3,4,1.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,21.0,40,中间型（int）,INFc,0.0,,2.0,,1.0,2.0,,,2016-12-15,2017-05-23,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren混合型,G3,,LMU 前Ant 后Post 大弯侧Gre  小弯侧Less ,80,40,10,R0 D2,,6.77,4.26,1.91,158.5,311.0,3.59,16.0,18.0,152.0,105.0,,19.19,5.53,79.0,352.0,49.0,30.0,6.4,6.7,96.0,218.0,,,,,,,,,,,,,1.56,16.66,1.33, 未做,无,无,无,无,,MLH1+90%弱 MSH2+90%弱-中 MSH6+90%中 PMS2+90%弱 CD4+ CD8散在+ VEGF弱+,90% 弱,90% 弱-中,90% 中,90% 弱,5.223390275952694,1643026
1724969,汪加良,693409,女,52,T3,N3b ,M0, ⅢC,3,3,0.0,1.0,1.0,0.0, 肠化生 慢性炎症,25.0,40,硬型（sci）,INFa,1.0,,,,,,,,2017-07-06,2017-11-30,2,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3,," MU 前Ant, 后Post, 小弯侧Less,",50,30,12,R0,,7.83,5.18,1.86,128.0,350.0,4.88,23.2,20.0,162.0,78.0,24.0,7.57,3.53,64.4,152.0,32.9,31.5,3.6,5.3,61.0,267.0,,,,,,,,,,,,,0.685,18.25,0.741, 未做,无,无,无,无,,,,,,,4.829172141918528,1724969
1604535,王炳华,629938,男,59,T4b,N3a ,M0, ⅢC,3,3,1.0,0.0,0.0,0.0,  慢性炎症（+）,13.0,43,髓样型（med）,INFb,2.0,,,,,,,,2016-02-23,2016-05-03,2,,,紫杉醇联合替吉奥,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】90 低粘附腺癌10 Lauren混合型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,30,30,,R2,8.34,5.65,2.25,109.7,357.0,2.97,16.0,22.0,138.0,92.0,15.0,5.3,2.0,68.0,249.0,41.0,27.0,4.4,2.8,65.0,246.0,80.3,63.1,15.9,3.97,0.1,8.9,10.3,1.0,2.57,1.82,11.4,,,,,,无,无,无,无,,,,,,,2.299605781865966,1604535
1738625,王春平,701215,男,56,T2,N3a ,M0, ⅢA,3,3,,1.0,1.0,1.0,,7.0,50,,,0.0,,,,,,,,2017-07-23,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por) 低粘附腺癌,G3,," M（胃体部）, 后Post, 小弯侧Less,",20,20,10,R0,,5.53,3.26,1.83,140.2,276.0,4.15,13.5,15.0,141.0,89.0,60.0,12.5,4.8,67.9,329.0,41.1,26.8,7.1,7.5,97.0,301.0,,,,,,,,,,,,,1.37,13.07,0.867,,无,无,无,无,,MLH1- MSH2+ MSH6+ PMS2-,0,1,1,0,61.333771353482256,1738625
1716121,王丹,683741,女,40,T4b,N2 ,M1, Ⅳ,3,4,2.0,1.0,1.0,1.0, 正常,5.0,12,硬型（sci）,INFc,0.0,,,,,,,,2017-05-04,2018-03-02,2,,,紫杉醇,紫杉醇,紫杉醇,紫杉醇联合替吉奥,紫杉醇联合替吉奥,紫杉醇联合替吉奥,9, 低粘附腺癌 低分化腺癌（G3)(por)25 Lauren弥漫型,G3,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,10, D1,R2,6.27,4.52,1.02,122.0,282.0,3.2,8.0,14.0,147.0,19.0,9.0,9.71,3.3,68.0,276.0,40.0,28.0,4.2,6.3,82.0,297.0,73.5,40.7,25.5,1.6,0.3,13.3,7.1,3.9,1.31,1.83,11.0,,0.391,245.6,3.89,,无,无,p1泛(M1 PER),无,,,,,,,9.921156373193167,1716121
1721922,王殿魁,686676,男,78,T4b,N3a ,M0, ⅢC,3,3,2.0,0.0,0.0,1.0, 肠化生 慢性炎症,12.0,25,髓样型（med）,INFc,1.0,,,,,,,,2017-06-15,2018-03-30,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,10,R0 D2,,3.44,2.18,0.91,135.0,117.0,3.08,20.0,14.0,168.0,57.0,7.0,8.29,3.31,66.0,201.0,38.0,28.0,5.4,7.2,105.0,322.0,65.3,41.9,17.0,2.46,0.1,11.1,21.2,3.5,0.864,2.79,11.5,,1.81,147.8,2.44, 阴性,无,无,无,无,,,,,,,9.461235216819974,1721922
1834385,王峰,745103,男,62,T4b,N2 ,M0, ⅢB,3,3,1.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,4.0,21,中间型（int）,INFb,2.0,,,,,,,,2018-08-27,2019-05-05,0,,,SOX,SOX,SOX,SOX,雷莫芦单抗+紫杉醇,雷莫芦单抗+紫杉醇,7,<胃>浸润溃疡型混合性癌（中低分化腺癌约90%，黏液腺癌约10%） Lauren混合型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,5,,R1,6.77,4.53,1.4,71.0,373.0,4.53,20.0,30.0,204.0,133.0,137.0,6.9,1.3,63.5,218.0,39.6,23.9,5.8,6.5,85.0,217.0,,,,,,,,,,,,,4.42,4.6,2.12,,无,无,无,无,,,,,,,8.245729303547963,1834385
1711896,王福安,671881,男,52,T3,N1 ,M0, ⅡB,3,3,2.0,0.0,0.0,0.0,  慢性炎症（+）,2.0,39,硬型（sci）,INFc,0.0,,,,,,,,2017-04-01,2018-01-02,2,,,XELOX,,,,,,1, 低粘附腺癌 90低分化腺癌（G3)(por)10 Lauren弥漫型,G3,," ML 前Ant, 后Post, 小弯侧Less,",60,45,15,R0,,5.43,4.26,0.65,132.9,163.0,3.93,12.0,15.0,146.0,53.0,51.0,21.61,6.48,65.0,363.0,39.0,26.0,5.2,8.2,111.0,377.0,,,,,,,,,,,,,1.11,3.68,6.84, 未做,无,无,无,无,,,,,,,9.067017082785808,1711896
1805805,王桂荣,706936,女,64,T4b,N1 ,M0, ⅢB,3,3,0.0,0.0,0.0,1.0, 肠化生,2.0,36,中间型（int）,INFb,0.0,,,,,,,,2018-02-07,2018-09-20,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,12, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," LD 前Ant, 后Post, 小弯侧Less,",60,50,8,D2+,R1,6.51,3.85,1.72,67.0,446.0,3.56,13.7,18.0,161.0,88.0,9.0,4.4,3.9,48.0,150.0,28.0,20.0,3.9,4.0,60.0,212.0,66.0,42.4,19.5,2.17,0.2,18.1,13.9,0.8,0.984,1.06,14.8,,4.07,35.74,3.3, 未做,无,无,无,无,,,,,,,7.391590013140604,1805805
1638730,王桂珍,677051,女,59,T3,N3a ,M0,ⅢB,3,3,1.0,1.0,1.0,1.0, 正常,10.0,39,髓样型（med）,INFb,1.0,,0.0,,2.0,2.0,,,2016-11-15,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】55% 粘液腺癌（muc）30% 低粘附腺癌15% Lauren混合型,G2,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,11, D2,,3.24,1.54,1.37,86.0,154.0,3.07,11.0,13.0,169.0,58.0,6.0,5.36,2.11,60.0,131.0,37.0,23.0,5.9,3.3,67.0,166.0,74.0,34.1,33.7,1.01,0.1,18.4,6.2,3.2,0.649,3.47,9.23,,1.09,1000.0,30.65, 阴性,无,无,无,无,,MLH1+80%弱-中 MSH2+80%弱 MSH6+80%中-强 PMS2+70%弱 CD4散在+ CD8散在+ VEGF-,80% 弱-中,80% 弱,80% 中-强,70% 弱,69.54664914586071,1638730
1630452,王国荣,653716,男,62,T3,N3b ,M0, ⅢC,3,3,1.0,0.0,0.0,1.0, 正常,32.0,41,髓样型（med）,INFb,1.0,,1.0,,1.0,2.0,,,2016-09-05,2017-11-01,2,,,紫杉醇联合替吉奥,紫杉醇联合替吉奥,XELOX+顺铂,XELOX,,,4, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren混合型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",60,50,20,D2+,R1,5.68,3.76,1.35,87.6,240.0,3.34,12.0,18.0,202.0,94.0,5.0,7.32,4.1,53.0,135.0,31.0,22.0,10.8,5.4,92.0,369.0,68.4,42.6,22.7,1.88,0.4,5.8,19.0,0.6,0.325,4.46,8.3,,1.23,69.01,3.43,,无,无,无,无,,MLH1+70%中 MSH2+80%中-强 MSH6+90%强 PMS2+50%弱-中 CD4+ CD8散在+ VEGF+,70% 中,80% 中-强,90% 强,50% 弱-中,13.863337713534822,1630452
1634507,王海礼,656304,男,60,T4b,N3a ,M0, ⅢC,3,3,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,10.0,25,硬型（sci）,INFb,1.0,,2.0,,1.0,2.0,,,2016-10-13,2017-10-01,2,,,SOX,,,,,,1, 管状腺癌（中分化【G2】35【tub2】 低分化腺癌（G3)(por)65 Lauren混合型,G3,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",90,70,15,D2,R1,6.9,4.47,1.82,143.2,240.0,3.48,11.0,17.0,153.0,89.0,32.0,6.87,4.02,55.0,196.0,33.0,22.0,4.9,4.8,85.0,281.0,,,,,,,,,,,,,1.39,15.36,2.44, 阴性,无,无,无,无,,MLH1+20%中 MSH2+70%中 MSH6+80%中-强 PMS2+5中 CD4灶+ CD8散在+ VEGF弱+,20% 中,70% 中,80% 中-强,5% 中,11.59658344283837,1634507
1628031,王丽华,649480,女,44,T4b,N2 ,M0, ⅢB,3,4,2.0,0.0,0.0,1.0,  慢性炎症（+）,5.0,21,硬型（sci）,INFc,0.0,,0.0,,2.0,2.0,,,2016-08-16,2017-07-14,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌 Lauren弥漫型,GX,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",150,80,10,,R2,6.02,4.16,1.27,99.0,281.0,2.06,8.0,14.0,112.0,48.0,5.0,7.74,2.64,61.0,161.0,37.0,24.0,4.5,3.3,64.0,283.0,,,,,,,,,,,,,0.832,10.58,1.17,,无,无,无,无,,MLH1+30%弱 MSH2+40%中 MSH6+70%中-强 PMS2+30%弱  CD4散在+ CD8散在+ VEGF-,30% 弱,40% 中,70% 中-强,30% 弱,10.90670170827858,1628031
1707735,王明发,674012,男,39,T2,N0 ,M0, ⅠB,3,3,0.0,0.0,0.0,1.0, 肠化生 慢性炎症,0.0,35,中间型（int）,INFa,0.0,,,,,,,,2017-03-07,2022-09-02,1,,,,,,,,,0, 粘液腺癌（muc） 管状腺癌（中分化【G2】【tub2】,G2,," M（胃体部）, 后Post,",30,16,6,R0,,6.74,4.19,1.78,155.1,210.0,2.08,8.0,19.0,165.0,55.0,13.0,11.72,3.89,68.0,341.0,42.0,26.0,4.2,3.4,80.0,186.0,,,,,,,,,,,,,4.36,8.67,1.68,,无,无,无,无,,,,,,,65.86727989487517,1707735
1712781,王宁,680188,男,25,T3,N2 ,M0, ⅢA,3,3,,1.0,1.0,1.0,,5.0,35,,,,,,,,,,,2017-04-11,2022-09-02,1,,,SOX,SOX,SOX,SOX,SOX,口服替吉奥,6, 低粘附腺癌 70低分化腺癌（G3)(por)30,G3,," SiewerⅢ, 小弯侧Less,",20,15,8,R0,,14.09,12.76,0.53,140.8,218.0,2.23,25.0,19.0,206.0,55.0,14.0,25.79,9.04,62.0,203.0,37.0,25.0,,2.4,92.0,270.0,,,,,,,,,,,,,2.18,17.37,0.526, 未做,无,无,无,无,,,,,,,64.71747700394218,1712781
1703961,王钦亮,666133,男,51,T2,N3a ,M0, ⅢA,3,5,1.0,1.0,1.0,0.0, 肠化生 慢性炎症,9.0,22,中间型（int）,INFb,0.0,,0.0,,2.0,2.0,,,2017-02-13,2017-10-05,2,,,SOX,SOX,SOX,SOX,,,4, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】50 粘液腺癌（muc）30 低粘附腺癌20 Lauren混合型,G3,," L（幽门窦部）, 前Ant, 大弯侧Gre, 小弯侧Less,",30,30,8,R0 D2+,,4.2,2.4,1.33,152.7,164.0,3.02,24.0,22.0,181.0,54.0,35.0,11.85,2.69,63.0,392.0,40.0,23.0,4.4,5.0,82.0,246.0,65.9,43.5,15.7,2.77,0.1,11.5,18.0,0.4,0.91,2.38,8.21,,5.67,77.48,106.2, 未做,无,无,无,无,,MLH1+90%中-强 MSH2+80%弱-中 MSH6+90%强 PMS2+60%弱 CD4散在+ CD8散在+  VEGF-,90% 中-强,80% 弱-中,90% 强,60% 弱,7.687253613666228,1703961
1641912,王庆申,664256,男,61,T4a,N3a ,M0, ⅢB,3,3,1.0,1.0,1.0,1.0, 正常,8.0,45,髓样型（med）,INFb,0.0,,0.0,,2.0,2.0,,,2016-12-08,2018-01-01,2,,,FOLFOX,XELOX,SOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】65 低粘附腺癌20 粘液腺癌（muc）15 Lauren混合型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",45,40,10,R0 D2+,,6.99,4.37,2.09,156.0,275.0,2.65,16.0,26.0,152.0,54.0,7.0,23.58,5.79,66.0,275.0,42.0,24.0,5.2,4.6,87.0,285.0,,,,,,,,,,,,,1.68,58.14,6.48,,无,无,无,无,,MLH1+60%弱-中 MSH2+70%中 MSH6+80%中-强 PMS2+50%弱-中 CD4灶+ CD8散在+ VEGF-,60% 弱-中,70% 中,80% 中-强,50% 弱-中,12.779237844940866,1641912
1616785,王胜荣,641482,女,44,T3,N3a ,M0,ⅢB,3,3,,0.0,0.0,1.0, 慢性炎症（+） 异型增生+,11.0,30,硬型（sci）,INFc,1.0,,,,,,,,2016-05-18,2018-07-05,2,,,XELOX,XELOX,XELOX,口服卡培他滨,,,4, 低粘附腺癌,GX,," L（幽门窦部）, 前Ant,",35,35,12,R0,,5.17,2.63,1.6,125.0,250.0,2.37,19.0,21.0,133.0,41.0,4.0,20.79,8.05,51.0,283.0,31.0,20.0,4.8,3.2,61.0,254.0,,,,,,,,,,,,,0.713,8.95,1.61,,无,无,无,无,,,,,,,25.558475689881732,1616785
1713271,王淑娥,666805,女,62,T4b,N3b ,M0, ⅢC,3,3,2.0,1.0,1.0,1.0,  慢性炎症（+）,19.0,34,髓样型（med）,INFb,0.0,,,,,,,,2017-04-13,2017-07-06,2,XELOX*3,1.0,XELOX,,,,,,1,低分化腺癌（G3)(por) Lauren弥漫型,G3,," LM 前Ant, 后Post, 小弯侧Less,",60,50,30,,R1,5.6,3.97,1.25,111.3,211.0,4.1,8.0,16.0,151.0,96.0,7.0,5.47,1.42,65.0,201.0,39.0,26.0,4.8,6.5,81.0,257.0,83.2,49.9,30.2,1.65,0.1,9.4,6.9,2.8,0.807,0.872,11.6,,5.23,78.27,17.71, 未做,无,无,无,无,,,,,,,2.759526938239159,1713271
1621944,王淑华,643898,女,52,T4b,N3b ,M1, Ⅳ,3,4,2.0,1.0,1.0,1.0,  慢性炎症（+）,35.0,45,硬型（sci）,INFc,0.0,,,,,,,,2016-06-29,2017-01-04,2,,,XELOX,FOLFIRI,,,,,2, 低粘附腺癌 Lauren弥漫型,GX,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",80,75,15, D1,R2,6.7,3.6,2.13,142.0,217.0,2.3,11.0,16.0,142.0,75.0,,18.46,5.32,66.0,281.0,40.0,26.0,4.6,3.7,62.0,227.0,47.4,33.9,12.1,2.8,0.2,14.8,28.9,0.5,0.8,1.88,11.2,,0.921,1000.0,11.86, 阳性+,无,无,p1泛(M1 PER),无,,,,,,,6.2089356110381075,1621944
1830716,王树革,740446,男,73,T4b,N3a ,M0, ⅢC,3,2,1.0,0.0,0.0,1.0, 肠化生 异型增生 慢性炎症,8.0,26,中间型（int）,INFb,0.0,,,,,,,,2018-08-01,2020-08-01,2,,,,,,,,,0, 粘液腺癌（muc）20 低粘附腺癌 Lauren混合型,GX,," L（幽门窦部）, 小弯侧Less,",50,30,15,R0 D2,,5.39,2.96,1.75,137.0,257.0,3.45,8.6,13.0,166.0,63.0,17.0,12.5,2.3,58.2,187.0,36.7,21.5,5.0,8.5,99.0,343.0,,,,,,,,,,,,,46.62,8.48,43.87, 未做,无,无,无,无,,,,,,,24.014454664914584,1830716
1623596,王文,647065,男,41,T4a,N3a ,M0, ⅢB,3,4,2.0,0.0,0.0,1.0, 正常,7.0,34,硬型（sci）,INFc,0.0,,,,,,,,2016-07-12,2019-05-05,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌 Lauren弥漫型,GX,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,10,R0,,4.6,2.17,2.0,157.0,280.0,2.23,22.0,17.0,156.0,60.0,19.0,12.95,3.82,69.0,445.0,47.0,22.0,4.6,4.9,84.0,366.0,,,,,,,,,,,,,1.41,2.66,6.38,,无,无,无,无,,,,,,,33.73850197109067,1623596
1805403,王宪滨,718842,男,52,T2 T1b T1a,N3a ,M0,,3,2,0.0,1.0,1.0,1.0, 肠化生,8.0,20,中间型（int）,INFb,2.0,,,,,,,,2018-02-05,2019-01-17,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," L（幽门窦部）, 后Post,",35 25 6,25 20,5,,R1,8.24,4.84,2.5,139.0,246.0,3.44,12.5,15.0,150.0,155.0,14.0,12.7,5.1,63.3,294.0,37.9,25.4,4.8,7.0,71.0,361.0,,,,,,,,,,,,,5.62,8.32,1.16, 阴性,无,无,无,无,,,,,,,11.366622864651774,1805403
1706802,王永青,671872,男,61,T3,N2 ,M0 , ⅢA,3,3,0.0,1.0,1.0,1.0, 肠化生,5.0,30,髓样型（med）,INFa,0.0,,,,,,,,2017-02-28,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," L（幽门窦部）, 小弯侧Less,",50,30,5,R0 D2,,7.7,4.32,2.83,157.0,257.0,2.09,38.0,27.0,185.0,80.0,50.6,24.39,5.22,72.7,426.0,43.4,29.3,5.4,4.5,96.0,345.0,,,,,,,,,,,,,10.43,19.37,4.78, 未做,无,无,无,无,,,,,,,66.09724047306176,1706802
1623715,王永兴,647093,男,69,T4a,N3a ,M0, ⅢB,3,3,2.0,1.0,1.0,1.0, 肠化生,13.0,23,中间型（int）,INFc,0.0,,,,,,,,2016-07-13,2017-04-13,2,,,,,,,,,0, 低粘附腺癌90 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】10 Lauren弥漫型,G3,, L（幽门窦部） 前Ant 后Post 小弯侧Less ,60,50,15,R0,,5.79,2.59,2.46,155.0,265.0,2.79,15.0,15.0,1668.0,75.0,25.0,9.78,4.46,48.0,186.0,29.0,19.0,4.7,8.2,80.0,212.0,57.6,29.3,29.2,1.0,0.3,8.0,22.1,1.0,0.848,1.66,9.5,,27.82,178.3,12.79,,无,无,无,无,,,,,,,9.00131406044678,1623715
1619474,王宇,638209,女,39,T3,N1 ,M0, ⅡB,3,3,1.0,1.0,1.0,1.0,  慢性炎症（+）,2.0,29,中间型（int）,INFb,0.0,,,,,,,,2016-06-08,2021-03-24,1,,,SOX,SOX,SOX,SOX,SOX,SOX,8, 低粘附腺癌80 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20,G3,," M（胃体部）, 前Ant,",20,15,10,R0 D2+,,5.51,3.38,1.62,100.5,295.0,2.44,17.0,19.0,132.0,45.0,7.0,11.15,3.18,71.0,281.0,44.0,27.0,4.8,3.6,49.0,299.0,41.3,18.4,18.4,2.24,0.1,17.9,8.2,2.4,0.567,2.03,10.8,,0.534,12.98,0.706, 阳性+,无,无,无,无,,,,,,,57.49014454664914,1619474
1725931,王玉花,686006,女,67,T1b,N0 ,M0,ⅠA,3,3,0.0,0.0,0.0,0.0, 肠化生 慢性炎症,0.0,34,中间型（int）,INFa,0.0,,,,,,,,2017-07-13,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por) Lauren肠型,G3,," M（胃体部）, 后Post, 小弯侧Less,",40,25,8,R0 D2,,11.62,6.22,3.88,134.0,306.0,2.19,48.0,38.0,270.0,139.0,41.0,11.63,3.02,73.4,205.0,40.3,33.1,7.2,3.9,72.0,55.0,,,,,,,,,,,,,0.441,7.15,1.18, 未做,无,无,无,无,,,,,,,61.662286465177395,1725931
1632007,王长军,656498,男,41,T3,N3a ,M0,ⅢB,3,5,2.0,1.0,1.0,1.0, 正常,9.0,16,硬型（sci）,INFc,0.0,,1.0,,1.0,2.0,,,2016-09-19,2020-11-30,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌 80低分化腺癌（G3)(por)20 Lauren弥漫型,G3,," U（胃底部）, 后Post,",30,20,10,R0 D2,,7.59,4.0,2.83,162.9,309.0,2.33,34.0,22.0,160.0,60.0,58.0,21.91,7.22,70.0,410.0,41.0,29.0,5.0,5.5,82.0,490.0,,,,,,,,,,,,,2.34,13.76,0.818, 未做,无,无,无,无,,MLH1+60%强 MSH2+40%中-强 MSH6+70%强 PMS2+50%弱-中  CD4+ CD8散在+ VEGF+,60% 强,40% 中-强,70% 强,50% 弱-中,50.36136662286465,1632007
1623060,魏淑玲,612783,女,43,T4b,N3a ,M1, Ⅳ,3,3,0.0,0.0,0.0,1.0, 正常,14.0,31,硬型（sci）,INFc,0.0,,,,,,,,2016-07-07,2017-06-22,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低粘附腺癌 70%低分化腺癌（G3)(por)30% Lauren肠型,G3,," MU 前Ant, 后Post, 大弯侧Gre,",55,40,15,,R1,7.46,5.62,1.27,89.2,433.0,2.23,21.0,15.0,154.0,90.0,35.0,6.85,2.31,74.0,380.0,46.0,28.0,4.6,4.3,59.0,254.0,,,,,,,,,,,,,4.29,18.3,, 未做,无,有,p1泛(M1 PER),无,,,,,,,11.498028909329829,1623060
1835521,吴靱峰,746881,男,65,T4b,N2,M0, ⅢB,3,3,2.0,0.0,0.0,1.0, 异型增生 慢性炎症,4.0,22,中间型（int）,INFb,0.0,,,,,,,,2018-09-04,2020-10-09,2,,,口服替吉奥,口服替吉奥,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren弥漫型,G2,," U（胃底部）, 后Post, 大弯侧Gre,",50,40,10,R0 D2,,9.69,7.74,0.87,122.0,185.0,4.71,12.0,18.0,165.0,87.0,29.0,11.1,2.9,43.9,65.0,22.7,21.1,,4.5,57.0,165.0,,,,,,,,,,,,,0.348,7.7,0.692,,无,无,无,无,,,,,,,25.164257555847566,1835521
1633139,吴淑媛,352990,女,73,T3,N2 ,M0, ⅢA,3,3,0.0,1.0,1.0,1.0,  慢性炎症（+）,6.0,9,中间型（int）,INFb,0.0,,0.0,,0.0,0.0,,,2016-09-27,2017-05-11,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】60  低粘附腺癌30 粘液腺癌（muc）10 Lauren肠型,G3,," U（胃底部）, SiewerⅡ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,10,D2+,R2,7.38,5.7,1.32,121.5,261.0,3.4,22.0,29.0,232.0,105.0,13.0,16.49,5.34,73.0,208.0,44.0,29.0,6.1,6.9,75.0,202.0,,,,,,,,,,,,,72.84,1.08,16.9,,无,无,无,无,,MLH1+20%弱 MSH2+40% MSH6+70%中-强 PMS2+15%弱 CD4- CD8- VEGF-,20% 弱,40% 中,70% 中-强,15% 弱,7.424441524310118,1633139
1711612,武学凤,679421,女,63,T3,N3b ,M0, ⅢC,3,3,2.0,1.0,1.0,1.0, 肠化生,21.0,22,硬型（sci）,INFc,0.0,,,,,,,,2017-03-31,2017-12-01,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,," LM 前Ant, 后Post, 小弯侧Less,",62,55,10,,R1,8.81,7.76,0.76,104.0,230.0,2.79,93.9,95.0,208.0,65.0,21.4,6.69,2.0,47.2,169.0,26.7,20.5,,1.4,94.0,173.0,,,,,,,,,,,,,1.4,2.57,4.77, 未做,无,无,无,无,,,,,,,8.04862023653088,1711612
1706690,夏凤春,673588,女,59,T4b,N2 ,M0, ⅢB,3,3,0.0,1.0,1.0,1.0, 肠化生,3.0,17,中间型（int）,INFa,1.0,,,,,,,,2017-02-28,2017-11-04,2,,,口服替吉奥,口服替吉奥,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,50,30,,R1,5.57,3.93,1.05,68.0,504.0,2.97,5.0,9.0,133.0,61.0,5.0,3.16,1.15,53.0,94.0,31.0,22.0,6.8,6.1,61.0,187.0,,,,,,,,,,,,,24.11,30.5,0.959,,无,无,无,无,,,,,,,8.180026281208935,1706690
1738758,夏志泉,701211,男,61,T3,N2 ,M0, ⅢA,3,3,0.0,0.0,0.0,1.0, 肠化生 慢性炎症,3.0,16,中间型（int）,INFb,1.0,,,,,,,,2017-10-24,2021-01-28,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," U（胃底部）, 小弯侧Less,",55,30,10,R0 D2+,,8.14,4.82,2.77,166.0,314.0,3.36,24.0,19.0,206.0,80.0,21.0,16.48,6.35,70.0,367.0,42.0,28.0,4.7,6.7,114.0,231.0,,,,,,,,,,,,,5.9,5.53,4.42,,无,无,无,无,,MLH1+80%弱 MSH2+80%中 MSH6+90%中-强 PMS2+80%弱 CD56- Syn- CgA-,80% 弱,80% 中,90% 中-强,80% 弱,39.15900131406045,1738758
1710469,肖永国,680113,男,75,T3,N2 ,M0, ⅢA,3,3,0.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,6.0,18,髓样型（med）,INFa,0.0,,2.0,,2.0,1.0,,,2017-03-23,2018-10-18,2,,,,,,,,,0, 乳头状癌（G1）（pap）70 低分化腺癌（G3)(por)30 Lauren肠型,G3,," MU 前Ant, 后Post, 小弯侧Less,",100,90,20,D2+,R1,6.2,4.11,1.51,88.4,332.0,4.82,11.0,20.0,161.0,58.0,17.0,3.83,1.72,55.0,117.0,33.0,22.0,8.5,5.8,92.0,336.0,,,,,,,,,,,,,28.2,21.82,2.05, 未做,无,无,无,无,,MLH1+90%弱-中 MSH2+90%弱-中 MSH6+90%中 PMS2+20%弱 CD4散在+ CD8+ VEGF局灶弱+,90% 弱-中,90% 弱-中,90% 中,20% 弱,18.85676741130092,1710469
1709289,谢桂荣,675000,女,63,T4b,N3b ,M0, ⅢC,3,3,0.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,27.0,53,中间型（int）,INFa,0.0,,2.0,,2.0,2.0,,,2017-03-16,2022-09-02,1,,,SOX,SOX,SOX,SOX,SOX,口服替吉奥,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," UM 前Ant, 大弯侧Gre, 小弯侧Less,",80,70,10,R0 D2,,9.16,5.74,2.58,84.1,383.0,4.56,18.0,24.0,202.0,84.0,12.0,9.99,2.87,61.0,149.0,35.0,26.0,5.2,4.6,62.0,194.0,80.2,45.0,19.9,2.26,0.0,8.7,8.6,1.4,0.449,1.77,7.39,,4.86,0.6,16.66, 未做,无,无,无,无,,MLH1+40%弱 MSH2+70%弱 MSH6+30%弱-中 PMS2+10%弱 CD4散在+ CD8散在+ VEGF弱+,40% 弱,70% 弱,30% 弱-中,10% 弱,65.57161629434954,1709289
1741834,辛向军,706550,男,48,T3,N3b ,M0, ⅢC,3,3,2.0,1.0,1.0,1.0,  慢性炎症（+）,16.0,27,中间型（int）,INFc,1.0,,,,,,,,2017-11-14,2021-03-02,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 低分化腺癌（G3)(por)70%  低粘附腺癌30% Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,40,10,R0,,13.84,11.88,0.8,138.0,236.0,,21.9,25.0,161.0,78.0,46.0,19.9,11.5,64.0,196.0,33.9,30.1,,5.0,82.0,234.0,,,,,,,,,,,,,0.638,4.39,1.89, 未做,无,无,无,无,,MLH1+90%弱-中 MSH2+90%中 MSH6+90%中 PMS2+90%弱-中,90% 弱-中,90% 中,90% 中,90% 弱-中,39.55321944809461,1741834
1625727,邢宝山,648595,男,66,T4a,N3a ,M0, ⅢB,3,3,1.0,1.0,1.0,1.0, 正常,10.0,39,中间型（int）,INFb,0.0,,,,,,,,2016-07-28,2017-02-15,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】70 低粘附腺癌30 Lauren混合型,G3,," SiewerⅡ, 前Ant, 后Post, 小弯侧Less,",35,30,8,R0 D2,,7.19,3.73,2.4,143.2,223.0,4.58,39.0,29.0,155.0,119.0,21.7,7.87,1.96,64.9,208.42,37.0,27.9,4.0,5.97,76.0,122.0,,,,,,,,,,,,,2.32,31.45,0.834, 未做,无,无,无,无,,,,,,,6.636005256241787,1625727
1629042,邢树义,651220,男,67,T4a,N2 ,M0, ⅢA,3,3,2.0,0.0,0.0,1.0, 肠化生,6.0,24,髓样型（med）,INFa,0.0,,0.0,,0.0,2.0,,,2016-08-24,2017-06-16,2,,,,,,,,,0, 低粘附腺癌-印戒细胞癌(sig)60 粘液腺癌（muc）40 Lauren弥漫型,GX,, LM 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,60,10,R0 D2,,13.13,11.39,0.91,135.0,344.0,4.48,24.0,25.0,219.0,75.0,16.0,16.07,7.2,67.0,229.0,39.0,28.0,4.3,7.5,83.0,327.0,,,,,,,,,,,,,4.09,5.09,300.0,,无,无,无,无,,MLH1+60%弱 MSH2+70%中-强 MSH6+80%强 PMS2+40%弱-中 CD4- CD8散在+ CEGF-,60% 弱,70% 中-强,80% 强,40% 弱-中,9.724047306176084,1629042
1807950,熊异明,720548,男,63,T3,N2,M0, ⅢA,3,3,0.0,0.0,0.0,1.0, 肠化生,4.0,14,中间型（int）,INFb,,,,,,,,,2018-03-07,2021-07-29,0,,,XELOX,XELOX,口服卡培他滨,口服卡培他滨,口服卡培他滨,口服卡培他滨,8, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," MU 前Ant, 后Post, 小弯侧Less,",50,37,7,D2+,,5.73,3.69,1.56,130.0,389.0,3.76,7.6,12.0,129.0,67.0,10.0,12.5,5.1,,,,,6.1,4.9,84.0,239.0,,,,,,,,,,,,,37.2,,4.33,,无,无,无,无,,,,,,,40.73587385019711,1807950
1708067,徐光,673785,男,40,T4b,N1 ,M0, ⅢB,3,3,0.0,0.0,0.0,1.0, 肠化生 慢性炎症,1.0,36,中间型（int）,INFa,0.0,,,,,,,,2017-03-08,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)70 低粘附腺癌30 Lauren肠型,G3,, UM SiewerⅢ型 小弯侧Less 后Post ,35,30,10,,R1,6.2,3.89,1.61,134.7,204.0,3.75,20.0,23.0,141.0,116.0,60.0,13.89,5.17,71.0,244.0,42.0,29.0,4.4,6.8,86.0,287.0,66.5,38.5,19.5,1.97,0.3,7.4,23.8,2.3,4.55,2.05,14.9,,0.462,6.09,0.85, 阳性+,无,无,无,无,,,,,,,65.83442838370564,1708067
1847271,徐建国,754334,男,55,T4b,N3a ,M0, ⅢC,3,3,2.0,0.0,0.0,1.0, 正常,7.0,48,硬型（sci）,INFc,2.0,,,,,,,,2018-11-28,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 低粘附腺癌,G3,," M（胃体部）, 后Post, 小弯侧Less,",35,35,7,R0,,6.23,3.62,2.15,155.0,266.0,2.22,12.0,15.0,182.0,117.0,19.0,12.2,2.1,67.1,234.0,43.7,23.4,4.7,6.2,80.0,248.0,,,,,,,,,,,,,1.72,5.16,14.87,,无,无,无,无,,,,,,,45.137976346911955,1847271
1637606,徐仁秀,676766,女,61,T3,N3b ,M0, ⅢC,3,3,2.0,0.0,0.0,1.0, 正常,16.0,24,硬型（sci）,INFc,0.0,,0.0,,2.0,2.0,,,2016-11-07,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 低粘附腺癌 Lauren弥漫型,GX,, ML 小弯侧Less 前Ant 后Post ,70,50,20,R0 D2,,4.92,2.68,1.59,129.0,201.0,1.9,33.0,32.0,200.0,132.0,26.0,10.59,2.85,68.0,216.0,36.0,32.0,4.4,2.7,74.0,239.0,,,,,,,,,,,,,0.756,11.14,1.04, 未做,无,无,无,无,,MLH1+10%弱 MSH2+2%弱 MSH6+2%弱 PMS2+1%弱 CD4散在+ CD8散在+ VEGF-,10% 弱,2% 弱,2% 弱,1% 弱,69.80946123521682,1637606
1641095,徐向荣,659754,男,58,T4b,N1 ,M0, ⅢB,3,2,0.0,1.0,1.0,1.0, 肠化生,2.0,24,髓样型（med）,INFa,3.0,,2.0,,2.0,2.0,,,2016-12-01,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,6, 管状腺癌（中分化【G2】【tub2】80% 乳头状癌（G1）（pap）20% Lauren肠型,G2,," M（胃体部）, 后Post,",35,30,10,R0,,5.87,3.8,1.46,124.3,309.0,4.13,10.0,18.0,173.0,64.0,10.0,11.05,3.17,69.0,208.0,45.0,24.0,5.6,5.4,92.0,203.0,,,,,,,,,,,,,2.82,212.3,3.76, 未做,无,无,无,无,,MLH1+80%中 MSH2+70%中 MSH6+90%中-强 PMS2+80%弱-中 CD4散在+ CD散在+ VEGF弱+,80% 中,70% 中,90% 中-强,80% 弱-中,69.02102496714849,1641095
1934300,薛洪林,786348,男,79,T4b,N3a ,M0, ⅢC,3,2,0.0,0.0,0.0,1.0,  慢性炎症（+）,7.0,30,中间型（int）,INFb,0.0,,,,,,,,2019-08-02,2022-05-03,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," M（胃体部）, 大弯侧Gre,",30,20,20,R0,,5.71,3.69,1.4,143.0,191.0,3.38,11.0,18.0,178.0,54.0,19.0,10.4,2.0,61.1,274.0,37.2,23.9,5.2,8.3,84.0,300.0,,,,,,,,,,,,,2.09,22.81,1.47, 未做,无,无,无,无,,,,,,,33.01576872536137,1934300
1629706,闫龙涛,652411,男,34,T3,N3b,M0, ⅢC,3,3,2.0,1.0,1.0,1.0, 正常,16.0,62,硬型（sci）,INFc,0.0,,0.0,,1.0,2.0,,,2016-08-30,2020-06-03,2,,,XELOX,,,,,,1, 低粘附腺癌,GX,," L（幽门窦部）, 小弯侧Less,",70,50,15,R0 D2,,6.12,3.34,2.01,163.3,179.0,1.83,21.0,20.0,135.0,111.0,13.0,5.31,2.22,68.0,282.0,42.0,26.0,5.1,6.9,105.0,378.0,,,,,,,,,,,,,2.58,6.19,2.96,,无,无,无,无,,MLH1+30%弱 MSH2+50%弱-中 MSH6+50%中 PMS2+40%弱 CD+ CD8散在+ VEGF-,30% 弱,50% 弱-中,50% 中,40% 弱,45.105124835742444,1629706
1609191,闫伟,631455,男,38,T3,N3a ,M0,ⅢB,3,3,1.0,1.0,1.0,0.0,  慢性炎症（+）,12.0,24,中间型（int）,INFc,0.0,,,,,,,,2016-03-24,2017-05-11,2,,,SOX,SOX,SOX,SOX,口服替吉奥,XELOX,9, 低分化腺癌（G3)(por)60 粘液腺癌（muc）25 低粘附腺癌150 Lauren混合型,G3,,L（幽门窦部） 前Ant 小弯侧Less 大弯侧Gre  ,55,45,6,R0,,7.13,4.68,1.76,160.0,276.0,2.95,19.0,22.0,142.0,75.0,19.0,19.88,6.94,72.0,368.0,48.0,24.0,4.7,5.1,89.0,325.0,77.5,24.8,37.5,0.66,0.2,8.1,9.8,5.0,1.07,1.93,8.47,,1.51,67.38,7.37, 阳性+,无,无,无,无,,,,,,,13.567674113009199,1609191
1737631,杨桂珍,704675,女,65,T4b,N3a ,M0, ⅢC,3,3,,0.0,0.0,1.0,,12.0,53,,,,,,,,,,,2017-10-17,2020-09-17,0,,,XELOX,XELOX,XELOX,XELOX,EP,XELOX,6, 粘液腺癌（muc）低分化管状腺癌 低粘附腺癌,G3,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,15,,R1,5.56,0.41,2.24,127.4,247.0,4.71,21.7,24.0,170.0,90.0,25.0,12.1,5.1,71.3,252.0,40.6,30.7,5.3,6.4,71.0,190.0,,,,,,,,,,,,,1.65,23.76,28.01, 未做,无,无,无,无,,MLH1+ MSH2+ MSH6+ PMS2+,1,1,1,1,35.019710906701704,1737631
1904182,杨海龙,761887,男,39,T4b,N1 ,M0, ⅢB,3,3,2.0,0.0,0.0,0.0, 肠化生 慢性炎症,1.0,27,硬型（sci）,INFc,0.0,,,,,,,,2019-01-25,2021-02-14,2,,,SOX,SOX,SOX,SOX,SOX,,5, 低分化腺癌（G3)(por) 低粘附腺癌 Lauren弥漫型,G3,, MU,30,30,20,R0,,6.31,4.01,1.75,78.0,451.0,4.83,9.0,18.0,133.0,66.0,21.0,12.9,2.1,66.4,189.0,41.0,25.4,4.7,6.1,83.0,317.0,,,,,,,,,,,,,1.76,13.81,1.19,,无,无,无,无,,,,,,,24.67148488830486,1904182
1733792,杨佳辉,698094,男,48,T4b,N3b ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0, 肠化生 慢性炎症,21.0,21,中间型（int）,INFc,1.0,,,,,,,,2017-09-11,2017-12-27,2,,,SOX,,,,,,1, 低粘附腺癌40% 粘液腺癌（muc）40% 低分化腺癌（G3)(por)20% Lauren弥漫型,G3,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,90,12,D2,R1,6.32,4.3,1.36,145.0,399.0,2.95,37.0,22.0,226.0,135.0,21.0,15.36,4.88,73.0,265.0,42.0,31.0,4.5,4.7,98.0,365.0,80.0,28.0,32.0,0.88,0.1,7.6,9.0,5.3,0.899,1.89,11.3,,4.39,32.36,17.41, 阳性+,无,无,无,无,,,,,,,3.515111695137976,1733792
1813994,杨在清,724976,男,67,T4b,N3b ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0, 肠化生 慢性炎症,19.0,22,中间型（int）,INFb,,,,,,,,,2018-04-12,2019-07-10,2,,,XELOX,XELOX,,,,,2, 低分化腺癌（G3)(por)60 低粘附腺癌40 Lauren弥漫型,G3,," L（幽门窦部）, M（胃体部）, U（胃底部）, 前Ant, 后Post, 小弯侧Less,",80,70,15,D2+,R2,7.12,4.81,1.26,160.0,287.0,3.76,7.3,12.0,183.0,91.0,22.0,24.8,8.3,61.4,235.0,38.1,23.3,5.1,9.5,88.0,441.0,,,,,,,,,,,,,2.06,7.9,17.16, 未做,无,无,无,无,,,,,,,14.914586070959263,1813994
1615531,杨中兴,640327,男,71,T3,N3a ,M0,ⅢB,3,3,0.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,10.0,22,中间型（int）,INFb,0.0,,,,,,,,2016-05-10,2017-05-16,2,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 低粘附腺癌5,G3,," SiewerⅢ, U（胃底部）, 后Post, 大弯侧Gre, 小弯侧Less,",40,30,3,R0 D2+,,5.5,3.79,0.97,138.0,199.0,3.81,25.0,27.0,235.0,73.0,22.0,8.94,2.37,56.0,303.0,32.0,24.0,4.5,6.9,102.0,325.0,64.2,42.8,20.3,2.11,2.0,14.9,14.8,0.4,0.406,2.28,7.38,,1.24,21.69,5.99, 阳性+,无,无,无,无,,,,,,,12.187910643889618,1615531
1724963,尹成林,691299,男,64,T4a,N3a ,M0, ⅢB,3,3,1.0,1.0,1.0,1.0, 异型增生 慢性炎症,9.0,23,中间型（int）,INFb,1.0,,,,,,,,2017-07-06,2018-01-14,2,,,,,,,,,0, 低粘附腺癌55 粘液腺癌（muc）40 管状腺癌（中分化【G2】【tub2】5 Lauren混合型,G2,, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,40,25,10,R0 D2,,6.21,3.47,1.56,105.4,185.0,3.39,17.0,18.0,162.0,58.0,8.0,4.56,2.29,69.0,118.0,37.0,32.0,7.2,4.5,86.0,281.0,,,,,,,,,,,,,112.9,5.31,7.31, 未做,无,无,无,无,,,,,,,6.307490144546649,1724963
1618956,尹淑杰,641041,女,49,T4b,N3b ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0, 腺体萎缩+ 慢性炎症（+）,26.0,26,硬型（sci）,INFc,0.0,,,,,,,,2016-06-03,2016-09-15,2,,,,,,,,,0, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",60,40,10,R0 D2+,,4.43,2.36,1.11,70.6,412.0,3.2,7.0,16.0,131.0,58.0,8.0,9.25,2.8,65.0,126.0,36.0,29.0,4.1,2.9,57.0,183.0,,,,,,,,,,,,,1.91,15.4,3.93, 未做,无,无,无,无,,,,,,,3.416557161629435,1618956
1634216,于安九,657351,女,75,T1b,N0 ,M0,ⅠA,3,3,,1.0,1.0,0.0,,0.0,14,,,0.0,,0.0,,1.0,2.0,,,2016-10-11,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3,," M（胃体部）, 小弯侧Less,",25,15,5,R0,,4.81,3.18,1.34,92.0,171.0,2.61,13.0,16.0,177.0,54.0,10.0,59.2,22.06,67.0,316.0,41.0,26.0,,9.3,77.0,378.0,,,,,,,,,,,,,0.896,4.82,12.29, 阳性+++,无,无,无,无,,MLH1+80%中 MSH2+85%中-强 MSH6+85%中-强 PMS2+70%中 CD4+ CD8散在+ VEGF-,80% 中,85% 中-强,85% 中-强,70% 中,70.69645203679369,1634216
1740768,于成香,706478,女,49,T4b,N3b ,M0, ⅢC,3,3,0.0,1.0,1.0,1.0,  慢性炎症（+）,23.0,35,中间型（int）,INFb,3.0,,,,,,,,2017-11-07,2020-07-30,2,,,曲妥珠单抗+SOX,曲妥珠单抗+SOX,曲妥珠单抗+SOX,曲妥珠单抗+SOX,口服替吉奥,,5, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,60,10,,R2,12.17,8.39,2.07,118.9,386.0,,24.0,12.0,200.0,70.0,9.0,15.12,6.31,67.0,139.0,37.0,30.0,,3.1,50.0,94.0,,,,,,,,,,,,,58.04,7.96,4.45, 未做,无,无,无,无,,MLH1+80%弱 MSH2+80%弱 MSH6+80%弱-中 PMS2+70%弱,80% 弱,80% 弱,80% 弱-中,70% 弱,32.72010512483574,1740768
1717222,于连志,683495,男,62,T4b,N2 ,M0, ⅢB,3,3,0.0,0.0,0.0,1.0, 正常,5.0,15,髓样型（med）,INFa,1.0,,,,,,,,2017-05-11,2018-01-20,2,,,SOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】75 乳头状癌（G1）（pap）20 低粘附腺癌5 Lauren肠型,G2,," U（胃底部）, SiewerⅡ, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,10,D2+,R1,8.93,6.43,1.79,177.0,246.0,5.12,13.0,22.0,156.0,75.0,38.0,34.76,6.03,78.0,328.0,45.0,33.0,5.5,5.7,94.0,309.0,,,,,,,,,,,,,289.3,12.0,2.25, 未做,无,无,无,无,,,,,,,8.344283837056505,1717222
1628980,于淑芳,651353,女,64,T4a,N3a ,M0, ⅢB,3,3,2.0,0.0,0.0,1.0, 正常,12.0,31,中间型（int）,INFc,1.0,,0.0,,1.0,2.0,,,2016-08-24,2017-02-09,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,,U（胃底部） 前Ant 后Post 小弯侧Less ,50,40,10,R0 D2,,4.74,2.68,1.4,112.5,259.0,2.75,11.0,16.0,178.0,52.0,16.0,9.44,3.4,62.0,163.0,36.0,26.0,4.2,6.2,86.0,294.0,,,,,,,,,,,,,0.717,5.98,1.13, 阴性,无,无,无,无,,MLH1+50%弱 MSH2+50%弱-中 MSH6+60%中-强 PMS2+30%弱 CD4+ CD8散在+ VEGF-,50% 弱,50% 弱-中,60% 中-强,30% 弱,5.551905387647832,1628980
1627146,于学舟,643190,男,61,T4b,N3a ,M0, ⅢC,3,3,2.0,1.0,1.0,1.0, 肠化生 慢性炎症,11.0,28,中间型（int）,INFc,0.0,,0.0,,1.0,2.0,,,2016-08-09,2016-12-08,2,,,XELOX,口服替吉奥,,,,,2, 低粘附腺癌70% 低分化腺癌（G3)(por)30% Lauren弥漫型,G3,," L（幽门窦部）, U（胃底部）, 前Ant, 小弯侧Less, 后Post, 大弯侧Gre,",60,40,10,,R2,5.85,3.76,1.48,142.0,282.0,2.64,8.0,13.0,158.0,51.0,11.0,12.06,4.6,51.0,134.0,31.0,20.0,6.1,5.5,91.0,186.0,,,,,,,,,,,,,7.64,11.5,7.44, 未做,无,无,无,无,,MLH1+40%弱 MSH2+60%弱-中 MSH6+70%中 PMS2+60%弱-中 CD4+ CD8散在+ VEGF-,40% 弱,60% 弱-中,70% 中,60% 弱-中,3.9750328515111693,1627146
1704178,于亚芬,669211,女,62,T3,N2 ,M0, ⅢA,3,3,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,5.0,35,中间型（int）,INFc,0.0,,1.0,,2.0,2.0,,,2017-02-14,2021-06-01,0,,,XELOX,,,,,,6, 低粘附腺癌80 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】20 Lauren混合型,G3,, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,50,40,12,R0 D2,,7.21,4.26,1.85,134.0,334.0,2.56,5.0,10.0,147.0,72.0,5.0,4.86,1.47,56.0,172.0,37.0,19.0,3.3,4.1,53.0,147.0,,,,,,,,,,,,,7.09,22.3,2.66, 未做,无,无,无,无,,MLH1+80%弱 MSH2+80%弱-中 MSH6+80%中-强 PMS2+70%弱 CD4散在+ CD8散在+ VEGF小区+,80% 弱,80% 弱-中,80% 中-强,70% 弱,51.51116951379763,1704178
1615529,袁媛,640603,女,37,T4b,N3a ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0,,8.0,17,硬型（sci）,INFc,0.0,,,,,,,,2016-05-10,2017-01-15,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型 异位胰腺组织,GX,," UM 后Post, 大弯侧Gre, 小弯侧Less,",100,60,6,D2,R2,6.82,3.77,2.35,117.0,347.0,2.14,12.0,18.0,118.0,40.0,7.0,13.36,3.9,65.0,314.0,39.0,26.0,4.1,4.0,64.0,173.0,,,,,,,,,,,,,2.25,35.35,0.842, 未做,无,无,无,无,,,,,,,8.21287779237845,1615529
1614004,云柏芳,637152,男,74,T2,N3a ,M0, ⅢA,3,2,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,13.0,31,中间型（int）,INFb,2.0,,2.0,,,,,,2016-04-27,2020-05-20,2,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) 60粘液腺癌（muc）30 低粘附腺癌10 Lauren混合型,G3,,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,60,40,10,R0 D2,,4.72,2.92,1.24,110.6,220.0,2.16,19.0,28.0,190.0,62.0,10.0,6.06,2.46,56.0,163.0,34.0,22.0,4.5,4.5,104.0,296.0,45.1,31.1,10.6,2.93,0.1,9.3,42.8,1.2,0.603,1.54,7.0,,2.53,34.41,23.98, 阴性,无,无,无,无,,,,,,,48.75164257555847,1614004
1740064,张爱民,701016,男,53,T4b,N1 ,M0, ⅢB,3,5,2.0,,,,  慢性炎症（+）,2.0,16,中间型（int）,INFc,1.0,,,,,,,,2017-11-02,2018-08-19,2,,,,,,,,,0, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren弥漫型,G3,, U（胃底部）残胃,50,30,15,R0,,4.45,3.14,0.87,86.1,437.0,3.58,22.0,20.0,168.0,69.0,12.0,5.46,2.32,56.0,56.0,27.0,29.0,5.4,3.2,65.0,184.0,84.3,26.5,55.2,0.48,0.8,9.0,6.1,9.3,0.886,2.4,9.89,,1.84,13.46,1.18, 未做,无,无,无,无,,,,,,,9.526938239159001,1740064
1637798,张福利,676974,男,60,T3,N2 ,M0, ⅢA,3,3,,1.0,1.0,1.0,,3.0,19,,,0.0,,0.0,,2.0,2.0,,,2016-11-08,2017-07-15,2,,,,,,,,,0, 管状腺癌（中低分化【G2】【tub2】,G3,," L（幽门窦部）, 后Post, 小弯侧Less,",20,15,6,D2,,6.87,4.38,2.05,141.0,240.0,3.43,10.0,15.0,176.0,80.0,10.0,5.99,1.61,68.0,393.0,42.0,26.0,5.3,6.9,108.0,234.0,69.3,25.1,37.1,0.68,0.4,10.9,19.0,8.3,0.779,1.3,6.76,,4.5,8.02,8.88, 未做,无,无,无,无,,MLH1+80%中 MSH2+65%弱-中 MSH6+70%弱-中 PMS2+70%弱 CD4散在+ CD8散在+ VEGF-,80% 中,65% 弱-中,70% 弱-中,70% 弱,8.180026281208935,1637798
1620831,张贵,477903,男,76,T3,N3b ,M0, ⅢC,3,3,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,23.0,34,中间型（int）,INFc,0.0,,,,,,,,2016-06-21,2017-10-01,2,,,,,,,,,0, 低粘附腺癌85 低分化腺癌（G3)(por)15 Lauren混合型,G3,," L（幽门窦部）, 前Ant,",35,25,10,R0,,4.43,3.04,0.96,156.3,155.0,3.33,20.0,27.0,162.0,74.0,28.0,17.26,6.12,60.0,244.0,38.0,22.0,4.3,10.1,89.0,300.0,,,,,,,,,,,,,,,,,无,无,无,无,,,,,,,15.341655716162943,1620831
1744824,张国强,706626,男,65,T3,N1 ,M0, ⅡB,3,3,0.0,0.0,0.0,1.0, 肠化生 慢性炎症,2.0,27,中间型（int）,INFb,1.0,,,,,,,,2017-12-05,2022-09-02,1,,,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,,"MU  后Post, 大弯侧Gre,",55,50,9,R0 D2+,,6.18,2.41,2.91,162.0,227.0,3.3,9.3,16.0,127.0,67.0,59.0,21.0,7.1,67.2,312.0,38.9,28.3,4.8,6.4,89.0,247.0,,,,,,,,,,,,,2.89,9.93,0.88,,无,无,无,无,,MLH1+20%弱 MSH2+60%中 MSH6+90%中-强 PMS2+20%弱,20% 弱,60% 中,90% 中-强,20% 弱,56.8988173455979,1744824
1736186,张继龙,699506,男,43,T3,N3a ,M0,ⅢB,3,3,2.0,1.0,1.0,1.0, 肠化生 慢性炎症 异型增生,7.0,43,中间型（int）,INFa,2.0,,,,,,,,2017-09-27,2021-07-30,0,,,SOX,SOX,SOX,SOX,SOX,,5, 低分化腺癌（G3)(por)20 低粘附腺癌80 Lauren弥漫型,G3,," L（幽门窦部）, 后Post, 小弯侧Less,",60,30,12,R0 D2+,,8.44,5.37,2.43,142.0,259.0,3.33,14.8,14.0,186.0,100.0,28.0,12.6,5.2,67.6,282.0,40.4,27.2,4.8,5.8,88.0,351.0,,,,,,,,,,,,,2.28,16.94,0.752, 阴性,无,无,无,无,,,,,,,46.057818659658345,1736186
1709829,张继有,671850,男,69,T4b,N2 ,M0, ⅢB,3,2,0.0,1.0,1.0,1.0, 肠化生 异型增生 慢性炎症,6.0,21,髓样型（med）,INFa,1.0,,0.0,,2.0,2.0,,,2017-03-20,2021-01-28,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,,U（胃底部） 小弯侧Less 后Post ,60,50,20,R0 D2,,8.5,5.15,2.77,118.8,288.0,3.93,11.0,13.0,128.0,73.0,14.0,7.65,2.39,56.0,286.0,37.0,19.0,3.6,10.0,92.0,382.0,,,,,,,,,,,,,1.89,6.05,1.1, 阴性,无,无,无,无,,MLH1+80%弱-中 MSH2+70%弱-中 MSH6+80%中 PMS2+60%弱 CD4散在+ CD8散在+ VEGF-,80% 弱-中,70% 弱-中,80% 中,60% 弱,46.320630749014455,1709829
1624163,张甲林,647049,男,56,T3,N3b ,M0, ⅢC,3,3,0.0,1.0,1.0,1.0, 肠化生 慢性炎症,30.0,35,中间型（int）,INFa,1.0,,,,,,,,2016-07-15,2017-11-24,2,,,XELOX,,,,,,1, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G3,," L（幽门窦部）, 后Post, 大弯侧Gre, 小弯侧Less,",25,15,5,R0,,6.06,3.44,1.95,131.0,216.0,2.17,16.0,23.0,115.0,52.0,16.0,13.04,5.55,54.0,223.0,34.0,20.0,4.2,4.3,71.0,210.0,,,,,,,,,,,,,2.25,15.88,41.83,,无,无,无,无,,,,,,,16.327201051248355,1624163
1612816,张健丰,637003,男,65,T3,N2 ,M0, ⅢA,3,3,0.0,1.0,1.0,1.0, 肠化生 慢性炎症,3.0,52,中间型（int）,INFa,0.0,,,,,,,,2016-04-19,2020-05-20,0,,,XELOX,XELOX,XELOX,XELOX,XELOX,,5, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】,G3,," L（幽门窦部）, 小弯侧Less,",35,25,7,R0 D2+,,4.44,2.68,1.03,159.0,175.0,1.86,16.0,21.0,166.0,58.0,7.0,15.36,5.21,58.0,337.0,38.0,20.0,3.9,9.6,97.0,396.0,68.6,51.1,16.4,3.12,0.4,8.1,21.4,0.6,0.538,3.22,7.95,,1.2,7.81,9.93, 阴性,无,无,无,无,,,,,,,49.01445466491458,1612816
1614708,张立三,640469,男,53,T4b,N3a ,M1, Ⅳ,3,4,2.0,1.0,1.0,1.0,  慢性炎症（+）,13.0,23,硬型（sci）,INFc,0.0,,,,,,,,2016-05-04,2016-11-15,2,,,,,,,,,0, 低粘附腺癌 Lauren弥漫型,GX,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",70,25,,,R2,4.6,3.04,1.11,132.4,141.0,4.69,27.0,25.0,130.0,53.0,10.0,7.1,3.01,58.0,199.0,34.0,24.0,3.7,8.5,80.0,349.0,,,,,,,,,,,,,1.38,45.65,4.24, 未做,无,无,p1泛(M1 PER),无,,,,,,,6.40604467805519,1614708
1740905,张利伟,694667,男,40,T2,N2 ,M0, ⅡB,3,3,1.0,0.0,0.0,1.0,  慢性炎症（+）,3.0,19,中间型（int）,INFb,1.0,,,,,,,,2017-11-08,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,14, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren混合型,G3,," L（幽门窦部）, 后Post, 小弯侧Less,",20,15,5, R0 D2+,,6.54,3.78,2.24,153.0,220.0,3.3,11.5,18.0,129.0,114.0,12.0,34.1,8.9,69.9,338.0,44.5,25.4,,5.7,79.0,374.0,,,,,,,,,,,,,0.839,5.16,3.53,,无,无,无,无,,MLH1+40%弱 MSH2+70%中-弱 MSH6+80%中-弱 PMS2+60%弱,40% 弱,70% 弱-中,80% 弱-中,60% 弱,57.78580814717477,1740905
1708686,张林发,673913,男,50,T2,N0 ,M0, ⅠB,3,3,2.0,0.0,0.0,0.0, 肠化生 慢性炎症,0.0,38,中间型（int）,INFb,1.0,,,,,,,,2017-03-13,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)90 低粘附腺癌10 Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",30,20,6,R0 D2,,5.64,3.46,1.72,157.0,213.0,2.27,15.0,23.0,167.0,84.0,29.0,17.18,4.8,70.0,300.0,44.0,26.0,3.3,5.2,76.0,266.0,,,,,,,,,,,,,1.68,7.11,0.681, 未做,无,无,无,无,,,,,,,65.67017082785807,1708686
1708951,张龙和,673903,男,70,T4b,N2 ,M0, ⅢB,3,3,0.0,0.0,0.0,0.0, 肠化生 异型增生 慢性炎症,5.0,17,髓样型（med）,INFa,0.0,,0.0,,0.0,0.0,,,2017-03-15,2020-11-30,2,,,,,,,,,0, 粘液腺癌（muc） Lauren肠型,GX,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",100,70,15,D2+,R1,9.6,4.71,2.89,133.7,328.0,5.12,10.0,12.0,154.0,72.0,27.0,5.6,1.79,71.0,249.0,40.0,31.0,4.9,6.7,84.0,215.0,,,,,,,,,,,,,7.23,0.6,47.43, 未做,无,无,无,无,,MLH1+20%弱 MSH2+70%中 MSH6+80%中 PMS2+10%弱 CD4- CD8- VEGF-,20% 弱,70% 中,80% 中,10% 弱,44.546649145860705,1708951
1623019,张明生,643800,男,51,T4a,N3a ,M0, ⅢB,3,3,2.0,0.0,0.0,1.0, 正常,7.0,36,硬型（sci）,INFc,1.0,,,,,,,,2016-07-07,2021-07-30,1,,,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,FOLFOX,6, 低粘附腺癌80 低分化腺癌（G3)(por)20 Lauren弥漫型,G3,,L（幽门窦部） 前Ant 后Post 大弯侧Gre  ,50,35,10,R0 D2,,4.74,2.5,1.81,157.0,237.0,2.52,21.0,24.0,170.0,95.0,84.0,15.81,4.59,73.0,369.0,49.0,24.0,5.0,4.4,83.0,342.0,73.4,46.1,22.7,2.03,0.1,5.6,19.8,4.8,0.96,2.9,10.0,,4.39,16.29,2.13, 未做,无,无,无,无,,,,,,,60.74244415243101,1623019
1709294,张奇,673934,男,67,T3,N0 ,M0, ⅡA,3,2,1.0,0.0,0.0,1.0, 肠化生 异型增生 慢性炎症,0.0,36,中间型（int）,INFb,0.0,,2.0,,1.0,2.0,,,2017-03-16,2022-09-02,1,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3,, L（幽门窦部） 前Ant 小弯侧Less ,25,15,5,R0 D2,,7.79,4.54,2.57,160.0,205.0,2.8,17.0,16.0,168.0,27.0,25.0,12.38,4.09,76.0,211.0,41.0,35.0,4.7,5.3,88.0,268.0,68.1,41.0,26.5,1.55,4.8,10.6,20.0,4.7,5.42,3.32,18.4,,3.01,2.14,11.27, 阳性+,无,无,无,无,,MLH1+90%弱-中 MSH2+80%中 MSH6+90%中-强 PMS2+80%弱-中 CD4+ CD8散在+ VEGF弱+,90% 弱-中,80% 中,90% 中-强,80% 弱-中,65.57161629434954,1709294
1737383,张千东,704096,男,61,T1b,N0 ,M0,ⅠA,3,2,,,,,,0.0,35,,,,,,,,,,,2017-10-16,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,15,2,R0,,5.97,3.54,1.77,152.0,281.0,2.36,17.6,21.0,189.0,48.0,21.0,8.7,4.5,69.2,452.0,41.7,27.5,5.8,7.5,103.0,426.0,,,,,,,,,,,,,1.16,7.03,1.98,,无,无,无,无,,,,,,,58.54139290407358,1737383
1714008,张青,673967,男,37,T3,N3a ,M0,ⅢB,3,3,2.0,1.0,1.0,1.0, 肠化生,8.0,30,中间型（int）,INFb,1.0,,,,,,,,2017-04-18,2020-06-02,0,XELOX*2,1.0,多西他赛+替吉奥,口服替吉奥,,,,,2, 低分化腺癌（G3)(por)90 粘液腺癌（muc）10 Lauren弥漫型,G3,,L（幽门窦部） 后Post 大弯侧Gre  小弯侧Less ,35,30,10,R0 D2,,4.64,1.41,2.62,104.0,172.0,2.61,32.0,26.0,205.0,95.0,25.0,5.43,1.85,75.0,293.0,39.0,36.0,5.4,4.8,107.0,307.0,,,,,,,,,,,,,,,, 未做,无,无,无,无,,,,,,,37.483574244415244,1714008
1739722,张尚玉,701778,男,63,T2,N0 ,M0, ⅠB,3,3,0.0,0.0,0.0,0.0,  慢性炎症（+）,0.0,24,中间型（int）,INFb,0.0,,,,,,,,2017-10-31,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,7, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," U（胃底部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",130,100,35,D2+,,7.42,4.47,2.05,82.0,403.0,3.16,13.9,17.0,143.0,83.0,59.0,9.32,3.6,58.8,503.0,32.2,26.6,5.1,6.5,83.0,341.0,,,,,,,,,,,,,1.42,19.76,7.98,,无,无,无,无,,MLH1+50%弱 MSH2+70%中-弱 MSH6+80%弱-中 PMS2+80%弱,50% 弱,70% 弱-中,80% 弱-中,80% 弱,58.04862023653088,1739722
1627170,张淑琴,641754,女,51,T4a,N2 ,M0, ⅢA,3,3,,0.0,0.0,0.0,,4.0,7,,,0.0,,,,,,,,2016-08-09,2017-11-05,2,XELOX*2,1.0,XELOX,XELOX,,,,,2, 管状腺癌（中分化【G2】【tub2】,G2,," SiewerⅢ, 前Ant, 后Post, 小弯侧Less,",20,20,15,R0 D2,,3.84,2.55,0.82,89.0,200.0,2.13,15.0,19.0,166.0,90.0,,6.47,2.28,55.0,182.0,35.0,20.0,4.7,4.0,68.0,263.0,69.4,44.3,21.9,2.02,0.7,20.5,8.8,1.6,1.09,2.87,11.8,,2.29,23.22,7.85, 阴性,无,无,无,无,,MLH1+40%中 MSH2+80%中 MSH6+80%中-强 PMS2+30%中 CD4+ CD8散在+ VEGF-,40% 中,80% 中,80% 中-强,30% 中,14.88173455978975,1627170
1609716,张树志,631472,男,82,T3,N0 ,M0, ⅡA,3,3,0.0,1.0,1.0,1.0,  慢性炎症（+）,0.0,27,中间型（int）,INFa,0.0,,,,,,,,2016-03-28,2017-04-18,2,,,,,,,,,0, 低分化腺癌（G3)(por),G3,," LMU 小弯侧Less, 大弯侧Gre, 后Post, 前Ant,",120,120,15,R0,,9.09,6.9,1.65,103.8,345.0,4.67,17.0,22.0,166.0,77.0,37.0,5.44,2.35,58.0,131.0,35.0,23.0,7.7,5.9,57.0,215.0,65.5,39.0,21.9,1.78,0.4,5.3,26.5,3.1,0.629,1.84,7.24,,1.73,17.65,1.24, 阳性+,无,无,无,无,,,,,,,12.680683311432325,1609716
1732954,张卫国,699616,男,49,T3,N3a ,M0,ⅢB,3,3,0.0,1.0,1.0,1.0, 肠化生,9.0,30,硬型（sci）,INFa,1.0,,,,,,,,2017-09-04,2020-09-16,2,,,SOX,SOX,SOX,SOX,SOX,SOX,11, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,, U（胃底部） SiewerⅢ型 前Ant 后Post 小弯侧Less ,65,45,8,R0 D2,,6.32,3.68,2.0,99.4,272.0,3.49,25.0,17.0,146.0,39.0,11.0,12.63,3.6,59.0,247.0,37.0,22.0,4.6,4.7,91.0,279.0,,,,,,,,,,,,,11.38,307.1,3.23, 未做,无,无,无,无,,,,,,,36.399474375821285,1732954
1620760,张文学,642994,男,67,T4a,N3a ,M0, ⅢB,3,2,0.0,1.0,1.0,1.0, 肠化生 慢性炎症,8.0,28,髓样型（med）,INFa,0.0,,,,,,,,2016-06-20,2020-10-05,2,,,口服卡培他滨,,,,,,1, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",75,35,8,R0,,6.08,3.87,1.62,81.0,270.0,2.84,16.0,18.0,131.0,76.0,21.0,5.91,2.1,58.0,323.0,37.0,21.0,5.5,5.9,80.0,144.0,76.1,55.8,19.2,2.91,0.2,14.7,7.1,1.3,0.314,1.16,8.23,,2.34,25.45,5.95,,无,无,无,无,,,,,,,51.51116951379763,1620760
1619232,张宪民,643514,男,59,T3,N3b ,M0, ⅢC,3,3,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,28.0,40,中间型（int）,INFc,0.0,,,,,,,,2016-06-07,2016-11-15,2,,,XELOX,XELOX,,,,,2, 低粘附腺癌65 粘液腺癌（muc）30 管状腺癌（中分化【G2】【tub2】5 Lauren混合型,G2,," LM 前Ant, 后Post, 小弯侧Less,",80,80,15,R0 D2,,5.8,4.36,0.97,142.6,229.0,2.56,16.0,22.0,128.0,77.0,17.0,9.75,3.9,70.0,276.0,41.0,29.0,5.2,4.7,74.0,444.0,,,,,,,,,,,,,32.86,1000.0,29.44, 阴性,无,无,无,无,,,,,,,5.289093298291721,1619232
1627881,张秀花,651110,女,46,T4b,N0 ,M0, ⅢA,3,3,,1.0,1.0,1.0,,0.0,21,,,1.0,,,,,,,,2016-08-15,2019-07-01,2,,,SOX,SOX,SOX,SOX,SOX,SOX,18, 管状腺癌（中分化【G2】【tub2】 粘液腺癌（muc）,G2,," M（胃体部）, 大弯侧Gre,",65,30,25,R0 D2,,4.85,3.04,1.28,105.1,382.0,3.4,15.0,23.0,160.0,96.0,12.0,8.17,3.31,71.0,195.0,43.0,28.0,4.3,4.4,60.0,323.0,,,,,,,,,,,,,10.52,103.4,1.14,,无,无,无,无,,,,,,,34.49408672798948,1627881
1644140,张学军,666178,男,53,T4b,N3a ,M0, ⅢC,3,2,2.0,0.0,0.0,1.0, 正常,8.0,34,中间型（int）,INFc,0.0,,1.0,,1.0,2.0,,,2016-12-23,2019-04-24,2,,,XELOX,XELOX,XELOX,XELOX,,,4, 低粘附腺癌 Lauren弥漫型,GX,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",35 30,25 25,15 10,R0,,5.73,3.84,1.16,123.0,276.0,3.36,21.0,18.0,147.0,88.0,18.0,10.15,3.36,67.0,200.0,42.0,25.0,4.6,5.7,86.0,278.0,86.2,56.7,22.4,2.53,0.4,7.3,5.7,4.9,0.868,1.23,9.78,,3.26,5.04,0.618, 未做,无,无,无,无,,MLH1+80%弱-中 MSH2+70%中 MSH6+80%中-强 PMS2+70%弱-中 CD4+ CD8散在+ VEGF+,80% 弱-中,70% 中,80% 中-强,70% 弱-中,27.989487516425754,1644140
1623876,张永富,643471,男,59,T3,N3a ,M0,ⅢB,3,3,2.0,1.0,1.0,1.0, 正常,14.0,38,中间型（int）,INFb,0.0,,,,,,,,2016-07-14,2020-05-21,0,,,XELOX,XELOX,XELOX,口服卡培他滨,口服卡培他滨,,5, 低粘附腺癌60 低分化腺癌（G3)(por)40 Lauren弥漫型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre,",40,35,10,R0,,6.86,4.02,2.05,149.3,197.0,2.7,42.0,29.0,196.0,68.0,46.0,8.72,3.23,67.0,320.0,42.0,25.0,5.3,6.2,96.0,368.0,78.7,34.9,37.3,0.94,0.0,8.5,6.6,2.5,0.689,1.7,9.81,,2.55,34.53,3.55, 阳性+,无,无,无,无,,,,,,,46.222076215505915,1623876
1735378,张玉玲,699528,女,38,T1a,N1 ,M0, ⅠB,3,2,,,,,,2.0,46,,,,,,,,,,,2017-09-21,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,XELOX,XELOX,8, 低粘附腺癌60 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)40,G3,," L（幽门窦部）, 小弯侧Less,",15,10,5,R0 D2+,,5.67,2.48,2.32,130.6,309.0,1.71,18.0,17.0,160.0,47.0,11.0,14.07,5.26,74.0,269.0,43.0,31.0,4.6,9.0,83.0,292.0,,,,,,,,,,,,,1.85,1.77,0.932, 阴性,无,无,无,无,,,,,,,59.36268068331143,1735378
1708577,张玉喜,671805,男,70,T3,N0 ,M0, ⅡA,3,1,0.0,0.0,0.0,0.0, 肠化生 慢性炎症,0.0,16,中间型（int）,INFb,0.0,,0.0,,0.0,2.0,,,2017-03-13,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2,," U（胃底部）, 前Ant, 小弯侧Less,",30,25,15,R0 D2,,6.48,4.52,1.0,94.2,174.0,3.66,33.0,25.0,213.0,106.0,19.4,8.9,1.58,64.9,271.0,42.6,22.3,8.7,4.61,116.0,259.0,,,,,,,,,,,,,1.74,10.66,1.7, 未做,无,无,无,无,,MLH1+10%弱 MSH2+80%中 MSH6+80%中-强 PMS2+10%弱 CD4- CD8散在+ VEGF-,10% 弱,80% 中,80% 中-强,10% 弱,65.67017082785807,1708577
1625540,张玉珍,585570,女,82,T4b,N1 ,M0, ⅢB,3,3,1.0,1.0,1.0,1.0, 肠化生 异型增生 慢性炎症,2.0,53,中间型（int）,INFb,3.0,,,,,,,,2016-07-27,2018-04-30,2,,,,,,,,,0, 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3,," LM 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",85,50,35,R0 D2,,5.49,4.03,0.99,60.9,395.0,3.66,17.0,24.0,217.0,73.0,10.0,12.85,3.98,57.0,233.0,34.0,23.0,5.6,5.61,68.0,282.0,,,,,,,,,,,,,65.46,189.9,20.13, 未做,无,无,无,无,,,,,,,21.090670170827856,1625540
1615244,张云起,639770,男,67,T3,N0 ,M0, ⅡA,3,2,0.0,0.0,0.0,1.0, 肠化生 慢性炎症,0.0,35,中间型（int）,INFa,0.0,,,,,,,,2016-05-09,2021-06-01,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,,M（胃体部） 前Ant 小弯侧Less 后Post ,55,35,10,R0,,10.9,8.5,1.46,109.9,275.0,4.97,8.0,15.0,201.0,67.0,14.0,13.96,5.66,58.0,126.0,34.0,24.0,3.3,5.4,80.0,356.0,82.6,49.7,29.8,1.67,0.0,9.3,7.1,3.3,0.874,3.2,8.32,,2.36,5.97,0.792, 未做,无,无,无,无,,,,,,,60.74244415243101,1615244
1628286,赵凤祥,650026,男,76,T1b,N3a,M0, ⅡB,3,3,0.0,1.0,1.0,0.0, 肠化生,9.0,34,硬型（sci）,INFa,2.0,,,,,,,,2016-08-18,2021-06-01,1,,,口服替吉奥,口服替吉奥,,,,,2, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," ML 前Ant, 后Post, 小弯侧Less,",60,40,4,R0 D2+,,4.35,2.75,1.22,88.0,259.0,1.66,17.0,24.0,134.0,44.0,16.0,15.37,7.57,49.0,229.0,32.0,17.0,5.2,6.1,116.0,359.0,66.9,37.4,22.0,1.7,0.3,11.8,20.2,3.1,0.378,0.998,5.45,,0.659,3.79,1.58,,无,无,无,无,,MLH1+40%弱 MSH2+70%中-强 MSH6+90%强 PMS2+20%弱 ,40% 弱,70% 中-强,90% 强,20% 弱,57.42444152431012,1628286
1705272,赵福成,670861,男,57,T3,N0 ,M0, ⅡA,3,3,0.0,1.0,1.0,1.0,,0.0,13,髓样型（med）,INFa,0.0,,,,,,,,2017-02-20,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por),G3,," U（胃底部）, 小弯侧Less,",20,20,10,R0,,3.87,2.23,1.28,141.0,290.0,1.54,20.0,24.0,164.0,60.0,19.0,14.56,5.75,62.0,239.0,41.0,21.0,4.3,4.3,74.0,299.0,,,,,,,,,,,,,2.18,17.45,6.34, 未做,无,无,无,无,,,,,,,66.36005256241786,1705272
1721777,赵国政,686360,男,73,T3,N0 ,M0, ⅡA,3,3,0.0,0.0,0.0,1.0,  慢性炎症（+）,0.0,27,髓样型（med）,INFb,3.0,,,,,,,,2017-06-14,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 Lauren肠型,G2,," U（胃底部）, 前Ant, 后Post, 小弯侧Less,",35,30,15,R0 D2,,5.63,2.9,1.94,94.9,312.0,3.15,18.0,17.0,161.0,67.0,16.0,12.57,5.44,71.0,157.0,43.0,28.0,4.6,5.9,87.0,354.0,51.2,39.1,10.8,3.62,0.5,7.2,37.3,0.7,0.884,1.72,10.1,,2.07,1.39,1.23, 阴性,无,无,无,无,,,,,,,62.614980289093296,1721777
1731748,赵洪君,698963,男,50,T3,N0 ,M0, ⅡA,3,3,,0.0,0.0,1.0,,0.0,29,,,1.0,,,,,,,,2017-08-25,2022-09-02,1,,,,,,,,,0, 低粘附腺癌,GX,," L（幽门窦部）, 后Post, 小弯侧Less,",40,30,10,R0 D2+,,6.34,4.41,1.3,117.6,234.0,3.15,23.0,23.0,161.0,54.0,15.0,19.07,5.85,60.0,255.0,34.0,26.0,6.4,2.9,88.0,253.0,,,,,,,,,,,,,0.59,5.65,2.8, 未做,无,无,无,无,,,,,,,60.2496714848883,1731748
1637797,赵军,676713,男,50,T3,N1 ,M0, ⅡB,3,2,2.0,0.0,0.0,1.0, 肠化生,1.0,68,髓样型（med）,INFb,1.0,,1.0,,2.0,2.0,,,2016-11-08,2022-09-02,1,,,XELOX,XELOX,XELOX,,,,3, 低粘附腺癌70 低分化腺癌（G3)(por)30 Lauren弥漫型,G3,,L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,100,80,10,R0 D2,,6.17,3.3,2.24,91.0,369.0,3.81,9.0,14.0,147.0,62.0,8.0,4.5,1.93,55.0,214.0,32.0,33.0,4.4,8.0,83.0,304.0,,,,,,,,,,,,,1.55,5.3,1.08, 未做,无,无,无,无,,MLH1+70%弱 MSH2+85%中 MSH6+70%中 PMS2+5%弱 CD4散在+ CD8散在+ VEGF+,70% 弱,85% 中,70% 中,5% 弱,69.7766097240473,1637797
1736102,赵玉敏,700904,女,60,T3,N0 ,M0, ⅡA,3,2,,1.0,1.0,0.0,,0.0,16,,,1.0,,,,,,,,2017-09-27,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】,G2,," L（幽门窦部）, 前Ant,",22,18,5,R0 D2,,9.3,56.5,3.41,4.78,283.0,3.62,8.3,14.0,172.0,177.0,45.0,9.4,4.5,72.5,200.0,43.1,29.4,4.0,3.9,67.0,207.0,,,,,,,,,,,,,8.82,79.38,3.11,,无,无,无,无,,,,,,,59.16557161629435,1736102
1734818,赵子明,699045,男,66,T3,N0 ,M0, ⅡA,3,3,1.0,0.0,0.0,1.0, 肠化生 慢性炎症,0.0,26,中间型（int）,INFb,1.0,,,,,,,,2017-09-18,2022-09-02,1,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren混合型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",25,15,10,R0 D2,,9.94,8.11,1.03,132.3,171.0,2.76,11.8,18.0,113.0,72.0,17.0,8.9,4.8,63.0,159.0,37.5,25.5,4.8,4.9,82.0,218.0,53.9,34.3,13.5,2.54,0.3,12.7,31.2,2.4,0.852,2.5,8.55,,1.94,6.46,7.06, 未做,无,无,无,无,,,,,,,59.46123521681997,1734818
1842746,郑凤杰,752193,女,48,T4b,N3b ,M0, ⅢC,3,3,0.0,1.0,1.0,1.0, 肠化生 异型增生 慢性炎症,25.0,38,中间型（int）,INFa,2.0,,,,,,,,2018-10-31,2021-07-05,2,,,SOX,SOX,SOX,SOX,SOX,SOX,6, 管状腺癌（中分化【G2】【tub2】,G2,," 小弯侧Less, L（幽门窦部）,",40,30,10,R0 D2+,,11.71,67.0,24.3,132.0,470.0,3.76,11.0,11.0,106.0,89.0,27.0,9.6,1.5,66.0,213.0,39.4,26.6,9.3,4.5,58.0,260.0,,,,,,,,,,,,,,,,,无,无,无,无,,,,,,,32.12877792378449,1842746
1632139,郑庆发,653670,男,69,T4b,N3a ,M0, ⅢC,3,4,2.0,1.0,1.0,1.0, 肠化生,12.0,46,中间型（int）,INFc,1.0,,2.0,,1.0,1.0,,,2016-09-20,2017-04-30,2,,,,,,,,,0, 低分化腺癌（G3)(por) 管状腺癌（中分化【G2】【tub2】30 低粘附腺癌70 Lauren弥漫型,G3,," LMU 前Ant, 大弯侧Gre, 小弯侧Less,",45,40,15,D2,R1,7.85,4.83,2.27,128.0,243.0,3.72,14.0,13.0,140.0,67.0,13.0,12.34,4.45,60.0,284.0,37.0,23.0,4.9,5.5,64.0,260.0,,,,,,,,,,,,,15.47,14.99,1.67, 阴性,无,无,无,无,,MLH1+50%弱 MSH2+70%中 MSH6+90%强 PMS2+40%弱 CD4+ CD8+ VEGF弱+,50% 弱,70% 中,90% 强,40% 弱,7.293035479632063,1632139
1615486,郑永财,631280,男,63,T4b,N3b ,M0, ⅢC,3,3,0.0,1.0,1.0,1.0,  慢性炎症（+）,18.0,36,中间型（int）,INFa,0.0,,,,,,,,2016-05-10,2020-05-20,0,,,XELOX,,,,,,1, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," U（胃底部）,",80,60,25,R0,,6.15,4.68,0.95,96.0,309.0,4.69,15.0,19.0,137.0,76.0,17.0,5.97,2.39,66.0,193.0,34.0,32.0,6.7,5.7,71.0,337.0,,,,,,,,,,,,,0.702,8.79,1.63, 未做,无,无,无,无,,,,,,,48.3245729303548,1615486
1739238,周冲,701273,男,63,T4b,N3a ,M0, ⅢC,3,3,1.0,0.0,0.0,1.0, 肠化生 慢性炎症,7.0,33,中间型（int）,INFc,0.0,,,,,,,,2017-10-27,2021-07-30,0,,,,,,,,,0, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3,," L（幽门窦部）, 前Ant, 后Post, 小弯侧Less,",55,40,8,R0 D2,,7.23,4.48,1.64,126.0,254.0,3.86,14.8,21.0,147.0,95.0,25.0,7.4,4.1,70.6,304.0,40.3,30.3,4.6,8.9,87.0,286.0,64.2,31.9,30.0,1.06,0.4,19.2,14.5,2.9,0.528,2.53,12.1,,9.51,27.04,2.03, 未做,无,无,无,无,,MLH1+80%弱-中 MSH2+80%弱-中 MSH6+80%弱-中 PMS2+75%弱 ,80% 弱-中,80% 弱-中,80% 弱-中,75% 弱,45.072273324572926,1739238
1710250,周桂芹,678875,女,59,T4a,N3a ,M0, ⅢB,3,2,0.0,1.0,1.0,1.0,  慢性炎症（+）,12.0,15,中间型（int）,INFa,0.0,,0.0,,1.0,2.0,,,2017-03-22,2018-01-10,2,,,口服替吉奥,口服替吉奥,,,,,2, 低分化腺癌（G3)(por) Lauren肠型,G3,," L（幽门窦部）, 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",50,40,10,R0 D2,,5.9,3.65,1.71,104.0,230.0,3.64,7.0,10.0,119.0,71.0,10.0,4.46,1.84,60.0,132.0,36.0,24.0,7.9,5.0,81.0,160.0,,,16.4,2.43,0.1,10.7,24.2,1.8,1.57,2.53,6.91,,1.43,10.53,3.4, 未做,无,无,无,无,,MLH1+70%弱-中 MSH2+90%中-强 MSH6+90%强 PMS2+90%弱,70% 弱-中,90% 中-强,90% 强,90% 弱,9.658344283837057,1710250
1714843,周景龙,683590,男,52,T3,N3a ,M0,ⅢB,3,3,0.0,1.0,1.0,1.0, 正常,12.0,32,髓样型（med）,INFa,3.0,,,,,,,,2017-04-24,2017-12-27,2,,,XELOX,XELOX,XELOX,,,,3, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por) Lauren肠型,G3,," M（胃体部）, 前Ant, 小弯侧Less,",70,70,10,R0 D2+,,11.03,8.31,1.82,117.0,265.0,3.59,9.0,15.0,132.0,41.0,48.0,8.2,3.27,60.0,265.0,35.0,25.0,4.5,3.9,104.0,404.0,,,,,,,,,,,,,2.02,0.6,1.25, 未做,无,无,无,无,,,,,,,8.114323258869907,1714843
1748321,周利红,708812,女,42,T1a,N0 ,M0,ⅠA,3,3,,,,,,0.0,42,,,0.0,,,,,,,,2017-12-29,2019-07-01,0,,,,,,,,,0, 低粘附癌,GX,," U（胃底部）, SiewerⅢ, 小弯侧Less,",20,10,6,R0 D2+,,12.52,11.8,0.34,137.0,174.0,2.14,15.1,15.0,145.0,74.0,13.0,12.4,4.8,64.7,236.0,41.2,23.5,,3.7,62.0,255.0,,,,,,,,,,,,,2.32,6.9,2.02,,无,无,无,无,,MLH1+70%弱 MSH2+80%中 MSH6+40%中-弱 PMS2+60%弱,70% 弱,80% 中,40% 弱-中,60% 弱,18.035479632063073,1748321
1816581,周玉祥,725347,男,51,T3,N0 ,M0, ⅡA,3,4,2.0,0.0,0.0,1.0,  慢性炎症（+）,0.0,47,髓样型（med）,INFc,,,,,,,,,2018-04-27,2022-09-02,1,,,XELOX,XELOX,XELOX,XELOX,,,4,<胃>浸润溃疡型低黏附性癌 Lauren弥漫型,GX,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",40,25,3,D2+,,10.52,9.23,0.67,163.0,117.0,2.49,13.1,19.0,159.0,94.0,23.0,20.9,3.4,63.0,258.0,40.4,22.6,4.3,3.8,92.0,366.0,,,,,,,,,,,,,0.293,,1.75,,无,无,无,无,,,,,,,52.20105124835742,1816581
1622926,朱道喜,647254,男,41,T4a,N3b ,M0, ⅢC,3,4,1.0,1.0,1.0,1.0, 异型增生 慢性炎症,20.0,37,硬型（sci）,INFc,0.0,,,,,,,,2016-07-06,2017-04-15,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,奥沙利铂单药化疗,6, 低粘附腺癌95 低分化腺癌（G3)(por)5 Lauren混合型,G3,," LMU 前Ant, 后Post, 小弯侧Less,",30,30,10,D2+,R2,5.44,2.33,2.65,166.0,232.0,2.03,38.0,25.0,159.0,67.0,38.0,25.78,9.68,63.0,382.0,44.0,19.0,3.9,3.5,86.0,321.0,,,,,,,,,,,,,2.64,7.12,3.42,,无,无,无,无,,,,,,,9.296977660972404,1622926
1729745,朱景芳,696356,男,57,T3,N0 ,M0, ⅡA,3,2,,1.0,1.0,0.0,,0.0,28,,,,,,,,,,,2017-08-10,2022-09-02,1,,,,,,,,,0,  低分化腺癌（G3)(por),G3,," U（胃底部）, SiewerⅡ, 小弯侧Less,",50,40,10,R0 D2+,,5.25,3.02,1.58,144.9,193.0,2.54,27.0,22.0,158.0,53.0,18.0,9.34,2.74,61.0,336.0,38.0,23.0,5.1,6.0,91.0,434.0,,,,,,,,,,,,,1.94,6.28,0.995, 未做,无,无,无,无,,,,,,,60.74244415243101,1729745
1638819,朱维杰,676894,男,63,T4b,N2 ,M0, ⅢB,3,2,1.0,1.0,1.0,0.0, 肠化生 慢性炎症 异型增生,6.0,21,硬型（sci）,INFb,3.0,,1.0,,2.0,2.0,,,2016-11-15,2017-12-20,2,,,XELOX,XELOX,XELOX,XELOX,XELOX,FOLFOX,6, 管状腺癌（中分化【G2】【tub2】 低分化腺癌（G3)(por)80 低粘附腺癌20 Lauren混合型,G3,, L（幽门窦部） 前Ant 后Post 大弯侧Gre  小弯侧Less ,20,20,10,R0 D2,,10.37,6.23,3.37,148.4,234.0,3.8,12.0,16.0,177.0,100.0,16.0,13.52,3.9,65.0,429.0,43.0,22.0,7.1,3.6,92.0,412.0,,,,,,,,,,,,,5.82,18.67,15.95, 未做,无,无,无,无,,MLH1+30%弱 MSH2+50%弱 MSH6+80%中 PMS2+30%弱,30% 弱,50% 弱,80% 中,30% 弱,13.140604467805518,1638819
1615986,左凤廷,640339,男,63,T4b,N3b ,M0, ⅢC,3,4,2.0,0.0,0.0,1.0,  慢性炎症（+）,27.0,39,髓样型（med）,INFb,0.0,,,,,,,,2016-05-12,2019-05-01,2,,,XELOX,,,,,,1, 低粘附腺癌80 粘液腺癌（muc）20 Lauren弥漫型,GX,," LMU 前Ant, 后Post, 大弯侧Gre, 小弯侧Less,",150,80,12,R0,,5.39,4.08,0.69,128.0,214.0,,25.0,34.0,156.0,66.0,21.0,6.69,2.75,59.0,217.0,35.0,24.0,5.6,6.4,68.0,240.0,,,,,,,,,,,,,5.86,422.3,300.0, 未做,无,无,无,无,,,,,,,35.611038107752954,1615986
1605354,任淑清,561635,女,69,T1b,N1 ,M0, ⅠB,3,2,1.0,,,, 肠化生,1.0,21,中间型（int）,INFa,0.0,,,,,,,,2016-02-29,2022-09-02,1,,,,,,,,,0,低分化管状腺癌70%，低粘附性腺癌30%,G3,,LM,40,30,,R0 D2,,11.52,5.57,5.14,147.1,309.0,3.33,14.0,20.0,162.0,79.0,15.0,9.99,3.29,76.0,411.0,49.0,27.0,6.4,13.6,138.0,470.0,,,,,,,,,,,,,1.77,7.47,2.09,,无,无,无,无,,,,,,,78.08804204993429,1605354
1607752,潘克顺,626166,男,70,T2,N0 ,M0, ⅠB,3,2,0.0,0.0,0.0,0.0, 肠化生,0.0,20,中间型（int）,INFa,1.0,,,,,,,,2016-03-15,2022-09-02,1,,,口服替吉奥,口服替吉奥,口服替吉奥,,,,3,高分化管状腺癌,G1,,L ,50,50,8,R0 D2,,8.85,4.72,2.77,135.0,200.0,2.85,17.0,20.0,156.0,62.0,2.0,12.17,4.51,66.0,269.0,38.0,22.0,5.7,7.8,88.0,273.0,,,,,,,,,,,,,0.68,33.27,2.62,,无,无,无,无,,,,,,,77.59526938239159,1607752
1607208,吴俊梅,629363,女,47,T3,N0 ,M0, ⅡA,3,2,2.0,0.0,0.0,1.0,  慢性炎症（+）,0.0,14,中间型（int）,INFc,0.0,,,,,,,,2016-03-10,2022-09-02,1,,,,,,,,,0,低黏附性癌,GX,,L,30,20,5,R0 D2+,,7.0,4.27,2.21,151.0,212.0,3.18,13.0,18.0,137.0,78.0,12.0,7.61,2.31,69.0,392.0,38.0,31.0,5.2,5.9,80.0,331.0,,,,,,,,,,,,,3.9,15.09,22.2,,无,无,无,无,,,,,,,77.75952693823916,1607208
1614220,黄宏春,633762,男,49,T1b,N0 ,M0,ⅠA,3,1,,,,,,0.0,24,,,,,,,,,,,2016-04-28,2021-08-10,1,,,,,,,,,0,中分化管状腺癌,G2,,L,40,20,10,R0 D2+,,4.39,2.34,1.57,145.2,150.0,2.04,43.0,35.0,144.0,53.0,28.0,11.01,3.38,57.0,335.0,34.0,23.0,4.6,4.2,89.0,483.0,,,,,,,,,,,,,0.903,11.29,3.83,,无,无,无,无,,,,,,,63.40341655716163,1614220
1616386,刘丰德,633872,男,60,T4b,N3a ,M0, ⅢC,3,2,0.0,1.0,1.0,1.0, 正常,13.0,32,中间型（int）,INFa,1.0,,,,,,,,2016-05-16,2019-11-01,2,,,,,,,,,0,低分化管状腺癌,G3,,U,60,35,8,D2+,R1,6.79,4.94,1.24,135.7,265.0,3.2,15.0,19.0,145.0,53.0,8.0,13.33,4.79,71.0,277.0,39.0,32.0,6.4,7.6,85.0,323.0,,,,,,,,,,,,,2.2,8.06,4.36,,无,无,无,无,,,,,,,41.52431011826544,1616386
1619315,闫秀华,635795,女,57,T3,N0 ,M0, ⅡA,3,2,1.0,0.0,0.0,0.0, 肠化生 慢性炎症,0.0,15,中间型（int）,INFb,2.0,,,,,,,,2016-06-07,2022-09-02,1,,,XELOX,XELOX,XELOX,,,,3,粘液腺癌80%中分化管状腺癌20%,G2,,L,30,23,7,R0 D2+,,5.18,1.95,2.65,136.0,182.0,2.9,22.0,30.0,229.0,54.0,10.0,16.64,4.76,79.0,261.0,48.0,31.0,5.0,5.4,64.0,324.0,,,,,,,,,,,,,1.38,31.8,1.7,,无,无,无,无,,,,,,,74.83574244415243,1619315
1619778,尚金华,643349,女,66,T2,N0 ,M0, ⅠB,3,3,0.0,1.0,1.0,1.0, 异型增生 慢性炎症,0.0,21,中间型（int）,INFa,3.0,,,,,,,,2016-06-13,2022-09-02,1,,,,,,,,,0,低分化管状腺癌,G3,,L,25,15,8,R0,,6.68,3.79,2.39,131.0,192.0,3.15,17.0,26.0,196.0,79.0,8.0,10.77,3.5,68.0,179.0,39.0,29.0,5.0,6.3,76.0,234.0,61.4,42.2,17.7,2.38,0.1,18.1,18.4,1.0,1.31,2.38,12.1,,0.585,6.96,6.35,,无,无,无,无,,,,,,,74.63863337713535,1619778
1625005,窦成军,648446,男,58,T3,N3b ,M0, ⅢC,3,3,1.0,1.0,1.0,1.0, 肠化生 慢性炎症,17.0,38,髓样型（med）,INFb,2.0,,,,,,,,2016-07-22,2022-09-02,1,,,,,,,,,0,低中分化管状腺癌80%地黏附性腺癌20%,G2,,L,50,40,20,R0,,8.74,6.03,1.67,159.0,307.0,3.2,16.0,20.0,176.0,73.0,12.0,5.16,3.79,59.0,90.0,38.0,21.0,5.7,7.3,75.0,336.0,,,,,,,,,,,,,5.09,42.42,24.64,,无,无,无,无,,,,,,,73.3574244415243,1625005
1631445,丁湖,653587,男,69,T1b,N0 ,M0,ⅠA,3,2,,,,,,0.0,29,,,2.0,,,,,,,,2016-09-13,2022-09-02,1,,,,,,,,,0,高中分化管状腺癌,G2,,L,35,30,10,R0 D2,,8.92,6.7,1.25,133.9,215.0,2.85,14.0,15.0,128.0,47.0,16.0,16.52,6.4,57.0,393.0,33.0,24.0,4.7,5.4,84.0,343.0,84.4,50.9,17.0,3.46,0.2,10.6,4.3,3.2,0.589,3.16,8.21,,1.52,10.21,1.32,,无,无,无,无,,,,,,,71.61629434954007,1631445
1635103,孙宪法,655782,男,65,T2,N0 ,M0, ⅠB,3,3,,1.0,1.0,1.0,,0.0,31,,,1.0,,1.0,,2.0,2.0,,,2016-10-18,2022-09-02,1,,,,,,,,,0,低中分化管状腺癌70%粘液腺癌20%低黏附性癌10%,G2,,L,40,40,3,R0 D2+,,7.02,3.37,2.75,171.0,216.0,2.7,17.0,20.0,133.0,80.0,16.0,21.5,7.67,65.0,402.0,38.0,27.0,6.0,6.9,103.0,235.0,,,,,,,,,,,,,2.24,11.98,1.22,,无,无,无,无,,MLH180%中 MSH280%中-强 MSH690%强 PMS280%中 CD4散在+ CD8散在+ VEGF+,80% 中,80% 中-强,90% 强,80% 中,70.4664914586071,1635103
1634856,蔡英,659846,女,54,T1b,N0 ,M0,ⅠA,3,3,,1.0,1.0,1.0,,2.0,40,,,1.0,,1.0,,1.0,2.0,,,2016-10-07,2022-09-02,1,,,SOX,SOX,SOX,,,,3,低分化管状腺癌,G3,,M,60,30,5,R0 D2,,5.26,2.65,2.03,137.0,213.0,1.94,13.0,16.0,189.0,83.0,9.0,15.59,4.97,70.0,385.0,72.0,28.0,5.6,5.2,75.0,271.0,,,,,,,,,,,,,0.271,0.6,0.666,,无,无,无,无,,MLH170%中 MSH285%中-强 MSH695%强 PMS260%弱-中 CD+ CD8散在+ VEGF+,70% 中,85% 中-强,95% 强,60% 弱-中,70.82785808147175,1634856
1637209,刘艳春,660896,女,65,T1b,N0 ,M0,ⅠA,3,1,,1.0,1.0,0.0,,0.0,16,,,,,,,,,,,2016-11-03,2022-09-02,1,,,XELOX,,,,,,1,高分化乳头状癌,G1,,M,30,40,,R0 D2,,7.98,5.71,1.76,109.0,273.0,2.16,12.0,12.0,216.0,81.0,11.0,30.9,11.25,55.0,90.0,31.0,24.0,,2.9,67.0,121.0,,,,,,,,,,,,,0.666,6.9,0.981,,无,无,无,无,,,,,,,69.94086727989487,1637209
1640389,季禄任,662786,男,66,T2,N2 ,M0, ⅡB,3,3,,0.0,0.0,0.0,,5.0,21,,,0.0,,,,,,,,2016-11-28,2022-09-02,1,,,SOX,SOX,SOX,口服替吉奥,口服替吉奥,口服替吉奥,8,乳头状腺癌55%低分化管状腺癌45%,G3,,L,50,25,7,R0 D2+,,9.28,7.93,0.6,101.5,168.0,2.9,13.0,17.0,181.0,73.0,8.0,6.88,2.38,59.0,284.0,38.0,21.0,5.5,6.6,100.0,425.0,65.6,40.4,20.1,2.01,0.4,10.3,13.7,0.5,0.898,0.892,8.59,,1.03,10.21,3.88,,无,无,无,无,,,,,,,69.11957950065703,1640389
1700842,王贵军,666377,男,54,T1b,N0 ,M0,ⅠA,3,0,,0.0,0.0,1.0,,0.0,25,,,0.0,,,,,,,,2017-01-09,2022-09-02,1,,,,,,,,,0,低黏附性癌,GX,,M,30,20,2,R0 D2,,7.29,3.34,2.46,151.0,192.0,2.41,21.0,22.0,183.0,82.0,29.0,22.4,4.01,67.0,294.0,40.0,27.0,5.0,6.9,77.0,378.0,,,,,,,,,,,,,1.4,6.6,1.5,,无,无,无,无,,,,,,,67.73981603153744,1700842
1712046,郁贵喜,680581,男,54,T2,N0 ,M0, ⅠB,3,3,0.0,1.0,1.0,0.0, 正常,0.0,30,髓样型（med）,INFa,1.0,,,,,,,,2017-04-05,2022-09-02,1,,,,,,,,,0,低中分化管状腺癌,G2,,L,40,30,10,R0 D2+,,4.28,3.06,0.76,146.2,164.0,3.9,12.0,16.0,124.0,61.0,8.0,6.21,2.36,61.0,187.0,38.0,23.0,6.5,6.2,85.0,238.0,,,,,,,,,,,,,,,,,无,无,无,无,,,,,,,64.91458607095926,1712046
1715919,何春,683474,男,65,T4b,N3b,M0, ⅢC,3,4,2.0,0.0,0.0,0.0, 正常,22.0,62,髓样型（med）,INFc,0.0,,,,,,,,2017-05-02,2020-02-01,2,,,,,,,,,0,粘液腺癌,GX,,UM,100,70,12,R0 D2,,8.2,5.83,1.77,138.0,243.0,3.43,16.0,21.0,150.0,121.0,73.0,4.61,1.47,67.0,249.0,38.0,39.0,5.2,5.5,92.0,279.0,,,,,,,,,,,,,375.1,1.21,38.01,,无,无,无,无,,,,,,,33.01576872536137,1715919
1737196,张淑兰,702750,女,59,T2,N0 ,M0, ⅠB,3,3,0.0,0.0,0.0,0.0, 肠化生 慢性炎症,0.0,16,中间型（int）,INFb,2.0,,,,,,,,2017-10-13,2020-09-17,0,,,,,,,,,0,中分化管状腺癌,G2,,L,60,50,4,R0 D2+,,4.85,3.64,0.93,128.0,182.0,2.7,23.0,25.0,226.0,82.0,10.0,12.06,2.63,66.0,223.0,37.0,29.0,5.2,4.6,79.0,259.0,,,,,,,,,,,,,3.94,36.35,6.69,,无,无,无,无,,,0,90% 中,90% 强,0,35.15111695137976,1737196
1736252,王淑云,704201,女,77,T1b,N0 ,M0,ⅠA,3,0,,,,,,0.0,21,,,,,,,,,,,2017-09-28,2022-09-02,1,,,,,,,,,0,低分化管状腺癌90%低黏附性癌10%,G3,,L,60,50,,R0 D2,,7.82,4.19,2.25,140.0,216.0,4.05,17.8,23.0,150.0,115.0,56.0,11.7,4.7,74.0,274.0,39.5,34.5,4.9,8.3,71.0,283.0,,,,,,,,,,,,,2.93,26.69,0.881,,无,无,无,无,,,,,,,59.13272010512483,1736252
1807581,王淑花,720060,女,67,T1b,N0 ,M0,ⅠA,3,2,0.0,,,, 肠化生 慢性炎症,0.0,26,髓样型（med）,INFa,,,,,,,,,2018-03-05,2022-09-02,1,,,,,,,,,0,低中分化管状腺癌,G2,,L,25,15,10,R0 D2,,5.78,2.77,2.38,135.0,242.0,2.49,21.1,18.0,167.0,87.0,21.0,11.6,4.6,74.6,291.0,44.6,30.0,9.8,5.2,63.0,216.0,,,,,,,,,,,,,4.06,38.01,1.21,,无,无,无,无,,,,,,,53.942181340341655,1807581
1814675,刘绍君,725310,男,63,T2,N0 ,M0, ⅠB,3,1,,,,,,0.0,30,,,,,,,,,,,2018-04-17,2022-09-02,1,,,,,,,,,0,中分化腺癌,G2,,L,70,50,35,R0 D2,,4.83,3.61,0.78,49.0,371.0,3.44,30.1,61.0,239.0,56.0,16.0,29.6,5.3,47.8,192.0,34.3,13.5,8.0,10.1,101.0,374.0,,,,,,,,,,,,,0.975,6.01,0.769,,无,无,无,无,,,,,,,52.52956636005256,1814675
1818938,孙宪军,728619,男,63,T3,N2 ,M0, ⅢA,3,2,2.0,1.0,1.0,1.0, 肠化生 异型增生 慢性炎症,5.0,23,中间型（int）,INFc,,,,,,,,,2018-05-15,2020-10-13,0,,,FOLFOX,,,,,,1,低分化管状腺癌,G3,,LM,50,30,10,R0,,5.83,3.45,1.9,148.0,295.0,4.58,9.0,15.0,161.0,81.0,18.0,12.0,2.2,69.5,275.0,45.7,23.8,,5.9,89.0,320.0,,,,,,,,,,,,,2.35,7.0,0.867,,无,无,无,无,,,,,,,28.97503285151117,1818938
